PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2560686-5 1989 Basal levels of ACTH were higher after simvastatin (2.9 +/- 1.9 pmol/l vs 4.1 +/- 2.9 pmol/l; P less than 0.05) whereas basal levels of steroid hormones were not significantly changed. Simvastatin 39-50 proopiomelanocortin Homo sapiens 16-20 2560686-0 1989 Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Simvastatin 50-61 proopiomelanocortin Homo sapiens 119-123 2634479-6 1989 Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values. Simvastatin 10-21 component of oligomeric golgi complex 2 Homo sapiens 264-268 2634479-6 1989 Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values. Simvastatin 10-21 apolipoprotein B Homo sapiens 307-311 2634479-6 1989 Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values. Simvastatin 10-21 lipoprotein(a) Homo sapiens 429-433 2742865-1 1989 MK-733 (simvastatin), a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, was found to inhibit the absorption of cholesterol from the gastrointestinal tract in cholesterol-fed rabbits (Ishida et al. Simvastatin 0-6 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 31-88 2742865-1 1989 MK-733 (simvastatin), a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, was found to inhibit the absorption of cholesterol from the gastrointestinal tract in cholesterol-fed rabbits (Ishida et al. Simvastatin 8-19 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 31-88 2742865-5 1989 To clarify the mechanism of action, the effects of MK-733 on acyl coenzyme A:cholesterol acyltransferase (ACAT) and cholesterol esterase activities, which are thought to participate in the absorption of cholesterol, were examined. Simvastatin 51-57 sterol O-acyltransferase 1 Oryctolagus cuniculus 106-110 2742865-7 1989 10 mg/kg) of MK-733 to cholesterol-fed rabbits was found to inhibit the increase in serum total cholesterol levels, and caused a 70% reduction in ACAT activity in microsomes of intestinal mucosa relative to those observed in concurrent control rabbits. Simvastatin 13-19 sterol O-acyltransferase 1 Oryctolagus cuniculus 146-150 2742865-9 1989 The inhibitory effect of MK-733 on cholesterol absorption in cholesterol-fed rabbits is though to be related to a reduction in microsomal ACAT activity in the intestinal mucosa. Simvastatin 25-31 sterol O-acyltransferase 1 Oryctolagus cuniculus 138-142 2904053-5 1988 With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%. Simvastatin 5-16 apolipoprotein B Homo sapiens 21-37 2736571-10 1989 These data indicate that simvastatin, even at a low dose of 2.5 to 5 mg daily, causes consistent reductions in serum TC, LDL-C, apo B, and TG, and a rise in HDL-C and antiatherogenic lipoproteins. Simvastatin 25-36 apolipoprotein B Homo sapiens 128-133 2502417-6 1989 Mean plasma HDL cholesterol concentration and the subfractions HDL2 and HDL3 cholesterol were significantly increased by simvastatin. Simvastatin 121-132 junctophilin 3 Homo sapiens 63-67 2502417-6 1989 Mean plasma HDL cholesterol concentration and the subfractions HDL2 and HDL3 cholesterol were significantly increased by simvastatin. Simvastatin 121-132 HDL3 Homo sapiens 72-76 2502417-7 1989 Simvastatin and cholestyramine reduced the mean plasma apolipoprotein B concentration by 28% and 13%, respectively. Simvastatin 0-11 apolipoprotein B Homo sapiens 55-71 2502417-8 1989 The mean plasma apolipoprotein A-I concentration was significantly higher only on simvastatin treatment. Simvastatin 82-93 apolipoprotein A1 Homo sapiens 16-34 2776246-1 1989 Relatively high concentrations of MK-733 (simvastatin) and MK-803 (lovastatin, mevinolin), which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were found to inhibit acyl coenzyme A: cholesterol acyltransferase (ACAT) of rabbit intestinal microsomes with IC50"s of 2.0 x 10(-5) and 3.6 x 10(-5) M, respectively. Simvastatin 34-40 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 101-158 2776246-1 1989 Relatively high concentrations of MK-733 (simvastatin) and MK-803 (lovastatin, mevinolin), which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were found to inhibit acyl coenzyme A: cholesterol acyltransferase (ACAT) of rabbit intestinal microsomes with IC50"s of 2.0 x 10(-5) and 3.6 x 10(-5) M, respectively. Simvastatin 34-40 liver carboxylesterase 1 Oryctolagus cuniculus 193-237 2776246-1 1989 Relatively high concentrations of MK-733 (simvastatin) and MK-803 (lovastatin, mevinolin), which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were found to inhibit acyl coenzyme A: cholesterol acyltransferase (ACAT) of rabbit intestinal microsomes with IC50"s of 2.0 x 10(-5) and 3.6 x 10(-5) M, respectively. Simvastatin 34-40 sterol O-acyltransferase 1 Oryctolagus cuniculus 239-243 2776246-3 1989 A kinetic analysis using a Lineweaver-Burk plot indicated that MK-733 is a competitive inhibitor of ACAT, with a Ki value of 1.2 x 10(-5) M. Simvastatin 63-69 sterol O-acyltransferase 1 Oryctolagus cuniculus 100-104 2487533-1 1989 We report the results of a two center study on the use of the HMG Co A reductase inhibitor, simvastatin, in 44 patients suffering from familial hypercholesterolemia or from primary hypercholesterolemia of unknown etiology. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-80 2646895-1 1989 This 12-week, randomized, double-blind, multicenter study compared the efficacy, tolerability and safety of simvastatin (a potent HMG-CoA reductase inhibitor) and probucol. Simvastatin 108-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-147 2646895-5 1989 Simvastatin significantly decreased total cholesterol, triglycerides and apolipo-protein B, and increased high density lipoprotein (HDL) cholesterol and apolipoprotein A-I. Simvastatin 0-11 apolipoprotein A1 Homo sapiens 153-171 3076126-2 1988 Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-120 2894548-2 1988 Simvastatin was better than bezafibrate at lowering total and low-density lipoprotein (LDL)-cholesterol and apolipoprotein B concentrations (30.4% [p less than 0.001], 37.3% [p less than 0.001], and 37.8% [p less than 0.001] vs 17.0%, 19.6%, and 24.0%, respectively). Simvastatin 0-11 apolipoprotein B Homo sapiens 108-124 2894548-7 1988 The results show that simvastatin was more effective than bezafibrate in lowering total-cholesterol, LDL-cholesterol, and apolipoprotein B, while bezafibrate was better at lowering triglycerides and VLDL-cholesterol and at raising HDL-cholesterol and apolipoprotein A-I. Simvastatin 22-33 apolipoprotein B Homo sapiens 122-138 2894548-7 1988 The results show that simvastatin was more effective than bezafibrate in lowering total-cholesterol, LDL-cholesterol, and apolipoprotein B, while bezafibrate was better at lowering triglycerides and VLDL-cholesterol and at raising HDL-cholesterol and apolipoprotein A-I. Simvastatin 22-33 apolipoprotein A1 Homo sapiens 251-269 3279966-1 1988 Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to 38 patients with heterozygous familial hypercholesterolaemia for 24 weeks. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-88 3279966-1 1988 Simvastatin (MK-733), a new inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to 38 patients with heterozygous familial hypercholesterolaemia for 24 weeks. Simvastatin 13-19 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-88 3254824-1 1988 Simvastatin (MK733), derived from lovastatin by substituting CH3 for H at the 2" position, is a potent hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 3254824-1 1988 Simvastatin (MK733), derived from lovastatin by substituting CH3 for H at the 2" position, is a potent hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Simvastatin 13-18 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 2968595-0 1988 [Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). Simvastatin 12-23 BCL2 related protein A1 Homo sapiens 72-80 3076124-4 1988 The bile acid sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibrate and inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase (e.g. lovastatin or simvastatin) are the most effective drugs for use in patients with primary hypercholesterolaemia; these agents reduce plasma concentrations of total and LDL-cholesterol by 15 to 45%. Simvastatin 179-190 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-158 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 35-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3234467-4 1988 Serum apolipoprotein B fell by 33.3% (simvastatin) and 15.7% (bezafibrate). Simvastatin 38-49 apolipoprotein B Homo sapiens 6-22 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 48-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3076125-2 1988 Lovastatin (MK-803, mevinolin) and simvastatin (MK-733, synvinolin), 2 highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been heralded as breakthrough therapy for the treatment of atherosclerotic disease. Simvastatin 56-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 3076125-5 1988 Lovastatin and simvastatin are the first HMG CoA reductase inhibitors to receive regulatory agency approval for marketed use. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 3234467-5 1988 Simvastatin and bezafibrate produced significant increases in the mean fractional esterification rate of LCAT, by +124.1% and +20.6%, respectively. Simvastatin 0-11 lecithin-cholesterol acyltransferase Homo sapiens 105-109 33755783-11 2021 Simvastatin may represent an innovative strategy for treating OSCC with high TMEM16A expression. Simvastatin 0-11 anoctamin 1 Homo sapiens 77-84 33278579-0 2021 Simvastatin accelerates the healing process of burn wound in Wistar rats through Akt/mTOR signaling pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 81-84 33278579-0 2021 Simvastatin accelerates the healing process of burn wound in Wistar rats through Akt/mTOR signaling pathway. Simvastatin 0-11 mechanistic target of rapamycin kinase Rattus norvegicus 85-89 33278579-2 2021 Hereby, we aimed to assess the impact of Simvastatin (SMV), one of the most commonly used statins, on Akt/mTOR signaling pathway during burn wound healing process. Simvastatin 41-52 AKT serine/threonine kinase 1 Rattus norvegicus 102-105 33278579-2 2021 Hereby, we aimed to assess the impact of Simvastatin (SMV), one of the most commonly used statins, on Akt/mTOR signaling pathway during burn wound healing process. Simvastatin 41-52 mechanistic target of rapamycin kinase Rattus norvegicus 106-110 33278579-2 2021 Hereby, we aimed to assess the impact of Simvastatin (SMV), one of the most commonly used statins, on Akt/mTOR signaling pathway during burn wound healing process. Simvastatin 54-57 AKT serine/threonine kinase 1 Rattus norvegicus 102-105 33278579-2 2021 Hereby, we aimed to assess the impact of Simvastatin (SMV), one of the most commonly used statins, on Akt/mTOR signaling pathway during burn wound healing process. Simvastatin 54-57 mechanistic target of rapamycin kinase Rattus norvegicus 106-110 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 platelet and endothelial cell adhesion molecule 1 Rattus norvegicus 110-114 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 vascular endothelial growth factor A Rattus norvegicus 116-120 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 AKT serine/threonine kinase 1 Rattus norvegicus 122-125 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 mechanistic target of rapamycin kinase Rattus norvegicus 127-131 33278579-7 2021 Moreover, qRT-PCR findings showed that the wounds treated with SMV alone had the highest expression levels of CD31, VEGF, Akt, mTOR, and p70S6K after 7 and 14 days of burn model (p < 0.001). Simvastatin 63-66 ribosomal protein S6 kinase B1 Rattus norvegicus 137-143 33278579-9 2021 In contrast, inhibition of Akt/mTOR signaling pathway by RM reduced SMV-induced wound healing process. Simvastatin 68-71 AKT serine/threonine kinase 1 Rattus norvegicus 27-30 33278579-9 2021 In contrast, inhibition of Akt/mTOR signaling pathway by RM reduced SMV-induced wound healing process. Simvastatin 68-71 mechanistic target of rapamycin kinase Rattus norvegicus 31-35 33278579-10 2021 Seemingly, SMV promotes burn wound healing, at least in part, through activating Akt/mTOR signaling pathway, suggesting topically applied SMV as an alternative therapeutic approach for managing burn wound healing. Simvastatin 11-14 AKT serine/threonine kinase 1 Rattus norvegicus 81-84 33278579-10 2021 Seemingly, SMV promotes burn wound healing, at least in part, through activating Akt/mTOR signaling pathway, suggesting topically applied SMV as an alternative therapeutic approach for managing burn wound healing. Simvastatin 11-14 mechanistic target of rapamycin kinase Rattus norvegicus 85-89 33278579-10 2021 Seemingly, SMV promotes burn wound healing, at least in part, through activating Akt/mTOR signaling pathway, suggesting topically applied SMV as an alternative therapeutic approach for managing burn wound healing. Simvastatin 138-141 AKT serine/threonine kinase 1 Rattus norvegicus 81-84 33278579-10 2021 Seemingly, SMV promotes burn wound healing, at least in part, through activating Akt/mTOR signaling pathway, suggesting topically applied SMV as an alternative therapeutic approach for managing burn wound healing. Simvastatin 138-141 mechanistic target of rapamycin kinase Rattus norvegicus 85-89 33936284-12 2021 Simvastatin intervention significantly mitigated hypercholesterolemia-induced alveolar bone loss and RANKL mRNA transcription, but increased the ratios of LC3/p62 protein expression in the alveolar bone tissues of rats. Simvastatin 0-11 TNF superfamily member 11 Rattus norvegicus 101-106 33936284-12 2021 Simvastatin intervention significantly mitigated hypercholesterolemia-induced alveolar bone loss and RANKL mRNA transcription, but increased the ratios of LC3/p62 protein expression in the alveolar bone tissues of rats. Simvastatin 0-11 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 159-162 33277702-3 2021 CASE DESCRIPTION: We report a case of simvastatin-induced rhabdomyolysis caused by an azithromycin drug interaction in a patient with heterozygous SLCO1B1 loss-of-function polymorphism. Simvastatin 38-49 solute carrier organic anion transporter family member 1B1 Homo sapiens 147-154 33277702-5 2021 Azithromycin mildly inhibits simvastatin"s CYP 3A4 hepatic metabolism, and the SLCO1B1 polymorphism reduces simvastatin hepatic uptake. Simvastatin 29-40 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-50 33277702-5 2021 Azithromycin mildly inhibits simvastatin"s CYP 3A4 hepatic metabolism, and the SLCO1B1 polymorphism reduces simvastatin hepatic uptake. Simvastatin 108-119 solute carrier organic anion transporter family member 1B1 Homo sapiens 79-86 33755783-9 2021 Furthermore, simvastatin could suppress TMEM16A channel activities, and inhibited cell proliferation in OSCC cells via TMEM16A. Simvastatin 13-24 anoctamin 1 Homo sapiens 40-47 33755783-9 2021 Furthermore, simvastatin could suppress TMEM16A channel activities, and inhibited cell proliferation in OSCC cells via TMEM16A. Simvastatin 13-24 anoctamin 1 Homo sapiens 119-126 33755783-10 2021 CONCLUSION: Our findings identify a novel anti-tumor mechanism of simvastatin by targeting TMEM16A. Simvastatin 66-77 anoctamin 1 Homo sapiens 91-98 33548270-10 2021 An ELISA assay was performed to investigate the antioxidant and anti-inflammatory effects of simvastatin by measuring the levels of tumor necrosis factor-alpha (TNF-alpha), and antioxidant enzymes. Simvastatin 93-104 tumor necrosis factor Rattus norvegicus 132-159 33992804-5 2021 Here, we found that simvastatin inhibited PD-L1 expression and promoted anti-tumor immunity via suppressing the expression of lncRNA SNHG29. Simvastatin 20-31 CD274 molecule Homo sapiens 42-47 33992804-8 2021 Collectively, our study uncovers simvastatin as a potential therapeutic drug for immunotherapy in CRC, which suppresses lncRNA SNHG29 mediated YAP activation and promotes anti-tumor immunity by inhibiting PD-L1 expression. Simvastatin 33-44 Yes1 associated transcriptional regulator Homo sapiens 143-146 33992804-8 2021 Collectively, our study uncovers simvastatin as a potential therapeutic drug for immunotherapy in CRC, which suppresses lncRNA SNHG29 mediated YAP activation and promotes anti-tumor immunity by inhibiting PD-L1 expression. Simvastatin 33-44 CD274 molecule Homo sapiens 205-210 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-71 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-78 33002367-4 2021 Therefore, the aim of the present study was to explore the modulatory effect of simvastatin (10 mg/kg/day) before and after the development of neurodegeneration (for 55 and 25 days, respectively) on redox state, caspase-3 expression, p-protein kinase B (p-Akt) and brain derived neurotrophic factor (BDNF) in ethanol (15% ethanol solution for 55 day) induced neurodegeneration. Simvastatin 80-91 caspase 3 Mus musculus 212-221 33548270-14 2021 Furthermore, in the simvastatin group, the hippocampal level of caspase-3 and the level of Iba1-positive cells, reduced (P<0.01). Simvastatin 20-31 caspase 3 Rattus norvegicus 64-73 33548270-10 2021 An ELISA assay was performed to investigate the antioxidant and anti-inflammatory effects of simvastatin by measuring the levels of tumor necrosis factor-alpha (TNF-alpha), and antioxidant enzymes. Simvastatin 93-104 tumor necrosis factor Rattus norvegicus 161-170 33548270-11 2021 To assess the expression levels of Iba1 immunohistochemical staining and caspase-3 immunofluorescence staining was performed.The current study demonstrated that administration of simvastatin significantly attenuates spatial memory impairment (P< 0.01) after ethanol neurotoxicity. Simvastatin 179-190 allograft inflammatory factor 1 Rattus norvegicus 35-39 33548270-14 2021 Furthermore, in the simvastatin group, the hippocampal level of caspase-3 and the level of Iba1-positive cells, reduced (P<0.01). Simvastatin 20-31 allograft inflammatory factor 1 Rattus norvegicus 91-95 33548270-11 2021 To assess the expression levels of Iba1 immunohistochemical staining and caspase-3 immunofluorescence staining was performed.The current study demonstrated that administration of simvastatin significantly attenuates spatial memory impairment (P< 0.01) after ethanol neurotoxicity. Simvastatin 179-190 caspase 3 Rattus norvegicus 73-82 33864447-3 2021 METHODS: Apolipoprotein E knockout (ApoE-/-) mice were administered with simvastatin (20 mg/kg/day) for 8 weeks. Simvastatin 73-84 apolipoprotein E Mus musculus 9-25 33967756-9 2021 Meanwhile, SV increased the systemic exposure of geniposide via inhibiting the activity of P-gp in both healthy and NASH rats. Simvastatin 11-13 phosphoglycolate phosphatase Rattus norvegicus 91-95 33923431-0 2021 PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. Simvastatin 94-105 proprotein convertase subtilisin/kexin type 9 Rattus norvegicus 0-5 33923431-9 2021 Finally, concentration-dependent experiments with simvastatin demonstrated that SMCsPCSK9 were partially resistant to the antiproliferative and antimigratory effect of this drug. Simvastatin 50-61 dymeclin Homo sapiens 80-89 33272595-10 2021 RESULTS: OE33 and FLO1 cells demonstrated decreased TLR4 expression after treatment with simvastatin or atorvastatin for 8 h (P < 0.05). Simvastatin 89-100 toll like receptor 4 Homo sapiens 52-56 34040513-9 2021 The most common medications coprescribed with DPP4is over all person-quarters were acetaminophen, simvastatin, fluvastatin, and colchicine (all >20,000 person-quarters). Simvastatin 98-109 dipeptidyl peptidase 4 Homo sapiens 46-50 33837531-4 2021 In EUR, N-acetyltransferase 2 (NAT2) metabolizer phenotype and activity score were associated with simvastatin use. Simvastatin 99-110 N-acetyltransferase 2 Homo sapiens 8-29 33837531-4 2021 In EUR, N-acetyltransferase 2 (NAT2) metabolizer phenotype and activity score were associated with simvastatin use. Simvastatin 99-110 N-acetyltransferase 2 Homo sapiens 31-35 33837531-5 2021 The dose of NAT2*1 was associated with simvastatin use when compared to NAT2*5 (the most common haplotype). Simvastatin 39-50 N-acetyltransferase 2 Homo sapiens 12-16 33437096-7 2021 Electrophysiological studies performed in our laboratory showed that statins: pravastatin, mevastatin and simvastatin are effective inhibitors of Kv1.3 channels in cancer cells of human T cell line Jurkat. Simvastatin 106-117 potassium voltage-gated channel subfamily A member 3 Homo sapiens 146-151 33846297-0 2021 Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles. Simvastatin 0-11 superoxide dismutase 1, soluble Mus musculus 45-49 33846297-0 2021 Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles. Simvastatin 0-11 RAB7, member RAS oncogene family Mus musculus 78-82 33846297-3 2021 However, our previous evidence has demonstrated that simvastatin leads to cytotoxicity in NSC34-hSOD1G93A cells by aggravating the impairment of autophagic flux, but the role of simvastatin in ALS model remains elusive. Simvastatin 53-64 superoxide dismutase 1 Homo sapiens 96-101 33846297-4 2021 In present study, we reported that after simvastatin treatment, SOD1G93A mice showed early onset of the disease phenotype and shortened life span, with aggravated autophagic flux impairment and increased aggregation of SOD1 protein in spinal cord motoneurons (MNs) of SOD1G93A mice. Simvastatin 41-52 superoxide dismutase 1, soluble Mus musculus 64-68 33846297-4 2021 In present study, we reported that after simvastatin treatment, SOD1G93A mice showed early onset of the disease phenotype and shortened life span, with aggravated autophagic flux impairment and increased aggregation of SOD1 protein in spinal cord motoneurons (MNs) of SOD1G93A mice. Simvastatin 41-52 superoxide dismutase 1, soluble Mus musculus 219-223 33846297-4 2021 In present study, we reported that after simvastatin treatment, SOD1G93A mice showed early onset of the disease phenotype and shortened life span, with aggravated autophagic flux impairment and increased aggregation of SOD1 protein in spinal cord motoneurons (MNs) of SOD1G93A mice. Simvastatin 41-52 superoxide dismutase 1, soluble Mus musculus 219-223 33846297-5 2021 In addition, simvastatin repressed the ability of Rab7 localization on the membrane by inhibiting isoprenoid synthesis, leading to impaired late stage of autophagic flux rather than initiation. Simvastatin 13-24 RAB7, member RAS oncogene family Mus musculus 50-54 33846297-6 2021 This study suggested that simvastatin significantly worsened impairment of late autophagic flux, resulting in massive MNs death in spinal cord and accelerated disease progression of SOD1G93A mice. Simvastatin 26-37 superoxide dismutase 1, soluble Mus musculus 182-186 31924353-8 2021 Expression levels of TLR4-induced nuclear factor kappa light chain enhancer of activated B cells (NF-kappaB) and TLR4 expression were assessed after treatment with simvastatin. Simvastatin 164-175 toll like receptor 4 Homo sapiens 21-25 33272595-14 2021 CONCLUSIONS: Treatment of EAC cells with simvastatin or atorvastatin decreases TLR4-mediated proliferation and in vivo tumor growth. Simvastatin 41-52 toll-like receptor 4 Mus musculus 79-83 31924353-10 2021 RESULTS: Simvastatin decreased LPS-induced ALP and Runx2 expression and inhibited in vitro calcium deposition in aortic valve interstitial cells. Simvastatin 9-20 RUNX family transcription factor 2 Homo sapiens 51-56 33742146-11 2021 Experiments in xenografts and in patients treated with Simvastatin confirm statin-mediated BMP pathway activation, activation of PTEN and downregulation of mTOR signalling. Simvastatin 55-66 phosphatase and tensin homolog Homo sapiens 129-133 31924353-12 2021 Simvastatin attenuated TLR4-dependent NF-kappaB signaling and down-regulated TLR4 levels. Simvastatin 0-11 toll like receptor 4 Homo sapiens 23-27 31924353-12 2021 Simvastatin attenuated TLR4-dependent NF-kappaB signaling and down-regulated TLR4 levels. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 38-47 31924353-12 2021 Simvastatin attenuated TLR4-dependent NF-kappaB signaling and down-regulated TLR4 levels. Simvastatin 0-11 toll like receptor 4 Homo sapiens 77-81 31924353-13 2021 CONCLUSIONS: Simvastatin prevented TLR4-induced osteogenic phenotypic changes in isolated aortic valve interstitial cells via down-regulation of TLR4 and inhibition of NF-kappaB signaling. Simvastatin 13-24 toll like receptor 4 Homo sapiens 35-39 31924353-13 2021 CONCLUSIONS: Simvastatin prevented TLR4-induced osteogenic phenotypic changes in isolated aortic valve interstitial cells via down-regulation of TLR4 and inhibition of NF-kappaB signaling. Simvastatin 13-24 toll like receptor 4 Homo sapiens 145-149 31924353-13 2021 CONCLUSIONS: Simvastatin prevented TLR4-induced osteogenic phenotypic changes in isolated aortic valve interstitial cells via down-regulation of TLR4 and inhibition of NF-kappaB signaling. Simvastatin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 168-177 33222146-0 2021 Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice. Simvastatin 0-11 mechanistic target of rapamycin kinase Mus musculus 93-97 33222146-8 2021 Nevertheless, long-term simvastatin treatment promoted the regeneration of damaged muscle by activating the mammalian target of rapamycin pathway. Simvastatin 24-35 mechanistic target of rapamycin kinase Homo sapiens 108-137 33755856-11 2021 It could be concluded that the co-administration of SV and SD offers a neuroprotective effect against irradiation-induced brain injury due to its NO donor/BH4 regulatory activities, anti-inflammatory and antioxidant properties that modulate IDO/KYN pathway. Simvastatin 52-54 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 241-244 33897882-10 2021 Importantly, targeting MYBL2, or treatment with either the YAP/TAZ inhibitor Verteporfin or the RhoA inhibitor Simvastatin, reversed the resistance to ADT and blocked bone metastasis in CRPC cells. Simvastatin 111-122 ras homolog family member A Homo sapiens 96-100 33742146-11 2021 Experiments in xenografts and in patients treated with Simvastatin confirm statin-mediated BMP pathway activation, activation of PTEN and downregulation of mTOR signalling. Simvastatin 55-66 mechanistic target of rapamycin kinase Homo sapiens 156-160 33711324-11 2021 Simvastatin inhibited POVPC-induced EndMT by decreasing oxidative stress, suppressing TGF-beta/Smad signaling, and inactivating Snail-1 and Twist-1. Simvastatin 0-11 transforming growth factor alpha Homo sapiens 86-94 33721286-6 2021 Simvastatin also downregulated miR-33a expression. Simvastatin 0-11 microRNA 33a Homo sapiens 31-38 33711324-11 2021 Simvastatin inhibited POVPC-induced EndMT by decreasing oxidative stress, suppressing TGF-beta/Smad signaling, and inactivating Snail-1 and Twist-1. Simvastatin 0-11 snail family transcriptional repressor 1 Homo sapiens 128-135 33711324-11 2021 Simvastatin inhibited POVPC-induced EndMT by decreasing oxidative stress, suppressing TGF-beta/Smad signaling, and inactivating Snail-1 and Twist-1. Simvastatin 0-11 twist family bHLH transcription factor 1 Homo sapiens 140-147 33594363-0 2021 Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. Simvastatin 88-99 nucleocapsid phosphoprotein Severe acute respiratory syndrome coronavirus 2 53-65 33705623-16 2021 The addition of 40 mg simvastatin may improve the efficacy of FAC in LABC patients with HER-2 overexpression. Simvastatin 22-33 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-93 32779819-5 2021 Simvastatin induced apoptotic cell death via activation of caspase-3 and cell cycle arrest. Simvastatin 0-11 caspase 3 Canis lupus familiaris 59-68 33554328-3 2021 Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. Simvastatin 10-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-83 32853776-7 2021 Ezetimibe is known to inhibit cholesterol absorption by blocking the activity of Niemann-Pick C1 like 1 (NPC1L1) protein, and simvastatin is known to enhance NPC1L1 expression in the human body"s small intestine. Simvastatin 126-137 NPC1 like intracellular cholesterol transporter 1 Homo sapiens 158-164 33119943-8 2021 In the small intestine of HFHC-NASH rats, thicker intestinal wall with more collagen fibers, increased Ces1 activity, and up-regulated P-gp protein would decrease the permeability of simvastatin, accelerate the hydrolysis of simvastatin, and promote the efflux of simvastatin acid, respectively. Simvastatin 183-194 phosphoglycolate phosphatase Rattus norvegicus 135-139 33119943-8 2021 In the small intestine of HFHC-NASH rats, thicker intestinal wall with more collagen fibers, increased Ces1 activity, and up-regulated P-gp protein would decrease the permeability of simvastatin, accelerate the hydrolysis of simvastatin, and promote the efflux of simvastatin acid, respectively. Simvastatin 225-236 phosphoglycolate phosphatase Rattus norvegicus 135-139 33119943-9 2021 In the liver of HFHC-NASH rats, higher hepatic P-gp expression accelerated the hepatic elimination of simvastatin. Simvastatin 102-113 phosphoglycolate phosphatase Rattus norvegicus 47-51 33093072-0 2021 Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo. Simvastatin 28-39 VAMAS6 Homo sapiens 74-82 33093072-2 2021 The purpose of this study is to analyze the clinical efficacy of simvastatin in the treatment of vitiligo. Simvastatin 65-76 VAMAS6 Homo sapiens 97-105 33093072-3 2021 From December 2016 to October 2019, five vitiligo patients from Peking Union Medical College Hospital were treated with simvastatin and tacrolimus. Simvastatin 120-131 VAMAS6 Homo sapiens 41-49 33597925-0 2020 Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves" Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways. Simvastatin 0-11 ras homolog family member A Homo sapiens 135-139 33597925-0 2020 Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves" Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 149-152 33597925-0 2020 Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves" Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 157-160 33597925-3 2020 Both simvastatin and Y-27632 inhibited TGF-beta-induced alpha-smooth muscle actin (alpha-SMA) expression, which serves as a marker of fibrosis. Simvastatin 5-16 transforming growth factor alpha Homo sapiens 39-47 33597925-3 2020 Both simvastatin and Y-27632 inhibited TGF-beta-induced alpha-smooth muscle actin (alpha-SMA) expression, which serves as a marker of fibrosis. Simvastatin 5-16 actin alpha 1, skeletal muscle Homo sapiens 83-92 33597925-4 2020 The inhibitory effect of simvastatin on TGF-beta-induced RhoA, ROCK1, and alpha-SMA expression could be reversed by geranylgeranyl pyrophosphate, an intermediate in the biosynthesis of cholesterol. Simvastatin 25-36 transforming growth factor alpha Homo sapiens 40-48 33597925-4 2020 The inhibitory effect of simvastatin on TGF-beta-induced RhoA, ROCK1, and alpha-SMA expression could be reversed by geranylgeranyl pyrophosphate, an intermediate in the biosynthesis of cholesterol. Simvastatin 25-36 ras homolog family member A Homo sapiens 57-61 33597925-4 2020 The inhibitory effect of simvastatin on TGF-beta-induced RhoA, ROCK1, and alpha-SMA expression could be reversed by geranylgeranyl pyrophosphate, an intermediate in the biosynthesis of cholesterol. Simvastatin 25-36 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 63-68 33597925-4 2020 The inhibitory effect of simvastatin on TGF-beta-induced RhoA, ROCK1, and alpha-SMA expression could be reversed by geranylgeranyl pyrophosphate, an intermediate in the biosynthesis of cholesterol. Simvastatin 25-36 actin alpha 1, skeletal muscle Homo sapiens 74-83 33597925-5 2020 This suggested that the mechanism of simvastatin-mediated antifibrotic effects may involve RhoA/ROCK signaling. Simvastatin 37-48 ras homolog family member A Homo sapiens 91-95 33597925-6 2020 Furthermore, simvastatin and Y-27632 suppressed TGF-beta-induced phosphorylation of ERK and p38. Simvastatin 13-24 transforming growth factor alpha Homo sapiens 48-56 33597925-6 2020 Furthermore, simvastatin and Y-27632 suppressed TGF-beta-induced phosphorylation of ERK and p38. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 84-87 33597925-6 2020 Furthermore, simvastatin and Y-27632 suppressed TGF-beta-induced phosphorylation of ERK and p38. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 92-95 33597925-8 2020 These results suggested that simvastatin inhibits TGF-beta-induced myofibroblast differentiation via suppression of the RhoA/ROCK/ERK and p38 MAPK signaling pathways. Simvastatin 29-40 transforming growth factor alpha Homo sapiens 50-58 33597925-8 2020 These results suggested that simvastatin inhibits TGF-beta-induced myofibroblast differentiation via suppression of the RhoA/ROCK/ERK and p38 MAPK signaling pathways. Simvastatin 29-40 ras homolog family member A Homo sapiens 120-124 33597925-8 2020 These results suggested that simvastatin inhibits TGF-beta-induced myofibroblast differentiation via suppression of the RhoA/ROCK/ERK and p38 MAPK signaling pathways. Simvastatin 29-40 mitogen-activated protein kinase 1 Homo sapiens 130-133 33394312-8 2021 In addition, the regulatory role of simvastatin in Smad7, TGFBR1 and Smad2/3 was investigated. Simvastatin 36-47 SMAD family member 7 Rattus norvegicus 51-56 33394312-9 2021 Simvastatin treatment improved hemodynamic condition, myocardial tissue remodeling, and myocardial energy metabolism, as well as increasing calmodulin expression in rats with PAH-induced RHF. Simvastatin 0-11 calmodulin 1 Rattus norvegicus 140-150 33394312-10 2021 After simvastatin treatment, the expression of miR-21-5p in myocardium of rats was decreased significantly. Simvastatin 6-17 microRNA 215 Rattus norvegicus 47-56 33394312-12 2021 Compared with RHF rats, the expressions of TGFBR1 and Smad2/3 in myocardium of simvastatin-treated rats were decreased significantly. Simvastatin 79-90 transforming growth factor, beta receptor 1 Rattus norvegicus 43-49 33394312-12 2021 Compared with RHF rats, the expressions of TGFBR1 and Smad2/3 in myocardium of simvastatin-treated rats were decreased significantly. Simvastatin 79-90 SMAD family member 2 Rattus norvegicus 54-61 33394312-13 2021 Collectively, we provided evidence that simvastatin can protect ATPase activity and maintain myocardial ATP energy reserve through the miR-21-5p/Smad/TGF-beta axis, thus ameliorating PAH induced RHF. Simvastatin 40-51 microRNA 215 Rattus norvegicus 135-144 33394312-13 2021 Collectively, we provided evidence that simvastatin can protect ATPase activity and maintain myocardial ATP energy reserve through the miR-21-5p/Smad/TGF-beta axis, thus ameliorating PAH induced RHF. Simvastatin 40-51 transforming growth factor alpha Rattus norvegicus 150-158 33183460-7 2021 After 24 hours of administration, the data shows that simvastatin-NLCs inhibit the levels of IL-6 and TNF-alpha inflammatory factor in the lungs of mice. Simvastatin 54-65 interleukin 6 Mus musculus 93-97 33183460-7 2021 After 24 hours of administration, the data shows that simvastatin-NLCs inhibit the levels of IL-6 and TNF-alpha inflammatory factor in the lungs of mice. Simvastatin 54-65 tumor necrosis factor Mus musculus 102-111 33575165-14 2021 Conclusions: Topical administration of simvastatin induces entochondrostosis and intramembranous ossification by enhancing expression of BMP-2 and HIF-1 alpha. Simvastatin 39-50 bone morphogenetic protein 2 Oryctolagus cuniculus 137-142 33517812-0 2021 Simvastatin suppresses renal cell carcinoma cells by regulating DDX5/DUSP5. Simvastatin 0-11 DEAD-box helicase 5 Homo sapiens 64-68 33517812-0 2021 Simvastatin suppresses renal cell carcinoma cells by regulating DDX5/DUSP5. Simvastatin 0-11 dual specificity phosphatase 5 Homo sapiens 69-74 33517812-7 2021 Mechanistic investigation showed that simvastatin significantly suppressed DDX5 and promoted DUSP5 expression. Simvastatin 38-49 DEAD-box helicase 5 Homo sapiens 75-79 33517812-7 2021 Mechanistic investigation showed that simvastatin significantly suppressed DDX5 and promoted DUSP5 expression. Simvastatin 38-49 dual specificity phosphatase 5 Homo sapiens 93-98 33517812-8 2021 CONCLUSION: Together, these results provide a novel mechanism underlying simvastatin-induced inhibition of RCC via regulation of the DDX5/DUSP5 axis. Simvastatin 73-84 DEAD-box helicase 5 Homo sapiens 133-137 33517812-8 2021 CONCLUSION: Together, these results provide a novel mechanism underlying simvastatin-induced inhibition of RCC via regulation of the DDX5/DUSP5 axis. Simvastatin 73-84 dual specificity phosphatase 5 Homo sapiens 138-143 33575165-14 2021 Conclusions: Topical administration of simvastatin induces entochondrostosis and intramembranous ossification by enhancing expression of BMP-2 and HIF-1 alpha. Simvastatin 39-50 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 147-158 33423318-5 2021 RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations. Simvastatin 160-171 microtubule associated protein 1 light chain 3 alpha Homo sapiens 99-102 33459228-7 2021 The statins like Simvastatin, Lovastatin, and Atorvastatin are substrates of CYP3A4 enzyme and P-glycoprotein and their concomitant use with the drugs inhibiting or inducing them would result in changes in plasma concentrations and toxicity/efficacy. Simvastatin 17-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 33459228-7 2021 The statins like Simvastatin, Lovastatin, and Atorvastatin are substrates of CYP3A4 enzyme and P-glycoprotein and their concomitant use with the drugs inhibiting or inducing them would result in changes in plasma concentrations and toxicity/efficacy. Simvastatin 17-28 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 33542676-0 2021 Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves" Ophthalmopathy through the Regulation of FoxO3a Signaling. Simvastatin 0-11 cellular communication network factor 1 Homo sapiens 21-26 33542676-0 2021 Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves" Ophthalmopathy through the Regulation of FoxO3a Signaling. Simvastatin 0-11 forkhead box O3 Homo sapiens 113-119 33542676-11 2021 The data revealed that simvastatin could inhibit TNF-alpha-induced CYR61 expression by modulating the activity of transcription factor FoxO3a. Simvastatin 23-34 tumor necrosis factor Homo sapiens 49-58 33542676-11 2021 The data revealed that simvastatin could inhibit TNF-alpha-induced CYR61 expression by modulating the activity of transcription factor FoxO3a. Simvastatin 23-34 cellular communication network factor 1 Homo sapiens 67-72 33542676-11 2021 The data revealed that simvastatin could inhibit TNF-alpha-induced CYR61 expression by modulating the activity of transcription factor FoxO3a. Simvastatin 23-34 forkhead box O3 Homo sapiens 135-141 33452755-4 2021 Here, we found that simvastatin decreased polyinosinic-polycytidylic acid [poly(I:C)]-induced expression of antiviral interferon (IFN)-beta and IFN-stimulated genes (ISGs) in the bronchoalveolar lavage fluid (BALF) and lungs of mice with high-fat diet-induced hyperlipidemia. Simvastatin 20-31 interferon alpha Mus musculus 118-139 33452755-6 2021 We examined the effects of simvastatin in primary lung macrophages and found that simvastatin suppressed poly(I:C)-induced expression of IFN-beta and ISGs. Simvastatin 82-93 interferon alpha Mus musculus 137-145 33452755-8 2021 Simvastatin and pitavastatin decreased poly(I:C)-induced expression of IFN-beta and ISGs. Simvastatin 0-11 interferon alpha Mus musculus 71-79 33466887-9 2021 Indeed, the ability of simvastatin to down regulate VEGFR2 and inhibit VEGF activity suggest a potential mechanism underlying the observation that this drug improves outcomes in the treatment of certain cancers. Simvastatin 23-34 kinase insert domain receptor Homo sapiens 52-58 33466887-9 2021 Indeed, the ability of simvastatin to down regulate VEGFR2 and inhibit VEGF activity suggest a potential mechanism underlying the observation that this drug improves outcomes in the treatment of certain cancers. Simvastatin 23-34 vascular endothelial growth factor A Homo sapiens 52-56 33423318-5 2021 RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations. Simvastatin 160-171 nucleoporin 62 Homo sapiens 132-135 33423318-5 2021 RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations. Simvastatin 160-171 interleukin 10 Homo sapiens 213-218 33423318-5 2021 RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations. Simvastatin 160-171 interleukin 4 Homo sapiens 231-235 33423318-6 2021 In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages. Simvastatin 40-51 beclin 1 Homo sapiens 145-153 33423318-6 2021 In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages. Simvastatin 40-51 microtubule associated protein 1 light chain 3 alpha Homo sapiens 158-161 33423318-6 2021 In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages. Simvastatin 40-51 nucleoporin 62 Homo sapiens 196-199 33423318-6 2021 In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages. Simvastatin 40-51 interleukin 10 Homo sapiens 228-233 33423318-8 2021 Neutralisation of IL-10 with recombinant specific blocking antibody and silencing IL-10 transcription reversed the inhibitory effects of budesonide and simvastatin on macrophage autophagy. Simvastatin 152-163 interleukin 10 Homo sapiens 18-23 33423318-8 2021 Neutralisation of IL-10 with recombinant specific blocking antibody and silencing IL-10 transcription reversed the inhibitory effects of budesonide and simvastatin on macrophage autophagy. Simvastatin 152-163 interleukin 10 Homo sapiens 82-87 32495222-12 2021 The MTT assay presented significant effects with MCT1 and 4 inhibition (simvastatin/AR-C122982/CHC: p < 0.007). Simvastatin 72-83 solute carrier family 16 member 1 Homo sapiens 49-59 33280091-4 2021 Here, a whole-body PBPK network of simvastatin was established, including three polymorphisms (SLCO1B1 (rs4149056), ABCG2 (rs2231142), and CYP3A5 (rs776746)) and four perpetrator drugs (clarithromycin, gemfibrozil, itraconazole, and rifampicin). Simvastatin 35-46 solute carrier organic anion transporter family member 1B1 Homo sapiens 95-102 33280091-4 2021 Here, a whole-body PBPK network of simvastatin was established, including three polymorphisms (SLCO1B1 (rs4149056), ABCG2 (rs2231142), and CYP3A5 (rs776746)) and four perpetrator drugs (clarithromycin, gemfibrozil, itraconazole, and rifampicin). Simvastatin 35-46 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 139-145 33161769-12 2021 Simvastatin-associated reports showed signals for higher objective muscular AEs relative to all other statins (ROR 1.53, 95% CI: 1.49-1.58). Simvastatin 0-11 receptor tyrosine kinase like orphan receptor 1 Homo sapiens 111-116 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 21-28 TNF receptor superfamily member 11b Homo sapiens 51-54 33356546-0 2021 Effect of ABCG1 gene DNA methylations on the lipid-lowering efficacy of simvastatin. Simvastatin 72-83 ATP binding cassette subfamily G member 1 Homo sapiens 10-15 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 21-28 TNF receptor superfamily member 11b Homo sapiens 174-177 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 21-28 TNF receptor superfamily member 11b Homo sapiens 174-177 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 73-80 TNF receptor superfamily member 11b Homo sapiens 51-54 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 73-80 TNF receptor superfamily member 11b Homo sapiens 51-54 31971101-8 2021 Considering that the statins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins could be suggested as illustration of the role of OPG in the bone/vessels crosstalk, if further studies consolidate the contribution of OPG to the cardioprotective role of statins. Simvastatin 73-80 TNF receptor superfamily member 11b Homo sapiens 51-54 33314684-0 2021 Local delivery of simvastatin maintains tooth anchorage during mechanical tooth moving via anti-inflammation property and AMPK/MAPK/NF-kB inhibition. Simvastatin 18-29 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 122-126 33314684-0 2021 Local delivery of simvastatin maintains tooth anchorage during mechanical tooth moving via anti-inflammation property and AMPK/MAPK/NF-kB inhibition. Simvastatin 18-29 RELA proto-oncogene, NF-kB subunit Rattus norvegicus 132-137 33314684-10 2021 Moreover, AMPK activation induced by SMV delivery significantly attenuated the osteoclastogenesis and decreased the expression of pro-inflammatory TNF-alpha and NF-kappaB in a rodent model of OTM. Simvastatin 37-40 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 10-14 33314684-10 2021 Moreover, AMPK activation induced by SMV delivery significantly attenuated the osteoclastogenesis and decreased the expression of pro-inflammatory TNF-alpha and NF-kappaB in a rodent model of OTM. Simvastatin 37-40 tumor necrosis factor Rattus norvegicus 147-156 33356546-1 2021 Aim: We investigated the effect of ABCG1 gene DNA methylation in the lipid-lowering efficacy of simvastatin. Simvastatin 96-107 ATP binding cassette subfamily G member 1 Homo sapiens 35-40 33356546-7 2021 Conclusion: DNA methylations at the ABCG1 gene play significant inhibitory effects in the lipid-lowering therapy of simvastatin. Simvastatin 116-127 ATP binding cassette subfamily G member 1 Homo sapiens 36-41 33719747-1 2021 Inhalable nanostructured microparticles of simvastatin, a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor, were rationally designed for targeted pulmonary delivery as dry powder inhalers (DPIs) for the treatment of pulmonary hypertension (PH). Simvastatin 43-54 NFE2 like bZIP transcription factor 2 Homo sapiens 58-62 33408770-0 2021 Endothelial Klf2-Foxp1-TGFbeta signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Simvastatin 73-84 Kruppel-like factor 2 (lung) Mus musculus 12-16 33719747-1 2021 Inhalable nanostructured microparticles of simvastatin, a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor, were rationally designed for targeted pulmonary delivery as dry powder inhalers (DPIs) for the treatment of pulmonary hypertension (PH). Simvastatin 43-54 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 82-92 33408770-0 2021 Endothelial Klf2-Foxp1-TGFbeta signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Simvastatin 73-84 forkhead box P1 Mus musculus 17-22 33408770-0 2021 Endothelial Klf2-Foxp1-TGFbeta signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Simvastatin 73-84 transforming growth factor alpha Mus musculus 23-30 33424602-7 2020 Omeprazole, a CYP2C19 inhibitor, and simvastatin, a CES1 and CES2 inhibitor, showed weak impact on the pharmacokinetics and pharmacodynamics of vicagrel. Simvastatin 37-48 carboxylesterase 1 Homo sapiens 52-56 33408770-3 2021 Simvastatin, a strong inducer of Kruppel-like Factor 2 (Klf2) in ECs, ameliorates pressure overload induced maladaptive cardiac remodeling and dysfunction. Simvastatin 0-11 Kruppel-like factor 2 (lung) Mus musculus 33-54 33408770-3 2021 Simvastatin, a strong inducer of Kruppel-like Factor 2 (Klf2) in ECs, ameliorates pressure overload induced maladaptive cardiac remodeling and dysfunction. Simvastatin 0-11 Kruppel-like factor 2 (lung) Mus musculus 56-60 33408770-6 2021 Mechanism studies showed that EC-Klf2 inhibition reversed the simvastatin-mediated reduction of fibroblast proliferation and myofibroblast formation, as well as cardiomyocyte size and cardiac hypertrophic genes, which suggested that EC-Klf2 might mediate the anti-fibrotic and anti-hypertrophy effects of simvastatin. Simvastatin 62-73 Kruppel-like factor 2 (lung) Mus musculus 33-37 33408770-6 2021 Mechanism studies showed that EC-Klf2 inhibition reversed the simvastatin-mediated reduction of fibroblast proliferation and myofibroblast formation, as well as cardiomyocyte size and cardiac hypertrophic genes, which suggested that EC-Klf2 might mediate the anti-fibrotic and anti-hypertrophy effects of simvastatin. Simvastatin 62-73 Kruppel-like factor 2 (lung) Mus musculus 236-240 33408770-6 2021 Mechanism studies showed that EC-Klf2 inhibition reversed the simvastatin-mediated reduction of fibroblast proliferation and myofibroblast formation, as well as cardiomyocyte size and cardiac hypertrophic genes, which suggested that EC-Klf2 might mediate the anti-fibrotic and anti-hypertrophy effects of simvastatin. Simvastatin 305-316 Kruppel-like factor 2 (lung) Mus musculus 33-37 33408770-6 2021 Mechanism studies showed that EC-Klf2 inhibition reversed the simvastatin-mediated reduction of fibroblast proliferation and myofibroblast formation, as well as cardiomyocyte size and cardiac hypertrophic genes, which suggested that EC-Klf2 might mediate the anti-fibrotic and anti-hypertrophy effects of simvastatin. Simvastatin 305-316 Kruppel-like factor 2 (lung) Mus musculus 236-240 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 103-114 Kruppel-like factor 2 (lung) Mus musculus 10-14 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 103-114 transforming growth factor, beta 1 Mus musculus 48-56 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 103-114 transforming growth factor, beta 1 Mus musculus 173-181 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 193-204 Kruppel-like factor 2 (lung) Mus musculus 10-14 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 193-204 Kruppel-like factor 2 (lung) Mus musculus 137-141 33408770-8 2021 Moreover, Klf2 regulated its direct target gene TGFbeta1 in ECs and mediated the protective effects of simvastatin, and inhibition of EC-Klf2 increased the expression of EC-TGFbeta1 leading to simvastatin losing its protective effects. Simvastatin 193-204 transforming growth factor, beta 1 Mus musculus 173-181 33408770-9 2021 Also, EC-Klf2 was found to regulate EC-Foxp1 and loss of EC-Foxp1 attenuated the protective effects of simvastatin similar to EC-Klf2 inhibition. Simvastatin 103-114 Kruppel-like factor 2 (lung) Mus musculus 9-13 33408770-9 2021 Also, EC-Klf2 was found to regulate EC-Foxp1 and loss of EC-Foxp1 attenuated the protective effects of simvastatin similar to EC-Klf2 inhibition. Simvastatin 103-114 forkhead box P1 Mus musculus 60-65 33408770-10 2021 Conclusions: We conclude that cardiac microvasculature ECs are important in the modulation of pressure overload induced maladaptive cardiac remodeling and dysfunction, and the endothelial Klf2-TGFbeta1 or Klf2-Foxp1-TGFbeta1 pathway mediates the preventive effects of simvastatin. Simvastatin 268-279 Kruppel-like factor 2 (lung) Mus musculus 188-192 33349105-0 2020 The protective effects of simvastatin in Cadmium-Induced preosteoblast injury through Nox4. Simvastatin 26-37 NADPH oxidase 4 Mus musculus 86-90 33349105-12 2020 Simvastatin increased the cell viability, relieved the cell apoptosis and Nox4 expression previously increased by CdCl2. Simvastatin 0-11 NADPH oxidase 4 Mus musculus 74-78 33349105-13 2020 The effects of CdCl2 on MC3T3-E1 cells and Nox4 expression could be attenuated by simvastatin, and promoted by Nox4 overexpression. Simvastatin 82-93 NADPH oxidase 4 Mus musculus 43-47 33349105-14 2020 The current study found that simvastatin protects Cd-induced preosteoblast injury via Nox4, thus, it can be used as a potential drug for treating cadmium-induced bone injury. Simvastatin 29-40 NADPH oxidase 4 Mus musculus 86-90 33327440-0 2020 Redox Regulation of Microvascular Permeability: IL-1beta Potentiation of Bradykinin-Induced Permeability Is Prevented by Simvastatin. Simvastatin 121-132 interleukin 1 alpha Rattus norvegicus 48-56 33327440-11 2020 This study highlights a novel mechanism by which simvastatin prevents the potentiation of bradykinin-induced permeability by IL-1beta, possibly by targeting the assembly of NADPH oxidase subunits. Simvastatin 49-60 interleukin 1 alpha Rattus norvegicus 125-133 33424602-7 2020 Omeprazole, a CYP2C19 inhibitor, and simvastatin, a CES1 and CES2 inhibitor, showed weak impact on the pharmacokinetics and pharmacodynamics of vicagrel. Simvastatin 37-48 carboxylesterase 2 Homo sapiens 61-65 32562563-0 2020 Involvement of H2 S, NO and BDNF-TrkB signalling pathway in the protective effects of simvastatin against pentylenetetrazole-induced kindling and cognitive impairments. Simvastatin 86-97 brain derived neurotrophic factor Mus musculus 28-32 33242792-9 2020 Simvastatin reduced ANGPTL3 mRNA expression and ANGPTL3 secretion of Huh7 cells. Simvastatin 0-11 angiopoietin like 3 Homo sapiens 20-27 33242792-9 2020 Simvastatin reduced ANGPTL3 mRNA expression and ANGPTL3 secretion of Huh7 cells. Simvastatin 0-11 angiopoietin like 3 Homo sapiens 48-55 33242792-11 2020 Adding simvastatin did not mitigate this effect but adding the LXR antagonist GSK2230 to simvastatin-incubated Huh7 cells diminished simvastatin-induced reductions in ANGPTL3 mRNA expression and ANGPTL3 secretion. Simvastatin 89-100 angiopoietin like 3 Homo sapiens 167-174 33242792-11 2020 Adding simvastatin did not mitigate this effect but adding the LXR antagonist GSK2230 to simvastatin-incubated Huh7 cells diminished simvastatin-induced reductions in ANGPTL3 mRNA expression and ANGPTL3 secretion. Simvastatin 89-100 angiopoietin like 3 Homo sapiens 195-202 33242792-11 2020 Adding simvastatin did not mitigate this effect but adding the LXR antagonist GSK2230 to simvastatin-incubated Huh7 cells diminished simvastatin-induced reductions in ANGPTL3 mRNA expression and ANGPTL3 secretion. Simvastatin 89-100 angiopoietin like 3 Homo sapiens 167-174 32562563-0 2020 Involvement of H2 S, NO and BDNF-TrkB signalling pathway in the protective effects of simvastatin against pentylenetetrazole-induced kindling and cognitive impairments. Simvastatin 86-97 neurotrophic tyrosine kinase, receptor, type 2 Mus musculus 33-37 33242792-11 2020 Adding simvastatin did not mitigate this effect but adding the LXR antagonist GSK2230 to simvastatin-incubated Huh7 cells diminished simvastatin-induced reductions in ANGPTL3 mRNA expression and ANGPTL3 secretion. Simvastatin 89-100 angiopoietin like 3 Homo sapiens 195-202 33242792-13 2020 Oxysterols are endogenous LXR ligands, implying that simvastatin suppresses ANGPTL3 secretion via reduced oxysterol-mediated LXR activation. Simvastatin 53-64 angiopoietin like 3 Homo sapiens 76-83 32562563-11 2020 These results suggested that SIM triggers multiple mechanisms that improve cognitive function in PTZ-kindled mice through modulation of oxidative stress, H2 S, NO and BDNF-TrkB signalling pathway. Simvastatin 29-32 brain derived neurotrophic factor Mus musculus 167-171 32562563-11 2020 These results suggested that SIM triggers multiple mechanisms that improve cognitive function in PTZ-kindled mice through modulation of oxidative stress, H2 S, NO and BDNF-TrkB signalling pathway. Simvastatin 29-32 neurotrophic tyrosine kinase, receptor, type 2 Mus musculus 172-176 33030783-5 2020 Here, we found that simvastatin treatment effectively promoted anti-proliferative effects and modulated lipid metabolism-related pathways in non-small cell lung cancer (NSCLC) cells, and that the anti-proliferative effects of statins were potentiated by overexpression of acyl-CoA synthetase long chain family member 3 (ACSL3). Simvastatin 20-31 acyl-CoA synthetase long chain family member 3 Homo sapiens 272-318 33010350-8 2020 Hippocampal neurotrophins and irisin levels were lower, but skeletal muscle brain-derived neurotrophic factor (BDNF) and irisin levels were higher in the simvastatin and rosuvastatin groups than in the control group (P < 0.05). Simvastatin 154-165 brain-derived neurotrophic factor Rattus norvegicus 76-109 33010350-9 2020 CONCLUSION: These findings suggest that high dose simvastatin and rosuvastatin impair cognitive functions via decreasing BDNF, NGF and irisin levels in the hippocampus. Simvastatin 50-61 brain-derived neurotrophic factor Rattus norvegicus 121-125 33010350-9 2020 CONCLUSION: These findings suggest that high dose simvastatin and rosuvastatin impair cognitive functions via decreasing BDNF, NGF and irisin levels in the hippocampus. Simvastatin 50-61 nerve growth factor Rattus norvegicus 127-130 32998959-6 2020 Here, we determined the potential of lovastatin, simvastatin, and rosuvastatin in preclinically modulating epidermal growth factor receptor (EGFR) and prostate-specific membrane antigen (PSMA) receptor density at the tumor cell surface. Simvastatin 49-60 epidermal growth factor receptor Homo sapiens 107-139 32998959-6 2020 Here, we determined the potential of lovastatin, simvastatin, and rosuvastatin in preclinically modulating epidermal growth factor receptor (EGFR) and prostate-specific membrane antigen (PSMA) receptor density at the tumor cell surface. Simvastatin 49-60 epidermal growth factor receptor Homo sapiens 141-145 32892025-6 2020 Additionally, DEHP abolished the anti-inflammatory effect of simvastatin on the tumor necrosis factor alpha-induced upregulation of adhesion molecules and monocyte adhesion to ECs. Simvastatin 61-72 tumor necrosis factor Homo sapiens 80-107 32892025-7 2020 Mechanistically, DEHP blunted the activation of transient receptor potential vanilloid type 1 (TRPV1), which is required for NO production by simvastatin in ECs. Simvastatin 142-153 transient receptor potential cation channel subfamily V member 1 Homo sapiens 48-93 32892025-7 2020 Mechanistically, DEHP blunted the activation of transient receptor potential vanilloid type 1 (TRPV1), which is required for NO production by simvastatin in ECs. Simvastatin 142-153 transient receptor potential cation channel subfamily V member 1 Homo sapiens 95-100 33270123-2 2020 The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. Simvastatin 101-112 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-62 33270123-2 2020 The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. Simvastatin 101-112 solute carrier organic anion transporter family member 1B1 Homo sapiens 64-71 33270123-12 2020 Overall, 120 participants (29%) had a SLCO1B1 genotype indicating increased simvastatin myopathy risk. Simvastatin 76-87 solute carrier organic anion transporter family member 1B1 Homo sapiens 38-45 33270123-18 2020 Among patients with a decreased or poor SLCO1B1 transporter function genotype, simvastatin was prescribed to 1 patient in the control group but none in the intervention group. Simvastatin 79-90 solute carrier organic anion transporter family member 1B1 Homo sapiens 40-47 33270123-19 2020 Conclusions and Relevance: Clinical testing and reporting of SLCO1B1 results for statin myopathy risk did not result in poorer ASCVD prevention in a routine primary care setting and may have been associated with physicians avoiding simvastatin prescriptions for patients at genetic risk for SAMS. Simvastatin 232-243 solute carrier organic anion transporter family member 1B1 Homo sapiens 61-68 33424274-0 2020 Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Simvastatin 10-21 asialoglycoprotein receptor 1 Homo sapiens 110-115 32848049-0 2020 The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis. Simvastatin 32-43 CREB regulated transcription coactivator 1 Mus musculus 101-107 32848049-6 2020 Using Western blot analysis and AMP/ATP measurements, we found that simvastatin treatment blocked activation of mechanistic target of rapamycin complex 1 (mTORC1), activated AMP-activated protein kinase (AMPK) through increased intracellular AMP:ATP ratios, and favored nuclear translocation of transcription factor EB (TFEB). Simvastatin 68-79 CREB regulated transcription coactivator 1 Mus musculus 155-161 32848049-8 2020 The biological effects of simvastatin on the AMPK-mTORC1-TFEB-autophagy axis were reversed by adding exogenous cholesterol to the cells. Simvastatin 26-37 CREB regulated transcription coactivator 1 Mus musculus 50-56 32848049-9 2020 Our data demonstrate that the anti-tubercular activity of simvastatin requires inhibiting cholesterol biosynthesis, reveal novel links between cholesterol homeostasis, AMPK- mTORC1-TFEB axis, and Mycobacterium tuberculosis infection control, and uncover new anti-tubercular therapy targets. Simvastatin 58-69 CREB regulated transcription coactivator 1 Mus musculus 174-180 33174049-0 2020 [Corrigendum] Effects of simvastatin on iNOS and caspase-3 levels and oxidative stress following smoke inhalation injury. Simvastatin 25-36 inositol-3-phosphate synthase 1 Homo sapiens 40-44 33174049-0 2020 [Corrigendum] Effects of simvastatin on iNOS and caspase-3 levels and oxidative stress following smoke inhalation injury. Simvastatin 25-36 caspase 3 Homo sapiens 49-58 32524380-7 2020 Simvastatin-treated rats that survived to sepsis showed a reduction in the levels of nitrate, IL1-beta, and IL-6 and an increase in Bcl-2 protein expression in the prefrontal cortex and hippocampus, and synaptophysin only in the hippocampus. Simvastatin 0-11 interleukin 1 alpha Rattus norvegicus 94-102 32524380-7 2020 Simvastatin-treated rats that survived to sepsis showed a reduction in the levels of nitrate, IL1-beta, and IL-6 and an increase in Bcl-2 protein expression in the prefrontal cortex and hippocampus, and synaptophysin only in the hippocampus. Simvastatin 0-11 interleukin 6 Rattus norvegicus 108-112 32524380-7 2020 Simvastatin-treated rats that survived to sepsis showed a reduction in the levels of nitrate, IL1-beta, and IL-6 and an increase in Bcl-2 protein expression in the prefrontal cortex and hippocampus, and synaptophysin only in the hippocampus. Simvastatin 0-11 BCL2, apoptosis regulator Rattus norvegicus 132-137 32524380-7 2020 Simvastatin-treated rats that survived to sepsis showed a reduction in the levels of nitrate, IL1-beta, and IL-6 and an increase in Bcl-2 protein expression in the prefrontal cortex and hippocampus, and synaptophysin only in the hippocampus. Simvastatin 0-11 synaptophysin Rattus norvegicus 203-216 33164619-9 2020 Simvastatin decreased apoptosis and attenuate injury by decreasing cell apoptosis ratio, elevating Bcl-2 expression while decreasing Bax and caspase-3 protein expressions. Simvastatin 0-11 BCL2, apoptosis regulator Rattus norvegicus 99-104 33164619-9 2020 Simvastatin decreased apoptosis and attenuate injury by decreasing cell apoptosis ratio, elevating Bcl-2 expression while decreasing Bax and caspase-3 protein expressions. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Rattus norvegicus 133-136 33164619-10 2020 Meanwhile, simvastatin restored the autophagy depicted by western blotting with increased ATG-5, Beclin1 and LC3II/LC3I protein expression and decreased p62 expression, as well as immunofluorescence with elevated LC3 fluorescence density. Simvastatin 11-22 autophagy related 5 Rattus norvegicus 90-95 33164619-10 2020 Meanwhile, simvastatin restored the autophagy depicted by western blotting with increased ATG-5, Beclin1 and LC3II/LC3I protein expression and decreased p62 expression, as well as immunofluorescence with elevated LC3 fluorescence density. Simvastatin 11-22 beclin 1 Rattus norvegicus 97-104 33164619-10 2020 Meanwhile, simvastatin restored the autophagy depicted by western blotting with increased ATG-5, Beclin1 and LC3II/LC3I protein expression and decreased p62 expression, as well as immunofluorescence with elevated LC3 fluorescence density. Simvastatin 11-22 microtubule-associated protein 1 light chain 3 alpha Rattus norvegicus 109-119 33164619-10 2020 Meanwhile, simvastatin restored the autophagy depicted by western blotting with increased ATG-5, Beclin1 and LC3II/LC3I protein expression and decreased p62 expression, as well as immunofluorescence with elevated LC3 fluorescence density. Simvastatin 11-22 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 153-156 33164619-10 2020 Meanwhile, simvastatin restored the autophagy depicted by western blotting with increased ATG-5, Beclin1 and LC3II/LC3I protein expression and decreased p62 expression, as well as immunofluorescence with elevated LC3 fluorescence density. Simvastatin 11-22 annexin A3 Rattus norvegicus 109-112 33030783-5 2020 Here, we found that simvastatin treatment effectively promoted anti-proliferative effects and modulated lipid metabolism-related pathways in non-small cell lung cancer (NSCLC) cells, and that the anti-proliferative effects of statins were potentiated by overexpression of acyl-CoA synthetase long chain family member 3 (ACSL3). Simvastatin 20-31 acyl-CoA synthetase long chain family member 3 Homo sapiens 320-325 32913122-7 2020 In addition, we observe that pharmacological inhibition of MVA pathway by simvastatin is sufficient to inhibit CYB5R3 translocation and induces smooth muscle death. Simvastatin 74-85 cytochrome b5 reductase 3 Homo sapiens 111-117 33250768-0 2020 Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1. Simvastatin 0-11 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 89-124 33237691-13 2000 One needs to be aware that certain drugs that are used to treat COVID-19 infections may interact with lipid lowering drugs. Remdesivir is metabolized by the Cyp3A4 pathway and statins that are also metabolized by this pathway should be avoided (atorvastatin, simvastatin, and lovastatin). Simvastatin 258-269 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 156-162 33250768-5 2020 Furthermore, we found that the expression of PTTG1 was markedly suppressed by lipophilic statins, such as simvastatin, fluvastatin, mevastatin, and lovastatin, but not by hydrophilic pravastatin. Simvastatin 106-117 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 45-50 33250768-6 2020 In a dose and time dependent manner, simvastatin suppressed PTTG1 expression by decreasing PTTG1 mRNA stability in MDA-MB-231 cells. Simvastatin 37-48 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 60-65 33250768-6 2020 In a dose and time dependent manner, simvastatin suppressed PTTG1 expression by decreasing PTTG1 mRNA stability in MDA-MB-231 cells. Simvastatin 37-48 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 91-96 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 54-65 matrix metallopeptidase 2 Homo sapiens 121-126 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 54-65 matrix metallopeptidase 9 Homo sapiens 131-136 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 54-65 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 169-174 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 54-65 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 169-174 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 285-296 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 33-38 33250768-8 2020 Mechanistically, we found that inhibition of PTTG1 expression by simvastatin was reversed by geranylgeranyl pyrophosphate, but not by farnesyl pyrophosphate, suggesting the involvement of geranylgeranyl synthesis in regulating PTTG1 expression. Simvastatin 65-76 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 45-50 33250768-8 2020 Mechanistically, we found that inhibition of PTTG1 expression by simvastatin was reversed by geranylgeranyl pyrophosphate, but not by farnesyl pyrophosphate, suggesting the involvement of geranylgeranyl synthesis in regulating PTTG1 expression. Simvastatin 65-76 PTTG1 regulator of sister chromatid separation, securin Homo sapiens 227-232 32417359-12 2020 RESULTS: We found that simvastatin significantly reduced the protein expression of beta1 integrin by 44% and type I collagen by 60% compared with untreated leiomyoma cells. Simvastatin 23-34 integrin subunit beta 1 Homo sapiens 83-97 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Simvastatin 204-215 C-reactive protein Homo sapiens 63-66 32417359-16 2020 Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in beta1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. Simvastatin 13-24 A-kinase anchoring protein 13 Homo sapiens 147-173 32417359-16 2020 Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in beta1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. Simvastatin 13-24 integrin subunit beta 1 Homo sapiens 102-116 32417359-16 2020 Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in beta1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. Simvastatin 13-24 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 175-206 33060739-10 2020 The mRNA expression of MMP-3, MMP-13, and leptin increased in the IL-1beta treated chondrocytes treated with IL-1beta, and decreased with simvastatin treatment. Simvastatin 138-149 matrix metallopeptidase 3 Mus musculus 23-28 32417359-16 2020 Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in beta1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. Simvastatin 13-24 myosin light chain kinase Homo sapiens 208-233 32417359-16 2020 Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in beta1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. Simvastatin 13-24 cyclin D1 Homo sapiens 239-248 32829010-5 2020 We identified and selected metformin, simvastatin and digoxin (C3) as a novel combination of FDA approved drugs, which were shown to effectively target PDX1 and BIRC5 in human PDAC tumors in mice with no toxicity. Simvastatin 38-49 pancreatic and duodenal homeobox 1 Homo sapiens 152-156 32829010-5 2020 We identified and selected metformin, simvastatin and digoxin (C3) as a novel combination of FDA approved drugs, which were shown to effectively target PDX1 and BIRC5 in human PDAC tumors in mice with no toxicity. Simvastatin 38-49 baculoviral IAP repeat containing 5 Homo sapiens 161-166 33105603-8 2020 In contrast, protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibition significantly increased Simva-TMZ-induced cell death in U87 cells. Simvastatin 108-113 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 13-65 33105603-8 2020 In contrast, protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibition significantly increased Simva-TMZ-induced cell death in U87 cells. Simvastatin 108-113 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 67-71 33105603-11 2020 More specifically, our results imply that the IRE1 and PERK signaling arms of the UPR regulate Simva-TMZ-mediated autophagy flux inhibition in U251 and U87 GBM cells. Simvastatin 95-100 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 46-50 33105603-11 2020 More specifically, our results imply that the IRE1 and PERK signaling arms of the UPR regulate Simva-TMZ-mediated autophagy flux inhibition in U251 and U87 GBM cells. Simvastatin 95-100 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 55-59 33295884-4 2020 Methods: Muscle cells were exposed separately to lactone- and acid-form simvastatin for 48 h. After pre-exposure, glucose uptake and glycogen synthesis were measured using radioactive tracers; insulin signalling was detected with Western blotting; and glycolysis, mitochondrial oxygen consumption and ATP production were measured with Seahorse XFe96 analyzer. Simvastatin 72-83 insulin Homo sapiens 193-200 33295884-6 2020 Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin. Simvastatin 176-187 insulin Homo sapiens 19-26 33295884-6 2020 Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin. Simvastatin 176-187 AKT serine/threonine kinase 1 Homo sapiens 46-49 33295884-6 2020 Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin. Simvastatin 176-187 TBC1 domain family member 4 Homo sapiens 69-74 33295884-6 2020 Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin. Simvastatin 176-187 glycogen synthase kinase 3 beta Homo sapiens 80-110 33295884-6 2020 Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin. Simvastatin 176-187 glycogen synthase kinase 3 alpha Homo sapiens 112-120 33295884-8 2020 Conclusions: These data suggest that lactone- and acid-forms of simvastatin exhibit differential effects on non-oxidative glucose metabolism as lactone-form increases and acid-form impairs glucose storage into glycogen, suggesting impaired insulin sensitivity in response to acid-form simvastatin. Simvastatin 64-75 insulin Homo sapiens 240-247 32998069-12 2020 Finally, co-administration of simvastatin and PT for 10 weeks further reduced plasma low-density lipoprotein-cholesterol (LDL-C) levels and stabilized the hepatic LDLR protein level compared with those resulting from single treatment of simvastatin in a high-fat diet-induced hypercholesterolemia mouse model. Simvastatin 30-41 low density lipoprotein receptor Mus musculus 163-167 33193079-19 2020 Targeting KCa3.1 channels by channel openers or L-type Ca2+ channels by DXM or simvastatin might be valuable approaches for treatment of CHI caused by mutations of KATP channels not sensitive to KATP channel openers. Simvastatin 79-90 potassium calcium-activated channel subfamily N member 4 Homo sapiens 10-16 33060739-10 2020 The mRNA expression of MMP-3, MMP-13, and leptin increased in the IL-1beta treated chondrocytes treated with IL-1beta, and decreased with simvastatin treatment. Simvastatin 138-149 leptin Mus musculus 42-48 33088426-8 2020 Treatments with simvastatin consistently reduced c-Myc protein expression in all OCCC cell lines and displayed evidence of causing both caspase-mediated apoptotic cell death and autophagic response in a cell line dependent manner. Simvastatin 16-27 MYC proto-oncogene, bHLH transcription factor Homo sapiens 49-54 32706497-0 2020 Simvastatin abolishes nitric oxide- and reactive oxygen species-induced cyclooxygenase-2 expression by blocking the nuclear factor kappaB pathway in rabbit articular chondrocytes. Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Homo sapiens 72-88 32706497-2 2020 Our study aimed to examine the effect of simvastatin on NO- or ROS-induced cyclooxygenase-2 (COX-2) expression in OA. Simvastatin 41-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 75-91 32706497-2 2020 Our study aimed to examine the effect of simvastatin on NO- or ROS-induced cyclooxygenase-2 (COX-2) expression in OA. Simvastatin 41-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 93-98 32706497-4 2020 Here, we report that simvastatin treatment blocked sodium nitroprusside (SNP)- and interleukin (IL)-1beta-induced COX-2 production. Simvastatin 21-32 interleukin 1 alpha Homo sapiens 83-105 32706497-4 2020 Here, we report that simvastatin treatment blocked sodium nitroprusside (SNP)- and interleukin (IL)-1beta-induced COX-2 production. Simvastatin 21-32 prostaglandin-endoperoxide synthase 2 Homo sapiens 114-119 32706497-5 2020 In addition, simvastatin attenuated SNP-induced NO production and IL-1beta-induced ROS generation. Simvastatin 13-24 interleukin 1 alpha Homo sapiens 66-74 32706497-6 2020 Treatment with simvastatin prevented SNP- and IL-1beta-induced nuclear factor (NF)-kappaB activity. Simvastatin 15-26 interleukin 1 alpha Homo sapiens 46-54 32706497-7 2020 Inhibiting NO production and ROS generation using N-acetylcysteine (NAC) and L-NG-monomethyl arginine acetate (L-NMMA), respectively, accelerated the influence of simvastatin on NF-kappaB activity. Simvastatin 163-174 nuclear factor kappa B subunit 1 Homo sapiens 178-187 32706497-8 2020 In addition, NAC blocked SNP and simvastatin-mediated COX-2 production and NF-kappaB activity but did not alter IL-1beta and simvastatin-mediated COX-2 expression. Simvastatin 33-44 prostaglandin-endoperoxide synthase 2 Homo sapiens 54-59 32706497-9 2020 L-NMMA treatment also abolished IL-1beta-mediated COX-2 expression and NF-kappaB activation, whereas SNP and simvastatin-mediated COX-2 expression was not altered compared with the levels in the SNP and simvastatin-treated cells. Simvastatin 109-120 prostaglandin-endoperoxide synthase 2 Homo sapiens 130-135 32706497-10 2020 Our findings suggested that simvastatin blocks COX-2 expression by inhibiting SNP-induced NO production and IL-1beta-induced ROS generation by blocking the NF-kappaB pathway. Simvastatin 28-39 prostaglandin-endoperoxide synthase 2 Homo sapiens 47-52 32706497-10 2020 Our findings suggested that simvastatin blocks COX-2 expression by inhibiting SNP-induced NO production and IL-1beta-induced ROS generation by blocking the NF-kappaB pathway. Simvastatin 28-39 interleukin 1 alpha Homo sapiens 108-116 32016638-10 2020 Simvastatin reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 25-32 32016638-10 2020 Simvastatin reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice. Simvastatin 0-11 nuclear receptor subfamily 4, group A, member 1 Mus musculus 52-57 32706497-10 2020 Our findings suggested that simvastatin blocks COX-2 expression by inhibiting SNP-induced NO production and IL-1beta-induced ROS generation by blocking the NF-kappaB pathway. Simvastatin 28-39 nuclear factor kappa B subunit 1 Homo sapiens 156-165 32479899-0 2020 The neuroprotective effect of simvastatin on the cerebellum of experimentally-induced diabetic rats through klotho upregulation: An immunohistochemical study. Simvastatin 30-41 Klotho Rattus norvegicus 108-114 32016638-10 2020 Simvastatin reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice. Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Mus musculus 98-103 32016638-10 2020 Simvastatin reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice. Simvastatin 0-11 tumor necrosis factor Mus musculus 108-117 32016638-11 2020 This role of simvastatin was consistent with MK801 in increasing the expression of Nur77 and inhibiting NMDAR2B and cytokines in MPTP-lesioned PD mice. Simvastatin 13-24 nuclear receptor subfamily 4, group A, member 1 Mus musculus 83-88 32016638-11 2020 This role of simvastatin was consistent with MK801 in increasing the expression of Nur77 and inhibiting NMDAR2B and cytokines in MPTP-lesioned PD mice. Simvastatin 13-24 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 104-111 32016638-12 2020 These findings suggest that reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice may be one of the mechanisms that simvastatin improves cognitive functions, depression, and anxiety in MPTP-lesioned mice. Simvastatin 189-200 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 41-48 32016638-12 2020 These findings suggest that reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice may be one of the mechanisms that simvastatin improves cognitive functions, depression, and anxiety in MPTP-lesioned mice. Simvastatin 189-200 nuclear receptor subfamily 4, group A, member 1 Mus musculus 68-73 32016638-12 2020 These findings suggest that reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice may be one of the mechanisms that simvastatin improves cognitive functions, depression, and anxiety in MPTP-lesioned mice. Simvastatin 189-200 prostaglandin-endoperoxide synthase 2 Mus musculus 114-119 32016638-12 2020 These findings suggest that reversed the NMDAR2B increase, restored Nur77 downward, and reduced the expression of COX-2 and TNF-alpha in MPTP-treated mice may be one of the mechanisms that simvastatin improves cognitive functions, depression, and anxiety in MPTP-lesioned mice. Simvastatin 189-200 tumor necrosis factor Mus musculus 124-133 32669485-9 2020 Pancreatic lipase activity was reduced in the SIM group and the group treated with doses of PCA (50 and 100 mg/kg). Simvastatin 46-49 lipase G, endothelial type Rattus norvegicus 11-17 32479899-4 2020 Simvastatin is a lipophilic statin that can enhance klotho expression. Simvastatin 0-11 Klotho Rattus norvegicus 52-58 32479899-17 2020 Simvastatin enhanced Klotho and diminished Caspase-3 expression. Simvastatin 0-11 Klotho Rattus norvegicus 21-27 32479899-17 2020 Simvastatin enhanced Klotho and diminished Caspase-3 expression. Simvastatin 0-11 caspase 3 Rattus norvegicus 43-52 32479899-18 2020 CONCLUSION: Simvastatin can ameliorate diabetic induced cerebellar changes through minimizing oxidative stress, enhancement of Klotho expression and reduction of apoptosis. Simvastatin 12-23 Klotho Rattus norvegicus 127-133 32945413-9 2020 Downregulation of H19 reduced the plaque area and promoted the expression of c-caspase3 in mouse aortic tissues in vivo, as well as enhancing the effects of simvastatin, a drug used for AS treatment. Simvastatin 157-168 H19, imprinted maternally expressed transcript Mus musculus 18-21 32942550-0 2020 Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1alpha Skeletal Muscle Expression. Simvastatin 0-11 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 61-71 33008033-0 2020 Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells" Survival and Hindering Cytochrome C-Mediated Apoptosis. Simvastatin 22-33 cytochrome c, somatic Homo sapiens 146-158 33008033-7 2020 Furthermore, simvastatin 40 mg/kg most profoundly attenuated tubular apoptosis, determined as a decrease of cytochrome C, caspase-3 expression, and AIs (p < 0.01 vs. LPS). Simvastatin 13-24 cytochrome c, somatic Homo sapiens 108-120 33008033-7 2020 Furthermore, simvastatin 40 mg/kg most profoundly attenuated tubular apoptosis, determined as a decrease of cytochrome C, caspase-3 expression, and AIs (p < 0.01 vs. LPS). Simvastatin 13-24 caspase 3 Homo sapiens 122-131 33008033-8 2020 Conversely, simvastatin induced a significant increase of Bcl-XL and survivin, both in the strong inverse correlations with cleaved caspase-3 and cytochrome C. Simvastatin 12-23 BCL2 like 1 Homo sapiens 58-64 33008033-8 2020 Conversely, simvastatin induced a significant increase of Bcl-XL and survivin, both in the strong inverse correlations with cleaved caspase-3 and cytochrome C. Simvastatin 12-23 caspase 3 Homo sapiens 132-141 33008033-8 2020 Conversely, simvastatin induced a significant increase of Bcl-XL and survivin, both in the strong inverse correlations with cleaved caspase-3 and cytochrome C. Simvastatin 12-23 cytochrome c, somatic Homo sapiens 146-158 33008033-9 2020 Our study indicates that simvastatin has cytoprotective effects against LPS-induced tubular apoptosis, seemingly mediated by upregulation of cell-survival molecules, such as Bcl-XL and survivin, and inhibition of the mitochondrial cytochrome C and downstream caspase-3 activation. Simvastatin 25-36 BCL2 like 1 Homo sapiens 174-180 33008033-9 2020 Our study indicates that simvastatin has cytoprotective effects against LPS-induced tubular apoptosis, seemingly mediated by upregulation of cell-survival molecules, such as Bcl-XL and survivin, and inhibition of the mitochondrial cytochrome C and downstream caspase-3 activation. Simvastatin 25-36 cytochrome c, somatic Homo sapiens 231-243 33008033-9 2020 Our study indicates that simvastatin has cytoprotective effects against LPS-induced tubular apoptosis, seemingly mediated by upregulation of cell-survival molecules, such as Bcl-XL and survivin, and inhibition of the mitochondrial cytochrome C and downstream caspase-3 activation. Simvastatin 25-36 caspase 3 Homo sapiens 259-268 33245648-11 2020 The activity of LAAP and NAG during simvastatin therapy during the follow-up period in the CHF I subgroup without DM2 significantly decreased. Simvastatin 36-47 NBAS subunit of NRZ tethering complex Homo sapiens 16-28 33245648-12 2020 In the subgroup of CHF I + DM2, a decrease in the concentration of LAAP and an increase in the activity of NAG was revealed, which may indicate that the brush border epithelium dystrophy occurred during simvastatin therapy. Simvastatin 203-214 sodium voltage-gated channel alpha subunit 7 Homo sapiens 107-110 33245648-15 2020 When treating dyslipidemia with simvastatin at a dose of 20 mg / day, there is a decrease in the activity of NAG and laap in patients with CHF I without DM2. Simvastatin 32-43 sodium voltage-gated channel alpha subunit 7 Homo sapiens 109-112 33245648-16 2020 In the result of lipid-lowering therapy with simvastatin in a daily dosage of 20 mg in patients with CHF I+D2M there is increased activity of NAG while reducing the concentration of the LAAP, which may be due to degeneration of the proximal tubular epithelium, amid additional load on a partially renal route of metabolism of simvastatin. Simvastatin 45-56 sodium voltage-gated channel alpha subunit 7 Homo sapiens 142-145 33245648-16 2020 In the result of lipid-lowering therapy with simvastatin in a daily dosage of 20 mg in patients with CHF I+D2M there is increased activity of NAG while reducing the concentration of the LAAP, which may be due to degeneration of the proximal tubular epithelium, amid additional load on a partially renal route of metabolism of simvastatin. Simvastatin 326-337 sodium voltage-gated channel alpha subunit 7 Homo sapiens 142-145 32945441-0 2020 Effects of simvastatin on iNOS and caspase-3 levels and oxidative stress following smoke inhalation injury. Simvastatin 11-22 nitric oxide synthase 2 Rattus norvegicus 26-30 32945441-0 2020 Effects of simvastatin on iNOS and caspase-3 levels and oxidative stress following smoke inhalation injury. Simvastatin 11-22 caspase 3 Rattus norvegicus 35-44 32945441-12 2020 In rats with smoke inhalation injury, simvastatin inhibited iNOS and caspase-3 expression in lung tissues and mitigated oxidative stress, thereby exerting a protective effect. Simvastatin 38-49 nitric oxide synthase 2 Rattus norvegicus 60-64 32945441-12 2020 In rats with smoke inhalation injury, simvastatin inhibited iNOS and caspase-3 expression in lung tissues and mitigated oxidative stress, thereby exerting a protective effect. Simvastatin 38-49 caspase 3 Rattus norvegicus 69-78 32157277-0 2020 Bone-Marrow-Derived Mesenchymal Stem Cells (BMSCs) combined with Simvastatin accelerates burn wound healing by activation of the Akt/mTOR pathway. Simvastatin 65-76 AKT serine/threonine kinase 1 Rattus norvegicus 129-132 32157277-0 2020 Bone-Marrow-Derived Mesenchymal Stem Cells (BMSCs) combined with Simvastatin accelerates burn wound healing by activation of the Akt/mTOR pathway. Simvastatin 65-76 mechanistic target of rapamycin kinase Rattus norvegicus 133-137 32157277-7 2020 In addition, the elevations of expression levels of Akt and mTOR genes, at both mRNA and protein levels, were more pronounced in the BMSCs+SMV group (P<0.05, at least, for both qRT-PCR and western blot assessments). Simvastatin 139-142 AKT serine/threonine kinase 1 Rattus norvegicus 52-55 32157277-7 2020 In addition, the elevations of expression levels of Akt and mTOR genes, at both mRNA and protein levels, were more pronounced in the BMSCs+SMV group (P<0.05, at least, for both qRT-PCR and western blot assessments). Simvastatin 139-142 mechanistic target of rapamycin kinase Rattus norvegicus 60-64 33042440-0 2020 Simvastatin ameliorates oxygen glucose deprivation/reoxygenation-induced pulmonary endothelial barrier dysfunction by restoring cell-cell junctions and actin cytoskeleton dynamics via the PI3K/Akt signaling pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 193-196 32942550-3 2020 Since statins impair skeletal muscle PGC-1alpha expression and reduced PGC-1alpha expression has been observed in diabetic patients, we investigated the possibility that skeletal muscle PGC1alpha expression influences the effect of simvastatin on muscle glucose metabolism. Simvastatin 232-243 PPARG coactivator 1 alpha Homo sapiens 186-195 32942550-5 2020 Mice were treated orally for 3 weeks with simvastatin (5 mg/kg/day) and investigated by intraperitoneal glucose tolerance (iGTT), in vivo skeletal muscle glucose uptake, muscle glycogen content, and Glut4 and hexokinase mRNA and protein expression. Simvastatin 42-53 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 199-204 32942550-8 2020 In OE mice, simvastatin treatment increased blood glucose and insulin concentrations during the iGTT, and increased skeletal muscle glucose uptake, glycogen stores, and Glut4 and hexokinase protein expression. Simvastatin 12-23 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 169-174 32942550-11 2020 Thus, simvastatin affected glucose homeostasis depending on PGC-1alpha expression. Simvastatin 6-17 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 60-70 32729746-3 2020 Potent inhibitors of cytochrome P450 (CYP) 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin, and atorvastatin. Simvastatin 115-126 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-46 32995293-12 2020 Interestingly, statins; RSV and SMV, disrupted CP-induced ER stress and the consequent apoptotic cell death evidenced by downregulation of ER-chaperone GRP78, calpain-1, ACASP3 and caspase-12 as well as decline in the Bax/Bcl-2 ratio. Simvastatin 32-35 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 152-157 32995293-12 2020 Interestingly, statins; RSV and SMV, disrupted CP-induced ER stress and the consequent apoptotic cell death evidenced by downregulation of ER-chaperone GRP78, calpain-1, ACASP3 and caspase-12 as well as decline in the Bax/Bcl-2 ratio. Simvastatin 32-35 calpain 1 Rattus norvegicus 159-168 32995293-12 2020 Interestingly, statins; RSV and SMV, disrupted CP-induced ER stress and the consequent apoptotic cell death evidenced by downregulation of ER-chaperone GRP78, calpain-1, ACASP3 and caspase-12 as well as decline in the Bax/Bcl-2 ratio. Simvastatin 32-35 caspase 12 Rattus norvegicus 181-191 32995293-12 2020 Interestingly, statins; RSV and SMV, disrupted CP-induced ER stress and the consequent apoptotic cell death evidenced by downregulation of ER-chaperone GRP78, calpain-1, ACASP3 and caspase-12 as well as decline in the Bax/Bcl-2 ratio. Simvastatin 32-35 BCL2 associated X, apoptosis regulator Rattus norvegicus 218-221 32995293-12 2020 Interestingly, statins; RSV and SMV, disrupted CP-induced ER stress and the consequent apoptotic cell death evidenced by downregulation of ER-chaperone GRP78, calpain-1, ACASP3 and caspase-12 as well as decline in the Bax/Bcl-2 ratio. Simvastatin 32-35 BCL2, apoptosis regulator Rattus norvegicus 222-227 32895407-0 2020 Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. Simvastatin 102-113 AKT serine/threonine kinase 1 Rattus norvegicus 15-18 32895407-0 2020 Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. Simvastatin 102-113 nitric oxide synthase 3 Rattus norvegicus 19-23 32895407-0 2020 Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. Simvastatin 102-113 endothelin 1 Rattus norvegicus 28-32 32895407-0 2020 Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. Simvastatin 102-113 Eph receptor B1 Rattus norvegicus 33-36 32895407-2 2020 Nevertheless, the involvement of ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 trajectories in the cardiotoxic effect and in the potential cardioprotective upshot of simvastatin has been elusive. Simvastatin 161-172 endothelin 1 Rattus norvegicus 62-66 32895407-2 2020 Nevertheless, the involvement of ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 trajectories in the cardiotoxic effect and in the potential cardioprotective upshot of simvastatin has been elusive. Simvastatin 161-172 mitogen activated protein kinase 3 Rattus norvegicus 67-73 32895407-6 2020 Contrariwise, co-administration with simvastatin overcame these disturbed events and modulated the ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 signaling pathways. Simvastatin 37-48 AKT serine/threonine kinase 1 Rattus norvegicus 115-118 32895407-6 2020 Contrariwise, co-administration with simvastatin overcame these disturbed events and modulated the ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 signaling pathways. Simvastatin 37-48 nitric oxide synthase 3 Rattus norvegicus 119-123 32895407-6 2020 Contrariwise, co-administration with simvastatin overcame these disturbed events and modulated the ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 signaling pathways. Simvastatin 37-48 endothelin 1 Rattus norvegicus 128-132 32895407-6 2020 Contrariwise, co-administration with simvastatin overcame these disturbed events and modulated the ROCK/NF-kappaB, Akt/eNOS and ET-1/ERK1/2 signaling pathways. Simvastatin 37-48 mitogen activated protein kinase 3 Rattus norvegicus 133-139 32895407-8 2020 Moreover, the cross-talk between ROCK/ NF-kappaB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU. Simvastatin 326-337 cytochrome c oxidase II, mitochondrial Rattus norvegicus 54-59 32895407-8 2020 Moreover, the cross-talk between ROCK/ NF-kappaB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU. Simvastatin 326-337 AKT serine/threonine kinase 1 Rattus norvegicus 66-69 32895407-8 2020 Moreover, the cross-talk between ROCK/ NF-kappaB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU. Simvastatin 326-337 nitric oxide synthase 3 Rattus norvegicus 70-74 32895407-8 2020 Moreover, the cross-talk between ROCK/ NF-kappaB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU. Simvastatin 326-337 endothelin 1 Rattus norvegicus 79-83 32895407-8 2020 Moreover, the cross-talk between ROCK/ NF-kappaB, ROS/COX-2/TXA2, Akt/eNOS and ET-1/ERK1/2 pathways contributes via different means to upsetting the vasoconstriction/vasodilatation equilibrium as well as endothelial cell function and finally leads to cardiomyocyte stress and death-the modulation of these trajectories offers simvastatin its potential cardio-protection against 5-FU. Simvastatin 326-337 mitogen activated protein kinase 3 Rattus norvegicus 84-90 32995293-0 2020 Rosuvastatin and simvastatin attenuate cisplatin-induced cardiotoxicity via disruption of endoplasmic reticulum stress-mediated apoptotic death in rats: targeting ER-Chaperone GRP78 and Calpain-1 pathways. Simvastatin 17-28 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 176-181 32995293-0 2020 Rosuvastatin and simvastatin attenuate cisplatin-induced cardiotoxicity via disruption of endoplasmic reticulum stress-mediated apoptotic death in rats: targeting ER-Chaperone GRP78 and Calpain-1 pathways. Simvastatin 17-28 calpain 1 Rattus norvegicus 186-195 32351149-6 2020 We genotyped variants in simvastatin-metabolizing enzymes (CYP3A4/rs35599367 and CYP3A5/rs776746) and drug transporters (ABCB1/rs2032582 and SLCO1B1/rs4149056), and estimated their association with recurrence with logistic regression models.Results: We observed protective (though imprecisely-measured) associations between variants in genes encoding drug transporters (ABCB1 and SLCO1B1) and simvastatin-metabolizing enzymes (CYP3A4 and CYP3A5) and breast cancer recurrence in simvastatin-treated women. Simvastatin 25-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 32351149-6 2020 We genotyped variants in simvastatin-metabolizing enzymes (CYP3A4/rs35599367 and CYP3A5/rs776746) and drug transporters (ABCB1/rs2032582 and SLCO1B1/rs4149056), and estimated their association with recurrence with logistic regression models.Results: We observed protective (though imprecisely-measured) associations between variants in genes encoding drug transporters (ABCB1 and SLCO1B1) and simvastatin-metabolizing enzymes (CYP3A4 and CYP3A5) and breast cancer recurrence in simvastatin-treated women. Simvastatin 25-36 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 81-87 32351149-7 2020 For example, carrying two variant alleles in ABCB1 was associated with a 31% lower rate of recurrence (multivariable OR = 0.69, 95% CI: 0.31, 1.5).Conclusion: Our study provides weak evidence to support the use of genetic variation in ABCB1, SLCO1B1, CYP3A4, and CYP3A5 as biomarkers of breast tumor response to simvastatin. Simvastatin 312-323 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 32062833-10 2020 Indeed, these data, pointing to the key role of lipid rafts in tPA triggered signaling involving beta-catenin, may have pharmacological implications, suggesting that cyclodextrins, and potentially other drugs, such as statins, may represent an useful tool. Simvastatin 218-225 chromosome 20 open reading frame 181 Homo sapiens 63-66 32062833-10 2020 Indeed, these data, pointing to the key role of lipid rafts in tPA triggered signaling involving beta-catenin, may have pharmacological implications, suggesting that cyclodextrins, and potentially other drugs, such as statins, may represent an useful tool. Simvastatin 218-225 catenin beta 1 Homo sapiens 97-109 32546662-8 2020 Simvastatin reduced estradiol production and decreased nuclear and mitochondrial ERalpha function. Simvastatin 0-11 estrogen receptor 1 Homo sapiens 81-88 32767644-9 2020 In contrast, simvastatin regulated the expression of Hmgcr, Mdr1 and Slco2b1 in a circadian manner, which potentially contributed to the chronopharmacological function of the drug. Simvastatin 13-24 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 53-58 32767644-9 2020 In contrast, simvastatin regulated the expression of Hmgcr, Mdr1 and Slco2b1 in a circadian manner, which potentially contributed to the chronopharmacological function of the drug. Simvastatin 13-24 malic enzyme complex, mitochondrial Mus musculus 60-64 32767644-9 2020 In contrast, simvastatin regulated the expression of Hmgcr, Mdr1 and Slco2b1 in a circadian manner, which potentially contributed to the chronopharmacological function of the drug. Simvastatin 13-24 solute carrier organic anion transporter family, member 2b1 Mus musculus 69-76 32546662-9 2020 A mitochondrial target of ERalpha, the respiratory complex IV (COXIV), was reduced after simvastatin treatment, which profoundly affected mitochondrial respiration activating apoptosis. Simvastatin 89-100 estrogen receptor 1 Homo sapiens 26-33 32546662-9 2020 A mitochondrial target of ERalpha, the respiratory complex IV (COXIV), was reduced after simvastatin treatment, which profoundly affected mitochondrial respiration activating apoptosis. Simvastatin 89-100 cytochrome c oxidase subunit 4I1 Homo sapiens 63-68 32546662-10 2020 Additionally, simvastatin reduced tumor volume and weight of grafted H295R cells, intratumor cholesterol content, Ki-67 and ERalpha, COXIV expression and activity and increase terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells. Simvastatin 14-25 estrogen receptor 1 Homo sapiens 124-131 32546662-10 2020 Additionally, simvastatin reduced tumor volume and weight of grafted H295R cells, intratumor cholesterol content, Ki-67 and ERalpha, COXIV expression and activity and increase terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells. Simvastatin 14-25 cytochrome c oxidase subunit 4I1 Homo sapiens 133-138 32173476-5 2020 Our study was aimed at testing the effect of three different drugs (pioglitazone, doxycycline, simvastatin) on MMP-9 and PPAR-gamma expression in AAA-MSCs. Simvastatin 95-106 matrix metallopeptidase 9 Homo sapiens 111-116 32819403-11 2020 CONCLUSIONS: The pleiotropic effects found for different SV concentrations were possibly originated from other mineralization pathways beside the ALP induced one. Simvastatin 57-59 alkaline phosphatase, placental Homo sapiens 146-149 32651266-2 2020 Recently, we compared the efficacy of lovastatin to the more potent and brain-penetrant drug simvastatin for correcting phenotypes in the Fmr1-/y mouse (Muscas et al., 2019). Simvastatin 93-104 fragile X messenger ribonucleoprotein 1 Mus musculus 138-142 32173476-5 2020 Our study was aimed at testing the effect of three different drugs (pioglitazone, doxycycline, simvastatin) on MMP-9 and PPAR-gamma expression in AAA-MSCs. Simvastatin 95-106 peroxisome proliferator activated receptor gamma Homo sapiens 121-131 32173476-11 2020 Interestingly, MMP-9 mRNA resulted significantly decreased after each treatment, recording a down-regulation of 50% in presence of pioglitazone, 90% with doxycycline and 40% with exposed to simvastatin, in comparison to untreated cells. Simvastatin 190-201 matrix metallopeptidase 9 Homo sapiens 15-20 32173476-13 2020 CONCLUSIONS: Our data support the potential therapeutic effect of pioglitazone, doxycycline and simvastatin on AAA by reducing the MMP-9 expression in a patient-specific model (AAA-MSCs). Simvastatin 96-107 matrix metallopeptidase 9 Homo sapiens 131-136 32468037-0 2020 Simvastatin inhibits the adipogenesis of bone marrow-derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling. Simvastatin 0-11 retinoic acid receptor responder 2 Rattus norvegicus 114-122 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 C-C motif chemokine ligand 3 Homo sapiens 32-36 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 interleukin 6 Homo sapiens 51-55 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 C-C motif chemokine ligand 2 Homo sapiens 57-61 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 intercellular adhesion molecule 1 Homo sapiens 63-69 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 vascular cell adhesion molecule 1 Homo sapiens 74-80 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 interleukin 6 Homo sapiens 257-261 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 C-C motif chemokine ligand 2 Homo sapiens 266-270 32418888-5 2020 We discovered that PCCs secrete CCL3 and stimulate IL-6, CCL2, ICAM-1 and VCAM-1 expression in MSCs and that the MSC-PCC crosstalk can be disrupted by the lipid-lowering drug simvastatin, which displays pleiotropic effects on cell metabolism and suppresses IL-6 and CCL2 production by MSCs and CCL3 secretion by PCCs. Simvastatin 175-186 C-C motif chemokine ligand 3 Homo sapiens 294-298 32485345-8 2020 We observed that free simvastatin (CS3) was able to reduce the enzymatic activity of pyruvate kinase, an important enzyme for brain energy homeostasis, without affecting the memory of the animals that received a standard diet. Simvastatin 22-33 calsyntenin 3 Rattus norvegicus 35-38 32468037-0 2020 Simvastatin inhibits the adipogenesis of bone marrow-derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling. Simvastatin 0-11 chemerin chemokine-like receptor 1 Rattus norvegicus 123-129 32468037-2 2020 The present study focused on the mechanisms responsible for the inhibitory effects of simvastatin on adipogenesis and examined the effects of simvastatin on the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), chemerin, chemokine-like receptor 1 (CMKLR1), G protein-coupled receptor 1 (GPR1) and the adipocyte marker gene, adiponectin. Simvastatin 142-153 peroxisome proliferator-activated receptor gamma Rattus norvegicus 175-223 32468037-6 2020 On days 7 and 14, the simvastatin-treated cells exhibited a downregulated expression of chemerin, whereas the upregulated expression of its receptor, CMKLR1 was observed. Simvastatin 22-33 retinoic acid receptor responder 2 Rattus norvegicus 88-96 32468037-6 2020 On days 7 and 14, the simvastatin-treated cells exhibited a downregulated expression of chemerin, whereas the upregulated expression of its receptor, CMKLR1 was observed. Simvastatin 22-33 chemerin chemokine-like receptor 1 Rattus norvegicus 150-156 32468037-7 2020 The results also revealed that CMKLR1 is required for adipogenesis and the simvastatin-mediated inhibitory effect on adipogenesis. Simvastatin 75-86 chemerin chemokine-like receptor 1 Rattus norvegicus 31-37 32468037-8 2020 Simvastatin regulated adipogenesis by negatively modulating chemerin-CMKLR1 signaling. Simvastatin 0-11 retinoic acid receptor responder 2 Rattus norvegicus 60-68 32468037-8 2020 Simvastatin regulated adipogenesis by negatively modulating chemerin-CMKLR1 signaling. Simvastatin 0-11 chemerin chemokine-like receptor 1 Rattus norvegicus 69-75 32468037-9 2020 Importantly, simvastatin stimulation inhibited the upregulation of PPARgamma and PPARgamma-mediated chemerin expression to prevent adipogenesis. Simvastatin 13-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 67-76 32468037-9 2020 Importantly, simvastatin stimulation inhibited the upregulation of PPARgamma and PPARgamma-mediated chemerin expression to prevent adipogenesis. Simvastatin 13-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 81-90 32468037-9 2020 Importantly, simvastatin stimulation inhibited the upregulation of PPARgamma and PPARgamma-mediated chemerin expression to prevent adipogenesis. Simvastatin 13-24 retinoic acid receptor responder 2 Rattus norvegicus 100-108 32468037-10 2020 Treatment with the PPARgamma agonist, rosiglitazone, partially reversed the negative regulatory effects of simvastatin. Simvastatin 107-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 19-28 32468037-11 2020 On the whole, the findings of the present study demonstrate that simvastatin inhibits the adipogenesis of BMSCs through the downregulation of PPARgamma and subsequently prevents the PPARgamma-mediated induction of chemerin/CMKLR1 signaling. Simvastatin 65-76 peroxisome proliferator-activated receptor gamma Rattus norvegicus 142-151 32468037-11 2020 On the whole, the findings of the present study demonstrate that simvastatin inhibits the adipogenesis of BMSCs through the downregulation of PPARgamma and subsequently prevents the PPARgamma-mediated induction of chemerin/CMKLR1 signaling. Simvastatin 65-76 peroxisome proliferator-activated receptor gamma Rattus norvegicus 182-191 32468037-11 2020 On the whole, the findings of the present study demonstrate that simvastatin inhibits the adipogenesis of BMSCs through the downregulation of PPARgamma and subsequently prevents the PPARgamma-mediated induction of chemerin/CMKLR1 signaling. Simvastatin 65-76 retinoic acid receptor responder 2 Rattus norvegicus 214-222 32468037-11 2020 On the whole, the findings of the present study demonstrate that simvastatin inhibits the adipogenesis of BMSCs through the downregulation of PPARgamma and subsequently prevents the PPARgamma-mediated induction of chemerin/CMKLR1 signaling. Simvastatin 65-76 chemerin chemokine-like receptor 1 Rattus norvegicus 223-229 32387414-10 2020 These data are consistent with simvastatin promoting alterations in peripheral febrigenic signaling (plasma levels of TNF-alpha, IL-1beta, and IL-10). Simvastatin 31-42 tumor necrosis factor Mus musculus 118-127 32387414-10 2020 These data are consistent with simvastatin promoting alterations in peripheral febrigenic signaling (plasma levels of TNF-alpha, IL-1beta, and IL-10). Simvastatin 31-42 interleukin 1 alpha Mus musculus 129-137 32387414-10 2020 These data are consistent with simvastatin promoting alterations in peripheral febrigenic signaling (plasma levels of TNF-alpha, IL-1beta, and IL-10). Simvastatin 31-42 interleukin 10 Mus musculus 143-148 32393497-0 2020 Simvastatin improves cardiac function through Notch1 activation in BALB/c mice with chronic Chagas cardiomyopathy. Simvastatin 0-11 notch 1 Mus musculus 46-52 32714018-6 2020 The results showed that both compounds inhibited HMGCR activity significantly compare to the control simvastatin (p < 0.05). Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 49-54 32727400-15 2020 However, similar to the effects in A2780 cells, simvastatin and zoledronic acid significantly induced caspase 3/7 activation (6-folds; p < 0.001). Simvastatin 48-59 caspase 3 Homo sapiens 102-113 32747455-9 2020 Tissue cholesterol, CRP levels and RAM 11 were significantly lower in simvastatin and ezetimibe rabbit groups compared with cholesterol diet alone. Simvastatin 70-81 C-reactive protein Homo sapiens 20-23 32393497-5 2020 Furthermore, several reports suggest that simvastatin activates the Notch pathway after stroke in cerebral endothelial cells, enhancing blood flow by promoting angiogenesis. Simvastatin 42-53 notch 1 Mus musculus 68-73 32393497-8 2020 At 80 days postinfection, the heart tissues were assessed for Notch1 activity.Key Results: T. cruzi infection activated the Notch1 pathway, and simvastatin (but not 15-epi-lipoxin A4) produced a further increase in that activity, correlating with improvement in the ejection fraction and histopathologic findings typical of T. cruzi infection, including improvements in inflammation and fibrosis. Simvastatin 144-155 notch 1 Mus musculus 62-68 32393497-9 2020 Moreover, simvastatin increased isolectin B4+ cells suggesting active angiogenesis in the chronically infected hearts without altering the parasitic load.Conclusions and Implications: Simvastatin, probably acting through the Notch1 pathway, decreases inflammation, improving cardiac function in chronically T. cruzi-infected mice. Simvastatin 10-21 notch 1 Mus musculus 225-231 32393497-9 2020 Moreover, simvastatin increased isolectin B4+ cells suggesting active angiogenesis in the chronically infected hearts without altering the parasitic load.Conclusions and Implications: Simvastatin, probably acting through the Notch1 pathway, decreases inflammation, improving cardiac function in chronically T. cruzi-infected mice. Simvastatin 184-195 notch 1 Mus musculus 225-231 32694763-0 2020 Author Correction: Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Simvastatin 19-30 histone deacetylase 1 Homo sapiens 121-142 32694763-0 2020 Author Correction: Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Simvastatin 19-30 ras homolog family member A Homo sapiens 158-162 32594255-2 2020 Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. Simvastatin 123-134 O-6-methylguanine-DNA methyltransferase Mus musculus 90-94 32643419-1 2020 The study aimed to assess the effect of simvastatin on gene expression of LDLR, SREBPs, and SCD1 in rat hepatic tissues fed with high-fat diets (HFD) and its association with some biochemical parameters. Simvastatin 40-51 low density lipoprotein receptor Rattus norvegicus 74-78 32643419-1 2020 The study aimed to assess the effect of simvastatin on gene expression of LDLR, SREBPs, and SCD1 in rat hepatic tissues fed with high-fat diets (HFD) and its association with some biochemical parameters. Simvastatin 40-51 stearoyl-CoA desaturase Rattus norvegicus 92-96 32643419-11 2020 Treatment of rats with HFD and simvastatin 20 mg/kg, triglyceride and LDL were almost the same as a control group and LDLR expression increased 98% in liver tissue. Simvastatin 31-42 low density lipoprotein receptor Rattus norvegicus 118-122 32629602-11 2020 The specific value of p-JAK2/JAK2 and p-STAT3/STAT3 protein relative expressions in the simvastatin-treated group (20, 40 mg/L) were significantly lower than that in the control group, respectively (both P<0.05). Simvastatin 88-99 Janus kinase 2 Homo sapiens 24-28 32629602-11 2020 The specific value of p-JAK2/JAK2 and p-STAT3/STAT3 protein relative expressions in the simvastatin-treated group (20, 40 mg/L) were significantly lower than that in the control group, respectively (both P<0.05). Simvastatin 88-99 signal transducer and activator of transcription 3 Homo sapiens 40-45 32629602-11 2020 The specific value of p-JAK2/JAK2 and p-STAT3/STAT3 protein relative expressions in the simvastatin-treated group (20, 40 mg/L) were significantly lower than that in the control group, respectively (both P<0.05). Simvastatin 88-99 signal transducer and activator of transcription 3 Homo sapiens 46-51 32629602-12 2020 The specific value of p-JAK2/JAK2 and p-STAT3/STAT3 protein relative expressions in IL-6 group were significantly higher than those in control group (both P<0.05), the specific value of p-JAK2/JAK2 and p-STAT3/STAT3 protein relative expressions in simvastatin (20, 40 mg/L) combined with IL-6 groups were lower than those in IL-6 group (all P<0.05), respectively. Simvastatin 248-259 interleukin 6 Homo sapiens 84-88 32629602-13 2020 Conclusion: Simvastatin can induce the apoptosis of A549 cells through a non-caspase-dependent mitochondrial apoptosis pathway, which may be achieved by inhibiting the JAK2/STAT3 pathway. Simvastatin 12-23 Janus kinase 2 Homo sapiens 168-172 32629602-13 2020 Conclusion: Simvastatin can induce the apoptosis of A549 cells through a non-caspase-dependent mitochondrial apoptosis pathway, which may be achieved by inhibiting the JAK2/STAT3 pathway. Simvastatin 12-23 signal transducer and activator of transcription 3 Homo sapiens 173-178 32594255-2 2020 Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. Simvastatin 123-134 guanidinoacetate methyltransferase Mus musculus 100-104 32594255-5 2020 In our study, simvastatin-induced damage showed a trend to be less pronounced in GAMT-deficient mice compared with wildtype mice. Simvastatin 14-25 guanidinoacetate methyltransferase Mus musculus 81-85 33102196-2 2020 Simvastatin serves as a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) inhibitor, with prolonged use proven to cause side effects. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1-like Malus domestica 73-77 33102196-10 2020 Quercetin could bind to HMGR at a similar location to amino acid residues as simvastatin. Simvastatin 77-88 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1-like Malus domestica 24-28 32428986-12 2020 Treatment of human foreskin fibroblasts with simvastatin or with liposome-encapsulated pravastatin resulted in decreased expression of transcript encoding CTGF. Simvastatin 45-56 cellular communication network factor 2 Homo sapiens 155-159 32554834-6 2020 Nevertheless, treatment with simvastatin, CFA and CGA normalized altered AChE, BChE and arginase activities as well as improved antioxidant status in hypercholesterolemic rats. Simvastatin 29-40 acetylcholinesterase Rattus norvegicus 73-77 32554834-6 2020 Nevertheless, treatment with simvastatin, CFA and CGA normalized altered AChE, BChE and arginase activities as well as improved antioxidant status in hypercholesterolemic rats. Simvastatin 29-40 butyrylcholinesterase Rattus norvegicus 79-83 32617140-0 2020 Simvastatin Attenuates Abdominal Aortic Aneurysm Formation Favoured by Lack of Nrf2 Transcriptional Activity. Simvastatin 0-11 nuclear factor, erythroid derived 2, like 2 Mus musculus 79-83 32606661-7 2020 Results: Complexation of SMV with hydroxypropyl beta-cyclodextrin (HP beta-CD) was superior to all other polymers as revealed by the equilibrium saturation solubility, stability constant, complexation efficiency and thermodynamic potential. Simvastatin 25-28 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 70-77 32617140-11 2020 The abrupt blood pressure rise induced by AngII was mitigated in simvastatin-treated animals regardless of the genotype. Simvastatin 65-76 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 42-47 32617140-12 2020 Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-beta1 mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R). Simvastatin 0-11 vascular cell adhesion molecule 1 Mus musculus 165-170 32617140-12 2020 Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-beta1 mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R). Simvastatin 0-11 transforming growth factor, beta 1 Mus musculus 229-238 32617140-12 2020 Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-beta1 mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R). Simvastatin 0-11 mitogen-activated protein kinase 1 Mus musculus 255-258 32617140-12 2020 Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-beta1 mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R). Simvastatin 0-11 angiotensin II, type I receptor-associated protein Mus musculus 322-352 32617140-12 2020 Simvastatin-affected parameters that differed between the healthy structure of the aorta and aneurysmal tissue included immune cell infiltration of the aortic wall, VCAM1 mRNA and protein level, extracellular matrix degradation, TGF-beta1 mRNA level, and ERK phosphorylation, but neither oxidative stress nor the level of Angiotensin II Type 1 Receptor (AT1R). Simvastatin 0-11 angiotensin II, type I receptor-associated protein Mus musculus 354-358 32617140-13 2020 Taken together, the inhibition of Nrf2 transcriptional activity facilitates AAA formation in mice, which can be prevented by simvastatin. Simvastatin 125-136 nuclear factor, erythroid derived 2, like 2 Mus musculus 34-38 32633363-0 2020 Simvastatin induces apoptosis of nasopharyngeal carcinoma cells through NF-kappaB signaling pathway. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 72-81 32172201-5 2020 It is revealed that Simvastatin can potentially interact with certain known targets or key regulators of GBM such as ErbB, c-Src and FGFR signaling pathways, but exhibit low affinity to the well-established GBM target of PI3K/Akt/mTOR pathway. Simvastatin 20-31 epidermal growth factor receptor Homo sapiens 117-121 32172201-5 2020 It is revealed that Simvastatin can potentially interact with certain known targets or key regulators of GBM such as ErbB, c-Src and FGFR signaling pathways, but exhibit low affinity to the well-established GBM target of PI3K/Akt/mTOR pathway. Simvastatin 20-31 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 123-128 32172201-5 2020 It is revealed that Simvastatin can potentially interact with certain known targets or key regulators of GBM such as ErbB, c-Src and FGFR signaling pathways, but exhibit low affinity to the well-established GBM target of PI3K/Akt/mTOR pathway. Simvastatin 20-31 AKT serine/threonine kinase 1 Homo sapiens 226-229 32172201-5 2020 It is revealed that Simvastatin can potentially interact with certain known targets or key regulators of GBM such as ErbB, c-Src and FGFR signaling pathways, but exhibit low affinity to the well-established GBM target of PI3K/Akt/mTOR pathway. Simvastatin 20-31 mechanistic target of rapamycin kinase Homo sapiens 230-234 32172201-6 2020 Further assays determine that Simvastatin can inhibit kinase hits EGFR, MET, SRC and HER2 at nanomolar level, which are comparable with those of cognate kinase inhibitors. Simvastatin 30-41 epidermal growth factor receptor Homo sapiens 66-70 32172201-6 2020 Further assays determine that Simvastatin can inhibit kinase hits EGFR, MET, SRC and HER2 at nanomolar level, which are comparable with those of cognate kinase inhibitors. Simvastatin 30-41 SAFB like transcription modulator Homo sapiens 72-75 32172201-6 2020 Further assays determine that Simvastatin can inhibit kinase hits EGFR, MET, SRC and HER2 at nanomolar level, which are comparable with those of cognate kinase inhibitors. Simvastatin 30-41 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 77-80 32172201-6 2020 Further assays determine that Simvastatin can inhibit kinase hits EGFR, MET, SRC and HER2 at nanomolar level, which are comparable with those of cognate kinase inhibitors. Simvastatin 30-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-89 32172201-7 2020 Structural analyses reveal that the sophisticated T790 M gatekeeper mutation can considerably reduce Simvastatin sensitivity to EGFR by inducing the ligand change between different binding modes. Simvastatin 101-112 epidermal growth factor receptor Homo sapiens 128-132 32633363-10 2020 Meanwhile, simvastatin treatment caused cell cycle arrest in G0/G1 phase, remarkably downregulated expression of cyclin D1, and upregulated expressions of p21 and Bim. Simvastatin 11-22 cyclin D1 Homo sapiens 113-122 32633363-10 2020 Meanwhile, simvastatin treatment caused cell cycle arrest in G0/G1 phase, remarkably downregulated expression of cyclin D1, and upregulated expressions of p21 and Bim. Simvastatin 11-22 H3 histone pseudogene 16 Homo sapiens 155-158 32633363-10 2020 Meanwhile, simvastatin treatment caused cell cycle arrest in G0/G1 phase, remarkably downregulated expression of cyclin D1, and upregulated expressions of p21 and Bim. Simvastatin 11-22 BCL2 like 11 Homo sapiens 163-166 32633363-11 2020 In addition, simvastatin induced apoptosis of NPC cells and enhanced the Luciferase activity of caspase-3. Simvastatin 13-24 caspase 3 Homo sapiens 96-105 32633363-12 2020 Western blot results indicated that simvastatin promoted the protein level of Bax and caspase-3, whereas suppressed the protein expression of Bcl-2. Simvastatin 36-47 BCL2 associated X, apoptosis regulator Homo sapiens 78-81 32633363-12 2020 Western blot results indicated that simvastatin promoted the protein level of Bax and caspase-3, whereas suppressed the protein expression of Bcl-2. Simvastatin 36-47 caspase 3 Homo sapiens 86-95 32633363-12 2020 Western blot results indicated that simvastatin promoted the protein level of Bax and caspase-3, whereas suppressed the protein expression of Bcl-2. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 142-147 32633363-14 2020 Further studies demonstrated that simvastatin remarkably attenuated the Luciferase activity of pNF-kappaB-Luc, thereby specifically inhibiting the NF-kappaB signaling pathway. Simvastatin 34-45 nuclear factor kappa B subunit 1 Homo sapiens 96-105 32633363-15 2020 CONCLUSIONS: Simvastatin inhibits proliferation and promotes apoptosis of NPC cells by inhibiting the NF-kappaB pathway. Simvastatin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 102-111 32695291-0 2020 Simvastatin combined with bone marrow mesenchymal stromal cells (BMSCs) improve burn wound healing by ameliorating angiogenesis through SDF-1alpha/CXCR4 pathway. Simvastatin 0-11 C-X-C motif chemokine receptor 4 Rattus norvegicus 147-152 32695291-2 2020 We hypothesized that Simvastatin in combination with the bone marrow mesenchymal stromal cells (BMSCs) improve burn wound healing by ameliorating angiogenesis via SDF-1alpha/CXCR4 pathway. Simvastatin 21-32 C-X-C motif chemokine receptor 4 Rattus norvegicus 174-179 32695291-10 2020 Conclusion: Treatment of deep partial-thickness of burns with co-treatment of BMSCs and Simvastatin resulted in improved burn wound healing through up-regulating of SDF-1alpha/CXCR4 pathway. Simvastatin 88-99 C-X-C motif chemokine receptor 4 Rattus norvegicus 176-181 31930449-14 2020 CONCLUSION: Statins used in AD patients had beneficial effects on the scores of MMSE scale in the short term (<= 12 months), and statins could slow the deterioration of neuropsychiatric status and significantly improve activities of daily living ability in AD patients, but statins did not show an advantage in the change of the ADAS-Cog scale scores. Simvastatin 12-19 alkylglycerone phosphate synthase Homo sapiens 332-336 32277945-9 2020 Simvastatin blocked oxidized LDL (ox-LDL)-induced increases in miR-652-3p and ox-LDL-induced decreases in ISL1 protein expression, endothelial NO synthase (eNOS) activation, and NO production. Simvastatin 0-11 ISL LIM homeobox 1 Rattus norvegicus 106-110 32277945-9 2020 Simvastatin blocked oxidized LDL (ox-LDL)-induced increases in miR-652-3p and ox-LDL-induced decreases in ISL1 protein expression, endothelial NO synthase (eNOS) activation, and NO production. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 156-160 32277945-12 2020 The impact of simvastatin in vivo was abolished by overexpressing miR-652-3p or knocking-down ISL1. Simvastatin 14-25 ISL1 transcription factor, LIM/homeodomain Mus musculus 94-98 32277945-13 2020 The rat model of dyslipidemia exhibited a similar pattern of miR-652-3p upregulation, attenuated ISL1 protein levels, decreased eNOS activation, and decreased NO production, effects mitigated by simvastatin. Simvastatin 195-206 nitric oxide synthase 3 Rattus norvegicus 128-132 32196851-8 2020 RSV was found to protect H9c2 cells from simvastatin-induced activation of caspase-3/7. Simvastatin 41-52 caspase 3 Rattus norvegicus 75-84 31930449-14 2020 CONCLUSION: Statins used in AD patients had beneficial effects on the scores of MMSE scale in the short term (<= 12 months), and statins could slow the deterioration of neuropsychiatric status and significantly improve activities of daily living ability in AD patients, but statins did not show an advantage in the change of the ADAS-Cog scale scores. Simvastatin 132-139 alkylglycerone phosphate synthase Homo sapiens 332-336 32421147-7 2020 Prior incubation with simvastatin, lovastatin, and atorvastatin inhibited TGF-beta2-mediated MMP-2 and MMP-9 expression and activities. Simvastatin 22-33 transforming growth factor beta 2 Homo sapiens 74-83 32402990-7 2020 Since simvastatin was reported to improve the survival of patients with pancreatic tumors at an early stage and suppress the metastasis of most cancers, we utilized it during YLG-1-PDT and discovered alleviated migration/invasion, metastasis and MMP-2/9 expression. Simvastatin 6-17 matrix metallopeptidase 2 Homo sapiens 246-253 32446297-13 2020 Oral administration of a HMG-CoA reductase inhibitor, simvastatin, or an AMPK activator, metformin, to young HFD offspring reversed maternal HFD-programmed increase in AT1R and decreases in SIRT1, PGC-1alpha and TFAM; alleviated ROS production in RVLM, and attenuated sympathoexcitation and hypertension. Simvastatin 54-65 angiotensin II receptor, type 1a Rattus norvegicus 168-172 32446297-13 2020 Oral administration of a HMG-CoA reductase inhibitor, simvastatin, or an AMPK activator, metformin, to young HFD offspring reversed maternal HFD-programmed increase in AT1R and decreases in SIRT1, PGC-1alpha and TFAM; alleviated ROS production in RVLM, and attenuated sympathoexcitation and hypertension. Simvastatin 54-65 sirtuin 1 Rattus norvegicus 190-195 32446297-13 2020 Oral administration of a HMG-CoA reductase inhibitor, simvastatin, or an AMPK activator, metformin, to young HFD offspring reversed maternal HFD-programmed increase in AT1R and decreases in SIRT1, PGC-1alpha and TFAM; alleviated ROS production in RVLM, and attenuated sympathoexcitation and hypertension. Simvastatin 54-65 PPARG coactivator 1 alpha Rattus norvegicus 197-207 32446297-13 2020 Oral administration of a HMG-CoA reductase inhibitor, simvastatin, or an AMPK activator, metformin, to young HFD offspring reversed maternal HFD-programmed increase in AT1R and decreases in SIRT1, PGC-1alpha and TFAM; alleviated ROS production in RVLM, and attenuated sympathoexcitation and hypertension. Simvastatin 54-65 transcription factor A, mitochondrial Rattus norvegicus 212-216 32483443-6 2020 We developed a dual-targeting liposomal system with modification of anti-PD-L1 nanobody and transferrin receptor (TfR)-binding peptide T12 for codelivery of simvastatin/gefitinib to treat BMs of NSCLC. Simvastatin 157-168 transferrin receptor Homo sapiens 92-112 32483443-6 2020 We developed a dual-targeting liposomal system with modification of anti-PD-L1 nanobody and transferrin receptor (TfR)-binding peptide T12 for codelivery of simvastatin/gefitinib to treat BMs of NSCLC. Simvastatin 157-168 transferrin receptor Homo sapiens 114-117 31816623-7 2020 Most importantly, simvastatin completely prevented hyperoxia-induced arterial remodeling, in association with partial restoration of VEGFA and VEGF receptor 2 (VEGFR2) expression. Simvastatin 18-29 vascular endothelial growth factor A Oryctolagus cuniculus 133-138 32421147-7 2020 Prior incubation with simvastatin, lovastatin, and atorvastatin inhibited TGF-beta2-mediated MMP-2 and MMP-9 expression and activities. Simvastatin 22-33 matrix metallopeptidase 2 Homo sapiens 93-98 32421147-7 2020 Prior incubation with simvastatin, lovastatin, and atorvastatin inhibited TGF-beta2-mediated MMP-2 and MMP-9 expression and activities. Simvastatin 22-33 matrix metallopeptidase 9 Homo sapiens 103-108 31955524-14 2020 DISCUSSION AND CONCLUSION: Simvastatin could enhance protective autophagy by activating the AMPK-SKP2-CARM1 pathway to improve erectile function in DMED rats. Simvastatin 27-38 S-phase kinase associated protein 2 Rattus norvegicus 97-101 31955524-14 2020 DISCUSSION AND CONCLUSION: Simvastatin could enhance protective autophagy by activating the AMPK-SKP2-CARM1 pathway to improve erectile function in DMED rats. Simvastatin 27-38 coactivator-associated arginine methyltransferase 1 Rattus norvegicus 102-107 31823428-0 2020 Astragaloside IV reverses simvastatin-induced skeletal muscle injury by activating the AMPK-PGC-1alpha signalling pathway. Simvastatin 26-37 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 92-102 30328567-9 2020 Middle-dose CONR had better effect on serum AGEs compared with the low-dose group (P<0.01); middle-dose CONR and simvastatin groups had better effect on the expression of caspase-3, bcl-2 protein, myocardium apoptosis compared with the CONR low-dose group (P<0.01). Simvastatin 113-124 caspase-3 Oryctolagus cuniculus 171-180 30328567-9 2020 Middle-dose CONR had better effect on serum AGEs compared with the low-dose group (P<0.01); middle-dose CONR and simvastatin groups had better effect on the expression of caspase-3, bcl-2 protein, myocardium apoptosis compared with the CONR low-dose group (P<0.01). Simvastatin 113-124 BCL-2 Oryctolagus cuniculus 182-187 32103508-3 2020 Reducing cholesterol content with a cholesterol scavenger (b-methylcyclodextrin) or statin compound (simvastatin) blocked ATP and IL-33 release by lowering the expression of VDAC-1 in the plasma membrane. Simvastatin 101-112 voltage dependent anion channel 1 Homo sapiens 174-180 32103508-11 2020 Similarly, reducing the cholesterol content of HBE cells with simvastatin or the cholesterol scavenger beta-methylcyclodextrin also blocked ATP release and IL-33 secretion by decreasing the level of VDAC-1 expression in the plasma membrane. Simvastatin 62-73 voltage dependent anion channel 1 Homo sapiens 199-205 32103508-14 2020 Furthermore, the simvastatin-evoked reduction of VDAC-1 expression in the plasma membrane, suggests the possibility that cholesterol lowering compounds may be beneficial in alleviating allergic airway inflammation induced by fungal allergens. Simvastatin 17-28 voltage dependent anion channel 1 Homo sapiens 49-55 31605661-0 2020 PGC-1alpha plays a pivotal role in simvastatin-induced exercise impairment in mice. Simvastatin 35-46 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 0-10 32005714-6 2020 We show here that statins induce a similar accumulation of immature LDLR that is resolved with class II correction. Simvastatin 18-25 low density lipoprotein receptor Homo sapiens 68-72 31605661-7 2020 Simvastatin increased mRNA expression of Sod1 and Sod2 in glycolytic and oxidative gastrocnemius of WT, but decreased it in KO mice. Simvastatin 0-11 superoxide dismutase 1, soluble Mus musculus 41-45 31605661-7 2020 Simvastatin increased mRNA expression of Sod1 and Sod2 in glycolytic and oxidative gastrocnemius of WT, but decreased it in KO mice. Simvastatin 0-11 superoxide dismutase 2, mitochondrial Mus musculus 50-54 31605661-8 2020 OE mice had a higher mitochondrial DNA content in both gastrocnemius than WT or KO mice and simvastatin exhibited a trend to decrease the citrate synthase activity in white and red gastrocnemius in all treatment groups. Simvastatin 92-103 citrate synthase Mus musculus 138-154 31605661-11 2020 CONCLUSIONS: Simvastatin impairs skeletal muscle function, muscle oxidative metabolism and mitochondrial morphology preferentially in WT and KO mice, whereas OE mice appear to be protected, suggesting a role of PGC-1alpha in preventing simvastatin-associated myotoxicity. Simvastatin 13-24 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 211-221 31605661-11 2020 CONCLUSIONS: Simvastatin impairs skeletal muscle function, muscle oxidative metabolism and mitochondrial morphology preferentially in WT and KO mice, whereas OE mice appear to be protected, suggesting a role of PGC-1alpha in preventing simvastatin-associated myotoxicity. Simvastatin 236-247 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 211-221 31960547-8 2020 Important markers for cancer progression (Bcl-2, Bax, NF-kB, and intratumor antioxidants) demonstrated that liposomal simvastatin might sensitize C26 cells to liposomal 5-fluorouracil administration in both regimens tested. Simvastatin 118-129 B cell leukemia/lymphoma 2 Mus musculus 42-47 31960547-8 2020 Important markers for cancer progression (Bcl-2, Bax, NF-kB, and intratumor antioxidants) demonstrated that liposomal simvastatin might sensitize C26 cells to liposomal 5-fluorouracil administration in both regimens tested. Simvastatin 118-129 BCL2-associated X protein Mus musculus 49-52 31974142-3 2020 We identified a common variant at the PPARA locus (rs6008845, C/T) displaying a study-wide-significant influence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported White subjects treated with simvastatin and randomized to fenofibrate or placebo in the Action-to-Control-Cardiovascular-Risk-in-Diabetes (ACCORD) Lipid Trial. Simvastatin 234-245 peroxisome proliferator activated receptor alpha Homo sapiens 38-43 31944822-0 2020 Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis. Simvastatin 40-47 yes-associated protein 1 Mus musculus 14-17 31944822-4 2020 Multiple hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) were found to inhibit YAP nuclear localization via induction of YAP phosphorylation, cytoplasmic retention and degradation. Simvastatin 78-85 yes-associated protein 1 Mus musculus 109-112 31944822-4 2020 Multiple hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) were found to inhibit YAP nuclear localization via induction of YAP phosphorylation, cytoplasmic retention and degradation. Simvastatin 78-85 yes-associated protein 1 Mus musculus 151-154 31944822-6 2020 Finally, we show simvastatin modulates YAP in vivo in mouse lung fibroblasts. Simvastatin 17-28 yes-associated protein 1 Mus musculus 39-42 31944822-7 2020 Our results highlight the potential of small molecule screens for YAP inhibitors and provide a mechanism for the anti-fibrotic activity of statins in IPF. Simvastatin 139-146 yes-associated protein 1 Mus musculus 66-69 32373962-0 2020 Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA. Simvastatin 0-11 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 65-71 32373962-0 2020 Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA. Simvastatin 0-11 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 100-104 32373962-4 2020 A549 cells were induced with different doses of Simvastatin for 24 h. Subsequently, relative levels of METTL3 and EZH2 in cells were detected. Simvastatin 48-59 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 103-109 32373962-7 2020 Relative levels of EZH2 and epithelial-mesenchymal transition (EMT)-associated genes (E-cadherin and N-cadherin), and metastatic abilities were detected in Simvastatin-induced A549 cells transfected with pcDNA-METTL3. Simvastatin 156-167 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 19-23 32373962-7 2020 Relative levels of EZH2 and epithelial-mesenchymal transition (EMT)-associated genes (E-cadherin and N-cadherin), and metastatic abilities were detected in Simvastatin-induced A549 cells transfected with pcDNA-METTL3. Simvastatin 156-167 cadherin 1 Homo sapiens 86-96 32373962-7 2020 Relative levels of EZH2 and epithelial-mesenchymal transition (EMT)-associated genes (E-cadherin and N-cadherin), and metastatic abilities were detected in Simvastatin-induced A549 cells transfected with pcDNA-METTL3. Simvastatin 156-167 cadherin 2 Homo sapiens 101-111 32373962-7 2020 Relative levels of EZH2 and epithelial-mesenchymal transition (EMT)-associated genes (E-cadherin and N-cadherin), and metastatic abilities were detected in Simvastatin-induced A549 cells transfected with pcDNA-METTL3. Simvastatin 156-167 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 210-216 32373962-12 2020 Simvastatin could abolish the role of METTL3 in regulating relative levels of EZH2 and EMT-associated genes, as well as metastatic abilities in A549 cells. Simvastatin 0-11 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 38-44 32373962-12 2020 Simvastatin could abolish the role of METTL3 in regulating relative levels of EZH2 and EMT-associated genes, as well as metastatic abilities in A549 cells. Simvastatin 0-11 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 78-82 32373962-13 2020 CONCLUSIONS: Simvastatin induces METTL3 down-regulation in lung cancer tissues, which further influences EMT via m6A modification on EZH2 mRNA and thus inhibits the malignant progression of lung cancer. Simvastatin 13-24 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 33-39 32373962-13 2020 CONCLUSIONS: Simvastatin induces METTL3 down-regulation in lung cancer tissues, which further influences EMT via m6A modification on EZH2 mRNA and thus inhibits the malignant progression of lung cancer. Simvastatin 13-24 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 133-137 32030813-4 2020 Statins induced GILZ expression in C2C12 cells, primary murine myoblasts/myotubes, primary human myoblasts, and in vivo in zebrafish embryos and human quadriceps femoris muscle. Simvastatin 0-7 TSC22 domain family, member 3 Mus musculus 16-20 31955599-3 2020 Adherence to statins and ezetimibe correlate with LDL-C reduction and risk, potentially accounting for approximately 12 000 avoidable cardiovascular events per 500 000 patients annually (1). Simvastatin 13-20 component of oligomeric golgi complex 2 Homo sapiens 50-55 32210573-0 2020 Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and beta-Catenin Signaling. Simvastatin 0-11 Yes1 associated transcriptional regulator Homo sapiens 99-102 32210573-0 2020 Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and beta-Catenin Signaling. Simvastatin 0-11 catenin beta 1 Homo sapiens 107-119 32210573-7 2020 Mechanistic studies showed that simvastatin treatment could inhibit the expression of beta-catenin and the activity of YAP and the downstream targets of YAP and beta-catenin in gastric cancer cells. Simvastatin 32-43 catenin beta 1 Homo sapiens 86-98 32210573-7 2020 Mechanistic studies showed that simvastatin treatment could inhibit the expression of beta-catenin and the activity of YAP and the downstream targets of YAP and beta-catenin in gastric cancer cells. Simvastatin 32-43 Yes1 associated transcriptional regulator Homo sapiens 119-122 32210573-7 2020 Mechanistic studies showed that simvastatin treatment could inhibit the expression of beta-catenin and the activity of YAP and the downstream targets of YAP and beta-catenin in gastric cancer cells. Simvastatin 32-43 Yes1 associated transcriptional regulator Homo sapiens 153-156 32210573-7 2020 Mechanistic studies showed that simvastatin treatment could inhibit the expression of beta-catenin and the activity of YAP and the downstream targets of YAP and beta-catenin in gastric cancer cells. Simvastatin 32-43 catenin beta 1 Homo sapiens 161-173 32210573-9 2020 Further investigation revealed that simvastatin mainly acted through by inhibiting the activity of RhoA to inhibit YAP and beta-catenin, and the geranylgeranyl pyrophosphate pathway mediated this regulation. Simvastatin 36-47 ras homolog family member A Homo sapiens 99-103 32210573-9 2020 Further investigation revealed that simvastatin mainly acted through by inhibiting the activity of RhoA to inhibit YAP and beta-catenin, and the geranylgeranyl pyrophosphate pathway mediated this regulation. Simvastatin 36-47 Yes1 associated transcriptional regulator Homo sapiens 115-118 32210573-9 2020 Further investigation revealed that simvastatin mainly acted through by inhibiting the activity of RhoA to inhibit YAP and beta-catenin, and the geranylgeranyl pyrophosphate pathway mediated this regulation. Simvastatin 36-47 catenin beta 1 Homo sapiens 123-135 32242391-10 2020 Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-kappaB, NLRP3, ASC, caspase-1, IL-1beta, and IL-6 (all P < 0.01). Simvastatin 5-16 NLR family, pyrin domain containing 3 Rattus norvegicus 121-126 32242391-10 2020 Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-kappaB, NLRP3, ASC, caspase-1, IL-1beta, and IL-6 (all P < 0.01). Simvastatin 5-16 PYD and CARD domain containing Rattus norvegicus 128-131 32242391-10 2020 Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-kappaB, NLRP3, ASC, caspase-1, IL-1beta, and IL-6 (all P < 0.01). Simvastatin 5-16 caspase 1 Rattus norvegicus 133-142 32242391-10 2020 Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-kappaB, NLRP3, ASC, caspase-1, IL-1beta, and IL-6 (all P < 0.01). Simvastatin 5-16 interleukin 1 alpha Rattus norvegicus 144-152 32242391-10 2020 Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-kappaB, NLRP3, ASC, caspase-1, IL-1beta, and IL-6 (all P < 0.01). Simvastatin 5-16 interleukin 6 Rattus norvegicus 158-162 32199147-12 2020 0.2 microM pravastatin and simvastatin significantly reduced ET-1 and sFLT-1 protein secretion. Simvastatin 27-38 endothelin 1 Homo sapiens 61-65 31605489-7 2020 Simvastatin, fluvastatin and pravastatin showed the most favorable therapeutic index, and enhanced the anti-tubercular activity of the first-line drugs isoniazid, rifampin and pyrazinamide in THP-1 cells. Simvastatin 0-11 GLI family zinc finger 2 Homo sapiens 192-197 31969375-7 2020 Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins. Simvastatin 113-120 mitogen-activated protein kinase kinase 5 Homo sapiens 22-26 31969375-7 2020 Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins. Simvastatin 113-120 mitogen-activated protein kinase 7 Homo sapiens 27-31 31969375-7 2020 Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins. Simvastatin 113-120 SCLC1 Homo sapiens 43-47 32030813-9 2020 Statins also impaired myoblast differentiation, and this effect was accompanied by GILZ induction. Simvastatin 0-7 TSC22 domain family, member 3 Mus musculus 83-87 31738647-5 2020 Interestingly, XPD transduction and treatment with statins and bisphosphonates known to accelerate the radiation-induced ATM nucleo-shuttling led to significant complementation of these impairments.Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Simvastatin 51-58 ATM serine/threonine kinase Homo sapiens 121-124 31734364-0 2020 In-silico and in-vitro analysis of endocan interaction with statins. Simvastatin 60-67 endothelial cell specific molecule 1 Homo sapiens 35-42 31734364-3 2020 Hence, we predicted the three-dimensional structure of human endocan and calculated the binding efficiency of statins towards endocan and determined their inhibition potential. Simvastatin 110-117 endothelial cell specific molecule 1 Homo sapiens 61-68 31734364-3 2020 Hence, we predicted the three-dimensional structure of human endocan and calculated the binding efficiency of statins towards endocan and determined their inhibition potential. Simvastatin 110-117 endothelial cell specific molecule 1 Homo sapiens 126-133 31734364-5 2020 Moreover, MD simulations and pull-down assay results confirmed that simvastatin binding is stable with human endocan. Simvastatin 68-79 endothelial cell specific molecule 1 Homo sapiens 109-116 31734364-6 2020 In-silico results obtained in the present study were validated under in-vitro condition by analysing the effect of endocan under simvastatin treatment. Simvastatin 129-140 endothelial cell specific molecule 1 Homo sapiens 115-122 31734364-7 2020 Western blot results have shown that simvastatin could reduce endocan expression in LPS-treated endothelial cells. Simvastatin 37-48 endothelial cell specific molecule 1 Homo sapiens 62-69 31734364-9 2020 However, endocan and simvastatin combination treatment could suppress NO, ROS production and iNOS, CRP activation. Simvastatin 21-32 nitric oxide synthase 2 Homo sapiens 93-97 31734364-9 2020 However, endocan and simvastatin combination treatment could suppress NO, ROS production and iNOS, CRP activation. Simvastatin 21-32 C-reactive protein Homo sapiens 99-102 31734364-11 2020 In addition, the results showed that simvastatin could interact with endocan and thereby suppress the stimuli-induced effect. Simvastatin 37-48 endothelial cell specific molecule 1 Homo sapiens 69-76 31738647-5 2020 Interestingly, XPD transduction and treatment with statins and bisphosphonates known to accelerate the radiation-induced ATM nucleo-shuttling led to significant complementation of these impairments.Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Simvastatin 51-58 ERCC excision repair 2, TFIIH core complex helicase subunit Homo sapiens 253-256 31738647-5 2020 Interestingly, XPD transduction and treatment with statins and bisphosphonates known to accelerate the radiation-induced ATM nucleo-shuttling led to significant complementation of these impairments.Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Simvastatin 330-337 ERCC excision repair 2, TFIIH core complex helicase subunit Homo sapiens 15-18 31738647-5 2020 Interestingly, XPD transduction and treatment with statins and bisphosphonates known to accelerate the radiation-induced ATM nucleo-shuttling led to significant complementation of these impairments.Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Simvastatin 330-337 ATM serine/threonine kinase Homo sapiens 121-124 31738647-5 2020 Interestingly, XPD transduction and treatment with statins and bisphosphonates known to accelerate the radiation-induced ATM nucleo-shuttling led to significant complementation of these impairments.Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Simvastatin 330-337 ERCC excision repair 2, TFIIH core complex helicase subunit Homo sapiens 253-256 31911428-2 2020 Statins, which are frequently prescribed for type 2 diabetic patients suffering from dyslipidemia, are known for their diabetogenic risk and are reported to interact with the FXR. Simvastatin 0-7 nuclear receptor subfamily 1 group H member 4 Homo sapiens 175-178 32153409-3 2020 The aim of this study was to investigate the effect of simvastatin on the Kv1.3 and KCa3.1 in monocyte. Simvastatin 55-66 potassium voltage-gated channel subfamily A member 3 Homo sapiens 74-79 31964553-0 2020 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. Simvastatin 59-70 thiamin pyrophosphokinase 1 Homo sapiens 0-4 31964553-6 2020 In simvastatin-sensitive SNU-5 cells, the levels of the PARP and cleaved caspase-3 apoptosis markers increased upon exposure to simvastatin. Simvastatin 3-14 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 31964553-6 2020 In simvastatin-sensitive SNU-5 cells, the levels of the PARP and cleaved caspase-3 apoptosis markers increased upon exposure to simvastatin. Simvastatin 128-139 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 31964553-10 2020 We confirmed that RNA expression of the TPK1 DEG was significantly increased in simvastatin-sensitive cell lines. Simvastatin 80-91 thiamin pyrophosphokinase 1 Homo sapiens 40-44 31964553-11 2020 TPK1 knockdown in a simvastatin-sensitive GC SNU5 cell line, decreased the anti-tumour effects of simvastatin, while TPK1 overexpression enhanced the anti-tumour effect of simvastatin. Simvastatin 20-31 thiamin pyrophosphokinase 1 Homo sapiens 0-4 31964553-11 2020 TPK1 knockdown in a simvastatin-sensitive GC SNU5 cell line, decreased the anti-tumour effects of simvastatin, while TPK1 overexpression enhanced the anti-tumour effect of simvastatin. Simvastatin 98-109 thiamin pyrophosphokinase 1 Homo sapiens 0-4 31964553-11 2020 TPK1 knockdown in a simvastatin-sensitive GC SNU5 cell line, decreased the anti-tumour effects of simvastatin, while TPK1 overexpression enhanced the anti-tumour effect of simvastatin. Simvastatin 98-109 thiamin pyrophosphokinase 1 Homo sapiens 0-4 32153409-3 2020 The aim of this study was to investigate the effect of simvastatin on the Kv1.3 and KCa3.1 in monocyte. Simvastatin 55-66 potassium calcium-activated channel subfamily N member 4 Homo sapiens 84-90 32153409-4 2020 Methods and Results: In human monocytic THP-1 cells, simvastatin significantly inhibited Kv1.3 mRNA and protein expression by real-time quantitative PCR analysis and western blotting. Simvastatin 53-64 potassium voltage-gated channel subfamily A member 3 Homo sapiens 89-94 32153409-6 2020 By whole-cell patch clamp, simvastatin (10 muM) remarkably inhibited the current intensity of Kv1.3, but had no effect on KCa3.1. Simvastatin 27-38 latexin Homo sapiens 43-46 32153409-6 2020 By whole-cell patch clamp, simvastatin (10 muM) remarkably inhibited the current intensity of Kv1.3, but had no effect on KCa3.1. Simvastatin 27-38 potassium voltage-gated channel subfamily A member 3 Homo sapiens 94-99 32153409-7 2020 Simvastatin (10 muM) treatment significantly reduced the monocyte chemoattractant protein 1 (MCP-1)-induced monocyte migration. Simvastatin 0-11 latexin Homo sapiens 16-19 32153409-7 2020 Simvastatin (10 muM) treatment significantly reduced the monocyte chemoattractant protein 1 (MCP-1)-induced monocyte migration. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 57-91 32153409-7 2020 Simvastatin (10 muM) treatment significantly reduced the monocyte chemoattractant protein 1 (MCP-1)-induced monocyte migration. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 93-98 32153409-10 2020 However, simvastatin (40 mg per day) significantly inhibited the Kv1.3 but not KCa3.1 mRNA expression after 1 month and 3 months therapy in CAD patients. Simvastatin 9-20 potassium voltage-gated channel subfamily A member 3 Homo sapiens 65-70 31948593-0 2020 Statin ameliorates adipose inflammation via NLRP3 suppression. Simvastatin 0-6 NLR family pyrin domain containing 3 Homo sapiens 44-49 32068819-2 2020 Objective: To evaluate the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the general population and in BRCA1/2 mutation carriers. Simvastatin 214-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 76-133 32068819-2 2020 Objective: To evaluate the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the general population and in BRCA1/2 mutation carriers. Simvastatin 214-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 185-202 31715145-15 2020 Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice. Simvastatin 0-11 transformation related protein 53, pseudogene Mus musculus 47-50 32041347-8 2020 Consistent with a Th1 cytokine-dependent mechanism, parenterally administered recombinant IFN-gamma could substitute for DC-based immunotherapy, likewise inhibiting tumor growth when combined with simvastatin. Simvastatin 197-208 negative elongation factor complex member C/D Homo sapiens 18-21 32041347-8 2020 Consistent with a Th1 cytokine-dependent mechanism, parenterally administered recombinant IFN-gamma could substitute for DC-based immunotherapy, likewise inhibiting tumor growth when combined with simvastatin. Simvastatin 197-208 interferon gamma Mus musculus 90-99 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 155-173 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 175-178 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 interleukin 6 Homo sapiens 184-202 31955966-5 2020 RCTs were included if they compared the effects of statins on serum concentrations of CRP and IL-6 in adults with abnormal glucose homeostasis. Simvastatin 51-58 C-reactive protein Homo sapiens 86-89 31955966-5 2020 RCTs were included if they compared the effects of statins on serum concentrations of CRP and IL-6 in adults with abnormal glucose homeostasis. Simvastatin 51-58 interleukin 6 Homo sapiens 94-98 31955966-11 2020 Pooling 6 effect sizes from 5 studies revealed a significantly reduced serum concentration of CRP after simvastatin therapy (WMD, -0.66; 95% CI, -0.79 to -0.54; I2 = 97.6%). Simvastatin 104-115 C-reactive protein Homo sapiens 94-97 31955966-12 2020 IMPLICATIONS: The administration of atorvastatin or simvastatin in patients with abnormal glucose hemostasis was associated with a reduced serum CRP concentration. Simvastatin 52-63 C-reactive protein Homo sapiens 145-148 31734315-0 2020 Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation. Simvastatin 0-11 sirtuin 1 Rattus norvegicus 133-163 31734315-0 2020 Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation. Simvastatin 0-11 sirtuin 1 Rattus norvegicus 165-170 31734315-3 2020 Sim potentiated the autophagy response induced by neonatal HI, as shown by the increased expression of both microtubule-associated protein 1 light chain 3 (LC3) and beclin 1, increased monodansylcadaverine (MDC) labeling, and reduced expression of p62. Simvastatin 0-3 beclin 1 Rattus norvegicus 165-173 31734315-3 2020 Sim potentiated the autophagy response induced by neonatal HI, as shown by the increased expression of both microtubule-associated protein 1 light chain 3 (LC3) and beclin 1, increased monodansylcadaverine (MDC) labeling, and reduced expression of p62. Simvastatin 0-3 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 248-251 31734315-6 2020 Sim preconditioning further decreased the activity of mTORC1, but did not affect that of mTORC2. Simvastatin 0-3 CREB regulated transcription coactivator 1 Mus musculus 54-60 31734315-7 2020 However, 24 h after injury, mTORC2 activity was significantly preserved in Sim-treated rats. Simvastatin 75-78 CREB regulated transcription coactivator 2 Mus musculus 28-34 31734315-8 2020 Sim preconditioning also prevented the depletion of SIRT1 induced by HI, an effect that was completely blocked by 3MA. Simvastatin 0-3 sirtuin 1 Rattus norvegicus 52-57 31734315-9 2020 These data show that Sim preconditioning may modulate autophagy and survival pathways by affecting mTORC1, mTORC2, and SIRT1 activities. Simvastatin 21-24 CREB regulated transcription coactivator 1 Mus musculus 99-105 31734315-9 2020 These data show that Sim preconditioning may modulate autophagy and survival pathways by affecting mTORC1, mTORC2, and SIRT1 activities. Simvastatin 21-24 CREB regulated transcription coactivator 2 Mus musculus 107-113 31734315-9 2020 These data show that Sim preconditioning may modulate autophagy and survival pathways by affecting mTORC1, mTORC2, and SIRT1 activities. Simvastatin 21-24 sirtuin 1 Rattus norvegicus 119-124 32040442-2 2020 However, with the increasing application of statins which mainly decrease low-density lipoprotein cholesterol (LDL-C) levels, clinical trials and meta-analysis showed a clearly increase of the incidence of new-onset DMs, partly due to genetic factors. Simvastatin 44-51 component of oligomeric golgi complex 2 Homo sapiens 111-116 31880914-0 2020 Statin-induced Chronic Cholesterol Depletion Switches GPCR Endocytosis and Trafficking: Insights from the Serotonin1A Receptor. Simvastatin 0-6 vomeronasal 1 receptor 17 pseudogene Homo sapiens 54-58 32010481-0 2020 Statins Induce a DAF-16/Foxo-dependent Longevity Phenotype via JNK-1 through Mevalonate Depletion in C. elegans. Simvastatin 0-7 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 17-23 32010481-0 2020 Statins Induce a DAF-16/Foxo-dependent Longevity Phenotype via JNK-1 through Mevalonate Depletion in C. elegans. Simvastatin 0-7 Stress-activated protein kinase jnk-1 Caenorhabditis elegans 63-68 32010481-8 2020 Accordingly, prolonged low-dose statin exposure leads to an increased expression of jnk-1, a known activator of DAF-16. Simvastatin 32-38 Stress-activated protein kinase jnk-1 Caenorhabditis elegans 84-89 32010481-8 2020 Accordingly, prolonged low-dose statin exposure leads to an increased expression of jnk-1, a known activator of DAF-16. Simvastatin 32-38 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 112-118 32010481-9 2020 Moreover, the beneficial effects of statins on aging pigments and lifespan depend on DAF-16 and JNK-1, as shown in epistasis analyses. Simvastatin 36-43 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 85-91 32010481-9 2020 Moreover, the beneficial effects of statins on aging pigments and lifespan depend on DAF-16 and JNK-1, as shown in epistasis analyses. Simvastatin 36-43 Stress-activated protein kinase jnk-1 Caenorhabditis elegans 96-101 31058344-2 2020 Simvastatin is a cholesterol-lowering drug via inhibiting HMG-CoA reductase, thereby inhibiting protein prenylation. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 58-75 31822926-4 2020 Documented evidence for prevention of CAD is available for the control of hypertension using angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) and calcium antagonists, for the treatment of hypercholesterolemia using statins, ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK-9) inhibitors and for the treatment of type 2 diabetes mellitus with metformin, sodium-glucose transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. Simvastatin 250-257 angiotensin I converting enzyme Homo sapiens 124-127 31715145-15 2020 Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice. Simvastatin 0-11 ring finger protein 128 Mus musculus 66-72 31715145-15 2020 Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice. Simvastatin 0-11 eukaryotic translation initiation factor 1 Homo sapiens 73-77 31663874-0 2020 The effect of Cytochrome P450 7A1(CYP7A1) polymorphism on lipid responses to simvastatin treatment. Simvastatin 77-88 cytochrome P450 family 7 subfamily A member 1 Homo sapiens 14-33 31663874-0 2020 The effect of Cytochrome P450 7A1(CYP7A1) polymorphism on lipid responses to simvastatin treatment. Simvastatin 77-88 cytochrome P450 family 7 subfamily A member 1 Homo sapiens 34-40 31663874-11 2020 CONCLUSIONS: The CYP7A1 gene polymorphism rs3824260 is related to inappropriate response of simvastatin treatment for hypercholesterolemia patients in Chinese Han population. Simvastatin 92-103 cytochrome P450 family 7 subfamily A member 1 Homo sapiens 17-23 31471919-7 2020 Moreover, simvastatin treatment upregulated the expression of genes related to osteogenic maturation, such as runt-related transcription factor 2, osteopontin, and osteocalcin, and increased the mineralization of the extracellular matrix in GCTB stromal cells. Simvastatin 10-21 RUNX family transcription factor 2 Homo sapiens 110-145 31471919-7 2020 Moreover, simvastatin treatment upregulated the expression of genes related to osteogenic maturation, such as runt-related transcription factor 2, osteopontin, and osteocalcin, and increased the mineralization of the extracellular matrix in GCTB stromal cells. Simvastatin 10-21 secreted phosphoprotein 1 Homo sapiens 147-158 31471919-7 2020 Moreover, simvastatin treatment upregulated the expression of genes related to osteogenic maturation, such as runt-related transcription factor 2, osteopontin, and osteocalcin, and increased the mineralization of the extracellular matrix in GCTB stromal cells. Simvastatin 10-21 bone gamma-carboxyglutamate protein Homo sapiens 164-175 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 cadherin EGF LAG seven-pass G-type receptor 2 Homo sapiens 143-149 31985637-10 2020 Enzyme-linked immunosorbent assay revealed that adiponectin concentrations in the diabetic rats with intraosseous injection of hydrogel vehicle plus simvastatin 0.5-mg group were significantly higher compared with the diabetic rats with intraosseous injection of hydrogel vehicle group beginning at day 4. Simvastatin 149-160 adiponectin, C1Q and collagen domain containing Rattus norvegicus 48-59 31985637-11 2020 Intraosseous administration of simvastatin decreased the expression of adiponectin and SDF-1 in bone tissue but enhanced the expression of adiponectin in wounded skin. Simvastatin 31-42 adiponectin, C1Q and collagen domain containing Rattus norvegicus 71-82 31985637-11 2020 Intraosseous administration of simvastatin decreased the expression of adiponectin and SDF-1 in bone tissue but enhanced the expression of adiponectin in wounded skin. Simvastatin 31-42 C-X-C motif chemokine ligand 12 Rattus norvegicus 87-92 31985637-11 2020 Intraosseous administration of simvastatin decreased the expression of adiponectin and SDF-1 in bone tissue but enhanced the expression of adiponectin in wounded skin. Simvastatin 31-42 adiponectin, C1Q and collagen domain containing Rattus norvegicus 139-150 31957803-1 2020 The current main treatment for coronary artery disease (CAD) is to reduce low-density lipoprotein cholesterol (LDL-C) by statins, which could decrease the incidence of major adverse cardiovascular events (MACEs) by 30%. Simvastatin 121-128 component of oligomeric golgi complex 2 Homo sapiens 111-116 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 proline and serine rich coiled-coil 1 Homo sapiens 150-155 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 apolipoprotein E Homo sapiens 171-175 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 apolipoprotein B Homo sapiens 177-181 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 Homo sapiens 187-194 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 low density lipoprotein receptor Homo sapiens 195-199 31969819-8 2019 Fluoxetine, simvastatin, and resveratrol significantly inhibited this IL-1beta- and TNF-alpha-induced ET-1 production. Simvastatin 12-23 interleukin 1 alpha Homo sapiens 70-78 31941676-0 2020 Statins Limit Coenzyme Q Synthesis and Metabolically Synergize with MEK Inhibition in Pancreatic Tumors. Simvastatin 0-7 mitogen-activated protein kinase kinase 7 Homo sapiens 68-71 31941676-4 2020 Simvastatin treatment reduces CoQ synthesis and promotes oxidative stress and apoptosis in tumors when administered in combination with a MEK inhibitor, providing a new mechanism through which statin treatment may impact PDAC growth.See related article by McGregor et al., p. 175. Simvastatin 0-11 mitogen-activated protein kinase kinase 7 Homo sapiens 138-141 31969805-7 2019 We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis. Simvastatin 223-234 presenilin 1 Mus musculus 73-76 31969819-8 2019 Fluoxetine, simvastatin, and resveratrol significantly inhibited this IL-1beta- and TNF-alpha-induced ET-1 production. Simvastatin 12-23 tumor necrosis factor Homo sapiens 84-93 31969805-7 2019 We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis. Simvastatin 223-234 3-hydroxy-3-methylglutaryl-CoA synthase 1 Homo sapiens 248-255 31915059-0 2020 Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Simvastatin 0-6 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-25 31915059-1 2020 OBJECTIVE: To describe successful therapeutic strategies in statin-induced anti-HMGCR myopathy. Simvastatin 60-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-85 31969819-8 2019 Fluoxetine, simvastatin, and resveratrol significantly inhibited this IL-1beta- and TNF-alpha-induced ET-1 production. Simvastatin 12-23 endothelin 1 Homo sapiens 102-106 31915059-2 2020 METHODS: Retrospective data from a cohort of 55 patients with statin-induced anti-HMGCR myopathy, sequentially stratified by the presence of proximal weakness, early remission, and corticosteroid and IVIG use at treatment induction, were analyzed for optimal successful induction and maintenance of remission strategies. Simvastatin 62-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-87 31969805-7 2019 We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis. Simvastatin 223-234 serine palmitoyltransferase long chain base subunit 1 Homo sapiens 317-365 31969805-7 2019 We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis. Simvastatin 223-234 serine palmitoyltransferase long chain base subunit 1 Homo sapiens 367-374 31969819-9 2019 Simvastatin and resveratrol significantly reduced ET-1 mRNA levels, indicating an effect at the level of transcription. Simvastatin 0-11 endothelin 1 Homo sapiens 50-54 31593483-2 2020 While statins are clear first-line drugs, new drug developments such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to statins. Simvastatin 202-209 proprotein convertase subtilisin/kexin type 9 Homo sapiens 119-124 32042518-0 2020 Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. Simvastatin 64-71 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 169-185 31853708-0 2020 Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure. Simvastatin 56-67 glycine amidinotransferase (L-arginine:glycine amidinotransferase) Mus musculus 20-24 31853708-0 2020 Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure. Simvastatin 56-67 guanidinoacetate methyltransferase Mus musculus 30-34 31853708-9 2020 We found that simvastatin induced muscle damage and reduced AGAT expression in wildtype mice (myocyte diameter: 34.1 +- 1.3 microm vs 21.5 +- 1.3 microm, P = 0.026; AGAT expression: 1.0 +- 0.3 vs 0.48 +- 0.05, P = 0.017). Simvastatin 14-25 glycine amidinotransferase (L-arginine:glycine amidinotransferase) Mus musculus 60-64 31853708-9 2020 We found that simvastatin induced muscle damage and reduced AGAT expression in wildtype mice (myocyte diameter: 34.1 +- 1.3 microm vs 21.5 +- 1.3 microm, P = 0.026; AGAT expression: 1.0 +- 0.3 vs 0.48 +- 0.05, P = 0.017). Simvastatin 14-25 glycine amidinotransferase (L-arginine:glycine amidinotransferase) Mus musculus 165-169 31853708-11 2020 Simvastatin-induced motor impairment was exacerbated in AGAT-deficient mice compared with AGAT-overexpressing GAMT-/- mice and therefore revealed an effect independent of Cr. Simvastatin 0-11 glycine amidinotransferase (L-arginine:glycine amidinotransferase) Mus musculus 56-60 32693758-0 2020 PHOSPHO1 Gene DNA Methylations Are Associated with a Change in HDL-C Response to Simvastatin Treatment. Simvastatin 81-92 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 0-8 32693758-1 2020 OBJECTIVE: Our aim was to detect the effects of DNA methylations in the phosphoethanolamine/phosphocholine phosphatase (PHOSPHO1) gene on the therapeutic efficacy of simvastatin. Simvastatin 166-177 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 72-118 32693758-1 2020 OBJECTIVE: Our aim was to detect the effects of DNA methylations in the phosphoethanolamine/phosphocholine phosphatase (PHOSPHO1) gene on the therapeutic efficacy of simvastatin. Simvastatin 166-177 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 120-128 32693758-7 2020 After stratifying by body mass index (BMI), the associations between the PHOSPHO1 DNA methylations and the change in HDL-C in response to simvastatin were more significant in obese subjects with a BMI of 25 kg/m2 or higher (beta=-0.027, P=0.002). Simvastatin 138-149 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 73-81 32693758-9 2020 There was a statistically significant additive interaction term (P=0.028) between BMI and mean PHOSPHO1 methylation in the model of the change in HDL-C in response to simvastatin. Simvastatin 167-178 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 95-103 32693758-10 2020 CONCLUSION: Our findings suggest that PHOSPHO1 DNA methylations are associated with a change in HDL-C in response to simvastatin treatment, and this association is especially dependent on the extent of patient obesity. Simvastatin 117-128 phosphoethanolamine/phosphocholine phosphatase 1 Homo sapiens 38-46 31935793-6 2020 Statins reverted the increased levels of Lp-PLA2 and CRP. Simvastatin 0-7 phospholipase A2 group VII Homo sapiens 41-48 31935793-6 2020 Statins reverted the increased levels of Lp-PLA2 and CRP. Simvastatin 0-7 C-reactive protein Homo sapiens 53-56 31935793-11 2020 Statins increased LDL size, decreased LDL(-), and lowered Lp-PLA2 in HDL from HTG. Simvastatin 0-7 phospholipase A2 group VII Homo sapiens 58-65 31957858-0 2020 Simvastatin promotes osteogenic differentiation of mesenchymal stem cells in rat model of osteoporosis through BMP-2/Smads signaling pathway. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 111-116 31957858-1 2020 OBJECTIVE: By establishing osteoporosis (OP) model in rats, the specific regulatory effect of simvastatin on promoting the differentiation of mesenchymal stem cells (MSCs) into osteoblasts through the bone morphogenetic protein 2 (BMP-2)/Smads signaling pathway was investigated. Simvastatin 94-105 bone morphogenetic protein 2 Rattus norvegicus 201-229 31957858-1 2020 OBJECTIVE: By establishing osteoporosis (OP) model in rats, the specific regulatory effect of simvastatin on promoting the differentiation of mesenchymal stem cells (MSCs) into osteoblasts through the bone morphogenetic protein 2 (BMP-2)/Smads signaling pathway was investigated. Simvastatin 94-105 bone morphogenetic protein 2 Rattus norvegicus 231-236 31957858-18 2020 CONCLUSIONS: Simvastatin can promote the differentiation of MSCs into osteoblasts in the OP rat model through the BMP-2/Smads signaling pathway. Simvastatin 13-24 bone morphogenetic protein 2 Rattus norvegicus 114-119 31585890-4 2020 The results showed that simvastatin, a clinically and widely used statin, prevented free fatty acid-induced endothelial hyperpermeability and disruption of ZO-1 and VE-cadherin junctions in mouse microvascular endothelial cells (MVECs). Simvastatin 24-35 tight junction protein 1 Mus musculus 156-160 31897100-1 2020 Effects of simvastatin-loaded PLGA sustained release microspheres on the treatment of rats with intervertebral disk degeneration (IVDD) and on 6-keto-prostaglandin F1alpha (6-K-PGF1alpha) and hypoxia inducible factor-1alpha (HIF-1alpha) were investigated. Simvastatin 11-22 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 192-223 31897100-1 2020 Effects of simvastatin-loaded PLGA sustained release microspheres on the treatment of rats with intervertebral disk degeneration (IVDD) and on 6-keto-prostaglandin F1alpha (6-K-PGF1alpha) and hypoxia inducible factor-1alpha (HIF-1alpha) were investigated. Simvastatin 11-22 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 225-235 31897100-10 2020 Simvastatin-loaded PLGA sustained release microspheres can improve the BMD of the vertebral body and increase the contents of 6-K-PGF1alpha and HIF-1alpha in the treatment of rats with IVDD, so they are important for the clinical treatment of the disease. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 144-154 31585890-4 2020 The results showed that simvastatin, a clinically and widely used statin, prevented free fatty acid-induced endothelial hyperpermeability and disruption of ZO-1 and VE-cadherin junctions in mouse microvascular endothelial cells (MVECs). Simvastatin 24-35 cadherin 5 Mus musculus 165-176 31585890-5 2020 This protective effect of simvastatin was largely due to improved lysosome function that attenuated lysosome injury-mediated Nlrp3 inflammasome activation and subsequent release of high mobility group box protein-1 (HMGB1). Simvastatin 26-37 NLR family pyrin domain containing 3 Homo sapiens 125-130 31940630-9 2020 Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion (but not expression), in primate cell cultures, by modulating MAPK/PI3K/mTOR pathways and expression of key receptors (GHRH-R/ghrelin-R/Kiss1-R) regulating pituitary function. Simvastatin 8-19 KISS1 receptor Homo sapiens 277-284 31585890-5 2020 This protective effect of simvastatin was largely due to improved lysosome function that attenuated lysosome injury-mediated Nlrp3 inflammasome activation and subsequent release of high mobility group box protein-1 (HMGB1). Simvastatin 26-37 high mobility group box 1 Homo sapiens 181-214 31585890-5 2020 This protective effect of simvastatin was largely due to improved lysosome function that attenuated lysosome injury-mediated Nlrp3 inflammasome activation and subsequent release of high mobility group box protein-1 (HMGB1). Simvastatin 26-37 high mobility group box 1 Homo sapiens 216-221 31585890-7 2020 Collectively, simvastatin treatment improves lysosome function via enhancing lysosome biogenesis and its autophagic turnover, which may be an important mechanism to suppress Nlrp3 inflammasome activation and prevents endothelial hyperpermeability in obesity. Simvastatin 14-25 NLR family pyrin domain containing 3 Homo sapiens 174-179 31866378-3 2020 So, the purpose of our study was to investigate whether survivin mediates the protective effect of statin against anthracycline-induced cardiotoxicity. Simvastatin 99-105 baculoviral IAP repeat-containing 5 Mus musculus 56-64 31834252-7 2020 RESULTS: There was a decrease in total cholesterol, triglycerides, low-density lipoprotein, C-reactive protein, fibrinogen, interleukin (IL)-1beta and right carotid intima-media thickness in the STA, PLET, and STAET groups compared with PL group (P < 0.001). Simvastatin 195-198 interleukin 1 beta Homo sapiens 124-146 31607677-17 2020 Patients in the simvastatin 40 mg/day plus rifaximin group showed a significant increase in AST and ALT compared with the placebo group (mean differences between the groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0 0009] and for ALT 61 IU/L [22 to 100; p=0 0025]. Simvastatin 16-27 solute carrier family 17 member 5 Homo sapiens 92-95 31607677-17 2020 Patients in the simvastatin 40 mg/day plus rifaximin group showed a significant increase in AST and ALT compared with the placebo group (mean differences between the groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0 0009] and for ALT 61 IU/L [22 to 100; p=0 0025]. Simvastatin 16-27 solute carrier family 17 member 5 Homo sapiens 201-204 31940630-9 2020 Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion (but not expression), in primate cell cultures, by modulating MAPK/PI3K/mTOR pathways and expression of key receptors (GHRH-R/ghrelin-R/Kiss1-R) regulating pituitary function. Simvastatin 8-19 mechanistic target of rapamycin kinase Homo sapiens 213-217 31940630-9 2020 Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion (but not expression), in primate cell cultures, by modulating MAPK/PI3K/mTOR pathways and expression of key receptors (GHRH-R/ghrelin-R/Kiss1-R) regulating pituitary function. Simvastatin 8-19 growth hormone releasing hormone receptor Homo sapiens 260-266 31934265-0 2019 Simvastatin Mitigates Apoptosis and Transforming Growth Factor-Beta Upregulation in Stretch-Induced Endothelial Cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 36-67 31759247-7 2020 Statin therapy, which is known to activate KLF2, also decreased CSE expression but increased CSE activity by preventing its phosphorylation on Ser377. Simvastatin 0-6 Kruppel like factor 2 Homo sapiens 43-47 31952675-2 2020 METHODS: A hybrid decision tree/Markov model was developed to simulate patients post-PCI for ACS requiring antiplatelet therapy (CYP2C19 to guide antiplatelet selection), statin therapy (SLCO1B1 to guide statin selection), and anticoagulant therapy in those that develop atrial fibrillation (CYP2C9/VKORC1 to guide warfarin dose) over 12 months, 24 months, and lifetime. Simvastatin 171-177 solute carrier organic anion transporter family member 1B1 Homo sapiens 187-194 31887837-8 2020 Compared with the sepsis group, the plasma levels of PAF in simvastatin intervention group at 1 h [(15.6+-2.5) pg/ml, 3 h(10.4+-5.3) pg/ml, 6 h (9.3+-1.4) pg/ml, 12 h(11.0+-2.7) pg/ml] were significantly decreased, so were the TM level at 6 h (1.6+-0.9) ng/ml, and the AT-III levels at 1 h[(190.3+-29.2) mug/ml],6 h [(104.4+-33.6) mug/ml] and 12 h [(73.6+-39.0) mug/ml, P<0.05]. Simvastatin 60-71 PCNA clamp associated factor Rattus norvegicus 53-56 31887837-8 2020 Compared with the sepsis group, the plasma levels of PAF in simvastatin intervention group at 1 h [(15.6+-2.5) pg/ml, 3 h(10.4+-5.3) pg/ml, 6 h (9.3+-1.4) pg/ml, 12 h(11.0+-2.7) pg/ml] were significantly decreased, so were the TM level at 6 h (1.6+-0.9) ng/ml, and the AT-III levels at 1 h[(190.3+-29.2) mug/ml],6 h [(104.4+-33.6) mug/ml] and 12 h [(73.6+-39.0) mug/ml, P<0.05]. Simvastatin 60-71 thrombomodulin Rattus norvegicus 227-229 31887837-8 2020 Compared with the sepsis group, the plasma levels of PAF in simvastatin intervention group at 1 h [(15.6+-2.5) pg/ml, 3 h(10.4+-5.3) pg/ml, 6 h (9.3+-1.4) pg/ml, 12 h(11.0+-2.7) pg/ml] were significantly decreased, so were the TM level at 6 h (1.6+-0.9) ng/ml, and the AT-III levels at 1 h[(190.3+-29.2) mug/ml],6 h [(104.4+-33.6) mug/ml] and 12 h [(73.6+-39.0) mug/ml, P<0.05]. Simvastatin 60-71 serpin family C member 1 Rattus norvegicus 269-275 31892709-7 2019 Significantly higher levels of cellular apoptosis, inhibited cell growth, and regulated lipid raft content were observed in mutant p53 lung cancer cells treated with simvastatin. Simvastatin 166-177 tumor protein p53 Homo sapiens 131-134 31892709-8 2019 Further, simvastatin increased the caspase-dependent apoptotic pathway, promotes mutant p53 protein degradation, and decreased motile activity in lung cancer cells with p53 missense mutations. Simvastatin 9-20 tumor protein p53 Homo sapiens 88-91 31892709-8 2019 Further, simvastatin increased the caspase-dependent apoptotic pathway, promotes mutant p53 protein degradation, and decreased motile activity in lung cancer cells with p53 missense mutations. Simvastatin 9-20 tumor protein p53 Homo sapiens 169-172 31861911-4 2019 Very rarely, statins induce an anti-HMGCR positive immune-mediated necrotizing myopathy. Simvastatin 13-20 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-41 31861911-8 2019 Increased exposure of skeletal muscle to statins increases the risk of mitochondrial dysfunction, calcium signalling disruption, reduced prenylation, atrogin-1 mediated atrophy and pro-apoptotic signalling. Simvastatin 41-48 F-box protein 32 Homo sapiens 150-159 31934265-8 2019 N-acetyl-cysteine (NAC) treatment before stretch not only reduced ROS levels but also mitigated the apoptosis of ECs; simvastatin had similar effects through targeting NOX2 and mitochondria. Simvastatin 118-129 cytochrome b-245 beta chain Homo sapiens 168-172 31934265-11 2019 After pretreatment with NAC, the phosphorylation of P38MAPK, JNK, and NF-kappaB and TGF-beta expressions in ECs under stretch was suppressed; similar results were observed in simvastatin-treated ECs. Simvastatin 175-186 nuclear factor kappa B subunit 1 Homo sapiens 70-79 31934265-12 2019 This study demonstrated that simvastatin could mitigate EC apoptosis and TGF-beta upregulation induced by continuous stretch by reducing the level of ROS. Simvastatin 29-40 transforming growth factor beta 1 Homo sapiens 73-81 31822735-2 2019 Here, we have investigated the binding affinity of dietary phytochemicals viz., ursolic acid, capsaicin, DL-alpha tocopherol acetate, quercetin, vanillin, citral, limonin and simvastatin with the SphK1. Simvastatin 175-186 sphingosine kinase 1 Homo sapiens 196-201 31886861-7 2021 Statin dosage, normalized to simvastatin 40 mg, increased from 50 to 58 mg/day (P < 0.0001), and was paralleled by a mean decrease of LDL-C from 97 to 82 mg/dL (P < 0.0001). Simvastatin 0-6 component of oligomeric golgi complex 2 Homo sapiens 137-142 31557051-6 2019 The up-regulation of galectin-3-positive microglial cells in white matter (WM) of HCD-fed TGF mice with cognitive deficits was significantly reduced by both SV and EX concurrently with cognitive recovery. Simvastatin 157-159 lectin, galactose binding, soluble 3 Mus musculus 21-31 31791994-0 2019 Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab. Simvastatin 0-6 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-25 32048627-8 2019 Inhibitor concentration 50 (IC50) values calculated for atorvastatin and simvastatin were determined as 94 and 38 muM, respectively. Simvastatin 73-84 latexin Homo sapiens 114-117 32048627-10 2019 When six concentrations of bortezomib used in the study were combined with 12.5 muM inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin. Simvastatin 194-205 latexin Homo sapiens 80-83 31784541-8 2019 In vitro experiments revealed an increased release of matrix metalloproteinase (MMP)-1 and MMP-13 and a weaker, disrupted matrix after simvastatin exposure. Simvastatin 135-146 matrix metallopeptidase 13 Homo sapiens 91-97 31576676-0 2019 Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFRbeta/PI3K/Akt/IQGAP1 signalling pathway. Simvastatin 0-11 platelet derived growth factor receptor beta Homo sapiens 104-113 31576676-0 2019 Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFRbeta/PI3K/Akt/IQGAP1 signalling pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 119-122 31576676-0 2019 Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFRbeta/PI3K/Akt/IQGAP1 signalling pathway. Simvastatin 0-11 IQ motif containing GTPase activating protein 1 Homo sapiens 123-129 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 165-167 IQ motif containing GTPase activating protein 1 Homo sapiens 0-30 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 165-167 IQ motif containing GTPase activating protein 1 Homo sapiens 32-38 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 165-167 IQ motif containing GTPase activating protein 1 Homo sapiens 79-85 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 165-167 IQ motif containing GTPase activating protein 1 Homo sapiens 79-85 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 168-170 IQ motif containing GTPase activating protein 1 Homo sapiens 0-30 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 168-170 IQ motif containing GTPase activating protein 1 Homo sapiens 32-38 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 168-170 IQ motif containing GTPase activating protein 1 Homo sapiens 79-85 31576676-9 2019 IQ-GTPase-activating protein 1 (IQGAP1) siRNA was used to knockdown endogenous IQGAP1, which was used to verify the role of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway in SV/SV-NPs-mediated barrier protection in HUVECs injured by LPS. Simvastatin 168-170 IQ motif containing GTPase activating protein 1 Homo sapiens 79-85 31576676-11 2019 LY294002, imatinib and IQGAP1 siRNA all suppressed the barrier protection of SV/SV-NPs. Simvastatin 77-79 IQ motif containing GTPase activating protein 1 Homo sapiens 23-29 31576676-11 2019 LY294002, imatinib and IQGAP1 siRNA all suppressed the barrier protection of SV/SV-NPs. Simvastatin 80-82 IQ motif containing GTPase activating protein 1 Homo sapiens 23-29 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 0-2 platelet derived growth factor receptor beta Homo sapiens 98-107 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 0-2 AKT serine/threonine kinase 1 Homo sapiens 113-116 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 0-2 IQ motif containing GTPase activating protein 1 Homo sapiens 117-123 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 3-5 platelet derived growth factor receptor beta Homo sapiens 98-107 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 3-5 AKT serine/threonine kinase 1 Homo sapiens 113-116 31576676-12 2019 SV/SV-NPs promoted the secretion of platelet-derived growth factor-BB (PDGF-BB) and activated the PDGFRbeta/PI3K/Akt/IQGAP1 pathway. Simvastatin 3-5 IQ motif containing GTPase activating protein 1 Homo sapiens 117-123 31576676-13 2019 SV preparations restored endothelial barrier function by restoring endothelial cell migration, which is involved in the regulation of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway and PDGF-BB secretion. Simvastatin 0-2 platelet derived growth factor receptor beta Homo sapiens 138-147 31576676-13 2019 SV preparations restored endothelial barrier function by restoring endothelial cell migration, which is involved in the regulation of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway and PDGF-BB secretion. Simvastatin 0-2 AKT serine/threonine kinase 1 Homo sapiens 153-156 31576676-13 2019 SV preparations restored endothelial barrier function by restoring endothelial cell migration, which is involved in the regulation of the PDGFRbeta/PI3K/Akt/IQGAP1 pathway and PDGF-BB secretion. Simvastatin 0-2 IQ motif containing GTPase activating protein 1 Homo sapiens 157-163 31861037-1 2019 Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Simvastatin 0-7 component of oligomeric golgi complex 2 Homo sapiens 30-65 31861037-1 2019 Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Simvastatin 0-7 component of oligomeric golgi complex 2 Homo sapiens 67-72 32133066-10 2019 Simvastatin could promote expressions of aggrecan, collagen type II, HIF-1alpha, VEGF and GLUT-1, while 0.1 mumol/l concentration reached the maximum effect. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 69-79 32133066-10 2019 Simvastatin could promote expressions of aggrecan, collagen type II, HIF-1alpha, VEGF and GLUT-1, while 0.1 mumol/l concentration reached the maximum effect. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 81-85 32133066-10 2019 Simvastatin could promote expressions of aggrecan, collagen type II, HIF-1alpha, VEGF and GLUT-1, while 0.1 mumol/l concentration reached the maximum effect. Simvastatin 0-11 solute carrier family 2 member 1 Rattus norvegicus 90-96 31452046-5 2019 Simvastatin showed different cytotoxic effect among AML cells, of which NRASG12D mutant THP1 was the most statin sensitive cell line (IC50 values: 1.96 uM in HL60, 7.87 uM in KG1, 0.83 uM in THP1 and 1.37 uM in U937). Simvastatin 0-11 GLI family zinc finger 2 Homo sapiens 88-92 31452046-5 2019 Simvastatin showed different cytotoxic effect among AML cells, of which NRASG12D mutant THP1 was the most statin sensitive cell line (IC50 values: 1.96 uM in HL60, 7.87 uM in KG1, 0.83 uM in THP1 and 1.37 uM in U937). Simvastatin 0-11 GLI family zinc finger 2 Homo sapiens 191-201 31452046-6 2019 Western blot analysis revealed that Ras downstream signaling molecules including Akt, MEK, and ERK1/2 were markedly inhibited in THP1 cells compared to other AML cells when exposed to simvastatin. Simvastatin 184-195 AKT serine/threonine kinase 1 Homo sapiens 81-84 31452046-6 2019 Western blot analysis revealed that Ras downstream signaling molecules including Akt, MEK, and ERK1/2 were markedly inhibited in THP1 cells compared to other AML cells when exposed to simvastatin. Simvastatin 184-195 mitogen-activated protein kinase kinase 7 Homo sapiens 86-89 31452046-6 2019 Western blot analysis revealed that Ras downstream signaling molecules including Akt, MEK, and ERK1/2 were markedly inhibited in THP1 cells compared to other AML cells when exposed to simvastatin. Simvastatin 184-195 mitogen-activated protein kinase 3 Homo sapiens 95-101 31452046-6 2019 Western blot analysis revealed that Ras downstream signaling molecules including Akt, MEK, and ERK1/2 were markedly inhibited in THP1 cells compared to other AML cells when exposed to simvastatin. Simvastatin 184-195 GLI family zinc finger 2 Homo sapiens 129-133 31452046-7 2019 In addition, only in THP1 cells, increased apoptosis and cell cycle arrest by simvastatin was observed. Simvastatin 78-89 GLI family zinc finger 2 Homo sapiens 21-25 31452046-8 2019 The combination of simvastatin and MEK inhibitor AZD6244 synergistically reduced THP1 cell proliferation compared to simvastatin alone and AZD6244 alone (IC50 values: 0.88 uM in simvastatin, 0.32 uM in AZD6244, and 0.23 uM in combination of simvastatin and AZD6244). Simvastatin 19-30 GLI family zinc finger 2 Homo sapiens 81-85 31452046-8 2019 The combination of simvastatin and MEK inhibitor AZD6244 synergistically reduced THP1 cell proliferation compared to simvastatin alone and AZD6244 alone (IC50 values: 0.88 uM in simvastatin, 0.32 uM in AZD6244, and 0.23 uM in combination of simvastatin and AZD6244). Simvastatin 117-128 mitogen-activated protein kinase kinase 7 Homo sapiens 35-38 31452046-8 2019 The combination of simvastatin and MEK inhibitor AZD6244 synergistically reduced THP1 cell proliferation compared to simvastatin alone and AZD6244 alone (IC50 values: 0.88 uM in simvastatin, 0.32 uM in AZD6244, and 0.23 uM in combination of simvastatin and AZD6244). Simvastatin 117-128 mitogen-activated protein kinase kinase 7 Homo sapiens 35-38 31452046-8 2019 The combination of simvastatin and MEK inhibitor AZD6244 synergistically reduced THP1 cell proliferation compared to simvastatin alone and AZD6244 alone (IC50 values: 0.88 uM in simvastatin, 0.32 uM in AZD6244, and 0.23 uM in combination of simvastatin and AZD6244). Simvastatin 117-128 mitogen-activated protein kinase kinase 7 Homo sapiens 35-38 31518751-11 2019 TBI-induced neuronal TNFR1 activation and apoptosis, as well as TNF-alpha expression in astrocytes in the ischemic cortex, were significantly attenuated by simvastatin, particularly when 20 mg/kg was administered. Simvastatin 156-167 TNF receptor superfamily member 1A Rattus norvegicus 21-26 31518751-11 2019 TBI-induced neuronal TNFR1 activation and apoptosis, as well as TNF-alpha expression in astrocytes in the ischemic cortex, were significantly attenuated by simvastatin, particularly when 20 mg/kg was administered. Simvastatin 156-167 tumor necrosis factor Rattus norvegicus 64-73 31663733-2 2019 Human CYP51 could be, and for a while was, considered as a potential target for cholesterol-lowering drugs (the role that is now played by statins, which are also in clinical trials for cancer) but revealed high intrinsic resistance to inhibition. Simvastatin 139-146 cytochrome P450 family 51 subfamily A member 1 Homo sapiens 6-11 31780674-0 2019 Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization. Simvastatin 0-6 RAB6A, member RAS oncogene family Homo sapiens 30-40 31780674-3 2019 Statins, in addition to their cholesterol lowering effects, can prevent isoprenylation of Rab-GTPase proteins, a protein family important for the regulation of membrane-bound protein trafficking. Simvastatin 0-7 RAB6A, member RAS oncogene family Homo sapiens 90-100 31780674-4 2019 Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin. Simvastatin 172-183 RAB5A, member RAS oncogene family Homo sapiens 57-61 31780674-4 2019 Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin. Simvastatin 172-183 RAB7B, member RAS oncogene family Homo sapiens 63-67 31780674-4 2019 Here we show that endosomal localization of Rab-GTPases (Rab5, Rab7 and Rab11) was inhibited in a statin-specific manner, with stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect by rosuvastatin. Simvastatin 172-183 RAB11A, member RAS oncogene family Homo sapiens 72-77 31558320-6 2019 Simvastatin administration significantly ameliorated the aortic root lesion size of asthmatic mice and significantly decreased HMGCR and CD36 expression. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 127-132 31849603-0 2019 Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse. Simvastatin 0-11 histone deacetylase 1 Mus musculus 21-26 31849603-5 2019 Restoration of HDAC1 and HDAC2 activities (as evident from the increased acetylation of histones H3 and H4) using simvastatin significantly improves the cognitive deficit and social interaction behavior in AS mice. Simvastatin 114-125 histone deacetylase 1 Mus musculus 15-20 31849603-5 2019 Restoration of HDAC1 and HDAC2 activities (as evident from the increased acetylation of histones H3 and H4) using simvastatin significantly improves the cognitive deficit and social interaction behavior in AS mice. Simvastatin 114-125 histone deacetylase 2 Mus musculus 25-30 31849603-6 2019 Simvastatin treatment also restores the reduced level of BDNF in AS mice brain. Simvastatin 0-11 brain derived neurotrophic factor Mus musculus 57-61 31849603-7 2019 Finally, we demonstrate that the treatment of simvastatin to primary cortical neuronal culture prepared from AS mice embryo also rescues altered acetylation of histones H3 and H4 and the level of BDNF. Simvastatin 46-57 brain derived neurotrophic factor Mus musculus 196-200 31752013-9 2019 Simvastatin was associated with suppression of miR-155 expression in HUVECs following TNF-alpha treatment, and with a corresponding reduction in TNF-alpha-induced senescence, whereas miR-155 overexpression had the opposite effect. Simvastatin 0-11 microRNA 155 Homo sapiens 47-54 31752013-9 2019 Simvastatin was associated with suppression of miR-155 expression in HUVECs following TNF-alpha treatment, and with a corresponding reduction in TNF-alpha-induced senescence, whereas miR-155 overexpression had the opposite effect. Simvastatin 0-11 tumor necrosis factor Homo sapiens 86-95 31752013-9 2019 Simvastatin was associated with suppression of miR-155 expression in HUVECs following TNF-alpha treatment, and with a corresponding reduction in TNF-alpha-induced senescence, whereas miR-155 overexpression had the opposite effect. Simvastatin 0-11 tumor necrosis factor Homo sapiens 145-154 31752013-11 2019 Simvastatin disrupted this senescence mechanism via the miR-155/SIRT1/FoxO-1/p21 pathway signaling. Simvastatin 0-11 microRNA 155 Homo sapiens 56-63 31752013-11 2019 Simvastatin disrupted this senescence mechanism via the miR-155/SIRT1/FoxO-1/p21 pathway signaling. Simvastatin 0-11 sirtuin 1 Homo sapiens 64-69 31752013-11 2019 Simvastatin disrupted this senescence mechanism via the miR-155/SIRT1/FoxO-1/p21 pathway signaling. Simvastatin 0-11 forkhead box O1 Homo sapiens 70-76 31752013-11 2019 Simvastatin disrupted this senescence mechanism via the miR-155/SIRT1/FoxO-1/p21 pathway signaling. Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 77-80 31731717-0 2019 Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice. Simvastatin 48-59 proprotein convertase subtilisin/kexin type 9 Mus musculus 75-80 31542485-0 2019 Simvastatin induces differentiation in rabbit articular chondrocytes via Wnt/beta-catenin pathway. Simvastatin 0-11 LOC100125986 Oryctolagus cuniculus 77-89 31542485-6 2019 Further, nuclear/cytosol fraction analysis revealed that simvastatin reduced the expression and translocation of beta-catenin into the nucleus from the cytoplasm by approximately 50% compared with that in the control. Simvastatin 57-68 LOC100125986 Oryctolagus cuniculus 113-125 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 0-11 LOC100125986 Oryctolagus cuniculus 69-81 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 0-11 LOC100125986 Oryctolagus cuniculus 124-136 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 0-11 LOC100125986 Oryctolagus cuniculus 124-136 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 86-97 LOC100125986 Oryctolagus cuniculus 69-81 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 86-97 LOC100125986 Oryctolagus cuniculus 124-136 31542485-8 2019 Simvastatin-induced differentiation was dependent on inactivation of beta-catenin, as simvastatin inhibited accumulation of beta-catenin, which was characterized by translocation of beta-catenin to the nucleus as shown by immunofluorescence staining and the luciferase assay. Simvastatin 86-97 LOC100125986 Oryctolagus cuniculus 124-136 31754207-16 2019 Thus, monocytes and macrophages display differential Rac1-geranylgeranylation-dependent functional capacities, that is, statins sway monocytes and macrophages differentially. Simvastatin 120-127 Rac family small GTPase 1 Homo sapiens 53-57 31731717-6 2019 Additionally, after combined therapy with simvastatin and lunasin for four weeks, ApoE-/- mice had significantly lower PCSK9 and higher LDLR levels in hepatic tissues and remarkably reduced plasma concentrations of total cholesterol (TC) and LDL-C, as compared to each monotherapy. Simvastatin 42-53 proprotein convertase subtilisin/kexin type 9 Mus musculus 119-124 31731717-6 2019 Additionally, after combined therapy with simvastatin and lunasin for four weeks, ApoE-/- mice had significantly lower PCSK9 and higher LDLR levels in hepatic tissues and remarkably reduced plasma concentrations of total cholesterol (TC) and LDL-C, as compared to each monotherapy. Simvastatin 42-53 low density lipoprotein receptor Mus musculus 136-140 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 46-57 proprotein convertase subtilisin/kexin type 9 Homo sapiens 107-112 31731717-7 2019 Conclusively, lunasin significantly improved the LDL-C lowering efficacy of simvastatin by counteracting simvastatin induced elevation of PCSK9 in hepatocytes and ApoE-/- mice. Simvastatin 76-87 proprotein convertase subtilisin/kexin type 9 Mus musculus 138-143 31542485-11 2019 Our findings demonstrate that simvastatin increases differentiation of rabbit articular chondrocytes via the beta-catenin pathway. Simvastatin 30-41 LOC100125986 Oryctolagus cuniculus 109-121 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 46-57 HNF1 homeobox A Homo sapiens 188-220 31731717-7 2019 Conclusively, lunasin significantly improved the LDL-C lowering efficacy of simvastatin by counteracting simvastatin induced elevation of PCSK9 in hepatocytes and ApoE-/- mice. Simvastatin 76-87 apolipoprotein E Mus musculus 163-167 31731717-7 2019 Conclusively, lunasin significantly improved the LDL-C lowering efficacy of simvastatin by counteracting simvastatin induced elevation of PCSK9 in hepatocytes and ApoE-/- mice. Simvastatin 105-116 proprotein convertase subtilisin/kexin type 9 Mus musculus 138-143 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 46-57 HNF1 homeobox A Homo sapiens 222-232 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 116-127 proprotein convertase subtilisin/kexin type 9 Homo sapiens 107-112 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 116-127 HNF1 homeobox A Homo sapiens 188-220 31731717-5 2019 In HepG2 cells, after co-treatment with 1 muM simvastatin and 5 muM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1alpha (HNF-1alpha), and the functional LDL uptake was additively enhanced. Simvastatin 116-127 HNF1 homeobox A Homo sapiens 222-232 31731717-6 2019 Additionally, after combined therapy with simvastatin and lunasin for four weeks, ApoE-/- mice had significantly lower PCSK9 and higher LDLR levels in hepatic tissues and remarkably reduced plasma concentrations of total cholesterol (TC) and LDL-C, as compared to each monotherapy. Simvastatin 42-53 apolipoprotein E Mus musculus 82-86 31685796-5 2019 Simvastatin, a mevalonate pathway inhibitor, efficiently abrogated ASPP2 depletion-induced anchorage-independent cell proliferation, resistance to chemotherapy drugs in vitro, and tumor growth in xenografted nude mice. Simvastatin 0-11 transformation related protein 53 binding protein 2 Mus musculus 67-72 31704948-0 2019 Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Simvastatin 0-6 insulin Homo sapiens 32-39 31449810-4 2019 However, simvastatin induced greater apoptosis in RH30 compared to C2C12 cells. Simvastatin 9-20 Rh blood group D antigen Homo sapiens 50-54 31449810-6 2019 Simvastatin inhibited autophagy flux in both C2C12 and RH30 cells and inhibited lysosomal acidification in C2C12 cells, while autophagy inhibition with Bafilomycin-A1 increased simvastatin myotoxicity in both cell lines. Simvastatin 0-11 Rh blood group D antigen Homo sapiens 55-59 31449810-7 2019 Simvastatin induced greater cell death in RH30 cells compared to C2C12 in a 3D culture model with similar effects on autophagy flux as in 2D culture. Simvastatin 0-11 Rh blood group D antigen Homo sapiens 42-46 31398467-8 2019 Simvastatin abrogated these effects by upregulating LAMP-1 and activating AMPK which phosphorylated ULK-1, resulting in increased formation of functional autolysosomes. Simvastatin 0-11 lysosomal-associated membrane protein 1 Mus musculus 52-58 31674929-9 2019 CONCLUSION: We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI. Simvastatin 34-41 endothelial cell specific molecule 1 Homo sapiens 66-73 31398467-8 2019 Simvastatin abrogated these effects by upregulating LAMP-1 and activating AMPK which phosphorylated ULK-1, resulting in increased formation of functional autolysosomes. Simvastatin 0-11 unc-51 like kinase 1 Mus musculus 100-105 31389048-9 2019 SMV caused a significant increase in myoglobin, creatinine kinase, ALT, AST, ALP, and bilirubin but, it decreased total proteins, globulin and albumin levels. Simvastatin 0-3 myoglobin Rattus norvegicus 37-46 31228727-9 2019 Pooling 5 effect sizes from 2 studies, we found a significant reduction in serum concentrations of CRP following administration of Simvastatin (WMD: -0.29; 95% CI: -0.49, -0.10; I2 = 88.5%). Simvastatin 131-142 C-reactive protein Homo sapiens 99-102 31389048-9 2019 SMV caused a significant increase in myoglobin, creatinine kinase, ALT, AST, ALP, and bilirubin but, it decreased total proteins, globulin and albumin levels. Simvastatin 0-3 PDZ and LIM domain 3 Rattus norvegicus 77-80 31269241-5 2019 We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs. Simvastatin 75-86 thymic stromal lymphopoietin Homo sapiens 27-31 31269241-5 2019 We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs. Simvastatin 75-86 prostaglandin D2 receptor 2 Homo sapiens 161-166 31269241-5 2019 We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs. Simvastatin 75-86 CD4 molecule Homo sapiens 168-171 31269241-5 2019 We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs. Simvastatin 75-86 TNF superfamily member 4 Homo sapiens 237-242 31269241-5 2019 We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs. Simvastatin 75-86 C-C motif chemokine ligand 17 Homo sapiens 247-252 31365836-3 2019 Here we demonstrate that simvastatin induces mitophagy in skeletal muscle cells and hypothesized that attenuating this process by silencing the mitophagy adapter p62/sequestosome-1 (SQSTM1) might mitigate myotoxicity. Simvastatin 25-36 sequestosome 1 Mus musculus 182-188 31420371-12 2019 MVA inhibitors such as simvastatin and zoledronic acid are potential therapeutic agents to re-sensitize the tumors that depend on the MVA to progress on anti-HER2 therapies. Simvastatin 23-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 31245876-0 2019 Identification of Gli1-interacting proteins during simvastatin-stimulated osteogenic differentiation of bone marrow mesenchymal stem cells. Simvastatin 51-62 GLI family zinc finger 1 Homo sapiens 18-22 31245876-7 2019 Our results indicated that simvastatin increased alkaline phosphatase (ALP) activity; mineralization of extracellular matrix; mRNA expression of ALP, COL1, and OCN; and expression and nuclear translocation of Gli1. Simvastatin 27-38 alkaline phosphatase, placental Homo sapiens 49-69 31245876-7 2019 Our results indicated that simvastatin increased alkaline phosphatase (ALP) activity; mineralization of extracellular matrix; mRNA expression of ALP, COL1, and OCN; and expression and nuclear translocation of Gli1. Simvastatin 27-38 alkaline phosphatase, placental Homo sapiens 71-74 31245876-7 2019 Our results indicated that simvastatin increased alkaline phosphatase (ALP) activity; mineralization of extracellular matrix; mRNA expression of ALP, COL1, and OCN; and expression and nuclear translocation of Gli1. Simvastatin 27-38 alkaline phosphatase, placental Homo sapiens 145-148 31245876-7 2019 Our results indicated that simvastatin increased alkaline phosphatase (ALP) activity; mineralization of extracellular matrix; mRNA expression of ALP, COL1, and OCN; and expression and nuclear translocation of Gli1. Simvastatin 27-38 bone gamma-carboxyglutamate protein Homo sapiens 160-163 31245876-7 2019 Our results indicated that simvastatin increased alkaline phosphatase (ALP) activity; mineralization of extracellular matrix; mRNA expression of ALP, COL1, and OCN; and expression and nuclear translocation of Gli1. Simvastatin 27-38 GLI family zinc finger 1 Homo sapiens 209-213 31245876-11 2019 In summary, the current study showed that the mechanism by which simvastatin stimulates osteogenic differentiation of BMSCs involves activation of Hedgehog signaling, as indicated by interactions with Gli1 and, most notably, the MAPK signaling pathway. Simvastatin 65-76 GLI family zinc finger 1 Homo sapiens 201-205 31676775-6 2019 C57BL/6 mice were exposed to TCDD in the presence or absence of simvastatin, a competitive inhibitor of HMGCR. Simvastatin 64-75 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 104-109 31612028-0 2019 Downregulation of ABCA1 and ABCG1 transporters by simvastatin in cholangiocarcinoma cells. Simvastatin 50-61 ATP binding cassette subfamily A member 1 Homo sapiens 18-23 31612028-0 2019 Downregulation of ABCA1 and ABCG1 transporters by simvastatin in cholangiocarcinoma cells. Simvastatin 50-61 ATP binding cassette subfamily G member 1 Homo sapiens 28-33 31612028-9 2019 A reduction in intracellular lipid level and a lower expression of ABCA1 and ABCG1 were observed in KKU-100 cells under simvastatin treatment. Simvastatin 120-131 ATP binding cassette subfamily A member 1 Homo sapiens 67-72 31612028-9 2019 A reduction in intracellular lipid level and a lower expression of ABCA1 and ABCG1 were observed in KKU-100 cells under simvastatin treatment. Simvastatin 120-131 ATP binding cassette subfamily G member 1 Homo sapiens 77-82 31545497-0 2019 Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential between P2Y12 inhibitors and statins. Simvastatin 104-111 purinergic receptor P2Y12 Rattus norvegicus 83-88 31545497-8 2019 An in vivo pharmacokinetic study demonstrated that the co-administration of ticagrelor or prasugrel with simvastatin caused an increase in the principal pharmacokinetic parameters of the probe drug dapsone [area under the concentration/time curve (AUC)0-t, AUC0- and t1/2] and a decrease in clearance compared with ticagrelor, prasugrel or simvastatin alone. Simvastatin 105-116 brachyury 2 Rattus norvegicus 257-272 31545497-9 2019 Additional studies confirmed that the two investigated P2Y12 inhibitors were able to decrease the protein level of CYP3A4 by promoting protein degradation through the proteasomal pathway, and combination with statins such as simvastatin had a synergistic inhibitory effect on CYP3A4 activity. Simvastatin 225-236 purinergic receptor P2Y12 Rattus norvegicus 55-60 31545497-10 2019 These results demonstrated that the co-administration of P2Y12 inhibitors with simvastatin could markedly inhibit the activity of CYP3A4, and these findings will further influence the assessment of the clinical effectiveness (reduced or enhanced efficacy) and safety (bleeding and rhabdomyolysis) in the clinic. Simvastatin 79-90 purinergic receptor P2Y12 Rattus norvegicus 57-62 31676775-8 2019 Simvastatin and TCDD (S + T) co-treatment increased hepatic AHR-battery gene expression and liver injury in male, but not female, mice. Simvastatin 0-11 aryl-hydrocarbon receptor Mus musculus 60-63 31676775-10 2019 Results from this study suggest that statins, which are amongst the most prescribed pharmaceuticals, may protect from AHR-mediated steatosis, but alter glycogen metabolism and increase the risk of TCDD-elicited liver damage in a sex-specific manner. Simvastatin 37-44 aryl-hydrocarbon receptor Mus musculus 118-121 31687506-5 2019 Exploration of the mechanisms revealed that simvastatin in low-dose range dose-dependently upregulated sets of cell cycle regulators, Cyclin D1 and Cyclin D2; proliferation marker, Ki-67; and anti-apoptotic gene; Bcl-2. Simvastatin 44-55 cyclin D1 Canis lupus familiaris 134-143 31652822-5 2019 Statins are largely prescribed to patients with myocardial infarction and diabetes, but their effects on IL-1beta synthesis and release remain to be fully characterized. Simvastatin 0-7 interleukin 1 beta Homo sapiens 105-113 31652822-6 2019 Of interest, preliminary studies even report IL-1beta secretion to rise after treatment with statins, with a potential impact on the inflammatory microenvironment and glycemic control. Simvastatin 93-100 interleukin 1 beta Homo sapiens 45-53 31652822-8 2019 In accordance with the dual lipid-lowering and anti-inflammatory effect of these drugs and in light of the important results achieved by IL-1beta inhibition through canakinumab in CV secondary prevention, we will dissect the current evidence linking statins with IL-1beta and outline the possible benefits of a potential double treatment with statins and canakinumab. Simvastatin 250-257 interleukin 1 beta Homo sapiens 137-145 31652822-8 2019 In accordance with the dual lipid-lowering and anti-inflammatory effect of these drugs and in light of the important results achieved by IL-1beta inhibition through canakinumab in CV secondary prevention, we will dissect the current evidence linking statins with IL-1beta and outline the possible benefits of a potential double treatment with statins and canakinumab. Simvastatin 250-257 interleukin 1 beta Homo sapiens 263-271 31513872-6 2019 Enhancement of anti-inflammatory effects of simvastatin could be attributed to inhibition of ERK1/2, JNK and AKT signaling pathways and internalization of polymersome delivery systems in activated microglia. Simvastatin 44-55 mitogen-activated protein kinase 3 Mus musculus 93-99 31513872-6 2019 Enhancement of anti-inflammatory effects of simvastatin could be attributed to inhibition of ERK1/2, JNK and AKT signaling pathways and internalization of polymersome delivery systems in activated microglia. Simvastatin 44-55 mitogen-activated protein kinase 8 Mus musculus 101-104 31513872-6 2019 Enhancement of anti-inflammatory effects of simvastatin could be attributed to inhibition of ERK1/2, JNK and AKT signaling pathways and internalization of polymersome delivery systems in activated microglia. Simvastatin 44-55 thymoma viral proto-oncogene 1 Mus musculus 109-112 31640597-11 2019 Rhabdomyolysis was most likely induced by toxic plasma concentrations of Simvastatin due to Palbociclibs inhibition of the CYP3A4 enzyme in combination with a decreased hepatic uptake of Simvastatin due to single nucleotide polymorphism rs4149056. Simvastatin 73-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 123-129 31687506-5 2019 Exploration of the mechanisms revealed that simvastatin in low-dose range dose-dependently upregulated sets of cell cycle regulators, Cyclin D1 and Cyclin D2; proliferation marker, Ki-67; and anti-apoptotic gene; Bcl-2. Simvastatin 44-55 cyclin D2 Canis lupus familiaris 148-157 31687506-5 2019 Exploration of the mechanisms revealed that simvastatin in low-dose range dose-dependently upregulated sets of cell cycle regulators, Cyclin D1 and Cyclin D2; proliferation marker, Ki-67; and anti-apoptotic gene; Bcl-2. Simvastatin 44-55 BCL2 apoptosis regulator Canis lupus familiaris 213-218 31788433-6 2019 Drug interaction of TAM and SIM was synergistic in T47D by increasing the apoptotic makers Bax/BCL-2 ratio and caspase 3 activity. Simvastatin 28-31 BCL2-associated X protein Mus musculus 91-94 31788433-6 2019 Drug interaction of TAM and SIM was synergistic in T47D by increasing the apoptotic makers Bax/BCL-2 ratio and caspase 3 activity. Simvastatin 28-31 B cell leukemia/lymphoma 2 Mus musculus 95-100 31788433-6 2019 Drug interaction of TAM and SIM was synergistic in T47D by increasing the apoptotic makers Bax/BCL-2 ratio and caspase 3 activity. Simvastatin 28-31 caspase 3 Mus musculus 111-120 31400433-0 2019 EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. Simvastatin 64-75 epidermal growth factor receptor Homo sapiens 0-4 31400433-2 2019 The main purpose of this study was to obtain targeted long circulating immunoliposomes containing simvastatin (tLCLS) with anti-EGFR antibody attached to their surface and to test whether they can be effective in treatment of TNBC. Simvastatin 98-109 epidermal growth factor receptor Homo sapiens 128-132 31632012-4 2019 Results: Simvastatin showed a minimal inhibitory concentration (MIC) ranging from 0.062 to 0.25 mg mL-1 against MRSA. Simvastatin 9-20 L1 cell adhesion molecule Mus musculus 99-103 31632012-7 2019 The combination of simvastatin and AgNPbio demonstrated antibacterial activity against Escherichia coli producing ESBL. Simvastatin 19-30 EsbL Escherichia coli 114-118 31265743-0 2019 Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure. Simvastatin 28-39 angiotensinogen Homo sapiens 48-62 31265743-13 2019 Simvastatin attenuated heart failure, induced by angiotensin II, via mitochondrial protection and might provide a new therapy to prevent heart failure. Simvastatin 0-11 angiotensinogen Homo sapiens 49-63 31311324-5 2019 Furthermore, neuroprotective agents, including fenofibrate and simvastatin, induced NEAT1 up-regulation, whereas RNA interference-mediated depletion of NEAT1 exacerbated death of PQ-exposed cells in a leucine-rich repeat kinase 2-mediated manner. Simvastatin 63-74 nuclear paraspeckle assembly transcript 1 Homo sapiens 84-89 31053884-11 2019 We found that the protein C promoter activity was increased by simvastatin, and this effect was inhibited by HNF1alpha knockdown and constitutively active Rac1. Simvastatin 63-74 HNF1 homeobox A Homo sapiens 109-118 31053884-11 2019 We found that the protein C promoter activity was increased by simvastatin, and this effect was inhibited by HNF1alpha knockdown and constitutively active Rac1. Simvastatin 63-74 Rac family small GTPase 1 Homo sapiens 155-159 31311324-5 2019 Furthermore, neuroprotective agents, including fenofibrate and simvastatin, induced NEAT1 up-regulation, whereas RNA interference-mediated depletion of NEAT1 exacerbated death of PQ-exposed cells in a leucine-rich repeat kinase 2-mediated manner. Simvastatin 63-74 leucine rich repeat kinase 2 Homo sapiens 201-229 31432100-0 2019 Simvastatin promotes endothelial dysfunction by activating the Wnt/beta-catenin pathway under oxidative stress. Simvastatin 0-11 catenin beta 1 Homo sapiens 67-79 31432100-6 2019 Moreover, inhibition of the Wnt/beta-catenin pathway by salinomycin significantly suppressed the simvastatin-associated HUVEC dysfunction. Simvastatin 97-108 catenin beta 1 Homo sapiens 32-44 31432100-7 2019 Western blot analysis further demonstrated that simvastatin promoted the phosphorylation of low-density lipoprotein receptor-related protein 6 (LRP6) and activated the Wnt/beta-catenin pathway. Simvastatin 48-59 LDL receptor related protein 6 Homo sapiens 92-142 31432100-7 2019 Western blot analysis further demonstrated that simvastatin promoted the phosphorylation of low-density lipoprotein receptor-related protein 6 (LRP6) and activated the Wnt/beta-catenin pathway. Simvastatin 48-59 LDL receptor related protein 6 Homo sapiens 144-148 31432100-7 2019 Western blot analysis further demonstrated that simvastatin promoted the phosphorylation of low-density lipoprotein receptor-related protein 6 (LRP6) and activated the Wnt/beta-catenin pathway. Simvastatin 48-59 catenin beta 1 Homo sapiens 172-184 31432100-9 2019 Based on these results, it was hypothesized that simvastatin may promote ER stress by facilitating LRP6 phosphorylation and the subsequent activation of the Wnt/beta-catenin pathway, thereby enhancing H2O2-induced ED. Simvastatin 49-60 LDL receptor related protein 6 Homo sapiens 99-103 31432100-9 2019 Based on these results, it was hypothesized that simvastatin may promote ER stress by facilitating LRP6 phosphorylation and the subsequent activation of the Wnt/beta-catenin pathway, thereby enhancing H2O2-induced ED. Simvastatin 49-60 catenin beta 1 Homo sapiens 161-173 31351770-4 2019 RESULTS: Sim preconditioning mitigated the damnification of intestinal tissues by decreasing oxidative stress, inflammatory damage, and apoptosis and downregulating the expression of Omi/HtrA2 compared to the ischemia/reperfusion group, while Sim+Ucf-101 significantly augmented this effect. Simvastatin 9-12 HtrA serine peptidase 2 Rattus norvegicus 187-192 30488773-0 2019 Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: a comparative docking and MD simulation studies. Simvastatin 38-49 integrin linked kinase Homo sapiens 57-79 30488773-4 2019 Thus, inhibiting the kinase activity of ILK by CA and simvastatin may be implicated in the cancer therapy. Simvastatin 54-65 integrin linked kinase Homo sapiens 40-43 30488773-5 2019 In this study, we have performed molecular docking followed by 100 ns MD simulations to understand the interaction mechanism of ILK protein with the CA and simvastatin. Simvastatin 156-167 integrin linked kinase Homo sapiens 128-131 30488773-8 2019 Our results indicate that simvastatin binds more effectively to the active pocket of ILK. Simvastatin 26-37 integrin linked kinase Homo sapiens 85-88 30488773-12 2019 Our study provides a deeper insight into the binding mechanism of simvastatin and CA to ILK, which further opens a promising channel for their implications in cancer therapy. Simvastatin 66-77 integrin linked kinase Homo sapiens 88-91 31351770-0 2019 Simvastatin Alleviates Intestinal Ischemia/Reperfusion Injury by Modulating Omi/HtrA2 Signaling Pathways. Simvastatin 0-11 HtrA serine peptidase 2 Rattus norvegicus 80-85 29587611-9 2019 In the simvastatin-treated endometriosis group, levels of miR-150-5p and miR-451a were decreased, while miR-3613-5p levels were increased compared to the untreated endometriosis group. Simvastatin 7-18 microRNA 451a Homo sapiens 73-81 31351770-5 2019 CONCLUSION: These results suggest that Sim may alleviate intestinal ischemia/reperfusion injury by modulating Omi/HtrA2 signaling pathways. Simvastatin 39-42 HtrA serine peptidase 2 Rattus norvegicus 114-119 31351770-1 2019 PURPOSE: The objective of this research was to survey the therapeutic action of simvastatin (Sim) on intestinal ischemia/reperfusion injury (II/RI) by modulating Omi/HtrA2 signaling pathways. Simvastatin 80-91 HtrA serine peptidase 2 Rattus norvegicus 166-171 31351770-1 2019 PURPOSE: The objective of this research was to survey the therapeutic action of simvastatin (Sim) on intestinal ischemia/reperfusion injury (II/RI) by modulating Omi/HtrA2 signaling pathways. Simvastatin 93-96 HtrA serine peptidase 2 Rattus norvegicus 166-171 31555339-4 2019 Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Simvastatin 32-39 lipoprotein(a) Homo sapiens 148-153 31569521-3 2019 Furthermore, in 3T3-L1 cells, the synthetic PP1 remarkedly decreased the accumulation of intracellular triacylglycerol (27.9%, 600 mug/mL), which carried a similar consequence as the positive drug simvastatin (24.1%, 10 muM). Simvastatin 197-208 protein phosphatase 1 catalytic subunit gamma Mus musculus 44-47 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Simvastatin 0-7 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-56 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Simvastatin 0-7 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-63 31540279-8 2019 From the standpoint of therapeutic applications for hepatocellular carcinoma (HCC) treatment, HSF1 inhibition was shown to sensitize the antiproliferative effects of simvastatin in HCC cells. Simvastatin 166-177 heat shock transcription factor 1 Homo sapiens 94-98 31352795-7 2019 Donor simvastatin treatment did not affect donor lipid levels but was associated with a specific transplant myocardial biopsy gene expression profile, and a decrease in recipient postoperative plasma levels of CXCL10 (C-X-C motif chemokine 10), interleukin-1alpha, placental growth factor, and platelet-derived growth factor-BB. Simvastatin 6-17 C-X-C motif chemokine ligand 10 Homo sapiens 210-216 30552607-8 2019 One month of simvastatin therapy reduced serum Se levels. Simvastatin 13-24 squalene epoxidase Homo sapiens 47-49 31260663-0 2019 Effects of simvastatin on matrix metalloproteinase regulation in IL-1beta-induced SW1353 cells. Simvastatin 11-22 interleukin 1 beta Homo sapiens 65-73 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 3 Homo sapiens 80-85 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 13 Homo sapiens 87-93 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 2 Homo sapiens 95-100 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 9 Homo sapiens 102-107 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 TIMP metallopeptidase inhibitor 2 Homo sapiens 112-118 31394503-10 2019 Scd1, Ppar-gamma and adipogenesis were downregulated in simvastatin-treated preadipocytes compared to nontreated preadipocytes 55-, 44- and 1.7-fold, respectively. Simvastatin 56-67 stearoyl-CoA desaturase Homo sapiens 0-4 31394503-10 2019 Scd1, Ppar-gamma and adipogenesis were downregulated in simvastatin-treated preadipocytes compared to nontreated preadipocytes 55-, 44- and 1.7-fold, respectively. Simvastatin 56-67 peroxisome proliferator activated receptor gamma Homo sapiens 6-16 31394503-12 2019 Simvastatin downregulated adipogenesis, PPAR-gamma (2.6-fold) and SCD (41-fold) in OFs. Simvastatin 0-11 stearoyl-CoA desaturase Homo sapiens 40-69 31271758-7 2019 Induction of endothelial KLF2 by simvastatin treatment is associated with ADAM15 upregulation (1.8-fold) which is suppressed by counteracting simvastatin with geranylgeranyl pyrophosphate. Simvastatin 33-44 Kruppel like factor 2 Homo sapiens 25-29 31271758-7 2019 Induction of endothelial KLF2 by simvastatin treatment is associated with ADAM15 upregulation (1.8-fold) which is suppressed by counteracting simvastatin with geranylgeranyl pyrophosphate. Simvastatin 33-44 ADAM metallopeptidase domain 15 Homo sapiens 74-80 31271758-7 2019 Induction of endothelial KLF2 by simvastatin treatment is associated with ADAM15 upregulation (1.8-fold) which is suppressed by counteracting simvastatin with geranylgeranyl pyrophosphate. Simvastatin 142-153 Kruppel like factor 2 Homo sapiens 25-29 31271758-7 2019 Induction of endothelial KLF2 by simvastatin treatment is associated with ADAM15 upregulation (1.8-fold) which is suppressed by counteracting simvastatin with geranylgeranyl pyrophosphate. Simvastatin 142-153 ADAM metallopeptidase domain 15 Homo sapiens 74-80 31221720-0 2019 Cross-linking Proteomics Indicates Effects of Simvastatin on the TLR2 Interactome and Reveals ACTR1A as a Novel Regulator of the TLR2 Signal Cascade. Simvastatin 46-57 toll like receptor 2 Homo sapiens 65-69 31221720-6 2019 A hemagglutinin (HA)-tagged-TLR2 transfected HEK293 cell line was used to precipitate the TLR2 interactome upon cell exposure to the TLR2 agonist Pam3CSK4 and simvastatin, singly and in combination. Simvastatin 159-170 toll like receptor 2 Homo sapiens 28-32 31221720-6 2019 A hemagglutinin (HA)-tagged-TLR2 transfected HEK293 cell line was used to precipitate the TLR2 interactome upon cell exposure to the TLR2 agonist Pam3CSK4 and simvastatin, singly and in combination. Simvastatin 159-170 toll like receptor 2 Homo sapiens 90-94 31221720-6 2019 A hemagglutinin (HA)-tagged-TLR2 transfected HEK293 cell line was used to precipitate the TLR2 interactome upon cell exposure to the TLR2 agonist Pam3CSK4 and simvastatin, singly and in combination. Simvastatin 159-170 toll like receptor 2 Homo sapiens 90-94 31221720-8 2019 Proteomic analysis revealed important combinatorial effects of simvastatin and Pam3CSK4 on the TLR2 interactome. Simvastatin 63-74 toll like receptor 2 Homo sapiens 95-99 31318658-10 2019 Simvastatin upregulated the reduced expression of Klf2 and Foxp1 in atherosusceptible vascular endothelium and alleviated vascular inflammation contributing to its inhibitory effect in atherosclerosis. Simvastatin 0-11 Kruppel-like factor 2 (lung) Mus musculus 50-54 31318658-10 2019 Simvastatin upregulated the reduced expression of Klf2 and Foxp1 in atherosusceptible vascular endothelium and alleviated vascular inflammation contributing to its inhibitory effect in atherosclerosis. Simvastatin 0-11 forkhead box P1 Mus musculus 59-64 31318658-11 2019 CONCLUSIONS: These data are the first in vivo experimental validation of an atheroprotective role of endothelial Klf2 and Foxp1, which reveals a Klf2-Foxp1 transcriptional network in endothelial cells as a novel regulator of endothelial inflammasome activation for atherogenesis, therefore, provides opportunities for therapeutic intervention of atherosclerotic diseases and uncovers a novel atheroprotective mechanism for simvastatin. Simvastatin 423-434 Kruppel-like factor 2 (lung) Mus musculus 113-117 31318658-11 2019 CONCLUSIONS: These data are the first in vivo experimental validation of an atheroprotective role of endothelial Klf2 and Foxp1, which reveals a Klf2-Foxp1 transcriptional network in endothelial cells as a novel regulator of endothelial inflammasome activation for atherogenesis, therefore, provides opportunities for therapeutic intervention of atherosclerotic diseases and uncovers a novel atheroprotective mechanism for simvastatin. Simvastatin 423-434 Kruppel-like factor 2 (lung) Mus musculus 145-149 31318658-11 2019 CONCLUSIONS: These data are the first in vivo experimental validation of an atheroprotective role of endothelial Klf2 and Foxp1, which reveals a Klf2-Foxp1 transcriptional network in endothelial cells as a novel regulator of endothelial inflammasome activation for atherogenesis, therefore, provides opportunities for therapeutic intervention of atherosclerotic diseases and uncovers a novel atheroprotective mechanism for simvastatin. Simvastatin 423-434 forkhead box P1 Mus musculus 150-155 31352795-7 2019 Donor simvastatin treatment did not affect donor lipid levels but was associated with a specific transplant myocardial biopsy gene expression profile, and a decrease in recipient postoperative plasma levels of CXCL10 (C-X-C motif chemokine 10), interleukin-1alpha, placental growth factor, and platelet-derived growth factor-BB. Simvastatin 6-17 C-X-C motif chemokine ligand 10 Homo sapiens 218-242 31352795-7 2019 Donor simvastatin treatment did not affect donor lipid levels but was associated with a specific transplant myocardial biopsy gene expression profile, and a decrease in recipient postoperative plasma levels of CXCL10 (C-X-C motif chemokine 10), interleukin-1alpha, placental growth factor, and platelet-derived growth factor-BB. Simvastatin 6-17 interleukin 1 alpha Homo sapiens 245-263 30728467-9 2019 In HepG2 cells, rapamycin (a mTOR inhibitor) significantly reduced the OLZ-stimulated hepatocellular lipid contents and weakened the ability of Sim to lower lipids via a mechanism associated with the upregulation of SREBP1c-mediated de novo lipogenesis. Simvastatin 144-147 sterol regulatory element binding transcription factor 1 Homo sapiens 216-223 30728467-0 2019 Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway. Simvastatin 0-11 mechanistic target of rapamycin kinase Rattus norvegicus 88-92 30728467-9 2019 In HepG2 cells, rapamycin (a mTOR inhibitor) significantly reduced the OLZ-stimulated hepatocellular lipid contents and weakened the ability of Sim to lower lipids via a mechanism associated with the upregulation of SREBP1c-mediated de novo lipogenesis. Simvastatin 144-147 mechanistic target of rapamycin kinase Homo sapiens 29-33 31103630-5 2019 The aim of our study is to investigate the effect and regulatory mechanisms of simvastatin on ECP levels derived from eosinophils. Simvastatin 79-90 ribonuclease A family member 3 Homo sapiens 94-97 30728467-10 2019 Our data suggest that OLZ induces lipid accumulation in both plasma and liver, and Sim ameliorates OLZ-induced lipid metabolic dysfunction through its effects on mTOR signaling via reducing SREBP1c activation and the downregulation of gene expression involved in lipogenesis. Simvastatin 83-86 mechanistic target of rapamycin kinase Homo sapiens 162-166 30728467-10 2019 Our data suggest that OLZ induces lipid accumulation in both plasma and liver, and Sim ameliorates OLZ-induced lipid metabolic dysfunction through its effects on mTOR signaling via reducing SREBP1c activation and the downregulation of gene expression involved in lipogenesis. Simvastatin 83-86 sterol regulatory element binding transcription factor 1 Homo sapiens 190-197 31229924-0 2019 Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Simvastatin 121-132 glucagon Homo sapiens 33-56 31229924-8 2019 The treatment with simvastatin (40 mg/die) in HyC (n = 18) significantly reduced total and LDL cholesterol levels, platelet aggregability/activation, ROS production and NO action but did not modify platelet sensitivity to the GLP-1 effects. Simvastatin 19-30 glucagon like peptide 1 receptor Homo sapiens 226-231 32292723-9 2019 Conclusion: Ezetimibe co-administered with simvastatin (10 mg) and high-dose statin monotherapy may show similar effects in reducing LDL-C, TG, and hs-CRP levels and in increasing HDL-C levels. Simvastatin 43-54 C-reactive protein Homo sapiens 151-154 31369604-7 2019 Inhibiting RhoA/rho kinase (ROCK) with Y27632 (10 muM) suppressed contractions to U46619 and phenylephrine by ~80% and prevented their inhibition by simvastatin. Simvastatin 149-160 ras homolog family member A Rattus norvegicus 11-15 30896582-12 2019 Simvastatin and SimNP treated cells showed significantly greater expression of osteopontin (OPN) and osteocalcin (OCN). Simvastatin 0-11 secreted phosphoprotein 1 Rattus norvegicus 79-90 30896582-12 2019 Simvastatin and SimNP treated cells showed significantly greater expression of osteopontin (OPN) and osteocalcin (OCN). Simvastatin 0-11 secreted phosphoprotein 1 Rattus norvegicus 92-95 30896582-12 2019 Simvastatin and SimNP treated cells showed significantly greater expression of osteopontin (OPN) and osteocalcin (OCN). Simvastatin 0-11 bone gamma-carboxyglutamate protein Rattus norvegicus 101-112 30896582-12 2019 Simvastatin and SimNP treated cells showed significantly greater expression of osteopontin (OPN) and osteocalcin (OCN). Simvastatin 0-11 bone gamma-carboxyglutamate protein Rattus norvegicus 114-117 31331091-7 2019 Notably, simvastatin-mediated disaggregation of lipid rafts, where membrane-associated ERalpha is embedded, restored tamoxifen sensitivity, preventing anti-ERalpha Abs effects. Simvastatin 9-20 estrogen receptor 1 (alpha) Mus musculus 87-94 31839714-0 2019 Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells. Simvastatin 0-7 AKT serine/threonine kinase 1 Homo sapiens 54-57 31839714-0 2019 Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells. Simvastatin 0-7 forkhead box O1 Homo sapiens 58-63 31839714-7 2019 Results: Both simvastatin and fluvastatin produced a dose- and time-dependent inhibition of cell viability and colony formation while a promotion of cell apoptosis as evident with increases in caspase-3 activity, cleaved-caspase-3, cleaved-caspase-8 and cleaved-PARP levels in PC3 cells. Simvastatin 14-25 caspase 3 Homo sapiens 193-202 31839714-7 2019 Results: Both simvastatin and fluvastatin produced a dose- and time-dependent inhibition of cell viability and colony formation while a promotion of cell apoptosis as evident with increases in caspase-3 activity, cleaved-caspase-3, cleaved-caspase-8 and cleaved-PARP levels in PC3 cells. Simvastatin 14-25 caspase 3 Homo sapiens 221-230 31839714-7 2019 Results: Both simvastatin and fluvastatin produced a dose- and time-dependent inhibition of cell viability and colony formation while a promotion of cell apoptosis as evident with increases in caspase-3 activity, cleaved-caspase-3, cleaved-caspase-8 and cleaved-PARP levels in PC3 cells. Simvastatin 14-25 caspase 8 Homo sapiens 240-249 31839714-7 2019 Results: Both simvastatin and fluvastatin produced a dose- and time-dependent inhibition of cell viability and colony formation while a promotion of cell apoptosis as evident with increases in caspase-3 activity, cleaved-caspase-3, cleaved-caspase-8 and cleaved-PARP levels in PC3 cells. Simvastatin 14-25 poly(ADP-ribose) polymerase 1 Homo sapiens 262-266 31839714-10 2019 Conclusion: Statins decrease cell proliferation and induce cell apoptosis, probably mediated via a downregulation of AKT/FOXO1 phosphorylation in prostate cancer cells, which may have a potential benefit in prostate cancer prevention and therapy. Simvastatin 12-19 AKT serine/threonine kinase 1 Homo sapiens 117-120 31839714-10 2019 Conclusion: Statins decrease cell proliferation and induce cell apoptosis, probably mediated via a downregulation of AKT/FOXO1 phosphorylation in prostate cancer cells, which may have a potential benefit in prostate cancer prevention and therapy. Simvastatin 12-19 forkhead box O1 Homo sapiens 121-126 31331091-7 2019 Notably, simvastatin-mediated disaggregation of lipid rafts, where membrane-associated ERalpha is embedded, restored tamoxifen sensitivity, preventing anti-ERalpha Abs effects. Simvastatin 9-20 estrogen receptor 1 (alpha) Mus musculus 156-163 31319483-12 2019 Western blot analysis shows that simvastatin leads to changes in the expression of regulator proteins involved in apoptosis, such as Bax, Bcl-2, and Bcl-xl. Simvastatin 33-44 BCL2 associated X, apoptosis regulator Homo sapiens 133-136 31325047-0 2019 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling. Simvastatin 29-40 mitogen-activated protein kinase kinase 7 Homo sapiens 159-162 31325047-0 2019 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling. Simvastatin 29-40 mitogen-activated protein kinase 1 Homo sapiens 163-166 31319483-12 2019 Western blot analysis shows that simvastatin leads to changes in the expression of regulator proteins involved in apoptosis, such as Bax, Bcl-2, and Bcl-xl. Simvastatin 33-44 BCL2 apoptosis regulator Homo sapiens 138-143 31319483-12 2019 Western blot analysis shows that simvastatin leads to changes in the expression of regulator proteins involved in apoptosis, such as Bax, Bcl-2, and Bcl-xl. Simvastatin 33-44 BCL2 like 1 Homo sapiens 149-155 31410004-0 2019 Simvastatin pretreatment ameliorates t-PA-induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats. Simvastatin 0-11 plasminogen activator, tissue type Rattus norvegicus 37-41 31410004-0 2019 Simvastatin pretreatment ameliorates t-PA-induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 80-85 31410004-0 2019 Simvastatin pretreatment ameliorates t-PA-induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats. Simvastatin 0-11 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 86-92 31410004-2 2019 In this study, we investigated the effects of simvastatin pretreatment on t-PA-induced MMP-9/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and HT aggravation in a rat AIS model. Simvastatin 46-57 plasminogen activator, tissue type Rattus norvegicus 74-78 31410004-2 2019 In this study, we investigated the effects of simvastatin pretreatment on t-PA-induced MMP-9/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and HT aggravation in a rat AIS model. Simvastatin 46-57 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 87-132 31410004-2 2019 In this study, we investigated the effects of simvastatin pretreatment on t-PA-induced MMP-9/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and HT aggravation in a rat AIS model. Simvastatin 46-57 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 134-140 31410004-7 2019 Results: The results suggested that pretreatment with simvastatin suppressed the increase in t-PA-induced MMP-9 levels and neutralized the elevated MMP-9/TIMP-1 ratio, but had no effect on TIMP-1 levels. Simvastatin 54-65 plasminogen activator, tissue type Rattus norvegicus 93-97 31410004-7 2019 Results: The results suggested that pretreatment with simvastatin suppressed the increase in t-PA-induced MMP-9 levels and neutralized the elevated MMP-9/TIMP-1 ratio, but had no effect on TIMP-1 levels. Simvastatin 54-65 matrix metallopeptidase 9 Rattus norvegicus 106-111 31410004-7 2019 Results: The results suggested that pretreatment with simvastatin suppressed the increase in t-PA-induced MMP-9 levels and neutralized the elevated MMP-9/TIMP-1 ratio, but had no effect on TIMP-1 levels. Simvastatin 54-65 matrix metallopeptidase 9 Rattus norvegicus 148-153 31410004-7 2019 Results: The results suggested that pretreatment with simvastatin suppressed the increase in t-PA-induced MMP-9 levels and neutralized the elevated MMP-9/TIMP-1 ratio, but had no effect on TIMP-1 levels. Simvastatin 54-65 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 154-160 31410004-9 2019 Moreover, t-PA-induced HT aggravation was reduced by simvastatin pretreatment. Simvastatin 53-64 plasminogen activator, tissue type Rattus norvegicus 10-14 31410004-10 2019 In addition, we showed that t-PA-induced activation of RhoA was suppressed by simvastatin, and that t-PA-induced MMP-9/TIMP-1 imbalance and hemorrhage was reduced by Rho kinases (ROCK) inhibitor Y-27632. Simvastatin 78-89 plasminogen activator, tissue type Rattus norvegicus 28-32 31410004-10 2019 In addition, we showed that t-PA-induced activation of RhoA was suppressed by simvastatin, and that t-PA-induced MMP-9/TIMP-1 imbalance and hemorrhage was reduced by Rho kinases (ROCK) inhibitor Y-27632. Simvastatin 78-89 ras homolog family member A Rattus norvegicus 55-59 31410004-10 2019 In addition, we showed that t-PA-induced activation of RhoA was suppressed by simvastatin, and that t-PA-induced MMP-9/TIMP-1 imbalance and hemorrhage was reduced by Rho kinases (ROCK) inhibitor Y-27632. Simvastatin 78-89 plasminogen activator, tissue type Rattus norvegicus 100-104 31410004-11 2019 Conclusion: In this study, we showed that simvastatin pretreatment ameliorated t-PA-induced HT and MMP-9/TIMP-1 imbalance, and demonstrated that the RhoA/ROCK pathway was implicated. Simvastatin 42-53 plasminogen activator, tissue type Rattus norvegicus 79-83 31410004-11 2019 Conclusion: In this study, we showed that simvastatin pretreatment ameliorated t-PA-induced HT and MMP-9/TIMP-1 imbalance, and demonstrated that the RhoA/ROCK pathway was implicated. Simvastatin 42-53 matrix metallopeptidase 9 Rattus norvegicus 99-104 31410004-11 2019 Conclusion: In this study, we showed that simvastatin pretreatment ameliorated t-PA-induced HT and MMP-9/TIMP-1 imbalance, and demonstrated that the RhoA/ROCK pathway was implicated. Simvastatin 42-53 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 105-111 31410004-11 2019 Conclusion: In this study, we showed that simvastatin pretreatment ameliorated t-PA-induced HT and MMP-9/TIMP-1 imbalance, and demonstrated that the RhoA/ROCK pathway was implicated. Simvastatin 42-53 ras homolog family member A Rattus norvegicus 149-153 31364139-0 2019 Simvastatin alleviates inflammation and oxidative stress in rats with cerebral hemorrhage through Nrf2-ARE signaling pathway. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Rattus norvegicus 98-102 31364139-1 2019 OBJECTIVE: To investigate the regulatory effects of simvastatin on the inflammation and oxidative stress in rats with cerebral hemorrhage through the nuclear factor E2-related factor 2-antioxidant response element (Nrf2-ARE) signaling pathway. Simvastatin 52-63 NFE2 like bZIP transcription factor 2 Rattus norvegicus 215-219 31364139-14 2019 Western blotting and RT-PCR showed that simvastatin could increase the transcriptional level of Nrf2. Simvastatin 40-51 NFE2 like bZIP transcription factor 2 Rattus norvegicus 96-100 31364139-15 2019 After simvastatin intervention, expression levels of downstream molecules HO-1 and NQO1 were upregulated. Simvastatin 6-17 heme oxygenase 1 Rattus norvegicus 74-78 31364139-15 2019 After simvastatin intervention, expression levels of downstream molecules HO-1 and NQO1 were upregulated. Simvastatin 6-17 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 83-87 31364139-16 2019 CONCLUSIONS: Simvastatin alleviates TLR4-mediated inflammatory injury, promotes neurological recovery and resists oxidative stress through the Nrf2-ARE signaling pathway, thus exerting a neuroprotective effect in TBI. Simvastatin 13-24 toll-like receptor 4 Rattus norvegicus 36-40 31364139-16 2019 CONCLUSIONS: Simvastatin alleviates TLR4-mediated inflammatory injury, promotes neurological recovery and resists oxidative stress through the Nrf2-ARE signaling pathway, thus exerting a neuroprotective effect in TBI. Simvastatin 13-24 NFE2 like bZIP transcription factor 2 Rattus norvegicus 143-147 31051215-0 2019 Simvastatin aggravates impaired autophagic flux in NSC34-hSOD1G93A cells through inhibition of geranylgeranyl pyrophosphate synthesis. Simvastatin 0-11 superoxide dismutase 1 Homo sapiens 57-62 30218997-0 2019 Simvastatin Attenuates Hippocampal MMP-9 Expression in the Streptozotocin-Induced Cognitive Impairment Background: Matrix metalloproteinase-9 (MMP-9) expression has been implicated in molecular mechanisms of neurodegenerative disorders, and its abnormal level has been reported in Alzheimer"s disease (AD). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 35-40 30218997-0 2019 Simvastatin Attenuates Hippocampal MMP-9 Expression in the Streptozotocin-Induced Cognitive Impairment Background: Matrix metalloproteinase-9 (MMP-9) expression has been implicated in molecular mechanisms of neurodegenerative disorders, and its abnormal level has been reported in Alzheimer"s disease (AD). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 115-141 30218997-0 2019 Simvastatin Attenuates Hippocampal MMP-9 Expression in the Streptozotocin-Induced Cognitive Impairment Background: Matrix metalloproteinase-9 (MMP-9) expression has been implicated in molecular mechanisms of neurodegenerative disorders, and its abnormal level has been reported in Alzheimer"s disease (AD). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 143-148 30218997-2 2019 Here, we investigated the effect of simvastatin on the hippocampal MMP-9 expression in the context of AD. Simvastatin 36-47 matrix metallopeptidase 9 Rattus norvegicus 67-72 30218997-3 2019 Methods: We examined the influence of three-week simvastatin (5 mg/kg) administration on hippocampal MMP-9 expression in a rat model of cognitive decline induced by streptozotocin (STZ). Simvastatin 49-60 matrix metallopeptidase 9 Rattus norvegicus 101-106 30218997-7 2019 Simvastatin prevented the up-regulation of MMP-9 (1.05 +- 0.05 vs. 1.41 +- 0.2, p < 0.05), improved spatial memory impairment and attenuated hippocampal cell damage. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 43-48 30218997-9 2019 Conclusion: Our findings suggest that the neuroprotective influence of simvastatin in battle to cognitive impairment is mediated in part by the modulation of MMP-9 expression. Simvastatin 71-82 matrix metallopeptidase 9 Rattus norvegicus 158-163 30218997-10 2019 The reduction of MMP-9 expression in simvastatin-treated animals is in correlation with the improvement of cognitive functions. Simvastatin 37-48 matrix metallopeptidase 9 Rattus norvegicus 17-22 30834613-5 2019 Interestingly, simvastatin synergistically potentiated Dox-induced cytotoxicity by inhibiting ABCG4 in DU-145 and DU-145 Doxres cells. Simvastatin 15-26 ATP binding cassette subfamily G member 4 Homo sapiens 94-99 30834613-7 2019 Treatment of cells with N-acetylcysteine or simvastatin restored Dox-induced depletion of GSH levels that in turn inhibited ABCG4 levels. Simvastatin 44-55 ATP binding cassette subfamily G member 4 Homo sapiens 124-129 31316716-6 2019 Simvastatin activates antioxidant enzymes via Nrf2 and inhibits endoplasmic reticulum stress in the liver. Simvastatin 0-11 nuclear factor, erythroid derived 2, like 2 Mus musculus 46-50 31270045-0 2019 [Simvastatin promotes murine osteoclasts apoptosis in vitro through NFATc1 pathway]. Simvastatin 1-12 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 Mus musculus 68-74 31051215-5 2019 In the present study, we investigated the effect of simvastatin on NSC34cells stably transfected with the G93A mutation in human SOD1 (NSC34-hSOD1G93A cells), a recognized in vitro model of ALS. Simvastatin 52-63 superoxide dismutase 1 Homo sapiens 129-133 31051215-6 2019 Our results showed that simvastatin caused a decrease in cell viability and the accumulation of autophagic vacuoles with elevated levels of LC3 II/I and P62 in NSC34-hSOD1G93A cells. Simvastatin 24-35 superoxide dismutase 1 Homo sapiens 166-171 31051215-9 2019 These results indicated that the cytotoxic effect of simvastatin on NSC34-hSOD1G93A cells might be due to the aggravation of autophagic flux impairment through the inhibition of GGPP synthesis. Simvastatin 53-64 superoxide dismutase 1 Homo sapiens 74-79 30796916-6 2019 In simvastatin-treated C2C12 myotubes, mRNA and protein expression of the insulin receptor (IR) beta-chain was increased, but the phosphorylation (Tyr1361) was impaired. Simvastatin 3-14 insulin receptor Mus musculus 74-100 31173123-12 2019 Gene-drug interactions projected to have substantial clinical impacts in the VHA population include the interaction of SLCO1B1 with simvastatin (1 988 956 veterans [25.6%]), CYP2D6 with tramadol (318 544 veterans [4.1%]), and CYP2C9 or VKORC1 with warfarin (7 163 349 veterans [92.2%]). Simvastatin 132-143 solute carrier organic anion transporter family member 1B1 Homo sapiens 119-126 31147392-3 2019 Here, we perform a side-by-side comparison of the effects of lovastatin and simvastatin treatment on two core phenotypes in Fmr1-/y mice versus WT littermates: excessive hippocampal protein synthesis and susceptibility to audiogenic seizures (AGSs). Simvastatin 76-87 fragile X messenger ribonucleoprotein 1 Mus musculus 124-128 31147392-5 2019 In fact, simvastatin significantly increases protein synthesis in both Fmr1-/y and WT. Simvastatin 9-20 fragile X messenger ribonucleoprotein 1 Mus musculus 71-75 30796916-7 2019 Simvastatin decreased numerically Akt/PKB Thr308 phosphorylation (via insulin signaling pathway) and significantly Akt/PKB Ser473 phosphorylation (via mTORC2), which was explained by impaired phosphorylation of mTOR Ser2448. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 34-41 30796916-7 2019 Simvastatin decreased numerically Akt/PKB Thr308 phosphorylation (via insulin signaling pathway) and significantly Akt/PKB Ser473 phosphorylation (via mTORC2), which was explained by impaired phosphorylation of mTOR Ser2448. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 115-122 30796916-7 2019 Simvastatin decreased numerically Akt/PKB Thr308 phosphorylation (via insulin signaling pathway) and significantly Akt/PKB Ser473 phosphorylation (via mTORC2), which was explained by impaired phosphorylation of mTOR Ser2448. Simvastatin 0-11 CREB regulated transcription coactivator 2 Mus musculus 151-157 30796916-7 2019 Simvastatin decreased numerically Akt/PKB Thr308 phosphorylation (via insulin signaling pathway) and significantly Akt/PKB Ser473 phosphorylation (via mTORC2), which was explained by impaired phosphorylation of mTOR Ser2448. Simvastatin 0-11 mechanistic target of rapamycin kinase Mus musculus 151-155 30825184-8 2019 KEY RESULTS: Simvastatin improved mitochondrial function, alleviated oxidative stress and up-regulated the photoreceptor-specific markers IRBP and its upstream regulator CRX in Y79 cells and ex vivo human retinal explants under atRAL-induced stress. Simvastatin 13-24 retinol binding protein 3 Homo sapiens 138-142 30825184-8 2019 KEY RESULTS: Simvastatin improved mitochondrial function, alleviated oxidative stress and up-regulated the photoreceptor-specific markers IRBP and its upstream regulator CRX in Y79 cells and ex vivo human retinal explants under atRAL-induced stress. Simvastatin 13-24 cone-rod homeobox Homo sapiens 170-173 30825184-0 2019 Simvastatin protects photoreceptors from oxidative stress induced by all-trans-retinal, through the up-regulation of interphotoreceptor retinoid binding protein. Simvastatin 0-11 retinol binding protein 3 Homo sapiens 117-160 30825184-9 2019 Simvastatin attenuated photoreceptor degeneration in association with up-regulation of IRBP and CRX expression after knockdown of IRBP in a murine model. Simvastatin 0-11 retinol binding protein 3, interstitial Mus musculus 87-91 30825184-9 2019 Simvastatin attenuated photoreceptor degeneration in association with up-regulation of IRBP and CRX expression after knockdown of IRBP in a murine model. Simvastatin 0-11 cone-rod homeobox Mus musculus 96-99 30825184-9 2019 Simvastatin attenuated photoreceptor degeneration in association with up-regulation of IRBP and CRX expression after knockdown of IRBP in a murine model. Simvastatin 0-11 retinol binding protein 3, interstitial Mus musculus 130-134 30825184-11 2019 Simvastatin treatment resulted in up-regulation of IRBP and its upstream transcription factor CRX in Y79 cells, ex vivo human retinal explants, and murine retinas in vivo. Simvastatin 0-11 retinol binding protein 3 Homo sapiens 51-55 30825184-11 2019 Simvastatin treatment resulted in up-regulation of IRBP and its upstream transcription factor CRX in Y79 cells, ex vivo human retinal explants, and murine retinas in vivo. Simvastatin 0-11 cone-rod homeobox Homo sapiens 94-97 31105786-8 2019 Simvastatin markedly decreased cell viability in a concentration-dependent manner, increased caspase 3 activity and induced apoptosis in C666-1 cells. Simvastatin 0-11 caspase 3 Homo sapiens 93-102 31105786-9 2019 Simvastatin induced Bim expression by regulating phosphorylation of transcriptional factor c-Jun. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 91-96 31105786-10 2019 Simvastatin treatment induced cell cycle arrest in the G1 phase in C666-1 cells by inhibiting the expression of cyclin D1 and cyclin-dependent kinase 4, and enhancing p27 expression. Simvastatin 0-11 cyclin D1 Homo sapiens 112-121 31105786-10 2019 Simvastatin treatment induced cell cycle arrest in the G1 phase in C666-1 cells by inhibiting the expression of cyclin D1 and cyclin-dependent kinase 4, and enhancing p27 expression. Simvastatin 0-11 cyclin dependent kinase 4 Homo sapiens 126-151 31105786-10 2019 Simvastatin treatment induced cell cycle arrest in the G1 phase in C666-1 cells by inhibiting the expression of cyclin D1 and cyclin-dependent kinase 4, and enhancing p27 expression. Simvastatin 0-11 interferon alpha inducible protein 27 Homo sapiens 167-170 31105786-11 2019 Simvastatin treatment inhibited protein kinase B and extracellular signal regulated kinase 1/2 activation. Simvastatin 0-11 protein tyrosine kinase 2 beta Homo sapiens 32-48 31105786-11 2019 Simvastatin treatment inhibited protein kinase B and extracellular signal regulated kinase 1/2 activation. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 53-94 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 Yes1 associated transcriptional regulator Homo sapiens 127-130 31081050-0 2019 Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1. Simvastatin 0-11 caveolin 1 Homo sapiens 143-153 31081050-8 2019 Importantly, simvastatin was able to augment the anticancer effects of androgen receptor antagonists by downregulating the expression of Cav-1. Simvastatin 13-24 androgen receptor Homo sapiens 71-88 31081050-8 2019 Importantly, simvastatin was able to augment the anticancer effects of androgen receptor antagonists by downregulating the expression of Cav-1. Simvastatin 13-24 caveolin 1 Homo sapiens 137-142 31138773-5 2019 Our results showed that simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis, and we also found that SLC2A1 was a new target of miR-140-5p. Simvastatin 24-35 nuclear respiratory factor 1 Homo sapiens 138-142 31138773-5 2019 Our results showed that simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis, and we also found that SLC2A1 was a new target of miR-140-5p. Simvastatin 24-35 solute carrier family 2 member 1 Homo sapiens 217-223 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 Yes1 associated transcriptional regulator Homo sapiens 201-204 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 cellular communication network factor 2 Homo sapiens 226-257 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 cellular communication network factor 2 Homo sapiens 259-263 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 cellular communication network factor 1 Homo sapiens 269-304 31100067-2 2019 Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Simvastatin 77-88 cellular communication network factor 1 Homo sapiens 306-311 30729760-4 2019 MATERIAL AND METHODS: Three-dimensional cell spheroids were fabricated using concave silicon elastomerbased microwells in the presence of simvastatin at concentrations of 1 muM and 10 muM. Simvastatin 138-149 latexin Homo sapiens 184-187 31092879-0 2019 Insulin prevents and reverts simvastatin-induced toxicity in C2C12 skeletal muscle cells. Simvastatin 29-40 insulin Homo sapiens 0-7 31092879-3 2019 Our aims were to enlarge our knowledge regarding mechanisms and effects of insulin on simvastatin-associated myotoxicity in C2C12 myotubes. Simvastatin 86-97 insulin Homo sapiens 75-82 31092879-4 2019 Simvastatin (10 microM) reduced membrane integrity and ATP content in myotubes treated for 24 hours, which could be prevented and partially reversed concentration- and time-dependently by insulin. Simvastatin 0-11 insulin Homo sapiens 188-195 31092879-5 2019 Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2). Simvastatin 13-24 AKT serine/threonine kinase 1 Homo sapiens 57-60 31092879-5 2019 Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2). Simvastatin 13-24 protein tyrosine kinase 2 beta Homo sapiens 62-78 31092879-5 2019 Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2). Simvastatin 13-24 CREB regulated transcription coactivator 2 Mus musculus 194-200 31092879-9 2019 Insulin reduced the expression of the insulin receptor beta-chain but increased procaspase-12 activation in the presence of simvastatin. Simvastatin 124-135 insulin Homo sapiens 0-7 31092879-10 2019 In conclusion, simvastatin impaired activation of Akt Ser473 most likely as a consequence of reduced activity of mTORC2. Simvastatin 15-26 AKT serine/threonine kinase 1 Homo sapiens 50-53 31092879-10 2019 In conclusion, simvastatin impaired activation of Akt Ser473 most likely as a consequence of reduced activity of mTORC2. Simvastatin 15-26 CREB regulated transcription coactivator 2 Mus musculus 113-119 31092879-11 2019 Insulin could prevent the effects of simvastatin on the insulin signaling pathway and on apoptosis, but not on the endoplasmic reticulum (ER) stress induction. Simvastatin 37-48 insulin Homo sapiens 0-7 31092879-11 2019 Insulin could prevent the effects of simvastatin on the insulin signaling pathway and on apoptosis, but not on the endoplasmic reticulum (ER) stress induction. Simvastatin 37-48 insulin Homo sapiens 56-63 31071981-4 2019 Simvastatin was found to attenuate H2O2-induced human umbilical vein endothelial cells (HUVECs) dysfunction and inhibit the Wnt/beta-catenin pathway; however, when this pathway was activated by lithium chloride, endothelial dysfunction was clearly enhanced. Simvastatin 0-11 catenin beta 1 Homo sapiens 128-140 31071981-7 2019 We hypothesize that simvastatin does not affect transmembrane signal transduction in the Wnt/beta-catenin pathway, but inhibits ER stress by reducing intracellular cholesterol accumulation, which blocks intracellular signal transduction in the Wnt/beta-catenin pathway and ameliorates endothelial dysfunction. Simvastatin 20-31 catenin beta 1 Homo sapiens 248-260 30776567-6 2019 Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 muL/min/mg protein. Simvastatin 59-70 paraoxonase 1 Homo sapiens 88-92 30776567-6 2019 Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 muL/min/mg protein. Simvastatin 59-70 paraoxonase 3 Homo sapiens 101-105 31066788-9 2019 In defect + graft + simvastatin group, osteonectin and osteopontin expression were positive in osteoblast and osteocyte cells, and a positive expression in osteon formation was also seen in new bone trabeculae. Simvastatin 20-31 secreted protein acidic and cysteine rich Rattus norvegicus 39-50 31066788-9 2019 In defect + graft + simvastatin group, osteonectin and osteopontin expression were positive in osteoblast and osteocyte cells, and a positive expression in osteon formation was also seen in new bone trabeculae. Simvastatin 20-31 secreted phosphoprotein 1 Rattus norvegicus 55-66 29232287-7 2019 Similar effects on IL-1beta, IL-6, and IL-8 levels were observed when cells were treated with simvastatin, pravastatin, and the renin-angiotensin system inhibitors spironolactone, captopril, lisinopril, candesartan, and losartan. Simvastatin 94-105 interleukin 1 beta Homo sapiens 19-27 29232287-7 2019 Similar effects on IL-1beta, IL-6, and IL-8 levels were observed when cells were treated with simvastatin, pravastatin, and the renin-angiotensin system inhibitors spironolactone, captopril, lisinopril, candesartan, and losartan. Simvastatin 94-105 interleukin 6 Homo sapiens 29-33 29232287-7 2019 Similar effects on IL-1beta, IL-6, and IL-8 levels were observed when cells were treated with simvastatin, pravastatin, and the renin-angiotensin system inhibitors spironolactone, captopril, lisinopril, candesartan, and losartan. Simvastatin 94-105 C-X-C motif chemokine ligand 8 Homo sapiens 39-43 30729760-13 2019 The addition of simvastatin caused a statistically significant increase in the expression of collagen I and RUNX2. Simvastatin 16-27 RUNX family transcription factor 2 Homo sapiens 108-113 30729760-15 2019 CONCLUSIONS: The study clearly showed that the application of simvastatin enhanced collagen I and RUNX2 expression; however, this did not lead to increases in alkaline phosphatase activity or alizarin red S staining. Simvastatin 62-73 RUNX family transcription factor 2 Homo sapiens 98-103 31198358-1 2019 Purpose: The aim of this study was to estimate the Receptor activator of nuclear factor kappa-B ligand (RANKL) and Osteoprotegrin (OPG) levels in gingival crevicular fluid (GCF) after placement of collagen membrane with simvastatin in intrabony defects. Simvastatin 220-231 TNF superfamily member 11 Homo sapiens 51-102 31053084-11 2019 The sensitivity analyses of HTE effects for vasopressin, hydrocortisone and levosimendan were consistent with the main analyses and attenuated for simvastatin. Simvastatin 147-158 arginine vasopressin Homo sapiens 44-55 31198358-11 2019 Conclusion: Simvastatin-loaded collagen membrane expressed increased OPG and decreased RANKL levels, which could have a potential role in periodontal regeneration. Simvastatin 12-23 TNF superfamily member 11 Homo sapiens 87-92 30857920-0 2019 Simvastatin exerts antidepressant-like activity in mouse forced swimming test: Role of NO-cGMP-KATP channels pathway and PPAR-gamma receptors. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Mus musculus 121-131 30769001-5 2019 Our results showed that Clostridium Botulinum C3 toxin (C3) and simvastatin, as RhoA inhibitors, were able to protect DA neurons from rotenone damages. Simvastatin 64-75 ras homolog family member A Mus musculus 80-84 30769001-6 2019 In fact, pretreatment with C3 or simvastatin significantly prevented the reduction of [3H]dopamine uptake, neurites injury and the expression patterns of proteins like alpha-syn, actin and connexin 43. Simvastatin 33-44 synuclein, alpha Mus musculus 168-177 30769001-6 2019 In fact, pretreatment with C3 or simvastatin significantly prevented the reduction of [3H]dopamine uptake, neurites injury and the expression patterns of proteins like alpha-syn, actin and connexin 43. Simvastatin 33-44 gap junction protein, alpha 1 Mus musculus 189-200 30857920-17 2019 These results demonstrated that NO-cGMP-KATP channels pathway and PPARgamma receptors may be involved in the antidepressant-like effect of simvastatin. Simvastatin 139-150 peroxisome proliferator activated receptor gamma Mus musculus 66-75 30776329-3 2019 In all three models, while still in monolayer culture, simvastatin treatment alone promoted changes in phenotype and morphology indicative of re-differentiation most prominent being an increase in SOX9 mRNA and protein expression. Simvastatin 55-66 SRY-box transcription factor 9 Homo sapiens 197-201 30833076-0 2019 Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Simvastatin 81-92 Kruppel like factor 2 Homo sapiens 0-21 30833076-0 2019 Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Simvastatin 81-92 tumor protein p53 Homo sapiens 96-99 30833076-3 2019 Simvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, was found to exhibit therapeutic effects against many types of cancers including breast cancer, colon cancer, lung cancer, etc. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-73 30833076-5 2019 Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116. Simvastatin 64-75 Kruppel like factor 2 Homo sapiens 102-123 30833076-5 2019 Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116. Simvastatin 64-75 Kruppel like factor 2 Homo sapiens 125-129 30833076-5 2019 Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116. Simvastatin 64-75 cyclin dependent kinase inhibitor 1A Homo sapiens 135-147 30833076-5 2019 Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116. Simvastatin 64-75 tumor protein p53 Homo sapiens 165-168 30833076-6 2019 Meanwhile, we found that overexpression of KLF2 could significantly induce p21WAF1/CIP1 expression, inhibit Wnt signaling and suppress epithelial-mesenchymal transition, indicating that KL2 might mediate antitumor effect of simvastatin in SW1116 cells. Simvastatin 224-235 Kruppel like factor 2 Homo sapiens 43-47 30833076-10 2019 These data provide strong evidences for clinical application of simvastatin in treatment of colon cancer with p53 mutation. Simvastatin 64-75 tumor protein p53 Homo sapiens 110-113 30776329-4 2019 In passaged bovine chondrocytes, simvastatin stimulated the expression of SOX9, ACAN, BMP2 and inhibited the expression of COL1 and alpha-smooth muscle actin. Simvastatin 33-44 SRY-box transcription factor 9 Bos taurus 74-78 30776329-4 2019 In passaged bovine chondrocytes, simvastatin stimulated the expression of SOX9, ACAN, BMP2 and inhibited the expression of COL1 and alpha-smooth muscle actin. Simvastatin 33-44 aggrecan Bos taurus 80-84 30776329-4 2019 In passaged bovine chondrocytes, simvastatin stimulated the expression of SOX9, ACAN, BMP2 and inhibited the expression of COL1 and alpha-smooth muscle actin. Simvastatin 33-44 bone morphogenetic protein 2 Bos taurus 86-90 30776329-5 2019 Co-treatment of chondrocytes with simvastatin plus exogenous cholesterol-conditions that had previously reversed the inhibition on CD44 shedding, did not alter the effects of simvastatin on re-differentiation. Simvastatin 34-45 CD44 molecule (Indian blood group) Homo sapiens 131-135 30776329-7 2019 Treatment with simvastatin stimulated expression of SOX9 and COL2a and enhanced SOX9 protein in human OA chondrocytes. Simvastatin 15-26 SRY-box transcription factor 9 Homo sapiens 52-56 30776329-7 2019 Treatment with simvastatin stimulated expression of SOX9 and COL2a and enhanced SOX9 protein in human OA chondrocytes. Simvastatin 15-26 SRY-box transcription factor 9 Homo sapiens 80-84 30193394-9 2019 CONCLUSION: SLCO1B1 genotype is a useful biomarker for predicting an increased risk of simvastatin-induced myopathy. Simvastatin 87-98 solute carrier organic anion transporter family member 1B1 Homo sapiens 12-19 30274910-0 2019 Simvastatin ameliorates total liver ischemia/reperfusion injury via KLF2-mediated mechanism in rats. Simvastatin 0-11 Kruppel-like factor 2 Rattus norvegicus 68-72 30274910-8 2019 Moreover, simvastatin upregulated the expression of Kruppel-like factor 2 (KLF2), phosphorylated endothelial nitric oxide synthase and thrombomodulin (P < 0.05). Simvastatin 10-21 Kruppel-like factor 2 Rattus norvegicus 52-73 30274910-8 2019 Moreover, simvastatin upregulated the expression of Kruppel-like factor 2 (KLF2), phosphorylated endothelial nitric oxide synthase and thrombomodulin (P < 0.05). Simvastatin 10-21 Kruppel-like factor 2 Rattus norvegicus 75-79 30274910-8 2019 Moreover, simvastatin upregulated the expression of Kruppel-like factor 2 (KLF2), phosphorylated endothelial nitric oxide synthase and thrombomodulin (P < 0.05). Simvastatin 10-21 thrombomodulin Rattus norvegicus 135-149 30274910-9 2019 Furthermore, simvastatin pretreatment affected superoxide dismutase and malondialdehyde activities (P < 0.05) to reduce oxidative stress, and inhibited levels of high-mobility group box-1, CD68, toll-like receptor 4, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 (P < 0.05) to suppress inflammatory response. Simvastatin 13-24 high mobility group box 1 Rattus norvegicus 162-187 30274910-9 2019 Furthermore, simvastatin pretreatment affected superoxide dismutase and malondialdehyde activities (P < 0.05) to reduce oxidative stress, and inhibited levels of high-mobility group box-1, CD68, toll-like receptor 4, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 (P < 0.05) to suppress inflammatory response. Simvastatin 13-24 toll-like receptor 4 Rattus norvegicus 195-215 30274910-9 2019 Furthermore, simvastatin pretreatment affected superoxide dismutase and malondialdehyde activities (P < 0.05) to reduce oxidative stress, and inhibited levels of high-mobility group box-1, CD68, toll-like receptor 4, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 (P < 0.05) to suppress inflammatory response. Simvastatin 13-24 tumor necrosis factor Rattus norvegicus 217-244 30274910-9 2019 Furthermore, simvastatin pretreatment affected superoxide dismutase and malondialdehyde activities (P < 0.05) to reduce oxidative stress, and inhibited levels of high-mobility group box-1, CD68, toll-like receptor 4, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 (P < 0.05) to suppress inflammatory response. Simvastatin 13-24 interleukin 1 beta Rattus norvegicus 246-263 30274910-9 2019 Furthermore, simvastatin pretreatment affected superoxide dismutase and malondialdehyde activities (P < 0.05) to reduce oxidative stress, and inhibited levels of high-mobility group box-1, CD68, toll-like receptor 4, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 (P < 0.05) to suppress inflammatory response. Simvastatin 13-24 interleukin 6 Rattus norvegicus 268-281 30274910-10 2019 CONCLUSION: Simvastatin pretreatment ameliorates total hepatic IRI via a KLF2-mediated protective mechanism. Simvastatin 12-23 Kruppel-like factor 2 Rattus norvegicus 73-77 30987105-9 2019 Simvastatin strongly impaired Akt signaling and stimulated the reactive oxygen species (ROS) production; suggesting that Akt signaling and oxidative stress are important factors in statin-induced apoptosis in L6 myoblasts. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 30-33 30987105-9 2019 Simvastatin strongly impaired Akt signaling and stimulated the reactive oxygen species (ROS) production; suggesting that Akt signaling and oxidative stress are important factors in statin-induced apoptosis in L6 myoblasts. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 121-124 30536599-0 2019 Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie"s disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. Simvastatin 0-11 Yes1 associated transcriptional regulator Homo sapiens 146-149 30536599-0 2019 Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie"s disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. Simvastatin 0-11 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 150-153 30536599-8 2019 When treated with Y-27632 or simvastatin, the alpha-SMA, collagen III, elastin and CTGF mRNA expression was impeded. Simvastatin 29-40 elastin Homo sapiens 71-78 30536599-8 2019 When treated with Y-27632 or simvastatin, the alpha-SMA, collagen III, elastin and CTGF mRNA expression was impeded. Simvastatin 29-40 cellular communication network factor 2 Homo sapiens 83-87 30536599-9 2019 Additionally, TGF-beta1 stimulation showed a twofold increase in alpha-SMA protein expression, which was reversed to non-stimulated levels after treatment with Y-27632 and simvastatin. Simvastatin 172-183 transforming growth factor beta 1 Homo sapiens 14-23 30536599-14 2019 In our experiments, Rho-kinase inhibition and simvastatin treatment were shown to prevent this in TGF-beta1-stimulated cells on an RNA and protein level through the inhibition of YAP/TAZ nuclear translocation. Simvastatin 46-57 transforming growth factor beta 1 Homo sapiens 98-107 30536599-14 2019 In our experiments, Rho-kinase inhibition and simvastatin treatment were shown to prevent this in TGF-beta1-stimulated cells on an RNA and protein level through the inhibition of YAP/TAZ nuclear translocation. Simvastatin 46-57 Yes1 associated transcriptional regulator Homo sapiens 179-182 30536599-14 2019 In our experiments, Rho-kinase inhibition and simvastatin treatment were shown to prevent this in TGF-beta1-stimulated cells on an RNA and protein level through the inhibition of YAP/TAZ nuclear translocation. Simvastatin 46-57 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 183-186 30887238-1 2019 A physiologically based pharmacokinetic (PBPK) model was used to simulate the impact of elevated levels of interleukin (IL)-6 on the exposure of several orally administered cytochrome P450 (CYP) probe substrates (caffeine, S-warfarin, omeprazole, dextromethorphan, midazolam, and simvastatin). Simvastatin 280-291 interleukin 6 Homo sapiens 107-125 30288636-5 2019 Simvastatin and atorvastatin at 50 muM promoted reduction in all cytokine levels with statistical significance, except for IL-6, which had its reduction only induced by the use of simvastatin. Simvastatin 180-191 interleukin 6 Homo sapiens 123-127 30720104-8 2019 The addition of TMP and simvastatin demonstrated that, compared with the model group, the inflammatory factor levels and the ratio of p-NF-kappaB/NF-kappaB were decreased. Simvastatin 24-35 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 136-145 30720104-8 2019 The addition of TMP and simvastatin demonstrated that, compared with the model group, the inflammatory factor levels and the ratio of p-NF-kappaB/NF-kappaB were decreased. Simvastatin 24-35 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 146-155 30887238-4 2019 Moderate interactions [mean AUC fold change, <= 2.08 (midazolam) or 2.36 (simvastatin)] was predicted for CYP3A4 probe substrates and weak interactions (mean AUC fold change, <= 1.29-1.97) were predicted for CYP2C19, CYP2C9, and CYP2D6 substrates. Simvastatin 74-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 106-112 30872677-0 2019 Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Simvastatin 0-11 histone deacetylase 1 Homo sapiens 102-123 30872677-6 2019 Simvastatin abolished the detrimental effects of 3MC by reducing HDAC1 expression, with resulting RhoA upregulation, and reactivating RhoA in vitro and in vivo. Simvastatin 0-11 ras homolog family member A Homo sapiens 134-138 30872677-0 2019 Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Simvastatin 0-11 ras homolog family member A Homo sapiens 139-143 30872677-9 2019 Collectively, these results demonstrate that simvastatin restores RhoA function through HDAC1 inhibition; therefore, simvastatin might serve as adjunct therapy for RCC induced by 3MC. Simvastatin 45-56 ras homolog family member A Homo sapiens 66-70 30872677-6 2019 Simvastatin abolished the detrimental effects of 3MC by reducing HDAC1 expression, with resulting RhoA upregulation, and reactivating RhoA in vitro and in vivo. Simvastatin 0-11 histone deacetylase 1 Homo sapiens 65-70 30872677-9 2019 Collectively, these results demonstrate that simvastatin restores RhoA function through HDAC1 inhibition; therefore, simvastatin might serve as adjunct therapy for RCC induced by 3MC. Simvastatin 45-56 histone deacetylase 1 Homo sapiens 88-93 30872677-9 2019 Collectively, these results demonstrate that simvastatin restores RhoA function through HDAC1 inhibition; therefore, simvastatin might serve as adjunct therapy for RCC induced by 3MC. Simvastatin 117-128 ras homolog family member A Homo sapiens 66-70 30872677-6 2019 Simvastatin abolished the detrimental effects of 3MC by reducing HDAC1 expression, with resulting RhoA upregulation, and reactivating RhoA in vitro and in vivo. Simvastatin 0-11 ras homolog family member A Homo sapiens 98-102 30872677-9 2019 Collectively, these results demonstrate that simvastatin restores RhoA function through HDAC1 inhibition; therefore, simvastatin might serve as adjunct therapy for RCC induced by 3MC. Simvastatin 117-128 histone deacetylase 1 Homo sapiens 88-93 30851734-6 2019 Several statins, including atorvastatin, simvastatin, lovastatin, and fluvastatin, increased CD55 protein expression in astrocytes, including primary cultures, by three- to four-fold at 24 h, conferring significant protection against AQP4-IgG-induced CDC. Simvastatin 41-52 CD55 molecule (Cromer blood group) Homo sapiens 93-97 30956215-0 2019 Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats. Simvastatin 11-22 butyrylcholinesterase Rattus norvegicus 42-63 30668918-0 2019 Simvastatin With PRP Promotes Chondrogenesis of Bone Marrow Stem Cells In Vitro and Wounded Rat Achilles Tendon-Bone Interface Healing In Vivo. Simvastatin 0-11 proline rich protein 2-like 1 Rattus norvegicus 17-20 30668918-3 2019 PURPOSE:: To study the effect of simvastatin with platelet-rich plasma (PRP) on chondrogenesis of rat bone marrow stem cells (BMSCs) in vitro and wounded rat Achilles tendon-bone interface healing in vivo. Simvastatin 33-44 proline rich protein 2-like 1 Rattus norvegicus 72-75 30668918-9 2019 The wounds treated with simvastatin alone or with simvastatin-containing PRP gel healed much faster than the wounds treated with saline alone or PRP alone. Simvastatin 50-61 proline rich protein 2-like 1 Rattus norvegicus 73-76 30668918-9 2019 The wounds treated with simvastatin alone or with simvastatin-containing PRP gel healed much faster than the wounds treated with saline alone or PRP alone. Simvastatin 50-61 proline rich protein 2-like 1 Rattus norvegicus 145-148 30668918-10 2019 Histological analysis showed that higher percentages of healed tissues were positively stained with safranin O and fast green in wounds treated with simvastatin-containing PRP gel than in the other 3 groups. Simvastatin 149-160 proline rich protein 2-like 1 Rattus norvegicus 172-175 30668918-11 2019 Immunohistochemical analysis further demonstrated these findings, as evidenced by more positively stained healed tissues with collagen I and II antibodies in the wound areas treated with simvastatin-containing PRP gel than the other 3 groups. Simvastatin 187-198 proline rich protein 2-like 1 Rattus norvegicus 210-213 30956215-1 2019 The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats. Simvastatin 52-63 butyrylcholinesterase Rattus norvegicus 108-129 30956215-1 2019 The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats. Simvastatin 52-63 butyrylcholinesterase Rattus norvegicus 131-136 30956215-4 2019 Simvastatin and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the substrate. Simvastatin 0-11 butyrylcholinesterase Rattus norvegicus 56-61 30956215-6 2019 Simvastatin and fenofibrate also increased liver and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate. Simvastatin 0-11 butyrylcholinesterase Rattus norvegicus 60-65 30461427-0 2019 Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. Simvastatin 83-94 interleukin 6 Homo sapiens 102-115 30903492-4 2019 Here we analyze the effects of simvastatin and a new potential proteasome inhibitor K7174 inducing expression of IGFBP6 and EVOVL5 on the proliferation of breast cancer cells MDA-MB-231 and DU4475. Simvastatin 31-42 insulin like growth factor binding protein 6 Homo sapiens 113-119 30903492-5 2019 Compound K7174 potentiates the inhibitory effect of simvastatin on the proliferation of DU4475 cells characterized by low expression of ELOVL5-IGFBP6 pair, but not on the proliferation of MDA-MB-231 cells with high expression of these markers. Simvastatin 52-63 ELOVL fatty acid elongase 5 Homo sapiens 136-142 30903492-5 2019 Compound K7174 potentiates the inhibitory effect of simvastatin on the proliferation of DU4475 cells characterized by low expression of ELOVL5-IGFBP6 pair, but not on the proliferation of MDA-MB-231 cells with high expression of these markers. Simvastatin 52-63 insulin like growth factor binding protein 6 Homo sapiens 143-149 30783483-0 2019 The effects of simvastatin preconditioning on the expression of caspase-3 after myocardial ischemia reperfusion injury in rats. Simvastatin 15-26 caspase 3 Rattus norvegicus 64-73 30783483-1 2019 Effect of simvastatin on the expression of caspase-3 in myocardial ischemia reperfusion injury in rats was observed to explore the protective effect of caspase-3 through anti-apoptosis mechanism. Simvastatin 10-21 caspase 3 Rattus norvegicus 43-52 30783483-1 2019 Effect of simvastatin on the expression of caspase-3 in myocardial ischemia reperfusion injury in rats was observed to explore the protective effect of caspase-3 through anti-apoptosis mechanism. Simvastatin 10-21 caspase 3 Rattus norvegicus 152-161 30783483-7 2019 The positive rate of the expression of caspase-3 and the positive rate of the expression of apoptotic cells in the ischemic reperfusion and simvastatin groups were significantly higher than that of the blank and sham operation groups, and the positive rate of the expression of caspase-3 and apoptotic cells in the simvastatin group was significantly lower than that of the ischemia-reperfusion group (P<0.05). Simvastatin 140-151 caspase 3 Rattus norvegicus 278-287 30783483-9 2019 Compared with the blank and sham operation groups, the expression of caspase-3 protein in the ischemia-reperfusion and simvastatin groups was significantly increased, and the expression of caspase-3 protein in the simvastatin group was significantly lower than that of the ischemia reperfusion group (P<0.05). Simvastatin 119-130 caspase 3 Rattus norvegicus 69-78 30783483-9 2019 Compared with the blank and sham operation groups, the expression of caspase-3 protein in the ischemia-reperfusion and simvastatin groups was significantly increased, and the expression of caspase-3 protein in the simvastatin group was significantly lower than that of the ischemia reperfusion group (P<0.05). Simvastatin 214-225 caspase 3 Rattus norvegicus 189-198 30783483-10 2019 Simvastatin has a protective effect on myocardial ischemia-reperfusion injury, which may be related to the reduction of caspase-3 expression and inhibition of apoptosis. Simvastatin 0-11 caspase 3 Rattus norvegicus 120-129 30461427-4 2019 Interestingly, patients on simvastatin had lower interleukin-6 levels compared with patients not on simvastatin and controls. Simvastatin 27-38 interleukin 6 Homo sapiens 49-62 30644168-6 2019 Attenuation of OA in mice treated with simvastatin-conjugated gelatin hydrogel was associated with decreased expression of cartilage-degrading enzymes and interleukin (IL)-1beta and increased expression of type II collagen and an autophagic marker, LC3, in the articular cartilage. Simvastatin 39-50 interleukin 1 beta Mus musculus 155-177 30644168-6 2019 Attenuation of OA in mice treated with simvastatin-conjugated gelatin hydrogel was associated with decreased expression of cartilage-degrading enzymes and interleukin (IL)-1beta and increased expression of type II collagen and an autophagic marker, LC3, in the articular cartilage. Simvastatin 39-50 microtubule-associated protein 1 light chain 3 alpha Mus musculus 249-252 30644168-8 2019 Treatment with simvastatin down-regulated Mmp-13 and Il-1beta and up-regulated Col2a1 and autophagic activity. Simvastatin 15-26 matrix metallopeptidase 13 Mus musculus 42-48 30644168-8 2019 Treatment with simvastatin down-regulated Mmp-13 and Il-1beta and up-regulated Col2a1 and autophagic activity. Simvastatin 15-26 interleukin 1 beta Mus musculus 53-61 30644168-8 2019 Treatment with simvastatin down-regulated Mmp-13 and Il-1beta and up-regulated Col2a1 and autophagic activity. Simvastatin 15-26 collagen, type II, alpha 1 Mus musculus 79-85 30628692-0 2019 MicroRNA-192 acts as a tumor suppressor in colon cancer and simvastatin activates miR-192 to inhibit cancer cell growth. Simvastatin 60-71 microRNA 192 Homo sapiens 82-89 30628692-6 2019 Following the determination of the role of the miR-192-RAB2A pathway in colon cancer, small molecules that may regulate miR-192 were screened and the results demonstrated that simvastatin is an activator of miR-192. Simvastatin 176-187 microRNA 192 Homo sapiens 47-54 30628692-6 2019 Following the determination of the role of the miR-192-RAB2A pathway in colon cancer, small molecules that may regulate miR-192 were screened and the results demonstrated that simvastatin is an activator of miR-192. Simvastatin 176-187 RAB2A, member RAS oncogene family Homo sapiens 55-60 30628692-6 2019 Following the determination of the role of the miR-192-RAB2A pathway in colon cancer, small molecules that may regulate miR-192 were screened and the results demonstrated that simvastatin is an activator of miR-192. Simvastatin 176-187 microRNA 192 Homo sapiens 120-127 30628692-6 2019 Following the determination of the role of the miR-192-RAB2A pathway in colon cancer, small molecules that may regulate miR-192 were screened and the results demonstrated that simvastatin is an activator of miR-192. Simvastatin 176-187 microRNA 192 Homo sapiens 120-127 30628692-7 2019 Furthermore, simvastatin upregulated miR-192 and inhibited the expression of downstream targets of miR-192, which subsequently led to suppressed proliferation, migration and invasion of colon cancer cells. Simvastatin 13-24 microRNA 192 Homo sapiens 37-44 30628692-7 2019 Furthermore, simvastatin upregulated miR-192 and inhibited the expression of downstream targets of miR-192, which subsequently led to suppressed proliferation, migration and invasion of colon cancer cells. Simvastatin 13-24 microRNA 192 Homo sapiens 99-106 30699879-8 2019 Moreover, simvastatin markedly prevented and ameliorated LPS and CMS-induced neuroinflammation, as shown by the suppressed activation of microglia in hippocampus and decreased hippocampal pro-inflammatory cytokines expressions including IL-1beta, TNF-alpha, IL-6, which might be mediated via the inhibition of NF-kappaB pathway, as shown by the decreased nuclear NF-kappaB p65 expression. Simvastatin 10-21 interleukin 1 beta Mus musculus 237-245 30744543-1 2019 Background and Purpose- Previously, murine models Krit1 +/- Msh2 -/ - and Ccm2 +/ - Trp53 -/ - showed a reduction or no effect on cerebral cavernous malformation (CCM) burden and favorable effects on lesional hemorrhage by the robust Rock (Rho-associated protein kinase) inhibitor fasudil and by simvastatin (a weak pleiotropic inhibitor of Rock). Simvastatin 296-307 cerebral cavernous malformation 2 Mus musculus 74-78 30744543-7 2019 Results- The Pdcd10 +/ - Trp53 -/ - /Msh2 -/ - models showed a mean CCM lesion burden per mouse reduction from 0.0091 in placebos to 0.0042 ( P=0.027) by fasudil, and to 0.0047 ( P=0.025) by atorvastatin treatment, but was not changed significantly by simvastatin. Simvastatin 252-263 programmed cell death 10 Mus musculus 13-19 30744543-7 2019 Results- The Pdcd10 +/ - Trp53 -/ - /Msh2 -/ - models showed a mean CCM lesion burden per mouse reduction from 0.0091 in placebos to 0.0042 ( P=0.027) by fasudil, and to 0.0047 ( P=0.025) by atorvastatin treatment, but was not changed significantly by simvastatin. Simvastatin 252-263 transformation related protein 53 Mus musculus 25-30 30744543-7 2019 Results- The Pdcd10 +/ - Trp53 -/ - /Msh2 -/ - models showed a mean CCM lesion burden per mouse reduction from 0.0091 in placebos to 0.0042 ( P=0.027) by fasudil, and to 0.0047 ( P=0.025) by atorvastatin treatment, but was not changed significantly by simvastatin. Simvastatin 252-263 mutS homolog 2 Mus musculus 37-41 30937311-8 2019 Furthermore, STG or simvastatin treatment decreased the mRNA and protein levels of HMGCR and SREBP-2 in liver. Simvastatin 20-31 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 83-88 30937311-8 2019 Furthermore, STG or simvastatin treatment decreased the mRNA and protein levels of HMGCR and SREBP-2 in liver. Simvastatin 20-31 sterol regulatory element binding transcription factor 2 Rattus norvegicus 93-100 30808332-6 2019 CONCLUSION: Simvastatin, as well as lovastatin, because of their CYP3A4 metabolism, and to a lesser extent atorvastatin, which is only partially metabolized by CYP3A4, are the HMG-CoA reductase inhibitors with the greatest risk of drug interactions and should not be used in patients under HIV-therapy. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 30767945-8 2019 RESULTS Simvastatin improved the cardiac hypertrophy of diabetic rats, as demonstrated by decreases in the ratios of left ventricular weight/body weight (LVW/BW) and heart weight/body weight (HW/BW) and by the downregulation of mRNA expression of BNP and ANP in the heart tissue. Simvastatin 8-19 natriuretic peptide B Rattus norvegicus 247-250 30867758-11 2019 Furthermore, as a hydroxymethylglutaryl-Coenzyme A reductase inhibitor, treatment using simvastatin increased LDL receptor expression, leading to enhancement of the TS-PDT effect on MKN74 cells. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 110-122 30867758-12 2019 In conclusion, the difference in LDL receptor expression between the two gastric cell lines could influence TS-PDT efficacy; simvastatin may enhance the antitumor effect of TS-PDT through upregulating the LDL receptor even on PDT-resistant gastric cancer cells. Simvastatin 125-136 low density lipoprotein receptor Homo sapiens 205-217 30813251-7 2019 Additionally, COX-2 activity was diminished, and caspase-3 activity was increased to a higher extent by phenothiazine derivative:simvastatin mixtures than by phenothiazine derivatives themselves. Simvastatin 129-140 caspase 3 Homo sapiens 49-58 30828299-0 2019 Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-kappaB/p65 Expression. Simvastatin 0-11 synaptotagmin 1 Rattus norvegicus 113-116 30828299-7 2019 Simvastatin 40 mg/kg significantly decreased apoptotic index and caspase-3 cleavage in hepatocytes and lymphocytes (p < 0.01 vs. LPS group, respectively), while Bcl-XL markedly increased accordingly with simvastatin doses. Simvastatin 0-11 caspase 3 Rattus norvegicus 65-74 30828299-9 2019 Cell-protective effects of simvastatin against LPS seemed to be mediated by up-regulation of survivin, which leads to reduced caspase-3 activation and inhibition of hepatocytes and lymphocytes apoptosis. Simvastatin 27-38 caspase 3 Rattus norvegicus 126-135 30767945-9 2019 Simvastatin decreased the protein expressions of VCAM-1, ICAM-1, IL-6, and TNF-alpha, increased eNOS protein expression, and limited an increase in ROS levels in the heart tissue. Simvastatin 0-11 vascular cell adhesion molecule 1 Rattus norvegicus 49-55 30767945-9 2019 Simvastatin decreased the protein expressions of VCAM-1, ICAM-1, IL-6, and TNF-alpha, increased eNOS protein expression, and limited an increase in ROS levels in the heart tissue. Simvastatin 0-11 intercellular adhesion molecule 1 Rattus norvegicus 57-63 30699879-8 2019 Moreover, simvastatin markedly prevented and ameliorated LPS and CMS-induced neuroinflammation, as shown by the suppressed activation of microglia in hippocampus and decreased hippocampal pro-inflammatory cytokines expressions including IL-1beta, TNF-alpha, IL-6, which might be mediated via the inhibition of NF-kappaB pathway, as shown by the decreased nuclear NF-kappaB p65 expression. Simvastatin 10-21 tumor necrosis factor Mus musculus 247-256 30699879-8 2019 Moreover, simvastatin markedly prevented and ameliorated LPS and CMS-induced neuroinflammation, as shown by the suppressed activation of microglia in hippocampus and decreased hippocampal pro-inflammatory cytokines expressions including IL-1beta, TNF-alpha, IL-6, which might be mediated via the inhibition of NF-kappaB pathway, as shown by the decreased nuclear NF-kappaB p65 expression. Simvastatin 10-21 interleukin 6 Mus musculus 258-262 30767945-0 2019 Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-kappaB (NF-kappaB). Simvastatin 0-11 calpain 1 Rattus norvegicus 121-130 30767945-9 2019 Simvastatin decreased the protein expressions of VCAM-1, ICAM-1, IL-6, and TNF-alpha, increased eNOS protein expression, and limited an increase in ROS levels in the heart tissue. Simvastatin 0-11 interleukin 6 Rattus norvegicus 65-69 30767945-9 2019 Simvastatin decreased the protein expressions of VCAM-1, ICAM-1, IL-6, and TNF-alpha, increased eNOS protein expression, and limited an increase in ROS levels in the heart tissue. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 75-84 29659380-11 2019 We conclude that simvastatin and pioglitazone may have a protective effect against cognitive impairment induced by LPS, through targeting the glutamatergic and inflammatory pathways, especially in patients having hypercholesterolemia and diabetes. Simvastatin 17-28 toll-like receptor 4 Mus musculus 115-118 30767945-10 2019 Simvastatin increased IkBa protein expression in cytoplasm and inhibited the translocation of p65, the subunit of nuclear factor-kappaB (NF-kappaB) to the nucleus from the cytoplasm of the heart tissue. Simvastatin 0-11 synaptotagmin 1 Rattus norvegicus 94-135 30767945-11 2019 Furthermore, simvastatin attenuated the activity of calpain and calpain-1 protein expression in heart tissue. Simvastatin 13-24 calpain 1 Rattus norvegicus 64-73 30767945-12 2019 CONCLUSIONS Simvastatin attenuates cardiac hypertrophy in diabetic rats, which might be due to the attenuation of oxidative stress and inflammation induced by calpain-1-mediated activation of NF-kappaB. Simvastatin 12-23 calpain 1 Rattus norvegicus 159-168 29659380-4 2019 The aim of the present study was to investigate the protective effect of simvastatin, pioglitazone, and their combination in lipopolysaccharide (LPS)-induced neuroinflammation and amyloidogenesis. Simvastatin 73-84 toll-like receptor 4 Mus musculus 145-148 30312114-5 2019 In human myometrial cells, simvastatin reduced proinflammatory mediator mRNA and protein expression (IL-6 and IL-8) and increased anti-inflammatory cytokine mRNA expression (IL-10 and IL-13). Simvastatin 27-38 interleukin 6 Homo sapiens 101-105 30315647-4 2019 Under optimized conditions, calibration curves plotted in spiked plasma and urine samples were linear in the ranges of 0.363-25/0.49-25 mug L-1 for ezetimibe/simvastatin and 0.193-25/0.312-25 mug L-1 for ezetimibe/simvastatin in plasma and urine samples, respectively. Simvastatin 158-169 immunoglobulin kappa variable 1-16 Homo sapiens 140-143 30315647-5 2019 The limit of detection was 0.109/0.174 mug L-1 for ezetimibe/simvastatin in plasma and 0.058/0.093 mug L-1 for ezetimibe/simvastatin in urine. Simvastatin 61-72 immunoglobulin kappa variable 1-16 Homo sapiens 43-46 30315647-5 2019 The limit of detection was 0.109/0.174 mug L-1 for ezetimibe/simvastatin in plasma and 0.058/0.093 mug L-1 for ezetimibe/simvastatin in urine. Simvastatin 121-132 immunoglobulin kappa variable 1-16 Homo sapiens 103-106 30312114-4 2019 We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration. Simvastatin 13-24 interleukin 6 Mus musculus 166-170 30216432-5 2019 Simvastatin induced CAMP expression in bladder epithelial cells telomerase-immortalized uroepithelial cells (TERT-NHUCs), intestinal cells HT-29 and keratinocytes HEKa, but not in airway epithelial cells A549. Simvastatin 0-11 cathelicidin antimicrobial peptide Homo sapiens 20-24 30216432-5 2019 Simvastatin induced CAMP expression in bladder epithelial cells telomerase-immortalized uroepithelial cells (TERT-NHUCs), intestinal cells HT-29 and keratinocytes HEKa, but not in airway epithelial cells A549. Simvastatin 0-11 telomerase reverse transcriptase Homo sapiens 109-113 30216432-9 2019 In addition, simvastatin increased transcription of the vitamin D-activating enzyme CYP27B1 which, in turn, may activate LL-37/hCAP-18 production. Simvastatin 13-24 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 84-91 30216432-9 2019 In addition, simvastatin increased transcription of the vitamin D-activating enzyme CYP27B1 which, in turn, may activate LL-37/hCAP-18 production. Simvastatin 13-24 cathelicidin antimicrobial peptide Homo sapiens 121-126 30216432-9 2019 In addition, simvastatin increased transcription of the vitamin D-activating enzyme CYP27B1 which, in turn, may activate LL-37/hCAP-18 production. Simvastatin 13-24 cathelicidin antimicrobial peptide Homo sapiens 127-134 30216432-10 2019 Taken together, simvastatin is able to promote the expression of LL-37/hCAP-18, but cell line-specific differences in efficacy and the involved signalling pathways exist. Simvastatin 16-27 cathelicidin antimicrobial peptide Homo sapiens 65-70 30216432-10 2019 Taken together, simvastatin is able to promote the expression of LL-37/hCAP-18, but cell line-specific differences in efficacy and the involved signalling pathways exist. Simvastatin 16-27 cathelicidin antimicrobial peptide Homo sapiens 71-78 30312114-4 2019 We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration. Simvastatin 13-24 chemokine (C-X-C motif) ligand 1 Mus musculus 172-177 30312114-4 2019 We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration. Simvastatin 13-24 chemokine (C-C motif) ligand 2 Mus musculus 183-187 30312114-4 2019 We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration. Simvastatin 13-24 interleukin 6 Mus musculus 208-212 30312114-5 2019 In human myometrial cells, simvastatin reduced proinflammatory mediator mRNA and protein expression (IL-6 and IL-8) and increased anti-inflammatory cytokine mRNA expression (IL-10 and IL-13). Simvastatin 27-38 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 30312114-5 2019 In human myometrial cells, simvastatin reduced proinflammatory mediator mRNA and protein expression (IL-6 and IL-8) and increased anti-inflammatory cytokine mRNA expression (IL-10 and IL-13). Simvastatin 27-38 interleukin 10 Homo sapiens 174-179 30312114-5 2019 In human myometrial cells, simvastatin reduced proinflammatory mediator mRNA and protein expression (IL-6 and IL-8) and increased anti-inflammatory cytokine mRNA expression (IL-10 and IL-13). Simvastatin 27-38 interleukin 13 Homo sapiens 184-189 30612281-0 2019 PAI-1 inhibition by simvastatin as a positive adjuvant in cell therapy. Simvastatin 20-31 serpin family E member 1 Homo sapiens 0-5 29962034-8 2019 Additionally, simvastatin usage increased total antioxidant capacity (TAC) level, paraoxonase 1 (PON1) activity in serum and decreased total oxidant status (TOS) and malondialdehyde (MDA) levels in tumors similar to tamoxifen. Simvastatin 14-25 paraoxonase 1 Mus musculus 82-95 29962034-8 2019 Additionally, simvastatin usage increased total antioxidant capacity (TAC) level, paraoxonase 1 (PON1) activity in serum and decreased total oxidant status (TOS) and malondialdehyde (MDA) levels in tumors similar to tamoxifen. Simvastatin 14-25 paraoxonase 1 Mus musculus 97-101 30612281-5 2019 Simvastatin acts at several levels in the protein cascade regulating PAI-1 levels. Simvastatin 0-11 serpin family E member 1 Homo sapiens 69-74 30612281-6 2019 Thus, simvastatin-induced reduction of PAI-1 levels has a therapeutic potential by modulating the main processes involved in the creation of an inhospitable environment during the process of injury (fibrosis and cell migration). Simvastatin 6-17 serpin family E member 1 Homo sapiens 39-44 31187712-2 2019 Simvastatin, an inhibitor of cholesterol synthesis, stimulate bone formation by enhancing the expression of bone morphogenetic protein-2 (BMP-2) in osteoblasts. Simvastatin 0-11 bone morphogenetic protein 2 Oryctolagus cuniculus 138-143 30255302-3 2019 In this context, the aim of this study was to assess the influence of simvastatin, a leading member of the family of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known to display anti-inflammatory and immunomodulatory activity, on symptoms and lung function, as well as the proportion of inflammatory cells, cytokines, proteolytic enzymes, and surfactant protein D (SP-D) content in bronchoalveolar lavage fluid (BALF) in COPD patients. Simvastatin 70-81 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 117-174 30255302-3 2019 In this context, the aim of this study was to assess the influence of simvastatin, a leading member of the family of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known to display anti-inflammatory and immunomodulatory activity, on symptoms and lung function, as well as the proportion of inflammatory cells, cytokines, proteolytic enzymes, and surfactant protein D (SP-D) content in bronchoalveolar lavage fluid (BALF) in COPD patients. Simvastatin 70-81 surfactant protein D Homo sapiens 369-389 30255302-3 2019 In this context, the aim of this study was to assess the influence of simvastatin, a leading member of the family of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known to display anti-inflammatory and immunomodulatory activity, on symptoms and lung function, as well as the proportion of inflammatory cells, cytokines, proteolytic enzymes, and surfactant protein D (SP-D) content in bronchoalveolar lavage fluid (BALF) in COPD patients. Simvastatin 70-81 surfactant protein D Homo sapiens 391-395 30255302-6 2019 The major finding was that simvastatin treatment caused a distinct increase in the airway content of SP-D. Simvastatin 27-38 surfactant protein D Homo sapiens 101-105 31187712-2 2019 Simvastatin, an inhibitor of cholesterol synthesis, stimulate bone formation by enhancing the expression of bone morphogenetic protein-2 (BMP-2) in osteoblasts. Simvastatin 0-11 bone morphogenetic protein 2 Oryctolagus cuniculus 108-136 30528737-5 2019 Biochemical data showed that TUDCA, an ER stress inhibitor, inhibited atorvastatin- and simvastatin-induced protein cleavages of PARP-1 and caspase-3, respectively. Simvastatin 88-99 poly (ADP-ribose) polymerase family, member 1 Mus musculus 129-135 30528737-5 2019 Biochemical data showed that TUDCA, an ER stress inhibitor, inhibited atorvastatin- and simvastatin-induced protein cleavages of PARP-1 and caspase-3, respectively. Simvastatin 88-99 caspase 3 Mus musculus 140-149 31663349-5 2019 RESULTS: SIM caused Nrf2 over-activation (more localizations in the cellular nucleus), reduction in reactive oxygen species (ROS), induction of autophagy (decrease in p62 expression and increase in LC3II/LC3I ratio) and inhibition of apoptosis (decrease in Bax protein and increase in Bcl-2) in NSCs exposed to H2O2-induced oxidative stress, thereby prolonging the cell viability within 48 hours at low concentration (2 muM). Simvastatin 9-12 NFE2 like bZIP transcription factor 2 Homo sapiens 20-24 31663349-5 2019 RESULTS: SIM caused Nrf2 over-activation (more localizations in the cellular nucleus), reduction in reactive oxygen species (ROS), induction of autophagy (decrease in p62 expression and increase in LC3II/LC3I ratio) and inhibition of apoptosis (decrease in Bax protein and increase in Bcl-2) in NSCs exposed to H2O2-induced oxidative stress, thereby prolonging the cell viability within 48 hours at low concentration (2 muM). Simvastatin 9-12 nucleoporin 62 Homo sapiens 167-170 31663349-5 2019 RESULTS: SIM caused Nrf2 over-activation (more localizations in the cellular nucleus), reduction in reactive oxygen species (ROS), induction of autophagy (decrease in p62 expression and increase in LC3II/LC3I ratio) and inhibition of apoptosis (decrease in Bax protein and increase in Bcl-2) in NSCs exposed to H2O2-induced oxidative stress, thereby prolonging the cell viability within 48 hours at low concentration (2 muM). Simvastatin 9-12 BCL2 associated X, apoptosis regulator Homo sapiens 257-260 31663349-5 2019 RESULTS: SIM caused Nrf2 over-activation (more localizations in the cellular nucleus), reduction in reactive oxygen species (ROS), induction of autophagy (decrease in p62 expression and increase in LC3II/LC3I ratio) and inhibition of apoptosis (decrease in Bax protein and increase in Bcl-2) in NSCs exposed to H2O2-induced oxidative stress, thereby prolonging the cell viability within 48 hours at low concentration (2 muM). Simvastatin 9-12 BCL2 apoptosis regulator Homo sapiens 285-290 32369804-7 2019 We found that SIM decreased muscle performance on the rotarod, serum CoQ10, as well as muscle SOD and CAT activities while it increased serum CK, serum and muscle nitrite, as well as muscle MDA levels. Simvastatin 14-17 catalase Rattus norvegicus 102-105 29914792-8 2019 However, IL-13 and TGF-beta levels were significantly decreased by BMSCs and BMSC + simvastatin combination therapy (P < 0.05 for all cases). Simvastatin 84-95 transforming growth factor, beta 1 Mus musculus 19-27 31258074-8 2019 Consistent with previous characterization of ML141, simvastatin decreased host cell binding to fibronectin. Simvastatin 52-63 fibronectin 1 Homo sapiens 95-106 29914792-8 2019 However, IL-13 and TGF-beta levels were significantly decreased by BMSCs and BMSC + simvastatin combination therapy (P < 0.05 for all cases). Simvastatin 84-95 interleukin 13 Mus musculus 9-14 29914792-9 2019 The effect of simvastatin and BMSCs combination therapy on serum specific IgE levels as well as lung IL-13 and TGF-beta levels were significantly higher than the effect of BMSCs and simvastatin alone (P < 0.001 for IL-13 and P < 0.01 for other cases). Simvastatin 14-25 interleukin 13 Mus musculus 218-223 29914792-10 2019 CONCLUSIONS: Simvastatin and BMSCs combination therapy affects serum IgE as well as lung IL-13 and TGFbeta levels more than BMSC therapy and simvastatin therapy alone which may be due to increased BMSCs migration into the lung tissue. Simvastatin 13-24 interleukin 13 Mus musculus 89-94 29914792-10 2019 CONCLUSIONS: Simvastatin and BMSCs combination therapy affects serum IgE as well as lung IL-13 and TGFbeta levels more than BMSC therapy and simvastatin therapy alone which may be due to increased BMSCs migration into the lung tissue. Simvastatin 13-24 transforming growth factor, beta 1 Mus musculus 99-106 31543373-0 2019 Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function. Simvastatin 42-49 low density lipoprotein receptor Homo sapiens 53-82 30713570-9 2019 Conclusively, lipid-regulating and anti-inflammatory functions mediated by YQHP with lower hepatotoxicity than simvastatin hindered the progression of HSP65 aggravated AS in ApoE-/- mice, indicating the effectiveness of Yangyin Qingre Huoxue Method in the treatment of AS. Simvastatin 111-122 heat shock protein 1 (chaperonin) Mus musculus 151-156 30713570-9 2019 Conclusively, lipid-regulating and anti-inflammatory functions mediated by YQHP with lower hepatotoxicity than simvastatin hindered the progression of HSP65 aggravated AS in ApoE-/- mice, indicating the effectiveness of Yangyin Qingre Huoxue Method in the treatment of AS. Simvastatin 111-122 apolipoprotein E Mus musculus 174-178 30651784-9 2019 Additionally, treatment of HAEC and HPCASMC with simvastatin and gamma-carboxy-L-glutamic acid reduced CDKN2B promoter methylation and increased CDKN2B transcription concomitantly. Simvastatin 49-60 cyclin dependent kinase inhibitor 2B Homo sapiens 103-109 30651784-9 2019 Additionally, treatment of HAEC and HPCASMC with simvastatin and gamma-carboxy-L-glutamic acid reduced CDKN2B promoter methylation and increased CDKN2B transcription concomitantly. Simvastatin 49-60 cyclin dependent kinase inhibitor 2B Homo sapiens 145-151 31706904-1 2019 BACKGROUND: Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Simvastatin 36-43 low density lipoprotein receptor Homo sapiens 77-106 30193816-8 2019 Collectively, the ICAM-NLC/Pro/Ang that co-delivered simvastatin and Ang-1 gene may represent a potential treatment modality for ALI. Simvastatin 53-64 angiogenin Homo sapiens 31-34 30193816-0 2019 Combined delivery of angiopoietin-1 gene and simvastatin mediated by anti-intercellular adhesion molecule-1 antibody-conjugated ternary nanoparticles for acute lung injury therapy. Simvastatin 45-56 intercellular adhesion molecule 1 Homo sapiens 69-107 30745018-0 2019 Simvastatin and other inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase of Ustilago maydis (Um-Hmgr) affect the viability of the fungus, its synthesis of sterols and mating. Simvastatin 0-11 high mobility group AT-hook 1 Homo sapiens 118-122 30193816-2 2019 Lung-targeted ternary nanoparticles containing anti-intercellular adhesion molecule-1 (ICAM-1) antibody-conjugated simvastatin-loaded nanostructured lipid carrier (ICAM/NLC), protamine (Pro), and angiopoietin-1 (Ang-1) gene (ICAM-NLC/Pro/Ang) were developed for ALI therapy. Simvastatin 115-126 intercellular adhesion molecule 1 Homo sapiens 47-85 30193816-2 2019 Lung-targeted ternary nanoparticles containing anti-intercellular adhesion molecule-1 (ICAM-1) antibody-conjugated simvastatin-loaded nanostructured lipid carrier (ICAM/NLC), protamine (Pro), and angiopoietin-1 (Ang-1) gene (ICAM-NLC/Pro/Ang) were developed for ALI therapy. Simvastatin 115-126 intercellular adhesion molecule 1 Homo sapiens 87-93 30193816-2 2019 Lung-targeted ternary nanoparticles containing anti-intercellular adhesion molecule-1 (ICAM-1) antibody-conjugated simvastatin-loaded nanostructured lipid carrier (ICAM/NLC), protamine (Pro), and angiopoietin-1 (Ang-1) gene (ICAM-NLC/Pro/Ang) were developed for ALI therapy. Simvastatin 115-126 angiopoietin 1 Homo sapiens 196-210 30193816-2 2019 Lung-targeted ternary nanoparticles containing anti-intercellular adhesion molecule-1 (ICAM-1) antibody-conjugated simvastatin-loaded nanostructured lipid carrier (ICAM/NLC), protamine (Pro), and angiopoietin-1 (Ang-1) gene (ICAM-NLC/Pro/Ang) were developed for ALI therapy. Simvastatin 115-126 angiopoietin 1 Homo sapiens 212-217 30193816-2 2019 Lung-targeted ternary nanoparticles containing anti-intercellular adhesion molecule-1 (ICAM-1) antibody-conjugated simvastatin-loaded nanostructured lipid carrier (ICAM/NLC), protamine (Pro), and angiopoietin-1 (Ang-1) gene (ICAM-NLC/Pro/Ang) were developed for ALI therapy. Simvastatin 115-126 angiogenin Homo sapiens 212-215 30662566-12 2019 The elucidation of the molecular pathways (cholesterol/lipid raft/integrin beta3/FAK and cholesterol-associated LXR/ABCA1 regulation) for anti-EMT and the new application of simvastatin should be of clinical significance. Simvastatin 174-185 integrin subunit beta 3 Homo sapiens 66-80 30662566-7 2019 RESULTS: It was revealed simvastatin can disrupt lipid rafts (cholesterol-rich domains) and suppress integrin-beta3 and focal adhesion formation, thus inhibiting FAK signaling pathway and re-sensitizing the drug-resistant cancer cells to paclitaxel. Simvastatin 25-36 integrin subunit beta 3 Homo sapiens 101-115 30662566-12 2019 The elucidation of the molecular pathways (cholesterol/lipid raft/integrin beta3/FAK and cholesterol-associated LXR/ABCA1 regulation) for anti-EMT and the new application of simvastatin should be of clinical significance. Simvastatin 174-185 ATP binding cassette subfamily A member 1 Homo sapiens 116-121 30662566-7 2019 RESULTS: It was revealed simvastatin can disrupt lipid rafts (cholesterol-rich domains) and suppress integrin-beta3 and focal adhesion formation, thus inhibiting FAK signaling pathway and re-sensitizing the drug-resistant cancer cells to paclitaxel. Simvastatin 25-36 protein tyrosine kinase 2 Homo sapiens 162-165 30631264-10 2018 Simvastatin significantly downregulated the expression of antiapoptotic protein-Mcl-1 while increased the level of proapoptotic protein-Bax and cleaved caspase 3 in PMNs. Simvastatin 0-11 MCL1 apoptosis regulator, BCL2 family member Rattus norvegicus 80-85 30662566-8 2019 Furthermore, simvastatin was able to re-polarize tumor-associated macrophages (TAM), promoting M2-to-M1 phenotype switch via cholesterol-associated LXR/ABCA1 regulation. Simvastatin 13-24 ATP binding cassette subfamily A member 1 Homo sapiens 152-157 30579354-8 2018 Moreover, simvastatin suppressed the expression of COX-2 and PGE2 in both OE-19 and Eca-109 cells in a dose-dependent manner. Simvastatin 10-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 30579354-10 2018 The reduction of COX-2 and PGE2 by simvastatin suggested that the inhibitory effect of simvastatin on the proliferation of EC cells may be independent of its lipid-lowering effect. Simvastatin 35-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 30579354-10 2018 The reduction of COX-2 and PGE2 by simvastatin suggested that the inhibitory effect of simvastatin on the proliferation of EC cells may be independent of its lipid-lowering effect. Simvastatin 87-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 30563555-4 2018 Simvastatin, a HMG-CoA reductase enzyme inhibitor has been shown to have pleiotropic anti-inflammatory effects as well as being endothelial protective. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-32 30631264-10 2018 Simvastatin significantly downregulated the expression of antiapoptotic protein-Mcl-1 while increased the level of proapoptotic protein-Bax and cleaved caspase 3 in PMNs. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Rattus norvegicus 136-139 30336686-0 2018 Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Simvastatin 119-130 solute carrier organic anion transporter family member 1B1 Homo sapiens 20-27 30088351-0 2018 Simvastatin increases cell viability and suppresses the expression of cytokines and vascular endothelial growth factor in inflamed human dental pulp stem cells in vitro. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 84-118 30088351-4 2018 The expression of cytokines and vascular endothelial growth factor (VEGF) was also studied in response to simvastatin treatment. Simvastatin 106-117 vascular endothelial growth factor A Homo sapiens 32-66 30088351-4 2018 The expression of cytokines and vascular endothelial growth factor (VEGF) was also studied in response to simvastatin treatment. Simvastatin 106-117 vascular endothelial growth factor A Homo sapiens 68-72 30088351-11 2018 Moreover, the protein secretion and mRNA transcription of VEGF was observed to be markedly inhibited by simvastatin by inactivating mitogen-activated protein kinase (MAPK) signaling. Simvastatin 104-115 vascular endothelial growth factor A Homo sapiens 58-62 30584296-0 2018 The role of the ERK1/2 pathway in simvastatin-loaded nanomicelles and simvastatin in regulating the osteogenic effect in MG63 cells. Simvastatin 34-45 mitogen-activated protein kinase 3 Homo sapiens 16-22 30584296-1 2018 Objectives: The present study aimed to clarify the role of the ERK1/2 pathway in simvastatin (SV)-loaded nanomicelles (SVNs)- and SV-mediated promotion of cell osteogenic differentiation and explore the molecular mechanisms by which SVNs exhibited a greater efficacy in promoting osteogenic differentiation than SV. Simvastatin 81-92 mitogen-activated protein kinase 3 Homo sapiens 63-69 30584296-1 2018 Objectives: The present study aimed to clarify the role of the ERK1/2 pathway in simvastatin (SV)-loaded nanomicelles (SVNs)- and SV-mediated promotion of cell osteogenic differentiation and explore the molecular mechanisms by which SVNs exhibited a greater efficacy in promoting osteogenic differentiation than SV. Simvastatin 94-96 mitogen-activated protein kinase 3 Homo sapiens 63-69 30584296-12 2018 From 24 hours to 7 days, SVNs and SV exerted an inhibitory effect on the ERK1/2 pathway rather than an activating effect. Simvastatin 25-27 mitogen-activated protein kinase 3 Homo sapiens 73-79 30336686-1 2018 Our goal was to examine the associations of the 388A>G and 521T>C polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene with hepatic function, baseline lipid levels, and the lipid-lowering efficiency of simvastatin. Simvastatin 230-241 solute carrier organic anion transporter family member 1B1 Homo sapiens 87-131 30336686-1 2018 Our goal was to examine the associations of the 388A>G and 521T>C polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene with hepatic function, baseline lipid levels, and the lipid-lowering efficiency of simvastatin. Simvastatin 230-241 solute carrier organic anion transporter family member 1B1 Homo sapiens 133-140 30336686-9 2018 Our conclusion suggests that the interaction between the SLCO1B1 388A>G and 521T>C polymorphisms could be an important genetic determinant of hepatic function and the therapeutic efficiency of simvastatin in Chinese patients with hyperlipidemia. Simvastatin 193-204 solute carrier organic anion transporter family member 1B1 Homo sapiens 57-64 30216659-3 2018 The lipophilic fluvastatin, simvastatin, atorvastatin, and lovastatin as well as the nitrogenous BPs alendronate and ibandronate, but not hydrophilic pravastatin increased IL-33 mRNA and intracellular IL-33 protein levels in both human adult cardiac myocytes (HACM) and fibroblasts (HACF). Simvastatin 28-39 interleukin 33 Homo sapiens 172-177 30503138-8 2018 Simvastatin also regulated leiomyoma cell apoptosis through a concentration-dependent increase in activity of caspase-3. Simvastatin 0-11 caspase 3 Homo sapiens 110-119 30503138-9 2018 Simvastatin significantly inhibited expression of major ECM proteins collagen I, collagen III, fibronectin, versican, and brevican in leiomyoma cells at concentrations as low as 10-9 mol/L within 48 hours of exposure. Simvastatin 0-11 fibronectin 1 Homo sapiens 95-106 30463769-8 2018 In addition, simvastatin effectively reduced the intestinal levels of tumor necrosis factor alpha, interleukin-6, high-mobility group box 1, and malondialdehyde and increased the activity of superoxide dismutase in rats with sepsis. Simvastatin 13-24 interleukin 6 Rattus norvegicus 99-112 30463769-8 2018 In addition, simvastatin effectively reduced the intestinal levels of tumor necrosis factor alpha, interleukin-6, high-mobility group box 1, and malondialdehyde and increased the activity of superoxide dismutase in rats with sepsis. Simvastatin 13-24 high mobility group box 1 Rattus norvegicus 114-139 30463769-10 2018 Furthermore, the expression of Rho and ROCK1 was significantly downregulated and the protein expression levels of ZO-1 and occludin were significantly increased in simvastatin-treated rats (P < 0.05). Simvastatin 164-175 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 39-44 30463769-10 2018 Furthermore, the expression of Rho and ROCK1 was significantly downregulated and the protein expression levels of ZO-1 and occludin were significantly increased in simvastatin-treated rats (P < 0.05). Simvastatin 164-175 tight junction protein 1 Rattus norvegicus 114-118 30463769-10 2018 Furthermore, the expression of Rho and ROCK1 was significantly downregulated and the protein expression levels of ZO-1 and occludin were significantly increased in simvastatin-treated rats (P < 0.05). Simvastatin 164-175 occludin Rattus norvegicus 123-131 31070532-0 2018 Effect of simvastatin on the SIRT2/NF-kappaB pathway in rats with acute pulmonary embolism. Simvastatin 10-21 sirtuin 2 Rattus norvegicus 29-34 30250148-9 2018 The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin. Simvastatin 147-158 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-49 31070532-0 2018 Effect of simvastatin on the SIRT2/NF-kappaB pathway in rats with acute pulmonary embolism. Simvastatin 10-21 nuclear factor kappa B subunit 1 Homo sapiens 35-44 31070532-2 2018 OBJECTIVE: The current article studies the effect of simvastatin on the SIRT2/NF-kappaB pathway in rats with APE. Simvastatin 53-64 sirtuin 2 Rattus norvegicus 72-77 31070532-2 2018 OBJECTIVE: The current article studies the effect of simvastatin on the SIRT2/NF-kappaB pathway in rats with APE. Simvastatin 53-64 nuclear factor kappa B subunit 1 Homo sapiens 78-87 31070532-9 2018 CONCLUSIONS: Simvastatin protects against APE-induced pulmonary artery pressure, hypoxemia and inflammatory changes probably due to the regulation of SIRT2/NF-kappaB signalling pathway, which suggest that simvastatin may have promising protective effects in patients with APE. Simvastatin 13-24 sirtuin 2 Homo sapiens 150-155 31070532-9 2018 CONCLUSIONS: Simvastatin protects against APE-induced pulmonary artery pressure, hypoxemia and inflammatory changes probably due to the regulation of SIRT2/NF-kappaB signalling pathway, which suggest that simvastatin may have promising protective effects in patients with APE. Simvastatin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 156-165 31070532-9 2018 CONCLUSIONS: Simvastatin protects against APE-induced pulmonary artery pressure, hypoxemia and inflammatory changes probably due to the regulation of SIRT2/NF-kappaB signalling pathway, which suggest that simvastatin may have promising protective effects in patients with APE. Simvastatin 205-216 sirtuin 2 Homo sapiens 150-155 31070532-9 2018 CONCLUSIONS: Simvastatin protects against APE-induced pulmonary artery pressure, hypoxemia and inflammatory changes probably due to the regulation of SIRT2/NF-kappaB signalling pathway, which suggest that simvastatin may have promising protective effects in patients with APE. Simvastatin 205-216 nuclear factor kappa B subunit 1 Homo sapiens 156-165 30388834-0 2018 Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Simvastatin 21-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 30429503-7 2018 Interestingly, combination of simvastatin with AZD3965 (MCT1 inhibitor) led to further tumour growth delay as compared to monotherapies, without signs of toxicity. Simvastatin 30-41 solute carrier family 16 member 1 Homo sapiens 56-60 30388834-8 2018 The immunoliposomal formulation of simvastatin is characterized by long-term stability, high selectivity towards HER2-overexpressing breast cancer cells, low non-specific cytotoxicity and effective inhibition of the growth of target cells, presumably by inhibition of signalling pathways and induction of apoptosis. Simvastatin 35-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-117 30388834-9 2018 Hence, for the first time, we propose the use of immunoliposomes with simvastatin, targeted directly towards breast cancer cells overexpressing HER2. Simvastatin 70-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 144-148 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 SMAD family member 2 Homo sapiens 234-241 32459510-0 2018 Simvastatin prevents articular chondrocyte dedifferentiation induced by nitric oxide by inhibiting the expression of matrix metalloproteinases 1 and 13. Simvastatin 0-11 matrix metallopeptidase 1 Homo sapiens 117-151 32459510-4 2018 In this work we show that simvastatin (SVT) inhibits dedifferentiation by nitric oxide by blocking the expression of matrix metalloproteinases 1 and 13. Simvastatin 26-37 matrix metallopeptidase 1 Homo sapiens 117-151 30220377-0 2018 Simvastatin reduces TGF-beta1-induced SMAD2/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 20-29 30220377-0 2018 Simvastatin reduces TGF-beta1-induced SMAD2/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation. Simvastatin 0-11 SMAD family member 2 Homo sapiens 38-45 30220377-9 2018 Effect of simvastatin on TGF-beta1-induced fibroblast activation was annulled by okadaic acid, an inhibitor of protein-phosphatase. Simvastatin 10-21 transforming growth factor beta 1 Homo sapiens 25-34 30220377-4 2018 We aimed to assess whether simvastatin-mediated reduction in TGF-beta1-augmented profibrotic response involves reduction in phospho-SMAD2/3 owing to activation of protein-phosphatase in hVFs. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 61-70 30220377-10 2018 CONCLUSIONS: This proof-of-concept study using an in vitro experimental cell culture model identifies the protective role of simvastatin against TGF-beta1-induced hVF transformation into activated myofibroblasts through activation of protein phosphatase, a novel target that can be therapeutically modulated to curb excessive cardiac fibrosis associated with maladaptive cardiac remodeling. Simvastatin 125-136 transforming growth factor beta 1 Homo sapiens 145-154 30220377-4 2018 We aimed to assess whether simvastatin-mediated reduction in TGF-beta1-augmented profibrotic response involves reduction in phospho-SMAD2/3 owing to activation of protein-phosphatase in hVFs. Simvastatin 27-38 SMAD family member 3 Homo sapiens 132-139 30220377-7 2018 Simvastatin (1 muM) reduced effect of TGF-beta1 (5 ng/mL) on hVF proliferation, myofibroblast differentiation (reduced alpha-smooth muscle actin [alpha-SMA-expression]) and activation (decreased procollagen-peptide release). Simvastatin 0-11 latexin Homo sapiens 15-18 30279549-0 2018 Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-kappaB/p65 Expression. Simvastatin 0-11 synaptotagmin 1 Rattus norvegicus 108-111 30220377-7 2018 Simvastatin (1 muM) reduced effect of TGF-beta1 (5 ng/mL) on hVF proliferation, myofibroblast differentiation (reduced alpha-smooth muscle actin [alpha-SMA-expression]) and activation (decreased procollagen-peptide release). Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 38-47 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 25-34 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 SMAD family member 2 Homo sapiens 74-81 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 protein phosphatase, Mg2+/Mn2+ dependent 1A Homo sapiens 187-192 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 197-201 29764192-3 2018 Here, we investigated the effects of simvastatin treatment on expression levels of interleukin (IL) 1beta in both patient with hyperlipidemia and healthy human peripheral blood mononuclear cells (PBMCs) using cholesterol crystals (CC), a cardiovascular pathogenic stimulus for activation of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome. Simvastatin 37-48 interleukin 1 beta Homo sapiens 83-105 29764192-7 2018 The effects of simvastatin treatment on levels of IL-1beta expression were determined by enzyme-linked immunosorbent assay and western blot. Simvastatin 15-26 interleukin 1 beta Homo sapiens 50-58 29764192-8 2018 Both in vitro and in vivo treatments with simvastatin led to a significant reduction in the levels of expression of IL-1beta in response to stimulation with CC. Simvastatin 42-53 interleukin 1 beta Homo sapiens 116-124 29764192-9 2018 Simvastatin inhibits the expression and activation of IL-1beta induced by CC in PBMCs, which may contribute to its protective role in patients with cardiovascular disease. Simvastatin 0-11 interleukin 1 beta Homo sapiens 54-62 30443172-7 2018 Simvastatin alleviated excessive autophagy, characterized by a high LC3II/LC3I ratio and low level of p62, and blunted cardiac hypertrophy while increasing 14-3-3 protein expression in rats that had undergone AAB. Simvastatin 0-11 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 102-105 30304062-8 2018 RESULTS: The c.2155T> C variant of the KIF6 gene was shown to influence physiological responses to treatment with simvastatin and atorvastatin. Simvastatin 117-128 kinesin family member 6 Homo sapiens 42-46 30304062-11 2018 CONCLUSION: Being a carrier of the c.2155T> C variant of the KIF6 gene negatively impacts patient responses to simvastatin, atorvastatin or rosuvastatin in terms of lipid lowering effect. Simvastatin 114-125 kinesin family member 6 Homo sapiens 64-68 30279549-4 2018 Simvastatin in 20 mg/kg and 40 mg/kg pretreatment, dose dependently, attenuated myocardial apoptosis determined as apoptotic index (28.8 +- 4.5% and 18.9 +- 3.5, p < 0.05), decreased cleaved caspase-3 expression (32.1 +- 5.8%, p < 0.01), along with significant Bcl-xL expression in the simvastatin groups (p < 0.01). Simvastatin 0-11 caspase 3 Rattus norvegicus 191-200 30279549-4 2018 Simvastatin in 20 mg/kg and 40 mg/kg pretreatment, dose dependently, attenuated myocardial apoptosis determined as apoptotic index (28.8 +- 4.5% and 18.9 +- 3.5, p < 0.05), decreased cleaved caspase-3 expression (32.1 +- 5.8%, p < 0.01), along with significant Bcl-xL expression in the simvastatin groups (p < 0.01). Simvastatin 0-11 Bcl2-like 1 Rattus norvegicus 261-267 30279549-5 2018 Interestingly, in the simvastatin groups were determined significantly increased expression of survivin (p < 0.01), but in negative correlation with cleaved caspase-3 and apoptotic indices (p < 0.01). Simvastatin 22-33 caspase 3 Rattus norvegicus 157-166 29848667-3 2018 qPCR, immunoblotting and immunohistochemistry were used to assess simvastatin effects on proteins involved in stemness and epithelial-mesenchymal cell plasticity (EMT). Simvastatin 66-77 IL2 inducible T cell kinase Homo sapiens 163-166 29911323-10 2018 CONCLUSION: Both simvastatin and rosuvastatin downregulated OS-induced p38MAPK activation, senescence, and SASP, while rosuvastatin showed a pronounced effect. Simvastatin 17-28 mitogen-activated protein kinase 14 Homo sapiens 71-78 29911323-10 2018 CONCLUSION: Both simvastatin and rosuvastatin downregulated OS-induced p38MAPK activation, senescence, and SASP, while rosuvastatin showed a pronounced effect. Simvastatin 17-28 thioredoxin Homo sapiens 107-111 29911323-12 2018 Simvastatin or rosuvastatin may reduce the incidences of OS-associated PTB and pPROM by preventing premature senescence and SASP. Simvastatin 0-11 thioredoxin Homo sapiens 124-128 29911323-3 2018 We determined the effect of simvastatin, rosuvastatin, and progesterone in downregulating p38MAPK-mediated senescence and SASP. Simvastatin 28-39 mitogen-activated protein kinase 14 Homo sapiens 90-97 29911323-3 2018 We determined the effect of simvastatin, rosuvastatin, and progesterone in downregulating p38MAPK-mediated senescence and SASP. Simvastatin 28-39 thioredoxin Homo sapiens 122-126 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 mitogen-activated protein kinase 14 Homo sapiens 72-79 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 thioredoxin Homo sapiens 133-137 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 colony stimulating factor 2 Homo sapiens 147-153 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 tumor necrosis factor Homo sapiens 159-162 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 interleukin 10 Homo sapiens 213-218 30039622-0 2018 Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer. Simvastatin 0-11 heat shock protein, 3 Mus musculus 27-48 30039622-6 2018 Furthermore, we showed that simvastatin prevented, whereas LBH589 promoted, the progression of Hsp90 chaperone cycling and client maturation, resulting in an increment of cell apoptosis by the combination of simvastatin and LBH589 in a mouse xenograft model. Simvastatin 28-39 heat shock protein, 3 Mus musculus 95-100 30039622-7 2018 These data suggest that simvastatin is a novel Hsp90 inhibitor to disrupt the formation of the K292-acetylated Hsp90/Cdc37 complex in triple-negative breast cancer cells. Simvastatin 24-35 heat shock protein, 3 Mus musculus 47-52 30039622-7 2018 These data suggest that simvastatin is a novel Hsp90 inhibitor to disrupt the formation of the K292-acetylated Hsp90/Cdc37 complex in triple-negative breast cancer cells. Simvastatin 24-35 heat shock protein, 3 Mus musculus 111-116 30039622-7 2018 These data suggest that simvastatin is a novel Hsp90 inhibitor to disrupt the formation of the K292-acetylated Hsp90/Cdc37 complex in triple-negative breast cancer cells. Simvastatin 24-35 cell division cycle 37 Mus musculus 117-122 29848667-6 2018 Herein, we demonstrated that simvastatin modifies the stemness and EMT marker expression patterns (both in mRNA and protein levels) and severely impairs the spheroid assembly of CICs. Simvastatin 29-40 IL2 inducible T cell kinase Homo sapiens 67-70 30156968-6 2018 After 7, 14 and 21 days of culture, the simvastatin loaded multilayered films increased cell proliferation, improved osteoblastic differentiation of alkaline phosphatase (ALP) and mineralization. Simvastatin 40-51 alkaline phosphatase, placental Homo sapiens 149-169 30233664-0 2018 Effect of simvastatin on expression of VEGF and TGF-beta1 in atherosclerotic animal model of type 2 diabetes mellitus. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 39-43 30233664-0 2018 Effect of simvastatin on expression of VEGF and TGF-beta1 in atherosclerotic animal model of type 2 diabetes mellitus. Simvastatin 10-21 transforming growth factor, beta 1 Rattus norvegicus 48-57 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 vascular endothelial growth factor A Rattus norvegicus 14-48 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 vascular endothelial growth factor A Rattus norvegicus 50-54 30233664-1 2018 Expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in atherosclerosis animal model of type 2 diabetes mellitus treated with simvastatin was investigated. Simvastatin 178-189 transforming growth factor, beta 1 Rattus norvegicus 94-103 30233664-14 2018 Simvastatin may play a therapeutic role in T2MD AS by downregulating VEGF and upregulating the expression of TGF-beta1. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 69-73 30233664-14 2018 Simvastatin may play a therapeutic role in T2MD AS by downregulating VEGF and upregulating the expression of TGF-beta1. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 109-118 29985281-12 2018 Protein expression of Bcl-2 was increased in the simvastatin treatment group before surgery, and Bak expression was increased in the control treatment group after surgery. Simvastatin 49-60 BCL2 apoptosis regulator Homo sapiens 22-27 29985281-18 2018 Coincident with the change in miR-15a-5p, the mRNA expression of Bcl-2 was increased in the simvastatin treatment group. Simvastatin 92-103 BCL2 apoptosis regulator Homo sapiens 65-70 29985281-20 2018 Our findings strongly suggest that simvastatin treatment preoperatively protected the myocardium in patients undergoing noncoronary artery cardiac surgery, at least in part, by inhibiting apoptosis via suppressing miR-15a-5p expression, leading to increasing expression of Bcl-2 and decreasing expression of Bak. Simvastatin 35-46 BCL2 apoptosis regulator Homo sapiens 273-278 30524673-0 2018 Bone marrow-derived mesenchymal stem cell and simvastatin treatment leads to improved functional recovery and modified c-Fos expression levels in the brain following ischemic stroke. Simvastatin 46-57 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 119-124 30156968-6 2018 After 7, 14 and 21 days of culture, the simvastatin loaded multilayered films increased cell proliferation, improved osteoblastic differentiation of alkaline phosphatase (ALP) and mineralization. Simvastatin 40-51 alkaline phosphatase, placental Homo sapiens 171-174 30100024-0 2018 Simvastatin reduces the TLR4-induced inflammatory response in human aortic valve interstitial cells. Simvastatin 0-11 toll like receptor 4 Homo sapiens 24-28 30100024-7 2018 Our purposes were (1) to determine the effect of simvastatin on TLR4-induced expression of inflammatory mediators in human AVICs and (2) to determine the mechanism(s) through which simvastatin exert this effect. Simvastatin 49-60 toll like receptor 4 Homo sapiens 64-68 30100024-7 2018 Our purposes were (1) to determine the effect of simvastatin on TLR4-induced expression of inflammatory mediators in human AVICs and (2) to determine the mechanism(s) through which simvastatin exert this effect. Simvastatin 181-192 toll like receptor 4 Homo sapiens 64-68 30100024-14 2018 RESULTS: Simvastatin reduced TLR4-induced ICAM-1, IL-8, and MCP-1 expression in AVICs. Simvastatin 9-20 toll like receptor 4 Homo sapiens 29-33 30100024-14 2018 RESULTS: Simvastatin reduced TLR4-induced ICAM-1, IL-8, and MCP-1 expression in AVICs. Simvastatin 9-20 intercellular adhesion molecule 1 Homo sapiens 42-48 30100024-14 2018 RESULTS: Simvastatin reduced TLR4-induced ICAM-1, IL-8, and MCP-1 expression in AVICs. Simvastatin 9-20 C-X-C motif chemokine ligand 8 Homo sapiens 50-54 30100024-14 2018 RESULTS: Simvastatin reduced TLR4-induced ICAM-1, IL-8, and MCP-1 expression in AVICs. Simvastatin 9-20 C-C motif chemokine ligand 2 Homo sapiens 60-65 30100024-15 2018 Simvastatin down-regulated TLR4 levels and suppressed TLR4-induced phosphorylation of nuclear factor-kappa B. Simvastatin 0-11 toll like receptor 4 Homo sapiens 27-31 30100024-15 2018 Simvastatin down-regulated TLR4 levels and suppressed TLR4-induced phosphorylation of nuclear factor-kappa B. Simvastatin 0-11 toll like receptor 4 Homo sapiens 54-58 29784898-0 2018 Pretreatment with simvastatin upregulates expression of BK-2R and CD11b in the ischemic penumbra of rats. Simvastatin 18-29 integrin subunit alpha M Rattus norvegicus 66-71 30106444-6 2018 The combination of simvastatin and EGFR inhibitors inhibited YAP and EGFR signaling more markedly than each agent alone. Simvastatin 19-30 Yes1 associated transcriptional regulator Homo sapiens 61-64 30106444-6 2018 The combination of simvastatin and EGFR inhibitors inhibited YAP and EGFR signaling more markedly than each agent alone. Simvastatin 19-30 epidermal growth factor receptor Homo sapiens 69-73 30106444-7 2018 Adding back geranylgeranyl pyrophosphate (GGPP), a key product of the mevalonate pathway, reversed the YAP bioactivity inhibition induced by simvastatin and the cell proliferation inhibition induced by the combination of simvastatin and EGFR inhibitors. Simvastatin 141-152 Yes1 associated transcriptional regulator Homo sapiens 103-106 30106444-7 2018 Adding back geranylgeranyl pyrophosphate (GGPP), a key product of the mevalonate pathway, reversed the YAP bioactivity inhibition induced by simvastatin and the cell proliferation inhibition induced by the combination of simvastatin and EGFR inhibitors. Simvastatin 221-232 epidermal growth factor receptor Homo sapiens 237-241 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 nuclear receptor subfamily 1 group I member 2 Homo sapiens 30-33 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 NFE2 like bZIP transcription factor 2 Homo sapiens 38-42 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 aryl hydrocarbon receptor Homo sapiens 88-91 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 109-115 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 117-123 30092417-11 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 30092417-15 2018 Moreover, it was defined that simvastatin induced AhR and its related genes. Simvastatin 30-41 aryl hydrocarbon receptor Homo sapiens 50-53 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Simvastatin 0-11 Yes1 associated transcriptional regulator Homo sapiens 123-126 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Simvastatin 0-11 Yes1 associated transcriptional regulator Homo sapiens 179-182 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Simvastatin 0-11 epidermal growth factor receptor Homo sapiens 225-229 29784898-6 2018 However, the levels of BK-2R and CD11b mRNA in the ischemic penumbra, which were significantly decreased 3 hours after ischemia-reperfusion, were increased in simvastatin-pretreated rats. Simvastatin 159-170 integrin subunit alpha M Rattus norvegicus 33-38 29784898-8 2018 These results suggest that the beneficial effects of simvastatin pretreatment before cerebral ischemia/reperfusion injury in rats may be partially due to increased expression of BK-2R and CD11b in the ischemic penumbra. Simvastatin 53-64 integrin subunit alpha M Rattus norvegicus 188-193 30249030-8 2018 Simvastatin, theophylline, caffeine, and sildenafil, like KMUP-1, also enhanced HSL immunoreactivity. Simvastatin 0-11 lipase, hormone sensitive Mus musculus 80-83 30276217-0 2018 Simvastatin-Induced Insulin Resistance May Be Linked to Decreased Lipid Uptake and Lipid Synthesis in Human Skeletal Muscle: the LIFESTAT Study. Simvastatin 0-11 insulin Homo sapiens 20-27 30096386-10 2018 Further studies showed that the long-term administration of simvastatin could up-regulate the expression of CYP3A1/2 to account for the effect. Simvastatin 60-71 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 108-114 30298072-10 2018 Simvastatin induced a greater activation and proliferation of CD4+ T cells, as well as an increase in IL-6 and MCP-1 production, in chemotaxis to the peritoneum and in H2O2 secretion at this site. Simvastatin 0-11 interleukin 6 Mus musculus 102-106 30298072-10 2018 Simvastatin induced a greater activation and proliferation of CD4+ T cells, as well as an increase in IL-6 and MCP-1 production, in chemotaxis to the peritoneum and in H2O2 secretion at this site. Simvastatin 0-11 mast cell protease 1 Mus musculus 111-116 30089652-7 2018 Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. Simvastatin 26-37 androgen receptor Homo sapiens 227-244 30089652-7 2018 Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. Simvastatin 26-37 androgen receptor Homo sapiens 246-248 30089652-7 2018 Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. Simvastatin 183-194 androgen receptor Homo sapiens 227-244 30089652-7 2018 Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. Simvastatin 183-194 androgen receptor Homo sapiens 246-248 30089652-8 2018 We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. Simvastatin 54-65 androgen receptor Homo sapiens 33-35 30089652-8 2018 We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. Simvastatin 54-65 mechanistic target of rapamycin kinase Homo sapiens 93-97 30089652-8 2018 We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. Simvastatin 54-65 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 154-159 30089652-8 2018 We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. Simvastatin 54-65 androgen receptor Homo sapiens 164-166 30191610-8 2018 Whereas lovastatin and simvastatin significantly decreased the expression of CD44, atorvastatin drastically increased CD24 and caused more wide-ranging impacts. Simvastatin 23-34 CD44 molecule (Indian blood group) Homo sapiens 77-81 29916838-0 2018 Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 101-108 30185207-9 2018 At last, we combined trametinib with simvastatin, a common clinically used drug with a new reported function of transcriptional activity inhibition of ERRalpha, and found that this combination produced a synergistic effect in inhibiting the proliferation and survival of colon cancer cells in vitro as well as in vivo. Simvastatin 37-48 estrogen related receptor alpha Homo sapiens 151-159 29916838-7 2018 We found that simvastatin inhibited multiple myeloma serum-induced expression of procoagulant protein tissue factor and phosphatidylserine and generation of thrombin on HUVECs. Simvastatin 14-25 coagulation factor II, thrombin Homo sapiens 157-165 29916838-8 2018 In contrast, simvastatin increased multiple myeloma serum-inhibited expression of anticoagulant protein endothelial protein C receptor and activation of protein C on HUVECs. Simvastatin 13-24 protein C receptor Homo sapiens 104-134 29916838-9 2018 Moreover, simvastatin reversed the multiple myeloma serum-induced prothrombotic phenotype, at least in part, via the inhibition of ERK 1/2 activation in endothelial cells. Simvastatin 10-21 mitogen-activated protein kinase 3 Homo sapiens 131-138 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin 9-20 vascular endothelial growth factor A Rattus norvegicus 91-95 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin 9-20 transforming growth factor, beta 1 Rattus norvegicus 102-110 30056191-6 2018 Simvastatin increased some factors attenuated by glucose fluctuations: mRNA VEGF expression and mRNA VEGFR-1 expression in the myocardium and in the aorta. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 76-80 30056191-6 2018 Simvastatin increased some factors attenuated by glucose fluctuations: mRNA VEGF expression and mRNA VEGFR-1 expression in the myocardium and in the aorta. Simvastatin 0-11 Fms related receptor tyrosine kinase 1 Rattus norvegicus 101-108 30056191-5 2018 RESULTS: Simvastatin decreased several factors enhanced by glucose excursions: circulating VEGF, mRNA TGF-beta expression in the myocardium and mRNA VEGFR-2 expression in the aorta. Simvastatin 9-20 kinase insert domain receptor Rattus norvegicus 149-156 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 Eph receptor B1 Rattus norvegicus 97-134 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 Eph receptor B1 Rattus norvegicus 136-139 30150424-7 2018 Overexpression of CREB or knockdown of p66shc restored simvastatin-dependent induction of HO1 and MnSOD in the presence of nicotine. Simvastatin 55-66 superoxide dismutase 2 Rattus norvegicus 98-103 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 cAMP responsive element binding protein 1 Rattus norvegicus 172-176 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 heme oxygenase 1 Rattus norvegicus 209-225 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 heme oxygenase 1 Rattus norvegicus 227-230 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 Eph receptor B1 Rattus norvegicus 271-274 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 cAMP responsive element binding protein 1 Rattus norvegicus 275-279 30150424-1 2018 BACKGROUND/AIM: We have previously reported that simvastatin exhibits antioxidant properties via extracellular signal-regulated kinase (ERK)/cAMP-response element binding (CREB) protein-dependent induction of heme oxygenase-1 (HO1) and chronic nicotine exposure inhibits ERK/CREB signaling in renal proximal tubule cells (through p66shc). Simvastatin 49-60 SHC adaptor protein 1 Rattus norvegicus 330-336 30150424-2 2018 Herein, whether nicotine dampens simvastatin-dependent HO1 induction was determined. Simvastatin 33-44 heme oxygenase 1 Rattus norvegicus 55-58 30150424-6 2018 RESULTS: Nicotine suppressed simvastatin-dependent activation of HO1 and MnSOD promoters and activity of CREB and ELK1 via p66shc. Simvastatin 29-40 heme oxygenase 1 Rattus norvegicus 65-68 30150424-6 2018 RESULTS: Nicotine suppressed simvastatin-dependent activation of HO1 and MnSOD promoters and activity of CREB and ELK1 via p66shc. Simvastatin 29-40 superoxide dismutase 2 Rattus norvegicus 73-78 30150424-6 2018 RESULTS: Nicotine suppressed simvastatin-dependent activation of HO1 and MnSOD promoters and activity of CREB and ELK1 via p66shc. Simvastatin 29-40 cAMP responsive element binding protein 1 Rattus norvegicus 105-109 30150424-6 2018 RESULTS: Nicotine suppressed simvastatin-dependent activation of HO1 and MnSOD promoters and activity of CREB and ELK1 via p66shc. Simvastatin 29-40 ETS transcription factor ELK1 Rattus norvegicus 114-118 30150424-6 2018 RESULTS: Nicotine suppressed simvastatin-dependent activation of HO1 and MnSOD promoters and activity of CREB and ELK1 via p66shc. Simvastatin 29-40 SHC adaptor protein 1 Rattus norvegicus 123-129 30150424-7 2018 Overexpression of CREB or knockdown of p66shc restored simvastatin-dependent induction of HO1 and MnSOD in the presence of nicotine. Simvastatin 55-66 cAMP responsive element binding protein 1 Rattus norvegicus 18-22 30150424-7 2018 Overexpression of CREB or knockdown of p66shc restored simvastatin-dependent induction of HO1 and MnSOD in the presence of nicotine. Simvastatin 55-66 SHC adaptor protein 1 Rattus norvegicus 39-45 30150424-7 2018 Overexpression of CREB or knockdown of p66shc restored simvastatin-dependent induction of HO1 and MnSOD in the presence of nicotine. Simvastatin 55-66 heme oxygenase 1 Rattus norvegicus 90-93 29859160-1 2018 PURPOSE: Simvastatin has been reported to promote osteoblastic activity, inhibit osteoclastic activity, and support osteoblast differentiation induced by bone morphogenetic protein. Simvastatin 9-20 bone morphogenetic protein 1 Homo sapiens 154-180 30015955-0 2018 Low-frequency ultrasound and microbubbles combined with simvastatin promote the apoptosis of MCF-7 cells by affecting the LATS1/YAP/RHAMM pathway. Simvastatin 56-67 large tumor suppressor kinase 1 Homo sapiens 122-127 30015955-0 2018 Low-frequency ultrasound and microbubbles combined with simvastatin promote the apoptosis of MCF-7 cells by affecting the LATS1/YAP/RHAMM pathway. Simvastatin 56-67 Yes1 associated transcriptional regulator Homo sapiens 128-131 30015955-0 2018 Low-frequency ultrasound and microbubbles combined with simvastatin promote the apoptosis of MCF-7 cells by affecting the LATS1/YAP/RHAMM pathway. Simvastatin 56-67 hyaluronan mediated motility receptor Homo sapiens 132-137 30015955-2 2018 Simvastatin is a statins that is able to competitively inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-126 30066928-0 2018 Simvastatin improves cerebrovascular injury caused by ischemia-reperfusion through NF-kappaB-mediated apoptosis via MyD88/TRIF signaling. Simvastatin 0-11 MYD88, innate immune signal transduction adaptor Rattus norvegicus 116-121 30015955-8 2018 Furthermore, it was confirmed that LFU and microbubbles combined with simvastatin affected the large tumor suppressor 1 (LATS1)/yes-associated protein (YAP)/receptor of the hyaluronan-mediated motility (RHAMM) pathway in MCF-7 cells. Simvastatin 70-81 large tumor suppressor kinase 1 Homo sapiens 95-119 30015955-8 2018 Furthermore, it was confirmed that LFU and microbubbles combined with simvastatin affected the large tumor suppressor 1 (LATS1)/yes-associated protein (YAP)/receptor of the hyaluronan-mediated motility (RHAMM) pathway in MCF-7 cells. Simvastatin 70-81 large tumor suppressor kinase 1 Homo sapiens 121-126 30066928-0 2018 Simvastatin improves cerebrovascular injury caused by ischemia-reperfusion through NF-kappaB-mediated apoptosis via MyD88/TRIF signaling. Simvastatin 0-11 ring finger protein 138 Rattus norvegicus 122-126 30015955-8 2018 Furthermore, it was confirmed that LFU and microbubbles combined with simvastatin affected the large tumor suppressor 1 (LATS1)/yes-associated protein (YAP)/receptor of the hyaluronan-mediated motility (RHAMM) pathway in MCF-7 cells. Simvastatin 70-81 Yes1 associated transcriptional regulator Homo sapiens 152-155 30066928-8 2018 The results also revealed that simvastatin treatment inhibited neuronal apoptosis via the NF-kappaB-mediated MyD88/TRIF signaling pathway. Simvastatin 31-42 MYD88, innate immune signal transduction adaptor Rattus norvegicus 109-114 30015955-8 2018 Furthermore, it was confirmed that LFU and microbubbles combined with simvastatin affected the large tumor suppressor 1 (LATS1)/yes-associated protein (YAP)/receptor of the hyaluronan-mediated motility (RHAMM) pathway in MCF-7 cells. Simvastatin 70-81 hyaluronan mediated motility receptor Homo sapiens 203-208 30066928-8 2018 The results also revealed that simvastatin treatment inhibited neuronal apoptosis via the NF-kappaB-mediated MyD88/TRIF signaling pathway. Simvastatin 31-42 ring finger protein 138 Rattus norvegicus 115-119 30066928-9 2018 In conclusion, simvastatin treatment may reduce I/R-induced neuronal apoptosis via inhibition of the NF-kappaB-mediated MyD88/TRIF signaling pathway. Simvastatin 15-26 MYD88, innate immune signal transduction adaptor Rattus norvegicus 120-125 30066928-9 2018 In conclusion, simvastatin treatment may reduce I/R-induced neuronal apoptosis via inhibition of the NF-kappaB-mediated MyD88/TRIF signaling pathway. Simvastatin 15-26 ring finger protein 138 Rattus norvegicus 126-130 30015955-10 2018 In conclusion, the results of the present study indicate that LFU and microbubbles combined with simvastatin promotes the apoptosis of MCF-7 cells via the LATS1/YAP/RHAMM pathway. Simvastatin 97-108 large tumor suppressor kinase 1 Homo sapiens 155-160 30015955-10 2018 In conclusion, the results of the present study indicate that LFU and microbubbles combined with simvastatin promotes the apoptosis of MCF-7 cells via the LATS1/YAP/RHAMM pathway. Simvastatin 97-108 Yes1 associated transcriptional regulator Homo sapiens 161-164 30015955-10 2018 In conclusion, the results of the present study indicate that LFU and microbubbles combined with simvastatin promotes the apoptosis of MCF-7 cells via the LATS1/YAP/RHAMM pathway. Simvastatin 97-108 hyaluronan mediated motility receptor Homo sapiens 165-170 29498892-6 2018 This reporter is induced selectively by an atheroprotective shear stress waveform in human endothelial cells, is regulated by endogenous signaling events, and is activated by the pharmacological inducer of KLF2, simvastatin, in a dose-dependent manner. Simvastatin 212-223 Kruppel like factor 2 Homo sapiens 206-210 29795329-0 2018 Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Simvastatin 74-85 carbonic anhydrase 2 Homo sapiens 15-18 29795329-2 2018 Doxorubicin- and simvastatin-induced cytotoxicity has been associated with the modulation of Ca2+ signaling, but the underlying mechanisms remain incompletely understood. Simvastatin 17-28 carbonic anhydrase 2 Homo sapiens 93-96 29795329-3 2018 Here we identify how Ca2+ signaling regulates the breast tumor cell response to doxorubicin and simvastatin. Simvastatin 96-107 carbonic anhydrase 2 Homo sapiens 21-24 29795329-5 2018 Signal transduction and functional studies revealed that both simvastatin and doxorubicin trigger persistent cytosolic Ca2+ release, thereby stimulating the proapoptotic BIM pathway and mitochondrial Ca2+ overload, which are responsible for metabolic dysfunction and apoptosis induction. Simvastatin 62-73 carbonic anhydrase 2 Homo sapiens 119-122 29795329-5 2018 Signal transduction and functional studies revealed that both simvastatin and doxorubicin trigger persistent cytosolic Ca2+ release, thereby stimulating the proapoptotic BIM pathway and mitochondrial Ca2+ overload, which are responsible for metabolic dysfunction and apoptosis induction. Simvastatin 62-73 carbonic anhydrase 2 Homo sapiens 200-203 29795329-6 2018 Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 53-59 29795329-6 2018 Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. Simvastatin 0-11 carbonic anhydrase 2 Homo sapiens 73-76 29795329-6 2018 Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. Simvastatin 0-11 carbonic anhydrase 2 Homo sapiens 94-97 30024814-0 2018 Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Simvastatin 100-111 ATP binding cassette subfamily C member 2 Homo sapiens 15-20 30024814-5 2018 The aim of this study was to evaluate the association of rs717620 of ABCC2 with treatment response to simvastatin in a Chinese Han population. Simvastatin 102-113 ATP binding cassette subfamily C member 2 Homo sapiens 69-74 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 nuclear receptor subfamily 1 group I member 2 Homo sapiens 30-33 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 NFE2 like bZIP transcription factor 2 Homo sapiens 38-42 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 aryl hydrocarbon receptor Homo sapiens 88-91 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 109-115 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 117-123 32002969-10 2018 Under simvastatin stimulation PXR and NRF2 target transcripts were not altered, however AHR-regulated genes: CYP1A1, CYP1B1 and MDR1 were significantly induced. Simvastatin 6-17 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 32002969-14 2018 Moreover, it was defined that simvastatin induced AhR and its related genes. Simvastatin 30-41 aryl hydrocarbon receptor Homo sapiens 50-53 30067011-1 2018 The inexpensive hypolipidemic drug simvastatin (SIM), which promotes bone regeneration by enhancing bone morphogenetic protein 2 (BMP-2) expression, has been regarded as an ideal alternative to BMP-2 therapy. Simvastatin 35-46 bone morphogenetic protein 2 Mus musculus 100-128 30024814-13 2018 CONCLUSION: ABCC2 rs717620 and female gender may be related to the low-effect of simvastatin treatment on the HDL-C level in the Chinese Han population. Simvastatin 81-92 ATP binding cassette subfamily C member 2 Homo sapiens 12-17 30067011-1 2018 The inexpensive hypolipidemic drug simvastatin (SIM), which promotes bone regeneration by enhancing bone morphogenetic protein 2 (BMP-2) expression, has been regarded as an ideal alternative to BMP-2 therapy. Simvastatin 35-46 bone morphogenetic protein 2 Mus musculus 130-135 30067011-1 2018 The inexpensive hypolipidemic drug simvastatin (SIM), which promotes bone regeneration by enhancing bone morphogenetic protein 2 (BMP-2) expression, has been regarded as an ideal alternative to BMP-2 therapy. Simvastatin 48-51 bone morphogenetic protein 2 Mus musculus 100-128 30067011-1 2018 The inexpensive hypolipidemic drug simvastatin (SIM), which promotes bone regeneration by enhancing bone morphogenetic protein 2 (BMP-2) expression, has been regarded as an ideal alternative to BMP-2 therapy. Simvastatin 48-51 bone morphogenetic protein 2 Mus musculus 130-135 30067011-2 2018 However, SIM has low bioavailability and may induce the upregulation of the BMP-2-antagonistic noggin protein, which greatly limits the osteogenic effect. Simvastatin 9-12 bone morphogenetic protein 2 Mus musculus 76-81 30067011-2 2018 However, SIM has low bioavailability and may induce the upregulation of the BMP-2-antagonistic noggin protein, which greatly limits the osteogenic effect. Simvastatin 9-12 noggin Mus musculus 95-101 30067011-5 2018 The SIM-loaded micelle effectively delivered SIM into preosteoblast MC3T3-E1 cells and rapidly released it inside the acidic lysosome, resulting in the elevated expression of BMP-2. Simvastatin 4-7 bone morphogenetic protein 2 Mus musculus 175-180 30067011-7 2018 Consequently, SIM and N-siRNA synergistically increased the BMP-2/noggin ratio and resulted in an obviously higher osteogenetic effect than did simvastatin or N-siRNA alone, both in vitro and in vivo. Simvastatin 14-17 bone morphogenetic protein 2 Mus musculus 60-65 30067011-7 2018 Consequently, SIM and N-siRNA synergistically increased the BMP-2/noggin ratio and resulted in an obviously higher osteogenetic effect than did simvastatin or N-siRNA alone, both in vitro and in vivo. Simvastatin 14-17 noggin Mus musculus 66-72 30038146-7 2018 Results: Results showed that simvastatin alleviates UVB-induced cell death, cell apoptosis, and caspase-3 activity. Simvastatin 29-40 caspase 3 Homo sapiens 96-105 30138430-4 2018 Since our previous studies proved that simvastatin (SIM) exerts strong antiproliferative actions on B16.F10 murine melanoma cells via reduction of TAMs-mediated oxidative stress and inhibition of intratumor production of HIF-1alpha, we investigated whether the antitumor efficacy of the anti-angiogenic agent-5,6-dimethylxanthenone-4-acetic acid (DMXAA) could be improved by its co-administration with the lipophilic statin. Simvastatin 39-50 hypoxia inducible factor 1, alpha subunit Mus musculus 221-231 30127457-0 2018 ZNF542P is a pseudogene associated with LDL response to simvastatin treatment. Simvastatin 56-67 zinc finger protein 542, pseudogene Homo sapiens 0-7 30127457-7 2018 ZNF542P knock-down in a human hepatoma cell line increased intracellular cholesterol ester levels upon simvastatin treatment. Simvastatin 103-114 zinc finger protein 542, pseudogene Homo sapiens 0-7 30127457-8 2018 Together, these findings imply a role for ZNF542P in LDLC response to simvastatin and, importantly, highlight the potential significance of noncoding RNAs as a contributing factor to variation in drug response. Simvastatin 70-81 zinc finger protein 542, pseudogene Homo sapiens 42-49 30186882-0 2018 Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-alpha, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis. Simvastatin 20-31 interleukin 6 Homo sapiens 100-113 30186882-1 2018 Purpose: The objective of this study is to explore the relationship between the levels of interleukin- (IL-) 6, tumor necrosis factor- (TNF-) alpha, and visfatin and simvastatin usage, in the gingival crevicular fluids (GCFs) of diabetic patients afflicted with chronic periodontitis. Simvastatin 166-177 nicotinamide phosphoribosyltransferase Homo sapiens 153-161 29846274-0 2018 Effects of Simvastatin on the Viability and Secretion of Vascular Endothelial Growth Factor of Cell Spheroids Cultured in Growth Media. Simvastatin 11-22 vascular endothelial growth factor A Homo sapiens 57-91 29846274-7 2018 The addition of simvastatin significantly increased the secretion of VEGF. Simvastatin 16-27 vascular endothelial growth factor A Homo sapiens 69-73 29846274-10 2018 CONCLUSIONS: Based on these findings, the application of simvastatin clearly decreased the cellular viability of the cell spheroids made with stem cells and osteoblast-like cells but increased the secretion of VEGF by the cell spheroids. Simvastatin 57-68 vascular endothelial growth factor A Homo sapiens 210-214 30038146-8 2018 Conclusion: Our findings indicated that simvastatin alleviated UVB-induced corneal endothelial cell apoptosis via caspase-3 activity. Simvastatin 40-51 caspase 3 Homo sapiens 114-123 29853535-0 2018 Therapeutic effects of simvastatin on Galectin-3 and oxidative stress parameters in endotoxemic lung tissue. Simvastatin 23-34 galectin 3 Rattus norvegicus 38-48 31949780-0 2018 Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Simvastatin 0-11 toll-like receptor 4 Mus musculus 66-69 31949780-0 2018 Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Simvastatin 0-11 microRNA 22 Mus musculus 115-126 31949780-0 2018 Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Simvastatin 0-11 cellular communication network factor 1 Mus musculus 127-132 31949780-1 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to improve atherosclerosis (AS) via its anti-inflammatory activity. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 15-72 31949780-4 2018 This study was designed to investigate the roles and underlying mechanisms of simvastatin in LPS-stimulated RAW264.7 macrophages. Simvastatin 78-89 toll-like receptor 4 Mus musculus 93-96 31949780-5 2018 First, we examined the anti-inflammatory effects of simvastatin on LPS-treated macrophage RAW264.7 cells using an enzyme-linked immunosorbent assay (ELISA) and a quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Simvastatin 52-63 toll-like receptor 4 Mus musculus 67-70 31949780-6 2018 Then, a microarray assay was used to analyze the microRNA (miRNA) expression profile in RAW264.7 cells incubated with or without simvastatin in the presence of LPS. Simvastatin 129-140 toll-like receptor 4 Mus musculus 160-163 31949780-9 2018 Subsequently, we investigated the molecular mechanism by which miR-22 functions in the anti-inflammation of simvastatin in LPS-stimulated macrophages. Simvastatin 108-119 microRNA 22 Mus musculus 63-69 31949780-9 2018 Subsequently, we investigated the molecular mechanism by which miR-22 functions in the anti-inflammation of simvastatin in LPS-stimulated macrophages. Simvastatin 108-119 toll-like receptor 4 Mus musculus 123-126 31949780-10 2018 We found that simvastatin treatment could significantly inhibit inflammation by modulating the expression of mediators, such as IL-1beta, TNF-alpha and IL-6, whose expression were increased remarkably in the activated RAW264.7 cells. Simvastatin 14-25 interleukin 1 beta Mus musculus 128-136 31949780-10 2018 We found that simvastatin treatment could significantly inhibit inflammation by modulating the expression of mediators, such as IL-1beta, TNF-alpha and IL-6, whose expression were increased remarkably in the activated RAW264.7 cells. Simvastatin 14-25 tumor necrosis factor Mus musculus 138-147 31949780-10 2018 We found that simvastatin treatment could significantly inhibit inflammation by modulating the expression of mediators, such as IL-1beta, TNF-alpha and IL-6, whose expression were increased remarkably in the activated RAW264.7 cells. Simvastatin 14-25 interleukin 6 Mus musculus 152-156 31949780-11 2018 miR-22 was found to be one of the most significantly upregulated miRNAs in LPS-stimulated RAW264.7 macrophages after treatment with simvastatin. Simvastatin 132-143 microRNA 22 Mus musculus 0-6 31949780-11 2018 miR-22 was found to be one of the most significantly upregulated miRNAs in LPS-stimulated RAW264.7 macrophages after treatment with simvastatin. Simvastatin 132-143 toll-like receptor 4 Mus musculus 75-78 31949780-12 2018 Pre-treatment of simvastatin in LPS-stimulated RAW264.7 macrophages enhanced miR-22 expression in a dose dependent manner. Simvastatin 17-28 toll-like receptor 4 Mus musculus 32-35 31949780-12 2018 Pre-treatment of simvastatin in LPS-stimulated RAW264.7 macrophages enhanced miR-22 expression in a dose dependent manner. Simvastatin 17-28 microRNA 22 Mus musculus 77-83 31949780-14 2018 Overexpression of miR-22 enhanced the anti-inflammatory effects of simvastatin, whereas inhibition of miR-22 had an opposite effect. Simvastatin 67-78 microRNA 22 Mus musculus 18-24 31949780-15 2018 More importantly, further study demonstrated that the knockdown of Cyr61 by siRNA could attenuate the inhibitory effects of miR-22 inhibition on anti-inflammatory activities of simvastatin. Simvastatin 177-188 cellular communication network factor 1 Mus musculus 67-72 31949780-15 2018 More importantly, further study demonstrated that the knockdown of Cyr61 by siRNA could attenuate the inhibitory effects of miR-22 inhibition on anti-inflammatory activities of simvastatin. Simvastatin 177-188 microRNA 22 Mus musculus 124-130 31949780-16 2018 The results clearly show that simvastatin inhibits the inflammation response in LPS-stimulated RAW264.7 macrophages through the miR-22/Cyr61 axis and suggests that targeting the miR-22/Cyr61 axis may be a promising molecular target for AS therapy. Simvastatin 30-41 toll-like receptor 4 Mus musculus 80-83 31949780-16 2018 The results clearly show that simvastatin inhibits the inflammation response in LPS-stimulated RAW264.7 macrophages through the miR-22/Cyr61 axis and suggests that targeting the miR-22/Cyr61 axis may be a promising molecular target for AS therapy. Simvastatin 30-41 microRNA 22 Mus musculus 128-134 31949780-16 2018 The results clearly show that simvastatin inhibits the inflammation response in LPS-stimulated RAW264.7 macrophages through the miR-22/Cyr61 axis and suggests that targeting the miR-22/Cyr61 axis may be a promising molecular target for AS therapy. Simvastatin 30-41 cellular communication network factor 1 Mus musculus 135-140 31949780-16 2018 The results clearly show that simvastatin inhibits the inflammation response in LPS-stimulated RAW264.7 macrophages through the miR-22/Cyr61 axis and suggests that targeting the miR-22/Cyr61 axis may be a promising molecular target for AS therapy. Simvastatin 30-41 microRNA 22 Mus musculus 178-184 31949780-16 2018 The results clearly show that simvastatin inhibits the inflammation response in LPS-stimulated RAW264.7 macrophages through the miR-22/Cyr61 axis and suggests that targeting the miR-22/Cyr61 axis may be a promising molecular target for AS therapy. Simvastatin 30-41 cellular communication network factor 1 Mus musculus 185-190 29627496-6 2018 Overexpression of Shh prevented the anti-cancer effect of simvastatin, and inhibition of Shh mimicked the simvastatin effect. Simvastatin 58-69 sonic hedgehog signaling molecule Homo sapiens 18-21 29627496-6 2018 Overexpression of Shh prevented the anti-cancer effect of simvastatin, and inhibition of Shh mimicked the simvastatin effect. Simvastatin 106-117 sonic hedgehog signaling molecule Homo sapiens 89-92 29853535-8 2018 There were reduced densities, and the decreased number of Galectin-3 immunoreactivities in the simvastatin+LPS group compared with the LPS group in the pneumocytes, and in the bronchial epithelium of lung tissue. Simvastatin 95-106 galectin 3 Rattus norvegicus 58-68 29853535-11 2018 Simvastatin attenuates LPS-induced oxidative acute lung inflammation, oxidative stress, and suppresses LPS-induced Galectin-3 expression in the lung tissue. Simvastatin 0-11 galectin 3 Rattus norvegicus 115-125 29733433-13 2018 Moderate-intensity simvastatin lowered HbA1c compared with high-intensity rosuvastatin (SMD: -0.45) and high-intensity atorvastatin (SMD: -0.77). Simvastatin 19-30 hemoglobin subunit alpha 1 Homo sapiens 39-43 29775609-0 2018 Kruppel-like factor 4 (KLF-4) plays a crucial role in simvastatin (SVT)-induced differentiation of rabbit articular chondrocytes. Simvastatin 54-65 Krueppel-like factor 4 Oryctolagus cuniculus 0-21 29775609-0 2018 Kruppel-like factor 4 (KLF-4) plays a crucial role in simvastatin (SVT)-induced differentiation of rabbit articular chondrocytes. Simvastatin 54-65 Krueppel-like factor 4 Oryctolagus cuniculus 23-28 29865262-6 2018 Simvastatin or fluvastatin caused IL-8 (interleukin-8) suppression, but increased hBD-2 mRNA expression in Salmonella-infected SW480 cells. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 40-53 29643243-8 2018 Furthermore, simvastatin (SIMV) decreased the subpopulation of DC-SIGN+ MPhi as well as cis and trans infection. Simvastatin 13-24 CD209 molecule Homo sapiens 63-70 29643243-8 2018 Furthermore, simvastatin (SIMV) decreased the subpopulation of DC-SIGN+ MPhi as well as cis and trans infection. Simvastatin 26-30 CD209 molecule Homo sapiens 63-70 29862818-7 2018 Finally, we demonstrated that pinostrobin attenuated simvastatin-induced PCSK9 overexpression in HepG2 cells. Simvastatin 53-64 proprotein convertase subtilisin/kexin type 9 Homo sapiens 73-78 29865262-6 2018 Simvastatin or fluvastatin caused IL-8 (interleukin-8) suppression, but increased hBD-2 mRNA expression in Salmonella-infected SW480 cells. Simvastatin 0-11 defensin beta 4A Homo sapiens 82-87 29865262-8 2018 Akt or VDR knockdown by siRNA counteracted the suppressive effect of simvastatin on IL-8 expression, whereas VDR knockdown diminished the enhanced hBD-2 expression in Salmonella-infected SW480 cells. Simvastatin 69-80 AKT serine/threonine kinase 1 Homo sapiens 0-3 29188473-8 2018 Interestingly, both doses of simvastatin showed a neuroprotective effect and inhibited MPO activity without altering kidney and hepatic parameters. Simvastatin 29-40 myeloperoxidase Rattus norvegicus 87-90 30035738-0 2018 THE STATE OF THE CYSTATHIONINE GAMMA-LYASE / H2S SYSTEM IN THE LIVER AND SKELETAL MUSCLES OF RATS WITH HYPERCHOLESTEROLEMIA UNDER SIMVASTATIN ADMINISTRATION. Simvastatin 130-141 cystathionine gamma-lyase Rattus norvegicus 17-42 30035738-1 2018 In studies on 94 male Wistar rats changes in the hydrogen sulfide content (H2S) and cystathionine gamma-lyase (CSE) in the liver and skeletal muscles in hypercholesterolemia under simvastatin treatment were assessed, as well as the effect of propargylglycine (PAG) on hepato- and myotoxicity of simvastatin. Simvastatin 180-191 cystathionine gamma-lyase Rattus norvegicus 111-114 30035738-2 2018 It was determined, that simvastatin inhibited the CSE-mediated synthesis of H2S in the main target organs. Simvastatin 24-35 cystathionine gamma-lyase Rattus norvegicus 50-53 28716519-8 2018 In the lifetime horizon model, The ICER was $45,046 per QALY for combination treatment compared with simvastatin alone. Simvastatin 101-112 cAMP responsive element modulator Homo sapiens 35-39 28833099-0 2018 Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Simvastatin 0-11 cyclin dependent kinase 4 Homo sapiens 76-80 29568880-2 2018 simvastatin has been demonstrated to exhibit antitumor effects, and so the aim of the present study was to assess the effects of simvastatin on the growth of human PTEN haploinsufficient lipoma cells. Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 164-168 29568880-2 2018 simvastatin has been demonstrated to exhibit antitumor effects, and so the aim of the present study was to assess the effects of simvastatin on the growth of human PTEN haploinsufficient lipoma cells. Simvastatin 129-140 phosphatase and tensin homolog Homo sapiens 164-168 29568880-5 2018 Furthermore, it was demonstrated that the expression of cellular PTEN mRNA and protein was increased following simvastatin stimulation. Simvastatin 111-122 phosphatase and tensin homolog Homo sapiens 65-69 29568880-7 2018 It was also demonstrated that simvastatin induced PTEN transcriptional upregulation by increasing peroxisome proliferator-activated receptor (PPAR)gamma expression. Simvastatin 30-41 phosphatase and tensin homolog Homo sapiens 50-54 29568880-7 2018 It was also demonstrated that simvastatin induced PTEN transcriptional upregulation by increasing peroxisome proliferator-activated receptor (PPAR)gamma expression. Simvastatin 30-41 peroxisome proliferator activated receptor gamma Homo sapiens 142-152 29568880-8 2018 The small interfering RNA-mediated knockdown of PPARgamma abrogated the stimulatory effect of simvastatin on the PTEN protein, but did not influence apoptosis. Simvastatin 94-105 peroxisome proliferator activated receptor gamma Homo sapiens 48-57 29568880-8 2018 The small interfering RNA-mediated knockdown of PPARgamma abrogated the stimulatory effect of simvastatin on the PTEN protein, but did not influence apoptosis. Simvastatin 94-105 phosphatase and tensin homolog Homo sapiens 113-117 29568880-9 2018 The results of the present study suggest that simvastatin may be beneficial for patients with inoperable PTEN haploinsufficient lipomas. Simvastatin 46-57 phosphatase and tensin homolog Homo sapiens 105-109 28833099-0 2018 Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Simvastatin 0-11 glycogen synthase kinase 3 beta Homo sapiens 47-55 28833099-0 2018 Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Simvastatin 0-11 cyclin D1 Homo sapiens 81-90 28833099-0 2018 Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Simvastatin 0-11 cyclin dependent kinase 2 Homo sapiens 95-99 28833099-0 2018 Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Simvastatin 0-11 cyclin E1 Homo sapiens 100-109 28833099-7 2018 SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs. Simvastatin 0-3 cyclin dependent kinase 4 Homo sapiens 94-98 29469964-1 2018 This study investigated the impact of allelic variation in SLCO1B1, a gene encoding for the liver-specific solute carrier organic anion transporter family member 1B1 protein (SLCO1B1), on simvastatin and simvastatin acid (SVA) systemic exposure in children and adolescents. Simvastatin 188-199 solute carrier organic anion transporter family member 1B1 Homo sapiens 59-66 28833099-7 2018 SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs. Simvastatin 0-3 cyclin D1 Homo sapiens 99-108 28833099-7 2018 SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs. Simvastatin 0-3 cyclin dependent kinase 2 Homo sapiens 113-117 28833099-7 2018 SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs. Simvastatin 0-3 cyclin E1 Homo sapiens 118-127 28833099-7 2018 SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs. Simvastatin 0-3 glycogen synthase kinase 3 beta Homo sapiens 161-191 29551766-5 2018 Subsequently, we show that lung cancer cells primed with a TTF-1-driven decrease of cholesterol were more vulnerable to simvastatin, a frequently prescribed cholesterol biosynthesis inhibitor. Simvastatin 120-131 transcription termination factor 1 Homo sapiens 59-64 29569973-7 2018 We found that the combination of simvastatin and BRE caused the synergic induction of LDLR expression and LDL-C uptake, whereas simvastatin alone increased the expression of PCSK9 in the HepG2 cells. Simvastatin 33-44 low density lipoprotein receptor Homo sapiens 86-90 29569973-7 2018 We found that the combination of simvastatin and BRE caused the synergic induction of LDLR expression and LDL-C uptake, whereas simvastatin alone increased the expression of PCSK9 in the HepG2 cells. Simvastatin 128-139 proprotein convertase subtilisin/kexin type 9 Homo sapiens 174-179 29569973-8 2018 These results clearly demonstrated that the BRE from black raspberry suppressed simvastatin-induced PCSK9 expression and improved LDL-C uptake by hepatocytes through the induction of LDLR expression. Simvastatin 80-91 proprotein convertase subtilisin/kexin type 9 Homo sapiens 100-105 29569973-8 2018 These results clearly demonstrated that the BRE from black raspberry suppressed simvastatin-induced PCSK9 expression and improved LDL-C uptake by hepatocytes through the induction of LDLR expression. Simvastatin 80-91 low density lipoprotein receptor Homo sapiens 183-187 30788922-14 2018 After simvastatin administration, the expression levels of p53,p53-phospho-serine 15 (P<0.01) and Bax were decreased significantly (P<0.05) and the expression of Bcl-2 was increased (P<0.05). Simvastatin 6-17 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 63-66 29872377-0 2018 Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 49-52 29872377-6 2018 Mechanistic studies revealed that 6-OHDA-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase/p38 mitogen-activated protein kinase (MAPK) pathway was inhibited and nuclear factor-kappaB (NF-kappaB) nuclear transcription decreased in SH-SY5Y cells after simvastatin treatment. Simvastatin 282-293 mitogen-activated protein kinase 14 Homo sapiens 123-159 29872377-6 2018 Mechanistic studies revealed that 6-OHDA-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase/p38 mitogen-activated protein kinase (MAPK) pathway was inhibited and nuclear factor-kappaB (NF-kappaB) nuclear transcription decreased in SH-SY5Y cells after simvastatin treatment. Simvastatin 282-293 nuclear factor kappa B subunit 1 Homo sapiens 193-214 29872377-10 2018 An inhibitory effect on activation of the NADPH oxidase/p38 MAPK was observed, and increased antioxidant protein expression in the midbrain were seen in the simvastatin plus 6-OHDA group compared with the 6-OHDA-lesioned group. Simvastatin 157-168 mitogen-activated protein kinase 14 Homo sapiens 56-59 29872377-11 2018 Taken together, these results demonstrate that simvastatin might inhibit the activation of NADPH oxidase/p38 MAPK pathway, enhance antioxidant protein expression and protect against oxidative stress, thereby providing a novel antioxidant mechanism that has therapeutic validity. Simvastatin 47-58 mitogen-activated protein kinase 14 Homo sapiens 105-108 30788922-14 2018 After simvastatin administration, the expression levels of p53,p53-phospho-serine 15 (P<0.01) and Bax were decreased significantly (P<0.05) and the expression of Bcl-2 was increased (P<0.05). Simvastatin 6-17 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 59-62 30788922-14 2018 After simvastatin administration, the expression levels of p53,p53-phospho-serine 15 (P<0.01) and Bax were decreased significantly (P<0.05) and the expression of Bcl-2 was increased (P<0.05). Simvastatin 6-17 BCL2 associated X, apoptosis regulator Rattus norvegicus 101-104 30788922-14 2018 After simvastatin administration, the expression levels of p53,p53-phospho-serine 15 (P<0.01) and Bax were decreased significantly (P<0.05) and the expression of Bcl-2 was increased (P<0.05). Simvastatin 6-17 BCL2, apoptosis regulator Rattus norvegicus 168-173 29532562-0 2018 Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1alpha-induced pro-angiogenic factor. Simvastatin 22-33 hypoxia inducible factor 1, alpha subunit Mus musculus 83-93 29735887-10 2018 In ApoE-/- mice fed with an atherogenic diet, both UA (100 mg/kg/day) and simvastatin significantly attenuated atherosclerotic plaque formation and shrunk necrotic core areas. Simvastatin 74-85 apolipoprotein E Mus musculus 3-7 29314558-4 2018 Inhibiting neutrophil production of CSF1 or preventing macrophage proliferation, using targeted nanoparticles loaded with the cell cycle inhibitor simvastatin, abrogates the induction of tolerance. Simvastatin 147-158 colony stimulating factor 1 Homo sapiens 36-40 29532562-6 2018 Additionally, simvastatin induced angiogenic inhibition through a mechanism of post-transcriptional downregulation of HIF-1alpha by increasing the phosphorylation level of AMP kinase. Simvastatin 14-25 hypoxia inducible factor 1, alpha subunit Mus musculus 118-128 29532562-8 2018 Critically, inhibition of AMPK phosphorylation by compound C almost completely abrogated simvastatin-induced anti-angiogenesis, which was accompanied by the reduction of protein levels of HIF-1alpha and its downstream pro-angiogenic factors. Simvastatin 89-100 hypoxia inducible factor 1, alpha subunit Mus musculus 188-198 29401610-11 2018 In conclusion, this study identified vimentin as a direct molecular target that mediates simvastatin-induced cell death in 2 different cancer cell lines.-Trogden, K. P., Battaglia, R. A., Kabiraj, P., Madden, V. J., Herrmann, H., Snider, N. T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. Simvastatin 89-100 vimentin Homo sapiens 37-45 29401610-11 2018 In conclusion, this study identified vimentin as a direct molecular target that mediates simvastatin-induced cell death in 2 different cancer cell lines.-Trogden, K. P., Battaglia, R. A., Kabiraj, P., Madden, V. J., Herrmann, H., Snider, N. T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. Simvastatin 89-100 vimentin Homo sapiens 292-300 29401610-0 2018 An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. Simvastatin 99-110 vimentin Homo sapiens 48-56 29401610-11 2018 In conclusion, this study identified vimentin as a direct molecular target that mediates simvastatin-induced cell death in 2 different cancer cell lines.-Trogden, K. P., Battaglia, R. A., Kabiraj, P., Madden, V. J., Herrmann, H., Snider, N. T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. Simvastatin 343-354 vimentin Homo sapiens 37-45 29401610-5 2018 Simvastatin induced vimentin reorganization within 15-30 min and significant perinuclear bundling within 60 min (IC50 = 6.7 nM). Simvastatin 0-11 vimentin Homo sapiens 20-28 29771446-0 2018 Simvastatin induces osteogenic differentiation of MSCs via Wnt/beta-catenin pathway to promote fracture healing. Simvastatin 0-11 catenin beta 1 Rattus norvegicus 63-75 29401610-9 2018 In SW13-vim+ cells, simvastatin, but not pravastatin, reduced total cell numbers (IC50 = 48.1 nM) and promoted apoptosis after 24 h. In contrast, SW13-vim- cell viability was unaffected by simvastatin, unless vimentin was ectopically expressed. Simvastatin 20-31 vimentin Homo sapiens 209-217 29401610-10 2018 Simvastatin similarly targeted vimentin filaments and induced cell death in MDA-MB-231 (vim+), but lacked effect in MCF7 (vim-) breast cancer cells. Simvastatin 0-11 vimentin Homo sapiens 31-39 29771446-1 2018 OBJECTIVE: This study was designed to investigate whether Simvastatin could facilitate osteogenic differentiation of rat marrow mesenchymal stem cells (MSCs) by modulating the Wnt/beta-catenin pathway, thus promoting fracture healing. Simvastatin 58-69 catenin beta 1 Rattus norvegicus 180-192 29771446-7 2018 After treated with 0.3 nmol/L simvastatin for 7 days, the ALP activity of cells and the number of cell calcified nodules significantly increased. Simvastatin 30-41 PDZ and LIM domain 3 Rattus norvegicus 58-61 29771446-10 2018 Simvastatin markedly up-regulated the expression of the beta-catenin protein, while transfection of beta-catenin shRNA inhibited the expression of osteoblast-related genes including ALP, Runx2, OCN, and OPN. Simvastatin 0-11 catenin beta 1 Rattus norvegicus 56-68 29771446-11 2018 CONCLUSIONS: Simvastatin can promote the differentiation of rat MSCs into osteoblast-like cells, and its mechanism may be related to the Wnt/beta-catenin pathway. Simvastatin 13-24 catenin beta 1 Rattus norvegicus 141-153 29604489-7 2018 Accordingly, the TNF-induced elevation of neutrophil p50 activity was abolished by simvastatin. Simvastatin 83-94 tumor necrosis factor Homo sapiens 17-20 29604489-7 2018 Accordingly, the TNF-induced elevation of neutrophil p50 activity was abolished by simvastatin. Simvastatin 83-94 nuclear factor kappa B subunit 1 Homo sapiens 53-56 29604489-0 2018 Attenuation of TNF-induced neutrophil adhesion by simvastatin is associated with the inhibition of Rho-GTPase activity, p50 activity and morphological changes. Simvastatin 50-61 tumor necrosis factor Homo sapiens 15-18 29604489-9 2018 Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NFkappaB translocation and, consequently, beta2-integrin activity. Simvastatin 0-11 tumor necrosis factor Homo sapiens 69-72 29604489-0 2018 Attenuation of TNF-induced neutrophil adhesion by simvastatin is associated with the inhibition of Rho-GTPase activity, p50 activity and morphological changes. Simvastatin 50-61 nuclear factor kappa B subunit 1 Homo sapiens 120-123 29604489-9 2018 Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NFkappaB translocation and, consequently, beta2-integrin activity. Simvastatin 0-11 ras homolog family member A Homo sapiens 148-153 29604489-2 2018 Previous studies have shown that simvastatin, a statin with known pleiotropic anti-inflammatory properties, can partially abrogate the effects of TNF-induced neutrophil adhesion, in association with the modulation of beta2-integrin expression. Simvastatin 33-44 tumor necrosis factor Homo sapiens 146-149 29604489-9 2018 Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NFkappaB translocation and, consequently, beta2-integrin activity. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 164-172 29604489-2 2018 Previous studies have shown that simvastatin, a statin with known pleiotropic anti-inflammatory properties, can partially abrogate the effects of TNF-induced neutrophil adhesion, in association with the modulation of beta2-integrin expression. Simvastatin 33-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 217-222 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 46-57 tumor necrosis factor Homo sapiens 69-72 29436584-0 2018 Mitochondrial protective mechanism of simvastatin protects against amyloid beta peptide-induced injury in SH-SY5Y cells. Simvastatin 38-49 amyloid beta precursor protein Homo sapiens 67-79 29604489-9 2018 Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NFkappaB translocation and, consequently, beta2-integrin activity. Simvastatin 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 206-211 29436584-2 2018 Previous studies suggest that simvastatin (SV) ameliorates amyloid beta (Abeta)-mediated cognitive impairment in AD patients and transgenic mice; however, the mechanisms remain unknown. Simvastatin 30-41 amyloid beta precursor protein Homo sapiens 59-71 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 46-57 fibronectin 1 Homo sapiens 110-121 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 46-57 tumor necrosis factor Mus musculus 318-321 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 254-265 tumor necrosis factor Homo sapiens 69-72 29436584-2 2018 Previous studies suggest that simvastatin (SV) ameliorates amyloid beta (Abeta)-mediated cognitive impairment in AD patients and transgenic mice; however, the mechanisms remain unknown. Simvastatin 30-41 amyloid beta precursor protein Homo sapiens 73-78 29436584-2 2018 Previous studies suggest that simvastatin (SV) ameliorates amyloid beta (Abeta)-mediated cognitive impairment in AD patients and transgenic mice; however, the mechanisms remain unknown. Simvastatin 43-45 amyloid beta precursor protein Homo sapiens 59-71 29436584-2 2018 Previous studies suggest that simvastatin (SV) ameliorates amyloid beta (Abeta)-mediated cognitive impairment in AD patients and transgenic mice; however, the mechanisms remain unknown. Simvastatin 43-45 amyloid beta precursor protein Homo sapiens 73-78 29389739-0 2018 Simvastatin Modulates Interaction Between Vascular Smooth Muscle Cell/Macrophage and TNF-alpha-Activated Endothelial Cell. Simvastatin 0-11 tumor necrosis factor Homo sapiens 85-94 29436584-4 2018 The results demonstrated that SV protected against Abeta1-42-induced SH-SY5Y cell injury by inhibiting the release of cytochrome c from the mitochondria to the cytoplasm, and reducing the production of intracellular reactive oxygen species. Simvastatin 30-32 cytochrome c, somatic Homo sapiens 118-130 29389739-3 2018 The purpose of this study was to investigate the effects of simvastatin on VSMC/macrophage functions, which are induced by TNF-alpha-activated EC in coculture system in vitro. Simvastatin 60-71 tumor necrosis factor Homo sapiens 123-132 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 tumor necrosis factor Homo sapiens 115-124 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 interleukin 6 Homo sapiens 126-130 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 vascular endothelial growth factor A Homo sapiens 136-170 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 tumor necrosis factor Homo sapiens 230-239 29850244-4 2018 Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression. Simvastatin 27-38 oxidized low density lipoprotein receptor 1 Homo sapiens 71-76 29664056-12 2018 Simvastatin treatment (0.1, 0.5, and 2.5 mumol/L) blunted ox-LDL-induced expression of PERK (407.8%, 339.1%, and 187.5%, F = 10.121, all P < 0.05, compared with control group) and phosphorylation of eIF2alpha (407.8%, 339.1%, 187.5%, F = 11.430, all P < 0.05, compared with control group). Simvastatin 0-11 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 87-91 29664056-12 2018 Simvastatin treatment (0.1, 0.5, and 2.5 mumol/L) blunted ox-LDL-induced expression of PERK (407.8%, 339.1%, and 187.5%, F = 10.121, all P < 0.05, compared with control group) and phosphorylation of eIF2alpha (407.8%, 339.1%, 187.5%, F = 11.430, all P < 0.05, compared with control group). Simvastatin 0-11 eukaryotic translation initiation factor 2A Homo sapiens 202-211 29664056-14 2018 Exposure of HUVECs to ox-LDL also markedly induced caspase-3 activity together with increased CHOP mRNA level; these effects were inhibited by simvastatin treatment. Simvastatin 143-154 caspase 3 Homo sapiens 51-60 29664056-14 2018 Exposure of HUVECs to ox-LDL also markedly induced caspase-3 activity together with increased CHOP mRNA level; these effects were inhibited by simvastatin treatment. Simvastatin 143-154 DNA damage inducible transcript 3 Homo sapiens 94-98 29850244-5 2018 Objectives: To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin. Simvastatin 159-170 oxidized low density lipoprotein receptor 1 Homo sapiens 56-62 29850244-14 2018 Conclusion: High-dose simvastatin might be helpful to reduce serum sLOX-1. Simvastatin 22-33 oxidized low density lipoprotein receptor 1 Homo sapiens 67-73 29706890-0 2018 Simvastatin Enhances Activity and Trafficking of alpha7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. Simvastatin 0-11 proline rich transmembrane protein 2 Homo sapiens 120-123 29706890-0 2018 Simvastatin Enhances Activity and Trafficking of alpha7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. Simvastatin 0-11 calcium/calmodulin dependent protein kinase II gamma Homo sapiens 128-134 29706890-1 2018 Simvastatin (SV) enhances glutamate release and synaptic plasticity in hippocampal CA1 region upon activation of alpha7 nicotinic acetylcholine receptor (alpha7nAChR). Simvastatin 0-11 carbonic anhydrase 1 Homo sapiens 83-86 29706890-1 2018 Simvastatin (SV) enhances glutamate release and synaptic plasticity in hippocampal CA1 region upon activation of alpha7 nicotinic acetylcholine receptor (alpha7nAChR). Simvastatin 13-15 carbonic anhydrase 1 Homo sapiens 83-86 29695967-6 2018 By contrast, changes in HDL cholesterol, and triglycerides were only affected by the APOA5 genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Simvastatin 124-135 apolipoprotein A5 Homo sapiens 85-90 28635512-11 2018 Western blot analysis showed that CXCL16 expression was significantly increased (p < .05) in OxLDL-treated cells compared with the untreated cells, and was significantly inhibited by application of simvastatin (p < .05). Simvastatin 201-212 chemokine (C-X-C motif) ligand 16 Mus musculus 34-40 29255993-5 2018 Given their lipophilicity and CYP3A4 metabolic pathway, atorvastatin and simvastatin presented a higher prevalence of drug-drug interactions while fluvastatin presented the lowest prevalence. Simvastatin 73-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 29255993-6 2018 Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i.e., OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin. Simvastatin 187-198 solute carrier organic anion transporter family member 1B1 Homo sapiens 157-164 29255993-7 2018 The second most frequent contraindicated drug-drug interaction involved CYP3A4 interaction between atorvastatin or simvastatin with either posaconazole or erythromycin. Simvastatin 115-126 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 72-78 29532878-0 2018 Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 93-98 29532878-8 2018 Simvastatin significantly induced apoptosis, increased the Bax/Bcl-2 ratio, and cleavage of caspase-3 and PARP protein. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Homo sapiens 59-62 29532878-8 2018 Simvastatin significantly induced apoptosis, increased the Bax/Bcl-2 ratio, and cleavage of caspase-3 and PARP protein. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 63-68 29532878-8 2018 Simvastatin significantly induced apoptosis, increased the Bax/Bcl-2 ratio, and cleavage of caspase-3 and PARP protein. Simvastatin 0-11 caspase 3 Homo sapiens 92-101 29532878-8 2018 Simvastatin significantly induced apoptosis, increased the Bax/Bcl-2 ratio, and cleavage of caspase-3 and PARP protein. Simvastatin 0-11 collagen type XI alpha 2 chain Homo sapiens 106-110 29532878-12 2018 JNK and c-Jun phosphorylation was enhanced after simvastatin treatment, while those were abolished when either MA or GGPP were added. Simvastatin 49-60 mitogen-activated protein kinase 8 Homo sapiens 0-3 29532878-12 2018 JNK and c-Jun phosphorylation was enhanced after simvastatin treatment, while those were abolished when either MA or GGPP were added. Simvastatin 49-60 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 8-13 28635512-13 2018 Nephrin expression was significantly reduced by treatment with OxLDL (p < .01), and was significantly increased by application of simvastatin (p < .05). Simvastatin 133-144 nephrosis 1, nephrin Mus musculus 0-7 28635512-14 2018 CONCLUSION: Simvastatin treatment could significantly decrease lipid accumulation in murine podocytes and this protective effect was realized through inhibition of the expression of CXCL16 and increase in the expression of nephrin. Simvastatin 12-23 chemokine (C-X-C motif) ligand 16 Mus musculus 182-188 28635512-14 2018 CONCLUSION: Simvastatin treatment could significantly decrease lipid accumulation in murine podocytes and this protective effect was realized through inhibition of the expression of CXCL16 and increase in the expression of nephrin. Simvastatin 12-23 nephrosis 1, nephrin Mus musculus 223-230 29316250-9 2018 These observations were confirmed with cultured tumor fragments prepared from patients with TNBC after treatment with Wnt inhibitor ICG-001 and YAP inhibitor simvastatin. Simvastatin 158-169 Yes1 associated transcriptional regulator Homo sapiens 144-147 29541202-4 2018 The present study aimed to investigate whether simvastatin (SV) is able to induce SMCC-7721 cell apoptosis through the Wnt/beta-catenin signaling pathway. Simvastatin 47-58 catenin beta 1 Homo sapiens 123-135 29541202-4 2018 The present study aimed to investigate whether simvastatin (SV) is able to induce SMCC-7721 cell apoptosis through the Wnt/beta-catenin signaling pathway. Simvastatin 60-62 catenin beta 1 Homo sapiens 123-135 29460135-0 2018 Simvastatin reduces adrenal catecholamine secretion evoked by stimulation of cholinergic nicotinic and angiotensinergic AT1 receptors. Simvastatin 0-11 angiotensin II receptor, type 1a Rattus norvegicus 120-123 29611351-0 2018 Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. Simvastatin 38-49 arginine vasopressin Homo sapiens 53-56 29611351-5 2018 Recent reports suggested that sildenafil, metformin, and simvastatin might improve ADH-independent urine concentration. Simvastatin 57-68 arginine vasopressin Homo sapiens 83-86 29743974-0 2018 Simvastatin Treatment Upregulates HO-1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 34-38 29743974-0 2018 Simvastatin Treatment Upregulates HO-1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 103-107 29743974-6 2018 Simvastatin treatment increased HO-1 protein level in AAA, both in endothelial cells (ECs) and in smooth muscle cells (SMCs), but increased Nrf2 localization was restricted only to vasa vasorum. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 32-36 29743974-6 2018 Simvastatin treatment increased HO-1 protein level in AAA, both in endothelial cells (ECs) and in smooth muscle cells (SMCs), but increased Nrf2 localization was restricted only to vasa vasorum. Simvastatin 0-11 Keap1 Drosophila melanogaster 140-144 29743974-8 2018 In vitro studies showed that simvastatin raises HO-1 protein level slightly in ECs and to much higher extent in SMCs, which is not related to Nrf2/ARE activation, although HMOX1 expression is upregulated by simvastatin in both cell types. Simvastatin 29-40 heme oxygenase 1 Homo sapiens 48-52 29743974-8 2018 In vitro studies showed that simvastatin raises HO-1 protein level slightly in ECs and to much higher extent in SMCs, which is not related to Nrf2/ARE activation, although HMOX1 expression is upregulated by simvastatin in both cell types. Simvastatin 207-218 heme oxygenase 1 Homo sapiens 172-177 29743974-9 2018 In conclusion, simvastatin-induced modulation of HO-1 level in ECs and SMCs in vitro is not related to Nrf2/ARE activity. Simvastatin 15-26 heme oxygenase 1 Homo sapiens 49-53 29361314-0 2018 Simvastatin alters M1/M2 polarization of murine BV2 microglia via Notch signaling. Simvastatin 0-11 notch 1 Mus musculus 66-71 29361314-3 2018 M1 markers in LPS and Jagged-1 treated group were significantly increased and such increase was attenuated by simvastatin; however, M2 markers were enhanced. Simvastatin 110-121 jagged 1 Mus musculus 22-30 29361314-4 2018 Moreover, simvastatin enhance the expression of Notch signaling molecules, and its regulatory effects were blocked in Notch1 knocked down cells. Simvastatin 10-21 notch 1 Mus musculus 48-53 29361314-4 2018 Moreover, simvastatin enhance the expression of Notch signaling molecules, and its regulatory effects were blocked in Notch1 knocked down cells. Simvastatin 10-21 notch 1 Mus musculus 118-124 29361314-5 2018 In conclusion, these findings indicated that simvastatin alters M1/M2 polarization of murine BV2 microglia via Notch signaling. Simvastatin 45-56 notch 1 Mus musculus 111-116 29294374-9 2018 The DPC/NF-PLLA constructs treated with LPS/simvastatin also led to an increase in vessel-like structures, correlated with increased VEGF expression in both DPSCs and endothelial cells. Simvastatin 44-55 vascular endothelial growth factor A Homo sapiens 133-137 29460135-3 2018 In the presence of simvastatin, CA secretion evoked by 1.1-dimethyl-4-phenyl piperazinium iodide (DMPP), angiotensin II, high K+, veratridine, and Bay-K-8644 was time-dependently inhibited. Simvastatin 19-30 angiotensinogen Rattus norvegicus 105-119 29460135-4 2018 However, in the simultaneous presence of simvastatin and Nomega-nitro-L-arginine methyl ester hydrochloride, CA secretion evoked by angiotensin II and DMPP recovered to control levels. Simvastatin 41-52 angiotensinogen Rattus norvegicus 132-146 29460135-9 2018 We present the first evidence that simvastatin reduces adrenal CA secretion induced by stimulation of nicotinic and AT1-receptors. Simvastatin 35-46 angiotensin II receptor, type 1a Rattus norvegicus 116-119 29278865-0 2018 Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. Simvastatin 0-11 ryanodine receptor 1, skeletal muscle Mus musculus 38-42 29278865-0 2018 Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. Simvastatin 0-11 ryanodine receptor 2, cardiac Mus musculus 102-106 29278865-8 2018 In contrast, simvastatin reduced RyR2 Po and shifted the distribution of spark frequency towards lower values in ventricular cardiomyocytes. Simvastatin 13-24 ryanodine receptor 2, cardiac Mus musculus 33-37 29278865-9 2018 The lactone pro-drug form of simvastatin (inactive at HMG-CoA reductase) also activated RyR1, suggesting that the HMG-CoA inhibitor pharmacophore was not responsible for RyR1 activation. Simvastatin 29-40 ryanodine receptor 1, skeletal muscle Mus musculus 88-92 29278865-10 2018 CONCLUSION AND IMPLICATIONS: Simvastatin interacts with RyR1 to increase SR Ca2+ release and thus may contribute to its reported adverse effects on skeletal muscle. Simvastatin 29-40 ryanodine receptor 1, skeletal muscle Mus musculus 56-60 29278865-11 2018 The ability of low concentrations of simvastatin to reduce RyR2 Po may also protect against Ca2+ -dependent arrhythmias and sudden cardiac death. Simvastatin 37-48 ryanodine receptor 2, cardiac Mus musculus 59-63 29435052-0 2018 Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism. Simvastatin 0-11 aldo-keto reductase family 1 member C3 Homo sapiens 134-140 29435052-10 2018 Following treatment with simvastatin, aldo-keto reductase family 1 member C3 (AKR1C3) expression increased in PC-3 (>60-fold) and LNCaP-LA cells, however not in 22Rv1 cells. Simvastatin 25-36 aldo-keto reductase family 1 member C3 Homo sapiens 38-76 29435052-10 2018 Following treatment with simvastatin, aldo-keto reductase family 1 member C3 (AKR1C3) expression increased in PC-3 (>60-fold) and LNCaP-LA cells, however not in 22Rv1 cells. Simvastatin 25-36 aldo-keto reductase family 1 member C3 Homo sapiens 78-84 29435052-12 2018 The reduction in AKR1C3 expression in PC-3 cells following siRNA transfection was not associated with basal cell proliferation and migration; however, treatment with simvastatin decreased cell proliferation and migration. Simvastatin 166-177 aldo-keto reductase family 1 member C3 Homo sapiens 17-23 29435052-13 2018 The combination of simvastatin and meclofenamic acid, an AKR1C3 inhibitor, further enhanced the inhibition of cell proliferation and migration compared with treatment with either drug alone. Simvastatin 19-30 aldo-keto reductase family 1 member C3 Homo sapiens 57-63 29435052-14 2018 Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation. Simvastatin 28-39 insulin like growth factor 1 Homo sapiens 51-79 29435052-14 2018 Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation. Simvastatin 28-39 AKT serine/threonine kinase 1 Homo sapiens 88-91 29435052-14 2018 Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation. Simvastatin 28-39 AKT serine/threonine kinase 1 Homo sapiens 184-187 29435052-14 2018 Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation. Simvastatin 132-143 insulin like growth factor 1 Homo sapiens 51-79 29435052-14 2018 Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation. Simvastatin 132-143 AKT serine/threonine kinase 1 Homo sapiens 184-187 29692651-12 2018 The crocetin and simvastatin group rats significantly inhibited the expression of the p-p38 MAPK as compared to the AS group rats. Simvastatin 17-28 mitogen activated protein kinase 14 Rattus norvegicus 88-91 29624022-0 2018 Simvastatin modulates beta-catenin/MDR1 expression on spheres derived from CF41.Mg canine mammary carcinoma cells. Simvastatin 0-11 catenin beta 1 Canis lupus familiaris 22-34 29624022-0 2018 Simvastatin modulates beta-catenin/MDR1 expression on spheres derived from CF41.Mg canine mammary carcinoma cells. Simvastatin 0-11 ATP binding cassette subfamily B member 1 Canis lupus familiaris 35-39 29624022-4 2018 In the present study, we analyze the effect of simvastatin on beta-catenin/MDR1 expression in spheres obtained from the CF41.Mg cell line as a model of CSC. Simvastatin 47-58 catenin beta 1 Canis lupus familiaris 62-74 29624022-4 2018 In the present study, we analyze the effect of simvastatin on beta-catenin/MDR1 expression in spheres obtained from the CF41.Mg cell line as a model of CSC. Simvastatin 47-58 ATP binding cassette subfamily B member 1 Canis lupus familiaris 75-79 29624022-5 2018 Simvastatin increased phosphorylation of beta-catenin without affecting its total expression. Simvastatin 0-11 catenin beta 1 Canis lupus familiaris 41-53 29484149-0 2018 Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Simvastatin 31-42 neurofibromin 1 Homo sapiens 87-111 29624022-6 2018 Moreover, MDR1 expression was decreased by simvastatin. Simvastatin 43-54 ATP binding cassette subfamily B member 1 Canis lupus familiaris 10-14 29624022-7 2018 These results suggest that simvastatin would facilitate the degradation of beta-catenin, decreasing MDR1 expression and contributing to the chemosensitizing effects of the statin on canine mammary CSC. Simvastatin 27-38 catenin beta 1 Canis lupus familiaris 75-87 29624022-7 2018 These results suggest that simvastatin would facilitate the degradation of beta-catenin, decreasing MDR1 expression and contributing to the chemosensitizing effects of the statin on canine mammary CSC. Simvastatin 27-38 ATP binding cassette subfamily B member 1 Canis lupus familiaris 100-104 28916945-9 2018 On protein analyses of irradiated cells, simvastatin treatment inhibited phosphorylation of ERK1/2, in a dose-dependent manner, while the total levels of ERK1/2 remained stable. Simvastatin 41-52 mitogen-activated protein kinase 3 Homo sapiens 92-98 29484149-13 2018 Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. Simvastatin 42-53 neurofibromin 1 Homo sapiens 104-107 29447225-11 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor caused a 200% increase in HMG-CoA in the control HepG2 cells with a similar increase in the frataxin knockdown HepG2 cells, back to levels found in the control cells. Simvastatin 0-11 frataxin Homo sapiens 175-183 29449645-7 2018 Combined targeting of YAP and EGFR signaling by simvastatin and the EGFR signaling inhibitors, including the EGFR tyrosine kinase inhibitor (TKI) gefitinib, the RAF inhibitor sorafenib and the MEK inhibitor trametinib, presented strong synergistic cytotoxicities in HCC cells. Simvastatin 48-59 Yes1 associated transcriptional regulator Homo sapiens 22-25 29449645-7 2018 Combined targeting of YAP and EGFR signaling by simvastatin and the EGFR signaling inhibitors, including the EGFR tyrosine kinase inhibitor (TKI) gefitinib, the RAF inhibitor sorafenib and the MEK inhibitor trametinib, presented strong synergistic cytotoxicities in HCC cells. Simvastatin 48-59 epidermal growth factor receptor Homo sapiens 30-34 29447225-12 2018 There was a concomitant 20% increase in secreted ApoA-I to levels found in the control cells that were treated with simvastatin. Simvastatin 116-127 apolipoprotein A1 Homo sapiens 49-55 29175057-0 2018 Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 27-31 29376540-5 2018 Simvastatin and altenusin were confirmed to irreversibly inactivate biotin protein ligase. Simvastatin 0-11 holocarboxylase synthetase Homo sapiens 68-89 29175057-0 2018 Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 32-37 29421861-9 2018 Simvastatin also reduced the serum cytokine levels and transcriptional levels of tumor necrosis factor-alpha and interleukin-6 in the liver. Simvastatin 0-11 tumor necrosis factor Mus musculus 81-108 29421861-9 2018 Simvastatin also reduced the serum cytokine levels and transcriptional levels of tumor necrosis factor-alpha and interleukin-6 in the liver. Simvastatin 0-11 interleukin 6 Mus musculus 113-126 29421861-10 2018 The malonyldialdehyde and myeloperoxidase levels significantly decreased in the simvastatin treatment groups compared with the APAP group. Simvastatin 80-91 myeloperoxidase Mus musculus 26-41 29421861-11 2018 Simvastatin restored the decrease in superoxide dismutase, catalase, glutathione and glutathione peroxidase activities induced by APAP hepatotoxicity. Simvastatin 0-11 catalase Mus musculus 59-67 29175057-3 2018 We have studied simvastatin"s effects on the vascular enzyme semicarbazide-sensitive amine oxidase/vascular adhesion protein 1 (SSAO/VAP-1), which is involved in stroke-mediated brain injury. Simvastatin 16-27 amine oxidase copper containing 3 Homo sapiens 128-132 29175057-3 2018 We have studied simvastatin"s effects on the vascular enzyme semicarbazide-sensitive amine oxidase/vascular adhesion protein 1 (SSAO/VAP-1), which is involved in stroke-mediated brain injury. Simvastatin 16-27 amine oxidase copper containing 3 Homo sapiens 133-138 29175057-6 2018 Simvastatin blocks soluble SSAO/VAP-1 release and prevents E-selectin and VCAM-1 overexpression as well. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 27-31 29175057-6 2018 Simvastatin blocks soluble SSAO/VAP-1 release and prevents E-selectin and VCAM-1 overexpression as well. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 32-37 29175057-6 2018 Simvastatin blocks soluble SSAO/VAP-1 release and prevents E-selectin and VCAM-1 overexpression as well. Simvastatin 0-11 selectin E Homo sapiens 59-69 29175057-6 2018 Simvastatin blocks soluble SSAO/VAP-1 release and prevents E-selectin and VCAM-1 overexpression as well. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 74-80 29175057-7 2018 Simvastatin also effectively blocks SSAO/VAP-1-mediated leukocyte adhesion, although it is not an enzymatic inhibitor of SSAO in vitro. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 36-40 29175057-7 2018 Simvastatin also effectively blocks SSAO/VAP-1-mediated leukocyte adhesion, although it is not an enzymatic inhibitor of SSAO in vitro. Simvastatin 0-11 amine oxidase copper containing 3 Homo sapiens 41-46 29175057-8 2018 In addition, simvastatin-induced changes in adhesion molecules are greater in human brain endothelial cell cultures expressing SSAO/VAP-1, compared to those not expressing it, indicating some synergic effect with SSAO/VAP-1. Simvastatin 13-24 amine oxidase copper containing 3 Homo sapiens 127-131 29175057-8 2018 In addition, simvastatin-induced changes in adhesion molecules are greater in human brain endothelial cell cultures expressing SSAO/VAP-1, compared to those not expressing it, indicating some synergic effect with SSAO/VAP-1. Simvastatin 13-24 amine oxidase copper containing 3 Homo sapiens 132-137 29175057-8 2018 In addition, simvastatin-induced changes in adhesion molecules are greater in human brain endothelial cell cultures expressing SSAO/VAP-1, compared to those not expressing it, indicating some synergic effect with SSAO/VAP-1. Simvastatin 13-24 amine oxidase copper containing 3 Homo sapiens 213-217 29175057-8 2018 In addition, simvastatin-induced changes in adhesion molecules are greater in human brain endothelial cell cultures expressing SSAO/VAP-1, compared to those not expressing it, indicating some synergic effect with SSAO/VAP-1. Simvastatin 13-24 amine oxidase copper containing 3 Homo sapiens 218-223 29175057-9 2018 We think that part of the beneficial effect of simvastatin in stroke is mediated by the attenuation of the SSAO/VAP-1-dependent inflammatory response. Simvastatin 47-58 amine oxidase copper containing 3 Homo sapiens 107-111 29175057-9 2018 We think that part of the beneficial effect of simvastatin in stroke is mediated by the attenuation of the SSAO/VAP-1-dependent inflammatory response. Simvastatin 47-58 amine oxidase copper containing 3 Homo sapiens 112-117 29204687-9 2018 Specific DDI simulations using PBPK models of simvastatin (OATP1B3 substrate) and metformin (OCT2 substrate) predict no significant changes of the plasma concentrations of these two victim drugs during co-administration. Simvastatin 46-57 solute carrier organic anion transporter family member 1B3 Homo sapiens 59-66 30513525-0 2018 Simvastatin Protects Dopaminergic Neurons Against MPP+-Induced Oxidative Stress and Regulates the Endogenous Anti-Oxidant System Through ERK. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 137-140 29063606-5 2018 Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds. Simvastatin 211-222 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 66-72 29063606-5 2018 Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds. Simvastatin 211-222 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 74-81 29063606-5 2018 Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds. Simvastatin 211-222 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 87-93 29022140-4 2018 Treatment with simvastatin demonstrated significant decreases in the concentration of protein, TNF-alpha, IL-1beta, IL-6, and lipocalin 2, and the number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid in septic rats. Simvastatin 15-26 tumor necrosis factor Rattus norvegicus 95-104 29022140-4 2018 Treatment with simvastatin demonstrated significant decreases in the concentration of protein, TNF-alpha, IL-1beta, IL-6, and lipocalin 2, and the number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid in septic rats. Simvastatin 15-26 interleukin 1 beta Rattus norvegicus 106-114 29022140-4 2018 Treatment with simvastatin demonstrated significant decreases in the concentration of protein, TNF-alpha, IL-1beta, IL-6, and lipocalin 2, and the number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid in septic rats. Simvastatin 15-26 interleukin 6 Rattus norvegicus 116-120 29022140-4 2018 Treatment with simvastatin demonstrated significant decreases in the concentration of protein, TNF-alpha, IL-1beta, IL-6, and lipocalin 2, and the number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid in septic rats. Simvastatin 15-26 lipocalin 2 Rattus norvegicus 126-137 29022140-6 2018 Furthermore, expression levels of TLR4, NF-kappaB p65, and active caspase-3 proteins and Bax mRNA were also decreased by simvastatin. Simvastatin 121-132 toll-like receptor 4 Rattus norvegicus 34-38 29022140-6 2018 Furthermore, expression levels of TLR4, NF-kappaB p65, and active caspase-3 proteins and Bax mRNA were also decreased by simvastatin. Simvastatin 121-132 synaptotagmin 1 Rattus norvegicus 50-53 29022140-6 2018 Furthermore, expression levels of TLR4, NF-kappaB p65, and active caspase-3 proteins and Bax mRNA were also decreased by simvastatin. Simvastatin 121-132 caspase 3 Rattus norvegicus 66-75 29022140-6 2018 Furthermore, expression levels of TLR4, NF-kappaB p65, and active caspase-3 proteins and Bax mRNA were also decreased by simvastatin. Simvastatin 121-132 BCL2 associated X, apoptosis regulator Rattus norvegicus 89-92 29022140-8 2018 In conclusion, simvastatin improved endothelial permeability and mitigated the inflammatory response of lung tissue, the oxidative stress response, and cell apoptosis by inhibiting the TLR4/NF-kappaB signaling pathway, thereby alleviating sepsis-induced acute lung injury in rats. Simvastatin 15-26 toll-like receptor 4 Rattus norvegicus 185-189 28868611-10 2018 At 72 hours of culture, CD56, Ki-67 and Musashi-1 expression was significantly reduced (P < .001) in simvastatin-treated cells. Simvastatin 104-115 neural cell adhesion molecule 1 Homo sapiens 24-28 28868611-10 2018 At 72 hours of culture, CD56, Ki-67 and Musashi-1 expression was significantly reduced (P < .001) in simvastatin-treated cells. Simvastatin 104-115 musashi RNA binding protein 1 Homo sapiens 40-49 30166915-0 2018 Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1. Simvastatin 0-11 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 87-92 30166915-6 2018 PC3 cells were treated with simvastatin, irinotecan or combination. Simvastatin 28-39 proprotein convertase subtilisin/kexin type 1 Homo sapiens 0-3 30166915-10 2018 Results showed that simvastatin has a significant anti-proliferative activity on PC3 cells. Simvastatin 20-31 proprotein convertase subtilisin/kexin type 1 Homo sapiens 81-84 30166915-11 2018 Combined treatment of simvastatin with irinotecan exhibited a significant inhibition of PC3 cell growth compared to each treatment alone. Simvastatin 22-33 proprotein convertase subtilisin/kexin type 1 Homo sapiens 88-91 30166915-12 2018 Flow cytometry analysis showed that PC3 cell treatment with simvastatin and irinotecan combination demonstrated a remarkable increase in the percentage of apoptotic cells and those accumulated at G0/G1 phase when compared to each treatment alone. Simvastatin 60-71 proprotein convertase subtilisin/kexin type 1 Homo sapiens 36-39 29385181-0 2018 Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 86-90 29385181-0 2018 Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 102-106 29385181-7 2018 Simvastatin and metformin co-administered down-regulated mTOR and TCTP, while PTEN was increased. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 57-61 29385181-7 2018 Simvastatin and metformin co-administered down-regulated mTOR and TCTP, while PTEN was increased. Simvastatin 0-11 tumor protein, translationally-controlled 1 Homo sapiens 66-70 29175390-8 2018 The released SIM from BioCaP could significantly enhance the proliferation, ALP activities, mineralized nodules formation and osteogenic genes of hASCs. Simvastatin 13-16 alkaline phosphatase, placental Homo sapiens 76-79 29074491-5 2018 Simvastatin treatment significantly reduced lung permeability, serum LDL-C levels, tissue apoptosis, and inflammation. Simvastatin 0-11 component of oligomeric golgi complex 2 Mus musculus 69-74 29434788-7 2018 Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells. Simvastatin 15-26 forkhead box P3 Rattus norvegicus 146-151 29434788-7 2018 Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells. Simvastatin 15-26 Cd4 molecule Rattus norvegicus 177-180 29434788-7 2018 Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells. Simvastatin 15-26 Cd4 molecule Rattus norvegicus 189-192 29434788-7 2018 Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells. Simvastatin 15-26 Cd4 molecule Rattus norvegicus 189-192 29434788-7 2018 Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells. Simvastatin 15-26 forkhead box P3 Rattus norvegicus 241-246 29210030-11 2018 Simvastatin and atorvastatin improve endothelial dysfunction mainly by enhancing endothelial nitric oxide synthase (eNOS) expression and phosphorylation and NO production. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 81-114 29208461-0 2018 Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 148-152 29208461-0 2018 Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 158-161 29208461-6 2018 Simvastatin sensitized radioresistance of Ec9706-R cells and suppressed cell proliferation, but aggravated radiation-induced apoptosis and caspase-3 activity. Simvastatin 0-11 caspase 3 Homo sapiens 139-148 29208461-8 2018 Mechanism assay confirmed the activation of PI3K/AKT pathway after radiation, which was inhibited by simvastatin. Simvastatin 101-112 AKT serine/threonine kinase 1 Homo sapiens 49-52 29208461-10 2018 Further assay substantiated the PTEN suppression after irradiation, which was elevated following simvastatin pre-treatment. Simvastatin 97-108 phosphatase and tensin homolog Homo sapiens 32-36 29208461-11 2018 Moreover, PTEN cessation attenuated the inhibitory effect of simvastatin on PI3K/AKT activation, and subsequently antagonized simvastatin-induced radiosensitivity and EMT reversion. Simvastatin 61-72 phosphatase and tensin homolog Homo sapiens 10-14 29208461-11 2018 Moreover, PTEN cessation attenuated the inhibitory effect of simvastatin on PI3K/AKT activation, and subsequently antagonized simvastatin-induced radiosensitivity and EMT reversion. Simvastatin 61-72 AKT serine/threonine kinase 1 Homo sapiens 81-84 29208461-11 2018 Moreover, PTEN cessation attenuated the inhibitory effect of simvastatin on PI3K/AKT activation, and subsequently antagonized simvastatin-induced radiosensitivity and EMT reversion. Simvastatin 126-137 phosphatase and tensin homolog Homo sapiens 10-14 29208461-13 2018 Together, simvastatin inhibits the development of Ec9706-R cells by increasing radiosensitivity and reversing EMT via PTEN-PI3K/AKT pathway, implying a promising strategy against EC radioresistance. Simvastatin 10-21 phosphatase and tensin homolog Homo sapiens 118-122 29208461-13 2018 Together, simvastatin inhibits the development of Ec9706-R cells by increasing radiosensitivity and reversing EMT via PTEN-PI3K/AKT pathway, implying a promising strategy against EC radioresistance. Simvastatin 10-21 AKT serine/threonine kinase 1 Homo sapiens 128-131 29549671-0 2018 Lower levels of Caveolin-1 and higher levels of endothelial nitric oxide synthase are observed in abdominal aortic aneurysm patients treated with simvastatin. Simvastatin 146-157 caveolin 1 Homo sapiens 16-26 29549671-0 2018 Lower levels of Caveolin-1 and higher levels of endothelial nitric oxide synthase are observed in abdominal aortic aneurysm patients treated with simvastatin. Simvastatin 146-157 nitric oxide synthase 3 Homo sapiens 48-81 29549671-1 2018 This study was undertaken to verify whether simvastatin modulates Cav-1/eNOS expression, and if this modulation is associated with changes in pro- and anti-inflammatory cytokine and Toll-like receptor 4 (TLR4) level in abdominal aortic aneurysm (AAA). Simvastatin 44-55 caveolin 1 Homo sapiens 66-71 29549671-1 2018 This study was undertaken to verify whether simvastatin modulates Cav-1/eNOS expression, and if this modulation is associated with changes in pro- and anti-inflammatory cytokine and Toll-like receptor 4 (TLR4) level in abdominal aortic aneurysm (AAA). Simvastatin 44-55 nitric oxide synthase 3 Homo sapiens 72-76 29549671-1 2018 This study was undertaken to verify whether simvastatin modulates Cav-1/eNOS expression, and if this modulation is associated with changes in pro- and anti-inflammatory cytokine and Toll-like receptor 4 (TLR4) level in abdominal aortic aneurysm (AAA). Simvastatin 44-55 toll like receptor 4 Homo sapiens 182-202 29549671-3 2018 Simvastatin treatment decreased Cav-1 (p<0.05) and increased eNOS expression (p<0.01) in the AAA wall. Simvastatin 0-11 caveolin 1 Homo sapiens 32-37 29549671-3 2018 Simvastatin treatment decreased Cav-1 (p<0.05) and increased eNOS expression (p<0.01) in the AAA wall. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 64-68 29549671-5 2018 The changes in Cav-1 and eNOS were associated with a trend towards decreased IL-6 and IL-17 concentration (p>0.05) and increased IL-10 concentration (p=0.055); however, TLR4 expression was unaffected, suggesting that simvastatin influences Cav-1 and eNOS in the AAA wall by other mechanisms. Simvastatin 220-231 caveolin 1 Homo sapiens 15-20 29549671-5 2018 The changes in Cav-1 and eNOS were associated with a trend towards decreased IL-6 and IL-17 concentration (p>0.05) and increased IL-10 concentration (p=0.055); however, TLR4 expression was unaffected, suggesting that simvastatin influences Cav-1 and eNOS in the AAA wall by other mechanisms. Simvastatin 220-231 nitric oxide synthase 3 Homo sapiens 25-29 29549671-6 2018 Simvastatin may modulate Cav-1 and eNOS expression in the aneurysmal wall, indicating a potentially beneficial role for statins in AAA patients. Simvastatin 0-11 caveolin 1 Homo sapiens 25-30 29549671-6 2018 Simvastatin may modulate Cav-1 and eNOS expression in the aneurysmal wall, indicating a potentially beneficial role for statins in AAA patients. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 35-39 28941799-10 2018 Treatment of pBCEC with HMGCoA-reductase inhibitor simvastatin markedly increased intracellular and secreted apoJ levels, in parallel increased secreted Abeta oligomers and reduced Abeta uptake and cell-associated Abeta oligomers. Simvastatin 51-62 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 24-40 28941799-10 2018 Treatment of pBCEC with HMGCoA-reductase inhibitor simvastatin markedly increased intracellular and secreted apoJ levels, in parallel increased secreted Abeta oligomers and reduced Abeta uptake and cell-associated Abeta oligomers. Simvastatin 51-62 clusterin Mus musculus 109-113 28941799-11 2018 Simvastatin effects on apoJ, APP processing, and LRP1 expression in BCEC were confirmed in the mouse model. Simvastatin 0-11 clusterin Mus musculus 23-27 28941799-11 2018 Simvastatin effects on apoJ, APP processing, and LRP1 expression in BCEC were confirmed in the mouse model. Simvastatin 0-11 low density lipoprotein receptor-related protein 1 Mus musculus 49-53 30513525-3 2018 This study aimed to investigate how simvastatin affects experimental parkinsonian models via the regulation of extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated activation of the anti-oxidant system. Simvastatin 36-47 mitogen-activated protein kinase 1 Homo sapiens 111-152 30513525-3 2018 This study aimed to investigate how simvastatin affects experimental parkinsonian models via the regulation of extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated activation of the anti-oxidant system. Simvastatin 36-47 mitogen-activated protein kinase 3 Homo sapiens 154-160 29617679-13 2018 CONCLUSION: We for the first time showed that simvastatin, by upregulating Akt/GSK-3beta signaling pathway, alleviated isoflurane-induced neurogenetic damage and neurocognitive deficits in developing rat brain. Simvastatin 46-57 AKT serine/threonine kinase 1 Rattus norvegicus 75-78 30513525-11 2018 RESULTS: Simvastatin (1.5 muM) enhanced the viability of SH-SY5Y cells and primary neurons treated with MPP+, and significantly alleviated the oxidative stress induced by MPP+ in SH-SY5Y cells by regulating the production of SOD, analytical grade micro-reduced GSH, and ROS, which may be associated with the activation of the Nrf2 anti-oxidant system. Simvastatin 9-20 NFE2 like bZIP transcription factor 2 Homo sapiens 326-330 30513525-12 2018 An analysis involving ERK1/2 siRNA revealed that simvastatin can inhibit NOX2 expression via the activation of ERK1/2 in the MPP+-treated PD cell model. Simvastatin 49-60 mitogen-activated protein kinase 3 Homo sapiens 22-28 29617679-13 2018 CONCLUSION: We for the first time showed that simvastatin, by upregulating Akt/GSK-3beta signaling pathway, alleviated isoflurane-induced neurogenetic damage and neurocognitive deficits in developing rat brain. Simvastatin 46-57 glycogen synthase kinase 3 beta Rattus norvegicus 79-88 30513525-12 2018 An analysis involving ERK1/2 siRNA revealed that simvastatin can inhibit NOX2 expression via the activation of ERK1/2 in the MPP+-treated PD cell model. Simvastatin 49-60 cytochrome b-245 beta chain Homo sapiens 73-77 30513525-12 2018 An analysis involving ERK1/2 siRNA revealed that simvastatin can inhibit NOX2 expression via the activation of ERK1/2 in the MPP+-treated PD cell model. Simvastatin 49-60 mitogen-activated protein kinase 3 Homo sapiens 111-117 30513525-13 2018 CONCLUSION: Our results provide strong evidence that ERK1/2-mediated modulation of the anti-oxidant system after simvastatin treatment may partially explain the anti-oxidant activity in experimental parkinsonian models. Simvastatin 113-124 mitogen-activated protein kinase 3 Homo sapiens 53-59 30513525-14 2018 These findings contribute to a better understanding of the critical roles of simvastatin via the ERK1/2-mediated modulation of the anti-oxidant system, which may be relevant for treating PD. Simvastatin 77-88 mitogen-activated protein kinase 3 Homo sapiens 97-103 29319354-0 2018 Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Simvastatin 129-140 ras homolog family member A Homo sapiens 18-22 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 50-61 ras homolog family member A Homo sapiens 148-152 29319354-0 2018 Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Simvastatin 129-140 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 23-78 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 50-61 ras homolog family member A Homo sapiens 148-152 29319354-2 2018 This study aimed to investigate the role of RhoA/ROCK1 regulation in the therapeutic effects of simvastatin on PAH. Simvastatin 96-107 ras homolog family member A Homo sapiens 44-48 29319354-14 2018 The effects of simvastatin were mediated by inhibition of RhoA/ROCK1. Simvastatin 15-26 ras homolog family member A Homo sapiens 58-62 29319354-2 2018 This study aimed to investigate the role of RhoA/ROCK1 regulation in the therapeutic effects of simvastatin on PAH. Simvastatin 96-107 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 49-54 29319354-14 2018 The effects of simvastatin were mediated by inhibition of RhoA/ROCK1. Simvastatin 15-26 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 63-68 29319354-15 2018 Simvastatin decreased RhoA/ROCK1 overexpression by inhibition of mevalonate, FPP, and GGPP synthesis. Simvastatin 0-11 ras homolog family member A Homo sapiens 22-26 29319354-15 2018 Simvastatin decreased RhoA/ROCK1 overexpression by inhibition of mevalonate, FPP, and GGPP synthesis. Simvastatin 0-11 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 27-32 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 11-22 ras homolog family member A Homo sapiens 148-152 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 11-22 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 157-162 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 11-22 ras homolog family member A Homo sapiens 203-207 29319354-12 2018 The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group. Simvastatin 50-61 ras homolog family member A Homo sapiens 148-152 29296233-5 2017 Exposure of HepG2 cells to the cholesterol-lowering drug simvastatin or to a lipoprotein-deficient medium triggers SREBP-2 activation and increases SND1 promoter activity and transcript levels. Simvastatin 57-68 sterol regulatory element binding transcription factor 2 Homo sapiens 115-122 29138836-7 2018 Treatment with simvastatin, a drug known to preserve endothelial function through an unknown mechanism, improved endothelial cell function by upregulating GATA4 expression in HUVECs exposed to hyperglycemia. Simvastatin 15-26 GATA binding protein 4 Homo sapiens 155-160 29054366-0 2018 Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARgamma-dependent manner. Simvastatin 0-11 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-89 29054366-5 2018 Additionally, the effect of simvastatin on PPARgamma activation was also investigated in rat ICH model and primary microglia culture. Simvastatin 28-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-52 29054366-6 2018 Much more, the role of PPARgamma and CD36 in simvastatin-mediated erythrocyte phagocytosis was also detected by using in vivo or in vitro phagocytosis models, respectively. Simvastatin 45-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 23-32 29054366-8 2018 In addition, simvastatin increased PPARgamma activation and reinforced microglia-induced erythrocyte phagocytosis in vivo and in vitro. Simvastatin 13-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 35-44 29054366-9 2018 All above effects of simvastatin were abolished by PPARgamma inhibitor GW9662. Simvastatin 21-32 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-60 29054366-10 2018 In conclusion, our data suggested that simvastatin could enhance hematoma clearance and attenuate neurological deficits possibly by activating PPARgamma. Simvastatin 39-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 143-152 28987945-2 2017 In this study, we tried to find out the role of IL-10 in the mechanism of action of simvastatin. Simvastatin 84-95 interleukin 10 Mus musculus 48-53 28987945-8 2017 This may explain the role of IL-10 in the protective effect of simvastatin. Simvastatin 63-74 interleukin 10 Mus musculus 29-34 28987945-12 2017 Simvastatin has an additional pleiotropic effect halting inflammation and decreasing fibrosis due to increasing IL-10 leading to a hepatoprotective effect. Simvastatin 0-11 interleukin 10 Mus musculus 112-117 29285177-8 2017 The results demonstrated that after Simvastatin treatment of patients with acute cerebral hemorrhage at the ICU, the plasma concentrations of IL-4, IL-6, IL-8 and IL-10 were downregulated compared with those in placebo-treated controls. Simvastatin 36-47 interleukin 4 Homo sapiens 142-146 29285177-8 2017 The results demonstrated that after Simvastatin treatment of patients with acute cerebral hemorrhage at the ICU, the plasma concentrations of IL-4, IL-6, IL-8 and IL-10 were downregulated compared with those in placebo-treated controls. Simvastatin 36-47 interleukin 6 Homo sapiens 148-152 29285177-8 2017 The results demonstrated that after Simvastatin treatment of patients with acute cerebral hemorrhage at the ICU, the plasma concentrations of IL-4, IL-6, IL-8 and IL-10 were downregulated compared with those in placebo-treated controls. Simvastatin 36-47 C-X-C motif chemokine ligand 8 Homo sapiens 154-158 29285177-8 2017 The results demonstrated that after Simvastatin treatment of patients with acute cerebral hemorrhage at the ICU, the plasma concentrations of IL-4, IL-6, IL-8 and IL-10 were downregulated compared with those in placebo-treated controls. Simvastatin 36-47 interleukin 10 Homo sapiens 163-168 29039527-4 2017 In the present study, we hypothesized that simvastatin, likely through the inhibition of farnesylation and geranylgeranylation of Rac1, Cd42 and RhoA, induces a destruction/restructuration of the cytoskeleton that decreases mechanical strain transfer to the nuclei, inducing the loss of transmission of regulatory signals from the cytoskeleton to the nucleoskeleton. Simvastatin 43-54 Rac family small GTPase 1 Homo sapiens 130-134 29039527-4 2017 In the present study, we hypothesized that simvastatin, likely through the inhibition of farnesylation and geranylgeranylation of Rac1, Cd42 and RhoA, induces a destruction/restructuration of the cytoskeleton that decreases mechanical strain transfer to the nuclei, inducing the loss of transmission of regulatory signals from the cytoskeleton to the nucleoskeleton. Simvastatin 43-54 ras homolog family member A Homo sapiens 145-149 29071762-10 2017 Interestingly, CARV, when combined with SIM, significantly ameliorated SIM-induced liver and muscle injury by reducing the level of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, and myoglobin and restoring the normal histological picture of both liver and muscle as well as apoptosis. Simvastatin 40-43 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 158-184 29167415-2 2017 Yet combined therapeutic regimens have the potential of pharmacological interaction with both ticagrelor and simvastatin being metabolized by CYP3A4. Simvastatin 109-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 142-148 29375693-0 2018 Simvastatin improves intracerebral hemorrhage through NF-kappaB-mediated apoptosis via the MyD88/TRIF signaling pathway. Simvastatin 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 54-63 29375693-0 2018 Simvastatin improves intracerebral hemorrhage through NF-kappaB-mediated apoptosis via the MyD88/TRIF signaling pathway. Simvastatin 0-11 myeloid differentiation primary response gene 88 Mus musculus 91-96 29375693-0 2018 Simvastatin improves intracerebral hemorrhage through NF-kappaB-mediated apoptosis via the MyD88/TRIF signaling pathway. Simvastatin 0-11 toll-like receptor adaptor molecule 1 Mus musculus 97-101 29375693-6 2018 In addition, the expression levels of aquaporin-4, matrix metallopeptidase 9 and caspase-3 were downregulated and B-cell lymphoma-2 was upregulated by simvastatin treatment compared with the vehicle-treated model. Simvastatin 151-162 caspase 3 Mus musculus 81-90 29375693-8 2018 Mechanism analysis further indicated that simvastatin treatment downregulated nuclear factor (NF)-kappaB expression, and upregulated the myeloid differentiation primary response 88 (MyD88) and TIR domain-containing adaptor protein inducing interferon-beta (TRIF) expression levels in neuronal cells in experimental mice. Simvastatin 42-53 myeloid differentiation primary response gene 88 Mus musculus 182-187 29375693-8 2018 Mechanism analysis further indicated that simvastatin treatment downregulated nuclear factor (NF)-kappaB expression, and upregulated the myeloid differentiation primary response 88 (MyD88) and TIR domain-containing adaptor protein inducing interferon-beta (TRIF) expression levels in neuronal cells in experimental mice. Simvastatin 42-53 toll-like receptor adaptor molecule 1 Mus musculus 257-261 29375693-9 2018 Furthermore, the results revealed that NF-kappaB overexpression abolished the simvastatin-downregulated MyD88 and TRIF expression levels, as well as the apoptosis of neuronal cells. Simvastatin 78-89 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 39-48 29375693-9 2018 Furthermore, the results revealed that NF-kappaB overexpression abolished the simvastatin-downregulated MyD88 and TRIF expression levels, as well as the apoptosis of neuronal cells. Simvastatin 78-89 myeloid differentiation primary response gene 88 Mus musculus 104-109 29375693-9 2018 Furthermore, the results revealed that NF-kappaB overexpression abolished the simvastatin-downregulated MyD88 and TRIF expression levels, as well as the apoptosis of neuronal cells. Simvastatin 78-89 toll-like receptor adaptor molecule 1 Mus musculus 114-118 29375693-10 2018 In conclusion, these results indicated that simvastatin was able to attenuate brain edema and reduce cellular apoptosis by suppressing the NF-kappaB-mediated MyD88/TRIF signaling pathway subsequent to the induction of intracerebral hemorrhage in mice. Simvastatin 44-55 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 139-148 29375693-10 2018 In conclusion, these results indicated that simvastatin was able to attenuate brain edema and reduce cellular apoptosis by suppressing the NF-kappaB-mediated MyD88/TRIF signaling pathway subsequent to the induction of intracerebral hemorrhage in mice. Simvastatin 44-55 myeloid differentiation primary response gene 88 Mus musculus 158-163 29375693-10 2018 In conclusion, these results indicated that simvastatin was able to attenuate brain edema and reduce cellular apoptosis by suppressing the NF-kappaB-mediated MyD88/TRIF signaling pathway subsequent to the induction of intracerebral hemorrhage in mice. Simvastatin 44-55 toll-like receptor adaptor molecule 1 Mus musculus 164-168 29115437-0 2018 Simvastatin enhances the radiosensitivity of p53-deficient cells via inhibition of mouse double minute 2 homolog. Simvastatin 0-11 transformation related protein 53, pseudogene Mus musculus 45-48 29115437-3 2018 Using colony formation assays and a xenograft mouse model, we found that simvastatin potently stimulated radiosensitization of HCT116 p53-/- cells and xenograft tumors. Simvastatin 73-84 transformation related protein 53, pseudogene Mus musculus 134-137 29115437-5 2018 A further analysis revealed that simvastatin exhibited a novel function, namely, MDM2 suppression, regardless of p53 status. Simvastatin 33-44 transformed mouse 3T3 cell double minute 2 Mus musculus 81-85 29115437-6 2018 Interestingly, simvastatin induced radiosensitization by enhancing MDM2 suppression and elevating IR-induced p-ATM foci formation compared with IR alone in HCT116 p53-/- cells. Simvastatin 15-26 transformed mouse 3T3 cell double minute 2 Mus musculus 67-71 29115437-6 2018 Interestingly, simvastatin induced radiosensitization by enhancing MDM2 suppression and elevating IR-induced p-ATM foci formation compared with IR alone in HCT116 p53-/- cells. Simvastatin 15-26 transformation related protein 53, pseudogene Mus musculus 163-166 29115437-7 2018 Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53-/- cells. Simvastatin 13-24 forkhead box O3 Mus musculus 53-59 29115437-7 2018 Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53-/- cells. Simvastatin 13-24 cadherin 1 Mus musculus 61-71 29115437-7 2018 Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53-/- cells. Simvastatin 13-24 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 77-80 29115437-7 2018 Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53-/- cells. Simvastatin 13-24 transformed mouse 3T3 cell double minute 2 Mus musculus 140-144 29115437-7 2018 Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53-/- cells. Simvastatin 13-24 transformation related protein 53, pseudogene Mus musculus 156-159 29115437-8 2018 In conclusion, simvastatin enhanced radiosensitivity by inducing MDM2 inhibition and increasing tumor suppressor protein levels in radioresistant HCT116 p53-/- cells and xenografts. Simvastatin 15-26 transformed mouse 3T3 cell double minute 2 Mus musculus 65-69 29115437-8 2018 In conclusion, simvastatin enhanced radiosensitivity by inducing MDM2 inhibition and increasing tumor suppressor protein levels in radioresistant HCT116 p53-/- cells and xenografts. Simvastatin 15-26 transformation related protein 53, pseudogene Mus musculus 153-156 29115437-9 2018 Overall, our novel findings suggest a scientific rationale for the clinical use of simvastatin as an MDM2 inhibitor and radiosensitizer for p53-deficient colorectal tumor treatments. Simvastatin 83-94 transformed mouse 3T3 cell double minute 2 Mus musculus 101-105 29233637-6 2018 A combination of simvastatin 40 mg daily and ezetimibe 10 mg daily resulted in 57% lowering of LDL-C. Simvastatin 17-28 component of oligomeric golgi complex 2 Homo sapiens 95-100 29257256-0 2018 Simvastatin ameliorates cognitive impairments via inhibition of oxidative stress-induced apoptosis of hippocampal cells through the ERK/AKT signaling pathway in a rat model of senile dementia. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 132-135 29257256-0 2018 Simvastatin ameliorates cognitive impairments via inhibition of oxidative stress-induced apoptosis of hippocampal cells through the ERK/AKT signaling pathway in a rat model of senile dementia. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 136-139 29257256-8 2018 Notably, the administration of simvastatin inhibited activating transcription factor-6-mediated extracellular signal-regulated kinase/AKT serine/threonine kinase (ERK/AKT) signaling pathway in hippocampal cells. Simvastatin 31-42 Eph receptor B1 Rattus norvegicus 163-166 29257256-8 2018 Notably, the administration of simvastatin inhibited activating transcription factor-6-mediated extracellular signal-regulated kinase/AKT serine/threonine kinase (ERK/AKT) signaling pathway in hippocampal cells. Simvastatin 31-42 AKT serine/threonine kinase 1 Rattus norvegicus 134-137 29257256-9 2018 Taken together, the preclinical results of the present study indicate that simvastatin is efficient in preventing memory lapse and inhibiting apoptosis of hippocampal cells via the ERK/AKT signaling pathway, which may in the future improve cognitive decline and dementia in patients. Simvastatin 75-86 mitogen-activated protein kinase 1 Homo sapiens 181-184 29257256-9 2018 Taken together, the preclinical results of the present study indicate that simvastatin is efficient in preventing memory lapse and inhibiting apoptosis of hippocampal cells via the ERK/AKT signaling pathway, which may in the future improve cognitive decline and dementia in patients. Simvastatin 75-86 AKT serine/threonine kinase 1 Homo sapiens 185-188 29372612-6 2018 Therefore, we examined the effects of atorvastatin and simvastatin on leptin expression in cultured human white adipocytes. Simvastatin 55-66 leptin Homo sapiens 70-76 29372612-7 2018 We show that treatment of white adipocytes with simvastatin and atorvastatin decreases leptin mRNA expression (simvastatin: P = 0.008, atorvastatin: P = 0.03) and leptin secretion (simvastatin: P = 0.0001, atorvastatin: P = 0.0001). Simvastatin 48-59 leptin Homo sapiens 87-93 29372612-7 2018 We show that treatment of white adipocytes with simvastatin and atorvastatin decreases leptin mRNA expression (simvastatin: P = 0.008, atorvastatin: P = 0.03) and leptin secretion (simvastatin: P = 0.0001, atorvastatin: P = 0.0001). Simvastatin 48-59 leptin Homo sapiens 163-169 29372612-7 2018 We show that treatment of white adipocytes with simvastatin and atorvastatin decreases leptin mRNA expression (simvastatin: P = 0.008, atorvastatin: P = 0.03) and leptin secretion (simvastatin: P = 0.0001, atorvastatin: P = 0.0001). Simvastatin 111-122 leptin Homo sapiens 87-93 29372612-7 2018 We show that treatment of white adipocytes with simvastatin and atorvastatin decreases leptin mRNA expression (simvastatin: P = 0.008, atorvastatin: P = 0.03) and leptin secretion (simvastatin: P = 0.0001, atorvastatin: P = 0.0001). Simvastatin 111-122 leptin Homo sapiens 87-93 29372612-8 2018 Both simvastatin and atorvastatin mediate decreases in leptin expression via extracellular-signal-regulated kinases 1/2 and peroxisome proliferator-activated receptor gamma pathways (simvastatin: P = 0.01, atorvastatin: P = 0.026). Simvastatin 5-16 leptin Homo sapiens 55-61 29372612-8 2018 Both simvastatin and atorvastatin mediate decreases in leptin expression via extracellular-signal-regulated kinases 1/2 and peroxisome proliferator-activated receptor gamma pathways (simvastatin: P = 0.01, atorvastatin: P = 0.026). Simvastatin 5-16 peroxisome proliferator activated receptor gamma Homo sapiens 77-172 29372612-8 2018 Both simvastatin and atorvastatin mediate decreases in leptin expression via extracellular-signal-regulated kinases 1/2 and peroxisome proliferator-activated receptor gamma pathways (simvastatin: P = 0.01, atorvastatin: P = 0.026). Simvastatin 183-194 leptin Homo sapiens 55-61 29372612-8 2018 Both simvastatin and atorvastatin mediate decreases in leptin expression via extracellular-signal-regulated kinases 1/2 and peroxisome proliferator-activated receptor gamma pathways (simvastatin: P = 0.01, atorvastatin: P = 0.026). Simvastatin 183-194 peroxisome proliferator activated receptor gamma Homo sapiens 77-172 29236027-6 2017 Immunoblotting analysis illustrated that simvastatin diminished the activation of RhoA and Rac1 protein, and this effect was prevented by pre-treatment with MEV and GGpp. Simvastatin 41-52 ras homolog family member A Homo sapiens 82-86 29236027-6 2017 Immunoblotting analysis illustrated that simvastatin diminished the activation of RhoA and Rac1 protein, and this effect was prevented by pre-treatment with MEV and GGpp. Simvastatin 41-52 Rac family small GTPase 1 Homo sapiens 91-95 29236027-7 2017 Simvastatin increased the levels of p21cip and p27kip proteins and reduced the levels of hyperphosphorylated-Rb, E2F1 and CCND1 proteins. Simvastatin 0-11 E2F transcription factor 1 Homo sapiens 113-117 29236027-7 2017 Simvastatin increased the levels of p21cip and p27kip proteins and reduced the levels of hyperphosphorylated-Rb, E2F1 and CCND1 proteins. Simvastatin 0-11 cyclin D1 Homo sapiens 122-127 29236027-10 2017 The EGF-induced increases of Cyr61 protein expression and cell migration were prevented by simvastatin. Simvastatin 91-102 cellular communication network factor 1 Homo sapiens 29-34 29236027-11 2017 Taken together, these results suggest that simvastatin induced ATC proliferation inhibition through the deactivation of RhoA/Rac1 protein and overexpression of p21cip and p27kip, and migration inhibition through the abrogation of Cyr61 protein expression. Simvastatin 43-54 ras homolog family member A Homo sapiens 120-124 29236027-11 2017 Taken together, these results suggest that simvastatin induced ATC proliferation inhibition through the deactivation of RhoA/Rac1 protein and overexpression of p21cip and p27kip, and migration inhibition through the abrogation of Cyr61 protein expression. Simvastatin 43-54 Rac family small GTPase 1 Homo sapiens 125-129 29236027-11 2017 Taken together, these results suggest that simvastatin induced ATC proliferation inhibition through the deactivation of RhoA/Rac1 protein and overexpression of p21cip and p27kip, and migration inhibition through the abrogation of Cyr61 protein expression. Simvastatin 43-54 cellular communication network factor 1 Homo sapiens 230-235 28987945-0 2017 Simvastatin exerts antifibrotic effect and potentiates the antischistosomal effects of praziquantel in a murine model: Role of IL10. Simvastatin 0-11 interleukin 10 Mus musculus 127-131 28851085-0 2017 The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Simvastatin 53-64 apolipoprotein E Homo sapiens 14-18 28851085-0 2017 The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Simvastatin 53-64 cholesteryl ester transfer protein Homo sapiens 20-24 28851085-0 2017 The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Simvastatin 53-64 proprotein convertase subtilisin/kexin type 9 Homo sapiens 30-35 28851085-8 2017 CONCLUSION: APOE4 carriers and the CETP TaqIB B2B2 genotype were associated with a decreased response, but PCSK9 474IV carriers tended to be associated with an increased response to simvastatin therapy in Thai hypercholesterolemic patients. Simvastatin 182-193 proprotein convertase subtilisin/kexin type 9 Homo sapiens 107-112 28983618-0 2017 Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2-mediated CyPA secretion and CD147-ERK1/2-cyclin pathway. Simvastatin 0-11 Rho-associated coiled-coil containing protein kinase 2 Rattus norvegicus 67-72 28983618-0 2017 Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2-mediated CyPA secretion and CD147-ERK1/2-cyclin pathway. Simvastatin 0-11 peptidylprolyl isomerase A Rattus norvegicus 82-86 28983618-0 2017 Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2-mediated CyPA secretion and CD147-ERK1/2-cyclin pathway. Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 107-113 28983618-0 2017 Simvastatin attenuated rat thoracic aorta remodeling by decreasing ROCK2-mediated CyPA secretion and CD147-ERK1/2-cyclin pathway. Simvastatin 0-11 proliferating cell nuclear antigen Rattus norvegicus 114-120 28983618-1 2017 Reactive oxygen species-induced cyclophilin A (CyPA) release from vascular smooth muscle cells (VSMCs) may be inhibited by simvastatin in vitro. Simvastatin 123-134 peptidylprolyl isomerase A Rattus norvegicus 32-45 28983618-1 2017 Reactive oxygen species-induced cyclophilin A (CyPA) release from vascular smooth muscle cells (VSMCs) may be inhibited by simvastatin in vitro. Simvastatin 123-134 peptidylprolyl isomerase A Rattus norvegicus 47-51 28983618-2 2017 The present study aimed to further examine the effect of simvastatin on serum CyPA levels and the basigin (CD147)-extracellular signal-regulated kinase (ERK) 1/2-cyclin pathway during thoracic aorta remodeling. Simvastatin 57-68 peptidylprolyl isomerase A Rattus norvegicus 78-82 28983618-3 2017 The mechanisms through which simvastatin may inhibit CyPA secretion from VSMCs were further investigated. Simvastatin 29-40 peptidylprolyl isomerase A Rattus norvegicus 53-57 28983618-9 2017 VSMCs from simvastatin-treated rats secreted a decreased amount of CyPA compared with VSMCs from hypertensive rats. Simvastatin 11-22 peptidylprolyl isomerase A Rattus norvegicus 67-71 28983618-10 2017 In addition, pretreatment with geranylgeraniol partly reversed the inhibitory effect of simvastatin on LY83583-induced CyPA secretion in cultured VSMCs, whereas GGTI-298 and KD025 [a selective Rho-associated protein kinase 2 (ROCK2) inhibitor] mimicked the inhibitory effect of simvastatin. Simvastatin 88-99 peptidylprolyl isomerase A Rattus norvegicus 119-123 28983618-11 2017 The present study demonstrated that simvastatin alleviated thoracic aorta remodeling by reducing CyPA secretion and expression of the CD147-ERK1/2-cyclin signaling pathway. Simvastatin 36-47 peptidylprolyl isomerase A Rattus norvegicus 97-101 28983618-11 2017 The present study demonstrated that simvastatin alleviated thoracic aorta remodeling by reducing CyPA secretion and expression of the CD147-ERK1/2-cyclin signaling pathway. Simvastatin 36-47 mitogen activated protein kinase 3 Rattus norvegicus 140-146 28983618-11 2017 The present study demonstrated that simvastatin alleviated thoracic aorta remodeling by reducing CyPA secretion and expression of the CD147-ERK1/2-cyclin signaling pathway. Simvastatin 36-47 proliferating cell nuclear antigen Rattus norvegicus 147-153 29180324-7 2017 RESULTS: Compared with that in the control group, Bcl-2 protein expression in the aorta of atherosclerotic rats was significantly decreased (P<0.05); simvastatin treatment obviously increased the expression of Bcl-2 protein in atherosclerotic rats (P<0.05) to a level similar to that in the control group. Simvastatin 153-164 BCL2, apoptosis regulator Rattus norvegicus 50-55 29180324-7 2017 RESULTS: Compared with that in the control group, Bcl-2 protein expression in the aorta of atherosclerotic rats was significantly decreased (P<0.05); simvastatin treatment obviously increased the expression of Bcl-2 protein in atherosclerotic rats (P<0.05) to a level similar to that in the control group. Simvastatin 153-164 BCL2, apoptosis regulator Rattus norvegicus 213-218 29180324-9 2017 CONCLUSION: The therapeutic effect of simvastatin against atherosclerosis is probably mediated by up-regulation of Bcl-2 protein, which inhibits vascular endothelial cell apoptosis in rats with aortic atherosclerosis. Simvastatin 38-49 BCL2, apoptosis regulator Rattus norvegicus 115-120 29296233-5 2017 Exposure of HepG2 cells to the cholesterol-lowering drug simvastatin or to a lipoprotein-deficient medium triggers SREBP-2 activation and increases SND1 promoter activity and transcript levels. Simvastatin 57-68 staphylococcal nuclease and tudor domain containing 1 Homo sapiens 148-152 28864210-0 2017 Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins. Simvastatin 40-51 RAB27A, member RAS oncogene family Rattus norvegicus 130-136 29296187-4 2017 Multiple regression analyses showed that, in the Dongzhi region only, patients carrying the LEP AA genotype had a significantly greater increase in CK levels compared to those carrying the AG+GG genotypes after four weeks (P = 0.004) and eight weeks (P < 0.001) consecutive simvastatin treatment. Simvastatin 277-288 leptin Homo sapiens 92-95 28864210-0 2017 Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins. Simvastatin 40-51 double C2 domain alpha Rattus norvegicus 141-156 28864210-4 2017 Treatment with simvastatin for 24h inhibited histamine release in RBL-2H3 cells in a concentration-dependent manner after stimulation with dinitrophenylated bovine serum albumin (DNP-BSA, as an antigen), ionomycin (a calcium ion [Ca2+] ionophore), and thapsigargin (an inhibitor of Ca2+-ATPase in the endoplasmic reticulum). Simvastatin 15-26 albumin Rattus norvegicus 164-177 28864210-10 2017 In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction. Simvastatin 15-26 RAB27A, member RAS oncogene family Rattus norvegicus 105-111 28864210-10 2017 In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction. Simvastatin 15-26 RAB27A, member RAS oncogene family Rattus norvegicus 179-185 28864210-10 2017 In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction. Simvastatin 15-26 double C2 domain alpha Rattus norvegicus 186-191 29201188-0 2017 Simvastatin augments activation of liver regeneration through attenuating transforming growth factor-beta1 induced-apoptosis in obstructive jaundice rats. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 74-106 28915536-11 2017 Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-alpha, IL-6 and IL-1beta. Simvastatin 14-25 nitric oxide synthase 3 Rattus norvegicus 156-160 28915536-11 2017 Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-alpha, IL-6 and IL-1beta. Simvastatin 14-25 nitric oxide synthase 2 Rattus norvegicus 162-166 28915536-11 2017 Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-alpha, IL-6 and IL-1beta. Simvastatin 14-25 tumor necrosis factor Rattus norvegicus 168-177 28915536-11 2017 Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-alpha, IL-6 and IL-1beta. Simvastatin 14-25 interleukin 6 Rattus norvegicus 179-183 28915536-11 2017 Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-alpha, IL-6 and IL-1beta. Simvastatin 14-25 interleukin 1 beta Rattus norvegicus 188-196 29329611-10 2017 Compared to the diabetic non-intervention group, a significant increase in the expression of AMPKalpha1 and PGC-1alpha were observed in the early-stage, middle-stage DDD groups and simvastatin group (P < 0.05). Simvastatin 181-192 protein kinase AMP-activated catalytic subunit alpha 1 Rattus norvegicus 93-103 29329611-10 2017 Compared to the diabetic non-intervention group, a significant increase in the expression of AMPKalpha1 and PGC-1alpha were observed in the early-stage, middle-stage DDD groups and simvastatin group (P < 0.05). Simvastatin 181-192 PPARG coactivator 1 alpha Rattus norvegicus 108-118 28165814-0 2017 Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy. Simvastatin 22-33 intercellular adhesion molecule 1 Homo sapiens 40-46 28789942-3 2017 By using primary human ONH astrocytes, we found that both simvastatin and lovastatin inhibited TGF-beta2-mediated expression of ECM proteins such as connective tissue growth factor, collagen I, fibronectin, and plasminogen activator inhibitor-1. Simvastatin 58-69 transforming growth factor beta 2 Homo sapiens 95-104 28789942-3 2017 By using primary human ONH astrocytes, we found that both simvastatin and lovastatin inhibited TGF-beta2-mediated expression of ECM proteins such as connective tissue growth factor, collagen I, fibronectin, and plasminogen activator inhibitor-1. Simvastatin 58-69 serpin family E member 1 Homo sapiens 149-244 29201188-8 2017 Furthermore, Sim-treated animals demonstrated significantly downregulated TGF-beta1 expression and improved liver function vs. the BDL+NS group, indicating a TGF-beta1 antagonizing function. Simvastatin 13-16 transforming growth factor, beta 1 Rattus norvegicus 74-83 29201188-8 2017 Furthermore, Sim-treated animals demonstrated significantly downregulated TGF-beta1 expression and improved liver function vs. the BDL+NS group, indicating a TGF-beta1 antagonizing function. Simvastatin 13-16 transforming growth factor, beta 1 Rattus norvegicus 158-167 29201188-11 2017 Moreover, analysis of TGF-beta1 signaling pathways demonstrated that there was an increased hepatic TGF-beta1 and Smad3 expression in the BDL group, which was attenuated in the presence of Sim. Simvastatin 189-192 transforming growth factor, beta 1 Rattus norvegicus 22-31 29201188-11 2017 Moreover, analysis of TGF-beta1 signaling pathways demonstrated that there was an increased hepatic TGF-beta1 and Smad3 expression in the BDL group, which was attenuated in the presence of Sim. Simvastatin 189-192 transforming growth factor, beta 1 Rattus norvegicus 100-109 29201188-11 2017 Moreover, analysis of TGF-beta1 signaling pathways demonstrated that there was an increased hepatic TGF-beta1 and Smad3 expression in the BDL group, which was attenuated in the presence of Sim. Simvastatin 189-192 SMAD family member 3 Rattus norvegicus 114-119 29201188-13 2017 Sim displays hepatoprotective effects in liver cells via the upregulation of Smad7 expression and impaired TGF-beta signaling. Simvastatin 0-3 SMAD family member 7 Rattus norvegicus 77-82 29067120-0 2017 Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Rattus norvegicus 93-97 29201188-13 2017 Sim displays hepatoprotective effects in liver cells via the upregulation of Smad7 expression and impaired TGF-beta signaling. Simvastatin 0-3 transforming growth factor, beta 1 Rattus norvegicus 107-115 29113274-10 2017 Additionally, simvastatin in combination with doxorubicin significantly induced expression of the cyclin-dependent kinase inhibitor p21, increased cytochrome c and caspase 3 expression and reduced cyclin D1 expression. Simvastatin 14-25 H3 histone pseudogene 16 Homo sapiens 132-135 29067120-0 2017 Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 98-102 29067120-9 2017 Western blot analysis demonstrated that simvastatin upregulated I/R-induced increases of nuclear factor erythroid-2-related factor 2 (Nrf2) and anti-oxidant enzyme heme oxygenase-1 (HO-1). Simvastatin 40-51 NFE2 like bZIP transcription factor 2 Rattus norvegicus 134-138 29067120-9 2017 Western blot analysis demonstrated that simvastatin upregulated I/R-induced increases of nuclear factor erythroid-2-related factor 2 (Nrf2) and anti-oxidant enzyme heme oxygenase-1 (HO-1). Simvastatin 40-51 heme oxygenase 1 Rattus norvegicus 164-180 29067120-9 2017 Western blot analysis demonstrated that simvastatin upregulated I/R-induced increases of nuclear factor erythroid-2-related factor 2 (Nrf2) and anti-oxidant enzyme heme oxygenase-1 (HO-1). Simvastatin 40-51 heme oxygenase 1 Rattus norvegicus 182-186 29067120-11 2017 It was concluded that simvastatin treatment led to upregulation of HO-1 protein levels through activating the Nrf2 signaling pathway to ultimately protect the kidneys from I/R-associated oxidative damage. Simvastatin 22-33 heme oxygenase 1 Rattus norvegicus 67-71 29067120-11 2017 It was concluded that simvastatin treatment led to upregulation of HO-1 protein levels through activating the Nrf2 signaling pathway to ultimately protect the kidneys from I/R-associated oxidative damage. Simvastatin 22-33 NFE2 like bZIP transcription factor 2 Rattus norvegicus 110-114 27796742-9 2017 The CLP rats treated with simvastatin showed a reduction in nitric oxide (P < 0.05), IL1-beta (P < 0.001), IL-6 (P < 0.01), and TBARS levels (P < 0.001) and an increase in catalase activity (P < 0.01), citrate synthase enzyme (P < 0.05), and normalized GSH/GSSG ratio. Simvastatin 26-37 interleukin 1 beta Rattus norvegicus 88-96 27796742-9 2017 The CLP rats treated with simvastatin showed a reduction in nitric oxide (P < 0.05), IL1-beta (P < 0.001), IL-6 (P < 0.01), and TBARS levels (P < 0.001) and an increase in catalase activity (P < 0.01), citrate synthase enzyme (P < 0.05), and normalized GSH/GSSG ratio. Simvastatin 26-37 interleukin 6 Rattus norvegicus 113-117 27796742-9 2017 The CLP rats treated with simvastatin showed a reduction in nitric oxide (P < 0.05), IL1-beta (P < 0.001), IL-6 (P < 0.01), and TBARS levels (P < 0.001) and an increase in catalase activity (P < 0.01), citrate synthase enzyme (P < 0.05), and normalized GSH/GSSG ratio. Simvastatin 26-37 catalase Rattus norvegicus 184-192 27796742-9 2017 The CLP rats treated with simvastatin showed a reduction in nitric oxide (P < 0.05), IL1-beta (P < 0.001), IL-6 (P < 0.01), and TBARS levels (P < 0.001) and an increase in catalase activity (P < 0.01), citrate synthase enzyme (P < 0.05), and normalized GSH/GSSG ratio. Simvastatin 26-37 citrate synthase Rattus norvegicus 217-233 28762182-10 2017 LRP1 which plays a major role in lipoprotein uptake was also significantly decreased, and it was attenuated in simvastatin-treated hypercholesterolemic rats. Simvastatin 111-122 LDL receptor related protein 1 Rattus norvegicus 0-4 28865157-0 2017 Acute simvastatin treatment restores cerebral functional capillary density and attenuates angiotensin II-induced microcirculatory changes in a model of primary hypertension. Simvastatin 6-17 angiotensinogen Homo sapiens 90-104 29113274-10 2017 Additionally, simvastatin in combination with doxorubicin significantly induced expression of the cyclin-dependent kinase inhibitor p21, increased cytochrome c and caspase 3 expression and reduced cyclin D1 expression. Simvastatin 14-25 cytochrome c, somatic Homo sapiens 147-159 29113274-10 2017 Additionally, simvastatin in combination with doxorubicin significantly induced expression of the cyclin-dependent kinase inhibitor p21, increased cytochrome c and caspase 3 expression and reduced cyclin D1 expression. Simvastatin 14-25 caspase 3 Homo sapiens 164-173 29113274-10 2017 Additionally, simvastatin in combination with doxorubicin significantly induced expression of the cyclin-dependent kinase inhibitor p21, increased cytochrome c and caspase 3 expression and reduced cyclin D1 expression. Simvastatin 14-25 cyclin D1 Homo sapiens 197-206 28826913-0 2017 Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. Simvastatin 15-26 RAB7, member RAS oncogene family Mus musculus 106-110 29163155-10 2017 We demonstrated the utility of coupling GYY4137 with either simvastatin, known to inhibit monocarboxylate transporter 4 (MCT4), or metformin, to further boost glycolysis, in bringing about cell death for aggressive cancers. Simvastatin 60-71 solute carrier family 16 member 3 Homo sapiens 90-119 29163155-10 2017 We demonstrated the utility of coupling GYY4137 with either simvastatin, known to inhibit monocarboxylate transporter 4 (MCT4), or metformin, to further boost glycolysis, in bringing about cell death for aggressive cancers. Simvastatin 60-71 solute carrier family 16 member 3 Homo sapiens 121-125 28826913-18 2017 Combination between SAHA and Simvastatin could also significantly decrease the tumor growth in xenografted mice by inducing apoptosis and inhibiting Rab7 prenylation. Simvastatin 29-40 RAB7, member RAS oncogene family Mus musculus 149-153 28826913-19 2017 Rab7 is a potential target for the combined effects of Simvastatin and SAHA. Simvastatin 55-66 RAB7, member RAS oncogene family Mus musculus 0-4 29242847-4 2017 Results: Among 37 patients with simvastatin-induced liver symptoms the *3/*3 genotype of the CYP3A5 gene (p = 0.0001) and variant genotype of the CA BCRP gene were observed more frequently than in the control group (p = 0.0001). Simvastatin 32-43 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 93-99 29242847-4 2017 Results: Among 37 patients with simvastatin-induced liver symptoms the *3/*3 genotype of the CYP3A5 gene (p = 0.0001) and variant genotype of the CA BCRP gene were observed more frequently than in the control group (p = 0.0001). Simvastatin 32-43 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 149-153 27400856-5 2017 In the largest combined sample to date, we identified a novel association with rs149104283 (odds ratio (OR)=4.32, P=1.79 x 10-8), intronic to transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes previously implicated in adverse drug reactions including simvastatin-induced myopathy and docetaxel-induced neutropenia. Simvastatin 285-296 solute carrier organic anion transporter family member 1B3 Homo sapiens 157-164 28800541-7 2017 Expressions of TLR4 and NF-kappaB p65 protein were significantly lower in simvastatin-treated rats than that in sepsis rats at the same time point. Simvastatin 74-85 toll-like receptor 4 Rattus norvegicus 15-19 28800541-7 2017 Expressions of TLR4 and NF-kappaB p65 protein were significantly lower in simvastatin-treated rats than that in sepsis rats at the same time point. Simvastatin 74-85 synaptotagmin 1 Rattus norvegicus 34-37 28800541-8 2017 Levels of TNF-alpha, IL-1beta, IL-6, MCP-1 and NO in myocardial tissues, together with levels of CTnI in serum were significantly declined in simvastatin-treated rats. Simvastatin 142-153 tumor necrosis factor Rattus norvegicus 10-19 28800541-8 2017 Levels of TNF-alpha, IL-1beta, IL-6, MCP-1 and NO in myocardial tissues, together with levels of CTnI in serum were significantly declined in simvastatin-treated rats. Simvastatin 142-153 interleukin 1 beta Rattus norvegicus 21-29 28800541-8 2017 Levels of TNF-alpha, IL-1beta, IL-6, MCP-1 and NO in myocardial tissues, together with levels of CTnI in serum were significantly declined in simvastatin-treated rats. Simvastatin 142-153 interleukin 6 Rattus norvegicus 31-35 28800541-8 2017 Levels of TNF-alpha, IL-1beta, IL-6, MCP-1 and NO in myocardial tissues, together with levels of CTnI in serum were significantly declined in simvastatin-treated rats. Simvastatin 142-153 mast cell protease 1-like 1 Rattus norvegicus 37-42 28800541-8 2017 Levels of TNF-alpha, IL-1beta, IL-6, MCP-1 and NO in myocardial tissues, together with levels of CTnI in serum were significantly declined in simvastatin-treated rats. Simvastatin 142-153 troponin I3, cardiac type Rattus norvegicus 97-101 28601733-0 2017 Effect of 1.2% of simvastatin gel as a local drug delivery system on Gingival Crevicular Fluid interleukin-6 & interleukin-8 levels in non surgical treatment of chronic periodontitis patients. Simvastatin 18-29 adenine phosphoribosyltransferase Homo sapiens 110-113 28601733-0 2017 Effect of 1.2% of simvastatin gel as a local drug delivery system on Gingival Crevicular Fluid interleukin-6 & interleukin-8 levels in non surgical treatment of chronic periodontitis patients. Simvastatin 18-29 C-X-C motif chemokine ligand 8 Homo sapiens 115-128 28601733-1 2017 AIM: The present study was carried out to evaluate the effect of 1.2% simvastatin gel as local drug delivery (LDD) system on Gingival Crevicular Fluid (GCF) Interleukin -6 (IL-6) and Interleukin-8 (IL-8) levels in chronic periodontitis patients, in addition to scaling and root planing (SRP). Simvastatin 70-81 interleukin 6 Homo sapiens 157-171 28601733-1 2017 AIM: The present study was carried out to evaluate the effect of 1.2% simvastatin gel as local drug delivery (LDD) system on Gingival Crevicular Fluid (GCF) Interleukin -6 (IL-6) and Interleukin-8 (IL-8) levels in chronic periodontitis patients, in addition to scaling and root planing (SRP). Simvastatin 70-81 interleukin 6 Homo sapiens 173-177 28601733-1 2017 AIM: The present study was carried out to evaluate the effect of 1.2% simvastatin gel as local drug delivery (LDD) system on Gingival Crevicular Fluid (GCF) Interleukin -6 (IL-6) and Interleukin-8 (IL-8) levels in chronic periodontitis patients, in addition to scaling and root planing (SRP). Simvastatin 70-81 C-X-C motif chemokine ligand 8 Homo sapiens 183-196 28601733-1 2017 AIM: The present study was carried out to evaluate the effect of 1.2% simvastatin gel as local drug delivery (LDD) system on Gingival Crevicular Fluid (GCF) Interleukin -6 (IL-6) and Interleukin-8 (IL-8) levels in chronic periodontitis patients, in addition to scaling and root planing (SRP). Simvastatin 70-81 C-X-C motif chemokine ligand 8 Homo sapiens 198-202 27400856-5 2017 In the largest combined sample to date, we identified a novel association with rs149104283 (odds ratio (OR)=4.32, P=1.79 x 10-8), intronic to transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes previously implicated in adverse drug reactions including simvastatin-induced myopathy and docetaxel-induced neutropenia. Simvastatin 285-296 solute carrier organic anion transporter family member 1B7 (putative) Homo sapiens 169-176 28934253-0 2017 Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARalpha signaling pathway. Simvastatin 62-73 apolipoprotein A5 Rattus norvegicus 120-137 28950844-0 2017 Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial. Simvastatin 10-21 C-C motif chemokine ligand 2 Homo sapiens 25-59 28950844-3 2017 This study investigated the effect of pre-operative oral simvastatin administration on MCP-1 gene expression and serum MCP-1 protein levels in patients with endometriosis. Simvastatin 57-68 C-C motif chemokine ligand 2 Homo sapiens 87-92 28950844-10 2017 Serum MCP-1 levels following simvastatin treatment were higher than in samples obtained before treatment (297.89 +- 70.77 and 255.51 +- 63.79 pg/ml, respectively) (P = 0.01). Simvastatin 29-40 C-C motif chemokine ligand 2 Homo sapiens 6-11 28821686-11 2017 The potential disease-modifying effects of simvastatin on CSF phospho-tau should be further investigated in persons with hypercholesterolemia. Simvastatin 43-54 microtubule associated protein tau Homo sapiens 70-73 28803608-0 2017 Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling. Simvastatin 18-29 mitogen-activated protein kinase 8 Homo sapiens 64-67 28812343-8 2017 Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment. Simvastatin 139-150 myosin regulatory light chain interacting protein Homo sapiens 34-39 28812343-8 2017 Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment. Simvastatin 139-150 myosin regulatory light chain interacting protein Homo sapiens 40-44 28812343-8 2017 Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment. Simvastatin 139-150 low density lipoprotein receptor Homo sapiens 60-64 28910332-0 2017 Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. Simvastatin 26-37 nuclear factor kappa B subunit 1 Homo sapiens 172-181 28910332-0 2017 Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. Simvastatin 26-37 lin-28 homolog A Homo sapiens 182-187 28910332-11 2017 Finally, dual treatment with simvastatin and an NF-kappaB inhibitor (CAPE) synergistically induced apoptotic cell death, along with reduction of LIN28B expression, and restoration of let-7 miRNAs levels. Simvastatin 29-40 lin-28 homolog B Homo sapiens 145-151 28910332-12 2017 Our data illustrate that simvastatin remarkably inhibits the growth of human CRPC cells by suppressing NF-kappaB and LIN28B and subsequently upregulating let-7 miRNAs. Simvastatin 25-36 nuclear factor kappa B subunit 1 Homo sapiens 103-112 28910332-12 2017 Our data illustrate that simvastatin remarkably inhibits the growth of human CRPC cells by suppressing NF-kappaB and LIN28B and subsequently upregulating let-7 miRNAs. Simvastatin 25-36 lin-28 homolog B Homo sapiens 117-123 28928655-1 2017 Simvastatin is a lipid-lowering agent that blocks the production of cholesterol through inhibition of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-158 28928655-7 2017 Moreover, simvastatin oral treatment was able to reduce the nociception induced by acidified saline [an acid-sensing ion channels (ASICs) activator] and bradykinin (BK) stimulus, but not by TRPA1, TRPV1 or prostaglandin-E2 (PGE2). Simvastatin 10-21 kininogen 1 Homo sapiens 153-163 28928655-7 2017 Moreover, simvastatin oral treatment was able to reduce the nociception induced by acidified saline [an acid-sensing ion channels (ASICs) activator] and bradykinin (BK) stimulus, but not by TRPA1, TRPV1 or prostaglandin-E2 (PGE2). Simvastatin 10-21 kininogen 1 Homo sapiens 165-167 28928655-9 2017 These results indicate that simvastatin consistently inhibits mechanical hyperalgesia during neuropathic and inflammatory disorders, possibly by modulating the ascending pain signaling (TRPM8/ASIC/BK pathways expressed in the primary sensory neuron). Simvastatin 28-39 transient receptor potential cation channel subfamily M member 8 Homo sapiens 186-191 28928655-9 2017 These results indicate that simvastatin consistently inhibits mechanical hyperalgesia during neuropathic and inflammatory disorders, possibly by modulating the ascending pain signaling (TRPM8/ASIC/BK pathways expressed in the primary sensory neuron). Simvastatin 28-39 acid sensing ion channel subunit 1 Homo sapiens 192-196 28928655-9 2017 These results indicate that simvastatin consistently inhibits mechanical hyperalgesia during neuropathic and inflammatory disorders, possibly by modulating the ascending pain signaling (TRPM8/ASIC/BK pathways expressed in the primary sensory neuron). Simvastatin 28-39 kininogen 1 Homo sapiens 197-199 28803608-1 2017 The results of this study show that c-Jun N-terminal kinase (JNK) activation was associated with the enhancement of docetaxel-induced cytotoxicity by simvastatin in DU145 human prostate cancer cells. Simvastatin 150-161 mitogen-activated protein kinase 8 Homo sapiens 36-59 28803608-1 2017 The results of this study show that c-Jun N-terminal kinase (JNK) activation was associated with the enhancement of docetaxel-induced cytotoxicity by simvastatin in DU145 human prostate cancer cells. Simvastatin 150-161 mitogen-activated protein kinase 8 Homo sapiens 61-64 28803608-4 2017 Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin. Simvastatin 152-163 mitogen-activated protein kinase 8 Homo sapiens 14-17 28803608-4 2017 Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin. Simvastatin 152-163 N-myc downstream regulated 1 Homo sapiens 81-86 28859294-6 2017 We further found that simvastatin (a HMG-CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages. Simvastatin 22-33 CCAAT/enhancer binding protein (C/EBP), delta Mus musculus 79-84 28550977-1 2017 AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. Simvastatin 59-70 C-reactive protein Homo sapiens 111-114 28550977-10 2017 CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect. Simvastatin 61-72 C-reactive protein Homo sapiens 178-181 28677744-0 2017 Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 93-96 28677744-0 2017 Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice. Simvastatin 0-11 sirtuin 1 Mus musculus 97-106 28677744-8 2017 It was also found that simvastatin treatment increased AKT/sirtuin 1 expression following exposure to ionizing radiation in vivo and in vitro. Simvastatin 23-34 thymoma viral proto-oncogene 1 Mus musculus 55-58 28713941-5 2017 Celecoxib and simvastatin alone as well as a combined treatment showed a significant reduction in tumor cell viability, proliferation and secretion of IL-6 and IL-8 compared to the control group. Simvastatin 14-25 interleukin 6 Homo sapiens 151-155 28677744-8 2017 It was also found that simvastatin treatment increased AKT/sirtuin 1 expression following exposure to ionizing radiation in vivo and in vitro. Simvastatin 23-34 sirtuin 1 Mus musculus 59-68 28713941-5 2017 Celecoxib and simvastatin alone as well as a combined treatment showed a significant reduction in tumor cell viability, proliferation and secretion of IL-6 and IL-8 compared to the control group. Simvastatin 14-25 C-X-C motif chemokine ligand 8 Homo sapiens 160-164 28677744-9 2017 In the in vivo model, but not in the in vitro model, Bcl-2 and PARP expression was augmented and that of p53/p-p53 decreased following treatment with simvastatin. Simvastatin 150-161 B cell leukemia/lymphoma 2 Mus musculus 53-58 28677744-9 2017 In the in vivo model, but not in the in vitro model, Bcl-2 and PARP expression was augmented and that of p53/p-p53 decreased following treatment with simvastatin. Simvastatin 150-161 poly (ADP-ribose) polymerase family, member 1 Mus musculus 63-67 28677744-9 2017 In the in vivo model, but not in the in vitro model, Bcl-2 and PARP expression was augmented and that of p53/p-p53 decreased following treatment with simvastatin. Simvastatin 150-161 transformation related protein 53, pseudogene Mus musculus 105-108 28677744-9 2017 In the in vivo model, but not in the in vitro model, Bcl-2 and PARP expression was augmented and that of p53/p-p53 decreased following treatment with simvastatin. Simvastatin 150-161 transformation related protein 53, pseudogene Mus musculus 111-114 28677744-10 2017 On the whole, our findings indicate that simvastatin exerts a protective effect against ionizing radiation-induced damage in the mouse thymus, which may be partially attributed to the activation of the AKT/sirtuin 1 pathway. Simvastatin 41-52 thymoma viral proto-oncogene 1 Mus musculus 202-205 28677744-10 2017 On the whole, our findings indicate that simvastatin exerts a protective effect against ionizing radiation-induced damage in the mouse thymus, which may be partially attributed to the activation of the AKT/sirtuin 1 pathway. Simvastatin 41-52 sirtuin 1 Mus musculus 206-215 29181084-2 2017 Patients & methods: Test results for three common cardiovascular drug-gene tests (warfarin-CYP2C9-VKORC1, clopidogrel-CYP2C19 and simvastatin-SLCO1B1) of 208 patients in the Ohio State University-Coriell Personalized Medicine Collaborative were examined to determine the incidence of potentially actionable test results. Simvastatin 134-145 solute carrier organic anion transporter family member 1B1 Homo sapiens 146-153 27862237-1 2017 Simvastatin, an inexpensive lipid-lowering drug widely used to prevent cardiovascular disorders, is known to increase osteoblastic activity, inhibit osteoclastic activity, and stimulate osteoblastic production of bone morphogenetic protein 2. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 213-241 28419516-13 2017 SIM was blocked by GW-9662 (PPARgamma antagonist) at dose 2 mg/kg (i.p.). Simvastatin 0-3 peroxisome proliferator-activated receptor gamma Rattus norvegicus 28-37 28419516-24 2017 Moreover, the antinociceptive effect of SIM is partly mediated through PPARgamma receptors and NO pathway. Simvastatin 40-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 71-80 28546421-5 2017 Simvastatin or mevastatin significantly suppressed the effects of ox-LDL or TNFalpha Promoter reporter assays and small interfering RNA knockdown revealed that statins inhibit ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). Simvastatin 0-11 tumor necrosis factor Homo sapiens 76-84 28546421-5 2017 Simvastatin or mevastatin significantly suppressed the effects of ox-LDL or TNFalpha Promoter reporter assays and small interfering RNA knockdown revealed that statins inhibit ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). Simvastatin 0-11 NLR family pyrin domain containing 3 Homo sapiens 192-197 28546421-5 2017 Simvastatin or mevastatin significantly suppressed the effects of ox-LDL or TNFalpha Promoter reporter assays and small interfering RNA knockdown revealed that statins inhibit ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). Simvastatin 0-11 nuclear receptor subfamily 1 group I member 2 Homo sapiens 230-249 28546421-5 2017 Simvastatin or mevastatin significantly suppressed the effects of ox-LDL or TNFalpha Promoter reporter assays and small interfering RNA knockdown revealed that statins inhibit ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). Simvastatin 0-11 nuclear receptor subfamily 1 group I member 2 Homo sapiens 251-254 28839280-6 2017 From our results, HCE significantly restored simvastatin-induced reduction in muscle weights and reduced elevated plasma creatine kinase in rats. Simvastatin 45-56 RNA guanylyltransferase and 5'-phosphatase Mus musculus 18-21 28839280-7 2017 HCE also improved simvastatin-induced reduction in muscle glutathione levels, muscle mitochondrial membrane potential, and reduced simvastatin-induced muscle inflammation. Simvastatin 18-29 RNA guanylyltransferase and 5'-phosphatase Mus musculus 0-3 28839280-5 2017 The objective of this study was to determine if the aqueous extract of HC (HCE) could prevent simvastatin-induced muscle toxicity in rats, and whether HCE could also exert beneficial effects on reducing high-fat diet-induced hypercholesterolemia and elevated liver cholesterol, thereby reducing the dose of simvastatin when used in combined therapy. Simvastatin 94-105 RNA guanylyltransferase and 5'-phosphatase Mus musculus 75-78 28839280-7 2017 HCE also improved simvastatin-induced reduction in muscle glutathione levels, muscle mitochondrial membrane potential, and reduced simvastatin-induced muscle inflammation. Simvastatin 131-142 RNA guanylyltransferase and 5'-phosphatase Mus musculus 0-3 28839280-9 2017 In conclusion, our study provided in vivo evidence that HCE has potential protective effect on simvastatin-induced toxicity in muscles, and also beneficial effects on diet-induced non-alcoholic fatty liver and hyperlipidemia when being used alone or in combination with simvastatin at a reduced dose. Simvastatin 95-106 RNA guanylyltransferase and 5'-phosphatase Mus musculus 56-59 28839280-9 2017 In conclusion, our study provided in vivo evidence that HCE has potential protective effect on simvastatin-induced toxicity in muscles, and also beneficial effects on diet-induced non-alcoholic fatty liver and hyperlipidemia when being used alone or in combination with simvastatin at a reduced dose. Simvastatin 270-281 RNA guanylyltransferase and 5'-phosphatase Mus musculus 56-59 28499972-5 2017 Moreover, simvastatin pronouncedly attenuated amyloidogenesis by decreasing amyloid-beta, amyloid precursor protein (APP) and beta-site APP cleaving enzyme-1. Simvastatin 10-21 amyloid beta (A4) precursor protein Mus musculus 84-115 28805677-9 2017 Simvastatin, an inhibitor of albumin endocytosis, also prevented MMP-9 secretion. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 65-70 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 component of oligomeric golgi complex 2 Homo sapiens 83-87 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 lipoprotein(a) Homo sapiens 92-97 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 interleukin 1 beta Homo sapiens 169-177 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 CD68 molecule Homo sapiens 182-186 28711708-7 2017 Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05). Simvastatin 14-25 interleukin 18 Homo sapiens 270-275 28711708-9 2017 There was a suppression of TLR-2 and TLR-4 expression by 21 +- 8% and 18 +- 7%, respectively, compared to 0-h baseline, after cream intake following ezetimibe and simvastatin combination treatment. Simvastatin 163-174 toll like receptor 2 Homo sapiens 27-32 28711708-9 2017 There was a suppression of TLR-2 and TLR-4 expression by 21 +- 8% and 18 +- 7%, respectively, compared to 0-h baseline, after cream intake following ezetimibe and simvastatin combination treatment. Simvastatin 163-174 toll like receptor 4 Homo sapiens 37-42 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 79-90 P-selectin Oryctolagus cuniculus 313-323 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 79-90 C-C motif chemokine 2 Oryctolagus cuniculus 350-355 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 79-90 interleukin-6 Oryctolagus cuniculus 400-404 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 79-90 P-selectin Oryctolagus cuniculus 450-460 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 79-90 C-C motif chemokine 2 Oryctolagus cuniculus 465-470 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 123-134 P-selectin Oryctolagus cuniculus 313-323 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 123-134 C-C motif chemokine 2 Oryctolagus cuniculus 350-355 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 123-134 interleukin-6 Oryctolagus cuniculus 400-404 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 123-134 P-selectin Oryctolagus cuniculus 450-460 28442532-7 2017 Our data showed that compared with saline and heparin controls, monotherapy of simvastatin and the adjunctive therapy with simvastatin and heparin significantly improved the thrombus resolution and reduced inflammatory cells migration into the venous wall, the release of the inflammatory cell adhesion molecule (P-selectin), inflammatory chemokine (MCP-1) and pleiotropic proinflammatory cytokines (IL-6) into the blood, and the local expression of P-selectin and MCP-1 in the venous wall. Simvastatin 123-134 C-C motif chemokine 2 Oryctolagus cuniculus 465-470 28554582-8 2017 A Rac inhibitor, and N17Rac1 dominant negative mutant, significantly induced PCSK9 levels, and a suppression of Rac1 expression by siRNA, counteract the effect of simvastatin on the induction of PCSK9 mRNA. Simvastatin 163-174 AKT serine/threonine kinase 1 Homo sapiens 2-5 28554582-8 2017 A Rac inhibitor, and N17Rac1 dominant negative mutant, significantly induced PCSK9 levels, and a suppression of Rac1 expression by siRNA, counteract the effect of simvastatin on the induction of PCSK9 mRNA. Simvastatin 163-174 Rac family small GTPase 1 Homo sapiens 24-28 28554582-8 2017 A Rac inhibitor, and N17Rac1 dominant negative mutant, significantly induced PCSK9 levels, and a suppression of Rac1 expression by siRNA, counteract the effect of simvastatin on the induction of PCSK9 mRNA. Simvastatin 163-174 proprotein convertase subtilisin/kexin type 9 Homo sapiens 195-200 28554582-9 2017 Finally, simvastatin, and Rac inhibitor inhibited the nuclear translocation of STAT3 and its knock-down by siRNA increased significantly the susceptibility of Caco-2 to simvastatin on PCSK9 expression. Simvastatin 9-20 signal transducer and activator of transcription 3 Homo sapiens 79-84 28554582-9 2017 Finally, simvastatin, and Rac inhibitor inhibited the nuclear translocation of STAT3 and its knock-down by siRNA increased significantly the susceptibility of Caco-2 to simvastatin on PCSK9 expression. Simvastatin 9-20 proprotein convertase subtilisin/kexin type 9 Homo sapiens 184-189 28554582-9 2017 Finally, simvastatin, and Rac inhibitor inhibited the nuclear translocation of STAT3 and its knock-down by siRNA increased significantly the susceptibility of Caco-2 to simvastatin on PCSK9 expression. Simvastatin 169-180 AKT serine/threonine kinase 1 Homo sapiens 26-29 28554582-9 2017 Finally, simvastatin, and Rac inhibitor inhibited the nuclear translocation of STAT3 and its knock-down by siRNA increased significantly the susceptibility of Caco-2 to simvastatin on PCSK9 expression. Simvastatin 169-180 signal transducer and activator of transcription 3 Homo sapiens 79-84 28554582-9 2017 Finally, simvastatin, and Rac inhibitor inhibited the nuclear translocation of STAT3 and its knock-down by siRNA increased significantly the susceptibility of Caco-2 to simvastatin on PCSK9 expression. Simvastatin 169-180 proprotein convertase subtilisin/kexin type 9 Homo sapiens 184-189 28554582-10 2017 Taken together, the present study reveal a direct role of Rac1 on simvastatin-mediated PCSK9 expression via the reduction of STAT3 nuclear translocation. Simvastatin 66-77 Rac family small GTPase 1 Homo sapiens 58-62 28554582-10 2017 Taken together, the present study reveal a direct role of Rac1 on simvastatin-mediated PCSK9 expression via the reduction of STAT3 nuclear translocation. Simvastatin 66-77 proprotein convertase subtilisin/kexin type 9 Homo sapiens 87-92 28554582-10 2017 Taken together, the present study reveal a direct role of Rac1 on simvastatin-mediated PCSK9 expression via the reduction of STAT3 nuclear translocation. Simvastatin 66-77 signal transducer and activator of transcription 3 Homo sapiens 125-130 29207644-0 2017 Protection by simvastatin on hyperglycemia-induced endothelial dysfunction through inhibiting NLRP3 inflammasomes. Simvastatin 14-25 NLR family, pyrin domain containing 3 Rattus norvegicus 94-99 29207644-4 2017 Here, we explored the role and mechanisms of simvastatin in the activation of NLRP3 inflammasome which are involved in vascular endothelial hyperpermeability causing by the disruption of tight junction protein ZO-1 and adherens junction protein VE-Cadherin, an early initiation of cardiovascular complication. Simvastatin 45-56 NLR family, pyrin domain containing 3 Rattus norvegicus 78-83 29207644-4 2017 Here, we explored the role and mechanisms of simvastatin in the activation of NLRP3 inflammasome which are involved in vascular endothelial hyperpermeability causing by the disruption of tight junction protein ZO-1 and adherens junction protein VE-Cadherin, an early initiation of cardiovascular complication. Simvastatin 45-56 tight junction protein 1 Rattus norvegicus 210-214 29207644-4 2017 Here, we explored the role and mechanisms of simvastatin in the activation of NLRP3 inflammasome which are involved in vascular endothelial hyperpermeability causing by the disruption of tight junction protein ZO-1 and adherens junction protein VE-Cadherin, an early initiation of cardiovascular complication. Simvastatin 45-56 cadherin 5 Rattus norvegicus 245-256 29207644-6 2017 Simvastatin treatment remarkably abolished vascular endothelial hyperpermeability and enhanced the protein expression of ZO-1 and VE-Cadherin through NLRP3 inflammasome. Simvastatin 0-11 tight junction protein 1 Rattus norvegicus 121-125 29207644-6 2017 Simvastatin treatment remarkably abolished vascular endothelial hyperpermeability and enhanced the protein expression of ZO-1 and VE-Cadherin through NLRP3 inflammasome. Simvastatin 0-11 cadherin 5 Rattus norvegicus 130-141 29207644-6 2017 Simvastatin treatment remarkably abolished vascular endothelial hyperpermeability and enhanced the protein expression of ZO-1 and VE-Cadherin through NLRP3 inflammasome. Simvastatin 0-11 NLR family, pyrin domain containing 3 Rattus norvegicus 150-155 29207644-7 2017 Mechanistically, the inhibitory role of simvastatin endothelial hyperpermeability is attributed to the decreased release of cytoplasmic high mobility group box protein-1 (HMGB1) derived from endothelial NLRP3 inflammasome activation. Simvastatin 40-51 high mobility group box 1 Rattus norvegicus 136-169 29207644-7 2017 Mechanistically, the inhibitory role of simvastatin endothelial hyperpermeability is attributed to the decreased release of cytoplasmic high mobility group box protein-1 (HMGB1) derived from endothelial NLRP3 inflammasome activation. Simvastatin 40-51 high mobility group box 1 Rattus norvegicus 171-176 29207644-7 2017 Mechanistically, the inhibitory role of simvastatin endothelial hyperpermeability is attributed to the decreased release of cytoplasmic high mobility group box protein-1 (HMGB1) derived from endothelial NLRP3 inflammasome activation. Simvastatin 40-51 NLR family, pyrin domain containing 3 Rattus norvegicus 203-208 29207644-8 2017 We further confirm the protective role of simvastatin on vascular leakage in the heart of diabetic rats injected with Evans blue dye, which was associated with HMGB1 release in the serum. Simvastatin 42-53 high mobility group box 1 Rattus norvegicus 160-165 29207644-9 2017 Collectively, the mechanism of simvastatin treatment alleviating vascular endothelial permeability dysfunction may be through inhibiting the NLRP3 inflammasome-dependent HMGB1 release in RAECs. Simvastatin 31-42 NLR family, pyrin domain containing 3 Rattus norvegicus 141-146 29207644-9 2017 Collectively, the mechanism of simvastatin treatment alleviating vascular endothelial permeability dysfunction may be through inhibiting the NLRP3 inflammasome-dependent HMGB1 release in RAECs. Simvastatin 31-42 high mobility group box 1 Rattus norvegicus 170-175 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Simvastatin 50-61 component of oligomeric golgi complex 2 Homo sapiens 21-26 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Simvastatin 91-102 component of oligomeric golgi complex 2 Homo sapiens 21-26 28528185-0 2017 Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer"s disease via modulating the expression of miR-106b. Simvastatin 0-11 microRNA 106b Mus musculus 140-148 28528185-13 2017 Furthermore, miR-106b mediated apoptosis in SH-SY5Y cell and simvastatin could suppressed this process. Simvastatin 61-72 microRNA 106b Homo sapiens 13-21 28758631-13 2017 In contrast, simvastatin therapy did not reduce any of the tested genes, but did slightly increase the expression of Ccl2 and Cxcl13. Simvastatin 13-24 chemokine (C-C motif) ligand 2 Mus musculus 117-121 28758631-13 2017 In contrast, simvastatin therapy did not reduce any of the tested genes, but did slightly increase the expression of Ccl2 and Cxcl13. Simvastatin 13-24 chemokine (C-X-C motif) ligand 13 Mus musculus 126-132 28554582-0 2017 Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Simvastatin 29-40 proprotein convertase subtilisin/kexin type 9 Homo sapiens 49-54 28554582-0 2017 Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Simvastatin 29-40 Rac family small GTPase 1 Homo sapiens 95-99 28554582-3 2017 Simvastatin (40muM) induced both PCSK9 mRNA (10.7+-3.2 fold) and protein (2.2+-0.3 fold), after 24h incubation. Simvastatin 0-11 proprotein convertase subtilisin/kexin type 9 Homo sapiens 33-38 28554582-5 2017 Under the same experimental conditions, MVA, GGOH, but not FOH, prevented the activation of the PCSK9 promoter by simvastatin in a SRE-dependent manner. Simvastatin 114-125 proprotein convertase subtilisin/kexin type 9 Homo sapiens 96-101 28554582-6 2017 Simvastatin reduced by -35.7+-15.2% the Rac1-GTP levels, while no changes were observed on RhoA- and Cdc42-GTP. Simvastatin 0-11 Rac family small GTPase 1 Homo sapiens 40-44 28214453-0 2017 Reciprocal regulation of eNOS, H2S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin. Simvastatin 131-142 nitric oxide synthase 3 Homo sapiens 25-29 28214453-11 2017 Simvastatin decreased iNOS, HO-1, HIF-1alpha and CSE whilst it increased eNOS phosphorylation. Simvastatin 0-11 nitric oxide synthase 2 Homo sapiens 22-26 28214453-11 2017 Simvastatin decreased iNOS, HO-1, HIF-1alpha and CSE whilst it increased eNOS phosphorylation. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 28-32 28214453-11 2017 Simvastatin decreased iNOS, HO-1, HIF-1alpha and CSE whilst it increased eNOS phosphorylation. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-44 28214453-11 2017 Simvastatin decreased iNOS, HO-1, HIF-1alpha and CSE whilst it increased eNOS phosphorylation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 73-77 28214453-13 2017 Simvastatin, besides its known effect on eNOS upregulation, reduced the HIF-1alpha and its downstream targets. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 41-45 28214453-13 2017 Simvastatin, besides its known effect on eNOS upregulation, reduced the HIF-1alpha and its downstream targets. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 72-82 28463564-3 2017 This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer-induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre-osteoclast RAW264.7 cells, and osteoclastogenic CSF-1 and RANKL expressions in breast cancer MCF-7 cells. Simvastatin 32-43 signal sequence receptor, delta Mus musculus 116-120 28463564-3 2017 This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer-induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre-osteoclast RAW264.7 cells, and osteoclastogenic CSF-1 and RANKL expressions in breast cancer MCF-7 cells. Simvastatin 32-43 signal sequence receptor, delta Mus musculus 190-194 28463564-3 2017 This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer-induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre-osteoclast RAW264.7 cells, and osteoclastogenic CSF-1 and RANKL expressions in breast cancer MCF-7 cells. Simvastatin 32-43 cathepsin K Mus musculus 196-207 28463564-3 2017 This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer-induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre-osteoclast RAW264.7 cells, and osteoclastogenic CSF-1 and RANKL expressions in breast cancer MCF-7 cells. Simvastatin 32-43 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 Mus musculus 213-219 28463564-3 2017 This study documented that both simvastatin and MBCD (cholesterol depleting drug) blocked the breast cancer-induced TRAP and MMP activity, and expressions of various osteoclastogenic genes (TRAP, Cathepsin K, and NFATc1) in pre-osteoclast RAW264.7 cells, and osteoclastogenic CSF-1 and RANKL expressions in breast cancer MCF-7 cells. Simvastatin 32-43 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 286-291 28499972-5 2017 Moreover, simvastatin pronouncedly attenuated amyloidogenesis by decreasing amyloid-beta, amyloid precursor protein (APP) and beta-site APP cleaving enzyme-1. Simvastatin 10-21 beta-site APP cleaving enzyme 1 Mus musculus 126-157 28337819-7 2017 The expression of PAI-1 mRNA is suppressed by simvastatin. Simvastatin 46-57 serpin family E member 1 Homo sapiens 18-23 28594406-4 2017 Additional administration of apoptotic cells with simvastatin further enhanced the efferocytic ability of alveolar macrophages and PPARgamma activity, and induced hepatocyte growth factor and interleukin-10 expression, in alveolar macrophages and lung tissue. Simvastatin 50-61 peroxisome proliferator activated receptor gamma Mus musculus 131-140 28161429-0 2017 mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs. Simvastatin 95-106 vascular cell adhesion molecule 1 Homo sapiens 63-69 28161429-8 2017 Results of western blot showed SIM post-treatment increased significantly phosphor-eNOS (Ser1177) expression but no total eNOS expression. Simvastatin 31-34 nitric oxide synthase 3 Homo sapiens 83-87 27168098-6 2017 The measures are illustrated using examples of testing for HLA-B*5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (*5) associated with simvastatin-induced adverse events. Simvastatin 165-176 solute carrier organic anion transporter family member 1B1 Homo sapiens 124-131 27856999-0 2017 Simvastatin Alleviates Pathology in a Rat Model of Preeclampsia Involving ERK/MAPK Pathway. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 74-77 27856999-6 2017 Interestingly, simvastatin treatment significantly increased VEGF and IL-10 levels while decreased sFlt-1, TNF-alpha, and MDA levels compared to the untreated l-NAME group. Simvastatin 15-26 vascular endothelial growth factor A Rattus norvegicus 61-65 27856999-6 2017 Interestingly, simvastatin treatment significantly increased VEGF and IL-10 levels while decreased sFlt-1, TNF-alpha, and MDA levels compared to the untreated l-NAME group. Simvastatin 15-26 interleukin 10 Rattus norvegicus 70-75 27856999-6 2017 Interestingly, simvastatin treatment significantly increased VEGF and IL-10 levels while decreased sFlt-1, TNF-alpha, and MDA levels compared to the untreated l-NAME group. Simvastatin 15-26 tumor necrosis factor Rattus norvegicus 107-116 27856999-7 2017 Moreover, simvastatin treatment significantly upregulated protein expression of placental p-extracellular signal-regulated kinase (ERK1), p-p38 mitogen-activated protein kinase (MAPK), p-c-Jun N-terminal kinase, and p-protein kinase B compared to untreated l-NAME control. Simvastatin 10-21 mitogen activated protein kinase 3 Rattus norvegicus 131-135 27856999-8 2017 These results suggest that simvastatin treatment restores angiogenic balance and ameliorates inflammation and oxidative stress in a rat model of PE involving ERK/MAPK pathway. Simvastatin 27-38 Eph receptor B1 Rattus norvegicus 158-161 28594406-4 2017 Additional administration of apoptotic cells with simvastatin further enhanced the efferocytic ability of alveolar macrophages and PPARgamma activity, and induced hepatocyte growth factor and interleukin-10 expression, in alveolar macrophages and lung tissue. Simvastatin 50-61 hepatocyte growth factor Mus musculus 163-187 28594406-4 2017 Additional administration of apoptotic cells with simvastatin further enhanced the efferocytic ability of alveolar macrophages and PPARgamma activity, and induced hepatocyte growth factor and interleukin-10 expression, in alveolar macrophages and lung tissue. Simvastatin 50-61 interleukin 10 Mus musculus 192-206 28242047-5 2017 METHODS: Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose simvastatin twice daily for 3 days. Simvastatin 97-108 apolipoprotein A-I Mus musculus 29-46 28242047-5 2017 METHODS: Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose simvastatin twice daily for 3 days. Simvastatin 97-108 apolipoprotein A-I Mus musculus 48-53 27722854-3 2017 This study evaluated the pharmacokinetic profile of simvastatin (a CYP3A4 substrate) before and 1 week after a single dose of sarilumab (a human monoclonal antibody [mAb] blocking the IL-6Ralpha) in patients with RA, to assess potential interaction. Simvastatin 52-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 67-73 28188410-0 2017 Simvastatin Inhibits IL-1beta-Induced Apoptosis and Extracellular Matrix Degradation by Suppressing the NF-kB and MAPK Pathways in Nucleus Pulposus Cells. Simvastatin 0-11 interleukin 1 beta Homo sapiens 21-29 28188410-9 2017 Our findings indicate that simvastatin considerably inhibited IL-1beta-induced apoptosis in NP cells. Simvastatin 27-38 interleukin 1 beta Homo sapiens 62-70 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 interleukin 1 beta Homo sapiens 42-50 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 matrix metallopeptidase 3 Homo sapiens 74-79 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 matrix metallopeptidase 13 Homo sapiens 81-87 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 89-97 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 ADAM metallopeptidase with thrombospondin type 1 motif 5 Homo sapiens 103-111 28188410-11 2017 In addition, simvastatin considerably suppressed the nuclear translocation and activation of nuclear factor-kappa B (NF-KB) by inhibiting p65 phosphorylation and translocation and blocking inhibitor kB-alpha degradation. Simvastatin 13-24 RELA proto-oncogene, NF-kB subunit Homo sapiens 138-141 28820400-7 2017 The RhoA-inhibitor simvastatin relaxed the uterus contractions, although its inhibitory effects were not followed by the alteration of RhoA. Simvastatin 19-30 ras homolog family member A Rattus norvegicus 4-8 28174051-0 2017 Simvastatin Protects Human Melanocytes from H2O2-Induced Oxidative Stress by Activating Nrf2. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 88-92 28174051-6 2017 Furthermore, we found that simvastatin promoted the activation of nuclear erythroid 2-related factor (Nrf2) and that knockdown of Nrf2 abolished the protective effect of simvastatin against H2O2-induced oxidative damage. Simvastatin 27-38 NFE2 like bZIP transcription factor 2 Homo sapiens 102-106 28174051-6 2017 Furthermore, we found that simvastatin promoted the activation of nuclear erythroid 2-related factor (Nrf2) and that knockdown of Nrf2 abolished the protective effect of simvastatin against H2O2-induced oxidative damage. Simvastatin 170-181 NFE2 like bZIP transcription factor 2 Homo sapiens 130-134 28174051-7 2017 More importantly, the mutual enhancement between mitogen-activated protein kinase pathways and p62 contributed to simvastatin-induced Nrf2 activation in melanocytes. Simvastatin 114-125 nucleoporin 62 Homo sapiens 95-98 28174051-7 2017 More importantly, the mutual enhancement between mitogen-activated protein kinase pathways and p62 contributed to simvastatin-induced Nrf2 activation in melanocytes. Simvastatin 114-125 NFE2 like bZIP transcription factor 2 Homo sapiens 134-138 28174051-9 2017 Taken together, our results show that simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2, thus supporting simvastatin as a potential therapeutic agent for vitiligo. Simvastatin 38-49 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 28174051-9 2017 Taken together, our results show that simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2, thus supporting simvastatin as a potential therapeutic agent for vitiligo. Simvastatin 148-159 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 28539670-0 2017 Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice. Simvastatin 0-11 histocompatibility 40 Mus musculus 69-73 28665194-7 2017 In tissue, TNF-alpha (p < 0.01) and HIF-1alpha (p < 0.05) levels were increased in the simvastatin + LPS and LPS groups. Simvastatin 93-104 tumor necrosis factor Rattus norvegicus 11-20 28665194-7 2017 In tissue, TNF-alpha (p < 0.01) and HIF-1alpha (p < 0.05) levels were increased in the simvastatin + LPS and LPS groups. Simvastatin 93-104 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 39-49 28665194-9 2017 Ghrelin immunoreactivity was lower in the LPS group (p < 0.05) and higher in the simvastatin + LPS group than in the LPS group (p < 0.01). Simvastatin 84-95 ghrelin and obestatin prepropeptide Rattus norvegicus 0-7 28665194-12 2017 We observed that pretreatment of simvastatin caused favorable changes on ghrelin and TBARS levels in rats with sepsis. Simvastatin 33-44 ghrelin and obestatin prepropeptide Rattus norvegicus 73-80 28553143-11 2017 CONCLUSION: Oral treatment with simvastatin increased the release of IL-10 and reduced the MMP-9 in ligature-induced periodontitis model in rats. Simvastatin 32-43 matrix metallopeptidase 9 Rattus norvegicus 91-96 28553143-1 2017 PURPOSE: The aim of this study was to evaluate the effect of simvastatin on the synthesis of cytokines TNF-alpha and IL-10 and metalloproteinase (MMPs) 2 and 9 in a rat model of ligature-induced periodontitis. Simvastatin 61-72 tumor necrosis factor Rattus norvegicus 103-112 28553143-1 2017 PURPOSE: The aim of this study was to evaluate the effect of simvastatin on the synthesis of cytokines TNF-alpha and IL-10 and metalloproteinase (MMPs) 2 and 9 in a rat model of ligature-induced periodontitis. Simvastatin 61-72 interleukin 10 Rattus norvegicus 117-144 28378586-0 2017 Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice. Simvastatin 65-76 CD36 molecule Mus musculus 85-88 28553143-9 2017 However, IL-10 was upregulated in simvastatin-treated animals (1.8-fold increase) in comparison with the vehicle-treated group (p<0.05). Simvastatin 34-45 interleukin 10 Rattus norvegicus 9-14 28553143-10 2017 Simvastatin reduced the gingival levels of MMP-9 (64.3%) in comparison with vehicle-treated samples (p<0.05). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 43-48 28553143-11 2017 CONCLUSION: Oral treatment with simvastatin increased the release of IL-10 and reduced the MMP-9 in ligature-induced periodontitis model in rats. Simvastatin 32-43 interleukin 10 Rattus norvegicus 69-74 28613211-4 2017 This study was conducted to explore the effects of simvastatin and retinoic acid receptor-related orphan receptor alpha (RORalpha) ligands on apoptosis in human acute monocytic leukemia (THP-1) macrophage cells. Simvastatin 51-62 GLI family zinc finger 2 Homo sapiens 187-192 28613211-7 2017 RESULTS: We observed that simvastatin and both RORalpha ligands had a tendency to decrease THP-1 macrophage cell viability in culture. Simvastatin 26-37 GLI family zinc finger 2 Homo sapiens 91-96 28613211-9 2017 However, this negative effect of simvastatin seemed to be partly prevented by RORalpha ligands. Simvastatin 33-44 RAR related orphan receptor A Homo sapiens 78-86 28291866-1 2017 Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. Simvastatin 175-186 component of oligomeric golgi complex 2 Homo sapiens 136-141 27734117-0 2017 IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes. Simvastatin 15-26 insulin-like growth factor 1 Mus musculus 0-5 27734117-4 2017 The aims of the study were to investigate mechanisms of impaired AKT phosphorylation by simvastatin and to assess effects of IGF-1 on simvastatin-induced myotoxicity in C2C12 myotubes. Simvastatin 88-99 thymoma viral proto-oncogene 1 Mus musculus 65-68 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 44-55 insulin-like growth factor 1 Mus musculus 114-119 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 44-55 thymoma viral proto-oncogene 1 Mus musculus 120-123 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 88-99 insulin-like growth factor 1 Mus musculus 72-77 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 88-99 insulin-like growth factor 1 Mus musculus 114-119 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 88-99 thymoma viral proto-oncogene 1 Mus musculus 120-123 27734117-6 2017 Simvastatin inhibited AKT S473 phosphorylation, indicating reduced activity of mTORC2. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 22-25 27734117-6 2017 Simvastatin inhibited AKT S473 phosphorylation, indicating reduced activity of mTORC2. Simvastatin 0-11 CREB regulated transcription coactivator 2 Mus musculus 79-85 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 thymoma viral proto-oncogene 1 Mus musculus 49-52 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 insulin-like growth factor 1 Mus musculus 77-82 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 insulin-like growth factor I receptor Mus musculus 121-127 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 insulin-like growth factor 1 Mus musculus 121-126 27734117-8 2017 Nevertheless, simvastatin-induced myotoxicity could be at least partially prevented by IGF-1. Simvastatin 14-25 insulin-like growth factor 1 Mus musculus 87-92 27734117-13 2017 IGF-1 can prevent simvastatin-associated cytotoxicity and metabolic effects on C2C12 cells. Simvastatin 18-29 insulin-like growth factor 1 Mus musculus 0-5 26453564-9 2017 The serum MPO level in the model group was signifificantly higher than that in the control group (P<0.05), which was signifificantly lower in XSC groups as well as simvastatin group (P<0.05 or P<0.01), and no difference was found between XSC groups and simvastatin group (P>0.05). Simvastatin 167-178 myeloperoxidase Oryctolagus cuniculus 10-13 26453564-9 2017 The serum MPO level in the model group was signifificantly higher than that in the control group (P<0.05), which was signifificantly lower in XSC groups as well as simvastatin group (P<0.05 or P<0.01), and no difference was found between XSC groups and simvastatin group (P>0.05). Simvastatin 262-273 myeloperoxidase Oryctolagus cuniculus 10-13 28089685-5 2017 The model incorporated OATP-mediated clearance (CLint,T) for simvastatin and simvastatin acid to successfully describe the pharmacokinetic profiles of either analyte in the absence or presence of LCZ696. Simvastatin 61-72 solute carrier organic anion transporter family member 1A2 Homo sapiens 23-27 28220272-5 2017 Inhibition of Rac1 geranylgeranylation with simvastatin or GGTI-2147, significantly attenuated HG-induced p53 activation, suggesting requisite roles for this signaling step in HG-mediated effects on beta-cells. Simvastatin 44-55 Rac family small GTPase 1 Rattus norvegicus 14-18 28220272-5 2017 Inhibition of Rac1 geranylgeranylation with simvastatin or GGTI-2147, significantly attenuated HG-induced p53 activation, suggesting requisite roles for this signaling step in HG-mediated effects on beta-cells. Simvastatin 44-55 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 106-109 28369718-6 2017 Treatment with simvastatin resulted in a significant reduction in the frequency of pain (P = 0 0003), oral analgesic use (P = 0 003) and circulating hs-CRP (P = 0 003), soluble (s)E-selectin (P = 0 01), sICAM-1 (P = 0 02), sICAM-3 (P = 0 02) and sVEGF (P = 0 01). Simvastatin 15-26 selectin E Homo sapiens 180-190 26984935-10 2017 CONCLUSION: LEPR Q223R polymorphism, but not LEP G2548A, could modulate the efficacy of simvastatin in Chinese patients with primary hyperlipidemia. Simvastatin 88-99 leptin receptor Homo sapiens 12-16 26984935-10 2017 CONCLUSION: LEPR Q223R polymorphism, but not LEP G2548A, could modulate the efficacy of simvastatin in Chinese patients with primary hyperlipidemia. Simvastatin 88-99 leptin Homo sapiens 12-15 28291866-1 2017 Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. Simvastatin 201-212 component of oligomeric golgi complex 2 Homo sapiens 136-141 28089735-0 2017 Effects of simvastatin on CAT-1-mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lines (TR-iBRB). Simvastatin 11-22 solute carrier family 7 member 1 Rattus norvegicus 26-31 28291866-10 2017 Patients with LDL-C values less than 30 mg/dL (median, 25 mg/dL; interquartile range, 21-27 mg/dL) at 1 month were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C values, and were more likely older, male, nonwhite, diabetic, overweight, statin naive, and presenting with a first myocardial infarction. Simvastatin 151-162 component of oligomeric golgi complex 2 Homo sapiens 14-19 28089735-7 2017 Simvastatin pretreatment elevated [3H]l-arginine uptake, the expression levels of CAT-1 and eNOS mRNA, and NO production under high-glucose conditions. Simvastatin 0-11 solute carrier family 7 member 1 Rattus norvegicus 82-87 28089735-7 2017 Simvastatin pretreatment elevated [3H]l-arginine uptake, the expression levels of CAT-1 and eNOS mRNA, and NO production under high-glucose conditions. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 92-96 27003335-8 2017 Treatment with simvastatin significantly attenuated LPS-stimulated production of IL-1beta, IL-6, VCAM-1 and ICAM-1 (P < 0.05). Simvastatin 15-26 interleukin 1 beta Homo sapiens 81-89 28089735-9 2017 CONCLUSION: Our results suggest that, in the presence of high-glucose levels, increased l-arginine uptake due to simvastatin treatment was associated with increased CAT-1 and eNOS mRNA levels, leading to higher NO production in TR-iBRB cells. Simvastatin 113-124 solute carrier family 7 member 1 Rattus norvegicus 165-170 28089735-9 2017 CONCLUSION: Our results suggest that, in the presence of high-glucose levels, increased l-arginine uptake due to simvastatin treatment was associated with increased CAT-1 and eNOS mRNA levels, leading to higher NO production in TR-iBRB cells. Simvastatin 113-124 nitric oxide synthase 3 Rattus norvegicus 175-179 28521491-0 2017 HIF-1alpha acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia. Simvastatin 42-53 hypoxia inducible factor 1, alpha subunit Mus musculus 0-10 28550662-17 2017 Conclusions: Simvastatin inhibits the proliferation of Lewis cell line by inhibiting the activity of p38 and expression of p-p38. Simvastatin 13-24 mitogen-activated protein kinase 14 Mus musculus 125-128 28550662-18 2017 Meanwhile, simvastatin reduces the invasion and motility of Lewis cell line through down-regulating the expression of RhoA and MMP-2. Simvastatin 11-22 ras homolog family member A Mus musculus 118-122 28550662-18 2017 Meanwhile, simvastatin reduces the invasion and motility of Lewis cell line through down-regulating the expression of RhoA and MMP-2. Simvastatin 11-22 matrix metallopeptidase 2 Mus musculus 127-132 28263720-10 2017 We also found that MERTK (a proto-oncogene which is overexpressed in several malignancies) and PDGFRB (a member of the platelet-derived growth factor family whose expression is high in breast-cancer cells that have become resistant to endocrine therapy) were among the genes with a higher differential regulation by simvastatin. Simvastatin 316-327 MER proto-oncogene, tyrosine kinase Homo sapiens 19-24 28263720-10 2017 We also found that MERTK (a proto-oncogene which is overexpressed in several malignancies) and PDGFRB (a member of the platelet-derived growth factor family whose expression is high in breast-cancer cells that have become resistant to endocrine therapy) were among the genes with a higher differential regulation by simvastatin. Simvastatin 316-327 platelet derived growth factor receptor beta Homo sapiens 95-101 28550662-17 2017 Conclusions: Simvastatin inhibits the proliferation of Lewis cell line by inhibiting the activity of p38 and expression of p-p38. Simvastatin 13-24 mitogen-activated protein kinase 14 Mus musculus 101-104 28390432-0 2017 Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. Simvastatin 93-104 matrix metallopeptidase 9 Homo sapiens 10-36 28390432-2 2017 METHODS: We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Simvastatin 142-153 matrix metallopeptidase 9 Homo sapiens 44-48 28390432-9 2017 CONCLUSIONS: MMP9 rs3918242 TT genotype is associated with elevated serum TG and LDL-C, and enhanced LDL-C-lowering response upon simvastatin treatment in Chinese patients with CHD. Simvastatin 130-141 matrix metallopeptidase 9 Homo sapiens 13-17 28283529-10 2017 Th17 cells exhibited high ROCK activity that was inhibited by Y27632, KD025 or simvastatin; each also decreased IL-17 and IL-21 production by purified SLE T cells or Th17 cells. Simvastatin 79-90 Rho associated coiled-coil containing protein kinase 2 Homo sapiens 26-30 28192878-10 2017 Pretreatment with quercetin and simvastatin treatment in the hyperlipidemic groups significantly (P<0.05) increased AChE activity compared with the hyperlipidemic group. Simvastatin 32-43 acetylcholinesterase Rattus norvegicus 119-123 27003335-8 2017 Treatment with simvastatin significantly attenuated LPS-stimulated production of IL-1beta, IL-6, VCAM-1 and ICAM-1 (P < 0.05). Simvastatin 15-26 interleukin 6 Homo sapiens 91-95 27003335-8 2017 Treatment with simvastatin significantly attenuated LPS-stimulated production of IL-1beta, IL-6, VCAM-1 and ICAM-1 (P < 0.05). Simvastatin 15-26 vascular cell adhesion molecule 1 Homo sapiens 97-103 27003335-8 2017 Treatment with simvastatin significantly attenuated LPS-stimulated production of IL-1beta, IL-6, VCAM-1 and ICAM-1 (P < 0.05). Simvastatin 15-26 intercellular adhesion molecule 1 Homo sapiens 108-114 27003335-9 2017 Treatment with simvastatin decreased LPS-induced expression of p65 and phosphorylation of IkappaB and also significantly decreased the phosphorylation of p65 and IkappaB in the cytoplasm and the level of p65 in the nucleus (P < 0.05). Simvastatin 15-26 RELA proto-oncogene, NF-kB subunit Homo sapiens 63-66 27003335-9 2017 Treatment with simvastatin decreased LPS-induced expression of p65 and phosphorylation of IkappaB and also significantly decreased the phosphorylation of p65 and IkappaB in the cytoplasm and the level of p65 in the nucleus (P < 0.05). Simvastatin 15-26 RELA proto-oncogene, NF-kB subunit Homo sapiens 154-157 27003335-9 2017 Treatment with simvastatin decreased LPS-induced expression of p65 and phosphorylation of IkappaB and also significantly decreased the phosphorylation of p65 and IkappaB in the cytoplasm and the level of p65 in the nucleus (P < 0.05). Simvastatin 15-26 RELA proto-oncogene, NF-kB subunit Homo sapiens 154-157 28397043-1 2017 Simvastatin is a hypolipidemic drug that inhibits hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase to control elevated cholesterol, or hypercholesterolemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 50-102 28397043-9 2017 The results indicated that simvastatin significantly promoted heart systolic function and increased the level of uPA while simultaneously inhibited the expression of PAI-1 as compared with LPS group. Simvastatin 27-38 plasminogen activator, urokinase Rattus norvegicus 113-116 28397043-9 2017 The results indicated that simvastatin significantly promoted heart systolic function and increased the level of uPA while simultaneously inhibited the expression of PAI-1 as compared with LPS group. Simvastatin 27-38 serpin family E member 1 Rattus norvegicus 166-171 28122283-5 2017 Simvastatin improved the survival of aGVHD mice, attenuated the histopathological GVHD grades and plasma levels of Ang-2, and elevated the plasma levels of Ang-1 as well as the aortic endothelial levels of Ang-1 and Ang-2. Simvastatin 0-11 angiopoietin 1 Mus musculus 206-211 28122283-5 2017 Simvastatin improved the survival of aGVHD mice, attenuated the histopathological GVHD grades and plasma levels of Ang-2, and elevated the plasma levels of Ang-1 as well as the aortic endothelial levels of Ang-1 and Ang-2. Simvastatin 0-11 angiogenin, ribonuclease A family, member 2 Mus musculus 216-221 28122283-0 2017 Simvastatin ameliorates graft-vs-host disease by regulating angiopoietin-1 and angiopoietin-2 in a murine model. Simvastatin 0-11 angiopoietin 1 Mus musculus 60-74 28122283-6 2017 In summary, simvastatin represents a novel approach to combat GVHD by increasing Ang-1 production while suppressing Ang-2 release to stabilize endothelial cells. Simvastatin 12-23 angiopoietin 1 Mus musculus 81-86 28122283-0 2017 Simvastatin ameliorates graft-vs-host disease by regulating angiopoietin-1 and angiopoietin-2 in a murine model. Simvastatin 0-11 angiopoietin 2 Mus musculus 79-93 28122283-6 2017 In summary, simvastatin represents a novel approach to combat GVHD by increasing Ang-1 production while suppressing Ang-2 release to stabilize endothelial cells. Simvastatin 12-23 angiogenin, ribonuclease A family, member 2 Mus musculus 116-121 28122283-3 2017 In this study, we explored changes in Angiopoietin-1 (Ang-1) and Ang-2 expression in a aGVHD mouse model and determined whether simvastatin prevents GVHD through regulating Ang-1 and Ang-2 expression. Simvastatin 128-139 angiopoietin 1 Mus musculus 173-178 27662903-8 2017 Finally, simvastatin and the polyphenol quercetin potentiated the antiproliferative effect of insulin; on the contrary, the polyphenol resveratrol, the polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids, and folic acid were not able to change it. Simvastatin 9-20 insulin Homo sapiens 94-101 28122283-3 2017 In this study, we explored changes in Angiopoietin-1 (Ang-1) and Ang-2 expression in a aGVHD mouse model and determined whether simvastatin prevents GVHD through regulating Ang-1 and Ang-2 expression. Simvastatin 128-139 angiogenin, ribonuclease A family, member 2 Mus musculus 183-188 28122283-4 2017 In vitro simvastatin administration increased Ang-1 production and release but conversely inhibited Ang-2 release from EA.hy926 ECs. Simvastatin 9-20 angiopoietin 1 Mus musculus 46-51 28122283-4 2017 In vitro simvastatin administration increased Ang-1 production and release but conversely inhibited Ang-2 release from EA.hy926 ECs. Simvastatin 9-20 angiogenin, ribonuclease A family, member 2 Mus musculus 100-105 28122283-5 2017 Simvastatin improved the survival of aGVHD mice, attenuated the histopathological GVHD grades and plasma levels of Ang-2, and elevated the plasma levels of Ang-1 as well as the aortic endothelial levels of Ang-1 and Ang-2. Simvastatin 0-11 angiogenin, ribonuclease A family, member 2 Mus musculus 115-120 28122283-5 2017 Simvastatin improved the survival of aGVHD mice, attenuated the histopathological GVHD grades and plasma levels of Ang-2, and elevated the plasma levels of Ang-1 as well as the aortic endothelial levels of Ang-1 and Ang-2. Simvastatin 0-11 angiopoietin 1 Mus musculus 156-161 28029743-8 2017 RESULTS: Simvastatin attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling, plasma brain natriuretic peptide, ET-1, reactive oxygen species, and the NADPH oxidase 2 regulatory subunits, p47Phox and p67Phox , and upregulated pulmonary p-eNOS, NOx, and cGMP in both the early- and late-treated groups. Simvastatin 9-20 endothelin 1 Homo sapiens 135-139 28029743-8 2017 RESULTS: Simvastatin attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling, plasma brain natriuretic peptide, ET-1, reactive oxygen species, and the NADPH oxidase 2 regulatory subunits, p47Phox and p67Phox , and upregulated pulmonary p-eNOS, NOx, and cGMP in both the early- and late-treated groups. Simvastatin 9-20 cytochrome b-245 beta chain Homo sapiens 174-189 28029743-8 2017 RESULTS: Simvastatin attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling, plasma brain natriuretic peptide, ET-1, reactive oxygen species, and the NADPH oxidase 2 regulatory subunits, p47Phox and p67Phox , and upregulated pulmonary p-eNOS, NOx, and cGMP in both the early- and late-treated groups. Simvastatin 9-20 neutrophil cytosolic factor 1 Homo sapiens 211-218 28029743-8 2017 RESULTS: Simvastatin attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling, plasma brain natriuretic peptide, ET-1, reactive oxygen species, and the NADPH oxidase 2 regulatory subunits, p47Phox and p67Phox , and upregulated pulmonary p-eNOS, NOx, and cGMP in both the early- and late-treated groups. Simvastatin 9-20 neutrophil cytosolic factor 2 Homo sapiens 223-230 28350522-0 2017 The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Simvastatin 73-84 solute carrier organic anion transporter family member 1B1 Homo sapiens 18-25 28350522-0 2017 The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Simvastatin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 28350522-0 2017 The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Simvastatin 73-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-107 28350522-1 2017 AIM: To investigate the combined effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin and its active metabolite simvastatin acid, in relation to CYP3A4 inhibition. Simvastatin 99-110 solute carrier organic anion transporter family member 1B1 Homo sapiens 44-51 28350522-1 2017 AIM: To investigate the combined effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin and its active metabolite simvastatin acid, in relation to CYP3A4 inhibition. Simvastatin 99-110 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 28350522-1 2017 AIM: To investigate the combined effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin and its active metabolite simvastatin acid, in relation to CYP3A4 inhibition. Simvastatin 99-110 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 170-176 28350522-2 2017 METHODS: We conducted a single-dose pharmacokinetic study of simvastatin in 26 healthy volunteers screened for their SLCO1B1 c.521T>C and ABCB1 c.1236C>T-2677G>T-3435C>T genotypes, with and without amlodipine pretreatment. Simvastatin 61-72 solute carrier organic anion transporter family member 1B1 Homo sapiens 117-124 28350522-6 2017 CONCLUSION: Only SLCO1B1, not ABCB1 genotype, is likely to be associated with simvastatin-induced myopathy. Simvastatin 78-89 solute carrier organic anion transporter family member 1B1 Homo sapiens 17-24 28350522-7 2017 SLCO1B1 genotyping may be particularly beneficial in simvastatin users who are co-administered CYP3A4 inhibitors. Simvastatin 53-64 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-7 28350522-7 2017 SLCO1B1 genotyping may be particularly beneficial in simvastatin users who are co-administered CYP3A4 inhibitors. Simvastatin 53-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 95-101 27900797-15 2017 A sixfold induction of low density lipoprotein receptor mRNA was observed in ezetimibe and the combination with simvastatin versus control tumors. Simvastatin 112-123 low density lipoprotein receptor Mus musculus 23-55 28104473-6 2017 This association contributed to increased cellular uptake of simvastatin by C2C12 cells through lipoprotein lipase-mediated process, resulting in enhanced muscle toxicity in hyperlipidaemic conditions. Simvastatin 61-72 lipoprotein lipase Mus musculus 96-114 27782356-5 2017 METHODS: Ovalbumin (OVA)-sensitized and challenged mice were treated with simvastatin and sacrificed. Simvastatin 74-85 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 9-18 27782356-9 2017 Simvastatin increases autophagy-related protein Atg5, LC3B and Beclin1 expression and autophagosome formation in lung tissue. Simvastatin 0-11 autophagy related 5 Mus musculus 48-52 27782356-9 2017 Simvastatin increases autophagy-related protein Atg5, LC3B and Beclin1 expression and autophagosome formation in lung tissue. Simvastatin 0-11 microtubule-associated protein 1 light chain 3 beta Mus musculus 54-58 27782356-9 2017 Simvastatin increases autophagy-related protein Atg5, LC3B and Beclin1 expression and autophagosome formation in lung tissue. Simvastatin 0-11 beclin 1, autophagy related Mus musculus 63-70 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interferon gamma Mus musculus 59-75 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interferon gamma Mus musculus 77-86 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interleukin 4 Mus musculus 102-106 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interleukin 5 Mus musculus 108-112 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interleukin 13 Mus musculus 117-122 28680571-0 2017 Simvastatin-induced sphingosine 1-phosphate receptor 1 expression is KLF2-dependent in human lung endothelial cells. Simvastatin 0-11 sphingosine-1-phosphate receptor 1 Homo sapiens 20-54 28680571-5 2017 In vivo, transcription and expression of S1PR1 and KLF2 in mice lungs were detected by microarray profiling and immunoblotting after exposure to simvastatin (10 mg/kg). Simvastatin 145-156 sphingosine-1-phosphate receptor 1 Mus musculus 41-46 28680571-5 2017 In vivo, transcription and expression of S1PR1 and KLF2 in mice lungs were detected by microarray profiling and immunoblotting after exposure to simvastatin (10 mg/kg). Simvastatin 145-156 Kruppel-like factor 2 (lung) Mus musculus 51-55 28408819-0 2017 Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats. Simvastatin 0-11 bone morphogenetic protein 4 Rattus norvegicus 94-98 28408819-1 2017 The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) (PEG-b-PBLG50) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Simvastatin 69-80 bone morphogenetic protein 4 Rattus norvegicus 231-259 28408819-1 2017 The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) (PEG-b-PBLG50) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Simvastatin 69-80 bone morphogenetic protein 4 Rattus norvegicus 261-265 28408819-1 2017 The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) (PEG-b-PBLG50) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Simvastatin 69-80 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 267-283 28408819-4 2017 Both Sim and Sim/P pretreatment reduced intestinal oxidative damnification, restricted inflammatory harm, and downregulated the BMP4 and COX-2 expressions as compared to II/RI groups, while Sim/P remarkably improved this effect. Simvastatin 5-8 bone morphogenetic protein 4 Rattus norvegicus 128-132 28408819-4 2017 Both Sim and Sim/P pretreatment reduced intestinal oxidative damnification, restricted inflammatory harm, and downregulated the BMP4 and COX-2 expressions as compared to II/RI groups, while Sim/P remarkably improved this effect. Simvastatin 13-16 bone morphogenetic protein 4 Rattus norvegicus 128-132 28344327-5 2017 We confirmed that simvastatin caused the translocation of the small Rho GTPases RhoA, Cdc42, and Rac1/2/3 from cell membranes to the cytosol in U251 (glioblastoma), A549 (lung adenocarcinoma) and MDA-MB-231(breast cancer). Simvastatin 18-29 ras homolog family member A Homo sapiens 80-84 28344327-5 2017 We confirmed that simvastatin caused the translocation of the small Rho GTPases RhoA, Cdc42, and Rac1/2/3 from cell membranes to the cytosol in U251 (glioblastoma), A549 (lung adenocarcinoma) and MDA-MB-231(breast cancer). Simvastatin 18-29 cell division cycle 42 Homo sapiens 86-91 28344327-5 2017 We confirmed that simvastatin caused the translocation of the small Rho GTPases RhoA, Cdc42, and Rac1/2/3 from cell membranes to the cytosol in U251 (glioblastoma), A549 (lung adenocarcinoma) and MDA-MB-231(breast cancer). Simvastatin 18-29 Rac family small GTPase 1 Homo sapiens 97-105 28680571-7 2017 Both S1PR1 and KLF2 gene expression (mRNA, protein) were significantly increased by simvastatin in vitro and in vivo. Simvastatin 84-95 sphingosine-1-phosphate receptor 1 Homo sapiens 5-10 28680571-7 2017 Both S1PR1 and KLF2 gene expression (mRNA, protein) were significantly increased by simvastatin in vitro and in vivo. Simvastatin 84-95 Kruppel like factor 2 Homo sapiens 15-19 28680571-8 2017 S1PR1 promoter activity was significantly increased by simvastatin (P < 0.05), which was significantly attenuated by KLF2 silencing (siRNA). Simvastatin 55-66 sphingosine-1-phosphate receptor 1 Homo sapiens 0-5 28680571-9 2017 Simvastatin induced KLF2 recruitment to the S1PR1 promoter, and consequently, significantly augmented the effects of the S1PR1 agonist on EC barrier enhancement (P < 0.05), which was significantly attenuated by KLF2 silencing (P < 0.05). Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 20-24 28680571-9 2017 Simvastatin induced KLF2 recruitment to the S1PR1 promoter, and consequently, significantly augmented the effects of the S1PR1 agonist on EC barrier enhancement (P < 0.05), which was significantly attenuated by KLF2 silencing (P < 0.05). Simvastatin 0-11 sphingosine-1-phosphate receptor 1 Homo sapiens 44-49 28680571-9 2017 Simvastatin induced KLF2 recruitment to the S1PR1 promoter, and consequently, significantly augmented the effects of the S1PR1 agonist on EC barrier enhancement (P < 0.05), which was significantly attenuated by KLF2 silencing (P < 0.05). Simvastatin 0-11 sphingosine-1-phosphate receptor 1 Homo sapiens 121-126 28680571-0 2017 Simvastatin-induced sphingosine 1-phosphate receptor 1 expression is KLF2-dependent in human lung endothelial cells. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 69-73 28680571-9 2017 Simvastatin induced KLF2 recruitment to the S1PR1 promoter, and consequently, significantly augmented the effects of the S1PR1 agonist on EC barrier enhancement (P < 0.05), which was significantly attenuated by KLF2 silencing (P < 0.05). Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 214-218 28680571-10 2017 These results suggest that simvastatin upregulates S1PR1 transcription and expression via the transcription factor KLF2, and consequently augments the effects of S1PR1 agonists on preserving vascular barrier integrity. Simvastatin 27-38 sphingosine-1-phosphate receptor 1 Homo sapiens 51-56 28680571-3 2017 As Kruppel-like factor 2 (KLF2) serves as a critical regulator for cellular stress response in endothelial cells (EC), we hypothesized that simvastatin enhances endothelial barrier function via increasing expression of the barrier-promoting S1P receptor, S1PR1, via a KLF2-dependent mechanism. Simvastatin 140-151 Kruppel like factor 2 Homo sapiens 3-24 28680571-10 2017 These results suggest that simvastatin upregulates S1PR1 transcription and expression via the transcription factor KLF2, and consequently augments the effects of S1PR1 agonists on preserving vascular barrier integrity. Simvastatin 27-38 Kruppel like factor 2 Homo sapiens 115-119 28680571-10 2017 These results suggest that simvastatin upregulates S1PR1 transcription and expression via the transcription factor KLF2, and consequently augments the effects of S1PR1 agonists on preserving vascular barrier integrity. Simvastatin 27-38 sphingosine-1-phosphate receptor 1 Homo sapiens 162-167 28680571-3 2017 As Kruppel-like factor 2 (KLF2) serves as a critical regulator for cellular stress response in endothelial cells (EC), we hypothesized that simvastatin enhances endothelial barrier function via increasing expression of the barrier-promoting S1P receptor, S1PR1, via a KLF2-dependent mechanism. Simvastatin 140-151 Kruppel like factor 2 Homo sapiens 26-30 28680571-3 2017 As Kruppel-like factor 2 (KLF2) serves as a critical regulator for cellular stress response in endothelial cells (EC), we hypothesized that simvastatin enhances endothelial barrier function via increasing expression of the barrier-promoting S1P receptor, S1PR1, via a KLF2-dependent mechanism. Simvastatin 140-151 sphingosine-1-phosphate receptor 1 Homo sapiens 255-260 28680571-3 2017 As Kruppel-like factor 2 (KLF2) serves as a critical regulator for cellular stress response in endothelial cells (EC), we hypothesized that simvastatin enhances endothelial barrier function via increasing expression of the barrier-promoting S1P receptor, S1PR1, via a KLF2-dependent mechanism. Simvastatin 140-151 Kruppel like factor 2 Homo sapiens 268-272 28680571-4 2017 S1PR1 luciferase reporter promoter activity in human lung artery EC (HPAEC) was tested after simvastatin (5 muM), and S1PR1 and KLF2 protein expression detected by immunoblotting. Simvastatin 93-104 sphingosine-1-phosphate receptor 1 Homo sapiens 0-5 28300827-0 2017 Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Simvastatin 0-11 minichromosome maintenance complex component 7 Mus musculus 70-74 28300827-4 2017 Moreover, after a drug screening and further studies, we demonstrated that statin drug Simvastatin and Atorvastatin were able to inhibit MCM7 and RB expressions. Simvastatin 87-98 minichromosome maintenance complex component 7 Mus musculus 137-141 28288631-0 2017 Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials. Simvastatin 11-22 adiponectin, C1Q and collagen domain containing Homo sapiens 32-43 28287178-2 2017 In this study, simvastatin with both osteogenic and angiogenic activities was incorporated into the mesoporous hydroxyapatite microspheres (MHMs) synthesized through a microwave-assisted hydrothermal method using fructose 1,6-bisphosphate trisodium salt (FBP) as an organic phosphorous source. Simvastatin 15-26 ECB2 Homo sapiens 255-258 28288631-1 2017 BACKGROUND: Effects of simvastatin on serum level of adiponectin, a protein conferring benefits in both cardiovascular and metabolic system, are not fully determined. Simvastatin 23-34 adiponectin, C1Q and collagen domain containing Homo sapiens 53-64 28288631-10 2017 Subsequent meta-regression analyses indicated that treatment duration was a significant determinant of the effects of simvastatin treatment on serum adiponectin (Coefficient 0.04, p = 0.03). Simvastatin 118-129 adiponectin, C1Q and collagen domain containing Homo sapiens 149-160 28288631-11 2017 Subgroup analyses demonstrated that simvastatin treatment was associated with increased adiponectin in studies with treatment duration of 12 weeks (WMD: 3.65 mug/mL; p < 0.01), but not in studies with treatment duration of <= 8 weeks (WMD: -0.20 mug/mL; p = 0.38). Simvastatin 36-47 adiponectin, C1Q and collagen domain containing Homo sapiens 88-99 28288631-13 2017 CONCLUSIONS: Treatment with simvastatin of 12 weeks may increase the serum level adiponectin in patients at risk for cardiovascular diseases, but not for the short term treatment of <= 8 weeks. Simvastatin 28-39 adiponectin, C1Q and collagen domain containing Homo sapiens 81-92 28131832-0 2017 Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. Simvastatin 46-57 leptin Mus musculus 115-121 28131832-8 2017 Simvastatin treatment reduces the levels of glucose, lipid, leptin and neutrophil percentage, and improves airway inflammation and remodeling, which can be as a potential therapeutic target used in the treatment of obese asthma in humans. Simvastatin 0-11 leptin Homo sapiens 60-66 28131832-9 2017 Correlation analysis shows that there is positive correlation between neutrophil percentage and serum leptin/cholesterol level, which indicates that the therapeutic efficacy of simvastatin on obese asthma might be associated with improving dyslipidemia and decreasing leptin level. Simvastatin 177-188 leptin Mus musculus 102-108 28131832-9 2017 Correlation analysis shows that there is positive correlation between neutrophil percentage and serum leptin/cholesterol level, which indicates that the therapeutic efficacy of simvastatin on obese asthma might be associated with improving dyslipidemia and decreasing leptin level. Simvastatin 177-188 leptin Mus musculus 268-274 27862098-0 2017 Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells. Simvastatin 0-11 immunoglobulin kappa variable 6D-21 (non-functional) Homo sapiens 33-36 27513191-2 2017 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that crosses the blood-brain barrier, has been proposed for the treatment of SLOS based on in vitro and in vivo studies suggesting that simvastatin increases the expression of hypomorphic DHCR7 alleles. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 27513191-2 2017 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that crosses the blood-brain barrier, has been proposed for the treatment of SLOS based on in vitro and in vivo studies suggesting that simvastatin increases the expression of hypomorphic DHCR7 alleles. Simvastatin 0-11 7-dehydrocholesterol reductase Homo sapiens 261-266 27513191-2 2017 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that crosses the blood-brain barrier, has been proposed for the treatment of SLOS based on in vitro and in vivo studies suggesting that simvastatin increases the expression of hypomorphic DHCR7 alleles. Simvastatin 209-220 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 27984781-10 2017 Immunohistochemical analysis shows that simvastatin significantly augmented tissue VEGF expression from day 8 with increase in capillary density (CD31+) from day 14. Simvastatin 40-51 vascular endothelial growth factor A Mus musculus 83-87 27862098-3 2017 Using microarrays, we discovered up-regulation of annexin A10 (ANXA10) in PC-3 cells after simvastatin treatment. Simvastatin 91-102 annexin A10 Homo sapiens 50-61 27862098-3 2017 Using microarrays, we discovered up-regulation of annexin A10 (ANXA10) in PC-3 cells after simvastatin treatment. Simvastatin 91-102 annexin A10 Homo sapiens 63-69 27862098-3 2017 Using microarrays, we discovered up-regulation of annexin A10 (ANXA10) in PC-3 cells after simvastatin treatment. Simvastatin 91-102 chromobox 8 Homo sapiens 74-78 27862098-5 2017 In this study, we evaluated the effects of simvastatin on ANXA10 signaling in androgen-independent prostate cancer cells. Simvastatin 43-54 annexin A10 Homo sapiens 58-64 27513084-0 2017 Simvastatin Attenuates Acute Lung Injury via Regulating CDC42-PAK4 and Endothelial Microparticles. Simvastatin 0-11 cell division cycle 42 Mus musculus 56-61 27862098-9 2017 RESULTS: Simvastatin inhibited the proliferation, migration, and invasion of PC-3, LNCaP-LA, and DU145 cells. Simvastatin 9-20 chromobox 8 Homo sapiens 77-81 27513084-0 2017 Simvastatin Attenuates Acute Lung Injury via Regulating CDC42-PAK4 and Endothelial Microparticles. Simvastatin 0-11 p21 (RAC1) activated kinase 4 Mus musculus 62-66 27862098-10 2017 The expression level of ANXA10 was up-regulated by simvastatin in PC-3, LNCaP-LA, and DU145 cells. Simvastatin 51-62 annexin A10 Homo sapiens 24-30 27862098-10 2017 The expression level of ANXA10 was up-regulated by simvastatin in PC-3, LNCaP-LA, and DU145 cells. Simvastatin 51-62 chromobox 8 Homo sapiens 66-70 27862098-13 2017 In a nude mouse xenograft model of PC-3 cells, simvastatin induced both reduction in the tumor size and up-regulation of ANXA10 expression. Simvastatin 47-58 chromobox 8 Mus musculus 35-39 27862098-13 2017 In a nude mouse xenograft model of PC-3 cells, simvastatin induced both reduction in the tumor size and up-regulation of ANXA10 expression. Simvastatin 47-58 annexin A10 Mus musculus 121-127 27862098-16 2017 Expression of S100A4 was down-regulated by simvastatin. Simvastatin 43-54 S100 calcium binding protein A4 Homo sapiens 14-20 28150753-0 2017 Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Simvastatin 0-11 minichromosome maintenance complex component 7 Homo sapiens 60-64 27993857-5 2017 Here, the action of simvastatin in a murine model of chronic Chagas cardiomyopathy and the link with the production of the proresolving eicosanoid 15-epi-lipoxin A4, produced by 5-lipoxygenase, are evaluated. Simvastatin 20-31 arachidonate 5-lipoxygenase Mus musculus 178-192 28260878-0 2017 Effect of simvastatin on MMPs and TIMPs in cigarette smoke-induced rat COPD model. Simvastatin 10-21 matrix metallopeptidase 8 Rattus norvegicus 25-29 28260878-14 2017 Simvastatin significantly blocked upregulation of MMP-8 and -9 (P<0.01), but had no effect on MMP-12, TIMP-1 and TIMP-4 mRNA (P>0.05). Simvastatin 0-11 matrix metallopeptidase 8 Rattus norvegicus 50-62 28260878-15 2017 In addition, simvastatin significantly blocked cigarette smoke-induced MMP-8 and -9 protein synthesis, while it had no significant effect on TIMP-1 and -4 protein synthesis even in the presence of cigarette smoke. Simvastatin 13-24 matrix metallopeptidase 8 Rattus norvegicus 71-83 28260878-17 2017 Simvastatin partially blocked airway inflammation and MMP production and, thus, statins may modulate composition of the lung extracellular matrix. Simvastatin 0-11 matrix metallopeptidase 8 Rattus norvegicus 54-57 28225891-4 2017 After 60 days, both soy milk and simvastatin treatment prevented dyslipidemia, atherosclerotic lesion progression and left ventricle hypertrophy in LDLr-/- mice. Simvastatin 33-44 low density lipoprotein receptor Mus musculus 148-152 28225891-7 2017 On the other hand, simvastatin was more effective in preventing an increase in total cholesterol, LDLc and superoxide production in aorta, as well as CD40L both in aorta and left ventricle of LDLr-/-. Simvastatin 19-30 CD40 ligand Mus musculus 150-155 28225891-7 2017 On the other hand, simvastatin was more effective in preventing an increase in total cholesterol, LDLc and superoxide production in aorta, as well as CD40L both in aorta and left ventricle of LDLr-/-. Simvastatin 19-30 low density lipoprotein receptor Mus musculus 192-196 28207880-9 2017 However, Drp1, a marker of mitochondrial fission, was less in simvastatin treated mice, independent of exercise training, and there was a significant interaction between training and statin treatment (P<0.022) for LC3-II protein content, a marker of autophagy flux. Simvastatin 62-73 collapsin response mediator protein 1 Mus musculus 9-13 32095453-1 2017 Simvastatin is used to reduce plasma cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is primarily used to treat hypercholesterolemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-120 28230855-0 2017 Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 60-65 28230855-0 2017 Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Simvastatin 0-11 S-phase kinase associated protein 2 Homo sapiens 66-70 28230855-0 2017 Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Simvastatin 0-11 interferon alpha inducible protein 27 Homo sapiens 110-113 28230855-0 2017 Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 118-121 28230855-5 2017 In this study, we demonstrated simvastatin-induced G0/G1 arrest by inducing p21 and p27 accumulation in HepG2 and Hep3B cells. Simvastatin 31-42 H3 histone pseudogene 16 Homo sapiens 76-79 28230855-5 2017 In this study, we demonstrated simvastatin-induced G0/G1 arrest by inducing p21 and p27 accumulation in HepG2 and Hep3B cells. Simvastatin 31-42 interferon alpha inducible protein 27 Homo sapiens 84-87 28230855-6 2017 Simvastatin also promoted AMP-activated protein kinase (AMPK) activation, which induced p21 upregulation by increasing its transcription. Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 88-91 28230855-8 2017 Simvastatin decreased Skp2 expression at the transcriptional level, which resulted in p27 accumulation by preventing proteasomal degradation, an effect mediated by signal transducer and activator of transcription 3 (STAT3) inhibition. Simvastatin 0-11 S-phase kinase associated protein 2 Homo sapiens 22-26 28230855-8 2017 Simvastatin decreased Skp2 expression at the transcriptional level, which resulted in p27 accumulation by preventing proteasomal degradation, an effect mediated by signal transducer and activator of transcription 3 (STAT3) inhibition. Simvastatin 0-11 interferon alpha inducible protein 27 Homo sapiens 86-89 28230855-8 2017 Simvastatin decreased Skp2 expression at the transcriptional level, which resulted in p27 accumulation by preventing proteasomal degradation, an effect mediated by signal transducer and activator of transcription 3 (STAT3) inhibition. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 164-214 28230855-8 2017 Simvastatin decreased Skp2 expression at the transcriptional level, which resulted in p27 accumulation by preventing proteasomal degradation, an effect mediated by signal transducer and activator of transcription 3 (STAT3) inhibition. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 216-221 28230855-9 2017 Constitutive STAT3 activation maintained high-level Skp2 expression and lower level p27 expression and significantly prevented G0/G1 arrest in simvastatin-treated HCC cells. Simvastatin 143-154 signal transducer and activator of transcription 3 Homo sapiens 13-18 28230855-10 2017 Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation. Simvastatin 21-32 S-phase kinase associated protein 2 Homo sapiens 87-91 28230855-10 2017 Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation. Simvastatin 21-32 H3 histone pseudogene 16 Homo sapiens 188-191 28230855-10 2017 Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation. Simvastatin 21-32 interferon alpha inducible protein 27 Homo sapiens 196-199 28230855-12 2017 Consistently, we found that simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. Simvastatin 28-39 H3 histone pseudogene 16 Homo sapiens 55-58 28230855-12 2017 Consistently, we found that simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. Simvastatin 28-39 interferon alpha inducible protein 27 Homo sapiens 63-66 28230855-12 2017 Consistently, we found that simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. Simvastatin 28-39 S-phase kinase associated protein 2 Homo sapiens 108-112 28230855-12 2017 Consistently, we found that simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. Simvastatin 28-39 signal transducer and activator of transcription 3 Homo sapiens 157-162 28230855-13 2017 Taken together, these findings are demonstrative of the existence of a novel pathway in which simvastatin induces G0/G1 arrest by upregulating p21 and p27 by activating AMPK and inhibiting the STAT3-Skp2 axis, respectively. Simvastatin 94-105 H3 histone pseudogene 16 Homo sapiens 143-146 28230855-13 2017 Taken together, these findings are demonstrative of the existence of a novel pathway in which simvastatin induces G0/G1 arrest by upregulating p21 and p27 by activating AMPK and inhibiting the STAT3-Skp2 axis, respectively. Simvastatin 94-105 interferon alpha inducible protein 27 Homo sapiens 151-154 28230855-13 2017 Taken together, these findings are demonstrative of the existence of a novel pathway in which simvastatin induces G0/G1 arrest by upregulating p21 and p27 by activating AMPK and inhibiting the STAT3-Skp2 axis, respectively. Simvastatin 94-105 signal transducer and activator of transcription 3 Homo sapiens 193-198 28230855-13 2017 Taken together, these findings are demonstrative of the existence of a novel pathway in which simvastatin induces G0/G1 arrest by upregulating p21 and p27 by activating AMPK and inhibiting the STAT3-Skp2 axis, respectively. Simvastatin 94-105 S-phase kinase associated protein 2 Homo sapiens 199-203 28212683-6 2017 RESULTS: Re-analysis of AD patient-level data from failed clinical trials suggested by trend that use of simvastatin may slow the progression of cognitive decline, and to a greater extent in ApoE4 homozygotes. Simvastatin 105-116 apolipoprotein E Homo sapiens 191-196 28150753-5 2017 Simvastatin, an agent for hypercholesterolemia treatment, activated the MCM7/p-RB/gammaH2AX axis and induced DNA damage in TamR cells, especially when combined with tamoxifen. Simvastatin 0-11 minichromosome maintenance complex component 7 Homo sapiens 72-76 28150753-5 2017 Simvastatin, an agent for hypercholesterolemia treatment, activated the MCM7/p-RB/gammaH2AX axis and induced DNA damage in TamR cells, especially when combined with tamoxifen. Simvastatin 0-11 RB transcriptional corepressor 1 Homo sapiens 77-81 28150753-7 2017 In conclusion, simvastatin may suppress TamR cell growth by inhibiting MCM7 and Rb and subsequently inducing DNA damage. Simvastatin 15-26 minichromosome maintenance complex component 7 Homo sapiens 71-75 27900571-0 2017 Erratum to: Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. Simvastatin 12-23 insulin Homo sapiens 56-63 28237480-9 2017 CONCLUSIONS: Simvastatin can inhibit the expressions of NF-kappaB, TLR4 and IL-1beta proteins in rats with cerebral hemorrhage, and protect neurons and reduce secondary inflammatory damages by down-regulating the above protein-mediated inflammatory responses. Simvastatin 13-24 toll-like receptor 4 Rattus norvegicus 67-71 28237480-9 2017 CONCLUSIONS: Simvastatin can inhibit the expressions of NF-kappaB, TLR4 and IL-1beta proteins in rats with cerebral hemorrhage, and protect neurons and reduce secondary inflammatory damages by down-regulating the above protein-mediated inflammatory responses. Simvastatin 13-24 interleukin 1 beta Rattus norvegicus 76-84 27925372-7 2017 In the next step, we tested whether RORalpha activity in THP-1 macrophages was influenced by the presence of simvastatin, a cholesterol lowering drug. Simvastatin 109-120 RAR related orphan receptor A Homo sapiens 36-44 27810576-12 2017 Slight stimulatory effects were found for musk xylene, nerol, isoeugenol, alpha-amylcinnamaldehyde, alpha-hexylcinnamaldehyde and simvastatin indicating Abcb4 substrate/competitive inhibitor properties of those compounds. Simvastatin 130-141 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Danio rerio 153-158 27406816-9 2017 TBI-induced neuronal apoptosis, microglia and astrocyte activation, and TNF-alpha expression in the microglia and astrocytes of the CA3 area of the hippocampus were significantly reduced by simvastatin treatment, particularly when 20 mg/kg was administered for 3 days. Simvastatin 190-201 tumor necrosis factor Rattus norvegicus 72-81 28456771-7 2017 Simvastatin treatment reduced the mRNA levels of interleukin-6 and interleukin-8 by approximately 50% in TNF-alpha-stimulated IEC-6 cells. Simvastatin 0-11 interleukin 6 Rattus norvegicus 49-62 28456771-7 2017 Simvastatin treatment reduced the mRNA levels of interleukin-6 and interleukin-8 by approximately 50% in TNF-alpha-stimulated IEC-6 cells. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 105-114 28456771-8 2017 Treatment with a combination of 50 ng/ml TNF-alpha and muM simvastatin decreased activation of Akt, IkappaBalpha, and nuclear factor-kappaB p65 level in IEC-6 cells. Simvastatin 59-70 AKT serine/threonine kinase 1 Rattus norvegicus 95-98 28456771-8 2017 Treatment with a combination of 50 ng/ml TNF-alpha and muM simvastatin decreased activation of Akt, IkappaBalpha, and nuclear factor-kappaB p65 level in IEC-6 cells. Simvastatin 59-70 NFKB inhibitor alpha Rattus norvegicus 100-112 28456771-8 2017 Treatment with a combination of 50 ng/ml TNF-alpha and muM simvastatin decreased activation of Akt, IkappaBalpha, and nuclear factor-kappaB p65 level in IEC-6 cells. Simvastatin 59-70 synaptotagmin 1 Rattus norvegicus 140-143 28456771-9 2017 By DCF-DA staining, intracellular reactive oxygen species (ROS) production was increased in TNF-alpha-stimulated cells, and treatment with simvastatin decreased the level of ROS. Simvastatin 139-150 tumor necrosis factor Rattus norvegicus 92-101 27629819-0 2017 Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRalpha signalling pathway in oxLDL-loaded macrophages. Simvastatin 0-11 NPC intracellular cholesterol transporter 1 Homo sapiens 21-25 27629819-0 2017 Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRalpha signalling pathway in oxLDL-loaded macrophages. Simvastatin 0-11 cytochrome P450 family 7 subfamily A member 1 Homo sapiens 82-88 27629819-0 2017 Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRalpha signalling pathway in oxLDL-loaded macrophages. Simvastatin 0-11 nuclear receptor subfamily 1 group H member 3 Homo sapiens 89-97 27629819-7 2017 It was determined that the reduction of lysosomal free cholesterol buildup by simvastatin was due to the up-regulation of Niemann-Pick C1 (NPC1), a lysosomal residing cholesterol transporter. Simvastatin 78-89 NPC intracellular cholesterol transporter 1 Homo sapiens 122-137 27629819-7 2017 It was determined that the reduction of lysosomal free cholesterol buildup by simvastatin was due to the up-regulation of Niemann-Pick C1 (NPC1), a lysosomal residing cholesterol transporter. Simvastatin 78-89 NPC intracellular cholesterol transporter 1 Homo sapiens 139-143 27406816-9 2017 TBI-induced neuronal apoptosis, microglia and astrocyte activation, and TNF-alpha expression in the microglia and astrocytes of the CA3 area of the hippocampus were significantly reduced by simvastatin treatment, particularly when 20 mg/kg was administered for 3 days. Simvastatin 190-201 carbonic anhydrase 3 Rattus norvegicus 132-135 27406816-10 2017 CONCLUSIONS: Intraperitoneal injection of simvastatin attenuated TBI in rats during the acute stage by reducing neuronal apoptosis, microglia, and TNF-alpha expression, thereby resulting in a reduction of depressive-like behavior. Simvastatin 42-53 tumor necrosis factor Rattus norvegicus 147-156 27840243-0 2017 Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1 axis. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 120-129 27840243-0 2017 Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1 axis. Simvastatin 0-11 growth factor independent 1 transcriptional repressor Homo sapiens 130-135 27840243-5 2017 Further investigation found that simvastatin reversed the TAM-mediated down-regulation of Gfi-1 and up-regulation of CTGF and HMGB1. Simvastatin 33-44 growth factor independent 1 transcriptional repressor Homo sapiens 90-95 27840243-5 2017 Further investigation found that simvastatin reversed the TAM-mediated down-regulation of Gfi-1 and up-regulation of CTGF and HMGB1. Simvastatin 33-44 cellular communication network factor 2 Homo sapiens 117-121 27840243-5 2017 Further investigation found that simvastatin reversed the TAM-mediated down-regulation of Gfi-1 and up-regulation of CTGF and HMGB1. Simvastatin 33-44 high mobility group box 1 Homo sapiens 126-131 27840243-6 2017 Simvastatin induced Gfi-1 expression, which increased the sensitivity of PDAC cells to gemcitabine by decreasing TGF-beta1 secretion by TAMs. Simvastatin 0-11 growth factor independent 1 transcriptional repressor Homo sapiens 20-25 27840243-6 2017 Simvastatin induced Gfi-1 expression, which increased the sensitivity of PDAC cells to gemcitabine by decreasing TGF-beta1 secretion by TAMs. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 113-122 27840243-8 2017 Simvastatin also reversed the effects of gemcitabine on the expression of TGF-beta1 and Gfi-1 and reduced the resistance of PDAC to gemcitabine in vivo. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 74-83 27840243-8 2017 Simvastatin also reversed the effects of gemcitabine on the expression of TGF-beta1 and Gfi-1 and reduced the resistance of PDAC to gemcitabine in vivo. Simvastatin 0-11 growth factor independent 1 transcriptional repressor Homo sapiens 88-93 27840243-9 2017 These results provide the first evidence that simvastatin attenuates the TAM-mediated gemcitabine resistance of PDAC by blocking the TGF-beta1/Gfi-1 axis. Simvastatin 46-57 transforming growth factor beta 1 Homo sapiens 133-142 27840243-9 2017 These results provide the first evidence that simvastatin attenuates the TAM-mediated gemcitabine resistance of PDAC by blocking the TGF-beta1/Gfi-1 axis. Simvastatin 46-57 growth factor independent 1 transcriptional repressor Homo sapiens 143-148 27687042-0 2017 Simvastatin enhances the hippocampal klotho in a rat model of streptozotocin-induced cognitive decline. Simvastatin 0-11 Klotho Rattus norvegicus 37-43 27687042-5 2017 We examined the effect of simvastatin (5mg/kg, daily for 3weeks) on hippocampal klotho and MnSOD expression in the cognitive declined animal model induced by intracerebroventricular (ICV)-streptozotocin (STZ) administration. Simvastatin 26-37 Klotho Rattus norvegicus 80-86 27887848-0 2017 Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer. Simvastatin 0-11 erb-b2 receptor tyrosine kinase 2 Homo sapiens 43-47 27687042-11 2017 Our current study indicates that klotho upregulation may be a neuroprotective mechanism of simvastatin against cognitive decline in AD. Simvastatin 91-102 Klotho Rattus norvegicus 33-39 27887848-5 2017 Furthermore, simvastatin markedly inhibited tumor angiogenesis even in the presence of heregulin (HRG)-beta1 (a HER2 co-activator) pretreatment in HER2+ tumor cells. Simvastatin 13-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 112-116 27887848-5 2017 Furthermore, simvastatin markedly inhibited tumor angiogenesis even in the presence of heregulin (HRG)-beta1 (a HER2 co-activator) pretreatment in HER2+ tumor cells. Simvastatin 13-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-151 27887848-6 2017 Mechanistic investigation showed that simvastatin significantly abrogated HER2-induced tumor angiogenesis by inhibiting VEGF secretion. Simvastatin 38-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 74-78 27887848-6 2017 Mechanistic investigation showed that simvastatin significantly abrogated HER2-induced tumor angiogenesis by inhibiting VEGF secretion. Simvastatin 38-49 vascular endothelial growth factor A Homo sapiens 120-124 27887848-7 2017 Together, these results provide a novel mechanism underlying the simvastatin-induced inhibition of tumor angiogenesis through regulating HER2/VEGF axis. Simvastatin 65-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 137-141 27887848-7 2017 Together, these results provide a novel mechanism underlying the simvastatin-induced inhibition of tumor angiogenesis through regulating HER2/VEGF axis. Simvastatin 65-76 vascular endothelial growth factor A Homo sapiens 142-146 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 troponin T2, cardiac type Homo sapiens 48-52 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 tumor necrosis factor Homo sapiens 61-70 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 interleukin 6 Homo sapiens 72-76 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 82-86 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 beclin 1 Homo sapiens 145-153 28968609-8 2017 RESULTS: We report that exposure of pancreatic beta-cells to Simvastatin, an inhibitor of mevalonic acid (MVA) biosynthesis, and its downstream isoprenoid derivatives, or FTI-277, an inhibitor of farnesyltransferase that mediates farnesylation of lamins, leads to activation of caspase 3 and lamin B degradation. Simvastatin 61-72 caspase 3 Homo sapiens 278-287 29445744-0 2017 Simvastatin Ameliorates PAK4 Inhibitor-Induced Gut and Lung Injury. Simvastatin 0-11 p21 (RAC1) activated kinase 4 Rattus norvegicus 24-28 28930754-1 2017 BACKGROUND/AIMS: The 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitor simvastatin has been shown to trigger apoptosis of several cell types. Simvastatin 90-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-79 28930754-9 2017 RESULTS: A 48 h exposure of human erythrocytes to simvastatin (1 microg/ml) significantly decreased the forward scatter, significantly augmented the percentage of annexin-V-binding cells, significantly increased Fluo3-fluorescence, and significantly enhanced DCFDA fluorescence. Simvastatin 50-61 annexin A5 Homo sapiens 163-172 28930754-11 2017 The effect of simvastatin on annexin-V-binding was significantly blunted by removal of extracellular Ca2+ and by addition of SB203580 (2 microM). Simvastatin 14-25 annexin A5 Homo sapiens 29-38 29445744-9 2017 Therefore, in this lung injury process induced by PAK4 inhibitor, the protective effects of simvastatin were reflected by intestinal mucosal barrier protection, inflammatory response regulation via CD11c+ cells, and cytoskeleton stabilization. Simvastatin 92-103 p21 (RAC1) activated kinase 4 Homo sapiens 50-54 29445744-9 2017 Therefore, in this lung injury process induced by PAK4 inhibitor, the protective effects of simvastatin were reflected by intestinal mucosal barrier protection, inflammatory response regulation via CD11c+ cells, and cytoskeleton stabilization. Simvastatin 92-103 integrin subunit alpha X Homo sapiens 198-203 28968609-9 2017 Furthermore, Simvastatin-treatment increased activation of p38MAPK (a stress kinase) and inhibited ERK1/2 (regulator of cell proliferation). Simvastatin 13-24 mitogen-activated protein kinase 3 Homo sapiens 99-105 28682217-8 2017 After 2 hr SIM treatment in 24 hpf embryos, transcription of ppars, pxr, and ahr was up-regulated, while after 80 hr mRNA levels of pxr and ahr were decreased with no marked changes in ppars. Simvastatin 11-14 nuclear receptor subfamily 1, group I, member 2 Danio rerio 68-71 27665951-0 2017 Inhibition of inducible nitric oxide synthase (iNOS) by simvastatin attenuates cardiac hypertrophy in rats. Simvastatin 56-67 nitric oxide synthase 2 Rattus norvegicus 14-45 27665951-0 2017 Inhibition of inducible nitric oxide synthase (iNOS) by simvastatin attenuates cardiac hypertrophy in rats. Simvastatin 56-67 nitric oxide synthase 2 Rattus norvegicus 47-51 27545498-1 2017 BACKGROUND & AIMS: The transcription factor Kruppel-like factor 2 (KLF2), inducible by simvastatin, confers endothelial vasoprotection. Simvastatin 91-102 Kruppel like factor 2 Homo sapiens 48-69 27545498-1 2017 BACKGROUND & AIMS: The transcription factor Kruppel-like factor 2 (KLF2), inducible by simvastatin, confers endothelial vasoprotection. Simvastatin 91-102 Kruppel like factor 2 Homo sapiens 71-75 27545498-8 2017 Simvastatin pretreatment maintained autophagy (through the upregulation of rab7), resulting in increased KLF2, improved cell viability, and ameliorated hepatic damage and microvascular function. Simvastatin 0-11 RAB7B, member RAS oncogene family Homo sapiens 75-79 27545498-8 2017 Simvastatin pretreatment maintained autophagy (through the upregulation of rab7), resulting in increased KLF2, improved cell viability, and ameliorated hepatic damage and microvascular function. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 105-109 27545498-10 2017 These results help understanding the mechanisms of protection conferred by KLF2-inducers, such as simvastatin, in hepatic vascular disorders. Simvastatin 98-109 Kruppel like factor 2 Homo sapiens 75-79 29617547-1 2017 Simvastatin (SIM) accelerates new bone formation both in vitro and In Vivo by enhancing the expression of recombinant human bone morphogenetic protein-2 (rhBMP-2). Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 124-152 28095523-10 2017 Simvastatin significantly increased osteogenic differentiation of human BMSCs on the SLA titanium surface in the ED-OS medium, and the promoting effects of simvastatin corresponded with the increasing of BMP-2 gene expression on the SLA titanium surface in ED-OS-SIM culture medium. Simvastatin 0-11 Src like adaptor Homo sapiens 85-88 28095523-10 2017 Simvastatin significantly increased osteogenic differentiation of human BMSCs on the SLA titanium surface in the ED-OS medium, and the promoting effects of simvastatin corresponded with the increasing of BMP-2 gene expression on the SLA titanium surface in ED-OS-SIM culture medium. Simvastatin 0-11 Src like adaptor Homo sapiens 233-236 29056268-4 2017 Shortly after simvastatin treatment, patient developed severe myalgias in the proximal lower and upper extremities; and serum CK increased to 317 U/L. Simvastatin 14-25 cytidine/uridine monophosphate kinase 1 Homo sapiens 126-128 28682217-8 2017 After 2 hr SIM treatment in 24 hpf embryos, transcription of ppars, pxr, and ahr was up-regulated, while after 80 hr mRNA levels of pxr and ahr were decreased with no marked changes in ppars. Simvastatin 11-14 nuclear receptor subfamily 1, group I, member 2 Danio rerio 132-135 29732238-0 2017 Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Simvastatin 36-47 insulin Homo sapiens 60-67 27914033-4 2017 The aim of this study was to compare the effect of L-carnitine/simvastatin co-administration with that of simvastatin monotherapy on Lp(a) levels in subjects with mixed hyperlipidemia and elevated Lp(a) concentration. Simvastatin 63-74 lipoprotein(a) Homo sapiens 133-138 27914033-4 2017 The aim of this study was to compare the effect of L-carnitine/simvastatin co-administration with that of simvastatin monotherapy on Lp(a) levels in subjects with mixed hyperlipidemia and elevated Lp(a) concentration. Simvastatin 106-117 lipoprotein(a) Homo sapiens 133-138 27914033-7 2017 Lp(a) was significantly reduced in the L-carnitine/simvastatin group [-19.4%, from 52 (20-171) to 42 (15-102) mg/dL; p = 0.01], but not in the placebo/simvastatin group [-6.7%, from 56 (26-108) to 52 (27-93) mg/dL, p = NS versus baseline and p = 0.016 for the comparison between groups]. Simvastatin 51-62 lipoprotein(a) Homo sapiens 0-5 27914033-7 2017 Lp(a) was significantly reduced in the L-carnitine/simvastatin group [-19.4%, from 52 (20-171) to 42 (15-102) mg/dL; p = 0.01], but not in the placebo/simvastatin group [-6.7%, from 56 (26-108) to 52 (27-93) mg/dL, p = NS versus baseline and p = 0.016 for the comparison between groups]. Simvastatin 151-162 lipoprotein(a) Homo sapiens 0-5 27914033-9 2017 Co-administration of L-carnitine with simvastatin was associated with a significant, albeit modest, reduction in Lp(a) compared with simvastatin monotherapy in subjects with mixed hyperlipidemia and elevated baseline Lp(a) levels. Simvastatin 38-49 lipoprotein(a) Homo sapiens 113-118 27914033-9 2017 Co-administration of L-carnitine with simvastatin was associated with a significant, albeit modest, reduction in Lp(a) compared with simvastatin monotherapy in subjects with mixed hyperlipidemia and elevated baseline Lp(a) levels. Simvastatin 38-49 lipoprotein(a) Homo sapiens 217-222 29732238-9 2017 We identified initial signature of simvastatin-induced insulin resistance, including ethanolamine, hydroxylamine, hydroxycarbamate and isoleucine which, upon further replication and expansion, could be predictive biomarkers of individual susceptibility to simvastatin-induced new onset pre-type II diabetes mellitus. Simvastatin 35-46 insulin Homo sapiens 55-62 29732238-9 2017 We identified initial signature of simvastatin-induced insulin resistance, including ethanolamine, hydroxylamine, hydroxycarbamate and isoleucine which, upon further replication and expansion, could be predictive biomarkers of individual susceptibility to simvastatin-induced new onset pre-type II diabetes mellitus. Simvastatin 256-267 insulin Homo sapiens 55-62 29138670-11 2017 Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. Simvastatin 93-104 caspase 3 Rattus norvegicus 8-17 27799356-7 2017 Our findings suggest that simvastatin induces apoptosis in osteosarcoma cells via activation of AMPK and p38 MAPK, and that, in combination with other approaches, it holds therapeutic potential for osteosarcoma. Simvastatin 26-37 mitogen-activated protein kinase 14 Mus musculus 105-108 27799356-0 2017 Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity. Simvastatin 0-11 ras homolog family member A Mus musculus 67-71 27799356-0 2017 Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity. Simvastatin 0-11 mitogen-activated protein kinase 14 Mus musculus 77-80 27799356-5 2017 Inhibitors of AMPK or p38 MAPK attenuated the induction of apoptosis by simvastatin, whereas metformin enhanced this effect of simvastatin by further activation of AMPK. Simvastatin 72-83 mitogen-activated protein kinase 14 Mus musculus 22-30 27993685-5 2017 The present study observed the effect of simvastatin on Hcy-induced CRP expression in VSMCs and the molecular mechanisms. Simvastatin 41-52 C-reactive protein Rattus norvegicus 68-71 27879448-5 2017 Fasudil and simvastatin both significantly decreased the integrated iron density per mature lesion area in Ccm1+/-Msh2-/- mice, and in both models combined, compared with mice given placebo. Simvastatin 12-23 KRIT1, ankyrin repeat containing Mus musculus 107-111 29348789-0 2017 Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury through a KLF2-Dependent Mechanism in Rat. Simvastatin 49-60 Kruppel-like factor 2 Rattus norvegicus 116-120 29348789-9 2017 Simvastatin maintained the expression of KLF2 and its protective target genes (eNOS, TM, and HO-1), reduced oxidative stress, inhibited innate immune responses and inflammation, and increased the expression of Bcl-2/Bax to suppress hepatocyte apoptosis compared to DCD control group. Simvastatin 0-11 Kruppel-like factor 2 Rattus norvegicus 41-45 29348789-9 2017 Simvastatin maintained the expression of KLF2 and its protective target genes (eNOS, TM, and HO-1), reduced oxidative stress, inhibited innate immune responses and inflammation, and increased the expression of Bcl-2/Bax to suppress hepatocyte apoptosis compared to DCD control group. Simvastatin 0-11 BCL2, apoptosis regulator Rattus norvegicus 210-215 29348789-9 2017 Simvastatin maintained the expression of KLF2 and its protective target genes (eNOS, TM, and HO-1), reduced oxidative stress, inhibited innate immune responses and inflammation, and increased the expression of Bcl-2/Bax to suppress hepatocyte apoptosis compared to DCD control group. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Rattus norvegicus 216-219 29348789-10 2017 Conclusion: Pretreatment of DCD donors with simvastatin improves DCD livers" functional recovery probably through a KLF2-dependent mechanism. Simvastatin 44-55 Kruppel-like factor 2 Rattus norvegicus 116-120 27993685-0 2017 Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells. Simvastatin 0-11 C-reactive protein Rattus norvegicus 42-45 27993685-0 2017 Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells. Simvastatin 0-11 mitogen activated protein kinase 14 Rattus norvegicus 86-89 27993685-0 2017 Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells. Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 90-96 27993685-6 2017 The in vitro experiments revealed that pretreatment of VSMCs with simvastatin decreased Hcy-induced mRNA and protein expression of CRP in a concentration-dependent fashion. Simvastatin 66-77 C-reactive protein Rattus norvegicus 131-134 27993685-7 2017 The in vivo results showed that simvastatin not only inhibited CRP expression in the vessel walls in mRNA and protein levels, but also reduced the circulating CRP level in hyperhomocysteinemic rats. Simvastatin 32-43 C-reactive protein Rattus norvegicus 63-66 27993685-7 2017 The in vivo results showed that simvastatin not only inhibited CRP expression in the vessel walls in mRNA and protein levels, but also reduced the circulating CRP level in hyperhomocysteinemic rats. Simvastatin 32-43 C-reactive protein Rattus norvegicus 159-162 27993685-8 2017 Further experiments displayed that simvastatin reduced Hcy-induced reactive oxygen species (ROS) generation, ameliorated Hcy-activated phosphorylations of ERK1/2 and p38, and antagonized Hcy-downregulated peroxisome proliferator-activated receptor gamma expression in VSMCs. Simvastatin 35-46 mitogen activated protein kinase 3 Rattus norvegicus 155-161 27993685-8 2017 Further experiments displayed that simvastatin reduced Hcy-induced reactive oxygen species (ROS) generation, ameliorated Hcy-activated phosphorylations of ERK1/2 and p38, and antagonized Hcy-downregulated peroxisome proliferator-activated receptor gamma expression in VSMCs. Simvastatin 35-46 mitogen activated protein kinase 14 Rattus norvegicus 166-169 27993685-9 2017 These data demonstrate that simvastatin is able to inhibit Hcy-induced CRP generation in VSMCs so to relieve the vascular inflammatory response via interfering with the ROS-MAPK signal pathway. Simvastatin 28-39 C-reactive protein Rattus norvegicus 71-74 27993685-9 2017 These data demonstrate that simvastatin is able to inhibit Hcy-induced CRP generation in VSMCs so to relieve the vascular inflammatory response via interfering with the ROS-MAPK signal pathway. Simvastatin 28-39 mitogen activated protein kinase 3 Rattus norvegicus 173-177 27052517-8 2017 Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 +- 1.27 muM and 22.67 +- 1.42 muM, respectively). Simvastatin 0-11 solute carrier organic anion transporter family member 1B1 Homo sapiens 25-32 27818195-9 2016 Functionally, hypotonic solution increased the TNF-alpha mRNA expression, which could be decreased by tiron, DPI, NPPB, DIDS and simvastatin but not pravastatin. Simvastatin 129-140 tumor necrosis factor Homo sapiens 47-56 27052517-8 2017 Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 +- 1.27 muM and 22.67 +- 1.42 muM, respectively). Simvastatin 0-11 solute carrier organic anion transporter family member 1B3 Homo sapiens 37-44 27539103-2 2016 Among the frequent variants examined using the genome-wide association study approach, SLCO1B1 c.521T>C represents the only validated predictor of SAM in patients treated with high-dose simvastatin. Simvastatin 189-200 solute carrier organic anion transporter family member 1B1 Homo sapiens 87-94 27833018-2 2016 Simvastatin alone abolished androgen-induced growth in both cell lines but decreased androgen receptor (AR) and prostate-specific antigen protein expression only in LNCaP, indicating that statin-induced growth inhibition is beyond AR transcriptional activity in VCaP. Simvastatin 0-11 androgen receptor Homo sapiens 85-102 27601624-8 2016 Similarly, IRF4 inhibition in bone marrow cells using simvastatin, which has been known to inhibit IRF4 expression, increased PMN-MDSC numbers. Simvastatin 54-65 interferon regulatory factor 4 Homo sapiens 11-15 27833018-2 2016 Simvastatin alone abolished androgen-induced growth in both cell lines but decreased androgen receptor (AR) and prostate-specific antigen protein expression only in LNCaP, indicating that statin-induced growth inhibition is beyond AR transcriptional activity in VCaP. Simvastatin 0-11 androgen receptor Homo sapiens 104-106 27833018-2 2016 Simvastatin alone abolished androgen-induced growth in both cell lines but decreased androgen receptor (AR) and prostate-specific antigen protein expression only in LNCaP, indicating that statin-induced growth inhibition is beyond AR transcriptional activity in VCaP. Simvastatin 0-11 kallikrein related peptidase 3 Homo sapiens 112-137 28076507-7 2016 RESULTS:: Clinical scores, TNF-alpha, IL-1beta, liver/kidney proof levels, and lung injury were significantly reduced in coconut water+NaCl 3%+simvastatin group treated rats, comparing with the other resuscitation treatments. Simvastatin 143-154 tumor necrosis factor Rattus norvegicus 27-36 28076507-7 2016 RESULTS:: Clinical scores, TNF-alpha, IL-1beta, liver/kidney proof levels, and lung injury were significantly reduced in coconut water+NaCl 3%+simvastatin group treated rats, comparing with the other resuscitation treatments. Simvastatin 143-154 interleukin 1 beta Rattus norvegicus 38-46 27411707-7 2016 Interestingly, although very high concentrations (25-50 microM) of Simvastatin resulted in dramatically less IL-6 and IL-8 pro-inflammatory cytokine secretion, 2.5 microM Simvastatin did not reduce the total amount of pro-inflammatory cytokines secreted during mechanical stimulation. Simvastatin 67-78 interleukin 6 Homo sapiens 109-113 27411707-7 2016 Interestingly, although very high concentrations (25-50 microM) of Simvastatin resulted in dramatically less IL-6 and IL-8 pro-inflammatory cytokine secretion, 2.5 microM Simvastatin did not reduce the total amount of pro-inflammatory cytokines secreted during mechanical stimulation. Simvastatin 67-78 C-X-C motif chemokine ligand 8 Homo sapiens 118-122 26845478-6 2016 As a result, the RM-beta-CD/SV inclusion complexes showed significantly higher ALP production and the expression of bone sialoprotein (BSP) and osteocalcin (OCN) than the untreated and free SV-treated cells. Simvastatin 28-30 beta-carotene oxygenase 1 Mus musculus 20-27 26845478-6 2016 As a result, the RM-beta-CD/SV inclusion complexes showed significantly higher ALP production and the expression of bone sialoprotein (BSP) and osteocalcin (OCN) than the untreated and free SV-treated cells. Simvastatin 28-30 bone gamma-carboxyglutamate protein 2 Mus musculus 144-155 26845478-6 2016 As a result, the RM-beta-CD/SV inclusion complexes showed significantly higher ALP production and the expression of bone sialoprotein (BSP) and osteocalcin (OCN) than the untreated and free SV-treated cells. Simvastatin 28-30 bone gamma-carboxyglutamate protein 2 Mus musculus 157-160 26845478-7 2016 Additionally, the production of bone morphogenetic protein-2 (BMP-2) from MC3T3-E1 cells after the treatment with RM-beta-CD/SV inclusion complexes was significantly higher than the untreated and free SV-treated cells. Simvastatin 125-127 bone morphogenetic protein 2 Mus musculus 32-60 26845478-7 2016 Additionally, the production of bone morphogenetic protein-2 (BMP-2) from MC3T3-E1 cells after the treatment with RM-beta-CD/SV inclusion complexes was significantly higher than the untreated and free SV-treated cells. Simvastatin 125-127 bone morphogenetic protein 2 Mus musculus 62-67 26845478-7 2016 Additionally, the production of bone morphogenetic protein-2 (BMP-2) from MC3T3-E1 cells after the treatment with RM-beta-CD/SV inclusion complexes was significantly higher than the untreated and free SV-treated cells. Simvastatin 125-127 beta-carotene oxygenase 1 Mus musculus 117-124 26845478-7 2016 Additionally, the production of bone morphogenetic protein-2 (BMP-2) from MC3T3-E1 cells after the treatment with RM-beta-CD/SV inclusion complexes was significantly higher than the untreated and free SV-treated cells. Simvastatin 201-203 bone morphogenetic protein 2 Mus musculus 32-60 26845478-7 2016 Additionally, the production of bone morphogenetic protein-2 (BMP-2) from MC3T3-E1 cells after the treatment with RM-beta-CD/SV inclusion complexes was significantly higher than the untreated and free SV-treated cells. Simvastatin 201-203 bone morphogenetic protein 2 Mus musculus 62-67 27534996-6 2016 Sildenifil (through cGMP), erlotinib, and simvastatin each stimulate AQP2 insertion into the apical plasma membrane. Simvastatin 42-53 aquaporin 2 Homo sapiens 69-73 27830474-0 2016 Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. Simvastatin 0-11 insulin Homo sapiens 44-51 27830474-3 2016 METHODS: Here, we study the effect of simvastatin on insulin secretion using single-islet cultures, an optimal compromise between biological observability and physiologic fidelity. Simvastatin 38-49 insulin Homo sapiens 53-60 27830474-6 2016 RESULTS: We found that simvastatin reversibly inhibits insulin secretion, even in high-glucose. Simvastatin 23-34 insulin Homo sapiens 55-62 26845478-3 2016 In this study, the inclusion complexes of simvastatin (SV) with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated beta-cyclodextrin (RM-beta-CD) were prepared to improve the water-solubility and the osteogenic differentiation ability of the inclusion complexes in MC3T3-E1 cells was investigated. Simvastatin 42-53 beta-carotene oxygenase 1 Mus musculus 100-107 26845478-3 2016 In this study, the inclusion complexes of simvastatin (SV) with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated beta-cyclodextrin (RM-beta-CD) were prepared to improve the water-solubility and the osteogenic differentiation ability of the inclusion complexes in MC3T3-E1 cells was investigated. Simvastatin 42-53 beta-carotene oxygenase 1 Mus musculus 155-162 26845478-3 2016 In this study, the inclusion complexes of simvastatin (SV) with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated beta-cyclodextrin (RM-beta-CD) were prepared to improve the water-solubility and the osteogenic differentiation ability of the inclusion complexes in MC3T3-E1 cells was investigated. Simvastatin 55-57 beta-carotene oxygenase 1 Mus musculus 100-107 26845478-3 2016 In this study, the inclusion complexes of simvastatin (SV) with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated beta-cyclodextrin (RM-beta-CD) were prepared to improve the water-solubility and the osteogenic differentiation ability of the inclusion complexes in MC3T3-E1 cells was investigated. Simvastatin 55-57 beta-carotene oxygenase 1 Mus musculus 155-162 27541019-2 2016 Recently, research also indicated that simvastatin could promote regeneration in the dentate gyrus of adult mice by Wnt/beta-catenin signaling (Robin et al. Simvastatin 39-50 catenin (cadherin associated protein), beta 1 Mus musculus 120-132 27601624-8 2016 Similarly, IRF4 inhibition in bone marrow cells using simvastatin, which has been known to inhibit IRF4 expression, increased PMN-MDSC numbers. Simvastatin 54-65 interferon regulatory factor 4 Homo sapiens 99-103 28024473-1 2016 OBJECTIVE: To investigate the effects of simvastatin(SIM) and serum free medium(SFM) on the expression of multidrug resistance gene(MDR1) and protein of SHI-1 cells. Simvastatin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 28426854-0 2016 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial: Erratum. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 27743890-10 2016 In conclusion, our data indicate that simvastatin decreased both basal and insulin-stimulated glucose uptake through inhibiting the critical steps in IR/IRS-1/AKT signaling cascade, and by hindering GLUT4 function and normal regulation of glycogen synthesis, contributing to insulin resistance. Simvastatin 38-49 insulin receptor substrate 1 Homo sapiens 153-158 28024473-2 2016 METHODS: Trypan blue exclusion assay was used to detect the proliferation level and viability of SHI-1 cells after treatment with SIM and culture in SFM; The multi-drug resistant protein p-gp was measured by flow cytometry after culture in SFM for 1 to 3 days and treatment with various concentration of simvastatin. Simvastatin 304-315 phosphoglycolate phosphatase Homo sapiens 187-191 27743890-0 2016 Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation. Simvastatin 0-11 insulin Homo sapiens 20-27 27743890-10 2016 In conclusion, our data indicate that simvastatin decreased both basal and insulin-stimulated glucose uptake through inhibiting the critical steps in IR/IRS-1/AKT signaling cascade, and by hindering GLUT4 function and normal regulation of glycogen synthesis, contributing to insulin resistance. Simvastatin 38-49 AKT serine/threonine kinase 1 Homo sapiens 159-162 27743890-0 2016 Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation. Simvastatin 0-11 insulin Homo sapiens 85-92 27743890-0 2016 Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation. Simvastatin 0-11 solute carrier family 2 member 4 Homo sapiens 104-109 27743890-10 2016 In conclusion, our data indicate that simvastatin decreased both basal and insulin-stimulated glucose uptake through inhibiting the critical steps in IR/IRS-1/AKT signaling cascade, and by hindering GLUT4 function and normal regulation of glycogen synthesis, contributing to insulin resistance. Simvastatin 38-49 solute carrier family 2 member 4 Homo sapiens 199-204 27743890-0 2016 Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation. Simvastatin 0-11 glycogen synthase kinase 3 beta Homo sapiens 125-134 27743890-8 2016 The effect of simvastatin was reversed with geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate, implying that reduced protein geranylgeranylation has a role in simvastatin-induced insulin resistance. Simvastatin 14-25 insulin Homo sapiens 194-201 27743890-10 2016 In conclusion, our data indicate that simvastatin decreased both basal and insulin-stimulated glucose uptake through inhibiting the critical steps in IR/IRS-1/AKT signaling cascade, and by hindering GLUT4 function and normal regulation of glycogen synthesis, contributing to insulin resistance. Simvastatin 38-49 insulin Homo sapiens 275-282 27743890-8 2016 The effect of simvastatin was reversed with geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate, implying that reduced protein geranylgeranylation has a role in simvastatin-induced insulin resistance. Simvastatin 174-185 insulin Homo sapiens 194-201 27779188-0 2016 Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARgamma signalling pathway. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Homo sapiens 93-102 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 insulin receptor Homo sapiens 46-62 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 insulin receptor Homo sapiens 64-66 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 insulin receptor substrate 1 Homo sapiens 69-97 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 insulin receptor substrate 1 Homo sapiens 99-104 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 107-110 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 glycogen synthase kinase 3 beta Homo sapiens 115-145 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 glycogen synthase kinase 3 beta Homo sapiens 147-156 27743890-9 2016 Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4. Simvastatin 0-11 solute carrier family 2 member 4 Homo sapiens 177-182 27743890-10 2016 In conclusion, our data indicate that simvastatin decreased both basal and insulin-stimulated glucose uptake through inhibiting the critical steps in IR/IRS-1/AKT signaling cascade, and by hindering GLUT4 function and normal regulation of glycogen synthesis, contributing to insulin resistance. Simvastatin 38-49 insulin Homo sapiens 75-82 27694473-0 2016 Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 111-115 27694473-3 2016 Simvastatin has pleiotropic inhibitory effects on isoprenoid intermediates that may limit activity of RhoA, which signals upstream of ROCK. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 102-106 27694473-7 2016 Simvastatin reduced lung content of the isoprenoid intermediate farnesyl pyrophosphate and decreased RhoA/ROCK signaling in the hypoxia-exposed lung. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 101-105 27694473-11 2016 We conclude that simvastatin limits RhoA/ROCK activity in the chronic hypoxia-exposed lung, thus preventing or ameliorating hemodynamic and structural markers of chronic PHT and improving long-term outcome, without causing adverse effects. Simvastatin 17-28 ras homolog family member A Rattus norvegicus 36-40 27454615-7 2016 Logistic regression analysis showed that female gender, diabetes, and obesity were negative factors, whereas life-style modification and use of high-dose statin (40mg/d simvastatin equivalent) were favorable factors in predicting LDL-C target attainment in the primary care setting. Simvastatin 169-180 component of oligomeric golgi complex 2 Homo sapiens 230-235 27734263-11 2016 Simvastatin and fluvastatin showed very strong growth suppressive effects, and induced apoptosis in HLF cells, but not HuH1 cells. Simvastatin 0-11 HLF transcription factor, PAR bZIP family member Homo sapiens 100-103 27734263-12 2016 TAZ expression was suppressed in HLF cells by fluvastatin and simvastatin treatment. Simvastatin 62-73 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 0-3 27734263-12 2016 TAZ expression was suppressed in HLF cells by fluvastatin and simvastatin treatment. Simvastatin 62-73 HLF transcription factor, PAR bZIP family member Homo sapiens 33-36 26302681-2 2016 Thirteen single nucleotide polymorphisms (SNPs) within the ESR1 gene were evaluated with basal lipid and lipoprotein levels, as well as response to lipid-lowering therapy, in 495 hypercholesterolemic individuals of European descent receiving simvastatin or atorvastatin. Simvastatin 242-253 estrogen receptor 1 Homo sapiens 59-63 27865162-5 2016 We further demonstrate that Simvastatin inhibits the BMP4-mediated adipogenic commitment of marrow stromal cells by inhibiting Ppar-gamma expression. Simvastatin 28-39 bone morphogenetic protein 4 Homo sapiens 53-57 27865162-5 2016 We further demonstrate that Simvastatin inhibits the BMP4-mediated adipogenic commitment of marrow stromal cells by inhibiting Ppar-gamma expression. Simvastatin 28-39 peroxisome proliferator activated receptor gamma Homo sapiens 127-137 27779188-7 2016 Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT/GSK3beta. Simvastatin 13-24 IL2 inducible T cell kinase Homo sapiens 70-73 27779188-7 2016 Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT/GSK3beta. Simvastatin 13-24 AKT serine/threonine kinase 1 Homo sapiens 88-91 27779188-7 2016 Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT/GSK3beta. Simvastatin 13-24 glycogen synthase kinase 3 beta Homo sapiens 92-100 27779188-8 2016 More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells. Simvastatin 126-137 cyclin dependent kinase 4 Homo sapiens 92-98 27779188-8 2016 More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells. Simvastatin 126-137 cyclin D1 Homo sapiens 103-112 27758944-11 2016 In post hoc analyses, for patients receiving tissue-type plasminogen activator, a favorable effect for simvastatin treatment was noted with higher proportion of patients experiencing major neurological recovery (adjusted odds ratio, 4.14 [1.18-14.4]; P=0.02). Simvastatin 103-114 plasminogen activator, tissue type Homo sapiens 45-78 27779188-8 2016 More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells. Simvastatin 126-137 peroxisome proliferator activated receptor gamma Homo sapiens 160-169 27779188-5 2016 We observed simvastatin did not trigger BCa cell apoptosis, but reduced cell proliferation in a dose- and time-dependent manner, accompanied by PPARgamma-activation. Simvastatin 12-23 peroxisome proliferator activated receptor gamma Homo sapiens 144-153 27779188-8 2016 More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells. Simvastatin 126-137 peroxisome proliferator activated receptor alpha Homo sapiens 216-225 27779188-6 2016 Moreover, flow cytometry analysis indicated that simvastatin induced cell cycle arrest at G0/G1 phase, suggested by downregulation of CDK4/6 and Cyclin D1. Simvastatin 49-60 cyclin dependent kinase 4 Homo sapiens 134-140 27779188-9 2016 Taken together, our study for the first time revealed that simvastatin inhibited bladder cancer cell proliferation and induced cell cycle arrest at G1/G0 phase via PPARgamma signalling pathway. Simvastatin 59-70 peroxisome proliferator activated receptor gamma Homo sapiens 164-173 27779188-6 2016 Moreover, flow cytometry analysis indicated that simvastatin induced cell cycle arrest at G0/G1 phase, suggested by downregulation of CDK4/6 and Cyclin D1. Simvastatin 49-60 cyclin D1 Homo sapiens 145-154 27470565-5 2016 Mechanistically, the inhibition of glucose uptake and GLUT4 translocation elicited by simvastatin were associated with the suppression of the insulin receptor (IR)/IR substrate (IRS)/Akt signaling cascade. Simvastatin 86-97 insulin receptor Homo sapiens 142-158 27343379-8 2016 beta-hydroxy-simvastatin acid (activated simvastatin) suppressed IL-5 and IL-13 in pure Th2- and Tc2-cells. Simvastatin 13-24 interleukin 5 Homo sapiens 65-69 27343379-8 2016 beta-hydroxy-simvastatin acid (activated simvastatin) suppressed IL-5 and IL-13 in pure Th2- and Tc2-cells. Simvastatin 13-24 interleukin 13 Homo sapiens 74-79 27343379-8 2016 beta-hydroxy-simvastatin acid (activated simvastatin) suppressed IL-5 and IL-13 in pure Th2- and Tc2-cells. Simvastatin 13-24 transcobalamin 2 Homo sapiens 97-100 27343379-9 2016 Simvastatin suppressed IL-5 and IL-13 in Th2-cells co-cultivated with monocytes or AM, which was partially reversed by the carboxylesterase inhibitor benzil. Simvastatin 0-11 interleukin 5 Homo sapiens 23-27 27343379-9 2016 Simvastatin suppressed IL-5 and IL-13 in Th2-cells co-cultivated with monocytes or AM, which was partially reversed by the carboxylesterase inhibitor benzil. Simvastatin 0-11 interleukin 13 Homo sapiens 32-37 27343379-10 2016 Simvastatin suppressed IL-5 production of Th2/Tc2-cells in PBMCs without differences between cohorts and IL-13 stronger in never-smokers and asthma compared to COPD. Simvastatin 0-11 interleukin 5 Homo sapiens 23-27 27343379-10 2016 Simvastatin suppressed IL-5 production of Th2/Tc2-cells in PBMCs without differences between cohorts and IL-13 stronger in never-smokers and asthma compared to COPD. Simvastatin 0-11 transcobalamin 2 Homo sapiens 46-49 27343379-11 2016 Simvastatin induced IFNgamma in Th1/Tc1-cells in PBMCs of all cohorts except asthmatics. Simvastatin 0-11 interferon gamma Homo sapiens 20-28 27343379-11 2016 Simvastatin induced IFNgamma in Th1/Tc1-cells in PBMCs of all cohorts except asthmatics. Simvastatin 0-11 negative elongation factor complex member C/D Homo sapiens 32-35 27343379-11 2016 Simvastatin induced IFNgamma in Th1/Tc1-cells in PBMCs of all cohorts except asthmatics. Simvastatin 0-11 transcobalamin 1 Homo sapiens 36-39 27343379-12 2016 Simvastatin requires activation in accessory cells likely by carboxylesterase to suppress IL-5 and IL-13 in Th2/Tc2-cells. Simvastatin 0-11 interleukin 5 Homo sapiens 90-94 27343379-12 2016 Simvastatin requires activation in accessory cells likely by carboxylesterase to suppress IL-5 and IL-13 in Th2/Tc2-cells. Simvastatin 0-11 interleukin 13 Homo sapiens 99-104 27343379-12 2016 Simvastatin requires activation in accessory cells likely by carboxylesterase to suppress IL-5 and IL-13 in Th2/Tc2-cells. Simvastatin 0-11 transcobalamin 2 Homo sapiens 112-115 27343379-14 2016 Asthma pathogenesis prevents simvastatin-induced IFNgamma up-regulation. Simvastatin 29-40 interferon gamma Homo sapiens 49-57 27423725-0 2016 Effect of Simvastatin Treatment on "In Vitro" NLRP1 Inflammasome Expression in Peripheral Arterial Disease. Simvastatin 10-21 NLR family pyrin domain containing 1 Homo sapiens 46-51 27423725-2 2016 Our objective was to elucidate the effect of simvastatin treatment on NLRP1 inflammasome expression in endothelial cells exposed to the plasma of PAD patients. Simvastatin 45-56 NLR family pyrin domain containing 1 Homo sapiens 70-75 27423725-6 2016 RESULTS: HAECs exposed to the plasma of PAD patients with simvastatin therapy showed significantly higher expression of the NLRP1 gene compared with those exposed to the plasma of PAD patients without this treatment (relative quantitation [RQ] 1.12 +- 0.06 vs. 1.06 +- 0.07, P = 0.03). Simvastatin 58-69 NLR family pyrin domain containing 1 Homo sapiens 124-129 27423725-7 2016 Furthermore, HAECs exposed to the plasma of patients with critical limb ischemia and treated with simvastatin responded with a higher NLRP1 expression than those exposed to the plasma of simvastatin-treated patients with claudication (RQ 1.1 +- 0.3 vs. 0.99 +- 0.14, P < 0.001). Simvastatin 98-109 NLR family pyrin domain containing 1 Homo sapiens 134-139 27423725-8 2016 CONCLUSION: Simvastatin intake in PAD patients increases in vitro reactivity of NLRP1 inflammasome gene expression in HAECs, especially in critical limb ischemia patients. Simvastatin 12-23 NLR family pyrin domain containing 1 Homo sapiens 80-85 27470565-0 2016 Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes. Simvastatin 0-11 solute carrier family 2 member 4 Homo sapiens 49-54 27470565-0 2016 Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes. Simvastatin 0-11 insulin receptor substrate 1 Homo sapiens 96-104 27470565-0 2016 Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 105-108 27470565-1 2016 Simvastatin,a 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, is clinically used in the prevention and treatment of cardiovascular diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-64 27470565-5 2016 Mechanistically, the inhibition of glucose uptake and GLUT4 translocation elicited by simvastatin were associated with the suppression of the insulin receptor (IR)/IR substrate (IRS)/Akt signaling cascade. Simvastatin 86-97 insulin receptor Homo sapiens 160-162 27470565-4 2016 Our studies showed that simvastatin significantly inhibited glucose uptake activity and GLUT4 translocation, whereas the effect was reversible with mevalonolactone (ML), which acts as an intermediate of cholesterol synthesis pathway. Simvastatin 24-35 solute carrier family 2 member 4 Homo sapiens 88-93 27470565-5 2016 Mechanistically, the inhibition of glucose uptake and GLUT4 translocation elicited by simvastatin were associated with the suppression of the insulin receptor (IR)/IR substrate (IRS)/Akt signaling cascade. Simvastatin 86-97 solute carrier family 2 member 4 Homo sapiens 54-59 27470565-5 2016 Mechanistically, the inhibition of glucose uptake and GLUT4 translocation elicited by simvastatin were associated with the suppression of the insulin receptor (IR)/IR substrate (IRS)/Akt signaling cascade. Simvastatin 86-97 AKT serine/threonine kinase 1 Homo sapiens 183-186 27470565-6 2016 Simvastatin suppressed the phosphorylation of IR, IRS-1 and Akt, and total expression of IR or IRS-1, but did not affect Akt. Simvastatin 0-11 insulin receptor Homo sapiens 46-48 27470565-6 2016 Simvastatin suppressed the phosphorylation of IR, IRS-1 and Akt, and total expression of IR or IRS-1, but did not affect Akt. Simvastatin 0-11 insulin receptor substrate 1 Homo sapiens 50-55 27470565-6 2016 Simvastatin suppressed the phosphorylation of IR, IRS-1 and Akt, and total expression of IR or IRS-1, but did not affect Akt. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 60-63 27470565-6 2016 Simvastatin suppressed the phosphorylation of IR, IRS-1 and Akt, and total expression of IR or IRS-1, but did not affect Akt. Simvastatin 0-11 insulin receptor Homo sapiens 50-52 27470565-6 2016 Simvastatin suppressed the phosphorylation of IR, IRS-1 and Akt, and total expression of IR or IRS-1, but did not affect Akt. Simvastatin 0-11 insulin receptor substrate 1 Homo sapiens 95-100 27470565-7 2016 Furthermore, simvastatin decreased Rac1 GTP binding. Simvastatin 13-24 Rac family small GTPase 1 Homo sapiens 35-39 27470565-8 2016 In conclusion, our findings indicate that simvastatin suppresses glucose uptake activity and GLUT4 translocation via IR-dependent IRS-1/PI3K/Akt pathway. Simvastatin 42-53 solute carrier family 2 member 4 Homo sapiens 93-98 27470565-8 2016 In conclusion, our findings indicate that simvastatin suppresses glucose uptake activity and GLUT4 translocation via IR-dependent IRS-1/PI3K/Akt pathway. Simvastatin 42-53 insulin receptor Homo sapiens 117-119 27470565-8 2016 In conclusion, our findings indicate that simvastatin suppresses glucose uptake activity and GLUT4 translocation via IR-dependent IRS-1/PI3K/Akt pathway. Simvastatin 42-53 insulin receptor substrate 1 Homo sapiens 130-135 27470565-8 2016 In conclusion, our findings indicate that simvastatin suppresses glucose uptake activity and GLUT4 translocation via IR-dependent IRS-1/PI3K/Akt pathway. Simvastatin 42-53 AKT serine/threonine kinase 1 Homo sapiens 141-144 26830691-10 2016 Endothelial nitric oxide synthase activity as determined by acetylcholine-stimulated vasorelaxation recovered notably in diabetic mice that were treated with simvastatin but was not improved by ezetimibe (n = 6, each group). Simvastatin 158-169 nitric oxide synthase 3, endothelial cell Mus musculus 0-33 27021071-5 2016 Treatment ex vivo with simvastatin and atorvastatin reduced the proportion of CD16+ monocytes in peripheral blood mononuclear cells, as well as in purified monocytes, especially CD14++CD16+ "intermediate" monocytes most closely associated with neurocognitive disease. Simvastatin 23-34 Fc gamma receptor IIIa Homo sapiens 78-82 27021071-5 2016 Treatment ex vivo with simvastatin and atorvastatin reduced the proportion of CD16+ monocytes in peripheral blood mononuclear cells, as well as in purified monocytes, especially CD14++CD16+ "intermediate" monocytes most closely associated with neurocognitive disease. Simvastatin 23-34 CD14 molecule Homo sapiens 178-182 27021071-5 2016 Treatment ex vivo with simvastatin and atorvastatin reduced the proportion of CD16+ monocytes in peripheral blood mononuclear cells, as well as in purified monocytes, especially CD14++CD16+ "intermediate" monocytes most closely associated with neurocognitive disease. Simvastatin 23-34 Fc gamma receptor IIIa Homo sapiens 184-188 27021071-7 2016 Finally, simvastatin inhibited production of monocyte chemoattractant protein-1 (MCP-1) and other inflammatory cytokines following LPS stimulation and reduced monocyte chemotaxis in response to MCP-1, a major driver of myeloid cell accumulation in the CNS in HAND. Simvastatin 9-20 chemokine (C-C motif) ligand 2 Mus musculus 45-79 27021071-7 2016 Finally, simvastatin inhibited production of monocyte chemoattractant protein-1 (MCP-1) and other inflammatory cytokines following LPS stimulation and reduced monocyte chemotaxis in response to MCP-1, a major driver of myeloid cell accumulation in the CNS in HAND. Simvastatin 9-20 chemokine (C-C motif) ligand 2 Mus musculus 81-86 27021071-7 2016 Finally, simvastatin inhibited production of monocyte chemoattractant protein-1 (MCP-1) and other inflammatory cytokines following LPS stimulation and reduced monocyte chemotaxis in response to MCP-1, a major driver of myeloid cell accumulation in the CNS in HAND. Simvastatin 9-20 chemokine (C-C motif) ligand 2 Mus musculus 194-199 26830691-11 2016 Moreover, simvastatin led to a significant upregulation of endothelial nitric oxide synthase phosphorylation; vascular endothelial growth factor protein levels in ischemic tissues were also increased. Simvastatin 10-21 nitric oxide synthase 3, endothelial cell Mus musculus 59-92 27604655-6 2016 In addition, simvastatin could restore dusp4 deficiency and suppress ets-1 expression in TNBC. Simvastatin 13-24 dual specificity phosphatase 4 Homo sapiens 39-44 27161569-12 2016 CONCLUSION: These results indicated that simvastatin and BMSC combination therapy was superior to simvastatin therapy and BMSC therapy alone in reduction of airway remodeling and lung inflammation in the ovalbumin-induced asthma model in mouse. Simvastatin 41-52 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 204-213 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 CD83 molecule Homo sapiens 92-96 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 CD86 molecule Homo sapiens 102-106 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 tumor necrosis factor Homo sapiens 140-167 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 interleukin 1 beta Homo sapiens 169-177 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 interleukin 6 Homo sapiens 182-186 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 interleukin 10 Homo sapiens 238-243 27611832-8 2016 The expression mRNA of ROCK-1(1.74+-0.13) and CTGF (2.28+-0.11) can upregulated by TGF-beta1, and down-regulated by Simvastatin (1.22+-0.03 vs 2.27+-0.11), Y27632 (1.01+-0.04 vs 1.64+-0.03), Los (1.04+-0.11 vs 1.26+-0.05), respectively. Simvastatin 116-127 Rho associated coiled-coil containing protein kinase 1 Canis lupus familiaris 23-29 27611832-8 2016 The expression mRNA of ROCK-1(1.74+-0.13) and CTGF (2.28+-0.11) can upregulated by TGF-beta1, and down-regulated by Simvastatin (1.22+-0.03 vs 2.27+-0.11), Y27632 (1.01+-0.04 vs 1.64+-0.03), Los (1.04+-0.11 vs 1.26+-0.05), respectively. Simvastatin 116-127 cellular communication network factor 2 Canis lupus familiaris 46-50 27611832-9 2016 Losartan and Simvastatin attenuated the effects of TGF-beta1, inhibited RhoA activity as opposed to RhoA protein expression. Simvastatin 13-24 transforming growth factor beta-1 proprotein Canis lupus familiaris 51-60 27611832-9 2016 Losartan and Simvastatin attenuated the effects of TGF-beta1, inhibited RhoA activity as opposed to RhoA protein expression. Simvastatin 13-24 ras homolog family member A Canis lupus familiaris 72-76 27457035-0 2016 Involvement of inhibition of RhoA/Rho kinase signaling in simvastatin-induced amelioration of neuropathic pain. Simvastatin 58-69 ras homolog family member A Mus musculus 29-33 27457035-0 2016 Involvement of inhibition of RhoA/Rho kinase signaling in simvastatin-induced amelioration of neuropathic pain. Simvastatin 58-69 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 34-44 27457035-9 2016 Furthermore, simvastatin exerts antihyperalgesic and antiallodynic effects through the inhibition of spinal RhoA activation. Simvastatin 13-24 ras homolog family member A Mus musculus 108-112 26911804-0 2016 Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-kappaB signalling pathway in human chronic myelogenous leukaemia. Simvastatin 0-11 tumor necrosis factor Homo sapiens 56-59 26911804-0 2016 Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-kappaB signalling pathway in human chronic myelogenous leukaemia. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 100-109 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 CD80 molecule Homo sapiens 86-90 27632901-7 2016 Furthermore, simvastatin-treated macrophages displayed enhanced phagosome maturation, as revealed by increased LAMP-3 expression in fluorescent microscopy and Western blot analysis. Simvastatin 13-24 lysosomal-associated membrane protein 3 Mus musculus 111-117 27611832-7 2016 Simvastatin and Y27632 reversed Ang II-induced CFs proliferation, as well as ROCK-1(0.89+-0.05 and 1.27+-0.03, respectively) and CTGF (0.87+-0.04 and 0.91+-0.02, respectively) expression. Simvastatin 0-11 cellular communication network factor 2 Canis lupus familiaris 129-133 27604655-6 2016 In addition, simvastatin could restore dusp4 deficiency and suppress ets-1 expression in TNBC. Simvastatin 13-24 ETS proto-oncogene 1, transcription factor Homo sapiens 69-74 27604655-9 2016 Accordingly, our study indicates that simvastatin potentially affects the activity of transcriptional factors such as ets-1 and dusp4 through the MAPK pathway. Simvastatin 38-49 ETS proto-oncogene 1, transcription factor Homo sapiens 118-123 27604655-9 2016 Accordingly, our study indicates that simvastatin potentially affects the activity of transcriptional factors such as ets-1 and dusp4 through the MAPK pathway. Simvastatin 38-49 dual specificity phosphatase 4 Homo sapiens 128-133 27306926-0 2016 Simvastatin induces the apoptosis of normal vascular smooth muscle through the disruption of actin integrity via the impairment of RhoA/Rac-1 activity. Simvastatin 0-11 Rac family small GTPase 1 Rattus norvegicus 136-141 27605198-5 2016 Three commonly used statins-simvastatin, atorvastatin and lovastatin-are metabolised by the liver enzyme CYP3A4. Simvastatin 28-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 27216618-0 2016 Simvastatin Attenuates Neuropathic Pain by Inhibiting the RhoA/LIMK/Cofilin Pathway. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 58-62 27216618-5 2016 Treatments that reduced RhoA/LIMK/cofilin pathway activity, including simvastatin, the Rho kinase inhibitor Y-27632, and the synthetic peptide Tat-S3, attenuated actin filament disruption in the dorsal root ganglion and CCI-induced neuropathic pain. Simvastatin 70-81 ras homolog family member A Rattus norvegicus 24-28 27216618-7 2016 Here, we found that simvastatin significantly decreased the ratio of membrane/cytosolic RhoA, which was significantly increased after CCI, by inhibiting the RhoA/LIMK/cofilin pathway. Simvastatin 20-31 ras homolog family member A Rattus norvegicus 88-92 27216618-7 2016 Here, we found that simvastatin significantly decreased the ratio of membrane/cytosolic RhoA, which was significantly increased after CCI, by inhibiting the RhoA/LIMK/cofilin pathway. Simvastatin 20-31 ras homolog family member A Rattus norvegicus 157-161 27216618-9 2016 We conclude that simvastatin attenuated neuropathic pain in rats subjected to CCI by inhibiting actin-mediated intracellular trafficking to suppress RhoA/LIMK/cofilin pathway activity. Simvastatin 17-28 ras homolog family member A Rattus norvegicus 149-153 27583452-0 2016 Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice. Simvastatin 44-55 fibroblast growth factor 21 Mus musculus 8-13 27583452-7 2016 Hepatic Fgf21 protein and mRNA and circulating levels of FGF21significantly decreased in mice that had received simvastatin in their food (0.1% w/w) for 1 week. Simvastatin 112-123 fibroblast growth factor 21 Mus musculus 8-13 27583452-7 2016 Hepatic Fgf21 protein and mRNA and circulating levels of FGF21significantly decreased in mice that had received simvastatin in their food (0.1% w/w) for 1 week. Simvastatin 112-123 fibroblast growth factor 21 Mus musculus 57-62 27583452-9 2016 The reduction in Fgf21 mRNA levels was further verified in primary mouse hepatocytes, indicating that the effect of simvastatin is cell autonomous. Simvastatin 116-127 fibroblast growth factor 21 Mus musculus 17-22 27583452-10 2016 In conclusion, simvastatin treatment reduced the circulating and hepatic Fgf21 levels and this effect warrants further investigation with reference to its role in metabolism. Simvastatin 15-26 fibroblast growth factor 21 Mus musculus 73-78 27306926-0 2016 Simvastatin induces the apoptosis of normal vascular smooth muscle through the disruption of actin integrity via the impairment of RhoA/Rac-1 activity. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 131-135 27306926-7 2016 In rat VSMCs, simvastatin impaired the activation of small GTPases, RhoA along with Rac-1, which resulted in the disruption of actin integrity, a pivotal factor both for the generation of contractile force and survival of VSMCs. Simvastatin 14-25 ras homolog family member A Rattus norvegicus 68-72 27306926-7 2016 In rat VSMCs, simvastatin impaired the activation of small GTPases, RhoA along with Rac-1, which resulted in the disruption of actin integrity, a pivotal factor both for the generation of contractile force and survival of VSMCs. Simvastatin 14-25 Rac family small GTPase 1 Rattus norvegicus 84-89 27306926-9 2016 These events were all rescued by an actin stabilisation agent, jasplakinolide as well as geranylgeraniol, indicating that damages of the actin integrity from disrupted activation of RhoA/Rac-1 lies at the center of simvastatin-induced contractile dysfunction and apoptosis in vascular smooth muscle. Simvastatin 215-226 ras homolog family member A Rattus norvegicus 182-186 27306926-9 2016 These events were all rescued by an actin stabilisation agent, jasplakinolide as well as geranylgeraniol, indicating that damages of the actin integrity from disrupted activation of RhoA/Rac-1 lies at the center of simvastatin-induced contractile dysfunction and apoptosis in vascular smooth muscle. Simvastatin 215-226 Rac family small GTPase 1 Rattus norvegicus 187-192 27557561-0 2016 Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Simvastatin 0-11 adenosine deaminase Homo sapiens 25-44 27557561-0 2016 Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Simvastatin 0-11 secreted phosphoprotein 1 Homo sapiens 60-71 27557561-5 2016 RESULTS: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled corticosteroid treatment and smoking status in parallel to increased inosine levels. Simvastatin 9-20 5'-nucleotidase ecto Homo sapiens 53-57 27557561-0 2016 Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Simvastatin 0-11 interleukin 13 Homo sapiens 111-116 27557561-4 2016 METHODS: We extended a previous randomized double-blind placebo crossover study to investigate the effects of simvastatin (20 mg/day) on sputum ADA and OPN expression and explored the underlying signaling pathways involved by conducting in vitro experiments with cigarette smoke extract (CSE)-treated monocyte-derived macrophages (MDM) from COPD patients and healthy subjects. Simvastatin 110-121 adenosine deaminase Homo sapiens 144-147 27557561-4 2016 METHODS: We extended a previous randomized double-blind placebo crossover study to investigate the effects of simvastatin (20 mg/day) on sputum ADA and OPN expression and explored the underlying signaling pathways involved by conducting in vitro experiments with cigarette smoke extract (CSE)-treated monocyte-derived macrophages (MDM) from COPD patients and healthy subjects. Simvastatin 110-121 secreted phosphoprotein 1 Homo sapiens 152-155 27557561-5 2016 RESULTS: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled corticosteroid treatment and smoking status in parallel to increased inosine levels. Simvastatin 9-20 interleukin 13 Homo sapiens 38-43 27557561-5 2016 RESULTS: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled corticosteroid treatment and smoking status in parallel to increased inosine levels. Simvastatin 9-20 secreted phosphoprotein 1 Homo sapiens 45-48 27557561-5 2016 RESULTS: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled corticosteroid treatment and smoking status in parallel to increased inosine levels. Simvastatin 9-20 adenosine deaminase Homo sapiens 76-79 27557561-6 2016 The degree of simvastatin-restored ADA activity was significantly correlated with the magnitude of changes in pre-bronchodilator FEV1. Simvastatin 14-25 adenosine deaminase Homo sapiens 35-38 27557561-8 2016 Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-induced increase in OPN and restored IL-13-suppressed ADA. Simvastatin 0-11 interleukin 13 Homo sapiens 32-37 27557561-8 2016 Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-induced increase in OPN and restored IL-13-suppressed ADA. Simvastatin 0-11 interleukin 13 Homo sapiens 109-114 27557561-8 2016 Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-induced increase in OPN and restored IL-13-suppressed ADA. Simvastatin 0-11 secreted phosphoprotein 1 Homo sapiens 135-138 27557561-8 2016 Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-induced increase in OPN and restored IL-13-suppressed ADA. Simvastatin 0-11 interleukin 13 Homo sapiens 109-114 27557561-8 2016 Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-induced increase in OPN and restored IL-13-suppressed ADA. Simvastatin 0-11 adenosine deaminase Homo sapiens 169-172 27557561-10 2016 CONCLUSION: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway. Simvastatin 12-23 interleukin 13 Homo sapiens 33-38 27286913-9 2016 HCE significantly exerted a dose-dependent reduction on simvastatin-induced apoptotic cells, possibly via caspase-3 pathway. Simvastatin 56-67 caspase 3 Rattus norvegicus 106-115 27557561-10 2016 CONCLUSION: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway. Simvastatin 12-23 adenosine deaminase Homo sapiens 50-53 27557561-10 2016 CONCLUSION: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway. Simvastatin 12-23 secreted phosphoprotein 1 Homo sapiens 143-146 27557561-10 2016 CONCLUSION: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway. Simvastatin 12-23 interleukin 13 Homo sapiens 191-196 27557561-10 2016 CONCLUSION: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway. Simvastatin 12-23 signal transducer and activator of transcription 6 Homo sapiens 207-212 27606156-11 2016 The meta-analysis suggests that SLCO1B1 -521T>C polymorphism may be a risk factor for statin-induced ADRs, especially in simvastatin therapy. Simvastatin 124-135 solute carrier organic anion transporter family member 1B1 Homo sapiens 32-39 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 ADAM metallopeptidase domain 10 Homo sapiens 211-217 27242325-0 2016 Simvastatin inhibits CD44 fragmentation in chondrocytes. Simvastatin 0-11 CD44 molecule (Indian blood group) Homo sapiens 21-25 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 CD44 molecule (Indian blood group) Homo sapiens 151-155 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 interleukin 1 beta Homo sapiens 56-64 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 oncostatin M Homo sapiens 67-79 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 ADAM metallopeptidase domain 10 Homo sapiens 275-281 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 CD44 molecule (Indian blood group) Homo sapiens 103-107 27242325-8 2016 Inhibition of CD44 fragmentation by simvastatin also resulted in improved retention of pericellular matrix. Simvastatin 36-47 CD44 molecule (Indian blood group) Homo sapiens 14-18 27242325-6 2016 Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. Simvastatin 20-31 CD44 molecule (Indian blood group) Homo sapiens 151-155 27242325-10 2016 Thus, the addition of simvastatin exerts positive effects on chondrocytes including reduced CD44 fragmentation and enhanced the retention of pericellular matrix. Simvastatin 22-33 CD44 molecule (Indian blood group) Homo sapiens 92-96 27339893-5 2016 Simvastatin antagonizes I domain binding to the complement fragments iC3b and C3d but not to intercellular adhesion molecule-1. Simvastatin 0-11 endogenous retrovirus group K member 13 Homo sapiens 78-81 26542887-11 2016 Biomarker and cytokine analysis showed that IV simvastatin significantly reduced GFAP, interleukin (IL)-1alpha, and IL-17 serum levels by 4.0-, 2.6-, and 7.0-fold, respectively, at 4 h post-injury. Simvastatin 47-58 glial fibrillary acidic protein Rattus norvegicus 81-85 26542887-11 2016 Biomarker and cytokine analysis showed that IV simvastatin significantly reduced GFAP, interleukin (IL)-1alpha, and IL-17 serum levels by 4.0-, 2.6-, and 7.0-fold, respectively, at 4 h post-injury. Simvastatin 47-58 interleukin 1 alpha Rattus norvegicus 87-110 26542887-11 2016 Biomarker and cytokine analysis showed that IV simvastatin significantly reduced GFAP, interleukin (IL)-1alpha, and IL-17 serum levels by 4.0-, 2.6-, and 7.0-fold, respectively, at 4 h post-injury. Simvastatin 47-58 interleukin 17A Rattus norvegicus 116-121 29786238-12 2016 CONCLUSIONS: Simvastatin can increase the mRNA and protein expression levels of OCN and the protein of p-p38 in osteogenic differentiation of BMSCs at middle/ late stages, and its best induction time is 12 hours. Simvastatin 13-24 bone gamma-carboxyglutamate protein Rattus norvegicus 80-83 29786238-6 2016 The protein expressions of phospho-p38 (p-p38) and p38 in OM group, OM+SIM group, and OM+SIM+SB group were detected by Western blot at the best induction time of simvastatin. Simvastatin 162-173 mitogen activated protein kinase 14 Rattus norvegicus 35-38 29786238-6 2016 The protein expressions of phospho-p38 (p-p38) and p38 in OM group, OM+SIM group, and OM+SIM+SB group were detected by Western blot at the best induction time of simvastatin. Simvastatin 162-173 mitogen activated protein kinase 14 Rattus norvegicus 42-45 29786238-12 2016 CONCLUSIONS: Simvastatin can increase the mRNA and protein expression levels of OCN and the protein of p-p38 in osteogenic differentiation of BMSCs at middle/ late stages, and its best induction time is 12 hours. Simvastatin 13-24 mitogen activated protein kinase 14 Rattus norvegicus 105-108 29786238-6 2016 The protein expressions of phospho-p38 (p-p38) and p38 in OM group, OM+SIM group, and OM+SIM+SB group were detected by Western blot at the best induction time of simvastatin. Simvastatin 162-173 mitogen activated protein kinase 14 Rattus norvegicus 42-45 27335167-6 2016 The DNA synthesis and mRNA levels of cyclin A, D, and E were significantly reduced by simvastatin in atrial but not in ventricular fibroblasts. Simvastatin 86-97 cyclin A2 Homo sapiens 37-45 27180285-6 2016 We report that simvastatin significantly inhibits RhoA and Rab4, and Rab6 isoprenylation at doses as low as 50nM in vitro. Simvastatin 15-26 ras homolog family member A Homo sapiens 50-54 27180285-6 2016 We report that simvastatin significantly inhibits RhoA and Rab4, and Rab6 isoprenylation at doses as low as 50nM in vitro. Simvastatin 15-26 RAB4A, member RAS oncogene family Homo sapiens 59-63 27180285-6 2016 We report that simvastatin significantly inhibits RhoA and Rab4, and Rab6 isoprenylation at doses as low as 50nM in vitro. Simvastatin 15-26 RAB6A, member RAS oncogene family Homo sapiens 69-73 27180285-7 2016 We also provide the first in vivo evidence that statins inhibit the isoprenylation of RhoA in the brains of rats and RhoA, Cdc42, and H-Ras in the brains of mice treated with clinically relevant doses of simvastatin. Simvastatin 204-215 ras homolog family member A Rattus norvegicus 86-90 27180285-7 2016 We also provide the first in vivo evidence that statins inhibit the isoprenylation of RhoA in the brains of rats and RhoA, Cdc42, and H-Ras in the brains of mice treated with clinically relevant doses of simvastatin. Simvastatin 204-215 ras homolog family member A Rattus norvegicus 117-121 27180285-7 2016 We also provide the first in vivo evidence that statins inhibit the isoprenylation of RhoA in the brains of rats and RhoA, Cdc42, and H-Ras in the brains of mice treated with clinically relevant doses of simvastatin. Simvastatin 204-215 cell division cycle 42 Rattus norvegicus 123-128 27180285-7 2016 We also provide the first in vivo evidence that statins inhibit the isoprenylation of RhoA in the brains of rats and RhoA, Cdc42, and H-Ras in the brains of mice treated with clinically relevant doses of simvastatin. Simvastatin 204-215 HRas proto-oncogene, GTPase Rattus norvegicus 134-139 27335167-7 2016 The inhibitory effect of simvastatin on atrial fibroblasts was abrogated by mevalonic acid (500 muM) that bypasses 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-172 27478339-12 2016 Connective tissue growth factor (CTGF) and transforming growth factor (TGF)-beta1 gene expression decreased significantly in the simvastatin group compared to the control group (P < 0.001). Simvastatin 129-140 cellular communication network factor 2 Rattus norvegicus 0-31 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 interleukin 6 Homo sapiens 25-29 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 C-X-C motif chemokine ligand 8 Homo sapiens 31-35 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 tumor necrosis factor Homo sapiens 41-49 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 interleukin 6 Homo sapiens 84-88 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 C-X-C motif chemokine ligand 8 Homo sapiens 93-97 27478339-12 2016 Connective tissue growth factor (CTGF) and transforming growth factor (TGF)-beta1 gene expression decreased significantly in the simvastatin group compared to the control group (P < 0.001). Simvastatin 129-140 cellular communication network factor 2 Rattus norvegicus 33-37 27478339-12 2016 Connective tissue growth factor (CTGF) and transforming growth factor (TGF)-beta1 gene expression decreased significantly in the simvastatin group compared to the control group (P < 0.001). Simvastatin 129-140 transforming growth factor, beta 1 Rattus norvegicus 43-81 27016018-0 2016 Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 35-41 26169112-11 2016 The present study highlights a significant role of ROCK/p-Akt/eNOS pathway in the protective effects of fasudil and simvastatin on neurotoxicity and mitochondrial dysfunction induced by 3-NP in rats. Simvastatin 116-127 AKT serine/threonine kinase 1 Rattus norvegicus 58-61 26198568-0 2016 Simvastatin Enhances Spatial Memory and Long-Term Potentiation in Hippocampal CA1 via Upregulation of alpha7 Nicotinic Acetylcholine Receptor. Simvastatin 0-11 carbonic anhydrase 1 Mus musculus 78-81 27016018-0 2016 Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 76-82 27016018-0 2016 Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 87-93 27016018-0 2016 Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Simvastatin 0-11 Rous sarcoma oncogene Mus musculus 136-139 27016018-0 2016 Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Simvastatin 0-11 carbonic anhydrase 1 Mus musculus 165-168 27194589-0 2016 Simvastatin downregulated C35 expression and inhibited the proliferation of colon cancer cells Lovo and HT29 in vitro. Simvastatin 0-11 migration and invasion enhancer 1 Homo sapiens 26-29 27329838-6 2016 Treatment with simvastatin to inhibit HMG CoA reductase, the rate limiting enzyme of this pathway, induced apoptosis in the 28-2 cell line. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 38-55 27453531-10 2016 Moreover, simvastatin improved restenosis indicators by suppressing the HIF-1alpha/calpains/MMP2/TGF-beta1 pathway. Simvastatin 10-21 hypoxia inducible factor 1, alpha subunit Mus musculus 72-82 27453531-10 2016 Moreover, simvastatin improved restenosis indicators by suppressing the HIF-1alpha/calpains/MMP2/TGF-beta1 pathway. Simvastatin 10-21 matrix metallopeptidase 2 Mus musculus 92-96 27453531-10 2016 Moreover, simvastatin improved restenosis indicators by suppressing the HIF-1alpha/calpains/MMP2/TGF-beta1 pathway. Simvastatin 10-21 transforming growth factor, beta 1 Mus musculus 97-106 27453531-11 2016 However, MMP2 supplementation eliminated the vascular protection of calpastatin induction and simvastatin. Simvastatin 94-105 matrix metallopeptidase 2 Mus musculus 9-13 27194589-3 2016 Real-time PCR and Western blotting assays showed that simvastatin significantly suppressed C35 expression at both mRNA and protein levels. Simvastatin 54-65 migration and invasion enhancer 1 Homo sapiens 91-94 27194589-4 2016 Since C35 is known to have a significant oncogenic role in cancer development via promoting cell proliferation and migration, results obtained in the current study imply that downregulation of C35 expression might be involved in the antitumor effect of simvastatin on colon cancer. Simvastatin 253-264 migration and invasion enhancer 1 Homo sapiens 6-9 27194589-4 2016 Since C35 is known to have a significant oncogenic role in cancer development via promoting cell proliferation and migration, results obtained in the current study imply that downregulation of C35 expression might be involved in the antitumor effect of simvastatin on colon cancer. Simvastatin 253-264 migration and invasion enhancer 1 Homo sapiens 193-196 27159292-15 2016 In rabbit meniscal cells, BMP-2 and BMP-7 were upregulated after 4 and 8 hours and after 7 and 14 days, whereas COL1A1 and COL2A1 were significantly upregulated by simvastatin after 7 and 14 days. Simvastatin 164-175 collagen alpha-1(I) chain Oryctolagus cuniculus 112-118 27471375-8 2016 The protective benefits of SIM may be attributed to scavenging malondialdehyde, remitting collagen deposition, and reducing and delaying the elevation of transforming growth factor beta1 expression induced by radiation. Simvastatin 27-30 hemoglobin, beta adult major chain Mus musculus 181-186 27323826-0 2016 Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 20-36 27323826-0 2016 Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 41-63 27323826-0 2016 Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 65-69 27323826-0 2016 Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 90-93 27323826-0 2016 Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 103-106 27323826-4 2016 We investigated whether simvastatin stimulates the expression of Nrf2 and nuclear translocation of Nrf2 and which signal pathway is involved in the expression of Nrf2 and antioxidant enzymes. Simvastatin 24-35 NFE2 like bZIP transcription factor 2 Homo sapiens 65-69 27323826-4 2016 We investigated whether simvastatin stimulates the expression of Nrf2 and nuclear translocation of Nrf2 and which signal pathway is involved in the expression of Nrf2 and antioxidant enzymes. Simvastatin 24-35 NFE2 like bZIP transcription factor 2 Homo sapiens 99-103 27323826-4 2016 We investigated whether simvastatin stimulates the expression of Nrf2 and nuclear translocation of Nrf2 and which signal pathway is involved in the expression of Nrf2 and antioxidant enzymes. Simvastatin 24-35 NFE2 like bZIP transcription factor 2 Homo sapiens 99-103 27323826-5 2016 We investigated the effect of simvastatin on the expression of Nrf2 and nuclear translocation of Nrf2 in two human colon cancer cell lines, HT-29 and HCT 116 through cell proliferation assay, Western blotting and immunocytochemical analysis. Simvastatin 30-41 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 27323826-5 2016 We investigated the effect of simvastatin on the expression of Nrf2 and nuclear translocation of Nrf2 in two human colon cancer cell lines, HT-29 and HCT 116 through cell proliferation assay, Western blotting and immunocytochemical analysis. Simvastatin 30-41 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 27323826-6 2016 We evaluated which signal pathway such as ERK or PI3K pathway affect Nrf2 activation and whether simvastatin induces antioxidant enzymes (heme oxygenase-1 (HO-1), NAD(P)H: quinine oxidoreductase 1 (NQO1), gamma-glutamate-cysteine ligase catalytic subunit (GCLC)). Simvastatin 97-108 heme oxygenase 1 Homo sapiens 138-154 27323826-6 2016 We evaluated which signal pathway such as ERK or PI3K pathway affect Nrf2 activation and whether simvastatin induces antioxidant enzymes (heme oxygenase-1 (HO-1), NAD(P)H: quinine oxidoreductase 1 (NQO1), gamma-glutamate-cysteine ligase catalytic subunit (GCLC)). Simvastatin 97-108 NAD(P)H quinone dehydrogenase 1 Homo sapiens 163-196 27323826-7 2016 We demonstrated simvastatin-induced dose-dependent up-regulation of Nrf2 expression and stimulated Nrf2 nuclear translocation in colon cancer cells. Simvastatin 16-27 NFE2 like bZIP transcription factor 2 Homo sapiens 68-72 27323826-7 2016 We demonstrated simvastatin-induced dose-dependent up-regulation of Nrf2 expression and stimulated Nrf2 nuclear translocation in colon cancer cells. Simvastatin 16-27 NFE2 like bZIP transcription factor 2 Homo sapiens 99-103 27323826-8 2016 We also demonstrated that simvastatin-induced anti-oxidant enzymes (HO-1, NQO1, and GCLC) in HT-29 and HCT 116 cells. Simvastatin 26-37 heme oxygenase 1 Homo sapiens 68-72 27323826-8 2016 We also demonstrated that simvastatin-induced anti-oxidant enzymes (HO-1, NQO1, and GCLC) in HT-29 and HCT 116 cells. Simvastatin 26-37 NAD(P)H quinone dehydrogenase 1 Homo sapiens 74-78 27323826-8 2016 We also demonstrated that simvastatin-induced anti-oxidant enzymes (HO-1, NQO1, and GCLC) in HT-29 and HCT 116 cells. Simvastatin 26-37 glutamate-cysteine ligase catalytic subunit Homo sapiens 84-88 27323826-9 2016 PI3K/Akt inhibitor (LY294002) and ERK inhibitor (PD98059) suppressed simvastatin-induced Nrf2 and HO-1 expression in both HT-29 and HCT 116 cells. Simvastatin 69-80 AKT serine/threonine kinase 1 Homo sapiens 5-8 27323826-9 2016 PI3K/Akt inhibitor (LY294002) and ERK inhibitor (PD98059) suppressed simvastatin-induced Nrf2 and HO-1 expression in both HT-29 and HCT 116 cells. Simvastatin 69-80 mitogen-activated protein kinase 1 Homo sapiens 34-37 27323826-9 2016 PI3K/Akt inhibitor (LY294002) and ERK inhibitor (PD98059) suppressed simvastatin-induced Nrf2 and HO-1 expression in both HT-29 and HCT 116 cells. Simvastatin 69-80 NFE2 like bZIP transcription factor 2 Homo sapiens 89-93 27323826-9 2016 PI3K/Akt inhibitor (LY294002) and ERK inhibitor (PD98059) suppressed simvastatin-induced Nrf2 and HO-1 expression in both HT-29 and HCT 116 cells. Simvastatin 69-80 heme oxygenase 1 Homo sapiens 98-102 27323826-10 2016 This study shows that simvastatin induces the activation and nuclear translocation of Nrf2 and the expression of various anti-oxidant enzymes via ERK and PI3K/Akt pathway in colon cancer cells. Simvastatin 22-33 NFE2 like bZIP transcription factor 2 Homo sapiens 86-90 27323826-10 2016 This study shows that simvastatin induces the activation and nuclear translocation of Nrf2 and the expression of various anti-oxidant enzymes via ERK and PI3K/Akt pathway in colon cancer cells. Simvastatin 22-33 mitogen-activated protein kinase 1 Homo sapiens 146-149 27323826-10 2016 This study shows that simvastatin induces the activation and nuclear translocation of Nrf2 and the expression of various anti-oxidant enzymes via ERK and PI3K/Akt pathway in colon cancer cells. Simvastatin 22-33 AKT serine/threonine kinase 1 Homo sapiens 159-162 27159292-15 2016 In rabbit meniscal cells, BMP-2 and BMP-7 were upregulated after 4 and 8 hours and after 7 and 14 days, whereas COL1A1 and COL2A1 were significantly upregulated by simvastatin after 7 and 14 days. Simvastatin 164-175 collagen alpha-1(II) chain Oryctolagus cuniculus 123-129 27578133-8 2016 RESULTS: Patients who started statin therapy (N = 345, 59.42% atorvastatin and 40.58% simvastatin) experienced a greater decrease in insulin sensitivity (19.27% vs 12.82% P < .001) and metabolic control deterioration compared with statin-free group. Simvastatin 86-97 insulin Homo sapiens 133-140 27381601-0 2016 Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Through Induction of HO-1 in Cultured Renal Proximal Tubule Cells. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 79-83 27381601-1 2016 BACKGROUND/AIM: Studies have shown that simvastatin (SIM) inhibits epithelial-mesenchymal transition (EMT), a key step in fibrosis, and activates the anti-fibrotic heme oxygenase-1 (HO-1) gene in renal proximal tubule cells independent of its lipid-lowering. Simvastatin 40-51 heme oxygenase 1 Homo sapiens 164-180 27381601-1 2016 BACKGROUND/AIM: Studies have shown that simvastatin (SIM) inhibits epithelial-mesenchymal transition (EMT), a key step in fibrosis, and activates the anti-fibrotic heme oxygenase-1 (HO-1) gene in renal proximal tubule cells independent of its lipid-lowering. Simvastatin 40-51 heme oxygenase 1 Homo sapiens 182-186 27273142-9 2016 Simvastatin significantly inhibited the systemic and local expression of P-selectin, whereas LMWH was inhibitory only at the late stage of the acute phase. Simvastatin 0-11 P-selectin Oryctolagus cuniculus 73-83 27273142-10 2016 Plasma active concentration and local gene expression of PAI-1 was inhibited by simvastatin, whereas for u-PA; it was promoted at the early stage of the acute phase, but inhibited in the late stage. Simvastatin 80-91 plasminogen activator inhibitor 1 Oryctolagus cuniculus 57-62 27347133-6 2016 In addition, simvastatin suppressed the expression of IGF-1R and inhibited the activity of phosphorylated-extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-Akt activated by IGF-1. Simvastatin 13-24 insulin like growth factor 1 receptor Homo sapiens 54-60 26443048-0 2016 Simvastatin inhibits neural cell apoptosis and promotes locomotor recovery via activation of Wnt/beta-catenin signaling pathway after spinal cord injury. Simvastatin 0-11 catenin beta 1 Rattus norvegicus 97-109 26443048-3 2016 This study demonstrates that the hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin (Simv) exhibits neuroprotective effects on neuronal apoptosis and supports functional recovery in a rat SCI model by activating the Wnt/beta-catenin signaling pathway. Simvastatin 86-97 catenin beta 1 Rattus norvegicus 234-246 26443048-3 2016 This study demonstrates that the hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin (Simv) exhibits neuroprotective effects on neuronal apoptosis and supports functional recovery in a rat SCI model by activating the Wnt/beta-catenin signaling pathway. Simvastatin 99-103 catenin beta 1 Rattus norvegicus 234-246 26443048-7 2016 However, the anti-apoptotic effects of Simv were reduced in cultured spinal cord nerve cells when the Wnt/beta-catenin signaling pathway was suppressed in the lipopolysaccharide-induced model. Simvastatin 39-43 catenin beta 1 Rattus norvegicus 106-118 26443048-9 2016 This study is the first to report that Simv exerts neuroprotective effects by reducing neuronal apoptosis, and promoting functional and pathological recovery after SCI by activating the Wnt/beta-catenin signaling pathway. Simvastatin 39-43 catenin beta 1 Rattus norvegicus 190-202 26443048-11 2016 Simvastatin reduced neuronal apoptosis, improved the functional and pathological recovery via activating Wnt/beta-catenin signal pathway, however, the anti-apoptosis effects of simvastatin were reversed following suppressing Wnt/beta-catenin signaling pathway in primary spinal cord neurons. Simvastatin 0-11 catenin beta 1 Rattus norvegicus 109-121 26443048-11 2016 Simvastatin reduced neuronal apoptosis, improved the functional and pathological recovery via activating Wnt/beta-catenin signal pathway, however, the anti-apoptosis effects of simvastatin were reversed following suppressing Wnt/beta-catenin signaling pathway in primary spinal cord neurons. Simvastatin 177-188 catenin beta 1 Rattus norvegicus 109-121 26443048-11 2016 Simvastatin reduced neuronal apoptosis, improved the functional and pathological recovery via activating Wnt/beta-catenin signal pathway, however, the anti-apoptosis effects of simvastatin were reversed following suppressing Wnt/beta-catenin signaling pathway in primary spinal cord neurons. Simvastatin 177-188 catenin beta 1 Rattus norvegicus 229-241 27089822-5 2016 The production of HIF-alpha increased when the cells were stimulated by heme (p<0.01), while treatment with HU and simvastatin reduced the production (p<0.01), and treatment with ascorbic acid increased HIF-1a production by the cells (p<0.01). Simvastatin 118-129 hypoxia inducible factor 1 subunit alpha Homo sapiens 209-215 27347133-6 2016 In addition, simvastatin suppressed the expression of IGF-1R and inhibited the activity of phosphorylated-extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-Akt activated by IGF-1. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 106-152 27347133-6 2016 In addition, simvastatin suppressed the expression of IGF-1R and inhibited the activity of phosphorylated-extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-Akt activated by IGF-1. Simvastatin 13-24 AKT serine/threonine kinase 1 Homo sapiens 172-175 26988924-4 2016 RESULTS: The in vitro studies showed that simvastatin potently inhibited the expression of MMP-1, MMP-8, and MMP-9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. Simvastatin 42-53 matrix metallopeptidase 1 Homo sapiens 91-96 27347133-6 2016 In addition, simvastatin suppressed the expression of IGF-1R and inhibited the activity of phosphorylated-extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-Akt activated by IGF-1. Simvastatin 13-24 insulin like growth factor 1 Homo sapiens 54-59 26988924-4 2016 RESULTS: The in vitro studies showed that simvastatin potently inhibited the expression of MMP-1, MMP-8, and MMP-9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. Simvastatin 42-53 matrix metallopeptidase 8 Homo sapiens 98-103 27347133-7 2016 Simvastatin and IGF-1 each stimulated the activity of phosphorylated ERK1/2. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 69-75 26988924-4 2016 RESULTS: The in vitro studies showed that simvastatin potently inhibited the expression of MMP-1, MMP-8, and MMP-9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. Simvastatin 42-53 matrix metallopeptidase 9 Homo sapiens 109-114 27347133-9 2016 Mevalonic acid and PD98059 reversed the ERK activation and apoptosis induced by treatment with simvastatin. Simvastatin 95-106 mitogen-activated protein kinase 1 Homo sapiens 40-43 27347133-10 2016 It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin 22-33 insulin like growth factor 1 Homo sapiens 97-102 27347133-10 2016 It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin 22-33 mitogen-activated protein kinase 1 Homo sapiens 111-114 27347133-10 2016 It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin 22-33 AKT serine/threonine kinase 1 Homo sapiens 119-122 27347133-10 2016 It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin 22-33 insulin like growth factor 1 receptor Homo sapiens 160-166 27347133-10 2016 It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation. Simvastatin 22-33 mitogen-activated protein kinase 1 Homo sapiens 195-198 27275740-0 2016 Simvastatin Inhibits IL-5-Induced Chemotaxis and CCR3 Expression of HL-60-Derived and Human Primary Eosinophils. Simvastatin 0-11 interleukin 5 Homo sapiens 21-25 27155462-0 2016 Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion. Simvastatin 0-11 caspase 9 Rattus norvegicus 33-42 27155462-0 2016 Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion. Simvastatin 0-11 receptor interacting serine/threonine kinase 1 Rattus norvegicus 47-52 27155462-8 2016 Simvastatin pretreatment decreased mRNA expression of caspase-3 and -9, and RIPK1 and -3 and protein activity of caspase-9 and RIPK1 in the allografts. Simvastatin 0-11 caspase 3 Rattus norvegicus 54-70 27155462-8 2016 Simvastatin pretreatment decreased mRNA expression of caspase-3 and -9, and RIPK1 and -3 and protein activity of caspase-9 and RIPK1 in the allografts. Simvastatin 0-11 receptor interacting serine/threonine kinase 1 Rattus norvegicus 76-88 27155462-8 2016 Simvastatin pretreatment decreased mRNA expression of caspase-3 and -9, and RIPK1 and -3 and protein activity of caspase-9 and RIPK1 in the allografts. Simvastatin 0-11 caspase 9 Rattus norvegicus 113-122 27155462-8 2016 Simvastatin pretreatment decreased mRNA expression of caspase-3 and -9, and RIPK1 and -3 and protein activity of caspase-9 and RIPK1 in the allografts. Simvastatin 0-11 receptor interacting serine/threonine kinase 1 Rattus norvegicus 76-81 27453100-6 2016 CONCLUSIONS: PSSA indicated that there might be potential association between statins use and liver-injury, especially the uses of atorvastatin and simvastatin. Simvastatin 148-159 phosphatidylserine synthase 1 Homo sapiens 13-17 27493486-14 2016 The mRNA expressions of SIRT1 in the liver were increased by DSKT and simvastatin. Simvastatin 70-81 sirtuin 1 Rattus norvegicus 24-29 27493486-16 2016 High dose DSKT reveals a stronger effect than simvastatin on the expressions of SIRT1 and NF-kappaB. Simvastatin 46-57 sirtuin 1 Rattus norvegicus 80-85 27155397-0 2016 Reversal effect of simvastatin on the decrease in cannabinoid receptor 1 density in 6-hydroxydopamine lesioned rat brains. Simvastatin 19-30 cannabinoid receptor 1 Rattus norvegicus 50-72 27155397-5 2016 FINDINGS: The 6-OHDA induced a remarkable downregulation of CB1 receptor density in the prefrontal cortex, caudate putamen, nucleus accumbens, cingulate cortex, hippocampus, and substantia nigra; while simvastatin (10mg/kg/day) significantly ameliorated this downregulation in those regions. Simvastatin 202-213 cannabinoid receptor 1 Rattus norvegicus 60-63 27155397-6 2016 Furthermore, simvastatin (1mg/kg/day) reversed the 6-OHDA-induced downregulation of CB1 receptors in the substantia nigra and hippocampus. Simvastatin 13-24 cannabinoid receptor 1 Rattus norvegicus 84-87 27155397-9 2016 Our data suggest a critical role of CB1 receptors in treating PD with simvastatin, and implicate CB1 receptors as a potential therapeutic target in the treatment of PD. Simvastatin 70-81 cannabinoid receptor 1 Rattus norvegicus 36-39 27275740-0 2016 Simvastatin Inhibits IL-5-Induced Chemotaxis and CCR3 Expression of HL-60-Derived and Human Primary Eosinophils. Simvastatin 0-11 C-C motif chemokine receptor 3 Homo sapiens 49-53 27275740-3 2016 Our aim was to investigate the effect of simvastatin on IL-5-induced eosinophil chemotaxis and its regulatory mechanisms. Simvastatin 41-52 interleukin 5 Homo sapiens 56-60 27275740-12 2016 Simvastatin inhibited the effects of IL-5 on BA-E cells, but not in the presence of mevalonate. Simvastatin 0-11 interleukin 5 Homo sapiens 37-41 27275740-15 2016 Therefore, simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway. Simvastatin 11-22 interleukin 5 Homo sapiens 51-55 27275740-15 2016 Therefore, simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway. Simvastatin 11-22 C-C motif chemokine receptor 3 Homo sapiens 64-68 26875818-0 2016 Simvastatin and atorvastatin facilitates amyloid beta-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways. Simvastatin 0-11 membrane metalloendopeptidase Homo sapiens 112-122 26552039-8 2016 Chronic treatment with ezetimibe/simvastatin decreased the activity of the key enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase by 59% and 45%, respectively, which is probably the major reason for the decreased gluconeogenesis seen in ezetimibe-/simvastatin-treated rats. Simvastatin 33-44 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 87-108 26552039-8 2016 Chronic treatment with ezetimibe/simvastatin decreased the activity of the key enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase by 59% and 45%, respectively, which is probably the major reason for the decreased gluconeogenesis seen in ezetimibe-/simvastatin-treated rats. Simvastatin 259-270 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 87-108 27040680-10 2016 Simvastatin up-regulated abcb4 and cyp3a65 transcription (both concentrations), as well as abcc1 and abcc2 at 50 mug/L, and down-regulated gst, sod, cat at 5 mug/L. Simvastatin 0-11 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Danio rerio 25-30 27040680-10 2016 Simvastatin up-regulated abcb4 and cyp3a65 transcription (both concentrations), as well as abcc1 and abcc2 at 50 mug/L, and down-regulated gst, sod, cat at 5 mug/L. Simvastatin 0-11 cytochrome P450, family 3, subfamily A, polypeptide 65 Danio rerio 35-42 27040680-10 2016 Simvastatin up-regulated abcb4 and cyp3a65 transcription (both concentrations), as well as abcc1 and abcc2 at 50 mug/L, and down-regulated gst, sod, cat at 5 mug/L. Simvastatin 0-11 catalase Danio rerio 149-152 26875818-0 2016 Simvastatin and atorvastatin facilitates amyloid beta-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 171-175 26875818-0 2016 Simvastatin and atorvastatin facilitates amyloid beta-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 176-182 26875818-6 2016 Treating cultured rat astrocytes with simvastatin and atorvastatin significantly decreased the expression of NEP but not IDE in a concentration- and time-dependent manner. Simvastatin 38-49 membrane metallo-endopeptidase Rattus norvegicus 109-112 26875818-6 2016 Treating cultured rat astrocytes with simvastatin and atorvastatin significantly decreased the expression of NEP but not IDE in a concentration- and time-dependent manner. Simvastatin 38-49 insulin degrading enzyme Rattus norvegicus 121-124 26875818-9 2016 Furthermore, the cultured medium prepared from simvastatin- and atorvastatin-treated astrocytes significantly induced the degradation of exogenous Abeta. Simvastatin 47-58 amyloid beta precursor protein Homo sapiens 147-152 26875818-10 2016 These results suggest that simvastatin and atorvastatin induce the increase of Abeta degradation of NEP on the extracellular of astrocytes by inducing ERK-mediated pathway activity and that these reagents regulate the differential mechanisms between the secretion of NEP, the induction of cholesterol reduction, and the morphological changes in the cultured astrocytes. Simvastatin 27-38 membrane metalloendopeptidase Homo sapiens 100-103 26875818-10 2016 These results suggest that simvastatin and atorvastatin induce the increase of Abeta degradation of NEP on the extracellular of astrocytes by inducing ERK-mediated pathway activity and that these reagents regulate the differential mechanisms between the secretion of NEP, the induction of cholesterol reduction, and the morphological changes in the cultured astrocytes. Simvastatin 27-38 mitogen-activated protein kinase 1 Homo sapiens 151-154 26875818-10 2016 These results suggest that simvastatin and atorvastatin induce the increase of Abeta degradation of NEP on the extracellular of astrocytes by inducing ERK-mediated pathway activity and that these reagents regulate the differential mechanisms between the secretion of NEP, the induction of cholesterol reduction, and the morphological changes in the cultured astrocytes. Simvastatin 27-38 membrane metalloendopeptidase Homo sapiens 267-270 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Simvastatin 43-54 BCL2 apoptosis regulator Homo sapiens 154-159 26574150-5 2016 The effects of simvastatin on the EMT induced by LPS or TGF-beta1 were determined by the changes in the levels of EMT markers and TLR4 and in the c-Jun N-terminal kinase (JNK), p38, and nuclear factor-kappaB (NF-kappaB) signaling pathways. Simvastatin 15-26 transforming growth factor beta 1 Homo sapiens 56-65 26574150-6 2016 RESULTS: Compared with the BECs treated with LPS alone, co-treatment with simvastatin and LPS induced an increase in the expression of E-cadherin and decreases in the expression levels of mesenchymal cell markers. Simvastatin 74-85 cadherin 1 Homo sapiens 135-145 26574150-7 2016 The LPS-induced TLR4 expression level was slightly decreased by co-treatment with simvastatin. Simvastatin 82-93 toll like receptor 4 Homo sapiens 16-20 26574150-9 2016 Furthermore, pretreatment with simvastatin inhibited the LPS-induced EMT in BECs by downregulating NF-kappaB and JNK phosphorylation. Simvastatin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 99-108 26574150-9 2016 Furthermore, pretreatment with simvastatin inhibited the LPS-induced EMT in BECs by downregulating NF-kappaB and JNK phosphorylation. Simvastatin 31-42 mitogen-activated protein kinase 8 Homo sapiens 113-116 26574150-10 2016 The suppressive effects of simvastatin pretreatment on the induction of the EMT by TGF-beta1 were also demonstrated in H69 cells. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 83-92 26574150-11 2016 CONCLUSIONS: Our results demonstrate that LPS or TGF-beta1 promote the EMT in BECs that that pretreatment with simvastatin inhibited the induced EMT by downregulating toll-like receptor 4 and NF-kappaB phosphorylation. Simvastatin 111-122 transforming growth factor beta 1 Homo sapiens 49-58 26574150-11 2016 CONCLUSIONS: Our results demonstrate that LPS or TGF-beta1 promote the EMT in BECs that that pretreatment with simvastatin inhibited the induced EMT by downregulating toll-like receptor 4 and NF-kappaB phosphorylation. Simvastatin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 192-201 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Simvastatin 43-54 BCL2 associated X, apoptosis regulator Homo sapiens 160-163 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Simvastatin 43-54 caspase 3 Homo sapiens 183-192 27109251-7 2016 Pretreatment with KMUP-1, atorvastatin and simvastatin significantly prevented hypoxia-induced EPCs death and apoptosis, with associated increased of the Bcl-2/Bax ratio, and reduced caspase-3 and caspase-9 expression. Simvastatin 43-54 caspase 9 Homo sapiens 197-206 27358845-12 2016 In LNCaP cells, the protein level of LDLr was increased by simvastatin. Simvastatin 59-70 low density lipoprotein receptor Homo sapiens 37-41 27121011-0 2016 Simvastatin ameliorates ventricular remodeling via the TGF-beta1 signaling pathway in rats following myocardial infarction. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 55-64 27121011-7 2016 The results revealed that simvastatin significantly improved the hemodynamic indexes, left ventricular mass index, the myocardial tissue structure, the cardiomyocyte cross-sectional area and the collagen volume fraction, and also showed that the levels of TGF-beta1, TGF-activated kinase (TAK)1 and drosophila mothers against decapentaplegic (Smad)3 were significantly reduced following treatment with simvastatin, while the levels of Smad7 in the simvastatin treatment groups were markedly increased. Simvastatin 26-37 transforming growth factor, beta 1 Rattus norvegicus 256-265 27121011-7 2016 The results revealed that simvastatin significantly improved the hemodynamic indexes, left ventricular mass index, the myocardial tissue structure, the cardiomyocyte cross-sectional area and the collagen volume fraction, and also showed that the levels of TGF-beta1, TGF-activated kinase (TAK)1 and drosophila mothers against decapentaplegic (Smad)3 were significantly reduced following treatment with simvastatin, while the levels of Smad7 in the simvastatin treatment groups were markedly increased. Simvastatin 26-37 TGF-beta activated kinase 1 Drosophila melanogaster 267-294 27121011-7 2016 The results revealed that simvastatin significantly improved the hemodynamic indexes, left ventricular mass index, the myocardial tissue structure, the cardiomyocyte cross-sectional area and the collagen volume fraction, and also showed that the levels of TGF-beta1, TGF-activated kinase (TAK)1 and drosophila mothers against decapentaplegic (Smad)3 were significantly reduced following treatment with simvastatin, while the levels of Smad7 in the simvastatin treatment groups were markedly increased. Simvastatin 26-37 Mothers against dpp Drosophila melanogaster 310-349 27358845-15 2016 After knocking down LDLr expression by siRNA, intracellular cholesterol levels were decreased, and cell proliferation was inhibited by simvastatin in LNCaP cells. Simvastatin 135-146 low density lipoprotein receptor Homo sapiens 20-24 27358845-16 2016 CONCLUSION: Simvastatin inhibited prostate cancer cell growth by decreasing cellular cholesterol and could be more effective in androgen-independent prostate cancer, where there is loss of regulation of LDLr expression. Simvastatin 12-23 low density lipoprotein receptor Homo sapiens 203-207 27307760-4 2016 The strongest association between statin-induced myopathy and SLCO1B1 gene polymorphism was described for simvastatin. Simvastatin 106-117 solute carrier organic anion transporter family member 1B1 Homo sapiens 62-69 27142363-3 2016 We report a case of myoglobin-induced acute renal failure secondary to the concomitant use of simvastatin and amiodarone. Simvastatin 94-105 myoglobin Homo sapiens 20-29 27207105-9 2016 Simvastatin was the most potent inhibitor of sFlt-1 secretion from endothelial cells (IC 50 3.2 muM), trophoblast cells (IC 50 61.4 muM) and placental explants. Simvastatin 0-11 latexin Homo sapiens 96-99 27207105-9 2016 Simvastatin was the most potent inhibitor of sFlt-1 secretion from endothelial cells (IC 50 3.2 muM), trophoblast cells (IC 50 61.4 muM) and placental explants. Simvastatin 0-11 latexin Homo sapiens 132-135 27098189-11 2016 Simvastatin enhanced the release of cytochrome c, caspase 3, and increased p21 levels, especially for the KKU-100 cells. Simvastatin 0-11 cytochrome c, somatic Homo sapiens 36-48 27098189-11 2016 Simvastatin enhanced the release of cytochrome c, caspase 3, and increased p21 levels, especially for the KKU-100 cells. Simvastatin 0-11 caspase 3 Homo sapiens 50-59 27098189-11 2016 Simvastatin enhanced the release of cytochrome c, caspase 3, and increased p21 levels, especially for the KKU-100 cells. Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 75-78 26871266-0 2016 Simvastatin improves the homing of BMSCs via the PI3K/AKT/miR-9 pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 54-57 26575415-0 2016 Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking. Simvastatin 0-11 aquaporin 2 Homo sapiens 22-26 26575415-0 2016 Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking. Simvastatin 0-11 aquaporin 2 Homo sapiens 139-143 26871266-3 2016 Recent evidence indicates that simvastatin stimulates AKT phosphorylation, and p-AKT affects the expression of chemokine (CXC motif) receptor-4 (CXCR4). Simvastatin 31-42 AKT serine/threonine kinase 1 Rattus norvegicus 54-57 26871266-4 2016 Therefore, simvastatin may improve the expression of CXCR4 in BMSCs, and microRNAs (miRs) may participate in this process. Simvastatin 11-22 C-X-C motif chemokine receptor 4 Rattus norvegicus 53-58 26871266-5 2016 In this study, we demonstrated that simvastatin increased both the total and the surface expression of CXCR4 in BMSCs. Simvastatin 36-47 C-X-C motif chemokine receptor 4 Rattus norvegicus 103-108 26871266-7 2016 The PI3K/AKT pathway was activated by simvastatin in this process, and LY294002 reversed the overexpression of CXCR4 caused by simvastatin. Simvastatin 38-49 AKT serine/threonine kinase 1 Rattus norvegicus 9-12 26871266-7 2016 The PI3K/AKT pathway was activated by simvastatin in this process, and LY294002 reversed the overexpression of CXCR4 caused by simvastatin. Simvastatin 127-138 C-X-C motif chemokine receptor 4 Rattus norvegicus 111-116 26871266-11 2016 Taken together, our results indicated that simvastatin improved the migration of BMSCs via the PI3K/AKT pathway. Simvastatin 43-54 AKT serine/threonine kinase 1 Rattus norvegicus 100-103 26871266-12 2016 MiR-9 also participated in this process, and the phosphorylation of AKT affected miR-9 expression, suggesting that simvastatin might have beneficial effects in stem cell therapy. Simvastatin 115-126 AKT serine/threonine kinase 1 Rattus norvegicus 68-71 26952496-6 2016 Besides, SIM loaded MHA-PNIPAAM exhibited better performance on cell proliferation, ALP activity, and calcium deposition than pure MHA due to the sustained release of SIM. Simvastatin 9-12 alkaline phosphatase, placental Homo sapiens 84-87 27195204-0 2016 Effect of topical simvastatin (1.2 mg) on gingival crevicular fluid interleukin-6, interleukin-8 and interleukin-10 levels in chronic periodontitis - A clinicobiochemical study. Simvastatin 18-29 interleukin 6 Homo sapiens 68-81 27195204-0 2016 Effect of topical simvastatin (1.2 mg) on gingival crevicular fluid interleukin-6, interleukin-8 and interleukin-10 levels in chronic periodontitis - A clinicobiochemical study. Simvastatin 18-29 interleukin 10 Homo sapiens 101-115 27195204-2 2016 The present study aims to evaluate the in vivo effect of subgingivally delivered SMV gel (1.2 mg) as a local drug-delivery agent on clinical parameters and on interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) levels in gingival crevicular fluid (GCF) of chronic periodontitis patients. Simvastatin 81-84 C-X-C motif chemokine ligand 8 Homo sapiens 196-200 27195204-2 2016 The present study aims to evaluate the in vivo effect of subgingivally delivered SMV gel (1.2 mg) as a local drug-delivery agent on clinical parameters and on interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) levels in gingival crevicular fluid (GCF) of chronic periodontitis patients. Simvastatin 81-84 interleukin 10 Homo sapiens 206-220 27195204-2 2016 The present study aims to evaluate the in vivo effect of subgingivally delivered SMV gel (1.2 mg) as a local drug-delivery agent on clinical parameters and on interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) levels in gingival crevicular fluid (GCF) of chronic periodontitis patients. Simvastatin 81-84 interleukin 10 Homo sapiens 222-227 27195204-7 2016 RESULTS: SMV has an inhibitory effect on pro-inflammatory cytokines (IL-6, IL-8) and stimulatory effect on anti-inflammatory cytokines (IL-10) in GCF of periodontitis patients and has significantly positive effect on all clinical parameters except relative attachment level (RAL). Simvastatin 9-12 interleukin 6 Homo sapiens 69-73 27195204-7 2016 RESULTS: SMV has an inhibitory effect on pro-inflammatory cytokines (IL-6, IL-8) and stimulatory effect on anti-inflammatory cytokines (IL-10) in GCF of periodontitis patients and has significantly positive effect on all clinical parameters except relative attachment level (RAL). Simvastatin 9-12 C-X-C motif chemokine ligand 8 Homo sapiens 75-79 27195204-7 2016 RESULTS: SMV has an inhibitory effect on pro-inflammatory cytokines (IL-6, IL-8) and stimulatory effect on anti-inflammatory cytokines (IL-10) in GCF of periodontitis patients and has significantly positive effect on all clinical parameters except relative attachment level (RAL). Simvastatin 9-12 interleukin 10 Homo sapiens 136-141 26671887-7 2016 KLF2 expression was decreased in primary human aortic endothelial cells exposed to bacterial lipopolysaccharide or to oxidized low-density lipoprotein in vitro, and this could be prevented by simvastatin. Simvastatin 192-203 Kruppel like factor 2 Homo sapiens 0-4 27123120-0 2016 Simvastatin blocks TGF-beta1-induced epithelial-mesenchymal transition in human prostate cancer cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 19-28 26701313-0 2016 Simvastatin and a Plant Galactolipid Protect Animals from Septic Shock by Regulating Oxylipin Mediator Dynamics through the MAPK-cPLA2 Signaling Pathway. Simvastatin 0-11 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 129-134 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 toll-like receptor 4 Mus musculus 48-51 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 124-129 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 prostaglandin-endoperoxide synthase 2 Mus musculus 131-161 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 tumor necrosis factor Mus musculus 221-230 26701313-6 2016 dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Simvastatin 9-20 interleukin 6 Mus musculus 235-239 27123120-5 2016 It was demonstrated that simvastatin inhibited the EMT as assessed by reduced expression of N-cadherin and vimentin, and increased E-cadherin in TGF-beta1 treated DU145 PCa cells. Simvastatin 25-36 cadherin 2 Homo sapiens 92-102 27123120-5 2016 It was demonstrated that simvastatin inhibited the EMT as assessed by reduced expression of N-cadherin and vimentin, and increased E-cadherin in TGF-beta1 treated DU145 PCa cells. Simvastatin 25-36 vimentin Homo sapiens 107-115 27123120-5 2016 It was demonstrated that simvastatin inhibited the EMT as assessed by reduced expression of N-cadherin and vimentin, and increased E-cadherin in TGF-beta1 treated DU145 PCa cells. Simvastatin 25-36 cadherin 1 Homo sapiens 131-141 27123120-5 2016 It was demonstrated that simvastatin inhibited the EMT as assessed by reduced expression of N-cadherin and vimentin, and increased E-cadherin in TGF-beta1 treated DU145 PCa cells. Simvastatin 25-36 transforming growth factor beta 1 Homo sapiens 145-154 27123120-6 2016 Furthermore, simvastatin inhibited TGF-beta1-induced migration and invasion of DU145 cells. Simvastatin 13-24 transforming growth factor beta 1 Homo sapiens 35-44 27123120-9 2016 In the non-Smad pathway, simvastatin reduced TGF-beta1-induced p38 MAPK phosphorylation, but had no effect on TGF-beta1-induced Erk1/2 phosphorylation. Simvastatin 25-36 transforming growth factor beta 1 Homo sapiens 45-54 27123120-9 2016 In the non-Smad pathway, simvastatin reduced TGF-beta1-induced p38 MAPK phosphorylation, but had no effect on TGF-beta1-induced Erk1/2 phosphorylation. Simvastatin 25-36 mitogen-activated protein kinase 1 Homo sapiens 63-66 27165274-8 2016 CONCLUSION: According to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin. Simvastatin 172-183 erythropoietin Homo sapiens 233-247 27123120-9 2016 In the non-Smad pathway, simvastatin reduced TGF-beta1-induced p38 MAPK phosphorylation, but had no effect on TGF-beta1-induced Erk1/2 phosphorylation. Simvastatin 25-36 mitogen-activated protein kinase 3 Homo sapiens 67-71 27123120-10 2016 Simvastatin attenuated TGF-beta1-induced EMT, cell migration and invasion in DU145 cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 26541177-1 2016 Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor used clinically to reduce serum cholesterol. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 97-144 26842590-0 2016 Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. Simvastatin 0-11 NADPH oxidase 1 Mus musculus 111-132 26842590-9 2016 Real-time PCR showed that Hcy increased the mRNA expressions of Nox1 and Nox2, whereas simvastatin inhibited the stimulation of Nox1 and Nox2 expressions by Hcy. Simvastatin 87-98 NADPH oxidase 1 Mus musculus 128-132 26842590-9 2016 Real-time PCR showed that Hcy increased the mRNA expressions of Nox1 and Nox2, whereas simvastatin inhibited the stimulation of Nox1 and Nox2 expressions by Hcy. Simvastatin 87-98 cytochrome b-245, beta polypeptide Mus musculus 137-141 26842590-11 2016 These findings indicate that simvastatin prevents the detrimental effects of Hcy on the apoptosis of osteocytes by regulating the expressions of Nox1 and Nox2, suggesting that statins may be beneficial for preventing Hcy-induced osteocyte apoptosis and the resulting bone fragility. Simvastatin 29-40 NADPH oxidase 1 Mus musculus 145-149 26842590-11 2016 These findings indicate that simvastatin prevents the detrimental effects of Hcy on the apoptosis of osteocytes by regulating the expressions of Nox1 and Nox2, suggesting that statins may be beneficial for preventing Hcy-induced osteocyte apoptosis and the resulting bone fragility. Simvastatin 29-40 cytochrome b-245, beta polypeptide Mus musculus 154-158 27073470-9 2016 Treatment of HepG2 cells with increasing concentrations of simvastatin followed by treatment with 1 mM OA showed that low simvastatin concentrations (4-10 microM) were able to reduce lipid accumulation by ~40%, whereas high simvastatin concentrations (20 and 30 microM) induced apoptotic changes in cell morphology and increased the production of Annexin V+ microparticles. Simvastatin 59-70 annexin A5 Homo sapiens 347-356 26935883-8 2016 MCT4 knockdown suppressed atorvastatin-, simvastatin-, and fluvastatin-induced reduction of cell viability and apoptosis compared with negative control-treated cells. Simvastatin 41-52 solute carrier family 16 member 3 Homo sapiens 0-4 26996657-12 2016 The results in vivo demonstrated that the new bone formation and the expressions of BMP-2, OC and type I collagen were improved in the simvastatin-loaded CS-GEL group. Simvastatin 135-146 bone morphogenetic protein 2 Oryctolagus cuniculus 84-89 26917054-1 2016 Simvastatin and other statins (HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors) are extensively used in clinical practices and are very effective in decreasing serum low-density lipoprotein cholesterol. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 40-88 26917054-4 2016 We demonstrated: 1) a decrease in both serotonin transporter (SERT) activity and membrane microviscosity after treatment with simvastatin, 2) lower cholesterol content in all tested brain regions in animals from the simvastatin treated group, and 3) longer time spent in the open arms and a higher number of entrances to the closed arms in the elevated plus maze by animals from the simvastatin group compared to animals from the control group, but no differences in behavior in the open field test. Simvastatin 126-137 solute carrier family 6 member 4 Rattus norvegicus 62-66 26917054-4 2016 We demonstrated: 1) a decrease in both serotonin transporter (SERT) activity and membrane microviscosity after treatment with simvastatin, 2) lower cholesterol content in all tested brain regions in animals from the simvastatin treated group, and 3) longer time spent in the open arms and a higher number of entrances to the closed arms in the elevated plus maze by animals from the simvastatin group compared to animals from the control group, but no differences in behavior in the open field test. Simvastatin 216-227 solute carrier family 6 member 4 Rattus norvegicus 39-60 26917054-4 2016 We demonstrated: 1) a decrease in both serotonin transporter (SERT) activity and membrane microviscosity after treatment with simvastatin, 2) lower cholesterol content in all tested brain regions in animals from the simvastatin treated group, and 3) longer time spent in the open arms and a higher number of entrances to the closed arms in the elevated plus maze by animals from the simvastatin group compared to animals from the control group, but no differences in behavior in the open field test. Simvastatin 216-227 solute carrier family 6 member 4 Rattus norvegicus 62-66 26917054-4 2016 We demonstrated: 1) a decrease in both serotonin transporter (SERT) activity and membrane microviscosity after treatment with simvastatin, 2) lower cholesterol content in all tested brain regions in animals from the simvastatin treated group, and 3) longer time spent in the open arms and a higher number of entrances to the closed arms in the elevated plus maze by animals from the simvastatin group compared to animals from the control group, but no differences in behavior in the open field test. Simvastatin 216-227 solute carrier family 6 member 4 Rattus norvegicus 39-60 26917054-4 2016 We demonstrated: 1) a decrease in both serotonin transporter (SERT) activity and membrane microviscosity after treatment with simvastatin, 2) lower cholesterol content in all tested brain regions in animals from the simvastatin treated group, and 3) longer time spent in the open arms and a higher number of entrances to the closed arms in the elevated plus maze by animals from the simvastatin group compared to animals from the control group, but no differences in behavior in the open field test. Simvastatin 216-227 solute carrier family 6 member 4 Rattus norvegicus 62-66 27091343-0 2016 Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase. Simvastatin 51-62 nitric oxide synthase 3 Homo sapiens 74-107 27091343-9 2016 The detrimental effects of ADMA on simvastatin-induced NO production and angiogenesis were abolished by the antioxidant, N-acetylcysteine, NOX inhibitor, or apocynin or overexpression of dimethylarginine dimethylaminohydrolase 2 (DDAH-2). Simvastatin 35-46 dimethylarginine dimethylaminohydrolase 2 Homo sapiens 187-228 27091343-9 2016 The detrimental effects of ADMA on simvastatin-induced NO production and angiogenesis were abolished by the antioxidant, N-acetylcysteine, NOX inhibitor, or apocynin or overexpression of dimethylarginine dimethylaminohydrolase 2 (DDAH-2). Simvastatin 35-46 dimethylarginine dimethylaminohydrolase 2 Homo sapiens 230-236 27091343-10 2016 Moreover, in vivo, ADMA administration reduced Matrigel plug angiogenesis in wild-type mice and decreased simvastatin-induced eNOS phosphorylation in aortas of apolipoprotein E-deficient mice, but not endothelial DDAH-2-overexpressed aortas. Simvastatin 106-117 apolipoprotein E Mus musculus 160-176 27091343-10 2016 Moreover, in vivo, ADMA administration reduced Matrigel plug angiogenesis in wild-type mice and decreased simvastatin-induced eNOS phosphorylation in aortas of apolipoprotein E-deficient mice, but not endothelial DDAH-2-overexpressed aortas. Simvastatin 106-117 dimethylarginine dimethylaminohydrolase 2 Mus musculus 213-219 26868507-7 2016 Furthermore, simvastatin + ezetimibe increased catalase activity. Simvastatin 13-24 catalase Homo sapiens 47-55 26868507-9 2016 Finally, simvastatin, ezetimibe and simvastatin + ezetimibe reduced levels of the adhesion molecule ICAM-1, and ezetimibe + simvastatin significantly decreased levels of E-selectin. Simvastatin 9-20 intercellular adhesion molecule 1 Homo sapiens 100-106 26868507-9 2016 Finally, simvastatin, ezetimibe and simvastatin + ezetimibe reduced levels of the adhesion molecule ICAM-1, and ezetimibe + simvastatin significantly decreased levels of E-selectin. Simvastatin 36-47 intercellular adhesion molecule 1 Homo sapiens 100-106 26868507-9 2016 Finally, simvastatin, ezetimibe and simvastatin + ezetimibe reduced levels of the adhesion molecule ICAM-1, and ezetimibe + simvastatin significantly decreased levels of E-selectin. Simvastatin 36-47 intercellular adhesion molecule 1 Homo sapiens 100-106 27022048-1 2016 and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 157-168 C-reactive protein Homo sapiens 82-100 27022050-0 2016 Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 191-202 C-reactive protein Homo sapiens 116-134 27022257-9 2016 Tumors from all groups showed reduction in immunohistochemical expression of ICAM, MCP-1, and MMP-9; LDE-PTX and Simva presented the lowest MMP-9 expression. Simvastatin 113-118 matrix metallopeptidase 9 Mus musculus 140-145 27022257-10 2016 Expression of p21 was increased in the Simva, LDE-PTX, and LDE-PTX and Simva groups. Simvastatin 39-44 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 14-17 27022257-10 2016 Expression of p21 was increased in the Simva, LDE-PTX, and LDE-PTX and Simva groups. Simvastatin 71-76 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 14-17 27022257-11 2016 In the Simva and LDE-PTX and Simva groups, expression of cyclin D1, a proliferation and survival promoter of tumor cells, was decreased. Simvastatin 7-12 cyclin D1 Mus musculus 57-66 27022257-11 2016 In the Simva and LDE-PTX and Simva groups, expression of cyclin D1, a proliferation and survival promoter of tumor cells, was decreased. Simvastatin 29-34 cyclin D1 Mus musculus 57-66 26782071-3 2016 Acidic pHe-induced MMP-9 production was reduced by C3 exoenzyme, which inhibits the Rho family of GTPases; cytochalasin D, which inhibits actin reorganization; and simvastatin, which inhibits geranylgeranylation of Rho. Simvastatin 164-175 matrix metallopeptidase 9 Mus musculus 19-24 26470769-0 2016 Simvastatin Induces Apoptosis and Suppresses Insulin-Like Growth Factor 1 Receptor in Bile Duct Cancer Cells. Simvastatin 0-11 insulin like growth factor 1 receptor Homo sapiens 45-82 26470769-9 2016 Moreover, simvastatin suppressed the expression of the IGF-1 receptor and IGF-1-induced ERK/Akt activation. Simvastatin 10-21 insulin like growth factor 1 Homo sapiens 55-60 26470769-9 2016 Moreover, simvastatin suppressed the expression of the IGF-1 receptor and IGF-1-induced ERK/Akt activation. Simvastatin 10-21 insulin like growth factor 1 Homo sapiens 74-79 26470769-9 2016 Moreover, simvastatin suppressed the expression of the IGF-1 receptor and IGF-1-induced ERK/Akt activation. Simvastatin 10-21 mitogen-activated protein kinase 1 Homo sapiens 88-91 26470769-9 2016 Moreover, simvastatin suppressed the expression of the IGF-1 receptor and IGF-1-induced ERK/Akt activation. Simvastatin 10-21 AKT serine/threonine kinase 1 Homo sapiens 92-95 25727911-0 2016 Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia. Simvastatin 84-95 microRNA 146a Homo sapiens 18-26 25727911-0 2016 Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia. Simvastatin 84-95 prostaglandin-endoperoxide synthase 2 Homo sapiens 28-44 25727911-10 2016 Furthermore, simvastatin effectively reduced the expression of p53 and p21. Simvastatin 13-24 tumor protein p53 Homo sapiens 63-66 25727911-10 2016 Furthermore, simvastatin effectively reduced the expression of p53 and p21. Simvastatin 13-24 H3 histone pseudogene 16 Homo sapiens 71-74 26855507-0 2016 Changes of Apolipoprotein M Gene Expression During the Cell Differentiation and Apoptosis Induced by Simvastatin in Combination with All-Trans Retinoic Acid in Human Promyelocytic Leukemia Cell Line NB4. Simvastatin 101-112 apolipoprotein M Homo sapiens 11-27 30979140-4 2016 The release profile of simvastatin in the beta-CD grafted HAp was also evaluated. Simvastatin 23-34 reticulon 3 Homo sapiens 58-61 26238234-5 2016 RESULTS: Reduced post-castration tumor growth rate in simvastatin-treated mice correlated with delayed time to castration-resistant progression, determined by two serum PSA doublings from post-castration nadir, when compared with xenografts in mice on control diet. Simvastatin 54-65 aminopeptidase puromycin sensitive Mus musculus 169-172 26758890-6 2016 The results of our study indicated that all treatments promoted bone healing around implant compared to Control, but PTH + SIM treatment showed significantly stronger effects than PTH or SIM alone in histological, micro-CT, and biomechanical tests. Simvastatin 123-126 parathyroid hormone Rattus norvegicus 180-183 26758890-6 2016 The results of our study indicated that all treatments promoted bone healing around implant compared to Control, but PTH + SIM treatment showed significantly stronger effects than PTH or SIM alone in histological, micro-CT, and biomechanical tests. Simvastatin 187-190 parathyroid hormone Rattus norvegicus 117-120 30024693-1 2016 Objective: To explore the effect of simvastatin on the proliferation, apoptosis and protein expressions of keloid fibroblasts under normoxia,hypoxia or TGF-beta1 treatment. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 152-161 30024693-5 2016 Results: It showed that simvastatin could inhibit the proliferation of KFs in a concentration-and time-dependent manner with the concentration range of 10-500 mu mol/L for 24 h and 0.1-500 mu mol/L for 48 h. This inhibitory effect could be significantly enhanced when cells were incubated under hypoxia for 48h with 10-500 mu mol/L simvastatin.10 mu mol/L simvastatin could not influence the apoptosis of KFs under normoxia or TGF-beta1 treatment, neither incubated for 24 h nor 48 h.When incubated under hypoxia,10 mu mol/L simvastatin could significantly induce the apoptosis of KFs, with the rate of 155.6% for 24 h and 478.8% for 48 h, compared with no-drug control. Simvastatin 24-35 transforming growth factor beta 1 Homo sapiens 427-436 30024693-7 2016 KFs treated with 10 mu mol/L simvastatin under hypoxia for 48 h showed a significant decrease of type I collagen and CTGF, and a significant increase of TIMP-1. Simvastatin 29-40 cellular communication network factor 2 Homo sapiens 117-121 30024693-7 2016 KFs treated with 10 mu mol/L simvastatin under hypoxia for 48 h showed a significant decrease of type I collagen and CTGF, and a significant increase of TIMP-1. Simvastatin 29-40 TIMP metallopeptidase inhibitor 1 Homo sapiens 153-159 26905693-8 2016 In conclusion, WIR-induced injury to liver sinusoidal endothelial cells is mitigated by pre-treatment with Simvastatin probably through a KLF2-dependent mechanism. Simvastatin 107-118 Kruppel-like factor 2 Rattus norvegicus 138-142 26492285-0 2016 Simvastatin attenuates oleic acid-induced oxidative stress through CREB-dependent induction of heme oxygenase-1 in renal proximal tubule cells. Simvastatin 0-11 cAMP responsive element binding protein 1 Rattus norvegicus 67-71 26223190-11 2016 A single injection of the simvastatin/poloxamer 407 hydrogel significantly increased BMD, bone microstructure, and strength; the bone volume fraction and trabecular thickness increased nearly 150 %, bone strength almost doubled compared with controls (all P < 0.01); and induced higher expression of VEGF, BMP2, and osteocalcin. Simvastatin 26-37 vascular endothelial growth factor A Homo sapiens 303-307 26223190-11 2016 A single injection of the simvastatin/poloxamer 407 hydrogel significantly increased BMD, bone microstructure, and strength; the bone volume fraction and trabecular thickness increased nearly 150 %, bone strength almost doubled compared with controls (all P < 0.01); and induced higher expression of VEGF, BMP2, and osteocalcin. Simvastatin 26-37 bone morphogenetic protein 2 Homo sapiens 309-313 26223190-11 2016 A single injection of the simvastatin/poloxamer 407 hydrogel significantly increased BMD, bone microstructure, and strength; the bone volume fraction and trabecular thickness increased nearly 150 %, bone strength almost doubled compared with controls (all P < 0.01); and induced higher expression of VEGF, BMP2, and osteocalcin. Simvastatin 26-37 bone gamma-carboxyglutamate protein Homo sapiens 319-330 26403426-11 2016 RESULTS: Pretreatment with simvastatin prevented alendronate-induced macroscopic gastric damage and reduced the levels of MDA and GSH, TNF-alpha and IL-1beta, MPO activity, and mucus levels, in the stomach. Simvastatin 27-38 tumor necrosis factor Rattus norvegicus 135-144 26403426-11 2016 RESULTS: Pretreatment with simvastatin prevented alendronate-induced macroscopic gastric damage and reduced the levels of MDA and GSH, TNF-alpha and IL-1beta, MPO activity, and mucus levels, in the stomach. Simvastatin 27-38 interleukin 1 beta Rattus norvegicus 149-157 26403426-11 2016 RESULTS: Pretreatment with simvastatin prevented alendronate-induced macroscopic gastric damage and reduced the levels of MDA and GSH, TNF-alpha and IL-1beta, MPO activity, and mucus levels, in the stomach. Simvastatin 27-38 myeloperoxidase Rattus norvegicus 159-162 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 microRNA 192 Homo sapiens 11-18 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 microRNA 146a Homo sapiens 20-28 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 microRNA 148a Homo sapiens 30-38 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 microRNA 15a Homo sapiens 40-47 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 microRNA 21 Homo sapiens 53-59 26429200-8 2016 Changes in miR-192, miR-146a, miR-148a, miR-15a, and miR-21 were positively correlated (p<0.05) with alanine aminotransferase in simvastatin-only treated patients. Simvastatin 132-143 glutamic--pyruvic transaminase Homo sapiens 104-128 26307750-12 2016 In the simvastatin group and the icariin groups, the serum levels of IL-6 and TNF-alpha and the related tissue mRNA levels, as well as the expression of p-p38 MAPK, were markedly reduced compared with the AS group. Simvastatin 7-18 interleukin 6 Rattus norvegicus 69-73 26307750-12 2016 In the simvastatin group and the icariin groups, the serum levels of IL-6 and TNF-alpha and the related tissue mRNA levels, as well as the expression of p-p38 MAPK, were markedly reduced compared with the AS group. Simvastatin 7-18 tumor necrosis factor Rattus norvegicus 78-87 26307750-12 2016 In the simvastatin group and the icariin groups, the serum levels of IL-6 and TNF-alpha and the related tissue mRNA levels, as well as the expression of p-p38 MAPK, were markedly reduced compared with the AS group. Simvastatin 7-18 mitogen activated protein kinase 14 Rattus norvegicus 155-158 26492285-0 2016 Simvastatin attenuates oleic acid-induced oxidative stress through CREB-dependent induction of heme oxygenase-1 in renal proximal tubule cells. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 95-111 26492285-3 2016 We hypothesize that simvastatin (SIM) transcriptionally activates HO-1 that protects renal proximal tubule cells from lipotoxic injury. Simvastatin 20-31 heme oxygenase 1 Rattus norvegicus 66-70 26492285-3 2016 We hypothesize that simvastatin (SIM) transcriptionally activates HO-1 that protects renal proximal tubule cells from lipotoxic injury. Simvastatin 33-36 heme oxygenase 1 Rattus norvegicus 66-70 26492285-5 2016 Effect of SIM on the HO-1 promoter and its enhancer elements (antioxidant response element (ARE), CCAAT, AP1, and cAMP response element (CRE)) was also determined in reporter luciferase assays. Simvastatin 10-13 heme oxygenase 1 Rattus norvegicus 21-25 26492285-7 2016 RESULTS: SIM dose-dependently activated the HO-1 promoter that was essential for protection against OA-dependent ROS production/oxidative stress and LDH release/caspase-3 activation. Simvastatin 9-12 heme oxygenase 1 Rattus norvegicus 44-48 26492285-7 2016 RESULTS: SIM dose-dependently activated the HO-1 promoter that was essential for protection against OA-dependent ROS production/oxidative stress and LDH release/caspase-3 activation. Simvastatin 9-12 caspase 3 Rattus norvegicus 161-170 26492285-9 2016 CONCLUSION: SIM may protect the kidney from adverse effects of circulating fatty acids by upregulating the antioxidant HO-1, aside from its well-described lipid-lowering effects. Simvastatin 12-15 heme oxygenase 1 Rattus norvegicus 119-123 26869789-6 2016 Compared with the PET group and the COL/PET group, SIM could induce bone marrow stromal cells" osteoblastic differentiation, high alkaline phosphatase activity, more mineralization deposition, and more expression of osteoblast-related genes, such as osteocalcin, runt-related transcription factor 2, bone morphogenetic protein-2, and vascular endothelial growth factor, in the SIM/COL/PET group. Simvastatin 51-54 osteocalcin Oryctolagus cuniculus 250-261 26911949-0 2016 [Influence of simvastatin treatment on Toll-like receptor 4 in monocytes of peripheral blood in patients with sepsis and severe sepsis]. Simvastatin 14-25 toll like receptor 4 Homo sapiens 39-59 26911949-1 2016 OBJECTIVE: To investigate the influence of simvastatin treatment on Toll-like receptor 4 (TLR4) in monocytes of peripheral blood in patients with sepsis and severe sepsis and its significance. Simvastatin 43-54 toll like receptor 4 Homo sapiens 68-88 26911949-1 2016 OBJECTIVE: To investigate the influence of simvastatin treatment on Toll-like receptor 4 (TLR4) in monocytes of peripheral blood in patients with sepsis and severe sepsis and its significance. Simvastatin 43-54 toll like receptor 4 Homo sapiens 90-94 26911949-9 2016 RESULTS: TLR4 expression on the surface of monocytes showed a tendency of decreasing with prolongation of simvastatin treatment in the simvastatin group in patients with sepsis (n = 59) or severe sepsis (n = 54). Simvastatin 106-117 toll like receptor 4 Homo sapiens 9-13 26911949-9 2016 RESULTS: TLR4 expression on the surface of monocytes showed a tendency of decreasing with prolongation of simvastatin treatment in the simvastatin group in patients with sepsis (n = 59) or severe sepsis (n = 54). Simvastatin 135-146 toll like receptor 4 Homo sapiens 9-13 26911949-10 2016 However, in patients with sepsis, TLR4 level was significantly decreased from 10 days in simvastatin group as compared with that of conventional therapy group (n = 47), and it was decreased up to 15 days [mean fluorescence intensity (MFI): 21 (19, 28) vs. 27 (25, 33) at 10 days, Z = 2.198, P = 0.021; 16 (15, 21) vs. 26 (23, 34) at 15 days, Z = 4.611, P = 0.002]. Simvastatin 89-100 toll like receptor 4 Homo sapiens 34-38 26577051-11 2016 The expression levels of cdk1, cdk2, cyclin A, and cyclin E were downregulated by simvastatin in a dose-dependent manner. Simvastatin 82-93 cyclin-dependent kinase 1 Rattus norvegicus 25-29 26577051-11 2016 The expression levels of cdk1, cdk2, cyclin A, and cyclin E were downregulated by simvastatin in a dose-dependent manner. Simvastatin 82-93 cyclin dependent kinase 2 Rattus norvegicus 31-35 26577051-11 2016 The expression levels of cdk1, cdk2, cyclin A, and cyclin E were downregulated by simvastatin in a dose-dependent manner. Simvastatin 82-93 cyclin E1 Rattus norvegicus 51-59 26824358-0 2016 Correction: Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 12-23 low density lipoprotein receptor Mus musculus 103-107 26824358-0 2016 Correction: Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 12-23 tumor necrosis factor Mus musculus 162-189 26869789-6 2016 Compared with the PET group and the COL/PET group, SIM could induce bone marrow stromal cells" osteoblastic differentiation, high alkaline phosphatase activity, more mineralization deposition, and more expression of osteoblast-related genes, such as osteocalcin, runt-related transcription factor 2, bone morphogenetic protein-2, and vascular endothelial growth factor, in the SIM/COL/PET group. Simvastatin 51-54 runt-related transcription factor 2 Oryctolagus cuniculus 263-298 26869789-6 2016 Compared with the PET group and the COL/PET group, SIM could induce bone marrow stromal cells" osteoblastic differentiation, high alkaline phosphatase activity, more mineralization deposition, and more expression of osteoblast-related genes, such as osteocalcin, runt-related transcription factor 2, bone morphogenetic protein-2, and vascular endothelial growth factor, in the SIM/COL/PET group. Simvastatin 51-54 bone morphogenetic protein 2 Oryctolagus cuniculus 300-328 26503475-3 2016 Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor, is a widely used drug for inhibiting the synthesis of cholesterol and may also have anti-tumorigenic activity. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 58-63 26713363-6 2016 Simvastatin, an inhibitor of HMG-CoA reductase, significantly decreased Rankl expression and increased Sost expression in MLO-Y4 cells. Simvastatin 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 72-77 26713363-6 2016 Simvastatin, an inhibitor of HMG-CoA reductase, significantly decreased Rankl expression and increased Sost expression in MLO-Y4 cells. Simvastatin 0-11 sclerostin Mus musculus 103-107 29736450-7 2016 However, treatment with simvastatin increased the plasma levels of erythropoietin (Epo) (4.2 +- 2.2 mIU/mL to 6.8 +- 3.2 mlU/mL, p < 0.05) and reduced those of serum uric acid (7.1 +- 1.3 mg/dL to 6.5 +- 1.4 mg/dL, p < 0.01). Simvastatin 24-35 erythropoietin Homo sapiens 67-81 29736450-7 2016 However, treatment with simvastatin increased the plasma levels of erythropoietin (Epo) (4.2 +- 2.2 mIU/mL to 6.8 +- 3.2 mlU/mL, p < 0.05) and reduced those of serum uric acid (7.1 +- 1.3 mg/dL to 6.5 +- 1.4 mg/dL, p < 0.01). Simvastatin 24-35 erythropoietin Homo sapiens 83-86 29736450-8 2016 Conclusions: Short-term treatment with simvastatin in stable COPD patients did not modify lung function, pulmonary and systemic inflammation, or vascular stiffness, but it changed Epo and uric acid levels. Simvastatin 39-50 erythropoietin Homo sapiens 180-183 26519538-2 2016 METHODS: Data were analyzed from the Simvastatin for cognitive deficits and behavioral problems in patients with neurofibromatosis type 1 (NF1-SIMCODA) trial, a randomized placebo-controlled trial of simvastatin for cognitive deficits and behavioral problems in children with NF1. Simvastatin 37-48 neurofibromin 1 Homo sapiens 113-137 26519538-2 2016 METHODS: Data were analyzed from the Simvastatin for cognitive deficits and behavioral problems in patients with neurofibromatosis type 1 (NF1-SIMCODA) trial, a randomized placebo-controlled trial of simvastatin for cognitive deficits and behavioral problems in children with NF1. Simvastatin 37-48 neurofibromin 1 Homo sapiens 139-142 26565813-0 2016 Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 70-73 26565813-0 2016 Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 83-86 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 37-40 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 41-45 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 71-75 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 113-116 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 174-177 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 207-212 26565813-5 2016 Simvastatin markedly suppressed PI3K/Akt/mTOR signalling by activating PTEN (p = 0.005) and by dephosphorylating Akt (p = 0.002) and S6RP (p = 0.033); it also inhibited MAPK/ERK pathway by dephosphorylating c-Raf (p = 0.018) and ERK1/2 (p = 0.002). Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 229-235 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 AKT serine/threonine kinase 1 Homo sapiens 51-54 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 mechanistic target of rapamycin kinase Homo sapiens 55-59 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 phosphatase and tensin homolog Homo sapiens 81-85 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 AKT serine/threonine kinase 1 Homo sapiens 173-176 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 mechanistic target of rapamycin kinase Homo sapiens 178-182 26565813-7 2016 Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Simvastatin 14-25 ribosomal protein S6 kinase B1 Homo sapiens 184-190 26565813-8 2016 Furthermore, simvastatin significantly inhibited MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2 and ERK1/2. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 54-57 26565813-8 2016 Furthermore, simvastatin significantly inhibited MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2 and ERK1/2. Simvastatin 13-24 zinc fingers and homeoboxes 2 Homo sapiens 117-120 26565813-8 2016 Furthermore, simvastatin significantly inhibited MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2 and ERK1/2. Simvastatin 13-24 mitogen-activated protein kinase kinase 1 Homo sapiens 122-128 26565813-8 2016 Furthermore, simvastatin significantly inhibited MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2 and ERK1/2. Simvastatin 13-24 mitogen-activated protein kinase 3 Homo sapiens 133-139 26761203-2 2016 Notably, statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors whose pleiotropic effects include disrupting small GTPase activity; therefore, we hypothesized the statin simvastatin could be used to attenuate RhoA activity and inhibit the deleterious effects of increased age-related matrix stiffness on endothelial barrier function. Simvastatin 196-207 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-78 26761203-6 2016 Furthermore, we report that simvastatin increases activated Rac1 levels that contribute to endothelial barrier enhancing cytoskeletal reorganization. Simvastatin 28-39 Rac family small GTPase 1 Homo sapiens 60-64 26503475-5 2016 Simvastatin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, and caused cellular stress via reduction in the enzymatic activity of HMGCR and inhibition of the MAPK and mTOR pathways in ovarian cancer cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 174-179 26503475-5 2016 Simvastatin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, and caused cellular stress via reduction in the enzymatic activity of HMGCR and inhibition of the MAPK and mTOR pathways in ovarian cancer cells. Simvastatin 0-11 mechanistic target of rapamycin kinase Mus musculus 211-215 27511325-10 2016 The C-reactive protein concentration 48 h after trauma was significantly lower in the simvastatin group, but there was no significant difference according to the interleukin-6 level 48 h after trauma between the 2 groups. Simvastatin 86-97 C-reactive protein Homo sapiens 4-22 26503475-8 2016 Treatment with simvastatin in an orthotopic mouse model reduced ovarian tumor growth, coincident with decreased Ki-67, HMGCR, phosphorylated-Akt and phosphorylated-p42/44 protein expression. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 119-124 26503475-8 2016 Treatment with simvastatin in an orthotopic mouse model reduced ovarian tumor growth, coincident with decreased Ki-67, HMGCR, phosphorylated-Akt and phosphorylated-p42/44 protein expression. Simvastatin 15-26 thymoma viral proto-oncogene 1 Mus musculus 141-144 26927218-6 2016 Memory B cells, isolated 14 days after secondary infection, from simvastatin pretreated mice and stimulated ex vivo produced increased levels of IgG1 compared to memory B cells isolated from control mice, while levels of IgM and IgG2c remained similar. Simvastatin 65-76 LOC105243590 Mus musculus 145-149 26890413-6 2016 Therefore, we treated dmd/mdx mice with simvastatin and showed decreased CYBB/NOX2-mediated oxidative stress and enhanced autophagy induction. Simvastatin 40-51 cytochrome b-245, beta polypeptide Mus musculus 73-77 26890413-6 2016 Therefore, we treated dmd/mdx mice with simvastatin and showed decreased CYBB/NOX2-mediated oxidative stress and enhanced autophagy induction. Simvastatin 40-51 cytochrome b-245, beta polypeptide Mus musculus 78-82 26927337-11 2016 Both simvastatin and vitamin C ameliorated the aortic injury, decreased the plasma IMD level, and recovered the expression of IMD and its receptors within the aorta. Simvastatin 5-16 adrenomedullin 2 Rattus norvegicus 83-86 26927337-11 2016 Both simvastatin and vitamin C ameliorated the aortic injury, decreased the plasma IMD level, and recovered the expression of IMD and its receptors within the aorta. Simvastatin 5-16 adrenomedullin 2 Rattus norvegicus 126-129 25300705-0 2016 Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Simvastatin 0-11 F-box protein 32 Mus musculus 60-69 25300705-7 2016 Treatment of mice with 5 mg/kg/day simvastatin for 21 days was associated with a 5 % drop in heart weight as well as impaired activity of several enzyme complexes of the ETC and increased mRNA expression of atrogin-1 and of markers of apoptosis in cardiac tissue. Simvastatin 35-46 F-box protein 32 Mus musculus 207-216 25300705-8 2016 Cardiomyocytes exposed to simvastatin in vitro or in vivo sustain mitochondrial damage, which causes AMPK activation, dephosphorylation and nuclear transformation of FoxO3a as well as increased expression of atrogin-1. Simvastatin 26-37 forkhead box O3 Mus musculus 166-172 25300705-8 2016 Cardiomyocytes exposed to simvastatin in vitro or in vivo sustain mitochondrial damage, which causes AMPK activation, dephosphorylation and nuclear transformation of FoxO3a as well as increased expression of atrogin-1. Simvastatin 26-37 F-box protein 32 Mus musculus 208-217 26490838-5 2016 Similarly, simvastatin therapy activated Akt1 at the transplantation site and improved the revascularization and vascular support of ovarian grafts. Simvastatin 11-22 thymoma viral proto-oncogene 1 Mus musculus 41-45 26927218-6 2016 Memory B cells, isolated 14 days after secondary infection, from simvastatin pretreated mice and stimulated ex vivo produced increased levels of IgG1 compared to memory B cells isolated from control mice, while levels of IgM and IgG2c remained similar. Simvastatin 65-76 immunoglobulin heavy constant mu Mus musculus 221-224 26884289-6 2016 In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. Simvastatin 20-31 leptin Homo sapiens 64-70 27526788-9 2016 On the other hand, simvastatin reversed the increased protein expression of protein phosphatase 1beta (PP1beta), but not protein phosphatase 2A (PP2A), in I/R hearts. Simvastatin 19-30 protein phosphatase, Mg2+/Mn2+ dependent, 1B Rattus norvegicus 76-101 27526788-9 2016 On the other hand, simvastatin reversed the increased protein expression of protein phosphatase 1beta (PP1beta), but not protein phosphatase 2A (PP2A), in I/R hearts. Simvastatin 19-30 protein phosphatase 1 catalytic subunit beta Rattus norvegicus 103-110 26502771-6 2016 Within 2 weeks of taking simvastatin, a 3-hydroxy-3-methylglutaryl CoA reductase (statin) therapy, the patient redeveloped fatigue, jaundice, and cholestatic hepatitis. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 40-80 26502771-11 2016 Simvastatin inhibits the CYP3A4 isoenzyme. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-31 26884289-6 2016 In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. Simvastatin 20-31 nicotinamide phosphoribosyltransferase Homo sapiens 72-80 26884290-7 2016 In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin sensitivity only in this age group. Simvastatin 65-76 tumor necrosis factor Homo sapiens 81-90 26884289-6 2016 In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. Simvastatin 20-31 tumor necrosis factor Homo sapiens 86-95 26884290-7 2016 In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin sensitivity only in this age group. Simvastatin 65-76 interleukin 6 Homo sapiens 92-105 26884289-6 2016 In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. Simvastatin 20-31 adiponectin, C1Q and collagen domain containing Homo sapiens 132-143 26884289-11 2016 In turn, the effect of ezetimibe and simvastatin/ezetimibe combination therapy on leptin, adiponectin, and hsCRP was stronger in older than in younger adults. Simvastatin 37-48 leptin Homo sapiens 82-88 26884289-11 2016 In turn, the effect of ezetimibe and simvastatin/ezetimibe combination therapy on leptin, adiponectin, and hsCRP was stronger in older than in younger adults. Simvastatin 37-48 adiponectin, C1Q and collagen domain containing Homo sapiens 90-101 27213056-3 2016 The present study is aimed at assessing the effect of simvastatin treatment on PON1 activity and its relationship to Q192R and M55L polymorphisms in subjects with stable coronary artery disease (CAD). Simvastatin 54-65 paraoxonase 1 Homo sapiens 79-83 26756263-3 2016 This study investigated the hypothesis that simvastatin has pro-apoptotic effects in epidermal growth factor receptor (EGFR)-mutated lung cancer cell lines via the upregulation of the expression of the BIM protein. Simvastatin 44-55 epidermal growth factor receptor Homo sapiens 85-117 26756263-3 2016 This study investigated the hypothesis that simvastatin has pro-apoptotic effects in epidermal growth factor receptor (EGFR)-mutated lung cancer cell lines via the upregulation of the expression of the BIM protein. Simvastatin 44-55 epidermal growth factor receptor Homo sapiens 119-123 26756263-8 2016 RESULTS: H1975 cells showed significantly reduced viability compared with HCC827 cells after treatment with simvastatin (2 muM) for 48 hours. Simvastatin 108-119 latexin Homo sapiens 123-126 26756263-9 2016 In simvastatin-treated H1975 cells, expression of pro-apoptotic proteins was increased and the phosphorylation of ERK 1/2 (p-ERK 1/2) was reduced. Simvastatin 3-14 mitogen-activated protein kinase 3 Homo sapiens 114-121 26756263-9 2016 In simvastatin-treated H1975 cells, expression of pro-apoptotic proteins was increased and the phosphorylation of ERK 1/2 (p-ERK 1/2) was reduced. Simvastatin 3-14 mitogen-activated protein kinase 3 Homo sapiens 125-132 26756263-12 2016 CONCLUSIONS: Simvastatin restored the expression of BIM to induce apoptotic cell death in NSCLC cells harboring an EGFR-resistant mutation. Simvastatin 13-24 epidermal growth factor receptor Homo sapiens 115-119 26846205-9 2016 Aortic and renal myofibroblasts count, as expressed by alpha-SMA + density, was lower in the group of mice treated with simvastatin compared to HOCl-treated mice. Simvastatin 120-131 actin alpha 2, smooth muscle, aorta Mus musculus 55-64 26846205-10 2016 Simvastatin prevented the reduction in VEGFR2 and CD31 expression induced by HOCl. Simvastatin 0-11 kinase insert domain protein receptor Mus musculus 39-45 26846205-10 2016 Simvastatin prevented the reduction in VEGFR2 and CD31 expression induced by HOCl. Simvastatin 0-11 platelet/endothelial cell adhesion molecule 1 Mus musculus 50-54 26966430-6 2016 The IC50 values of simvastatin alone and irinotecan alone were 115.4 +- 0.14 muM (r = 0.98) and 62.5 +- 0.18 muM (r = 0.98) in HT-29 cells without resistance to irinotecan. Simvastatin 19-30 latexin Homo sapiens 77-80 26966430-6 2016 The IC50 values of simvastatin alone and irinotecan alone were 115.4 +- 0.14 muM (r = 0.98) and 62.5 +- 0.18 muM (r = 0.98) in HT-29 cells without resistance to irinotecan. Simvastatin 19-30 latexin Homo sapiens 109-112 26000813-0 2016 Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease. Simvastatin 11-22 nitric oxide synthase 2 Rattus norvegicus 44-75 26000813-0 2016 Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease. Simvastatin 11-22 brain-derived neurotrophic factor Rattus norvegicus 80-113 26000813-1 2016 OBJECTIVE: To investigate the effects of simvastatin on the expression of inducible nitric oxide synthase (iNOS) and brain-derived neurotrophic factor (BDNF) in the substantia nigra in a lipopolysaccharide (LPS)-induced rat model of Parkinson disease (PD), and to study the mechanisms underlying the neuroprotective effects of simvastatin in PD. Simvastatin 41-52 nitric oxide synthase 2 Rattus norvegicus 74-105 26000813-1 2016 OBJECTIVE: To investigate the effects of simvastatin on the expression of inducible nitric oxide synthase (iNOS) and brain-derived neurotrophic factor (BDNF) in the substantia nigra in a lipopolysaccharide (LPS)-induced rat model of Parkinson disease (PD), and to study the mechanisms underlying the neuroprotective effects of simvastatin in PD. Simvastatin 41-52 nitric oxide synthase 2 Rattus norvegicus 107-111 26000813-1 2016 OBJECTIVE: To investigate the effects of simvastatin on the expression of inducible nitric oxide synthase (iNOS) and brain-derived neurotrophic factor (BDNF) in the substantia nigra in a lipopolysaccharide (LPS)-induced rat model of Parkinson disease (PD), and to study the mechanisms underlying the neuroprotective effects of simvastatin in PD. Simvastatin 41-52 brain-derived neurotrophic factor Rattus norvegicus 117-150 26000813-1 2016 OBJECTIVE: To investigate the effects of simvastatin on the expression of inducible nitric oxide synthase (iNOS) and brain-derived neurotrophic factor (BDNF) in the substantia nigra in a lipopolysaccharide (LPS)-induced rat model of Parkinson disease (PD), and to study the mechanisms underlying the neuroprotective effects of simvastatin in PD. Simvastatin 41-52 brain-derived neurotrophic factor Rattus norvegicus 152-156 27213056-10 2016 Simvastatin treatment significantly increased FMD value, decreased CRP and TNF-alpha concentration. Simvastatin 0-11 C-reactive protein Homo sapiens 67-70 26757191-8 2016 NMDAr antagonist blocked the neurotoxicity of Abeta1-42 and SV (80 mg/kg) in Abeta1-42-mice, whereas FOH only inhibited SV (80 mg/kg)-neurotoxicity. Simvastatin 60-62 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 0-5 27213056-10 2016 Simvastatin treatment significantly increased FMD value, decreased CRP and TNF-alpha concentration. Simvastatin 0-11 tumor necrosis factor Homo sapiens 75-84 27213056-16 2016 The effect of simvastatin therapy on PON1 activity is not modulated by Q192R and M55L polymorphisms. Simvastatin 14-25 paraoxonase 1 Homo sapiens 37-41 26556031-0 2016 Simvastatin inhibits oxidative stress via the activation of nuclear factor erythroid 2-related factor 2 signaling in trophoblast cells. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 60-103 26484803-4 2016 Simvastatin, a cholesterol-lowering drug, also increased the LDLR expression in PC6.3 cells. Simvastatin 0-11 low density lipoprotein receptor Rattus norvegicus 61-65 26556031-6 2016 Real-time quantitative reverse transcriptase polymerase chain reaction and Western blotting were used to evaluate the influence of oxidative stress (H2O2 100 muM) and simvastatin (50 muM) on Nrf2 and its target genes. Simvastatin 167-178 NFE2 like bZIP transcription factor 2 Homo sapiens 191-195 26556031-10 2016 In contrast, Nrf2 signaling was augmented by simvastatin, which suppressed the induction of oxidative stress in trophoblasts. Simvastatin 45-56 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 26556031-11 2016 CONCLUSION: Hypoxia is one of the important negative regulators of Nrf2 activation, and simvastatin inhibits oxidative stress through the activation of Nrf2 signaling in trophoblasts, indicating the potential therapeutic role of statin for pre-eclampsia. Simvastatin 88-99 NFE2 like bZIP transcription factor 2 Homo sapiens 152-156 26765458-1 2016 Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Simvastatin 14-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-96 26765458-1 2016 Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Simvastatin 14-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 26319048-2 2016 We have previously shown that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin directly inhibits ABCB1, alters the glycosylation of the transporter, and enhances the intracellular accumulation of doxorubicin with subsequent anti-cancer action. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 26319048-2 2016 We have previously shown that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin directly inhibits ABCB1, alters the glycosylation of the transporter, and enhances the intracellular accumulation of doxorubicin with subsequent anti-cancer action. Simvastatin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 26319048-3 2016 Here, we show that simvastatin reduces endogenous dolichol levels and ABCB1 in human neuroblastoma SH-SY5Y cells. Simvastatin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 26319048-6 2016 Direct monitoring of the fluorescent fusion protein YFP-ABCB1 further confirms concentration-dependent reduction of ABCB1 in HEK293 cells by simvastatin. Simvastatin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 26319048-6 2016 Direct monitoring of the fluorescent fusion protein YFP-ABCB1 further confirms concentration-dependent reduction of ABCB1 in HEK293 cells by simvastatin. Simvastatin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 26319048-7 2016 In simvastatin-treated murine xenografts, ABCB1 was also reduced in the liver and rhabdomyosarcoma but did not reach significance in neuroblastoma. Simvastatin 3-14 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 42-47 27042994-1 2016 Simvastatin is a cholesterol-lowering drug, inhibiting 3-hydroxy-3-methylglutaryl-coenzyme CoA (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-114 27197424-11 2016 The Q192R polymorphism was associated with simvastatin effectiveness on hs-CRP and FMD. Simvastatin 43-54 C-reactive protein Homo sapiens 75-78 27359361-0 2016 Simvastatin Treatment Upregulates Anti-Fibrotic Bone Morphogenetic Protein-7 Expression at Rat Cardiac Allograft Rejection. Simvastatin 0-11 bone morphogenetic protein 7 Rattus norvegicus 48-76 27359361-3 2016 METHODS: Here, we investigated the effect of simvastatin treatment on BMP-7 expression in major MHC-mismatched rat cardiac allografts subjected to ischemia-reperfusion injury and adaptive immune activation at 10 days. Simvastatin 45-56 bone morphogenetic protein 7 Rattus norvegicus 70-75 27359361-5 2016 Simvastatin donor and recipient combination treatment significantly upregulated cardiac allograft BMP-7 expression when compared to nontreated controls at 10 days. Simvastatin 0-11 bone morphogenetic protein 7 Homo sapiens 98-103 26798426-1 2016 We show that hypercholesterolemia contributes to oxidative stress injury progression in brain and simvastatin counteracts the cholesterol-induced peroxidation injury in rabbit hippocampus, and we demonstrate for the first time that the simvastatin is a critical role in brain protection and identify HO-1 and other related antioxidant enzymes as molecular target for active redox compounds. Simvastatin 236-247 heme oxygenase 1 Oryctolagus cuniculus 300-304 26798426-3 2016 The balance effects of simvastatin to ROS and antioxidants enzymes network are most probably due to improved SOD functional activity, increase in GSH-Px, increase in HO-1 expression, and decrease of MDA generation. Simvastatin 23-34 heme oxygenase 1 Oryctolagus cuniculus 166-170 29629740-7 2016 Results: 17beta-estradiol supplementationand simvastatin treatmentreduced basal and exercise testinduced endothelin-1 plasma level.17beta-estradiol supplementation graduallyincreased NO release, whereassimvastatin initially reduced andfinally increased nitric oxide release.NO/ET-1 ratio was increased at peakexercise and recovery time in group1 whereas only at peak exercise ingroup 2. Simvastatin 45-56 endothelin 1 Homo sapiens 105-117 27197424-12 2016 CONCLUSION: Obesity and Q192R PON1 polymorphism are significantly associated with pleiotropic effects of simvastatin therapy in patients with stable CAD. Simvastatin 105-116 paraoxonase 1 Homo sapiens 30-34 27400100-10 2016 The thickness of VSMCs in the SAH group increased and the expression of PDGF-beta, PCNA, and alpha-SMA in SAH group were all increased compared to the control group (p < 0.05), and decreased while prophylactic giving simvastatin (p < 0.05). Simvastatin 220-231 platelet-derived growth factor subunit B Oryctolagus cuniculus 72-81 25845641-9 2016 CAEF and CGA increased mRNA expression of ABCA1, CYP7A1, and AMPKalpha2, while CAEF and simvastatin decreased SREBP2. Simvastatin 88-99 sterol regulatory element binding transcription factor 2 Homo sapiens 110-116 26819423-10 2016 Compared with the COPD group, lung function indexes were significantly increased in the aminophylline group and simvastatin group (P<0.01), while pulmonary pathological damages, the levels of IL-8, IL-17, and TNF-alpha in BALF as well as the mRNA and protein levels of MUC5AC and TLR4 were significantly decreased (P<0.01). Simvastatin 112-123 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 272-278 26819423-10 2016 Compared with the COPD group, lung function indexes were significantly increased in the aminophylline group and simvastatin group (P<0.01), while pulmonary pathological damages, the levels of IL-8, IL-17, and TNF-alpha in BALF as well as the mRNA and protein levels of MUC5AC and TLR4 were significantly decreased (P<0.01). Simvastatin 112-123 toll-like receptor 4 Rattus norvegicus 283-287 26819423-11 2016 Compared with the aminophylline group, the peak expiratory flow as well as the levels of IL-8, IL-17, and TNF-alpha in the simvastatin group were elevated (P<0.05). Simvastatin 123-134 interleukin 17A Rattus norvegicus 95-100 26819423-11 2016 Compared with the aminophylline group, the peak expiratory flow as well as the levels of IL-8, IL-17, and TNF-alpha in the simvastatin group were elevated (P<0.05). Simvastatin 123-134 tumor necrosis factor Rattus norvegicus 106-115 26819423-13 2016 : CONCLUSION: Aminophylline and simvastatin can decrease IL-8, IL-17, and TNF-alpha levels in BALF and inhibit the expression of MUC5AC and TLR4 in airway and lung tissues in COPD rats, suggesting that they may have a preventive and therapeutic effect on COPD through reducing the airway inflammation and mucus hypersecretion. Simvastatin 33-44 interleukin 17A Rattus norvegicus 64-69 26819423-13 2016 : CONCLUSION: Aminophylline and simvastatin can decrease IL-8, IL-17, and TNF-alpha levels in BALF and inhibit the expression of MUC5AC and TLR4 in airway and lung tissues in COPD rats, suggesting that they may have a preventive and therapeutic effect on COPD through reducing the airway inflammation and mucus hypersecretion. Simvastatin 33-44 tumor necrosis factor Rattus norvegicus 75-84 26819423-13 2016 : CONCLUSION: Aminophylline and simvastatin can decrease IL-8, IL-17, and TNF-alpha levels in BALF and inhibit the expression of MUC5AC and TLR4 in airway and lung tissues in COPD rats, suggesting that they may have a preventive and therapeutic effect on COPD through reducing the airway inflammation and mucus hypersecretion. Simvastatin 33-44 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 130-136 26819423-13 2016 : CONCLUSION: Aminophylline and simvastatin can decrease IL-8, IL-17, and TNF-alpha levels in BALF and inhibit the expression of MUC5AC and TLR4 in airway and lung tissues in COPD rats, suggesting that they may have a preventive and therapeutic effect on COPD through reducing the airway inflammation and mucus hypersecretion. Simvastatin 33-44 toll-like receptor 4 Rattus norvegicus 141-145 26334381-0 2015 Simvastatin protects the heart against ischemia reperfusion injury via inhibiting HMGB1 expression through PI3K/Akt signal pathways. Simvastatin 0-11 high mobility group box 1 Homo sapiens 82-87 26602073-9 2015 In Cox multivariate analysis adjusted for age, gender, prednisolone treatment, smoking, baseline LDL cholesterol and high sensitivity C-reactive protein; simvastatin plus ezetimibe versus placebo was associated with 44% lower risk of cataract development (hazard ratio 0.56, 95% confidence interval 0.33 to 0.96, p = 0.034). Simvastatin 154-165 C-reactive protein Homo sapiens 134-152 26334381-0 2015 Simvastatin protects the heart against ischemia reperfusion injury via inhibiting HMGB1 expression through PI3K/Akt signal pathways. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 112-115 26658759-4 2015 The Rho family GTPases Rac1 and Cdc42 were activated in senescent cells, and simvastatin reduced both activities. Simvastatin 77-88 Rac family small GTPase 1 Homo sapiens 23-27 26884839-0 2015 Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy. Simvastatin 0-11 chemokine (C-X-C motif) ligand 16 Mus musculus 73-79 26410676-0 2015 Estrogen receptor mediates simvastatin-stimulated osteogenic effects in bone marrow mesenchymal stem cells. Simvastatin 27-38 estrogen receptor 1 (alpha) Mus musculus 0-17 26410676-3 2015 In this study, we hypothesize that the estrogen receptor (ER) mediates simvastatin-induced osteogenic differentiation. Simvastatin 71-82 estrogen receptor 1 (alpha) Mus musculus 39-56 26410676-3 2015 In this study, we hypothesize that the estrogen receptor (ER) mediates simvastatin-induced osteogenic differentiation. Simvastatin 71-82 estrogen receptor 1 (alpha) Mus musculus 58-60 26410676-4 2015 ER antagonists and siRNA were used to determine the involvement of the ER in simvastatin-induced osteogenesis in mouse bone marrow mesenchymal stem cells (D1 cells). Simvastatin 77-88 estrogen receptor 1 (alpha) Mus musculus 71-73 26410676-7 2015 Our results showed that the simvastatin-induced osteogenic effects were decreased by treatment with ERalpha antagonists and ERalpha siRNA but not by an antagonist specific for the G protein-coupled estrogen receptor (GPER-1). Simvastatin 28-39 estrogen receptor 1 (alpha) Mus musculus 100-107 26410676-7 2015 Our results showed that the simvastatin-induced osteogenic effects were decreased by treatment with ERalpha antagonists and ERalpha siRNA but not by an antagonist specific for the G protein-coupled estrogen receptor (GPER-1). Simvastatin 28-39 estrogen receptor 1 (alpha) Mus musculus 124-131 26410676-8 2015 The simvastatin-induced osteogenic effects were further increased by E2 treatment and were reversed by ERalpha antagonists or siRNA treatment. Simvastatin 4-15 estrogen receptor 1 (alpha) Mus musculus 103-110 26410676-9 2015 Luciferase reporter gene assays demonstrated that simvastatin increase ERalpha-dependent transcriptional activity that was suppressed by ERalpha antagonists. Simvastatin 50-61 estrogen receptor 1 (alpha) Mus musculus 71-78 26410676-9 2015 Luciferase reporter gene assays demonstrated that simvastatin increase ERalpha-dependent transcriptional activity that was suppressed by ERalpha antagonists. Simvastatin 50-61 estrogen receptor 1 (alpha) Mus musculus 137-144 26410676-10 2015 Furthermore, the ERalpha-simvastatin binding assay showed that IC50 value of simvastatin is 7.85 muM and that of E2 is 32.8 nM, indicating that simvastatin is a weak ligand for ERalpha. Simvastatin 25-36 estrogen receptor 1 (alpha) Mus musculus 17-24 26410676-10 2015 Furthermore, the ERalpha-simvastatin binding assay showed that IC50 value of simvastatin is 7.85 muM and that of E2 is 32.8 nM, indicating that simvastatin is a weak ligand for ERalpha. Simvastatin 77-88 estrogen receptor 1 (alpha) Mus musculus 17-24 26410676-10 2015 Furthermore, the ERalpha-simvastatin binding assay showed that IC50 value of simvastatin is 7.85 muM and that of E2 is 32.8 nM, indicating that simvastatin is a weak ligand for ERalpha. Simvastatin 77-88 estrogen receptor 1 (alpha) Mus musculus 177-184 26410676-10 2015 Furthermore, the ERalpha-simvastatin binding assay showed that IC50 value of simvastatin is 7.85 muM and that of E2 is 32.8 nM, indicating that simvastatin is a weak ligand for ERalpha. Simvastatin 77-88 estrogen receptor 1 (alpha) Mus musculus 17-24 26410676-10 2015 Furthermore, the ERalpha-simvastatin binding assay showed that IC50 value of simvastatin is 7.85 muM and that of E2 is 32.8 nM, indicating that simvastatin is a weak ligand for ERalpha. Simvastatin 77-88 estrogen receptor 1 (alpha) Mus musculus 177-184 26410676-11 2015 These results suggest that simvastatin-stimulated osteogenesis is mediated by ERalpha but not GPER-1. Simvastatin 27-38 estrogen receptor 1 (alpha) Mus musculus 78-85 26410676-12 2015 Moreover, this is the first report to demonstrate that simvastatin acts as an ERalpha ligand and a co-activator to enhance ERalpha-dependent transcriptional activity and thus promotes osteogenesis. Simvastatin 55-66 estrogen receptor 1 (alpha) Mus musculus 78-85 26410676-12 2015 Moreover, this is the first report to demonstrate that simvastatin acts as an ERalpha ligand and a co-activator to enhance ERalpha-dependent transcriptional activity and thus promotes osteogenesis. Simvastatin 55-66 estrogen receptor 1 (alpha) Mus musculus 123-130 26410676-13 2015 These results indicate that simvastatin-induced osteogenesis is mediated via an ERalpha-dependent pathway. Simvastatin 28-39 estrogen receptor 1 (alpha) Mus musculus 80-87 26590814-0 2015 Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Simvastatin 0-11 forkhead box O3 Homo sapiens 107-113 26590814-5 2015 RNA interference targeting FOXO3a was used to measure the impact of simvastatin on FOXO3a-expressing cells. Simvastatin 68-79 forkhead box O3 Homo sapiens 83-89 26590814-9 2015 Phosphorylated FOXO3a was downregulated after simvastatin treatment in (RPPA) analysis. Simvastatin 46-57 forkhead box O3 Homo sapiens 15-21 26590814-11 2015 Knockdown of FOXO3a attenuated the effect of simvastatin on mammosphere formation and migration. Simvastatin 45-56 forkhead box O3 Homo sapiens 13-19 26590814-13 2015 Simvastatin inhibits in vitro endpoints associated with metastasis through a FOXO3a mechanism and reduced metastasis formation in vivo. Simvastatin 0-11 forkhead box O3 Homo sapiens 77-83 26559850-0 2015 Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Simvastatin 0-11 negative elongation factor complex member C/D Homo sapiens 80-83 26559850-10 2015 RESULTS: Simvastatin (5 mg/kg/day) improved clinical outcome, induced an increase in TGF-beta mRNA expression and inhibited IL-6, IL-12p40, IL-12p70, RANTES and MIP-1beta secretion (p < 0.05). Simvastatin 9-20 transforming growth factor beta 1 Homo sapiens 85-93 26559850-10 2015 RESULTS: Simvastatin (5 mg/kg/day) improved clinical outcome, induced an increase in TGF-beta mRNA expression and inhibited IL-6, IL-12p40, IL-12p70, RANTES and MIP-1beta secretion (p < 0.05). Simvastatin 9-20 interleukin 6 Homo sapiens 124-128 26559850-10 2015 RESULTS: Simvastatin (5 mg/kg/day) improved clinical outcome, induced an increase in TGF-beta mRNA expression and inhibited IL-6, IL-12p40, IL-12p70, RANTES and MIP-1beta secretion (p < 0.05). Simvastatin 9-20 C-C motif chemokine ligand 5 Homo sapiens 150-156 26559850-13 2015 CONCLUSIONS: Simvastatin treatment promotes EAE clinical amelioration by inhibiting T cell proliferation and CNS infiltration by pathogenic Th1 and Th17 cells. Simvastatin 13-24 negative elongation factor complex member C/D Homo sapiens 140-143 26515701-5 2015 Thus, the reduction of the DKK-1 expression and secretion in the human osteotropic tumor cell lines MDA-MB-231, MDA-MET, and MDA-BONE by zoledronic acid was potentiated by the combination with low concentrations of statins (atorvastatin, simvastatin, and rosuvastatin) by up to 75% (p < 0.05). Simvastatin 238-249 dickkopf WNT signaling pathway inhibitor 1 Homo sapiens 27-32 26515701-7 2015 Moreover, combining low concentrations of statins (1 microM atorvastatin or 0.25 microM simvastatin) and zoledronic acid at low concentrations resulted in an at least 50% reversal of breast cancer-derived DKK-1-mediated inhibition of osteogenic markers in C2C12 cells (p < 0.05). Simvastatin 88-99 dickkopf WNT signaling pathway inhibitor 1 Mus musculus 205-210 26884839-10 2015 The beneficial effects of simvastatin might be related to the decreasing expression of CXCL16 in glomerular podocytes followed by the decreasing endocytosis of ox-LDL in podocytes and inhibition of NF-kappaB pathway activation. Simvastatin 26-37 chemokine (C-X-C motif) ligand 16 Mus musculus 87-93 26367500-0 2015 Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Simvastatin 115-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 43-50 26670440-0 2015 Protective effect of simvastatin on impaired intestine tight junction protein ZO-1 in a mouse model of Parkinson"s disease. Simvastatin 21-32 tight junction protein 1 Mus musculus 78-82 26670440-4 2015 In this study, the protective effect of simvastatin on ZO-1 was investigated using an MPTP mouse model of PD. Simvastatin 40-51 tight junction protein 1 Mus musculus 55-59 26670440-9 2015 Treatment with simvastatin could partly reverse the MPTP-induced changes in ZO-1 expression and reduce MMP-9 protein and activity. Simvastatin 15-26 tight junction protein 1 Mus musculus 76-80 26670440-9 2015 Treatment with simvastatin could partly reverse the MPTP-induced changes in ZO-1 expression and reduce MMP-9 protein and activity. Simvastatin 15-26 matrix metallopeptidase 9 Mus musculus 103-108 26670440-10 2015 Taken together, these findings suggest that simvastatin administration may partially reverse the impairment of ZO-1 induced by MPTP via inhibiting the activity of MMP9, fortify the impaired intestinal barrier and limit gut-derived toxins that pass across the intestinal barrier. Simvastatin 44-55 tight junction protein 1 Mus musculus 111-115 26670440-10 2015 Taken together, these findings suggest that simvastatin administration may partially reverse the impairment of ZO-1 induced by MPTP via inhibiting the activity of MMP9, fortify the impaired intestinal barrier and limit gut-derived toxins that pass across the intestinal barrier. Simvastatin 44-55 matrix metallopeptidase 9 Mus musculus 163-167 26499955-5 2015 Following treatment with simvastatin, the alkaline phosphatase activity, and mRNA expression levels of osteocalcin and bone sialoprotein were increased significantly in the BMSCs. Simvastatin 25-36 bone gamma-carboxyglutamate protein Homo sapiens 103-114 26367500-5 2015 RESULTS: CYP2D6*5 and CYP2D6*14 were found to be associated with a higher area under the curve (AUC) for simvastatin, whereas the AUC of simvastatin acid was significantly increased in patients with the SLCO1B1 rs4149056, ABCG2 rs2231142, and CYP2D6*41 allele variants. Simvastatin 105-116 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 9-15 26367500-5 2015 RESULTS: CYP2D6*5 and CYP2D6*14 were found to be associated with a higher area under the curve (AUC) for simvastatin, whereas the AUC of simvastatin acid was significantly increased in patients with the SLCO1B1 rs4149056, ABCG2 rs2231142, and CYP2D6*41 allele variants. Simvastatin 105-116 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 22-28 26367500-5 2015 RESULTS: CYP2D6*5 and CYP2D6*14 were found to be associated with a higher area under the curve (AUC) for simvastatin, whereas the AUC of simvastatin acid was significantly increased in patients with the SLCO1B1 rs4149056, ABCG2 rs2231142, and CYP2D6*41 allele variants. Simvastatin 105-116 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 22-28 26367500-6 2015 Patients with the CYP2D6*41 variant showed a higher peak serum concentration (Cmax) of both simvastatin and simvastatin acid. Simvastatin 92-103 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 18-24 26367500-7 2015 The SLCO1B1 rs4149056 and rs4149015 polymorphisms were associated with an increased AUC ratio (i.e. ratio of simvastatin acid to simvastatin), whereas the SLCO1B1 rs4149056 and CYP2D6*5 variants were related to a higher Cmax ratio. Simvastatin 109-120 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 26386973-0 2015 Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. Simvastatin 39-50 KRAS proto-oncogene, GTPase Homo sapiens 86-90 26386973-2 2015 Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS. Simvastatin 0-11 KRAS proto-oncogene, GTPase Homo sapiens 123-127 26386973-3 2015 We hypothesize that the activated KRAS pathway in KRAS mutant tumors can be inhibited by simvastatin rendering these tumors sensitive to the EGFR inhibitor cetuximab. Simvastatin 89-100 KRAS proto-oncogene, GTPase Homo sapiens 34-38 26386973-3 2015 We hypothesize that the activated KRAS pathway in KRAS mutant tumors can be inhibited by simvastatin rendering these tumors sensitive to the EGFR inhibitor cetuximab. Simvastatin 89-100 KRAS proto-oncogene, GTPase Homo sapiens 50-54 26386973-3 2015 We hypothesize that the activated KRAS pathway in KRAS mutant tumors can be inhibited by simvastatin rendering these tumors sensitive to the EGFR inhibitor cetuximab. Simvastatin 89-100 epidermal growth factor receptor Homo sapiens 141-145 26386973-4 2015 METHODS: A Simon two-stage, single-arm, phase II study was performed to test the efficacy and safety of the addition of simvastatin to cetuximab in patients with a KRAS mutation in their CRC tumour who were previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens. Simvastatin 120-131 KRAS proto-oncogene, GTPase Homo sapiens 164-168 26386973-9 2015 CONCLUSION: Based on the current study we conclude that the theoretical concept of KRAS modulation with simvastatin was not applicable in the clinic, as we were not able to restore sensitivity to cetuximab in CRC patients harbouring a somatic KRAS mutation. Simvastatin 104-115 KRAS proto-oncogene, GTPase Homo sapiens 83-87 26163326-2 2015 This study aimed to test the hypotheses that long-term use of simvastatin could affect the incidence and severity of ventilator-induced lung injury after mechanical ventilation, and the process may involve heme oxygenase-1 (HO-1). Simvastatin 62-73 heme oxygenase 1 Rattus norvegicus 224-228 26163326-9 2015 The pathologic damage was substantially alleviated in rats treated with simvastatin before mechanical ventilation: reduced protein concentration, wet/dry weight ratio, myeloperoxidase activity, and malondialdehyde level, and increased superoxide dismutase activity in lung tissues, compared with the ventilation group. Simvastatin 72-83 myeloperoxidase Rattus norvegicus 168-183 26163326-10 2015 Both mechanical ventilation and simvastatin administration induced HO-1 messenger RNA and protein expression in lung tissues. Simvastatin 32-43 heme oxygenase 1 Rattus norvegicus 67-71 26163326-11 2015 CONCLUSIONS: Long-term administration of simvastatin significantly reduces the inflammatory response and pulmonary injury induced by mechanical ventilation, potentially by upregulating HO-1 in lung tissues. Simvastatin 41-52 heme oxygenase 1 Rattus norvegicus 185-189 26367500-0 2015 Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Simvastatin 115-126 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-68 26561346-5 2015 In addition to its established effects on ATP-sensitive potassium channels (p = 0.004) and voltage-gated calcium channels (p = 0.004), simvastatin suppressed insulin secretion stimulated by muscarinic M3 or GPR40 receptor agonists (Tak875 by 33%, p = 0.002; GW9508 by 77%, p = 0.01) at glucose level of 5.5 mmol/l, and inhibited calcium release from the endoplasmic reticulum. Simvastatin 135-146 free fatty acid receptor 1 Mus musculus 207-212 26625143-0 2015 Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 0-11 low density lipoprotein receptor Mus musculus 91-95 26625143-0 2015 Simvastatin Attenuates Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1. Simvastatin 0-11 tumor necrosis factor Mus musculus 150-177 26188833-2 2015 We first reported that simvastatin dose-dependently worsens insulin sensitivity. Simvastatin 23-34 insulin Homo sapiens 60-67 26383260-10 2015 In addition, analysis of caspase 3 assays and multiple proteins involved in cellular apoptosis demonstrated that mutant cells were more resistant to simvastatin treatment-induced apoptosis than wild type control cells. Simvastatin 149-160 caspase 3 Homo sapiens 25-34 26882614-15 2015 Compared with the model group, mRNA expressions of Rho kinase and NF-kappaB p65 obviously decreased in low and high dose BYHWD groups, the Simvastatin control group, and the BYHWD prevention group (P < 0.01). Simvastatin 139-150 synaptotagmin 1 Rattus norvegicus 76-79 26564598-10 2015 In contrast, rosuvastatin and simvastatin significantly reduced total and ABCA1-specific CEC, whereas atorvastatin had no significant effect. Simvastatin 30-41 ATP binding cassette subfamily A member 1 Homo sapiens 74-79 26572585-1 2015 Simvastatin, an HMG-CoA reductase inhibitor, has lung vascular-protective effects that are associated with decreased agonist-induced integrin beta4 (ITGB4) tyrosine phosphorylation. Simvastatin 0-11 integrin subunit beta 4 Homo sapiens 133-147 26572585-1 2015 Simvastatin, an HMG-CoA reductase inhibitor, has lung vascular-protective effects that are associated with decreased agonist-induced integrin beta4 (ITGB4) tyrosine phosphorylation. Simvastatin 0-11 integrin subunit beta 4 Homo sapiens 149-154 26561346-6 2015 Impaired insulin secretion caused by simvastatin treatment were efficiently restored by GPR119 or GLP-1 receptor stimulation and by direct activation of cAMP-dependent signaling pathways with forskolin. Simvastatin 37-48 G-protein coupled receptor 119 Mus musculus 88-94 26561346-6 2015 Impaired insulin secretion caused by simvastatin treatment were efficiently restored by GPR119 or GLP-1 receptor stimulation and by direct activation of cAMP-dependent signaling pathways with forskolin. Simvastatin 37-48 glucagon-like peptide 1 receptor Mus musculus 98-112 26412035-6 2015 UGT1A3 appeared to have the highest lactonization capacity with marked differences in statin conversion rates: pitavastatin >> atorvastatin > cerivastatin > lovastatin > rosuvastatin (simvastatin not converted). Simvastatin 199-210 UDP glucuronosyltransferase family 1 member A3 Homo sapiens 0-6 26535078-3 2015 Simvastatin, 3-hydroxy-3-methylgultaryl (HMG)-CoA reductase inhibitor, has been shown to reduce inflammatory responses in vascular diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 13-59 26535078-7 2015 Treatment of simvastatin reduced the LPS-accelerated infarct size by 73%, and decreased the ischemia/reperfusion-induced expressions of pro-inflammatory mediators such as iNOS, COX-2 and IL-1beta in LPS-injected rat brains. Simvastatin 13-24 nitric oxide synthase 2 Rattus norvegicus 171-175 26535078-7 2015 Treatment of simvastatin reduced the LPS-accelerated infarct size by 73%, and decreased the ischemia/reperfusion-induced expressions of pro-inflammatory mediators such as iNOS, COX-2 and IL-1beta in LPS-injected rat brains. Simvastatin 13-24 cytochrome c oxidase II, mitochondrial Rattus norvegicus 177-182 26535078-7 2015 Treatment of simvastatin reduced the LPS-accelerated infarct size by 73%, and decreased the ischemia/reperfusion-induced expressions of pro-inflammatory mediators such as iNOS, COX-2 and IL-1beta in LPS-injected rat brains. Simvastatin 13-24 interleukin 1 beta Rattus norvegicus 187-195 26823851-3 2015 The aim of the present study was to investigate the effects of simvastatin on iNOS expression based on a lipopolysaccharide (LPS)-induced septic rat model. Simvastatin 63-74 nitric oxide synthase 2 Rattus norvegicus 78-82 26329790-2 2015 Organic anion transporting polypeptide (OATP) 1B1 activity markedly affects the hepatic uptake of simvastatin acid, whereas both simvastatin and simvastatin acid are sensitive to changes in cytochrome P450 3A4 activity. Simvastatin 98-109 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-49 26043025-0 2015 Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. Simvastatin 0-11 interleukin 17A Homo sapiens 30-35 26043025-0 2015 Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. Simvastatin 0-11 interleukin 10 Homo sapiens 52-57 26043025-10 2015 CONCLUSIONS: Simvastatin reversed the IL-17A/IL-10 imbalance in the airways and reduced sputum macrophage but not neutrophil counts in patients with COPD. Simvastatin 13-24 interleukin 17A Homo sapiens 38-44 26043025-10 2015 CONCLUSIONS: Simvastatin reversed the IL-17A/IL-10 imbalance in the airways and reduced sputum macrophage but not neutrophil counts in patients with COPD. Simvastatin 13-24 interleukin 10 Homo sapiens 45-50 26823851-9 2015 RESULTS: Compared with the septic group, significant decreases in the oxygenation index and expression level of iNOS were observed in the simvastatin group. Simvastatin 138-149 nitric oxide synthase 2 Rattus norvegicus 112-116 26823851-10 2015 Furthermore, simvastatin treatment resulted in a significant decrease in iNOS levels and the pathological integral of lung injury score in septic rats. Simvastatin 13-24 nitric oxide synthase 2 Rattus norvegicus 73-77 26823851-12 2015 Decreasing iNOS levels may contribute to the protective role of simvastatin in lung injury. Simvastatin 64-75 nitric oxide synthase 2 Rattus norvegicus 11-15 26520569-3 2015 RESULTS: In this study, we found that simvastatin (0.2 muM for 12 h) induced the degradation of extracellular Abeta40, which depended on IDE secretion from primary astrocytes. Simvastatin 38-49 insulin degrading enzyme Homo sapiens 137-140 26304628-2 2015 To determine if an atherogenic diet can induce pulmonary fibrosis and whether simvastatin treatment is beneficial by up-regulating heat shock protein 70 and 90. Simvastatin 78-89 LOW QUALITY PROTEIN: heat shock 70 kDa protein 1-like Oryctolagus cuniculus 131-152 26322850-0 2015 Simvastatin Inhibits Toll-like Receptor 8 (TLR8) Signaling in Primary Human Monocytes and Spontaneous Tumor Necrosis Factor Production from Rheumatoid Synovial Membrane Cultures. Simvastatin 0-11 toll like receptor 8 Homo sapiens 21-41 26322850-0 2015 Simvastatin Inhibits Toll-like Receptor 8 (TLR8) Signaling in Primary Human Monocytes and Spontaneous Tumor Necrosis Factor Production from Rheumatoid Synovial Membrane Cultures. Simvastatin 0-11 toll like receptor 8 Homo sapiens 43-47 26322850-3 2015 A short pretreatment with simvastatin dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha in response to TLR8 activation (but not TLR2, -4 or -5). Simvastatin 26-37 tumor necrosis factor Homo sapiens 83-116 26322850-3 2015 A short pretreatment with simvastatin dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha in response to TLR8 activation (but not TLR2, -4 or -5). Simvastatin 26-37 toll like receptor 8 Homo sapiens 132-136 26322850-5 2015 TLR8 signaling was examined in HEK 293 cells stably expressing TLR8, where simvastatin inhibited I kappa B kinase (IKK)alpha/beta phosphorylation and subsequent nuclear factor (NF)-kappaB activation without affecting the pathway to activating protein-1 (AP-1). Simvastatin 75-86 toll like receptor 8 Homo sapiens 0-4 26322850-5 2015 TLR8 signaling was examined in HEK 293 cells stably expressing TLR8, where simvastatin inhibited I kappa B kinase (IKK)alpha/beta phosphorylation and subsequent nuclear factor (NF)-kappaB activation without affecting the pathway to activating protein-1 (AP-1). Simvastatin 75-86 toll like receptor 8 Homo sapiens 63-67 26322850-5 2015 TLR8 signaling was examined in HEK 293 cells stably expressing TLR8, where simvastatin inhibited I kappa B kinase (IKK)alpha/beta phosphorylation and subsequent nuclear factor (NF)-kappaB activation without affecting the pathway to activating protein-1 (AP-1). Simvastatin 75-86 component of inhibitor of nuclear factor kappa B kinase complex Homo sapiens 97-124 26322850-7 2015 Simvastatin significantly inhibited the spontaneous release of TNF in this model, which was not reversed by mevalonate. Simvastatin 0-11 tumor necrosis factor Homo sapiens 63-66 26322850-8 2015 Together, these results demonstrate a hitherto unrecognized mechanism of simvastatin inhibition of TLR8 signaling that may in part explain its beneficial antiinflammatory effects. Simvastatin 73-84 toll like receptor 8 Homo sapiens 99-103 26280117-0 2015 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 26520569-4 2015 In addition, simvastatin increased IDE secretion from astrocytes in a time- and dose-dependent manner. Simvastatin 13-24 insulin degrading enzyme Homo sapiens 35-38 26520569-5 2015 Moreover, simvastatin-mediated IDE secretion was mediated by an autophagy-based unconventional secretory pathway, and autophagic flux regulated simvastatin-mediated IDE secretion. Simvastatin 10-21 insulin degrading enzyme Homo sapiens 31-34 26520569-5 2015 Moreover, simvastatin-mediated IDE secretion was mediated by an autophagy-based unconventional secretory pathway, and autophagic flux regulated simvastatin-mediated IDE secretion. Simvastatin 144-155 insulin degrading enzyme Homo sapiens 165-168 26520569-6 2015 Finally, simvastatin activated autophagy via the LKB1-AMPK-mTOR signaling pathway in astrocytes. Simvastatin 9-20 serine/threonine kinase 11 Homo sapiens 49-53 26334320-6 2015 3-Methyladenine (3-MA), ATG5 siRNA, bafilomycin A, and E64D/pepstatin A enhanced the apoptotic potential of pemetrexed and simvastatin, whereas rapamycin and LY294002 attenuated their induction of caspase-dependent apoptosis. Simvastatin 123-134 autophagy related 5 Homo sapiens 24-28 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 NPHS1 adhesion molecule, nephrin Rattus norvegicus 43-50 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 NPHS2 stomatin family member, podocin Rattus norvegicus 52-59 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 65-99 26770424-0 2015 Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 101-105 26770424-9 2015 Simvastatin (SVT) could reduce serum creatinine levels and the UAER, maintain the expression of nephrin and podocin, reduce the expression of VEGF, and improve the pathological changes of podocytes, which were much more pronounced at 8 weeks (P < 0.01). Simvastatin 0-11 NPHS1 adhesion molecule, nephrin Rattus norvegicus 96-103 26770424-9 2015 Simvastatin (SVT) could reduce serum creatinine levels and the UAER, maintain the expression of nephrin and podocin, reduce the expression of VEGF, and improve the pathological changes of podocytes, which were much more pronounced at 8 weeks (P < 0.01). Simvastatin 0-11 NPHS2 stomatin family member, podocin Rattus norvegicus 108-115 26770424-9 2015 Simvastatin (SVT) could reduce serum creatinine levels and the UAER, maintain the expression of nephrin and podocin, reduce the expression of VEGF, and improve the pathological changes of podocytes, which were much more pronounced at 8 weeks (P < 0.01). Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 142-146 26770424-10 2015 Simvastatin could maintain the distribution of nephrin and podocin in podocytes, inhibit VEGF expression, and thus improve podocyte injuries and protect kidney functions in diabetic rats. Simvastatin 0-11 NPHS1 adhesion molecule, nephrin Rattus norvegicus 47-54 26770424-10 2015 Simvastatin could maintain the distribution of nephrin and podocin in podocytes, inhibit VEGF expression, and thus improve podocyte injuries and protect kidney functions in diabetic rats. Simvastatin 0-11 NPHS2 stomatin family member, podocin Rattus norvegicus 59-66 26770424-10 2015 Simvastatin could maintain the distribution of nephrin and podocin in podocytes, inhibit VEGF expression, and thus improve podocyte injuries and protect kidney functions in diabetic rats. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 89-93 26284584-0 2015 Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Simvastatin 0-11 immunoglobulin heavy variable 3/OR16-17 (non-functional) Homo sapiens 116-120 26284584-5 2015 Mevalonate pathway inhibition with simvastatin abrogated these signaling pathways and reversed the resistance of IGHV unmutated cells to doxorubicin, also counteracting the protective effect exerted by stromal cells. Simvastatin 35-46 immunoglobulin heavy variable 3/OR16-17 (non-functional) Homo sapiens 113-117 26277021-0 2015 Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. Simvastatin 22-33 baculoviral IAP repeat containing 5 Homo sapiens 106-111 26277021-0 2015 Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. Simvastatin 22-33 cellular communication network factor 2 Homo sapiens 116-147 26277021-1 2015 PURPOSE: We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells. Simvastatin 51-62 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-113 26277021-7 2015 Simvastatin suppressed the expression of BIRC5 and CTGF genes in these cancer cells. Simvastatin 0-11 baculoviral IAP repeat containing 5 Homo sapiens 41-46 26277021-7 2015 Simvastatin suppressed the expression of BIRC5 and CTGF genes in these cancer cells. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 51-55 26277021-9 2015 CONCLUSION: We suggest that simvastatin has a synergistic effect with radiation on GC and CRC through the induction of apoptosis, which may be mediated by a simultaneous inhibition of BIRC5 and CTGF expression. Simvastatin 28-39 baculoviral IAP repeat containing 5 Homo sapiens 184-189 26277021-9 2015 CONCLUSION: We suggest that simvastatin has a synergistic effect with radiation on GC and CRC through the induction of apoptosis, which may be mediated by a simultaneous inhibition of BIRC5 and CTGF expression. Simvastatin 28-39 cellular communication network factor 2 Homo sapiens 194-198 26239701-12 2015 Simvastatin exerted a significant impact on the expression of VEGF and attenuated cigarette smoke-induced emphysema in rats. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 62-66 26260290-5 2015 When gap junction function was decreased by the gap junction inhibitor or by siRNA targeting connexin 43, the protective effect of simvastatin to cisplatin toxicity was substantially attenuated. Simvastatin 131-142 gap junction protein alpha 1 Homo sapiens 93-104 26051402-0 2015 Simvastatin prevents beta-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. Simvastatin 0-11 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-111 26051402-0 2015 Simvastatin prevents beta-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 137-140 26051402-0 2015 Simvastatin prevents beta-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. Simvastatin 0-11 brain derived neurotrophic factor Mus musculus 156-160 26398384-1 2015 BACKGROUND: We investigated the possible non-lipid effects of simvastatin (SIMV) on paraoxonase 1 (PON1) and butyrylcholinesterase (BuChE) activity, as well as on malondialdehyde (MDA) levels in normolipidemic rats. Simvastatin 75-79 paraoxonase 1 Rattus norvegicus 84-97 27116885-5 2015 Decreasing of ceruloplasmin concentration can be used as additional biochemical test in estimation of the state of liver affection at prolonged Simvastatin intake. Simvastatin 144-155 ceruloplasmin Rattus norvegicus 14-27 26398384-1 2015 BACKGROUND: We investigated the possible non-lipid effects of simvastatin (SIMV) on paraoxonase 1 (PON1) and butyrylcholinesterase (BuChE) activity, as well as on malondialdehyde (MDA) levels in normolipidemic rats. Simvastatin 75-79 paraoxonase 1 Rattus norvegicus 99-103 26330412-0 2015 Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Simvastatin 152-163 C-reactive protein Homo sapiens 77-95 25500203-3 2015 DESIGN: Activation phenotype was evaluated in human and rat cirrhotic hepatic stellate cells (HSC) treated with the pharmacological inductor of KLF2 simvastatin, with adenovirus codifying for this transcription factor (Ad-KLF2), or vehicle, in presence/absence of inhibitors of KLF2. Simvastatin 149-160 Kruppel-like factor 2 Rattus norvegicus 144-148 26345110-0 2015 Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism. Simvastatin 0-11 insulin Homo sapiens 23-30 26345110-4 2015 We explored the possible mechanism of statin induced insulin resistance using a well-established cell based model and simvastatin as a prototype statin. Simvastatin 118-129 insulin Homo sapiens 53-60 26345110-5 2015 Our data show that simvastatin induces insulin resistance in a cholesterol biosynthesis inhibition independent fashion but does so by a fatty acid mediated effect on insulin signaling pathway. Simvastatin 19-30 insulin Homo sapiens 39-46 26345110-5 2015 Our data show that simvastatin induces insulin resistance in a cholesterol biosynthesis inhibition independent fashion but does so by a fatty acid mediated effect on insulin signaling pathway. Simvastatin 19-30 insulin Homo sapiens 166-173 26336957-0 2015 Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Simvastatin 92-103 insulin Homo sapiens 44-51 26336957-5 2015 Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Simvastatin 10-21 apolipoprotein B Homo sapiens 91-107 26336957-5 2015 Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Simvastatin 10-21 apolipoprotein A1 Homo sapiens 202-229 26053280-0 2015 Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Simvastatin 39-50 KRAS proto-oncogene, GTPase Homo sapiens 88-92 26053280-2 2015 Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification of KRAS. Simvastatin 0-11 KRAS proto-oncogene, GTPase Homo sapiens 109-113 26053280-3 2015 We hypothesize that the activity of the RAS-induced pathway in patients with a KRAS mutation might be inhibited by simvastatin. Simvastatin 115-126 KRAS proto-oncogene, GTPase Homo sapiens 79-83 26053280-5 2015 A Simon two-stage design single-arm, phase II study was designed to test the safety and efficacy of the addition of simvastatin to panitumumab in colorectal cancer patients with a KRAS mutation after failing fluoropyrimidine-based, oxaliplatin-based and irinotecan-based therapy. Simvastatin 116-127 KRAS proto-oncogene, GTPase Homo sapiens 180-184 26053280-11 2015 We conclude that the concept of mutant KRAS phenotype expression modulation with simvastatin was not applicable in the clinic. Simvastatin 81-92 KRAS proto-oncogene, GTPase Homo sapiens 39-43 26451103-4 2015 We thus hypothesized that RhoA signaling is involved in simvastatin-induced osteogenesis in bone marrow mesenchymal stem cells. Simvastatin 56-67 ras homolog family member A Homo sapiens 26-30 26451103-5 2015 We found that although treatment with simvastatin shifts localization of RhoA protein from the membrane to the cytosol, the treatment still activates RhoA dose-dependently because it reduces the association with RhoGDIalpha. Simvastatin 38-49 ras homolog family member A Homo sapiens 73-77 26451103-5 2015 We found that although treatment with simvastatin shifts localization of RhoA protein from the membrane to the cytosol, the treatment still activates RhoA dose-dependently because it reduces the association with RhoGDIalpha. Simvastatin 38-49 ras homolog family member A Homo sapiens 150-154 25500203-9 2015 Cirrhotic rats treated with simvastatin or Ad-KLF2 showed hepatic upregulation in the KLF2-Nrf2 pathway, deactivation of HSC and prominent reduction in liver fibrosis. Simvastatin 28-39 Kruppel-like factor 2 Rattus norvegicus 86-90 25500203-9 2015 Cirrhotic rats treated with simvastatin or Ad-KLF2 showed hepatic upregulation in the KLF2-Nrf2 pathway, deactivation of HSC and prominent reduction in liver fibrosis. Simvastatin 28-39 NFE2 like bZIP transcription factor 2 Rattus norvegicus 91-95 26775449-11 2015 Refrigerated samples of simvastatin in SyrSpend SF PH4 were stable for at least 90 days. Simvastatin 24-35 prolyl 4-hydroxylase, transmembrane Homo sapiens 51-54 26304753-0 2015 Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Simvastatin 72-83 epoxide hydrolase 2 Homo sapiens 32-57 26225047-1 2015 INTRODUCTION: Simvastatin, a common cholesterol-lowering drug that inhibits hepatic hydroxymethylglutaryl coenzyme A reductase, the rate-limiting enzyme in the mevalonate pathway, increases expression of the BMP-2 gene and thus promotes bone regeneration. Simvastatin 14-25 bone morphogenetic protein 2 Homo sapiens 208-213 26376374-11 2015 The available evidence suggests that SLCO1B1 gene T521C polymorphism is associated with an increased risk of statin-related myopathy, especially in individuals receiving simvastatin. Simvastatin 170-181 solute carrier organic anion transporter family member 1B1 Homo sapiens 37-44 26638446-9 2015 The addition of ezetimibe to simvastatin resulted in an incremental lowering of LDL-C (reached value 53.2 versus 69.9 mg/dl, p < 0.001) and a further improvement of the patient prognosis (relative reduction of primary endpoint: -6.4%, p = 0.016). Simvastatin 29-40 component of oligomeric golgi complex 2 Homo sapiens 80-85 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 epoxide hydrolase 2 Homo sapiens 28-31 26304753-0 2015 Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Simvastatin 72-83 nitric oxide synthase 3 Homo sapiens 94-127 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 nitric oxide synthase 3 Homo sapiens 96-100 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 AKT serine/threonine kinase 1 Homo sapiens 117-120 26304753-4 2015 Simvastatin, a clinical lipid-lowering drug, also has a pleiotropic effect on eNOS activation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 78-82 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 nitric oxide synthase 3 Homo sapiens 126-130 26304753-5 2015 However, whether sEH phosphatase is involved in simvastatin-activated eNOS activity remains elusive. Simvastatin 48-59 epoxide hydrolase 2 Homo sapiens 17-20 26304753-5 2015 However, whether sEH phosphatase is involved in simvastatin-activated eNOS activity remains elusive. Simvastatin 48-59 nitric oxide synthase 3 Homo sapiens 70-74 26304753-6 2015 We investigated the role of sEH phosphatase activity in simvastatin-mediated activation of eNOS in endothelial cells (ECs). Simvastatin 56-67 epoxide hydrolase 2 Homo sapiens 28-31 26304753-6 2015 We investigated the role of sEH phosphatase activity in simvastatin-mediated activation of eNOS in endothelial cells (ECs). Simvastatin 56-67 nitric oxide synthase 3 Homo sapiens 91-95 26304753-8 2015 In addition, pharmacological inhibition of sEH phosphatase or overexpressing the inactive phosphatase domain of sEH enhanced simvastatin-induced NO bioavailability, tube formation and phosphorylation of eNOS, Akt, and AMP-activated protein kinase (AMPK). Simvastatin 125-136 epoxide hydrolase 2 Homo sapiens 43-46 26304753-8 2015 In addition, pharmacological inhibition of sEH phosphatase or overexpressing the inactive phosphatase domain of sEH enhanced simvastatin-induced NO bioavailability, tube formation and phosphorylation of eNOS, Akt, and AMP-activated protein kinase (AMPK). Simvastatin 125-136 epoxide hydrolase 2 Homo sapiens 112-115 26304753-8 2015 In addition, pharmacological inhibition of sEH phosphatase or overexpressing the inactive phosphatase domain of sEH enhanced simvastatin-induced NO bioavailability, tube formation and phosphorylation of eNOS, Akt, and AMP-activated protein kinase (AMPK). Simvastatin 125-136 nitric oxide synthase 3 Homo sapiens 203-207 26304753-8 2015 In addition, pharmacological inhibition of sEH phosphatase or overexpressing the inactive phosphatase domain of sEH enhanced simvastatin-induced NO bioavailability, tube formation and phosphorylation of eNOS, Akt, and AMP-activated protein kinase (AMPK). Simvastatin 125-136 AKT serine/threonine kinase 1 Homo sapiens 209-212 26304753-9 2015 In contrast, overexpressing the phosphatase domain of sEH limited the simvastatin-increased NO biosynthesis and eNOS phosphorylation at Ser1179. Simvastatin 70-81 epoxide hydrolase 2 Homo sapiens 54-57 26304753-9 2015 In contrast, overexpressing the phosphatase domain of sEH limited the simvastatin-increased NO biosynthesis and eNOS phosphorylation at Ser1179. Simvastatin 70-81 nitric oxide synthase 3 Homo sapiens 112-116 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 epidermal growth factor receptor Homo sapiens 19-51 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 52-57 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 epoxide hydrolase 2 Homo sapiens 91-94 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 epoxide hydrolase 2 Homo sapiens 115-118 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 119-122 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 128-132 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 C-terminal Src kinase Homo sapiens 169-181 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 neuropeptide Y receptor Y4 Homo sapiens 192-195 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 169-174 25884615-2 2015 We examined the role of the TGF-beta receptor III (TGFBR3) in the inhibition of cardiac fibrosis by simvastatin. Simvastatin 100-111 transforming growth factor, beta receptor III Mus musculus 51-57 26550333-0 2015 Different regulation of Toll-like receptor 4 expression on blood CD14(+) monocytes by simvastatin in patients with sepsis and severe sepsis. Simvastatin 86-97 toll like receptor 4 Homo sapiens 24-44 26550333-0 2015 Different regulation of Toll-like receptor 4 expression on blood CD14(+) monocytes by simvastatin in patients with sepsis and severe sepsis. Simvastatin 86-97 CD14 molecule Homo sapiens 65-69 26550333-1 2015 We have demonstrated that regulation of Toll-like receptor 4 (TLR4) surface expression levels on blood CD14(+) monocytes by simvastatin treatment in patient with sepsis is different from that in patients with severe sepsis. Simvastatin 124-135 toll like receptor 4 Homo sapiens 40-60 26550333-1 2015 We have demonstrated that regulation of Toll-like receptor 4 (TLR4) surface expression levels on blood CD14(+) monocytes by simvastatin treatment in patient with sepsis is different from that in patients with severe sepsis. Simvastatin 124-135 toll like receptor 4 Homo sapiens 62-66 26550333-1 2015 We have demonstrated that regulation of Toll-like receptor 4 (TLR4) surface expression levels on blood CD14(+) monocytes by simvastatin treatment in patient with sepsis is different from that in patients with severe sepsis. Simvastatin 124-135 CD14 molecule Homo sapiens 103-107 26550333-2 2015 In patients with sepsis simvastatin treatment statistically significantly decreased TLR4 surface expression level on blood CD14(+) monocytes, while in patients with severe sepsis simvastatin treatment had no significant influence on TLR4 surface expression level on blood CD14(+) monocytes. Simvastatin 24-35 toll like receptor 4 Homo sapiens 84-88 26550333-2 2015 In patients with sepsis simvastatin treatment statistically significantly decreased TLR4 surface expression level on blood CD14(+) monocytes, while in patients with severe sepsis simvastatin treatment had no significant influence on TLR4 surface expression level on blood CD14(+) monocytes. Simvastatin 24-35 CD14 molecule Homo sapiens 123-127 26550333-3 2015 The changes of plasma interleukin-6 (IL-6) induced by simvastatin in patients with sepsis and severe sepsis were similar with that of TLR4. Simvastatin 54-65 interleukin 6 Homo sapiens 22-35 26550333-3 2015 The changes of plasma interleukin-6 (IL-6) induced by simvastatin in patients with sepsis and severe sepsis were similar with that of TLR4. Simvastatin 54-65 interleukin 6 Homo sapiens 37-41 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 cAMP responsive element binding protein 1 Mus musculus 35-39 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 brain derived neurotrophic factor Mus musculus 44-77 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 brain derived neurotrophic factor Mus musculus 79-83 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 peroxisome proliferator activated receptor alpha Mus musculus 107-112 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 peroxisome proliferator activated receptor alpha Mus musculus 156-165 26118928-5 2015 Accordingly, simvastatin increases CREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of Ppara null mice receiving full-length lentiviral PPARalpha, but not L331M/Y334D statin-binding domain-mutated lentiviral PPARalpha. Simvastatin 13-24 peroxisome proliferator activated receptor alpha Mus musculus 228-237 26118928-6 2015 This study identifies statins as ligands of PPARalpha, describes neurotrophic function of statins via the PPARalpha-CREB pathway, and analyzes the importance of PPARalpha in the therapeutic success of simvastatin in an animal model of Alzheimer"s disease. Simvastatin 201-212 peroxisome proliferator activated receptor alpha Mus musculus 44-53 25840272-7 2015 Simvastatin induced dose-dependent apoptosis in leiomyoma cells as measured by a fluorometric caspase-3 activity assay, and inhibited proliferation as demonstrated by an (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (both were significant at 5 and 10 muM). Simvastatin 0-11 caspase 3 Homo sapiens 94-103 25840272-7 2015 Simvastatin induced dose-dependent apoptosis in leiomyoma cells as measured by a fluorometric caspase-3 activity assay, and inhibited proliferation as demonstrated by an (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (both were significant at 5 and 10 muM). Simvastatin 0-11 latexin Homo sapiens 274-277 25884615-10 2015 KEY RESULTS: Simvastatin prevented fibrosis following MI, improved heart ultrastructure and function, up-regulated TGFBR3 and decreased ERK1/2 and JNK phosphorylation. Simvastatin 13-24 transforming growth factor, beta receptor III Mus musculus 115-121 25884615-10 2015 KEY RESULTS: Simvastatin prevented fibrosis following MI, improved heart ultrastructure and function, up-regulated TGFBR3 and decreased ERK1/2 and JNK phosphorylation. Simvastatin 13-24 mitogen-activated protein kinase 3 Mus musculus 136-142 25884615-10 2015 KEY RESULTS: Simvastatin prevented fibrosis following MI, improved heart ultrastructure and function, up-regulated TGFBR3 and decreased ERK1/2 and JNK phosphorylation. Simvastatin 13-24 mitogen-activated protein kinase 8 Mus musculus 147-150 25884615-11 2015 Simvastatin up-regulated TGFBR3 in NMCFs, whereas silencing TGFBR3 reversed inhibitory effects of simvastatin on cell proliferation and collagen production. Simvastatin 0-11 transforming growth factor, beta receptor III Mus musculus 25-31 25884615-11 2015 Simvastatin up-regulated TGFBR3 in NMCFs, whereas silencing TGFBR3 reversed inhibitory effects of simvastatin on cell proliferation and collagen production. Simvastatin 98-109 transforming growth factor, beta receptor III Mus musculus 60-66 25884615-12 2015 Simvastatin inhibited ERK1/2 and JNK signalling while silencing TGFBR3 opposed this effect. Simvastatin 0-11 mitogen-activated protein kinase 3 Mus musculus 22-28 25884615-12 2015 Simvastatin inhibited ERK1/2 and JNK signalling while silencing TGFBR3 opposed this effect. Simvastatin 0-11 mitogen-activated protein kinase 8 Mus musculus 33-36 25884615-15 2015 In vivo, suppression of cardiac TGFBR3 abolished anti-fibrotic effects, improvement of cardiac function and changes in related proteins after simvastatin. Simvastatin 142-153 transforming growth factor, beta receptor III Mus musculus 32-38 25884615-16 2015 CONCLUSIONS AND IMPLICATIONS: TGFBR3 mediated the decreased cardiac fibrosis, collagen deposition and fibroblast activity, induced by simvastatin, following MI. Simvastatin 134-145 transforming growth factor, beta receptor III Mus musculus 30-36 25903419-5 2015 RESULTS: Simvastatin/ezetimibe combination, but not the monotherapies, reduced the mRNA expression of the PSGL-1, LFA-1, and Mac-1 genes in PBMC from hypercholesterolemics. Simvastatin 9-20 selectin P ligand Homo sapiens 106-112 26622396-1 2015 The aim of the present study was to investigate the effects of simvastatin on the protein kinase B (PKB) signaling pathway and the expression of phosphatase and tensin homolog (PTEN). Simvastatin 63-74 phosphatase and tensin homolog Rattus norvegicus 177-181 25903419-5 2015 RESULTS: Simvastatin/ezetimibe combination, but not the monotherapies, reduced the mRNA expression of the PSGL-1, LFA-1, and Mac-1 genes in PBMC from hypercholesterolemics. Simvastatin 9-20 integrin subunit alpha L Homo sapiens 114-119 25903419-5 2015 RESULTS: Simvastatin/ezetimibe combination, but not the monotherapies, reduced the mRNA expression of the PSGL-1, LFA-1, and Mac-1 genes in PBMC from hypercholesterolemics. Simvastatin 9-20 integrin subunit beta 2 Homo sapiens 125-130 25903419-8 2015 Atorvastatin and simvastatin at 10 muM reduced mRNA and protein expression of L-selectin, PSGL-1, and VLA-4 in THP-1 cells (P < 0.05). Simvastatin 17-28 selectin L Homo sapiens 78-88 25903419-8 2015 Atorvastatin and simvastatin at 10 muM reduced mRNA and protein expression of L-selectin, PSGL-1, and VLA-4 in THP-1 cells (P < 0.05). Simvastatin 17-28 selectin P ligand Homo sapiens 90-96 26622396-9 2015 Notably, simvastatin increased PTEN expression and inhibited PKB expression in the SHR model, as well as in the cardiomyocytes in culture. Simvastatin 9-20 phosphatase and tensin homolog Rattus norvegicus 31-35 26622396-10 2015 In addition, the use of PTEN antisense oligodeoxynucleotides was revealed to inhibit the effects of simvastatin on cardiomyocytes. Simvastatin 100-111 phosphatase and tensin homolog Rattus norvegicus 24-28 26032258-7 2015 KEY FINDINGS: Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin 14-25 component of oligomeric golgi complex 2 Homo sapiens 164-169 26622396-11 2015 Therefore, these results indicated that simvastatin was able to reverse cardiomyocyte hypertrophy in vivo and in vitro, possibly by increasing the expression of PTEN. Simvastatin 40-51 phosphatase and tensin homolog Rattus norvegicus 161-165 26063345-0 2015 Simvastatin inhibits ischemia/reperfusion injury-induced apoptosis of retinal cells via downregulation of the tumor necrosis factor-alpha/nuclear factor-kappaB pathway. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 110-137 26063345-7 2015 Conversely, the levels of pro-apoptotic protein Bax were downregulated in the simvastatin/IR group compared to those in the saline/IR group. Simvastatin 78-89 BCL2 associated X, apoptosis regulator Rattus norvegicus 48-51 26063345-8 2015 Furthermore, the results of the present study showed for the first time, to the best of our knowledge, that simvastatin decreased IR injury-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor-kappaB (NF-kappaB) expression in the retina. Simvastatin 108-119 tumor necrosis factor Rattus norvegicus 148-175 26063345-8 2015 Furthermore, the results of the present study showed for the first time, to the best of our knowledge, that simvastatin decreased IR injury-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor-kappaB (NF-kappaB) expression in the retina. Simvastatin 108-119 tumor necrosis factor Rattus norvegicus 177-186 26063345-9 2015 These findings strongly suggested that simvastatin inhibits apoptosis following IR-induced retinal injury by inhibition of the TNF-alpha/NF-kappaB pathway. Simvastatin 39-50 tumor necrosis factor Rattus norvegicus 127-136 26032258-9 2015 Strong positive correlations between serum angiostatin level versus concentrations of TC, LDL-C, and C-RP were demonstrated before onset of the study (r = 0.48311, 0.6252, and 0.653, respectively) and after simvastatin therapy (r = 0.67752, 0.6485, and 0.8244, respectively). Simvastatin 207-218 C-reactive protein Homo sapiens 101-105 26032258-7 2015 KEY FINDINGS: Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin 14-25 C-reactive protein Homo sapiens 214-218 26207907-0 2015 Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition. Simvastatin 0-11 fibulin 2 Homo sapiens 22-31 26020489-3 2015 This study aimed to investigate the IL-6 susceptibility of melanoma cells from different stages in the presence of simvastatin to overcome loss of growth arrest. Simvastatin 115-126 interleukin 6 Homo sapiens 36-40 26020489-9 2015 Although WM35 cells are highly resistant to simvastatin-induced apoptosis, coadministration with IL-6 enhanced the susceptibility to undergo apoptosis. Simvastatin 44-55 interleukin 6 Homo sapiens 97-101 26020489-11 2015 Furthermore, the IL-6 receptor blocking antibody tocilizumab was coadministered and unmasked an IL-6-sensitive proportion in the simvastatin-induced caspase 3 activity of metastatic melanoma cells. Simvastatin 129-140 interleukin 6 Homo sapiens 17-21 26020489-11 2015 Furthermore, the IL-6 receptor blocking antibody tocilizumab was coadministered and unmasked an IL-6-sensitive proportion in the simvastatin-induced caspase 3 activity of metastatic melanoma cells. Simvastatin 129-140 interleukin 6 Homo sapiens 96-100 26020489-11 2015 Furthermore, the IL-6 receptor blocking antibody tocilizumab was coadministered and unmasked an IL-6-sensitive proportion in the simvastatin-induced caspase 3 activity of metastatic melanoma cells. Simvastatin 129-140 caspase 3 Homo sapiens 149-158 26020121-1 2015 OBJECTIVE: Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1 gene) is a hepatic uptake transporter, and its genetic variability is associated with pharmacokinetics and muscle toxicity risk of simvastatin. Simvastatin 214-225 solute carrier organic anion transporter family member 1B1 Homo sapiens 11-53 26020121-1 2015 OBJECTIVE: Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1 gene) is a hepatic uptake transporter, and its genetic variability is associated with pharmacokinetics and muscle toxicity risk of simvastatin. Simvastatin 214-225 solute carrier organic anion transporter family member 1B1 Homo sapiens 55-62 26020121-1 2015 OBJECTIVE: Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1 gene) is a hepatic uptake transporter, and its genetic variability is associated with pharmacokinetics and muscle toxicity risk of simvastatin. Simvastatin 214-225 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-82 26228060-0 2015 Dose-specific effect of simvastatin on hypoxia-induced HIF-1alpha and BACE expression in Alzheimer"s disease cybrid cells. Simvastatin 24-35 hypoxia inducible factor 1 subunit alpha Homo sapiens 55-65 26228060-0 2015 Dose-specific effect of simvastatin on hypoxia-induced HIF-1alpha and BACE expression in Alzheimer"s disease cybrid cells. Simvastatin 24-35 beta-secretase 1 Homo sapiens 70-74 26228060-6 2015 In the presence of 1 muM simvastatin, intracellular levels of HIF-1alpha and BACE decreased by 40-70% in SAD, but not CTL cybrids. Simvastatin 25-36 hypoxia inducible factor 1 subunit alpha Homo sapiens 62-72 26228060-6 2015 In the presence of 1 muM simvastatin, intracellular levels of HIF-1alpha and BACE decreased by 40-70% in SAD, but not CTL cybrids. Simvastatin 25-36 beta-secretase 1 Homo sapiens 77-81 26228060-7 2015 However, 10 muM simvastatin increased HIF-1alpha and BACE expression in both cybrid models. Simvastatin 16-27 hypoxia inducible factor 1 subunit alpha Homo sapiens 38-48 26228060-7 2015 However, 10 muM simvastatin increased HIF-1alpha and BACE expression in both cybrid models. Simvastatin 16-27 beta-secretase 1 Homo sapiens 53-57 26228060-8 2015 CONCLUSION: Our results suggest demonstrate differential dose-dependent effects of simvastatin on HIF-1alpha and BACE in cultured Alzheimer"s disease cybrid cells. Simvastatin 83-94 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-108 26228060-8 2015 CONCLUSION: Our results suggest demonstrate differential dose-dependent effects of simvastatin on HIF-1alpha and BACE in cultured Alzheimer"s disease cybrid cells. Simvastatin 83-94 beta-secretase 1 Homo sapiens 113-117 26207907-0 2015 Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition. Simvastatin 0-11 ras homolog family member A Homo sapiens 92-96 26207907-4 2015 We evaluated the in vitro effect of simvastatin on the expression of fibulin-1, -2, -4 and -5 in human coronary artery smooth muscle cells (SMCs) and the mechanisms involved. Simvastatin 36-47 fibulin 1 Homo sapiens 69-93 26207907-7 2015 Simvastatin induced a significant increase in mRNA and protein levels of fibulin-2 at 24 hours of incubation (p<0.05), but it did not affect fibulin-1, -4, and -5 expression. Simvastatin 0-11 fibulin 2 Homo sapiens 73-82 26207907-11 2015 Simvastatin increased mRNA levels and protein expression of the ECM protein fibulin-2 through a RhoA and Rho-Kinase-mediated pathway. Simvastatin 0-11 fibulin 2 Homo sapiens 76-85 26207907-11 2015 Simvastatin increased mRNA levels and protein expression of the ECM protein fibulin-2 through a RhoA and Rho-Kinase-mediated pathway. Simvastatin 0-11 ras homolog family member A Homo sapiens 96-100 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 interleukin 6 Homo sapiens 45-49 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 tumor necrosis factor Homo sapiens 62-71 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 matrix metallopeptidase 9 Homo sapiens 88-93 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 interleukin 1 beta Homo sapiens 135-143 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 tumor necrosis factor Homo sapiens 159-168 25704622-9 2015 Simvastatin reduced the molar ratio of TNF-alpha/sTNFR1 or R2 and IL-1beta/sIL-1R2 (P = 0.01 and 0.04 in S-L group; P = 0.01 and 0.004 in L-S group, respectively). Simvastatin 0-11 tumor necrosis factor Homo sapiens 39-48 25704622-9 2015 Simvastatin reduced the molar ratio of TNF-alpha/sTNFR1 or R2 and IL-1beta/sIL-1R2 (P = 0.01 and 0.04 in S-L group; P = 0.01 and 0.004 in L-S group, respectively). Simvastatin 0-11 interleukin 1 beta Homo sapiens 66-74 26307847-6 2015 Moreover, the expression of the cell cycle protein cyclin D1 was dramatically inhibited by simvastatin in both cells, with simvastatin-loaded star-shaped CA-PLGA nanoparticles having the greatest effect. Simvastatin 91-102 cyclin D1 Homo sapiens 51-60 25612169-12 2015 In conclusion, we demonstrated that the suppressive effect of simvastatin on LPS-stimulated MMP-9 release does not occur via the NF-kappaB pathway and the MAPKs pathway, but via the RhoA/ROCK pathway. Simvastatin 62-73 matrix metallopeptidase 9 Rattus norvegicus 92-97 25612169-12 2015 In conclusion, we demonstrated that the suppressive effect of simvastatin on LPS-stimulated MMP-9 release does not occur via the NF-kappaB pathway and the MAPKs pathway, but via the RhoA/ROCK pathway. Simvastatin 62-73 ras homolog family member A Rattus norvegicus 182-186 26307847-6 2015 Moreover, the expression of the cell cycle protein cyclin D1 was dramatically inhibited by simvastatin in both cells, with simvastatin-loaded star-shaped CA-PLGA nanoparticles having the greatest effect. Simvastatin 123-134 cyclin D1 Homo sapiens 51-60 25916803-5 2015 KEY FINDINGS: The combination of ezetimibe and simvastatin is required to observe a drop in cholesterolemia, linked to a huge activation of hepatic SREBP-2 and the consequent increased expression of genes involved in LDL cholesterol uptake and cholesterol synthesis. Simvastatin 47-58 sterol regulatory element binding factor 2 Mus musculus 148-155 26164721-0 2015 Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Simvastatin 93-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 26164721-0 2015 Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Simvastatin 93-104 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 68-74 26164721-0 2015 Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Simvastatin 93-104 solute carrier organic anion transporter family member 1B1 Homo sapiens 80-87 26091905-0 2015 The effect of simvastatin treatment on endothelial cell response to shear stress and tumor necrosis factor alpha stimulation. Simvastatin 14-25 tumor necrosis factor Homo sapiens 85-112 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 180-197 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 199-204 25738368-4 2015 The present study demonstrated that simvastatin inhibited the proliferation of MDA-MB-231 human breast cancer cells in a dose-dependent manner, decreased the protein expression of B cell lymphoma 2 (Bcl-2) and increased the protein expression of Bcl-2-associated X protein in time- and dose-dependent manners. Simvastatin 36-47 BCL2 apoptosis regulator Homo sapiens 246-251 25738368-5 2015 In addition, simvastatin arrested cells in the G0/G1 phase of the cell cycle, downregulated the protein expression levels of cyclin D1 and cyclin-dependent kinase (CDK)2, mediated the mitochondria-dependent caspase cascade by increasing the protein expression levels of caspase-3, -8 and -9, and downregulated the protein expression of X-linked inhibitor of apoptosis, which induced cell apoptosis. Simvastatin 13-24 cyclin D1 Homo sapiens 125-134 25738368-5 2015 In addition, simvastatin arrested cells in the G0/G1 phase of the cell cycle, downregulated the protein expression levels of cyclin D1 and cyclin-dependent kinase (CDK)2, mediated the mitochondria-dependent caspase cascade by increasing the protein expression levels of caspase-3, -8 and -9, and downregulated the protein expression of X-linked inhibitor of apoptosis, which induced cell apoptosis. Simvastatin 13-24 cyclin dependent kinase 2 Homo sapiens 164-169 25738368-5 2015 In addition, simvastatin arrested cells in the G0/G1 phase of the cell cycle, downregulated the protein expression levels of cyclin D1 and cyclin-dependent kinase (CDK)2, mediated the mitochondria-dependent caspase cascade by increasing the protein expression levels of caspase-3, -8 and -9, and downregulated the protein expression of X-linked inhibitor of apoptosis, which induced cell apoptosis. Simvastatin 13-24 caspase 3 Homo sapiens 270-290 25738368-5 2015 In addition, simvastatin arrested cells in the G0/G1 phase of the cell cycle, downregulated the protein expression levels of cyclin D1 and cyclin-dependent kinase (CDK)2, mediated the mitochondria-dependent caspase cascade by increasing the protein expression levels of caspase-3, -8 and -9, and downregulated the protein expression of X-linked inhibitor of apoptosis, which induced cell apoptosis. Simvastatin 13-24 X-linked inhibitor of apoptosis Homo sapiens 336-367 25738368-6 2015 In addition, simvastatin decreased the protein expression of matrix metalloproteinase (MMP)-2 and suppressed the activation of nuclear factor (NF)-kappaB in the MDA-MB-231 cells. Simvastatin 13-24 matrix metallopeptidase 2 Homo sapiens 61-93 25738368-6 2015 In addition, simvastatin decreased the protein expression of matrix metalloproteinase (MMP)-2 and suppressed the activation of nuclear factor (NF)-kappaB in the MDA-MB-231 cells. Simvastatin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 127-153 25738368-7 2015 Taken together, these results demonstrated that the antitumor effect of simvastatin in the human MDA-MB-231 breast cancer cell line was via the inhibition of cell proliferation, affecting the cell cycle, downregulating the expression levels of cyclin D1 and CDKs, inducing apoptosis and decreasing the expression of MMP-2, possibly by inhibiting the activation of NF-kappaB. Simvastatin 72-83 cyclin D1 Homo sapiens 244-262 25738368-7 2015 Taken together, these results demonstrated that the antitumor effect of simvastatin in the human MDA-MB-231 breast cancer cell line was via the inhibition of cell proliferation, affecting the cell cycle, downregulating the expression levels of cyclin D1 and CDKs, inducing apoptosis and decreasing the expression of MMP-2, possibly by inhibiting the activation of NF-kappaB. Simvastatin 72-83 matrix metallopeptidase 2 Homo sapiens 316-321 25738368-7 2015 Taken together, these results demonstrated that the antitumor effect of simvastatin in the human MDA-MB-231 breast cancer cell line was via the inhibition of cell proliferation, affecting the cell cycle, downregulating the expression levels of cyclin D1 and CDKs, inducing apoptosis and decreasing the expression of MMP-2, possibly by inhibiting the activation of NF-kappaB. Simvastatin 72-83 nuclear factor kappa B subunit 1 Homo sapiens 364-373 26132393-14 2015 Testosterone-drop on statins predicted aggression-decline: beta=0.64(SE=0.30)P=0.034, particularly on simvastatin: beta=1.29(SE=0.49)P=0.009. Simvastatin 102-113 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 115-121 26132393-15 2015 Sleep-worsening on statins significantly predicted aggression-increase: beta=2.2(SE=0.55)P<0.001, particularly on simvastatin (potentially explaining two of the outliers): beta=3.3(SE=0.83)P<0.001. Simvastatin 117-128 eukaryotic translation elongation factor 1 beta 2 pseudogene 2 Homo sapiens 175-181 26704155-13 2015 Compared with COPD group, the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein were significantly lower in the simvastatin group, but still higher than the control group (all P <0.01). Simvastatin 126-137 intercellular adhesion molecule 1 Rattus norvegicus 51-57 26704155-13 2015 Compared with COPD group, the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein were significantly lower in the simvastatin group, but still higher than the control group (all P <0.01). Simvastatin 126-137 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 70-76 26704155-13 2015 Compared with COPD group, the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein were significantly lower in the simvastatin group, but still higher than the control group (all P <0.01). Simvastatin 126-137 toll-like receptor 4 Rattus norvegicus 81-85 26704155-14 2015 Furthermore, the expression levels of mRNA and protein of MUC5AC and TLR4 were significantly lower in the simvastatin group than those in the COPD group (all P <0.05). Simvastatin 106-117 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 58-64 26704155-14 2015 Furthermore, the expression levels of mRNA and protein of MUC5AC and TLR4 were significantly lower in the simvastatin group than those in the COPD group (all P <0.05). Simvastatin 106-117 toll-like receptor 4 Rattus norvegicus 69-73 26704155-15 2015 CONCLUSIONS: In COPD model rats, simvastatin can decrease the levels of IL-8, IL-17 and TNF-alpha in BALF and inhibit the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein in airway and lung tissue. Simvastatin 33-44 interleukin 17A Rattus norvegicus 78-83 26704155-15 2015 CONCLUSIONS: In COPD model rats, simvastatin can decrease the levels of IL-8, IL-17 and TNF-alpha in BALF and inhibit the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein in airway and lung tissue. Simvastatin 33-44 tumor necrosis factor Rattus norvegicus 88-97 26704155-15 2015 CONCLUSIONS: In COPD model rats, simvastatin can decrease the levels of IL-8, IL-17 and TNF-alpha in BALF and inhibit the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein in airway and lung tissue. Simvastatin 33-44 intercellular adhesion molecule 1 Rattus norvegicus 143-149 26704155-15 2015 CONCLUSIONS: In COPD model rats, simvastatin can decrease the levels of IL-8, IL-17 and TNF-alpha in BALF and inhibit the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein in airway and lung tissue. Simvastatin 33-44 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 162-168 26704155-15 2015 CONCLUSIONS: In COPD model rats, simvastatin can decrease the levels of IL-8, IL-17 and TNF-alpha in BALF and inhibit the expression levels of ICAM-1, NF-kappaB, MUC5AC and TLR4 protein in airway and lung tissue. Simvastatin 33-44 toll-like receptor 4 Rattus norvegicus 173-177 25207459-4 2015 OBJECTIVES: To analyze how RNO and simvastatin (SIM) interact on CSE-induced EMT in well-differentiated human bronchial epithelial cells (WD-HBEC) from small bronchi in vitro. Simvastatin 35-46 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 65-68 25207459-12 2015 CONCLUSIONS: The PDE4 inhibitor roflumilast N-oxide acts (over)additively with simvastatin to prevent CSE-induced EMT in WD-HBEC in vitro. Simvastatin 79-90 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 102-105 26353590-1 2015 The aim of the present study was to evaluate whether coating pristine titanium (Ti) with nano-sized hydroxyapatite (HAp) and simvastatin could enhance bone formation and osseointegration in vitro and in vivo because both HAp and simvastatin have the characteristic of osteogenetic induction. Simvastatin 229-240 retinoic acid receptor, beta Mus musculus 116-119 25726750-6 2015 Simvastatin (7.5 and 15 mg/kg) reversed vincristine-induced neuropathic pain and attenuated vincristine-induced increase in MPO, without altering cholesterol levels. Simvastatin 0-11 myeloperoxidase Rattus norvegicus 124-127 25726750-7 2015 Simvastatin at higher dose (30 mg/kg) did not alter neuropathic pain despite decreasing MPO levels. Simvastatin 0-11 myeloperoxidase Rattus norvegicus 88-91 25992810-4 2015 However, the impact of SLCO1B1 gene polymorphism on this risk in patients treated with other statins or lower doses of simvastatin needs to be assessed. Simvastatin 119-130 solute carrier organic anion transporter family member 1B1 Homo sapiens 23-30 26353590-4 2015 Modification of the Ti surface with nano-sized HAp and simvastatin (Ti/beta-CD/HAp/Sim) discs enhanced the osteogenic differentiation of MC3T3-E1 cells in vitro. Simvastatin 55-66 beta-carotene oxygenase 1 Mus musculus 71-78 26353590-4 2015 Modification of the Ti surface with nano-sized HAp and simvastatin (Ti/beta-CD/HAp/Sim) discs enhanced the osteogenic differentiation of MC3T3-E1 cells in vitro. Simvastatin 55-66 retinoic acid receptor, beta Mus musculus 79-82 26020641-5 2015 In the absence of overt muscle damage, simvastatin treatment induced an increase in atrogin-1, MuRF1 and myostatin mRNA expression; however, these were not associated with changes in peroxisome proliferator gamma co-activator 1 alpha (PGC-1alpha) protein or markers of mitochondrial content. Simvastatin 39-50 F-box protein 32 Rattus norvegicus 84-93 26020641-5 2015 In the absence of overt muscle damage, simvastatin treatment induced an increase in atrogin-1, MuRF1 and myostatin mRNA expression; however, these were not associated with changes in peroxisome proliferator gamma co-activator 1 alpha (PGC-1alpha) protein or markers of mitochondrial content. Simvastatin 39-50 tripartite motif containing 63 Rattus norvegicus 95-100 26020641-5 2015 In the absence of overt muscle damage, simvastatin treatment induced an increase in atrogin-1, MuRF1 and myostatin mRNA expression; however, these were not associated with changes in peroxisome proliferator gamma co-activator 1 alpha (PGC-1alpha) protein or markers of mitochondrial content. Simvastatin 39-50 myostatin Rattus norvegicus 105-114 26020641-5 2015 In the absence of overt muscle damage, simvastatin treatment induced an increase in atrogin-1, MuRF1 and myostatin mRNA expression; however, these were not associated with changes in peroxisome proliferator gamma co-activator 1 alpha (PGC-1alpha) protein or markers of mitochondrial content. Simvastatin 39-50 PPARG coactivator 1 alpha Rattus norvegicus 235-245 26020641-6 2015 Simvastatin did, however, increase neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and AMPK alpha-subunit protein expression, and tended to increase total NOS activity, in FT but not ST muscles. Simvastatin 0-11 nitric oxide synthase 1 Rattus norvegicus 35-65 26020641-6 2015 Simvastatin did, however, increase neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and AMPK alpha-subunit protein expression, and tended to increase total NOS activity, in FT but not ST muscles. Simvastatin 0-11 nitric oxide synthase 1 Rattus norvegicus 67-71 26020641-6 2015 Simvastatin did, however, increase neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and AMPK alpha-subunit protein expression, and tended to increase total NOS activity, in FT but not ST muscles. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 74-89 25992810-6 2015 MATERIAL/METHODS: SLCO1B1 tagging rs4363657 polymorphism was analyzed in 2 groups of patients with dyslipidemia (treated with simvastatin or atorvastatin, 10 or 20 mg per day), subgroup with statin-induced myalgia (N=286), and subgroup (N=707) without myalgia/myopathy, and in 2301 population controls without lipid-lowering treatment. Simvastatin 126-137 solute carrier organic anion transporter family member 1B1 Homo sapiens 18-25 25786435-7 2015 With high simvastatin doses, laminin and vinculin were reduced and appeared discontinuous along the septa, with almost no myofibrils, and small amounts of desmin accumulating close to the septa. Simvastatin 10-21 vinculin a Danio rerio 41-49 25704916-9 2015 Pharmacological repression of TAZ by simvastatin resulted in potent anti-cancer effects against OSCC. Simvastatin 37-48 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 30-33 25631750-0 2015 Simvastatin downregulates expression of TGF-betaRII and inhibits proliferation of A549 cells via ERK. Simvastatin 0-11 transforming growth factor beta receptor 2 Homo sapiens 40-51 25631750-0 2015 Simvastatin downregulates expression of TGF-betaRII and inhibits proliferation of A549 cells via ERK. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 97-100 25631750-7 2015 Our results demonstrated that simvastatin inhibited activation of ERK, downregulated expression of TGF-betaRII, and suppressed A549 cell proliferation. Simvastatin 30-41 mitogen-activated protein kinase 1 Homo sapiens 66-69 25631750-7 2015 Our results demonstrated that simvastatin inhibited activation of ERK, downregulated expression of TGF-betaRII, and suppressed A549 cell proliferation. Simvastatin 30-41 transforming growth factor beta receptor 2 Homo sapiens 99-110 25631750-9 2015 Therefore, these results suggest that simvastatin may inhibit A549 cell proliferation and downregulate TGF-betaRII expression by inhibiting activation of ERK. Simvastatin 38-49 transforming growth factor beta receptor 2 Homo sapiens 103-114 25631750-9 2015 Therefore, these results suggest that simvastatin may inhibit A549 cell proliferation and downregulate TGF-betaRII expression by inhibiting activation of ERK. Simvastatin 38-49 mitogen-activated protein kinase 1 Homo sapiens 154-157 25978361-10 2015 The effect of 5 muM simvastatin or 20 muM benznidazole upon endothelial activation was assessed in EA.hy926 or HUVEC cells, by E-selectin, ICAM-1 and VCAM-1 expression. Simvastatin 20-31 selectin E Homo sapiens 127-137 25982544-0 2015 Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): study protocol for a randomized controlled trial. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-74 25993292-4 2015 Simvastatin strongly inhibited the activation of nuclear factor (NF)-kappaB induced by tumor necrosis factor (TNF)-alpha in human AAA walls, but showed little effect on c-jun N-terminal kinase (JNK) activation. Simvastatin 0-11 tumor necrosis factor Homo sapiens 87-120 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 76-108 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 C-C motif chemokine ligand 8 Homo sapiens 110-150 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 C-X-C motif chemokine ligand 5 Homo sapiens 197-202 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 tumor necrosis factor Homo sapiens 225-234 25993292-7 2015 Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5. Simvastatin 24-35 matrix metallopeptidase 9 Homo sapiens 111-116 25993292-7 2015 Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5. Simvastatin 24-35 C-C motif chemokine ligand 8 Homo sapiens 118-123 25993292-7 2015 Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5. Simvastatin 24-35 C-X-C motif chemokine ligand 5 Homo sapiens 128-133 25978361-14 2015 In conclusion, Simvastatin and benznidazole prevent endothelial activation induced by T. cruzi infection, and the effect of simvastatin is mediated by the inhibition of the NFkappaB pathway by inducing 15-epi-LXA4 production. Simvastatin 124-135 nuclear factor kappa B subunit 1 Homo sapiens 173-181 25978361-13 2015 Indeed, 5 muM simvastatin as well as 20 muM benznidazole prevented the increase in E-selectin, ICAM-1 and VCAM-1 expression in T. cruzi-infected endothelial cells by decreasing the NF-kappaB pathway. Simvastatin 14-25 selectin E Homo sapiens 83-93 25978361-13 2015 Indeed, 5 muM simvastatin as well as 20 muM benznidazole prevented the increase in E-selectin, ICAM-1 and VCAM-1 expression in T. cruzi-infected endothelial cells by decreasing the NF-kappaB pathway. Simvastatin 14-25 intercellular adhesion molecule 1 Homo sapiens 95-101 25978361-13 2015 Indeed, 5 muM simvastatin as well as 20 muM benznidazole prevented the increase in E-selectin, ICAM-1 and VCAM-1 expression in T. cruzi-infected endothelial cells by decreasing the NF-kappaB pathway. Simvastatin 14-25 vascular cell adhesion molecule 1 Homo sapiens 106-112 25780404-1 2015 The aim of the present study was to investigate whether postconditioning with simvastatin attenuated myocardial ischemia reperfusion injury by inhibiting the expression of high mobility group box 1 (HMGB1) in rat myocardium following acute myocardial ischemia. Simvastatin 78-89 high mobility group box 1 Rattus norvegicus 172-197 25961956-8 2015 In contrast, simvastatin increased the COX-2 expression compared to WA-25. Simvastatin 13-24 prostaglandin-endoperoxide synthase 2 Mus musculus 39-44 25961956-10 2015 We also observed that transforming growth factor beta1 (TGF-beta1) was up-regulated by WA-25 and simvastatin in LPS-induced RAW 264.7 cells, and the promising anti-atherosclerosis effects of WA-25 were disrupted by blockade of TGF-beta1 signaling. Simvastatin 97-108 transforming growth factor, beta 1 Mus musculus 22-54 25961956-10 2015 We also observed that transforming growth factor beta1 (TGF-beta1) was up-regulated by WA-25 and simvastatin in LPS-induced RAW 264.7 cells, and the promising anti-atherosclerosis effects of WA-25 were disrupted by blockade of TGF-beta1 signaling. Simvastatin 97-108 transforming growth factor, beta 1 Mus musculus 56-65 26273214-0 2015 CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. Simvastatin 63-74 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 26273214-1 2015 In this work, we examined the impact of polymorphism in the cytochrome P450 (CYP) 3A5 gene, CYP3A5*1 (6986A > G, rs 776746), on the reduction in the lipid levels caused by simvastatin and atorvastatin. Simvastatin 175-186 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 60-85 26273214-1 2015 In this work, we examined the impact of polymorphism in the cytochrome P450 (CYP) 3A5 gene, CYP3A5*1 (6986A > G, rs 776746), on the reduction in the lipid levels caused by simvastatin and atorvastatin. Simvastatin 175-186 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 92-98 26273214-8 2015 In individuals with the same CYP3A5 genotype, a head to head comparison of the efficacy of the same dose of simvastatin vs. atorvastatin revealed an advantage for atorvastatin. Simvastatin 108-119 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 26002428-3 2015 The aim of the present study is to evaluate the effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on morphine-induced tolerance and withdrawal symptoms. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 73-130 25778435-8 2015 Exposure to simvastatin induced a decrease in the sphere-forming capacity and cell viability, accompanied by a concentration- and time-dependent increase in caspase-3/7 activity. Simvastatin 12-23 caspase 3 Canis lupus familiaris 157-166 25701710-4 2015 Here we report that simvastatin increases the fEPSP, the N-methyl-D-aspartate (NMDA) receptor-mediated fEPSP using extracellular recordings in the dendritic region of the CA1 of hippocampal slices taken from 8-week-old C57Black6J mice. Simvastatin 20-31 carbonic anhydrase 1 Mus musculus 171-174 25701710-6 2015 We have also observed that acute application of simvastatin increased the amplitude of the compound action potential in the CA1 region. Simvastatin 48-59 carbonic anhydrase 1 Mus musculus 124-127 25862838-0 2015 Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate. Simvastatin 89-100 chromobox 8 Homo sapiens 33-36 24950285-0 2015 Simvastatin reduces burn injury-induced splenic apoptosis via downregulation of the TNF-alpha/NF-kappaB pathway. Simvastatin 0-11 tumor necrosis factor Mus musculus 84-93 24950285-9 2015 Simvastatin decreased burn-induced TNF-alpha and NF-kappaB expression in the spleen and serum. Simvastatin 0-11 tumor necrosis factor Mus musculus 35-44 24950285-12 2015 CONCLUSIONS: Simvastatin reduces burn-induced splenic apoptosis via downregulation of the TNF-alpha/NF-kappaB pathway. Simvastatin 13-24 tumor necrosis factor Mus musculus 90-99 25824885-0 2015 Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4(+)CD25(+) Treg cells and enhancing vascular endothelial cell protection. Simvastatin 0-11 Cd4 molecule Rattus norvegicus 95-98 25754552-9 2015 Decreases in insulin sensitivity and insulin secretion were dose dependent for simvastatin and atorvastatin. Simvastatin 79-90 insulin Homo sapiens 13-20 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 92-103 matrix metallopeptidase 9 Homo sapiens 36-40 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 92-103 TIMP metallopeptidase inhibitor 2 Homo sapiens 41-46 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 141-152 matrix metallopeptidase 9 Homo sapiens 36-40 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 141-152 TIMP metallopeptidase inhibitor 2 Homo sapiens 41-46 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Simvastatin 85-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-54 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Simvastatin 85-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Simvastatin 85-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 133-139 25780404-1 2015 The aim of the present study was to investigate whether postconditioning with simvastatin attenuated myocardial ischemia reperfusion injury by inhibiting the expression of high mobility group box 1 (HMGB1) in rat myocardium following acute myocardial ischemia. Simvastatin 78-89 high mobility group box 1 Rattus norvegicus 199-204 25780404-7 2015 Postconditioning with simvastatin was shown to decrease the infarct size and HMGB1 expression levels in the myocardium following AMI (P<0.05). Simvastatin 22-33 high mobility group box 1 Rattus norvegicus 77-82 25780404-8 2015 In addition, postconditioning with simvastatin not only decreased the serum levels of c-TnI and TNF-alpha (P<0.05), but also inhibited the increase in MDA levels and the reduction in SOD activity (P<0.05). Simvastatin 35-46 troponin I3, cardiac type Rattus norvegicus 86-91 25780404-8 2015 In addition, postconditioning with simvastatin not only decreased the serum levels of c-TnI and TNF-alpha (P<0.05), but also inhibited the increase in MDA levels and the reduction in SOD activity (P<0.05). Simvastatin 35-46 tumor necrosis factor Rattus norvegicus 96-105 25521459-6 2015 Activation of signal transducer and activator of transcription 1 (STAT1) is required for IFN-gamma signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Simvastatin 142-153 signal transducer and activator of transcription 1 Mus musculus 14-64 25901147-4 2015 The galacotsylated albumin nanoparticles were prepared for the selective delivery of a Simvastatin to the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) the rate-limiting enzyme in the pathway of cholesterol biosynthesis that is particularly presents on hepatocytes. Simvastatin 87-98 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-172 25521459-6 2015 Activation of signal transducer and activator of transcription 1 (STAT1) is required for IFN-gamma signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Simvastatin 142-153 signal transducer and activator of transcription 1 Mus musculus 66-71 25521459-6 2015 Activation of signal transducer and activator of transcription 1 (STAT1) is required for IFN-gamma signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Simvastatin 142-153 interferon gamma Mus musculus 89-98 25521459-6 2015 Activation of signal transducer and activator of transcription 1 (STAT1) is required for IFN-gamma signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Simvastatin 142-153 signal transducer and activator of transcription 1 Mus musculus 214-219 25476155-0 2015 Effect of simvastatin on MMPs and TIMPs in human brain endothelial cells and experimental stroke. Simvastatin 10-21 matrix metallopeptidase 2 Homo sapiens 25-29 25534234-11 2015 Moreover, levels of claudin-3 and claudin-5 fragmentation in rats receiving CLP plus simvastatin were significantly lower than those receiving CLP. Simvastatin 85-96 claudin 3 Rattus norvegicus 20-29 25534234-11 2015 Moreover, levels of claudin-3 and claudin-5 fragmentation in rats receiving CLP plus simvastatin were significantly lower than those receiving CLP. Simvastatin 85-96 claudin 5 Rattus norvegicus 34-43 26295063-5 2015 To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E deficient mice (Apoe-/- ) with advanced atherosclerotic plaques. Simvastatin 64-75 apolipoprotein E Mus musculus 122-138 26295063-5 2015 To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E deficient mice (Apoe-/- ) with advanced atherosclerotic plaques. Simvastatin 64-75 apolipoprotein E Mus musculus 155-162 25476155-8 2015 Our results provide evidence for a positive effect of simvastatin on the MMP metabolism in human BMECs and experimental stroke mainly by means of the increased expression and secretion of TIMP-1 and TIMP-2. Simvastatin 54-65 TIMP metallopeptidase inhibitor 1 Homo sapiens 188-194 25476155-8 2015 Our results provide evidence for a positive effect of simvastatin on the MMP metabolism in human BMECs and experimental stroke mainly by means of the increased expression and secretion of TIMP-1 and TIMP-2. Simvastatin 54-65 TIMP metallopeptidase inhibitor 2 Homo sapiens 199-205 25861297-11 2015 After simvastatin therapy hyperlipidemic patients showed a reduction of the percentage of resting CD62P(+) platelets (p = 0.005) and a reduction of expression and percentage of CD62P(+) platelets after activation by thrombin (median p < 0.05; percentage: p = 0.001). Simvastatin 6-17 selectin P Homo sapiens 98-103 25445996-6 2015 Western blot was applied to detect the expression level of Notch-1 protein in TBI rats with simvastatin. Simvastatin 92-103 notch receptor 1 Rattus norvegicus 59-66 25445996-8 2015 In in vitro experiment, simvastatin induced enhanced proliferation and neurogenesis of cultured NSCs and elevated Notch-1 protein expression. Simvastatin 24-35 notch receptor 1 Rattus norvegicus 114-121 25445996-9 2015 Co-incubation of gamma-secretase inhibitor, an inhibitor of Notch-1 pathway, with simvastatin abolished its neurorestoration effect. Simvastatin 82-93 notch receptor 1 Rattus norvegicus 60-67 25445996-11 2015 CONCLUSION: Simvastatin treatment enhanced neurological functional recovery after TBI possibly via activation of Notch signaling and increasing neurogenesis in the injured area. Simvastatin 12-23 notch receptor 1 Rattus norvegicus 113-118 25861297-11 2015 After simvastatin therapy hyperlipidemic patients showed a reduction of the percentage of resting CD62P(+) platelets (p = 0.005) and a reduction of expression and percentage of CD62P(+) platelets after activation by thrombin (median p < 0.05; percentage: p = 0.001). Simvastatin 6-17 selectin P Homo sapiens 177-182 25861297-11 2015 After simvastatin therapy hyperlipidemic patients showed a reduction of the percentage of resting CD62P(+) platelets (p = 0.005) and a reduction of expression and percentage of CD62P(+) platelets after activation by thrombin (median p < 0.05; percentage: p = 0.001). Simvastatin 6-17 coagulation factor II, thrombin Homo sapiens 216-224 25517390-8 2015 Atorvastatin, simvastatin and ezetimibe down-regulated the expression of miR-221, whereas miR-222 was reduced only after the atorvastatin treatment. Simvastatin 14-25 microRNA 221 Homo sapiens 73-80 25578243-6 2015 In both cell lines, concentration-dependent inhibition of prenylation was observed for cerivastatin and simvastatin, which could be rescued with the pathway intermediate mevalonate; in general, muscle cells were more sensitive to this effect, as measured by the levels of unprenylated Rap1A, a marker for prenylation by geranylgeranyl transferase I. Concentration-dependent toxicity was observed in both cell lines, with muscle cells again being more sensitive. Simvastatin 104-115 RAP1A, member of RAS oncogene family Homo sapiens 285-290 26064259-1 2015 We aimed to investigate the effects of prior treatment of simvastatin on mitochondrial enzyme, ghrelin, and hypoxia-inducible factor 1 alpha (HIF-1 alpha) on hepatic tissue in rats treated with Lipopolysaccharides (LPS) during the early phase of sepsis. Simvastatin 58-69 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 108-140 26064259-12 2015 In the Simvastatin group, Ghrelin levels were increased in comparison with the other groups (P < 0.01). Simvastatin 7-18 ghrelin and obestatin prepropeptide Rattus norvegicus 26-33 26064259-14 2015 We observed that the degree of hepatocellular degeneration was partially reduced depending on the dosage and duration of prior simvastatin treatment with LPS, probably due to alterations of Ghrelin and HIF-1alpha levels. Simvastatin 127-138 ghrelin and obestatin prepropeptide Rattus norvegicus 190-197 26064259-14 2015 We observed that the degree of hepatocellular degeneration was partially reduced depending on the dosage and duration of prior simvastatin treatment with LPS, probably due to alterations of Ghrelin and HIF-1alpha levels. Simvastatin 127-138 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 202-212 26157709-7 2015 Bax pro-apoptotic protein was upregulated in renal tissue after I/R injury and downregulated in simvastatin pretreated group. Simvastatin 96-107 BCL2 associated X, apoptosis regulator Rattus norvegicus 0-3 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Simvastatin 125-136 solute carrier organic anion transporter family member 1B1 Homo sapiens 17-24 25304741-17 2015 Bcl-2 levels significantly increased in the simvastatin treatment group compared with the myocardial infarction group, but Bcl-2 levels in both groups were significantly lower than the sham group. Simvastatin 44-55 BCL-2 Oryctolagus cuniculus 0-5 25304741-20 2015 Simvastatin can improve cardiac function after myocardial infarction and reduce apoptosis of myocardial cells, possibly by decreasing Bax and Caspase-3 expression and increasing the expression level of Bcl-2. Simvastatin 0-11 apoptosis regulator BAX Oryctolagus cuniculus 134-137 25304741-20 2015 Simvastatin can improve cardiac function after myocardial infarction and reduce apoptosis of myocardial cells, possibly by decreasing Bax and Caspase-3 expression and increasing the expression level of Bcl-2. Simvastatin 0-11 caspase-3 Oryctolagus cuniculus 142-151 25304741-20 2015 Simvastatin can improve cardiac function after myocardial infarction and reduce apoptosis of myocardial cells, possibly by decreasing Bax and Caspase-3 expression and increasing the expression level of Bcl-2. Simvastatin 0-11 BCL-2 Oryctolagus cuniculus 202-207 25712896-13 2015 CONCLUSIONS: TNF-alpha suppresses SERCA2a gene expression via the IKK/IkappaB/NF-kappaB pathway and binding of NF-kappaB to the SERCA2a gene promoter, and its effect is blocked by simvastatin, demonstrating the potential therapeutic effect of statins in treating inflammation-related diastolic dysfunction. Simvastatin 180-191 tumor necrosis factor Rattus norvegicus 13-22 25274942-3 2015 We analyzed the association of CYP3A4*22 allele with response to atorvastatin and simvastatin. Simvastatin 82-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-37 25274942-7 2015 RESULTS: In the entire cohort population, 41 individuals carried CYP3A4*22 allele (18 in atorvastatin and 23 in simvastatin treatment). Simvastatin 112-123 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Simvastatin 125-136 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-43 25848815-0 2015 Inhibition of HMGCoA reductase by simvastatin protects mice from injurious mechanical ventilation. Simvastatin 34-45 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 14-30 25547946-3 2015 We examined the in vitro effects of three HMG-CoA reductase inhibitors atorvastatin, simvastatin, and pravastatin on the viability of MSCs and expression of nuclear factor kappa B (NF-kappaB). Simvastatin 85-96 nuclear factor kappa B subunit 1 Homo sapiens 157-179 25547946-5 2015 Human MSC treatment with 1 and 10 muM simvastatin or atorvastatin resulted in progressively reduced cell viability, which was associated with a decline in NF-kappaB p65. Simvastatin 38-49 nuclear factor kappa B subunit 1 Homo sapiens 155-164 25547946-5 2015 Human MSC treatment with 1 and 10 muM simvastatin or atorvastatin resulted in progressively reduced cell viability, which was associated with a decline in NF-kappaB p65. Simvastatin 38-49 RELA proto-oncogene, NF-kB subunit Homo sapiens 165-168 25564230-6 2015 Simvastatin restored baseline levels of nitric oxide (NO), NO-, and KATP channel-mediated dilations and endothelin-1-induced contractions. Simvastatin 0-11 endothelin 1 Mus musculus 104-116 25924429-10 2015 Compared with those treated with pilocarpine + saline, simvastatin, levetiracetam and levetiracetam + simvastatin reduced the level of calpain-1 24 h after seizures (P<0.05). Simvastatin 55-66 calpain 1 Rattus norvegicus 135-144 25924429-10 2015 Compared with those treated with pilocarpine + saline, simvastatin, levetiracetam and levetiracetam + simvastatin reduced the level of calpain-1 24 h after seizures (P<0.05). Simvastatin 102-113 calpain 1 Rattus norvegicus 135-144 25412322-0 2015 Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Simvastatin 0-11 MIR7-3 host gene Homo sapiens 65-69 25412322-0 2015 Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Simvastatin 0-11 notch receptor 1 Homo sapiens 121-127 25412322-3 2015 The aim of the present study was to investigate the role of simvastatin in the regulation of cell viability, proliferation and apoptosis in HepG2 and Huh7 HCC cells, and to elucidate the specific regulatory mechanisms by which simvastatin proceeds. Simvastatin 60-71 MIR7-3 host gene Homo sapiens 150-154 25412322-5 2015 The results of the present study demonstrated that simvastatin significantly decreased cell viability and proliferation as well as increased apoptosis in HepG2 and Huh7 cells compared to that in untreated cells. Simvastatin 51-62 MIR7-3 host gene Homo sapiens 164-168 25412322-6 2015 In addition, reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that simvastatin-treated cells exhibited increased expression levles of Notch1, p53, and Bax, as well as decreased expression levels of B cell lymphoma 2; furthermore, Notch1 upregulation resulted in the inhibition of Akt phosphorylation. Simvastatin 114-125 notch receptor 1 Homo sapiens 181-187 25412322-6 2015 In addition, reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that simvastatin-treated cells exhibited increased expression levles of Notch1, p53, and Bax, as well as decreased expression levels of B cell lymphoma 2; furthermore, Notch1 upregulation resulted in the inhibition of Akt phosphorylation. Simvastatin 114-125 tumor protein p53 Homo sapiens 189-192 25412322-6 2015 In addition, reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that simvastatin-treated cells exhibited increased expression levles of Notch1, p53, and Bax, as well as decreased expression levels of B cell lymphoma 2; furthermore, Notch1 upregulation resulted in the inhibition of Akt phosphorylation. Simvastatin 114-125 BCL2 associated X, apoptosis regulator Homo sapiens 198-201 25412322-6 2015 In addition, reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that simvastatin-treated cells exhibited increased expression levles of Notch1, p53, and Bax, as well as decreased expression levels of B cell lymphoma 2; furthermore, Notch1 upregulation resulted in the inhibition of Akt phosphorylation. Simvastatin 114-125 notch receptor 1 Homo sapiens 277-283 25412322-7 2015 In conclusion, the results of the present study indicated that simvastatin significantly promoted apoptosis in HCC cells, the mechanism of which may have proceeded via the upregualtion of the Notch1 gene in the Akt-dependent signaling pathway. Simvastatin 63-74 notch receptor 1 Homo sapiens 192-198 25848815-16 2015 There was a 3-fold increase in plasma Tumor Necrosis Factor-alpha, a 7-fold increase in plasma Interleukin-6 and a 20-fold increase in lavage fluid Matrix-Metalloprotease-9 by HVt but simvastatin reduced these levels to control. Simvastatin 184-195 tumor necrosis factor Mus musculus 38-65 25848815-17 2015 Lung tissue vascular endothelial cadherin expression was significantly reduced by injurious ventilation but remained preserved by simvastatin. Simvastatin 130-141 cadherin 5 Mus musculus 12-41 25749868-5 2015 In J774A.1 mouse macrophage, labelled with 3H-cholesterol, ABCA1 mRNA and ABCA1-mediated cholesterol efflux were decreased by 1 muM statin: simvastatin > pitavastatin > atorvastatin > rosuvastatin > pravastatin. Simvastatin 140-151 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 59-64 24047541-0 2015 Thermoresponsive biodegradable HEMA-lactate-Dextran-co-NIPA cryogels for controlled release of simvastatin. Simvastatin 95-106 zinc finger C3HC-type containing 1 Homo sapiens 55-59 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 161-172 C-reactive protein Homo sapiens 60-78 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 196-207 C-reactive protein Homo sapiens 60-78 25749868-9 2015 However, simvastatin >=1 muM virtually eliminated any HDL-ABCA1-mediated cholesterol efflux and any augmentation of that process by dalcetrapib. Simvastatin 9-20 ATP binding cassette subfamily A member 1 Homo sapiens 61-66 25749868-5 2015 In J774A.1 mouse macrophage, labelled with 3H-cholesterol, ABCA1 mRNA and ABCA1-mediated cholesterol efflux were decreased by 1 muM statin: simvastatin > pitavastatin > atorvastatin > rosuvastatin > pravastatin. Simvastatin 140-151 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 74-79 25351979-6 2015 Notably, treatment of the cells with simvastatin elevated ox-LDL-induced macrophage autophagy, this was detected through the conversion of LC3 I to LC3 II and the increased expression of Beclin1, another autophagy marker. Simvastatin 37-48 microtubule-associated protein 1 light chain 3 alpha Mus musculus 139-142 25324279-7 2015 The closest prediction was obtained for CYP3A (simvastatin) DDI when the competitive inhibition from both AMIO and MDEA was considered, for CYP2D6 (dextromethorphan) DDI when the competitive inhibition from AMIO and the competitive plus time-dependent inhibition from MDEA were incorporated, and for CYP2C9 (warfarin) DDI when the competitive plus time-dependent inhibition from AMIO and the competitive inhibition from MDEA were considered. Simvastatin 47-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 40-45 25324279-7 2015 The closest prediction was obtained for CYP3A (simvastatin) DDI when the competitive inhibition from both AMIO and MDEA was considered, for CYP2D6 (dextromethorphan) DDI when the competitive inhibition from AMIO and the competitive plus time-dependent inhibition from MDEA were incorporated, and for CYP2C9 (warfarin) DDI when the competitive plus time-dependent inhibition from AMIO and the competitive inhibition from MDEA were considered. Simvastatin 47-58 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 300-306 25236593-0 2015 Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Simvastatin 22-33 KRAS proto-oncogene, GTPase Homo sapiens 64-68 25866715-17 2015 Simvastatin clearly lowers the serum levels of CRP and IL-6, and the white blood cell count in dialysis patients. Simvastatin 0-11 interleukin 6 Homo sapiens 55-59 25374119-0 2015 Simvastatin attenuates angiotensin II-induced inflammation and oxidative stress in human mesangial cells. Simvastatin 0-11 angiotensinogen Homo sapiens 23-37 25374119-2 2015 In the present study, the effect of simvastatin on inflammation and oxidative stress induced by angiotensin II (Ang II) in human mesangial cells (HMCs) and its corresponding mechanism was examined. Simvastatin 36-47 angiotensinogen Homo sapiens 96-110 25351979-6 2015 Notably, treatment of the cells with simvastatin elevated ox-LDL-induced macrophage autophagy, this was detected through the conversion of LC3 I to LC3 II and the increased expression of Beclin1, another autophagy marker. Simvastatin 37-48 beclin 1, autophagy related Mus musculus 187-194 25351979-8 2015 Simvastatin promoted the ox-LDL-induced formation of GFP-LC3 puncta, as detected by confocal laser scanning microscopy. Simvastatin 0-11 microtubule-associated protein 1 light chain 3 alpha Mus musculus 57-60 25351979-6 2015 Notably, treatment of the cells with simvastatin elevated ox-LDL-induced macrophage autophagy, this was detected through the conversion of LC3 I to LC3 II and the increased expression of Beclin1, another autophagy marker. Simvastatin 37-48 microtubule-associated protein 1 light chain 3 alpha Mus musculus 148-151 26736984-1 2015 BACKGROUND: Concomitant use of simvastatin, a HMG-CoA reductase inhibitor, with a potent CYP3A4 inhibitor, itraconazole, can result in a serious drug-drug interaction induced severe adverse event, rhabdomyolysis. Simvastatin 31-42 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 89-95 25453767-5 2015 Among HMG-CoA reductase inhibitors, simvastatin-treatment was less effective in terms of spike frequency as compared with atorvastatin- and rosuvastatin-treated animals. Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 6-23 25432415-7 2015 PCSK9 levels were increased with statin therapy, but decreased with the simvastatin 20 mg/ER niacin combination (mean -13%, CI -3 to -23). Simvastatin 72-83 proprotein convertase subtilisin/kexin type 9 Homo sapiens 0-5 25374119-2 2015 In the present study, the effect of simvastatin on inflammation and oxidative stress induced by angiotensin II (Ang II) in human mesangial cells (HMCs) and its corresponding mechanism was examined. Simvastatin 36-47 angiotensinogen Homo sapiens 112-118 25374119-2 2015 In the present study, the effect of simvastatin on inflammation and oxidative stress induced by angiotensin II (Ang II) in human mesangial cells (HMCs) and its corresponding mechanism was examined. Simvastatin 36-47 MKKS centrosomal shuttling protein Homo sapiens 146-150 25374119-5 2015 The results demonstrated that simvastatin suppressed the increased mRNA expression of monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 and the content of reactive oxygen species induced by Ang II in a dose-dependent manner. Simvastatin 30-41 C-C motif chemokine ligand 2 Homo sapiens 86-149 25374119-5 2015 The results demonstrated that simvastatin suppressed the increased mRNA expression of monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 and the content of reactive oxygen species induced by Ang II in a dose-dependent manner. Simvastatin 30-41 interleukin 1 beta Homo sapiens 151-173 25374119-5 2015 The results demonstrated that simvastatin suppressed the increased mRNA expression of monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 and the content of reactive oxygen species induced by Ang II in a dose-dependent manner. Simvastatin 30-41 interleukin 6 Homo sapiens 178-182 25374119-5 2015 The results demonstrated that simvastatin suppressed the increased mRNA expression of monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 and the content of reactive oxygen species induced by Ang II in a dose-dependent manner. Simvastatin 30-41 angiotensinogen Homo sapiens 237-243 25374119-6 2015 In addition, simvastatin decreased the protein expression of cyclooxygenase-2 (COX-2), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and protein kinase C (PKC) as well as the content of prostaglandin E2 and the phosphorylation level of nuclear factor-kappaB (NF-kappaB) p65 in a dose-dependent manner. Simvastatin 13-24 prostaglandin-endoperoxide synthase 2 Homo sapiens 61-77 25374119-6 2015 In addition, simvastatin decreased the protein expression of cyclooxygenase-2 (COX-2), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and protein kinase C (PKC) as well as the content of prostaglandin E2 and the phosphorylation level of nuclear factor-kappaB (NF-kappaB) p65 in a dose-dependent manner. Simvastatin 13-24 prostaglandin-endoperoxide synthase 2 Homo sapiens 79-84 25374119-6 2015 In addition, simvastatin decreased the protein expression of cyclooxygenase-2 (COX-2), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and protein kinase C (PKC) as well as the content of prostaglandin E2 and the phosphorylation level of nuclear factor-kappaB (NF-kappaB) p65 in a dose-dependent manner. Simvastatin 13-24 RELA proto-oncogene, NF-kB subunit Homo sapiens 284-287 25374119-7 2015 Furthermore, simvastatin significantly increased the protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 13-24 peroxisome proliferator activated receptor gamma Homo sapiens 75-123 25374119-7 2015 Furthermore, simvastatin significantly increased the protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 13-24 peroxisome proliferator activated receptor gamma Homo sapiens 125-134 25374119-8 2015 Therefore, simvastatin suppressed inflammation and oxidative stress in Ang II-stimulated HMCs via COX-2, PPARgamma, NF-kappaB, NADPH oxidase and PKCs, thereby exerting a protective effect on CKD. Simvastatin 11-22 angiotensinogen Homo sapiens 71-77 25374119-8 2015 Therefore, simvastatin suppressed inflammation and oxidative stress in Ang II-stimulated HMCs via COX-2, PPARgamma, NF-kappaB, NADPH oxidase and PKCs, thereby exerting a protective effect on CKD. Simvastatin 11-22 MKKS centrosomal shuttling protein Homo sapiens 89-93 25374119-8 2015 Therefore, simvastatin suppressed inflammation and oxidative stress in Ang II-stimulated HMCs via COX-2, PPARgamma, NF-kappaB, NADPH oxidase and PKCs, thereby exerting a protective effect on CKD. Simvastatin 11-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 98-103 25374119-8 2015 Therefore, simvastatin suppressed inflammation and oxidative stress in Ang II-stimulated HMCs via COX-2, PPARgamma, NF-kappaB, NADPH oxidase and PKCs, thereby exerting a protective effect on CKD. Simvastatin 11-22 peroxisome proliferator activated receptor gamma Homo sapiens 105-114 25659387-0 2015 Simvastatin suppresses the proangiogenic microenvironment of human hepatic stellate cells via the Kruppel-like factor 2 pathway. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 98-119 25659387-5 2015 METHOD: TGFa-induced human HSCs were exposed to simvastatin. Simvastatin 48-59 transforming growth factor alpha Homo sapiens 8-12 25659387-11 2015 RESULT: Simvastatin was found to reduced cell migration and proliferation and inhibit expression of alpha smooth muscle actin in TGFa-induced HSCs. Simvastatin 8-19 transforming growth factor alpha Homo sapiens 129-133 25659387-12 2015 Furthermore, simvastatin promoted already increased mRNA and protein levels of KLF2 in TGFa-induced HSCs. Simvastatin 13-24 Kruppel like factor 2 Homo sapiens 79-83 25659387-12 2015 Furthermore, simvastatin promoted already increased mRNA and protein levels of KLF2 in TGFa-induced HSCs. Simvastatin 13-24 transforming growth factor alpha Homo sapiens 87-91 25659387-13 2015 In accordance with KLF2 overexpression, simvastatin increased production of endothelial nitric oxide synthesis (eNOS) and downregulated expression of some proangiogenic proteins, such as vascular endothelial growth factor, hypoxia inducible factor-1a and nuclear factor-kappa B in TGFa-induced HSCs. Simvastatin 40-51 Kruppel like factor 2 Homo sapiens 19-23 25659387-13 2015 In accordance with KLF2 overexpression, simvastatin increased production of endothelial nitric oxide synthesis (eNOS) and downregulated expression of some proangiogenic proteins, such as vascular endothelial growth factor, hypoxia inducible factor-1a and nuclear factor-kappa B in TGFa-induced HSCs. Simvastatin 40-51 transforming growth factor alpha Homo sapiens 281-285 25659387-14 2015 At the same time, secretion of interferon-gamma increased in TGFa induced HSCs, which was decreased by simultaneous addition of simvastatin. Simvastatin 128-139 interferon gamma Homo sapiens 31-47 25659387-14 2015 At the same time, secretion of interferon-gamma increased in TGFa induced HSCs, which was decreased by simultaneous addition of simvastatin. Simvastatin 128-139 transforming growth factor alpha Homo sapiens 61-65 25659387-15 2015 CONCLUSION: Simvastatin suppressed the proangiogenic environment of HSCs activated by TGFa, and KLF2 pathway is involved in the course. Simvastatin 12-23 transforming growth factor alpha Homo sapiens 86-90 26539474-6 2015 Simvastatin significantly increased the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 54-87 25901927-6 2015 The TH positive cell count in substantia nigra and striatum were significantly increased (P<0.05) and TNF- alpha expression was significantly decreased (P<0.05) in simvastatin group compared to untreated group. Simvastatin 170-181 tumor necrosis factor Rattus norvegicus 105-115 25901927-7 2015 CONCLUSIONS: Simvastatin could effectively inhibit the activation of astrocytes, reduce TNF- alpha expression, and exert anti-inflammatory effects, and thus protect the dopaminergic neurons in substantia nigra and striatum of the rat model of PD. Simvastatin 13-24 tumor necrosis factor Rattus norvegicus 88-98 25802481-11 2015 Simvastatin reversed hyperlipidemia and significantly rectified the deleterious effect of AlCl3 on AChE activity. Simvastatin 0-11 acetylcholinesterase Rattus norvegicus 99-103 25802481-12 2015 Further, in hippocampus and frontal cortex, aluminium-induced elevation in nitrite and TNF-alpha and reduction in antioxidant enzymes were inhibited by simvastatin. Simvastatin 152-163 tumor necrosis factor Rattus norvegicus 87-96 25520153-0 2015 Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin. Simvastatin 35-46 AKT serine/threonine kinase 1 Homo sapiens 94-97 25520153-4 2015 MATERIALS AND METHODS: Cell viability was measured by an MTT assay, while the expression of apoptotic markers, AKT, and survivin in response to sulindac and simvastatin was examined by Western blotting. Simvastatin 157-168 AKT serine/threonine kinase 1 Homo sapiens 111-114 25520153-13 2015 CONCLUSION: Combined treatment with sulindac and simvastatin augmented their apoptotic potential in lung cancer cells through AKT signaling-dependent downregulation of survivin. Simvastatin 49-60 AKT serine/threonine kinase 1 Homo sapiens 126-129 26514497-6 2015 Interestingly, simvastatin treatment of P3NS1 cells increased the intracellular ROS production and decreased antioxidant enzyme activity with increased P53, Bax and Caspase3 gene expression while that of Bcl2 was decreased. Simvastatin 15-26 transformation related protein 53, pseudogene Mus musculus 152-155 26514497-6 2015 Interestingly, simvastatin treatment of P3NS1 cells increased the intracellular ROS production and decreased antioxidant enzyme activity with increased P53, Bax and Caspase3 gene expression while that of Bcl2 was decreased. Simvastatin 15-26 BCL2-associated X protein Mus musculus 157-160 26514497-6 2015 Interestingly, simvastatin treatment of P3NS1 cells increased the intracellular ROS production and decreased antioxidant enzyme activity with increased P53, Bax and Caspase3 gene expression while that of Bcl2 was decreased. Simvastatin 15-26 caspase 3 Mus musculus 165-173 26514497-6 2015 Interestingly, simvastatin treatment of P3NS1 cells increased the intracellular ROS production and decreased antioxidant enzyme activity with increased P53, Bax and Caspase3 gene expression while that of Bcl2 was decreased. Simvastatin 15-26 B cell leukemia/lymphoma 2 Mus musculus 204-208 25747989-0 2015 Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. Simvastatin 75-86 carboxylesterase 1 Homo sapiens 0-18 25747989-3 2015 Both CYP enzymes and carboxylesterase 1 (CES1) are involved in the metabolism of clopidogrel, while CES1 is believed to be the enzyme responsible for the activation of simvastatin. Simvastatin 168-179 carboxylesterase 1 Homo sapiens 21-39 25747989-3 2015 Both CYP enzymes and carboxylesterase 1 (CES1) are involved in the metabolism of clopidogrel, while CES1 is believed to be the enzyme responsible for the activation of simvastatin. Simvastatin 168-179 carboxylesterase 1 Homo sapiens 41-45 25747989-3 2015 Both CYP enzymes and carboxylesterase 1 (CES1) are involved in the metabolism of clopidogrel, while CES1 is believed to be the enzyme responsible for the activation of simvastatin. Simvastatin 168-179 carboxylesterase 1 Homo sapiens 100-104 25747989-4 2015 Some in vitro studies have suggested that simvastatin could attenuate clopidogrel activation via inhibiting CYP3A activity. Simvastatin 42-53 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-113 25747989-6 2015 The present study addresses these inconsistencies by exploring the potential role of CES1 in the metabolism of clopidogrel and simvastatin. Simvastatin 127-138 carboxylesterase 1 Homo sapiens 85-89 25747989-7 2015 Our in vitro human liver s9 fraction incubation study demonstrated that simvastatin significantly enhanced the formation of the intermediate metabolite 2-oxo-clopidogrel, and inhibited the CES1-mediated hydrolysis of clopidogrel, 2-oxo-clopidogrel, and the active metabolite. Simvastatin 72-83 carboxylesterase 1 Homo sapiens 189-193 25747989-11 2015 In summary, the inhibitory effect of simvastatin on the hydrolysis of clopidogrel and its principal metabolites may have offset the influence of simvastatin-mediated inhibition of CYP3A, and permitted the unaltered formation of the clopidogrel active metabolite. Simvastatin 37-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 180-185 25747989-11 2015 In summary, the inhibitory effect of simvastatin on the hydrolysis of clopidogrel and its principal metabolites may have offset the influence of simvastatin-mediated inhibition of CYP3A, and permitted the unaltered formation of the clopidogrel active metabolite. Simvastatin 145-156 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 180-185 26539474-6 2015 Simvastatin significantly increased the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 89-93 26539474-6 2015 Simvastatin significantly increased the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Simvastatin 0-11 glial cell derived neurotrophic factor Rattus norvegicus 99-142 26539474-6 2015 Simvastatin significantly increased the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Simvastatin 0-11 glial cell derived neurotrophic factor Rattus norvegicus 144-148 26539474-9 2015 The findings of this study showed that simvastatin induced autophagy by inhibiting the mTOR signaling pathway and contributed to neuroprotection after SCI. Simvastatin 39-50 mechanistic target of rapamycin kinase Rattus norvegicus 87-91 26235711-2 2015 Simvastatin (ST) was incorporated into the micelles of gelatin grafted with L-lactic acid oligomers (LAo) to allow water-solubilization. Simvastatin 0-11 interleukin 4 induced 1 Mus musculus 76-99 26544069-8 2015 In addition, circulating 5-HTand expression of 5-HTT in the lung were significantly increased in the smoked rats compared to control rats, and it was significantly reduced by simvastatin. Simvastatin 175-186 huntingtin Rattus norvegicus 49-52 26544069-11 2015 Simvastatin could significantly inhibited 5-HT and 5-HTT expression, and by which mechanism, it may protect animals from development of PAH. Simvastatin 0-11 huntingtin Rattus norvegicus 53-56 26235711-2 2015 Simvastatin (ST) was incorporated into the micelles of gelatin grafted with L-lactic acid oligomers (LAo) to allow water-solubilization. Simvastatin 0-11 interleukin 4 induced 1 Mus musculus 101-104 26235711-2 2015 Simvastatin (ST) was incorporated into the micelles of gelatin grafted with L-lactic acid oligomers (LAo) to allow water-solubilization. Simvastatin 13-15 interleukin 4 induced 1 Mus musculus 76-99 26235711-3 2015 The simvastatin-LAo-grafted gelatin (LAo-g-gelatin) micelles were mixed with gelatin, followed by chemical crosslinking to form gelatin hydrogels (ST Mi/GH). Simvastatin 4-15 interleukin 4 induced 1 Mus musculus 16-19 26235711-3 2015 The simvastatin-LAo-grafted gelatin (LAo-g-gelatin) micelles were mixed with gelatin, followed by chemical crosslinking to form gelatin hydrogels (ST Mi/GH). Simvastatin 4-15 interleukin 4 induced 1 Mus musculus 37-40 25931040-5 2015 Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. Simvastatin 18-29 leptin Homo sapiens 112-118 25931040-5 2015 Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. Simvastatin 18-29 nicotinamide phosphoribosyltransferase Homo sapiens 120-128 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 0-11 tumor necrosis factor Homo sapiens 102-111 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 0-11 interleukin 6 Homo sapiens 131-144 25931040-5 2015 Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. Simvastatin 18-29 tumor necrosis factor Homo sapiens 134-143 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 150-155 25931040-5 2015 Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. Simvastatin 18-29 adiponectin, C1Q and collagen domain containing Homo sapiens 175-186 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 30-41 tumor necrosis factor Homo sapiens 102-111 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 30-41 interleukin 6 Homo sapiens 131-144 25323804-0 2015 Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. Simvastatin 37-48 prostaglandin D2 receptor 2 Homo sapiens 68-73 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 30-41 C-C motif chemokine ligand 2 Homo sapiens 150-155 26136131-7 2015 The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population. Simvastatin 14-25 interleukin 6 Homo sapiens 81-94 26136131-7 2015 The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population. Simvastatin 14-25 C-C motif chemokine ligand 2 Homo sapiens 99-104 26136131-8 2015 The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance. Simvastatin 14-25 tumor necrosis factor Homo sapiens 68-77 26136131-8 2015 The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance. Simvastatin 14-25 interleukin 1 beta Homo sapiens 79-96 25821305-8 2015 Simvastatin or rosuvastatin counteracted the reduction in colon length, decreased colon weight, neutrophil accumulation, and tumor necrosis factor-alpha level in TNBS-induced colitis. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 125-152 25683950-1 2015 OBJECTIVE: This paper aims to investigate the interaction mechanism between pioglitazone/simvastatin and the CD40-CD40 ligand (CD40-CD40L) system and to determine their interaction effects on atherosclerosis in rabbits. Simvastatin 89-100 tumor necrosis factor receptor superfamily member 5 Oryctolagus cuniculus 109-125 25683950-1 2015 OBJECTIVE: This paper aims to investigate the interaction mechanism between pioglitazone/simvastatin and the CD40-CD40 ligand (CD40-CD40L) system and to determine their interaction effects on atherosclerosis in rabbits. Simvastatin 89-100 tumor necrosis factor receptor superfamily member 5 Oryctolagus cuniculus 109-113 25683950-7 2015 CONCLUSIONS: Pioglitazone and simvastatin may inhibit different functions, such as inflammatory response and lipid regulation, by inhibiting the CD40-CD40L signaling pathway to suppress the formation of atherosclerosis. Simvastatin 30-41 tumor necrosis factor receptor superfamily member 5 Oryctolagus cuniculus 145-149 26845845-6 2015 Administration of simvastatin and ARIL-1 during the development of experimental pathology was accompanied by decrease of total number of AhR(+) (by 24-38%, P < 0.05) and ATG16L1(+)-lymphocytes (by 43% - 2 fold, P < 0.05) in the colon. Simvastatin 18-29 aryl hydrocarbon receptor Rattus norvegicus 137-140 26845845-6 2015 Administration of simvastatin and ARIL-1 during the development of experimental pathology was accompanied by decrease of total number of AhR(+) (by 24-38%, P < 0.05) and ATG16L1(+)-lymphocytes (by 43% - 2 fold, P < 0.05) in the colon. Simvastatin 18-29 autophagy related 16-like 1 Rattus norvegicus 173-180 25676434-3 2015 Therefore, we enrolled 23 obese women without comorbidity and evaluated if simvastatin 20 mg/day dose therapy for 6 weeks (n=15) may modulate plasma levels of inflammatory CXCL-10, CCL-2, CXCL-9, CXCL-8, and CCL-5. Simvastatin 75-86 C-X-C motif chemokine ligand 10 Homo sapiens 172-179 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 131-142 mitogen-activated protein kinase 8 Homo sapiens 151-155 25379722-7 2015 Restricting the analysis to patients receiving simvastatin, pravastatin, lovastatin and fluvastatin indicated a statistically significant association of the OATP1B1 genotype on lipid parameters at the 5-year follow-up. Simvastatin 47-58 solute carrier organic anion transporter family member 1B1 Homo sapiens 157-164 27012115-7 2015 The significant decrease of hs-CRP (p = 0.017) and TNFalpha (p = 0.003) concentration after simvastatin was found in smokers, and 8-iso-PGF2alpha in smokers and 192QQ allele carriers (p = 0.038). Simvastatin 92-103 tumor necrosis factor Homo sapiens 51-59 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 20-28 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 RELA proto-oncogene, NF-kB subunit Homo sapiens 29-32 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 mitogen-activated protein kinase 8 Homo sapiens 53-57 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 58-63 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 activating transcription factor 2 Homo sapiens 64-69 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 93-119 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 131-142 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 156-161 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 121-126 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 131-142 activating transcription factor 2 Homo sapiens 162-167 25316568-1 2014 The aim of the present study was to explore the signaling pathways associated with the effect of simvastatin on matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia K562 cells. Simvastatin 97-108 matrix metallopeptidase 2 Homo sapiens 112-138 25316568-1 2014 The aim of the present study was to explore the signaling pathways associated with the effect of simvastatin on matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia K562 cells. Simvastatin 97-108 matrix metallopeptidase 2 Homo sapiens 140-145 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 131-142 matrix metallopeptidase 2 Homo sapiens 193-198 25316568-1 2014 The aim of the present study was to explore the signaling pathways associated with the effect of simvastatin on matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia K562 cells. Simvastatin 97-108 matrix metallopeptidase 9 Homo sapiens 147-152 25316568-2 2014 In sharp contrast to its insignificant effect on MMP-2, simvastatin down-regulated MMP-9 protein expression and mRNA levels in K562 cells. Simvastatin 56-67 matrix metallopeptidase 9 Homo sapiens 83-88 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 131-142 RELA proto-oncogene, NF-kB subunit Homo sapiens 221-224 25316568-3 2014 Simvastatin-induced Pin1 down-regulation evoked NFkappaB/p65 degradation. Simvastatin 0-11 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 Homo sapiens 20-24 25091578-7 2014 KEY RESULTS: Simvastatin was shown to activate a stress cascade, leading to the synthesis of 15-deoxy-12,14-PGJ2 (15d-PGJ2 ), in a p38- and COX-2-dependent manner. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 131-134 25316568-3 2014 Simvastatin-induced Pin1 down-regulation evoked NFkappaB/p65 degradation. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 48-56 25316568-3 2014 Simvastatin-induced Pin1 down-regulation evoked NFkappaB/p65 degradation. Simvastatin 0-11 RELA proto-oncogene, NF-kB subunit Homo sapiens 57-60 25316568-4 2014 Meanwhile, simvastatin induced JNK-mediated c-Jun and ATF-2 activation. Simvastatin 11-22 mitogen-activated protein kinase 8 Homo sapiens 31-34 25316568-4 2014 Meanwhile, simvastatin induced JNK-mediated c-Jun and ATF-2 activation. Simvastatin 11-22 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 44-49 25316568-4 2014 Meanwhile, simvastatin induced JNK-mediated c-Jun and ATF-2 activation. Simvastatin 11-22 activating transcription factor 2 Homo sapiens 54-59 25316568-5 2014 Over-expression of Pin1 suppressed simvastatin-induced MMP-9 down-regulation. Simvastatin 35-46 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 Homo sapiens 19-23 25316568-5 2014 Over-expression of Pin1 suppressed simvastatin-induced MMP-9 down-regulation. Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 55-60 25316568-6 2014 Treatment with SP600125 (a JNK inhibitor) or knock-down of JNK1 reduced MMP-2 expression in simvastatin-treated cells. Simvastatin 92-103 mitogen-activated protein kinase 8 Homo sapiens 27-30 25316568-6 2014 Treatment with SP600125 (a JNK inhibitor) or knock-down of JNK1 reduced MMP-2 expression in simvastatin-treated cells. Simvastatin 92-103 mitogen-activated protein kinase 8 Homo sapiens 59-63 25316568-6 2014 Treatment with SP600125 (a JNK inhibitor) or knock-down of JNK1 reduced MMP-2 expression in simvastatin-treated cells. Simvastatin 92-103 matrix metallopeptidase 2 Homo sapiens 72-77 25316568-7 2014 Simvastatin enhanced the binding of c-Jun/ATF-2 with the MMP-2 promoter. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 36-41 25316568-7 2014 Simvastatin enhanced the binding of c-Jun/ATF-2 with the MMP-2 promoter. Simvastatin 0-11 activating transcription factor 2 Homo sapiens 42-47 25316568-7 2014 Simvastatin enhanced the binding of c-Jun/ATF-2 with the MMP-2 promoter. Simvastatin 0-11 matrix metallopeptidase 2 Homo sapiens 57-62 25316568-11 2014 Simvastatin treatment also suppressed MMP-9 but not MMP-2 expression in human leukemia U937 and KU812 cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 38-43 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 39-50 RELA proto-oncogene, NF-kB subunit Homo sapiens 59-62 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 39-50 matrix metallopeptidase 9 Homo sapiens 84-89 25463129-6 2014 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Simvastatin 154-165 component of oligomeric golgi complex 2 Homo sapiens 9-14 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Simvastatin 183-194 component of oligomeric golgi complex 2 Homo sapiens 69-74 25091578-7 2014 KEY RESULTS: Simvastatin was shown to activate a stress cascade, leading to the synthesis of 15-deoxy-12,14-PGJ2 (15d-PGJ2 ), in a p38- and COX-2-dependent manner. Simvastatin 13-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 140-145 25091578-10 2014 Moreover, 15d-PGJ2 was shown to bind to the fatty acid-binding protein 5 (FABP5), which was up-regulated and predominantly detected in the secretome of simvastatin-stressed cells. Simvastatin 152-163 fatty acid binding protein 5 Homo sapiens 44-72 25091578-10 2014 Moreover, 15d-PGJ2 was shown to bind to the fatty acid-binding protein 5 (FABP5), which was up-regulated and predominantly detected in the secretome of simvastatin-stressed cells. Simvastatin 152-163 fatty acid binding protein 5 Homo sapiens 74-79 25091578-11 2014 Knockdown of FABP5 abolished simvastatin-induced activation of PPAR-gamma and amplified the apoptotic response. Simvastatin 29-40 fatty acid binding protein 5 Homo sapiens 13-18 25091578-11 2014 Knockdown of FABP5 abolished simvastatin-induced activation of PPAR-gamma and amplified the apoptotic response. Simvastatin 29-40 peroxisome proliferator activated receptor gamma Homo sapiens 63-73 25389630-0 2014 Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastatin [correction of simvastain] in chronic mild stress in mice: a possible link with dopaminergic pathway. Simvastatin 98-109 brain derived neurotrophic factor Mus musculus 56-89 25091578-12 2014 CONCLUSIONS AND IMPLICATIONS: We characterized simvastatin-induced activation of the 15d-PGJ2 /FABP5 signalling cascades, which triggered an apoptotic burst in melanoma cells but did not affect primary human melanocytes. Simvastatin 47-58 fatty acid binding protein 5 Homo sapiens 95-100 25389630-9 2014 Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. Simvastatin 36-47 brain derived neurotrophic factor Mus musculus 82-86 25580270-8 2014 From these data, the concept evolved that a combination of sirolimus with disruption of Rho activity with statins (e.g. simvastatin) may increase TSC-null cell death and reduce LAM cell survival. Simvastatin 120-131 TSC complex subunit 1 Homo sapiens 146-149 25674219-7 2014 Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). Simvastatin 15-26 phospholipid phosphatase 1 Mus musculus 74-78 24346863-5 2014 Additionally, the use of simvastatin plus classII histone deacetylase (HDAC) inhibitor (MC1568) induced further overexpression of p27(KIP1) by inhibiting HDAC5 induction originated from downregulated EZH2 in CRC cells and synergistically led to considerable antiproliferative effects. Simvastatin 25-36 zinc ribbon domain containing 2 Homo sapiens 130-133 24346863-5 2014 Additionally, the use of simvastatin plus classII histone deacetylase (HDAC) inhibitor (MC1568) induced further overexpression of p27(KIP1) by inhibiting HDAC5 induction originated from downregulated EZH2 in CRC cells and synergistically led to considerable antiproliferative effects. Simvastatin 25-36 cyclin dependent kinase inhibitor 1B Homo sapiens 134-138 24346863-5 2014 Additionally, the use of simvastatin plus classII histone deacetylase (HDAC) inhibitor (MC1568) induced further overexpression of p27(KIP1) by inhibiting HDAC5 induction originated from downregulated EZH2 in CRC cells and synergistically led to considerable antiproliferative effects. Simvastatin 25-36 histone deacetylase 5 Homo sapiens 154-159 24346863-5 2014 Additionally, the use of simvastatin plus classII histone deacetylase (HDAC) inhibitor (MC1568) induced further overexpression of p27(KIP1) by inhibiting HDAC5 induction originated from downregulated EZH2 in CRC cells and synergistically led to considerable antiproliferative effects. Simvastatin 25-36 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 200-204 25674219-7 2014 Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). Simvastatin 15-26 huntingtin Rattus norvegicus 104-107 25674219-7 2014 Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). Simvastatin 15-26 huntingtin Rattus norvegicus 192-195 25674219-7 2014 Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). Simvastatin 15-26 phospholipid phosphatase 1 Mus musculus 206-210 25674219-8 2014 CONCLUSION: Simvastatin partly reverses lung function decline and attenuates structural impairments of lung and right ventricle possibly through reducing 5-HTT content in the model of COPD. Simvastatin 12-23 huntingtin Rattus norvegicus 156-159 24752488-0 2014 Simvastatin pretreatment protects cerebrum from neuronal injury by decreasing the expressions of phosphor-CaMK II and AQP4 in ischemic stroke rats. Simvastatin 0-11 aquaporin 4 Rattus norvegicus 118-122 25492829-5 2014 Controls and simvastatin and pravastatin groups showed a significant increase in mean arterial BP and heart rate in response to Ang II. Simvastatin 13-24 angiotensinogen Rattus norvegicus 128-134 25492829-7 2014 In contrast, when pretreated with hexamethonium, a ganglionic blocker, simvastatin and pravastatin groups showed a similar hypertensive response to Ang II, which was smaller than in controls. Simvastatin 71-82 angiotensinogen Rattus norvegicus 148-154 25492829-8 2014 Likewise, the Ang II-induced vasoconstrictor response of femoral artery branches was comparable between simvastatin and pravastatin groups and smaller than in controls. Simvastatin 104-115 angiotensinogen Rattus norvegicus 14-20 25492829-10 2014 This study shows that simvastatin and pravastatin differ in their effects on the Ang II-dependent mechanisms controlling BP. Simvastatin 22-33 angiotensinogen Rattus norvegicus 81-87 24752488-7 2014 The results showed that simvastatin reduced degenerated cells and brain edema while decreasing the protein expressions of phosphor-CaMK II and AQP4, and increasing the ratios of Bcl-2/Bax, which was independent of cholesterol-lowering effect. Simvastatin 24-35 aquaporin 4 Rattus norvegicus 143-147 24752488-7 2014 The results showed that simvastatin reduced degenerated cells and brain edema while decreasing the protein expressions of phosphor-CaMK II and AQP4, and increasing the ratios of Bcl-2/Bax, which was independent of cholesterol-lowering effect. Simvastatin 24-35 BCL2, apoptosis regulator Rattus norvegicus 178-183 24752488-7 2014 The results showed that simvastatin reduced degenerated cells and brain edema while decreasing the protein expressions of phosphor-CaMK II and AQP4, and increasing the ratios of Bcl-2/Bax, which was independent of cholesterol-lowering effect. Simvastatin 24-35 BCL2 associated X, apoptosis regulator Rattus norvegicus 184-187 24752488-9 2014 It was concluded that simvastatin could protect the cerebrum from neuronal excitotoxicity and cytotoxic edema by downregulating the expressions of phosphor-CaMK II and AQP4, and that the interaction between NR3A and AQP4 might provide the base for AQP4 involving in the signaling pathways mediated by NMDARs. Simvastatin 22-33 aquaporin 4 Rattus norvegicus 168-172 24752488-6 2014 The present study used a middle cerebral artery occlusion (MCAO) model to further explore the pleiotropic effect of simvastatin via CaMK II and AQP4. Simvastatin 116-127 aquaporin 4 Rattus norvegicus 144-148 24752488-9 2014 It was concluded that simvastatin could protect the cerebrum from neuronal excitotoxicity and cytotoxic edema by downregulating the expressions of phosphor-CaMK II and AQP4, and that the interaction between NR3A and AQP4 might provide the base for AQP4 involving in the signaling pathways mediated by NMDARs. Simvastatin 22-33 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 207-211 25432084-4 2014 Therefore, the aim of this study was to evaluate, in the human lung adenocarcinoma cell line GLC-82, the effects of a 24-hour treatment with simvastatin on hydrogen peroxide (H2O2)-induced changes in cell viability, ERK phosphorylation, matrix metalloproteinase (MMP) expression, innate immunity signaling, NF-kappaB activation and IL-8 secretion. Simvastatin 141-152 mitogen-activated protein kinase 3 Homo sapiens 216-219 24752488-9 2014 It was concluded that simvastatin could protect the cerebrum from neuronal excitotoxicity and cytotoxic edema by downregulating the expressions of phosphor-CaMK II and AQP4, and that the interaction between NR3A and AQP4 might provide the base for AQP4 involving in the signaling pathways mediated by NMDARs. Simvastatin 22-33 aquaporin 4 Rattus norvegicus 216-220 24752488-9 2014 It was concluded that simvastatin could protect the cerebrum from neuronal excitotoxicity and cytotoxic edema by downregulating the expressions of phosphor-CaMK II and AQP4, and that the interaction between NR3A and AQP4 might provide the base for AQP4 involving in the signaling pathways mediated by NMDARs. Simvastatin 22-33 aquaporin 4 Rattus norvegicus 216-220 25432084-4 2014 Therefore, the aim of this study was to evaluate, in the human lung adenocarcinoma cell line GLC-82, the effects of a 24-hour treatment with simvastatin on hydrogen peroxide (H2O2)-induced changes in cell viability, ERK phosphorylation, matrix metalloproteinase (MMP) expression, innate immunity signaling, NF-kappaB activation and IL-8 secretion. Simvastatin 141-152 C-X-C motif chemokine ligand 8 Homo sapiens 332-336 25432084-7 2014 Our results show that simvastatin (30 muM) significantly (P <0.01) inhibited the proliferative effect of H2O2 (0.5 mM) and its stimulatory actions on ERK1/2 phosphorylation, NF-kappaB activation and IL-8 production. Simvastatin 22-33 mitogen-activated protein kinase 3 Homo sapiens 153-159 25432084-7 2014 Our results show that simvastatin (30 muM) significantly (P <0.01) inhibited the proliferative effect of H2O2 (0.5 mM) and its stimulatory actions on ERK1/2 phosphorylation, NF-kappaB activation and IL-8 production. Simvastatin 22-33 C-X-C motif chemokine ligand 8 Homo sapiens 202-206 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 matrix metallopeptidase 2 Homo sapiens 89-94 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 99-104 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 MYD88 innate immune signal transduction adaptor Homo sapiens 212-217 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 TNF receptor associated factor 2 Homo sapiens 219-224 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 TNF receptor associated factor 6 Homo sapiens 226-231 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 TNFRSF1A associated via death domain Homo sapiens 236-241 25412314-0 2014 Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Simvastatin 12-23 receptor interacting serine/threonine kinase 1 Homo sapiens 77-82 25424483-5 2014 Simvastatin treatment altered the release of cytokines and trophic factors from microglia, including interleukin-1-beta, tumour necrosis factor-alpha, and brain derived neurotrophic factor in a cholesterol-dependent manner. Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 155-188 25412314-0 2014 Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Simvastatin 12-23 receptor interacting serine/threonine kinase 3 Homo sapiens 88-93 24506800-0 2014 Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Simvastatin 88-99 angiopoietin 2 Homo sapiens 17-31 25311809-5 2014 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-54 25311809-5 2014 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells. Simvastatin 138-149 CD40 molecule Homo sapiens 226-230 23901824-4 2014 RESULTS: HL-1 cardiomyocytes exposed to simvastatin for 24 h exhibited diminished protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling, increased activation of unc-51-like kinase 1, and upregulation of autophagy and mitophagy. Simvastatin 40-51 AKT serine/threonine kinase 1 Homo sapiens 100-103 23901824-4 2014 RESULTS: HL-1 cardiomyocytes exposed to simvastatin for 24 h exhibited diminished protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling, increased activation of unc-51-like kinase 1, and upregulation of autophagy and mitophagy. Simvastatin 40-51 mechanistic target of rapamycin kinase Homo sapiens 105-134 23901824-4 2014 RESULTS: HL-1 cardiomyocytes exposed to simvastatin for 24 h exhibited diminished protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling, increased activation of unc-51-like kinase 1, and upregulation of autophagy and mitophagy. Simvastatin 40-51 mechanistic target of rapamycin kinase Homo sapiens 136-140 23901824-6 2014 Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Simvastatin 21-32 thymoma viral proto-oncogene 1 Mus musculus 46-49 23901824-6 2014 Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Simvastatin 21-32 mechanistic target of rapamycin kinase Mus musculus 50-54 23901824-6 2014 Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Simvastatin 21-32 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 167-224 23901824-7 2014 Simvastatin-treated HL-1 cells exhibited mitochondrial translocation of Parkin and p62/SQSTM1, fission, and mitophagy. Simvastatin 0-11 sequestosome 1 Mus musculus 83-86 23901824-7 2014 Simvastatin-treated HL-1 cells exhibited mitochondrial translocation of Parkin and p62/SQSTM1, fission, and mitophagy. Simvastatin 0-11 sequestosome 1 Mus musculus 87-93 23901824-13 2014 INNOVATION AND CONCLUSION: Acute simvastatin treatment suppresses mTOR signaling and triggers Parkin-dependent mitophagy, the latter which is required for cardioprotection. Simvastatin 33-44 mechanistic target of rapamycin kinase Mus musculus 66-70 25183024-0 2014 The essential role of transient receptor potential vanilloid 1 in simvastatin-induced activation of endothelial nitric oxide synthase and angiogenesis. Simvastatin 66-77 nitric oxide synthase 3, endothelial cell Mus musculus 100-133 25183024-1 2014 AIMS: We investigated the role of transient receptor potential vanilloid receptor type 1 (TRPV1) in simvastatin-mediated activation of endothelial nitric oxide synthase (eNOS) and angiogenesis. Simvastatin 100-111 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 90-95 25183024-1 2014 AIMS: We investigated the role of transient receptor potential vanilloid receptor type 1 (TRPV1) in simvastatin-mediated activation of endothelial nitric oxide synthase (eNOS) and angiogenesis. Simvastatin 100-111 nitric oxide synthase 3, endothelial cell Mus musculus 135-168 25183024-1 2014 AIMS: We investigated the role of transient receptor potential vanilloid receptor type 1 (TRPV1) in simvastatin-mediated activation of endothelial nitric oxide synthase (eNOS) and angiogenesis. Simvastatin 100-111 nitric oxide synthase 3, endothelial cell Mus musculus 170-174 25183024-4 2014 Pharmacological inhibition or genetic disruption of TRPV1 abrogated simvastatin-mediated elevation of intracellular Ca(2+) in ECs or TRPV1-transfected HEK293 cells. Simvastatin 68-79 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 52-57 24506800-0 2014 Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Simvastatin 88-99 vascular endothelial growth factor A Homo sapiens 36-40 25183024-4 2014 Pharmacological inhibition or genetic disruption of TRPV1 abrogated simvastatin-mediated elevation of intracellular Ca(2+) in ECs or TRPV1-transfected HEK293 cells. Simvastatin 68-79 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 133-138 24506800-5 2014 RESULTS: Intravitreal levels of Ang-2 (p = 0.029), VEGF (p = 0.001) and proMMP-9 (p = 0.015) were lower in simvastatin-treated than in non-statin-treated controls. Simvastatin 107-118 angiopoietin 2 Homo sapiens 32-37 25183024-5 2014 Loss of TRPV1 function abolished simvastatin-induced NO production and phosphorylation of eNOS and calmodulin protein kinase II (CaMKII) in ECs and in aortas of mice. Simvastatin 33-44 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 8-13 25183024-5 2014 Loss of TRPV1 function abolished simvastatin-induced NO production and phosphorylation of eNOS and calmodulin protein kinase II (CaMKII) in ECs and in aortas of mice. Simvastatin 33-44 nitric oxide synthase 3, endothelial cell Mus musculus 90-94 24506800-5 2014 RESULTS: Intravitreal levels of Ang-2 (p = 0.029), VEGF (p = 0.001) and proMMP-9 (p = 0.015) were lower in simvastatin-treated than in non-statin-treated controls. Simvastatin 107-118 vascular endothelial growth factor A Homo sapiens 51-55 25183024-5 2014 Loss of TRPV1 function abolished simvastatin-induced NO production and phosphorylation of eNOS and calmodulin protein kinase II (CaMKII) in ECs and in aortas of mice. Simvastatin 33-44 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 99-127 24506800-6 2014 In diabetics with macular oedema (DME), intravitreal Ang-2 (p = 0.006) and VEGF (p = 0.002) levels were lower in simvastatin-treated patients compared with non-statin-treated controls. Simvastatin 113-124 angiopoietin 2 Homo sapiens 53-58 25183024-5 2014 Loss of TRPV1 function abolished simvastatin-induced NO production and phosphorylation of eNOS and calmodulin protein kinase II (CaMKII) in ECs and in aortas of mice. Simvastatin 33-44 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 129-135 24506800-6 2014 In diabetics with macular oedema (DME), intravitreal Ang-2 (p = 0.006) and VEGF (p = 0.002) levels were lower in simvastatin-treated patients compared with non-statin-treated controls. Simvastatin 113-124 vascular endothelial growth factor A Homo sapiens 75-79 25183024-6 2014 Inhibition of TRPV1 activation prevented the simvastatin-elicited increase in the formation of TRPV1-Akt-CaMKII-AMPK-eNOS complex. Simvastatin 45-56 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 14-19 24506800-8 2014 CONCLUSIONS: In diabetic patients with DME or PDR, the intravitreal levels of permeability and proangiogenic factors Ang-2 and VEGF were lower in simvastatin-treated than in those without statin medication. Simvastatin 146-157 angiopoietin 2 Homo sapiens 117-122 25183024-6 2014 Inhibition of TRPV1 activation prevented the simvastatin-elicited increase in the formation of TRPV1-Akt-CaMKII-AMPK-eNOS complex. Simvastatin 45-56 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 95-100 25183024-6 2014 Inhibition of TRPV1 activation prevented the simvastatin-elicited increase in the formation of TRPV1-Akt-CaMKII-AMPK-eNOS complex. Simvastatin 45-56 thymoma viral proto-oncogene 1 Mus musculus 101-104 24506800-8 2014 CONCLUSIONS: In diabetic patients with DME or PDR, the intravitreal levels of permeability and proangiogenic factors Ang-2 and VEGF were lower in simvastatin-treated than in those without statin medication. Simvastatin 146-157 vascular endothelial growth factor A Homo sapiens 127-131 25183024-6 2014 Inhibition of TRPV1 activation prevented the simvastatin-elicited increase in the formation of TRPV1-Akt-CaMKII-AMPK-eNOS complex. Simvastatin 45-56 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 105-111 24506800-9 2014 Moreover, the levels of MMP-9 and TGF-beta1, factors involved in the breakdown of basement membrane and fibroproliferation, were lower in patients with PDR having simvastatin medication. Simvastatin 163-174 matrix metallopeptidase 9 Homo sapiens 24-29 25183024-6 2014 Inhibition of TRPV1 activation prevented the simvastatin-elicited increase in the formation of TRPV1-Akt-CaMKII-AMPK-eNOS complex. Simvastatin 45-56 nitric oxide synthase 3, endothelial cell Mus musculus 117-121 25183024-7 2014 In mice, Matrigel plug assay showed that simvastatin-evoked angiogenesis was abolished by TRPV1 antagonist and genetic ablation of TRPV1. Simvastatin 41-52 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 90-95 25183024-7 2014 In mice, Matrigel plug assay showed that simvastatin-evoked angiogenesis was abolished by TRPV1 antagonist and genetic ablation of TRPV1. Simvastatin 41-52 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 131-136 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 76-81 24506800-9 2014 Moreover, the levels of MMP-9 and TGF-beta1, factors involved in the breakdown of basement membrane and fibroproliferation, were lower in patients with PDR having simvastatin medication. Simvastatin 163-174 transforming growth factor beta 1 Homo sapiens 34-43 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 82-87 24506800-10 2014 When acetylsalicylic acid was combined with simvastatin treatment, the intraocular levels of Ang-2 and VEGF were significantly lower than in diabetics treated with simvastatin alone. Simvastatin 44-55 angiopoietin 2 Homo sapiens 93-98 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 134-140 24506800-10 2014 When acetylsalicylic acid was combined with simvastatin treatment, the intraocular levels of Ang-2 and VEGF were significantly lower than in diabetics treated with simvastatin alone. Simvastatin 44-55 vascular endothelial growth factor A Homo sapiens 103-107 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 172-177 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 calcium/calmodulin-dependent protein kinase II, beta Mus musculus 178-184 25443902-8 2014 For example, after adjusting for age, the percentage of men having a PSA level >4.0 ng/mL ranged from 8.2% in non-statin users to 6.2% in men prescribed with >40 mg of simvastatin dose. Simvastatin 174-185 kallikrein related peptidase 3 Homo sapiens 69-72 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 nitric oxide synthase 3, endothelial cell Mus musculus 190-194 25183024-9 2014 CONCLUSION: Simvastatin-induced Ca(2+) influx may through the activation of TRPV1-TRPA1 signalling, which leads to phosphorylation of CaMKII, increases in the formation of TRPV1-CaMKII-AMPK-eNOS complex, eNOS activation, NO production and, ultimately, angiogenesis in ECs. Simvastatin 12-23 nitric oxide synthase 3, endothelial cell Mus musculus 204-208 25161155-1 2014 OBJECTIVE: This study was undertaken to investigate potential drugdrug interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and simvastatin. Simvastatin 155-166 solute carrier family 5 member 2 Homo sapiens 96-126 24803100-1 2014 AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin. Simvastatin 260-271 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 209-224 24803100-1 2014 AIMS: Variability in responsiveness to clopidogrel is a clinical problem in secondary prevention after cerebral ischaemia which has been suggested to be linked to competitive metabolization of clopidogrel and cytochrome P450 (CYP) 3A4-oxidated statins such as simvastatin. Simvastatin 260-271 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 226-229 24803100-10 2014 CONCLUSIONS: Our data indicate that treatment with CYP 3A4-metabolized simvastatin does not jeopardize clopidogrel-mediated inhibition of platelet aggregation. Simvastatin 71-82 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 51-54 25262449-0 2014 Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 148-151 25262449-6 2014 These findings demonstrate that combining tipifarnib and simvastatin was successful in targeting RAS/ERK signaling and inducing apoptosis in leukemia cells. Simvastatin 57-68 mitogen-activated protein kinase 1 Homo sapiens 101-104 25493567-0 2014 Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Simvastatin 56-67 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 25-30 25493567-1 2014 Aim: Simvastatin is a lactone prodrug that exists in equilibrium with its active hydroxyacid through a process mediated by UGT1A enzymes. Simvastatin 5-16 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 123-128 25493567-2 2014 The UGT1A locus has been associated with simvastatin response and disposition in humans. Simvastatin 41-52 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 4-9 25493567-3 2014 Therefore, we fine-mapped the UGT1A locus to identify genetic variations contributing to simvastatin disposition and response variability. Simvastatin 89-100 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 30-35 25493567-11 2014 Conclusion: We identified a UGT1A1 promoter variant (rs2003569) associated with simvastatin efficacy. Simvastatin 80-91 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 28-34 25443902-9 2014 Adjusted relative risks of having a PSA level >4.0 ng/mL were 0.89 (95% confidence interval [CI], 0.86-0.93), 0.87 (95% CI, 0.84-0.91), and 0.83 (95% CI, 0.80-0.87), respectively for men on simvastatin dose of 5-20, >20-40, and >40 mg vs non-statin users. Simvastatin 193-204 kallikrein related peptidase 3 Homo sapiens 36-39 25331390-11 2014 CONCLUSION: The API, FMD and plasma levels of MCP-1 of hypercholesterolemia patients without clear coronary heart disease can be improved by simvastatin treatment. Simvastatin 141-152 C-C motif chemokine ligand 2 Homo sapiens 46-51 25582208-0 2014 [Effect of simvastatin on retinal Bcl-2/Bax expression and cell apoptosis in rats with ischemia-reperfusion injury]. Simvastatin 11-22 BCL2, apoptosis regulator Rattus norvegicus 34-39 25582208-0 2014 [Effect of simvastatin on retinal Bcl-2/Bax expression and cell apoptosis in rats with ischemia-reperfusion injury]. Simvastatin 11-22 BCL2 associated X, apoptosis regulator Rattus norvegicus 40-43 25582208-9 2014 Expression of Bax protein in simvastatin group were lower than model group at each time point, with the information of (0.222 +- 0.012), (0.219 +- 0.017), (0.223 +- 0.008), (0.232 +- 0.021) and (0.214 +- 0.008). Simvastatin 29-40 BCL2 associated X, apoptosis regulator Rattus norvegicus 14-17 25582208-15 2014 But Bcl-2 mRNA in simvastatin group were higher than those in model group, with the information of (1.718 +- 0.247), (1.981 +- 0.317), (1.309 +- 0.031), (1.289 +- 0.209) and (0.684 +- 0.071). Simvastatin 18-29 BCL2, apoptosis regulator Rattus norvegicus 4-9 25582208-18 2014 However, Bax mRNA in simvastatin group were lower than those in model group, with the information of (0.658 +- 0.197), (1.746 +- 0.315), (0.670 +- 0.221), (0.952 +- 0.164) and (0.575 +- 0.174). Simvastatin 21-32 BCL2 associated X, apoptosis regulator Rattus norvegicus 9-12 25582208-20 2014 CONCLUSIONS: Simvastatin has protective effects on retinal ischemia reperfusion injury, and the mechanism is closely related to inhibiting retinal cell apoptosis by adjusting the express of Bcl-2 and Bax. Simvastatin 13-24 BCL2, apoptosis regulator Rattus norvegicus 190-195 25582208-20 2014 CONCLUSIONS: Simvastatin has protective effects on retinal ischemia reperfusion injury, and the mechanism is closely related to inhibiting retinal cell apoptosis by adjusting the express of Bcl-2 and Bax. Simvastatin 13-24 BCL2 associated X, apoptosis regulator Rattus norvegicus 200-203 25129462-0 2014 Effect of simvastatin on expression of IL17, HMGB1 and TLR4 in LN kidney tissues of rats. Simvastatin 10-21 interleukin 17A Rattus norvegicus 39-43 25275561-8 2014 RESULTS: Compared to NG cells, E-cadherin expression was significantly decreased, while alpha-SMA, Snail, and fibronectin expression were significantly increased in HPMCs exposed to HG, and these changes were abrogated by simvastatin (p<0.05). Simvastatin 222-233 cadherin 1 Rattus norvegicus 31-41 25275561-8 2014 RESULTS: Compared to NG cells, E-cadherin expression was significantly decreased, while alpha-SMA, Snail, and fibronectin expression were significantly increased in HPMCs exposed to HG, and these changes were abrogated by simvastatin (p<0.05). Simvastatin 222-233 fibronectin 1 Rattus norvegicus 110-121 25275561-11 2014 HG significantly increased the protein expression of RhoA and Rac1 in the membrane fractions, and these increases were ameliorated by simvastatin (p<0.05). Simvastatin 134-145 ras homolog family member A Rattus norvegicus 53-57 25128605-7 2014 Cholesterol depletion with methyl-beta-cyclodextrin or simvastatin resulted in the dislocation (relocation) of AQP4 from lipid rafts to non-rafts fraction of the membrane and AQP4 was not internalized intracellularly. Simvastatin 55-66 aquaporin 4 Homo sapiens 111-115 25128605-7 2014 Cholesterol depletion with methyl-beta-cyclodextrin or simvastatin resulted in the dislocation (relocation) of AQP4 from lipid rafts to non-rafts fraction of the membrane and AQP4 was not internalized intracellularly. Simvastatin 55-66 aquaporin 4 Homo sapiens 175-179 25129462-0 2014 Effect of simvastatin on expression of IL17, HMGB1 and TLR4 in LN kidney tissues of rats. Simvastatin 10-21 high mobility group box 1 Rattus norvegicus 45-50 25129462-0 2014 Effect of simvastatin on expression of IL17, HMGB1 and TLR4 in LN kidney tissues of rats. Simvastatin 10-21 toll-like receptor 4 Rattus norvegicus 55-59 25129462-1 2014 OBJECTIVES: To observe the intervention influence and effect of simvastatin on the expression of interleukin 17 (LI17), high mobility group protein 1 (HMGB1) and TLR4 path in Lupus nephritis (LN) rats. Simvastatin 64-75 high mobility group box 1 Rattus norvegicus 120-149 25129462-1 2014 OBJECTIVES: To observe the intervention influence and effect of simvastatin on the expression of interleukin 17 (LI17), high mobility group protein 1 (HMGB1) and TLR4 path in Lupus nephritis (LN) rats. Simvastatin 64-75 high mobility group box 1 Rattus norvegicus 151-156 25129462-1 2014 OBJECTIVES: To observe the intervention influence and effect of simvastatin on the expression of interleukin 17 (LI17), high mobility group protein 1 (HMGB1) and TLR4 path in Lupus nephritis (LN) rats. Simvastatin 64-75 toll-like receptor 4 Rattus norvegicus 162-166 25129462-7 2014 CONCLUSIONS: Simvastatin can reduce the expression of IL17, HMGB1 and TLR4 protein in LN mice, thereby can inhibit the autoimmune response as a potential treatment function of LN. Simvastatin 13-24 interleukin 17A Mus musculus 54-58 25129462-7 2014 CONCLUSIONS: Simvastatin can reduce the expression of IL17, HMGB1 and TLR4 protein in LN mice, thereby can inhibit the autoimmune response as a potential treatment function of LN. Simvastatin 13-24 high mobility group box 1 Mus musculus 60-65 25129462-7 2014 CONCLUSIONS: Simvastatin can reduce the expression of IL17, HMGB1 and TLR4 protein in LN mice, thereby can inhibit the autoimmune response as a potential treatment function of LN. Simvastatin 13-24 toll-like receptor 4 Mus musculus 70-74 24918167-2 2014 A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. Simvastatin 107-118 solute carrier organic anion transporter family member 1B1 Homo sapiens 68-75 25115547-0 2014 Homocysteine and nitrite levels are modulated by MTHFR 677C>T polymorphism in obese women treated with simvastatin. Simvastatin 106-117 methylenetetrahydrofolate reductase Homo sapiens 49-54 25115547-8 2014 Our findings demonstrate that obese women without comorbidities and carrying the T variant of the 677C>T polymorphism of MTHFR exhibit benefits with simvastatin treatment, mainly in terms of increased NO levels. Simvastatin 152-163 methylenetetrahydrofolate reductase Homo sapiens 124-129 24918167-3 2014 We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. Simvastatin 114-125 solute carrier organic anion transporter family member 1B1 Homo sapiens 135-142 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 36-47 latexin Homo sapiens 32-35 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 36-47 alkaline phosphatase, placental Homo sapiens 67-70 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 36-47 bone morphogenetic protein 2 Homo sapiens 95-123 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 36-47 alkaline phosphatase, placental Homo sapiens 170-173 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 249-260 latexin Homo sapiens 32-35 24112098-11 2014 After the administration of 0.1 muM simvastatin, the expression of ALP, bone sialoprotein, and bone morphogenetic protein-2 genes were significantly upregulated, and the ALP activity and mineralized nodule formation were significantly higher in the simvastatin-treated cells than the control cells. Simvastatin 249-260 bone morphogenetic protein 2 Homo sapiens 95-123 24535918-8 2014 Considering the essential role of RhoA activation in cell migration, we evaluated the potential use of simvastatin, a RhoA inhibitor, as a therapeutic intervention in vivo using matrigel plug formation assays. Simvastatin 103-114 ras homolog family member A Homo sapiens 118-122 25096993-0 2014 Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction. Simvastatin 37-48 BCL2 like 11 Homo sapiens 164-167 25096993-9 2014 In addition, Bim siRNA conferred protection against apoptosis induced by pemetrexed and simvastatin. Simvastatin 88-99 BCL2 like 11 Homo sapiens 13-16 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 chemokine (C-X-C motif) ligand 2 Mus musculus 34-39 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 tumor necrosis factor Mus musculus 45-54 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 myeloperoxidase Mus musculus 56-59 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 interleukin 6 Mus musculus 61-65 24912811-10 2014 Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P<0.05). Simvastatin 0-11 selectin, platelet Mus musculus 71-81 24535918-9 2014 Our results provide a molecular basis for the therapeutic application of simvastatin to reduce RhoA/PTEN activation, restore cytosolic levels of phosphorylated p21/p27, and induce angiogenic processes. Simvastatin 73-84 ras homolog family member A Homo sapiens 95-99 24535918-9 2014 Our results provide a molecular basis for the therapeutic application of simvastatin to reduce RhoA/PTEN activation, restore cytosolic levels of phosphorylated p21/p27, and induce angiogenic processes. Simvastatin 73-84 phosphatase and tensin homolog Homo sapiens 100-104 24535918-9 2014 Our results provide a molecular basis for the therapeutic application of simvastatin to reduce RhoA/PTEN activation, restore cytosolic levels of phosphorylated p21/p27, and induce angiogenic processes. Simvastatin 73-84 H3 histone pseudogene 16 Homo sapiens 160-163 24535918-9 2014 Our results provide a molecular basis for the therapeutic application of simvastatin to reduce RhoA/PTEN activation, restore cytosolic levels of phosphorylated p21/p27, and induce angiogenic processes. Simvastatin 73-84 dynactin subunit 6 Homo sapiens 164-167 25051018-14 2014 Genetic variations in CYP3A4 and CYP3A5 were associated with plasma simvastatin concentrations in self-reported African-Americans. Simvastatin 68-79 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 33-39 24555750-5 2014 Serum OPG concentrations were significantly higher in the simvastatin-treated patients with hyperlipidemia than in the diet-treated patients with hyperlipidemia (P = 0.05). Simvastatin 58-69 TNF receptor superfamily member 11b Homo sapiens 6-9 24555750-7 2014 CONCLUSIONS: Within the limits of this study, the findings suggest that the intake of simvastatin is associated with increasing serum OPG concentrations, and this could have a protective effect against bone breakdown and periodontal attachment loss. Simvastatin 86-97 TNF receptor superfamily member 11b Homo sapiens 134-137 25093998-4 2014 Our aims were to compare the effects of placebo, aspirin, and simvastatin alone, and with alpha-lipoic acid, on HO-1 protein concentration and activity in humans. Simvastatin 62-73 heme oxygenase 1 Homo sapiens 112-116 25051018-0 2014 CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Simvastatin 70-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 25051018-0 2014 CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Simvastatin 70-81 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 14-20 25122066-6 2014 Combination of simvastatin and metformin decreased Akt Ser-473 and Thr-308 phosphorylation and AMPKalpha Ser-485/491 phosphorylation; increased Thr-172 phosphorylation and AMPKalpha activity, as assessed by increased Ser-79 and Ser-872 phosphorylation of acetyl-CoA carboxylase and HMG-CoAR, respectively; decreased HMG-CoAR activity; and reduced total cellular cholesterol and its synthesis in both cell lines. Simvastatin 15-26 AKT serine/threonine kinase 1 Homo sapiens 51-54 25122066-6 2014 Combination of simvastatin and metformin decreased Akt Ser-473 and Thr-308 phosphorylation and AMPKalpha Ser-485/491 phosphorylation; increased Thr-172 phosphorylation and AMPKalpha activity, as assessed by increased Ser-79 and Ser-872 phosphorylation of acetyl-CoA carboxylase and HMG-CoAR, respectively; decreased HMG-CoAR activity; and reduced total cellular cholesterol and its synthesis in both cell lines. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 282-290 25122066-6 2014 Combination of simvastatin and metformin decreased Akt Ser-473 and Thr-308 phosphorylation and AMPKalpha Ser-485/491 phosphorylation; increased Thr-172 phosphorylation and AMPKalpha activity, as assessed by increased Ser-79 and Ser-872 phosphorylation of acetyl-CoA carboxylase and HMG-CoAR, respectively; decreased HMG-CoAR activity; and reduced total cellular cholesterol and its synthesis in both cell lines. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 316-324 25089948-0 2014 Ancestry and other genetic associations with plasma PCSK9 response to simvastatin. Simvastatin 70-81 proprotein convertase subtilisin/kexin type 9 Homo sapiens 52-57 25089948-3 2014 METHODS: We measured plasma PCSK9 levels before and after 6 weeks of treatment with 40 mg/day simvastatin in 901 participants of the Cholesterol and Pharmacogenetics clinical trial and tested phenotypic and genetic factors for correlation with PCSK9 statin response. Simvastatin 94-105 proprotein convertase subtilisin/kexin type 9 Homo sapiens 28-33 25051018-1 2014 OBJECTIVE: Simvastatin is primarily metabolized by CYP3A4. Simvastatin 11-22 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 25161239-8 2014 The novel observations include: previously unknown similarities in the effects induced by 15-delta prostaglandin J2 and HSP90 inhibitors, which are linked to the 3D descriptors of the drugs; and the induction by simvastatin of leukemia-specific response, resembling the effects of corticosteroids. Simvastatin 212-223 heat shock protein 90 alpha family class A member 1 Homo sapiens 120-125 25051018-3 2014 We aim to determine whether CYP3A4*22 and CYP3A5*3 alleles are associated with increased plasma concentrations of simvastatin lactone (SV) and simvastatin acid (SVA). Simvastatin 114-133 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-34 25051018-3 2014 We aim to determine whether CYP3A4*22 and CYP3A5*3 alleles are associated with increased plasma concentrations of simvastatin lactone (SV) and simvastatin acid (SVA). Simvastatin 114-133 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 42-48 25051018-4 2014 This is the first report evaluating associations between in-vivo simvastatin concentrations and CYP3A4*22, alone or in a combined CYP3A4/5 genotype-defined classification. Simvastatin 65-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 25051018-7 2014 Associations between simvastatin concentrations and CYP3A4*22 and CYP3A5*3 alleles were tested separately and in a combined CYP3A4/5 genotype-defined classification system. Simvastatin 21-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 25051018-7 2014 Associations between simvastatin concentrations and CYP3A4*22 and CYP3A5*3 alleles were tested separately and in a combined CYP3A4/5 genotype-defined classification system. Simvastatin 21-32 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 66-72 25051018-13 2014 CONCLUSION: Genetic variation in CYP3A4 was associated with plasma simvastatin concentrations in self-reported Whites. Simvastatin 67-78 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-39 25051018-14 2014 Genetic variations in CYP3A4 and CYP3A5 were associated with plasma simvastatin concentrations in self-reported African-Americans. Simvastatin 68-79 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-28 25213768-6 2014 The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Simvastatin 22-33 interleukin 4 Mus musculus 120-138 25213768-6 2014 The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Simvastatin 22-33 interleukin 5 Mus musculus 140-144 25213768-6 2014 The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Simvastatin 22-33 interleukin 13 Mus musculus 149-154 25213768-8 2014 Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P<0.05). Simvastatin 27-38 CD4 antigen Mus musculus 99-102 25213768-8 2014 Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P<0.05). Simvastatin 27-38 CD4 antigen Mus musculus 120-123 25213768-9 2014 Simvastatin treatment also decreased the expression of the vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 proteins, as measured in homogenized lung tissues (P<0.05) and human epithelial cells. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 59-130 25152023-8 2014 Both simvastatin metabolism and Cyp3a activity were markedly increased in hepatocytes of diabetic rats, accompanied by increased expression of hepatic Cyp3a1 mRNA. Simvastatin 5-16 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 151-157 25152023-9 2014 Furthermore, the uptake of simvastatin by hepatocytes of diabetic rats was markedly increased, which was associated with increased expression of the influx transporter Oatp2, and decreased expression of the efflux transporters Mrp2 and Bcrp. Simvastatin 27-38 solute carrier organic anion transporter family, member 1a4 Rattus norvegicus 168-173 25152023-9 2014 Furthermore, the uptake of simvastatin by hepatocytes of diabetic rats was markedly increased, which was associated with increased expression of the influx transporter Oatp2, and decreased expression of the efflux transporters Mrp2 and Bcrp. Simvastatin 27-38 ATP binding cassette subfamily C member 2 Rattus norvegicus 227-231 25152023-10 2014 CONCLUSION: Diabetes enhances the metabolism of simvastatin and simvastatin acid in rats via up-regulating hepatic Cyp3a activity and expression and increasing hepatic uptake. Simvastatin 48-59 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 115-120 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 leptin Homo sapiens 139-145 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 tumor necrosis factor Homo sapiens 150-159 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 adiponectin, C1Q and collagen domain containing Homo sapiens 199-210 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 C-reactive protein Homo sapiens 259-262 25211146-8 2014 Simvastatin treatment reduced myocyte cholesterol, caveolin 3 and caveolar density. Simvastatin 0-11 caveolin 3 Rattus norvegicus 51-61 25211146-12 2014 Simvastatin increased NO production without significant effects on eNOS expression or phosphorylation (Ser1177), consistent with the reduced expression of caveolin 3, its constitutive inhibitor. Simvastatin 0-11 caveolin 3 Rattus norvegicus 155-165 25230879-10 2014 We thus concluded that HDL (mostly HDL3), stimulates PON1 antiatherogenic activities in macrophages, and these PON1 activities were further stimulated by quercetin, or by simvastatin. Simvastatin 171-182 high density lipoprotein (HDL) level 3 Mus musculus 23-26 25230879-10 2014 We thus concluded that HDL (mostly HDL3), stimulates PON1 antiatherogenic activities in macrophages, and these PON1 activities were further stimulated by quercetin, or by simvastatin. Simvastatin 171-182 high density lipoprotein (HDL) level 3 Mus musculus 35-39 25230879-10 2014 We thus concluded that HDL (mostly HDL3), stimulates PON1 antiatherogenic activities in macrophages, and these PON1 activities were further stimulated by quercetin, or by simvastatin. Simvastatin 171-182 paraoxonase 1 Mus musculus 111-115 25230879-9 2014 Upon adding the hypocholesterolemic drug simvastatin (15 microg/mL) to HDL + rePON1, PON1 activity and the ability to induce macrophage cholesterol efflux increased, in comparison to HDL + rePON1. Simvastatin 41-52 high density lipoprotein (HDL) level 3 Mus musculus 71-74 25230879-9 2014 Upon adding the hypocholesterolemic drug simvastatin (15 microg/mL) to HDL + rePON1, PON1 activity and the ability to induce macrophage cholesterol efflux increased, in comparison to HDL + rePON1. Simvastatin 41-52 paraoxonase 1 Mus musculus 79-83 25230879-9 2014 Upon adding the hypocholesterolemic drug simvastatin (15 microg/mL) to HDL + rePON1, PON1 activity and the ability to induce macrophage cholesterol efflux increased, in comparison to HDL + rePON1. Simvastatin 41-52 high density lipoprotein (HDL) level 3 Mus musculus 183-186 24819315-0 2014 Effect of simvastatin treatment on plasma visfatin levels in obese women. Simvastatin 10-21 nicotinamide phosphoribosyltransferase Homo sapiens 42-50 24989890-8 2014 Based on REF scaling, we demonstrated that the active hepatic uptake clearances of reference substrates, atorvastatin, pravastatin, rosuvastatin, and simvastatin were well predicted within twofold error, demonstrating that OATP1B1 and OATP1B3 were major contributors. Simvastatin 150-161 solute carrier organic anion transporter family member 1B1 Homo sapiens 223-230 25153633-6 2014 The reduced expressions of atrial eNOS, SERCA, thrombomodulin, tissue factor pathway inhibitor and tissue plasminogen activator in the MI group were significantly improved by simvastatin. Simvastatin 175-186 thrombomodulin Rattus norvegicus 47-61 25153633-6 2014 The reduced expressions of atrial eNOS, SERCA, thrombomodulin, tissue factor pathway inhibitor and tissue plasminogen activator in the MI group were significantly improved by simvastatin. Simvastatin 175-186 tissue factor pathway inhibitor Rattus norvegicus 63-94 25153633-7 2014 Furthermore, the increased expression of atrial iNOS, INCX and Rac1 activity were significantly decreased by the simvastatin. Simvastatin 113-124 nitric oxide synthase 2 Rattus norvegicus 48-52 25153633-7 2014 Furthermore, the increased expression of atrial iNOS, INCX and Rac1 activity were significantly decreased by the simvastatin. Simvastatin 113-124 Rac family small GTPase 1 Rattus norvegicus 63-67 25023790-10 2014 3 weeks post-MI simvastatin-treated animals showed P-PKCepsilon increase, lower intramyocardial lipotoxicity, TbetaRII/Smad2/3 signaling restoration and subsequent myofibroblast differentiation and collagen-fibril formation in the evolving scar (p<0.05 vs. control). Simvastatin 16-27 transforming growth factor beta receptor 2 Homo sapiens 110-118 25023790-10 2014 3 weeks post-MI simvastatin-treated animals showed P-PKCepsilon increase, lower intramyocardial lipotoxicity, TbetaRII/Smad2/3 signaling restoration and subsequent myofibroblast differentiation and collagen-fibril formation in the evolving scar (p<0.05 vs. control). Simvastatin 16-27 SMAD family member 2 Homo sapiens 119-126 25023790-11 2014 Simvastatin suppressed cardiac RhoA mobilization and triggered Akt/eNOS signaling. Simvastatin 0-11 ras homolog family member A Homo sapiens 31-35 25023790-11 2014 Simvastatin suppressed cardiac RhoA mobilization and triggered Akt/eNOS signaling. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 63-66 24907641-8 2014 NEDD4 was down-regulated in persons taking statins, and simvastatin treatment of C2C12 cells suppressed NEDD4 transcription. Simvastatin 56-67 neural precursor cell expressed, developmentally down-regulated 4 Mus musculus 104-109 25257410-5 2014 Simvastatin therapy significantly reduced the levels of C-reactive protein and IL-6. Simvastatin 0-11 interleukin 6 Homo sapiens 79-83 24855121-5 2014 RESULTS: Exposure to 5 muM simvastatin significantly increased the tuberculocidal activity of isoniazid in J774 macrophages at Day 3 after infection versus isoniazid alone (P=0.02). Simvastatin 27-38 latexin Homo sapiens 23-26 24887036-8 2014 Simvastatin therapy partially reduced HDL inflammation index, improved the capacity of HDL to stimulate eNOS and Akt phosphorylation at S1177, eNOS associated with HSP90, NO production, reduced eNOS phosphorylation at T495 and superoxide generation, and improved endothelium-dependent vasodilation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 113-116 24887036-8 2014 Simvastatin therapy partially reduced HDL inflammation index, improved the capacity of HDL to stimulate eNOS and Akt phosphorylation at S1177, eNOS associated with HSP90, NO production, reduced eNOS phosphorylation at T495 and superoxide generation, and improved endothelium-dependent vasodilation. Simvastatin 0-11 heat shock protein 90 alpha family class A member 1 Homo sapiens 164-169 24806822-1 2014 Simvastatin (SV), a drug of the statin class currently used orally as an anti-cholesterolemic via the inhibition of the 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase, has been found not only to reduce cholesterol but also to have several other pharmacological actions that might be beneficial in airway inflammatory diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 120-178 25066560-3 2014 The simvastatin monotherapy arm"s LDL-C target is <70 mg/dL. Simvastatin 4-15 component of oligomeric golgi complex 2 Homo sapiens 34-39 24819315-3 2014 Our objective in this study was to determinate if simvastatin treatment may modulate visfatin levels in obese women without any other metabolic disorder. Simvastatin 50-61 nicotinamide phosphoribosyltransferase Homo sapiens 85-93 24493323-3 2014 Monotherapy with simvastatin or ezetimibe and the ezetimibe + simvastatin combination effectively reduced the cytokine levels (interleukin-6 and tumor necrosis factor) and articular lesions that are characteristic of this experimental disease. Simvastatin 17-28 interleukin 6 Rattus norvegicus 127-140 24880141-7 2014 The effects of simvastatin on the AKT/mTOR and MAPK pathways were determined by Western blotting. Simvastatin 15-26 AKT serine/threonine kinase 1 Homo sapiens 34-37 24880141-7 2014 The effects of simvastatin on the AKT/mTOR and MAPK pathways were determined by Western blotting. Simvastatin 15-26 mechanistic target of rapamycin kinase Homo sapiens 38-42 24880141-10 2014 Treatment with simvastatin resulted in inhibition of the MAPK pathway and exhibited differential effects on the AKT/mTOR pathway in the ECC-1 and Ishikawa cells. Simvastatin 15-26 AKT serine/threonine kinase 1 Homo sapiens 112-115 24880141-10 2014 Treatment with simvastatin resulted in inhibition of the MAPK pathway and exhibited differential effects on the AKT/mTOR pathway in the ECC-1 and Ishikawa cells. Simvastatin 15-26 mechanistic target of rapamycin kinase Homo sapiens 116-120 24880141-14 2014 CONCLUSION: Simvastatin had significant anti-proliferative and anti-metastatic effects in endometrial cancer cells, possibly through modulation of the MAPK and AKT/mTOR pathways, suggesting that statins may be a promising treatment strategy for endometrial cancer. Simvastatin 12-23 AKT serine/threonine kinase 1 Homo sapiens 160-163 24880141-14 2014 CONCLUSION: Simvastatin had significant anti-proliferative and anti-metastatic effects in endometrial cancer cells, possibly through modulation of the MAPK and AKT/mTOR pathways, suggesting that statins may be a promising treatment strategy for endometrial cancer. Simvastatin 12-23 mechanistic target of rapamycin kinase Homo sapiens 164-168 24493323-3 2014 Monotherapy with simvastatin or ezetimibe and the ezetimibe + simvastatin combination effectively reduced the cytokine levels (interleukin-6 and tumor necrosis factor) and articular lesions that are characteristic of this experimental disease. Simvastatin 62-73 interleukin 6 Rattus norvegicus 127-140 24637330-6 2014 We observed that simvastatin exposure activates UPR (activated transcription factor 4, activated transcription factor 6 and IRE1alpha) and caspase-4 in primary human airway fibroblasts and smooth muscle cells. Simvastatin 17-28 transcription factor A, mitochondrial Homo sapiens 97-119 25013486-3 2014 Changes were noted in the expression levels of 56 genes involved in the NF-kappaB signaling pathways in the NB4 cells treated with 15 mum simvastatin at 48 h post-incubation, among which, 47 genes were downregulated and 9 were upregulated. Simvastatin 138-149 nuclear factor kappa B subunit 1 Homo sapiens 72-81 25013486-4 2014 In conclusion, simvastatin potentially inhibits the proliferation and induces the apoptosis of NB4 cells through the regulation of the expression levels of genes involved in the NF-kappaB signaling pathway. Simvastatin 15-26 nuclear factor kappa B subunit 1 Homo sapiens 178-187 25171892-9 2014 The EGFR-overexpressing A431 cell line was used to reproduce these antitumor effects of simvastatin. Simvastatin 88-99 epidermal growth factor receptor Homo sapiens 4-8 24945998-9 2014 CONCLUSIONS: The addition of simvastatin at a dose used in patients with cardiovascular diseases (40-80 mg once daily) may potentiate the anti-angiogenic effects of bevacizumab on CRC by suppressing angiopoietin2, BiP, and Hsp90alpha in cancer cells. Simvastatin 29-40 angiopoietin 2 Homo sapiens 199-212 24945998-9 2014 CONCLUSIONS: The addition of simvastatin at a dose used in patients with cardiovascular diseases (40-80 mg once daily) may potentiate the anti-angiogenic effects of bevacizumab on CRC by suppressing angiopoietin2, BiP, and Hsp90alpha in cancer cells. Simvastatin 29-40 heat shock protein family A (Hsp70) member 5 Homo sapiens 214-217 24945998-9 2014 CONCLUSIONS: The addition of simvastatin at a dose used in patients with cardiovascular diseases (40-80 mg once daily) may potentiate the anti-angiogenic effects of bevacizumab on CRC by suppressing angiopoietin2, BiP, and Hsp90alpha in cancer cells. Simvastatin 29-40 heat shock protein 90 alpha family class A member 1 Homo sapiens 223-233 24927617-9 2014 The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin 56-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 40-46 25389496-0 2014 Effects of simvastatin treatment on serum adiponectin concentrations in patients with dislipidemia. Simvastatin 11-22 adiponectin, C1Q and collagen domain containing Homo sapiens 42-53 25389496-3 2014 OBJECTIVES: In the current study, we aimed to assess the effects of simvastatin on serum levels of adiponectin in patients with dyslipidemia, recruited from Ghaem Hospital, Mashhad, Iran. Simvastatin 68-79 adiponectin, C1Q and collagen domain containing Homo sapiens 99-110 25013486-0 2014 Suppressive effects of simvastatin on the human acute promyelocytic leukemia NB4 cell line through the regulation of the nuclear factor-kappaB signaling pathway. Simvastatin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 121-142 25013486-1 2014 The present study examined the effects of simvastatin on the proliferation, apoptosis and gene expression levels involved in the nuclear factor-kappaB (NF-kappaB) signaling pathway in the human acute promyelocytic leukemia NB4 cell line by methyl thiazolyl tetrazolium assay, flow cytometry and the Human NF-kappaB Signaling Pathway RT2 Profiler PCR Array profiles. Simvastatin 42-53 nuclear factor kappa B subunit 1 Homo sapiens 129-150 25013486-1 2014 The present study examined the effects of simvastatin on the proliferation, apoptosis and gene expression levels involved in the nuclear factor-kappaB (NF-kappaB) signaling pathway in the human acute promyelocytic leukemia NB4 cell line by methyl thiazolyl tetrazolium assay, flow cytometry and the Human NF-kappaB Signaling Pathway RT2 Profiler PCR Array profiles. Simvastatin 42-53 nuclear factor kappa B subunit 1 Homo sapiens 152-161 25158572-0 2014 Simvastatin inhibits the proliferation of A549 lung cancer cells through oxidative stress and up-regulation of SOD2. Simvastatin 0-11 superoxide dismutase 2 Homo sapiens 111-115 25158572-5 2014 Treatment with 50 microM simvastatin for 48 h significantly increased reactive oxygen species (ROS) production and malondialdehyde (MDA), a lipid peroxidation production, and augmented the activity of total superoxide dismutase (SOD) and manganese SOD (SOD2). Simvastatin 25-36 superoxide dismutase 2 Homo sapiens 229-232 25158572-5 2014 Treatment with 50 microM simvastatin for 48 h significantly increased reactive oxygen species (ROS) production and malondialdehyde (MDA), a lipid peroxidation production, and augmented the activity of total superoxide dismutase (SOD) and manganese SOD (SOD2). Simvastatin 25-36 superoxide dismutase 2 Homo sapiens 248-251 25158572-5 2014 Treatment with 50 microM simvastatin for 48 h significantly increased reactive oxygen species (ROS) production and malondialdehyde (MDA), a lipid peroxidation production, and augmented the activity of total superoxide dismutase (SOD) and manganese SOD (SOD2). Simvastatin 25-36 superoxide dismutase 2 Homo sapiens 253-257 25158572-6 2014 Moreover, western blotting analysis showed that simvastatin effectively up-regulated the SOD2 relative protein level. Simvastatin 48-59 superoxide dismutase 2 Homo sapiens 89-93 25158572-7 2014 These findings suggested that simvastatin could inhibit the proliferation of A549 lung cells through oxidative stress and up-regulation of SOD2. Simvastatin 30-41 superoxide dismutase 2 Homo sapiens 139-143 24637330-6 2014 We observed that simvastatin exposure activates UPR (activated transcription factor 4, activated transcription factor 6 and IRE1alpha) and caspase-4 in primary human airway fibroblasts and smooth muscle cells. Simvastatin 17-28 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 124-133 24637330-6 2014 We observed that simvastatin exposure activates UPR (activated transcription factor 4, activated transcription factor 6 and IRE1alpha) and caspase-4 in primary human airway fibroblasts and smooth muscle cells. Simvastatin 17-28 caspase 4 Homo sapiens 139-148 24637330-8 2014 Caspase-4 inhibition decreased simvastatin-induced apoptosis, whereas inhibition of autophagy by ATG7 or ATG3 knockdown significantly increased cell death. Simvastatin 31-42 caspase 4 Homo sapiens 0-9 24637330-9 2014 In BAX(-/-)/BAK(-/-) murine embryonic fibroblasts, simvastatin-triggered apoptotic and UPR events were abrogated, but autophagy flux was increased leading to cell death via necrosis. Simvastatin 51-62 BCL2-associated X protein Mus musculus 3-6 24468885-1 2014 PURPOSE: Preclinical data has demonstrated the potential of simvastatin to overcome cetuximab resistance in KRAS mutant CRC patients. Simvastatin 60-71 KRAS proto-oncogene, GTPase Homo sapiens 108-112 24788303-6 2014 The expression of important pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), which was quantified using ELISA showed that simvastatin decreased the expression of pro-inflammatory cytokines to an average of 2-fold. Simvastatin 167-178 tumor necrosis factor Homo sapiens 56-83 24788303-6 2014 The expression of important pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), which was quantified using ELISA showed that simvastatin decreased the expression of pro-inflammatory cytokines to an average of 2-fold. Simvastatin 167-178 interleukin 6 Homo sapiens 85-98 24788303-6 2014 The expression of important pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), which was quantified using ELISA showed that simvastatin decreased the expression of pro-inflammatory cytokines to an average of 2-fold. Simvastatin 167-178 interferon gamma Homo sapiens 103-119 25041770-1 2014 Clarithromycin is the most documented cytochrome P450 3A4 (CYP3A4) inhibitor to cause an adverse interaction with simvastatin. Simvastatin 114-125 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-57 25041770-1 2014 Clarithromycin is the most documented cytochrome P450 3A4 (CYP3A4) inhibitor to cause an adverse interaction with simvastatin. Simvastatin 114-125 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 24661059-8 2014 Interestingly, analyzing one of the proteins (HSP75) in plasma from stroke patients who had received simvastatin during the acute phase, we confirmed the results found in the pre-clinical model. Simvastatin 101-112 TNF receptor associated protein 1 Homo sapiens 46-51 24856644-0 2014 Effects of peroxisome proliferator-activated receptor gamma in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases. Simvastatin 63-74 peroxisome proliferator activated receptor gamma Homo sapiens 11-59 24856644-5 2014 The aim of this study was to examine the mechanisms by which the PPAR-mediated pathways contribute to the antiplatelet activity of simvastatin. Simvastatin 131-142 peroxisome proliferator activated receptor alpha Homo sapiens 65-69 24856644-6 2014 Simvastatin (3-50 muM) induced PPARalpha and PPARgamma activation in a dose-dependent manner in washed platelets. Simvastatin 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 31-40 24856644-6 2014 Simvastatin (3-50 muM) induced PPARalpha and PPARgamma activation in a dose-dependent manner in washed platelets. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Homo sapiens 45-54 24856644-7 2014 Additionally, simvastatin inhibited collagen-induced platelet aggregation, expression of CD62 and PAC-1, and Ca(2+) mobilization. Simvastatin 14-25 selectin P Homo sapiens 89-93 24856644-7 2014 Additionally, simvastatin inhibited collagen-induced platelet aggregation, expression of CD62 and PAC-1, and Ca(2+) mobilization. Simvastatin 14-25 ADCYAP receptor type I Homo sapiens 98-103 24856644-8 2014 These effects of simvastatin on platelet responses were strongly reduced by adding a selective PPARgamma antagonist (GW9662), but not PPARalpha antagonist (GW6471). Simvastatin 17-28 peroxisome proliferator activated receptor gamma Homo sapiens 95-104 24856644-9 2014 Moreover, in the presence of GW9662, simvastatin-mediated increase of cyclic adenosine monophosphate (cAMP) production, vasodilator-stimulated phosphoprotein (VASP) Ser(157) phosphorylation and inhibition of Akt phosphorylation were markedly reversed. Simvastatin 37-48 vasodilator stimulated phosphoprotein Homo sapiens 159-163 24856644-10 2014 Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARgamma and the components of MAPKs after platelet activation. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 113-116 24856644-10 2014 Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARgamma and the components of MAPKs after platelet activation. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 100-104 24856644-10 2014 Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARgamma and the components of MAPKs after platelet activation. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 123-126 24856644-10 2014 Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARgamma and the components of MAPKs after platelet activation. Simvastatin 13-24 peroxisome proliferator activated receptor gamma Homo sapiens 166-175 24865757-5 2014 Lomitapide undergoes hepatic metabolism via cytochrome P-450 (CYP) isoenzyme 3A4 and interacts with CYP3A4 substrates including atorvastatin and simvastatin; dose adjustment is recommended when lomitapide is used concurrently with these agents. Simvastatin 145-156 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 24687455-0 2014 Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 31-36 24687455-0 2014 Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit. Simvastatin 0-11 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 116-122 24687455-11 2014 We conclude that SV-induced enhancement of synaptic plasticity in the hippocampus is likely mediated by augmentation of synaptic NMDAR components that are largely responsible for driving synaptic plasticity in the CA1 region. Simvastatin 17-19 glutamate receptor, ionotropic, NMDA1 (zeta 1) Mus musculus 129-134 24687455-11 2014 We conclude that SV-induced enhancement of synaptic plasticity in the hippocampus is likely mediated by augmentation of synaptic NMDAR components that are largely responsible for driving synaptic plasticity in the CA1 region. Simvastatin 17-19 carbonic anhydrase 1 Mus musculus 214-217 24718722-0 2014 Simvastatin attenuates TNF-alpha-induced apoptosis in endothelial progenitor cells via the upregulation of SIRT1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 23-32 24718722-0 2014 Simvastatin attenuates TNF-alpha-induced apoptosis in endothelial progenitor cells via the upregulation of SIRT1. Simvastatin 0-11 sirtuin 1 Homo sapiens 107-112 24718722-8 2014 The aim of this study was to demonstrate the effectiveness of one of the most commonly used statins, simvastatin, on decreasing TNF-alpha-induced apoptosis in EPCs. Simvastatin 101-112 tumor necrosis factor Homo sapiens 128-137 24718722-9 2014 The results indicated that SIRT1 protein expression was decreased by TNF-alpha in a time- and dose-dependent manner and that while TNF-alpha caused a marked increase in the percentage of apoptotic EPCs, application of simvastatin decreased this percentage. Simvastatin 218-229 sirtuin 1 Homo sapiens 27-32 24718722-9 2014 The results indicated that SIRT1 protein expression was decreased by TNF-alpha in a time- and dose-dependent manner and that while TNF-alpha caused a marked increase in the percentage of apoptotic EPCs, application of simvastatin decreased this percentage. Simvastatin 218-229 tumor necrosis factor Homo sapiens 69-78 24718722-10 2014 A high concentration of simvastatin promoted the expression of SIRT1 and increased the proliferation of EPCs. Simvastatin 24-35 sirtuin 1 Homo sapiens 63-68 24718722-11 2014 In conclusion, findings of this study showed that simvastatin is crucial in counteracting the TNF-alpha-induced apoptosis of EPCs and that this protection may involve the actions of SIRT1. Simvastatin 50-61 tumor necrosis factor Homo sapiens 94-103 25089134-11 2014 The differences in the effect of simvastatin on total cholesterol and LDL-C between the patients with and without ezetimibe showed borderline significance (p=0.10 and p=0.055, respectively). Simvastatin 33-44 component of oligomeric golgi complex 2 Homo sapiens 70-75 24668570-2 2014 Organic anion-transporting polypeptide 1B1 (OATP1B1) encoded by SLCO1B1 gene (solute carrier organic anion transporter family member 1B1) facilitates hepatic uptake of simvastatin and atorvastatin. Simvastatin 168-179 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-42 24668570-2 2014 Organic anion-transporting polypeptide 1B1 (OATP1B1) encoded by SLCO1B1 gene (solute carrier organic anion transporter family member 1B1) facilitates hepatic uptake of simvastatin and atorvastatin. Simvastatin 168-179 solute carrier organic anion transporter family member 1B1 Homo sapiens 44-51 24668570-2 2014 Organic anion-transporting polypeptide 1B1 (OATP1B1) encoded by SLCO1B1 gene (solute carrier organic anion transporter family member 1B1) facilitates hepatic uptake of simvastatin and atorvastatin. Simvastatin 168-179 solute carrier organic anion transporter family member 1B1 Homo sapiens 64-71 24668570-2 2014 Organic anion-transporting polypeptide 1B1 (OATP1B1) encoded by SLCO1B1 gene (solute carrier organic anion transporter family member 1B1) facilitates hepatic uptake of simvastatin and atorvastatin. Simvastatin 168-179 solute carrier organic anion transporter family member 1B1 Homo sapiens 78-136 24668570-4 2014 In the present study, we analyzed the association of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms with response to atorvastatin and simvastatin in 386 adults (201 atorvastatin-treated and 185 simvastatin-treated) with primary hypercholesterolemia, all of Greek origin. Simvastatin 144-155 solute carrier organic anion transporter family member 1B1 Homo sapiens 53-60 24668570-4 2014 In the present study, we analyzed the association of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms with response to atorvastatin and simvastatin in 386 adults (201 atorvastatin-treated and 185 simvastatin-treated) with primary hypercholesterolemia, all of Greek origin. Simvastatin 204-215 solute carrier organic anion transporter family member 1B1 Homo sapiens 53-60 24856644-11 2014 Taken together, the present results confirm that simvastatin inhibition of platelet activation is mediated by PPARgamma-dependent processes, which involves mediating MAPKs signaling, increase of cAMP formation and VASP Ser(157) phosphorylation, inhibition of Akt phosphorylation and intracellular Ca(2+) mobilization. Simvastatin 49-60 peroxisome proliferator activated receptor gamma Homo sapiens 110-119 24856644-11 2014 Taken together, the present results confirm that simvastatin inhibition of platelet activation is mediated by PPARgamma-dependent processes, which involves mediating MAPKs signaling, increase of cAMP formation and VASP Ser(157) phosphorylation, inhibition of Akt phosphorylation and intracellular Ca(2+) mobilization. Simvastatin 49-60 vasodilator stimulated phosphoprotein Homo sapiens 214-218 24242131-7 2014 However, the rabbits in the Wenxiao Decoction groups and the Simvastatin group showed significantly lower levels of IL-6, ICAM-1, and MCP-1 expression than those in the model group (P<0.05). Simvastatin 61-72 interleukin-6 Oryctolagus cuniculus 116-120 24242131-7 2014 However, the rabbits in the Wenxiao Decoction groups and the Simvastatin group showed significantly lower levels of IL-6, ICAM-1, and MCP-1 expression than those in the model group (P<0.05). Simvastatin 61-72 ICAM-1 Oryctolagus cuniculus 122-128 24242131-7 2014 However, the rabbits in the Wenxiao Decoction groups and the Simvastatin group showed significantly lower levels of IL-6, ICAM-1, and MCP-1 expression than those in the model group (P<0.05). Simvastatin 61-72 C-C motif chemokine 2 Oryctolagus cuniculus 134-139 23488690-8 2014 Simvastatin inhibited the contractile responses of isolated aortic rings induced by angiotensin II and enhanced the inhibitory effect of losartan on this preparation. Simvastatin 0-11 angiotensinogen Homo sapiens 84-98 24468885-2 2014 Therefore, we designed a study using simvastatin/cetuximab/irinotecan for KRAS mutant CRC patients who are refractory to irinotecan and oxaliplatin-based chemotherapy. Simvastatin 37-48 KRAS proto-oncogene, GTPase Homo sapiens 74-78 24468885-13 2014 CONCLUSION: The simvastatin/cetuximab/irinotecan regimen showed promising efficacy and safety in KRAS mutant CRC patients who failed irinotecan and oxaliplatin-based chemotherapy. Simvastatin 16-27 KRAS proto-oncogene, GTPase Homo sapiens 97-101 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 24532643-0 2014 Simvastatin attenuates rhinovirus-induced interferon and CXCL10 secretion from monocytic cells in vitro. Simvastatin 0-11 C-X-C motif chemokine ligand 10 Homo sapiens 57-63 24702774-6 2014 The hydroxymethylglutaryl-coenzyme A reductase inhibitor simvastatin abrogated the IL-33-induced increase in u-PA, thus providing further evidence for pleiotropic effects of statins. Simvastatin 57-68 interleukin 33 Homo sapiens 83-88 24702774-6 2014 The hydroxymethylglutaryl-coenzyme A reductase inhibitor simvastatin abrogated the IL-33-induced increase in u-PA, thus providing further evidence for pleiotropic effects of statins. Simvastatin 57-68 plasminogen activator, urokinase Homo sapiens 109-113 24430948-2 2014 The polymorphic enzyme P450 oxidoreductase (POR) transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P450 (CYP) 3A enzymes, which metabolize atorvastatin and simvastatin. Simvastatin 197-208 cytochrome p450 oxidoreductase Homo sapiens 23-42 24430948-2 2014 The polymorphic enzyme P450 oxidoreductase (POR) transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P450 (CYP) 3A enzymes, which metabolize atorvastatin and simvastatin. Simvastatin 197-208 cytochrome p450 oxidoreductase Homo sapiens 44-47 24430948-2 2014 The polymorphic enzyme P450 oxidoreductase (POR) transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P450 (CYP) 3A enzymes, which metabolize atorvastatin and simvastatin. Simvastatin 197-208 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-153 24430948-4 2014 We analyzed the association of the POR*28 allele with response to atorvastatin and simvastatin. Simvastatin 83-94 cytochrome p450 oxidoreductase Homo sapiens 35-38 24932304-0 2014 Enhanced antitumor effects of low-frequency ultrasound and microbubbles in combination with simvastatin by downregulating caveolin-1 in prostatic DU145 cells. Simvastatin 92-103 caveolin 1 Homo sapiens 122-132 24932304-15 2014 The expression of caveolin-1 was lowest in the LFUM combined with simvastatin treatment group. Simvastatin 66-77 caveolin 1 Homo sapiens 18-28 24932304-17 2014 The results indicate that LFUM in combination with simvastatin may additively or synergistically inhibit cell viability and induce apoptosis of DU145 cells by downregulating caveolin-1 and p-Akt protein expression. Simvastatin 51-62 caveolin 1 Homo sapiens 174-184 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Simvastatin 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 83-89 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Simvastatin 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 113-119 24846270-8 2014 Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Simvastatin 80-91 mitogen-activated protein kinase 1 Mus musculus 14-19 24884548-13 2014 Minocycline, chloroquine or simvastatin attenuated upregulation of IL-1beta and iNOS transcripts in different brain regions. Simvastatin 28-39 interleukin 1 beta Homo sapiens 67-75 24291703-3 2014 Simvastatin is known to upregulate expression of BMP-2. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 49-54 24516105-4 2014 In other disease models, Simvastatin (statin) treatment increases endothelial NOS, in part, by increasing Kruppel-like Factor 2 expression. Simvastatin 25-36 nitric oxide synthase 3 Rattus norvegicus 66-81 24375611-0 2014 Simvastatin promotes cardiac microvascular endothelial cells proliferation, migration and survival by phosphorylation of p70 S6K and FoxO3a. Simvastatin 0-11 ribosomal protein S6 kinase B1 Rattus norvegicus 121-128 24375611-0 2014 Simvastatin promotes cardiac microvascular endothelial cells proliferation, migration and survival by phosphorylation of p70 S6K and FoxO3a. Simvastatin 0-11 forkhead box O3 Rattus norvegicus 133-139 24375611-4 2014 This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin. Simvastatin 35-46 AKT serine/threonine kinase 1 Rattus norvegicus 50-53 24375611-4 2014 This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin. Simvastatin 35-46 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 24375611-4 2014 This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin. Simvastatin 35-46 ribosomal protein S6 kinase B1 Rattus norvegicus 59-66 24375611-4 2014 This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin. Simvastatin 35-46 forkhead box O3 Rattus norvegicus 71-77 24375611-7 2014 Western blot assay showed that, after treatment with simvastatin, the phosphorylation of Akt/mTOR/p70 S6K and FoxO3a were up-regulated in rapamycin-induced CMECs, which was significantly reversed by pretreatment with LY294002. Simvastatin 53-64 AKT serine/threonine kinase 1 Rattus norvegicus 89-92 24375611-7 2014 Western blot assay showed that, after treatment with simvastatin, the phosphorylation of Akt/mTOR/p70 S6K and FoxO3a were up-regulated in rapamycin-induced CMECs, which was significantly reversed by pretreatment with LY294002. Simvastatin 53-64 mechanistic target of rapamycin kinase Rattus norvegicus 93-97 24375611-7 2014 Western blot assay showed that, after treatment with simvastatin, the phosphorylation of Akt/mTOR/p70 S6K and FoxO3a were up-regulated in rapamycin-induced CMECs, which was significantly reversed by pretreatment with LY294002. Simvastatin 53-64 ribosomal protein S6 kinase B1 Rattus norvegicus 98-105 24375611-7 2014 Western blot assay showed that, after treatment with simvastatin, the phosphorylation of Akt/mTOR/p70 S6K and FoxO3a were up-regulated in rapamycin-induced CMECs, which was significantly reversed by pretreatment with LY294002. Simvastatin 53-64 forkhead box O3 Rattus norvegicus 110-116 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Simvastatin 22-33 AKT serine/threonine kinase 1 Rattus norvegicus 130-133 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Simvastatin 22-33 mechanistic target of rapamycin kinase Rattus norvegicus 134-138 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Simvastatin 22-33 ribosomal protein S6 kinase B1 Rattus norvegicus 139-146 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Simvastatin 22-33 mechanistic target of rapamycin kinase Rattus norvegicus 151-155 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Simvastatin 22-33 forkhead box O3 Rattus norvegicus 156-162 24855368-7 2014 CONCLUSION: Greater dissociation of apoB, LDL-C, and non-HDL-C targets occur following treatment with ERN/LRPT, SIMVA, and ERN/LRPT + SIMVA in patients with dyslipidemia. Simvastatin 112-117 apolipoprotein B Homo sapiens 36-40 24631288-0 2014 Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Simvastatin 10-21 epidermal growth factor receptor Homo sapiens 43-47 24631288-0 2014 Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Simvastatin 10-21 epidermal growth factor receptor Homo sapiens 134-138 24631288-3 2014 This study investigated overcoming resistance to EGFR-TKI using simvastatin. Simvastatin 64-75 epidermal growth factor receptor Homo sapiens 49-53 24631288-5 2014 Simvastatin also strongly inhibited AKT activation, leading to suppression of beta-catenin activity and the expression of its targets, survivin and cyclin D1. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 36-39 24631288-5 2014 Simvastatin also strongly inhibited AKT activation, leading to suppression of beta-catenin activity and the expression of its targets, survivin and cyclin D1. Simvastatin 0-11 catenin beta 1 Homo sapiens 78-90 24631288-5 2014 Simvastatin also strongly inhibited AKT activation, leading to suppression of beta-catenin activity and the expression of its targets, survivin and cyclin D1. Simvastatin 0-11 cyclin D1 Homo sapiens 148-157 24631288-6 2014 Both insulin treatment and AKT overexpression markedly increased p-beta-catenin and survivin levels, even in the presence of gefitinib and simvastatin. Simvastatin 139-150 AKT serine/threonine kinase 1 Homo sapiens 27-30 24631288-11 2014 Overall, these data indicate that simvastatin may overcome EGFR-TKI resistance in T790M mutant NSCLCs via an AKT/beta-catenin signaling-dependent down-regulation of survivin and apoptosis induction. Simvastatin 34-45 epidermal growth factor receptor Homo sapiens 59-63 24631288-11 2014 Overall, these data indicate that simvastatin may overcome EGFR-TKI resistance in T790M mutant NSCLCs via an AKT/beta-catenin signaling-dependent down-regulation of survivin and apoptosis induction. Simvastatin 34-45 AKT serine/threonine kinase 1 Homo sapiens 109-112 24631288-11 2014 Overall, these data indicate that simvastatin may overcome EGFR-TKI resistance in T790M mutant NSCLCs via an AKT/beta-catenin signaling-dependent down-regulation of survivin and apoptosis induction. Simvastatin 34-45 catenin beta 1 Homo sapiens 113-125 23934055-6 2014 Simvastatin-treated femurs contained fewer adipocytes and a higher Runx2 expression. Simvastatin 0-11 RUNX family transcription factor 2 Rattus norvegicus 67-72 23934055-9 2014 Simvastatin induces Runx2 expression, which may function to induce osteogenesis and inhibit adipogenesis as an underlying mechanism to augment bone mass. Simvastatin 0-11 RUNX family transcription factor 2 Rattus norvegicus 20-25 24998652-5 2014 Compared with ApoE-/- group, simvastatin significantly decreased atherosclerotic lesion area in aortic root (89 818.05+-16 980.93 mum2 vs 34 937.01+-13 280.65 mum2, P<0.05). Simvastatin 29-40 apolipoprotein E Mus musculus 14-18 24482148-0 2014 Simvastatin prevents neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. Simvastatin 0-11 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 53-88 24482148-9 2014 The 6-OHDA-stimulated mRNA and protein levels of the proinflammatory cytokines NMDAR1, TNF-alpha, IL-1beta, and IL-6 were reduced by simvastatin. Simvastatin 133-144 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 79-85 24482148-9 2014 The 6-OHDA-stimulated mRNA and protein levels of the proinflammatory cytokines NMDAR1, TNF-alpha, IL-1beta, and IL-6 were reduced by simvastatin. Simvastatin 133-144 tumor necrosis factor Rattus norvegicus 87-96 24482148-9 2014 The 6-OHDA-stimulated mRNA and protein levels of the proinflammatory cytokines NMDAR1, TNF-alpha, IL-1beta, and IL-6 were reduced by simvastatin. Simvastatin 133-144 interleukin 1 beta Rattus norvegicus 98-106 24482148-9 2014 The 6-OHDA-stimulated mRNA and protein levels of the proinflammatory cytokines NMDAR1, TNF-alpha, IL-1beta, and IL-6 were reduced by simvastatin. Simvastatin 133-144 interleukin 6 Rattus norvegicus 112-116 24482148-11 2014 Simvastatin could also inhibit the expression of NMDAR1 and cytokines to a degree similar to silencing of NMDAR1 with siRNA. Simvastatin 0-11 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 49-55 24482148-12 2014 Our results suggest that NMDAR1 modulation could explain the anti-inflammatory mechanisms of simvastatin in experimental parkinsonian cell models. Simvastatin 93-104 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 25-31 24851101-0 2014 The Nuclear Orphan Receptor NR4A1 is Involved in the Apoptotic Pathway Induced by LPS and Simvastatin in RAW 264.7 Macrophages. Simvastatin 90-101 nuclear receptor subfamily 4, group A, member 1 Mus musculus 28-33 24998652-12 2014 CONCLUSION: Simvastatin can attenuate atherosclerosis of aorta in ApoE-/- mice, which is associated with the reduced central aortic systolic pressure but not with the serum lipids levels. Simvastatin 12-23 apolipoprotein E Mus musculus 66-70 24354929-5 2014 RESULTS: Apart from improving lipid profile, simvastatin administered alone or in combination with ezetimibe, decreased plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 45-56 leptin Homo sapiens 149-155 24354929-5 2014 RESULTS: Apart from improving lipid profile, simvastatin administered alone or in combination with ezetimibe, decreased plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 45-56 nicotinamide phosphoribosyltransferase Homo sapiens 157-165 24354929-5 2014 RESULTS: Apart from improving lipid profile, simvastatin administered alone or in combination with ezetimibe, decreased plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 45-56 tumor necrosis factor Homo sapiens 171-180 24354929-5 2014 RESULTS: Apart from improving lipid profile, simvastatin administered alone or in combination with ezetimibe, decreased plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 45-56 adiponectin, C1Q and collagen domain containing Homo sapiens 220-231 24354929-8 2014 CONCLUSIONS: The obtained results suggest that insulin-resistant patients with hypercholesterolemia and high cardiovascular risk may benefit the most from the combined treatment with simvastatin and ezetimibe. Simvastatin 183-194 insulin Homo sapiens 47-54 24595005-10 2014 TEM was reduced by SIM treatment of PC3-GFP and DU-145, which inhibited Rho pathway signalling. Simvastatin 19-22 proprotein convertase subtilisin/kexin type 1 Homo sapiens 36-39 24851101-3 2014 Here, we show that the nuclear orphan receptor NR4A1 is involved in a caspase-independent apoptotic process induced by LPS and simvastatin. Simvastatin 127-138 nuclear receptor subfamily 4, group A, member 1 Mus musculus 47-52 24851101-4 2014 Simvastatin-induced NR4A1 expression in RAW 264.7 macrophages and ectopic expression of a dominant-negative mutant form of NR4A1 effectively suppressed both DNA fragmentation and the disruption of mitochondrial membrane potential (MMP) during LPS- and simvastatin-induced apoptosis. Simvastatin 0-11 nuclear receptor subfamily 4, group A, member 1 Mus musculus 20-25 24851101-4 2014 Simvastatin-induced NR4A1 expression in RAW 264.7 macrophages and ectopic expression of a dominant-negative mutant form of NR4A1 effectively suppressed both DNA fragmentation and the disruption of mitochondrial membrane potential (MMP) during LPS- and simvastatin-induced apoptosis. Simvastatin 0-11 nuclear receptor subfamily 4, group A, member 1 Mus musculus 123-128 24419251-5 2014 RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). Simvastatin 99-110 interleukin 17A Homo sapiens 13-19 24851101-4 2014 Simvastatin-induced NR4A1 expression in RAW 264.7 macrophages and ectopic expression of a dominant-negative mutant form of NR4A1 effectively suppressed both DNA fragmentation and the disruption of mitochondrial membrane potential (MMP) during LPS- and simvastatin-induced apoptosis. Simvastatin 252-263 nuclear receptor subfamily 4, group A, member 1 Mus musculus 123-128 24419251-5 2014 RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). Simvastatin 99-110 interleukin 6 Homo sapiens 21-25 24851101-6 2014 Our findings suggest that NR4A1 expression and mitochondrial translocation of Bax are related to simvastatin-induced apoptosis in LPS-activated RAW 264.7 macrophages. Simvastatin 97-108 nuclear receptor subfamily 4, group A, member 1 Mus musculus 26-31 24851101-6 2014 Our findings suggest that NR4A1 expression and mitochondrial translocation of Bax are related to simvastatin-induced apoptosis in LPS-activated RAW 264.7 macrophages. Simvastatin 97-108 BCL2-associated X protein Mus musculus 78-81 24419251-5 2014 RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). Simvastatin 99-110 interleukin 22 Homo sapiens 27-32 24449418-9 2014 Consistently, activation of RhoA, a representative isoprenylated protein, was disrupted by simvastatin in VSMCs and RhoA-mediated phosphorylation of MYPT1 and CPI-17, and tonic tension were also suppressed. Simvastatin 91-102 ras homolog family member A Rattus norvegicus 28-32 24419251-5 2014 RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). Simvastatin 99-110 interferon gamma Homo sapiens 37-46 24419251-5 2014 RESULTS: The IL-17A, IL-6, IL-22 and IFN-gamma were significantly reduced in a dose response after simvastatin treatment (50 muM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). Simvastatin 99-110 latexin Homo sapiens 125-128 24419251-6 2014 The IL-17A and IL-6 cytokines were also significantly reduced in lower concentrations of simvastatin (10 muM) compared to controls (p = 0.018; p = 0.04) and compared to the standard drug (p = 0.007; p = 0.0001). Simvastatin 89-100 interleukin 17A Homo sapiens 4-10 24419251-6 2014 The IL-17A and IL-6 cytokines were also significantly reduced in lower concentrations of simvastatin (10 muM) compared to controls (p = 0.018; p = 0.04) and compared to the standard drug (p = 0.007; p = 0.0001). Simvastatin 89-100 interleukin 6 Homo sapiens 15-19 24419251-6 2014 The IL-17A and IL-6 cytokines were also significantly reduced in lower concentrations of simvastatin (10 muM) compared to controls (p = 0.018; p = 0.04) and compared to the standard drug (p = 0.007; p = 0.0001). Simvastatin 89-100 latexin Homo sapiens 105-108 24419251-7 2014 The results also showed that only RA patients with severe disease (DAS28 >5.1 and CDAI >22) had poor response to simvastatin in reducing cytokines levels, mainly for IL-17A and IL-22 cytokines (p = 0.03; p = 0.039, respectively). Simvastatin 119-130 interleukin 17A Homo sapiens 172-178 24419251-7 2014 The results also showed that only RA patients with severe disease (DAS28 >5.1 and CDAI >22) had poor response to simvastatin in reducing cytokines levels, mainly for IL-17A and IL-22 cytokines (p = 0.03; p = 0.039, respectively). Simvastatin 119-130 interleukin 22 Homo sapiens 183-188 24016468-5 2014 In addition, we investigated the effect of simvastatin on TF expression and coagulation. Simvastatin 43-54 coagulation factor III, tissue factor Homo sapiens 58-60 24016468-6 2014 We found that simvastatin reduced leukocyte TF expression, TF+ microparticles, and coagulation. Simvastatin 14-25 coagulation factor III, tissue factor Homo sapiens 44-46 24016468-6 2014 We found that simvastatin reduced leukocyte TF expression, TF+ microparticles, and coagulation. Simvastatin 14-25 coagulation factor III, tissue factor Homo sapiens 59-61 24449418-9 2014 Consistently, activation of RhoA, a representative isoprenylated protein, was disrupted by simvastatin in VSMCs and RhoA-mediated phosphorylation of MYPT1 and CPI-17, and tonic tension were also suppressed. Simvastatin 91-102 protein phosphatase 1, regulatory subunit 12A Rattus norvegicus 149-154 24449418-9 2014 Consistently, activation of RhoA, a representative isoprenylated protein, was disrupted by simvastatin in VSMCs and RhoA-mediated phosphorylation of MYPT1 and CPI-17, and tonic tension were also suppressed. Simvastatin 91-102 protein phosphatase 1, regulatory (inhibitor) subunit 14A Rattus norvegicus 159-165 24449418-12 2014 Collectively, these results demonstrate that simvastatin can impair the normal vascular contractility by disturbing Ca2+ influx and RhoA activity, ultimately leading to apoptosis and structural remodeling. Simvastatin 45-56 ras homolog family member A Rattus norvegicus 132-136 24666612-11 2014 HMGCR activity was significantly decreased up to 50% and 70% at 50 muM and 75 muM of Simvastatin respectively compared to the vehicle control in C4-2 cells. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-5 24684779-7 2014 RESULTS: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin 9-20 interleukin 6 Homo sapiens 50-63 24684779-7 2014 RESULTS: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin 9-20 leptin Homo sapiens 65-71 24684779-7 2014 RESULTS: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin 9-20 C-C motif chemokine ligand 2 Homo sapiens 86-120 24684779-7 2014 RESULTS: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 224-250 24684779-8 2014 Simvastatin + pioglitazone treatment further reduced plasmatic variables, including interleukin-6, tumoral necrose factor-alpha, resistin, asymmetric dimethylarginine and metalloproteinase-9 vs. the control group (p < 0.001). Simvastatin 0-11 interleukin 6 Homo sapiens 84-97 25563221-2 2014 The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin. Simvastatin 114-125 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 29805875-2 2013 Individuals, who carry the T allele at each SNP (i.e., the T-T-T haplotype), have higher systemic exposure to simvastatin.A triallelic thymine (T) - guanine (G) - adenine (A), which is a point mutation at nucleotide 2677 in exon 22, leads to ABCB1 in a non-synonymous codons (GCT alanine, TCT serine, threonine ACT) at position 893 in a cytoplasmic loop of ATP-dependent membrane transporters. Simvastatin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 242-247 24582560-6 2014 RESULTS: We found that simvastatin dose-dependently decreased CCL17-induced colon cancer cell migration. Simvastatin 23-34 C-C motif chemokine ligand 17 Homo sapiens 62-67 24582560-9 2014 Moreover, administration of mevalonate reversed the inhibitory effect of simvastatin on CCL17-induced colon cancer cell migration. Simvastatin 73-84 C-C motif chemokine ligand 17 Homo sapiens 88-93 24582560-10 2014 Interestingly, co-incubation with geranylgeranyl pyrophosphate (GGPP) antagonized the inhibitory impact of simvastatin on colon cancer cell migration triggered by CCL17. Simvastatin 107-118 C-C motif chemokine ligand 17 Homo sapiens 163-168 24582560-11 2014 Moreover, we observed that simvastatin decreased CCL17-induced activation of RhoA in colon cancer cells. Simvastatin 27-38 C-C motif chemokine ligand 17 Homo sapiens 49-54 24582560-11 2014 Moreover, we observed that simvastatin decreased CCL17-induced activation of RhoA in colon cancer cells. Simvastatin 27-38 ras homolog family member A Homo sapiens 77-81 24582560-12 2014 Administration of mevalonate and GGPP reversed the inhibitory effect of simvastatin on CCL17-provoked RhoA activation in colon cancer cells. Simvastatin 72-83 C-C motif chemokine ligand 17 Homo sapiens 87-92 24582560-12 2014 Administration of mevalonate and GGPP reversed the inhibitory effect of simvastatin on CCL17-provoked RhoA activation in colon cancer cells. Simvastatin 72-83 ras homolog family member A Homo sapiens 102-106 24582560-14 2014 Thus, statins, such as simvastatin, might be effective tools to antagonize CCL17-dependent migration and metastasis of colon cancer cells. Simvastatin 23-34 C-C motif chemokine ligand 17 Homo sapiens 75-80 24666612-15 2014 CONCLUSION: The inhibition of HMGCR via Simvastatin lowered the viability of castration-resistant C4-2 cells. Simvastatin 40-51 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-35 24662777-12 2014 Part of these differential effects may be due to the stronger LDL-C-lowering effects of simvastatin. Simvastatin 88-99 component of oligomeric golgi complex 2 Homo sapiens 62-67 24307429-2 2014 Our aim was to investigate whether simvastatin treatment affects serum levels of vascular calcification inhibitors, such as fetuin-A, osteoprotegerin (OPG) and osteopontin (OPN), in patients with coronary artery disease (CAD). Simvastatin 35-46 alpha 2-HS glycoprotein Homo sapiens 124-132 24658119-6 2014 Co-immunoprecipitation and electrophoretic mobility shift assay (EMSA) results showed that simvastatin prevented the 3MC-increased binding activities of E2F1 proteins in their promoter regions. Simvastatin 91-102 E2F transcription factor 1 Homo sapiens 153-157 24629144-0 2014 Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 45-58 24629144-2 2014 Aim of the study is to investigate the production of IL-8 by PMN leukocytes from dyslipidemic patients treated with simvastatin. Simvastatin 116-127 C-X-C motif chemokine ligand 8 Homo sapiens 53-57 24629144-6 2014 Moreover, the fMLP-induced IL-8 production in dyslipidemic untreated patients was higher than that of controls (p < 0.05) and was reduced after simvastatin treatment (p < 0.01). Simvastatin 147-158 formyl peptide receptor 1 Homo sapiens 14-18 24629144-6 2014 Moreover, the fMLP-induced IL-8 production in dyslipidemic untreated patients was higher than that of controls (p < 0.05) and was reduced after simvastatin treatment (p < 0.01). Simvastatin 147-158 C-X-C motif chemokine ligand 8 Homo sapiens 27-31 24629144-8 2014 CONCLUSIONS: Prolonged treatment with simvastatin is associated with a reduction of IL-8 production, suggesting the possibility of statin to modulate the pro-inflammatory response in PMNs of patients with moderately increased cardiovascular risk. Simvastatin 38-49 C-X-C motif chemokine ligand 8 Homo sapiens 84-88 22964779-5 2014 After simvastatin therapy, arterial endothelial cell aging was significantly reduced, and SIRT1 expression was significantly increased. Simvastatin 6-17 sirtuin 1 Homo sapiens 90-95 22964779-7 2014 The OX-LDL-induced downregulation of SIRT1 was blocked by simvastatin. Simvastatin 58-69 sirtuin 1 Homo sapiens 37-42 22964779-8 2014 Simvastatin treatment also reduced umbilical vein endothelial cell aging and increased SIRT1 expression. Simvastatin 0-11 sirtuin 1 Homo sapiens 87-92 24370551-7 2014 Finally, oral administration of simvastatin or the antioxidant apocynin reduced aneurysm formation in Nf1(+/-) mice. Simvastatin 32-43 neurofibromin 1 Mus musculus 102-105 24307429-2 2014 Our aim was to investigate whether simvastatin treatment affects serum levels of vascular calcification inhibitors, such as fetuin-A, osteoprotegerin (OPG) and osteopontin (OPN), in patients with coronary artery disease (CAD). Simvastatin 35-46 secreted phosphoprotein 1 Homo sapiens 173-176 24307429-7 2014 Apart from significantly reducing plasma total cholesterol and LDL, simvastatin also reduced serum levels of fetuin-A (by ~62.6 %), OPG (by ~47.2 %), OPN (by ~44.6 %) and hsCRP (by ~45.3 %) (p < 0.05) in SG patients. Simvastatin 68-79 alpha 2-HS glycoprotein Homo sapiens 109-117 24307429-7 2014 Apart from significantly reducing plasma total cholesterol and LDL, simvastatin also reduced serum levels of fetuin-A (by ~62.6 %), OPG (by ~47.2 %), OPN (by ~44.6 %) and hsCRP (by ~45.3 %) (p < 0.05) in SG patients. Simvastatin 68-79 TNF receptor superfamily member 11b Homo sapiens 132-135 24307429-7 2014 Apart from significantly reducing plasma total cholesterol and LDL, simvastatin also reduced serum levels of fetuin-A (by ~62.6 %), OPG (by ~47.2 %), OPN (by ~44.6 %) and hsCRP (by ~45.3 %) (p < 0.05) in SG patients. Simvastatin 68-79 secreted phosphoprotein 1 Homo sapiens 150-153 24307429-8 2014 In standard multiple regression analysis, the simvastatin-induced reduction in fetuin-A was independently associated with changes in total cholesterol (beta = -0.289, p = 0.048) and LDL (beta = -0.302, p = 0.032) (R (2) = 0.305, p = 0.040). Simvastatin 46-57 alpha 2-HS glycoprotein Homo sapiens 79-87 24307429-10 2014 Simvastatin treatment for 6 months significantly decreased serum fetuin-A, OPG and OPN levels, but the clinical relevance of this requires further investigation. Simvastatin 0-11 alpha 2-HS glycoprotein Homo sapiens 65-73 24322971-6 2014 There is an increased risk of simvastatin-induced muscle toxicity in SLCO1B1*5 carriers, ADRB1 and ADRA2C polymorphisms are associated with differential response to bucindolol, and rare congenital arrhythmia gene variants have been identified in drug-induced torsade de pointes. Simvastatin 30-41 solute carrier organic anion transporter family member 1B1 Homo sapiens 69-76 24307429-10 2014 Simvastatin treatment for 6 months significantly decreased serum fetuin-A, OPG and OPN levels, but the clinical relevance of this requires further investigation. Simvastatin 0-11 TNF receptor superfamily member 11b Homo sapiens 75-78 24322971-6 2014 There is an increased risk of simvastatin-induced muscle toxicity in SLCO1B1*5 carriers, ADRB1 and ADRA2C polymorphisms are associated with differential response to bucindolol, and rare congenital arrhythmia gene variants have been identified in drug-induced torsade de pointes. Simvastatin 30-41 adrenoceptor beta 1 Homo sapiens 89-94 24307429-10 2014 Simvastatin treatment for 6 months significantly decreased serum fetuin-A, OPG and OPN levels, but the clinical relevance of this requires further investigation. Simvastatin 0-11 secreted phosphoprotein 1 Homo sapiens 83-86 24233024-4 2014 The effect of simvastatin on the proliferation of gastric cancer cells was examined by mitochondrial dye-uptake 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method, apoptosis by esterase staining, NF-kappaB activation by DNA binding assay, and protein expression by western blot analysis. Simvastatin 14-25 nuclear factor kappa B subunit 1 Homo sapiens 213-222 24322971-6 2014 There is an increased risk of simvastatin-induced muscle toxicity in SLCO1B1*5 carriers, ADRB1 and ADRA2C polymorphisms are associated with differential response to bucindolol, and rare congenital arrhythmia gene variants have been identified in drug-induced torsade de pointes. Simvastatin 30-41 adrenoceptor alpha 2C Homo sapiens 99-105 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 156-165 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Homo sapiens 199-215 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Homo sapiens 217-222 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 cyclin D1 Homo sapiens 225-234 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 236-241 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 253-284 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 nuclear factor kappa B subunit 1 Homo sapiens 82-91 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 cyclin D1 Homo sapiens 124-133 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 prostaglandin-endoperoxide synthase 2 Homo sapiens 135-140 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 intercellular adhesion molecule 1 Homo sapiens 142-148 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 matrix metallopeptidase 9 Homo sapiens 150-155 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 BCL2 like 1 Homo sapiens 167-173 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 X-linked inhibitor of apoptosis Homo sapiens 179-183 24233024-9 2014 Overall, our results demonstrate that simvastatin can enhance the effects of capecitabine through suppression of NF-kappaB-regulated markers of proliferation, invasion, angiogenesis, and metastasis. Simvastatin 38-49 nuclear factor kappa B subunit 1 Homo sapiens 113-122 24403518-2 2014 The pharmacokinetics of SIM hydroxy acid (SIMA), the bioactive form of SIM, and the occurrence of SIM-induced myopathy are linked to the function of the organic anion transporting polypeptide (Oatp) hepatic uptake transporters. Simvastatin 24-27 solute carrier organic anion transporter family member 1A2 Homo sapiens 153-191 24403518-2 2014 The pharmacokinetics of SIM hydroxy acid (SIMA), the bioactive form of SIM, and the occurrence of SIM-induced myopathy are linked to the function of the organic anion transporting polypeptide (Oatp) hepatic uptake transporters. Simvastatin 24-27 solute carrier organic anion transporter family member 1A2 Homo sapiens 193-197 24403518-2 2014 The pharmacokinetics of SIM hydroxy acid (SIMA), the bioactive form of SIM, and the occurrence of SIM-induced myopathy are linked to the function of the organic anion transporting polypeptide (Oatp) hepatic uptake transporters. Simvastatin 42-45 solute carrier organic anion transporter family member 1A2 Homo sapiens 153-191 24524197-2 2014 Previously, our group has demonstrated that simvastatin, competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), a rate-limiting step of the mevalonate pathway, reduces rat-theca interstitial cell steroidogenesis by inhibiting Cyp17a1 gene expression, the key enzyme of the androgen biosynthesis pathway. Simvastatin 44-55 cytochrome P450, family 17, subfamily a, polypeptide 1 Rattus norvegicus 259-266 24403518-2 2014 The pharmacokinetics of SIM hydroxy acid (SIMA), the bioactive form of SIM, and the occurrence of SIM-induced myopathy are linked to the function of the organic anion transporting polypeptide (Oatp) hepatic uptake transporters. Simvastatin 42-45 solute carrier organic anion transporter family member 1A2 Homo sapiens 193-197 24388572-9 2014 Simvastatin treatment significantly decreased RAGEs expression in ECs from diabetic patients and determined a slight increase in PPAR-gamma expression but the latter failed to reach statistical significance. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Homo sapiens 129-139 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 transforming growth factor, beta 1 Rattus norvegicus 195-203 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 fibroblast growth factor 2 Rattus norvegicus 206-236 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 fibroblast growth factor 2 Rattus norvegicus 238-242 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 platelet derived growth factor subunit B Rattus norvegicus 245-277 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 platelet derived growth factor subunit B Rattus norvegicus 279-285 24083846-2 2014 The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFkappaB), transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). Simvastatin 60-71 fibronectin 1 Rattus norvegicus 288-299 24524197-9 2014 This suppressive effect correlated with profound inhibition in Cyp17a1 mRNA expression in the presence of a combination of resveratrol and simvastatin. Simvastatin 139-150 cytochrome P450, family 17, subfamily a, polypeptide 1 Rattus norvegicus 63-70 24653785-0 2014 Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. Simvastatin 50-61 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 10-16 24653785-2 2014 Therefore, we evaluated the impact of CYP3A5 gene polymorphism on the effectiveness of simvastatin (a HMG-CoA reductase inhibitor). Simvastatin 87-98 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 38-44 24028293-0 2014 Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin. Simvastatin 68-79 claudin 5 Mus musculus 8-17 24028293-3 2014 Western blotting of human pulmonary artery ECs treated with simvastatin (5 muM) confirmed a significant time-dependent increase (16-48 h) in claudin-5 protein expression compared with controls, without detectable alterations in zonula occludens-1 or occludin. Simvastatin 60-71 latexin Homo sapiens 75-78 24028293-3 2014 Western blotting of human pulmonary artery ECs treated with simvastatin (5 muM) confirmed a significant time-dependent increase (16-48 h) in claudin-5 protein expression compared with controls, without detectable alterations in zonula occludens-1 or occludin. Simvastatin 60-71 claudin 5 Homo sapiens 141-150 24028293-3 2014 Western blotting of human pulmonary artery ECs treated with simvastatin (5 muM) confirmed a significant time-dependent increase (16-48 h) in claudin-5 protein expression compared with controls, without detectable alterations in zonula occludens-1 or occludin. Simvastatin 60-71 occludin Homo sapiens 250-258 24028293-4 2014 These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Simvastatin 168-179 cadherin 5 Mus musculus 61-72 24028293-4 2014 These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Simvastatin 168-179 cadherin 5 Mus musculus 99-128 24028293-4 2014 These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Simvastatin 168-179 cadherin 5 Mus musculus 130-141 24028293-4 2014 These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Simvastatin 168-179 claudin 5 Mus musculus 188-197 24028293-5 2014 Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and beta-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Simvastatin 10-21 forkhead box O1 Mus musculus 81-86 24028293-5 2014 Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and beta-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Simvastatin 10-21 catenin (cadherin associated protein), beta 1 Mus musculus 91-103 24028293-5 2014 Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and beta-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Simvastatin 10-21 claudin 5 Mus musculus 135-144 24028293-5 2014 Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and beta-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Simvastatin 10-21 cadherin 5 Mus musculus 168-179 24028293-7 2014 However, silencing of claudin-5 did significantly attenuate simvastatin-mediated EC barrier protection in response to thrombin, as measured by monolayer flux of sodium fluorescein (376 Da). Simvastatin 60-71 claudin 5 Mus musculus 22-31 24028293-7 2014 However, silencing of claudin-5 did significantly attenuate simvastatin-mediated EC barrier protection in response to thrombin, as measured by monolayer flux of sodium fluorescein (376 Da). Simvastatin 60-71 coagulation factor II Mus musculus 118-126 24372369-9 2014 Simvastatin significantly reduced serum level of CRP and exudates levels of TNF-alpha, IL-6 and MDA as well as significantly elevated exudates level of NO and IL-4. Simvastatin 0-11 C-reactive protein Rattus norvegicus 49-52 24156754-1 2014 PURPOSE: To investigate the distribution of statin therapy correlated gene polymorphism allele CYP2D6*10 (C188T) in Ningxia Hui nationality and to discuss the relationship between the gene polymorphism allele CYP2D6*10 (C188T) and the lipid-lowering efficacy of simvastatin and hyperlipidemia. Simvastatin 262-273 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 209-215 24372369-9 2014 Simvastatin significantly reduced serum level of CRP and exudates levels of TNF-alpha, IL-6 and MDA as well as significantly elevated exudates level of NO and IL-4. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 76-85 24372369-9 2014 Simvastatin significantly reduced serum level of CRP and exudates levels of TNF-alpha, IL-6 and MDA as well as significantly elevated exudates level of NO and IL-4. Simvastatin 0-11 interleukin 6 Rattus norvegicus 87-91 24372369-9 2014 Simvastatin significantly reduced serum level of CRP and exudates levels of TNF-alpha, IL-6 and MDA as well as significantly elevated exudates level of NO and IL-4. Simvastatin 0-11 interleukin 4 Rattus norvegicus 159-163 24372369-12 2014 The anti-inflammatory effects of simvastatin are comparable to aspirin and their combination may produce better effects especially in the attenuation of the oxidative stress and IL-6. Simvastatin 33-44 interleukin 6 Rattus norvegicus 178-182 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 hyaluronan mediated motility receptor Homo sapiens 18-23 24489959-0 2014 Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells. Simvastatin 0-11 gonadotropin releasing hormone receptor Rattus norvegicus 20-34 24489959-9 2014 This effect correlated with a time- and dose-dependent increase of SOCS-3 expression levels in cells treated with simvastatin, a regulatory role that has not been previously described. Simvastatin 114-125 suppressor of cytokine signaling 3 Rattus norvegicus 67-73 24489959-10 2014 Furthermore, the finding that simvastatin is capable of inducing SOCS-3 and CIS genes expression shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma. Simvastatin 30-41 suppressor of cytokine signaling 3 Rattus norvegicus 65-71 24489959-10 2014 Furthermore, the finding that simvastatin is capable of inducing SOCS-3 and CIS genes expression shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma. Simvastatin 30-41 cytokine inducible SH2-containing protein Rattus norvegicus 76-79 24489959-10 2014 Furthermore, the finding that simvastatin is capable of inducing SOCS-3 and CIS genes expression shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma. Simvastatin 194-205 cytokine inducible SH2-containing protein Rattus norvegicus 76-79 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 Yes1 associated transcriptional regulator Homo sapiens 97-119 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 Yes1 associated transcriptional regulator Homo sapiens 121-124 24482817-8 2014 Treatment of B cells with methyl-beta-cyclodextrin (MbetaCD) / simvastatin caused protein rearrangement; however, FRET demonstrated only minimal effect of these chemicals on the association between CD1d and GM1 ganglioside on cell-surface.Likewise, a modest effect was only observed in a co-culture assay between MbetaCD/simvastatin treated C1R-CD1d cells and invariant natural killer T cells on measuring secreted cytokines (IFNgamma and IL4). Simvastatin 63-74 CD1d molecule Homo sapiens 345-349 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 hyaluronan mediated motility receptor Homo sapiens 144-149 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 Yes1 associated transcriptional regulator Homo sapiens 326-329 24367099-5 2014 Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription. Simvastatin 285-296 hyaluronan mediated motility receptor Homo sapiens 144-149 24367099-6 2014 Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization. Simvastatin 122-133 Yes1 associated transcriptional regulator Homo sapiens 44-47 24367099-6 2014 Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization. Simvastatin 122-133 hyaluronan mediated motility receptor Homo sapiens 58-63 24367099-6 2014 Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization. Simvastatin 122-133 hyaluronan mediated motility receptor Homo sapiens 150-155 24367099-6 2014 Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization. Simvastatin 122-133 Yes1 associated transcriptional regulator Homo sapiens 184-187 24367099-7 2014 Further, modulation by mevalonate/simvastatin of YAP-activated RHAMM transcription requires geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, but is largely independent of MST and LATS kinase activity. Simvastatin 34-45 Yes1 associated transcriptional regulator Homo sapiens 49-52 24367099-7 2014 Further, modulation by mevalonate/simvastatin of YAP-activated RHAMM transcription requires geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, but is largely independent of MST and LATS kinase activity. Simvastatin 34-45 hyaluronan mediated motility receptor Homo sapiens 63-68 24367099-8 2014 These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents. Simvastatin 152-163 hyaluronan mediated motility receptor Homo sapiens 96-101 24367099-8 2014 These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents. Simvastatin 314-325 hyaluronan mediated motility receptor Homo sapiens 96-101 23817506-11 2014 Simvastatin resulted in a significant decrease in plasma MCP-1 on day 3 and reduced exhaled breath condensate acidification. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 57-62 24392131-0 2014 Systemic simvastatin rescues retinal ganglion cells from optic nerve injury possibly through suppression of astroglial NF-kappaB activation. Simvastatin 9-20 nuclear factor kappa B subunit 1 Homo sapiens 119-128 24392131-13 2014 Simvastatin (1.0 microM) significantly reduced the TNF-alpha-induced NF-kappaB activation in cultured optic nerve astrocytes. Simvastatin 0-11 tumor necrosis factor Homo sapiens 51-60 24392131-13 2014 Simvastatin (1.0 microM) significantly reduced the TNF-alpha-induced NF-kappaB activation in cultured optic nerve astrocytes. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 69-78 24392131-14 2014 We conclude that systemic simvastatin can reduce the death of RGCs induced by crushing the optic nerve possibly by suppressing astroglial NF-kappaB activation. Simvastatin 26-37 nuclear factor kappa B subunit 1 Homo sapiens 138-147 25571290-1 2014 BACKGROUND: Simvastatin is a HMG-CoA reductase Inhibitor and a substrate of CYP3A4. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-82 25571292-4 2014 Simvastatin, a commonly used HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia is extensively metabolized by CYP3A4. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-135 25571293-1 2014 BACKGROUND: Simvastatin, a commonly used HMG-CoA reductase inhibitor, is extensively metabolized by CYP3A4. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 25571293-2 2014 Therefore, co-administration of simvastatin and CYP3A4 inhibitor can affect simvastatin pharmacokinetics. Simvastatin 76-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 48-54 32288932-0 2014 Simvastatin attenuates the lipopolysaccharideinduced inflammatory response of rat pulmonary microvascular endothelial cells by downregulating toll-like receptor 4 expression. Simvastatin 0-11 toll-like receptor 4 Rattus norvegicus 142-162 32288932-6 2014 Simvastatin inhibited LPS-induced TLR4 expression at the mRNA and protein levels in a time-dependent manner (p<0.01), and alleviated inflammation in RPMVECs by inhibiting the release of inflammatory factors such as TNF-alpha and iNOS. Simvastatin 0-11 toll-like receptor 4 Rattus norvegicus 34-38 32288932-6 2014 Simvastatin inhibited LPS-induced TLR4 expression at the mRNA and protein levels in a time-dependent manner (p<0.01), and alleviated inflammation in RPMVECs by inhibiting the release of inflammatory factors such as TNF-alpha and iNOS. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 215-224 32288932-6 2014 Simvastatin inhibited LPS-induced TLR4 expression at the mRNA and protein levels in a time-dependent manner (p<0.01), and alleviated inflammation in RPMVECs by inhibiting the release of inflammatory factors such as TNF-alpha and iNOS. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 229-233 32288932-7 2014 Further study indicated that simvastatin significantly attenuated NF-kappaB activity by inhibiting the degradation of IkappaB-alpha. Simvastatin 29-40 NFKB inhibitor alpha Rattus norvegicus 118-131 32288932-9 2014 Conclusion: Simvastatin inhibits the LPS-induced inflammatory response in RPMVECs by down-regulating TLR4 expression, suggesting its role as a potential inhibitor of LPS-induced inflammation. Simvastatin 12-23 toll-like receptor 4 Rattus norvegicus 101-105 23965645-5 2014 When CYP3A4/5 polymorphisms were assessed by a mixture model, extensive metabolizers yielded a decrease in simvastatin bioavailability of 81% and a decrease in simvastatin clearance by 4.6 times as compared to poor metabolizers. Simvastatin 107-118 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 5-11 24438607-0 2014 Effect of simvastatin on the expression of farnesoid X receptor in diabetic animal models of altered glucose homeostasis. Simvastatin 10-21 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 43-63 24438607-11 2014 The late simvastatin induced diabetic rats displayed higher glucose and TBA and lower expression of FXR compared with diabetic model rats (P < 0.05). Simvastatin 9-20 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 100-103 23965645-5 2014 When CYP3A4/5 polymorphisms were assessed by a mixture model, extensive metabolizers yielded a decrease in simvastatin bioavailability of 81% and a decrease in simvastatin clearance by 4.6 times as compared to poor metabolizers. Simvastatin 160-171 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 5-11 24325778-10 2014 CONCLUSION: Simvastatin and bezafibrate increase cholesterol efflux, parallel to HDL cholesterol and apoA-I responses. Simvastatin 12-23 apolipoprotein A1 Homo sapiens 101-107 25185849-6 2014 Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 18-29 leptin Homo sapiens 81-87 25185849-6 2014 Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 18-29 nicotinamide phosphoribosyltransferase Homo sapiens 89-97 25185849-6 2014 Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 18-29 tumor necrosis factor Homo sapiens 99-108 25185849-6 2014 Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 18-29 adiponectin, C1Q and collagen domain containing Homo sapiens 148-159 25289390-11 2014 Additionally, in primary rat hepatocytes treated with cholesterol and 25-hydroxycholesterol or simvastatin, ACMSD gene and protein expression was subjected to sterol-dependent regulation. Simvastatin 95-106 aminocarboxymuconate semialdehyde decarboxylase Rattus norvegicus 108-113 24528691-0 2014 Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 116-121 24135266-0 2014 Simvastatin reduces CCL2 expression in monocyte-derived cells by induction of a repressive CCL2 chromatin state. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 20-24 24135266-0 2014 Simvastatin reduces CCL2 expression in monocyte-derived cells by induction of a repressive CCL2 chromatin state. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 91-95 24135266-5 2014 In this study, we found that simvastatin reduces secretion and gene expression of CCL2 in monocyte-derived immature dendritic cells and in type 1 macrophages, which is accompanied by increased levels of the 3meK27H3 and 3meK9H3 repressive histone marks and decreased levels of the permissive histone marks AcH3 and 3meK4H3 in CCL2 promoter chromatin. Simvastatin 29-40 C-C motif chemokine ligand 2 Homo sapiens 82-86 24135266-5 2014 In this study, we found that simvastatin reduces secretion and gene expression of CCL2 in monocyte-derived immature dendritic cells and in type 1 macrophages, which is accompanied by increased levels of the 3meK27H3 and 3meK9H3 repressive histone marks and decreased levels of the permissive histone marks AcH3 and 3meK4H3 in CCL2 promoter chromatin. Simvastatin 29-40 C-C motif chemokine ligand 2 Homo sapiens 326-330 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Simvastatin 145-156 component of oligomeric golgi complex 2 Homo sapiens 0-5 24528691-7 2014 LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). Simvastatin 145-156 component of oligomeric golgi complex 2 Homo sapiens 48-53 24379677-11 2014 The interaction with simvastatin seems mainly driven by CYP3A4 inhibition at the intestinal level, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition. Simvastatin 21-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 24995341-8 2014 Compared with control group, the mRNA and protein expression of Kir6.2 increased with treatment of simvastatin (P < 0.05), and mRNA and protein expression of Cav1.2 and GLUT2 decreased in response to simvastatin (P < 0.05). Simvastatin 99-110 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 64-70 24995341-8 2014 Compared with control group, the mRNA and protein expression of Kir6.2 increased with treatment of simvastatin (P < 0.05), and mRNA and protein expression of Cav1.2 and GLUT2 decreased in response to simvastatin (P < 0.05). Simvastatin 203-214 potassium inwardly rectifying channel, subfamily J, member 11 Mus musculus 64-70 24995341-8 2014 Compared with control group, the mRNA and protein expression of Kir6.2 increased with treatment of simvastatin (P < 0.05), and mRNA and protein expression of Cav1.2 and GLUT2 decreased in response to simvastatin (P < 0.05). Simvastatin 203-214 calcium channel, voltage-dependent, L type, alpha 1C subunit Mus musculus 161-167 24995341-8 2014 Compared with control group, the mRNA and protein expression of Kir6.2 increased with treatment of simvastatin (P < 0.05), and mRNA and protein expression of Cav1.2 and GLUT2 decreased in response to simvastatin (P < 0.05). Simvastatin 203-214 solute carrier family 2 (facilitated glucose transporter), member 2 Mus musculus 172-177 24263182-1 2014 OBJECTIVE: The SLCO1B1 c.521T>C polymorphism is associated with statin plasma levels and simvastatin-induced adverse drug reactions. Simvastatin 92-103 solute carrier organic anion transporter family member 1B1 Homo sapiens 15-22 24164738-2 2014 Extensive data also indicates that the amyloid beta-protein (Abeta) plays a central role in the disease process, and it has been suggested that the protective effects of simvastatin may be mediated by reducing Abeta production or by counteracting the toxic effects of Abeta. Simvastatin 170-181 amyloid beta (A4) precursor protein Mus musculus 61-66 24164738-2 2014 Extensive data also indicates that the amyloid beta-protein (Abeta) plays a central role in the disease process, and it has been suggested that the protective effects of simvastatin may be mediated by reducing Abeta production or by counteracting the toxic effects of Abeta. Simvastatin 170-181 amyloid beta (A4) precursor protein Mus musculus 210-215 24164738-2 2014 Extensive data also indicates that the amyloid beta-protein (Abeta) plays a central role in the disease process, and it has been suggested that the protective effects of simvastatin may be mediated by reducing Abeta production or by counteracting the toxic effects of Abeta. Simvastatin 170-181 amyloid beta (A4) precursor protein Mus musculus 210-215 24164738-8 2014 Importantly, a diet supplemented with 0.04% simvastatin for one month (at 7 months) positively affected synaptic plasticity in AbetaPPswe/PS1dE9 mice and did not significantly alter levels of water-soluble, detergent-soluble, or FA-soluble Abeta, but did increase phosphorylation of both Akt and GSK-3, while tau and tau phosphorylation were unaltered. Simvastatin 44-55 amyloid beta (A4) precursor protein Mus musculus 127-132 24164738-8 2014 Importantly, a diet supplemented with 0.04% simvastatin for one month (at 7 months) positively affected synaptic plasticity in AbetaPPswe/PS1dE9 mice and did not significantly alter levels of water-soluble, detergent-soluble, or FA-soluble Abeta, but did increase phosphorylation of both Akt and GSK-3, while tau and tau phosphorylation were unaltered. Simvastatin 44-55 thymoma viral proto-oncogene 1 Mus musculus 288-291 24164738-8 2014 Importantly, a diet supplemented with 0.04% simvastatin for one month (at 7 months) positively affected synaptic plasticity in AbetaPPswe/PS1dE9 mice and did not significantly alter levels of water-soluble, detergent-soluble, or FA-soluble Abeta, but did increase phosphorylation of both Akt and GSK-3, while tau and tau phosphorylation were unaltered. Simvastatin 44-55 glycogen synthase kinase 3 beta Mus musculus 296-301 23954171-4 2014 Simvastatin significantly decreased insoluble Abeta peptide levels and Abeta plaque load despite no effect on beta-site amyloid precursor protein-cleaving enzyme and Abeta-degrading enzyme neprilysin protein levels. Simvastatin 0-11 amyloid beta (A4) precursor protein Mus musculus 46-51 23954171-4 2014 Simvastatin significantly decreased insoluble Abeta peptide levels and Abeta plaque load despite no effect on beta-site amyloid precursor protein-cleaving enzyme and Abeta-degrading enzyme neprilysin protein levels. Simvastatin 0-11 amyloid beta (A4) precursor protein Mus musculus 71-76 24379677-12 2014 The interaction of CYP3A4 inhibitor with simvastatin has been more pronounced compared with atorvastatin. Simvastatin 41-52 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 19-25 25548604-0 2014 Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 109-114 24200505-3 2014 In a concentration-dependent manner, simvastatin treatment enhanced expression of several promyogenic nuclear transcription factors, including GATA4, Nkx2.5, DTEF-1 and myocardin A. Simvastatin 37-48 GATA binding protein 4 Mus musculus 143-148 24200505-3 2014 In a concentration-dependent manner, simvastatin treatment enhanced expression of several promyogenic nuclear transcription factors, including GATA4, Nkx2.5, DTEF-1 and myocardin A. Simvastatin 37-48 NK2 homeobox 5 Mus musculus 150-156 24200505-3 2014 In a concentration-dependent manner, simvastatin treatment enhanced expression of several promyogenic nuclear transcription factors, including GATA4, Nkx2.5, DTEF-1 and myocardin A. Simvastatin 37-48 TEA domain family member 3 Mus musculus 158-164 24471776-0 2014 Simvastatin inhibits transforming growth factor-beta1-induced expression of type I collagen, CTGF, and alpha-SMA in keloid fibroblasts. Simvastatin 0-11 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 48-53 24471776-0 2014 Simvastatin inhibits transforming growth factor-beta1-induced expression of type I collagen, CTGF, and alpha-SMA in keloid fibroblasts. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 93-97 24471776-6 2014 We examined the effect of simvastatin on transforming growth factor (TGF)-beta1-induced production of type I collagen, connective tissue growth factor (CTGF or CCN2), and alpha-smooth muscle actin (alpha-SMA). Simvastatin 26-37 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 74-79 24471776-10 2014 Simvastatin suppressed TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in a concentration-dependent manner. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 25548604-0 2014 Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Homo sapiens 134-137 24471776-10 2014 Simvastatin suppressed TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in a concentration-dependent manner. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 58-62 24471776-11 2014 The TGF-beta1-induced Smad2 and Smad3 phosphorylation levels were abrogated by simvastatin pretreatment. Simvastatin 79-90 transforming growth factor beta 1 Homo sapiens 4-13 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 apoptosis regulator Homo sapiens 18-23 24471776-11 2014 The TGF-beta1-induced Smad2 and Smad3 phosphorylation levels were abrogated by simvastatin pretreatment. Simvastatin 79-90 SMAD family member 2 Homo sapiens 22-27 24471776-11 2014 The TGF-beta1-induced Smad2 and Smad3 phosphorylation levels were abrogated by simvastatin pretreatment. Simvastatin 79-90 SMAD family member 3 Homo sapiens 32-37 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 calcineurin like EF-hand protein 1 Homo sapiens 72-75 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 76-80 24471776-12 2014 The inhibition of type I collagen, CTGF, and alpha-SMA expression by simvastatin was reversed by geranylgeranyl pyrophosphate, suggesting that the simvastatin-induced cellular responses were due to inhibition of small GTPase Rho involvement. Simvastatin 69-80 cellular communication network factor 2 Homo sapiens 35-39 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 associated X, apoptosis regulator Homo sapiens 86-89 24471776-12 2014 The inhibition of type I collagen, CTGF, and alpha-SMA expression by simvastatin was reversed by geranylgeranyl pyrophosphate, suggesting that the simvastatin-induced cellular responses were due to inhibition of small GTPase Rho involvement. Simvastatin 147-158 cellular communication network factor 2 Homo sapiens 35-39 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 88-92 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 95-104 24471776-13 2014 A RhoA activation assay showed that preincubation with simvastatin significantly blocked TGF-beta1-induced RhoA activation. Simvastatin 55-66 ras homolog family member A Homo sapiens 2-6 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 apoptosis regulator Homo sapiens 190-195 24471776-13 2014 A RhoA activation assay showed that preincubation with simvastatin significantly blocked TGF-beta1-induced RhoA activation. Simvastatin 55-66 transforming growth factor beta 1 Homo sapiens 89-98 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 CD33 molecule Homo sapiens 109-112 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 88-92 24471776-13 2014 A RhoA activation assay showed that preincubation with simvastatin significantly blocked TGF-beta1-induced RhoA activation. Simvastatin 55-66 ras homolog family member A Homo sapiens 107-111 25548604-8 2014 Expression of the Bcl-2 gene in HUVECs decreased obviously, but the expression of the Bax gene increased obviously after 24-hour incubation with sepsis serum; however, the expression of the Bcl-2 and Bax genes was just the opposite in the simvastatin group. Simvastatin 239-250 BCL2 associated X, apoptosis regulator Homo sapiens 200-203 24471776-16 2014 In conclusion, the present study suggests that simvastatin is an effective inhibitor of TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in keloid fibroblasts. Simvastatin 47-58 transforming growth factor beta 1 Homo sapiens 88-97 24471776-16 2014 In conclusion, the present study suggests that simvastatin is an effective inhibitor of TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in keloid fibroblasts. Simvastatin 47-58 cellular communication network factor 2 Homo sapiens 123-127 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 95-98 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 88-92 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 calcineurin like EF-hand protein 1 Homo sapiens 178-181 24680269-8 2014 In addition, simvastatin significantly downregulated mRNA expression of p22(phox), gp91(phox), p47(phox) and p67(phox) (all P < 0.05), as well as the interaction of p47(phox)/p22(phox) (P < 0.01). Simvastatin 13-24 pleckstrin Homo sapiens 88-92 24680269-9 2014 CONCLUSIONS: Simvastatin is an important regulator on NADPH subunits mRNA expressions and p47(phox)/p22(phox) interaction. Simvastatin 13-24 pleckstrin Homo sapiens 90-93 25548604-9 2014 CONCLUSIONS: Our study suggests that simvastatin can inhibit apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 37-48 BCL2 apoptosis regulator Homo sapiens 149-154 24680269-9 2014 CONCLUSIONS: Simvastatin is an important regulator on NADPH subunits mRNA expressions and p47(phox)/p22(phox) interaction. Simvastatin 13-24 pleckstrin Homo sapiens 94-98 25548604-9 2014 CONCLUSIONS: Our study suggests that simvastatin can inhibit apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. Simvastatin 37-48 BCL2 associated X, apoptosis regulator Homo sapiens 174-177 24680269-9 2014 CONCLUSIONS: Simvastatin is an important regulator on NADPH subunits mRNA expressions and p47(phox)/p22(phox) interaction. Simvastatin 13-24 calcineurin like EF-hand protein 1 Homo sapiens 100-103 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 75-85 24680269-9 2014 CONCLUSIONS: Simvastatin is an important regulator on NADPH subunits mRNA expressions and p47(phox)/p22(phox) interaction. Simvastatin 13-24 pleckstrin Homo sapiens 104-108 24511465-0 2014 Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Simvastatin 0-11 catenin (cadherin associated protein), beta 1 Mus musculus 69-81 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 C-C motif chemokine ligand 3 Rattus norvegicus 111-122 24391822-14 2013 CONCLUSION/SIGNIFICANCE: Simvastatin may slow progression of non-advanced AMD, especially for those with the at risk CFH genotype CC (Y402H). Simvastatin 25-36 complement factor H Homo sapiens 117-120 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 88-93 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 troponin I3, cardiac type Rattus norvegicus 132-136 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 interleukin 6 Rattus norvegicus 95-99 24455299-17 2013 Simvastatin significantly counteracted the increase in myocardium level of TNF- alpha , IL-1B, IL-6, MCP-1 and MIP-1 alpha , plasma cTnI, and apoptosis (P < 0.05). Simvastatin 0-11 C-C motif chemokine ligand 2 Rattus norvegicus 101-106 24016857-7 2013 Also, local simvastatin implant induced the HIF-1alpha and BMP-2 expression. Simvastatin 12-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 44-54 24459608-3 2013 The SEARCH genome-wide association study, which has been independently replicated, found a significant association between the rs4149056 (c.521T>C) single-nucleotide polymorphism (SNP) in the SLCO1B1 gene, and myopathy in individuals taking 80 mg simvastatin per day, with an odds ratio of 4.5 per rs4149056 C allele. Simvastatin 250-261 solute carrier organic anion transporter family member 1B1 Homo sapiens 195-202 24184927-6 2013 In mice, cotreatment with colchicine and simvastatin also led to muscle necrosis and LC3 accumulation, suggesting that, like rapamycin, simvastatin activates autophagy. Simvastatin 41-52 microtubule-associated protein 1 light chain 3 alpha Mus musculus 85-88 24184927-6 2013 In mice, cotreatment with colchicine and simvastatin also led to muscle necrosis and LC3 accumulation, suggesting that, like rapamycin, simvastatin activates autophagy. Simvastatin 136-147 microtubule-associated protein 1 light chain 3 alpha Mus musculus 85-88 24016857-7 2013 Also, local simvastatin implant induced the HIF-1alpha and BMP-2 expression. Simvastatin 12-23 bone morphogenetic protein 2 Homo sapiens 59-64 24016857-8 2013 In conclusion, local simvastatin implantation promotes bone defect healing, where the underlying mechanism appears to involve the higher expression of HIF-1alpha and BMP-2, thus recruit autogenous osteogenic and angiogenetic stem cells to the bone defect area implanted with simvastatin. Simvastatin 21-32 hypoxia inducible factor 1 subunit alpha Homo sapiens 151-161 24016857-8 2013 In conclusion, local simvastatin implantation promotes bone defect healing, where the underlying mechanism appears to involve the higher expression of HIF-1alpha and BMP-2, thus recruit autogenous osteogenic and angiogenetic stem cells to the bone defect area implanted with simvastatin. Simvastatin 21-32 bone morphogenetic protein 2 Homo sapiens 166-171 24016857-8 2013 In conclusion, local simvastatin implantation promotes bone defect healing, where the underlying mechanism appears to involve the higher expression of HIF-1alpha and BMP-2, thus recruit autogenous osteogenic and angiogenetic stem cells to the bone defect area implanted with simvastatin. Simvastatin 275-286 hypoxia inducible factor 1 subunit alpha Homo sapiens 151-161 24101161-7 2013 Moreover, simvastatin induced a strong downregulation of NonO gene expression, an important growth factor involved in the splicing regulation. Simvastatin 10-21 non-POU-domain-containing, octamer binding protein Mus musculus 57-61 23335094-0 2013 Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone. Simvastatin 76-87 insulin like growth factor 1 receptor Homo sapiens 18-55 23335094-5 2013 The aims of this study were to confirm stimulating effects of bone-derived IGF-1 on PC cells and to test if IGF-1R inhibition enhances growth inhibitory effects of simvastatin on PC cells in a bone microenvironment. Simvastatin 164-175 insulin like growth factor 1 receptor Homo sapiens 108-114 23335094-10 2013 Effects of simvastatin involved down-regulation of IGF-1R in PC-3 and of constitutively active androgen receptor variants in 22Rv1 cells. Simvastatin 11-22 insulin like growth factor 1 receptor Homo sapiens 51-57 23335094-10 2013 Effects of simvastatin involved down-regulation of IGF-1R in PC-3 and of constitutively active androgen receptor variants in 22Rv1 cells. Simvastatin 11-22 androgen receptor Homo sapiens 95-112 23339033-0 2013 Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin. Simvastatin 117-128 TNF superfamily member 11 Homo sapiens 76-81 23339033-4 2013 Adipogenesis and mRNA up-regulation of peroxisome proliferator-activated receptor gamma and adipocyte fatty acid-binding protein were induced by troglitazone, and those events were efficiently inhibited by simvastatin. Simvastatin 206-217 peroxisome proliferator activated receptor gamma Homo sapiens 39-87 23339033-5 2013 In addition, RANKL expression induced by calcitriol was abrogated by simvastatin in ST2 cells. Simvastatin 69-80 TNF superfamily member 11 Homo sapiens 13-18 24092915-10 2013 The elevation in apoB-containing lipoproteins in hypercholesterolemic patients is mainly attributed to the relative increase in the proatherogenic apoB/Lp-PLA2, while simvastatin reduces these particles to a higher extent compared with apoB/Lp-PLA2-. Simvastatin 167-178 apolipoprotein B Homo sapiens 17-21 23580160-10 2013 Moreover, SIM and vitamin E decreased QTc interval, serum ALT, AST, ALP, GGT, and cardiac and hepatic TBARS and increased antioxidants in HFD rats. Simvastatin 10-13 gamma-glutamyltransferase 1 Rattus norvegicus 73-76 23947572-5 2013 The goal of this study was to determine which statin (simvastatin or atorvastatin) is more effective in suppressing TSC2-null cell growth and signaling. Simvastatin 54-65 TSC complex subunit 2 Homo sapiens 116-120 24555011-8 2013 The relative expression and secretion of osteocalcin was significantly increased by cells cultured on scaffolds with 10 microM simvastatin when compared to scaffolds without simvastatin after 21 days. Simvastatin 127-138 bone gamma-carboxyglutamate protein Homo sapiens 41-52 24555011-8 2013 The relative expression and secretion of osteocalcin was significantly increased by cells cultured on scaffolds with 10 microM simvastatin when compared to scaffolds without simvastatin after 21 days. Simvastatin 174-185 bone gamma-carboxyglutamate protein Homo sapiens 41-52 24555011-9 2013 In addition, secretion of vascular endothelial growth factor A was significantly enhanced from cells cultured on scaffolds with both 10 nM and 10 microM simvastatin when compared to scaffolds without simvastatin at day 21. Simvastatin 153-164 vascular endothelial growth factor A Homo sapiens 26-62 24555011-9 2013 In addition, secretion of vascular endothelial growth factor A was significantly enhanced from cells cultured on scaffolds with both 10 nM and 10 microM simvastatin when compared to scaffolds without simvastatin at day 21. Simvastatin 200-211 vascular endothelial growth factor A Homo sapiens 26-62 23933099-0 2013 Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Simvastatin 0-11 tumor protein p53 Homo sapiens 113-116 23933099-0 2013 Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 117-120 23933099-3 2013 Our results demonstrated that exposure of human metastatic melanoma cells (WM9) to simvastatin induces a senescent phenotype, characterized by G1 arrest, positive staining for senescence-associated beta-galactosidase assay, and morphological changes. Simvastatin 83-94 galactosidase beta 1 Homo sapiens 198-216 23933099-4 2013 Also, the main pathways leading to cell senescence were examined in simvastatin-treated human melanoma cells, and the expression levels of phospho-p53 and p21 were upregulated by simvastatin, suggesting that cell cycle regulators and DNA damage pathways are involved in the onset of senescence. Simvastatin 68-79 tumor protein p53 Homo sapiens 147-150 23933099-4 2013 Also, the main pathways leading to cell senescence were examined in simvastatin-treated human melanoma cells, and the expression levels of phospho-p53 and p21 were upregulated by simvastatin, suggesting that cell cycle regulators and DNA damage pathways are involved in the onset of senescence. Simvastatin 68-79 H3 histone pseudogene 16 Homo sapiens 155-158 23933099-4 2013 Also, the main pathways leading to cell senescence were examined in simvastatin-treated human melanoma cells, and the expression levels of phospho-p53 and p21 were upregulated by simvastatin, suggesting that cell cycle regulators and DNA damage pathways are involved in the onset of senescence. Simvastatin 179-190 tumor protein p53 Homo sapiens 147-150 23933099-4 2013 Also, the main pathways leading to cell senescence were examined in simvastatin-treated human melanoma cells, and the expression levels of phospho-p53 and p21 were upregulated by simvastatin, suggesting that cell cycle regulators and DNA damage pathways are involved in the onset of senescence. Simvastatin 179-190 H3 histone pseudogene 16 Homo sapiens 155-158 23933099-7 2013 Collectively, our results demonstrated that simvastatin can induce senescence in human melanoma cells by activation of p53/p21 pathway, and that oxidative stress may be related to this process. Simvastatin 44-55 tumor protein p53 Homo sapiens 119-122 23933099-7 2013 Collectively, our results demonstrated that simvastatin can induce senescence in human melanoma cells by activation of p53/p21 pathway, and that oxidative stress may be related to this process. Simvastatin 44-55 H3 histone pseudogene 16 Homo sapiens 123-126 24244596-10 2013 Simvastatin prevented high glucose or hyperglycemia-induced dysregulation of occludin and ZO-1 by inhibition of RhoA/ROCK1 signaling in cultured GEnCs and in db/db mice with early-stage DN. Simvastatin 0-11 occludin Mus musculus 77-85 24244596-10 2013 Simvastatin prevented high glucose or hyperglycemia-induced dysregulation of occludin and ZO-1 by inhibition of RhoA/ROCK1 signaling in cultured GEnCs and in db/db mice with early-stage DN. Simvastatin 0-11 tight junction protein 1 Mus musculus 90-94 24244596-10 2013 Simvastatin prevented high glucose or hyperglycemia-induced dysregulation of occludin and ZO-1 by inhibition of RhoA/ROCK1 signaling in cultured GEnCs and in db/db mice with early-stage DN. Simvastatin 0-11 ras homolog family member A Mus musculus 112-116 24244596-10 2013 Simvastatin prevented high glucose or hyperglycemia-induced dysregulation of occludin and ZO-1 by inhibition of RhoA/ROCK1 signaling in cultured GEnCs and in db/db mice with early-stage DN. Simvastatin 0-11 Rho-associated coiled-coil containing protein kinase 1 Mus musculus 117-122 24244596-11 2013 CONCLUSION: Our results indicate that activation of RhoA/ROCK1 by high glucose disrupts the expression and translocation of occludin/ZO-1 and that simvastatin alleviates occludin/ZO-1 dysregulation and albuminuria by suppressing RhoA/ROCK1 signaling during early-stage DN. Simvastatin 147-158 ras homolog family member A Mus musculus 52-56 24244596-11 2013 CONCLUSION: Our results indicate that activation of RhoA/ROCK1 by high glucose disrupts the expression and translocation of occludin/ZO-1 and that simvastatin alleviates occludin/ZO-1 dysregulation and albuminuria by suppressing RhoA/ROCK1 signaling during early-stage DN. Simvastatin 147-158 occludin Mus musculus 170-178 24244596-11 2013 CONCLUSION: Our results indicate that activation of RhoA/ROCK1 by high glucose disrupts the expression and translocation of occludin/ZO-1 and that simvastatin alleviates occludin/ZO-1 dysregulation and albuminuria by suppressing RhoA/ROCK1 signaling during early-stage DN. Simvastatin 147-158 tight junction protein 1 Mus musculus 179-183 24244596-11 2013 CONCLUSION: Our results indicate that activation of RhoA/ROCK1 by high glucose disrupts the expression and translocation of occludin/ZO-1 and that simvastatin alleviates occludin/ZO-1 dysregulation and albuminuria by suppressing RhoA/ROCK1 signaling during early-stage DN. Simvastatin 147-158 ras homolog family member A Mus musculus 229-233 24244596-11 2013 CONCLUSION: Our results indicate that activation of RhoA/ROCK1 by high glucose disrupts the expression and translocation of occludin/ZO-1 and that simvastatin alleviates occludin/ZO-1 dysregulation and albuminuria by suppressing RhoA/ROCK1 signaling during early-stage DN. Simvastatin 147-158 Rho-associated coiled-coil containing protein kinase 1 Mus musculus 234-239 23941814-0 2013 Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism. Simvastatin 0-11 thymidylate synthetase Homo sapiens 90-92 24080182-0 2013 Simvastatin increases Prolyl-4-Hydroxylase alpha1 expression in atherosclerotic plaque and ox-LDL-stimulated human aortic smooth muscle cells via p38 MAPK and ERK1/2 signaling. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 146-149 24080182-0 2013 Simvastatin increases Prolyl-4-Hydroxylase alpha1 expression in atherosclerotic plaque and ox-LDL-stimulated human aortic smooth muscle cells via p38 MAPK and ERK1/2 signaling. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 159-165 24080182-6 2013 Simvastatin significantly attenuated the suppressive effect of ox-LDL on P4Halpha1 and collagen production by inhibiting ox-LDL uptake and the activation of p38 MAPK and ERK1/2. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 157-160 24080182-6 2013 Simvastatin significantly attenuated the suppressive effect of ox-LDL on P4Halpha1 and collagen production by inhibiting ox-LDL uptake and the activation of p38 MAPK and ERK1/2. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 170-176 24080182-7 2013 In apolipoprotein E-deficient mice, simvastatin and the inhibitors of p38 and ERK1/2 significantly increased the stability of the carotid plaques. Simvastatin 36-47 apolipoprotein E Mus musculus 3-19 24080182-8 2013 We also found that simvastatin significantly increased the expression of P4Halpha1 and collagen possibly due to decreased ox-LDL content and phosphorylation of p38 and ERK1/2 in plaques. Simvastatin 19-30 mitogen-activated protein kinase 1 Homo sapiens 160-163 24080182-8 2013 We also found that simvastatin significantly increased the expression of P4Halpha1 and collagen possibly due to decreased ox-LDL content and phosphorylation of p38 and ERK1/2 in plaques. Simvastatin 19-30 mitogen-activated protein kinase 3 Homo sapiens 168-174 24080182-9 2013 Thus, simvastatin increases P4Halpha1 and collagen expression in ox-LDL-stimulated HASMCs and atherosclerotic plaques via p38 MAPK and ERK1/2, thereby exerting a plaque stabilizing effect. Simvastatin 6-17 mitogen-activated protein kinase 1 Homo sapiens 122-125 24080182-9 2013 Thus, simvastatin increases P4Halpha1 and collagen expression in ox-LDL-stimulated HASMCs and atherosclerotic plaques via p38 MAPK and ERK1/2, thereby exerting a plaque stabilizing effect. Simvastatin 6-17 mitogen-activated protein kinase 3 Homo sapiens 135-141 24092915-6 2013 The plasma apoB/Lp-PLA2 concentration in 50 normolipidemic controls and 53 patients with primary hypercholesterolemia at baseline and at 3 months posttreatment with simvastatin (40 mg/day) was determined by an enzyme-linked immunosorbent assay. Simvastatin 165-176 apolipoprotein B Homo sapiens 11-15 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 apolipoprotein B Homo sapiens 40-44 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 phospholipase A2 group VII Homo sapiens 45-52 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 apolipoprotein B Homo sapiens 57-61 24092915-9 2013 After 3 months of simvastatin treatment apoB/Lp-PLA2 and apoB/Lp-PLA2- levels were reduced by 52% and 33%, respectively. Simvastatin 18-29 phospholipase A2 group VII Homo sapiens 62-69 24244596-0 2013 Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. Simvastatin 0-11 ras homolog family member A Mus musculus 126-130 24244596-0 2013 Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. Simvastatin 0-11 Rho-associated coiled-coil containing protein kinase 1 Mus musculus 131-136 23941814-11 2013 Simvastatin plus S-1 induced greater tumor inhibition than simvastatin or S-1 alone with E2F-1/TS downregulation in vivo (all P < 0.05). Simvastatin 0-11 thymidylate synthetase Homo sapiens 95-97 23941814-9 2013 Simvastatin alone or plus 5-FU significantly suppressed E2F-1 and TS expressions in EGI-1 and MZ-ChA-1. Simvastatin 0-11 E2F transcription factor 1 Homo sapiens 56-61 23941814-9 2013 Simvastatin alone or plus 5-FU significantly suppressed E2F-1 and TS expressions in EGI-1 and MZ-ChA-1. Simvastatin 0-11 thymidylate synthetase Homo sapiens 66-68 23941814-11 2013 Simvastatin plus S-1 induced greater tumor inhibition than simvastatin or S-1 alone with E2F-1/TS downregulation in vivo (all P < 0.05). Simvastatin 0-11 E2F transcription factor 1 Homo sapiens 89-94 23947572-6 2013 Simvastatin, but not atorvastatin, showed a concentration-dependent (0.5-10 muM) inhibitory effect on mouse TSC2-null and human LAM-derived cell growth. Simvastatin 0-11 TSC complex subunit 2 Mus musculus 108-112 23941814-12 2013 Simvastatin and S-1 exerted synergistic effects against bile duct cancer, which might be mediated by E2F-1/TS downregulation. Simvastatin 0-11 E2F transcription factor 1 Homo sapiens 101-106 23941814-12 2013 Simvastatin and S-1 exerted synergistic effects against bile duct cancer, which might be mediated by E2F-1/TS downregulation. Simvastatin 0-11 thymidylate synthetase Homo sapiens 107-109 23947572-7 2013 Treatment with 10 muM simvastatin induced dramatic disruption of TSC2-null cell monolayer and cell rounding; in contrast, few changes were observed in cells treated with the same concentration of atorvastatin. Simvastatin 22-33 TSC complex subunit 2 Homo sapiens 65-69 23947572-8 2013 Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells. Simvastatin 37-48 TSC complex subunit 2 Homo sapiens 124-128 23947572-9 2013 Simvastatin, but not atorvastatin, inhibited the activity of prosurvival serine-threonine kinase Akt and induced marked up-regulation of cleaved caspase-3, a marker of cell apoptosis. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 97-100 23947572-10 2013 Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Simvastatin 0-11 cyclin dependent kinase like 1 Homo sapiens 86-89 23947572-10 2013 Simvastatin, but not atorvastatin, also induced concentration-dependent inhibition of p42/p44 Erk and mTORC1. Simvastatin 0-11 CREB regulated transcription coactivator 1 Mus musculus 102-108 23947572-11 2013 Thus, our data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null cells compared with atorvastatin. Simvastatin 66-77 TSC complex subunit 2 Homo sapiens 81-85 23947572-12 2013 These findings have translational significance for combinatorial therapeutic strategies of simvastatin to inhibit TSC2-null cell survival in TS and LAM. Simvastatin 91-102 TSC complex subunit 2 Homo sapiens 114-118 24256019-12 2013 Therefore, statins metabolized through CYP3A4 (simvastatin, lovastatin and atorvastatin) are the ones with the highest number of clinically relevant interactions. Simvastatin 47-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 24125402-8 2013 In all treatment groups a significant reduction in total plasma Lp-PLA2 activity and mass was observed (by 36%, 31% and 38% and 36%, 32% and 32% for simvastatin, simvastatin/ezetimibe and rosuvastatin, respectively, p < 0.001 compared with baseline). Simvastatin 149-160 phospholipase A2 group VII Homo sapiens 64-71 24125402-8 2013 In all treatment groups a significant reduction in total plasma Lp-PLA2 activity and mass was observed (by 36%, 31% and 38% and 36%, 32% and 32% for simvastatin, simvastatin/ezetimibe and rosuvastatin, respectively, p < 0.001 compared with baseline). Simvastatin 162-173 phospholipase A2 group VII Homo sapiens 64-71 24125402-10 2013 CONCLUSIONS: Simvastatin 40 mg, simvastatin/ezetimibe 10/10 mg and rosuvastatin 10 mg significantly reduced 8-epiPGF2a, oxLDL and Lp-PLA2 activity and mass to a similar extent. Simvastatin 13-24 phospholipase A2 group VII Homo sapiens 130-137 24125402-10 2013 CONCLUSIONS: Simvastatin 40 mg, simvastatin/ezetimibe 10/10 mg and rosuvastatin 10 mg significantly reduced 8-epiPGF2a, oxLDL and Lp-PLA2 activity and mass to a similar extent. Simvastatin 32-43 phospholipase A2 group VII Homo sapiens 130-137 24254555-9 2013 Simvastatin and fluvastatin but not cerivastatin, were able to inhibit the HGF-depending migration and showed a significant effect on the inhibition of the isoprenylation (GGPP). Simvastatin 0-11 hepatocyte growth factor Homo sapiens 75-78 24254555-10 2013 Only simvastatin influenced the HGF-depending migration via inhibiting the isoprenylation process through GGPP. Simvastatin 5-16 hepatocyte growth factor Homo sapiens 32-35 23980058-17 2013 Treatment with either metformin or simvastatin attenuated the fibrosis progression induced by DHEA exposure, as evidenced by a reduction of TGF-beta, plus CTGF or not, in both ovarian and uterine tissues. Simvastatin 35-46 cellular communication network factor 2 Rattus norvegicus 155-159 23559257-0 2013 Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. Simvastatin 99-110 intercellular adhesion molecule 1 Homo sapiens 89-95 23594090-1 2013 AIM: To evaluate the therapeutic effect of Simvastatin on apical periodontitis in rats by assessing the osteoblast production of receptor activator of nuclear factor-Kappa B Ligand (RANKL) and Osteoprotegerin (OPG) cytokines that are essential for bone resorption. Simvastatin 43-54 TNF superfamily member 11 Rattus norvegicus 129-180 23594090-1 2013 AIM: To evaluate the therapeutic effect of Simvastatin on apical periodontitis in rats by assessing the osteoblast production of receptor activator of nuclear factor-Kappa B Ligand (RANKL) and Osteoprotegerin (OPG) cytokines that are essential for bone resorption. Simvastatin 43-54 TNF superfamily member 11 Rattus norvegicus 182-187 23594090-1 2013 AIM: To evaluate the therapeutic effect of Simvastatin on apical periodontitis in rats by assessing the osteoblast production of receptor activator of nuclear factor-Kappa B Ligand (RANKL) and Osteoprotegerin (OPG) cytokines that are essential for bone resorption. Simvastatin 43-54 TNF receptor superfamily member 11B Rattus norvegicus 210-213 23594090-10 2013 RESULTS: Simvastatin significantly (P < 0.05) enhanced the expression of OPG and reduced the mRNA expression of RANKL in the experimental group compared with the control group. Simvastatin 9-20 TNF receptor superfamily member 11B Rattus norvegicus 76-79 23594090-10 2013 RESULTS: Simvastatin significantly (P < 0.05) enhanced the expression of OPG and reduced the mRNA expression of RANKL in the experimental group compared with the control group. Simvastatin 9-20 TNF superfamily member 11 Rattus norvegicus 115-120 23594090-11 2013 CONCLUSIONS: Oral administration of Simvastatin attenuated RANKL expression and accelerated OPG expression in induced rat periapical lesions. Simvastatin 36-47 TNF superfamily member 11 Rattus norvegicus 59-64 23594090-11 2013 CONCLUSIONS: Oral administration of Simvastatin attenuated RANKL expression and accelerated OPG expression in induced rat periapical lesions. Simvastatin 36-47 TNF receptor superfamily member 11B Rattus norvegicus 92-95 23559257-5 2013 First, we showed that simvastatin inhibited the ability of human PC3 prostate cancer cells for transendothelial migration in vitro. Simvastatin 22-33 chromobox 8 Homo sapiens 65-68 23559257-6 2013 Second, our data indicated that simvastatin modulates the expression of tumor-derived factors such as angiopoietins and VEGF-A at the mRNA and protein levels by the PC3 cells, thus preventing endothelial-barrier disruption. Simvastatin 32-43 vascular endothelial growth factor A Homo sapiens 120-126 23559257-6 2013 Second, our data indicated that simvastatin modulates the expression of tumor-derived factors such as angiopoietins and VEGF-A at the mRNA and protein levels by the PC3 cells, thus preventing endothelial-barrier disruption. Simvastatin 32-43 chromobox 8 Homo sapiens 165-168 23559257-8 2013 Apart from this, our study revealed that simvastatin-mediated effect on PC3 micrometastasis was mediated through inhibition of integrin alphav beta3 activity and suppression of interaction between prostate cancer cell integrin alphav beta3 with endothelial ICAM-1. Simvastatin 41-52 chromobox 8 Homo sapiens 72-75 23559257-8 2013 Apart from this, our study revealed that simvastatin-mediated effect on PC3 micrometastasis was mediated through inhibition of integrin alphav beta3 activity and suppression of interaction between prostate cancer cell integrin alphav beta3 with endothelial ICAM-1. Simvastatin 41-52 eukaryotic translation elongation factor 1 beta 2 pseudogene 2 Homo sapiens 143-148 23559257-8 2013 Apart from this, our study revealed that simvastatin-mediated effect on PC3 micrometastasis was mediated through inhibition of integrin alphav beta3 activity and suppression of interaction between prostate cancer cell integrin alphav beta3 with endothelial ICAM-1. Simvastatin 41-52 eukaryotic translation elongation factor 1 beta 2 pseudogene 2 Homo sapiens 234-239 23559257-8 2013 Apart from this, our study revealed that simvastatin-mediated effect on PC3 micrometastasis was mediated through inhibition of integrin alphav beta3 activity and suppression of interaction between prostate cancer cell integrin alphav beta3 with endothelial ICAM-1. Simvastatin 41-52 intercellular adhesion molecule 1 Homo sapiens 257-263 23939663-0 2013 Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. Simvastatin 52-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-41 23939663-0 2013 Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. Simvastatin 52-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 93-98 24090588-0 2013 Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Simvastatin 0-11 neurofibromin 1 Homo sapiens 77-101 23939663-1 2013 This study aimed to demonstrate that the dose of a CYP3A substrate (simvastatin) can be adapted individually on the basis of CYP3A activity as assessed by midazolam metabolic clearance. Simvastatin 68-79 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-56 23939663-1 2013 This study aimed to demonstrate that the dose of a CYP3A substrate (simvastatin) can be adapted individually on the basis of CYP3A activity as assessed by midazolam metabolic clearance. Simvastatin 68-79 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 125-130 23939663-7 2013 CYP3A activity-based dose adaptation can be used to reduce interindividual variability in simvastatin exposure. Simvastatin 90-101 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-5 23900131-0 2013 Simvastatin attenuates formalin-induced nociceptive behaviors by inhibiting microglial RhoA and p38 MAPK activation. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 87-91 23900131-0 2013 Simvastatin attenuates formalin-induced nociceptive behaviors by inhibiting microglial RhoA and p38 MAPK activation. Simvastatin 0-11 mitogen activated protein kinase 14 Rattus norvegicus 96-99 23900131-7 2013 The spinal RhoA activation in microglia was reversed by simvastatin treatment. Simvastatin 56-67 ras homolog family member A Rattus norvegicus 11-15 23900131-8 2013 These findings suggest that simvastatin attenuates formalin-induced nociceptive behaviors, at least in part, by inhibiting microglial RhoA and p38 mitogen-activated protein kinase activation. Simvastatin 28-39 ras homolog family member A Rattus norvegicus 134-138 23900131-8 2013 These findings suggest that simvastatin attenuates formalin-induced nociceptive behaviors, at least in part, by inhibiting microglial RhoA and p38 mitogen-activated protein kinase activation. Simvastatin 28-39 mitogen activated protein kinase 14 Rattus norvegicus 143-146 23900131-9 2013 PERSPECTIVE: Our novel findings indicated that simvastatin attenuated formalin-induced nociceptive responses by inhibiting microglial RhoA and p38 mitogen-activated protein kinase activation. Simvastatin 47-58 ras homolog family member A Rattus norvegicus 134-138 23900131-9 2013 PERSPECTIVE: Our novel findings indicated that simvastatin attenuated formalin-induced nociceptive responses by inhibiting microglial RhoA and p38 mitogen-activated protein kinase activation. Simvastatin 47-58 mitogen activated protein kinase 14 Rattus norvegicus 143-146 24090588-0 2013 Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Simvastatin 0-11 neurofibromin 1 Homo sapiens 103-106 24090588-3 2013 We aimed to assess the use of simvastatin for the improvement of cognitive and behavioural deficits in children with neurofibromatosis type 1 for 12 months. Simvastatin 30-41 neurofibromin 1 Homo sapiens 117-141 24090588-16 2013 The use of 20-40 mg simvastatin per day for cognitive enhancement in children with neurofibromatosis type 1 is not recommended. Simvastatin 20-31 neurofibromin 1 Homo sapiens 83-107 23973688-6 2013 Baseline and on-study Lp(a) were predictive of CV events in both simvastatin plus placebo (baseline HR: 1.24 [p = 0.002] and on-study HR: 1.21 [p = 0.017]) and the simvastatin plus ERN group (baseline HR: 1.25 [p = 0.001] and on-study HR: 1.18 [p = 0.028]). Simvastatin 65-76 lipoprotein(a) Homo sapiens 22-27 23543392-0 2013 Simvastatin reduces VEGF and NO levels in acute stages of experimental traumatic brain injury. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 20-24 23543392-7 2013 In the T group, significant increases of VEGF levels in serum and brain tissues were noted, which were prevented with simvastatin treatment in the T + S group. Simvastatin 118-129 vascular endothelial growth factor A Rattus norvegicus 41-45 23973688-6 2013 Baseline and on-study Lp(a) were predictive of CV events in both simvastatin plus placebo (baseline HR: 1.24 [p = 0.002] and on-study HR: 1.21 [p = 0.017]) and the simvastatin plus ERN group (baseline HR: 1.25 [p = 0.001] and on-study HR: 1.18 [p = 0.028]). Simvastatin 164-175 lipoprotein(a) Homo sapiens 22-27 23590933-0 2013 Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 31-63 23995691-5 2013 This analysis identified six expression quantitative trait loci (eQTLs) that interacted with simvastatin exposure, including rs9806699, a cis-eQTL for the gene glycine amidinotransferase (GATM) that encodes the rate-limiting enzyme in creatine synthesis. Simvastatin 93-104 glycine amidinotransferase Homo sapiens 160-186 23995691-5 2013 This analysis identified six expression quantitative trait loci (eQTLs) that interacted with simvastatin exposure, including rs9806699, a cis-eQTL for the gene glycine amidinotransferase (GATM) that encodes the rate-limiting enzyme in creatine synthesis. Simvastatin 93-104 glycine amidinotransferase Homo sapiens 188-192 23978459-0 2013 Simvastatin-induced up-regulation of gap junctions composed of connexin 43 sensitize Leydig tumor cells to etoposide: an involvement of PKC pathway. Simvastatin 0-11 gap junction protein alpha 1 Homo sapiens 63-74 23978459-2 2013 The authors investigated the involvement of Cx43-mediated gap junction intercellular communication (GJIC) in the effect of simvastatin on the cellular toxicity induced by etoposide in this study. Simvastatin 123-134 gap junction protein alpha 1 Homo sapiens 44-48 23978459-4 2013 The augmentative effect of simvastatin on GJIC was related to the inhibition of PKC-mediated Cx43 phosphorylation at ser368 and subsequent enhancement of Cx43 membrane location induced by the agent. Simvastatin 27-38 gap junction protein alpha 1 Homo sapiens 93-97 23978459-4 2013 The augmentative effect of simvastatin on GJIC was related to the inhibition of PKC-mediated Cx43 phosphorylation at ser368 and subsequent enhancement of Cx43 membrane location induced by the agent. Simvastatin 27-38 gap junction protein alpha 1 Homo sapiens 154-158 23590933-0 2013 Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Simvastatin 0-11 egl-9 family hypoxia-inducible factor 3 Rattus norvegicus 77-99 23590933-0 2013 Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Simvastatin 0-11 egl-9 family hypoxia-inducible factor 3 Rattus norvegicus 101-106 23728830-9 2013 However, the increments of ApoA1 were significantly greater in the ezetimibe/simvastatin group than in the atorvastatin group (2.8 +- 10.0 vs. -1.8 +- 9.8 %; p = 0.002). Simvastatin 77-88 apolipoprotein A1 Homo sapiens 27-32 24098525-8 2013 Compared with model rats in 24(th) week group, rats in simvastatin group had less expressions of iNOS, alpha-SMA, and Collagen I and more expressions of eNOS. Simvastatin 55-66 nitric oxide synthase 2 Rattus norvegicus 97-101 24098525-8 2013 Compared with model rats in 24(th) week group, rats in simvastatin group had less expressions of iNOS, alpha-SMA, and Collagen I and more expressions of eNOS. Simvastatin 55-66 actin gamma 2, smooth muscle Rattus norvegicus 103-112 24098525-8 2013 Compared with model rats in 24(th) week group, rats in simvastatin group had less expressions of iNOS, alpha-SMA, and Collagen I and more expressions of eNOS. Simvastatin 55-66 nitric oxide synthase 3 Rattus norvegicus 153-157 24098525-10 2013 Simvastatin inhibited LX-2 cells activation due to TGF-beta1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 51-60 24098525-10 2013 Simvastatin inhibited LX-2 cells activation due to TGF-beta1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 103-107 24098525-10 2013 Simvastatin inhibited LX-2 cells activation due to TGF-beta1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS. Simvastatin 0-11 nitric oxide synthase 2 Homo sapiens 141-145 24098525-11 2013 CONCLUSIONS: Simvastatin improves the prognosis of NASH-related fibrosis by increasing the expression of eNOS, decreasing the expression of iNOS, and inhibiting the activation of HSC. Simvastatin 13-24 nitric oxide synthase 3 Rattus norvegicus 105-109 24098525-11 2013 CONCLUSIONS: Simvastatin improves the prognosis of NASH-related fibrosis by increasing the expression of eNOS, decreasing the expression of iNOS, and inhibiting the activation of HSC. Simvastatin 13-24 nitric oxide synthase 2 Rattus norvegicus 140-144 23889671-7 2013 KEY RESULTS: FTS significantly attenuated the decrease in BP and increased NO evoked by simvastatin and reversed the decrease in basal RSNA induced by simvastatin. Simvastatin 88-99 AKT interacting protein Rattus norvegicus 13-16 23889671-7 2013 KEY RESULTS: FTS significantly attenuated the decrease in BP and increased NO evoked by simvastatin and reversed the decrease in basal RSNA induced by simvastatin. Simvastatin 151-162 AKT interacting protein Rattus norvegicus 13-16 23889671-8 2013 Immunoblotting and pharmacological studies showed that inhibition of Ras activity by FTS significantly abolished simvastatin-induced phosphorylation of ERK1/2, ribosomal protein S6 kinase (RSK), Akt and decreased eNOS phosphorylation. Simvastatin 113-124 AKT interacting protein Rattus norvegicus 85-88 23889671-8 2013 Immunoblotting and pharmacological studies showed that inhibition of Ras activity by FTS significantly abolished simvastatin-induced phosphorylation of ERK1/2, ribosomal protein S6 kinase (RSK), Akt and decreased eNOS phosphorylation. Simvastatin 113-124 mitogen activated protein kinase 3 Rattus norvegicus 152-158 23889671-8 2013 Immunoblotting and pharmacological studies showed that inhibition of Ras activity by FTS significantly abolished simvastatin-induced phosphorylation of ERK1/2, ribosomal protein S6 kinase (RSK), Akt and decreased eNOS phosphorylation. Simvastatin 113-124 ribosomal protein S6 kinase B1 Rattus norvegicus 160-187 23889671-8 2013 Immunoblotting and pharmacological studies showed that inhibition of Ras activity by FTS significantly abolished simvastatin-induced phosphorylation of ERK1/2, ribosomal protein S6 kinase (RSK), Akt and decreased eNOS phosphorylation. Simvastatin 113-124 ribosomal protein S6 kinase B1 Rattus norvegicus 189-192 23889671-8 2013 Immunoblotting and pharmacological studies showed that inhibition of Ras activity by FTS significantly abolished simvastatin-induced phosphorylation of ERK1/2, ribosomal protein S6 kinase (RSK), Akt and decreased eNOS phosphorylation. Simvastatin 113-124 AKT serine/threonine kinase 1 Rattus norvegicus 195-198 23889671-9 2013 Likewise, administration of Akt and ERK1/2 signalling inhibitors, LY294002 and PD98059, attenuated the reduction in BP evoked by simvastatin. Simvastatin 129-140 AKT serine/threonine kinase 1 Rattus norvegicus 28-31 23889671-9 2013 Likewise, administration of Akt and ERK1/2 signalling inhibitors, LY294002 and PD98059, attenuated the reduction in BP evoked by simvastatin. Simvastatin 129-140 mitogen activated protein kinase 3 Rattus norvegicus 36-42 23889671-11 2013 simvastatin decreased Rac1 activation and the number of ROS-positive cells in the NTS. Simvastatin 0-11 Rac family small GTPase 1 Rattus norvegicus 22-26 23889671-12 2013 CONCLUSIONS AND IMPLICATIONS: Simvastatin modulates central BP control in the NTS of SHRs by increasing Ras-mediated activation of the PI3K-Akt and ERK1/2-RSK signalling pathways, which then up-regulates eNOS activation. Simvastatin 30-41 AKT serine/threonine kinase 1 Rattus norvegicus 140-143 23889671-12 2013 CONCLUSIONS AND IMPLICATIONS: Simvastatin modulates central BP control in the NTS of SHRs by increasing Ras-mediated activation of the PI3K-Akt and ERK1/2-RSK signalling pathways, which then up-regulates eNOS activation. Simvastatin 30-41 mitogen activated protein kinase 3 Rattus norvegicus 148-154 23889671-12 2013 CONCLUSIONS AND IMPLICATIONS: Simvastatin modulates central BP control in the NTS of SHRs by increasing Ras-mediated activation of the PI3K-Akt and ERK1/2-RSK signalling pathways, which then up-regulates eNOS activation. Simvastatin 30-41 ribosomal protein S6 kinase B1 Rattus norvegicus 155-158 23703578-6 2013 Drug-drug interactions are dependent on statins" pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP. Simvastatin 74-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 139-163 23703578-14 2013 Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 23703578-14 2013 Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-121 24040277-2 2013 We found that simvastatin (SIM) maintains CSC as shown by Fillipin III staining, Flotillin-2 protein expression / localization and phosphorylation of various receptor tyrosine kinases (RTKs) in the plasma membrane. Simvastatin 14-25 flotillin 2 Homo sapiens 81-92 23424208-5 2013 Simvastatin inhibited cholesterol synthesis and decreased I KCNQ1 and I(Ks). Simvastatin 0-11 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 60-65 23913656-0 2013 Simvastatin therapy decreases MMP-9 levels in obese women. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 30-35 23913656-6 2013 Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Simvastatin 15-26 matrix metallopeptidase 9 Homo sapiens 49-54 23913656-6 2013 Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Simvastatin 15-26 matrix metallopeptidase 9 Homo sapiens 70-75 23913656-6 2013 Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Simvastatin 15-26 TIMP metallopeptidase inhibitor 1 Homo sapiens 76-82 23913656-9 2013 These findings may have clinical importance since simvastatin therapy reduced cardiovascular risk and MMP-9 levels in obese woman without comorbidities, indicating a potentially new therapeutic approach. Simvastatin 50-61 matrix metallopeptidase 9 Homo sapiens 102-107 23973711-7 2013 Compared with PTEN wild-type TNBC cells, PTEN mutant-type TNBC cells showed a decreased response to simvastatin. Simvastatin 100-111 phosphatase and tensin homolog Homo sapiens 14-18 23973711-7 2013 Compared with PTEN wild-type TNBC cells, PTEN mutant-type TNBC cells showed a decreased response to simvastatin. Simvastatin 100-111 phosphatase and tensin homolog Homo sapiens 41-45 23973711-9 2013 The TNBC cell lines, which showed increased expression of p-Akt, appeared to attenuate the expression of p-Akt by PTEN loss in simvastatin-treated TNBC cells. Simvastatin 127-138 AKT serine/threonine kinase 1 Homo sapiens 60-63 23973711-9 2013 The TNBC cell lines, which showed increased expression of p-Akt, appeared to attenuate the expression of p-Akt by PTEN loss in simvastatin-treated TNBC cells. Simvastatin 127-138 AKT serine/threonine kinase 1 Homo sapiens 107-110 23973711-9 2013 The TNBC cell lines, which showed increased expression of p-Akt, appeared to attenuate the expression of p-Akt by PTEN loss in simvastatin-treated TNBC cells. Simvastatin 127-138 phosphatase and tensin homolog Homo sapiens 114-118 23973711-10 2013 The Akt inhibitor, LY294002, augmented the effect of simvastatin on PTEN wild-type TNBC cells. Simvastatin 53-64 AKT serine/threonine kinase 1 Homo sapiens 4-7 23973711-10 2013 The Akt inhibitor, LY294002, augmented the effect of simvastatin on PTEN wild-type TNBC cells. Simvastatin 53-64 phosphatase and tensin homolog Homo sapiens 68-72 24039733-0 2013 Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss. Simvastatin 105-116 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 39-44 24039733-3 2013 We found that in vitro, IRF4 expression is upregulated during osteoclast differentiation induced by RANKL (receptor activator of nuclear factor-kappaB ligand), while simvastatin blocks RANKL-induced osteoclastogenesis and decreases expression of NFATc1 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1), IRF4 and osteoclast markers. Simvastatin 166-177 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 185-190 24039733-7 2013 To investigate the in vivo effects of simvastatin in RANKL-treated mice, we examined the bone mineral density (BMD) of a mouse model of bone loss, and found that simvastatin significantly reduced bone loss by suppressing osteoclast numbers in vivo, even in the presence of high concentrations of RANKL. Simvastatin 162-173 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 53-58 24039733-7 2013 To investigate the in vivo effects of simvastatin in RANKL-treated mice, we examined the bone mineral density (BMD) of a mouse model of bone loss, and found that simvastatin significantly reduced bone loss by suppressing osteoclast numbers in vivo, even in the presence of high concentrations of RANKL. Simvastatin 162-173 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 296-301 24039733-9 2013 The results are consistent with the hypothesis that simvastatin blocks RANKL-induced IRF4 expression in osteoclastogenesis. Simvastatin 52-63 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 71-76 24039733-9 2013 The results are consistent with the hypothesis that simvastatin blocks RANKL-induced IRF4 expression in osteoclastogenesis. Simvastatin 52-63 interferon regulatory factor 4 Mus musculus 85-89 24004537-0 2013 Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin. Simvastatin 67-78 ryanodine receptor 1, skeletal muscle Mus musculus 10-14 24040034-4 2013 The lipophilic statins, fluvastatin and simvastatin, reversed LPS-induced downregulation of CD9 and CD81, simultaneously preventing TNF-alpha and matrix metalloproteinase-9 production and spreading of RAW264.7 cells. Simvastatin 40-51 CD81 antigen Mus musculus 100-104 24040034-4 2013 The lipophilic statins, fluvastatin and simvastatin, reversed LPS-induced downregulation of CD9 and CD81, simultaneously preventing TNF-alpha and matrix metalloproteinase-9 production and spreading of RAW264.7 cells. Simvastatin 40-51 tumor necrosis factor Mus musculus 132-141 24040034-4 2013 The lipophilic statins, fluvastatin and simvastatin, reversed LPS-induced downregulation of CD9 and CD81, simultaneously preventing TNF-alpha and matrix metalloproteinase-9 production and spreading of RAW264.7 cells. Simvastatin 40-51 matrix metallopeptidase 9 Mus musculus 146-172 24040034-4 2013 The lipophilic statins, fluvastatin and simvastatin, reversed LPS-induced downregulation of CD9 and CD81, simultaneously preventing TNF-alpha and matrix metalloproteinase-9 production and spreading of RAW264.7 cells. Simvastatin 40-51 CD9 antigen Mus musculus 92-95 24004537-6 2013 METHODS: We assessed the ability of simvastatin to induce a hypermetabolic response in the YS mice using indirect calorimetry and to alter Ca2+ release via RyR1 in isolated flexor digitorum brevis (FDB) fibers from WT and YS mice using fluorescent Ca2+ indicators. Simvastatin 36-47 ryanodine receptor 1, skeletal muscle Mus musculus 156-160 24023786-8 2013 Circulating irisin increased significantly in simvastatin-treated but not in ezetimibe-treated subjects. Simvastatin 46-57 fibronectin type III domain containing 5 Homo sapiens 12-18 24004537-12 2013 CONCLUSIONS: A mutation in RyR1 associated with malignant hyperthermia increases susceptibility to an adverse response to simvastatin due to enhanced Ca2+ release from the sarcoplasmic reticulum, suggesting that RyR1 mutations may underlie enhanced susceptibility to statin-induced myopathies. Simvastatin 122-133 ryanodine receptor 1, skeletal muscle Mus musculus 27-31 24023786-10 2013 In HSKMCs, simvastatin significantly increased irisin secretion as well as mRNA expression of its parent peptide hormone FNDC5. Simvastatin 11-22 fibronectin type III domain containing 5 Homo sapiens 47-53 24004537-12 2013 CONCLUSIONS: A mutation in RyR1 associated with malignant hyperthermia increases susceptibility to an adverse response to simvastatin due to enhanced Ca2+ release from the sarcoplasmic reticulum, suggesting that RyR1 mutations may underlie enhanced susceptibility to statin-induced myopathies. Simvastatin 122-133 ryanodine receptor 1, skeletal muscle Mus musculus 212-216 24023786-10 2013 In HSKMCs, simvastatin significantly increased irisin secretion as well as mRNA expression of its parent peptide hormone FNDC5. Simvastatin 11-22 fibronectin type III domain containing 5 Homo sapiens 121-126 24649034-12 2013 The combination of 1.0 muM simvastatin and 2 ng/ml FGF-2 achieved a higher estrogen receptor-alpha expression compared to the 2 ng/ml FGF-2-only group. Simvastatin 27-38 fibroblast growth factor 2 Rattus norvegicus 134-139 24023786-11 2013 Simvastatin significantly induced cellular reactive oxygen species levels along with expression of pro- and anti-oxidative genes such as Nox2, and MnSOD and catalase, respectively. Simvastatin 0-11 cytochrome b-245 beta chain Homo sapiens 137-141 24023786-11 2013 Simvastatin significantly induced cellular reactive oxygen species levels along with expression of pro- and anti-oxidative genes such as Nox2, and MnSOD and catalase, respectively. Simvastatin 0-11 superoxide dismutase 2 Homo sapiens 147-152 24023786-11 2013 Simvastatin significantly induced cellular reactive oxygen species levels along with expression of pro- and anti-oxidative genes such as Nox2, and MnSOD and catalase, respectively. Simvastatin 0-11 catalase Homo sapiens 157-165 24023786-12 2013 Markers of cellular stress such as atrogin-1 mRNA and Bax protein expression were also induced by simvastatin. Simvastatin 98-109 F-box protein 32 Homo sapiens 35-44 24023786-12 2013 Markers of cellular stress such as atrogin-1 mRNA and Bax protein expression were also induced by simvastatin. Simvastatin 98-109 BCL2 associated X, apoptosis regulator Homo sapiens 54-57 24023786-13 2013 Decreased cell viability and increased irisin secretion by simvastatin was reversed by antioxidant mito-TEMPO, implying in part that irisin is secreted as a result of increased mitochondrial oxidative stress and subsequent myocyte damage. Simvastatin 59-70 fibronectin type III domain containing 5 Homo sapiens 39-45 24023786-13 2013 Decreased cell viability and increased irisin secretion by simvastatin was reversed by antioxidant mito-TEMPO, implying in part that irisin is secreted as a result of increased mitochondrial oxidative stress and subsequent myocyte damage. Simvastatin 59-70 fibronectin type III domain containing 5 Homo sapiens 133-139 24023786-14 2013 CONCLUSIONS: Simvastatin increases irisin concentrations in vivo and in vitro. Simvastatin 13-24 fibronectin type III domain containing 5 Homo sapiens 35-41 24288725-1 2013 Analysis of metabolic changes in rat erythrocytes against the background of long-term simvastatin treatment revealed an increase in glycolysis metabolite concentrations and glucose-6-phosphate dehydrogenase activity and oppositely directed shifts in antioxidant defense enzyme activities. Simvastatin 86-97 glucose-6-phosphate dehydrogenase Rattus norvegicus 173-206 24649034-11 2013 The cultures grown in the presence of 1 muM of simvastatin and 2 ng/ml of FGF-2 exhibited increased ALP activity when compared to that in the 2 ng/ml FGF-2-only group. Simvastatin 47-58 fibroblast growth factor 2 Rattus norvegicus 150-155 24028188-6 2013 Simvastatin significantly attenuated TNF-alpha-induced CCL2 secretion without affecting CCL2 mRNA or protein expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 37-46 24028188-6 2013 Simvastatin significantly attenuated TNF-alpha-induced CCL2 secretion without affecting CCL2 mRNA or protein expression. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 55-59 24028188-8 2013 By comparison, inhibiting protein isoprenylation with GGTI-298, but not FTI-277, mimicked the effect of simvastatin and significantly attenuated transendothelial migration in vitro. Simvastatin 104-115 protein geranylgeranyltransferase type I subunit beta Homo sapiens 54-58 24075515-9 2013 RESULTS: After five months of treatment, simvastatin was able to significantly delay progression of mPanINs in LsL-Kras(G12D); Pdx1-Cre mice. Simvastatin 41-52 Kirsten rat sarcoma viral oncogene homolog Mus musculus 115-119 23876348-0 2013 Simvastatin treatment increases nitrite levels in obese women: modulation by T(-786)C polymorphism of eNOS. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 102-106 24075515-9 2013 RESULTS: After five months of treatment, simvastatin was able to significantly delay progression of mPanINs in LsL-Kras(G12D); Pdx1-Cre mice. Simvastatin 41-52 pancreatic and duodenal homeobox 1 Mus musculus 127-131 24075515-10 2013 Furthermore, formation of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by simvastatin. Simvastatin 142-153 Kirsten rat sarcoma viral oncogene homolog Mus musculus 60-64 24075515-10 2013 Furthermore, formation of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by simvastatin. Simvastatin 142-153 transformation related protein 53 Mus musculus 76-81 24075515-10 2013 Furthermore, formation of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by simvastatin. Simvastatin 142-153 pancreatic and duodenal homeobox 1 Mus musculus 90-94 23583255-9 2013 Similarly, skeletal muscle citrate synthase activity increased by 13% in the exercise-only group (p < 0.05), but decreased by 4.5% in the simvastatin-plus-exercise group (p < 0.05 for group-by-time interaction). Simvastatin 141-152 citrate synthase Homo sapiens 27-43 23961716-5 2013 METHODS: Human embryonic kidney cells HEK-293T and human pancreatic cancer cells MiaPaCa-2 were treated with simvastatin (6 and 12 muM) for 24 and 48 hours respectively. Simvastatin 109-120 latexin Homo sapiens 131-134 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 cyclin D2 Homo sapiens 119-128 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 130-135 23769741-4 2013 Because the mitochondrial function is crucial for cell survival and proliferation, we hypothesize that simvastatin may promote human osteoblast (hOBs) proliferation and it may be related to mitochondrial function. Simvastatin 103-114 leptin Homo sapiens 145-149 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 153-158 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 associated X, apoptosis regulator Homo sapiens 162-165 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 153-158 23769741-5 2013 Our results showed that simvastatin significantly enhanced proliferation and increased both mRNA and protein levels of cyclin D2, Bcl-2 and the ratio of Bcl-2 to Bax (Bcl-2/Bax). Simvastatin 24-35 BCL2 associated X, apoptosis regulator Homo sapiens 173-176 23769741-6 2013 Furthermore, simvastatin increased mitochondrial activity and ATP content of hOBs. Simvastatin 13-24 leptin Homo sapiens 77-81 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 96-107 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 96-107 leptin Homo sapiens 254-258 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 183-194 cyclin D2 Homo sapiens 220-229 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 183-194 BCL2 apoptosis regulator Homo sapiens 234-239 23769741-7 2013 Most importantly, treatment with ATP synthase blocker, oligomycin, significantly decreased both simvastatin-stimulated ATP content and cell proliferation, and completely reversed the simvastatin-induced up-regulation of cyclin D2 and Bcl-2 expression in hOBs. Simvastatin 183-194 leptin Homo sapiens 254-258 23769741-9 2013 These results indicate that the up-regulation of cyclin D2 and Bcl-2/Bax by simvastatin depends on the intact function of ATP synthase in the mitochondria of hOBs. Simvastatin 76-87 cyclin D2 Homo sapiens 49-58 23769741-9 2013 These results indicate that the up-regulation of cyclin D2 and Bcl-2/Bax by simvastatin depends on the intact function of ATP synthase in the mitochondria of hOBs. Simvastatin 76-87 BCL2 apoptosis regulator Homo sapiens 63-68 23769741-9 2013 These results indicate that the up-regulation of cyclin D2 and Bcl-2/Bax by simvastatin depends on the intact function of ATP synthase in the mitochondria of hOBs. Simvastatin 76-87 BCL2 associated X, apoptosis regulator Homo sapiens 69-72 23769741-9 2013 These results indicate that the up-regulation of cyclin D2 and Bcl-2/Bax by simvastatin depends on the intact function of ATP synthase in the mitochondria of hOBs. Simvastatin 76-87 leptin Homo sapiens 158-162 23769741-10 2013 It suggests that simvastatin may promote hOB proliferation, at least partly, via up-regulating mitochondrial function and subsequently cyclin D2 and Bcl-2/Bax expression. Simvastatin 17-28 cyclin D2 Homo sapiens 135-144 23769741-10 2013 It suggests that simvastatin may promote hOB proliferation, at least partly, via up-regulating mitochondrial function and subsequently cyclin D2 and Bcl-2/Bax expression. Simvastatin 17-28 BCL2 apoptosis regulator Homo sapiens 149-154 23769741-10 2013 It suggests that simvastatin may promote hOB proliferation, at least partly, via up-regulating mitochondrial function and subsequently cyclin D2 and Bcl-2/Bax expression. Simvastatin 17-28 BCL2 associated X, apoptosis regulator Homo sapiens 155-158 23773358-5 2013 In fully MHC-mismatched kidney allografts with 16-h cold and 1-h warm ischemia, donor simvastatin treatment increased the expression of flow-regulated transcription factor KLF2 and vasculoprotective eNOS and HO-1, and preserved glomerular and peritubular capillary barrier integrity during preservation. Simvastatin 86-97 Kruppel like factor 2 Homo sapiens 172-176 23732466-0 2013 CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. Simvastatin 17-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 23583370-0 2013 Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 68-75 23583370-0 2013 Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Simvastatin 0-11 tumor protein p53 Homo sapiens 76-79 23583370-9 2013 Simvastatin"s actions on p21(cip/Waf1), survivin and apoptosis were reduced in p53 null HCT116 cells. Simvastatin 0-11 cyclin dependent kinase inhibitor 1A Homo sapiens 25-28 23583370-9 2013 Simvastatin"s actions on p21(cip/Waf1), survivin and apoptosis were reduced in p53 null HCT116 cells. Simvastatin 0-11 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 23583370-9 2013 Simvastatin"s actions on p21(cip/Waf1), survivin and apoptosis were reduced in p53 null HCT116 cells. Simvastatin 0-11 tumor protein p53 Homo sapiens 79-82 23583370-10 2013 Simvastatin caused an increase in p53 phosphorylation and acetylation. Simvastatin 0-11 tumor protein p53 Homo sapiens 34-37 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 35-71 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 73-80 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 135-146 mitogen-activated protein kinase 14 Homo sapiens 107-114 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 135-146 tumor protein p53 Homo sapiens 171-174 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 135-146 cyclin dependent kinase inhibitor 1A Homo sapiens 179-182 23583370-11 2013 In addition, simvastatin activated p38 mitogen-activated protein kinase (p38MAPK), whereas an inhibitor of p38MAPK signaling abrogated simvastatin"s effects of increasing p53 and p21(cip/Waf1) promoter luciferase activity. Simvastatin 135-146 cyclin dependent kinase inhibitor 1A Homo sapiens 187-191 23583370-12 2013 Cell viability and survivin promoter luciferase activity in the presence of simvastatin were also restored by p38MAPK inhibitor. Simvastatin 76-87 mitogen-activated protein kinase 14 Homo sapiens 110-117 23583370-13 2013 Furthermore, Sp1 binding to the survivin promoter region decreased while p53 and p63 binding to the promoter region increased after simvastatin exposure. Simvastatin 132-143 tumor protein p53 Homo sapiens 73-76 23583370-13 2013 Furthermore, Sp1 binding to the survivin promoter region decreased while p53 and p63 binding to the promoter region increased after simvastatin exposure. Simvastatin 132-143 tumor protein p63 Homo sapiens 81-84 23583370-14 2013 CONCLUSIONS: Simvastatin activates the p38MAPK-p53-survivin cascade to cause HCT116 colorectal cancer cell apoptosis. Simvastatin 13-24 mitogen-activated protein kinase 14 Homo sapiens 39-46 23583370-14 2013 CONCLUSIONS: Simvastatin activates the p38MAPK-p53-survivin cascade to cause HCT116 colorectal cancer cell apoptosis. Simvastatin 13-24 tumor protein p53 Homo sapiens 47-50 23773358-6 2013 In vitro EC Weibel-Palade body exocytosis assays showed that simvastatin inhibited ischemia-induced release of vasoactive angiopoietin-2 and endothelin-1. Simvastatin 61-72 angiopoietin 2 Homo sapiens 122-136 23773358-6 2013 In vitro EC Weibel-Palade body exocytosis assays showed that simvastatin inhibited ischemia-induced release of vasoactive angiopoietin-2 and endothelin-1. Simvastatin 61-72 endothelin 1 Homo sapiens 141-153 23773358-7 2013 After reperfusion, donor simvastatin treatment prevented microvascular permeability, danger-associated ligand hyaluronan induction, tubulointerstitial injury marker Kim-1 immunoreactivity and serum creatinine and NGAL levels, and activation of innate and adaptive immune responses. Simvastatin 25-36 hepatitis A virus cellular receptor 1 Homo sapiens 165-170 23773358-7 2013 After reperfusion, donor simvastatin treatment prevented microvascular permeability, danger-associated ligand hyaluronan induction, tubulointerstitial injury marker Kim-1 immunoreactivity and serum creatinine and NGAL levels, and activation of innate and adaptive immune responses. Simvastatin 25-36 lipocalin 2 Homo sapiens 213-217 23603515-8 2013 Simvastatin, an inhibitor of cholesterol synthesis, also abrogated rituximab-mediated Syk and Akt activation. Simvastatin 0-11 spleen associated tyrosine kinase Homo sapiens 86-89 23880197-0 2013 Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Simvastatin 48-59 apolipoprotein B Homo sapiens 84-100 23865383-11 2013 MTHFR C677T genetic variant contributes to simvastatin"s effects among Chinese subjects with primary hyperlipidemia. Simvastatin 43-54 methylenetetrahydrofolate reductase Homo sapiens 0-5 23588308-4 2013 Elevated simvastatin area under the plasma concentration-time curve (AUC) in virtual rheumatoid arthritis (RA) patients, following 100 pg/ml of IL-6, was comparable to observed clinical data (59 vs. 58%). Simvastatin 9-20 interleukin 6 Homo sapiens 144-148 23583640-6 2013 In comparison, neutralizing ICAM-1 and LFA-1 antibodies, as well as the LFA-1 blocker simvastatin, caused a dose-dependent reduction in the number of viable SNK6 cells. Simvastatin 86-97 integrin subunit alpha L Homo sapiens 72-77 23603515-8 2013 Simvastatin, an inhibitor of cholesterol synthesis, also abrogated rituximab-mediated Syk and Akt activation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 94-97 23941653-0 2013 Simvastatin decreases stent-induced in-stent restenosis rate via downregulating the expression of PCNA and upregulating that of p27kip1. Simvastatin 0-11 proliferating cell nuclear antigen Oryctolagus cuniculus 98-102 23941653-9 2013 Finally, the expression of p27kip1 increased, while that of PCNA decreased significantly in the simvastatin group compared to the control group (P<0.05). Simvastatin 96-107 proliferating cell nuclear antigen Oryctolagus cuniculus 60-64 23941653-10 2013 CONCLUSIONS: Simvastatin may inhibit VSMC phenotype modulation and proliferation by downregulating the expression of PCNA and upregulating that of p27kip1. Simvastatin 13-24 proliferating cell nuclear antigen Oryctolagus cuniculus 117-121 23181416-11 2013 Simvastatin reduced expression of iNOS, MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 34-38 24471035-3 2013 The adequate concentration of simvastatin for osteogenic induction was determined using bone morphogenetic protein (BMP-2). Simvastatin 30-41 bone morphogenetic protein 1 Homo sapiens 88-114 24471035-3 2013 The adequate concentration of simvastatin for osteogenic induction was determined using bone morphogenetic protein (BMP-2). Simvastatin 30-41 bone morphogenetic protein 2 Homo sapiens 116-121 24471035-5 2013 RESULTS: Expression of BMP-2 mRNA and protein was observed after three days and was dependent on the concentration of simvastatin. Simvastatin 118-129 bone morphogenetic protein 2 Homo sapiens 23-28 24471035-6 2013 Expression of osteocalcin mRNA was observed after three days in the 1.0 microM simvastatin-treated group. Simvastatin 79-90 bone gamma-carboxyglutamate protein Homo sapiens 14-25 23181416-11 2013 Simvastatin reduced expression of iNOS, MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue. Simvastatin 0-11 matrix metallopeptidase 1 Rattus norvegicus 40-52 23181416-11 2013 Simvastatin reduced expression of iNOS, MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue. Simvastatin 0-11 TNF superfamily member 11 Rattus norvegicus 64-69 23181416-11 2013 Simvastatin reduced expression of iNOS, MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 84-89 23181416-11 2013 Simvastatin reduced expression of iNOS, MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue. Simvastatin 0-11 TNF receptor superfamily member 11B Rattus norvegicus 94-97 23636169-4 2013 Simvastatin was used to decrease VEGF-A and MMP-9 gene expression in our murine arteriovenous fistula model created by connecting the right carotid artery to the ipsilateral jugular vein. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 33-39 23636169-4 2013 Simvastatin was used to decrease VEGF-A and MMP-9 gene expression in our murine arteriovenous fistula model created by connecting the right carotid artery to the ipsilateral jugular vein. Simvastatin 0-11 matrix metallopeptidase 9 Mus musculus 44-49 23636169-5 2013 Compared to fistulae of vehicle-treated mice, the fistulae of simvastatin-treated mice had the expected decrease in VEGF-A and MMP-9 but also showed a significant reduction in MMP-2 expression with a significant decrease in VNH and a significant increase in the mean lumen vessel area. Simvastatin 62-73 vascular endothelial growth factor A Mus musculus 116-122 23636169-5 2013 Compared to fistulae of vehicle-treated mice, the fistulae of simvastatin-treated mice had the expected decrease in VEGF-A and MMP-9 but also showed a significant reduction in MMP-2 expression with a significant decrease in VNH and a significant increase in the mean lumen vessel area. Simvastatin 62-73 matrix metallopeptidase 9 Mus musculus 127-132 23636169-5 2013 Compared to fistulae of vehicle-treated mice, the fistulae of simvastatin-treated mice had the expected decrease in VEGF-A and MMP-9 but also showed a significant reduction in MMP-2 expression with a significant decrease in VNH and a significant increase in the mean lumen vessel area. Simvastatin 62-73 matrix metallopeptidase 2 Mus musculus 176-181 23636169-8 2013 Simvastatin-treated fibroblasts had a significant decrease in myofibroblast production along with decreased cellular proliferation, migration, and MMP-9 activity but increased caspase 3 activity suggesting increased apoptosis. Simvastatin 0-11 matrix metallopeptidase 9 Mus musculus 147-152 23636169-8 2013 Simvastatin-treated fibroblasts had a significant decrease in myofibroblast production along with decreased cellular proliferation, migration, and MMP-9 activity but increased caspase 3 activity suggesting increased apoptosis. Simvastatin 0-11 caspase 3 Mus musculus 176-185 23636169-9 2013 Thus, simvastatin results in a significant reduction in VNH, with increase in mean lumen vessel area by decreasing VEGF-A/MMP-9 pathway activity. Simvastatin 6-17 vascular endothelial growth factor A Mus musculus 115-121 23636169-9 2013 Thus, simvastatin results in a significant reduction in VNH, with increase in mean lumen vessel area by decreasing VEGF-A/MMP-9 pathway activity. Simvastatin 6-17 matrix metallopeptidase 9 Mus musculus 122-127 23496027-0 2013 Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Simvastatin 82-93 solute carrier family 2 member 4 Homo sapiens 42-47 24100891-6 2013 Concentrations of 0.05 and 0.1 mumol/L simvastatin were administrated to ASCs for real-time PCR of angiogenesis-osteogenesis related genes like RUNX2, OPN, OCN, and VEGF on day 1, 7. Simvastatin 39-50 runt-related transcription factor 2 Oryctolagus cuniculus 144-149 23496027-9 2013 RESULTS: Treatment with simvastatin (P<0.001) and simvastatin plus ezetimibe (P<0.001) significantly decreased GLUT4 protein expression in the adipocytes compared to control conditions. Simvastatin 24-35 solute carrier family 2 member 4 Homo sapiens 117-122 23496027-9 2013 RESULTS: Treatment with simvastatin (P<0.001) and simvastatin plus ezetimibe (P<0.001) significantly decreased GLUT4 protein expression in the adipocytes compared to control conditions. Simvastatin 53-64 solute carrier family 2 member 4 Homo sapiens 117-122 23496027-12 2013 CONCLUSION: Our studies have shown that lipophilic statins (simvastatin) reduce the GLUT4 protein levels in adipocytes, whereas hydrophilic statins (pravastatin) or ezetimibe do not. Simvastatin 60-71 solute carrier family 2 member 4 Homo sapiens 84-89 23496027-13 2013 Co-treatment with CoQ10 appears to prevent the reduction in GLUT4 protein levels caused by simvastatin. Simvastatin 91-102 solute carrier family 2 member 4 Homo sapiens 60-65 23620550-12 2013 Increased cutaneous and pulmonary expression of VEGF, ERK, Ras and Rho in mice treated with HOCl was significantly lower in mice treated with HOCl plus simvastatin. Simvastatin 152-163 vascular endothelial growth factor A Mus musculus 48-52 23620550-12 2013 Increased cutaneous and pulmonary expression of VEGF, ERK, Ras and Rho in mice treated with HOCl was significantly lower in mice treated with HOCl plus simvastatin. Simvastatin 152-163 mitogen-activated protein kinase 1 Mus musculus 54-57 23930676-0 2013 Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Simvastatin 55-66 peroxisome proliferator activated receptor alpha Homo sapiens 25-30 23930676-7 2013 CONCLUSION: The minor alleles of the PPARA rs4253728 and rs4823613 polymorphisms are associated with a better total and LDL-cholesterol-lowering response to simvastatin, possibly through influence on CYP3A4. Simvastatin 157-168 peroxisome proliferator activated receptor alpha Homo sapiens 37-42 23930676-7 2013 CONCLUSION: The minor alleles of the PPARA rs4253728 and rs4823613 polymorphisms are associated with a better total and LDL-cholesterol-lowering response to simvastatin, possibly through influence on CYP3A4. Simvastatin 157-168 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 200-206 24100891-6 2013 Concentrations of 0.05 and 0.1 mumol/L simvastatin were administrated to ASCs for real-time PCR of angiogenesis-osteogenesis related genes like RUNX2, OPN, OCN, and VEGF on day 1, 7. Simvastatin 39-50 osteopontin Oryctolagus cuniculus 151-154 24100891-6 2013 Concentrations of 0.05 and 0.1 mumol/L simvastatin were administrated to ASCs for real-time PCR of angiogenesis-osteogenesis related genes like RUNX2, OPN, OCN, and VEGF on day 1, 7. Simvastatin 39-50 vascular endothelial growth factor A Oryctolagus cuniculus 165-169 24100891-13 2013 RESULTS: The use of simvastatin with the concentration of 0.05 mumol/L enhanced the expression of angiogenic-osteogenic related genes like RUNX2, OPN, OCN, and VEGF. Simvastatin 20-31 runt-related transcription factor 2 Oryctolagus cuniculus 139-144 24100891-13 2013 RESULTS: The use of simvastatin with the concentration of 0.05 mumol/L enhanced the expression of angiogenic-osteogenic related genes like RUNX2, OPN, OCN, and VEGF. Simvastatin 20-31 osteopontin Oryctolagus cuniculus 146-149 24100891-13 2013 RESULTS: The use of simvastatin with the concentration of 0.05 mumol/L enhanced the expression of angiogenic-osteogenic related genes like RUNX2, OPN, OCN, and VEGF. Simvastatin 20-31 vascular endothelial growth factor A Oryctolagus cuniculus 160-164 23870614-0 2013 Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury. Simvastatin 0-11 azurocidin 1 Homo sapiens 35-58 23870614-2 2013 We sought to investigate whether oral administration of simvastatin to patients with acute lung injury reduces plasma heparin-binding protein levels and improves intensive care unit outcome. Simvastatin 56-67 azurocidin 1 Homo sapiens 118-141 23870614-7 2013 Simvastatin 80 mg administered enterally for 14 days reduced plasma level of heparin-binding protein in patients. Simvastatin 0-11 azurocidin 1 Homo sapiens 77-100 23870614-9 2013 CONCLUSIONS: A reduction in heparin-binding protein with simvastatin is a potential mechanism by which the statin may modify outcome from acute lung injury. Simvastatin 57-68 azurocidin 1 Homo sapiens 28-51 23846804-0 2013 HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. Simvastatin 30-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 23314557-9 2013 Urinary albumin concentrations were significantly higher in patients taking simvastatin than in patients on rosuvastatin treatment and they were also higher in patients on statin therapy with a total serum cholesterol concentration below 3.88 mmol/L than in patients with a total serum cholesterol concentration above 5.17 mmol/L. Simvastatin 76-87 albumin Homo sapiens 8-15 23661227-6 2013 The combination of sulindac and simvastatin also increased the loss of mitochondrial transmembrane potential ( Psim) and the cytosolic release of cytochrome c. Simvastatin 32-43 cytochrome c, somatic Homo sapiens 146-158 23661227-8 2013 The enhancement of ROS generation by sulindac and simvastatin was abrogated by pretreatment with NAC, which also prevented apoptosis and mitochondrial dysfunction induced by sulindac and simvastatin. Simvastatin 50-61 synuclein alpha Homo sapiens 97-100 23661227-8 2013 The enhancement of ROS generation by sulindac and simvastatin was abrogated by pretreatment with NAC, which also prevented apoptosis and mitochondrial dysfunction induced by sulindac and simvastatin. Simvastatin 187-198 synuclein alpha Homo sapiens 97-100 23846804-0 2013 HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. Simvastatin 30-41 ATP binding cassette subfamily G member 1 Homo sapiens 73-78 23846804-4 2013 Treatment with statins significantly decreased ABCG1-mediated cholesterol efflux in human macrophages (from 33.8% +- 2.8% of control to 22.9% +- 1.7% of 10 microM simvastatin or to 23.3% +- 3.3% of 10 microM atorvastatin; P < 0.01, n = 4), whereas the protein expression of ABCG1 remained unaltered on statins. Simvastatin 163-174 ATP binding cassette subfamily G member 1 Homo sapiens 47-52 23846804-9 2013 In conclusion, simvastatin and atorvastatin decreased ABCG1-mediated cholesterol efflux in human macrophages without alteration of total ABCG1 protein level. Simvastatin 15-26 ATP binding cassette subfamily G member 1 Homo sapiens 54-59 23866306-5 2013 In non-obese subjects (n = 342), percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. Simvastatin 135-146 apolipoprotein B Homo sapiens 89-94 23866306-5 2013 In non-obese subjects (n = 342), percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. Simvastatin 135-146 apolipoprotein A1 Homo sapiens 99-106 23866306-7 2013 CONCLUSIONS: Regardless of baseline obesity status, switching to ezetimibe/simvastatin was more effective at reducing LDL-C, total cholesterol, non-HDL-C, and Apo B vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg. Simvastatin 75-86 apolipoprotein B Homo sapiens 159-164 24169290-6 2013 After a 9-hour incubation with 1.0, 2.5, 5.0 micromol/L simvastatin, the CD206 expression levels were 68.10% +- 2.48%, 75.28% +- 1.66%, 86.32% +- 2.19% and the secretion of IL-10 (500 +- 5), (675 +- 28) and (916 +- 15) pg/ml respectively. Simvastatin 56-67 mannose receptor, C type 1 Mus musculus 73-78 24169290-6 2013 After a 9-hour incubation with 1.0, 2.5, 5.0 micromol/L simvastatin, the CD206 expression levels were 68.10% +- 2.48%, 75.28% +- 1.66%, 86.32% +- 2.19% and the secretion of IL-10 (500 +- 5), (675 +- 28) and (916 +- 15) pg/ml respectively. Simvastatin 56-67 interleukin 10 Mus musculus 173-178 23890516-0 2013 Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Simvastatin 216-227 apolipoprotein B Homo sapiens 176-192 23697627-2 2013 In this work the widely prescribed cholesterol-lowering drug simvastatin was investigated by combining experimental (combustion calorimetry and differential scanning calorimetry, DSC) and computational chemistry (quantum chemistry and molecular dynamics calculations) results. Simvastatin 61-72 desmocollin 3 Homo sapiens 179-182 24380094-3 2013 To identify the conditions for beneficial effects, this study investigated the response to atorvastatin and simvastatin treatment in type 2 diabetic patients with elevated low-density lipoprotein cholesterol (LDL-C). Simvastatin 108-119 component of oligomeric golgi complex 2 Homo sapiens 209-214 23564041-7 2013 Here we show that simvastatin treatment leads to ABCB1 inhibition and down-regulation of the transporter. Simvastatin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 24380094-7 2013 There were significant reductions in LDL-C in both the atorvastatin (37.1%) and simvastatin (34.3%) group after one year of treatment compared with baseline levels. Simvastatin 80-91 component of oligomeric golgi complex 2 Homo sapiens 37-42 23672611-0 2013 Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats. Simvastatin 11-22 endothelin 1 Rattus norvegicus 78-90 23816135-0 2013 Simvastatin increases ADAMTS13 expression in podocytes. Simvastatin 0-11 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 22-30 23672611-11 2013 Simvastatin preincubation reduced collateral perfusion pressure changes to ET-1 (p < 0.05), which were partially reversed by NNA (p < 0.05), but not by indomethacin. Simvastatin 0-11 endothelin 1 Rattus norvegicus 75-79 23816135-4 2013 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has a beneficial effect on atherosclerosis and also has anti-inflammatory and antithrombotic properties. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 15-62 23816135-6 2013 In our study, we investigated the effects of simvastatin on inflammatory cytokines-induced ADAMTS13 expression in podocytes. Simvastatin 45-56 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 91-99 23816135-8 2013 The influence of TNF-alpha, IL-4, IL-6 and simvastatin on ADAMTS13 was investigated. Simvastatin 43-54 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 58-66 23816135-10 2013 RESULTS: Simvastatin significantly up-regulated the expression levels of ADAMTS13 mRNA and protein in podocytes. Simvastatin 9-20 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 73-81 23816135-13 2013 Simvastatin was able also reversed the inhibitory effect of IL-6. Simvastatin 0-11 interleukin 6 Mus musculus 60-64 23816135-14 2013 CONCLUSIONS: We demonstrate that simvastatin increases the expression of ADAMTS13 in a dose-dependent manner in podocytes, which likely contributes to the antithrombotic property of statin. Simvastatin 33-44 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 73-81 23799098-8 2013 A time (2-30 min)- and concentration (0.1-10 microM)-dependent increase by simvastatin of p-AMPKalpha-Thr(172) and p-PP2A-Tyr(307) expression was observed. Simvastatin 75-86 protein phosphatase 2 phosphatase activator Homo sapiens 117-121 24124673-10 2013 CONCLUSIONS: The combined use of beraprost and simvastatin may delay the increase of mPAP and remodeling of pulmonary vessels and inhibit right ventricular hypertrophy in pulmonary arterial hypertension rats. Simvastatin 47-58 phospholipid phosphatase 1 Mus musculus 85-89 23799098-10 2013 Simvastatin-induced p-PP2A-Tyr(307) expression was suppressed by okadaic acid, compound C, ryanodine, KN93, phloridzin (1 mM), ouabain (10 microM), and in [glucose]o-free or [Na(+)]o-free conditions. Simvastatin 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 22-26 23799098-11 2013 CONCLUSIONS: Simvastatin causes ryanodine-sensitive Ca(2+) release which is important for AMPKalpha-Thr(172) phosphorylation via Ca(2+)/CaMK II. Simvastatin 13-24 calcium/calmodulin dependent protein kinase II gamma Homo sapiens 136-143 23527830-10 2013 Simvastatin administered from day 13 to 28 had no effect on HPC and LC, but reduced RV/(LV+S) significantly and induced a strong trend to lower RVSP and BNP levels. Simvastatin 0-11 natriuretic peptide B Rattus norvegicus 153-156 23564080-0 2013 Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Simvastatin 0-11 apolipoprotein E Mus musculus 68-72 23564080-0 2013 Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Simvastatin 0-11 high mobility group box 1 Mus musculus 105-110 23564080-0 2013 Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Simvastatin 0-11 MOK protein kinase Mus musculus 111-115 23579966-14 2013 Polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene is associated with increased statin exposure and simvastatin-induced myopathy. Simvastatin 130-141 solute carrier organic anion transporter family member 1B1 Homo sapiens 21-65 23579966-14 2013 Polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene is associated with increased statin exposure and simvastatin-induced myopathy. Simvastatin 130-141 solute carrier organic anion transporter family member 1B1 Homo sapiens 67-74 23564080-2 2013 The aim of this study was to determine whether the HMGB1-RAGE axis was involved in the actions of simvastatin on vascular inflammation and atherosclerosis in ApoE(-/-) mice. Simvastatin 98-109 high mobility group box 1 Mus musculus 51-56 23708174-1 2013 BACKGROUND: Carriers of the rs4363657C and rs4149056C alleles in SLCO1B1 have increased myopathic complaints when taking simvastatin. Simvastatin 121-132 solute carrier organic anion transporter family member 1B1 Homo sapiens 65-72 23564080-2 2013 The aim of this study was to determine whether the HMGB1-RAGE axis was involved in the actions of simvastatin on vascular inflammation and atherosclerosis in ApoE(-/-) mice. Simvastatin 98-109 MOK protein kinase Mus musculus 57-61 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 apolipoprotein E Mus musculus 35-39 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 high mobility group box 1 Mus musculus 168-173 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 MOK protein kinase Mus musculus 175-179 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 vascular cell adhesion molecule 1 Mus musculus 181-187 23564080-11 2013 Administration with simvastatin in ApoE(-/-) mice markedly attenuated the vascular inflammation and atherosclerotic lesion area, and decreased the aortic expression of HMGB1, RAGE, VCAM-1, and MCP-1. Simvastatin 20-31 chemokine (C-C motif) ligand 2 Mus musculus 193-198 23564080-13 2013 Exposure of HUVECs to HMGB1 (100 ng/mL) markedly increased the expression of HMGB1, RAGE and VCAM-1, whereas pretreatment of the cells with simvastatin (10 mumol/L) blocked the HMGB1-caused changes. Simvastatin 140-151 vascular cell adhesion molecule 1 Mus musculus 93-99 23564080-14 2013 CONCLUSION: Simvastatin inhibits vascular inflammation and atherosclerosis in ApoE(-/-) mice, which may be mediated through downregulation of the HMGB1-RAGE axis. Simvastatin 12-23 apolipoprotein E Mus musculus 78-82 23564080-14 2013 CONCLUSION: Simvastatin inhibits vascular inflammation and atherosclerosis in ApoE(-/-) mice, which may be mediated through downregulation of the HMGB1-RAGE axis. Simvastatin 12-23 high mobility group box 1 Mus musculus 146-151 23564080-14 2013 CONCLUSION: Simvastatin inhibits vascular inflammation and atherosclerosis in ApoE(-/-) mice, which may be mediated through downregulation of the HMGB1-RAGE axis. Simvastatin 12-23 MOK protein kinase Mus musculus 152-156 23580143-9 2013 Administering simvastatin to CIA mice ameliorated the endothelial dysfunction, with attendant decreased aortic level of MCPIP. Simvastatin 14-25 zinc finger CCCH type containing 12A Mus musculus 120-125 23275311-0 2013 Simvastatin protects hepatocytes from apoptosis by suppressing the TNF-alpha/caspase-3 signaling pathway in mice with burn injury. Simvastatin 0-11 tumor necrosis factor Mus musculus 67-76 23275311-0 2013 Simvastatin protects hepatocytes from apoptosis by suppressing the TNF-alpha/caspase-3 signaling pathway in mice with burn injury. Simvastatin 0-11 caspase 3 Mus musculus 77-86 23275311-6 2013 The effects of simvastatin on TNF-alpha and caspase-3 expressions were also evaluated in cultured mouse hepatocytes. Simvastatin 15-26 tumor necrosis factor Mus musculus 30-39 23275311-8 2013 Simvastatin reduced the apoptotic index in the livers of mice with burn injury and this effect could be abrogated by TNF-alpha or caspase-3 inhibitors. Simvastatin 0-11 tumor necrosis factor Mus musculus 117-126 23275311-8 2013 Simvastatin reduced the apoptotic index in the livers of mice with burn injury and this effect could be abrogated by TNF-alpha or caspase-3 inhibitors. Simvastatin 0-11 caspase 3 Mus musculus 130-139 23275311-9 2013 Simvastatin also decreased burn-induced TNF-alpha and caspase-3 expression in the liver. Simvastatin 0-11 tumor necrosis factor Mus musculus 40-49 23275311-9 2013 Simvastatin also decreased burn-induced TNF-alpha and caspase-3 expression in the liver. Simvastatin 0-11 caspase 3 Mus musculus 54-63 23275311-11 2013 An in vitro study demonstrated that simvastatin suppresses TNF-alpha and caspase-3 expression in primary cultures of mouse hepatocytes. Simvastatin 36-47 tumor necrosis factor Mus musculus 59-68 23275311-11 2013 An in vitro study demonstrated that simvastatin suppresses TNF-alpha and caspase-3 expression in primary cultures of mouse hepatocytes. Simvastatin 36-47 caspase 3 Mus musculus 73-82 23275311-12 2013 CONCLUSIONS: Simvastatin reduces mouse hepatocyte apoptosis by suppressing expression of the TNF-alpha/caspase-3 pathway. Simvastatin 13-24 tumor necrosis factor Mus musculus 93-102 23275311-12 2013 CONCLUSIONS: Simvastatin reduces mouse hepatocyte apoptosis by suppressing expression of the TNF-alpha/caspase-3 pathway. Simvastatin 13-24 caspase 3 Mus musculus 103-112 23263738-2 2013 Our goal was to investigate the impact of SLCO1B1 genetic polymorphism on the lipid-lowering effects of atorvastatin and simvastatin. Simvastatin 121-132 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-49 23625729-11 2013 In addition, simvastatin significantly decreased the expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, nuclear factor-kappaB, and caspase-3, and increased heme oxygenase-1 expression in testicular tissue of rats exposed to cadmium toxicity. Simvastatin 13-24 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 100-145 23625729-11 2013 In addition, simvastatin significantly decreased the expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, nuclear factor-kappaB, and caspase-3, and increased heme oxygenase-1 expression in testicular tissue of rats exposed to cadmium toxicity. Simvastatin 13-24 caspase 3 Rattus norvegicus 174-183 23625729-11 2013 In addition, simvastatin significantly decreased the expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, nuclear factor-kappaB, and caspase-3, and increased heme oxygenase-1 expression in testicular tissue of rats exposed to cadmium toxicity. Simvastatin 13-24 heme oxygenase 1 Rattus norvegicus 199-215 23618917-0 2013 Simvastatin attenuates the additive effects of TNF-alpha and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Simvastatin 0-11 tumor necrosis factor Oryctolagus cuniculus 47-56 23618917-0 2013 Simvastatin attenuates the additive effects of TNF-alpha and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Simvastatin 0-11 interleukin-18 Oryctolagus cuniculus 61-66 23618917-0 2013 Simvastatin attenuates the additive effects of TNF-alpha and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Simvastatin 0-11 gap junction alpha-1 protein Oryctolagus cuniculus 74-85 23618917-2 2013 The aims of this study were to examine the regulatory role of interleukin-18 (IL-18) in the connexin 43 (Cx43) and the proliferation of cultured aortic smooth muscle cells (SMCs) as well as to elucidate the underlying therapeutic mechanism of simvastatin. Simvastatin 243-254 interleukin-18 Oryctolagus cuniculus 62-76 23618917-5 2013 Simvastatin treatment alone reduced constitutive Cx43 levels and prevented the TNF-alpha-induced IL-18 up-regulation. Simvastatin 0-11 gap junction alpha-1 protein Oryctolagus cuniculus 49-53 23618917-5 2013 Simvastatin treatment alone reduced constitutive Cx43 levels and prevented the TNF-alpha-induced IL-18 up-regulation. Simvastatin 0-11 tumor necrosis factor Oryctolagus cuniculus 79-88 23618917-5 2013 Simvastatin treatment alone reduced constitutive Cx43 levels and prevented the TNF-alpha-induced IL-18 up-regulation. Simvastatin 0-11 interleukin-18 Oryctolagus cuniculus 97-102 23618917-6 2013 Mechanistic investigation using kinase-specific inhibitors showed that simvastatin pretreatment attenuated TNF-alpha-elicited Akt and ERK1/2 phosphorylation, whereas PI3K and all MAPK activities were also implied in the additive effect of TNF-alpha and IL-18 on Cx43 up-regulation. Simvastatin 71-82 tumor necrosis factor Oryctolagus cuniculus 107-116 23618917-6 2013 Mechanistic investigation using kinase-specific inhibitors showed that simvastatin pretreatment attenuated TNF-alpha-elicited Akt and ERK1/2 phosphorylation, whereas PI3K and all MAPK activities were also implied in the additive effect of TNF-alpha and IL-18 on Cx43 up-regulation. Simvastatin 71-82 tumor necrosis factor Oryctolagus cuniculus 239-248 23618917-6 2013 Mechanistic investigation using kinase-specific inhibitors showed that simvastatin pretreatment attenuated TNF-alpha-elicited Akt and ERK1/2 phosphorylation, whereas PI3K and all MAPK activities were also implied in the additive effect of TNF-alpha and IL-18 on Cx43 up-regulation. Simvastatin 71-82 interleukin-18 Oryctolagus cuniculus 253-258 23618917-6 2013 Mechanistic investigation using kinase-specific inhibitors showed that simvastatin pretreatment attenuated TNF-alpha-elicited Akt and ERK1/2 phosphorylation, whereas PI3K and all MAPK activities were also implied in the additive effect of TNF-alpha and IL-18 on Cx43 up-regulation. Simvastatin 71-82 gap junction alpha-1 protein Oryctolagus cuniculus 262-266 23618917-8 2013 Likewise, simvastatin treatment suppressed the SMC over-proliferation induced not only by TNF-alpha alone, but also by simultaneous treatment with TNF-alpha and IL-18. Simvastatin 10-21 tumor necrosis factor Oryctolagus cuniculus 90-99 23618917-8 2013 Likewise, simvastatin treatment suppressed the SMC over-proliferation induced not only by TNF-alpha alone, but also by simultaneous treatment with TNF-alpha and IL-18. Simvastatin 10-21 tumor necrosis factor Oryctolagus cuniculus 147-156 23618917-8 2013 Likewise, simvastatin treatment suppressed the SMC over-proliferation induced not only by TNF-alpha alone, but also by simultaneous treatment with TNF-alpha and IL-18. Simvastatin 10-21 interleukin-18 Oryctolagus cuniculus 161-166 23618917-10 2013 In conclusion, simvastatin attenuates the additive effects of TNF-alpha and IL-18 on Cx43 up-regulation and over-proliferation of aortic SMCs, mainly through the blockade of Akt signaling pathway. Simvastatin 15-26 tumor necrosis factor Oryctolagus cuniculus 62-71 23618917-10 2013 In conclusion, simvastatin attenuates the additive effects of TNF-alpha and IL-18 on Cx43 up-regulation and over-proliferation of aortic SMCs, mainly through the blockade of Akt signaling pathway. Simvastatin 15-26 interleukin-18 Oryctolagus cuniculus 76-81 23618917-10 2013 In conclusion, simvastatin attenuates the additive effects of TNF-alpha and IL-18 on Cx43 up-regulation and over-proliferation of aortic SMCs, mainly through the blockade of Akt signaling pathway. Simvastatin 15-26 gap junction alpha-1 protein Oryctolagus cuniculus 85-89 23832723-1 2013 OBJECTIVES: The aim of this study was to investigate the influences of Simvastatin (Zocor) on nitric oxide (NO), calcitonin gene related peptide (CGRP) and endothelin (ET) in blood plasma of patients with coronary heart disease (CHD) complicated with congestive heart failure (CHF). Simvastatin 71-82 calcitonin related polypeptide alpha Homo sapiens 113-144 23832723-1 2013 OBJECTIVES: The aim of this study was to investigate the influences of Simvastatin (Zocor) on nitric oxide (NO), calcitonin gene related peptide (CGRP) and endothelin (ET) in blood plasma of patients with coronary heart disease (CHD) complicated with congestive heart failure (CHF). Simvastatin 84-89 calcitonin related polypeptide alpha Homo sapiens 113-144 23832723-10 2013 CONCLUSIONS: The combination of conventional treatment and Simvastatin could significantly improve metabolic disturbances of NO, CGRP and ET of patients with CHD complicated with CHF. Simvastatin 59-70 calcitonin related polypeptide alpha Homo sapiens 129-133 23541442-2 2013 We investigated the role of TRAF3 interacting protein 2 (TRAF3IP2), a redox-sensitive adapter protein and an upstream regulator of IKK and JNK in interleukin (IL)-18 induced smooth muscle cell migration, and the mechanism of its inhibition by simvastatin. Simvastatin 243-254 TRAF3 interacting protein 2 Homo sapiens 28-55 23541442-2 2013 We investigated the role of TRAF3 interacting protein 2 (TRAF3IP2), a redox-sensitive adapter protein and an upstream regulator of IKK and JNK in interleukin (IL)-18 induced smooth muscle cell migration, and the mechanism of its inhibition by simvastatin. Simvastatin 243-254 TRAF3 interacting protein 2 Homo sapiens 57-65 23541442-7 2013 Importantly, the HMG-coA reductase inhibitor simvastatin attenuated IL-18-induced TRAF3IP2 induction. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 17-34 23541442-7 2013 Importantly, the HMG-coA reductase inhibitor simvastatin attenuated IL-18-induced TRAF3IP2 induction. Simvastatin 45-56 interleukin 18 Homo sapiens 68-73 23541442-7 2013 Importantly, the HMG-coA reductase inhibitor simvastatin attenuated IL-18-induced TRAF3IP2 induction. Simvastatin 45-56 TRAF3 interacting protein 2 Homo sapiens 82-90 23541442-11 2013 Further, Simvastatin inhibits inducible, but not ectopically-xpressed TRAF3IP2. Simvastatin 9-20 TRAF3 interacting protein 2 Homo sapiens 70-78 23558220-0 2013 Decreased tissue levels of cyclophilin A, a cyclosporine a target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. Simvastatin 88-99 peptidylprolyl isomerase A Homo sapiens 27-40 23558220-0 2013 Decreased tissue levels of cyclophilin A, a cyclosporine a target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. Simvastatin 88-99 mitogen-activated protein kinase 3 Homo sapiens 78-84 23558220-7 2013 RESULTS: The AAA wall tissue from simvastatin-treated patients had significantly lower CyPA gene expression and protein levels (P = 0.0018, P = 0.0083, respectively). Simvastatin 34-45 peptidylprolyl isomerase A Homo sapiens 87-91 23558220-8 2013 Furthermore, phosphorylation of ERK1 and ERK2 was markedly suppressed in the simvastatin group (P = 0.0002, P = 0.0027, respectively). Simvastatin 77-88 mitogen-activated protein kinase 3 Homo sapiens 32-36 23558220-8 2013 Furthermore, phosphorylation of ERK1 and ERK2 was markedly suppressed in the simvastatin group (P = 0.0002, P = 0.0027, respectively). Simvastatin 77-88 mitogen-activated protein kinase 1 Homo sapiens 41-45 23558220-10 2013 CONCLUSION: Simvastatin-treated patients with AAA exert lower CyPA messenger RNA (mRNA), as well as CyPA intracellular protein levels and a decreased amount of phospho-ERK1/2. Simvastatin 12-23 peptidylprolyl isomerase A Homo sapiens 62-66 23558220-10 2013 CONCLUSION: Simvastatin-treated patients with AAA exert lower CyPA messenger RNA (mRNA), as well as CyPA intracellular protein levels and a decreased amount of phospho-ERK1/2. Simvastatin 12-23 peptidylprolyl isomerase A Homo sapiens 100-104 23558220-10 2013 CONCLUSION: Simvastatin-treated patients with AAA exert lower CyPA messenger RNA (mRNA), as well as CyPA intracellular protein levels and a decreased amount of phospho-ERK1/2. Simvastatin 12-23 mitogen-activated protein kinase 3 Homo sapiens 168-174 23334403-0 2013 Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. Simvastatin 105-116 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-28 23334403-10 2013 This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition. Simvastatin 63-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 106-112 23443172-7 2013 Post-injury treatment of Abeta transgenic mice with simvastatin lowered brain Abeta concentrations, attenuated deficits in CBF ipsilateral to injury, restored hyperemia contralateral to injury, and reduced brain tissue loss. Simvastatin 52-63 amyloid beta (A4) precursor protein Mus musculus 25-30 23443172-7 2013 Post-injury treatment of Abeta transgenic mice with simvastatin lowered brain Abeta concentrations, attenuated deficits in CBF ipsilateral to injury, restored hyperemia contralateral to injury, and reduced brain tissue loss. Simvastatin 52-63 amyloid beta (A4) precursor protein Mus musculus 78-83 23256625-2 2013 This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. Simvastatin 131-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-119 23683283-4 2013 RESULTS: The cell growth and ALP activity of TCP containing simvastatin-treated cells was greater than MTA-treated cells. Simvastatin 60-71 alkaline phosphatase, placental Homo sapiens 29-32 22186618-0 2013 Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Simvastatin 125-136 ATP binding cassette subfamily C member 2 Homo sapiens 25-30 22186618-2 2013 We analyzed in the Rotterdam Study whether the common polymorphisms -24C>T, 1249G>A and 3972C>T in the ABCC2 gene were associated with a dose decrease or switch to another cholesterol-lowering drug in simvastatin and atorvastatin users. Simvastatin 210-221 ATP binding cassette subfamily C member 2 Homo sapiens 112-117 22186618-8 2013 To conclude, genetic variation in the ABCC2 gene is associated with these events in simvastatin users. Simvastatin 84-95 ATP binding cassette subfamily C member 2 Homo sapiens 38-43 23750308-8 2013 Results indicated that treatment with simvastatin significantly enhanced levels of GPx and GST and decreased lipid peroxide levels induced by L-arginine compared to the vehicle. Simvastatin 38-49 hematopoietic prostaglandin D synthase Rattus norvegicus 91-94 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 45-56 Janus kinase 2 Homo sapiens 174-178 23717538-3 2013 Simvastatin and fluvastatin induced HO-1. Simvastatin 0-11 heme oxygenase 1 Mus musculus 36-40 23717538-6 2013 In RAW 264.7 cells, both statins increased the activity of reporter genes linked to the proximal 1.3 kbp promoter of HO-1 (EC50 of 1.4+-0.3 microM for simvastatin and 0.6+-0.03 microM for fluvastatin). Simvastatin 151-162 heme oxygenase 1 Mus musculus 117-121 23466635-5 2013 RESULTS: Six hours after reperfusion, donor treatment either with simvastatin alone or with high dose of methylprednisolone alone or in combination with simvastatin and methylprednisolone significantly reduced cardiac troponin T release and the number of allograft infiltrating ED1 macrophages MPO neutrophils. Simvastatin 66-77 ectodysplasin A Homo sapiens 278-281 23466635-5 2013 RESULTS: Six hours after reperfusion, donor treatment either with simvastatin alone or with high dose of methylprednisolone alone or in combination with simvastatin and methylprednisolone significantly reduced cardiac troponin T release and the number of allograft infiltrating ED1 macrophages MPO neutrophils. Simvastatin 153-164 ectodysplasin A Homo sapiens 278-281 23690956-0 2013 Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 65-68 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 45-56 signal transducer and activator of transcription 3 Homo sapiens 179-184 23690956-0 2013 Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 69-73 23690956-0 2013 Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 75-78 23690956-0 2013 Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Simvastatin 0-11 Janus kinase 2 Homo sapiens 83-87 23690956-0 2013 Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 88-93 23690956-7 2013 Mechanically, we presented that simvastatin could suppress the proliferation and motility of RCC cells via inhibiting the phosphorylation of AKT, mTOR, and ERK in a time- and dose- dependent manner. Simvastatin 32-43 AKT serine/threonine kinase 1 Homo sapiens 141-144 23690956-7 2013 Mechanically, we presented that simvastatin could suppress the proliferation and motility of RCC cells via inhibiting the phosphorylation of AKT, mTOR, and ERK in a time- and dose- dependent manner. Simvastatin 32-43 mechanistic target of rapamycin kinase Homo sapiens 146-150 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 212-223 Janus kinase 2 Homo sapiens 174-178 23690956-7 2013 Mechanically, we presented that simvastatin could suppress the proliferation and motility of RCC cells via inhibiting the phosphorylation of AKT, mTOR, and ERK in a time- and dose- dependent manner. Simvastatin 32-43 mitogen-activated protein kinase 1 Homo sapiens 156-159 22915623-8 2013 Simvastatin restored the level of IL-33 mRNA which was decreased by IL-17. Simvastatin 0-11 interleukin 33 Homo sapiens 34-39 23690956-8 2013 Further investigation of the underlying mechanism revealed simvastatin could exert the anti-tumor effects by suppressing IL-6-induced phosphorylation of JAK2 and STAT3. Simvastatin 59-70 interleukin 6 Homo sapiens 121-125 23690956-8 2013 Further investigation of the underlying mechanism revealed simvastatin could exert the anti-tumor effects by suppressing IL-6-induced phosphorylation of JAK2 and STAT3. Simvastatin 59-70 Janus kinase 2 Homo sapiens 153-157 23690956-8 2013 Further investigation of the underlying mechanism revealed simvastatin could exert the anti-tumor effects by suppressing IL-6-induced phosphorylation of JAK2 and STAT3. Simvastatin 59-70 signal transducer and activator of transcription 3 Homo sapiens 162-167 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 45-56 AKT serine/threonine kinase 1 Homo sapiens 155-158 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 45-56 mechanistic target of rapamycin kinase Homo sapiens 159-163 23690956-9 2013 In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients. Simvastatin 45-56 mitogen-activated protein kinase 1 Homo sapiens 165-168 22584245-0 2013 Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy? Simvastatin 111-122 cholesteryl ester transfer protein Homo sapiens 0-34 22915623-8 2013 Simvastatin restored the level of IL-33 mRNA which was decreased by IL-17. Simvastatin 0-11 interleukin 17A Homo sapiens 68-73 22584245-0 2013 Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy? Simvastatin 111-122 ATP binding cassette subfamily A member 1 Homo sapiens 39-74 22915623-11 2013 Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination. Simvastatin 0-11 ectonucleoside triphosphate diphosphohydrolase 1 Homo sapiens 39-43 22915623-11 2013 Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination. Simvastatin 0-11 thrombomodulin Homo sapiens 48-62 22915623-0 2013 Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Simvastatin 0-11 interleukin 17A Homo sapiens 72-77 22915623-0 2013 Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 82-91 22915623-11 2013 Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination. Simvastatin 0-11 interleukin 17A Homo sapiens 89-94 22915623-3 2013 The aim of this study was to assess whether simvastatin modulates the vascular effects of interleukin (IL)-17, an emerging actor in atherosclerosis. Simvastatin 44-55 interleukin 17A Homo sapiens 90-109 22915623-11 2013 Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination. Simvastatin 0-11 tumor necrosis factor Homo sapiens 99-108 22915623-4 2013 METHODS: The effect of simvastatin was assessed in human umbilical vein endothelial cells treated by IL-17 alone or combined with tumour necrosis factor (TNF)-alpha, with or without mevalonate, an inhibitor of simvastatin. Simvastatin 23-34 interleukin 17A Homo sapiens 101-106 22915623-12 2013 Simvastatin suppressed IL-17-induced endothelial cells invasion. Simvastatin 0-11 interleukin 17A Homo sapiens 23-28 22915623-4 2013 METHODS: The effect of simvastatin was assessed in human umbilical vein endothelial cells treated by IL-17 alone or combined with tumour necrosis factor (TNF)-alpha, with or without mevalonate, an inhibitor of simvastatin. Simvastatin 23-34 tumor necrosis factor Homo sapiens 130-164 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 interleukin 17A Homo sapiens 31-36 22915623-14 2013 Finally, simvastatin had an additive effect with infliximab to decrease the effect of the combination of IL-17 and TNF-alpha on IL-6 mRNA expression. Simvastatin 9-20 interleukin 17A Homo sapiens 105-110 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 interleukin 6 Homo sapiens 45-49 22915623-14 2013 Finally, simvastatin had an additive effect with infliximab to decrease the effect of the combination of IL-17 and TNF-alpha on IL-6 mRNA expression. Simvastatin 9-20 tumor necrosis factor Homo sapiens 115-124 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 C-X-C motif chemokine ligand 8 Homo sapiens 51-55 22915623-14 2013 Finally, simvastatin had an additive effect with infliximab to decrease the effect of the combination of IL-17 and TNF-alpha on IL-6 mRNA expression. Simvastatin 9-20 interleukin 6 Homo sapiens 128-132 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 C-X3-C motif chemokine ligand 1 Homo sapiens 57-64 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 C-C motif chemokine ligand 5 Homo sapiens 66-72 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 C-X3-C motif chemokine ligand 1 Homo sapiens 82-89 23288881-3 2013 Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). Simvastatin 152-163 component of oligomeric golgi complex 2 Homo sapiens 36-41 22915623-7 2013 RESULTS: Simvastatin decreased IL-17-induced IL-6, IL-8, CX3CL-1, RANTES mRNA and CX3CL-1 and CCL20 production. Simvastatin 9-20 C-C motif chemokine ligand 20 Homo sapiens 94-99 23402903-5 2013 Autophagy induced by simvastatin was assessed by measuring LC3-II, p62 or Rab7 by immunoblotting or immunocytochemistry. Simvastatin 21-32 nucleoporin 62 Homo sapiens 67-70 22835616-0 2013 Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia. Simvastatin 0-11 chemokine (C-C motif) ligand 5 Mus musculus 23-29 22835616-3 2013 In this study, we hypothesised that simvastatin inhibits polyinosinic-polycytidylic acid (poly I:C)-induced airway inflammation, such as RANTES (regulated on activation, normal T-cell expressed and secreted) expression and inflammatory cell recruitment. Simvastatin 36-47 chemokine (C-C motif) ligand 5 Mus musculus 137-143 22835616-4 2013 In bronchial cells, the effect of simvastatin on poly I:C-induced RANTES expression and signal transducer and activator of transcription (STAT)3-mediated signal transduction was determined using an ELISA and short hairpin (sh)RNA system. Simvastatin 34-45 chemokine (C-C motif) ligand 5 Mus musculus 66-72 22835616-6 2013 In poly I:C-stimulated bronchial cells, RANTES secretion was increased by STAT3 activation, and simvastatin suppressed poly I:C-induced STAT3 activation, resulting in inhibition of RANTES expression. Simvastatin 96-107 signal transducer and activator of transcription 3 Mus musculus 136-141 22835616-6 2013 In poly I:C-stimulated bronchial cells, RANTES secretion was increased by STAT3 activation, and simvastatin suppressed poly I:C-induced STAT3 activation, resulting in inhibition of RANTES expression. Simvastatin 96-107 chemokine (C-C motif) ligand 5 Mus musculus 181-187 22835616-8 2013 However, simvastatin treatment attenuated STAT3 activation, RANTES release and subsequent neutrophilia in the lungs. Simvastatin 9-20 signal transducer and activator of transcription 3 Mus musculus 42-47 22835616-8 2013 However, simvastatin treatment attenuated STAT3 activation, RANTES release and subsequent neutrophilia in the lungs. Simvastatin 9-20 chemokine (C-C motif) ligand 5 Mus musculus 60-66 23480783-0 2013 Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Simvastatin 106-117 fatty acid binding protein 4 Homo sapiens 5-33 23402903-5 2013 Autophagy induced by simvastatin was assessed by measuring LC3-II, p62 or Rab7 by immunoblotting or immunocytochemistry. Simvastatin 21-32 RAB7B, member RAS oncogene family Homo sapiens 74-78 23480783-0 2013 Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Simvastatin 106-117 retinol binding protein 4 Homo sapiens 38-63 23402903-9 2013 Simvastatin caused accumulation of p62 but loss of Rab7, suggesting inhibition of autophagosome trafficking. Simvastatin 0-11 nucleoporin 62 Homo sapiens 35-38 23402903-9 2013 Simvastatin caused accumulation of p62 but loss of Rab7, suggesting inhibition of autophagosome trafficking. Simvastatin 0-11 RAB7B, member RAS oncogene family Homo sapiens 51-55 23402903-11 2013 Knockdown of the key autophagy regulator Atg5 caused a modest increase in the sensitivity of Ovcar-8 cells to simvastatin. Simvastatin 110-121 autophagy related 5 Homo sapiens 41-45 23858814-14 2013 Also, simvastatin is associated with single-nucleotide polymorphisms located within the SLCO1B1 gene on the chromosome 12 and established myopathy, while pravastatin lacks this association. Simvastatin 6-17 solute carrier organic anion transporter family member 1B1 Homo sapiens 88-95 23611379-0 2013 Simvastatin suppresses osteoblastic expression of Cyr61 and progression of apical periodontitis through enhancement of the transcription factor Forkhead/winged helix box protein O3a. Simvastatin 0-11 cellular communication network factor 1 Rattus norvegicus 50-55 23611379-5 2013 The modulation of CCL2 secretion and macrophage chemotaxis by simvastatin were examined by enzyme-linked immunosorbent assay and transwell migration assay, respectively. Simvastatin 62-73 C-C motif chemokine ligand 2 Rattus norvegicus 18-22 23611379-8 2013 Simvastatin significantly counteracted the actions of TNF-alpha. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 54-63 23611379-10 2013 Simvastatin and FoxO3a diminished TNF-alpha-induced CCL2 secretion and macrophage recruitment, whereas Cyr61 partially restored the stimulating action. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 34-43 23611379-10 2013 Simvastatin and FoxO3a diminished TNF-alpha-induced CCL2 secretion and macrophage recruitment, whereas Cyr61 partially restored the stimulating action. Simvastatin 0-11 C-C motif chemokine ligand 2 Rattus norvegicus 52-56 23611379-11 2013 In rat periapical lesions, simvastatin significantly attenuated bone resorption, reduced osteoblastic expressions of Cyr61, p-FoxO3a, and CCL2, and suppressed macrophage recruitment. Simvastatin 27-38 cellular communication network factor 1 Rattus norvegicus 117-122 23611379-11 2013 In rat periapical lesions, simvastatin significantly attenuated bone resorption, reduced osteoblastic expressions of Cyr61, p-FoxO3a, and CCL2, and suppressed macrophage recruitment. Simvastatin 27-38 forkhead box O3 Rattus norvegicus 126-132 23611379-11 2013 In rat periapical lesions, simvastatin significantly attenuated bone resorption, reduced osteoblastic expressions of Cyr61, p-FoxO3a, and CCL2, and suppressed macrophage recruitment. Simvastatin 27-38 C-C motif chemokine ligand 2 Rattus norvegicus 138-142 23611379-12 2013 CONCLUSIONS: Simvastatin may alleviate periapical lesions by enhancing FoxO3a activity to suppress the synthesis of Cyr61 in osteoblasts. Simvastatin 13-24 forkhead box O3 Rattus norvegicus 71-77 23611379-12 2013 CONCLUSIONS: Simvastatin may alleviate periapical lesions by enhancing FoxO3a activity to suppress the synthesis of Cyr61 in osteoblasts. Simvastatin 13-24 cellular communication network factor 1 Rattus norvegicus 116-121 23434428-5 2013 The combination of simvastatin and thalidomide augmented caspase 8 and 3 activation, and the additional application of p38 MAPK inhibitor resulted in enhanced apoptosis of MM cells concomitant with increased caspase 9 and 3 activation, as well as JNK phosphorylation. Simvastatin 19-30 caspase 8 Homo sapiens 57-66 23677263-0 2013 Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Simvastatin 0-11 formyl peptide receptor 1 Homo sapiens 103-144 23677263-0 2013 Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Simvastatin 0-11 formyl peptide receptor 1 Homo sapiens 146-150 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 proteinase 3 Homo sapiens 116-128 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 proteinase 3 Homo sapiens 130-133 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 myeloperoxidase Homo sapiens 188-203 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 myeloperoxidase Homo sapiens 205-208 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 formyl peptide receptor 1 Homo sapiens 264-305 23677263-1 2013 OBJECTIVE: To test the hypothesis that simvastatin is capable of blocking human neutrophil degranulation induced by proteinase 3 (PR3)-anti-neutrophil cytoplasm auto-antibodies (ANCA) and myeloperoxidase (MPO)-ANCA, and by the chemotactic and inflammatory peptide N-formyl-methionine-leucine-phenylalanine (fMLP). Simvastatin 39-50 formyl peptide receptor 1 Homo sapiens 307-311 23677263-4 2013 The ability of the same dose of simvastatin to block fMLP-induced neutrophil degranulation was also tested. Simvastatin 32-43 formyl peptide receptor 1 Homo sapiens 53-57 23677263-8 2013 Simvastatin also inhibited neutrophil degranulation induced by 1 uM fMLP (30%, p=0.04). Simvastatin 0-11 formyl peptide receptor 1 Homo sapiens 68-72 23677263-9 2013 We further demonstrated that serum from rats that received simvastatin significantly inhibited neutrophil degranulation induced by ANCA (31.7%, p=0.01) and fMLP (23.5%, p=0.03) compared to serum from control animals. Simvastatin 59-70 formyl peptide receptor 1 Homo sapiens 156-160 23677263-10 2013 CONCLUSION: Simvastatin blocked both ANCA and fMLP-induced neutrophil degranulation. Simvastatin 12-23 formyl peptide receptor 1 Homo sapiens 46-50 23794945-6 2013 The highest reduction could be seen after treatment with irbesartan and simvastatin in combination (all P<0.001).There were strongly positive correlations between AngII or CVF with PDGF, Rac1, NF-kappaB, and among PDGF, Rac1 and NF-kappaB (all P<0.05). Simvastatin 72-83 Rac family small GTPase 1 Homo sapiens 190-194 23794945-6 2013 The highest reduction could be seen after treatment with irbesartan and simvastatin in combination (all P<0.001).There were strongly positive correlations between AngII or CVF with PDGF, Rac1, NF-kappaB, and among PDGF, Rac1 and NF-kappaB (all P<0.05). Simvastatin 72-83 nuclear factor kappa B subunit 1 Homo sapiens 196-205 23794945-6 2013 The highest reduction could be seen after treatment with irbesartan and simvastatin in combination (all P<0.001).There were strongly positive correlations between AngII or CVF with PDGF, Rac1, NF-kappaB, and among PDGF, Rac1 and NF-kappaB (all P<0.05). Simvastatin 72-83 Rac family small GTPase 1 Homo sapiens 223-227 23794945-6 2013 The highest reduction could be seen after treatment with irbesartan and simvastatin in combination (all P<0.001).There were strongly positive correlations between AngII or CVF with PDGF, Rac1, NF-kappaB, and among PDGF, Rac1 and NF-kappaB (all P<0.05). Simvastatin 72-83 nuclear factor kappa B subunit 1 Homo sapiens 232-241 23794945-7 2013 CONCLUSIONS: Irbesartan or/and simvastatin can improve atrial fibrosis by regulating PDGF/Rac1/NF-kappaB axis. Simvastatin 31-42 Rac family small GTPase 1 Homo sapiens 90-94 23794945-7 2013 CONCLUSIONS: Irbesartan or/and simvastatin can improve atrial fibrosis by regulating PDGF/Rac1/NF-kappaB axis. Simvastatin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 95-104 23559002-0 2013 Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Simvastatin 46-57 ras homolog family member A Homo sapiens 140-144 23559002-0 2013 Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Simvastatin 46-57 Rac family small GTPase 1 Homo sapiens 149-153 23559002-4 2013 Indeed, simvastatin treatment led to increased levels of unprenylated Ras homolog gene family, member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division cycle 42 (Cdc42). Simvastatin 8-19 ras homolog family member A Homo sapiens 105-109 23559002-4 2013 Indeed, simvastatin treatment led to increased levels of unprenylated Ras homolog gene family, member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division cycle 42 (Cdc42). Simvastatin 8-19 Rac family small GTPase 1 Homo sapiens 112-154 23559002-4 2013 Indeed, simvastatin treatment led to increased levels of unprenylated Ras homolog gene family, member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division cycle 42 (Cdc42). Simvastatin 8-19 Rac family small GTPase 1 Homo sapiens 156-160 23559002-4 2013 Indeed, simvastatin treatment led to increased levels of unprenylated Ras homolog gene family, member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division cycle 42 (Cdc42). Simvastatin 8-19 cell division cycle 42 Homo sapiens 190-195 23559002-5 2013 Intriguingly, instead of inhibiting the functions of Rho GTPases as was expected with loss of prenylation, simvastatin caused a paradoxical increase in the GTP-bound forms of RhoA, Rac1 and Cdc42. Simvastatin 107-118 ras homolog family member A Homo sapiens 175-179 23559002-5 2013 Intriguingly, instead of inhibiting the functions of Rho GTPases as was expected with loss of prenylation, simvastatin caused a paradoxical increase in the GTP-bound forms of RhoA, Rac1 and Cdc42. Simvastatin 107-118 Rac family small GTPase 1 Homo sapiens 181-185 23559002-5 2013 Intriguingly, instead of inhibiting the functions of Rho GTPases as was expected with loss of prenylation, simvastatin caused a paradoxical increase in the GTP-bound forms of RhoA, Rac1 and Cdc42. Simvastatin 107-118 cell division cycle 42 Homo sapiens 190-195 23559002-7 2013 We also show that the unprenylated RhoA- and Rac1-GTP retained at least part of their functional activities, as evidenced by the increase in intracellular superoxide production and JNK activation in response to simvastatin. Simvastatin 211-222 ras homolog family member A Homo sapiens 35-39 23559002-7 2013 We also show that the unprenylated RhoA- and Rac1-GTP retained at least part of their functional activities, as evidenced by the increase in intracellular superoxide production and JNK activation in response to simvastatin. Simvastatin 211-222 Rac family small GTPase 1 Homo sapiens 45-49 23559002-7 2013 We also show that the unprenylated RhoA- and Rac1-GTP retained at least part of their functional activities, as evidenced by the increase in intracellular superoxide production and JNK activation in response to simvastatin. Simvastatin 211-222 mitogen-activated protein kinase 8 Homo sapiens 181-184 23559002-9 2013 Finally, we provide evidence for the involvement of the B-cell lymphoma protein 2 family, Bcl-2-interacting mediator (Bim), in a JNK-dependent manner, in the apoptosis-inducing activity of simvastatin. Simvastatin 189-200 BCL2 apoptosis regulator Homo sapiens 90-95 23559002-9 2013 Finally, we provide evidence for the involvement of the B-cell lymphoma protein 2 family, Bcl-2-interacting mediator (Bim), in a JNK-dependent manner, in the apoptosis-inducing activity of simvastatin. Simvastatin 189-200 mitogen-activated protein kinase 8 Homo sapiens 129-132 23559002-10 2013 Taken together, our data highlight the critical role of non-canonical regulation of Rho GTPases and involvement of downstream superoxide-mediated activation of JNK pathway in the anticancer activity of simvastatin, which would have potential clinical implications. Simvastatin 202-213 mitogen-activated protein kinase 8 Homo sapiens 160-163 23481641-0 2013 Preclinical Activity of Simvastatin Induces Cell Cycle Arrest in G1 via Blockade of Cyclin D-Cdk4 Expression in Non-Small Cell Lung Cancer (NSCLC). Simvastatin 24-35 cyclin dependent kinase 4 Homo sapiens 93-97 23568231-7 2013 Treatment with simvastatin significantly reduced the MPO activity in the continuously ventilated lung but had no effect on lung edema after OLV. Simvastatin 15-26 myeloperoxidase Rattus norvegicus 53-56 22092686-14 2013 CONCLUSION: The results from this study indicate that the serum level of bone formation markers, especially BALP and BGP, could be correlated with the degree of osseointegration around titanium implants in osteoporotic rats treated with simvastatin. Simvastatin 237-248 bone gamma-carboxyglutamate protein Rattus norvegicus 117-120 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 component of oligomeric golgi complex 2 Homo sapiens 48-53 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 apolipoprotein B Homo sapiens 58-74 23100282-3 2013 METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Simvastatin 100-111 apolipoprotein B Homo sapiens 76-80 23426387-4 2013 In tumor-bearing mice, low-dose simvastatin (0.2 mg/kg) induced upregulation of endothelial NO synthase (eNOS) skewed vessels to a pericyte-coated and stable pattern, while high-dose simvastatin (10 mg/kg) remarkably deceased reactive oxygen species (ROS)-induced hypoxia-inducible factor (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression, attenuating VEGF-drived tumor vessel hyperpermeability. Simvastatin 32-43 hypoxia inducible factor 1, alpha subunit Mus musculus 290-300 23426387-4 2013 In tumor-bearing mice, low-dose simvastatin (0.2 mg/kg) induced upregulation of endothelial NO synthase (eNOS) skewed vessels to a pericyte-coated and stable pattern, while high-dose simvastatin (10 mg/kg) remarkably deceased reactive oxygen species (ROS)-induced hypoxia-inducible factor (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression, attenuating VEGF-drived tumor vessel hyperpermeability. Simvastatin 32-43 vascular endothelial growth factor A Mus musculus 306-340 23426387-4 2013 In tumor-bearing mice, low-dose simvastatin (0.2 mg/kg) induced upregulation of endothelial NO synthase (eNOS) skewed vessels to a pericyte-coated and stable pattern, while high-dose simvastatin (10 mg/kg) remarkably deceased reactive oxygen species (ROS)-induced hypoxia-inducible factor (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression, attenuating VEGF-drived tumor vessel hyperpermeability. Simvastatin 32-43 vascular endothelial growth factor A Mus musculus 342-346 23426387-4 2013 In tumor-bearing mice, low-dose simvastatin (0.2 mg/kg) induced upregulation of endothelial NO synthase (eNOS) skewed vessels to a pericyte-coated and stable pattern, while high-dose simvastatin (10 mg/kg) remarkably deceased reactive oxygen species (ROS)-induced hypoxia-inducible factor (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression, attenuating VEGF-drived tumor vessel hyperpermeability. Simvastatin 32-43 vascular endothelial growth factor A Mus musculus 372-376 23085058-2 2013 MATERIALS AND METHODS: After treating PC3 and DU-145 cells with simvastatin, cell viability and apoptosis were determined using tetrazolium salt based colorimetric assay and annexin-V-fluorescein isothiocyanate/propidium iodide double staining assay, respectively. Simvastatin 64-75 proprotein convertase subtilisin/kexin type 1 Homo sapiens 38-41 23085058-2 2013 MATERIALS AND METHODS: After treating PC3 and DU-145 cells with simvastatin, cell viability and apoptosis were determined using tetrazolium salt based colorimetric assay and annexin-V-fluorescein isothiocyanate/propidium iodide double staining assay, respectively. Simvastatin 64-75 annexin A5 Homo sapiens 174-183 23085058-5 2013 RESULTS: After treating PC3 and DU-145 cells with 0, 20 or 40 muM simvastatin for 24, 48 or 72 hours, the proportion of viable cells decreased and the proportion of apoptotic cells increased in a dose and time dependent manner. Simvastatin 66-77 proprotein convertase subtilisin/kexin type 1 Homo sapiens 24-27 23085058-6 2013 Western blot analysis showed that simvastatin inhibited IkappaBalpha phosphorylation and degradation. Simvastatin 34-45 NFKB inhibitor alpha Homo sapiens 56-68 23085058-7 2013 It also demonstrated that simvastatin increased p65 protein levels in cytoplasmic fractions and decreased phosphorylated p65 protein levels in nuclear fractions but did not change p65 protein levels in cytoplasm. Simvastatin 26-37 RELA proto-oncogene, NF-kB subunit Homo sapiens 48-51 23085058-7 2013 It also demonstrated that simvastatin increased p65 protein levels in cytoplasmic fractions and decreased phosphorylated p65 protein levels in nuclear fractions but did not change p65 protein levels in cytoplasm. Simvastatin 26-37 RELA proto-oncogene, NF-kB subunit Homo sapiens 121-124 23085058-7 2013 It also demonstrated that simvastatin increased p65 protein levels in cytoplasmic fractions and decreased phosphorylated p65 protein levels in nuclear fractions but did not change p65 protein levels in cytoplasm. Simvastatin 26-37 RELA proto-oncogene, NF-kB subunit Homo sapiens 121-124 23085058-9 2013 Reverse transcriptase-polymerase chain reaction and Western blot revealed that simvastatin inhibited nuclear factor-kappaB regulated cIAP-1 and 2, cFLIP-S and XIAP expression in dose and time dependent fashion. Simvastatin 79-90 baculoviral IAP repeat containing 2 Homo sapiens 133-145 23085058-9 2013 Reverse transcriptase-polymerase chain reaction and Western blot revealed that simvastatin inhibited nuclear factor-kappaB regulated cIAP-1 and 2, cFLIP-S and XIAP expression in dose and time dependent fashion. Simvastatin 79-90 CASP8 and FADD like apoptosis regulator Homo sapiens 147-154 23085058-9 2013 Reverse transcriptase-polymerase chain reaction and Western blot revealed that simvastatin inhibited nuclear factor-kappaB regulated cIAP-1 and 2, cFLIP-S and XIAP expression in dose and time dependent fashion. Simvastatin 79-90 X-linked inhibitor of apoptosis Homo sapiens 159-163 23391769-7 2013 RESULTS: Simvastatin reduced stroke-induced spleen atrophy and splenic apoptosis via increased mitochrondrial antiapoptotic Bcl-2 expression and decreased proapoptotic Bax translocation from cytosol into mitochondria. Simvastatin 9-20 B cell leukemia/lymphoma 2 Mus musculus 124-129 23391769-7 2013 RESULTS: Simvastatin reduced stroke-induced spleen atrophy and splenic apoptosis via increased mitochrondrial antiapoptotic Bcl-2 expression and decreased proapoptotic Bax translocation from cytosol into mitochondria. Simvastatin 9-20 BCL2-associated X protein Mus musculus 168-171 23391769-9 2013 Simvastatin inhibited brain interferon-gamma (3 days) and reduced infarct volume and neurological deficits (5 days) after stroke, and these protective effects were observed not only in naive stroke mice but also in splenectomied stroke mice adoptively transferred with splenocytes. Simvastatin 0-11 interferon gamma Mus musculus 28-44 23510472-4 2013 In the malignant tissues, simvastatin and rosuvastatin significantly (P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-kappaB-p65 expression. Simvastatin 26-37 matrix metallopeptidase 2 Homo sapiens 125-132 23510472-4 2013 In the malignant tissues, simvastatin and rosuvastatin significantly (P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-kappaB-p65 expression. Simvastatin 26-37 RELA proto-oncogene, NF-kB subunit Homo sapiens 147-150 23510472-5 2013 CONCLUSIONS: In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-kappaB-p65. Simvastatin 53-64 matrix metallopeptidase 2 Homo sapiens 146-153 23510472-5 2013 CONCLUSIONS: In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-kappaB-p65. Simvastatin 53-64 RELA proto-oncogene, NF-kB subunit Homo sapiens 168-171 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 tumor necrosis factor Homo sapiens 67-94 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 interleukin 6 Homo sapiens 96-109 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 interleukin 1 beta Homo sapiens 111-128 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 C-C motif chemokine ligand 2 Homo sapiens 133-167 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 C-reactive protein Homo sapiens 204-222 23352311-0 2013 Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Simvastatin 78-89 phospholipase A2 group IVA Homo sapiens 22-48 23352311-7 2013 Atorvastatin and simvastatin concentration-dependently inhibited the collagen-induced increase in cytosolic calcium and the kinetics of cPLA2 phosphorylation. Simvastatin 17-28 phospholipase A2 group IVA Homo sapiens 136-141 23352311-9 2013 CONCLUSION: We report for the first time a direct downregulation by atorvastatin and simvastatin of platelet cPLA2 activity through effects on calcium and MAPK, which reduce collagen-induced TXA2 synthesis. Simvastatin 85-96 phospholipase A2 group IVA Homo sapiens 109-114 23352311-9 2013 CONCLUSION: We report for the first time a direct downregulation by atorvastatin and simvastatin of platelet cPLA2 activity through effects on calcium and MAPK, which reduce collagen-induced TXA2 synthesis. Simvastatin 85-96 mitogen-activated protein kinase 3 Homo sapiens 155-159 23239110-0 2013 Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Simvastatin 0-11 cellular communication network factor 1 Rattus norvegicus 21-45 23376721-3 2013 The aim of this study is to evaluate the effect of simvastatin on the ox-LDL-induced ER stress and expression and secretion of TNF-alpha and MCP-1 in 3T3-L1 adipocytes. Simvastatin 51-62 tumor necrosis factor Homo sapiens 127-136 23376721-3 2013 The aim of this study is to evaluate the effect of simvastatin on the ox-LDL-induced ER stress and expression and secretion of TNF-alpha and MCP-1 in 3T3-L1 adipocytes. Simvastatin 51-62 C-C motif chemokine ligand 2 Homo sapiens 141-146 23376721-11 2013 Simvastatin could inhibit ox-LDL-induced ER stress and reduce the expression of TNF-alpha and MCP-1 at mRNA and protien level in dose dependent manner. Simvastatin 0-11 tumor necrosis factor Homo sapiens 80-89 23376721-11 2013 Simvastatin could inhibit ox-LDL-induced ER stress and reduce the expression of TNF-alpha and MCP-1 at mRNA and protien level in dose dependent manner. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 94-99 23239110-0 2013 Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Simvastatin 0-11 sirtuin 1 Rattus norvegicus 128-137 23239110-0 2013 Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Simvastatin 0-11 forkhead box O3 Rattus norvegicus 138-144 23239110-1 2013 OBJECTIVE: To examine the role of sirtuin-1 (SIRT-1)/FoxO3a in the expression of cysteine-rich protein 61 (CYR-61) in rheumatoid arthritis synovial fibroblasts (RASFs) and the influence of simvastatin on this pathway, and to determine the relationship between disease progression and FoxO3a/CYR-61 signaling in synovial fibroblasts in vivo using a rat model of collagen-induced arthritis (CIA). Simvastatin 189-200 cellular communication network factor 1 Rattus norvegicus 81-105 23239110-1 2013 OBJECTIVE: To examine the role of sirtuin-1 (SIRT-1)/FoxO3a in the expression of cysteine-rich protein 61 (CYR-61) in rheumatoid arthritis synovial fibroblasts (RASFs) and the influence of simvastatin on this pathway, and to determine the relationship between disease progression and FoxO3a/CYR-61 signaling in synovial fibroblasts in vivo using a rat model of collagen-induced arthritis (CIA). Simvastatin 189-200 cellular communication network factor 1 Rattus norvegicus 107-113 23239110-7 2013 RESULTS: In RASFs, simvastatin suppressed the tumor necrosis factor alpha (TNFalpha)-induced production of CYR-61 and CCL20. Simvastatin 19-30 tumor necrosis factor Rattus norvegicus 46-73 23239110-7 2013 RESULTS: In RASFs, simvastatin suppressed the tumor necrosis factor alpha (TNFalpha)-induced production of CYR-61 and CCL20. Simvastatin 19-30 tumor necrosis factor Rattus norvegicus 75-83 23239110-7 2013 RESULTS: In RASFs, simvastatin suppressed the tumor necrosis factor alpha (TNFalpha)-induced production of CYR-61 and CCL20. Simvastatin 19-30 cellular communication network factor 1 Rattus norvegicus 107-113 23239110-7 2013 RESULTS: In RASFs, simvastatin suppressed the tumor necrosis factor alpha (TNFalpha)-induced production of CYR-61 and CCL20. Simvastatin 19-30 C-C motif chemokine ligand 20 Rattus norvegicus 118-123 23239110-9 2013 Simvastatin inhibited the nuclear export, phosphorylation, and acetylation of FoxO3a and maintained its binding to the Cyr61 promoter. Simvastatin 0-11 forkhead box O3 Rattus norvegicus 78-84 23239110-9 2013 Simvastatin inhibited the nuclear export, phosphorylation, and acetylation of FoxO3a and maintained its binding to the Cyr61 promoter. Simvastatin 0-11 cellular communication network factor 1 Rattus norvegicus 119-124 23239110-11 2013 Following treatment with simvastatin, the expression of SIRT-1 was up-regulated and SIRT-1/FoxO3a binding was enhanced in RASFs. Simvastatin 25-36 sirtuin 1 Rattus norvegicus 56-62 23239110-11 2013 Following treatment with simvastatin, the expression of SIRT-1 was up-regulated and SIRT-1/FoxO3a binding was enhanced in RASFs. Simvastatin 25-36 sirtuin 1 Rattus norvegicus 84-90 23239110-11 2013 Following treatment with simvastatin, the expression of SIRT-1 was up-regulated and SIRT-1/FoxO3a binding was enhanced in RASFs. Simvastatin 25-36 forkhead box O3 Rattus norvegicus 91-97 23239110-12 2013 In rats with CIA, intraarticular injection of simvastatin alleviated arthritis and suppressed CYR-61 expression and FoxO3a phosphorylation in synovial fibroblasts. Simvastatin 46-57 cellular communication network factor 1 Rattus norvegicus 94-100 23239110-12 2013 In rats with CIA, intraarticular injection of simvastatin alleviated arthritis and suppressed CYR-61 expression and FoxO3a phosphorylation in synovial fibroblasts. Simvastatin 46-57 forkhead box O3 Rattus norvegicus 116-122 23239110-14 2013 Simvastatin plays a beneficial role in inflammatory arthritis through its up-regulation of SIRT-1/FoxO3a signaling in synovial fibroblasts. Simvastatin 0-11 sirtuin 1 Rattus norvegicus 91-97 23239110-14 2013 Simvastatin plays a beneficial role in inflammatory arthritis through its up-regulation of SIRT-1/FoxO3a signaling in synovial fibroblasts. Simvastatin 0-11 forkhead box O3 Rattus norvegicus 98-104 23279934-3 2013 This study aims to investigate how simvastatin affects 6-hydroxydopamine-lesioned PC12 via regulating PI3K/AKT/caspase 3 and modulating inflammatory mediators. Simvastatin 35-46 caspase 3 Rattus norvegicus 111-120 23279934-0 2013 Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 73-76 23279934-3 2013 This study aims to investigate how simvastatin affects 6-hydroxydopamine-lesioned PC12 via regulating PI3K/AKT/caspase 3 and modulating inflammatory mediators. Simvastatin 35-46 AKT serine/threonine kinase 1 Rattus norvegicus 107-110 23279934-6 2013 RESULTS: Simvastatin-mediated neuroprotection was associated with a robust reduction in the upregulation induced by 6-OHDA of inflammatory mediators including IL-6, COX2, and TNF-alpha. Simvastatin 9-20 interleukin 6 Rattus norvegicus 159-163 23279934-0 2013 Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses. Simvastatin 0-11 caspase 3 Rattus norvegicus 77-86 23279934-6 2013 RESULTS: Simvastatin-mediated neuroprotection was associated with a robust reduction in the upregulation induced by 6-OHDA of inflammatory mediators including IL-6, COX2, and TNF-alpha. Simvastatin 9-20 cytochrome c oxidase II, mitochondrial Rattus norvegicus 165-169 23279934-6 2013 RESULTS: Simvastatin-mediated neuroprotection was associated with a robust reduction in the upregulation induced by 6-OHDA of inflammatory mediators including IL-6, COX2, and TNF-alpha. Simvastatin 9-20 tumor necrosis factor Rattus norvegicus 175-184 23279934-7 2013 The downregulated DAT and TH levels in 6-OHDA-lesioned PC12 were restored after simvastatin treatment. Simvastatin 80-91 tyrosine hydroxylase Rattus norvegicus 26-28 23279934-8 2013 Simvastatin reversed 6-OHDA-induced downregulation of PI3K/Akt phosphorylation and attenuated 6-OHDA-induced upregulation of caspase 3 in PC12. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 59-62 23279934-8 2013 Simvastatin reversed 6-OHDA-induced downregulation of PI3K/Akt phosphorylation and attenuated 6-OHDA-induced upregulation of caspase 3 in PC12. Simvastatin 0-11 caspase 3 Rattus norvegicus 125-134 23279934-9 2013 Furthermore, the PI3K inhibitor LY294002 pronouncedly abolished the simvastatin-mediated attenuation in caspase 3. Simvastatin 68-79 caspase 3 Rattus norvegicus 104-113 23279934-10 2013 CONCLUSIONS: Our results demonstrate that simvastatin provides robust neuroprotection against dopaminergic neurodegeneration, partially via antiinflammatory mechanisms and the PI3K/Akt/caspase 3 pathway. Simvastatin 42-53 AKT serine/threonine kinase 1 Rattus norvegicus 181-184 23279934-10 2013 CONCLUSIONS: Our results demonstrate that simvastatin provides robust neuroprotection against dopaminergic neurodegeneration, partially via antiinflammatory mechanisms and the PI3K/Akt/caspase 3 pathway. Simvastatin 42-53 caspase 3 Rattus norvegicus 185-194 23220613-3 2013 This study attempted to investigate the effect of CAP on the pharmacokinetics of simvastatin (SV), a cytochrome P450 (CYP) 3A substrate and an important cholesterol-lowering agent. Simvastatin 81-92 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 101-125 23354132-7 2013 Furthermore, the eIF2alpha knockdown sensitized cells to simvastatin-induced apoptosis and the overexpression of a non-phosphorylatable eIF2alpha-mutant [serine 51(Ser51)/alanine] enhanced the stabilization of p53 and its translocation to the mitochondria in response to simvastatin treatment. Simvastatin 307-318 eukaryotic translation initiation factor 2A Homo sapiens 17-26 23354132-2 2013 We previously reported that simvastatin triggered the mitochondrial apoptotic pathway in MethA fibrosarcoma cells, which was accompanied by the translocation of stabilized p53 to the mitochondria. Simvastatin 28-39 tumor protein p53 Homo sapiens 196-199 23354132-7 2013 Furthermore, the eIF2alpha knockdown sensitized cells to simvastatin-induced apoptosis and the overexpression of a non-phosphorylatable eIF2alpha-mutant [serine 51(Ser51)/alanine] enhanced the stabilization of p53 and its translocation to the mitochondria in response to simvastatin treatment. Simvastatin 307-318 eukaryotic translation initiation factor 2A Homo sapiens 160-169 23354132-7 2013 Furthermore, the eIF2alpha knockdown sensitized cells to simvastatin-induced apoptosis and the overexpression of a non-phosphorylatable eIF2alpha-mutant [serine 51(Ser51)/alanine] enhanced the stabilization of p53 and its translocation to the mitochondria in response to simvastatin treatment. Simvastatin 69-80 eukaryotic translation initiation factor 2A Homo sapiens 17-26 23620998-4 2013 Simvastatin was loaded into the PLLA/HAp microcylinders. Simvastatin 0-11 reticulon 3 Homo sapiens 37-40 23386644-7 2013 Simvastatin inhibited cholesterol biosynthesis and enzyme activity but increased HMGCR mRNA and protein expression. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 81-86 23337719-9 2013 In HES cells, simvastatin induced expression of STRA6 and CRABP2 but not FABP5. Simvastatin 14-25 cellular retinoic acid binding protein 2 Homo sapiens 58-64 23337719-10 2013 Similarly, simvastatin treatment of nude mice bearing human endometrial xenografts led to an increased expression of CRABP2 and STRA6 proteins in ectopic lesions. Simvastatin 11-22 cellular retinoic acid binding protein 2 Homo sapiens 117-123 23337719-10 2013 Similarly, simvastatin treatment of nude mice bearing human endometrial xenografts led to an increased expression of CRABP2 and STRA6 proteins in ectopic lesions. Simvastatin 11-22 signaling receptor and transporter of retinol STRA6 Homo sapiens 128-133 23337719-11 2013 CONCLUSIONS: Simvastatin interacts with the RA system, inducing the expression of the key protein regulating the uptake of retinol (STRA6) and the expression of apoptosis-promoting CRABP2. Simvastatin 13-24 cellular retinoic acid binding protein 2 Homo sapiens 181-187 23337719-11 2013 CONCLUSIONS: Simvastatin interacts with the RA system, inducing the expression of the key protein regulating the uptake of retinol (STRA6) and the expression of apoptosis-promoting CRABP2. Simvastatin 13-24 signaling receptor and transporter of retinol STRA6 Homo sapiens 132-137 23337719-9 2013 In HES cells, simvastatin induced expression of STRA6 and CRABP2 but not FABP5. Simvastatin 14-25 signaling receptor and transporter of retinol STRA6 Homo sapiens 48-53 23492463-4 2013 Ranolazine is a weak inhibitor of CYP3A4 known to increase the serum level of simvastatin and its active metabolite 2-fold. Simvastatin 78-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-40 23386644-8 2013 Resveratrol potentiated the inhibitory effects of simvastatin on cholesterol biosynthesis and HMGCR enzyme activity and abrogated the stimulatory effects of simvastatin on HMGCR mRNA transcripts and protein expression. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-99 23386644-8 2013 Resveratrol potentiated the inhibitory effects of simvastatin on cholesterol biosynthesis and HMGCR enzyme activity and abrogated the stimulatory effects of simvastatin on HMGCR mRNA transcripts and protein expression. Simvastatin 157-168 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 172-177 23449454-4 2013 Statins (atorvastatin, fluvastatin and simvastatin) treatment enhanced the DNA fragmentation and the activation of proapoptotic members such as caspase-3, PARP and Bax, but suppressed the activation of anti-apoptotic molecule Bcl-2 in lymphoma cells including A20 and EL4 cells, which was accompanied by inhibition of cell survival. Simvastatin 39-50 caspase 3 Mus musculus 144-153 23449454-4 2013 Statins (atorvastatin, fluvastatin and simvastatin) treatment enhanced the DNA fragmentation and the activation of proapoptotic members such as caspase-3, PARP and Bax, but suppressed the activation of anti-apoptotic molecule Bcl-2 in lymphoma cells including A20 and EL4 cells, which was accompanied by inhibition of cell survival. Simvastatin 39-50 poly (ADP-ribose) polymerase family, member 1 Mus musculus 155-159 23449454-4 2013 Statins (atorvastatin, fluvastatin and simvastatin) treatment enhanced the DNA fragmentation and the activation of proapoptotic members such as caspase-3, PARP and Bax, but suppressed the activation of anti-apoptotic molecule Bcl-2 in lymphoma cells including A20 and EL4 cells, which was accompanied by inhibition of cell survival. Simvastatin 39-50 BCL2-associated X protein Mus musculus 164-167 23449454-4 2013 Statins (atorvastatin, fluvastatin and simvastatin) treatment enhanced the DNA fragmentation and the activation of proapoptotic members such as caspase-3, PARP and Bax, but suppressed the activation of anti-apoptotic molecule Bcl-2 in lymphoma cells including A20 and EL4 cells, which was accompanied by inhibition of cell survival. Simvastatin 39-50 B cell leukemia/lymphoma 2 Mus musculus 226-231 23331562-8 2013 The enhancing effects of simvastatin on FP effects were mediated through the up-regulation of indoleamine 2, 3-dioxygenase and interleukin (IL)-10, together with down-regulation of IL-6 and IL-23 expression in mDCs. Simvastatin 25-36 interleukin 6 Homo sapiens 181-185 23333250-0 2013 Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. Simvastatin 127-138 chromobox 8 Homo sapiens 98-101 22960596-0 2013 Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Simvastatin 0-11 mitogen-activated protein kinase 8 Homo sapiens 110-113 22960596-0 2013 Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Simvastatin 0-11 DNA damage inducible transcript 3 Homo sapiens 114-118 22960596-0 2013 Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Simvastatin 0-11 TNF receptor superfamily member 10b Homo sapiens 119-122 22960596-1 2013 Simvastatin (SVA) was shown to up-regulate expression of death receptor-5 (DR5), CCAAT/enhancer binding protein homologous protein (CHOP) and phosphorylated c-Jun N-terminal kinase (pJNK) in human breast cancer cell lines. Simvastatin 0-11 TNF receptor superfamily member 10b Homo sapiens 57-73 22960596-1 2013 Simvastatin (SVA) was shown to up-regulate expression of death receptor-5 (DR5), CCAAT/enhancer binding protein homologous protein (CHOP) and phosphorylated c-Jun N-terminal kinase (pJNK) in human breast cancer cell lines. Simvastatin 0-11 TNF receptor superfamily member 10b Homo sapiens 75-78 22960596-1 2013 Simvastatin (SVA) was shown to up-regulate expression of death receptor-5 (DR5), CCAAT/enhancer binding protein homologous protein (CHOP) and phosphorylated c-Jun N-terminal kinase (pJNK) in human breast cancer cell lines. Simvastatin 0-11 DNA damage inducible transcript 3 Homo sapiens 81-130 22960596-1 2013 Simvastatin (SVA) was shown to up-regulate expression of death receptor-5 (DR5), CCAAT/enhancer binding protein homologous protein (CHOP) and phosphorylated c-Jun N-terminal kinase (pJNK) in human breast cancer cell lines. Simvastatin 0-11 DNA damage inducible transcript 3 Homo sapiens 132-136 23424259-0 2013 A transcriptomics-informed genetic association study identifies RHOA in simvastatin-induced low-density lipoprotein cholesterol lowering. Simvastatin 72-83 ras homolog family member A Homo sapiens 64-68 23331562-8 2013 The enhancing effects of simvastatin on FP effects were mediated through the up-regulation of indoleamine 2, 3-dioxygenase and interleukin (IL)-10, together with down-regulation of IL-6 and IL-23 expression in mDCs. Simvastatin 25-36 interleukin 23 subunit alpha Homo sapiens 190-195 23257173-2 2013 This study of hypertensive subjects with lower plasma cholesterol tested the hypotheses that lipophilic simvastatin would attenuate resting sympathoexcitation and augment baroreflex modulation of MSNA and heart rate (HR), flow-mediated vasodilation and insulin sensitivity. Simvastatin 104-115 insulin Homo sapiens 253-260 23290865-6 2013 Both simvastatin and lovastatin suppressed IEL production of IFN-gamma, TNF-alpha, IL-2, and IL-4 in a dose-dependent manner, whereas 48-h treatment with high concentrations (5 x 10(-5)M) of simvastatin and lovastatin did not affect the number of IELs. Simvastatin 5-16 interferon gamma Mus musculus 61-70 23290865-6 2013 Both simvastatin and lovastatin suppressed IEL production of IFN-gamma, TNF-alpha, IL-2, and IL-4 in a dose-dependent manner, whereas 48-h treatment with high concentrations (5 x 10(-5)M) of simvastatin and lovastatin did not affect the number of IELs. Simvastatin 5-16 tumor necrosis factor Mus musculus 72-81 23290865-6 2013 Both simvastatin and lovastatin suppressed IEL production of IFN-gamma, TNF-alpha, IL-2, and IL-4 in a dose-dependent manner, whereas 48-h treatment with high concentrations (5 x 10(-5)M) of simvastatin and lovastatin did not affect the number of IELs. Simvastatin 5-16 interleukin 2 Mus musculus 83-87 23290865-6 2013 Both simvastatin and lovastatin suppressed IEL production of IFN-gamma, TNF-alpha, IL-2, and IL-4 in a dose-dependent manner, whereas 48-h treatment with high concentrations (5 x 10(-5)M) of simvastatin and lovastatin did not affect the number of IELs. Simvastatin 5-16 interleukin 4 Mus musculus 93-97 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Simvastatin 11-22 interleukin 6 Homo sapiens 40-53 23250325-0 2013 Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity. Simvastatin 0-11 integrin subunit alpha M Homo sapiens 101-106 23250325-4 2013 RESULTS: In the presence of a TNF-alpha inflammatory stimulus, neutrophils displayed a rapid and substantial enhancement in their adhesive properties that was abrogated by preincubation of cells with simvastatin. Simvastatin 200-211 tumor necrosis factor Homo sapiens 30-39 23250325-5 2013 Neutrophil surface expression of the Mac-1 integrin subunit, CD11b, was augmented by TNF-alpha, and this increased expression was also inhibited by simvastatin. Simvastatin 148-159 integrin subunit alpha M Homo sapiens 37-42 23250325-5 2013 Neutrophil surface expression of the Mac-1 integrin subunit, CD11b, was augmented by TNF-alpha, and this increased expression was also inhibited by simvastatin. Simvastatin 148-159 integrin subunit alpha M Homo sapiens 61-66 22451024-0 2013 Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA. Simvastatin 22-33 ras homolog family member A Homo sapiens 140-144 22451024-5 2013 Simvastatin inhibits FBS- or GM-CSF-induced migration in a dose-dependent manner by RA FLS, and this inhibitory effect is independent of cell apoptosis. Simvastatin 0-11 colony stimulating factor 2 Homo sapiens 29-35 22451024-6 2013 We also found that simvastatin suppressed in vitro invasion, adhesion, MMP-2 activity, cytoskeletal reorganization and RhoA activation. Simvastatin 19-30 matrix metallopeptidase 2 Homo sapiens 71-76 22451024-6 2013 We also found that simvastatin suppressed in vitro invasion, adhesion, MMP-2 activity, cytoskeletal reorganization and RhoA activation. Simvastatin 19-30 ras homolog family member A Homo sapiens 119-123 23469684-0 2013 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Simvastatin 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 23469684-0 2013 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 88-94 23469684-0 2013 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Simvastatin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 23469684-0 2013 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Simvastatin 0-11 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 103-108 23469684-0 2013 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Simvastatin 0-11 solute carrier organic anion transporter family member 1B1 Homo sapiens 113-120 23469684-6 2013 Effect of ABCB1 G2677T/A SNP on dispostion of simvastatin was observed. Simvastatin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 23469684-10 2013 The gene-dose effects of ABCG2 c.421 C > A and CYP3A5*3 g.6986A > G on simvastatin pharmacokinetics are not strong enough in Chinese subjects. Simvastatin 77-88 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-30 23469684-10 2013 The gene-dose effects of ABCG2 c.421 C > A and CYP3A5*3 g.6986A > G on simvastatin pharmacokinetics are not strong enough in Chinese subjects. Simvastatin 77-88 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 50-56 22451024-7 2013 Furthermore, mevalonate or GGPP treatment reversed the inhibitory effect of simvastatin not only on migration and invasion in vitro but also on RhoA activation, and inhibition of RhoA by specific siRNA transfection reduced migration, adhesion and invasion of RA FLS. Simvastatin 76-87 ras homolog family member A Homo sapiens 144-148 22451024-7 2013 Furthermore, mevalonate or GGPP treatment reversed the inhibitory effect of simvastatin not only on migration and invasion in vitro but also on RhoA activation, and inhibition of RhoA by specific siRNA transfection reduced migration, adhesion and invasion of RA FLS. Simvastatin 76-87 ras homolog family member A Homo sapiens 179-183 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Simvastatin 11-22 C-reactive protein Homo sapiens 75-93 22451024-8 2013 This study shows that simvastatin reduces RA FLS migration and invasion through the prevention of protein geranylgeranylation and RhoA activation. Simvastatin 22-33 ras homolog family member A Homo sapiens 130-134 23013513-7 2013 Median changes (interquartile range) in IL-6 and hsCRP concentrations were -22% (-43 to 0%) and -30% (-44 to +19%) after simvastatin, -5% (-36 to +30%) and +9% (-22 to +107%) after ezetimibe, and +15% (-15 to +86%) and +1 (-30 to +49%) after the combination. Simvastatin 121-132 interleukin 6 Homo sapiens 40-44 23013513-9 2013 CONCLUSIONS: Simvastatin decreases the pro-inflammatory markers IL-6 and almost significantly hsCRP while ezetimibe monotherapy or the combination with simvastatin has no effect. Simvastatin 13-24 interleukin 6 Homo sapiens 64-68 23063651-2 2013 Simvastatin (SVA) and gamma-tocotrienol (gammaT3) eliminate enriched CSCs and suppress expression of Stat-3 signaling mediators via inhibition of the mevalonate pathway and activation of de novo ceramide synthesis pathway, respectively. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 101-107 23223429-0 2013 Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Simvastatin 0-11 Kruppel like factor 1 Homo sapiens 45-49 23223429-0 2013 Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Simvastatin 0-11 BAF chromatin remodeling complex subunit BCL11A Homo sapiens 54-60 23223429-4 2013 Experiments in K562 cells showed that simvastatin increased KLF2 mRNA and protein and KLF2 binding to HS2 of the beta-globin locus control region and enhanced -globin mRNA production by the NRF2 activator Tert-butylhydroquinone (tBHQ). Simvastatin 38-49 Kruppel like factor 2 Homo sapiens 60-64 23223429-4 2013 Experiments in K562 cells showed that simvastatin increased KLF2 mRNA and protein and KLF2 binding to HS2 of the beta-globin locus control region and enhanced -globin mRNA production by the NRF2 activator Tert-butylhydroquinone (tBHQ). Simvastatin 38-49 Kruppel like factor 2 Homo sapiens 86-90 23223429-4 2013 Experiments in K562 cells showed that simvastatin increased KLF2 mRNA and protein and KLF2 binding to HS2 of the beta-globin locus control region and enhanced -globin mRNA production by the NRF2 activator Tert-butylhydroquinone (tBHQ). Simvastatin 38-49 spectrin beta, erythrocytic Homo sapiens 102-105 23223429-4 2013 Experiments in K562 cells showed that simvastatin increased KLF2 mRNA and protein and KLF2 binding to HS2 of the beta-globin locus control region and enhanced -globin mRNA production by the NRF2 activator Tert-butylhydroquinone (tBHQ). Simvastatin 38-49 NFE2 like bZIP transcription factor 2 Homo sapiens 190-194 23223429-4 2013 Experiments in K562 cells showed that simvastatin increased KLF2 mRNA and protein and KLF2 binding to HS2 of the beta-globin locus control region and enhanced -globin mRNA production by the NRF2 activator Tert-butylhydroquinone (tBHQ). Simvastatin 38-49 telomerase reverse transcriptase Homo sapiens 205-209 23223429-6 2013 Investigating alternative mechanisms of action, we found that both simvastatin and tBHQ suppress beta-globin mRNA and KLF1 and BCL11A mRNA and protein, similar to what is seen in people with an HPFH phenotype because of KLF1 haploinsufficiency. Simvastatin 67-78 Kruppel like factor 1 Homo sapiens 118-122 23223429-6 2013 Investigating alternative mechanisms of action, we found that both simvastatin and tBHQ suppress beta-globin mRNA and KLF1 and BCL11A mRNA and protein, similar to what is seen in people with an HPFH phenotype because of KLF1 haploinsufficiency. Simvastatin 67-78 BAF chromatin remodeling complex subunit BCL11A Homo sapiens 127-133 23223429-8 2013 KEY POINTS: Simvastatin and tBHQ suppress KLF1 and BCL11 gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Simvastatin 12-23 Kruppel like factor 1 Homo sapiens 42-46 23154180-0 2013 Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells. Simvastatin 0-11 thioredoxin reductase 1 Homo sapiens 46-52 23154180-6 2013 Simvastatin, but not fluvastatin or atorvastatin, also reduced the TXNRD1 promoter activity in HepG2 cells by 20% (p<0.01). Simvastatin 0-11 thioredoxin reductase 1 Homo sapiens 67-73 23154180-7 2013 In line with this result, TrxR1 mRNA levels decreased with about 25% in non-transfected HepG2 cells upon treatment with simvastatin (p<0.01). Simvastatin 120-131 thioredoxin reductase 1 Homo sapiens 26-31 23154180-11 2013 Thus, our results reveal a simvastatin-specific reduction of cellular TrxR1 levels that at least in part involves direct inhibitory effects on the basal activity of the core promoter guiding TrxR1 expression. Simvastatin 27-38 thioredoxin reductase 1 Homo sapiens 70-75 23154180-11 2013 Thus, our results reveal a simvastatin-specific reduction of cellular TrxR1 levels that at least in part involves direct inhibitory effects on the basal activity of the core promoter guiding TrxR1 expression. Simvastatin 27-38 thioredoxin reductase 1 Homo sapiens 191-196 22922248-0 2013 Simvastatin prevents the induction of interleukin-6 gene expression by titanium particles in human osteoblastic cells. Simvastatin 0-11 interleukin 6 Homo sapiens 38-51 22922248-5 2013 We hypothesized that simvastatin (Simv) could modulate the osteoblastic response to titanium particles (Ti) by attenuating the production of IL-6. Simvastatin 21-32 interleukin 6 Homo sapiens 141-145 24273760-0 2013 Antihyperlipidemic and antiatherogenic activity of simvastatin may involve modulation of the expression of lecithin:cholesterol acyl transferase. Simvastatin 51-62 lecithin cholesterol acyltransferase Rattus norvegicus 107-144 22922248-5 2013 We hypothesized that simvastatin (Simv) could modulate the osteoblastic response to titanium particles (Ti) by attenuating the production of IL-6. Simvastatin 34-38 interleukin 6 Homo sapiens 141-145 23072789-0 2013 Simvastatin inhibits the additive activation of ERK1/2 and proliferation of rat vascular smooth muscle cells induced by combined mechanical stress and oxLDL through LOX-1 pathway. Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 48-54 23075630-7 2013 Simvastatin also killed primary CD34 cells from patients with CML more efficiently, compared with CD34 CML cells. Simvastatin 0-11 CD34 molecule Homo sapiens 32-36 22881993-0 2013 Selective inhibition by simvastatin of IRF3 phosphorylation and TSLP production in dsRNA-challenged bronchial epithelial cells from COPD donors. Simvastatin 24-35 interferon regulatory factor 3 Homo sapiens 39-43 22881993-4 2013 This study tests the hypothesis that simvastatin inhibits dsRNA-induced TSLP. Simvastatin 37-48 thymic stromal lymphopoietin Homo sapiens 72-76 22881993-10 2013 Simvastatin, but not dexamethasone, concentration-dependently inhibited dsRNA-induced TSLP. Simvastatin 0-11 thymic stromal lymphopoietin Homo sapiens 86-90 22881993-12 2013 Instead, simvastatin inhibited dsRNA-induced IRF3 phosphorylation and generation of IFN-beta. Simvastatin 9-20 interferon regulatory factor 3 Homo sapiens 45-49 22881993-12 2013 Instead, simvastatin inhibited dsRNA-induced IRF3 phosphorylation and generation of IFN-beta. Simvastatin 9-20 interferon beta 1 Homo sapiens 84-92 22881993-13 2013 CONCLUSIONS AND IMPLICATIONS: Independent of mevalonate and NF-kappaB, previously acknowledged anti-inflammatory mechanisms of pleiotropic statins, simvastatin selectively inhibited dsRNA-induced IRF3 activation and production of TSLP and IFN-beta in COPD epithelium. Simvastatin 148-159 interferon regulatory factor 3 Homo sapiens 196-200 22881993-13 2013 CONCLUSIONS AND IMPLICATIONS: Independent of mevalonate and NF-kappaB, previously acknowledged anti-inflammatory mechanisms of pleiotropic statins, simvastatin selectively inhibited dsRNA-induced IRF3 activation and production of TSLP and IFN-beta in COPD epithelium. Simvastatin 148-159 thymic stromal lymphopoietin Homo sapiens 230-234 22881993-13 2013 CONCLUSIONS AND IMPLICATIONS: Independent of mevalonate and NF-kappaB, previously acknowledged anti-inflammatory mechanisms of pleiotropic statins, simvastatin selectively inhibited dsRNA-induced IRF3 activation and production of TSLP and IFN-beta in COPD epithelium. Simvastatin 148-159 interferon beta 1 Homo sapiens 239-247 22890678-12 2013 IL-1beta was significantly elevated following the induction of SAH but was inhibited by high-dose simvastatin. Simvastatin 98-109 interleukin 1 beta Rattus norvegicus 0-8 22890678-14 2013 Expression of TGF-beta1 by lymphocytes was markedly increased following treatment with high-dose simvastatin. Simvastatin 97-108 transforming growth factor, beta 1 Rattus norvegicus 14-23 23072789-0 2013 Simvastatin inhibits the additive activation of ERK1/2 and proliferation of rat vascular smooth muscle cells induced by combined mechanical stress and oxLDL through LOX-1 pathway. Simvastatin 0-11 oxidized low density lipoprotein receptor 1 Rattus norvegicus 165-170 23072789-6 2013 Simvastatin was found to inhibit increased ERK activation and Ki-67 expression in VSMCs subjected to stretch stress with or without oxLDL. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 43-46 23072789-7 2013 Mechanically, simvastatin was also found to inhibit increased expression of LOX-1 (a receptor of oxLDL) in VSMCs subjected to stretch stress with or without oxLDL. Simvastatin 14-25 oxidized low density lipoprotein receptor 1 Rattus norvegicus 76-81 23817018-0 2013 Simvastatin attenuates TGF-beta1-induced epithelial-mesenchymal transition in human alveolar epithelial cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 23817018-3 2013 Simvastatin (Sim), a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, has been previously reported to inhibit EMT in human proximal tubular epithelial cells and porcine lens epithelial cells and to suppress Smad2/3 phosphorylation in animal models. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-71 23817226-0 2013 Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Simvastatin 28-39 Rac family small GTPase 1 Homo sapiens 62-66 23817226-0 2013 Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Simvastatin 28-39 mechanistic target of rapamycin kinase Homo sapiens 67-71 23817226-4 2013 Western blot analysis confirmed that simvastatin significantly increased protein expression of typical autophagy markers LC3B and Beclin1 in these CAMs. Simvastatin 37-48 microtubule associated protein 1 light chain 3 beta Homo sapiens 121-125 23817018-3 2013 Simvastatin (Sim), a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, has been previously reported to inhibit EMT in human proximal tubular epithelial cells and porcine lens epithelial cells and to suppress Smad2/3 phosphorylation in animal models. Simvastatin 0-11 SMAD family member 2 Homo sapiens 220-227 23817226-4 2013 Western blot analysis confirmed that simvastatin significantly increased protein expression of typical autophagy markers LC3B and Beclin1 in these CAMs. Simvastatin 37-48 beclin 1 Homo sapiens 130-137 23817018-3 2013 Simvastatin (Sim), a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, has been previously reported to inhibit EMT in human proximal tubular epithelial cells and porcine lens epithelial cells and to suppress Smad2/3 phosphorylation in animal models. Simvastatin 0-3 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-71 23817226-5 2013 Confocal microscopy further demonstrated that simvastatin increased fusion of autophagosomes with lysosomes, which was blocked by autophagy inhibitor 3-methyladenine or silencing of Atg7 genes. Simvastatin 46-57 autophagy related 7 Homo sapiens 182-186 23817226-6 2013 Simvastatin reduced mammalian target of rapamycin (mTOR) activity, which was reversed by Rac1-GTPase overexpression and the mTOR agonist phosphatidic acid. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 20-49 23817226-6 2013 Simvastatin reduced mammalian target of rapamycin (mTOR) activity, which was reversed by Rac1-GTPase overexpression and the mTOR agonist phosphatidic acid. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 51-55 23817018-4 2013 However, whether Sim can attenuate TGF-beta1-induced EMT in A549 cells and its underlying mechanisms remains unknown. Simvastatin 17-20 transforming growth factor beta 1 Homo sapiens 35-44 23817018-10 2013 RESULTS: Sim significantly attenuated the TGF-beta1-induced decrease in E-Cad levels and elevated the levels of alpha-SMA, Vi and FN via the suppression of Smad2 and Smad3 phosphorylation. Simvastatin 9-12 transforming growth factor beta 1 Homo sapiens 42-51 23817018-10 2013 RESULTS: Sim significantly attenuated the TGF-beta1-induced decrease in E-Cad levels and elevated the levels of alpha-SMA, Vi and FN via the suppression of Smad2 and Smad3 phosphorylation. Simvastatin 9-12 cadherin 1 Homo sapiens 72-77 23817018-10 2013 RESULTS: Sim significantly attenuated the TGF-beta1-induced decrease in E-Cad levels and elevated the levels of alpha-SMA, Vi and FN via the suppression of Smad2 and Smad3 phosphorylation. Simvastatin 9-12 SMAD family member 2 Homo sapiens 156-161 23817226-6 2013 Simvastatin reduced mammalian target of rapamycin (mTOR) activity, which was reversed by Rac1-GTPase overexpression and the mTOR agonist phosphatidic acid. Simvastatin 0-11 Rac family small GTPase 1 Homo sapiens 89-93 23817018-10 2013 RESULTS: Sim significantly attenuated the TGF-beta1-induced decrease in E-Cad levels and elevated the levels of alpha-SMA, Vi and FN via the suppression of Smad2 and Smad3 phosphorylation. Simvastatin 9-12 SMAD family member 3 Homo sapiens 166-171 23817226-6 2013 Simvastatin reduced mammalian target of rapamycin (mTOR) activity, which was reversed by Rac1-GTPase overexpression and the mTOR agonist phosphatidic acid. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 124-128 23817018-11 2013 Furthermore, Sim inhibited the mesenchymal-like responses in A549 cells, including cell migration, CTGF expression and secretion of MMP-2 and -9. Simvastatin 13-16 cellular communication network factor 2 Homo sapiens 99-103 23817226-7 2013 Moreover, both Rac1-GTPase overexpression and activation of mTOR by phosphatidic acid drastically blocked simvastatin-induced autophagosome formation in CAMs. Simvastatin 106-117 Rac family small GTPase 1 Homo sapiens 15-19 23817226-7 2013 Moreover, both Rac1-GTPase overexpression and activation of mTOR by phosphatidic acid drastically blocked simvastatin-induced autophagosome formation in CAMs. Simvastatin 106-117 mechanistic target of rapamycin kinase Homo sapiens 60-64 23817018-11 2013 Furthermore, Sim inhibited the mesenchymal-like responses in A549 cells, including cell migration, CTGF expression and secretion of MMP-2 and -9. Simvastatin 13-16 matrix metallopeptidase 2 Homo sapiens 132-144 23817226-10 2013 However, this inhibitory effect of simvastatin on CAM proliferation was blocked by by autophagy inhibitor 3-methyladenine or silencing of Atg7 genes. Simvastatin 35-46 autophagy related 7 Homo sapiens 138-142 23438960-6 2013 In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. Simvastatin 149-160 CD40 antigen Mus musculus 59-63 23817226-11 2013 Lastly, animal experiments demonstrated that simvastatin increased protein expression of LC3B and calponin in mouse coronary arteries. Simvastatin 45-56 microtubule-associated protein 1 light chain 3 beta Mus musculus 89-93 23817226-12 2013 CONCLUSION: Our results indicate that simvastatin inhibits the Rac1-mTOR pathway and thereby increases autophagy in CAMs which may stabilize CAMs in the contractile phenotype to prevent proliferation and growth of these cells. Simvastatin 38-49 Rac family small GTPase 1 Homo sapiens 63-67 23817226-12 2013 CONCLUSION: Our results indicate that simvastatin inhibits the Rac1-mTOR pathway and thereby increases autophagy in CAMs which may stabilize CAMs in the contractile phenotype to prevent proliferation and growth of these cells. Simvastatin 38-49 mechanistic target of rapamycin kinase Homo sapiens 68-72 23449848-6 2013 RESULTS: After 8 weeks of treatment, vaspin levels were increased in patients treated with simvastatin (504.58 +- 203.07 pg/mL at baseline versus 629.15 +- 68.39 pg/mL after 8 weeks, P < 0.01), but not in patients who were not treated with simvastatin (613.33 +- 357.53 pg/mL at baseline versus 582.37 +- 84.63 pg/mL after 8 weeks, P > 0.05). Simvastatin 91-102 serpin family A member 12 Homo sapiens 37-43 23449848-6 2013 RESULTS: After 8 weeks of treatment, vaspin levels were increased in patients treated with simvastatin (504.58 +- 203.07 pg/mL at baseline versus 629.15 +- 68.39 pg/mL after 8 weeks, P < 0.01), but not in patients who were not treated with simvastatin (613.33 +- 357.53 pg/mL at baseline versus 582.37 +- 84.63 pg/mL after 8 weeks, P > 0.05). Simvastatin 243-254 serpin family A member 12 Homo sapiens 37-43 23652826-2 2013 The addition of ezetimibe to simvastatin over a 4-week period was associated with reduced expression of CD141 (thrombomodulin; p = 0.02), platelet endothelial cell adhesion molecule (p < 0.0001) and CD51/61 (vitronectin receptor; p = 0.048) compared to statin monotherapy. Simvastatin 29-40 thrombomodulin Homo sapiens 104-109 23652826-2 2013 The addition of ezetimibe to simvastatin over a 4-week period was associated with reduced expression of CD141 (thrombomodulin; p = 0.02), platelet endothelial cell adhesion molecule (p < 0.0001) and CD51/61 (vitronectin receptor; p = 0.048) compared to statin monotherapy. Simvastatin 29-40 integrin subunit alpha V Homo sapiens 202-209 23652826-2 2013 The addition of ezetimibe to simvastatin over a 4-week period was associated with reduced expression of CD141 (thrombomodulin; p = 0.02), platelet endothelial cell adhesion molecule (p < 0.0001) and CD51/61 (vitronectin receptor; p = 0.048) compared to statin monotherapy. Simvastatin 29-40 vitronectin Homo sapiens 211-222 23438960-6 2013 In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. Simvastatin 149-160 CD86 antigen Mus musculus 65-69 23438960-6 2013 In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. Simvastatin 149-160 CD80 antigen Mus musculus 74-78 23260085-4 2013 In vivo, an osteotomy model was made in rat tibia, and fractured tibias were treated with CS, CS/simvastatin, CS/MSC sheet or simvastatin-loaded CS with MSC or untreated (control). Simvastatin 126-137 musculin Rattus norvegicus 153-156 23260085-7 2013 At 2 weeks, the CS/simvastatin/MSC sheet group showed significantly higher expressions of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor, with more callus formation around the fracture site compared with the other four groups. Simvastatin 19-30 bone morphogenetic protein 2 Rattus norvegicus 90-118 23260085-6 2013 The expression levels of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor of simvastatin-induced MSCs increased with the concentrations of the simvastatin, significantly higher than those in the MSCs group. Simvastatin 148-159 bone morphogenetic protein 2 Rattus norvegicus 25-53 23260085-7 2013 At 2 weeks, the CS/simvastatin/MSC sheet group showed significantly higher expressions of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor, with more callus formation around the fracture site compared with the other four groups. Simvastatin 19-30 bone gamma-carboxyglutamate protein Rattus norvegicus 142-153 23260085-7 2013 At 2 weeks, the CS/simvastatin/MSC sheet group showed significantly higher expressions of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor, with more callus formation around the fracture site compared with the other four groups. Simvastatin 19-30 TNF receptor superfamily member 11B Rattus norvegicus 155-170 23260085-10 2013 These results show that both simvastatin and the MSC sheet contributed to the formation of new bone and that the tibia fracture was completely healed by transplantation of the MSC sheet with locally applied simvastatin. Simvastatin 207-218 musculin Rattus norvegicus 49-52 23260085-6 2013 The expression levels of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor of simvastatin-induced MSCs increased with the concentrations of the simvastatin, significantly higher than those in the MSCs group. Simvastatin 148-159 TNF receptor superfamily member 11B Rattus norvegicus 90-105 23260085-6 2013 The expression levels of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor of simvastatin-induced MSCs increased with the concentrations of the simvastatin, significantly higher than those in the MSCs group. Simvastatin 214-225 bone morphogenetic protein 2 Rattus norvegicus 25-53 23260085-6 2013 The expression levels of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor of simvastatin-induced MSCs increased with the concentrations of the simvastatin, significantly higher than those in the MSCs group. Simvastatin 214-225 bone gamma-carboxyglutamate protein Rattus norvegicus 77-88 23260085-6 2013 The expression levels of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor of simvastatin-induced MSCs increased with the concentrations of the simvastatin, significantly higher than those in the MSCs group. Simvastatin 214-225 TNF receptor superfamily member 11B Rattus norvegicus 90-105 23260085-10 2013 These results show that both simvastatin and the MSC sheet contributed to the formation of new bone and that the tibia fracture was completely healed by transplantation of the MSC sheet with locally applied simvastatin. Simvastatin 207-218 musculin Rattus norvegicus 176-179 23260085-7 2013 At 2 weeks, the CS/simvastatin/MSC sheet group showed significantly higher expressions of bone morphogenetic protein 2, alkaline phosphatase, osteocalcin, osteoprotegerin and vascular endothelial growth factor, with more callus formation around the fracture site compared with the other four groups. Simvastatin 19-30 musculin Rattus norvegicus 31-34 23260085-11 2013 Such MSC sheet with locally applied simvastatin might contribute to the treatment of fractures, bone delayed unions or nonunions in clinical practice. Simvastatin 36-47 musculin Rattus norvegicus 5-8 23479762-6 2013 PAI-1 mRNA and protein expression levels were both increased with high glucose concentrations, but they were significantly suppressed by simvastatin and atorvastatin treatment (P < 0.01) and the effects were reversed by mevalonate (100 mumol/L) and geranylgeranyl pyrophosphate (10 mumol/L) but not farnesyl pyrophosphate (10 mumol/L). Simvastatin 137-148 serpin family E member 1 Homo sapiens 0-5 23076801-3 2013 We report that simvastatin inhibits IL-1beta, IL-23, TGF-beta, IL-21, IL-12p70, and induces IL-27 secretion from DCs in RRMS patients, providing an inhibitory cytokine milieu for Th17 and Th1-cell differentiation. Simvastatin 15-26 interleukin 1 beta Homo sapiens 36-44 23076801-3 2013 We report that simvastatin inhibits IL-1beta, IL-23, TGF-beta, IL-21, IL-12p70, and induces IL-27 secretion from DCs in RRMS patients, providing an inhibitory cytokine milieu for Th17 and Th1-cell differentiation. Simvastatin 15-26 interleukin 23 subunit alpha Homo sapiens 46-51 23076801-3 2013 We report that simvastatin inhibits IL-1beta, IL-23, TGF-beta, IL-21, IL-12p70, and induces IL-27 secretion from DCs in RRMS patients, providing an inhibitory cytokine milieu for Th17 and Th1-cell differentiation. Simvastatin 15-26 interleukin 21 Homo sapiens 63-68 23076801-3 2013 We report that simvastatin inhibits IL-1beta, IL-23, TGF-beta, IL-21, IL-12p70, and induces IL-27 secretion from DCs in RRMS patients, providing an inhibitory cytokine milieu for Th17 and Th1-cell differentiation. Simvastatin 15-26 interleukin 27 Homo sapiens 92-97 23076801-6 2013 Simvastatin inhibited antigen presentation by DCs via suppression of the MHC class I expression, costimulatory molecules CD80 and CD40, and by inducing a dramatic loss of dendritic processes. Simvastatin 0-11 CD80 molecule Homo sapiens 121-125 23314529-2 2013 Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. Simvastatin 188-199 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-68 23314529-2 2013 Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. Simvastatin 188-199 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 83-89 23762985-2 2013 Simvastatin at a concentration of 100 ng/ml increases p50 (the blood pO2 corresponding to its 50% oxygen saturation) at real values of pH and pCO2 from 39.53 + 2.41 (p <0.05) to 36.60 (36, 40, 37, 60) (p <0.05) mm Hg. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 54-57 23479762-9 2013 Simvastatin and atorvastatin equally suppress high glucose-induced PAI-1 expression. Simvastatin 0-11 serpin family E member 1 Homo sapiens 67-72 22716163-0 2013 Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells. Simvastatin 0-11 hepcidin antimicrobial peptide Homo sapiens 44-52 22716163-0 2013 Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells. Simvastatin 0-11 erythropoietin Homo sapiens 57-71 22716163-3 2013 Therefore, we examined the effects of a statin (simvastatin) on the expression of hepcidin, erythropoietin receptor (EPOR) and erythropoietin (EPO) in cultured HepG2 cells. Simvastatin 48-59 hepcidin antimicrobial peptide Homo sapiens 82-90 22716163-3 2013 Therefore, we examined the effects of a statin (simvastatin) on the expression of hepcidin, erythropoietin receptor (EPOR) and erythropoietin (EPO) in cultured HepG2 cells. Simvastatin 48-59 erythropoietin receptor Homo sapiens 92-115 22716163-3 2013 Therefore, we examined the effects of a statin (simvastatin) on the expression of hepcidin, erythropoietin receptor (EPOR) and erythropoietin (EPO) in cultured HepG2 cells. Simvastatin 48-59 erythropoietin receptor Homo sapiens 117-121 22716163-3 2013 Therefore, we examined the effects of a statin (simvastatin) on the expression of hepcidin, erythropoietin receptor (EPOR) and erythropoietin (EPO) in cultured HepG2 cells. Simvastatin 48-59 erythropoietin Homo sapiens 92-106 22716163-3 2013 Therefore, we examined the effects of a statin (simvastatin) on the expression of hepcidin, erythropoietin receptor (EPOR) and erythropoietin (EPO) in cultured HepG2 cells. Simvastatin 48-59 erythropoietin Homo sapiens 117-120 22716163-10 2013 The relative mRNA expression of hepcidin in HepG2 cells treated with 0.5, 1, 3, 5, and 10 muM simvastatin, relative to the control group, was 0.7273, 0.3303, 0.2418, 0.4131, and 0.4064, respectively. Simvastatin 94-105 hepcidin antimicrobial peptide Homo sapiens 32-40 22987053-3 2013 Single-dose administration of simvastatin significantly decreased urinary prostacyclin excretion of healthy volunteers (P < 0.01) and increased the ratio between thromboxane A2 and prostacyclin (2-fold increase, P < 0.01), as assessed by enzyme immunoassays of the corresponding metabolites in urine. Simvastatin 30-41 ATPase H+ transporting V0 subunit a2 Homo sapiens 177-196 23776861-9 2013 Following Simvastatin (Simvor) treatment, the mean LDL-C value was reduced by 16%, TCHOL by 23%, TG by 6% and HDL-C increased by 10%. Simvastatin 10-21 component of oligomeric golgi complex 2 Homo sapiens 51-56 24143094-4 2013 This study aimed to prevent this degradation by developing a locally administered formulation of simvastatin that is encapsulated in poly(lactic-co-glycolic acid)/hydroxyapatite (SIM/PLGA/HAp) microspheres with controlled-release properties. Simvastatin 97-108 scaffold attachment factor B Mus musculus 188-191 24143094-6 2013 The simvastatin released over 12 days from 3 mg and 5 mg of SIM/PLGA/HAp was 0.03-1.6 mug/day and 0.05-2.6 mug/day, respectively. Simvastatin 4-15 scaffold attachment factor B Mus musculus 69-72 24143094-9 2013 The low dose of simvastatin released from SIM/PLGA/HAp enhanced initial callus formation, neovascularization, and cell ingrowth in the grafted bone, indicating that SIM/PLGA/HAp facilitates bone regeneration. Simvastatin 16-27 scaffold attachment factor B Mus musculus 51-54 24143094-9 2013 The low dose of simvastatin released from SIM/PLGA/HAp enhanced initial callus formation, neovascularization, and cell ingrowth in the grafted bone, indicating that SIM/PLGA/HAp facilitates bone regeneration. Simvastatin 16-27 scaffold attachment factor B Mus musculus 174-177 24159421-4 2013 At concentrations that inhibited anti-CD3/28-stimulated T-cell proliferation (P < 0.01), simvastatin significantly decreased intracellular CD4(+) T-cell expression of IFN-gamma (P < 0.01) to levels similar to those induced by conventional immunosuppressives. Simvastatin 92-103 CD4 molecule Homo sapiens 142-145 24159421-4 2013 At concentrations that inhibited anti-CD3/28-stimulated T-cell proliferation (P < 0.01), simvastatin significantly decreased intracellular CD4(+) T-cell expression of IFN-gamma (P < 0.01) to levels similar to those induced by conventional immunosuppressives. Simvastatin 92-103 interferon gamma Homo sapiens 170-179 24159421-7 2013 However, in response to anti-CD3/28 stimulation, simvastatin significantly upregulated IL-1beta production (P < 0.05). Simvastatin 49-60 interleukin 1 beta Homo sapiens 87-95 22987053-4 2013 Human vascular endothelial cells, exposed to corresponding concentrations of simvastatin and assayed in the same way, reduced the release of prostacyclin about 40% (P < 0.05), altered the transcriptional expression of cyclooxygenase and prostacyclin synthase as analyzed by real-time polymerase chain reaction, and reduced the prostacyclin synthase promoter activity by 50% (P < 0.05), evaluated in a luciferase reporter system. Simvastatin 77-88 prostaglandin I2 synthase Homo sapiens 240-261 22987053-4 2013 Human vascular endothelial cells, exposed to corresponding concentrations of simvastatin and assayed in the same way, reduced the release of prostacyclin about 40% (P < 0.05), altered the transcriptional expression of cyclooxygenase and prostacyclin synthase as analyzed by real-time polymerase chain reaction, and reduced the prostacyclin synthase promoter activity by 50% (P < 0.05), evaluated in a luciferase reporter system. Simvastatin 77-88 prostaglandin I2 synthase Homo sapiens 330-351 22987053-5 2013 We speculate that simvastatin shifts the balance between thromboxane A2 and prostacyclin in favor of the thromboxane pathway in vivo, and after exposure to clinically relevant concentrations in vitro. Simvastatin 18-29 ATPase H+ transporting V0 subunit a2 Homo sapiens 69-88 23373992-13 2013 CONCLUSIONS: The HMGR inhibitor simvastatin prevents proliferation and osteolytic bone metastases of lung adenocarcinoma cells in vitro and vivo. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 17-21 22989565-4 2013 METHODS: Expression of KLF2 and its vasoprotective target genes was determined in SEC freshly isolated from control or CCl(4)-cirrhotic rats treated with four different statins (atorvastatin, mevastatin, simvastatin, and lovastatin), in the presence of mevalonate (or vehicle), under static or controlled shear stress conditions. Simvastatin 204-215 Kruppel-like factor 2 Rattus norvegicus 23-27 23228261-4 2013 This study further explored the role of extracellular signal-regulated kinase (ERK) as a target and mediator of the differentiation induced by simvastatin in hDPCs. Simvastatin 143-154 mitogen-activated protein kinase 1 Homo sapiens 40-77 23228261-4 2013 This study further explored the role of extracellular signal-regulated kinase (ERK) as a target and mediator of the differentiation induced by simvastatin in hDPCs. Simvastatin 143-154 mitogen-activated protein kinase 1 Homo sapiens 79-82 23228261-6 2013 We also explored the role of ERK signaling as a mediator of simvastatin by Western blotting and real-time PCR. Simvastatin 60-71 mitogen-activated protein kinase 1 Homo sapiens 29-32 23228261-8 2013 RESULTS: The alkaline phosphatase activity and the expression of odontoblastic markers (ie, dentin sialophosphoprotein and dentin matrix protein 1) increased in simvastatin/EMD-treated cells. Simvastatin 161-172 dentin matrix acidic phosphoprotein 1 Homo sapiens 123-146 23228261-11 2013 Simvastatin activated ERK phosphorylation and treatment with ERK inhibitor blocked the messenger RNA expression of odontoblastic markers. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 22-25 23228261-14 2013 CONCLUSIONS: Simvastatin promotes odontoblastic differentiation of hDPCs via the ERK signaling pathway. Simvastatin 13-24 mitogen-activated protein kinase 1 Homo sapiens 81-84 24090379-5 2013 RESULTS: Combined treatment with ezetimibe and simvastatin led to significantly greater declines in Lp-PLA2 and cholesterol fractions compared with treatment only with simvastatin: Lp-PLA2 decreased by 46 vs 38%, total cholesterol by 35 vs 28%, LDL cholesterol by 50 vs 40%, respectively (p<0.05). Simvastatin 47-58 phospholipase A2 group VII Homo sapiens 100-107 24090379-5 2013 RESULTS: Combined treatment with ezetimibe and simvastatin led to significantly greater declines in Lp-PLA2 and cholesterol fractions compared with treatment only with simvastatin: Lp-PLA2 decreased by 46 vs 38%, total cholesterol by 35 vs 28%, LDL cholesterol by 50 vs 40%, respectively (p<0.05). Simvastatin 47-58 phospholipase A2 group VII Homo sapiens 181-188 24090379-5 2013 RESULTS: Combined treatment with ezetimibe and simvastatin led to significantly greater declines in Lp-PLA2 and cholesterol fractions compared with treatment only with simvastatin: Lp-PLA2 decreased by 46 vs 38%, total cholesterol by 35 vs 28%, LDL cholesterol by 50 vs 40%, respectively (p<0.05). Simvastatin 168-179 phospholipase A2 group VII Homo sapiens 181-188 23373992-2 2013 METHODS: The HMGR inhibitor simvastatin, human lung cancer cell line A549 and Balb/c nude mouse were used in this study. Simvastatin 28-39 high mobility group AT-hook 1 Homo sapiens 13-17 23373992-11 2013 Incubation of A549 cells with simvastatin significantly reduced the levels of CD44, MMP2 and MMP9 (p <0.01), while significantly increased p53 (p < 0.01). Simvastatin 30-41 CD44 antigen Mus musculus 78-82 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 tumor necrosis factor Homo sapiens 72-81 23373992-11 2013 Incubation of A549 cells with simvastatin significantly reduced the levels of CD44, MMP2 and MMP9 (p <0.01), while significantly increased p53 (p < 0.01). Simvastatin 30-41 matrix metallopeptidase 2 Mus musculus 84-88 23373992-11 2013 Incubation of A549 cells with simvastatin significantly reduced the levels of CD44, MMP2 and MMP9 (p <0.01), while significantly increased p53 (p < 0.01). Simvastatin 30-41 matrix metallopeptidase 9 Mus musculus 93-97 23373992-11 2013 Incubation of A549 cells with simvastatin significantly reduced the levels of CD44, MMP2 and MMP9 (p <0.01), while significantly increased p53 (p < 0.01). Simvastatin 30-41 transformation related protein 53, pseudogene Mus musculus 142-145 23924855-5 2013 Simvastatin inhibited the survival of A549 cells in a dose-dependent manner, decreased Bcl-2 protein expression, and increased Bax protein expression time and dose dependently. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 87-92 23924855-5 2013 Simvastatin inhibited the survival of A549 cells in a dose-dependent manner, decreased Bcl-2 protein expression, and increased Bax protein expression time and dose dependently. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Homo sapiens 127-130 23924855-6 2013 In addition, simvastatin blocked cells in the G1 phase of the cell cycle, downregulated cyclin D1 and CDKs protein expression, mediated the mitochondria-dependent caspase cascade by increasing caspase-3, -8, and -9 mRNA and protein expression, downregulated Xiap levels to induce cells apoptosis. Simvastatin 13-24 cyclin D1 Homo sapiens 88-106 23924855-6 2013 In addition, simvastatin blocked cells in the G1 phase of the cell cycle, downregulated cyclin D1 and CDKs protein expression, mediated the mitochondria-dependent caspase cascade by increasing caspase-3, -8, and -9 mRNA and protein expression, downregulated Xiap levels to induce cells apoptosis. Simvastatin 13-24 caspase 3 Homo sapiens 193-214 23924855-6 2013 In addition, simvastatin blocked cells in the G1 phase of the cell cycle, downregulated cyclin D1 and CDKs protein expression, mediated the mitochondria-dependent caspase cascade by increasing caspase-3, -8, and -9 mRNA and protein expression, downregulated Xiap levels to induce cells apoptosis. Simvastatin 13-24 X-linked inhibitor of apoptosis Homo sapiens 258-262 23924855-7 2013 Importantly, simvastatin suppressed decreased MMP-9 protein expression and suppressed NF-kappaB activation in A549 cells. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 46-51 23924855-8 2013 Taken together, these results showed that the anticancer effect of simvastatin in lung cancer A549 cells via the inhibiting cell proliferation, influencing the cell cycle, downregulating cyclin D1 and CDKs expression, inducing apoptosis, and decreasing MMP-9 levels, possibly by inhibiting the activation of NF-kappaB. Simvastatin 67-78 cyclin D1 Homo sapiens 187-196 23924855-8 2013 Taken together, these results showed that the anticancer effect of simvastatin in lung cancer A549 cells via the inhibiting cell proliferation, influencing the cell cycle, downregulating cyclin D1 and CDKs expression, inducing apoptosis, and decreasing MMP-9 levels, possibly by inhibiting the activation of NF-kappaB. Simvastatin 67-78 matrix metallopeptidase 9 Homo sapiens 253-258 23252946-0 2013 Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Simvastatin 84-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-57 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 interleukin 2 Homo sapiens 83-96 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 interferon gamma Homo sapiens 101-117 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 C-reactive protein Homo sapiens 165-183 23544125-0 2013 Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. Simvastatin 38-49 proprotein convertase subtilisin/kexin type 9 Homo sapiens 94-99 23544125-3 2013 The purpose of this study was to investigate how ezetimibe and simvastatin, alone and in combination, affect PCSK9 circulating concentrations. Simvastatin 63-74 proprotein convertase subtilisin/kexin type 9 Homo sapiens 109-114 23678211-0 2013 Simvastatin activates the PPARgamma-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling. Simvastatin 0-11 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 26-35 23678211-0 2013 Simvastatin activates the PPARgamma-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling. Simvastatin 0-11 transforming protein RhoA Oryctolagus cuniculus 124-128 23678211-3 2013 In this study, we examined whether the effect of simvastatin on left ventricular hypertrophy can be mediated with the peroxisome proliferator-activated receptor (PPAR)gamma-dependent pathway in rabbits with nonischemic heart failure (HF). Simvastatin 49-60 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 162-172 23678211-9 2013 Our results indicate that simvastatin therapy attenuates the PPARgamma-dependent pathway in association with the inhibition of RhoA and Rho GTPase signaling to inhibit nuclear factor-kappaB activation, thus preventing the development of left ventricular hypertrophy and fibrosis in rabbits with nonischemic heart failure. Simvastatin 26-37 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 61-70 23678211-9 2013 Our results indicate that simvastatin therapy attenuates the PPARgamma-dependent pathway in association with the inhibition of RhoA and Rho GTPase signaling to inhibit nuclear factor-kappaB activation, thus preventing the development of left ventricular hypertrophy and fibrosis in rabbits with nonischemic heart failure. Simvastatin 26-37 transforming protein RhoA Oryctolagus cuniculus 127-131 23838355-8 2013 The IL-6 levels in the 10 and 20 mg/kg/d simvastatin groups were lower than those of the controls (p = 0.005 and p = 0.008). Simvastatin 41-52 interleukin 6 Rattus norvegicus 4-8 23838355-9 2013 The IGF-1 levels of the 20 mg/kg/d simvastatin group were reduced compared to the control group (p = 0.016). Simvastatin 35-46 insulin-like growth factor 1 Rattus norvegicus 4-9 23041512-9 2012 These findings indicated that a combination of sub-therapeutic doses of Simvastatin and HUCBCs treatment of stroke increases Ang1/Tie2 and Occludin expression in the ischemic brain, amplifies endogenous angiogenesis and arteriogenesis, and enhances vascular remodeling which in concert may contribute to functional outcome after stroke. Simvastatin 72-83 angiopoietin 1 Homo sapiens 125-129 24265554-0 2013 Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 11-16 24265554-6 2013 In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. Simvastatin 127-138 component of oligomeric golgi complex 2 Homo sapiens 57-62 24265554-7 2013 The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. Simvastatin 168-179 component of oligomeric golgi complex 2 Homo sapiens 22-27 23041512-9 2012 These findings indicated that a combination of sub-therapeutic doses of Simvastatin and HUCBCs treatment of stroke increases Ang1/Tie2 and Occludin expression in the ischemic brain, amplifies endogenous angiogenesis and arteriogenesis, and enhances vascular remodeling which in concert may contribute to functional outcome after stroke. Simvastatin 72-83 TEK receptor tyrosine kinase Homo sapiens 130-134 23041512-9 2012 These findings indicated that a combination of sub-therapeutic doses of Simvastatin and HUCBCs treatment of stroke increases Ang1/Tie2 and Occludin expression in the ischemic brain, amplifies endogenous angiogenesis and arteriogenesis, and enhances vascular remodeling which in concert may contribute to functional outcome after stroke. Simvastatin 72-83 occludin Homo sapiens 139-147 23062767-10 2012 Three months of treatment with either simvastatin or its combination with ezetimibe resulted in a significant reduction of TLR2 and TLR4 expression (p < 0.01 compared with baseline values) with no intergroup differences. Simvastatin 38-49 toll like receptor 2 Homo sapiens 123-127 23045346-5 2012 Compared with control, simvastatin reduced body mass gain and food intake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-box (MAFbx) and cathepsin-L mRNA expression, increased PDK4 protein expression, and proteasome and cathepsin-L activity, and reduced muscle PDC activity. Simvastatin 23-34 pyruvate dehydrogenase kinase 4 Rattus norvegicus 146-150 23045346-5 2012 Compared with control, simvastatin reduced body mass gain and food intake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-box (MAFbx) and cathepsin-L mRNA expression, increased PDK4 protein expression, and proteasome and cathepsin-L activity, and reduced muscle PDC activity. Simvastatin 23-34 F-box protein 32 Rattus norvegicus 174-179 23045346-5 2012 Compared with control, simvastatin reduced body mass gain and food intake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-box (MAFbx) and cathepsin-L mRNA expression, increased PDK4 protein expression, and proteasome and cathepsin-L activity, and reduced muscle PDC activity. Simvastatin 23-34 cathepsin L Rattus norvegicus 185-196 23045346-5 2012 Compared with control, simvastatin reduced body mass gain and food intake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-box (MAFbx) and cathepsin-L mRNA expression, increased PDK4 protein expression, and proteasome and cathepsin-L activity, and reduced muscle PDC activity. Simvastatin 23-34 pyruvate dehydrogenase kinase 4 Rattus norvegicus 224-228 23045346-5 2012 Compared with control, simvastatin reduced body mass gain and food intake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-box (MAFbx) and cathepsin-L mRNA expression, increased PDK4 protein expression, and proteasome and cathepsin-L activity, and reduced muscle PDC activity. Simvastatin 23-34 cathepsin L Rattus norvegicus 268-279 23045346-6 2012 Simvastatin with DCA maintained body mass gain and food intake, abrogated the myopathy, decreased muscle PDK4 mRNA and protein, MAFbx and cathepsin-L mRNA, increased activity of PDC and reduced proteasome activity compared with simvastatin. Simvastatin 0-11 pyruvate dehydrogenase kinase 4 Rattus norvegicus 105-109 23045346-6 2012 Simvastatin with DCA maintained body mass gain and food intake, abrogated the myopathy, decreased muscle PDK4 mRNA and protein, MAFbx and cathepsin-L mRNA, increased activity of PDC and reduced proteasome activity compared with simvastatin. Simvastatin 0-11 F-box protein 32 Rattus norvegicus 128-133 23045346-6 2012 Simvastatin with DCA maintained body mass gain and food intake, abrogated the myopathy, decreased muscle PDK4 mRNA and protein, MAFbx and cathepsin-L mRNA, increased activity of PDC and reduced proteasome activity compared with simvastatin. Simvastatin 0-11 cathepsin L Rattus norvegicus 138-149 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Simvastatin 44-55 C-reactive protein Homo sapiens 102-120 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Simvastatin 44-55 interleukin 2 Homo sapiens 198-211 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Simvastatin 44-55 interferon gamma Homo sapiens 213-261 23216643-0 2012 Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice. Simvastatin 48-59 apolipoprotein E Mus musculus 98-102 23216643-6 2012 RESULTS: The combination treatment with simvastatin and pinocembrin resulted in significantly decreased levels of serum total cholesterol, triglycerides and low-density lipoprotein cholesterol, augmented NO levels and SOD activity, inhibited ET and VEGF expression. Simvastatin 40-51 vascular endothelial growth factor A Mus musculus 249-253 23216643-10 2012 CONCLUSION: The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium. Simvastatin 31-42 apolipoprotein E Mus musculus 123-127 23138019-8 2012 Furthermore, simvastatin promoted infiltration of macrophages, which produced vascular endothelial growth factor C in granulation tissues. Simvastatin 13-24 vascular endothelial growth factor C Mus musculus 78-114 23045963-7 2012 RESULTS AND CONCLUSION: In both GLC-82 and CALU-1 cell lines, simvastatin and R115777 significantly reduced ERK phosphorylation; this effect, which reached the greatest intensity after 36 h treatment, was paralleled by a concomitant induction of apoptosis, documented by significant increase in both caspase-3 activation and TUNEL-positive cells, associated with a reduction in cell numbers. Simvastatin 62-73 mitogen-activated protein kinase 1 Homo sapiens 108-111 23045963-7 2012 RESULTS AND CONCLUSION: In both GLC-82 and CALU-1 cell lines, simvastatin and R115777 significantly reduced ERK phosphorylation; this effect, which reached the greatest intensity after 36 h treatment, was paralleled by a concomitant induction of apoptosis, documented by significant increase in both caspase-3 activation and TUNEL-positive cells, associated with a reduction in cell numbers. Simvastatin 62-73 caspase 3 Homo sapiens 300-309 23045963-8 2012 Our results thus suggest that simvastatin and R115777 may exert, in susceptible lung cancer cell phenotypes, a pro-apoptotic and anti-proliferative activity, which appears to be mediated by inhibition of the Ras/Raf/MEK/ERK signalling cascade. Simvastatin 30-41 zinc fingers and homeoboxes 2 Homo sapiens 212-215 23045963-8 2012 Our results thus suggest that simvastatin and R115777 may exert, in susceptible lung cancer cell phenotypes, a pro-apoptotic and anti-proliferative activity, which appears to be mediated by inhibition of the Ras/Raf/MEK/ERK signalling cascade. Simvastatin 30-41 mitogen-activated protein kinase kinase 7 Homo sapiens 216-219 23045963-8 2012 Our results thus suggest that simvastatin and R115777 may exert, in susceptible lung cancer cell phenotypes, a pro-apoptotic and anti-proliferative activity, which appears to be mediated by inhibition of the Ras/Raf/MEK/ERK signalling cascade. Simvastatin 30-41 mitogen-activated protein kinase 1 Homo sapiens 220-223 23062767-10 2012 Three months of treatment with either simvastatin or its combination with ezetimibe resulted in a significant reduction of TLR2 and TLR4 expression (p < 0.01 compared with baseline values) with no intergroup differences. Simvastatin 38-49 toll like receptor 4 Homo sapiens 132-136 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 20-31 toll like receptor 2 Homo sapiens 124-128 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 20-31 toll like receptor 4 Homo sapiens 130-134 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 20-31 interleukin 6 Homo sapiens 171-175 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 20-31 interleukin 1 beta Homo sapiens 180-188 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 70-81 toll like receptor 2 Homo sapiens 124-128 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 70-81 toll like receptor 4 Homo sapiens 130-134 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 70-81 interleukin 6 Homo sapiens 171-175 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Simvastatin 70-81 interleukin 1 beta Homo sapiens 180-188 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 42-53 C-reactive protein Homo sapiens 241-259 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 67-78 C-reactive protein Homo sapiens 241-259 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 tumor necrosis factor Homo sapiens 50-77 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 microRNA 155 Homo sapiens 102-109 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 tumor necrosis factor Homo sapiens 141-168 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 nitric oxide synthase 3 Homo sapiens 172-176 23108656-11 2012 Simvastatin decreased miR-155 expression through interfering mevalonate-geranylgeranyl-pyrophosphate-RhoA signaling pathway. Simvastatin 0-11 microRNA 155 Homo sapiens 22-29 22949548-2 2012 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to inhibit streptococcal M1 protein-induced acute lung damage, although downstream mechanisms remain elusive. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 15-72 23076613-4 2012 In this study, we provide new evidence that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may restore the function of impaired ATII cells in vitro and in vivo. Simvastatin 116-127 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 48-105 23076613-6 2012 Simvastatin pretreatment at low (5-20 microM), but not high (50-100 microM) doses markedly reduced apoptosis and increased proliferation and SP-C expression. Simvastatin 0-11 surfactant protein C Rattus norvegicus 141-145 23076613-7 2012 In a rat lung ischemia-reperfusion (I/R) model, simvastatin treatment also increased ATII cell proliferation in vivo, as demonstrated by proliferating cell nuclear antigen/SP-C double staining. Simvastatin 48-59 surfactant protein C Rattus norvegicus 172-176 23076613-9 2012 The protective effects of simvastatin were reversed in vitro by PI3-kinase (PI3K) inhibitors wortmannin and L-mevalonate, indicating that the PI3K/Akt and mevalonate pathways may be involved in simvastatin-induced ATII cell function restoration. Simvastatin 26-37 AKT serine/threonine kinase 1 Rattus norvegicus 147-150 23076613-10 2012 These data demonstrate that an appropriate dose of simvastatin has a protective effect on LIRI in vitro and in vivo, due at least partially to restored ATII cell function via the HMG-CoA reductase pathway-dependent activation of PI3K/Akt signaling in a mevalonate pathway-dependent manner. Simvastatin 51-62 AKT serine/threonine kinase 1 Rattus norvegicus 234-237 29403775-1 2012 Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely used in hyperlipidemia therapy. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-70 29403775-1 2012 Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely used in hyperlipidemia therapy. Simvastatin 13-16 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-70 22971207-1 2012 OBJECTIVES: Tadalafil, an oral phosphodiesterase type-5 inhibitor, induces pulmonary vasorelaxation by inhibiting the breakdown of cyclic guanosine monophosphate whereas simvastatin, an oral 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor, has been shown to reverse pulmonary hypertension (PH) and attenuate vascular remodeling in animal models of pulmonary hypertension. Simvastatin 170-181 phosphodiesterase 5A Rattus norvegicus 31-55 22971207-1 2012 OBJECTIVES: Tadalafil, an oral phosphodiesterase type-5 inhibitor, induces pulmonary vasorelaxation by inhibiting the breakdown of cyclic guanosine monophosphate whereas simvastatin, an oral 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor, has been shown to reverse pulmonary hypertension (PH) and attenuate vascular remodeling in animal models of pulmonary hypertension. Simvastatin 170-181 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 191-237 22971207-5 2012 RESULTS: The combination of tadalafil and simvastatin showed significantly more improvement in the mean pulmonary hypertension pressure (mPAP) and right ventricular hypertrophy compared with each monotherapy (p < 0.05). Simvastatin 42-53 phospholipid phosphatase 1 Mus musculus 137-141 23087098-0 2012 Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats. Simvastatin 0-11 matrix metallopeptidase 19 Rattus norvegicus 73-106 23087098-10 2012 In addition, lung MMP-1,9 mRNA and proteins levels decreased toward normal levels in simvastatin-treated rats. Simvastatin 85-96 matrix metallopeptidase 19 Rattus norvegicus 18-25 23087098-11 2012 CONCLUSIONS: Simvastatin ameliorated the structural and functional derangements of pulmonary arterioles caused by the CA-JV shunt, partly associated with the suppression of up-regulated MMP-1, as well as MMP-9. Simvastatin 13-24 matrix metallopeptidase 1 Rattus norvegicus 186-191 23087098-11 2012 CONCLUSIONS: Simvastatin ameliorated the structural and functional derangements of pulmonary arterioles caused by the CA-JV shunt, partly associated with the suppression of up-regulated MMP-1, as well as MMP-9. Simvastatin 13-24 matrix metallopeptidase 9 Rattus norvegicus 204-209 23026078-9 2012 Simvastatin decreased the density of APP-positive profiles and increased the density of NF-H -positive profiles. Simvastatin 0-11 neurofilament heavy chain Homo sapiens 88-92 23026078-12 2012 Simvastatin activated Akt and mTOR, inactivated GSK-3beta and dephosphorylated APC in the injured PCNs. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 22-25 23026078-12 2012 Simvastatin activated Akt and mTOR, inactivated GSK-3beta and dephosphorylated APC in the injured PCNs. Simvastatin 0-11 mechanistic target of rapamycin kinase Homo sapiens 30-34 23026078-12 2012 Simvastatin activated Akt and mTOR, inactivated GSK-3beta and dephosphorylated APC in the injured PCNs. Simvastatin 0-11 glycogen synthase kinase 3 beta Homo sapiens 48-57 23026078-14 2012 The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways. Simvastatin 26-37 AKT serine/threonine kinase 1 Homo sapiens 109-112 23026078-14 2012 The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways. Simvastatin 26-37 mechanistic target of rapamycin kinase Homo sapiens 113-117 23026078-14 2012 The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways. Simvastatin 26-37 glycogen synthase kinase 3 beta Homo sapiens 128-137 23866408-10 2012 In addition, Simvastatin (10, 20, and 40mg/kg) significantly reduced the total number of abnormal pyramidal cells in CA1 and CA3 hippocampal regions compared to the picrotoxin-alone group. Simvastatin 13-24 carbonic anhydrase 1 Mus musculus 117-120 22689023-4 2012 Simvastatin or fluvastatin induced a significant increase in HO-1 protein expression and mRNA levels. Simvastatin 0-11 heme oxygenase 1 Mus musculus 61-65 22689023-7 2012 Gel retardation experiments for C/EBP and upstream stimulatory factor (USF) DNA-binding activities using simvastatin- or fluvastatin-treated cells showed significant nuclear protein-DNA complexes which were supershifted with antibodies specific for C/EBP beta and delta or USF-1 and USF-2. Simvastatin 105-116 CCAAT/enhancer binding protein (C/EBP), alpha Mus musculus 32-37 22689023-7 2012 Gel retardation experiments for C/EBP and upstream stimulatory factor (USF) DNA-binding activities using simvastatin- or fluvastatin-treated cells showed significant nuclear protein-DNA complexes which were supershifted with antibodies specific for C/EBP beta and delta or USF-1 and USF-2. Simvastatin 105-116 CCAAT/enhancer binding protein (C/EBP), beta Mus musculus 249-259 22689023-7 2012 Gel retardation experiments for C/EBP and upstream stimulatory factor (USF) DNA-binding activities using simvastatin- or fluvastatin-treated cells showed significant nuclear protein-DNA complexes which were supershifted with antibodies specific for C/EBP beta and delta or USF-1 and USF-2. Simvastatin 105-116 upstream transcription factor 1 Mus musculus 273-278 22689023-7 2012 Gel retardation experiments for C/EBP and upstream stimulatory factor (USF) DNA-binding activities using simvastatin- or fluvastatin-treated cells showed significant nuclear protein-DNA complexes which were supershifted with antibodies specific for C/EBP beta and delta or USF-1 and USF-2. Simvastatin 105-116 upstream transcription factor 2 Mus musculus 283-288 23105125-0 2012 Comments on "CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women". Simvastatin 76-87 cytochrome P450 family 3 subfamily A member 51, pseudogene Homo sapiens 13-20 23866408-10 2012 In addition, Simvastatin (10, 20, and 40mg/kg) significantly reduced the total number of abnormal pyramidal cells in CA1 and CA3 hippocampal regions compared to the picrotoxin-alone group. Simvastatin 13-24 carbonic anhydrase 3 Mus musculus 125-128 23035046-5 2012 TSC2-null lesions and alveolar destruction were differentially inhibited by the macrolide antibiotic rapamycin (which inhibits TSC2-null lesion growth by a cytostatic mechanism) and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin (which inhibits growth of TSC2-null lesions by a predominantly proapoptotic mechanism). Simvastatin 243-254 TSC complex subunit 2 Mus musculus 0-4 23148630-2 2012 A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Simvastatin 58-69 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 99-105 23042198-11 2012 Simvastatin completely reversed this sepsis-mediated inhibition of IFN-gamma and IL-4 formation in the spleen. Simvastatin 0-11 interferon gamma Homo sapiens 67-76 23042198-11 2012 Simvastatin completely reversed this sepsis-mediated inhibition of IFN-gamma and IL-4 formation in the spleen. Simvastatin 0-11 interleukin 4 Homo sapiens 81-85 23042198-13 2012 Notably, treatment with simvastatin abolished this CLP-evoked increase in HMBG1 and IL-6 levels in the plasma, suggesting that simvastatin is a potent inhibitor of systemic inflammation in sepsis. Simvastatin 24-35 interleukin 6 Homo sapiens 84-88 23042198-13 2012 Notably, treatment with simvastatin abolished this CLP-evoked increase in HMBG1 and IL-6 levels in the plasma, suggesting that simvastatin is a potent inhibitor of systemic inflammation in sepsis. Simvastatin 127-138 interleukin 6 Homo sapiens 84-88 22668755-1 2012 Whole-genome studies have identified several intronic single nucleotide polymorphisms (SNPs) in SLCO1B1 associated with simvastatin-induced myopathy. Simvastatin 120-131 solute carrier organic anion transporter family member 1B1 Homo sapiens 96-103 22668755-2 2012 The present study determined the effect of an intronic SNP rs4149081 in SLCO1B1 on the lipid-lowering effects of simvastatin and rosuvastatin in Chinese patients with hypercholesterolaemia. Simvastatin 113-124 solute carrier organic anion transporter family member 1B1 Homo sapiens 72-79 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Simvastatin 257-268 component of oligomeric golgi complex 2 Homo sapiens 128-163 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Simvastatin 257-268 component of oligomeric golgi complex 2 Homo sapiens 165-170 23148630-0 2012 Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin. Simvastatin 89-100 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 17-23 23102098-1 2012 BACKGROUND: Simvastatin increases the expression of bone morphogenetic protein 2 (BMP-2) in osteoblasts, therefore it is important to investigate the influence of statins on bone formation, fracture healing and implant integration. Simvastatin 12-23 bone morphogenetic protein 2 Rattus norvegicus 52-80 23102098-1 2012 BACKGROUND: Simvastatin increases the expression of bone morphogenetic protein 2 (BMP-2) in osteoblasts, therefore it is important to investigate the influence of statins on bone formation, fracture healing and implant integration. Simvastatin 12-23 bone morphogenetic protein 2 Rattus norvegicus 82-87 23035046-6 2012 Treatment with simvastatin markedly inhibited MMP-2, MMP-3, and MMP-9 levels in lung and prevented alveolar destruction. Simvastatin 15-26 matrix metallopeptidase 2 Mus musculus 46-51 23035046-6 2012 Treatment with simvastatin markedly inhibited MMP-2, MMP-3, and MMP-9 levels in lung and prevented alveolar destruction. Simvastatin 15-26 matrix metallopeptidase 3 Mus musculus 53-58 23035046-6 2012 Treatment with simvastatin markedly inhibited MMP-2, MMP-3, and MMP-9 levels in lung and prevented alveolar destruction. Simvastatin 15-26 matrix metallopeptidase 9 Mus musculus 64-69 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Simvastatin 33-44 TSC complex subunit 2 Mus musculus 70-74 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Simvastatin 33-44 matrix metallopeptidase 2 Mus musculus 123-128 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Simvastatin 33-44 matrix metallopeptidase 3 Mus musculus 130-135 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Simvastatin 33-44 matrix metallopeptidase 9 Mus musculus 141-146 23035046-8 2012 Our findings demonstrate a mechanistic link between loss of TSC2 and alveolar destruction and suggest that treatment with rapamycin and simvastatin together could benefit patients with LAM by targeting cells with TSC2 dysfunction and preventing airspace enlargement. Simvastatin 136-147 TSC complex subunit 2 Homo sapiens 60-64 22842798-0 2012 The effects of simvastatin on hippocampal caspase-3 and Bcl-2 expression following kainate-induced seizures in rats. Simvastatin 15-26 caspase 3 Rattus norvegicus 42-51 23044320-8 2012 When compared to the simvastatin group, the IR index and protein levels of LXRalpha in the Ilex asprella root group decreased (P < 0.05), and the serum adiponectin and SOD increased (P < 0.05). Simvastatin 21-32 nuclear receptor subfamily 1, group H, member 3 Rattus norvegicus 75-83 22658637-10 2012 Simvastatin also attenuated the increase in expression and secretion of PAI-1 induced by TNF-alpha (16898.6 +- 1663.3 vs 12922.1 +- 843.9 and 5.19 +- 3.12 vs 0.59 +- 0.16, respectively p<0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1. Simvastatin 0-11 serpin family E member 1 Homo sapiens 72-77 22658637-10 2012 Simvastatin also attenuated the increase in expression and secretion of PAI-1 induced by TNF-alpha (16898.6 +- 1663.3 vs 12922.1 +- 843.9 and 5.19 +- 3.12 vs 0.59 +- 0.16, respectively p<0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 89-98 22658637-10 2012 Simvastatin also attenuated the increase in expression and secretion of PAI-1 induced by TNF-alpha (16898.6 +- 1663.3 vs 12922.1 +- 843.9 and 5.19 +- 3.12 vs 0.59 +- 0.16, respectively p<0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1. Simvastatin 0-11 serpin family E member 1 Homo sapiens 275-280 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 tumor necrosis factor Homo sapiens 92-101 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 C-C motif chemokine ligand 2 Homo sapiens 133-138 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 serpin family E member 1 Homo sapiens 140-145 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 adiponectin, C1Q and collagen domain containing Homo sapiens 150-161 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 292-309 22902096-0 2012 Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Simvastatin 0-11 phospholipase A2 group VII Homo sapiens 49-88 22902096-5 2012 RESULTS: Plasma Lp-PLA(2) decreased (-21 +- 4%) in response to simvastatin (p<0.05 from baseline and placebo), but was unaffected by bezafibrate (1 +- 5%). Simvastatin 63-74 phospholipase A2 group VII Homo sapiens 16-25 22842798-0 2012 The effects of simvastatin on hippocampal caspase-3 and Bcl-2 expression following kainate-induced seizures in rats. Simvastatin 15-26 BCL2, apoptosis regulator Rattus norvegicus 56-61 22842798-9 2012 Interestingly, simvastatin could reverse the aforementioned SE-induced changes, suggesting that the neuroprotective effects of simvastatin against neuronal apoptosis may be achieved by inhibiting caspase-3 expression and increasing Bcl-2 expression. Simvastatin 15-26 caspase 3 Rattus norvegicus 196-205 22842798-9 2012 Interestingly, simvastatin could reverse the aforementioned SE-induced changes, suggesting that the neuroprotective effects of simvastatin against neuronal apoptosis may be achieved by inhibiting caspase-3 expression and increasing Bcl-2 expression. Simvastatin 15-26 BCL2, apoptosis regulator Rattus norvegicus 232-237 22842798-9 2012 Interestingly, simvastatin could reverse the aforementioned SE-induced changes, suggesting that the neuroprotective effects of simvastatin against neuronal apoptosis may be achieved by inhibiting caspase-3 expression and increasing Bcl-2 expression. Simvastatin 127-138 caspase 3 Rattus norvegicus 196-205 22842798-9 2012 Interestingly, simvastatin could reverse the aforementioned SE-induced changes, suggesting that the neuroprotective effects of simvastatin against neuronal apoptosis may be achieved by inhibiting caspase-3 expression and increasing Bcl-2 expression. Simvastatin 127-138 BCL2, apoptosis regulator Rattus norvegicus 232-237 22985805-0 2012 Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial. Simvastatin 52-63 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-35 23040777-1 2012 OBJECTIVE: To study the impact of simvastatin on alpha-subunit epithelial sodium channel (alpha-ENaC) mRNA expression in primary culture alveolar typeII (ATII) epithelial cell of rats induced by lipopolysaccharide (LPS) in vitro. Simvastatin 34-45 sodium channel epithelial 1 subunit alpha Rattus norvegicus 90-100 23040777-10 2012 Expressions of alpha-ENaC mRNA in simvastatin low concentration group evidently increased compared with those in LPS injured group (12 hours: 0.363+-0.030 vs. 0.211+-0.021, 24 hours: 0.309+-0.024 vs. 0.253+-0.030, both P<0.05). Simvastatin 34-45 sodium channel epithelial 1 subunit alpha Rattus norvegicus 15-25 23040777-11 2012 Expressions of alpha-ENaC mRNA in simvastatin high concentration group increased more obviously compared with those in low concentration group (12 hours: 0.413+-0.034 vs. 0.363+-0.030, 24 hours: 0.346+-0.024 vs. 0.309+-0.024, both P<0.05), but decreased compared with blank control group. Simvastatin 34-45 sodium channel epithelial 1 subunit alpha Rattus norvegicus 15-25 23040777-13 2012 CONCLUSIONS: High dose simvastatin could improve alpha-ENaC mRNA expression in primary culture ATII epithelial cells of rats. Simvastatin 23-34 sodium channel epithelial 1 subunit alpha Rattus norvegicus 49-59 22918643-0 2012 Effects of simvastatin on the expression of heme oxygenase-1 in human RPE cells. Simvastatin 11-22 heme oxygenase 1 Homo sapiens 44-60 22918643-8 2012 Simvastatin increased the HO-1 mRNA and protein levels in a concentration-dependent manner up to 10 muM. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 26-30 22918643-9 2012 HO-1 protein induction by simvastatin was unaffected by mevalonate or N-nitro-L-arginine methyl ester, showing that the isoprenoid- and NO-dependent pathways are not involved. Simvastatin 26-37 heme oxygenase 1 Homo sapiens 0-4 22820842-4 2012 More importantly, we found that Tin-protoporphyrin (SnPP), a selective inhibitor of HO-1, could block the effect of simvastatin on inhibition of cell proliferation in response to serotonin and abolish simvastatin-induced p21(WAF1) expression. Simvastatin 116-127 cyclin dependent kinase inhibitor 1A Homo sapiens 221-224 22820842-4 2012 More importantly, we found that Tin-protoporphyrin (SnPP), a selective inhibitor of HO-1, could block the effect of simvastatin on inhibition of cell proliferation in response to serotonin and abolish simvastatin-induced p21(WAF1) expression. Simvastatin 116-127 cyclin dependent kinase inhibitor 1A Homo sapiens 225-229 22820842-5 2012 The inhibitive effect of simvastatin on cell proliferation was also significantly suppressed by silencing p21(WAF1) with siRNA transfection. Simvastatin 25-36 cyclin dependent kinase inhibitor 1A Homo sapiens 106-109 22820842-5 2012 The inhibitive effect of simvastatin on cell proliferation was also significantly suppressed by silencing p21(WAF1) with siRNA transfection. Simvastatin 25-36 cyclin dependent kinase inhibitor 1A Homo sapiens 110-114 22820842-7 2012 Taken together, our study suggests that simvastatin inhibits PASMCs proliferation by sequential upregulation of HO-1 and p21(WAF1) to benefit pulmonary hypertension. Simvastatin 40-51 cyclin dependent kinase inhibitor 1A Homo sapiens 121-124 22820842-7 2012 Taken together, our study suggests that simvastatin inhibits PASMCs proliferation by sequential upregulation of HO-1 and p21(WAF1) to benefit pulmonary hypertension. Simvastatin 40-51 cyclin dependent kinase inhibitor 1A Homo sapiens 125-129 22918643-10 2012 Simvastatin-dependent HO-1 protein induction was reduced significantly by pharmacological inhibition of the phosphotidylinositol-3-kinase (PI3K)/Akt pathways. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 22-26 22918643-10 2012 Simvastatin-dependent HO-1 protein induction was reduced significantly by pharmacological inhibition of the phosphotidylinositol-3-kinase (PI3K)/Akt pathways. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 145-148 22918643-12 2012 CONCLUSIONS: These results demonstrate that HO-1 is a target site and an antioxidant mediator of simvastatin in human RPE cells. Simvastatin 97-108 heme oxygenase 1 Homo sapiens 44-48 22918643-13 2012 Simvastatin-dependent upregulation of HO-1 is mainly via PI3K/Akt-dependent signaling pathways. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 38-42 22918643-13 2012 Simvastatin-dependent upregulation of HO-1 is mainly via PI3K/Akt-dependent signaling pathways. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 62-65 22985805-3 2012 The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI. Simvastatin 56-67 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-39 22985805-3 2012 The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI. Simvastatin 303-314 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-39 22524173-5 2012 Indeed a genome-wide study in patients treated with simvastatin found an impressive association between single-nucleotide polymorphisms (SNPs) located within SLCO1B1 gene on chromosome 12 and established myopathy. Simvastatin 52-63 solute carrier organic anion transporter family member 1B1 Homo sapiens 158-165 22974127-6 2012 Protein expression of major candidates of the intrinsic pathway downstream of simvastatin-mediated Akt inactivation was analyzed. Simvastatin 78-89 AKT serine/threonine kinase 1 Homo sapiens 99-102 22974127-8 2012 RESULTS: Data indicated that simvastatin inhibited intrinsic cell survival pathway in PC3 cells by enhancing phosphorylation of Bad, reducing the protein expression of Bcl-2, Bcl-xL and cleaved caspases 9/3. Simvastatin 29-40 BCL2 apoptosis regulator Homo sapiens 168-173 22974127-8 2012 RESULTS: Data indicated that simvastatin inhibited intrinsic cell survival pathway in PC3 cells by enhancing phosphorylation of Bad, reducing the protein expression of Bcl-2, Bcl-xL and cleaved caspases 9/3. Simvastatin 29-40 BCL2 like 1 Homo sapiens 175-181 22974127-8 2012 RESULTS: Data indicated that simvastatin inhibited intrinsic cell survival pathway in PC3 cells by enhancing phosphorylation of Bad, reducing the protein expression of Bcl-2, Bcl-xL and cleaved caspases 9/3. Simvastatin 29-40 caspase 9 Homo sapiens 194-206 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 tumor necrosis factor Homo sapiens 93-96 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 Fas ligand Homo sapiens 98-103 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 TNF receptor associated factor 1 Homo sapiens 105-110 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 caspase 8 Homo sapiens 123-132 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 LIM homeobox 4 Homo sapiens 230-234 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 NME/NM23 family member 5 Homo sapiens 239-243 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 1 beta Mus musculus 20-28 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 6 Mus musculus 33-37 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 6 Mus musculus 70-74 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 79-106 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 108-117 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 1 beta Mus musculus 138-146 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 2 Mus musculus 148-152 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 13 Mus musculus 164-169 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 tumor necrosis factor Mus musculus 171-180 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 182-188 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interferon gamma Mus musculus 194-210 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 6 Mus musculus 70-74 22705060-8 2012 CD31 immunostaining revealed an increased capillary density in ischemic gastrocnemious tissue of diabetic rats treated with either simvastatin or its combination with vitamin C. Simvastatin 131-142 platelet and endothelial cell adhesion molecule 1 Rattus norvegicus 0-4 22796581-8 2012 Simvastatin significantly reduced plasma troponin T, isoenzyme of creatine kinase, C-reaction protein, blood urea nitrogen , creatinine, interleukin-6, interleukin-8, and the requirement of inotropic postoperatively. Simvastatin 0-11 interleukin 6 Homo sapiens 137-150 22796581-8 2012 Simvastatin significantly reduced plasma troponin T, isoenzyme of creatine kinase, C-reaction protein, blood urea nitrogen , creatinine, interleukin-6, interleukin-8, and the requirement of inotropic postoperatively. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 152-165 22796581-9 2012 Simvastatin increased NO production, the expression of eNOS and phosphorylation at serine1177, phosphorylation of Akt, expression of heat shock protein 90, heat shock protein 90 association with eNOS and decreased eNOS phosphorylation at threonine 495, phosphorylation of p38, and expression of caveolin-1. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 114-117 22796581-9 2012 Simvastatin increased NO production, the expression of eNOS and phosphorylation at serine1177, phosphorylation of Akt, expression of heat shock protein 90, heat shock protein 90 association with eNOS and decreased eNOS phosphorylation at threonine 495, phosphorylation of p38, and expression of caveolin-1. Simvastatin 0-11 activator of HSP90 ATPase activity 1 Homo sapiens 272-275 22796581-9 2012 Simvastatin increased NO production, the expression of eNOS and phosphorylation at serine1177, phosphorylation of Akt, expression of heat shock protein 90, heat shock protein 90 association with eNOS and decreased eNOS phosphorylation at threonine 495, phosphorylation of p38, and expression of caveolin-1. Simvastatin 0-11 caveolin 1 Homo sapiens 295-305 22970034-6 2012 The results of the western blot analysis indicated that the addition of simvastatin upregulated pSmad1/5/8 expression and the combination of 0.1 muM simvastatin and 60 ng/ml BMP-2 produced a significant increase in protein expression. Simvastatin 72-83 bone morphogenetic protein 2 Homo sapiens 174-179 22670687-10 2012 Decreased levels of phosphorylated (p-) MYPT-1 and p-IRS-1 (Ser307) and increased levels of p-Akt were found in hearts from the MS + simvastatin compared with the MS group. Simvastatin 133-144 insulin receptor substrate 1 Rattus norvegicus 53-58 22670687-10 2012 Decreased levels of phosphorylated (p-) MYPT-1 and p-IRS-1 (Ser307) and increased levels of p-Akt were found in hearts from the MS + simvastatin compared with the MS group. Simvastatin 133-144 AKT serine/threonine kinase 1 Rattus norvegicus 94-97 22670687-11 2012 These results suggest that simvastatin reduces ROCK activity and increases Akt activity. Simvastatin 27-38 AKT serine/threonine kinase 1 Rattus norvegicus 75-78 22670687-13 2012 Simvastatin exerts cardioprotective effects and improves IR, which can be attributed, at least in part, to the inhibition of ROCK and activation of PI3-K/Akt. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 154-157 22970034-5 2012 Cultures grown in the presence of 0.1 muM simvastatin with 60 ng/ml BMP-2 exhibited the highest value for ALP activity. Simvastatin 42-53 bone morphogenetic protein 2 Homo sapiens 68-73 22970034-5 2012 Cultures grown in the presence of 0.1 muM simvastatin with 60 ng/ml BMP-2 exhibited the highest value for ALP activity. Simvastatin 42-53 alkaline phosphatase, placental Homo sapiens 106-109 22451032-10 2012 Three clinical studies investigated the interaction showing simvastatin (CYP3A4 substrate) bioavailability reduced by TCZ and omeprazole bioavailability was decreased by TCZ-induced CYP2C19 activity. Simvastatin 60-71 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 73-79 22683568-0 2012 Critical role for integrin-beta4 in the attenuation of murine acute lung injury by simvastatin. Simvastatin 83-94 integrin beta 4 Mus musculus 18-32 22683568-3 2012 In particular, simvastatin induces the upregulation of integrin-beta4, which in turn inhibits EC inflammatory responses via attenuation of MAPK signaling. Simvastatin 15-26 integrin beta 4 Mus musculus 55-69 22683568-5 2012 We initially confirmed a time- and dose-dependent effect of simvastatin on increased integrin-beta4 mRNA expression in human lung EC with peak protein expression evident at 16 h. Subsequently, reciprocal immunoprecipitation demonstrated an attenuation of LPS-induced integrin-beta4 tyrosine phosphorylation by simvastatin (5 muM, 16 h). Simvastatin 60-71 integrin subunit beta 4 Homo sapiens 85-99 22683568-5 2012 We initially confirmed a time- and dose-dependent effect of simvastatin on increased integrin-beta4 mRNA expression in human lung EC with peak protein expression evident at 16 h. Subsequently, reciprocal immunoprecipitation demonstrated an attenuation of LPS-induced integrin-beta4 tyrosine phosphorylation by simvastatin (5 muM, 16 h). Simvastatin 60-71 integrin beta 4 Mus musculus 267-281 22683568-5 2012 We initially confirmed a time- and dose-dependent effect of simvastatin on increased integrin-beta4 mRNA expression in human lung EC with peak protein expression evident at 16 h. Subsequently, reciprocal immunoprecipitation demonstrated an attenuation of LPS-induced integrin-beta4 tyrosine phosphorylation by simvastatin (5 muM, 16 h). Simvastatin 310-321 integrin subunit beta 4 Homo sapiens 85-99 22683568-7 2012 Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). Simvastatin 18-29 interleukin 6 Mus musculus 189-193 22683568-7 2012 Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). Simvastatin 18-29 interleukin 1 beta Mus musculus 195-203 22683568-7 2012 Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). Simvastatin 18-29 chemokine (C-C motif) ligand 2 Mus musculus 205-210 22683568-7 2012 Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). Simvastatin 18-29 chemokine (C-C motif) ligand 5 Mus musculus 212-218 22683568-7 2012 Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). Simvastatin 18-29 integrin beta 4 Mus musculus 350-364 22683568-8 2012 These findings support integrin-beta4 as an important mediator of ALI protection by simvastatin and implicate signaling by integrin-beta4 as a novel therapeutic target in patients with ALI. Simvastatin 84-95 integrin subunit beta 4 Homo sapiens 23-37 22694979-0 2012 Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-kappaB. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 94-103 22694979-5 2012 RESULTS: Treatment with simvastatin resulted in a decrease in 4-HNE and TNF-alpha concentration (median 4.18 mug/mg protein vs. 4.75, p = 0.012; median 10.33 pg/ml vs. 11.81, p = 0.026, respectively). Simvastatin 24-35 tumor necrosis factor Homo sapiens 72-81 22694979-6 2012 CAT activity was higher in the simvastatin group (median 3.98 U ml vs. 3.19, p = 0.023). Simvastatin 31-42 catalase Homo sapiens 0-3 22694979-7 2012 NF-kappaB expression was lower (p = 0.018) in the simvastatin group. Simvastatin 50-61 nuclear factor kappa B subunit 1 Homo sapiens 0-9 22694979-9 2012 CONCLUSION: Simvastatin inhibits free radicals and TNF-alpha generation and improves antioxidant capacity of human AAA wall tissue, possibly through the suppression of NF-kappaB activity. Simvastatin 12-23 tumor necrosis factor Homo sapiens 51-60 22694979-9 2012 CONCLUSION: Simvastatin inhibits free radicals and TNF-alpha generation and improves antioxidant capacity of human AAA wall tissue, possibly through the suppression of NF-kappaB activity. Simvastatin 12-23 nuclear factor kappa B subunit 1 Homo sapiens 168-177 22970034-6 2012 The results of the western blot analysis indicated that the addition of simvastatin upregulated pSmad1/5/8 expression and the combination of 0.1 muM simvastatin and 60 ng/ml BMP-2 produced a significant increase in protein expression. Simvastatin 149-160 bone morphogenetic protein 2 Homo sapiens 174-179 21730017-7 2012 Repeated administration of SB-649868 dose-dependently increased exposure to simvastatin (10 mg), suggesting CYP3A4 inhibition ranging from very mild (5 mg) to strong (30 mg). Simvastatin 76-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-114 22659288-11 2012 Moreover after exposure to simvastatin, a well-known KLF2 inducer, KLF2 binds to the Cx37 promoter region as shown by ChIP. Simvastatin 27-38 Kruppel-like factor 2 (lung) Mus musculus 53-57 22659288-11 2012 Moreover after exposure to simvastatin, a well-known KLF2 inducer, KLF2 binds to the Cx37 promoter region as shown by ChIP. Simvastatin 27-38 Kruppel-like factor 2 (lung) Mus musculus 67-71 22659288-11 2012 Moreover after exposure to simvastatin, a well-known KLF2 inducer, KLF2 binds to the Cx37 promoter region as shown by ChIP. Simvastatin 27-38 gap junction protein, alpha 4 Mus musculus 85-89 22659288-12 2012 Finally, GJIC dye transfer was highly reduced after KLF2 silencing and was increased after exposure to simvastatin. Simvastatin 103-114 Kruppel-like factor 2 (lung) Mus musculus 52-56 22525429-0 2012 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Canis lupus familiaris 0-47 22977450-0 2012 Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein e(-/-) mice. Simvastatin 0-11 apolipoprotein E Mus musculus 87-103 22525429-0 2012 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Simvastatin 58-69 homeobox A13 Canis lupus familiaris 105-111 22529023-7 2012 The CYP3A4 statins (i.e., simvastatin, atorvastatin and lovastatin) accounted for 85% of all statins in 2004, increasing to 93% in 2008. Simvastatin 26-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-10 22683506-11 2012 Immunofluorescence revealed that simvastatin increased the number of GFP-positive cells in the injured spinal cord, and the number of cells double positive for GFP/NeuN or GFP/GFAP was larger in the simvastatin treated group than the control group. Simvastatin 199-210 RNA binding fox-1 homolog 3 Rattus norvegicus 164-168 22683506-11 2012 Immunofluorescence revealed that simvastatin increased the number of GFP-positive cells in the injured spinal cord, and the number of cells double positive for GFP/NeuN or GFP/GFAP was larger in the simvastatin treated group than the control group. Simvastatin 199-210 glial fibrillary acidic protein Rattus norvegicus 176-180 22683506-12 2012 Western blot and immunohistochemistry showed higher expression of BDNF and VEGF in the simvastatin treated group than the control group. Simvastatin 87-98 brain-derived neurotrophic factor Rattus norvegicus 66-70 22683506-12 2012 Western blot and immunohistochemistry showed higher expression of BDNF and VEGF in the simvastatin treated group than the control group. Simvastatin 87-98 vascular endothelial growth factor A Rattus norvegicus 75-79 22683506-13 2012 In conclusion, simvastatin can help to repair spinal cord injury in rat, where the underlying mechanism appears to involve the mobilization of bone marrow stromal cells to the injured area and higher expression of BNDF and VEGF. Simvastatin 15-26 vascular endothelial growth factor A Rattus norvegicus 223-227 22659627-11 2012 Intravenous infusion of the PKA inhibitor H-89 (1 mug kg(-1) min(-1)) partially abrogated the SIM-induced cardioprotection and eNOS phosphorylation. Simvastatin 94-97 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 28-31 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 0-11 matrix metallopeptidase 2 Homo sapiens 44-48 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 0-11 matrix metallopeptidase 3 Homo sapiens 50-54 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 0-11 CD44 molecule (Indian blood group) Homo sapiens 60-64 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 0-11 TIMP metallopeptidase inhibitor 2 Homo sapiens 80-85 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 113-124 TIMP metallopeptidase inhibitor 2 Homo sapiens 80-85 22659627-10 2012 SIM significantly increased the activities of PKA and constitutive NOS, and increased Ser(133) p-CREB protein, Ser(1179) p-eNOS, and Ser(635) p-eNOS in ischemic myocardium. Simvastatin 0-3 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 46-49 22659627-12 2012 In contrast, intravenous infusion of the eNOS inhibitor L-NNA (10 mg kg(-1)) completely abrogated the SIM-induced cardioprotection and eNOS phosphorylation during ischemia and reperfusion, but did not affect the activity of PKA. Simvastatin 102-105 nitric oxide synthase 3 Sus scrofa 41-45 22659627-10 2012 SIM significantly increased the activities of PKA and constitutive NOS, and increased Ser(133) p-CREB protein, Ser(1179) p-eNOS, and Ser(635) p-eNOS in ischemic myocardium. Simvastatin 0-3 cAMP response element binding protein Sus scrofa 97-101 22659627-12 2012 In contrast, intravenous infusion of the eNOS inhibitor L-NNA (10 mg kg(-1)) completely abrogated the SIM-induced cardioprotection and eNOS phosphorylation during ischemia and reperfusion, but did not affect the activity of PKA. Simvastatin 102-105 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 224-227 22659627-10 2012 SIM significantly increased the activities of PKA and constitutive NOS, and increased Ser(133) p-CREB protein, Ser(1179) p-eNOS, and Ser(635) p-eNOS in ischemic myocardium. Simvastatin 0-3 nitric oxide synthase 3 Sus scrofa 123-127 22659627-10 2012 SIM significantly increased the activities of PKA and constitutive NOS, and increased Ser(133) p-CREB protein, Ser(1179) p-eNOS, and Ser(635) p-eNOS in ischemic myocardium. Simvastatin 0-3 nitric oxide synthase 3 Sus scrofa 144-148 22223195-10 2012 This modification of RhoB required for its correct function can be prevented by the cholesterol lowering drug simvastatin, which was also able to abolish the anti-angiogenic effects of celiac anti-TG2 autoantibodies. Simvastatin 110-121 ras homolog family member B Homo sapiens 21-25 22720799-9 2012 In addition, simvastatin and pravastatin treatment reversed 3MC-mediated alterations in mouse cerebrovascular endothelial cells by RhoA inactivation, and the in vitro findings were substantiated by an in vivo blood-brain barrier assay. Simvastatin 13-24 ras homolog family member A Mus musculus 131-135 22720799-10 2012 Thus, endothelial barrier dysfunction due to 3MC occurs through AhR/RhoA-mediated beta-catenin down-regulation, which is reversed by simvastatin treatment in vivo. Simvastatin 133-144 aryl-hydrocarbon receptor Mus musculus 64-67 22720799-10 2012 Thus, endothelial barrier dysfunction due to 3MC occurs through AhR/RhoA-mediated beta-catenin down-regulation, which is reversed by simvastatin treatment in vivo. Simvastatin 133-144 ras homolog family member A Mus musculus 68-72 22720799-10 2012 Thus, endothelial barrier dysfunction due to 3MC occurs through AhR/RhoA-mediated beta-catenin down-regulation, which is reversed by simvastatin treatment in vivo. Simvastatin 133-144 catenin (cadherin associated protein), beta 1 Mus musculus 82-94 22617227-3 2012 A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. Simvastatin 124-135 solute carrier organic anion transporter family member 1B1 Homo sapiens 76-83 22633472-11 2012 CONCLUSION: High dose simvastatin therapy reduces proinflammatory transcription factor NF-kappaB binding activity and hsCRP levels, while combination of low dose simvastatin with ezetimibe resulting in a similar LDL-reduction does not affect these inflammatory markers. Simvastatin 22-33 nuclear factor kappa B subunit 1 Homo sapiens 87-96 22658255-1 2012 OBJECTIVE: We evaluated the long-term effects of rosuvastatin and simvastatin on insulin sensitivity and secretion in patients with well-controlled type 2 diabetes. Simvastatin 66-77 insulin Homo sapiens 81-88 22658255-11 2012 CONCLUSIONS: In well-controlled type 2 diabetic patients both rosuvastatin and simvastatin significantly impaired glycemic control and insulin secretion, without affecting insulin sensitivity. Simvastatin 79-90 insulin Homo sapiens 135-142 22805089-7 2012 After the treatment, GXK decoction and simvastatin decreased the expressions of PPARgamma, LXRalpha and ABCA1 (P<0.05). Simvastatin 39-50 peroxisome proliferator activated receptor gamma Mus musculus 80-89 22748975-0 2012 Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin. Simvastatin 145-156 fatty acid desaturase 2 Homo sapiens 25-30 22748975-8 2012 Simvastatin and the LXR agonist GW3965 both upregulated expression of FADS1 and FADS2; no response was found for PPARgamma agonist rosiglitazone. Simvastatin 0-11 fatty acid desaturase 1 Homo sapiens 70-75 22748975-8 2012 Simvastatin and the LXR agonist GW3965 both upregulated expression of FADS1 and FADS2; no response was found for PPARgamma agonist rosiglitazone. Simvastatin 0-11 fatty acid desaturase 2 Homo sapiens 80-85 22748975-9 2012 The minor haplotype homozygotes had 20-40% higher induction of FADS1 and FADS2 after simvastatin or GW3965 treatment. Simvastatin 85-96 fatty acid desaturase 1 Homo sapiens 63-68 22748975-9 2012 The minor haplotype homozygotes had 20-40% higher induction of FADS1 and FADS2 after simvastatin or GW3965 treatment. Simvastatin 85-96 fatty acid desaturase 2 Homo sapiens 73-78 22805089-7 2012 After the treatment, GXK decoction and simvastatin decreased the expressions of PPARgamma, LXRalpha and ABCA1 (P<0.05). Simvastatin 39-50 nuclear receptor subfamily 1, group H, member 3 Mus musculus 91-99 22805089-7 2012 After the treatment, GXK decoction and simvastatin decreased the expressions of PPARgamma, LXRalpha and ABCA1 (P<0.05). Simvastatin 39-50 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 104-109 22367687-5 2012 The simvastatin release rate changed depending on dissolution media, it repeated twice, and the rate under SOC was 15 times higher than under SOB. Simvastatin 4-15 UBX domain protein 11 Rattus norvegicus 107-110 22717585-5 2012 Pharmacologic blockade of the activation of ER-dependent cysteine-dependent aspartate-directed protease (caspase)-4 and lysosomal cathepsin-B and -L significantly decreased simvastatin-induced cell death. Simvastatin 173-184 caspase 4 Homo sapiens 57-115 22717585-5 2012 Pharmacologic blockade of the activation of ER-dependent cysteine-dependent aspartate-directed protease (caspase)-4 and lysosomal cathepsin-B and -L significantly decreased simvastatin-induced cell death. Simvastatin 173-184 cathepsin B Homo sapiens 130-141 22717585-8 2012 In mouse embryonic fibroblasts that are deficient in autophagy protein 5 and refractory to autophagy induction, caspase-7 and UPR were hyper-induced upon treatment with simvastatin. Simvastatin 169-180 caspase 7 Mus musculus 112-121 22399266-4 2012 The alkaline phosphatase (ALP) activity was measured after stimulation with simvastatin using specific colorimetric assay. Simvastatin 76-87 alkaline phosphatase, placental Homo sapiens 4-24 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 40-42 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 61-65 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 102-106 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 102-106 22913213-6 2012 RESULTS: The current results showed that the treatment of HFD rats with either rimonabant or simvastatin significantly reduced body mass index, total cholesterol, triacylglycerides, low density lipoproteins, tumor necrosis factor alpha and monocyte chemoattractant protein-1, while increased adiponectin serum levels. Simvastatin 93-104 tumor necrosis factor Rattus norvegicus 208-235 22913213-6 2012 RESULTS: The current results showed that the treatment of HFD rats with either rimonabant or simvastatin significantly reduced body mass index, total cholesterol, triacylglycerides, low density lipoproteins, tumor necrosis factor alpha and monocyte chemoattractant protein-1, while increased adiponectin serum levels. Simvastatin 93-104 C-C motif chemokine ligand 2 Rattus norvegicus 240-274 22281720-1 2012 PURPOSE: Although CYP3A4/5 enzymes play the predominant role in the metabolism of simvastatin and lovastatin, polymorphisms in CYP2D6 were reported to be associated with the cholesterol-lowering effect and/or tolerability of simvastatin. Simvastatin 82-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-24 22281720-1 2012 PURPOSE: Although CYP3A4/5 enzymes play the predominant role in the metabolism of simvastatin and lovastatin, polymorphisms in CYP2D6 were reported to be associated with the cholesterol-lowering effect and/or tolerability of simvastatin. Simvastatin 82-93 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 127-133 22281720-1 2012 PURPOSE: Although CYP3A4/5 enzymes play the predominant role in the metabolism of simvastatin and lovastatin, polymorphisms in CYP2D6 were reported to be associated with the cholesterol-lowering effect and/or tolerability of simvastatin. Simvastatin 225-236 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 127-133 22399266-4 2012 The alkaline phosphatase (ALP) activity was measured after stimulation with simvastatin using specific colorimetric assay. Simvastatin 76-87 alkaline phosphatase, placental Homo sapiens 26-29 22399266-8 2012 ALP activity of AOBs and PDLs was increased by 1 and 100 nM simvastatin, respectively. Simvastatin 60-71 alkaline phosphatase, placental Homo sapiens 0-3 22399266-9 2012 Simvastatin induced a dose-dependent increase in OC mRNA expression of AOBs and did not influence that in PDLs. Simvastatin 0-11 bone gamma-carboxyglutamate protein Homo sapiens 49-51 22399266-10 2012 RANKL expression of AOBs was increased at all tested simvastatin concentrations and that in PDLs was increased by higher simvastatin concentrations (10-100 nM). Simvastatin 53-64 TNF superfamily member 11 Homo sapiens 0-5 22399266-11 2012 Finally, the expression of OPG in AOBs and PDLs was stimulated by 1-10 and 100 nM simvastatin, respectively. Simvastatin 82-93 TNF receptor superfamily member 11b Homo sapiens 27-30 22392066-8 2012 Moreover, simvastatin, the RhoA inhibitor C3, and the RhoA-kinase inhibitor Y27632 all attenuated the proliferation rate induced by ET-1 in basilar artery smooth muscle cells via the Rho/Rho-kinase signaling pathway. Simvastatin 10-21 endothelin 1 Rattus norvegicus 132-136 22392066-9 2012 In conclusion, simvastatin attenuated ET-1-induced proliferation through the Rho/Rho-kinase signaling pathway in hypertensive rat basilar artery, and it may be an excellent reagent to protect vascular remodeling and stroke. Simvastatin 15-26 endothelin 1 Rattus norvegicus 38-42 23482588-2 2012 This study is designed to examine whether simvastatin and atorvastatin affect levels of growth factors and activate the Akt signaling pathway during the recovery phase after intracerebral hemorrhage (ICH) in rats. Simvastatin 42-53 AKT serine/threonine kinase 1 Rattus norvegicus 120-123 22595108-10 2012 The number of Beclin-1-synthesizing osteoblasts also increased markedly after simvastatin treatment. Simvastatin 78-89 beclin 1 Rattus norvegicus 14-22 21243006-0 2012 Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Simvastatin 84-95 solute carrier organic anion transporter family member 1B1 Homo sapiens 48-55 21243006-3 2012 Recently, variation in the SLCO1B1 gene was reported to predict simvastatin-associated myopathy. Simvastatin 64-75 solute carrier organic anion transporter family member 1B1 Homo sapiens 27-34 21243006-7 2012 However, when subjects were stratified by statin type, the SLCO1B1 rs4149056 genotype was significantly associated with myopathy in patients who received simvastatin, but not in patients who received atorvastatin. Simvastatin 154-165 solute carrier organic anion transporter family member 1B1 Homo sapiens 59-66 21243006-8 2012 Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin. Simvastatin 72-83 solute carrier organic anion transporter family member 1B1 Homo sapiens 52-59 21243006-8 2012 Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin. Simvastatin 159-170 solute carrier organic anion transporter family member 1B1 Homo sapiens 52-59 22267540-5 2012 In mouse model, simvastatin decreased MCP-1 expression in a dose-dependent manner in endometriotic implants (P < .05). Simvastatin 16-27 chemokine (C-C motif) ligand 2 Mus musculus 38-43 22267540-6 2012 Similarly, both simvastatin and mevastatin revealed a dose-dependent inhibition of MCP-1 production in cultured endometriotic cells (P < .01). Simvastatin 16-27 chemokine (C-C motif) ligand 2 Mus musculus 83-88 23482588-8 2012 Simvastatin and atorvastatin treatment increased the expression of BDNF, VEGF and NGF in both low- and high-dose groups at 7 days after ICH (p < 0.05). Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 67-71 23482588-8 2012 Simvastatin and atorvastatin treatment increased the expression of BDNF, VEGF and NGF in both low- and high-dose groups at 7 days after ICH (p < 0.05). Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 73-77 23482588-8 2012 Simvastatin and atorvastatin treatment increased the expression of BDNF, VEGF and NGF in both low- and high-dose groups at 7 days after ICH (p < 0.05). Simvastatin 0-11 nerve growth factor Rattus norvegicus 82-85 21324392-9 2012 The results of the Western blot analysis indicated that the addition of simvastatin up-regulated ER-alpha and ER-beta expression with a statistically significant difference in ER-alpha expression. Simvastatin 72-83 estrogen receptor 1 Homo sapiens 97-105 21324392-9 2012 The results of the Western blot analysis indicated that the addition of simvastatin up-regulated ER-alpha and ER-beta expression with a statistically significant difference in ER-alpha expression. Simvastatin 72-83 estrogen receptor 2 Homo sapiens 110-117 21324392-9 2012 The results of the Western blot analysis indicated that the addition of simvastatin up-regulated ER-alpha and ER-beta expression with a statistically significant difference in ER-alpha expression. Simvastatin 72-83 estrogen receptor 1 Homo sapiens 176-184 21324392-12 2012 Our results also suggested that osteoinductive effects of simvastatin were achieved through ER pathway via the increase of ER-alpha expression. Simvastatin 58-69 estrogen receptor 1 Homo sapiens 123-131 22583375-0 2012 Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells. Simvastatin 24-35 interleukin 13 Mus musculus 39-44 22583375-4 2012 OBJECTIVES: In this study, we evaluated whether simvastatin inhibits IL-13-induced pro-inflammatory gene expression of asthma-related cytokines in well-differentiated primary mouse tracheal epithelial (MTE) cell cultures. Simvastatin 48-59 interleukin 13 Mus musculus 69-74 22583375-5 2012 We hypothesized that simvastatin reduces the expression of IL-13-inducible genes in MTE cells. Simvastatin 21-32 interleukin 13 Mus musculus 59-64 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 interleukin 13 Mus musculus 63-68 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 chemokine (C-C motif) ligand 2 Mus musculus 116-121 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 secreted phosphoprotein 1 Mus musculus 133-144 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 secreted phosphoprotein 1 Mus musculus 146-150 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 caspase 1 Mus musculus 170-179 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 chemokine (C-C motif) ligand 20 Mus musculus 184-189 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 chemokine (C-C motif) ligand 20 Mus musculus 191-201 22583375-9 2012 CONCLUSIONS: Simvastatin modulates the gene expression of selected IL-13-inducible pro-inflammatory cytokines and chemokines in primary mouse tracheal epithelial cells. Simvastatin 13-24 interleukin 13 Mus musculus 67-72 22382501-3 2012 The clinical significance of variants modulating toxicity (e.g. SLCO1B1 with simvastatin) has also been confirmed. Simvastatin 77-88 solute carrier organic anion transporter family member 1B1 Homo sapiens 64-71 22331026-7 2012 Simvastatin significantly increased the number of Tregs and the expression of Treg marker Foxp3 (Forkhead/winged helix transcription factor), transforming growth factor (TGF)-beta and interleukin (IL)-10 in atherosclerotic plaques. Simvastatin 0-11 forkhead box P3 Homo sapiens 90-95 22331026-7 2012 Simvastatin significantly increased the number of Tregs and the expression of Treg marker Foxp3 (Forkhead/winged helix transcription factor), transforming growth factor (TGF)-beta and interleukin (IL)-10 in atherosclerotic plaques. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 142-179 22331026-7 2012 Simvastatin significantly increased the number of Tregs and the expression of Treg marker Foxp3 (Forkhead/winged helix transcription factor), transforming growth factor (TGF)-beta and interleukin (IL)-10 in atherosclerotic plaques. Simvastatin 0-11 interleukin 10 Homo sapiens 184-203 22418440-10 2012 These results suggest that the CD44 and RHAMM receptors function on membrane lipid rafts during invasion and that simvastatin may have a potential therapeutic role in C. neoformans infections of the brain. Simvastatin 114-125 CD44 antigen Mus musculus 31-35 22418440-10 2012 These results suggest that the CD44 and RHAMM receptors function on membrane lipid rafts during invasion and that simvastatin may have a potential therapeutic role in C. neoformans infections of the brain. Simvastatin 114-125 hyaluronan mediated motility receptor (RHAMM) Mus musculus 40-45 22386866-6 2012 The lack of ERK involvement in LPS-stimulated IL-6 in fibroblasts was further supported by the observations that simvastatin, which is known to target ERK-AP-1, failed to inhibit LPS-stimulated IL-6 by fibroblasts. Simvastatin 113-124 mitogen-activated protein kinase 1 Homo sapiens 151-154 22237927-1 2012 PURPOSE: The co-administration of cytochrome P450 3A4 (CYP3A4) inhibitors with simvastatin or atorvastatin (CYP3A4-metabolised statins) is associated with increased statin exposure and can increase the risk of adverse drug reactions. Simvastatin 79-90 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-53 22237927-7 2012 Ninety-three percent of the patients were prescribed CYP3A4-metabolised statins, most whom received simvastatin (72%) and atorvastatin (24%). Simvastatin 100-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 22245985-0 2012 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 20-26 22245985-5 2012 RESULTS: VCAM-1 mRNA appeared to be the only target that was affected by the statins, with its expression being partially and almost completely reduced by simvastatin at 50 and 125 muM concentrations, respectively, and only partially reduced by atorvastatin, but not reduced by rosuvastatin. Simvastatin 155-166 vascular cell adhesion molecule 1 Homo sapiens 9-15 22245985-6 2012 VCAM-1 protein production was inhibited by simvastatin at concentrations from 5 to 125 muM. Simvastatin 43-54 vascular cell adhesion molecule 1 Homo sapiens 0-6 22245985-8 2012 CONCLUSIONS: This study showed that simvastatin reduces VCAM-1 expression in HUVECs exposed to LPS and decreases leukocyte-endothelial cell adhesion. Simvastatin 36-47 vascular cell adhesion molecule 1 Homo sapiens 56-62 22237927-1 2012 PURPOSE: The co-administration of cytochrome P450 3A4 (CYP3A4) inhibitors with simvastatin or atorvastatin (CYP3A4-metabolised statins) is associated with increased statin exposure and can increase the risk of adverse drug reactions. Simvastatin 79-90 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 22537532-1 2012 BACKGROUND: Statins such as simvastatin are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase used in the prevention of cardiovascular disease. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 58-115 22594507-0 2012 A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Simvastatin 58-69 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 99-105 22594507-2 2012 PATIENTS & METHODS: The influence of the CYP2C9*2 and CYP2C9*3 polymorphisms on the interaction between simvastatin and warfarin was analyzed in data from 1132 patients. Simvastatin 108-119 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 22594507-2 2012 PATIENTS & METHODS: The influence of the CYP2C9*2 and CYP2C9*3 polymorphisms on the interaction between simvastatin and warfarin was analyzed in data from 1132 patients. Simvastatin 108-119 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 58-64 22594507-3 2012 RESULTS: Simvastatin use reduced warfarin dose requirements by 29% in carriers of the CYP2C9*3 allele, compared with 5% in noncarriers. Simvastatin 9-20 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 86-92 22594507-5 2012 CONCLUSION: Our data indicate that the CYP2C9*3 polymorphism predisposes for a pharmacologic interaction between warfarin and simvastatin. Simvastatin 126-137 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-45 22537532-3 2012 Recently it has been demonstrated that the peroxisome proliferator-activated receptor (PPAR)-alpha mediates anti-inflammatory effects of simvastatin in vivo models of acute inflammation. Simvastatin 137-148 peroxisome proliferator activated receptor alpha Mus musculus 43-98 22537532-9 2012 RESULTS: Results indicate that simvastatin activity is weakened in PPAR-alpha KO mice, as compared to WT controls. Simvastatin 31-42 peroxisome proliferator activated receptor alpha Mus musculus 67-77 22537532-10 2012 In particular, simvastatin was less effective in PPAR-alpha KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-kappaB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. Simvastatin 15-26 peroxisome proliferator activated receptor alpha Mus musculus 49-59 22537532-10 2012 In particular, simvastatin was less effective in PPAR-alpha KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-kappaB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. Simvastatin 15-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 244-270 22537532-10 2012 In particular, simvastatin was less effective in PPAR-alpha KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-kappaB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. Simvastatin 15-26 nitric oxide synthase 2, inducible Mus musculus 283-314 22537532-10 2012 In particular, simvastatin was less effective in PPAR-alpha KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-kappaB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. Simvastatin 15-26 nitric oxide synthase 2, inducible Mus musculus 316-320 22537532-12 2012 CONCLUSIONS: This study indicates that PPAR-alpha can contribute to the anti-inflammatory activity of simvastatin in SCI. Simvastatin 102-113 peroxisome proliferator activated receptor alpha Mus musculus 39-49 20946258-0 2012 Simvastatin inhibits glucose-stimulated vascular smooth muscle cell migration involving increased expression of RhoB and a block of Ras/Akt signal. Simvastatin 0-11 ras homolog family member B Homo sapiens 112-116 22932337-0 2012 [Effects of simvastatin on expression of connective tissue growth factor in vitreous and retina of diabetic rats]. Simvastatin 12-23 cellular communication network factor 2 Rattus norvegicus 41-72 22932337-1 2012 OBJECTIVE: To study the effects of simvastatin on the expression of connective tissue growth factor (CTGF) that cause fibrosis in the vitreous and retina after intravitreal injection in diabetic rats, and to explore the safety of this procedure. Simvastatin 35-46 cellular communication network factor 2 Rattus norvegicus 68-99 22932337-1 2012 OBJECTIVE: To study the effects of simvastatin on the expression of connective tissue growth factor (CTGF) that cause fibrosis in the vitreous and retina after intravitreal injection in diabetic rats, and to explore the safety of this procedure. Simvastatin 35-46 cellular communication network factor 2 Rattus norvegicus 101-105 22932337-11 2012 Concentrations of CTGF in vitreous of simvastatin intervention group, diabetes positive control group and normal control group rats were 359.21 microg/L, 478.47 microg/L and 210.78 microg/L, respectively (F = 252.366, P < 0.05). Simvastatin 38-49 cellular communication network factor 2 Rattus norvegicus 18-22 22932337-12 2012 The levels of CTGF in the vitreous of simvastatin intervention group and diabetic positive control group was significantly higher than that of the normal control group and showed significant difference (t = 12.123, 23.816;P < 0.05). Simvastatin 38-49 cellular communication network factor 2 Rattus norvegicus 14-18 22932337-13 2012 CTGF levels in simvastatin intervention group were significantly lower than those in diabetic positive control group, and the difference was statistically significant. Simvastatin 15-26 cellular communication network factor 2 Rattus norvegicus 0-4 22932337-16 2012 Retinal expression of CTGF in simvastatin intervention group and diabetic positive control group were (26.60 +- 2.95)% and (42.31 +- 2.59)%, respectively. Simvastatin 30-41 cellular communication network factor 2 Rattus norvegicus 22-26 22932337-17 2012 Retinal expression of CTGF in simvastatin intervention group was reduced as compared to the diabetic positive control group, the difference was statistically significant (t = 12.112, P < 0.05). Simvastatin 30-41 cellular communication network factor 2 Rattus norvegicus 22-26 22932337-22 2012 CONCLUSIONS: Simvastatin could inhibit the expression of CTGF in the vitreous body and retina in diabetic rats. Simvastatin 13-24 cellular communication network factor 2 Rattus norvegicus 57-61 22014153-1 2012 BACKGROUND AND PURPOSE: Imatinib, a cytochrome P450 2C8 (CYP2C8) and CYP3A4 substrate, markedly increases plasma concentrations of the CYP3A4/5 substrate simvastatin and reduces hepatic CYP3A4/5 activity in humans. Simvastatin 154-165 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 36-55 22014153-1 2012 BACKGROUND AND PURPOSE: Imatinib, a cytochrome P450 2C8 (CYP2C8) and CYP3A4 substrate, markedly increases plasma concentrations of the CYP3A4/5 substrate simvastatin and reduces hepatic CYP3A4/5 activity in humans. Simvastatin 154-165 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 57-63 22014153-1 2012 BACKGROUND AND PURPOSE: Imatinib, a cytochrome P450 2C8 (CYP2C8) and CYP3A4 substrate, markedly increases plasma concentrations of the CYP3A4/5 substrate simvastatin and reduces hepatic CYP3A4/5 activity in humans. Simvastatin 154-165 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 22014153-1 2012 BACKGROUND AND PURPOSE: Imatinib, a cytochrome P450 2C8 (CYP2C8) and CYP3A4 substrate, markedly increases plasma concentrations of the CYP3A4/5 substrate simvastatin and reduces hepatic CYP3A4/5 activity in humans. Simvastatin 154-165 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-141 22014153-1 2012 BACKGROUND AND PURPOSE: Imatinib, a cytochrome P450 2C8 (CYP2C8) and CYP3A4 substrate, markedly increases plasma concentrations of the CYP3A4/5 substrate simvastatin and reduces hepatic CYP3A4/5 activity in humans. Simvastatin 154-165 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-141 22492027-0 2012 Age-dependent rescue by simvastatin of Alzheimer"s disease cerebrovascular and memory deficits. Simvastatin 24-35 renin binding protein Mus musculus 0-3 22492027-3 2012 Here, we report that simvastatin (3-6 months, 40 mg/kg/d) completely rescued cerebrovascular reactivity, basal endothelial nitric oxide synthesis, and activity-induced neurometabolic and neurovascular coupling in adult (6 months) and aged (12 months) transgenic mice overexpressing the Swedish and Indiana mutations of the human amyloid precursor protein (AD mice). Simvastatin 21-32 amyloid beta precursor protein Homo sapiens 329-354 22014153-8 2012 CONCLUSIONS AND IMPLICATIONS: Imatinib is a potent mechanism-based inhibitor of CYP3A4 in vitro and this finding explains the imatinib-simvastatin interaction and suggests that imatinib could markedly increase plasma concentrations of other CYP3A4 substrates. Simvastatin 135-146 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 80-86 20946258-0 2012 Simvastatin inhibits glucose-stimulated vascular smooth muscle cell migration involving increased expression of RhoB and a block of Ras/Akt signal. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 136-139 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 RB transcriptional corepressor 1 Homo sapiens 214-217 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 cyclin dependent kinase 2 Homo sapiens 243-247 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 tumor protein p53 Homo sapiens 281-284 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 H3 histone pseudogene 16 Homo sapiens 286-289 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 cyclin dependent kinase inhibitor 2A Homo sapiens 291-294 20946258-4 2012 Our previous study has demonstrated that simvastatin inhibits VSMC proliferation in high glucose status without dyslipidemia, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and upregulation of p53, p21, p16, and p27. Simvastatin 41-52 interferon alpha inducible protein 27 Homo sapiens 300-303 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 AKT serine/threonine kinase 1 Homo sapiens 110-113 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 140-145 22182511-9 2012 Moreover, the statin, simvastatin, was demonstrated to upregulate expression of KLF2 in MCs. Simvastatin 22-33 Kruppel like factor 2 Homo sapiens 80-84 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 ras homolog family member B Homo sapiens 176-180 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 Rac family small GTPase 1 Homo sapiens 195-199 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 cyclin dependent kinase 1 Homo sapiens 205-209 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 matrix metallopeptidase 2 Homo sapiens 249-254 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 matrix metallopeptidase 9 Homo sapiens 264-269 24250467-0 2012 Preparation, Characterization and Pharmacodynamic Evaluation of Fused Dispersions of Simvastatin using PEO-PPO Block Copolymer. Simvastatin 85-96 protoporphyrinogen oxidase Homo sapiens 107-110 22134829-0 2012 Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Homo sapiens 102-105 22134829-0 2012 Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 129-134 22134829-5 2012 In this study, we have demonstrated that simvastatin, at a dose of 20 microM for 24-72 h, induced in cancer cells but not in normal cells precise features of apoptosis including increased DNA fragmentation while, at the molecular level simvastatin induced overexpression of the pro-apoptotic gene Bax together with an inhibition of BCL-2, the gene that has the well-known function of protecting cells from apoptosis. Simvastatin 41-52 BCL2 associated X, apoptosis regulator Homo sapiens 297-300 22134829-5 2012 In this study, we have demonstrated that simvastatin, at a dose of 20 microM for 24-72 h, induced in cancer cells but not in normal cells precise features of apoptosis including increased DNA fragmentation while, at the molecular level simvastatin induced overexpression of the pro-apoptotic gene Bax together with an inhibition of BCL-2, the gene that has the well-known function of protecting cells from apoptosis. Simvastatin 41-52 BCL2 apoptosis regulator Homo sapiens 332-337 22233179-3 2012 In the present study we tested the hypothesis that simvastatin affects haemodynamic responses to air-jet stress and intracerebroventricular infusions of vasopressin and AngII. Simvastatin 51-62 arginine vasopressin Rattus norvegicus 153-164 22233179-3 2012 In the present study we tested the hypothesis that simvastatin affects haemodynamic responses to air-jet stress and intracerebroventricular infusions of vasopressin and AngII. Simvastatin 51-62 angiotensinogen Rattus norvegicus 169-174 22233179-7 2012 In rats given 60 mg/L simvastatin, the hypertensive response to air-jet stress was significantly smaller than in controls, as was the increase in MAP in response to AngII. Simvastatin 22-33 angiotensinogen Rattus norvegicus 165-170 22326624-11 2012 simvastatin significantly and dose-dependently attenuated airway inflammation, remodeling and hyperresponsiveness in a RhoA-dependent pathway. Simvastatin 0-11 ras homolog family member A Mus musculus 119-123 24250467-2 2012 Fused dispersions (FDs) of simvastatin (SIM) using PEO-PPO block copolymer were prepared which paved the way for the formation of an amorphous product with enhanced dissolution and bioavailability. Simvastatin 27-38 protoporphyrinogen oxidase Homo sapiens 55-58 24250467-2 2012 Fused dispersions (FDs) of simvastatin (SIM) using PEO-PPO block copolymer were prepared which paved the way for the formation of an amorphous product with enhanced dissolution and bioavailability. Simvastatin 40-43 protoporphyrinogen oxidase Homo sapiens 55-58 24250467-3 2012 The accumulative solubility of simvastatin (SIM) from PEO-PPO block copolymer (Lutrol NF 127 prill surfactant) was found to be superior to the drug alone which may be due to the increased oxyethylene content that played the major role in solubility enhancement. Simvastatin 31-42 protoporphyrinogen oxidase Homo sapiens 58-61 24250467-3 2012 The accumulative solubility of simvastatin (SIM) from PEO-PPO block copolymer (Lutrol NF 127 prill surfactant) was found to be superior to the drug alone which may be due to the increased oxyethylene content that played the major role in solubility enhancement. Simvastatin 44-47 protoporphyrinogen oxidase Homo sapiens 58-61 22792801-7 2012 They could enhance the NO content in cell culture supernatants, down-regulate the expression of Cav-1 and up-regulate the expression of eNOS at mRNA and protein levels, which was especially notable after treatment with serum containing TYTZF and simvastatin in large doses. Simvastatin 246-257 caveolin 1 Homo sapiens 96-101 22428554-1 2012 The current study investigated the effects of 14-day pioglitazone (PIO) and/or simvastatin (SIM) treatments on serum adiponectin (Adp) and TNFalpha levels (markers of adipocyte dysfunction), as well as on metabolic perturbations that arise from prolonged (8 week) consumption of a high fructose (HFD; 60%) diet in a rat model of pre-diabetic insulin resistance. Simvastatin 92-95 adiponectin, C1Q and collagen domain containing Rattus norvegicus 117-128 22428554-5 2012 SIM amended hepatic and overall lipid metabolism, regulated TNFalpha, but failed to alter the glucose intolerance or significantly impact on the HFD-altered Adp levels. Simvastatin 0-3 tumor necrosis factor Rattus norvegicus 60-68 22426045-8 2012 Upregulation of the BMP pathway via other agents, namely simvastatin and LIM mineralization protein-1, has resulted in similar outcomes. Simvastatin 57-68 bone morphogenetic protein 1 Homo sapiens 20-23 22541079-0 2012 [Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1]. Simvastatin 12-23 AKT serine/threonine kinase 1 Homo sapiens 32-35 22541079-1 2012 To investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (SV) on proliferation, apoptosis and the PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 22428554-0 2012 Effects of pioglitazone and/or simvastatin on circulating TNFalpha and adiponectin levels in insulin resistance. Simvastatin 31-42 adiponectin, C1Q and collagen domain containing Rattus norvegicus 71-82 22792801-7 2012 They could enhance the NO content in cell culture supernatants, down-regulate the expression of Cav-1 and up-regulate the expression of eNOS at mRNA and protein levels, which was especially notable after treatment with serum containing TYTZF and simvastatin in large doses. Simvastatin 246-257 nitric oxide synthase 3 Homo sapiens 136-140 22405819-10 2012 Simvastatin blocked the TNF-alpha suppressive effect on thrombomodulin and eNOS, irrespective of shear stress. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 22405819-9 2012 Simvastatin had a counteracting effect on t-PA and PAI-1 compared to TNF-alpha and shear stress. Simvastatin 0-11 plasminogen activator, tissue type Homo sapiens 42-46 22405819-11 2012 The strong inductive effect of TNF-alpha on VCAM-1 was counteracted by simvastatin and shear stress in an additive dose-response dependent way. Simvastatin 71-82 tumor necrosis factor Homo sapiens 31-40 22405819-9 2012 Simvastatin had a counteracting effect on t-PA and PAI-1 compared to TNF-alpha and shear stress. Simvastatin 0-11 serpin family E member 1 Homo sapiens 51-56 22405819-11 2012 The strong inductive effect of TNF-alpha on VCAM-1 was counteracted by simvastatin and shear stress in an additive dose-response dependent way. Simvastatin 71-82 vascular cell adhesion molecule 1 Homo sapiens 44-50 21820929-6 2012 RESULTS: CYP3A4 was responsible for the metabolism of lovastatin, simvastatin and atorvastatin; fluvastatin depends on CYP2C9; P-glycoprotein is responsible for decreased atorvastatin, pravastatin, simvastatin and lovastatin concentrations. Simvastatin 66-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 9-15 22505549-0 2012 SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Simvastatin 63-74 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-7 22505549-2 2012 This study aimed to investigate the influence of SLCO1B1 gene polymorphism on simvastatin treatment efficacy in a Brazilian population of European ancestry. Simvastatin 78-89 solute carrier organic anion transporter family member 1B1 Homo sapiens 49-56 22505549-7 2012 RESULTS: Carriers of the SLCO1B1 388G allele had a greater reduction of total cholesterol and LDL cholesterol with simvastatin treatment, when compared with 56 388A homozygotes (-28.8% vs. -15.8%, p=0.005 and -39.0% vs. -30.6%, p=0.003; respectively). Simvastatin 115-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 25-32 22505549-10 2012 CONCLUSIONS: The present study suggests that the SLCO1B1 c.388A>G polymorphism could play a role in the inter-individual variation of clinical response to simvastatin in Brazilians. Simvastatin 158-169 solute carrier organic anion transporter family member 1B1 Homo sapiens 49-56 21928084-1 2012 PURPOSE: Recent studies reported the association of SLCO1B1 haplotypes with the development of musculoskeletal side effects during simvastatin use. Simvastatin 131-142 solute carrier organic anion transporter family member 1B1 Homo sapiens 52-59 21928084-10 2012 CONCLUSIONS: Our findings reaffirm that the SLCO1B1 genetic risk appears to be greater in those patients receiving simvastatin compared with those receiving atorvastatin. Simvastatin 115-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 44-51 22306966-7 2012 Our results show that simvastatin disrupts actin cytoskeleton and focal adhesion complex evaluated by phalloidin stain and immunocytochemistry for paxillin and vinculin. Simvastatin 22-33 paxillin Homo sapiens 147-155 22306966-7 2012 Our results show that simvastatin disrupts actin cytoskeleton and focal adhesion complex evaluated by phalloidin stain and immunocytochemistry for paxillin and vinculin. Simvastatin 22-33 vinculin Homo sapiens 160-168 22306966-10 2012 Finally, simvastatin decreased angiotensin II-induced phospho-paxillin levels and cell adhesion. Simvastatin 9-20 angiotensinogen Homo sapiens 31-45 22306966-10 2012 Finally, simvastatin decreased angiotensin II-induced phospho-paxillin levels and cell adhesion. Simvastatin 9-20 paxillin Homo sapiens 62-70 21820929-6 2012 RESULTS: CYP3A4 was responsible for the metabolism of lovastatin, simvastatin and atorvastatin; fluvastatin depends on CYP2C9; P-glycoprotein is responsible for decreased atorvastatin, pravastatin, simvastatin and lovastatin concentrations. Simvastatin 198-209 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 9-15 22120639-6 2012 Gene set enrichment analysis on microarray data of AML patient cells and Western blot analysis for the isoprenylated proteins DnaJ and Rap1 on murine and AML patient MNCs demonstrated that in vivo simvastatin treatment resulted in inhibition of geranylgeranylation in murine MNCs and in a subset of patient AML MNCs. Simvastatin 197-208 DnaJ heat shock protein family (Hsp40) member C14 Homo sapiens 126-130 21820929-6 2012 RESULTS: CYP3A4 was responsible for the metabolism of lovastatin, simvastatin and atorvastatin; fluvastatin depends on CYP2C9; P-glycoprotein is responsible for decreased atorvastatin, pravastatin, simvastatin and lovastatin concentrations. Simvastatin 198-209 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 22120639-6 2012 Gene set enrichment analysis on microarray data of AML patient cells and Western blot analysis for the isoprenylated proteins DnaJ and Rap1 on murine and AML patient MNCs demonstrated that in vivo simvastatin treatment resulted in inhibition of geranylgeranylation in murine MNCs and in a subset of patient AML MNCs. Simvastatin 197-208 RAP1A, member of RAS oncogene family Homo sapiens 135-139 22341085-7 2012 The simvastatin and Emdogain groups increased the odontogenic potential of the BPC group with respect to ALP activity, mineralization nodules, messenger RNA expression of ALP, osteopontin, osteocalcin, Runx2, and osterix. Simvastatin 4-15 alkaline phosphatase, placental Homo sapiens 105-108 22031447-4 2012 Expression of KLF2 and its vasoprotective programs was determined in (i) hepatic endothelial cells (HEC) incubated under cold storage conditions with or without the KLF2-inducer simvastatin, and (ii) rat livers not cold stored or preserved in cold University of Wisconsin solution (UWS) supplemented with simvastatin or its vehicle. Simvastatin 305-316 Kruppel-like factor 2 Rattus norvegicus 14-18 22031447-8 2012 The addition of simvastatin to the storage solution, maintained KLF2-dependent vasoprotective programs, prevented liver damage, inflammation, and oxidative stress and improved endothelial dysfunction. Simvastatin 16-27 Kruppel-like factor 2 Rattus norvegicus 64-68 22160096-0 2012 Effect of simvastatin on the expression and regulation mechanism of apolipoprotein M. Simvastatin 10-21 apolipoprotein M Homo sapiens 80-96 22160096-4 2012 In the present study, we investigated the effects of simvastatin on ApoM expression and the underlying mechanism(s). Simvastatin 53-64 apolipoprotein M Homo sapiens 68-72 22160096-5 2012 Simvastatin up-regulated hepatic ApoM mRNA and protein expression in mice. Simvastatin 0-11 apolipoprotein M Mus musculus 33-37 22160096-6 2012 In HepG2 cells, simvastatin significantly enhanced ApoM mRNA and protein expression in a dose-dependent manner. Simvastatin 16-27 apolipoprotein M Homo sapiens 51-55 22160096-7 2012 Simvastatin increased hepatic hepatocyte nuclear factor-1alpha (HNF-1alpha) mRNA and reduced liver X receptor-alpha (LXRalpha) mRNA expression in mice. Simvastatin 0-11 HNF1 homeobox A Mus musculus 30-62 22160096-7 2012 Simvastatin increased hepatic hepatocyte nuclear factor-1alpha (HNF-1alpha) mRNA and reduced liver X receptor-alpha (LXRalpha) mRNA expression in mice. Simvastatin 0-11 HNF1 homeobox A Mus musculus 64-74 22160096-7 2012 Simvastatin increased hepatic hepatocyte nuclear factor-1alpha (HNF-1alpha) mRNA and reduced liver X receptor-alpha (LXRalpha) mRNA expression in mice. Simvastatin 0-11 nuclear receptor subfamily 1, group H, member 3 Mus musculus 93-115 22160096-7 2012 Simvastatin increased hepatic hepatocyte nuclear factor-1alpha (HNF-1alpha) mRNA and reduced liver X receptor-alpha (LXRalpha) mRNA expression in mice. Simvastatin 0-11 nuclear receptor subfamily 1, group H, member 3 Mus musculus 117-125 22160096-8 2012 The simvastatin-induced up-regulation of ApoM was blocked by an HNF-1alpha inhibitor (UCDA) or an LXRalpha agonist (TO901317) in HepG2 cells which indicates that this effect is mediated via the regulation of HNF-1alpha and LXRalpha. Simvastatin 4-15 apolipoprotein M Homo sapiens 41-45 22160096-8 2012 The simvastatin-induced up-regulation of ApoM was blocked by an HNF-1alpha inhibitor (UCDA) or an LXRalpha agonist (TO901317) in HepG2 cells which indicates that this effect is mediated via the regulation of HNF-1alpha and LXRalpha. Simvastatin 4-15 HNF1 homeobox A Homo sapiens 64-74 22160096-8 2012 The simvastatin-induced up-regulation of ApoM was blocked by an HNF-1alpha inhibitor (UCDA) or an LXRalpha agonist (TO901317) in HepG2 cells which indicates that this effect is mediated via the regulation of HNF-1alpha and LXRalpha. Simvastatin 4-15 nuclear receptor subfamily 1 group H member 3 Homo sapiens 98-106 22160096-8 2012 The simvastatin-induced up-regulation of ApoM was blocked by an HNF-1alpha inhibitor (UCDA) or an LXRalpha agonist (TO901317) in HepG2 cells which indicates that this effect is mediated via the regulation of HNF-1alpha and LXRalpha. Simvastatin 4-15 HNF1 homeobox A Homo sapiens 208-218 22160096-8 2012 The simvastatin-induced up-regulation of ApoM was blocked by an HNF-1alpha inhibitor (UCDA) or an LXRalpha agonist (TO901317) in HepG2 cells which indicates that this effect is mediated via the regulation of HNF-1alpha and LXRalpha. Simvastatin 4-15 nuclear receptor subfamily 1 group H member 3 Homo sapiens 223-231 22160096-9 2012 In conclusion, simvastatin significantly up-regulated ApoM expression in vivo and in vitro, which indicates that ApoM is another novel apolipoprotein regulated by simvastatin. Simvastatin 15-26 apolipoprotein M Homo sapiens 54-58 22160096-9 2012 In conclusion, simvastatin significantly up-regulated ApoM expression in vivo and in vitro, which indicates that ApoM is another novel apolipoprotein regulated by simvastatin. Simvastatin 15-26 apolipoprotein M Homo sapiens 113-117 22160096-9 2012 In conclusion, simvastatin significantly up-regulated ApoM expression in vivo and in vitro, which indicates that ApoM is another novel apolipoprotein regulated by simvastatin. Simvastatin 163-174 apolipoprotein M Homo sapiens 54-58 22160096-9 2012 In conclusion, simvastatin significantly up-regulated ApoM expression in vivo and in vitro, which indicates that ApoM is another novel apolipoprotein regulated by simvastatin. Simvastatin 163-174 apolipoprotein M Homo sapiens 113-117 22341085-7 2012 The simvastatin and Emdogain groups increased the odontogenic potential of the BPC group with respect to ALP activity, mineralization nodules, messenger RNA expression of ALP, osteopontin, osteocalcin, Runx2, and osterix. Simvastatin 4-15 alkaline phosphatase, placental Homo sapiens 171-174 22341085-7 2012 The simvastatin and Emdogain groups increased the odontogenic potential of the BPC group with respect to ALP activity, mineralization nodules, messenger RNA expression of ALP, osteopontin, osteocalcin, Runx2, and osterix. Simvastatin 4-15 secreted phosphoprotein 1 Homo sapiens 176-187 22341085-7 2012 The simvastatin and Emdogain groups increased the odontogenic potential of the BPC group with respect to ALP activity, mineralization nodules, messenger RNA expression of ALP, osteopontin, osteocalcin, Runx2, and osterix. Simvastatin 4-15 bone gamma-carboxyglutamate protein Homo sapiens 189-200 22341085-7 2012 The simvastatin and Emdogain groups increased the odontogenic potential of the BPC group with respect to ALP activity, mineralization nodules, messenger RNA expression of ALP, osteopontin, osteocalcin, Runx2, and osterix. Simvastatin 4-15 RUNX family transcription factor 2 Homo sapiens 202-207 22353921-5 2012 Moreover, we found that in vivo bone formation could be detected by our novel tissue engineered bone composed with hASCs and hPRP; simvastatin could enhance the bone formation capability of this tissue-engineered structure. Simvastatin 131-142 complement component 4 binding protein alpha Homo sapiens 125-129 22127053-4 2012 Simvastatin inhibited the SPC-induced alpha-SMA expression and sustained phosphorylation of Smad2 in hASCs. Simvastatin 0-11 SMAD family member 2 Homo sapiens 92-97 22127053-5 2012 SPC treatment caused RhoA activation via a simvastatin-sensitive mechanism. Simvastatin 43-54 ras homolog family member A Homo sapiens 21-25 22127053-7 2012 Furthermore, SPC induced secretion of TGF-beta1 and pretreatment with either Y27632 or simvastatin inhibited the SPC-induced TGF-beta1 secretion. Simvastatin 87-98 transforming growth factor beta 1 Homo sapiens 125-134 22127053-8 2012 These results suggest that simvastatin inhibits SPC-induced differentiation of hASCs into smooth muscle cells by attenuating the RhoA/Rho kinase-dependent activation of autocrine TGF-beta1/Smad2 signaling pathway. Simvastatin 27-38 ras homolog family member A Homo sapiens 129-133 22127053-8 2012 These results suggest that simvastatin inhibits SPC-induced differentiation of hASCs into smooth muscle cells by attenuating the RhoA/Rho kinase-dependent activation of autocrine TGF-beta1/Smad2 signaling pathway. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 179-188 22127053-8 2012 These results suggest that simvastatin inhibits SPC-induced differentiation of hASCs into smooth muscle cells by attenuating the RhoA/Rho kinase-dependent activation of autocrine TGF-beta1/Smad2 signaling pathway. Simvastatin 27-38 SMAD family member 2 Homo sapiens 189-194 22326143-6 2012 Thus, modest anti-Abeta titers can increase soluble Abeta and simvastatin may reduce inflammation associated with vaccination in aged Alzheimer mouse models. Simvastatin 62-73 histocompatibility 2, class II antigen A, beta 1 Mus musculus 18-23 22038096-7 2012 In addition, simvastatin down-regulated the expression of vascular cell adhesion molecule-1 (VCAM-1) by both inhibition of nuclear factor kappa B (NF-kB) activation and suppression of the expression of the receptor for advanced glycation end products (RAGE). Simvastatin 13-24 vascular cell adhesion molecule 1 Mus musculus 58-91 22083280-0 2012 Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway. Simvastatin 0-11 angiotensinogen Rattus norvegicus 24-38 22038096-7 2012 In addition, simvastatin down-regulated the expression of vascular cell adhesion molecule-1 (VCAM-1) by both inhibition of nuclear factor kappa B (NF-kB) activation and suppression of the expression of the receptor for advanced glycation end products (RAGE). Simvastatin 13-24 vascular cell adhesion molecule 1 Mus musculus 93-99 22083280-7 2012 Notably, GTPCH I activity, BH4 production, p-eNOS expression and NO levels in the vascular endothelium were elevated as a result of simvastatin administration. Simvastatin 132-143 GTP cyclohydrolase 1 Rattus norvegicus 9-16 22038096-0 2012 Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL. Simvastatin 0-11 B cell leukemia/lymphoma 2 Mus musculus 115-120 22038096-7 2012 In addition, simvastatin down-regulated the expression of vascular cell adhesion molecule-1 (VCAM-1) by both inhibition of nuclear factor kappa B (NF-kB) activation and suppression of the expression of the receptor for advanced glycation end products (RAGE). Simvastatin 13-24 advanced glycosylation end product-specific receptor Mus musculus 206-250 22038096-0 2012 Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL. Simvastatin 0-11 BCL2-like 1 Mus musculus 125-131 22038096-1 2012 PURPOSE: Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has antioxidant and anti-inflammatory properties that are independent of lipid-lowering abilities. Simvastatin 9-20 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 24-71 22038096-6 2012 Analysis of plaque composition showed that simvastatin decreased the area of lipid core and increased the amounts of macrophages and smooth muscle cells in atherosclerotic plaques of apoE(-/-) mice. Simvastatin 43-54 apolipoprotein E Mus musculus 183-187 22083280-8 2012 In cultured rat arterial endothelial cells, simvastatin restored BH4, GTPCH I activity and NO release impaired by angiotensin II, and pretreatment with mevalonate (MVA) or geranylgeranyl pyrophosphate (GGPP) abolished the beneficial effects exerted by simvastatin. Simvastatin 44-55 GTP cyclohydrolase 1 Rattus norvegicus 70-77 22083280-8 2012 In cultured rat arterial endothelial cells, simvastatin restored BH4, GTPCH I activity and NO release impaired by angiotensin II, and pretreatment with mevalonate (MVA) or geranylgeranyl pyrophosphate (GGPP) abolished the beneficial effects exerted by simvastatin. Simvastatin 44-55 angiotensinogen Rattus norvegicus 114-128 22038096-7 2012 In addition, simvastatin down-regulated the expression of vascular cell adhesion molecule-1 (VCAM-1) by both inhibition of nuclear factor kappa B (NF-kB) activation and suppression of the expression of the receptor for advanced glycation end products (RAGE). Simvastatin 13-24 advanced glycosylation end product-specific receptor Mus musculus 252-256 22038096-8 2012 Moreover, we found that simvastatin administration led to reduced TUNEL-positive cells in the aortic root lesions, accompanied by up-regulation of Bcl-2 and Bcl-xL expression, and decreased P(53) expression as shown by Western blot. Simvastatin 24-35 B cell leukemia/lymphoma 2 Mus musculus 147-152 22038096-8 2012 Moreover, we found that simvastatin administration led to reduced TUNEL-positive cells in the aortic root lesions, accompanied by up-regulation of Bcl-2 and Bcl-xL expression, and decreased P(53) expression as shown by Western blot. Simvastatin 24-35 BCL2-like 1 Mus musculus 157-163 22038096-9 2012 CONCLUSION: In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE(-/-) mice by regulating the expression of apoptosis-related proteins, such as p(53), Bcl-2 and Bcl-xL. Simvastatin 69-80 apolipoprotein E Mus musculus 147-151 22038096-9 2012 CONCLUSION: In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE(-/-) mice by regulating the expression of apoptosis-related proteins, such as p(53), Bcl-2 and Bcl-xL. Simvastatin 69-80 B cell leukemia/lymphoma 2 Mus musculus 237-242 22038096-9 2012 CONCLUSION: In the present study, we show novel data to suggest that simvastatin could suppress apoptosis in vulnerable atherosclerotic plaques of apoE(-/-) mice by regulating the expression of apoptosis-related proteins, such as p(53), Bcl-2 and Bcl-xL. Simvastatin 69-80 BCL2-like 1 Mus musculus 247-253 22052376-0 2012 The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al. Simvastatin 89-100 tumor protein p53 Homo sapiens 197-200 22052376-0 2012 The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al. Simvastatin 89-100 BCL2 apoptosis regulator Homo sapiens 202-207 22052376-0 2012 The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al. Simvastatin 89-100 BCL2 like 1 Homo sapiens 211-217 22052376-0 2012 The pleiotropic effects of statins in the prevention of atherosclerosis : Editorial to: "Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al. Simvastatin 89-100 forkhead box G1 Homo sapiens 229-232 22214850-0 2012 Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. Simvastatin 116-127 coagulation factor III Mus musculus 9-22 22113625-5 2012 VEGF has been demonstrated in cultured human aortic endothelial cells in the presence of simvastatin and in kidney biopsies in lupus nephritis. Simvastatin 89-100 vascular endothelial growth factor A Homo sapiens 0-4 22214850-12 2012 Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation, without affecting total cholesterol levels. Simvastatin 0-11 coagulation factor III Mus musculus 87-89 22012179-7 2012 A significant, dose-dependent reduction in the expression of caspase-3 and caspase-9 protein induced by H2O2 in MG63 cells was observed in response to simvastatin and the Bcl-2 levels were increased. Simvastatin 151-162 caspase 3 Homo sapiens 61-70 22305382-9 2012 Simvastatin treatment markedly reduced IL-23 mRNA and lymphocyte chemokine CCL20 production, and the infiltration of CD4(+) and CD8(+) T cells into allografts already at 3 days. Simvastatin 0-11 C-C motif chemokine ligand 20 Rattus norvegicus 75-80 22305382-10 2012 At 10 days, simvastatin significantly attenuated the production of pro-inflammatory cytokines, IL-1beta, TNF-alpha, MCP-1 and IP-10, and Th17-polarizing cytokines, IL-6 and IL-17e, and inhibited allograft infiltration by inflammatory cells. Simvastatin 12-23 interleukin 1 beta Rattus norvegicus 95-103 22305382-10 2012 At 10 days, simvastatin significantly attenuated the production of pro-inflammatory cytokines, IL-1beta, TNF-alpha, MCP-1 and IP-10, and Th17-polarizing cytokines, IL-6 and IL-17e, and inhibited allograft infiltration by inflammatory cells. Simvastatin 12-23 tumor necrosis factor Rattus norvegicus 105-114 22305382-10 2012 At 10 days, simvastatin significantly attenuated the production of pro-inflammatory cytokines, IL-1beta, TNF-alpha, MCP-1 and IP-10, and Th17-polarizing cytokines, IL-6 and IL-17e, and inhibited allograft infiltration by inflammatory cells. Simvastatin 12-23 mast cell protease 1-like 1 Rattus norvegicus 116-121 22305382-10 2012 At 10 days, simvastatin significantly attenuated the production of pro-inflammatory cytokines, IL-1beta, TNF-alpha, MCP-1 and IP-10, and Th17-polarizing cytokines, IL-6 and IL-17e, and inhibited allograft infiltration by inflammatory cells. Simvastatin 12-23 C-X-C motif chemokine ligand 10 Rattus norvegicus 126-131 22305382-10 2012 At 10 days, simvastatin significantly attenuated the production of pro-inflammatory cytokines, IL-1beta, TNF-alpha, MCP-1 and IP-10, and Th17-polarizing cytokines, IL-6 and IL-17e, and inhibited allograft infiltration by inflammatory cells. Simvastatin 12-23 interleukin 6 Rattus norvegicus 164-168 22019884-6 2012 Furthermore, J16 greatly lowered LDL-C in hypercholesterolemic monkeys treated with the HMG-CoA reductase inhibitor simvastatin. Simvastatin 116-127 component of oligomeric golgi complex 2 Mus musculus 33-38 22012179-7 2012 A significant, dose-dependent reduction in the expression of caspase-3 and caspase-9 protein induced by H2O2 in MG63 cells was observed in response to simvastatin and the Bcl-2 levels were increased. Simvastatin 151-162 caspase 9 Homo sapiens 75-84 22012179-8 2012 In conclusion, simvastatin protects MG63 cells from oxidative stress-induced apoptosis through downregulation of caspase-3 and caspase-9 activation and upregulation of Bcl-2 expression, suggesting a protective effect in osteoporosis. Simvastatin 15-26 caspase 3 Homo sapiens 113-122 22012179-8 2012 In conclusion, simvastatin protects MG63 cells from oxidative stress-induced apoptosis through downregulation of caspase-3 and caspase-9 activation and upregulation of Bcl-2 expression, suggesting a protective effect in osteoporosis. Simvastatin 15-26 caspase 9 Homo sapiens 127-136 22012179-8 2012 In conclusion, simvastatin protects MG63 cells from oxidative stress-induced apoptosis through downregulation of caspase-3 and caspase-9 activation and upregulation of Bcl-2 expression, suggesting a protective effect in osteoporosis. Simvastatin 15-26 BCL2 apoptosis regulator Homo sapiens 168-173 21918126-0 2012 Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells. Simvastatin 0-11 cytochrome P450, family 17, subfamily a, polypeptide 1 Rattus norvegicus 50-57 22286441-9 2012 Analysis of mRNA in a subset of rabbits treated with low-dose simvastatin demonstrated a significant reduction in CTGF expression (p = 0.009). Simvastatin 62-73 connective tissue growth factor Oryctolagus cuniculus 114-118 21035882-0 2012 Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 123-131 22144680-4 2012 284, 14734-14743) that simvastatin treatment of endothelial cells leads to a marked decrease in PKA-modulated phosphorylation of the protein VASP. Simvastatin 23-34 vasodilator-stimulated phosphoprotein Mus musculus 141-145 22144680-11 2012 Finally, we found that simvastatin treatment inhibits Galpha(s) translation mediated by Akt/mTOR/eIF4/4EBP. Simvastatin 23-34 thymoma viral proto-oncogene 1 Mus musculus 88-91 22144680-11 2012 Finally, we found that simvastatin treatment inhibits Galpha(s) translation mediated by Akt/mTOR/eIF4/4EBP. Simvastatin 23-34 mechanistic target of rapamycin kinase Mus musculus 92-96 22144680-11 2012 Finally, we found that simvastatin treatment inhibits Galpha(s) translation mediated by Akt/mTOR/eIF4/4EBP. Simvastatin 23-34 eukaryotic translation initiation factor 4A2 Mus musculus 97-106 22130356-8 2012 Simvastatin abated oxidative stress through enhancing catalase, heme oxygenase 1 (HO-1), and superoxide dismutase (SOD) activity and suppressing NADPH oxidase activity. Simvastatin 0-11 catalase Rattus norvegicus 54-62 22130356-8 2012 Simvastatin abated oxidative stress through enhancing catalase, heme oxygenase 1 (HO-1), and superoxide dismutase (SOD) activity and suppressing NADPH oxidase activity. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 64-80 22130356-8 2012 Simvastatin abated oxidative stress through enhancing catalase, heme oxygenase 1 (HO-1), and superoxide dismutase (SOD) activity and suppressing NADPH oxidase activity. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 82-86 22130356-9 2012 In addition, simvastatin raised nitric oxide synthase (NOS) activity and eNOS expression at basal condition; inhibited NOS activity and iNOS expression when treated with H(2)O(2). Simvastatin 13-24 nitric oxide synthase 2 Rattus norvegicus 136-140 22298164-0 2012 Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 39-45 22391067-8 2012 RESULTS: In TGF-beta-1-induced NPDFs, simvastatin significantly inhibited the expressions of alpha-SMA and collagen type IV mRNA and reduced alpha-SMA and collagen protein levels. Simvastatin 38-49 transforming growth factor beta 1 Homo sapiens 12-22 22391067-11 2012 The TGF-beta-1-induced expression of pSmad 2/3 protein was notably decreased by pretreatment with simvastatin. Simvastatin 98-109 transforming growth factor beta 1 Homo sapiens 4-14 22391067-12 2012 CONCLUSION: We showed that simvastatin inhibits TGF-beta-1-induced myofibroblast differentiation (expression of alpha-SMA) and collagen production in NPDFs and Rho/Rock and TGF-beta/Smad signaling is involved as an underlying mechanism. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 48-58 22391067-12 2012 CONCLUSION: We showed that simvastatin inhibits TGF-beta-1-induced myofibroblast differentiation (expression of alpha-SMA) and collagen production in NPDFs and Rho/Rock and TGF-beta/Smad signaling is involved as an underlying mechanism. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 48-56 21819236-5 2012 For simvastatin-related myotoxicity, a strong association with SLCO1B1, which encodes the hepatic statin uptake transporter, has been detected. Simvastatin 4-15 solute carrier organic anion transporter family member 1B1 Homo sapiens 63-70 22391067-0 2012 Effect of simvastatin on transforming growth factor beta-1-induced myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Simvastatin 10-21 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 52-58 22391067-3 2012 The purpose of this study was to determine the effect of simvastatin on transforming growth factor (TGF)-beta-1-induced myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts (NPDFs) and to verify the mechanism of the effect of simvastatin in TGF-beta-1-induced myofibroblast differentiation in NPDFs. Simvastatin 57-68 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 106-112 22391067-3 2012 The purpose of this study was to determine the effect of simvastatin on transforming growth factor (TGF)-beta-1-induced myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts (NPDFs) and to verify the mechanism of the effect of simvastatin in TGF-beta-1-induced myofibroblast differentiation in NPDFs. Simvastatin 263-274 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 106-112 22391067-4 2012 METHODS: NPDFs were pretreated with simvastatin with or without mevalonate or Y-27643 for 2 hours before induction by TGF-beta-1. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 118-128 22298164-0 2012 Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Simvastatin 0-11 plasminogen activator, urokinase receptor Homo sapiens 50-54 22298164-0 2012 Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Simvastatin 0-11 CD40 molecule Homo sapiens 128-132 22298164-7 2012 The increased expression of VCAM-1 and uPAR on endothelial cells by stimulation with LPS and by direct contact with activated platelets was significantly reduced to a similar extent through pre-incubation with both atorvastatin and simvastatin (p < 0.05). Simvastatin 232-243 vascular cell adhesion molecule 1 Homo sapiens 28-34 22298164-7 2012 The increased expression of VCAM-1 and uPAR on endothelial cells by stimulation with LPS and by direct contact with activated platelets was significantly reduced to a similar extent through pre-incubation with both atorvastatin and simvastatin (p < 0.05). Simvastatin 232-243 plasminogen activator, urokinase receptor Homo sapiens 39-43 22814256-0 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Simvastatin 17-28 toll-like receptor 4 Mus musculus 63-66 22814256-0 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Simvastatin 17-28 matrix metallopeptidase 9 Mus musculus 75-80 22814256-0 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Simvastatin 17-28 mitogen-activated protein kinase 1 Mus musculus 140-143 22814256-0 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Simvastatin 17-28 cAMP responsive element binding protein 1 Mus musculus 148-152 22814256-6 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulated LPS-induced MMP-9 expression in murine RAW 264.7 macrophages and BV2 microglia. Simvastatin 17-28 toll-like receptor 4 Mus musculus 64-67 22814256-6 2012 Atorvastatin and simvastatin, but not pravastatin, up-regulated LPS-induced MMP-9 expression in murine RAW 264.7 macrophages and BV2 microglia. Simvastatin 17-28 matrix metallopeptidase 9 Mus musculus 76-81 22814256-9 2012 Geranylgeranyl pyrophosphate, a precursor for cholesterol synthesis, could suppress up-regulation of LPS-mediated MMP-9 gene expression by atorvastatin and simvastatin. Simvastatin 156-167 toll-like receptor 4 Mus musculus 101-104 22814256-9 2012 Geranylgeranyl pyrophosphate, a precursor for cholesterol synthesis, could suppress up-regulation of LPS-mediated MMP-9 gene expression by atorvastatin and simvastatin. Simvastatin 156-167 matrix metallopeptidase 9 Mus musculus 114-119 22814256-10 2012 Atorvastatin and simvastatin-mediated up-regulation of LPS-induced MMP-9 gene expression in macrophages and microglia in vitro raises an important concern about use of the widely-prescribed statins in certain inflammatory conditions that are mediated by LPS. Simvastatin 17-28 toll-like receptor 4 Mus musculus 55-58 22814256-10 2012 Atorvastatin and simvastatin-mediated up-regulation of LPS-induced MMP-9 gene expression in macrophages and microglia in vitro raises an important concern about use of the widely-prescribed statins in certain inflammatory conditions that are mediated by LPS. Simvastatin 17-28 matrix metallopeptidase 9 Mus musculus 67-72 22814256-10 2012 Atorvastatin and simvastatin-mediated up-regulation of LPS-induced MMP-9 gene expression in macrophages and microglia in vitro raises an important concern about use of the widely-prescribed statins in certain inflammatory conditions that are mediated by LPS. Simvastatin 17-28 toll-like receptor 4 Mus musculus 254-257 22355267-8 2012 Importantly, a combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than either agent alone, consistent with a mechanism of action that predicts additive effects of anti-PCSK9 agents with statins. Simvastatin 39-50 proprotein convertase subtilisin/kexin type 9 Macaca mulatta 203-208 22176629-9 2012 Simvastatin, or other statins predominantly metabolized by CYP3A4, should not be co-administered with posaconazole. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 22080086-6 2012 In addition, simvastatin markedly increased protein levels of Bax (proapoptotic, +53%) and Bcl-2 (antiapoptotic, +100%, P<0.05), mitochondrial PTP opening (+44%, P<0.05), and TUNEL-positive nuclei in human skeletal myotubes, demonstrating up-regulation of mitochondrial-mediated myonuclear apoptotic mechanisms. Simvastatin 13-24 BCL2 associated X, apoptosis regulator Homo sapiens 62-65 22080086-6 2012 In addition, simvastatin markedly increased protein levels of Bax (proapoptotic, +53%) and Bcl-2 (antiapoptotic, +100%, P<0.05), mitochondrial PTP opening (+44%, P<0.05), and TUNEL-positive nuclei in human skeletal myotubes, demonstrating up-regulation of mitochondrial-mediated myonuclear apoptotic mechanisms. Simvastatin 13-24 BCL2 apoptosis regulator Homo sapiens 91-96 22405262-10 2012 Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke. Simvastatin 35-46 brain derived neurotrophic factor Homo sapiens 87-91 22405262-10 2012 Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke. Simvastatin 35-46 neurotrophic receptor tyrosine kinase 2 Homo sapiens 92-96 22253567-0 2012 Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes. Simvastatin 0-11 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 36-41 22253567-3 2012 It is hypothesized that remodeling of Kv4.3 occurs in rat hypertrophied cardiomyocytes and is regulated by simvastatin. Simvastatin 107-118 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 38-43 22253567-8 2012 Simvastatin partially prevented the reduction of Kv4.3 expression in NRVMs and subepicardial myocardium but not in the subendocardial myocardium. Simvastatin 0-11 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 49-54 23214015-5 2012 Simvastatin therapy led to normalization of osteocalcin level (p<0.01) within 6 months. Simvastatin 0-11 bone gamma-carboxyglutamate protein Homo sapiens 44-55 22253567-10 2012 CONCLUSIONS: Simvastatin alleviated the reduction of Kv4.3 expression, I(to) currents in hypertrophied NRVMs and alleviated the reduced Kv4.3 expression in subepicardial myocardium from the hypertrophied left ventricle. Simvastatin 13-24 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 53-58 22253567-10 2012 CONCLUSIONS: Simvastatin alleviated the reduction of Kv4.3 expression, I(to) currents in hypertrophied NRVMs and alleviated the reduced Kv4.3 expression in subepicardial myocardium from the hypertrophied left ventricle. Simvastatin 13-24 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 136-141 22253567-11 2012 It can be speculated that among the pleiotropic effects of simvastatin, the anti-arrhythmia effect is partly mediated by its effect on Kv4.3. Simvastatin 59-70 potassium voltage-gated channel subfamily D member 3 Rattus norvegicus 135-140 21987590-1 2012 This work describes a novel mechanism of neuroprotection by simvastatin: the modulation of seladin-1, an enzyme involved in Alzheimer"s disease. Simvastatin 60-71 24-dehydrocholesterol reductase Homo sapiens 91-100 21987590-2 2012 Genomic and proteomic studies in human neuronal cells showed seladin-1 production to be increased in a dose- and time-dependent manner by simvastatin. Simvastatin 138-149 24-dehydrocholesterol reductase Homo sapiens 61-70 21623963-7 2012 This lymphocyte-suppressing effect, which was accompanied by a decrease in plasma levels of hsCRP and ICAM-1 (P<0.001), was strongest in patients receiving both simvastatin and ezetimibe. Simvastatin 164-175 intercellular adhesion molecule 1 Homo sapiens 102-108 21987590-0 2012 Simvastatin modulates the Alzheimer"s disease-related gene seladin-1. Simvastatin 0-11 24-dehydrocholesterol reductase Homo sapiens 59-68 22850448-0 2012 Simvastatin reduces endothelial NOS: caveolin-1 ratio but not the phosphorylation status of eNOS in vivo. Simvastatin 0-11 caveolin-1 Oryctolagus cuniculus 37-47 22850448-7 2012 Although eNOS significantly increased in MC and MCS (p<0.01), simvastatin treatment significantly reduced endothelial caveolin-1 by 35% (p=0.038), causing a 2.5-fold (p=0.026) increase in the eNOS: caveolin-1 ratio. Simvastatin 65-76 caveolin-1 Oryctolagus cuniculus 121-131 22850448-7 2012 Although eNOS significantly increased in MC and MCS (p<0.01), simvastatin treatment significantly reduced endothelial caveolin-1 by 35% (p=0.038), causing a 2.5-fold (p=0.026) increase in the eNOS: caveolin-1 ratio. Simvastatin 65-76 caveolin-1 Oryctolagus cuniculus 201-211 22102723-10 2012 Blockade of apoptosis by a pan-caspase inhibitor or by simvastatin sharply reduced the release of TNF-alpha but enhanced IL-10. Simvastatin 55-66 tumor necrosis factor Mus musculus 98-107 22102723-10 2012 Blockade of apoptosis by a pan-caspase inhibitor or by simvastatin sharply reduced the release of TNF-alpha but enhanced IL-10. Simvastatin 55-66 interleukin 10 Mus musculus 121-126 23581225-0 2012 Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Simvastatin 0-11 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-30 23032911-7 2012 Simvastatin is a substrate of CYP3A4 enzyme. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 23032911-8 2012 Clinical and pharmacological data, available in the published literature, allow the assumption that simvastatin may induce CYP3A4 and result in increased hepatoxicity of paracetamol. Simvastatin 100-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 123-129 21904947-0 2012 Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4. Simvastatin 0-11 NADPH oxidase 4 Mus musculus 105-109 21904947-6 2012 Then, we examined the effects of simvastatin (10(-7) M) on Nox1, Nox2, and Nox4 expressions in osteoblastic cells treated by H(2)O(2) (100 muM). Simvastatin 33-44 NADPH oxidase 1 Mus musculus 59-63 21904947-6 2012 Then, we examined the effects of simvastatin (10(-7) M) on Nox1, Nox2, and Nox4 expressions in osteoblastic cells treated by H(2)O(2) (100 muM). Simvastatin 33-44 NADPH oxidase 4 Mus musculus 75-79 21904947-7 2012 We found that in MC3T3-E1 cells, H(2)O(2)-induced upregulation of Nox4 expression was inhibited by simvastatin, which was restored by farnesyl pyrophosphate (5 muM) as well as geranylgeranyl pyrophosphate (5 muM). Simvastatin 99-110 NADPH oxidase 4 Mus musculus 66-70 21904947-10 2012 We concluded that simvastatin protected osteoblast against H(2)O(2)-induced oxidative damage, at least in part, via inhibiting the upregulation of Nox4. Simvastatin 18-29 NADPH oxidase 4 Mus musculus 147-151 22668016-5 2012 In treated animals (simvastatin 180 mg/kg), significant decrease by 12% in Bcl-2 protein expression and non-significant decrease by 27% of Ki67 protein expression in tumor cells compared to tumor cells in control animals were observed after semiquantitative evaluation. Simvastatin 20-31 BCL2, apoptosis regulator Rattus norvegicus 75-80 22668016-9 2012 The noticeable decrease of mammary tumor frequency and incidence in rats after simvastatin treatment was accompanied with antiapoptotic Blc-2 protein decrease and proapoptotic Bax protein increase in this experiment. Simvastatin 79-90 BCL2 associated X, apoptosis regulator Rattus norvegicus 176-179 20678906-7 2012 Simvastatin use was associated with significant reductions in total cholesterol, LDL, ox-LDL and CRP. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 23581225-0 2012 Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Simvastatin 0-11 ETS variant transcription factor 4 Homo sapiens 51-55 23581225-0 2012 Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Simvastatin 0-11 erb-b2 receptor tyrosine kinase 2 Homo sapiens 80-84 23581225-4 2012 Simvastatin induced cell death in MDA-MB-361, SK-Ov3, and SKBR3, HER2-overexpressing cell lines, in both time- and dose-dependent manners, but did not exert cytotoxicity in MCF10A and MDA-MB-231, HER2 low/negative cell lines. Simvastatin 0-11 erb-b2 receptor tyrosine kinase 2 Homo sapiens 65-69 23581225-4 2012 Simvastatin induced cell death in MDA-MB-361, SK-Ov3, and SKBR3, HER2-overexpressing cell lines, in both time- and dose-dependent manners, but did not exert cytotoxicity in MCF10A and MDA-MB-231, HER2 low/negative cell lines. Simvastatin 0-11 erb-b2 receptor tyrosine kinase 2 Homo sapiens 196-200 23581225-5 2012 The protein expression of HER2 decreased after the cells were treated with simvastatin; however, HER2 protein and mRNA stabilities were not changed. Simvastatin 75-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-30 23581225-6 2012 Furthermore, simvastatin inhibited the activity of the HER2 promoter. Simvastatin 13-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-59 23581225-8 2012 In addition, simvastatin treatment induced the expression of PEA3, which is a HER2 promoter inhibitor. Simvastatin 13-24 ETS variant transcription factor 4 Homo sapiens 61-65 23581225-8 2012 In addition, simvastatin treatment induced the expression of PEA3, which is a HER2 promoter inhibitor. Simvastatin 13-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 23581225-10 2012 These findings provide alternative mechanisms for the antitumor effects of simvastatin, suggesting that simvastatin could also be used as a combination therapy with other chemotherapy agents in HER2-positive patients. Simvastatin 75-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 194-198 23581225-10 2012 These findings provide alternative mechanisms for the antitumor effects of simvastatin, suggesting that simvastatin could also be used as a combination therapy with other chemotherapy agents in HER2-positive patients. Simvastatin 104-115 erb-b2 receptor tyrosine kinase 2 Homo sapiens 194-198 21871960-10 2012 Inhibition of autophagy with bafilomycin A1, 3-methyladenine and LC3beta shRNA, as well as AMPK inhibition with compound C or AMPK siRNA, markedly increased apoptotic death of simvastatin-treated U251 cells. Simvastatin 176-187 microtubule associated protein 1 light chain 3 beta Homo sapiens 65-72 21871960-0 2012 Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin. Simvastatin 78-89 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 14-18 21871960-10 2012 Inhibition of autophagy with bafilomycin A1, 3-methyladenine and LC3beta shRNA, as well as AMPK inhibition with compound C or AMPK siRNA, markedly increased apoptotic death of simvastatin-treated U251 cells. Simvastatin 176-187 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 91-95 21871960-1 2012 The role of autophagy, a process in which the cell self-digests its own components, was investigated in glioma cell death induced by the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase-inhibiting drug simvastatin. Simvastatin 206-217 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-189 21871960-7 2012 Simvastatin induced the activation of AMP-activated protein kinase (AMPK) and its target Raptor, while simultaneously downregulating activation of Akt. Simvastatin 0-11 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 38-66 21871960-10 2012 Inhibition of autophagy with bafilomycin A1, 3-methyladenine and LC3beta shRNA, as well as AMPK inhibition with compound C or AMPK siRNA, markedly increased apoptotic death of simvastatin-treated U251 cells. Simvastatin 176-187 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 126-130 21871960-7 2012 Simvastatin induced the activation of AMP-activated protein kinase (AMPK) and its target Raptor, while simultaneously downregulating activation of Akt. Simvastatin 0-11 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 68-72 22589709-7 2012 In vitro assays confirmed that five old drugs, namely montelukast, diclofenac, simvastatin, ketoconazole, and itraconazole, showed polypharmacological features on estrogen receptors or dipeptidyl peptidase-IV with half maximal inhibitory or effective concentration ranged from 0.2 to 10 microM. Simvastatin 79-90 dipeptidyl peptidase 4 Homo sapiens 185-208 21871960-7 2012 Simvastatin induced the activation of AMP-activated protein kinase (AMPK) and its target Raptor, while simultaneously downregulating activation of Akt. Simvastatin 0-11 regulatory associated protein of MTOR complex 1 Homo sapiens 89-95 21871960-7 2012 Simvastatin induced the activation of AMP-activated protein kinase (AMPK) and its target Raptor, while simultaneously downregulating activation of Akt. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 147-150 21871960-8 2012 Mammalian target of rapamycin (mTOR), a major AMPK/Akt downstream target and a major negative autophagy regulator, and its substrate p70 S6 kinase 1 were also inhibited by simvastatin. Simvastatin 172-183 mechanistic target of rapamycin kinase Homo sapiens 0-29 21871960-8 2012 Mammalian target of rapamycin (mTOR), a major AMPK/Akt downstream target and a major negative autophagy regulator, and its substrate p70 S6 kinase 1 were also inhibited by simvastatin. Simvastatin 172-183 mechanistic target of rapamycin kinase Homo sapiens 31-35 21871960-8 2012 Mammalian target of rapamycin (mTOR), a major AMPK/Akt downstream target and a major negative autophagy regulator, and its substrate p70 S6 kinase 1 were also inhibited by simvastatin. Simvastatin 172-183 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 46-50 21871960-8 2012 Mammalian target of rapamycin (mTOR), a major AMPK/Akt downstream target and a major negative autophagy regulator, and its substrate p70 S6 kinase 1 were also inhibited by simvastatin. Simvastatin 172-183 AKT serine/threonine kinase 1 Homo sapiens 51-54 21871960-9 2012 Mevalonate, the product of HMG-CoA reductase enzymatic activity, AMPK siRNA or pharmacological inactivation of AMPK with compound C suppressed, while the inhibitors of Akt (10-DEBC hydrochloride) and mTOR (rapamycin) mimicked autophagy induction by simvastatin. Simvastatin 249-260 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 111-115 22814022-4 2012 RESULTS: Both alpha-tocopherol and simvastatin almost equally restored the age-induced changes in liver TBARS and CAT activity, serum aspartate aminotransferase (GOT), alanine aminotransferase (GPT) and alkaline phosphatase (ALP). Simvastatin 35-46 catalase Rattus norvegicus 114-117 22814022-4 2012 RESULTS: Both alpha-tocopherol and simvastatin almost equally restored the age-induced changes in liver TBARS and CAT activity, serum aspartate aminotransferase (GOT), alanine aminotransferase (GPT) and alkaline phosphatase (ALP). Simvastatin 35-46 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 134-160 22814022-4 2012 RESULTS: Both alpha-tocopherol and simvastatin almost equally restored the age-induced changes in liver TBARS and CAT activity, serum aspartate aminotransferase (GOT), alanine aminotransferase (GPT) and alkaline phosphatase (ALP). Simvastatin 35-46 glutamic--pyruvic transaminase Rattus norvegicus 194-197 22912565-8 2012 Based on additional literature data on in vitro drug metabolism and inhibition potency, loratadine and simvastatin and tegaserod and promethazine were predicted to have a strong DDI through the CYP3A4 and CYP2D6 enzymes, respectively. Simvastatin 103-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 194-200 22912565-8 2012 Based on additional literature data on in vitro drug metabolism and inhibition potency, loratadine and simvastatin and tegaserod and promethazine were predicted to have a strong DDI through the CYP3A4 and CYP2D6 enzymes, respectively. Simvastatin 103-114 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 205-211 23097681-0 2012 Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Simvastatin 0-11 myeloperoxidase Rattus norvegicus 108-123 23251573-8 2012 The results indicated that Simvastatin could protect the cerebrum from ischemic injury through a signaling mechanism involving elevated levels of PP2A and NR3A, and that PP2A might involve in the regulatory mechanism of NR3A expression. Simvastatin 27-38 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 155-159 23166513-6 2012 Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Simvastatin 207-218 ras homolog family member A Homo sapiens 58-62 23166513-6 2012 Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Simvastatin 207-218 apolipoprotein B Homo sapiens 191-195 23251573-0 2012 Upregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats. Simvastatin 70-81 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 43-47 23251573-4 2012 It is meaningful to uncover whether protein phosphatase 2A (PP2A) and NR3A play a role in the protective effect of Simvastatin on ischemic stroke. Simvastatin 115-126 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 70-74 22911825-6 2012 Simvastatin impaired poly (I:C)-induced IFN-alpha expression in macrophages or dendritic cells, possibly due to lowered toll-like receptor (TLR) 3 expression; however, the mechanisms were not related to interferon regulatory factor 3 or nuclear factor kappa B signaling pathway. Simvastatin 0-11 interferon-alpha-14 Sus scrofa 40-49 23251573-6 2012 The results showed that Simvastatin decreased brain ischemic infarct area significantly while increasing the expression levels of PP2A and NR3A, thus dephosphorylating the serine sites of NR1 (ser896 and ser897) along with increased enzymatic activities of PP2A. Simvastatin 24-35 glutamate ionotropic receptor NMDA type subunit 3A Rattus norvegicus 139-143 23251573-6 2012 The results showed that Simvastatin decreased brain ischemic infarct area significantly while increasing the expression levels of PP2A and NR3A, thus dephosphorylating the serine sites of NR1 (ser896 and ser897) along with increased enzymatic activities of PP2A. Simvastatin 24-35 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 188-191 23029183-10 2012 The expression of H-FABP was related to Simvastatin treatment, albuminuria and triglycerides, while it was only linked with triglycerides and albuminuria (r = 0.643, P = 0.036). Simvastatin 40-51 fatty acid binding protein 3 Homo sapiens 18-24 22911825-8 2012 In contrast to the increased HuNoV shedding that simvastatin induced, viral shedding during the treatment period was reduced or curtailed in the HuNoV-inoculated pigs pre-treated/treated with human IFN-alpha. Simvastatin 49-60 interferon alpha 1 Homo sapiens 198-207 22737247-1 2012 Statins such as simvastatin are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and standard therapy for the prevention and treatment of cardiovascular diseases in mammals. Simvastatin 16-27 HMG Coenzyme A reductase Drosophila melanogaster 32-89 21968084-1 2011 We evaluate the protective role of simvastatin-induced HO-1 in remote preconditioning against testis ischemia-reperfusion (IR) injury in vivo. Simvastatin 35-46 heme oxygenase 1 Rattus norvegicus 55-59 22950641-5 2012 Simvastatin resulted in a significant decrease in CRP, which correlated with decreases in both total (r = 0.87, p < 0.05) and low-density lipoprotein cholesterol, IL-6, sICAM-1, sVCAM-1, oxLDL, and sFas at 6 months, compared to baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 50-53 22950641-5 2012 Simvastatin resulted in a significant decrease in CRP, which correlated with decreases in both total (r = 0.87, p < 0.05) and low-density lipoprotein cholesterol, IL-6, sICAM-1, sVCAM-1, oxLDL, and sFas at 6 months, compared to baseline. Simvastatin 0-11 interleukin 6 Homo sapiens 166-170 23208905-7 2012 RESULTS: Co-administration of G-CSF with simvastatin significantly promoted functional recovery and expedited the recovery time. Simvastatin 41-52 colony stimulating factor 3 Rattus norvegicus 30-35 22761797-8 2012 Treatment with cholesterol-lowering simvastatin induced up to 90% reduction in relative cell number of normal cell lines but a 15-20% reduction in relative number of cancer cells, an effect accompanied by sharp upregulation of HMGCR and LDLR. Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 227-232 22761797-8 2012 Treatment with cholesterol-lowering simvastatin induced up to 90% reduction in relative cell number of normal cell lines but a 15-20% reduction in relative number of cancer cells, an effect accompanied by sharp upregulation of HMGCR and LDLR. Simvastatin 36-47 low density lipoprotein receptor Homo sapiens 237-241 22645493-0 2012 Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. Simvastatin 49-60 serpin family E member 1 Rattus norvegicus 90-95 22645493-2 2012 The aim of the paper was to investigate the effect its dose-dependent drug-drug interaction with simvastatin inhibitor HMGCo-A has on PAI-1 blood level, heart rate and blood pressure. Simvastatin 97-108 serpin family E member 1 Rattus norvegicus 134-139 22645493-4 2012 Ivabradine exacerbated the decrease of PAI-1 in normocholesterolemic animals receiving simvastatin at a dose of 1 mg/kg bw and was not observed to have any significant influence on the PAI-1 values in rats receiving 20 mg x kg(-1) bw simvastatin. Simvastatin 87-98 serpin family E member 1 Rattus norvegicus 39-44 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 32-43 heme oxygenase 1 Rattus norvegicus 13-17 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 32-43 heme oxygenase 1 Rattus norvegicus 150-154 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 32-43 caspase 3 Rattus norvegicus 258-267 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 110-121 heme oxygenase 1 Rattus norvegicus 13-17 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 110-121 heme oxygenase 1 Rattus norvegicus 150-154 21968084-8 2011 Induction of HO-1 expression by simvastatin was significantly increased at 24 and 48 h. Rats pre-treated with simvastatin showed higher expression of HO-1 protein by Western blotting and immunohistochemistry (IHC), and presented lower caspases-3 activity by caspase-3 activity assay. Simvastatin 110-121 caspase 3 Rattus norvegicus 258-267 21968084-11 2011 Further, lower caspase-3 activities were also noted in simvastatin plus Snpp (SS) group than the control plus Snpp (CS) group. Simvastatin 55-66 caspase 3 Rattus norvegicus 15-24 21839782-0 2011 Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Simvastatin 18-29 thymoma viral proto-oncogene 1 Mus musculus 126-129 21910007-1 2011 Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically modified activities of the main cell signaling pathways resulting in the induction of heme oxygenase-1 (HO-1) and in a downregulation of cyclooxygenase-2 (COX-2) protein levels. Simvastatin 59-70 heme oxygenase 1 Homo sapiens 186-202 21910007-1 2011 Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically modified activities of the main cell signaling pathways resulting in the induction of heme oxygenase-1 (HO-1) and in a downregulation of cyclooxygenase-2 (COX-2) protein levels. Simvastatin 59-70 heme oxygenase 1 Homo sapiens 204-208 21910007-1 2011 Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically modified activities of the main cell signaling pathways resulting in the induction of heme oxygenase-1 (HO-1) and in a downregulation of cyclooxygenase-2 (COX-2) protein levels. Simvastatin 59-70 prostaglandin-endoperoxide synthase 2 Homo sapiens 237-253 21910007-1 2011 Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically modified activities of the main cell signaling pathways resulting in the induction of heme oxygenase-1 (HO-1) and in a downregulation of cyclooxygenase-2 (COX-2) protein levels. Simvastatin 59-70 prostaglandin-endoperoxide synthase 2 Homo sapiens 255-260 22022992-3 2011 We observed the shape of simvastatin ethosome through TEM. Simvastatin 25-36 MFT2 Homo sapiens 54-57 21839782-9 2011 HepG2 mitochondrial respiration became susceptible to simvastatin-treatment after Akt inhibition, and mitochondrial respiration was rescued in Igf-1-treated C2C12 myotubes. Simvastatin 54-65 thymoma viral proto-oncogene 1 Mus musculus 82-85 21839782-10 2011 These results suggest that disruption of Igf-1/Akt signaling is a causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells are protected by maintaining Igf-1/Akt signaling. Simvastatin 86-97 insulin-like growth factor 1 Mus musculus 41-46 21839782-10 2011 These results suggest that disruption of Igf-1/Akt signaling is a causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells are protected by maintaining Igf-1/Akt signaling. Simvastatin 86-97 thymoma viral proto-oncogene 1 Mus musculus 47-50 21839782-10 2011 These results suggest that disruption of Igf-1/Akt signaling is a causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells are protected by maintaining Igf-1/Akt signaling. Simvastatin 86-97 AKT serine/threonine kinase 1 Homo sapiens 206-209 21839782-15 2011 Transient transfection of constitutively active Rap1 into C2C12 myotubes led to a partial rescue of simvastatin-induced inhibition of mitochondrial respiration, providing a novel link between signaling and respiration. Simvastatin 100-111 RAS-related protein 1a Mus musculus 48-52 21832867-4 2011 Simvastatin, which inhibits 3-hydroxy-3-methylglutaryl coenzyme A, is a hypolipidemic drug which is known to affect bone metabolism and suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand (RANKL). Simvastatin 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 177-227 21256697-1 2011 Simvastatin was recently demonstrated to stimulate bone morphogenetic protein-2 expression, leading to bone formation. Simvastatin 0-11 bone morphogenetic protein 2 Canis lupus familiaris 51-79 22101558-8 2011 Clinical outcome data with ezetimibe combined with simvastatin have recently become available, and definitive evidence that the incremental LDL-C lowering attributable to the ezetimibe component reduces cardiovascular events beyond simvastatin alone is currently under study. Simvastatin 232-243 component of oligomeric golgi complex 2 Homo sapiens 140-145 21874229-0 2011 Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and beta1 integrin. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 105-111 21874229-0 2011 Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and beta1 integrin. Simvastatin 0-11 integrin subunit beta 1 Homo sapiens 116-130 21874229-9 2011 Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin 100-111 vascular cell adhesion molecule 1 Homo sapiens 37-43 21874229-9 2011 Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin 100-111 intercellular adhesion molecule 1 Homo sapiens 45-51 21874229-9 2011 Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin 100-111 integrin subunit beta 1 Homo sapiens 56-70 21874229-10 2011 Simvastatin significantly reduced the adhesion of all ovarian cancer cells and HT29 to HMCs (P<=0.001). Simvastatin 0-11 MKKS centrosomal shuttling protein Homo sapiens 87-91 21874229-11 2011 Concomitantly simvastatin decreased the expression of VCAM-1 on HMCs. Simvastatin 14-25 vascular cell adhesion molecule 1 Homo sapiens 54-60 21874229-11 2011 Concomitantly simvastatin decreased the expression of VCAM-1 on HMCs. Simvastatin 14-25 MKKS centrosomal shuttling protein Homo sapiens 64-68 21874229-14 2011 Simvastatin clearly inhibits tumor cell adhesion to HMCs. Simvastatin 0-11 MKKS centrosomal shuttling protein Homo sapiens 52-56 21946898-0 2011 Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Simvastatin 72-83 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 6-12 21946898-1 2011 OBJECTIVES: CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. Simvastatin 131-142 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 12-18 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-135 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 component of oligomeric golgi complex 2 Homo sapiens 206-221 21946898-2 2011 The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study. Simvastatin 163-174 component of oligomeric golgi complex 2 Homo sapiens 223-227 21946898-3 2011 METHODS: In a total of 80 incident simvastatin users, the association between the CYP3A4 intron 6 C>T SNP (rs35599367) and reduction in cholesterol levels was analyzed using linear regression analysis and adjusting for potential confounding factors. Simvastatin 35-46 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 82-88 21946898-4 2011 RESULTS: The CYP3A4*22 allele was associated with a trend towards a stronger simvastatin lipid-lowering response, as reflected by the greater reduction in both TOTc and LDLc levels when compared with homozygous wild type. Simvastatin 77-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 21946898-4 2011 RESULTS: The CYP3A4*22 allele was associated with a trend towards a stronger simvastatin lipid-lowering response, as reflected by the greater reduction in both TOTc and LDLc levels when compared with homozygous wild type. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 169-173 21946898-7 2011 CONCLUSION: The CYP3A4*22 intron 6 SNP T-variant allele was associated with reduced CYP3A4 activity, resulting in a better lipid lowering response to simvastatin, when data were adjusted for confounding factors. Simvastatin 150-161 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 16-22 21946898-7 2011 CONCLUSION: The CYP3A4*22 intron 6 SNP T-variant allele was associated with reduced CYP3A4 activity, resulting in a better lipid lowering response to simvastatin, when data were adjusted for confounding factors. Simvastatin 150-161 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 84-90 21914450-8 2011 Simvastatin induced an increase in eNOS mRNA expression and protein levels in the presence of arginine or citrulline. Simvastatin 0-11 nitric oxide synthase 3 Bos taurus 35-39 21925249-0 2011 Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 69-85 21925249-3 2011 Here, the possibility that HO-1 is involved in the anti-inflammatory action of simvastatin, using lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages as a model system has been specifically addressed. Simvastatin 79-90 heme oxygenase 1 Homo sapiens 27-31 21832867-4 2011 Simvastatin, which inhibits 3-hydroxy-3-methylglutaryl coenzyme A, is a hypolipidemic drug which is known to affect bone metabolism and suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand (RANKL). Simvastatin 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 229-234 21925249-4 2011 Our results demonstrated that in the presence of LPS, simvastatin significantly increased HO-1 expression and activity in a dose-dependent manner compared to that of LPS-stimulated alone macrophages. Simvastatin 54-65 heme oxygenase 1 Homo sapiens 90-94 21832867-6 2011 We found that simvastatin decreased expression of tartrate-resistant acid phosphatase (TRAP), a genetic marker of osteoclast differentiation, and inhibited intracellular ROS generation in RAW 264.7 cell lines. Simvastatin 14-25 acid phosphatase 5, tartrate resistant Mus musculus 50-85 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 nitric oxide synthase 2 Homo sapiens 68-89 21958871-0 2011 Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Simvastatin 52-63 checkpoint kinase 1 Homo sapiens 15-19 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 tumor necrosis factor Homo sapiens 163-190 21832867-6 2011 We found that simvastatin decreased expression of tartrate-resistant acid phosphatase (TRAP), a genetic marker of osteoclast differentiation, and inhibited intracellular ROS generation in RAW 264.7 cell lines. Simvastatin 14-25 acid phosphatase 5, tartrate resistant Mus musculus 87-91 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 tumor necrosis factor Homo sapiens 192-201 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 interleukin 10 Homo sapiens 244-258 21958871-0 2011 Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Simvastatin 52-63 cell division cycle 25A Homo sapiens 20-26 21958871-0 2011 Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Simvastatin 52-63 cyclin A2 Homo sapiens 27-35 21958871-0 2011 Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Simvastatin 52-63 cyclin dependent kinase 2 Homo sapiens 36-40 21958871-2 2011 Recently simvastatin has been found to result in the synergistic induction of apoptosis with 7-hydroxystaurosporine (UCN-01) (a Chk1 inhibitor) in myeloma cells. Simvastatin 9-20 checkpoint kinase 1 Homo sapiens 128-132 21841162-3 2011 Simvastatin, a potent inhibitor of HMG-CoA reductase, suppressed 15(S)-HETE-induced Rac1 activation in HDMVECs affecting their migration and tube formation. Simvastatin 0-11 Rac family small GTPase 1 Mus musculus 84-88 21958871-3 2011 Therefore we hypothesized that Chk1 plays a role in the anti-myeloma effect of simvastatin. Simvastatin 79-90 checkpoint kinase 1 Homo sapiens 31-35 21958871-5 2011 The results of western blot showed that simvastatin-induced S-phase cell cycle arrest was associated with activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression. Simvastatin 40-51 checkpoint kinase 1 Homo sapiens 120-124 21958871-5 2011 The results of western blot showed that simvastatin-induced S-phase cell cycle arrest was associated with activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression. Simvastatin 40-51 cell division cycle 25A Homo sapiens 144-150 21958871-5 2011 The results of western blot showed that simvastatin-induced S-phase cell cycle arrest was associated with activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression. Simvastatin 40-51 cyclin A2 Homo sapiens 152-160 21958871-5 2011 The results of western blot showed that simvastatin-induced S-phase cell cycle arrest was associated with activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression. Simvastatin 40-51 cyclin dependent kinase 2 Homo sapiens 165-169 21958871-6 2011 Additionally, simvastatin-induced apoptosis was accompanied by diminished Bcl-2 protein expression, increased cytosolic cytochrome c level, and activation of caspase 9 and caspase 3. Simvastatin 14-25 BCL2 apoptosis regulator Homo sapiens 74-79 21958871-6 2011 Additionally, simvastatin-induced apoptosis was accompanied by diminished Bcl-2 protein expression, increased cytosolic cytochrome c level, and activation of caspase 9 and caspase 3. Simvastatin 14-25 cytochrome c, somatic Homo sapiens 120-132 21958871-6 2011 Additionally, simvastatin-induced apoptosis was accompanied by diminished Bcl-2 protein expression, increased cytosolic cytochrome c level, and activation of caspase 9 and caspase 3. Simvastatin 14-25 caspase 9 Homo sapiens 158-167 21958871-6 2011 Additionally, simvastatin-induced apoptosis was accompanied by diminished Bcl-2 protein expression, increased cytosolic cytochrome c level, and activation of caspase 9 and caspase 3. Simvastatin 14-25 caspase 3 Homo sapiens 172-181 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 checkpoint kinase 1 Homo sapiens 47-51 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 checkpoint kinase 1 Homo sapiens 66-70 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 checkpoint kinase 1 Homo sapiens 66-70 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 cell division cycle 25A Homo sapiens 154-160 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 cyclin A2 Homo sapiens 162-170 21958871-7 2011 Further investigation revealed that silence of Chk1 expression by Chk1 specific siRNA inhibited simvastatin-induced activation of Chk1, downregulation of Cdc25A, cyclin A and CDK2 expression, and diminished S phase cell cycle arrest. Simvastatin 96-107 cyclin dependent kinase 2 Homo sapiens 175-179 21958871-8 2011 Additionally, inhibition of Chk1 expression enhanced simvastatin-induced downregulation of Bcl-2, caspase 9 cleavage and subsequent apoptosis. Simvastatin 53-64 checkpoint kinase 1 Homo sapiens 28-32 21958871-8 2011 Additionally, inhibition of Chk1 expression enhanced simvastatin-induced downregulation of Bcl-2, caspase 9 cleavage and subsequent apoptosis. Simvastatin 53-64 BCL2 apoptosis regulator Homo sapiens 91-96 21958871-8 2011 Additionally, inhibition of Chk1 expression enhanced simvastatin-induced downregulation of Bcl-2, caspase 9 cleavage and subsequent apoptosis. Simvastatin 53-64 caspase 9 Homo sapiens 98-107 21958871-9 2011 These results suggested that the Chk1-Cdc25A-cyclin A/CDk2 pathway was involved in simvastatin-induced S-phase cell cycle arrest and apoptosis in multiple myeloma cell lines. Simvastatin 83-94 checkpoint kinase 1 Homo sapiens 33-37 21958871-9 2011 These results suggested that the Chk1-Cdc25A-cyclin A/CDk2 pathway was involved in simvastatin-induced S-phase cell cycle arrest and apoptosis in multiple myeloma cell lines. Simvastatin 83-94 cell division cycle 25A Homo sapiens 38-44 21958871-9 2011 These results suggested that the Chk1-Cdc25A-cyclin A/CDk2 pathway was involved in simvastatin-induced S-phase cell cycle arrest and apoptosis in multiple myeloma cell lines. Simvastatin 83-94 cyclin A2 Homo sapiens 45-53 21958871-9 2011 These results suggested that the Chk1-Cdc25A-cyclin A/CDk2 pathway was involved in simvastatin-induced S-phase cell cycle arrest and apoptosis in multiple myeloma cell lines. Simvastatin 83-94 cyclin dependent kinase 2 Homo sapiens 54-58 21945488-1 2011 It has been reported that polymorphisms in the organic anion transporting polypeptide 1B1 (OATP1B1, SLCO1B1) result in decreased hepatic uptake of simvastatin carboxy acid, the active metabolite of simvastatin. Simvastatin 147-158 solute carrier organic anion transporter family member 1B1 Homo sapiens 47-89 21945488-1 2011 It has been reported that polymorphisms in the organic anion transporting polypeptide 1B1 (OATP1B1, SLCO1B1) result in decreased hepatic uptake of simvastatin carboxy acid, the active metabolite of simvastatin. Simvastatin 147-158 solute carrier organic anion transporter family member 1B1 Homo sapiens 91-98 21945488-1 2011 It has been reported that polymorphisms in the organic anion transporting polypeptide 1B1 (OATP1B1, SLCO1B1) result in decreased hepatic uptake of simvastatin carboxy acid, the active metabolite of simvastatin. Simvastatin 147-158 solute carrier organic anion transporter family member 1B1 Homo sapiens 100-107 21841162-7 2011 Hind-limb ischemia induced Rac1 farnesylation and activation leading to increased angiogenesis and these effects were blocked by simvastatin and rescued by mevalonate in WT mice. Simvastatin 129-140 Rac family small GTPase 1 Mus musculus 27-31 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 interleukin 10 Homo sapiens 260-265 21925249-6 2011 Similarly, the IkappaB-alpha degradation and nuclear transcription factor-kappaB translocation and activation caused by LPS were significantly suppressed by simvastatin. Simvastatin 157-168 NFKB inhibitor alpha Homo sapiens 15-28 21925249-7 2011 However, these anti-inflammatory activities of simvastatin were markedly reversed by addition of a HO-1 inhibitor zinc protoporphyrin (ZnPP). Simvastatin 47-58 heme oxygenase 1 Homo sapiens 99-103 21925249-8 2011 Accordingly, the present results indicate that the anti-inflammatory activity of simvastatin could, at least in part, be regulated by induction of HO-1-mediated processes. Simvastatin 81-92 heme oxygenase 1 Homo sapiens 147-151 21841162-5 2011 Mevalonate rescued 15(S)-HETE-induced Rac1 farnesylation and membrane translocation in HDMVECs and the migration and tube formation of these cells from inhibition by simvastatin. Simvastatin 166-177 Rac family small GTPase 1 Mus musculus 38-42 22082490-3 2011 Research in the retina has shown that simvastatin, a commonly used statin, increases Akt phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to the protective effects achieved. Simvastatin 38-49 AKT serine/threonine kinase 1 Rattus norvegicus 85-88 22082490-3 2011 Research in the retina has shown that simvastatin, a commonly used statin, increases Akt phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to the protective effects achieved. Simvastatin 38-49 AKT serine/threonine kinase 1 Rattus norvegicus 139-142 22082490-0 2011 Simvastatin protects auditory hair cells from gentamicin-induced toxicity and activates Akt signaling in vitro. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 88-91 22082490-6 2011 Furthermore, we evaluated whether simvastatin increases Akt phosphorylation in the organ of Corti. Simvastatin 34-45 AKT serine/threonine kinase 1 Rattus norvegicus 56-59 22082490-10 2011 Finally, Western blotting showed an increase in organ of Corti Akt phosphorylation after simvastatin treatment in vitro. Simvastatin 89-100 AKT serine/threonine kinase 1 Rattus norvegicus 63-66 21883349-7 2011 Similarly, statins such as simvastatin are metabolized by CYP3A4, whereas others like pravastatin are not. Simvastatin 27-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-64 21671887-0 2011 Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Simvastatin 6-17 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 82-110 21732983-11 2011 CONCLUSION: This study suggests that both the simvastatin with hydrogel and simvastatin with ACS implants showed similar BMP-2 expression and new bone formation, and there were no significant differences between the two carriers. Simvastatin 46-57 bone morphogenetic protein 2 Oryctolagus cuniculus 121-126 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Simvastatin 5-16 C-reactive protein Homo sapiens 124-142 21985375-5 2011 Simvastatin arrested phytohaemaglutinin (PHA)-induced T cells at the G0/G1 phase, inhibiting T helper type 1 (Th1), Th2, interleukin (IL)-10 and IL-17A cytokine secretion in both patients and healthy control groups. Simvastatin 0-11 interleukin 10 Homo sapiens 121-140 21985375-5 2011 Simvastatin arrested phytohaemaglutinin (PHA)-induced T cells at the G0/G1 phase, inhibiting T helper type 1 (Th1), Th2, interleukin (IL)-10 and IL-17A cytokine secretion in both patients and healthy control groups. Simvastatin 0-11 interleukin 17A Homo sapiens 145-151 21777583-0 2011 Simvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina. Simvastatin 0-11 BCL2, apoptosis regulator Rattus norvegicus 24-29 21777583-8 2011 Using western blot analysis, we found that simvastatin upregulated the expression of Bcl-2 in the retina. Simvastatin 43-54 BCL2, apoptosis regulator Rattus norvegicus 85-90 21551187-12 2011 In a xenograft mouse model, simvastatin treatment induces BMP2 expression, leading to differentiation and reduced proliferation of CRC cells. Simvastatin 28-39 bone morphogenetic protein 2 Mus musculus 58-62 21968503-13 2011 TGF-beta-inducible PAI-1 expression was attenuated by simvastatin and curcumin, a natural polyphenol. Simvastatin 54-65 transforming growth factor beta 1 Homo sapiens 0-8 21968503-13 2011 TGF-beta-inducible PAI-1 expression was attenuated by simvastatin and curcumin, a natural polyphenol. Simvastatin 54-65 serpin family E member 1 Homo sapiens 19-24 21968503-15 2011 As both oxidative stress and PAI-1 production were reduced by simvastatin and curcumin, modulation of oxidative stress and PAI-1 production are attractive targets for pharmacotherapy of cardiovascular disorders associated with an increased PAI-1 including type 2 diabetes and its associated consequences including accelerated coronary artery disease and an increased fibrosis that may exacerbate adverse left ventricular remodeling after myocardial infarction. Simvastatin 62-73 serpin family E member 1 Homo sapiens 29-34 21968503-15 2011 As both oxidative stress and PAI-1 production were reduced by simvastatin and curcumin, modulation of oxidative stress and PAI-1 production are attractive targets for pharmacotherapy of cardiovascular disorders associated with an increased PAI-1 including type 2 diabetes and its associated consequences including accelerated coronary artery disease and an increased fibrosis that may exacerbate adverse left ventricular remodeling after myocardial infarction. Simvastatin 62-73 serpin family E member 1 Homo sapiens 123-128 21968503-15 2011 As both oxidative stress and PAI-1 production were reduced by simvastatin and curcumin, modulation of oxidative stress and PAI-1 production are attractive targets for pharmacotherapy of cardiovascular disorders associated with an increased PAI-1 including type 2 diabetes and its associated consequences including accelerated coronary artery disease and an increased fibrosis that may exacerbate adverse left ventricular remodeling after myocardial infarction. Simvastatin 62-73 serpin family E member 1 Homo sapiens 123-128 21907337-11 2011 In contrast, simvastatin inhibited HMGCR activity with a compensatory increase in HMGCR expression. Simvastatin 13-24 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 35-40 21907337-11 2011 In contrast, simvastatin inhibited HMGCR activity with a compensatory increase in HMGCR expression. Simvastatin 13-24 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 82-87 21907337-12 2011 Resveratrol counteracted this effect of simvastatin on HMGCR expression but augmented the simvastatin-induced inhibition on HMGCR activity and cholesterol synthesis. Simvastatin 40-51 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 55-60 21907337-12 2011 Resveratrol counteracted this effect of simvastatin on HMGCR expression but augmented the simvastatin-induced inhibition on HMGCR activity and cholesterol synthesis. Simvastatin 90-101 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 124-129 21995692-0 2011 Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Simvastatin 29-40 insulin Homo sapiens 101-108 21995692-0 2011 Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Simvastatin 62-73 insulin Homo sapiens 101-108 21995692-12 2011 CONCLUSION: To the extent that simvastatin 40 mg, rosuvastatin 10 mg and simvastatin/ezetimibe 10/10 mg are associated with adverse effects on insulin resistance, they appear to be of the same magnitude. Simvastatin 31-42 insulin Homo sapiens 143-150 21995692-12 2011 CONCLUSION: To the extent that simvastatin 40 mg, rosuvastatin 10 mg and simvastatin/ezetimibe 10/10 mg are associated with adverse effects on insulin resistance, they appear to be of the same magnitude. Simvastatin 73-84 insulin Homo sapiens 143-150 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Simvastatin 5-16 vascular cell adhesion molecule 1 Homo sapiens 156-189 22014341-8 2011 Simvastatin attenuated total cellular and cell-surface ICAM-1 expression as well as nuclear factor-kappa beta activation (P < .05). Simvastatin 0-11 intercellular adhesion molecule 1 Homo sapiens 55-61 22259685-2 2011 This study reports the effect of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, simvastatin given before experimental ICH. Simvastatin 103-114 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 33-91 22058016-0 2011 Simvastatin promotes osteogenic differentiation of mouse embryonic stem cells via canonical Wnt/beta-catenin signaling. Simvastatin 0-11 catenin (cadherin associated protein), beta 1 Mus musculus 96-108 22058016-1 2011 Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, has been known to reduce cholesterol biosynthesis. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 29-86 22058016-7 2011 Osteogenic differentiation of ESCs by simvastatin was determined by upregulation of the mRNA expression of runtrelated gene 2 (Runx2), osterix (OSX), and osteocalcin (OCN) as osteogenic transcription factors. Simvastatin 38-49 runt related transcription factor 2 Mus musculus 127-132 22058016-7 2011 Osteogenic differentiation of ESCs by simvastatin was determined by upregulation of the mRNA expression of runtrelated gene 2 (Runx2), osterix (OSX), and osteocalcin (OCN) as osteogenic transcription factors. Simvastatin 38-49 Sp7 transcription factor 7 Mus musculus 135-142 22058016-7 2011 Osteogenic differentiation of ESCs by simvastatin was determined by upregulation of the mRNA expression of runtrelated gene 2 (Runx2), osterix (OSX), and osteocalcin (OCN) as osteogenic transcription factors. Simvastatin 38-49 Sp7 transcription factor 7 Mus musculus 144-147 22058016-7 2011 Osteogenic differentiation of ESCs by simvastatin was determined by upregulation of the mRNA expression of runtrelated gene 2 (Runx2), osterix (OSX), and osteocalcin (OCN) as osteogenic transcription factors. Simvastatin 38-49 bone gamma-carboxyglutamate protein 2 Mus musculus 154-165 22058016-7 2011 Osteogenic differentiation of ESCs by simvastatin was determined by upregulation of the mRNA expression of runtrelated gene 2 (Runx2), osterix (OSX), and osteocalcin (OCN) as osteogenic transcription factors. Simvastatin 38-49 bone gamma-carboxyglutamate protein 2 Mus musculus 167-170 22058016-9 2011 However, the blockage of canonical Wnt signaling by DKK-1 downregulated simvastatin-induced ALP activity and the mRNA expression of each osteogenic transcription factor. Simvastatin 72-83 dickkopf WNT signaling pathway inhibitor 1 Mus musculus 52-57 22058016-11 2011 Collectively, these findings suggest that simvastatin enhances the differentiation of ESCs toward osteogenic lineage through activation of canonical Wnt/beta-catenin signaling. Simvastatin 42-53 catenin (cadherin associated protein), beta 1 Mus musculus 153-165 20473500-0 2011 HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 20473500-0 2011 HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Simvastatin 28-39 ras homolog family member A Homo sapiens 138-142 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 93-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 93-96 toll like receptor 2 Homo sapiens 142-162 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 80-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 93-96 toll like receptor 2 Homo sapiens 164-169 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 80-91 toll like receptor 2 Homo sapiens 142-162 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 93-96 ras homolog family member A Homo sapiens 207-211 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 80-91 toll like receptor 2 Homo sapiens 164-169 20473500-8 2011 SMV mitigated PG-induced increase in RhoA activity and NF-kappaB activation as well as secretion of TNFalpha and IL-1beta. Simvastatin 0-3 ras homolog family member A Homo sapiens 37-41 20473500-1 2011 To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses. Simvastatin 80-91 ras homolog family member A Homo sapiens 207-211 20473500-8 2011 SMV mitigated PG-induced increase in RhoA activity and NF-kappaB activation as well as secretion of TNFalpha and IL-1beta. Simvastatin 0-3 tumor necrosis factor Homo sapiens 100-108 20473500-8 2011 SMV mitigated PG-induced increase in RhoA activity and NF-kappaB activation as well as secretion of TNFalpha and IL-1beta. Simvastatin 0-3 interleukin 1 beta Homo sapiens 113-121 21790657-10 2011 Conclusively, adjunctive use of simvastatin to conventional insulin treatment showed more effectiveness in restoring erectile responses of diabetic rats by controlling the RhoA/Rho-kinase pathway than conventional insulin treatment alone. Simvastatin 32-43 ras homolog family member A Rattus norvegicus 172-176 21999923-7 2011 Lipophilic statins, such as simvastatin, also enhanced the anti-proliferative effects of iloprost and sildenafil, promoted apoptosis and inhibited the release of the mitogen and survival factor endothelin-1. Simvastatin 28-39 endothelin 1 Homo sapiens 194-206 20345493-5 2011 There was a statistically significant decrease in total cholesterol, triglycerides, low-density lipoprotein cholesterol, and apolipoprotein-B levels as well as in the apolipoprotein-B/apolipoprotein-A1 index after a 1-month therapy with 40 mg simvastatin (P <0.001). Simvastatin 243-254 apolipoprotein B Homo sapiens 167-183 21666443-15 2011 The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Simvastatin 29-40 claudin 5 Rattus norvegicus 107-116 21666443-15 2011 The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Simvastatin 29-40 intercellular adhesion molecule 1 Rattus norvegicus 131-164 21666443-15 2011 The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Simvastatin 29-40 matrix metallopeptidase 9 Rattus norvegicus 265-291 21666443-15 2011 The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Simvastatin 29-40 cadherin 5 Rattus norvegicus 304-333 21824198-7 2011 In the chemotaxis migration assay, pretreatment with fluvastatin and simvastatin inhibited the migration of human CD4+ T cells towards CCL20. Simvastatin 69-80 C-C motif chemokine ligand 20 Homo sapiens 135-140 21867382-0 2011 Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1-dependent pathway. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 107-123 21867382-4 2011 The aim of this study was to evaluate whether HO-1 is required for the pulmonary vascular protective effects of simvastatin. Simvastatin 112-123 heme oxygenase 1 Rattus norvegicus 46-50 21867382-9 2011 In addition, perivascular infiltration of inflammatory cells and the level of IL-6 were decreased in simvastatin treatment group. Simvastatin 101-112 interleukin 6 Rattus norvegicus 78-82 21867382-10 2011 Simvastatin also increased significantly lung HO-1 protein expression. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 46-50 21867382-11 2011 Inhibiting HO-1 using Znpp resulted in a loss of the effect of simvastatin in MCT rats. Simvastatin 63-74 heme oxygenase 1 Rattus norvegicus 11-15 21867382-12 2011 These results suggest that HO-1 expression is critical for the vascular protective effects of simvastatin in MCT-induced PH rats. Simvastatin 94-105 heme oxygenase 1 Rattus norvegicus 27-31 21519925-9 2011 Western blot verified activation of SREBP2 in these cells, and apoptosis was enhanced by pretreatment with simvastatin, an activator of SREBP2, and by overexpression of the N-terminal fragment of SREBP2. Simvastatin 107-118 sterol regulatory element binding transcription factor 2 Homo sapiens 36-42 21519925-9 2011 Western blot verified activation of SREBP2 in these cells, and apoptosis was enhanced by pretreatment with simvastatin, an activator of SREBP2, and by overexpression of the N-terminal fragment of SREBP2. Simvastatin 107-118 sterol regulatory element binding transcription factor 2 Homo sapiens 136-142 21519925-9 2011 Western blot verified activation of SREBP2 in these cells, and apoptosis was enhanced by pretreatment with simvastatin, an activator of SREBP2, and by overexpression of the N-terminal fragment of SREBP2. Simvastatin 107-118 sterol regulatory element binding transcription factor 2 Homo sapiens 136-142 21859750-5 2011 Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). Simvastatin 25-36 apolipoprotein B Homo sapiens 203-219 21778416-13 2011 Vasodilatory response to ACh was impaired when aorta from untreated mice was incubated with ex vivo IL-6 (P = 0.004), whereas in the aorta from mice pretreated with SS, the vasodilatory response did not change with IL-6 incubation (P = 0.387). Simvastatin 165-167 interleukin 6 Mus musculus 215-219 20464445-0 2011 Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Simvastatin 23-34 AKT serine/threonine kinase 1 Homo sapiens 71-74 20464445-5 2011 Simvastatin also resulted in a decrease in the expression of phosphorylated Akt. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 76-79 20464445-7 2011 The combination of simvastatin and 10 muM LY294002 (non-toxic dose) augmented apoptosis significantly, as evidenced by cleavage of PARP. Simvastatin 19-30 collagen type XI alpha 2 chain Homo sapiens 131-135 20464445-10 2011 Taken together, these data suggest that the anti-cancer effect of simvastatin via induction of apoptosis is related to Akt signaling dependent down-regulation of survivin in lung cancer A549 cells. Simvastatin 66-77 AKT serine/threonine kinase 1 Homo sapiens 119-122 20467885-1 2011 Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-82 20467885-1 2011 Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 84-91 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 component of oligomeric golgi complex 2 Homo sapiens 116-121 20467885-10 2011 Irinotecan and simvastatin combination treatment of A549 and H460 cells increased G(1) phase arrest, which was associated with up-regulation of p21(WAF1/CIP) and p53 compared with irinotecan alone. Simvastatin 15-26 cyclin dependent kinase inhibitor 1A Homo sapiens 144-147 20467885-10 2011 Irinotecan and simvastatin combination treatment of A549 and H460 cells increased G(1) phase arrest, which was associated with up-regulation of p21(WAF1/CIP) and p53 compared with irinotecan alone. Simvastatin 15-26 tumor protein p53 Homo sapiens 162-165 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 C-reactive protein Homo sapiens 123-126 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 tumor necrosis factor Homo sapiens 128-137 21856936-0 2011 Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. Simvastatin 0-11 interferon regulatory factor 4 Homo sapiens 21-44 21856936-4 2011 We report that simvastatin, one of the most hydrophobic statins with good CNS penetration, inhibited Th17 cell differentiation and IL-17A, IL-17F, IL-21, and IL-22 secretion in in vitro-differentiated naive CD4(+) T cells from RR MS patients. Simvastatin 15-26 interleukin 17A Homo sapiens 131-137 21856936-4 2011 We report that simvastatin, one of the most hydrophobic statins with good CNS penetration, inhibited Th17 cell differentiation and IL-17A, IL-17F, IL-21, and IL-22 secretion in in vitro-differentiated naive CD4(+) T cells from RR MS patients. Simvastatin 15-26 interleukin 17F Homo sapiens 139-145 21856936-4 2011 We report that simvastatin, one of the most hydrophobic statins with good CNS penetration, inhibited Th17 cell differentiation and IL-17A, IL-17F, IL-21, and IL-22 secretion in in vitro-differentiated naive CD4(+) T cells from RR MS patients. Simvastatin 15-26 interleukin 21 Homo sapiens 147-152 21856936-4 2011 We report that simvastatin, one of the most hydrophobic statins with good CNS penetration, inhibited Th17 cell differentiation and IL-17A, IL-17F, IL-21, and IL-22 secretion in in vitro-differentiated naive CD4(+) T cells from RR MS patients. Simvastatin 15-26 interleukin 22 Homo sapiens 158-163 21856936-5 2011 Simvastatin exerted a less prominent effect on the cells from healthy controls, as it inhibited only IL-17F secretion. Simvastatin 0-11 interleukin 17F Homo sapiens 101-107 21856936-8 2011 Selective inhibition of geranylgeranylated RhoA-associated kinase replicated the effect of simvastatin on the inhibition of IRF4 expression and IL-17A, IL-17F, IL-21, and IL-22 secretion, presenting a promising new therapeutic approach for this disabling disease. Simvastatin 91-102 interferon regulatory factor 4 Homo sapiens 124-128 21856936-8 2011 Selective inhibition of geranylgeranylated RhoA-associated kinase replicated the effect of simvastatin on the inhibition of IRF4 expression and IL-17A, IL-17F, IL-21, and IL-22 secretion, presenting a promising new therapeutic approach for this disabling disease. Simvastatin 91-102 interleukin 17A Homo sapiens 144-150 21856936-8 2011 Selective inhibition of geranylgeranylated RhoA-associated kinase replicated the effect of simvastatin on the inhibition of IRF4 expression and IL-17A, IL-17F, IL-21, and IL-22 secretion, presenting a promising new therapeutic approach for this disabling disease. Simvastatin 91-102 interleukin 17F Homo sapiens 152-158 21856936-8 2011 Selective inhibition of geranylgeranylated RhoA-associated kinase replicated the effect of simvastatin on the inhibition of IRF4 expression and IL-17A, IL-17F, IL-21, and IL-22 secretion, presenting a promising new therapeutic approach for this disabling disease. Simvastatin 91-102 interleukin 21 Homo sapiens 160-165 21693384-6 2011 Immunohistochemistry studies suggested that vein graft neointima was mainly composed of vascular smooth muscle cells (VSMCs), and the rate of proliferating cell nuclear antigen (PCNA)-positive cells in the intima of vein grafts was significantly lower in simvastatin-treated groups than in control group. Simvastatin 255-266 proliferating cell nuclear antigen Mus musculus 142-176 21844074-4 2011 During allograft preservation, donor simvastatin treatment inhibited microvascular endothelial cell and pericyte RhoA/Rho-associated protein kinase activation and endothelial cell-endothelial cell gap formation; decreased intragraft mRNA levels of hypoxia-inducible factor-1alpha, inducible nitric oxide synthase, and endothelin-1; and increased heme oxygenase-1. Simvastatin 37-48 ras homolog family member A Homo sapiens 113-117 21844074-4 2011 During allograft preservation, donor simvastatin treatment inhibited microvascular endothelial cell and pericyte RhoA/Rho-associated protein kinase activation and endothelial cell-endothelial cell gap formation; decreased intragraft mRNA levels of hypoxia-inducible factor-1alpha, inducible nitric oxide synthase, and endothelin-1; and increased heme oxygenase-1. Simvastatin 37-48 hypoxia inducible factor 1 subunit alpha Homo sapiens 248-279 21844074-4 2011 During allograft preservation, donor simvastatin treatment inhibited microvascular endothelial cell and pericyte RhoA/Rho-associated protein kinase activation and endothelial cell-endothelial cell gap formation; decreased intragraft mRNA levels of hypoxia-inducible factor-1alpha, inducible nitric oxide synthase, and endothelin-1; and increased heme oxygenase-1. Simvastatin 37-48 endothelin 1 Homo sapiens 318-330 21844074-6 2011 The beneficial effects of simvastatin on vascular stability and the no-reflow phenomenon were abolished by concomitant nitric oxide synthase inhibition with N-nitro-l-arginine methyl ester and RhoA activation by geranylgeranyl pyrophosphate supplementation, respectively. Simvastatin 26-37 ras homolog family member A Homo sapiens 193-197 21693384-6 2011 Immunohistochemistry studies suggested that vein graft neointima was mainly composed of vascular smooth muscle cells (VSMCs), and the rate of proliferating cell nuclear antigen (PCNA)-positive cells in the intima of vein grafts was significantly lower in simvastatin-treated groups than in control group. Simvastatin 255-266 proliferating cell nuclear antigen Mus musculus 178-182 21620604-4 2011 Applications of simvastatin and tongxinluo to endothelial dysfunction rats improved endothelial function according to the results of histopathology and measurements of endothelin-1 and nitric oxide. Simvastatin 16-27 endothelin 1 Rattus norvegicus 168-180 22022327-8 2011 On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Simvastatin 97-108 endothelin 1 Rattus norvegicus 30-34 22022327-8 2011 On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Simvastatin 97-108 nitric oxide synthase 2 Rattus norvegicus 41-45 22022327-8 2011 On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Simvastatin 97-108 nitric oxide synthase 3 Rattus norvegicus 47-51 22022327-8 2011 On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Simvastatin 97-108 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 61-65 21863259-0 2011 Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3. Simvastatin 121-132 matrix metallopeptidase 3 Rattus norvegicus 151-177 21863259-1 2011 BACKGROUND: We investigated the anti-inflammatory and immunomodulatory effect of simvastatin on articular cartilage via the inhibition of matrix metalloproteinase-3 (MMP-3), a matrix-degrading enzyme, in a mechanically induced experimental osteoarthritis (OA) animal model. Simvastatin 81-92 matrix metallopeptidase 3 Rattus norvegicus 138-164 21863259-1 2011 BACKGROUND: We investigated the anti-inflammatory and immunomodulatory effect of simvastatin on articular cartilage via the inhibition of matrix metalloproteinase-3 (MMP-3), a matrix-degrading enzyme, in a mechanically induced experimental osteoarthritis (OA) animal model. Simvastatin 81-92 matrix metallopeptidase 3 Rattus norvegicus 166-171 21863259-8 2011 RESULTS: Simvastatin treatment significantly down-regulated the percentage of MMP-3 expression in chondrocytes as assessed by immunohistochemistry methods. Simvastatin 9-20 matrix metallopeptidase 3 Rattus norvegicus 78-83 21775746-0 2011 Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Simvastatin 14-25 KRAS proto-oncogene, GTPase Homo sapiens 82-86 21864337-0 2011 Simvastatin inhibits TGFbeta1-induced fibronectin in human airway fibroblasts. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 21-29 21864337-0 2011 Simvastatin inhibits TGFbeta1-induced fibronectin in human airway fibroblasts. Simvastatin 0-11 fibronectin 1 Homo sapiens 38-49 21864337-5 2011 METHODS: We used simvastatin (1-15 muM) to inhibit 3-hydroxy-3-methlyglutaryl-coenzyme A (HMG-CoA) reductase which converts HMG-CoA to mevalonate. Simvastatin 17-28 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 51-108 21864337-8 2011 RESULTS: Immunoblotting revealed concentration-dependent simvastatin inhibition of TGFbeta1 (2.5 ng/ml, 48 h)-induced fibronectin. Simvastatin 57-68 transforming growth factor beta 1 Homo sapiens 83-91 21864337-8 2011 RESULTS: Immunoblotting revealed concentration-dependent simvastatin inhibition of TGFbeta1 (2.5 ng/ml, 48 h)-induced fibronectin. Simvastatin 57-68 fibronectin 1 Homo sapiens 118-129 21864337-10 2011 The effects of simvastatin were mimicked by GGTI-286, but not FTI-277, suggesting fundamental involvement of GGT1 in TGFbeta1-induced signaling. Simvastatin 15-26 protein geranylgeranyltransferase type I subunit beta Homo sapiens 44-48 21864337-10 2011 The effects of simvastatin were mimicked by GGTI-286, but not FTI-277, suggesting fundamental involvement of GGT1 in TGFbeta1-induced signaling. Simvastatin 15-26 gamma-glutamyltransferase 1 Homo sapiens 109-113 21864337-10 2011 The effects of simvastatin were mimicked by GGTI-286, but not FTI-277, suggesting fundamental involvement of GGT1 in TGFbeta1-induced signaling. Simvastatin 15-26 transforming growth factor beta 1 Homo sapiens 117-125 21864337-11 2011 Asthmatic fibroblasts exhibited greater TGFbeta1-induced fibronectin expression compared to non-asthmatic cells; this enhanced response was effectively reduced by simvastatin. Simvastatin 163-174 transforming growth factor beta 1 Homo sapiens 40-48 21864337-11 2011 Asthmatic fibroblasts exhibited greater TGFbeta1-induced fibronectin expression compared to non-asthmatic cells; this enhanced response was effectively reduced by simvastatin. Simvastatin 163-174 fibronectin 1 Homo sapiens 57-68 21617139-8 2011 Strikingly, simvastatin upregulated CNP expression in VICs cultured under myofibrogenic conditions, and small interfering RNA knockdown of natriuretic peptide receptor-b (a CNP receptor) significantly reduced the antifibrotic effect of simvastatin, suggesting that it acts in part via CNP/NPR-B autocrine/paracrine signaling. Simvastatin 12-23 natriuretic peptide C Homo sapiens 36-39 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 144-149 21762915-3 2011 Phagocytosis was found to be enhanced by pravastatin, rosuvastatin and simvastatin and cyclodextrin in J774 macrophages, as cellular cholesterol was reduced and expressions of the cholesterol-related genes were modulated, including an increase of ABCA7 mRNA and decrease of ABCA1 mRNA. Simvastatin 71-82 ATP-binding cassette, sub-family A (ABC1), member 7 Mus musculus 247-252 21762915-3 2011 Phagocytosis was found to be enhanced by pravastatin, rosuvastatin and simvastatin and cyclodextrin in J774 macrophages, as cellular cholesterol was reduced and expressions of the cholesterol-related genes were modulated, including an increase of ABCA7 mRNA and decrease of ABCA1 mRNA. Simvastatin 71-82 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 274-279 21511701-0 2011 Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Simvastatin 0-11 aquaporin 2 Rattus norvegicus 21-32 21511701-0 2011 Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Simvastatin 0-11 arginine vasopressin Rattus norvegicus 81-92 21511701-3 2011 Here, we report an effect of simvastatin on the trafficking of aquaporin-2 (AQP2). Simvastatin 29-40 aquaporin 2 Rattus norvegicus 63-74 21511701-3 2011 Here, we report an effect of simvastatin on the trafficking of aquaporin-2 (AQP2). Simvastatin 29-40 aquaporin 2 Rattus norvegicus 76-80 21511701-4 2011 Specifically, simvastatin induced the membrane accumulation of AQP2 in cell cultures and kidneys in situ. Simvastatin 14-25 aquaporin 2 Rattus norvegicus 63-67 21511701-5 2011 The effect of simvastatin was independent of protein kinase A activation and phosphorylation at AQP2-Ser(256), a critical event involved in vasopressin (VP)-regulated AQP2 trafficking. Simvastatin 14-25 arginine vasopressin Rattus norvegicus 140-151 21511701-5 2011 The effect of simvastatin was independent of protein kinase A activation and phosphorylation at AQP2-Ser(256), a critical event involved in vasopressin (VP)-regulated AQP2 trafficking. Simvastatin 14-25 arginine vasopressin Rattus norvegicus 153-155 21511701-5 2011 The effect of simvastatin was independent of protein kinase A activation and phosphorylation at AQP2-Ser(256), a critical event involved in vasopressin (VP)-regulated AQP2 trafficking. Simvastatin 14-25 aquaporin 2 Rattus norvegicus 167-171 21511701-6 2011 Further investigation showed that simvastatin inhibited endocytosis in parallel with downregulation of RhoA activity. Simvastatin 34-45 ras homolog family member A Rattus norvegicus 103-107 21511701-7 2011 Overexpression of active RhoA attenuated simvastatin"s effect, suggesting the involvement of this small GTPase in simvastatin-mediated AQP2 trafficking. Simvastatin 41-52 ras homolog family member A Rattus norvegicus 25-29 21511701-7 2011 Overexpression of active RhoA attenuated simvastatin"s effect, suggesting the involvement of this small GTPase in simvastatin-mediated AQP2 trafficking. Simvastatin 41-52 aquaporin 2 Rattus norvegicus 135-139 21511701-7 2011 Overexpression of active RhoA attenuated simvastatin"s effect, suggesting the involvement of this small GTPase in simvastatin-mediated AQP2 trafficking. Simvastatin 114-125 ras homolog family member A Rattus norvegicus 25-29 21511701-7 2011 Overexpression of active RhoA attenuated simvastatin"s effect, suggesting the involvement of this small GTPase in simvastatin-mediated AQP2 trafficking. Simvastatin 114-125 aquaporin 2 Rattus norvegicus 135-139 21511701-10 2011 In summary, simvastatin regulates AQP2 trafficking in vitro and urinary concentration in vivo via events involving downregulation of Rho GTPase activity and inhibition of endocytosis. Simvastatin 12-23 aquaporin 2 Rattus norvegicus 34-38 21699369-15 2011 CONCLUSIONS: A single tablet combination of 10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia provided high LDL-C goal attainment rates and resulted in significant reductions in LDL-C. Simvastatin 70-81 component of oligomeric golgi complex 2 Homo sapiens 214-219 20607595-2 2011 Our aim was to investigate the effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases (MMPs). Simvastatin 42-53 matrix metallopeptidase 3 Homo sapiens 114-118 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 44-62 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 64-67 20607595-5 2011 The ex vivo release of IL-1beta and IL-6 was not altered by simvastatin, whereas the release of TNF-alpha and IL-8 increased after 6 weeks of simvastatin treatment. Simvastatin 142-153 tumor necrosis factor Homo sapiens 96-105 20607595-5 2011 The ex vivo release of IL-1beta and IL-6 was not altered by simvastatin, whereas the release of TNF-alpha and IL-8 increased after 6 weeks of simvastatin treatment. Simvastatin 142-153 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 21477071-4 2011 Activation of c-jun NH2-terminal kinase 1 (JNK1) after simvastatin (10 nM) treatment of DCX(+) neurabin II(+) BTSC from YU-PG, HF66, and U87 cells induced terminal differentiation into neuron-like cells. Simvastatin 55-66 mitogen-activated protein kinase 8 Homo sapiens 14-41 22093791-0 2011 [Effects of simvastatin plus all-trans retinoic acid on WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4]. Simvastatin 12-23 WT1 transcription factor Homo sapiens 56-59 22093791-0 2011 [Effects of simvastatin plus all-trans retinoic acid on WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4]. Simvastatin 12-23 dentin matrix acidic phosphoprotein 1 Homo sapiens 60-65 22093791-1 2011 OBJECTIVE: To investigate the effects of simvastatin (SV) plus all-trans retinoic acid (ATRA) on the proliferation, differentiation, apoptosis and WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4. Simvastatin 41-52 WT1 transcription factor Homo sapiens 147-150 22093791-1 2011 OBJECTIVE: To investigate the effects of simvastatin (SV) plus all-trans retinoic acid (ATRA) on the proliferation, differentiation, apoptosis and WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4. Simvastatin 41-52 dentin matrix acidic phosphoprotein 1 Homo sapiens 151-156 22093791-1 2011 OBJECTIVE: To investigate the effects of simvastatin (SV) plus all-trans retinoic acid (ATRA) on the proliferation, differentiation, apoptosis and WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4. Simvastatin 54-56 WT1 transcription factor Homo sapiens 147-150 22093791-1 2011 OBJECTIVE: To investigate the effects of simvastatin (SV) plus all-trans retinoic acid (ATRA) on the proliferation, differentiation, apoptosis and WT1/hDMP1 gene expression profiles of human promyelocytic leukemia cell line NB4. Simvastatin 54-56 dentin matrix acidic phosphoprotein 1 Homo sapiens 151-156 21729290-0 2011 Effects of simvastatin on apolipoprotein M in vivo and in vitro. Simvastatin 11-22 apolipoprotein M Mus musculus 26-42 21729290-1 2011 OBJECTIVE: To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the hyperlipidemic mice and in hepatic cell line, HepG2 cells. Simvastatin 58-69 apolipoprotein M Mus musculus 74-90 21729290-5 2011 Effects of simvastatin on apoM mRNA expression in the HepG2 cells were determined by real-time RT-PCR. Simvastatin 11-22 apolipoprotein M Homo sapiens 26-30 21729290-8 2011 It demonstrated also that treatment of simvastatin did not influence serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10 mg/kg simvastatin group than in the vehicle control group without simvastatin. Simvastatin 180-191 apolipoprotein M Mus musculus 124-128 21729290-8 2011 It demonstrated also that treatment of simvastatin did not influence serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10 mg/kg simvastatin group than in the vehicle control group without simvastatin. Simvastatin 180-191 apolipoprotein M Mus musculus 124-128 21729290-9 2011 In HepG2 cell cultures, simvastatin could significantly decrease apoM mRNA levels with dose- and time-dependent manners. Simvastatin 24-35 apolipoprotein M Homo sapiens 65-69 21729290-10 2011 At 10 muM simvastatin treatment, apoM mRNA decreased by 52% compared to the controls. Simvastatin 10-21 apolipoprotein M Mus musculus 33-37 21729290-12 2011 ApoM serum levels in mice were significantly correlated to the animal"s age, whereas in cell cultures simvastatin does inhibit apoM expression in the HepG2 cells. Simvastatin 102-113 apolipoprotein M Mus musculus 127-131 21527854-9 2011 In addition, hsCRP and vascular cell adhesion protein-1 were both significantly lower after simvastatin therapy compared to controls (P <= 0.005 for both). Simvastatin 92-103 vascular cell adhesion molecule 1 Homo sapiens 23-55 21527854-14 2011 Although the observed improvements in reproductive function were mild, the reductions in hsCRP and vascular cell adhesion protein-1 after simvastatin treatment were significant, suggesting the need for further clinical trials to clarify simvastatin"s impact on reproductive physiology. Simvastatin 138-149 vascular cell adhesion molecule 1 Homo sapiens 99-131 21395587-12 2011 RESULTS: Simvastatin diminished cell adhesion and spreading over a fibronectin matrix. Simvastatin 9-20 fibronectin 1 Homo sapiens 67-78 21395587-14 2011 Simvastatin-treated cells displayed an altered lamellipodia with poorly developed focal adhesion contacts and reduced levels of beta1 integrin activation. Simvastatin 0-11 integrin subunit beta 1 Homo sapiens 128-142 21395587-15 2011 During cell spreading, simvastatin diminished Rac activation. Simvastatin 23-34 AKT serine/threonine kinase 1 Homo sapiens 46-49 21396178-8 2011 Simvastatin decreased myeloperoxidase only in the oleic acid group (P = .01). Simvastatin 0-11 myeloperoxidase Mus musculus 22-37 21477071-4 2011 Activation of c-jun NH2-terminal kinase 1 (JNK1) after simvastatin (10 nM) treatment of DCX(+) neurabin II(+) BTSC from YU-PG, HF66, and U87 cells induced terminal differentiation into neuron-like cells. Simvastatin 55-66 mitogen-activated protein kinase 8 Homo sapiens 43-47 21477071-4 2011 Activation of c-jun NH2-terminal kinase 1 (JNK1) after simvastatin (10 nM) treatment of DCX(+) neurabin II(+) BTSC from YU-PG, HF66, and U87 cells induced terminal differentiation into neuron-like cells. Simvastatin 55-66 doublecortin Homo sapiens 88-91 21477071-4 2011 Activation of c-jun NH2-terminal kinase 1 (JNK1) after simvastatin (10 nM) treatment of DCX(+) neurabin II(+) BTSC from YU-PG, HF66, and U87 cells induced terminal differentiation into neuron-like cells. Simvastatin 55-66 protein phosphatase 1 regulatory subunit 9B Homo sapiens 95-106 21477071-6 2011 Western blot analysis showed that procaspase-3 was induced after DCX transfection and activated after simvastatin treatment in YU-PG, HF66, and U87 BTSC. Simvastatin 102-113 caspase 3 Homo sapiens 34-46 21063740-0 2011 Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERalpha expression and uterine wet weight in ovariectomized rats. Simvastatin 0-11 estrogen receptor 1 Rattus norvegicus 98-105 21844990-13 2011 No significant clinical interaction or effect was observed, even with the use of atorvastatin or simvastatin, which are metabolized by CYP3A4 such as tacrolimus. Simvastatin 97-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-141 21063740-1 2011 We previously reported that simvastatin induces estrogen receptor-alpha (ERalpha) in murine bone marrow stromal cells in vitro. Simvastatin 28-39 estrogen receptor 1 (alpha) Mus musculus 73-80 21063740-2 2011 In this study, we investigated the effect of simvastatin on ERalpha expression in bone and uterus in ovariectomized (OVX) rats and evaluated bone mass, bone strength, and uterine wet weight. Simvastatin 45-56 estrogen receptor 1 Rattus norvegicus 60-67 21063740-7 2011 More interestingly, simvastatin could increase ERalpha expression and synergy with estradiol in bone while antagonizing estradiol in the uterus, along with uterus atrophy and uterine wet weight decreases. Simvastatin 20-31 estrogen receptor 1 Rattus norvegicus 47-54 21063740-8 2011 In conclusion, these data suggest that simvastatin exert opposing modulatory effects on ERalpha expression on bone and uterus in ovariectomized rats, inducing ERalpha expression and synergy with estrogen to perform anabolic effects on the bones while decreasing E2 efficacy and uterine wet weight. Simvastatin 39-50 estrogen receptor 1 Rattus norvegicus 88-95 21063740-8 2011 In conclusion, these data suggest that simvastatin exert opposing modulatory effects on ERalpha expression on bone and uterus in ovariectomized rats, inducing ERalpha expression and synergy with estrogen to perform anabolic effects on the bones while decreasing E2 efficacy and uterine wet weight. Simvastatin 39-50 estrogen receptor 1 Rattus norvegicus 159-166 20018301-13 2011 HO-1 up-regulation by simvastatin treatment or down-regulation by additional injection of ZnPP did not demonstrate significant correlation with the inflammatory status of the capsule. Simvastatin 22-33 heme oxygenase 1 Rattus norvegicus 0-4 21635264-6 2011 Simvastatin and atorvastatin also remarkably diminished myeloperoxidase activity, even at low concentrations (0.03 mg/ear). Simvastatin 0-11 myeloperoxidase Mus musculus 56-71 20018301-15 2011 Although simvastatin induced HO-1 expression throughout the experimental time, up-regulated HO-1 expression could not be attributed to the inflammatory status of the capsule. Simvastatin 9-20 heme oxygenase 1 Rattus norvegicus 29-33 20018301-0 2011 Simvastatin induces heme oxygenase-1 expression but fails to reduce inflammation in the capsule surrounding a silicone shell implant in rats. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 20-36 20018301-11 2011 Although daily feeding of the rats with simvastatin at 2 mg/kg induced HO-1 expression in the capsule throughout the experimental period, simvastatin treatment failed to reduce the production of TNF-alpha, IL-1beta, and COX-2, or limit NF-kappaB activation in the early or late stages after implantation. Simvastatin 40-51 heme oxygenase 1 Rattus norvegicus 71-75 21441352-10 2011 In addition, M1 protein-induced Mac-1 expression on neutrophils was abolished by simvastatin. Simvastatin 81-92 integrin subunit alpha M Homo sapiens 32-37 21477202-10 2011 Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD. Simvastatin 58-69 C-reactive protein Homo sapiens 88-91 21323892-0 2011 PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Simvastatin 51-62 peroxisome proliferator activated receptor alpha Mus musculus 0-9 21417623-7 2011 CONCLUSION: We identified lipidomic biomarkers of simvastatin treatment effect that are consistent with statin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase (ClinicalTrials.gov: NCT00935259). Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 125-183 21323892-12 2011 KEY RESULTS: Simvastatin significantly and dose-dependently increased the zymosan-induced expression of PPARalpha levels in all tissues analysed. Simvastatin 13-24 peroxisome proliferator activated receptor alpha Mus musculus 104-113 21477202-10 2011 Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD. Simvastatin 58-69 interleukin 6 Homo sapiens 96-100 21323892-5 2011 We used a zymosan-induced non-septic shock experimental model to investigate the role of PPARalpha in the anti-inflammatory effects of simvastatin. Simvastatin 135-146 peroxisome proliferator activated receptor alpha Mus musculus 89-98 21477202-10 2011 Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD. Simvastatin 142-153 interleukin 6 Homo sapiens 96-100 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Simvastatin 47-58 apolipoprotein B Homo sapiens 110-126 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Simvastatin 47-58 component of oligomeric golgi complex 2 Homo sapiens 128-143 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 component of oligomeric golgi complex 2 Homo sapiens 71-76 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 apolipoprotein B Homo sapiens 108-113 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Simvastatin 38-49 component of oligomeric golgi complex 2 Homo sapiens 157-162 20354828-0 2011 Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Simvastatin 15-26 CD34 molecule Homo sapiens 55-59 20354828-6 2011 In contrast, combination of simvastatin and imatinib induced a significant cell death in the subpopulation, which is dependent on the induced ROS by simvastatin as the effect was blocked by ROS scavenger N-acetyl-L: -cysteine (NAC). Simvastatin 28-39 X-linked Kx blood group Homo sapiens 227-230 20354828-6 2011 In contrast, combination of simvastatin and imatinib induced a significant cell death in the subpopulation, which is dependent on the induced ROS by simvastatin as the effect was blocked by ROS scavenger N-acetyl-L: -cysteine (NAC). Simvastatin 149-160 X-linked Kx blood group Homo sapiens 227-230 21764683-1 2011 OBJECTIVE: To investigate the effects of simvastatin on the expression of nuclear factor-kappaB (NF-kappaB) and intercellular adhesion molecule-1 (ICAM-1) in the lung tissue of rats with lung injury induced by ischemia-reperfusion (IR) of the hind limbs. Simvastatin 41-52 intercellular adhesion molecule 1 Rattus norvegicus 112-145 21482669-10 2011 Our data demonstrate that mTORC2-dependent activation of RhoA is required for TSC2-null cell growth and survival and suggest that targeting both mTORC2 and mTORC1 by a combination of proapoptotic simvastatin and cytostatic rapamycin shows promise for combinational therapeutic intervention in diseases with TSC2 dysfunction. Simvastatin 196-207 CREB regulated transcription coactivator 2 Mus musculus 26-32 21482669-10 2011 Our data demonstrate that mTORC2-dependent activation of RhoA is required for TSC2-null cell growth and survival and suggest that targeting both mTORC2 and mTORC1 by a combination of proapoptotic simvastatin and cytostatic rapamycin shows promise for combinational therapeutic intervention in diseases with TSC2 dysfunction. Simvastatin 196-207 CREB regulated transcription coactivator 2 Mus musculus 145-151 21482669-10 2011 Our data demonstrate that mTORC2-dependent activation of RhoA is required for TSC2-null cell growth and survival and suggest that targeting both mTORC2 and mTORC1 by a combination of proapoptotic simvastatin and cytostatic rapamycin shows promise for combinational therapeutic intervention in diseases with TSC2 dysfunction. Simvastatin 196-207 CREB regulated transcription coactivator 1 Mus musculus 156-162 21764683-1 2011 OBJECTIVE: To investigate the effects of simvastatin on the expression of nuclear factor-kappaB (NF-kappaB) and intercellular adhesion molecule-1 (ICAM-1) in the lung tissue of rats with lung injury induced by ischemia-reperfusion (IR) of the hind limbs. Simvastatin 41-52 intercellular adhesion molecule 1 Rattus norvegicus 147-153 21764683-9 2011 Lung W/D, MPO activity and PMN counting were significantly lowered in the 3 simvastatin groups as compared with IR group (P<0.01). Simvastatin 76-87 myeloperoxidase Rattus norvegicus 10-13 21764683-10 2011 IR-induced decrease in PaO(2) was significantly increased in the 3 simvastatin groups (P<0.01), which also showed significantly lowered expressions of NF-kappaB p65mRNA and ICAM-1 protein in a dose-dependent manner (P<0.01). Simvastatin 67-78 synaptotagmin 1 Rattus norvegicus 164-167 21764683-10 2011 IR-induced decrease in PaO(2) was significantly increased in the 3 simvastatin groups (P<0.01), which also showed significantly lowered expressions of NF-kappaB p65mRNA and ICAM-1 protein in a dose-dependent manner (P<0.01). Simvastatin 67-78 intercellular adhesion molecule 1 Rattus norvegicus 176-182 21764683-11 2011 CONCLUSION: Simvastatin attenuates lung injury induced by IR of the hind limbs in rats by suppressing the activation of NF-kappaB and subsequent accumulation of neutrophils mediated by ICAM-1. Simvastatin 12-23 intercellular adhesion molecule 1 Rattus norvegicus 185-191 21448567-11 2011 Our results suggest that more lipophilic statins (simvastatin and atorvastatin), but not the hydrophilic statin pravastatin, downregulate net MMP-9 activity. Simvastatin 50-61 matrix metallopeptidase 9 Homo sapiens 142-147 21448567-9 2011 Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 61-66 21448567-9 2011 Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Simvastatin 0-11 TIMP metallopeptidase inhibitor 1 Homo sapiens 67-73 21448567-9 2011 Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Simvastatin 0-11 matrix metallopeptidase 2 Homo sapiens 183-188 21289285-8 2011 Inhibitors of RhoA activation (simvastatin, 0.1 muM) or Rho kinase (ROCK) (Y-27632, 10 muM; H1152, 0.5 muM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Simvastatin 31-42 ras homolog family member A Mus musculus 14-18 21448567-9 2011 Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Simvastatin 0-11 TIMP metallopeptidase inhibitor 2 Homo sapiens 189-195 20452610-13 2011 Simvastatin treatment caused a decrease in epithelial iNOS levels, while MPO levels were not modulated. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 54-58 21289285-8 2011 Inhibitors of RhoA activation (simvastatin, 0.1 muM) or Rho kinase (ROCK) (Y-27632, 10 muM; H1152, 0.5 muM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Simvastatin 31-42 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 119-125 21285396-5 2011 Consistently, simvastatin reduces RIP140 levels, which can be reversed by mevalonate. Simvastatin 14-25 nuclear receptor interacting protein 1 Homo sapiens 34-40 21367616-1 2011 PURPOSE: To assess the in vitro effects of simvastatin on IL-10 and TNF-alpha secretion from peripheral blood mononuclear cells (PBMC) of critically ill patients with and without acute kidney injury (AKI). Simvastatin 43-54 interleukin 10 Homo sapiens 58-63 21367616-1 2011 PURPOSE: To assess the in vitro effects of simvastatin on IL-10 and TNF-alpha secretion from peripheral blood mononuclear cells (PBMC) of critically ill patients with and without acute kidney injury (AKI). Simvastatin 43-54 tumor necrosis factor Homo sapiens 68-77 21367616-8 2011 The simultaneous incubation with LPS and simvastatin caused decreased IL-10 production in cells from patients compared to control (337 (135-626) vs 540 (345-871) pg/mL, p<0.05) and increased TNF-alpha release (711 (619-832) vs 324 (155-355) pg/mL, p<0.05). Simvastatin 41-52 interleukin 10 Homo sapiens 70-75 21367616-8 2011 The simultaneous incubation with LPS and simvastatin caused decreased IL-10 production in cells from patients compared to control (337 (135-626) vs 540 (345-871) pg/mL, p<0.05) and increased TNF-alpha release (711 (619-832) vs 324 (155-355) pg/mL, p<0.05). Simvastatin 41-52 tumor necrosis factor Homo sapiens 194-203 21324313-5 2011 Using a cell line-based model for CHOP resistant DLBCL, we show that treatment with simvastatin, which inhibits protein farnesylation and geranylgeranylation, sensitizes DLBCL cells to cytotoxic treatment. Simvastatin 84-95 DNA damage inducible transcript 3 Homo sapiens 34-38 21285396-9 2011 This study uncovers a cholesterol-miR-33-RIP140 regulatory pathway that modulates the proinflammatory potential in macrophages in response to an alteration in the intracellular cholesterol status, and identifies RIP140 as a direct target of miR-33 that mediates simvastatin-triggered anti-inflammation. Simvastatin 262-273 microRNA 33a Homo sapiens 34-40 21285396-9 2011 This study uncovers a cholesterol-miR-33-RIP140 regulatory pathway that modulates the proinflammatory potential in macrophages in response to an alteration in the intracellular cholesterol status, and identifies RIP140 as a direct target of miR-33 that mediates simvastatin-triggered anti-inflammation. Simvastatin 262-273 nuclear receptor interacting protein 1 Homo sapiens 41-47 21285396-9 2011 This study uncovers a cholesterol-miR-33-RIP140 regulatory pathway that modulates the proinflammatory potential in macrophages in response to an alteration in the intracellular cholesterol status, and identifies RIP140 as a direct target of miR-33 that mediates simvastatin-triggered anti-inflammation. Simvastatin 262-273 nuclear receptor interacting protein 1 Homo sapiens 212-218 20803306-6 2011 After 96 h the 50% inhibition concentration (IC(50)) of SMV in MTT assays for two more sensitive meningioma cell lines (one benign and one malignant) was below 0.9 muM, while the IC(50) was 2.8 muM or higher for two other meningioma lines. Simvastatin 56-59 latexin Homo sapiens 164-167 21330348-0 2011 Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. Simvastatin 0-11 CD40 ligand Mus musculus 24-29 21330348-8 2011 Moreover, Mac-1 expression increased on septic neutrophils, which was significantly attenuated by simvastatin. Simvastatin 98-109 integrin alpha M Mus musculus 10-15 21330348-10 2011 Simvastatin prevented CD40L shedding from the surface of platelets and reduced circulating levels of CD40L in septic mice. Simvastatin 0-11 CD40 ligand Mus musculus 22-27 21330348-10 2011 Simvastatin prevented CD40L shedding from the surface of platelets and reduced circulating levels of CD40L in septic mice. Simvastatin 0-11 CD40 ligand Mus musculus 101-106 21330348-13 2011 Our data suggest that the inhibitory effect of simvastatin on pulmonary accumulation of neutrophils may be related to a reduction of CD40L secretion into the circulation, as well as a decrease in CXC chemokine formation in the lung. Simvastatin 47-58 CD40 ligand Mus musculus 133-138 21334995-0 2011 Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Simvastatin 0-11 Rac family small GTPase 1 Homo sapiens 72-76 21334995-9 2011 Treatment with simvastatin triggered the loss of lipid raft localised Rac1 and reduction of Rac1 activity in Mz-ChA-1 cells. Simvastatin 15-26 Rac family small GTPase 1 Homo sapiens 70-74 21334995-9 2011 Treatment with simvastatin triggered the loss of lipid raft localised Rac1 and reduction of Rac1 activity in Mz-ChA-1 cells. Simvastatin 15-26 Rac family small GTPase 1 Homo sapiens 92-96 21334995-11 2011 CONCLUSION: Collectively, our results demonstrate that simvastatin induces cholangiocarcinoma cancer cell death by disrupting Rac1/lipid raft colocalisation and depression of Rac1 activity. Simvastatin 55-66 Rac family small GTPase 1 Homo sapiens 126-130 21334995-11 2011 CONCLUSION: Collectively, our results demonstrate that simvastatin induces cholangiocarcinoma cancer cell death by disrupting Rac1/lipid raft colocalisation and depression of Rac1 activity. Simvastatin 55-66 Rac family small GTPase 1 Homo sapiens 175-179 21390048-5 2011 We found that, surprisingly, simvastatin and other statins inhibit K6a promoter activity and K6a protein expression. Simvastatin 29-40 keratin 6A Homo sapiens 67-70 21390048-5 2011 We found that, surprisingly, simvastatin and other statins inhibit K6a promoter activity and K6a protein expression. Simvastatin 29-40 keratin 6A Homo sapiens 93-96 20803306-6 2011 After 96 h the 50% inhibition concentration (IC(50)) of SMV in MTT assays for two more sensitive meningioma cell lines (one benign and one malignant) was below 0.9 muM, while the IC(50) was 2.8 muM or higher for two other meningioma lines. Simvastatin 56-59 latexin Homo sapiens 194-197 20803306-10 2011 Addition of 40 muM PGZ significantly decreased the fraction of clonogenic cells in soft-agar assays, as compared with 2.8 muM SMV alone. Simvastatin 126-129 latexin Homo sapiens 15-18 21307798-0 2011 Induction of angiogenesis and modulation of vascular endothelial growth factor receptor-2 by simvastatin after traumatic brain injury. Simvastatin 93-104 kinase insert domain receptor Rattus norvegicus 44-89 21307798-7 2011 Western blot analysis was carried out to examine the simvastatin-induced activation of the v-akt murine thymoma viral oncogene homolog (Akt) signaling pathway. Simvastatin 53-64 AKT serine/threonine kinase 1 Rattus norvegicus 93-96 21236270-7 2011 Brains treated with simvastatin lactone showed i) reduced amplitude and delayed onset of ischemic depressions, ii) preservation of MAP-2 immunoreactivity, iii) activation of ERK signaling in the ischemic hemisphere and iv) increase in whole-brain anti-oxidant capacity. Simvastatin 20-39 microtubule-associated protein 2 Cavia porcellus 131-136 21307798-7 2011 Western blot analysis was carried out to examine the simvastatin-induced activation of the v-akt murine thymoma viral oncogene homolog (Akt) signaling pathway. Simvastatin 53-64 thymoma viral proto-oncogene 1 Mus musculus 136-139 21307798-11 2011 VEGFR-2 expression in both brain tissues and cultured rat brain microvascular endothelial cells was enhanced after simvastatin treatment, which may be modulated by activation of Akt. Simvastatin 115-126 kinase insert domain receptor Rattus norvegicus 0-7 21307798-11 2011 VEGFR-2 expression in both brain tissues and cultured rat brain microvascular endothelial cells was enhanced after simvastatin treatment, which may be modulated by activation of Akt. Simvastatin 115-126 AKT serine/threonine kinase 1 Rattus norvegicus 178-181 21307798-12 2011 Akt-dependent endothelial nitric oxide synthase phosphorylation was also induced by simvastatin in vivo and in vitro. Simvastatin 84-95 AKT serine/threonine kinase 1 Rattus norvegicus 0-3 21307798-15 2011 These beneficial effects on angiogenesis may be related to simvastatin-induced activation of the VEGFR-2/Akt/endothelial nitric oxide synthase signaling pathway. Simvastatin 59-70 kinase insert domain receptor Rattus norvegicus 97-104 21307798-15 2011 These beneficial effects on angiogenesis may be related to simvastatin-induced activation of the VEGFR-2/Akt/endothelial nitric oxide synthase signaling pathway. Simvastatin 59-70 AKT serine/threonine kinase 1 Rattus norvegicus 105-108 21414721-11 2011 Additionally, quantitative analysis with Iba-1 and glial fibrillary acid protein immunoreactivity demonstrated that rosuvastatin and simvastatin significantly reduced the spinal microglial and astrocyte activation produced by sciatic nerve injury. Simvastatin 133-144 allograft inflammatory factor 1 Rattus norvegicus 41-46 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 53-58 20952225-6 2011 RESULTS: All simvastatin-loaded groups showed increased ALP activity compared with the control group at every time point, especially the 10(-7) mol/L group, which significantly increased the activity almost fourfold at 4 days (P < .05). Simvastatin 13-24 alkaline phosphatase, placental Homo sapiens 56-59 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 180-185 21398618-0 2011 Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Simvastatin 10-21 KRAS proto-oncogene, GTPase Homo sapiens 78-82 21524281-0 2011 Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes. Simvastatin 0-11 serpin family E member 1 Homo sapiens 58-91 21524281-7 2011 The purpose of the present study is to examine the effects of simvastatin on PAI-1 secretion from human bone marrow adipocytes in vitro. Simvastatin 62-73 serpin family E member 1 Homo sapiens 77-82 21524281-11 2011 RESULTS: PAI-1 mRNA expression was up-regulated by 388% (P=0.002) with dexamethasone, and down-regulated by 45% (P=0.002) with simvastatin, as compared to control levels. Simvastatin 127-138 serpin family E member 1 Homo sapiens 9-14 21524281-12 2011 Dexamethasone increased total PAI-1 secretion by 166% (P=0.001) and simvastatin decreased total PAI-1 secretion by 64% (P=0.002). Simvastatin 68-79 serpin family E member 1 Homo sapiens 96-101 21524281-13 2011 No significant changes were observed in adiponectin mRNA expression and secretion by dexamethasone and simvastatin, while pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion by 89%, as compared to control levels. Simvastatin 141-152 serpin family E member 1 Homo sapiens 184-189 21524281-14 2011 CONCLUSION: The present study confirmed the suppressive effects of simvastatin on PAI-1 expression and secretion from bone marrow adipocytes. Simvastatin 67-78 serpin family E member 1 Homo sapiens 82-87 21524281-15 2011 Furthermore, pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion. Simvastatin 32-43 serpin family E member 1 Homo sapiens 75-80 21524281-16 2011 Simvastatin may thus exhibit preventive effects against steroid-induced osteonecrosis of the femoral head by suppressing PAI-1 secretion. Simvastatin 0-11 serpin family E member 1 Homo sapiens 121-126 21398618-2 2011 Statins have reported antitumor activity, but it is unknown whether simvastatin can reverse cetuximab resistance in KRAS mutant CRC. Simvastatin 68-79 KRAS proto-oncogene, GTPase Homo sapiens 116-120 21398618-4 2011 Because BRAF(V600E) mutant may be responsible for cetuximab resistance in KRAS wild-type cells, we measured the growth of xenograft tumors originating from KRAS mutant and BRAF mutant cells in mice treated with cetuximab alone or plus simvastatin (n = 5 mice per treatment group). Simvastatin 235-246 Braf transforming gene Mus musculus 8-12 21398618-5 2011 We used immunoblot assays to study RAS-regulated activation of BRAF protein after simvastatin treatment. Simvastatin 82-93 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 63-67 21398618-7 2011 RESULTS: Addition of simvastatin (0.2 muM) to cetuximab (0.03-1.0 muM) reduced cell proliferation of KRAS mutant (P < .001) but not of BRAF mutant CRC cells in vitro. Simvastatin 21-32 KRAS proto-oncogene, GTPase Homo sapiens 101-105 21398618-7 2011 RESULTS: Addition of simvastatin (0.2 muM) to cetuximab (0.03-1.0 muM) reduced cell proliferation of KRAS mutant (P < .001) but not of BRAF mutant CRC cells in vitro. Simvastatin 21-32 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 138-142 21398618-8 2011 Treatment of KRAS mutant cells with simvastatin reduced BRAF activity and induced apoptosis. Simvastatin 36-47 KRAS proto-oncogene, GTPase Homo sapiens 13-17 21398618-8 2011 Treatment of KRAS mutant cells with simvastatin reduced BRAF activity and induced apoptosis. Simvastatin 36-47 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 56-60 21398618-10 2011 CONCLUSION: Simvastatin may overcome cetuximab resistance in colon cancer cells with KRAS mutations by modulating BRAF activity and inducing apoptosis. Simvastatin 12-23 KRAS proto-oncogene, GTPase Homo sapiens 85-89 21398618-10 2011 CONCLUSION: Simvastatin may overcome cetuximab resistance in colon cancer cells with KRAS mutations by modulating BRAF activity and inducing apoptosis. Simvastatin 12-23 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 114-118 21483694-0 2011 NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. Simvastatin 89-100 ELL associated factor 2 Homo sapiens 66-70 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 tumor necrosis factor Homo sapiens 58-85 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 interleukin 1 beta Homo sapiens 87-104 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 interleukin 6 Homo sapiens 106-119 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 125-159 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 interleukin 2 Homo sapiens 186-199 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 interferon gamma Homo sapiens 201-250 20558777-8 2011 ADMA and inducible nitric oxide synthase were reduced by simvastatin, but eNOS was increased. Simvastatin 57-68 nitric oxide synthase 1, neuronal Mus musculus 19-40 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 C-reactive protein Homo sapiens 298-316 21443601-8 2011 The CYP3A4 +- PgP substrates of simvastatin and ciclosporin A did not affect the single or repeated dose PK of alitretinoin. Simvastatin 32-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-10 20805097-4 2011 Several statins, including simvastatin, exhibited an inhibitory effect against PAF, comparable with that of PAF-inhibitors. Simvastatin 27-38 PCNA clamp associated factor Homo sapiens 79-82 20805097-5 2011 Simvastatin also suppressed in vivo PAF-biosynthesis via the de novo pathway, in leukocytes of 6 simvastatin-treated volunteers. Simvastatin 0-11 PCNA clamp associated factor Homo sapiens 36-39 20805097-5 2011 Simvastatin also suppressed in vivo PAF-biosynthesis via the de novo pathway, in leukocytes of 6 simvastatin-treated volunteers. Simvastatin 97-108 PCNA clamp associated factor Homo sapiens 36-39 20805097-7 2011 Simvastatin with an intact lactone ring also inhibited PAF-activities, while incubation of human mesangial cells with it also resulted in decreased de novo PAF-biosynthesis. Simvastatin 0-11 PCNA clamp associated factor Homo sapiens 55-58 21443601-8 2011 The CYP3A4 +- PgP substrates of simvastatin and ciclosporin A did not affect the single or repeated dose PK of alitretinoin. Simvastatin 32-43 phosphoglycolate phosphatase Homo sapiens 14-17 21797102-11 2011 The results of the study demonstrated that simvastatin in a dose of 80 mg exerted an effect on the levels of some CAM, and particularly on VCAM-1 in contrast to the same drug used in a dose of 40 mg. Simvastatin 43-54 vascular cell adhesion molecule 1 Homo sapiens 139-145 20191585-0 2011 Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis. Simvastatin 0-11 cellular communication network factor 1 Homo sapiens 41-46 20191585-7 2011 RESULTS: In primary human osteoblasts and U2OS cells, Cyr61 expression stimulated by tumor necrosis factor alpha, interleukin-1beta (IL-1beta), oncostatin M (OSM), and other IL-6-family cytokines was suppressed by simvastatin. Simvastatin 214-225 cellular communication network factor 1 Homo sapiens 54-59 20191585-8 2011 In U2OS cells, simvastatin inhibited OSM-induced CREB phosphorylation and CREB-DNA binding. Simvastatin 15-26 cAMP responsive element binding protein 1 Homo sapiens 49-53 20191585-8 2011 In U2OS cells, simvastatin inhibited OSM-induced CREB phosphorylation and CREB-DNA binding. Simvastatin 15-26 cAMP responsive element binding protein 1 Homo sapiens 74-78 20191585-10 2011 OSM-induced Cyr61 promoter activation was dependent on CRE-CREB interaction and inhibited by simvastatin. Simvastatin 93-104 cellular communication network factor 1 Homo sapiens 12-17 20191585-12 2011 Intraarticular injection of simvastatin inhibited CIA progression and diminished the number of Cyr61+ osteoblasts and infiltrating macrophages. Simvastatin 28-39 cellular communication network factor 1 Homo sapiens 95-100 20191585-13 2011 CONCLUSION: Simvastatin inhibited cytokine-stimulated Cyr61 expression in osteoblastic cells and suppressed disease progression and osteoblastic expression of Cyr61 in inflammatory arthritis. Simvastatin 12-23 cellular communication network factor 1 Homo sapiens 54-59 20191585-13 2011 CONCLUSION: Simvastatin inhibited cytokine-stimulated Cyr61 expression in osteoblastic cells and suppressed disease progression and osteoblastic expression of Cyr61 in inflammatory arthritis. Simvastatin 12-23 cellular communication network factor 1 Homo sapiens 159-164 21173096-2 2011 We investigated, in vitro, the adhesion molecules involved in endothelial-sickle cell disease neutrophil interactions and the effect of simvastatin on sickle cell disease neutrophil adhesion to tumor necrosis factor-alpha-activated endothelial monolayers (human umbilical vein endothelial cells), and neutrophil chemotaxis. Simvastatin 136-147 tumor necrosis factor Homo sapiens 194-221 21173096-5 2011 Neutrophils treated with simvastatin were submitted to interleukin 8-stimulated chemotaxis assays. Simvastatin 25-36 C-X-C motif chemokine ligand 8 Homo sapiens 55-68 21112949-13 2011 Simvastatin administration further increased hepatic KLF2 and target genes expression. Simvastatin 0-11 Kruppel-like factor 2 Rattus norvegicus 53-57 21385244-11 2011 When the LDL-C goal was <70mg/dl (1.81mmol/l), 40.2% simvastatin users was considered appropriate, while 58.6% needed atorvastatin to be prescribed. Simvastatin 56-67 component of oligomeric golgi complex 2 Homo sapiens 9-14 20158569-9 2011 Simvastatin, atorvastatin, fluvastatin or pravastatin reduced the IL-6 production by 53%, 50%, 64% and 60%, respectively. Simvastatin 0-11 interleukin 6 Homo sapiens 66-70 21173096-10 2011 Furthermore, intercellular adhesion molecule-1 expression was significantly abrogated on tumor necrosis factor-alpha-stimulated endothelium incubated with simvastatin, and statin treatment inhibited the interleukin-8-stimulated migration of both control and sickle cell disease neutrophils. Simvastatin 155-166 intercellular adhesion molecule 1 Homo sapiens 13-46 21173096-10 2011 Furthermore, intercellular adhesion molecule-1 expression was significantly abrogated on tumor necrosis factor-alpha-stimulated endothelium incubated with simvastatin, and statin treatment inhibited the interleukin-8-stimulated migration of both control and sickle cell disease neutrophils. Simvastatin 155-166 tumor necrosis factor Homo sapiens 89-116 21173096-10 2011 Furthermore, intercellular adhesion molecule-1 expression was significantly abrogated on tumor necrosis factor-alpha-stimulated endothelium incubated with simvastatin, and statin treatment inhibited the interleukin-8-stimulated migration of both control and sickle cell disease neutrophils. Simvastatin 155-166 C-X-C motif chemokine ligand 8 Homo sapiens 203-216 21199873-0 2011 Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. Simvastatin 0-11 tumor protein p53 Homo sapiens 95-98 21199873-0 2011 Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. Simvastatin 0-11 CD44 molecule (Indian blood group) Homo sapiens 103-107 21199873-10 2011 Finally, we demonstrate an inverse correlation between expression of p53 and CD44 in the tumors of mice that received simvastatin. Simvastatin 118-129 transformation related protein 53, pseudogene Mus musculus 69-72 21199873-10 2011 Finally, we demonstrate an inverse correlation between expression of p53 and CD44 in the tumors of mice that received simvastatin. Simvastatin 118-129 CD44 antigen Mus musculus 77-81 21224482-0 2011 Simvastatin represses protein synthesis in the muscle-derived C2C12 cell line with a concomitant reduction in eukaryotic initiation factor 2B expression. Simvastatin 0-11 eukaryotic translation initiation factor 2B, subunit 4 delta Mus musculus 110-141 21198644-10 2011 Lovastatin or simvastatin at 0.1 muM increased the levels of ALP, osteocalcin, bone sialoprotein and bone morphogenetic protein-2 mRNA in mouse periodontal ligament cells. Simvastatin 14-25 bone gamma-carboxyglutamate protein 2 Mus musculus 66-77 21198644-10 2011 Lovastatin or simvastatin at 0.1 muM increased the levels of ALP, osteocalcin, bone sialoprotein and bone morphogenetic protein-2 mRNA in mouse periodontal ligament cells. Simvastatin 14-25 bone morphogenetic protein 2 Mus musculus 101-129 21198644-11 2011 In addition, the ALP activity, mineralized nodule formation and OG2 and OSE promoter activity were higher in the lovastatin- or simvastatin-treated cells than the control cells. Simvastatin 128-139 bone gamma-carboxyglutamate protein 2 Mus musculus 64-67 21198644-13 2011 CONCLUSION: Lovastatin and simvastatin may stimulate the osteoblastic differentiation of periodontal ligament cells via the ERK1/2 pathway. Simvastatin 27-38 mitogen-activated protein kinase 3 Mus musculus 124-130 20463291-10 2011 Our findings suggest that simvastatin and GGTI-286 inhibit synthesis and secretion of extracellular matrix proteins by human airway smooth muscle cells by suppressing GGT1-mediated posttranslational modification of signaling molecules such as RhoA. Simvastatin 26-37 ras homolog family member A Homo sapiens 243-247 20508068-3 2011 Simvastatin reduced multiple RILI indices, including vascular leak, leukocyte infiltration, and histological evidence of oxidative stress, while reversing RILI-associated dysregulated gene expression, including p53, nuclear factor-erythroid-2-related factor, and sphingolipid metabolic pathway genes. Simvastatin 0-11 transformation related protein 53, pseudogene Mus musculus 211-214 20463291-6 2011 Simvastatin also abrogated TGFbeta1-induced collagen I and fibronectin expression, and prevented collagen I secretion. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 27-35 20463291-6 2011 Simvastatin also abrogated TGFbeta1-induced collagen I and fibronectin expression, and prevented collagen I secretion. Simvastatin 0-11 fibronectin 1 Homo sapiens 59-70 20463291-8 2011 We also showed that human airway myocytes express both geranylgeranyl transferase 1 (GGT1) and farnesyltransferase (FT), and the inhibition of GGT1 (GGTI inhibitor-286, 10 muM), but not FT (FTI inhibitor-277, 10 muM), mirrored the suppressive effects of simvastatin on collagen I and fibronectin expression and collagen I secretion. Simvastatin 254-265 gamma-glutamyltransferase 1 Homo sapiens 143-147 20463291-8 2011 We also showed that human airway myocytes express both geranylgeranyl transferase 1 (GGT1) and farnesyltransferase (FT), and the inhibition of GGT1 (GGTI inhibitor-286, 10 muM), but not FT (FTI inhibitor-277, 10 muM), mirrored the suppressive effects of simvastatin on collagen I and fibronectin expression and collagen I secretion. Simvastatin 254-265 protein geranylgeranyltransferase type I subunit beta Homo sapiens 149-153 20463291-9 2011 Moreover, simvastatin and GGTI-286 both prevented TGFbeta1-induced membrane association of RhoA, a downstream target of GGT1. Simvastatin 10-21 transforming growth factor beta 1 Homo sapiens 50-58 20463291-9 2011 Moreover, simvastatin and GGTI-286 both prevented TGFbeta1-induced membrane association of RhoA, a downstream target of GGT1. Simvastatin 10-21 ras homolog family member A Homo sapiens 91-95 20463291-9 2011 Moreover, simvastatin and GGTI-286 both prevented TGFbeta1-induced membrane association of RhoA, a downstream target of GGT1. Simvastatin 10-21 gamma-glutamyltransferase 1 Homo sapiens 120-124 20463291-10 2011 Our findings suggest that simvastatin and GGTI-286 inhibit synthesis and secretion of extracellular matrix proteins by human airway smooth muscle cells by suppressing GGT1-mediated posttranslational modification of signaling molecules such as RhoA. Simvastatin 26-37 gamma-glutamyltransferase 1 Homo sapiens 167-171 21224482-8 2011 Simvastatin treatment also resulted in a proteasome-sensitive reduction in the protein expression of all the subunits of the eIF2B heteropentameric complex. Simvastatin 0-11 eukaryotic translation initiation factor 2B, subunit 4 delta Mus musculus 125-130 21145172-0 2011 Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6. Simvastatin 0-11 interleukin 6 Mus musculus 82-95 20870757-17 2011 Simvastatin decreased bronchoalveolar lavage IL-8 by 2.5-fold (P = 0.04). Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 45-49 21310849-7 2011 Two known active compounds (curcumin and simvastatin) inhibiting TF activity were tested by the simplified assay to validate the screening method. Simvastatin 41-52 coagulation factor III, tissue factor Homo sapiens 65-67 20821229-11 2011 Simvastatin treatment blocked hyperglycemia-induced increases in VEGF, angiopoietin 2 and erythropoietin levels, as demonstrated by RT-PCR and Western blot analysis. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 65-69 20821229-11 2011 Simvastatin treatment blocked hyperglycemia-induced increases in VEGF, angiopoietin 2 and erythropoietin levels, as demonstrated by RT-PCR and Western blot analysis. Simvastatin 0-11 angiopoietin 2 Rattus norvegicus 71-85 20821229-11 2011 Simvastatin treatment blocked hyperglycemia-induced increases in VEGF, angiopoietin 2 and erythropoietin levels, as demonstrated by RT-PCR and Western blot analysis. Simvastatin 0-11 erythropoietin Rattus norvegicus 90-104 20821229-12 2011 CONCLUSIONS: Simvastatin treatment led to suppression of superoxide formation and decreased expression of VEGF, angiopoietin 2 and erythropoietin in diabetic rat retinas. Simvastatin 13-24 vascular endothelial growth factor A Rattus norvegicus 106-110 20821229-12 2011 CONCLUSIONS: Simvastatin treatment led to suppression of superoxide formation and decreased expression of VEGF, angiopoietin 2 and erythropoietin in diabetic rat retinas. Simvastatin 13-24 angiopoietin 2 Rattus norvegicus 112-126 20821229-12 2011 CONCLUSIONS: Simvastatin treatment led to suppression of superoxide formation and decreased expression of VEGF, angiopoietin 2 and erythropoietin in diabetic rat retinas. Simvastatin 13-24 erythropoietin Rattus norvegicus 131-145 21271793-6 2011 The changes in total cholesterol, LDL-C and non-HDL-C were greater in the simvastatin/ezetimibe group (all p < 0.05). Simvastatin 74-85 component of oligomeric golgi complex 2 Homo sapiens 34-39 21124329-0 2011 Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Simvastatin 0-11 ras homolog family member A Rattus norvegicus 132-136 21124329-0 2011 Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 141-144 21124329-11 2011 In SAD-operated SHRs, simvastatin attenuated myocyte hypertrophy and BNP expression, as well as RhoA, Ras and ERK1/2 activities. Simvastatin 22-33 natriuretic peptide B Rattus norvegicus 69-72 21160482-11 2011 Treatment with simvastatin significantly increased the suppressed expression of c-Kit and Sca-1 mRNAs. Simvastatin 15-26 KIT proto-oncogene receptor tyrosine kinase Mus musculus 80-85 21160482-11 2011 Treatment with simvastatin significantly increased the suppressed expression of c-Kit and Sca-1 mRNAs. Simvastatin 15-26 ataxin 1 Mus musculus 90-95 21206971-2 2011 It has been suggested that the 3-hydroxy-3-methyl-glutarylcoenzyme-CoA (HMG-CoA) reductase inhibitor simvastatin exhibits anticancer properties. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-90 21206971-9 2011 The inhibitory effect of simvastatin on cell adhesion was associated with decreased expression of ss1, ss3 and alpha2 integrins. Simvastatin 25-36 major histocompatibility complex, class II, DR beta 1 Homo sapiens 98-101 21206971-9 2011 The inhibitory effect of simvastatin on cell adhesion was associated with decreased expression of ss1, ss3 and alpha2 integrins. Simvastatin 25-36 SS3 Homo sapiens 103-106 21206971-10 2011 Furthermore, simvastatin strongly reduced the expression of ROCK-I and activated MYPT, an indicator of ROCK activity. Simvastatin 13-24 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 60-66 20717902-5 2011 RESULTS: Western blotting revealed that both mevastatin and simvastatin downregulated AR and PSA protein. Simvastatin 60-71 androgen receptor Homo sapiens 86-88 21419084-10 2011 After treatment, GXK decoction and simvastatin improved the dyslipidemia by increasing the concentrations of ApoA I and HDL-C and decreasing the concentrations of TC, TAG, LDL-C, ApoB, CRP, SAA and Fbg (P<0.05). Simvastatin 35-46 apolipoprotein A-I Mus musculus 109-115 21419084-10 2011 After treatment, GXK decoction and simvastatin improved the dyslipidemia by increasing the concentrations of ApoA I and HDL-C and decreasing the concentrations of TC, TAG, LDL-C, ApoB, CRP, SAA and Fbg (P<0.05). Simvastatin 35-46 apolipoprotein B Mus musculus 179-183 21419084-10 2011 After treatment, GXK decoction and simvastatin improved the dyslipidemia by increasing the concentrations of ApoA I and HDL-C and decreasing the concentrations of TC, TAG, LDL-C, ApoB, CRP, SAA and Fbg (P<0.05). Simvastatin 35-46 C-reactive protein, pentraxin-related Mus musculus 185-188 21419084-10 2011 After treatment, GXK decoction and simvastatin improved the dyslipidemia by increasing the concentrations of ApoA I and HDL-C and decreasing the concentrations of TC, TAG, LDL-C, ApoB, CRP, SAA and Fbg (P<0.05). Simvastatin 35-46 serum amyloid A cluster Mus musculus 190-193 21364936-5 2011 Compared to conventional markers, such as AST, ALT, and CK, the urine metabolic profile provided clearer distinction between the pre- and post-treatment groups treated with toxic levels of simvastatin. Simvastatin 189-200 solute carrier family 17 member 5 Homo sapiens 42-45 21075647-9 2011 These potential benefits of simvastatin were all abolished by co-application of tin protoporphyrin-IX (SnPP), a specific heme oxygenase-1 (HO-1) inhibitor. Simvastatin 28-39 heme oxygenase 1 Rattus norvegicus 121-137 21075647-9 2011 These potential benefits of simvastatin were all abolished by co-application of tin protoporphyrin-IX (SnPP), a specific heme oxygenase-1 (HO-1) inhibitor. Simvastatin 28-39 heme oxygenase 1 Rattus norvegicus 139-143 21519514-2 2011 The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 126-131 21519514-11 2011 CONCLUSION: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk. Simvastatin 22-33 component of oligomeric golgi complex 2 Homo sapiens 109-114 21440087-3 2011 The secretion of the pro-inflammatory cytokines IL-1beta and IFNgamma and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Simvastatin 172-183 interleukin 1 beta Homo sapiens 48-56 21440087-3 2011 The secretion of the pro-inflammatory cytokines IL-1beta and IFNgamma and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Simvastatin 172-183 interferon gamma Homo sapiens 61-69 21440087-3 2011 The secretion of the pro-inflammatory cytokines IL-1beta and IFNgamma and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Simvastatin 172-183 interleukin 1 receptor antagonist Homo sapiens 114-120 21440087-3 2011 The secretion of the pro-inflammatory cytokines IL-1beta and IFNgamma and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Simvastatin 172-183 interleukin 10 Homo sapiens 125-130 21440087-3 2011 The secretion of the pro-inflammatory cytokines IL-1beta and IFNgamma and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Simvastatin 172-183 interleukin 6 Homo sapiens 224-228 21373645-0 2011 Simvastatin re-couples dysfunctional endothelial nitric oxide synthase in experimental subarachnoid hemorrhage. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 37-70 20717902-5 2011 RESULTS: Western blotting revealed that both mevastatin and simvastatin downregulated AR and PSA protein. Simvastatin 60-71 kallikrein related peptidase 3 Homo sapiens 93-96 21497705-0 2011 Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 77-112 20875810-5 2011 RESULTS: Treatment with simvastatin was associated with significant reductions in serum anti-HSP60, 65, and 70 titers in the dyslipidemic patients (10%, 14%, and 15% decrease, respectively) (p<0.001). Simvastatin 24-35 heat shock protein family D (Hsp60) member 1 Homo sapiens 93-98 21497705-3 2011 Data to support the LDL-C lowering efficacy of ezetimibe/simvastatin (EZE/SMV) outside of controlled clinical studies are currently lacking. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 20-25 20519697-0 2011 CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. Simvastatin 63-74 cytochrome P450 family 3 subfamily A member 51, pseudogene Homo sapiens 0-7 21268089-0 2011 Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. Simvastatin 127-138 interferon gamma Homo sapiens 50-59 21268089-0 2011 Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. Simvastatin 127-138 signal transducer and activator of transcription 1 Homo sapiens 69-74 21268089-7 2011 These studies reveal differences in the mechanism of action of agonists of PPARs (and simvastatin) and LXRs on the IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages. Simvastatin 86-97 interferon gamma Homo sapiens 115-124 20519697-7 2011 In the simvastatin treatment group, the percentage reduction of LDL-C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. Simvastatin 7-18 component of oligomeric golgi complex 2 Homo sapiens 64-69 21268089-7 2011 These studies reveal differences in the mechanism of action of agonists of PPARs (and simvastatin) and LXRs on the IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages. Simvastatin 86-97 signal transducer and activator of transcription 1 Homo sapiens 134-139 20519697-7 2011 In the simvastatin treatment group, the percentage reduction of LDL-C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. Simvastatin 7-18 cytochrome P450 family 3 subfamily A member 51, pseudogene Homo sapiens 95-102 20519697-7 2011 In the simvastatin treatment group, the percentage reduction of LDL-C level was greater in the CYP3AP1*3/*3 carriers than in the CYP3AP1*1 carriers. Simvastatin 7-18 cytochrome P450 family 3 subfamily A member 51, pseudogene Homo sapiens 129-136 20519697-11 2011 These findings suggest that the CYP3AP1*3 allele may be a biomarker for the lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women with hyperlipidemia. Simvastatin 103-114 cytochrome P450 family 3 subfamily A member 51, pseudogene Homo sapiens 32-39 21059805-0 2011 Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. Simvastatin 23-34 AKT serine/threonine kinase 1 Homo sapiens 114-117 21059805-0 2011 Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. Simvastatin 23-34 kallikrein related peptidase 3 Homo sapiens 130-155 21059805-5 2011 In the current study, we sought to investigate the effects of simvastatin on the Akt pathway in prostate cancer cells with respect to the regulation of various cell functions in vitro and tumor growth in vivo. Simvastatin 62-73 AKT serine/threonine kinase 1 Homo sapiens 81-84 21059805-6 2011 Time- and dose-dependent effects of simvastatin on LNCaP (androgen-dependent) and PC3 (androgen-independent) cells indicate that treatment with simvastatin at concentrations as low as 25 muM was sufficient to inhibit serum-stimulated Akt activity. Simvastatin 144-155 chromobox 8 Homo sapiens 82-85 21059805-6 2011 Time- and dose-dependent effects of simvastatin on LNCaP (androgen-dependent) and PC3 (androgen-independent) cells indicate that treatment with simvastatin at concentrations as low as 25 muM was sufficient to inhibit serum-stimulated Akt activity. Simvastatin 144-155 AKT serine/threonine kinase 1 Homo sapiens 234-237 21059805-8 2011 Simvastatin-mediated effects on colony formation were rescued by adenovirus-mediated expression of constitutively active Akt (myristoylated Akt) in PC3 cell lines. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 121-124 21059805-8 2011 Simvastatin-mediated effects on colony formation were rescued by adenovirus-mediated expression of constitutively active Akt (myristoylated Akt) in PC3 cell lines. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 140-143 21059805-8 2011 Simvastatin-mediated effects on colony formation were rescued by adenovirus-mediated expression of constitutively active Akt (myristoylated Akt) in PC3 cell lines. Simvastatin 0-11 chromobox 8 Homo sapiens 148-151 21059805-9 2011 A PC3 xenograft model performed in nude mice exhibited reduced tumor growth with simvastatin treatment associated with decreased Akt activity and reduced prostate-specific antigen (PSA) levels. Simvastatin 81-92 chromobox 8 Mus musculus 2-5 21059805-9 2011 A PC3 xenograft model performed in nude mice exhibited reduced tumor growth with simvastatin treatment associated with decreased Akt activity and reduced prostate-specific antigen (PSA) levels. Simvastatin 81-92 thymoma viral proto-oncogene 1 Mus musculus 129-132 21059805-9 2011 A PC3 xenograft model performed in nude mice exhibited reduced tumor growth with simvastatin treatment associated with decreased Akt activity and reduced prostate-specific antigen (PSA) levels. Simvastatin 81-92 aminopeptidase puromycin sensitive Mus musculus 154-185 21059805-10 2011 Our findings demonstrate the therapeutic benefits of simvastatin for prostate cancer and suggest a link between simvastatin, regulation of Akt activity, and PSA expression in prostate tumors. Simvastatin 112-123 AKT serine/threonine kinase 1 Homo sapiens 139-142 21052011-0 2011 Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. Simvastatin 0-11 ras homolog family member A Homo sapiens 194-198 22020943-8 2011 RESULTS: In the EASEGO scenario, incremental cost-effectiveness ratio for E10/S20 was <euro>3497/quality-adjusted life-years (QALY) vs atorvastatin 20 mg and <euro>26,417/QALY vs simvastatin 40 mg. Simvastatin 191-202 ribosomal protein S20 Homo sapiens 74-81 21052011-0 2011 Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 199-235 21052011-4 2011 Our results showed that treatment with simvastatin inhibited lipopolysaccharide (LPS)-induced increases in Lp-PLA(2) expression and secreted activity in human monocyte-derived macrophages in a dose- and time-dependent manner. Simvastatin 39-50 phospholipase A2 group VII Homo sapiens 107-116 21052011-7 2011 In addition, treatment with simvastatin blocked LPS-induced activation of RhoA, which could be abolished by treatment with GGPP. Simvastatin 28-39 ras homolog family member A Homo sapiens 74-78 21052011-10 2011 Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway. Simvastatin 37-48 phospholipase A2 group VII Homo sapiens 57-66 21052011-10 2011 Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway. Simvastatin 37-48 ras homolog family member A Homo sapiens 199-203 21052011-10 2011 Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway. Simvastatin 37-48 mitogen-activated protein kinase 3 Homo sapiens 208-212 21304979-8 2011 Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy). Simvastatin 95-106 tumor protein p53 Homo sapiens 80-83 21297370-3 2011 Analysis of 30000 genetic markers in 85 patients with myopathy induced by high-dose simvastatin showed a strong association with 521T>C polymorphism of SLCO1B1. Simvastatin 84-95 solute carrier organic anion transporter family member 1B1 Homo sapiens 155-162 21304979-8 2011 Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy). Simvastatin 95-106 tumor protein p53 Homo sapiens 125-128 21304979-6 2011 Similarly, Atg5 silencing with shRNA, thus preventing Atg5-12 complex formation, increased pro-apoptotic effects of simvastatin. Simvastatin 116-127 autophagy related 5 Homo sapiens 11-15 21304979-8 2011 Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy). Simvastatin 95-106 tumor protein p53 Homo sapiens 125-128 21304979-6 2011 Similarly, Atg5 silencing with shRNA, thus preventing Atg5-12 complex formation, increased pro-apoptotic effects of simvastatin. Simvastatin 116-127 autophagy related 5 Homo sapiens 54-58 21304979-8 2011 Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy). Simvastatin 95-106 autophagy related 5 Homo sapiens 290-294 21304979-7 2011 Simvastatin concomitantly increased p53-dependent expression of p53 up-regulated modulator of apoptosis (PUMA), NOXA, and damage-regulated autophagy modulator (DRAM). Simvastatin 0-11 tumor protein p53 Homo sapiens 36-39 21304979-7 2011 Simvastatin concomitantly increased p53-dependent expression of p53 up-regulated modulator of apoptosis (PUMA), NOXA, and damage-regulated autophagy modulator (DRAM). Simvastatin 0-11 tumor protein p53 Homo sapiens 64-67 21304979-8 2011 Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy). Simvastatin 95-106 microtubule associated protein 1 light chain 3 alpha Homo sapiens 317-320 20946921-5 2011 Its efficacy was further increased by simvastatin, which up-regulates the LDLR levels and contemporarily reduces the Pgp activity, thus increasing the liposomes uptake and limiting the drug efflux. Simvastatin 38-49 low density lipoprotein receptor Homo sapiens 74-78 20946921-5 2011 Its efficacy was further increased by simvastatin, which up-regulates the LDLR levels and contemporarily reduces the Pgp activity, thus increasing the liposomes uptake and limiting the drug efflux. Simvastatin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 117-120 21345291-7 2011 CONCLUSIONS: Although simvastatin inhibited the production of PTX3 and MCP-1 in RA FLS, the mechanisms were quite different. Simvastatin 22-33 pentraxin 3 Homo sapiens 62-66 20851742-0 2011 Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF. Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 123-127 20851742-0 2011 Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF. Simvastatin 0-11 glial cell derived neurotrophic factor Rattus norvegicus 132-136 20851742-9 2011 Results show that the simvastatin-treated animals showed significantly better locomotor function recovery, better electrophysiological outcome, less myelin loss, and higher expression of BDNF and GDNF. Simvastatin 22-33 brain-derived neurotrophic factor Rattus norvegicus 187-191 20851742-9 2011 Results show that the simvastatin-treated animals showed significantly better locomotor function recovery, better electrophysiological outcome, less myelin loss, and higher expression of BDNF and GDNF. Simvastatin 22-33 glial cell derived neurotrophic factor Rattus norvegicus 196-200 20851742-10 2011 These findings suggest that simvastatin treatment starting 1 day after SCI can significantly improve locomotor recovery, and this neuroprotective effect may be related to the upregulation of BDNF and GDNF. Simvastatin 28-39 brain-derived neurotrophic factor Rattus norvegicus 191-195 20851742-10 2011 These findings suggest that simvastatin treatment starting 1 day after SCI can significantly improve locomotor recovery, and this neuroprotective effect may be related to the upregulation of BDNF and GDNF. Simvastatin 28-39 glial cell derived neurotrophic factor Rattus norvegicus 200-204 21115572-0 2011 Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Simvastatin 67-78 apolipoprotein A1 Homo sapiens 44-61 20696189-4 2011 Atorvastatin (10, 20 mg/kg), simvastatin (30 mg/kg) and fluvastatin (10 mg/kg) treatment significantly attenuated the quinolinic acid induced behavioral (locomotor activity, rotarod performance and beam walk test), biochemical (lipid peroxidation, nitrite concentration, SOD and catalase), mitochondrial enzyme complex alterations in rats suggesting their free radical scavenging potential. Simvastatin 29-40 catalase Rattus norvegicus 279-287 20696189-5 2011 Additionally, atorvastatin (10, 20 mg/kg), simvastatin (30 mg/kg) and fluvastatin (10 mg/kg) significantly decrease the TNF-alpha level and striatal lesion volume in quinolinic acid treated animals indicating their anti-inflammatory effects. Simvastatin 43-54 tumor necrosis factor Rattus norvegicus 120-129 21241519-0 2011 Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Simvastatin 0-11 apolipoprotein E Mus musculus 128-132 21241519-4 2011 RESULTS: The atherosclerotic lesion formation displayed by oil red O staining positive area was reduced significantly by 35% or 47% in either aortic root section or aortic arch en face in simvastatin administrated apoE-/- mice compared to the control. Simvastatin 188-199 apolipoprotein E Mus musculus 214-218 21241519-5 2011 Plasma analysis by enzymatic method or ELISA showed that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) contents were remarkably increased by treatment with simvastatin. Simvastatin 187-198 apolipoprotein A-I Mus musculus 106-124 21241519-5 2011 Plasma analysis by enzymatic method or ELISA showed that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) contents were remarkably increased by treatment with simvastatin. Simvastatin 187-198 apolipoprotein A-I Mus musculus 126-132 21241519-6 2011 And plasma lecithin-cholesterol acyltransferase (LCAT) activity was markedly increased by simvastatin treatment. Simvastatin 90-101 lecithin cholesterol acyltransferase Mus musculus 11-47 21241519-6 2011 And plasma lecithin-cholesterol acyltransferase (LCAT) activity was markedly increased by simvastatin treatment. Simvastatin 90-101 lecithin cholesterol acyltransferase Mus musculus 49-53 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 258-269 scavenger receptor class B, member 1 Mus musculus 142-175 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 258-269 ATP binding cassette subfamily G member 5 Mus musculus 225-230 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 258-269 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Mus musculus 236-241 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 258-269 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 307-312 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 258-269 apolipoprotein A-I Mus musculus 317-323 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 392-403 scavenger receptor class B, member 1 Mus musculus 142-175 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 392-403 ATP binding cassette subfamily G member 5 Mus musculus 225-230 21241519-7 2011 Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups. Simvastatin 392-403 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Mus musculus 236-241 21241519-8 2011 CONCLUSIONS: We demonstrated the anti-atherogenesis effects of simvastatin in apoE-/- mice fed a high-fat diet. Simvastatin 63-74 apolipoprotein E Mus musculus 78-82 21241519-9 2011 We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I. Simvastatin 37-48 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Mus musculus 85-90 21241519-9 2011 We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I. Simvastatin 37-48 ATP binding cassette subfamily G member 5 Mus musculus 95-100 21241519-9 2011 We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I. Simvastatin 37-48 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 195-200 21241519-9 2011 We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I. Simvastatin 37-48 apolipoprotein A-I Mus musculus 205-211 21241519-10 2011 The elevated HDL-C level, increased LCAT activity and the stimulation of several transporters involved in RCT may all contribute to the anti-atherosclerotic effect of simvastatin. Simvastatin 167-178 lecithin cholesterol acyltransferase Mus musculus 36-40 20737288-3 2011 Simvastatin, steady flow, and non-reversing pulsatile flow each separately upregulated KLF2, eNOS, and TM mRNA. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 87-91 20737288-3 2011 Simvastatin, steady flow, and non-reversing pulsatile flow each separately upregulated KLF2, eNOS, and TM mRNA. Simvastatin 0-11 thrombomodulin Homo sapiens 103-105 20737288-5 2011 At higher simvastatin concentration (10 muM), a synergistic increase in eNOS and TM mRNA expression was observed. Simvastatin 10-21 latexin Homo sapiens 40-43 20737288-5 2011 At higher simvastatin concentration (10 muM), a synergistic increase in eNOS and TM mRNA expression was observed. Simvastatin 10-21 thrombomodulin Homo sapiens 81-83 20737288-7 2011 A higher simvastatin concentration of 10 muM overcame the inhibitory effect of oscillating flow. Simvastatin 9-20 latexin Homo sapiens 41-44 21345291-2 2011 In this study, we have investigated the mechanism by which simvastatin inhibits the production of the mediators of inflammation, such as pentraxin 3 (PTX3) and monocyte chemoattractant protein-1 (MCP-1), from fibroblast-like synoviocytes (FLS) derived from patients with RA. Simvastatin 59-70 pentraxin 3 Homo sapiens 137-148 21345291-2 2011 In this study, we have investigated the mechanism by which simvastatin inhibits the production of the mediators of inflammation, such as pentraxin 3 (PTX3) and monocyte chemoattractant protein-1 (MCP-1), from fibroblast-like synoviocytes (FLS) derived from patients with RA. Simvastatin 59-70 pentraxin 3 Homo sapiens 150-154 21345291-2 2011 In this study, we have investigated the mechanism by which simvastatin inhibits the production of the mediators of inflammation, such as pentraxin 3 (PTX3) and monocyte chemoattractant protein-1 (MCP-1), from fibroblast-like synoviocytes (FLS) derived from patients with RA. Simvastatin 59-70 C-C motif chemokine ligand 2 Homo sapiens 160-194 21345291-2 2011 In this study, we have investigated the mechanism by which simvastatin inhibits the production of the mediators of inflammation, such as pentraxin 3 (PTX3) and monocyte chemoattractant protein-1 (MCP-1), from fibroblast-like synoviocytes (FLS) derived from patients with RA. Simvastatin 59-70 C-C motif chemokine ligand 2 Homo sapiens 196-201 21345291-7 2011 CONCLUSIONS: Although simvastatin inhibited the production of PTX3 and MCP-1 in RA FLS, the mechanisms were quite different. Simvastatin 22-33 C-C motif chemokine ligand 2 Homo sapiens 71-76 20954800-6 2011 In contrast to our previous experiment, in which simvastatin activated ERK and p38, but not JNK or Akt, both atorvastatin and rosuvastatin phosphorylated ERK, but not p38. Simvastatin 49-60 mitogen-activated protein kinase 1 Mus musculus 71-74 21345291-3 2011 METHODS: FLS from RA patients were cultured with 0-10 muM simvastatin for 24 h. ELISA and real-time PCR were used to quantitate the protein level and the mRNA level of PTX3 and MCP-1, respectively. Simvastatin 58-69 pentraxin 3 Homo sapiens 168-172 21345291-4 2011 RESULTS: Simvastatin both reduced the secretion of PTX3 and MCP-1 in FLS cultures and inhibited their mRNA expression in these cells. Simvastatin 9-20 pentraxin 3 Homo sapiens 51-55 21345291-4 2011 RESULTS: Simvastatin both reduced the secretion of PTX3 and MCP-1 in FLS cultures and inhibited their mRNA expression in these cells. Simvastatin 9-20 C-C motif chemokine ligand 2 Homo sapiens 60-65 21045210-9 2011 We used atorvastatin and simvastatin, drugs that cause bleeding in wild-type zebrafish larvae, to challenge vessel stability in tie-2 mutants. Simvastatin 25-36 TEK tyrosine kinase, endothelial Danio rerio 128-133 20954800-2 2011 However, we previously demonstrated simvastatin-induced HO-1-exaggerated nuclear factor kappa beta (NF-kappabeta) activation and superoxide production on exposure to lipopolysaccharide (LPS). Simvastatin 36-47 heme oxygenase 1 Mus musculus 56-60 20954800-6 2011 In contrast to our previous experiment, in which simvastatin activated ERK and p38, but not JNK or Akt, both atorvastatin and rosuvastatin phosphorylated ERK, but not p38. Simvastatin 49-60 mitogen-activated protein kinase 14 Mus musculus 79-82 20954800-2 2011 However, we previously demonstrated simvastatin-induced HO-1-exaggerated nuclear factor kappa beta (NF-kappabeta) activation and superoxide production on exposure to lipopolysaccharide (LPS). Simvastatin 36-47 toll-like receptor 4 Mus musculus 186-189 20954800-7 2011 Inhibition of p38 activation by 5 muM of SB203580 effectively reduced exaggerated HO-1 upregulation in cells pretreated with simvastatin, but not atorvastatin or rosuvastatin, plus exposure to LPS. Simvastatin 125-136 mitogen-activated protein kinase 14 Mus musculus 14-17 20954800-7 2011 Inhibition of p38 activation by 5 muM of SB203580 effectively reduced exaggerated HO-1 upregulation in cells pretreated with simvastatin, but not atorvastatin or rosuvastatin, plus exposure to LPS. Simvastatin 125-136 heme oxygenase 1 Mus musculus 82-86 22287853-6 2011 Mean exposure (AUC) of the CYP3A4-generated active metabolite of saxagliptin, 5-hydroxy saxagliptin, decreased with coadministration of simvastatin, diltiazem, and ketoconazole by 2%, 34%, and 88%, respectively. Simvastatin 136-147 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 21189431-11 2011 Effects of atorvastatin and simvastatin on the LDLC levels were significant, while lovastatin had a marginal effect. Simvastatin 28-39 component of oligomeric golgi complex 2 Homo sapiens 47-51 21417795-6 2011 ABCA1 was downregulated after 12-h and 24-h treatment with atorvastatin (0.1 and 1.0 mumol/L) or simvastatin (0.01, 0.1 and 1 mumol/L) (p<0.05). Simvastatin 97-108 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 21417795-10 2011 Moreover, simvastatin combined with ezetimibe treatment also decrease the ABCG1 levels in these cells. Simvastatin 10-21 ATP binding cassette subfamily G member 1 Homo sapiens 74-79 21461233-6 2011 The A2 and B2 were treated with simvastatin (Zocor) 40 mg/kg/daily p.o. Simvastatin 32-43 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 4-13 21461233-6 2011 The A2 and B2 were treated with simvastatin (Zocor) 40 mg/kg/daily p.o. Simvastatin 45-50 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 4-13 21189431-15 2011 However, simvastatin had the greatest impact on LDLC. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 48-52 21258176-4 2011 This actin reorganization assessed by fluorescein isothiocyanate (FITC)-conjugated phalloidin staining appeared at 1 h after PAR1 stimulation, and this response was reduced by a protein kinase C (PKC) inhibitor, chelerythrine, inhibitors of Rho (simvastatin) and Rho-associated kinase (ROCK) (Y-27632), but not by pertussis toxin (PTX). Simvastatin 246-257 coagulation factor II (thrombin) receptor Rattus norvegicus 125-129 32272531-4 2011 This actin reorganization assessed by fluorescein isothiocyanate (FITC)-conjugated phalloidin staining appeared at 1 h after PAR1 stimulation, and this response was reduced by a protein kinase C (PKC) inhibitor, chelerythrine, inhibitors of Rho (simvastatin) and Rho-associated kinase (ROCK) (Y-27632), but not by pertussis toxin (PTX). Simvastatin 246-257 coagulation factor II (thrombin) receptor Rattus norvegicus 125-129 32272531-4 2011 This actin reorganization assessed by fluorescein isothiocyanate (FITC)-conjugated phalloidin staining appeared at 1 h after PAR1 stimulation, and this response was reduced by a protein kinase C (PKC) inhibitor, chelerythrine, inhibitors of Rho (simvastatin) and Rho-associated kinase (ROCK) (Y-27632), but not by pertussis toxin (PTX). Simvastatin 246-257 protein kinase C, alpha Rattus norvegicus 196-199 21943003-0 2011 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Simvastatin 93-104 kinesin family member 6 Homo sapiens 50-54 21943003-3 2011 We studied influence of polymorphic marker Trp719Arg of KIF6 gene on lipid and nonlipid effects of atorvastatin and simvastatin. Simvastatin 116-127 kinesin family member 6 Homo sapiens 56-60 21521932-4 2011 Pitavastatin, atorvastatin, and simvastatin increased total ABCA1 mRNA levels, whereas pravastatin had no effect. Simvastatin 32-43 ATP binding cassette subfamily A member 1 Rattus norvegicus 60-65 21258176-4 2011 This actin reorganization assessed by fluorescein isothiocyanate (FITC)-conjugated phalloidin staining appeared at 1 h after PAR1 stimulation, and this response was reduced by a protein kinase C (PKC) inhibitor, chelerythrine, inhibitors of Rho (simvastatin) and Rho-associated kinase (ROCK) (Y-27632), but not by pertussis toxin (PTX). Simvastatin 246-257 protein kinase C, alpha Rattus norvegicus 196-199 21952298-2 2011 Since simvastatin has been proposed to decrease renal interstitial fibrosis, we hypothesized that the protective effect of statins was related to the expression of transforming growth factor-beta (TGF-beta) and type IV collagen (Col IV). Simvastatin 6-17 transforming growth factor, beta 1 Rattus norvegicus 197-205 21709429-1 2011 The present study was designed to investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin, pravastatin, simvastatin) on the pharmacokinetics of losartan and its active metabolite EXP-3174 in rats. Simvastatin 158-169 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 61-118 21952298-6 2011 Simvastatin significantly inhibited HG-, AGE- or H(2)O(2)-induced expression of TGF-beta and Col IV (p < 0.05). Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 80-88 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 10-21 mitogen activated protein kinase 14 Rattus norvegicus 82-85 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 10-21 transforming growth factor, beta 1 Rattus norvegicus 181-189 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 10-21 mitogen activated protein kinase 14 Rattus norvegicus 224-227 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 166-177 mitogen activated protein kinase 14 Rattus norvegicus 82-85 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 166-177 transforming growth factor, beta 1 Rattus norvegicus 181-189 22358108-1 2011 The purpose of this study was to investigate the possible effects of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Simvastatin 133-144 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 69-121 21952298-7 2011 Moreover, simvastatin also inhibited HG-, AGE- and H(2)O(2)-induced activation of p38 mitogen-activated protein kinase, which indicated that the preventive effect of simvastatin on TGF-beta and Col IV may be associated with p38. Simvastatin 166-177 mitogen activated protein kinase 14 Rattus norvegicus 224-227 22358108-3 2011 The effect of simvastatin on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 activity was evaluated. Simvastatin 14-25 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 29-43 21952298-8 2011 CONCLUSION: These findings suggest that simvastatin can reduce HG-, AGE- and H(2)O(2)-induced expression of TGF-beta and Col IV by inhibition of the p38 pathway. Simvastatin 40-51 transforming growth factor, beta 1 Rattus norvegicus 108-116 22358108-3 2011 The effect of simvastatin on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 activity was evaluated. Simvastatin 14-25 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-49 21952298-8 2011 CONCLUSION: These findings suggest that simvastatin can reduce HG-, AGE- and H(2)O(2)-induced expression of TGF-beta and Col IV by inhibition of the p38 pathway. Simvastatin 40-51 mitogen activated protein kinase 14 Rattus norvegicus 149-152 22358108-5 2011 In addition, simvastatin significantly enhanced the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-gp. Simvastatin 13-24 phosphoglycolate phosphatase Homo sapiens 125-129 22216116-11 2011 Both statins, hydrophilic pravastatin and hypdrophobic simvastatin caused redistribution of OATP1B1 and HMGCR to perinuclear sites. Simvastatin 55-66 solute carrier organic anion transporter family member 1B1 Homo sapiens 92-99 22216116-11 2011 Both statins, hydrophilic pravastatin and hypdrophobic simvastatin caused redistribution of OATP1B1 and HMGCR to perinuclear sites. Simvastatin 55-66 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 104-109 22034597-0 2011 Combination use of sildenafil and simvastatin increases BMPR-II signal transduction in rats with monocrotaline-mediated pulmonary hypertension. Simvastatin 34-45 bone morphogenetic protein receptor type 2 Rattus norvegicus 56-63 21949812-2 2011 First, we evaluated cytokines expression at 3 days post KA-lesion in hippocampus and found that simvastatin-treatment suppressed lesion-induced expression of interleukin (IL)-1beta and tumor necrosis factor-alpha (TNF-alpha). Simvastatin 96-107 interleukin 1 beta Rattus norvegicus 158-180 21949812-2 2011 First, we evaluated cytokines expression at 3 days post KA-lesion in hippocampus and found that simvastatin-treatment suppressed lesion-induced expression of interleukin (IL)-1beta and tumor necrosis factor-alpha (TNF-alpha). Simvastatin 96-107 tumor necrosis factor Rattus norvegicus 185-212 21949812-2 2011 First, we evaluated cytokines expression at 3 days post KA-lesion in hippocampus and found that simvastatin-treatment suppressed lesion-induced expression of interleukin (IL)-1beta and tumor necrosis factor-alpha (TNF-alpha). Simvastatin 96-107 tumor necrosis factor Rattus norvegicus 214-223 21949812-4 2011 We found that simvastatin suppressed reactive astrocytosis demonstrated by a significant decrease in GFAP-positive cells, and attenuated loss of pyramidal neurons in CA3 and interneurons in dentate hilar (DH). Simvastatin 14-25 glial fibrillary acidic protein Rattus norvegicus 101-105 21949812-4 2011 We found that simvastatin suppressed reactive astrocytosis demonstrated by a significant decrease in GFAP-positive cells, and attenuated loss of pyramidal neurons in CA3 and interneurons in dentate hilar (DH). Simvastatin 14-25 carbonic anhydrase 3 Rattus norvegicus 166-169 21949812-7 2011 Attenuated MFS was related to decreased neuronal loss in CA3 and DH, which is possibly a mechanism underlying decreased hippocampal susceptibility in animal treated with simvastatin. Simvastatin 170-181 carbonic anhydrase 3 Rattus norvegicus 57-60 21731633-8 2011 Significant positive correlations were identified between anxiolytic-like activity and the restoration of expression of NMDA receptors in the hippocampus, amygdala and CA1 following simvastatin administration. Simvastatin 182-193 carbonic anhydrase 1 Rattus norvegicus 168-171 21731633-9 2011 Simvastatin exerted neuroprotection in 6-hydroxydopamine-lesioned rat brain and 6-hydroxydopamine treated PC12, partially by regulating NMDA receptors, MMP9 (matrix metalloproteinase-9), and TNF-a (tumour necrosis factor-alpha). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 152-156 21731633-9 2011 Simvastatin exerted neuroprotection in 6-hydroxydopamine-lesioned rat brain and 6-hydroxydopamine treated PC12, partially by regulating NMDA receptors, MMP9 (matrix metalloproteinase-9), and TNF-a (tumour necrosis factor-alpha). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 158-184 21731633-9 2011 Simvastatin exerted neuroprotection in 6-hydroxydopamine-lesioned rat brain and 6-hydroxydopamine treated PC12, partially by regulating NMDA receptors, MMP9 (matrix metalloproteinase-9), and TNF-a (tumour necrosis factor-alpha). Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 191-196 20858481-0 2010 Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Simvastatin 0-11 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-155 20885069-3 2010 In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry. Simvastatin 22-33 CD14 molecule Homo sapiens 59-63 20885069-3 2010 In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry. Simvastatin 22-33 selectin L Homo sapiens 71-76 20885069-3 2010 In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry. Simvastatin 22-33 Fc gamma receptor Ia Homo sapiens 81-85 20863785-3 2010 In this study, the effect of simvastatin on vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) expression was evaluated in human abdominal aortic endothelial cells (HAAEC) conditioned with various levels of laminar wall shear stress with or without tumor necrosis factor alpha (TNFalpha). Simvastatin 29-40 vascular cell adhesion molecule 1 Homo sapiens 44-77 20851116-6 2010 Therapeutic doses of statins (pravastatin, simvastatin, atorvastatin and fluvastatin) in patients with hypercholesterolemia almost completely suppressed all of the EPO-induced effects in a concentration-dependent manner. Simvastatin 43-54 erythropoietin Homo sapiens 164-167 20858481-14 2010 The anti-inflammatory effect of simvastatin in myocardium may be partly related to the activation of PPARgamma and inhibition of NF-kappaB. Simvastatin 32-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 101-110 20863785-3 2010 In this study, the effect of simvastatin on vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) expression was evaluated in human abdominal aortic endothelial cells (HAAEC) conditioned with various levels of laminar wall shear stress with or without tumor necrosis factor alpha (TNFalpha). Simvastatin 29-40 vascular cell adhesion molecule 1 Homo sapiens 79-85 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 19-30 tumor necrosis factor Homo sapiens 47-55 20883752-6 2010 The signaling pathway induced by simvastatin breaks down the antioxidant defense system by suppressing the expression of reactive oxygen species scavengers, particularly Mn-SOD, CAT, GPx1, and SESN 3, thereby inducing oxidative stress and apoptotic cell death. Simvastatin 33-44 catalase Mus musculus 178-181 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 19-30 vascular cell adhesion molecule 1 Homo sapiens 76-82 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 19-30 intercellular adhesion molecule 1 Homo sapiens 87-93 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 208-219 tumor necrosis factor Homo sapiens 47-55 20863785-7 2010 A shear stress of 12.5 dyn/cm2 eliminated the increase in VCAM-1 by simvastatin, while 25 dyn/cm2 was needed for ICAM-1. Simvastatin 68-79 vascular cell adhesion molecule 1 Homo sapiens 58-64 20863785-8 2010 We conclude that simvastatin enhances VCAM-1 and ICAM-1 gene expression in TNFalpha-activated endothelial cells through inhibition of HMG-CoA reductase. Simvastatin 17-28 vascular cell adhesion molecule 1 Homo sapiens 38-44 20863785-8 2010 We conclude that simvastatin enhances VCAM-1 and ICAM-1 gene expression in TNFalpha-activated endothelial cells through inhibition of HMG-CoA reductase. Simvastatin 17-28 intercellular adhesion molecule 1 Homo sapiens 49-55 20863785-8 2010 We conclude that simvastatin enhances VCAM-1 and ICAM-1 gene expression in TNFalpha-activated endothelial cells through inhibition of HMG-CoA reductase. Simvastatin 17-28 tumor necrosis factor Homo sapiens 75-83 20863785-9 2010 High levels of laminar shear stress prevented the upregulation of VCAM-1 and ICAM-1 by simvastatin suggesting that an induction of cell adhesion molecules by statins may not occur in endothelial cells exposed to shear stress from blood flow. Simvastatin 87-98 vascular cell adhesion molecule 1 Homo sapiens 66-72 20863785-9 2010 High levels of laminar shear stress prevented the upregulation of VCAM-1 and ICAM-1 by simvastatin suggesting that an induction of cell adhesion molecules by statins may not occur in endothelial cells exposed to shear stress from blood flow. Simvastatin 87-98 intercellular adhesion molecule 1 Homo sapiens 77-83 20883752-6 2010 The signaling pathway induced by simvastatin breaks down the antioxidant defense system by suppressing the expression of reactive oxygen species scavengers, particularly Mn-SOD, CAT, GPx1, and SESN 3, thereby inducing oxidative stress and apoptotic cell death. Simvastatin 33-44 glutathione peroxidase 1 Mus musculus 183-187 20883752-6 2010 The signaling pathway induced by simvastatin breaks down the antioxidant defense system by suppressing the expression of reactive oxygen species scavengers, particularly Mn-SOD, CAT, GPx1, and SESN 3, thereby inducing oxidative stress and apoptotic cell death. Simvastatin 33-44 sestrin 3 Mus musculus 193-199 20809215-8 2010 RESULTS: In ApoE(-/-) mice suprarenal aortic diameters were modestly smaller in animals receiving simvastatin without significant change despite reduction in macrophage infiltration. Simvastatin 98-109 apolipoprotein E Mus musculus 12-16 21045169-9 2010 DISCUSSION: Simvastatin undergoes extensive first-pass metabolism mediated by CYP3A4, making it susceptible to significant drug interactions. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 78-84 20614159-7 2010 SIM interacts with PI3K/Akt and ERK1/2 signaling pathways thereby decreasing the serum withdrawal-enhanced levels of the CDK inhibitor p21(Cip1) (p21) and restoring the vulnerability of AD cells to trophic factor deprivation. Simvastatin 0-3 AKT serine/threonine kinase 1 Homo sapiens 24-27 20614159-7 2010 SIM interacts with PI3K/Akt and ERK1/2 signaling pathways thereby decreasing the serum withdrawal-enhanced levels of the CDK inhibitor p21(Cip1) (p21) and restoring the vulnerability of AD cells to trophic factor deprivation. Simvastatin 0-3 mitogen-activated protein kinase 3 Homo sapiens 32-38 20614159-7 2010 SIM interacts with PI3K/Akt and ERK1/2 signaling pathways thereby decreasing the serum withdrawal-enhanced levels of the CDK inhibitor p21(Cip1) (p21) and restoring the vulnerability of AD cells to trophic factor deprivation. Simvastatin 0-3 cyclin dependent kinase inhibitor 1A Homo sapiens 135-144 20614159-7 2010 SIM interacts with PI3K/Akt and ERK1/2 signaling pathways thereby decreasing the serum withdrawal-enhanced levels of the CDK inhibitor p21(Cip1) (p21) and restoring the vulnerability of AD cells to trophic factor deprivation. Simvastatin 0-3 cyclin dependent kinase inhibitor 1A Homo sapiens 135-138 20809215-9 2010 Aortic arch atheroma was substantially reduced in LDLR(-/-) mice receiving simvastatin with borderline significant reduction in suprarenal aortic diameters. Simvastatin 75-86 low density lipoprotein receptor Mus musculus 50-54 20810539-6 2010 The activity in human liver microsomes was also strongly inhibited by simvastatin and troglitazone (K(i) = 0.8 +- 0.1 and 5.6 +- 0.2 muM, respectively). Simvastatin 70-81 latexin Homo sapiens 133-136 20810539-8 2010 7-Ethyl-10-[4-(1-piperidono)-1-piperidono]carbonyloxycamptothecin hydrolase activity by recombinant human CES2 was substantially inhibited by fenofibrate (K(i) = 0.04 +- 0.01 muM) as well as by simvastatin (0.67 +- 0.09 muM). Simvastatin 194-205 carboxylesterase 2 Homo sapiens 106-110 20810539-11 2010 Some statins such as simvastatin and lovastatin, thiazolidinediones, and fenofibrate might attenuate the drug efficacy of prodrugs biotransformed by CES1A and CES2. Simvastatin 21-32 carboxylesterase 2 Homo sapiens 159-163 21080865-0 2010 Simvastatin prevents ERK activation in myocardial hypertrophy of spontaneously hypertensive rats. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 21-24 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 192-203 C-reactive protein Homo sapiens 97-100 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 51-62 TNF receptor superfamily member 11b Homo sapiens 181-184 20177788-9 2010 Twenty-two patients were started on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin or simvastatin). Simvastatin 122-133 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-93 21080865-10 2010 SIM treatment caused a significant reduction in the expression of phosphorylated-ERK, the kinase activity of ERK, the levels of mitogen-activated protein kinase phosphatase-1 protein and its mRNA (p <0.01 for all). Simvastatin 0-3 Eph receptor B1 Rattus norvegicus 81-84 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 51-62 bone gamma-carboxyglutamate protein Homo sapiens 189-191 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 148-159 TNF receptor superfamily member 11b Homo sapiens 181-184 21080865-10 2010 SIM treatment caused a significant reduction in the expression of phosphorylated-ERK, the kinase activity of ERK, the levels of mitogen-activated protein kinase phosphatase-1 protein and its mRNA (p <0.01 for all). Simvastatin 0-3 Eph receptor B1 Rattus norvegicus 109-112 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 148-159 bone gamma-carboxyglutamate protein Homo sapiens 189-191 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 148-159 TNF receptor superfamily member 11b Homo sapiens 181-184 21080865-10 2010 SIM treatment caused a significant reduction in the expression of phosphorylated-ERK, the kinase activity of ERK, the levels of mitogen-activated protein kinase phosphatase-1 protein and its mRNA (p <0.01 for all). Simvastatin 0-3 dual specificity phosphatase 1 Rattus norvegicus 128-174 21431270-4 2010 RESULTS: 10-9mol/L and 10-8mol/L concentrations of simvastatin slightly promoted MG63 cell proliferation; 10-7mol/L and 10-6mol/L concentrations of simvastatin greatly enhanced the OPG and OC mRNA expression; All concentrations of simvastatin had an inhibitory effect on MG63 cell migration. Simvastatin 148-159 bone gamma-carboxyglutamate protein Homo sapiens 189-191 21080865-11 2010 CONCLUSIONS: The Hydroxymethylglutaryl coenzyme A reductase inhibitor SIM prevents the activation of ERK in SHR to mediate regression of myocardial hypertrophy in SHR. Simvastatin 70-73 Eph receptor B1 Rattus norvegicus 101-104 21078495-5 2010 We hypothesized that simvastatin treatment of ovalbumin (OVA)-exposed mice would attenuate early features of airway remodeling by a mevalonate-dependent mechanism. Simvastatin 21-32 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 46-55 21078495-8 2010 Treatment with simvastatin attenuated goblet cell hyperplasia, arginase-1 protein expression, and total arginase enzyme activity, but it did not alter airway hydroxyproline content or transforming growth factor-beta1. Simvastatin 15-26 arginase, liver Mus musculus 63-73 20833152-9 2010 This is the first study showing the efficacy of erythropoietin-simvastatin combinational therapeutic approach in achieving greater structural and cognitive recovery after TBI. Simvastatin 63-74 erythropoietin Homo sapiens 48-62 21152444-5 2010 Treatment with atorvastatin or simvastatin inhibited AngII-induced Smad activation and related-fibrosis. Simvastatin 31-42 angiotensinogen Rattus norvegicus 53-58 20499237-6 2010 Results of our study revealed that simvastatin induced apoptosis of CLL cells concurrently with lowering of BCL-2/BAX ratio, and its pro-apoptotic effect is tumor-specific, not affecting normal lymphocytes. Simvastatin 35-46 BCL2 apoptosis regulator Homo sapiens 108-113 21029821-6 2010 Improvements in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and lipoprotein ratios were significantly greater with ezetimibe/simvastatin than atorvastatin for all comparisons (p <0.01 to <0.001). Simvastatin 160-171 apolipoprotein B Homo sapiens 77-93 20499237-6 2010 Results of our study revealed that simvastatin induced apoptosis of CLL cells concurrently with lowering of BCL-2/BAX ratio, and its pro-apoptotic effect is tumor-specific, not affecting normal lymphocytes. Simvastatin 35-46 BCL2 associated X, apoptosis regulator Homo sapiens 114-117 21055594-9 2010 CONCLUSIONS: These results indicate that simvastatin inhibits the bone-resorbing activity of osteoclasts while stimulating bone formation, probably by controlling the ratio of local osteoprotegerin to RANKL in the periodontal tissues. Simvastatin 41-52 TNF receptor superfamily member 11B Rattus norvegicus 182-197 21076490-8 2010 Concurrently, simvastatin significantly suppressed the over-expression of NF-kappaB, osteopontin, and collagen I in the non-infarcted region following MI. Simvastatin 14-25 secreted phosphoprotein 1 Rattus norvegicus 85-96 21055594-9 2010 CONCLUSIONS: These results indicate that simvastatin inhibits the bone-resorbing activity of osteoclasts while stimulating bone formation, probably by controlling the ratio of local osteoprotegerin to RANKL in the periodontal tissues. Simvastatin 41-52 TNF superfamily member 11 Rattus norvegicus 201-206 21076490-11 2010 The anti-fibrotic effect of simvastatin following MI is associated with the attenuation of the expression of osteopontin and NF-kappaB. Simvastatin 28-39 secreted phosphoprotein 1 Rattus norvegicus 109-120 21076490-12 2010 The inhibition of NF-kappaB activation could be the process upstream of osteopontin suppression in the simvastatin-mediated effect. Simvastatin 103-114 secreted phosphoprotein 1 Rattus norvegicus 72-83 20564244-8 2010 Specifically, we found that a simvastatin concentration in the micromolar range and higher was toxic to the cells and that an effective concentration for osteoinduction is 0.1 nM, as shown by increased alizarin red staining as well as increased osteocalcin and osetrix gene expression. Simvastatin 30-41 bone gamma-carboxyglutamate protein 2 Mus musculus 245-256 20079899-12 2010 CONCLUSION(S): This report has demonstrated that the combination of metformin and simvastatin could lead to a better reduction of T and LH levels and thus reversing the LH:FSH ratio, lipid profile, and insulin resistance in patients with PCOS and may be an appropriate management option for patients with PCOS. Simvastatin 82-93 insulin Homo sapiens 202-209 20828695-5 2010 RESULTS: ApoM was decreased by 7% in response to simvastatin (P<0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin+bezafibrate administration. Simvastatin 49-60 apolipoprotein M Homo sapiens 9-13 20878096-2 2010 Simvastatin is a cholesterol-lowering drug which inhibits 3-hydroxy-3-methylglutarylcoenzyme CoA (HMG-CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-116 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 cyclin dependent kinase 1 Homo sapiens 60-64 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 cyclin dependent kinase 2 Homo sapiens 66-70 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 cyclin dependent kinase 4 Homo sapiens 72-76 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 cyclin D1 Homo sapiens 78-87 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 cyclin dependent kinase inhibitor 2D Homo sapiens 99-102 20878096-12 2010 Protein expression levels of cell cycle regulating proteins CDK1, CDK2, CDK4, cyclin D1, cyclin E, p19 and p27 were markedly altered by simvastatin. Simvastatin 136-147 interferon alpha inducible protein 27 Homo sapiens 107-110 20878096-14 2010 Collectively, these results suggest that simvastatin induces apoptosis in tumor cells and its anti-proliferative activity was accompanied by inhibition of cyclin-dependent kinases and cyclins, whereas CDK inhibitors p19 and p27 were enhanced. Simvastatin 41-52 interferon alpha inducible protein 27 Homo sapiens 224-227 20433776-10 2010 Simvastatin treatment greatly increased the densities of MBP immunostaining, inhibited microglial activation and reduced the numbers of pyknotic cells and neuronal loss. Simvastatin 0-11 myelin basic protein Rattus norvegicus 57-60 21122696-2 2010 OBJECTIVE: To assess the impact of switches from high-efficacy lipid-lowering therapy to simvastatin on low-density lipoprotein cholesterol (LDL-C) and goal attainment in coronary heart disease (CHD) or CHD risk-equivalent patients in a managed care setting. Simvastatin 89-100 component of oligomeric golgi complex 2 Homo sapiens 141-146 21122696-5 2010 The difference in percent change in LDL-C levels from baseline were 25.2 (95% confidence interval 21.2-29.2), 13.0 (6.0-20.0), and 3.1 (0.3-5.9) greater in switchers to simvastatin in the E/S, rosuvastatin, and atorvastatin comparisons, respectively, after adjusting for age, sex, and starting dose of the initial therapy. Simvastatin 169-180 component of oligomeric golgi complex 2 Homo sapiens 36-41 21122696-8 2010 CONCLUSIONS: Among CHD/CHD risk-equivalent patients, switching to simvastatin was associated with increases in LDL-C levels and lower LDL-C goal attainment rates. Simvastatin 66-77 component of oligomeric golgi complex 2 Homo sapiens 111-116 21122696-8 2010 CONCLUSIONS: Among CHD/CHD risk-equivalent patients, switching to simvastatin was associated with increases in LDL-C levels and lower LDL-C goal attainment rates. Simvastatin 66-77 component of oligomeric golgi complex 2 Homo sapiens 134-139 20870034-6 2010 In pulmonary arterial smooth muscle cells (PASMCs), KMUP-1 (1-100 muM) and simvastatin (10 muM) inhibited 5-HT-induced cell migration and proliferation and KMUP-1 (1-100 muM) inhibited 5-HT-induced Ca2+ influx. Simvastatin 75-86 latexin Homo sapiens 91-94 21273666-7 2010 In both IFG and hypercholesterolemic patients, simvastatin reduced fibrinogen and PAI-1 levels and factor VII activity, and it prolonged the prothrombin and partial thromboplastin time in a lipid- and glucose-independent manner. Simvastatin 47-58 fibrinogen beta chain Homo sapiens 67-77 21273666-7 2010 In both IFG and hypercholesterolemic patients, simvastatin reduced fibrinogen and PAI-1 levels and factor VII activity, and it prolonged the prothrombin and partial thromboplastin time in a lipid- and glucose-independent manner. Simvastatin 47-58 serpin family E member 1 Homo sapiens 82-87 20870034-4 2010 In isolated PA, KMUP-1 and simvastatin (0.1-100 muM) inhibited 5-HT (10 muM)-induced PA constriction. Simvastatin 27-38 latexin Homo sapiens 48-51 20870034-6 2010 In pulmonary arterial smooth muscle cells (PASMCs), KMUP-1 (1-100 muM) and simvastatin (10 muM) inhibited 5-HT-induced cell migration and proliferation and KMUP-1 (1-100 muM) inhibited 5-HT-induced Ca2+ influx. Simvastatin 75-86 latexin Homo sapiens 91-94 20870034-4 2010 In isolated PA, KMUP-1 and simvastatin (0.1-100 muM) inhibited 5-HT (10 muM)-induced PA constriction. Simvastatin 27-38 latexin Homo sapiens 72-75 20870034-7 2010 Similar to Y27632, KMUP-1 (1-100 muM) inhibited 5-HT-induced RhoA/ROCK expression, while KMUP-1, Y27632 and simvastatin at 10 muM inhibited 5-HT-induced 5-HTT expression and KMUP-1 inhibited 5-HT-induced phosphorylation of AKT and ERK1/2 in PASMCs. Simvastatin 108-119 latexin Homo sapiens 126-129 20835264-0 2010 Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels. Simvastatin 0-11 peroxisome proliferator activated receptor alpha Mus musculus 131-141 21211366-13 2010 CONCLUSIONS: simvastatin ameliorated the development of cigarette smoke-induced COPD in rats, partly by promoting alveolar epithelial cell proliferation and up-regulating the expression of VEGF. Simvastatin 13-24 vascular endothelial growth factor A Rattus norvegicus 189-193 20691674-9 2010 Simvastatin significantly increased the number of the mice responding to vaccination compared with the mice receiving only AdPEDI-(Abeta1-6)(11). Simvastatin 0-11 histocompatibility 2, O region beta locus Mus musculus 131-139 20691674-11 2010 Simvastatin treatment prevented Abeta-induced production of IFN-gamma in splenocytes. Simvastatin 0-11 interferon gamma Mus musculus 60-69 20691674-13 2010 Our results indicate that simvastatin clearly enhances the immune responses of C57BL/6 mice to the nasal vaccination with AdPEDI-(Abeta1-6)(11). Simvastatin 26-37 histocompatibility 2, P region beta locus Mus musculus 130-138 20835264-0 2010 Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels. Simvastatin 0-11 matrix metallopeptidase 9 Mus musculus 180-185 20835264-0 2010 Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels. Simvastatin 0-11 cathepsin S Mus musculus 191-196 20835264-8 2010 Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05). Simvastatin 28-39 matrix metallopeptidase 9 Mus musculus 105-110 20835264-8 2010 Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05). Simvastatin 28-39 cathepsin S Mus musculus 115-120 20835264-8 2010 Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05). Simvastatin 28-39 peroxisome proliferator activated receptor alpha Mus musculus 178-188 20835264-8 2010 Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05). Simvastatin 28-39 peroxisome proliferator activated receptor gamma Mus musculus 193-203 20835264-10 2010 Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S. Simvastatin 0-11 peroxisome proliferator activated receptor alpha Mus musculus 144-154 20835264-10 2010 Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Mus musculus 159-169 20835264-10 2010 Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S. Simvastatin 0-11 matrix metallopeptidase 9 Mus musculus 196-201 20835264-10 2010 Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S. Simvastatin 0-11 cathepsin S Mus musculus 207-212 20941469-9 2010 Whether the strong LDL-C lowering combination of simvastatin plus ezetimibe will reduce cardiovascular events over and above simvastatin monotherapy is currently being tested in the ongoing IMPROVE-IT trial. Simvastatin 49-60 component of oligomeric golgi complex 2 Homo sapiens 19-24 20920765-8 2010 Simvastatin enhanced corticosteroid-activated noncanonical nuclear factor kappaB-dependent induction of IDO by activating type I interferons and also enhanced the effect of corticosteroid on IL-10 release. Simvastatin 0-11 indoleamine 2,3-dioxygenase 1 Homo sapiens 104-107 20920765-8 2010 Simvastatin enhanced corticosteroid-activated noncanonical nuclear factor kappaB-dependent induction of IDO by activating type I interferons and also enhanced the effect of corticosteroid on IL-10 release. Simvastatin 0-11 interleukin 10 Homo sapiens 191-196 19926543-2 2010 We examined the therapeutic potential of simvastatin which up-regulates endothelial cell TM expression and activity in the dorsal ischaemic skin flap model. Simvastatin 41-52 thrombomodulin Rattus norvegicus 89-91 20150526-1 2010 Diltiazem increases systemic exposure to simvastatin via inhibition of CYP3A. Simvastatin 41-52 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-76 21050287-9 2010 Simvastatin reduced Lp-PLA2 levels by about one-quarter, but simvastatin"s vascular protection did not vary with baseline Lp-PLA2 concentration. Simvastatin 0-11 phospholipase A2 group VII Homo sapiens 20-27 19926543-12 2010 In this study, it was demonstrated that simvastatin prevented shedding of endothelial TM and contributed to flap survival. Simvastatin 40-51 thrombomodulin Rattus norvegicus 86-88 21176638-0 2010 [Simvastatin suppress lipopolysaccharides induced upregulation of lipoprotein associated phospholipase A(2) expression in macrophages via inactivation of p38MAPK pathway]. Simvastatin 1-12 phospholipase A2 group VII Homo sapiens 66-106 21059291-1 2010 OBJECTIVE: To investigate the effects of simvastatin on the proliferation, cell cycle and expression of cyclin-dependent kinase inhibitor p21 protein in human hepatocellular carcinoma (HepG2) cells in vitro. Simvastatin 41-52 H3 histone pseudogene 16 Homo sapiens 138-141 21176638-1 2010 OBJECTIVE: To investigate the effects of simvastatin on lipopolysaccharides (LPS) induced upregulation of Lp-PLA(2) in human peripheral blood monocytes-macrophages and the related mechanisms. Simvastatin 41-52 phospholipase A2 group VII Homo sapiens 106-115 21059291-7 2010 Simvastatin could also increase cyclin-dependent kinase inhibitor p21 protein expression (F = 512.133, P value less than 0.001). Simvastatin 0-11 H3 histone pseudogene 16 Homo sapiens 66-69 21176638-7 2010 RESULTS: (1) LPS significantly upregulated Lp-PLA(2) mRNA and protein expression, as well as the enzyme activity in a time and concentration dependent manner, which could be significantly attenuated by simvastatin in a time and concentration dependent manner. Simvastatin 202-213 phospholipase A2 group VII Homo sapiens 43-51 21059291-8 2010 CONCLUSION: Simvastatin can inhibit the growth of HepG2 cells in vitro, which may be explained by its effects of enhancing cyclin-dependent kinase inhibitor p21 protein expression and arresting HepG2 cells at G0/G1 phase of cell cycle. Simvastatin 12-23 H3 histone pseudogene 16 Homo sapiens 157-160 21176638-8 2010 (2) Simvastatin significantly reduced LPS-induced p38MAPK phosphorylation. Simvastatin 4-15 mitogen-activated protein kinase 14 Homo sapiens 50-53 21176638-10 2010 CONCLUSION: This study demonstrated that LPS significantly upregulated Lp-PLA(2) mRNA and protein expression, as well as the enzyme activity in a time and concentration dependent manner via Rho-p38MAPK pathway, which could be significantly suppressed by simvastatin. Simvastatin 254-265 phospholipase A2 group VII Homo sapiens 71-79 20594940-0 2010 Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 39-55 20846454-8 2010 Release of VEGF by MSCs incubated with different doses of simvastatin was assayed using ELISA. Simvastatin 58-69 vascular endothelial growth factor A Mus musculus 11-15 20846454-9 2010 RESULTS: Combined treatment with simvastatin and MSCs induced a significant improvement in blood reperfusion, a notable increase in capillary density, a highest level of VEGF protein and a significant decrease in muscle cell apoptosis compared with other groups. Simvastatin 33-44 vascular endothelial growth factor A Mus musculus 170-174 20846454-10 2010 In vitro, simvastatin inhibited MSCs apoptosis and increased VEGF release by MSCs. Simvastatin 10-21 vascular endothelial growth factor A Mus musculus 61-65 20594940-3 2010 To further investigate the statin-specific HO-1 regulation, we examined HO-1 gene expression by simvastatin in cell cultures of human endothelial cells. Simvastatin 96-107 heme oxygenase 1 Homo sapiens 72-76 20594940-4 2010 Simvastatin-dependent HO-1 gene activation was significantly reduced by pharmacological inhibition of the p38 MAPK and phosphotidylinositol-3-kinase (PI3K)/Akt pathways. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 22-26 20594940-4 2010 Simvastatin-dependent HO-1 gene activation was significantly reduced by pharmacological inhibition of the p38 MAPK and phosphotidylinositol-3-kinase (PI3K)/Akt pathways. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 156-159 20594940-5 2010 Although HO-1 is considered to be primarily regulated at the transcriptional level, simvastatin induced activity of a human HO-1 promoter gene construct only to a minor extent. Simvastatin 84-95 heme oxygenase 1 Homo sapiens 124-128 20594940-6 2010 By contrast, studies with actinomycin D indicated that the half-life of HO-1 mRNA was significantly prolonged in the presence of simvastatin suggesting a post-transcriptional mode of HO-1 regulation. Simvastatin 129-140 heme oxygenase 1 Homo sapiens 72-76 20594940-6 2010 By contrast, studies with actinomycin D indicated that the half-life of HO-1 mRNA was significantly prolonged in the presence of simvastatin suggesting a post-transcriptional mode of HO-1 regulation. Simvastatin 129-140 heme oxygenase 1 Homo sapiens 183-187 20644009-8 2010 Moreover, ClC-3 overexpression decreased the suppressive effect of simvastatin on cell proliferation and increased estimated IC(50) of simvastatin on endothelin 1- and hypo-osmolarity-induced cell proliferation from 3.40+/-0.08 and 3.50+/-0.10 micromol/L to 5.30+/-0.70 and 5.60+/-0.70 micromol/L, respectively (P<0.01; n=6). Simvastatin 67-78 chloride voltage-gated channel 3 Rattus norvegicus 10-15 20676966-4 2010 The results showed that lycopene and simvastatin applied together reduced TNFalpha and IFNgamma secretion, and abolished the increased production of the proinflammatory cytokine IL-1gamma caused by incubation with simvastatin only, an observation suggesting that simultaneous administration of both substances may reduce inflammatory responses. Simvastatin 37-48 tumor necrosis factor Homo sapiens 74-82 20676966-4 2010 The results showed that lycopene and simvastatin applied together reduced TNFalpha and IFNgamma secretion, and abolished the increased production of the proinflammatory cytokine IL-1gamma caused by incubation with simvastatin only, an observation suggesting that simultaneous administration of both substances may reduce inflammatory responses. Simvastatin 37-48 interferon gamma Homo sapiens 87-95 20676966-4 2010 The results showed that lycopene and simvastatin applied together reduced TNFalpha and IFNgamma secretion, and abolished the increased production of the proinflammatory cytokine IL-1gamma caused by incubation with simvastatin only, an observation suggesting that simultaneous administration of both substances may reduce inflammatory responses. Simvastatin 37-48 interleukin 18 Homo sapiens 178-187 20676966-4 2010 The results showed that lycopene and simvastatin applied together reduced TNFalpha and IFNgamma secretion, and abolished the increased production of the proinflammatory cytokine IL-1gamma caused by incubation with simvastatin only, an observation suggesting that simultaneous administration of both substances may reduce inflammatory responses. Simvastatin 214-225 interleukin 18 Homo sapiens 178-187 20489687-0 2010 Simvastatin reduces pressor response to centrally administered angiotensin II. Simvastatin 0-11 angiotensinogen Rattus norvegicus 63-77 20489687-11 2010 ICV infusion of Ang II elicited a significant increase in HR in the untreated group but not in the simvastatin group. Simvastatin 99-110 angiotensinogen Rattus norvegicus 16-22 20489687-13 2010 CONCLUSIONS: The results show that simvastatin reduces the pressor response to ICV-infused Ang II in rats. Simvastatin 35-46 angiotensinogen Rattus norvegicus 91-97 20566666-7 2010 RESULTS: Simvastatin significantly upregulated PGC-1alpha (P < 0.01), subsequently decreased Deltapsim (P < 0.05) and ROS generation (P < 0.01), inhibited PARP activation (P < 0.01), and further reduced VEGF expression (P < 0.01) and p38 MAPK activity (P < 0.01). Simvastatin 9-20 PPARG coactivator 1 alpha Rattus norvegicus 47-57 20566666-7 2010 RESULTS: Simvastatin significantly upregulated PGC-1alpha (P < 0.01), subsequently decreased Deltapsim (P < 0.05) and ROS generation (P < 0.01), inhibited PARP activation (P < 0.01), and further reduced VEGF expression (P < 0.01) and p38 MAPK activity (P < 0.01). Simvastatin 9-20 vascular endothelial growth factor A Rattus norvegicus 215-219 20566666-7 2010 RESULTS: Simvastatin significantly upregulated PGC-1alpha (P < 0.01), subsequently decreased Deltapsim (P < 0.05) and ROS generation (P < 0.01), inhibited PARP activation (P < 0.01), and further reduced VEGF expression (P < 0.01) and p38 MAPK activity (P < 0.01). Simvastatin 9-20 mitogen activated protein kinase 14 Rattus norvegicus 249-252 20566666-9 2010 CONCLUSIONS: Simvastatin decreases diabetes-induced mitochondrial ROS production and exerts protective effects against early retinal vascular damage in diabetic rats in association with the inhibition of mitochondrial ROS/PARP pathway mediated by PGC-1alpha. Simvastatin 13-24 PPARG coactivator 1 alpha Rattus norvegicus 247-257 20644009-8 2010 Moreover, ClC-3 overexpression decreased the suppressive effect of simvastatin on cell proliferation and increased estimated IC(50) of simvastatin on endothelin 1- and hypo-osmolarity-induced cell proliferation from 3.40+/-0.08 and 3.50+/-0.10 micromol/L to 5.30+/-0.70 and 5.60+/-0.70 micromol/L, respectively (P<0.01; n=6). Simvastatin 135-146 chloride voltage-gated channel 3 Rattus norvegicus 10-15 20644009-8 2010 Moreover, ClC-3 overexpression decreased the suppressive effect of simvastatin on cell proliferation and increased estimated IC(50) of simvastatin on endothelin 1- and hypo-osmolarity-induced cell proliferation from 3.40+/-0.08 and 3.50+/-0.10 micromol/L to 5.30+/-0.70 and 5.60+/-0.70 micromol/L, respectively (P<0.01; n=6). Simvastatin 135-146 endothelin 1 Rattus norvegicus 150-162 20644009-9 2010 Furthermore, the expression of ClC-3 was increased in basilar artery during hypertension, and simvastatin normalized the upregulation of ClC-3. Simvastatin 94-105 chloride voltage-gated channel 3 Rattus norvegicus 137-142 20936727-0 2010 [Effects of simvastatin on expression of CTGF and alpha-SMA in renal tubulointerstitium of rats with diabetic nephropathy]. Simvastatin 12-23 cellular communication network factor 2 Rattus norvegicus 41-45 19895202-11 2010 These beneficial effects of simvastatin may be mediated by inhibiting astrocyte activation after TBI through modifying the caveolin-1 expression in lipid rafts and the subsequent modulation of EGFR phosphorylation in lipid rafts. Simvastatin 28-39 caveolin 1 Rattus norvegicus 123-133 19895202-11 2010 These beneficial effects of simvastatin may be mediated by inhibiting astrocyte activation after TBI through modifying the caveolin-1 expression in lipid rafts and the subsequent modulation of EGFR phosphorylation in lipid rafts. Simvastatin 28-39 epidermal growth factor receptor Rattus norvegicus 193-197 21472326-8 2010 This effect was statin-specific as the down-regulation of SATB1 was brought about by hydrophobic statins, such as simvastatin and fluvastatin, but not by hydrophilic pravastatin. Simvastatin 114-125 SATB homeobox 1 Homo sapiens 58-63 19895202-9 2010 Simvastatin modified the caveolin-1 expression in lipid rafts in astrocyte cell membrane, suppressed the phosphorylation of EGFR in lipid rafts of astrocytes after OGD, and inhibited the OGD-induced interleukin-1 production. Simvastatin 0-11 caveolin 1 Rattus norvegicus 25-35 19895202-9 2010 Simvastatin modified the caveolin-1 expression in lipid rafts in astrocyte cell membrane, suppressed the phosphorylation of EGFR in lipid rafts of astrocytes after OGD, and inhibited the OGD-induced interleukin-1 production. Simvastatin 0-11 epidermal growth factor receptor Rattus norvegicus 124-128 20671065-7 2010 Simvastatin, which inhibited ABCA1 expression in PC-3 and DU145 cells, attenuated HDL-induced PC-3 and DU145 cell proliferation, migration, and ERK1/2 and Akt phosphorylation. Simvastatin 0-11 ATP binding cassette subfamily A member 1 Homo sapiens 29-34 20671065-7 2010 Simvastatin, which inhibited ABCA1 expression in PC-3 and DU145 cells, attenuated HDL-induced PC-3 and DU145 cell proliferation, migration, and ERK1/2 and Akt phosphorylation. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 144-150 20671065-7 2010 Simvastatin, which inhibited ABCA1 expression in PC-3 and DU145 cells, attenuated HDL-induced PC-3 and DU145 cell proliferation, migration, and ERK1/2 and Akt phosphorylation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 155-158 20809760-4 2010 Close focus is directed at mice model studies involving the Ccm2 gene product signaling pathway, revealing an important role for the use of simvastatin or other RhoA inhibitors as a therapeutic modality in the treatment of CCM. Simvastatin 140-151 cerebral cavernous malformation 2 Mus musculus 60-64 20936727-0 2010 [Effects of simvastatin on expression of CTGF and alpha-SMA in renal tubulointerstitium of rats with diabetic nephropathy]. Simvastatin 12-23 actin gamma 2, smooth muscle Rattus norvegicus 50-59 20936727-1 2010 OBJECTIVE: To investigate the effects of low-dose simvastatin on the expression of connective tissue growth factor (CTGF) and alpha-smooth muscle actin (alpha-SMA) in the renal tubulointerstitium of rats with diabetic nephropathy. Simvastatin 50-61 cellular communication network factor 2 Rattus norvegicus 83-114 20936727-1 2010 OBJECTIVE: To investigate the effects of low-dose simvastatin on the expression of connective tissue growth factor (CTGF) and alpha-smooth muscle actin (alpha-SMA) in the renal tubulointerstitium of rats with diabetic nephropathy. Simvastatin 50-61 cellular communication network factor 2 Rattus norvegicus 116-120 20936727-1 2010 OBJECTIVE: To investigate the effects of low-dose simvastatin on the expression of connective tissue growth factor (CTGF) and alpha-smooth muscle actin (alpha-SMA) in the renal tubulointerstitium of rats with diabetic nephropathy. Simvastatin 50-61 actin gamma 2, smooth muscle Rattus norvegicus 126-151 20936727-1 2010 OBJECTIVE: To investigate the effects of low-dose simvastatin on the expression of connective tissue growth factor (CTGF) and alpha-smooth muscle actin (alpha-SMA) in the renal tubulointerstitium of rats with diabetic nephropathy. Simvastatin 50-61 actin gamma 2, smooth muscle Rattus norvegicus 153-162 20936727-8 2010 CONCLUSION: Simvastatin with a under cholesterol-lowering dose, can decrease the expression levels of CTGF and alpha-SMA in renal tubulointerstitium of rats with diabetic nephropathy, by which the progression of the tubulointerstitial fibrosis would be delayed. Simvastatin 12-23 cellular communication network factor 2 Rattus norvegicus 102-106 20936727-8 2010 CONCLUSION: Simvastatin with a under cholesterol-lowering dose, can decrease the expression levels of CTGF and alpha-SMA in renal tubulointerstitium of rats with diabetic nephropathy, by which the progression of the tubulointerstitial fibrosis would be delayed. Simvastatin 12-23 actin gamma 2, smooth muscle Rattus norvegicus 111-120 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 126-129 20545695-8 2010 Simvastatin significantly reduced expression of OPN and the integrins, and decreased ECM invasion. Simvastatin 0-11 secreted phosphoprotein 1 Homo sapiens 48-51 20545695-8 2010 Simvastatin significantly reduced expression of OPN and the integrins, and decreased ECM invasion. Simvastatin 0-11 multimerin 1 Homo sapiens 85-88 20491794-5 2010 In this study, we investigated the effect of simvastatin on the production of IL-10, TGF-beta and IDO production and the proliferation of T(regs) using several cancer cell lines, and Lewis lung cancer (3LL) cells-inoculated mouse tumour model. Simvastatin 45-56 indoleamine 2,3-dioxygenase 1 Mus musculus 98-101 20491794-7 2010 The production of the immune regulatory markers IL-10, TGF-beta in 3LL and NCI-H292 cells increased after treatment with simvastatin. Simvastatin 121-132 interleukin 10 Mus musculus 48-53 20491794-7 2010 The production of the immune regulatory markers IL-10, TGF-beta in 3LL and NCI-H292 cells increased after treatment with simvastatin. Simvastatin 121-132 transforming growth factor, beta 1 Mus musculus 55-63 20491794-8 2010 The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. Simvastatin 109-120 indoleamine 2,3-dioxygenase 1 Mus musculus 18-21 20491794-8 2010 The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. Simvastatin 109-120 forkhead box P3 Mus musculus 26-41 20491794-8 2010 The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. Simvastatin 109-120 forkhead box P3 Mus musculus 43-48 20408897-0 2010 Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Simvastatin 0-11 forkhead box P3 Mus musculus 20-25 20408897-5 2010 We demonstrate here that simvastatin blockade of the mevalonate pathway can mediate induction of mouse Foxp3(+) T cells and that simvastatin can synergize with low levels of TGF-beta to induce Foxp3(+) T cells. Simvastatin 25-36 forkhead box P3 Mus musculus 103-108 20408897-5 2010 We demonstrate here that simvastatin blockade of the mevalonate pathway can mediate induction of mouse Foxp3(+) T cells and that simvastatin can synergize with low levels of TGF-beta to induce Foxp3(+) T cells. Simvastatin 129-140 forkhead box P3 Mus musculus 193-198 20408897-6 2010 The effects of simvastatin are secondary to a blockade of protein geranylgeranylation, are mediated at late time-points after T-cell activation, and are associated with demethylation of the Foxp3 promoter. Simvastatin 15-26 forkhead box P3 Mus musculus 190-195 20408897-7 2010 One major effect of simvastatin was inhibition of the induction of Smad6 and Smad7, inhibitory Smads that inhibit TGF-beta signalling. Simvastatin 20-31 SMAD family member 6 Mus musculus 67-72 20408897-7 2010 One major effect of simvastatin was inhibition of the induction of Smad6 and Smad7, inhibitory Smads that inhibit TGF-beta signalling. Simvastatin 20-31 SMAD family member 7 Mus musculus 77-82 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 134-137 19631345-8 2010 Simvastatin pretreatment reduced the LPS-induced increase in serum levels of ALT by 65% in hepatectomized animals. Simvastatin 0-11 glutamic pyruvic transaminase, soluble Mus musculus 77-80 20653799-1 2010 BACKGROUND: The introduction of a generic formulation of simvastatin has created the potential to provide significant low-density lipoprotein cholesterol (LDL-C) reduction in a highly cost-effective manner. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 118-153 20653799-1 2010 BACKGROUND: The introduction of a generic formulation of simvastatin has created the potential to provide significant low-density lipoprotein cholesterol (LDL-C) reduction in a highly cost-effective manner. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 155-160 20220057-5 2010 Inhibition of H-Ras by simvastatin on diabetes-induced activation of H-Ras was evaluated. Simvastatin 23-34 HRas proto-oncogene, GTPase Rattus norvegicus 14-19 20220057-5 2010 Inhibition of H-Ras by simvastatin on diabetes-induced activation of H-Ras was evaluated. Simvastatin 23-34 HRas proto-oncogene, GTPase Rattus norvegicus 69-74 20220057-9 2010 Inhibition of H-Ras, both in diabetic rats (simvastatin) and in isolated endothelial cells (H-Ras siRNA), abrogated the activation of MMP-9 and prevented the reduction of TIMP-1. Simvastatin 44-55 HRas proto-oncogene, GTPase Rattus norvegicus 14-19 20659230-10 2010 Chronic simvastatin treatment reduced baseline collateral vascular resistance and portal pressure and enhanced SRS eNOS, COX-2 and TXA(2)-S mRNA expression. Simvastatin 8-19 cytochrome c oxidase II, mitochondrial Rattus norvegicus 121-126 19631345-10 2010 LPS-provoked serum levels of TNF-alpha were decreased by 83% in hepatectomized animals treated with simvastatin. Simvastatin 100-111 tumor necrosis factor Mus musculus 29-38 19631345-11 2010 TNF-alpha-induced leukocyte adhesion as well as P-selectin expression in endothelial cells and LFA-1 function were inhibited by simvastatin in vitro. Simvastatin 128-139 tumor necrosis factor Mus musculus 0-9 19631345-11 2010 TNF-alpha-induced leukocyte adhesion as well as P-selectin expression in endothelial cells and LFA-1 function were inhibited by simvastatin in vitro. Simvastatin 128-139 selectin, platelet Mus musculus 48-58 19631345-11 2010 TNF-alpha-induced leukocyte adhesion as well as P-selectin expression in endothelial cells and LFA-1 function were inhibited by simvastatin in vitro. Simvastatin 128-139 integrin alpha L Mus musculus 95-100 20493886-4 2010 KEY FINDINGS: As expected, simvastatin and LSS separately enhanced KLF2, eNOS, and TM mRNA expressions. Simvastatin 27-38 Kruppel like factor 2 Homo sapiens 67-71 20606606-7 2010 Importantly, simvastatin treatment blocked the decay of KLF2, sustaining a vasoprotective phenotype, and preventing endothelial activation and apoptosis. Simvastatin 13-24 Kruppel like factor 2 Homo sapiens 56-60 20493886-4 2010 KEY FINDINGS: As expected, simvastatin and LSS separately enhanced KLF2, eNOS, and TM mRNA expressions. Simvastatin 27-38 thrombomodulin Homo sapiens 83-85 20493886-0 2010 Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. Simvastatin 10-21 thrombomodulin Homo sapiens 85-99 20493886-6 2010 The highest KLF2, eNOS, and TM mRNA levels were detected at 10 microM simvastatin and 25 dynes/cm(2). Simvastatin 70-81 Kruppel like factor 2 Homo sapiens 12-16 20493886-6 2010 The highest KLF2, eNOS, and TM mRNA levels were detected at 10 microM simvastatin and 25 dynes/cm(2). Simvastatin 70-81 thrombomodulin Homo sapiens 28-30 20493886-8 2010 Combining LSS and simvastatin produced an overall additive increase in KLF2, eNOS, and TM mRNA. Simvastatin 18-29 Kruppel like factor 2 Homo sapiens 71-75 20493886-8 2010 Combining LSS and simvastatin produced an overall additive increase in KLF2, eNOS, and TM mRNA. Simvastatin 18-29 thrombomodulin Homo sapiens 87-89 20493886-10 2010 SIGNIFICANCE: Our results suggest an additive increase in KLF2, eNOS, and TM expressions when simvastatin and LSS are combined. Simvastatin 94-105 Kruppel like factor 2 Homo sapiens 58-62 20493886-10 2010 SIGNIFICANCE: Our results suggest an additive increase in KLF2, eNOS, and TM expressions when simvastatin and LSS are combined. Simvastatin 94-105 thrombomodulin Homo sapiens 74-76 20562903-0 2010 Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 118-121 20676836-5 2010 In both groups studied, simvastatin significantly improved lipids, and reduced C-reactive protein and fibrinogen levels. Simvastatin 24-35 fibrinogen beta chain Homo sapiens 102-112 20381859-3 2010 We found 0.01 microm, 0.1 microm, and 1 microm simvastatin could induce hADSCs" osteoblastic differentiation in vitro that accompanied with non-inhibition on cell proliferation, high alkaline phosphatase activity, more mineralization deposition and more expression of osteoblast-related genes such as osteocalcin, core binding factor alpha1, bone morphogenetic protein-2, vascular endothelial growth factor, and basic fibroblast growth factor. Simvastatin 47-58 bone gamma-carboxyglutamate protein Homo sapiens 301-312 20381859-3 2010 We found 0.01 microm, 0.1 microm, and 1 microm simvastatin could induce hADSCs" osteoblastic differentiation in vitro that accompanied with non-inhibition on cell proliferation, high alkaline phosphatase activity, more mineralization deposition and more expression of osteoblast-related genes such as osteocalcin, core binding factor alpha1, bone morphogenetic protein-2, vascular endothelial growth factor, and basic fibroblast growth factor. Simvastatin 47-58 bone morphogenetic protein 2 Homo sapiens 342-370 20381859-3 2010 We found 0.01 microm, 0.1 microm, and 1 microm simvastatin could induce hADSCs" osteoblastic differentiation in vitro that accompanied with non-inhibition on cell proliferation, high alkaline phosphatase activity, more mineralization deposition and more expression of osteoblast-related genes such as osteocalcin, core binding factor alpha1, bone morphogenetic protein-2, vascular endothelial growth factor, and basic fibroblast growth factor. Simvastatin 47-58 vascular endothelial growth factor A Homo sapiens 372-406 20381859-4 2010 Simvastatin at 1 mum seemed the most optimal concentration due to its high osteocalcin secretion in media (P < 0.01). Simvastatin 0-11 bone gamma-carboxyglutamate protein Homo sapiens 75-86 20487050-8 2010 In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a significantly higher proportion of patients during a 6-week period than switching to either atorvastatin 40 mg or rosuvastatin 5-10 mg. Simvastatin 40-51 component of oligomeric golgi complex 2 Homo sapiens 77-82 20413733-0 2010 Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Simvastatin 86-97 low density lipoprotein receptor Homo sapiens 22-26 20413733-0 2010 Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-36 20413733-3 2010 METHODS AND RESULTS: Haplotypes in the LDLR 3"-untranslated region (3-UTR) were tested for association with lipid-lowering response to simvastatin treatment in the Cholesterol and Pharmacogenetics trial (335 blacks and 609 whites). Simvastatin 135-146 low density lipoprotein receptor Homo sapiens 39-43 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 low density lipoprotein receptor Homo sapiens 0-4 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 low density lipoprotein receptor Homo sapiens 18-22 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 apolipoprotein B Homo sapiens 191-207 20413733-6 2010 We observed similar differences when measuring simvastatin-mediated induction of low-density lipoprotein receptor surface expression using lymphoblast cell lines (P=0.03). Simvastatin 47-58 low density lipoprotein receptor Homo sapiens 81-113 20413733-7 2010 CONCLUSIONS: We have identified a common LDLR 3-UTR haplotype that is associated with attenuated lipid-lowering response to simvastatin treatment. Simvastatin 124-135 low density lipoprotein receptor Homo sapiens 41-45 20676836-5 2010 In both groups studied, simvastatin significantly improved lipids, and reduced C-reactive protein and fibrinogen levels. Simvastatin 24-35 C-reactive protein Homo sapiens 79-97 20525309-8 2010 Simvastatin inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)gamma2, protein kinase C (PKC), and mitogen-activated protein kinases (i.e., p38 MAPK, JNKs) phosphorylation in washed platelets. Simvastatin 0-11 phospholipase C gamma 2 Homo sapiens 153-163 20417291-6 2010 RESULTS: Treatment of osteoarthritic chondrocytes with simvastatin decreased mRNA levels of MMP-13 and MMP-1 whether under basal conditions or during stimulation with IL-1beta. Simvastatin 55-66 matrix metallopeptidase 13 Homo sapiens 92-98 20417291-6 2010 RESULTS: Treatment of osteoarthritic chondrocytes with simvastatin decreased mRNA levels of MMP-13 and MMP-1 whether under basal conditions or during stimulation with IL-1beta. Simvastatin 55-66 matrix metallopeptidase 1 Homo sapiens 92-97 20417291-6 2010 RESULTS: Treatment of osteoarthritic chondrocytes with simvastatin decreased mRNA levels of MMP-13 and MMP-1 whether under basal conditions or during stimulation with IL-1beta. Simvastatin 55-66 interleukin 1 beta Homo sapiens 167-175 20417291-10 2010 An inhibitor of GGT-1 mimicked the simvastatin-mediated reduction in MMP-13 expression by chondrocytes. Simvastatin 35-46 gamma-glutamyltransferase 1 Homo sapiens 16-21 20417291-10 2010 An inhibitor of GGT-1 mimicked the simvastatin-mediated reduction in MMP-13 expression by chondrocytes. Simvastatin 35-46 matrix metallopeptidase 13 Homo sapiens 69-75 20417291-11 2010 Finally, consistent with impacts on MMP-13 and MMP-1 expression, simvastatin as well as the GGT-1 inhibitor both blocked type II collagen degradation in primary human articular cartilage explants. Simvastatin 65-76 matrix metallopeptidase 13 Homo sapiens 36-42 20417291-11 2010 Finally, consistent with impacts on MMP-13 and MMP-1 expression, simvastatin as well as the GGT-1 inhibitor both blocked type II collagen degradation in primary human articular cartilage explants. Simvastatin 65-76 matrix metallopeptidase 1 Homo sapiens 36-41 20361961-5 2010 Simvastatin and atorvastatin dose-dependently reduced the OGD and simulated reperfusion-induced lactate dehydrogenase (LDH) release from primary BPAEC and BPAEC between passage 4 and 15. Simvastatin 0-11 LDH Bos taurus 96-117 20361961-5 2010 Simvastatin and atorvastatin dose-dependently reduced the OGD and simulated reperfusion-induced lactate dehydrogenase (LDH) release from primary BPAEC and BPAEC between passage 4 and 15. Simvastatin 0-11 LDH Bos taurus 119-122 20361961-7 2010 Consistent with those results, simvastatin and atorvastatin increased the expression of phospho-Akt/activated Akt, and did not change the expression of phospho-ERK/activated ERK after the OGD and simulated reperfusion. Simvastatin 31-42 AKT serine/threonine kinase 1 Bos taurus 96-99 20361961-7 2010 Consistent with those results, simvastatin and atorvastatin increased the expression of phospho-Akt/activated Akt, and did not change the expression of phospho-ERK/activated ERK after the OGD and simulated reperfusion. Simvastatin 31-42 AKT serine/threonine kinase 1 Bos taurus 110-113 20529243-10 2010 CONCLUSION: Expected synergistic lowering effects of a simvastatin and ezetimibe combination on LDL-cholesterol, apolipoprotein B and triglycerides levels were confirmed in subjects with early disturbances of glucose metabolism. Simvastatin 55-66 apolipoprotein B Homo sapiens 113-129 20488825-0 2010 Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Simvastatin 0-11 interferon beta 1 Homo sapiens 88-103 20488825-15 2010 This interventional study provides Class I evidence stating that adding simvastatin 40 mg/day to IFNb 1a 30 microg a week in patients with relapsing-remitting multiple sclerosis may reduce the relapse rate (moderate effect size r = 0.29) (p = 0.01) compared with treatment with IFNb 1a alone. Simvastatin 72-83 interferon beta 1 Homo sapiens 97-103 20488825-15 2010 This interventional study provides Class I evidence stating that adding simvastatin 40 mg/day to IFNb 1a 30 microg a week in patients with relapsing-remitting multiple sclerosis may reduce the relapse rate (moderate effect size r = 0.29) (p = 0.01) compared with treatment with IFNb 1a alone. Simvastatin 72-83 interferon beta 1 Homo sapiens 97-101 20602615-1 2010 AIM: Administered at maximal dosages, the most common statins--atorvastatin, simvastatin and rosuvastatin--lower low-density lipoprotein cholesterol (LDLC) by an average of 37-57% in patients with primary hypercholesterolemia. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 150-154 22049271-7 2010 The results indicated that simvastatin in low concentration (0.25 muM) seems to be growth stimulator although cell viability was reduced in concentrations of >=2 muM. Simvastatin 27-38 latexin Homo sapiens 66-69 22049271-7 2010 The results indicated that simvastatin in low concentration (0.25 muM) seems to be growth stimulator although cell viability was reduced in concentrations of >=2 muM. Simvastatin 27-38 latexin Homo sapiens 165-168 20346376-0 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Simvastatin 0-11 bone morphogenetic protein 2 Mus musculus 59-87 20346376-0 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Simvastatin 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 92-97 20346376-0 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 117-121 20346376-0 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 123-126 20346376-0 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Simvastatin 0-11 Rous sarcoma oncogene Mus musculus 131-134 20346376-2 2010 Here we examined roles of simvastatin in osteoclast function and differentiation induced by RANKL and BMP-2 using mouse macrophage-like MLC-6 cells and human osteoclast precursor cells. Simvastatin 26-37 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 92-97 20346376-2 2010 Here we examined roles of simvastatin in osteoclast function and differentiation induced by RANKL and BMP-2 using mouse macrophage-like MLC-6 cells and human osteoclast precursor cells. Simvastatin 26-37 bone morphogenetic protein 2 Mus musculus 102-107 20346376-5 2010 Simvastatin suppressed osteoclastic activity shown by increases in RANK, TRAP and cathepsin-K expression induced by RANKL and BMP-2. Simvastatin 0-11 acid phosphatase 5, tartrate resistant Mus musculus 73-77 20346376-5 2010 Simvastatin suppressed osteoclastic activity shown by increases in RANK, TRAP and cathepsin-K expression induced by RANKL and BMP-2. Simvastatin 0-11 cathepsin K Mus musculus 82-93 20346376-5 2010 Simvastatin suppressed osteoclastic activity shown by increases in RANK, TRAP and cathepsin-K expression induced by RANKL and BMP-2. Simvastatin 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 116-121 20346376-5 2010 Simvastatin suppressed osteoclastic activity shown by increases in RANK, TRAP and cathepsin-K expression induced by RANKL and BMP-2. Simvastatin 0-11 bone morphogenetic protein 2 Mus musculus 126-131 20346376-7 2010 Simvastatin activated ERK, SAPK/JNK and AKT pathways and inactivated Ras in MLC-6 cells. Simvastatin 0-11 mitogen-activated protein kinase 1 Mus musculus 22-25 20346376-7 2010 Simvastatin activated ERK, SAPK/JNK and AKT pathways and inactivated Ras in MLC-6 cells. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 40-43 20346376-10 2010 In addition, Src phosphorylation induced by RANKL, which is involved in osteoclast differentiation, was suppressed by simvastatin. Simvastatin 118-129 Rous sarcoma oncogene Mus musculus 13-16 20346376-10 2010 In addition, Src phosphorylation induced by RANKL, which is involved in osteoclast differentiation, was suppressed by simvastatin. Simvastatin 118-129 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 44-49 20346376-11 2010 We further confirmed an inhibitory mechanism of simvastatin on osteoclast differentiation using human osteoclast precursor cells which express BMP receptor and Smad signaling machinery. Simvastatin 48-59 SMAD family member 1 Mus musculus 160-164 20346376-12 2010 Simvastatin also activated ERK pathways and inactivated Src phosphorylation in human osteoclasts differentiated by M-CSF and RANKL treatments. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 27-30 20346376-12 2010 Simvastatin also activated ERK pathways and inactivated Src phosphorylation in human osteoclasts differentiated by M-CSF and RANKL treatments. Simvastatin 0-11 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 56-59 20346376-12 2010 Simvastatin also activated ERK pathways and inactivated Src phosphorylation in human osteoclasts differentiated by M-CSF and RANKL treatments. Simvastatin 0-11 colony stimulating factor 1 Homo sapiens 115-120 20346376-12 2010 Simvastatin also activated ERK pathways and inactivated Src phosphorylation in human osteoclasts differentiated by M-CSF and RANKL treatments. Simvastatin 0-11 TNF superfamily member 11 Homo sapiens 125-130 20346376-13 2010 The inhibition of TRAP and RANK expression by simvastatin was reversed by ERK inhibition, whereas Src inhibitor enhanced simvastatin-induced suppression of osteoclast markers. Simvastatin 46-57 acid phosphatase 5, tartrate resistant Mus musculus 18-22 20346376-13 2010 The inhibition of TRAP and RANK expression by simvastatin was reversed by ERK inhibition, whereas Src inhibitor enhanced simvastatin-induced suppression of osteoclast markers. Simvastatin 46-57 mitogen-activated protein kinase 1 Mus musculus 74-77 20346376-13 2010 The inhibition of TRAP and RANK expression by simvastatin was reversed by ERK inhibition, whereas Src inhibitor enhanced simvastatin-induced suppression of osteoclast markers. Simvastatin 121-132 Rous sarcoma oncogene Mus musculus 98-101 20346376-14 2010 Collectively, our data show that simvastatin inhibits osteoclastic differentiation through inhibiting Src as well as enhancing MAPK/AKT pathways. Simvastatin 33-44 Rous sarcoma oncogene Mus musculus 102-105 20346376-14 2010 Collectively, our data show that simvastatin inhibits osteoclastic differentiation through inhibiting Src as well as enhancing MAPK/AKT pathways. Simvastatin 33-44 mitogen-activated protein kinase 1 Homo sapiens 127-131 20346376-14 2010 Collectively, our data show that simvastatin inhibits osteoclastic differentiation through inhibiting Src as well as enhancing MAPK/AKT pathways. Simvastatin 33-44 thymoma viral proto-oncogene 1 Mus musculus 132-135 20525309-8 2010 Simvastatin inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)gamma2, protein kinase C (PKC), and mitogen-activated protein kinases (i.e., p38 MAPK, JNKs) phosphorylation in washed platelets. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 234-237 20525309-9 2010 Simvastatin obviously increased both cyclic AMP and cyclic GMP levels. Simvastatin 0-11 5'-nucleotidase, cytosolic II Homo sapiens 59-62 20525309-10 2010 Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. Simvastatin 0-11 vasodilator stimulated phosphoprotein Homo sapiens 43-80 20525309-10 2010 Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. Simvastatin 0-11 vasodilator stimulated phosphoprotein Homo sapiens 82-86 20525309-10 2010 Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 109-142 20525309-11 2010 SQ22536, an inhibitor of adenylate cyclase, markedly reversed the simvastatin-mediated inhibitory effects on platelet aggregation, PLCgamma2 and p38 MAPK phosphorylation, and simvastatin-mediated stimulatory effects on VASP and eNOS phosphorylation. Simvastatin 66-77 phospholipase C gamma 2 Homo sapiens 131-140 20525309-11 2010 SQ22536, an inhibitor of adenylate cyclase, markedly reversed the simvastatin-mediated inhibitory effects on platelet aggregation, PLCgamma2 and p38 MAPK phosphorylation, and simvastatin-mediated stimulatory effects on VASP and eNOS phosphorylation. Simvastatin 66-77 mitogen-activated protein kinase 14 Homo sapiens 145-148 20525309-11 2010 SQ22536, an inhibitor of adenylate cyclase, markedly reversed the simvastatin-mediated inhibitory effects on platelet aggregation, PLCgamma2 and p38 MAPK phosphorylation, and simvastatin-mediated stimulatory effects on VASP and eNOS phosphorylation. Simvastatin 66-77 vasodilator stimulated phosphoprotein Homo sapiens 219-223 20525309-12 2010 CONCLUSION: The most important findings of this study demonstrate for the first time that inhibitory effect of simvastatin in platelet activation may involve activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of the PLCgamma2-PKC-p38 MAPK-TxA2 cascade, and finally inhibition of platelet aggregation. Simvastatin 111-122 5'-nucleotidase, cytosolic II Homo sapiens 202-205 20525309-12 2010 CONCLUSION: The most important findings of this study demonstrate for the first time that inhibitory effect of simvastatin in platelet activation may involve activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of the PLCgamma2-PKC-p38 MAPK-TxA2 cascade, and finally inhibition of platelet aggregation. Simvastatin 111-122 phospholipase C gamma 2 Homo sapiens 246-255 20525309-12 2010 CONCLUSION: The most important findings of this study demonstrate for the first time that inhibitory effect of simvastatin in platelet activation may involve activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of the PLCgamma2-PKC-p38 MAPK-TxA2 cascade, and finally inhibition of platelet aggregation. Simvastatin 111-122 mitogen-activated protein kinase 14 Homo sapiens 260-263 20378830-6 2010 The decrease in the IAS tone by simvastatin was associated with the decrease in the prenylation of RhoA, as well as RhoA/ROCK in the membrane fractions of the IAS, in the basal state. Simvastatin 32-43 ras homolog family member A Homo sapiens 99-103 20378830-6 2010 The decrease in the IAS tone by simvastatin was associated with the decrease in the prenylation of RhoA, as well as RhoA/ROCK in the membrane fractions of the IAS, in the basal state. Simvastatin 32-43 ras homolog family member A Homo sapiens 116-120 20378830-8 2010 Relaxation of the IAS smooth muscle via HMGCRI simvastatin is mediated via the downstream decrease in the levels of RhoA prenylation and ROCK activity. Simvastatin 47-58 ras homolog family member A Homo sapiens 116-120 20359552-0 2010 Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Simvastatin 0-11 solute carrier family 13 member 2 Rattus norvegicus 40-45 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Simvastatin 66-77 vascular endothelial growth factor A Rattus norvegicus 241-245 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Simvastatin 66-77 von Willebrand factor Rattus norvegicus 273-294 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Simvastatin 66-77 von Willebrand factor Rattus norvegicus 296-299 20144589-7 2010 The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. Simvastatin 66-77 tumor necrosis factor Rattus norvegicus 344-353 20144589-8 2010 A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Simvastatin 191-202 tumor necrosis factor Rattus norvegicus 69-78 20144589-8 2010 A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Simvastatin 191-202 vascular endothelial growth factor A Rattus norvegicus 80-84 20144589-8 2010 A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Simvastatin 191-202 von Willebrand factor Rattus norvegicus 89-92 20359552-7 2010 In vivo, simvastatin treatment dose-dependently suppressed acrolein-induced goblet cell hyperplasia and metaplasia in bronchial epithelium and inhibited ERK phosphorylation in rat lung homogenates. Simvastatin 9-20 Eph receptor B1 Rattus norvegicus 153-156 20359552-8 2010 Moreover, simvastatin inhibited Muc5AC mucin synthesis at both the mRNA and protein levels in the lung. Simvastatin 10-21 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 32-38 20359552-8 2010 Moreover, simvastatin inhibited Muc5AC mucin synthesis at both the mRNA and protein levels in the lung. Simvastatin 10-21 solute carrier family 13 member 2 Rattus norvegicus 39-44 20207952-7 2010 Furthermore, multivariate logistic-regression analysis revealed that patients with at least 1 variant CYP3A5 and/or BCRP allele (n=186) were more likely to achieve the LDL cholesterol target (odds ratio: 2.289; 95% CI: 1.157, 4.527; P=0.017; rosuvastatin 54.0% to target vs simvastatin 33.7%). Simvastatin 274-285 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 102-108 20207952-7 2010 Furthermore, multivariate logistic-regression analysis revealed that patients with at least 1 variant CYP3A5 and/or BCRP allele (n=186) were more likely to achieve the LDL cholesterol target (odds ratio: 2.289; 95% CI: 1.157, 4.527; P=0.017; rosuvastatin 54.0% to target vs simvastatin 33.7%). Simvastatin 274-285 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 116-120 20203109-8 2010 Buspirone, sildenafil, and simvastatin exhibited similar or greater sensitivity than midazolam to CYP3A4 inhibition in vivo. Simvastatin 27-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 20203109-9 2010 Finally, Simcyp was used to predict the in vivo magnitude of CYP3A4 DDIs caused by AMG 458 using midazolam, sildenafil, simvastatin, and testosterone as probe substrates. Simvastatin 120-131 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 20497745-1 2010 OBJECTIVE: This study was conducted to investigate any potential effect of the dipeptidyl peptidase-4 inhibitor linagliptin (which is being developed to improve glycemic control in patients with Type 2 diabetes) on the pharmacokinetics of simvastatin (a lipid-lowering, HMG-CoA reductase inhibitor). Simvastatin 239-250 dipeptidyl peptidase 4 Homo sapiens 79-101 20359552-2 2010 Since the small G-protein Ras is known to modulate cellular functions in the lung, we sought to investigate whether the Ras inhibitor simvastatin could attenuate acrolein-induced mucin production in rat airways. Simvastatin 134-145 solute carrier family 13 member 2 Rattus norvegicus 179-184 20199786-4 2010 This study assessed the effects of simvastatin and ezetimibe, in monotherapy or in combination, on markers of endothelial function and insulin sensitivity. Simvastatin 35-46 insulin Homo sapiens 135-142 20512931-1 2010 We previously identified the marked upregulation of integrin beta4 in human lung endothelial cells (EC) treated with simvastatin, an HMG coA-reductase inhibitor with vascular-protective and anti-inflammatory properties in murine models of acute lung injury (ALI). Simvastatin 117-128 integrin subunit beta 4 Homo sapiens 52-66 20512931-1 2010 We previously identified the marked upregulation of integrin beta4 in human lung endothelial cells (EC) treated with simvastatin, an HMG coA-reductase inhibitor with vascular-protective and anti-inflammatory properties in murine models of acute lung injury (ALI). Simvastatin 117-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 133-150 20461472-0 2010 Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia. Simvastatin 13-24 apolipoprotein B Homo sapiens 28-36 20461472-3 2010 The objective of the study was to examine the influence of simvastatin on the secretion of apoB-100-containing lipoproteins in fasting non-obese subjects. Simvastatin 59-70 apolipoprotein B Homo sapiens 91-99 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Simvastatin 10-21 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 91-97 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Simvastatin 10-21 solute carrier family 13 member 2 Rattus norvegicus 98-103 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Simvastatin 10-21 epidermal growth factor receptor Rattus norvegicus 140-144 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Simvastatin 10-21 Eph receptor B1 Rattus norvegicus 145-148 20359552-11 2010 Our results suggest that simvastatin may attenuate acrolein-induced mucin protein synthesis in the airway and airway inflammation, possibly by blocking ERK activation mediated by Ras protein isoprenylation. Simvastatin 25-36 solute carrier family 13 member 2 Rattus norvegicus 68-73 20359552-11 2010 Our results suggest that simvastatin may attenuate acrolein-induced mucin protein synthesis in the airway and airway inflammation, possibly by blocking ERK activation mediated by Ras protein isoprenylation. Simvastatin 25-36 Eph receptor B1 Rattus norvegicus 152-155 19555424-9 2010 In wild-type mice, systemic treatment with either telmisartan or simvastatin elevated the number of sca-1/flk-1-positive EPC in bone marrow and peripheral blood, spleen-derived acLDL/lectin double-positive EPC, EPC migration and EC-CFU. Simvastatin 65-76 ataxin 1 Mus musculus 100-105 19555424-9 2010 In wild-type mice, systemic treatment with either telmisartan or simvastatin elevated the number of sca-1/flk-1-positive EPC in bone marrow and peripheral blood, spleen-derived acLDL/lectin double-positive EPC, EPC migration and EC-CFU. Simvastatin 65-76 kinase insert domain protein receptor Mus musculus 106-111 20445760-9 2010 There was no overlap of lipids whose changes correlated with LDL-C or CRP responses to simvastatin suggesting that distinct metabolic pathways govern statin effects on these two biomarkers. Simvastatin 87-98 C-reactive protein Homo sapiens 70-73 20199786-9 2010 After 12 weeks of monotherapy, plasminogen activator inhibitor-1 levels and urinary albumin excretion were lower in the simvastatin than in the ezetimibe group. Simvastatin 120-131 serpin family E member 1 Homo sapiens 31-64 20199786-11 2010 However, simvastatin combined with ezetimibe provoked significant reductions in E-selectin and intravascular cellular adhesion molecule-1 levels that were independent of LDL-C changes. Simvastatin 9-20 selectin E Homo sapiens 80-90 19739078-9 2010 Atorvastatin and simvastatin reduced the 180-kDa form of P-gp, but not verapamil. Simvastatin 17-28 phosphoglycolate phosphatase Homo sapiens 57-61 20369390-0 2010 Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 63-68 20369390-0 2010 Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Simvastatin 0-11 endothelin 1 Homo sapiens 73-85 20369390-0 2010 Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Simvastatin 0-11 nuclear factor of activated T cells 3 Homo sapiens 90-96 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 27-38 BCL2 apoptosis regulator Homo sapiens 129-134 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 27-38 BCL2 apoptosis regulator Homo sapiens 172-177 20369390-3 2010 Recently, we reported that simvastatin stimulated neuronal gene expression and protein levels of the major antiapoptotic protein Bcl-2 in vivo and in vitro; suppression of Bcl-2 in SH-SY5Y cells reduced simvastatin neuroprotection; effects were independent of cholesterol and other products of the 3-hydroxy-3-methylglutaryl-CoA reductase pathway. Simvastatin 203-214 BCL2 apoptosis regulator Homo sapiens 172-177 20369390-4 2010 Endothelin-1 (ET-1) can increase Bcl-2 abundance via the transcription factor nuclear factor of activated thymocytes (NFATc), and simvastatin was reported to increase ET-1 gene expression. Simvastatin 130-141 endothelin 1 Homo sapiens 167-171 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 BCL2 apoptosis regulator Homo sapiens 57-62 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 endothelin 1 Homo sapiens 89-93 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 nuclear factor of activated T cells 1 Homo sapiens 109-114 20369390-5 2010 We tested the hypothesis that simvastatin stimulation of Bcl-2 involves up-regulation of ET-1 and binding of NFATc to Bcl-2 promoter sites in SH-SY5Y human neuroblastoma cells. Simvastatin 30-41 BCL2 apoptosis regulator Homo sapiens 118-123 20369390-6 2010 Simvastatin increased both intracellular and secreted ET-1 protein levels. Simvastatin 0-11 endothelin 1 Homo sapiens 54-58 20369390-8 2010 Simvastatin increased translocation of NFATc3 to the nucleus while reducing nuclear NFATc1 and having no effect on NFATc4. Simvastatin 0-11 nuclear factor of activated T cells 3 Homo sapiens 39-45 20369390-8 2010 Simvastatin increased translocation of NFATc3 to the nucleus while reducing nuclear NFATc1 and having no effect on NFATc4. Simvastatin 0-11 nuclear factor of activated T cells 1 Homo sapiens 84-90 20369390-10 2010 Treatment of cells with simvastatin stimulated binding of NFATc3 to the Bcl-2 promoter. Simvastatin 24-35 nuclear factor of activated T cells 3 Homo sapiens 58-64 20369390-10 2010 Treatment of cells with simvastatin stimulated binding of NFATc3 to the Bcl-2 promoter. Simvastatin 24-35 BCL2 apoptosis regulator Homo sapiens 72-77 20369390-11 2010 We report novel findings showing that up-regulation of Bcl-2 by simvastatin involves ET-1 and the transcription factor NFATc3. Simvastatin 64-75 BCL2 apoptosis regulator Homo sapiens 55-60 20369390-11 2010 We report novel findings showing that up-regulation of Bcl-2 by simvastatin involves ET-1 and the transcription factor NFATc3. Simvastatin 64-75 endothelin 1 Homo sapiens 85-89 20369390-11 2010 We report novel findings showing that up-regulation of Bcl-2 by simvastatin involves ET-1 and the transcription factor NFATc3. Simvastatin 64-75 nuclear factor of activated T cells 3 Homo sapiens 119-125 20338208-1 2010 The goal of this study was to investigate the effects of simvastatin on the levels of plasma leptin and nitric oxide (NO) in patients with coronary heart disease (CHD). Simvastatin 57-68 leptin Homo sapiens 93-99 20338208-8 2010 Simvastatin may provide beneficial effects of reducing leptin levels, independent of its lipid-lowering action, which may play an important role in patients with CHD. Simvastatin 0-11 leptin Homo sapiens 55-61 20096260-7 2010 Aspirin, quercetin, and simvastatin are compounds reported to increase PON1 expression. Simvastatin 24-35 paraoxonase 1 Homo sapiens 71-75 20299979-3 2010 We have previously reported that physiologic and pharmacologic concentrations of insulin induce PAI-1 synthesis in human HepG2 cells and that simvastatin can attenuate its effects. Simvastatin 142-153 insulin Homo sapiens 81-88 20299979-10 2010 Insulin-inducible PAI-1 promoter activity was attenuated by simvastatin. Simvastatin 60-71 insulin Homo sapiens 0-7 20299979-10 2010 Insulin-inducible PAI-1 promoter activity was attenuated by simvastatin. Simvastatin 60-71 serpin family E member 1 Homo sapiens 18-23 20299979-13 2010 Both insulin-inducible luciferase activity through the 3"-UTR and oxidative stress were attenuated by simvastatin. Simvastatin 102-113 insulin Homo sapiens 5-12 20155363-7 2010 Simvastatin significantly inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream mediators, p44/42 MAP kinase and MLC. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 36-40 20155363-7 2010 Simvastatin significantly inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream mediators, p44/42 MAP kinase and MLC. Simvastatin 0-11 kinase insert domain receptor Homo sapiens 68-74 20155363-7 2010 Simvastatin significantly inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream mediators, p44/42 MAP kinase and MLC. Simvastatin 0-11 modulator of VRAC current 1 Homo sapiens 127-130 20155363-9 2010 CONCLUSION: These data indicate that simvastatin exerts its anti-angiogenic effects through the reduction of VEGFR2 phosphorylation in RECs at least in part. Simvastatin 37-48 kinase insert domain receptor Homo sapiens 109-115 20417615-0 2010 Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Simvastatin 0-11 nuclear factor, erythroid derived 2, like 2 Mus musculus 52-56 20417615-0 2010 Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 77-80 20417615-4 2010 We show for the first time that simvastatin lowers reactive oxygen species (ROS) by activating Nrf2 through the PI3K/Akt pathway. Simvastatin 32-43 nuclear factor, erythroid derived 2, like 2 Mus musculus 95-99 20417615-4 2010 We show for the first time that simvastatin lowers reactive oxygen species (ROS) by activating Nrf2 through the PI3K/Akt pathway. Simvastatin 32-43 thymoma viral proto-oncogene 1 Mus musculus 117-120 20060890-0 2010 Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 36-40 20060890-0 2010 Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 56-64 20060890-4 2010 We demonstrate that in the tumors derived from MDA-MB-231 human breast cancer cell xenografts, simvastatin significantly inhibited phosphorylation of Akt with concomitant attenuation of the expression of the anti-apoptotic protein Bcl(XL). Simvastatin 95-106 AKT serine/threonine kinase 1 Homo sapiens 150-153 20060890-4 2010 We demonstrate that in the tumors derived from MDA-MB-231 human breast cancer cell xenografts, simvastatin significantly inhibited phosphorylation of Akt with concomitant attenuation of the expression of the anti-apoptotic protein Bcl(XL). Simvastatin 95-106 BCL2 like 1 Homo sapiens 231-238 20060890-6 2010 Simvastatin inhibited the DNA binding and transcriptional activities of NFkappaB resulting in marked reduction in transcription of Bcl(XL). Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 72-80 20060890-6 2010 Simvastatin inhibited the DNA binding and transcriptional activities of NFkappaB resulting in marked reduction in transcription of Bcl(XL). Simvastatin 0-11 BCL2 like 1 Homo sapiens 131-138 20060890-9 2010 We provide the first evidence for significantly increased levels of PTEN in the tumors of simvastatin-administered mice. Simvastatin 90-101 phosphatase and tensin homolog Mus musculus 68-72 20060890-10 2010 Importantly, simvastatin markedly prevented binding of NFkappaB to the two canonical recognition elements, NFRE-1 and NFRE-2 present in the PTEN promoter. Simvastatin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 55-63 20060890-10 2010 Importantly, simvastatin markedly prevented binding of NFkappaB to the two canonical recognition elements, NFRE-1 and NFRE-2 present in the PTEN promoter. Simvastatin 13-24 phosphatase and tensin homolog Homo sapiens 140-144 20060890-11 2010 Contrary to the transcriptional suppression of Bcl(XL), simvastatin significantly increased the transcription of PTEN. Simvastatin 56-67 phosphatase and tensin homolog Homo sapiens 113-117 20060890-13 2010 Taken together, our data present a novel bifaceted mechanism where simvastatin acts on a nodal transcription factor NFkappaB, which attenuates the expression of anti-apoptotic Bcl(XL) and simultaneously derepresses the expression of anti-proliferative/proapoptotic tumor suppressor PTEN to prevent breast cancer cell growth. Simvastatin 67-78 nuclear factor kappa B subunit 1 Homo sapiens 116-124 20060890-13 2010 Taken together, our data present a novel bifaceted mechanism where simvastatin acts on a nodal transcription factor NFkappaB, which attenuates the expression of anti-apoptotic Bcl(XL) and simultaneously derepresses the expression of anti-proliferative/proapoptotic tumor suppressor PTEN to prevent breast cancer cell growth. Simvastatin 67-78 BCL2 like 1 Homo sapiens 180-182 20060890-13 2010 Taken together, our data present a novel bifaceted mechanism where simvastatin acts on a nodal transcription factor NFkappaB, which attenuates the expression of anti-apoptotic Bcl(XL) and simultaneously derepresses the expression of anti-proliferative/proapoptotic tumor suppressor PTEN to prevent breast cancer cell growth. Simvastatin 67-78 phosphatase and tensin homolog Homo sapiens 282-286 20155363-2 2010 We investigated intracellular mechanisms of simvastatin-mediated reduction in VEGF-induced signalings. Simvastatin 44-55 vascular endothelial growth factor A Homo sapiens 78-82 20155363-4 2010 The impact of simvastatin on VEGF-induced phosphorylation of p44/42 mitogen-activated protein (MAP) kinase, myosin light chain (MLC), and VEGF-receptor (VEGFR) 2 were examined by Western blotting. Simvastatin 14-25 vascular endothelial growth factor A Homo sapiens 29-33 20155363-6 2010 RESULTS: Simvastatin (1 and 10 microM) suppressed VEGF-induced RECs proliferation in a concentration-dependent manner, without affecting cell viability. Simvastatin 9-20 vascular endothelial growth factor A Homo sapiens 50-54 20629317-5 2010 RESULTS: Simvastatin and Y-27632 obviously increased the level of mRNA of alpha-SM-actin and promoted the protein expression of alpha-SM-actin, SM22alpha while inhibiting the proliferation of PASMC induced by PDGF-BB. Simvastatin 9-20 transgelin Rattus norvegicus 144-153 19820293-0 2010 Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 90-116 19820293-1 2010 OBJECTIVE: To observe the effects of simvastatin on urinary excretion of matrix metalloproteinase-9 (MMP- 9), renal expression of MMP-9, and investigate its possible renoprotective mechanisms in streptozotocin (STZ)-induced diabetic rats. Simvastatin 37-48 matrix metallopeptidase 9 Rattus norvegicus 73-99 19820293-1 2010 OBJECTIVE: To observe the effects of simvastatin on urinary excretion of matrix metalloproteinase-9 (MMP- 9), renal expression of MMP-9, and investigate its possible renoprotective mechanisms in streptozotocin (STZ)-induced diabetic rats. Simvastatin 37-48 matrix metallopeptidase 9 Rattus norvegicus 101-107 19820293-8 2010 CONCLUSION: Simvastatin may has a potential therapeutic target in diabetic nephropathy, which may be partly attributed to down-regulating over-expression of MMP-9 in renal tissue. Simvastatin 12-23 matrix metallopeptidase 9 Rattus norvegicus 157-162 20217863-5 2010 All 11 differential spots showed reduced intensity in simvastatin-treated samples and were identified as adipocyte plasma membrane associated protein, enolase, calretinin, coronin 1a, f-actin capping protein alpha1, f-actin capping protein alpha2, heat shock cognate protein 71, malate dehydrogenase, n-myc downregulated gene 1, prohibitin 2, Rab GDP dissociation inhibitor, translationally controlled tumor protein and voltage dependent anion selective channel protein 1. Simvastatin 54-65 calbindin 2 Homo sapiens 160-170 20217863-5 2010 All 11 differential spots showed reduced intensity in simvastatin-treated samples and were identified as adipocyte plasma membrane associated protein, enolase, calretinin, coronin 1a, f-actin capping protein alpha1, f-actin capping protein alpha2, heat shock cognate protein 71, malate dehydrogenase, n-myc downregulated gene 1, prohibitin 2, Rab GDP dissociation inhibitor, translationally controlled tumor protein and voltage dependent anion selective channel protein 1. Simvastatin 54-65 coronin 1A Homo sapiens 172-182 20217863-5 2010 All 11 differential spots showed reduced intensity in simvastatin-treated samples and were identified as adipocyte plasma membrane associated protein, enolase, calretinin, coronin 1a, f-actin capping protein alpha1, f-actin capping protein alpha2, heat shock cognate protein 71, malate dehydrogenase, n-myc downregulated gene 1, prohibitin 2, Rab GDP dissociation inhibitor, translationally controlled tumor protein and voltage dependent anion selective channel protein 1. Simvastatin 54-65 malic enzyme 2 Homo sapiens 279-299 20217863-5 2010 All 11 differential spots showed reduced intensity in simvastatin-treated samples and were identified as adipocyte plasma membrane associated protein, enolase, calretinin, coronin 1a, f-actin capping protein alpha1, f-actin capping protein alpha2, heat shock cognate protein 71, malate dehydrogenase, n-myc downregulated gene 1, prohibitin 2, Rab GDP dissociation inhibitor, translationally controlled tumor protein and voltage dependent anion selective channel protein 1. Simvastatin 54-65 prohibitin 2 Homo sapiens 329-341 20217863-5 2010 All 11 differential spots showed reduced intensity in simvastatin-treated samples and were identified as adipocyte plasma membrane associated protein, enolase, calretinin, coronin 1a, f-actin capping protein alpha1, f-actin capping protein alpha2, heat shock cognate protein 71, malate dehydrogenase, n-myc downregulated gene 1, prohibitin 2, Rab GDP dissociation inhibitor, translationally controlled tumor protein and voltage dependent anion selective channel protein 1. Simvastatin 54-65 voltage dependent anion channel 1 Homo sapiens 420-471 19631970-0 2010 Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Simvastatin 6-17 coagulation factor II, thrombin Homo sapiens 55-63 19631970-10 2010 CONCLUSIONS: Prior simvastatin use is associated with lower thrombin generation and platelet activation following vascular injury in the early phase of STEMI. Simvastatin 19-30 coagulation factor II, thrombin Homo sapiens 60-68 20629317-6 2010 Simultaneously, inhibited expression of RhoA induced by simvastatin and Y-27632 was also observed. Simvastatin 56-67 ras homolog family member A Rattus norvegicus 40-44 20403180-13 2010 Moreover, SCI-induced renal caspase-3 activity was significantly decreased in the simvastatin group indicating the ability of simvastatin to reduce the renal tubular apoptosis. Simvastatin 82-93 caspase 3 Rattus norvegicus 28-37 20519084-0 2010 [The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats]. Simvastatin 15-26 high mobility group box 1 Rattus norvegicus 48-73 20519084-1 2010 OBJECTIVE: To observe the effect of simvastatin on the expression of high mobility group box-1 protein (HMGB1) and morphology of atherosclerotic plaques in atherosclerotic rats, to ascertain whether HMGB1 plays a role in the preventive mechanism of simvastatin from atherosclerosis (AS). Simvastatin 36-47 high mobility group box 1 Rattus norvegicus 69-94 20519084-1 2010 OBJECTIVE: To observe the effect of simvastatin on the expression of high mobility group box-1 protein (HMGB1) and morphology of atherosclerotic plaques in atherosclerotic rats, to ascertain whether HMGB1 plays a role in the preventive mechanism of simvastatin from atherosclerosis (AS). Simvastatin 36-47 high mobility group box 1 Rattus norvegicus 104-109 20519084-8 2010 RESULTS: The expression of HMGB1 increased significantly in atherosclerotic plaques in model group, and simvastatin could evidently inhibit the expression of HMGB1, and it was more obvious in 12-week group. Simvastatin 104-115 high mobility group box 1 Rattus norvegicus 158-163 20519084-10 2010 In the simvastatin treatment group, the gene expression of HMGB1 was lower than the age-match model group at 10 weeks (15.798+/-0.891) and 12 weeks (12.641+/-0.734), and in the 12-week treatment group it was lower than that in the 10-week treatment group (P<0.05 or P<0.01). Simvastatin 7-18 high mobility group box 1 Rattus norvegicus 59-64 20403180-13 2010 Moreover, SCI-induced renal caspase-3 activity was significantly decreased in the simvastatin group indicating the ability of simvastatin to reduce the renal tubular apoptosis. Simvastatin 126-137 caspase 3 Rattus norvegicus 28-37 20381662-0 2010 Differential effects of statins (pravastatin or simvastatin) on ventricular ectopic complexes: Galpha(i2), a possible molecular marker for ventricular irritability. Simvastatin 48-59 succinate-CoA ligase GDP/ADP-forming subunit alpha Homo sapiens 95-104 20519084-13 2010 CONCLUSION: Simvastatin can alleviate the formation of the atherosclerotic plaques in the atherosclerotic rats, decrease the protein and mRNA expression of HMGB1. Simvastatin 12-23 high mobility group box 1 Rattus norvegicus 156-161 20440247-8 2010 RESULTS: Five months of simvastatin treatment showed a decrease in lipid levels, concomitantly with reduction in PMNL priming, PMNL apoptosis, fibrinogen and CRP levels. Simvastatin 24-35 fibrinogen beta chain Homo sapiens 143-153 20227028-7 2010 Epidemiologic data suggest the risk of pancreatitis is highest for mesalazine (HR 3.5,) azathioprine (HR 2,5) and simvastatine (HR 1,8). Simvastatin 114-126 RAD18 E3 ubiquitin protein ligase Homo sapiens 128-134 20024970-8 2010 BMP-2 expression was significantly higher in simvastatin group on day 3 and day 14 (p < 0.05) and maintained until day 21. Simvastatin 45-56 bone morphogenetic protein 2 Rattus norvegicus 0-5 20024970-9 2010 Increased upregulation of TGF-beta1 was also observed in the simvastatin group on day 7 (p < 0.05) which was maintained until day 14. Simvastatin 61-72 transforming growth factor, beta 1 Rattus norvegicus 26-35 20024970-10 2010 These findings suggest that the proliferation and recruitment of osteoprogenitor cells were critical steps in early stage of bone healing and that these steps were enhanced by TGF-beta1 and BMP-2, which were stimulated by simvastatin. Simvastatin 222-233 transforming growth factor, beta 1 Rattus norvegicus 176-185 20024970-10 2010 These findings suggest that the proliferation and recruitment of osteoprogenitor cells were critical steps in early stage of bone healing and that these steps were enhanced by TGF-beta1 and BMP-2, which were stimulated by simvastatin. Simvastatin 222-233 bone morphogenetic protein 2 Rattus norvegicus 190-195 20097734-4 2010 We found that both AGGC, which inhibits CAAX carboxyl methylation, and simvastatin, which inhibits CAAX geranylgeranylation, caused relocalization of GRP94, calnexin, and calreticulin, effects that were not seen during endothelial apoptosis induced by TNF-alpha or ultraviolet (UV) irradiation. Simvastatin 71-82 heat shock protein 90 beta family member 1 Homo sapiens 150-155 20097734-4 2010 We found that both AGGC, which inhibits CAAX carboxyl methylation, and simvastatin, which inhibits CAAX geranylgeranylation, caused relocalization of GRP94, calnexin, and calreticulin, effects that were not seen during endothelial apoptosis induced by TNF-alpha or ultraviolet (UV) irradiation. Simvastatin 71-82 calnexin Homo sapiens 157-165 20097734-4 2010 We found that both AGGC, which inhibits CAAX carboxyl methylation, and simvastatin, which inhibits CAAX geranylgeranylation, caused relocalization of GRP94, calnexin, and calreticulin, effects that were not seen during endothelial apoptosis induced by TNF-alpha or ultraviolet (UV) irradiation. Simvastatin 71-82 calreticulin Homo sapiens 171-183 20097734-4 2010 We found that both AGGC, which inhibits CAAX carboxyl methylation, and simvastatin, which inhibits CAAX geranylgeranylation, caused relocalization of GRP94, calnexin, and calreticulin, effects that were not seen during endothelial apoptosis induced by TNF-alpha or ultraviolet (UV) irradiation. Simvastatin 71-82 tumor necrosis factor Homo sapiens 252-261 20045437-6 2010 Simvastatin increased expression of Bax, oligomerization of Bax and Bak, and expression of BH3-only p53-dependent genes, PUMA and NOXA. Simvastatin 0-11 tumor protein p53 Homo sapiens 100-103 20045437-7 2010 Inhibition of p53 and silencing of p53 unregulated modulator of apoptosis (PUMA) expression partly counteracted simvastatin-induced cell death, suggesting a role for p53-independent mechanisms. Simvastatin 112-123 tumor protein p53 Homo sapiens 35-38 20045437-7 2010 Inhibition of p53 and silencing of p53 unregulated modulator of apoptosis (PUMA) expression partly counteracted simvastatin-induced cell death, suggesting a role for p53-independent mechanisms. Simvastatin 112-123 tumor protein p53 Homo sapiens 35-38 20045437-10 2010 Thus, simvastatin activates novel apoptosis pathways in lung mesenchymal cells involving p53, IAP inhibitor release, and disruption of mitochondrial fission. Simvastatin 6-17 tumor protein p53 Homo sapiens 89-92 20440247-8 2010 RESULTS: Five months of simvastatin treatment showed a decrease in lipid levels, concomitantly with reduction in PMNL priming, PMNL apoptosis, fibrinogen and CRP levels. Simvastatin 24-35 C-reactive protein Homo sapiens 158-161 20339536-10 2010 CONCLUSIONS AND SIGNIFICANCE: Using combined GWA analysis from three clinical trials involving nearly 4,000 individuals treated with simvastatin, pravastatin, or atorvastatin, we have identified SNPs that may be associated with variation in the magnitude of statin-mediated reduction in total and LDL-cholesterol, including one in the CLMN gene for which statistical evidence for association exceeds conventional levels of genome-wide significance. Simvastatin 133-144 calmin Homo sapiens 335-339 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 145-156 carbonic anhydrase 1 Mus musculus 102-105 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 145-156 thymoma viral proto-oncogene 1 Mus musculus 181-184 20040368-8 2010 Our results demonstrate that a prolonged in vitro simvastatin treatment for 2-4 h, but not a short-term 20-min exposure, significantly increases the magnitude of LTP at CA3-CA1 synapses without altering basal synaptic transmission or the paired-pulse facilitation ratio in hippocampal slices. Simvastatin 50-61 carbonic anhydrase 3 Mus musculus 169-176 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 216-227 thymoma viral proto-oncogene 1 Mus musculus 45-48 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 145-156 thymoma viral proto-oncogene 1 Mus musculus 45-48 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 216-227 carbonic anhydrase 1 Mus musculus 102-105 20040368-9 2010 Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. Simvastatin 216-227 thymoma viral proto-oncogene 1 Mus musculus 181-184 20040368-10 2010 These findings suggest activation of Akt as a molecular pathway for augmented hippocampal LTP by simvastatin treatment, and implicate enhancement of hippocampal LTP as a potential cellular mechanism underlying the beneficial effects of simvastatin on cognitive function. Simvastatin 97-108 thymoma viral proto-oncogene 1 Mus musculus 37-40 20040368-10 2010 These findings suggest activation of Akt as a molecular pathway for augmented hippocampal LTP by simvastatin treatment, and implicate enhancement of hippocampal LTP as a potential cellular mechanism underlying the beneficial effects of simvastatin on cognitive function. Simvastatin 236-247 thymoma viral proto-oncogene 1 Mus musculus 37-40 20124108-6 2010 Simvastatin, which upregulates heme oxygenase 1, also suppressed PAR-2-mediated sVEGFR-1 release. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 31-47 19770794-0 2010 Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Simvastatin 31-42 component of oligomeric golgi complex 2 Homo sapiens 95-130 19770794-2 2010 We examined the association between switching from atorvastatin to simvastatin and changes in low-density lipoprotein cholesterol (LDL-C) levels in clinical practice. Simvastatin 67-78 component of oligomeric golgi complex 2 Homo sapiens 94-129 19770794-2 2010 We examined the association between switching from atorvastatin to simvastatin and changes in low-density lipoprotein cholesterol (LDL-C) levels in clinical practice. Simvastatin 67-78 component of oligomeric golgi complex 2 Homo sapiens 131-136 19770794-7 2010 Switched patients who were not prescribed a higher milligram dose of simvastatin were significantly less likely to reach an LDL-C less than 100 mg/dL (62.3% versus 74.0%; odds ratio, 0.55; 95% confidence interval, 0.36-0.84; P = 0.006) and had higher LDL-C (95.1 versus 87.2 mg/dL; P = 0.002) than control subjects. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 124-129 19770794-8 2010 A large proportion of patients who switch from atorvastatin to simvastatin are prescribed doses that are not therapeutically equivalent, and these patients were significantly less likely to meet LDL-C treatment goals compared with patients who remained on atorvastatin. Simvastatin 63-74 component of oligomeric golgi complex 2 Homo sapiens 195-200 20124108-6 2010 Simvastatin, which upregulates heme oxygenase 1, also suppressed PAR-2-mediated sVEGFR-1 release. Simvastatin 0-11 F2R like trypsin receptor 1 Homo sapiens 65-70 19892847-4 2010 We provide evidence that: simvastatin blocks the biological effects rapidly triggered by IgG-opsonized bacteria (phagocytosis and oxidative burst) while enhancing the delayed effects elicited by FcgammaR stimulation (production of proinflammatory mediators); these opposite effects of simvastatin result from enhancement of the JNK pathway and concomitant impairment of other signaling modules activated by FcgammaR engagement; and these activities are dependent on the capacity of simvastatin to block protein prenylation. Simvastatin 26-37 mitogen-activated protein kinase 8 Homo sapiens 328-331 20171361-7 2010 The inducing effect of simvastatin on odontoblastic differentiation and angiogenesis was nullified by an HO-1 inhibitor and a carbon monoxide (CO) scavenger. Simvastatin 23-34 heme oxygenase 1 Homo sapiens 105-109 20171361-8 2010 CONCLUSIONS: These results suggested that simvastatin exerts its odontoblastic differentiation and angiogenesis-inducing effects in HDPCs through a mechanism that involves the action of HO-1 and its product CO. Simvastatin 42-53 heme oxygenase 1 Homo sapiens 186-190 20171361-0 2010 Simvastatin promotes odontoblastic differentiation and expression of angiogenic factors via heme oxygenase-1 in primary cultured human dental pulp cells. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 92-108 20203452-0 2010 LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Simvastatin 112-123 component of oligomeric golgi complex 2 Homo sapiens 0-5 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 62-67 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 20203452-14 2010 Patients switched to an equivalent simvastatin dose had lower LDL-C levels and were more likely to achieve LDL-C targets than patients switched to a non-equivalent dose, suggesting physicians must consider dosage equivalence when switching statins, and should measure LDL-C and titrate statins as necessary to achieve LDL-C control. Simvastatin 35-46 component of oligomeric golgi complex 2 Homo sapiens 107-112 20074780-0 2010 Prothrombinase formation at the site of microvascular injury and aspirin resistance: the effect of simvastatin. Simvastatin 99-110 coagulation factor X Homo sapiens 0-14 20117462-6 2010 In neonatal rat cardiomyocytes and fibroblasts, a specific small molecule inhibitor of Rac1 or simvastatin completely prevented the angiotensin II-induced up-regulation of CTGF, Cx43, and N-cadherin expression. Simvastatin 95-106 angiotensinogen Rattus norvegicus 132-146 20417880-0 2010 Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 75-78 20417880-0 2010 Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 79-84 20417880-5 2010 Our hypothesis is that simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/bone morphogenic protein (BMP)-2 signaling pathway. Simvastatin 23-34 mitogen-activated protein kinase 1 Homo sapiens 98-101 20417880-5 2010 Our hypothesis is that simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/bone morphogenic protein (BMP)-2 signaling pathway. Simvastatin 23-34 bone morphogenetic protein 1 Homo sapiens 128-131 20417880-8 2010 After administration of 10(-6) M simvastatin, the ALP activity was significantly enhanced, and the expression of BMP-2, ALP, sialoprotein, and type I collagen genes were up-regulated. Simvastatin 33-44 alkaline phosphatase, placental Homo sapiens 50-53 20417880-8 2010 After administration of 10(-6) M simvastatin, the ALP activity was significantly enhanced, and the expression of BMP-2, ALP, sialoprotein, and type I collagen genes were up-regulated. Simvastatin 33-44 bone morphogenetic protein 2 Homo sapiens 113-118 20417880-8 2010 After administration of 10(-6) M simvastatin, the ALP activity was significantly enhanced, and the expression of BMP-2, ALP, sialoprotein, and type I collagen genes were up-regulated. Simvastatin 33-44 alkaline phosphatase, placental Homo sapiens 120-123 20417880-9 2010 After simvastatin treatment, both the RasGRF1 and phospho-RasGRF1 in the cytoplasm decreased significantly, whereas those on the plasma membrane increased. Simvastatin 6-17 Ras protein specific guanine nucleotide releasing factor 1 Homo sapiens 38-45 20417880-9 2010 After simvastatin treatment, both the RasGRF1 and phospho-RasGRF1 in the cytoplasm decreased significantly, whereas those on the plasma membrane increased. Simvastatin 6-17 Ras protein specific guanine nucleotide releasing factor 1 Homo sapiens 58-65 20417880-12 2010 Simvastatin can promote osteoblast viability and differentiation via membrane-bound Ras/Smad/Erk/BMP-2 pathway. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 93-96 20417880-12 2010 Simvastatin can promote osteoblast viability and differentiation via membrane-bound Ras/Smad/Erk/BMP-2 pathway. Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 97-102 20117462-6 2010 In neonatal rat cardiomyocytes and fibroblasts, a specific small molecule inhibitor of Rac1 or simvastatin completely prevented the angiotensin II-induced up-regulation of CTGF, Cx43, and N-cadherin expression. Simvastatin 95-106 cellular communication network factor 2 Rattus norvegicus 172-176 20117462-6 2010 In neonatal rat cardiomyocytes and fibroblasts, a specific small molecule inhibitor of Rac1 or simvastatin completely prevented the angiotensin II-induced up-regulation of CTGF, Cx43, and N-cadherin expression. Simvastatin 95-106 gap junction protein, alpha 1 Rattus norvegicus 178-182 20117462-6 2010 In neonatal rat cardiomyocytes and fibroblasts, a specific small molecule inhibitor of Rac1 or simvastatin completely prevented the angiotensin II-induced up-regulation of CTGF, Cx43, and N-cadherin expression. Simvastatin 95-106 cadherin 2 Rattus norvegicus 188-198 19225884-8 2010 Simvastatin, pravastatin, and NO-pravastatin increased expression of the proteins PPARalpha, PPARgamma, and ABCA1, and expression of the mRNA of ABCA1 and LXRalpha in GBEC. Simvastatin 0-11 peroxisome proliferator activated receptor alpha Canis lupus familiaris 82-91 19225884-8 2010 Simvastatin, pravastatin, and NO-pravastatin increased expression of the proteins PPARalpha, PPARgamma, and ABCA1, and expression of the mRNA of ABCA1 and LXRalpha in GBEC. Simvastatin 0-11 peroxisome proliferator activated receptor gamma Canis lupus familiaris 93-102 19225884-5 2010 Expression of the proteins PPARalpha, PPARgamma, and ABCA1 was measured by western blotting analysis after treatment with simvastatin, pravastatin, NO-pravastatin, PPARalpha ligand, or PPARgamma ligand in the culture media. Simvastatin 122-133 ATP binding cassette subfamily A member 1 Canis lupus familiaris 53-58 19225884-8 2010 Simvastatin, pravastatin, and NO-pravastatin increased expression of the proteins PPARalpha, PPARgamma, and ABCA1, and expression of the mRNA of ABCA1 and LXRalpha in GBEC. Simvastatin 0-11 ATP binding cassette subfamily A member 1 Canis lupus familiaris 108-113 19225884-8 2010 Simvastatin, pravastatin, and NO-pravastatin increased expression of the proteins PPARalpha, PPARgamma, and ABCA1, and expression of the mRNA of ABCA1 and LXRalpha in GBEC. Simvastatin 0-11 ATP binding cassette subfamily A member 1 Canis lupus familiaris 145-150 19225884-9 2010 Pre-treatment with simvastatin, pravastatin, and NO-pravastatin suppressed the production of TNFalpha mRNA induced by LPS. Simvastatin 19-30 tumor necrosis factor Canis lupus familiaris 93-101 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 9-14 19730988-0 2010 Simvastatin attenuates TNF-alpha-induced growth inhibition and apoptosis in murine osteoblastic MC3T3-E1 cells. Simvastatin 0-11 tumor necrosis factor Mus musculus 23-32 19965915-7 2010 RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Simvastatin 93-104 component of oligomeric golgi complex 2 Homo sapiens 9-14 19965915-9 2010 Although individual responses varied widely, change in LDL-C on ezetimibe correlated with response to simvastatin (r = 0.46, P < 0.001). Simvastatin 102-113 component of oligomeric golgi complex 2 Homo sapiens 55-60 20043868-0 2010 Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Simvastatin 105-116 tumor protein p53 Homo sapiens 35-38 20159699-7 2010 Simvastatin treatment also significantly increased VEGF and NO levels and a positive correlation was noted between their levels. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 51-55 20159699-9 2010 Simvastatin increases VEGF and NO and promotes neogenesis of the vasa vasorum for the benefit of the aortic function. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 22-26 20414574-10 2010 Peripheral blood TNFalpha, IL-1beta, IL-6, C-reactive protein, procalcitonin, leukocytes and neutrophils were lower in diabetic and non diabetics septic rats treated with simvastatin, than after saline treatment. Simvastatin 171-182 tumor necrosis factor Rattus norvegicus 17-25 20414574-10 2010 Peripheral blood TNFalpha, IL-1beta, IL-6, C-reactive protein, procalcitonin, leukocytes and neutrophils were lower in diabetic and non diabetics septic rats treated with simvastatin, than after saline treatment. Simvastatin 171-182 interleukin 1 beta Rattus norvegicus 27-35 20414574-10 2010 Peripheral blood TNFalpha, IL-1beta, IL-6, C-reactive protein, procalcitonin, leukocytes and neutrophils were lower in diabetic and non diabetics septic rats treated with simvastatin, than after saline treatment. Simvastatin 171-182 interleukin 6 Rattus norvegicus 37-41 20414574-10 2010 Peripheral blood TNFalpha, IL-1beta, IL-6, C-reactive protein, procalcitonin, leukocytes and neutrophils were lower in diabetic and non diabetics septic rats treated with simvastatin, than after saline treatment. Simvastatin 171-182 C-reactive protein Rattus norvegicus 43-61 20043868-0 2010 Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Simvastatin 105-116 BCL2 associated X, apoptosis regulator Homo sapiens 68-71 20043868-3 2010 Simvastatin induced cardinal features of apoptosis including increased DNA fragmentation, disruption of mitochondrial membrane potential (MMP), and increased caspase-3 activity by depleting isoprenoids in MethA fibrosarcoma cells. Simvastatin 0-11 caspase 3 Homo sapiens 158-167 20043868-4 2010 Interestingly, the simvastatin-induced apoptosis was accompanied by p53 stabilization involving Mdm2 degradation. Simvastatin 19-30 tumor protein p53 Homo sapiens 68-71 20043868-4 2010 Interestingly, the simvastatin-induced apoptosis was accompanied by p53 stabilization involving Mdm2 degradation. Simvastatin 19-30 MDM2 proto-oncogene Homo sapiens 96-100 20043868-7 2010 Moreover, knockdown or deficiency of p53 expression reduced both Bax translocation to mitochondria and MMP disruption in simvastatin-induced apoptosis. Simvastatin 121-132 tumor protein p53 Homo sapiens 37-40 20043868-8 2010 Taken together, these all indicate that stabilization and translocation of p53 to mitochondria is involved in Bax translocation to mitochondria in simvastatin-induced apoptosis. Simvastatin 147-158 tumor protein p53 Homo sapiens 75-78 20043868-8 2010 Taken together, these all indicate that stabilization and translocation of p53 to mitochondria is involved in Bax translocation to mitochondria in simvastatin-induced apoptosis. Simvastatin 147-158 BCL2 associated X, apoptosis regulator Homo sapiens 110-113 20142117-0 2010 Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand"s factor and C-reactive protein in patients with hypercholesterolaemia. Simvastatin 12-23 coagulation factor III, tissue factor Homo sapiens 40-53 20034462-7 2010 LPS-induced cleavage (activation) of caspase-3, an indicator of apoptotic change, and increased protein expression of proapoptotic molecules, Bax and Bim, and activation of c-Jun NH(2)-terminal kinase (JNK/SAPK) in the liver and spleen were attenuated by both simvastatin and FTI-277. Simvastatin 260-271 mitogen-activated protein kinase 8 Mus musculus 202-210 21090830-14 2010 Simvastatin was the most cost-effective statin to achieve the LDL-C goal in patients with moderate or low CHD risk, with a cost per patient of Euro 217 and Euro 190, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 62-67 19915177-4 2010 Because the promoters of both DDAH1 and DDAH2 isoforms contain sterol response elements, we tested the hypothesis that simvastatin regulates DDAH1 and DDAH2 transcription via SREBP. Simvastatin 119-130 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 30-35 19915177-4 2010 Because the promoters of both DDAH1 and DDAH2 isoforms contain sterol response elements, we tested the hypothesis that simvastatin regulates DDAH1 and DDAH2 transcription via SREBP. Simvastatin 119-130 dimethylarginine dimethylaminohydrolase 2 Homo sapiens 40-45 19915177-4 2010 Because the promoters of both DDAH1 and DDAH2 isoforms contain sterol response elements, we tested the hypothesis that simvastatin regulates DDAH1 and DDAH2 transcription via SREBP. Simvastatin 119-130 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 141-146 19915177-4 2010 Because the promoters of both DDAH1 and DDAH2 isoforms contain sterol response elements, we tested the hypothesis that simvastatin regulates DDAH1 and DDAH2 transcription via SREBP. Simvastatin 119-130 dimethylarginine dimethylaminohydrolase 2 Homo sapiens 151-156 19915177-5 2010 In cultured endothelial cells, simvastatin increased DDAH1 mRNA expression compared with vehicle. Simvastatin 31-42 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 53-58 19915177-6 2010 In an ADMA loading experiment, simvastatin treatment resulted in a decrease in ADMA content, an indication of increased DDAH activity. Simvastatin 31-42 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 120-124 19915177-8 2010 The role of SREBP2 in the activation of the DDAH1 was supported by chromatin immunoprecipitation studies demonstrating increased binding of SREBP2 to the DDAH1 promoter upon simvastatin stimulation. Simvastatin 174-185 sterol regulatory element binding transcription factor 2 Homo sapiens 12-18 19915177-8 2010 The role of SREBP2 in the activation of the DDAH1 was supported by chromatin immunoprecipitation studies demonstrating increased binding of SREBP2 to the DDAH1 promoter upon simvastatin stimulation. Simvastatin 174-185 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 44-49 19915177-8 2010 The role of SREBP2 in the activation of the DDAH1 was supported by chromatin immunoprecipitation studies demonstrating increased binding of SREBP2 to the DDAH1 promoter upon simvastatin stimulation. Simvastatin 174-185 sterol regulatory element binding transcription factor 2 Homo sapiens 140-146 19915177-8 2010 The role of SREBP2 in the activation of the DDAH1 was supported by chromatin immunoprecipitation studies demonstrating increased binding of SREBP2 to the DDAH1 promoter upon simvastatin stimulation. Simvastatin 174-185 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 154-159 21348380-8 2010 The combination of ezetimibe and low-dose simvastatin significantly reduced levels of total cholesterol (by a mean of 27%), triglycerides (by 9%), and LDL-C (by 33%) and increased levels of high-density lipoprotein cholesterol (by 15%). Simvastatin 42-53 component of oligomeric golgi complex 2 Homo sapiens 151-156 20142117-0 2010 Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand"s factor and C-reactive protein in patients with hypercholesterolaemia. Simvastatin 12-23 C-reactive protein Homo sapiens 83-101 20142117-7 2010 Simvastatin also reduced the concentration of apolipoprotein B (125 to 93 mg/dL, p < 0.001). Simvastatin 0-11 apolipoprotein B Homo sapiens 46-62 19916706-0 2010 Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Simvastatin 126-137 component of oligomeric golgi complex 2 Homo sapiens 26-61 19968965-3 2010 Here, we show that diverse vasoprotective stimuli including an atheroprotective shear stress waveform, simvastatin, and resveratrol induce the expression of KLF4 in cultured human endothelial cells. Simvastatin 103-114 Kruppel like factor 4 Homo sapiens 157-161 19515066-0 2010 Simvastatin inhibits angiotensin II-induced cardiac cell hypertrophy: role of Homer 1a. Simvastatin 0-11 angiotensinogen Rattus norvegicus 21-35 19515066-9 2010 Homer 1a protein levels were upregulated following AngII-induced hypertrophy in H9C2 cells and neonatal rat cardiomyocytes, and these increases were augmented by simvastatin pretreatment. Simvastatin 162-173 angiotensinogen Rattus norvegicus 51-56 19515066-10 2010 Concomitantly, simvastatin pretreatment inhibited extracellular signal-regulated kinase (ERK) 1/2 phosphorylation and AngII-induced hypertrophy. Simvastatin 15-26 mitogen activated protein kinase 3 Rattus norvegicus 50-97 19515066-10 2010 Concomitantly, simvastatin pretreatment inhibited extracellular signal-regulated kinase (ERK) 1/2 phosphorylation and AngII-induced hypertrophy. Simvastatin 15-26 angiotensinogen Rattus norvegicus 118-123 19515066-12 2010 The inhibitory effects of simvastatin against AngII-induced hypertrophy were attenuated by Homer 1a silencing, suggesting that simvastatin suppresses cardiac hypertrophy in a Homer 1a-dependent manner. Simvastatin 26-37 angiotensinogen Rattus norvegicus 46-51 19515066-12 2010 The inhibitory effects of simvastatin against AngII-induced hypertrophy were attenuated by Homer 1a silencing, suggesting that simvastatin suppresses cardiac hypertrophy in a Homer 1a-dependent manner. Simvastatin 127-138 angiotensinogen Rattus norvegicus 46-51 21105332-4 2010 In this review we present results of studies assessing effect of various allele variants of CYP3A4 and CYP3A5 on efficacy and tolerability of atorvastatin, lovastatin,, and simvastatin in different populations of patients. Simvastatin 173-184 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 19365639-0 2010 A patient with Smith-Lemli-Opitz syndrome: novel mutation of the DHCR7 gene and effects of therapy with simvastatin and cholesterol supplement. Simvastatin 104-115 7-dehydrocholesterol reductase Homo sapiens 65-70 19943026-3 2010 All protease inhibitors are inhibitors of CYP3A, which is important in the metabolism of approximately 50% of all drugs, e.g. simvastatin, atorvastatin, sildenafil, and clarithromycin. Simvastatin 126-137 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 42-47 19786891-6 2010 Western blot analysis revealed that simvastatin significantly increased the expression of cell cycle inhibitor p27. Simvastatin 36-47 interferon alpha inducible protein 27 Homo sapiens 111-114 19786891-8 2010 Immunofluorescence staining revealed that simvastatin (1 micromol/L) inhibited translocation of Rho A from the cytoplasm to membrane and disorganized actin fibers in PASMCs from patients with IPAH. Simvastatin 42-53 ras homolog family member A Homo sapiens 96-101 19932975-0 2010 Effect of simvastatin on endothelial cell apoptosis mediated by Fas and TNF-alpha. Simvastatin 10-21 tumor necrosis factor Homo sapiens 72-81 19932975-8 2010 Further, simvastatin increased LSEC-apoptosis induced by Fas and TNF-alpha. Simvastatin 9-20 tumor necrosis factor Homo sapiens 65-74 19932975-9 2010 Mevalonate and GGPP partially prevented simvastatin-induced sensitization to LSEC death mediated by Jo2 and TNF-alpha, but not Jo2 alone. Simvastatin 40-51 tumor necrosis factor Homo sapiens 108-117 21105332-4 2010 In this review we present results of studies assessing effect of various allele variants of CYP3A4 and CYP3A5 on efficacy and tolerability of atorvastatin, lovastatin,, and simvastatin in different populations of patients. Simvastatin 173-184 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 103-109 19887846-3 2010 We further examined the effect of losartan and simvastatin on myoglobin-induced VCAM-1 expression and the signaling pathways. Simvastatin 47-58 myoglobin Homo sapiens 62-71 19887846-3 2010 We further examined the effect of losartan and simvastatin on myoglobin-induced VCAM-1 expression and the signaling pathways. Simvastatin 47-58 vascular cell adhesion molecule 1 Homo sapiens 80-86 19887846-9 2010 Losartan and simvastatin suppressed myoglobin-induced VCAM-1 expression via inhibition of c-Src kinase. Simvastatin 13-24 myoglobin Homo sapiens 36-45 19887846-9 2010 Losartan and simvastatin suppressed myoglobin-induced VCAM-1 expression via inhibition of c-Src kinase. Simvastatin 13-24 vascular cell adhesion molecule 1 Homo sapiens 54-60 19887846-9 2010 Losartan and simvastatin suppressed myoglobin-induced VCAM-1 expression via inhibition of c-Src kinase. Simvastatin 13-24 C-terminal Src kinase Homo sapiens 90-102 19887846-11 2010 Losartan and simvastatin might be beneficial in attenuating myoglobin-induced tubular injury. Simvastatin 13-24 myoglobin Homo sapiens 60-69 19639539-8 2010 And the plasma levels of cholesterol (Chol), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and ApoE all decreased in both the rhein and the simvastatin groups. Simvastatin 157-168 apolipoprotein E Mus musculus 112-116 19802823-0 2010 Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Simvastatin 88-99 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-40 19802823-0 2010 Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Simvastatin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 19802823-1 2010 PURPOSE: Simvastatin and atorvastatin are metabolized by the CYP3A4 enzyme and transported by the ABCB1 transporter. Simvastatin 9-20 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 19802823-1 2010 PURPOSE: Simvastatin and atorvastatin are metabolized by the CYP3A4 enzyme and transported by the ABCB1 transporter. Simvastatin 9-20 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 19802823-2 2010 We studied whether the polymorphism CYP3A4*1B and the polymorphisms C1236T, G2677A/T and C3435T in the ABCB1 gene were associated with a decrease of the prescribed dose or a switch to another cholesterol lowering drug during simvastatin and atorvastatin therapy. Simvastatin 225-236 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 19802823-6 2010 RESULTS: Simvastatin and atorvastatin users with the CYP3A4*1B variant G allele had a lower risk (HR 0.46; 95%CI 0.24-0.90) for these events than users with the wild-type AA genotype. Simvastatin 9-20 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 19802823-10 2010 CONCLUSION: In simvastatin and atorvastatin users, the CYP3A4*1B G allele is associated with a lower risk of elevated statin plasma levels, particularly in women and in users with the ABCB1 3435T variant allele. Simvastatin 15-26 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 19802823-10 2010 CONCLUSION: In simvastatin and atorvastatin users, the CYP3A4*1B G allele is associated with a lower risk of elevated statin plasma levels, particularly in women and in users with the ABCB1 3435T variant allele. Simvastatin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 184-189 20829626-7 2010 The use of ketoconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), may significantly increase plasma concentrations of certain statins (such as simvastatin and atorvastatin) that undergo metabolism by the same pathway, thus increasing the risk of complications and side effects. Simvastatin 154-165 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-66 20829626-7 2010 The use of ketoconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), may significantly increase plasma concentrations of certain statins (such as simvastatin and atorvastatin) that undergo metabolism by the same pathway, thus increasing the risk of complications and side effects. Simvastatin 154-165 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 20150839-12 2010 There was a nonsignificant reduction of CRP and IL-6 in the subgroup with FEV1 >50% during simvastatin treatment. Simvastatin 94-105 C-reactive protein Homo sapiens 40-43 20090898-4 2009 Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. Simvastatin 115-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 17-24 20150839-12 2010 There was a nonsignificant reduction of CRP and IL-6 in the subgroup with FEV1 >50% during simvastatin treatment. Simvastatin 94-105 interleukin 6 Homo sapiens 48-52 20041128-6 2009 The relative quantification of mRNA demonstrated a different effect of simvastatin on the expression of the wild-type and mutated hHMGR gene. Simvastatin 71-82 high mobility group AT-hook 1 Homo sapiens 130-135 20041128-9 2009 Changes in the level of ergosterol and its precursors in cells treated with simvastatin depend on the mutation in the hHMGR gene. Simvastatin 76-87 high mobility group AT-hook 1 Homo sapiens 118-123 20041128-12 2009 First, cells treated with simvastatin develop an adaptive response compensating the lower activity of HMGR. Simvastatin 26-37 high mobility group AT-hook 1 Homo sapiens 102-106 19781532-0 2009 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Simvastatin 62-73 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 4-51 20004738-0 2010 Simvastatin activates Akt/glycogen synthase kinase-3beta signal and inhibits caspase-3 activation after experimental subarachnoid hemorrhage. Simvastatin 0-11 glycogen synthase kinase-3 beta Oryctolagus cuniculus 26-56 20004738-0 2010 Simvastatin activates Akt/glycogen synthase kinase-3beta signal and inhibits caspase-3 activation after experimental subarachnoid hemorrhage. Simvastatin 0-11 caspase-3 Oryctolagus cuniculus 77-86 20004738-1 2010 This study was designed to explore the role of simvastatin and its effects on the Akt/GSK3beta survival signal and apoptosis pathway after experimental subarachnoid hemorrhage (SAH). Simvastatin 47-58 glycogen synthase kinase-3 beta Oryctolagus cuniculus 86-94 20004738-5 2010 Simvastatin, at both low dose (10 mg/kg) and high dose (40 mg/kg), further increased expression of phospho-Akt and phospho-GSK3beta, decreased activation of caspase-3, and inhibited apoptosis. Simvastatin 0-11 glycogen synthase kinase-3 beta Oryctolagus cuniculus 123-131 20004738-5 2010 Simvastatin, at both low dose (10 mg/kg) and high dose (40 mg/kg), further increased expression of phospho-Akt and phospho-GSK3beta, decreased activation of caspase-3, and inhibited apoptosis. Simvastatin 0-11 caspase-3 Oryctolagus cuniculus 157-166 19781532-8 2009 Simvastatin treatment significantly decreased tPA-induced hemorrhage incidence (p=0.022) and volume (p=0.0001) following embolization. Simvastatin 0-11 plasminogen activator, tissue type Homo sapiens 46-49 19781532-9 2009 The study suggests that simvastatin treatment blocks or attenuates mechanisms involved in tPA-induced hemorrhage. Simvastatin 24-35 plasminogen activator, tissue type Homo sapiens 90-93 19781532-10 2009 Based upon our results, patients on simvastatin treatment may have significantly reduced tPA-induced side effects should they require tPA administration following an embolic stroke. Simvastatin 36-47 plasminogen activator, tissue type Homo sapiens 89-92 19781532-10 2009 Based upon our results, patients on simvastatin treatment may have significantly reduced tPA-induced side effects should they require tPA administration following an embolic stroke. Simvastatin 36-47 plasminogen activator, tissue type Homo sapiens 134-137 20128155-0 2009 In rats with myocardial infarction, interference by simvastatin with the TLR4 signal pathway attenuates ventricular remodelling. Simvastatin 52-63 toll-like receptor 4 Rattus norvegicus 73-77 20128155-1 2009 OBJECTIVE: The objective of this study was to investigate the effect of simvastatin on TLR4,TNF-alpha and IL-6 expression in the myocardium and its relation to left ventricular (LV) remodelling in a rat model of myocardial infarction (MI) and to investigate the mechanism by which simvastatin improves LV remodelling in rats after MI. Simvastatin 72-83 toll-like receptor 4 Rattus norvegicus 87-91 20128155-1 2009 OBJECTIVE: The objective of this study was to investigate the effect of simvastatin on TLR4,TNF-alpha and IL-6 expression in the myocardium and its relation to left ventricular (LV) remodelling in a rat model of myocardial infarction (MI) and to investigate the mechanism by which simvastatin improves LV remodelling in rats after MI. Simvastatin 72-83 tumor necrosis factor Rattus norvegicus 92-101 20128155-1 2009 OBJECTIVE: The objective of this study was to investigate the effect of simvastatin on TLR4,TNF-alpha and IL-6 expression in the myocardium and its relation to left ventricular (LV) remodelling in a rat model of myocardial infarction (MI) and to investigate the mechanism by which simvastatin improves LV remodelling in rats after MI. Simvastatin 72-83 interleukin 6 Rattus norvegicus 106-110 20128155-6 2009 The expression of TLR4, TNF-alpha and IL-6 in the myocardium significantly increased in the MI group and simvastatin markedly inhibits the expression of TLR4, TNF-alpha, and IL-6 in the myocardium after MI. Simvastatin 105-116 toll-like receptor 4 Rattus norvegicus 153-157 20128155-6 2009 The expression of TLR4, TNF-alpha and IL-6 in the myocardium significantly increased in the MI group and simvastatin markedly inhibits the expression of TLR4, TNF-alpha, and IL-6 in the myocardium after MI. Simvastatin 105-116 tumor necrosis factor Rattus norvegicus 159-168 20128155-6 2009 The expression of TLR4, TNF-alpha and IL-6 in the myocardium significantly increased in the MI group and simvastatin markedly inhibits the expression of TLR4, TNF-alpha, and IL-6 in the myocardium after MI. Simvastatin 105-116 interleukin 6 Rattus norvegicus 174-178 20128155-8 2009 Both in the MI group and the simvastatin group,TLR4 protein positively related to LVEDD and to the levels of TNF-alpha and IL-6 in the myocardium, respectively. Simvastatin 29-40 toll-like receptor 4 Rattus norvegicus 47-51 20128155-8 2009 Both in the MI group and the simvastatin group,TLR4 protein positively related to LVEDD and to the levels of TNF-alpha and IL-6 in the myocardium, respectively. Simvastatin 29-40 tumor necrosis factor Rattus norvegicus 109-118 20128155-8 2009 Both in the MI group and the simvastatin group,TLR4 protein positively related to LVEDD and to the levels of TNF-alpha and IL-6 in the myocardium, respectively. Simvastatin 29-40 interleukin 6 Rattus norvegicus 123-127 20128155-9 2009 CONCLUSION: Amelioration of LV remodelling in rats after MI by simvastatin might be associated with its effect on the TLR4-mediated signalling pathway in the myocardium. Simvastatin 63-74 toll-like receptor 4 Rattus norvegicus 118-122 19889690-0 2009 Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Simvastatin 10-21 adiponectin, C1Q and collagen domain containing Homo sapiens 42-53 19745745-4 2009 There were statistically significant differences for simvastatin versus rosuvastatin, respectively, for mean LDLc 2.03 mmol/l (78 mg/dl) versus 1.94 mmol/l (75 mg/dl; P = 0.009) and also mean TC 3.88 mmol/l (150 mg/dl) versus 3.75 mmol/l (145 mg/dl; P = 0.005). Simvastatin 53-64 component of oligomeric golgi complex 2 Homo sapiens 109-113 20029539-4 2009 To clarify this issue, we explored a potential link between a response to I/R and changes in cardiac PPARalpha protein and gene expression in simvastatin-treated normocholesterolaemic rats. Simvastatin 142-153 peroxisome proliferator activated receptor alpha Rattus norvegicus 101-110 20029539-7 2009 Baseline PPARalpha mRNA and protein levels were increased by 3-fold and 2-fold, respectively, in simvastatin-treated hearts compared with the untreated controls. Simvastatin 97-108 peroxisome proliferator activated receptor alpha Rattus norvegicus 9-18 20065508-0 2009 IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. Simvastatin 92-103 interleukin 6 Homo sapiens 0-4 20065508-0 2009 IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. Simvastatin 92-103 C-X-C motif chemokine ligand 8 Homo sapiens 9-13 20183988-17 2009 The risk is strongly intensified by drug interactions through CYP3A4 (for simvastatin and atorvastatin), high doses, and combination therapy with fibrates. Simvastatin 74-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-68 20065508-6 2009 Treatment of CRC with simvastatin (80 mg/day for 14 days) led to a significant decrease of serum IL-6, while the IL-8 level was less affected. Simvastatin 22-33 interleukin 6 Homo sapiens 97-101 20065508-6 2009 Treatment of CRC with simvastatin (80 mg/day for 14 days) led to a significant decrease of serum IL-6, while the IL-8 level was less affected. Simvastatin 22-33 C-X-C motif chemokine ligand 8 Homo sapiens 113-117 20065508-7 2009 The in vitro experiments on colorectal cancer-derived cell lines (HT-29 and Caco-2) demonstrated that application of simvastatin decreased generation of both IL-6 and IL-8. Simvastatin 117-128 interleukin 6 Homo sapiens 158-162 20065508-7 2009 The in vitro experiments on colorectal cancer-derived cell lines (HT-29 and Caco-2) demonstrated that application of simvastatin decreased generation of both IL-6 and IL-8. Simvastatin 117-128 C-X-C motif chemokine ligand 8 Homo sapiens 167-171 20065508-9 2009 We conclude that 1) colorectal carcinogenesis is accompanied by increased synthesis and release of proinflammatory cytokines such as IL-6 and IL-8; 2) simvastatin therapy results in a decrease in serum level of proinflammatory cytokines, especially IL-6 in CRC and 3) simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines. Simvastatin 151-162 interleukin 6 Homo sapiens 133-137 20065508-9 2009 We conclude that 1) colorectal carcinogenesis is accompanied by increased synthesis and release of proinflammatory cytokines such as IL-6 and IL-8; 2) simvastatin therapy results in a decrease in serum level of proinflammatory cytokines, especially IL-6 in CRC and 3) simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines. Simvastatin 151-162 C-X-C motif chemokine ligand 8 Homo sapiens 142-146 20065508-9 2009 We conclude that 1) colorectal carcinogenesis is accompanied by increased synthesis and release of proinflammatory cytokines such as IL-6 and IL-8; 2) simvastatin therapy results in a decrease in serum level of proinflammatory cytokines, especially IL-6 in CRC and 3) simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines. Simvastatin 151-162 interleukin 6 Homo sapiens 249-266 20065508-9 2009 We conclude that 1) colorectal carcinogenesis is accompanied by increased synthesis and release of proinflammatory cytokines such as IL-6 and IL-8; 2) simvastatin therapy results in a decrease in serum level of proinflammatory cytokines, especially IL-6 in CRC and 3) simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines. Simvastatin 151-162 C-X-C motif chemokine ligand 8 Homo sapiens 300-304 20065508-9 2009 We conclude that 1) colorectal carcinogenesis is accompanied by increased synthesis and release of proinflammatory cytokines such as IL-6 and IL-8; 2) simvastatin therapy results in a decrease in serum level of proinflammatory cytokines, especially IL-6 in CRC and 3) simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines. Simvastatin 151-162 interleukin 6 Homo sapiens 249-253 19481207-10 2009 Simvastatin (1 micromol/L) suppressed the non-uniform shear stress- and TNF-alpha-induced increase in monocytic cell adhesion by about 30% via inhibition of VCAM-1 expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 72-81 19934968-8 2009 Simvastatin induced an increase of caspase-3 activity and annexin V staining, and down-regulated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Simvastatin 0-11 caspase 3 Homo sapiens 35-44 19934968-8 2009 Simvastatin induced an increase of caspase-3 activity and annexin V staining, and down-regulated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Simvastatin 0-11 annexin A5 Homo sapiens 58-67 19934968-8 2009 Simvastatin induced an increase of caspase-3 activity and annexin V staining, and down-regulated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Simvastatin 0-11 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 101-130 19934968-8 2009 Simvastatin induced an increase of caspase-3 activity and annexin V staining, and down-regulated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 138-141 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 0-11 caveolin 1 Homo sapiens 83-93 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 234-237 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 0-11 caspase 3 Homo sapiens 258-267 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 189-200 caveolin 1 Homo sapiens 83-93 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 189-200 AKT serine/threonine kinase 1 Homo sapiens 234-237 19934968-9 2009 Simvastatin also decreased cholesterol content in lipid raft fractions, suppressed caveolin-1 expression in the lipid rafts, and induced Fas translocation into lipid rafts, suggesting that simvastatin may inhibit the prosurvival PI3K/Akt pathway and trigger caspase-3-dependent apoptotic cell death through the modulation of lipid rafts. Simvastatin 189-200 caspase 3 Homo sapiens 258-267 19934968-10 2009 CONCLUSION: These results suggest that modulation of lipid rafts, Fas translocation, and PI3K/Akt/caspase-3 pathway are involved in the antitumor effect of simvastatin and may have a potential role in cancer prevention and treatment. Simvastatin 156-167 AKT serine/threonine kinase 1 Homo sapiens 94-97 19934968-10 2009 CONCLUSION: These results suggest that modulation of lipid rafts, Fas translocation, and PI3K/Akt/caspase-3 pathway are involved in the antitumor effect of simvastatin and may have a potential role in cancer prevention and treatment. Simvastatin 156-167 caspase 3 Homo sapiens 98-107 19729613-0 2009 Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Simvastatin 0-11 apolipoprotein E Mus musculus 83-99 19729613-4 2009 Here we determined the effect of simvastatin and the ERK inhibitor, CI1040, on AngII-stimulated AAA formation. Simvastatin 33-44 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 79-84 19729613-8 2009 Furthermore, simvastatin and the ERK inhibitor U0126 reversed AngII-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells. Simvastatin 13-24 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 62-67 19729613-9 2009 CONCLUSIONS: These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE(-/-) mice at least in part via ERK inhibition. Simvastatin 52-63 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 105-110 19729613-9 2009 CONCLUSIONS: These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE(-/-) mice at least in part via ERK inhibition. Simvastatin 52-63 apolipoprotein E Mus musculus 114-118 19729613-9 2009 CONCLUSIONS: These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE(-/-) mice at least in part via ERK inhibition. Simvastatin 52-63 mitogen-activated protein kinase 1 Mus musculus 150-153 19481207-10 2009 Simvastatin (1 micromol/L) suppressed the non-uniform shear stress- and TNF-alpha-induced increase in monocytic cell adhesion by about 30% via inhibition of VCAM-1 expression. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 157-163 23496050-6 2009 Genetic factors are relevant to both the efficacy and the toxicity of statin therapy, with efficacy being associated with polymorphisms in lipid-related genes, whereas a function-related polymorphism in the organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1) is associated with 60% of the cases of myopathy with high-dose simvastatin. Simvastatin 332-343 solute carrier organic anion transporter family member 1B1 Homo sapiens 207-249 19748147-8 2009 On the other hand, 3-month treatment with simvastatin reduced both lyso-PC contents in LDL and serum Lp-PLA(2) activity in hypercholesterolemic diabetic patients, while serum HTLase or paraoxonase activities did not change. Simvastatin 42-53 phospholipase A2 group VII Homo sapiens 101-110 19664625-7 2009 These data demonstrate that even a single prophylactic Sim administration protects from hypoxic ischemic brain damage and that neuroprotection is in part obtained by preserving Akt and stimulating CREB phosphorylation in neuronal cells. Simvastatin 55-58 AKT serine/threonine kinase 1 Rattus norvegicus 177-180 19664625-7 2009 These data demonstrate that even a single prophylactic Sim administration protects from hypoxic ischemic brain damage and that neuroprotection is in part obtained by preserving Akt and stimulating CREB phosphorylation in neuronal cells. Simvastatin 55-58 cAMP responsive element binding protein 1 Rattus norvegicus 197-201 19664625-0 2009 Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 74-77 19664625-0 2009 Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Simvastatin 0-11 cAMP responsive element binding protein 1 Rattus norvegicus 82-86 19664625-4 2009 Sim was given at the dose of 10 or 5 mg/kg, s.c. from postnatal day 1 (PN1) to PN7, or at 20 mg/kg from PN4 to PN7, or at 20 mg/kg in a single administration 18 h before the onset of the ischemic procedure. Simvastatin 0-3 sodium voltage-gated channel alpha subunit 8 Rattus norvegicus 104-107 19664625-6 2009 Sim increased both Akt and CREB phosphorylation in neuronal cells and treatment with wortmannin completely blocked neuroprotection and p-Akt. Simvastatin 0-3 AKT serine/threonine kinase 1 Rattus norvegicus 19-22 19664625-6 2009 Sim increased both Akt and CREB phosphorylation in neuronal cells and treatment with wortmannin completely blocked neuroprotection and p-Akt. Simvastatin 0-3 cAMP responsive element binding protein 1 Rattus norvegicus 27-31 19664625-6 2009 Sim increased both Akt and CREB phosphorylation in neuronal cells and treatment with wortmannin completely blocked neuroprotection and p-Akt. Simvastatin 0-3 AKT serine/threonine kinase 1 Rattus norvegicus 137-140 23496050-6 2009 Genetic factors are relevant to both the efficacy and the toxicity of statin therapy, with efficacy being associated with polymorphisms in lipid-related genes, whereas a function-related polymorphism in the organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1) is associated with 60% of the cases of myopathy with high-dose simvastatin. Simvastatin 332-343 solute carrier organic anion transporter family member 1B1 Homo sapiens 251-258 19864567-0 2009 Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson"s disease. Simvastatin 0-11 Harvey rat sarcoma virus oncogene Mus musculus 39-45 19602044-6 2009 Simvastatin and lovastatin enhanced bone morphogenetic protein 2 (BMP-2) mRNA levels. Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 36-64 19602044-6 2009 Simvastatin and lovastatin enhanced bone morphogenetic protein 2 (BMP-2) mRNA levels. Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 66-71 19556010-9 2009 In addition, we demonstrated that the statins simvastatin and pravastatin downregulate TF and PAR-2 expression in neutrophils and thus prevent pregnancy loss. Simvastatin 46-57 coagulation factor III Mus musculus 87-89 19556010-9 2009 In addition, we demonstrated that the statins simvastatin and pravastatin downregulate TF and PAR-2 expression in neutrophils and thus prevent pregnancy loss. Simvastatin 46-57 coagulation factor II (thrombin) receptor-like 1 Mus musculus 94-99 19449197-0 2009 Caveolin-1 restoration by cholesterol enhances the inhibitory effect of simvastatin on arginine vasopressin-induced cardiac fibroblasts proliferation. Simvastatin 72-83 caveolin 1 Rattus norvegicus 0-10 19449197-0 2009 Caveolin-1 restoration by cholesterol enhances the inhibitory effect of simvastatin on arginine vasopressin-induced cardiac fibroblasts proliferation. Simvastatin 72-83 arginine vasopressin Rattus norvegicus 96-107 19449197-5 2009 Simvastatin, a HMG-CoA reductase inhibitor, further down-regulated cav1 protein, whereas repleting cells with cholesterol increased cav1 protein and enhanced the anti-growth effect of simvastatin. Simvastatin 0-11 caveolin 1 Rattus norvegicus 67-71 19449197-6 2009 Our results provide a novel finding that cholesterol restoration may confer an additional inhibitory effect over simvastatin on AVP-induced CFs proliferation through cholesterol-cav1 interaction. Simvastatin 113-124 caveolin 1 Rattus norvegicus 178-182 19891551-0 2009 Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Simvastatin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 19891551-1 2009 AIMS: The cholesterol-lowering drug simvastatin is a substrate for P-glycoprotein (P-gp). Simvastatin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 19891551-1 2009 AIMS: The cholesterol-lowering drug simvastatin is a substrate for P-glycoprotein (P-gp). Simvastatin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 19891551-3 2009 We examined the Rotterdam Study, which is a population-based cohort study of people aged 55 years and older, to see whether the C1236T, G2677T/A and C3435T polymorphisms and haplotypes in the ABCB1 gene are associated with the total cholesterol and low-density lipoprotein cholesterol-lowering effect of simvastatin. Simvastatin 304-315 ATP binding cassette subfamily B member 1 Homo sapiens 192-197 19891551-10 2009 CONCLUSION: Male simvastatin users with the ABCB1 1236/2677/3435 TTT and CGT haplotype have larger reductions in total cholesterol and low-density lipoprotein cholesterol compared with the wild-type CGC haplotype. Simvastatin 17-28 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 19891551-10 2009 CONCLUSION: Male simvastatin users with the ABCB1 1236/2677/3435 TTT and CGT haplotype have larger reductions in total cholesterol and low-density lipoprotein cholesterol compared with the wild-type CGC haplotype. Simvastatin 17-28 UDP glycosyltransferase 8 Homo sapiens 73-76 19968183-0 2009 [Effect of simvastatin on mRNA expressions of some components of Wnt signaling pathway in differentiation process of osteoblasts derived from BMSCs of rats]. Simvastatin 11-22 Wnt family member 5A Rattus norvegicus 65-68 19968183-11 2009 CONCLUSION: Simvastatin can promote the osteogenic differentiation of BMSCs and change the expression of mRNA of some components of Wnt signaling pathway. Simvastatin 12-23 Wnt family member 5A Rattus norvegicus 132-135 19864567-6 2009 Interestingly, simvastatin attenuated activation of both p21(ras) and NF-kappaB in MPP(+)-stimulated microglial cells. Simvastatin 15-26 transcription elongation factor A (SII)-like 1 Mus musculus 57-60 19864567-6 2009 Interestingly, simvastatin attenuated activation of both p21(ras) and NF-kappaB in MPP(+)-stimulated microglial cells. Simvastatin 15-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 70-79 19864567-8 2009 However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21(ras), attenuated nigral activation of NF-kappaB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. Simvastatin 36-47 transcription elongation factor A (SII)-like 1 Mus musculus 101-104 19864567-8 2009 However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21(ras), attenuated nigral activation of NF-kappaB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. Simvastatin 36-47 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 143-152 19833260-3 2009 Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation. Simvastatin 171-182 solute carrier organic anion transporter family member 1B1 Homo sapiens 106-113 20079143-0 2009 Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells. Simvastatin 11-22 plasminogen activator, tissue type Homo sapiens 58-91 19608720-6 2009 MEASUREMENTS AND MAIN RESULTS: Simvastatin reduced total lung lavage leukocytes, eosinophils, and macrophages (P < 0.05) in the ovalbumin-exposed mice. Simvastatin 31-42 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 131-140 19608720-8 2009 Lung lavage IL-4, IL-13, and tumor necrosis factor-alpha levels were all reduced by treatment with simvastatin (P < 0.05). Simvastatin 99-110 interleukin 4 Mus musculus 12-16 19608720-8 2009 Lung lavage IL-4, IL-13, and tumor necrosis factor-alpha levels were all reduced by treatment with simvastatin (P < 0.05). Simvastatin 99-110 interleukin 13 Mus musculus 18-56 20079143-0 2009 Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells. Simvastatin 11-22 serpin family E member 1 Homo sapiens 96-129 20079143-16 2009 Simvastatin plays a protective role in CSE-induced fibrinolytic malfunction. Simvastatin 0-11 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 39-42 20079143-5 2009 The role of simvastatin in CSE-induced fibrinolytic activity changes was investigated as well. Simvastatin 12-23 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 27-30 20079143-13 2009 The levels of PAI-1 mRNA and protein increased significantly in 5% CSE-treated group ((8.8030 +/- 0.4745) ng/ml, (1.8155 +/- 0.0412) ng/ml) compared with those of control groups ((5.0588 +/- 0.2315) ng/ml, (1.3030 +/- 0.0647) ng/ml) (P < 0.01), and decreased after 2-hour simvastatin pre-treatment ((5.4875 +/- 0.3166) ng/ml, (1.3975 +/- 0.0297) ng/ml) (P < 0.01). Simvastatin 275-286 serpin family E member 1 Homo sapiens 14-19 20079143-13 2009 The levels of PAI-1 mRNA and protein increased significantly in 5% CSE-treated group ((8.8030 +/- 0.4745) ng/ml, (1.8155 +/- 0.0412) ng/ml) compared with those of control groups ((5.0588 +/- 0.2315) ng/ml, (1.3030 +/- 0.0647) ng/ml) (P < 0.01), and decreased after 2-hour simvastatin pre-treatment ((5.4875 +/- 0.3166) ng/ml, (1.3975 +/- 0.0297) ng/ml) (P < 0.01). Simvastatin 275-286 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 67-70 19785645-8 2009 For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concentrations of simvastatin acid and an enhanced risk of simvastatin-induced myopathy. Simvastatin 165-176 solute carrier organic anion transporter family member 1B1 Homo sapiens 82-89 19785645-8 2009 For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concentrations of simvastatin acid and an enhanced risk of simvastatin-induced myopathy. Simvastatin 165-176 solute carrier organic anion transporter family member 1B1 Homo sapiens 104-111 19785645-8 2009 For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concentrations of simvastatin acid and an enhanced risk of simvastatin-induced myopathy. Simvastatin 165-176 solute carrier organic anion transporter family member 1B1 Homo sapiens 137-144 19461118-5 2009 Simvastatin significantly reduced expression of ABCA1 in astrocytes and neuroblastoma cells (by 79% and 97%, respectively; both P < 0.001). Simvastatin 0-11 ATP binding cassette subfamily A member 1 Homo sapiens 48-53 19461118-7 2009 Simvastatin reduced expression of apolipoprotein E in astrocytes (P < 0.01). Simvastatin 0-11 apolipoprotein E Homo sapiens 34-50 19461118-9 2009 In SK-N-SH cells, simvastatin significantly increased cyclin-dependent kinase 5 and glycogen synthase kinase 3beta expression, while pravastatin increased amyloid precursor protein expression. Simvastatin 18-29 cyclin dependent kinase 5 Homo sapiens 54-79 19461118-9 2009 In SK-N-SH cells, simvastatin significantly increased cyclin-dependent kinase 5 and glycogen synthase kinase 3beta expression, while pravastatin increased amyloid precursor protein expression. Simvastatin 18-29 glycogen synthase kinase 3 beta Homo sapiens 84-114 19777282-3 2009 Treatment with 8 microM simvastatin inhibited cell growth and isoprenylation of Rap1A and Rab6, and supplementation with 2 microM mevalonate reversed these effects. Simvastatin 24-35 RAP1A, member of RAS oncogene family Homo sapiens 80-85 19777282-3 2009 Treatment with 8 microM simvastatin inhibited cell growth and isoprenylation of Rap1A and Rab6, and supplementation with 2 microM mevalonate reversed these effects. Simvastatin 24-35 RAB6A, member RAS oncogene family Homo sapiens 90-94 19842935-1 2009 AIMS: This study aimed to investigate possible effects of the ABCG2 c.421C>A (p.Gln141Lys; rs2231142) genotype on fluvastatin, pravastatin and simvastatin pharmacokinetics. Simvastatin 146-157 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 62-67 19591934-5 2009 Simvastatin significantly increased stromal cell-derived factor-1 (SDF1) expression in the ischemic brain and chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, and increased BMSC migration to RBMECs and astrocytes. Simvastatin 0-11 C-X-C motif chemokine ligand 12 Rattus norvegicus 36-65 19591934-5 2009 Simvastatin significantly increased stromal cell-derived factor-1 (SDF1) expression in the ischemic brain and chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, and increased BMSC migration to RBMECs and astrocytes. Simvastatin 0-11 C-X-C motif chemokine ligand 12 Rattus norvegicus 67-71 19591934-5 2009 Simvastatin significantly increased stromal cell-derived factor-1 (SDF1) expression in the ischemic brain and chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, and increased BMSC migration to RBMECs and astrocytes. Simvastatin 0-11 C-X-C motif chemokine receptor 4 Rattus norvegicus 110-142 19591934-5 2009 Simvastatin significantly increased stromal cell-derived factor-1 (SDF1) expression in the ischemic brain and chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, and increased BMSC migration to RBMECs and astrocytes. Simvastatin 0-11 C-X-C motif chemokine receptor 4 Rattus norvegicus 144-149 19842935-0 2009 Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Simvastatin 103-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-30 19842935-7 2009 CONCLUSIONS: Genetic variability in ABCG2 markedly affects the pharmacokinetics of fluvastatin and simvastatin lactone, but has no significant effect on pravastatin or active simvastatin acid. Simvastatin 99-118 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 36-41 19816600-7 2009 When simvastatin or EGF was added to HG-treated LECs, caveolin-1 levels increased and the apoptosis rate of LECs decreased. Simvastatin 5-16 caveolin 1 Homo sapiens 54-64 19816600-11 2009 The observation that simvastatin inhibited the apoptosis of HG-treated LECs in its therapeutic concentration suggests that daily dosage of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used by diabetic patients may increase PCO formation. Simvastatin 21-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-196 19798641-0 2009 Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Simvastatin 0-11 amyloid beta precursor protein Homo sapiens 63-83 19615978-6 2009 RT-PCR analysis and cytoimmunostaining of HUVECs treated with simvastatin revealed increased expression of VE-cadherin (p<0.05). Simvastatin 62-73 cadherin 5 Homo sapiens 107-118 19615978-7 2009 The blockade of VE-cadherin with a specific antibody reversed simvastatin-induced tube formation (p<0.002). Simvastatin 62-73 cadherin 5 Homo sapiens 16-27 19798641-2 2009 We investigated the effects of simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, on hippocampal A beta burden in a clinically relevant head injury/intervention model using mice expressing human A beta. Simvastatin 31-42 amyloid beta precursor protein Homo sapiens 113-119 19798641-3 2009 Simvastatin therapy blunted TBI-induced increases in A beta, reduced hippocampal tissue damage and microglial activation, and improved behavioral outcome. Simvastatin 0-11 amyloid beta precursor protein Homo sapiens 53-59 19825520-8 2009 Simvastatin did not modify pro-IL-1beta expression, but enhanced caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation. Simvastatin 0-11 caspase 1 Homo sapiens 65-74 19464400-2 2009 Simvastatin was shown to increase the expression of Bone morphogenetic protein (BMP-2), which is one of the most potent growth factors targeting bone formation. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 80-85 19825520-8 2009 Simvastatin did not modify pro-IL-1beta expression, but enhanced caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation. Simvastatin 0-11 interleukin 1 beta Homo sapiens 112-120 19825520-8 2009 Simvastatin did not modify pro-IL-1beta expression, but enhanced caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation. Simvastatin 0-11 interleukin 18 Homo sapiens 125-130 19825520-10 2009 Additionally, simvastatin enhanced Rac-1 activity. Simvastatin 14-25 Rac family small GTPase 1 Homo sapiens 35-40 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 135-170 19692918-14 2009 The conclusion of this study was that simvastatin potently increased endothelial TM expression in the zone of stasis and preserved the zone. Simvastatin 38-49 thrombomodulin Rattus norvegicus 81-83 19578821-1 2009 BACKGROUND: Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor commonly known as a cholesterol-lowering drug with additional pleiotropic effects. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 29-76 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 172-177 19721860-6 2009 RESULTS: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. Simvastatin 32-43 component of oligomeric golgi complex 2 Homo sapiens 233-238 19660610-0 2009 Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Simvastatin 125-136 apolipoprotein B Homo sapiens 101-117 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 0-11 apolipoprotein B Homo sapiens 118-122 19524673-4 2009 Simvastatin improved reactivity of cerebral arteries, rescued the blood flow response to neuronal activation, attenuated oxidative stress and inflammation, and reduced cortical soluble amyloid-beta (Abeta) levels and the number of Abeta plaque-related dystrophic neurites. Simvastatin 0-11 amyloid beta (A4) precursor protein Mus musculus 199-204 19524673-4 2009 Simvastatin improved reactivity of cerebral arteries, rescued the blood flow response to neuronal activation, attenuated oxidative stress and inflammation, and reduced cortical soluble amyloid-beta (Abeta) levels and the number of Abeta plaque-related dystrophic neurites. Simvastatin 0-11 amyloid beta (A4) precursor protein Mus musculus 231-236 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 0-11 apolipoprotein B Homo sapiens 154-158 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 33-44 apolipoprotein B Homo sapiens 118-122 19660610-4 2009 Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. Simvastatin 33-44 apolipoprotein B Homo sapiens 154-158 19660610-2 2009 The present analysis of the previously reported Simvastatin plus Fenofibrate for Combined Hyperlipidemia (SAFARI) trial assessed the associations of non-HDL cholesterol and LDL cholesterol with ApoB levels in patients with combined hyperlipidemia treated with combination simvastatin (20 mg) and fenofibrate (160 mg) or simvastatin monotherapy (20 mg). Simvastatin 48-59 apolipoprotein B Homo sapiens 194-198 19563533-7 2009 Continuous refreshing of the simvastatin-containing medium abrogated the mitochondrial amplification loop via caspase 8. Simvastatin 29-40 caspase 8 Homo sapiens 110-119 19886038-0 2009 Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 0-11 interferon gamma Homo sapiens 36-52 19886038-0 2009 Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 0-11 GLI family zinc finger 2 Homo sapiens 97-102 19886038-4 2009 Based on the above description, we compared the effect of simvastatin on IFNgamma-induced COX-2 expression in human monocytes versus murine macrophages. Simvastatin 58-69 interferon gamma Homo sapiens 73-81 19886038-4 2009 Based on the above description, we compared the effect of simvastatin on IFNgamma-induced COX-2 expression in human monocytes versus murine macrophages. Simvastatin 58-69 prostaglandin-endoperoxide synthase 2 Homo sapiens 90-95 19886038-5 2009 In a result, we found that simvastatin suppresses IFNgamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFNgamma-induced COX-2 expression in murine RAW264.7 macrophages. Simvastatin 27-38 interferon gamma Homo sapiens 50-58 19886038-5 2009 In a result, we found that simvastatin suppresses IFNgamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFNgamma-induced COX-2 expression in murine RAW264.7 macrophages. Simvastatin 27-38 prostaglandin-endoperoxide synthase 2 Homo sapiens 67-72 19886038-5 2009 In a result, we found that simvastatin suppresses IFNgamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFNgamma-induced COX-2 expression in murine RAW264.7 macrophages. Simvastatin 27-38 GLI family zinc finger 2 Homo sapiens 93-98 19886038-5 2009 In a result, we found that simvastatin suppresses IFNgamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFNgamma-induced COX-2 expression in murine RAW264.7 macrophages. Simvastatin 27-38 interferon gamma Homo sapiens 134-142 19886038-5 2009 In a result, we found that simvastatin suppresses IFNgamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFNgamma-induced COX-2 expression in murine RAW264.7 macrophages. Simvastatin 27-38 prostaglandin-endoperoxide synthase 2 Homo sapiens 151-156 19886038-6 2009 However, signal transducer and activator of transcription 1/3 (STAT1/3), known as a transcription factor on COX-2 expression, is inactivated by simvastatin in both cells. Simvastatin 144-155 signal transducer and activator of transcription 1 Homo sapiens 9-61 19886038-6 2009 However, signal transducer and activator of transcription 1/3 (STAT1/3), known as a transcription factor on COX-2 expression, is inactivated by simvastatin in both cells. Simvastatin 144-155 signal transducer and activator of transcription 1 Homo sapiens 63-70 19886038-6 2009 However, signal transducer and activator of transcription 1/3 (STAT1/3), known as a transcription factor on COX-2 expression, is inactivated by simvastatin in both cells. Simvastatin 144-155 prostaglandin-endoperoxide synthase 2 Homo sapiens 108-113 19618992-5 2009 RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05). Simvastatin 54-65 aminopeptidase O (putative) Homo sapiens 217-220 19886038-7 2009 Our findings showed that simvastatin is likely to suppress IFNgamma-induced COX-2 expression by inhibiting STAT1/3 activation in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 25-36 interferon gamma Homo sapiens 59-67 19886038-7 2009 Our findings showed that simvastatin is likely to suppress IFNgamma-induced COX-2 expression by inhibiting STAT1/3 activation in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 25-36 prostaglandin-endoperoxide synthase 2 Homo sapiens 76-81 19886038-7 2009 Our findings showed that simvastatin is likely to suppress IFNgamma-induced COX-2 expression by inhibiting STAT1/3 activation in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 25-36 signal transducer and activator of transcription 1 Homo sapiens 107-114 19886038-7 2009 Our findings showed that simvastatin is likely to suppress IFNgamma-induced COX-2 expression by inhibiting STAT1/3 activation in human THP-1 cells, but not in murine RAW264.7 cells. Simvastatin 25-36 GLI family zinc finger 2 Homo sapiens 135-140 19886038-8 2009 Thus, we concluded that IFNgamma-induced COX-2 expression is differently regulated by simvastatin depending on species specific mechanism. Simvastatin 86-97 interferon gamma Homo sapiens 24-32 19886038-8 2009 Thus, we concluded that IFNgamma-induced COX-2 expression is differently regulated by simvastatin depending on species specific mechanism. Simvastatin 86-97 prostaglandin-endoperoxide synthase 2 Homo sapiens 41-46 19406911-5 2009 METHODS AND RESULTS: We observed that pharmacological concentrations of statins (atorvastatin and simvastatin) modulated LOX transcriptional activity, counteracting the down-regulation of LOX (at the mRNA, protein, and activity level) caused by tumour necrosis factor-alpha (TNFalpha) in porcine, bovine, and human aortic endothelial cells. Simvastatin 98-109 lysyl oxidase Bos taurus 121-124 19406911-5 2009 METHODS AND RESULTS: We observed that pharmacological concentrations of statins (atorvastatin and simvastatin) modulated LOX transcriptional activity, counteracting the down-regulation of LOX (at the mRNA, protein, and activity level) caused by tumour necrosis factor-alpha (TNFalpha) in porcine, bovine, and human aortic endothelial cells. Simvastatin 98-109 lysyl oxidase Bos taurus 188-191 19406911-5 2009 METHODS AND RESULTS: We observed that pharmacological concentrations of statins (atorvastatin and simvastatin) modulated LOX transcriptional activity, counteracting the down-regulation of LOX (at the mRNA, protein, and activity level) caused by tumour necrosis factor-alpha (TNFalpha) in porcine, bovine, and human aortic endothelial cells. Simvastatin 98-109 tumor necrosis factor Bos taurus 275-283 19640331-0 2009 Effect of simvastatin on plasma interleukin-6 in patients with unstable angina. Simvastatin 10-21 interleukin 6 Homo sapiens 32-45 19327776-11 2009 The reduction in risk by intensive lipid-lowering treatment as compared to usual-dose simvastatin was well predicted by the difference in apoB/apoA-1 on-treatment levels. Simvastatin 86-97 apolipoprotein B Homo sapiens 138-142 19327776-11 2009 The reduction in risk by intensive lipid-lowering treatment as compared to usual-dose simvastatin was well predicted by the difference in apoB/apoA-1 on-treatment levels. Simvastatin 86-97 apolipoprotein A1 Homo sapiens 143-149 19555253-5 2009 At the end of the study apolipoprotein A-1 (Apo A-1) increased with fenofibrate + simvastatin, while apolipoprotein B (Apo B) decreased in all groups compared to baseline. Simvastatin 82-93 apolipoprotein A1 Homo sapiens 24-42 19555253-5 2009 At the end of the study apolipoprotein A-1 (Apo A-1) increased with fenofibrate + simvastatin, while apolipoprotein B (Apo B) decreased in all groups compared to baseline. Simvastatin 82-93 apolipoprotein A1 Homo sapiens 44-51 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 143-154 serpin family E member 1 Homo sapiens 0-33 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 143-154 C-reactive protein Homo sapiens 63-81 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 179-190 serpin family E member 1 Homo sapiens 35-40 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 179-190 serpin family E member 1 Homo sapiens 35-40 19555253-7 2009 After 12 months, fibrinogen (Fg) decreased compared to baseline with fenofibrate + simvastatin. Simvastatin 83-94 fibrinogen beta chain Homo sapiens 17-27 19618992-6 2009 CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. Simvastatin 51-62 lipoprotein(a) Homo sapiens 102-107 19618992-6 2009 CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. Simvastatin 51-62 aminopeptidase O (putative) Homo sapiens 112-115 19618992-6 2009 CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. Simvastatin 51-62 lipoprotein(a) Homo sapiens 181-186 19618992-6 2009 CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. Simvastatin 51-62 apolipoprotein B Homo sapiens 215-223 19618992-5 2009 RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05). Simvastatin 54-65 lipoprotein(a) Homo sapiens 238-243 19618992-5 2009 RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05). Simvastatin 54-65 aminopeptidase O (putative) Homo sapiens 259-262 20166433-10 2009 These results implied that simvastatin significantly enhanced the oral bioavailability of verapamil by inhibiting the CYP3A-mediated metabolism in small intestine or in the liver and P-glycoprotein (P-gp) efflux pump in small intestine. Simvastatin 27-38 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 118-123 19076990-11 2009 CONCLUSION: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1beta and prostaglandin E(2) production. Simvastatin 34-45 interleukin 1 beta Rattus norvegicus 158-175 19008785-8 2009 Our data suggest that simvastatin, despite lowering circulating low-density lipoprotein cholesterol, decreased LPS toxicity by reduction of NF-kappaB activation and subsequent release of TNF by modulating 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and therefore deserves consideration as a possible adjuvant therapy in acute inflammatory disease. Simvastatin 22-33 nuclear factor kappa B subunit 1 Homo sapiens 140-149 19008785-8 2009 Our data suggest that simvastatin, despite lowering circulating low-density lipoprotein cholesterol, decreased LPS toxicity by reduction of NF-kappaB activation and subsequent release of TNF by modulating 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and therefore deserves consideration as a possible adjuvant therapy in acute inflammatory disease. Simvastatin 22-33 tumor necrosis factor Homo sapiens 187-190 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 96-101 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 ATP binding cassette subfamily C member 2 Homo sapiens 106-111 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 solute carrier organic anion transporter family member 1B1 Homo sapiens 125-132 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 solute carrier organic anion transporter family member 2B1 Homo sapiens 134-141 19543298-3 2009 In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated. Simvastatin 47-58 solute carrier family 22 member 1 Homo sapiens 146-153 19640331-6 2009 Following treatment, the average left ventricular ejection fraction in the simvastatin group was higher than in the placebo group (0.54+/-0.06 vs 0.51+/-0.05, P < 0.05), whereas the plasma BNP levels were lower (16.8+/-6.6 vs 26.4+/-1.4, P < 0.01). Simvastatin 75-86 natriuretic peptide B Homo sapiens 192-195 19640331-8 2009 Following treatment, the IL-6 levels in the simvastatin group were lower than in the placebo group (0.7+/-0.4 vs 1.2+/-0.4 pg/ml, P < 0.05). Simvastatin 44-55 interleukin 6 Homo sapiens 25-29 19640331-9 2009 CONCLUSIONS: Short-term treatment with simvastatin reduces plasma IL-6. Simvastatin 39-50 interleukin 6 Homo sapiens 66-70 20166433-10 2009 These results implied that simvastatin significantly enhanced the oral bioavailability of verapamil by inhibiting the CYP3A-mediated metabolism in small intestine or in the liver and P-glycoprotein (P-gp) efflux pump in small intestine. Simvastatin 27-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 183-197 20166433-10 2009 These results implied that simvastatin significantly enhanced the oral bioavailability of verapamil by inhibiting the CYP3A-mediated metabolism in small intestine or in the liver and P-glycoprotein (P-gp) efflux pump in small intestine. Simvastatin 27-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 199-203 19205663-11 2009 Both TNF-alpha and IL-6 levels were significantly reduced in the simvastatin group (p = 0.02 and p = 0.02, respectively), while no such difference was observed in the placebo group (p = 0.35 and 0.39, respectively). Simvastatin 65-76 tumor necrosis factor Homo sapiens 5-14 19205663-11 2009 Both TNF-alpha and IL-6 levels were significantly reduced in the simvastatin group (p = 0.02 and p = 0.02, respectively), while no such difference was observed in the placebo group (p = 0.35 and 0.39, respectively). Simvastatin 65-76 interleukin 6 Homo sapiens 19-23 18544044-0 2009 Increasing Ang1/Tie2 expression by simvastatin treatment induces vascular stabilization and neuroblast migration after stroke. Simvastatin 35-46 angiopoietin 1 Rattus norvegicus 11-15 18544044-0 2009 Increasing Ang1/Tie2 expression by simvastatin treatment induces vascular stabilization and neuroblast migration after stroke. Simvastatin 35-46 TEK receptor tyrosine kinase Rattus norvegicus 16-20 18544044-1 2009 In this study, we tested the hypothesis that the Angiopoietin 1 (Ang1)/Tie2 pathway mediates simvastatin-induced vascular integrity and migration of neuroblasts after stroke. Simvastatin 93-104 angiopoietin 1 Rattus norvegicus 49-63 19366846-12 2009 Simvastatin also induced a concentration-dependent decrease in MMP-3 in the absence and presence of inflammatory challenge (using IL-1alpha). Simvastatin 0-11 matrix metallopeptidase 3 Mus musculus 63-68 18544044-1 2009 In this study, we tested the hypothesis that the Angiopoietin 1 (Ang1)/Tie2 pathway mediates simvastatin-induced vascular integrity and migration of neuroblasts after stroke. Simvastatin 93-104 angiopoietin 1 Rattus norvegicus 65-69 19366846-12 2009 Simvastatin also induced a concentration-dependent decrease in MMP-3 in the absence and presence of inflammatory challenge (using IL-1alpha). Simvastatin 0-11 interleukin 1 alpha Mus musculus 130-139 18544044-1 2009 In this study, we tested the hypothesis that the Angiopoietin 1 (Ang1)/Tie2 pathway mediates simvastatin-induced vascular integrity and migration of neuroblasts after stroke. Simvastatin 93-104 TEK receptor tyrosine kinase Rattus norvegicus 71-75 19366846-14 2009 Mechanisms of action of simvastatin may include inhibition of MMP-3. Simvastatin 24-35 matrix metallopeptidase 3 Mus musculus 62-67 18544044-3 2009 Simvastatin treatment significantly decreased blood-brain barrier (BBB) leakage and concomitantly, increased Ang1, Tie2 and Occludin expression in the ischaemic border (IBZ) compared to the MCAo control group. Simvastatin 0-11 angiopoietin 1 Rattus norvegicus 109-113 18544044-3 2009 Simvastatin treatment significantly decreased blood-brain barrier (BBB) leakage and concomitantly, increased Ang1, Tie2 and Occludin expression in the ischaemic border (IBZ) compared to the MCAo control group. Simvastatin 0-11 TEK receptor tyrosine kinase Rattus norvegicus 115-119 18544044-3 2009 Simvastatin treatment significantly decreased blood-brain barrier (BBB) leakage and concomitantly, increased Ang1, Tie2 and Occludin expression in the ischaemic border (IBZ) compared to the MCAo control group. Simvastatin 0-11 occludin Rattus norvegicus 124-132 18544044-4 2009 Simvastatin also significantly increased doublecortin (DCX, a marker of migrating neuroblasts) expression in the IBZ compared to control MCAo rats. Simvastatin 0-11 doublecortin Rattus norvegicus 41-53 18544044-4 2009 Simvastatin also significantly increased doublecortin (DCX, a marker of migrating neuroblasts) expression in the IBZ compared to control MCAo rats. Simvastatin 0-11 doublecortin Rattus norvegicus 55-58 18544044-7 2009 The data show that simvastatin treatment of RBMEC increased Ang1 and Tie2 gene and protein expression and promoted phosphorylated-Tie2 activity. Simvastatin 19-30 angiopoietin 1 Rattus norvegicus 60-64 18544044-7 2009 The data show that simvastatin treatment of RBMEC increased Ang1 and Tie2 gene and protein expression and promoted phosphorylated-Tie2 activity. Simvastatin 19-30 TEK receptor tyrosine kinase Rattus norvegicus 69-73 18544044-7 2009 The data show that simvastatin treatment of RBMEC increased Ang1 and Tie2 gene and protein expression and promoted phosphorylated-Tie2 activity. Simvastatin 19-30 TEK receptor tyrosine kinase Rattus norvegicus 130-134 18544044-9 2009 Inhibition of Ang1 or knockdown of Tie2 gene expression in endothelial cells significantly attenuated simvastatin-induced capillary tube formation. Simvastatin 102-113 angiopoietin 1 Rattus norvegicus 14-18 18544044-9 2009 Inhibition of Ang1 or knockdown of Tie2 gene expression in endothelial cells significantly attenuated simvastatin-induced capillary tube formation. Simvastatin 102-113 TEK receptor tyrosine kinase Rattus norvegicus 35-39 18544044-11 2009 Inhibition of Ang1 significantly attenuated simvastatin-induced SVZ cell migration. Simvastatin 44-55 angiopoietin 1 Rattus norvegicus 14-18 18544044-12 2009 Simvastatin treatment of stroke increases Ang1/Tie2 expression and thereby reduces BBB leakage and promotes vascular stabilization. Simvastatin 0-11 TEK receptor tyrosine kinase Rattus norvegicus 47-51 18544044-13 2009 Ang1/Tie2 expression induced by simvastatin treatment promotes neuroblast micro-vascular coupling after stroke. Simvastatin 32-43 angiopoietin 1 Rattus norvegicus 0-4 18544044-13 2009 Ang1/Tie2 expression induced by simvastatin treatment promotes neuroblast micro-vascular coupling after stroke. Simvastatin 32-43 TEK receptor tyrosine kinase Rattus norvegicus 5-9 19504041-1 2009 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, is used for lowering elevated low-density lipoprotein cholesterol concentrations. Simvastatin 63-74 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 4-51 19574840-0 2009 Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 79-96 19305020-0 2009 Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. Simvastatin 25-36 apolipoprotein B Homo sapiens 40-56 19305020-7 2009 Our results indicate that treatment with simvastatin plus ezetimibe is effective in reducing plasma TRL apoB-48 levels and that this effect is most likely mediated by a reduction in the intestinal secretion of TRL apoB-48. Simvastatin 41-52 apolipoprotein B Homo sapiens 104-111 19305020-7 2009 Our results indicate that treatment with simvastatin plus ezetimibe is effective in reducing plasma TRL apoB-48 levels and that this effect is most likely mediated by a reduction in the intestinal secretion of TRL apoB-48. Simvastatin 41-52 apolipoprotein B Homo sapiens 214-221 19574840-9 2009 Simvastatin only reduced the level of IL-1beta but not IL-6 and tumor necrosis factor-alpha, compared with the saline group. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 38-46 19574840-13 2009 Simvastatin selectively reduces IL-1beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 32-40 19574840-13 2009 Simvastatin selectively reduces IL-1beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI. Simvastatin 202-213 interleukin 1 beta Rattus norvegicus 32-40 19574841-11 2009 Enzyme-linked immunosorbent assay studies showed that 0.5 mg/kg simvastatin significantly increased BDNF levels within the hippocampus, but 1.0 mg/kg had no significant effect. Simvastatin 64-75 brain-derived neurotrophic factor Rattus norvegicus 100-104 19574841-14 2009 It also enhances neuronal survival in the hippocampus and increases BDNF levels in the hippocampus secondary to simvastatin treatment. Simvastatin 112-123 brain-derived neurotrophic factor Rattus norvegicus 68-72 19659652-5 2009 In addition, simvastatin downregulated transforming growth factor-beta1 and connective tissue growth factor protein and gene expression in the lungs. Simvastatin 13-24 myotrophin Rattus norvegicus 52-65 19815947-2 2009 The aim of this study was to investigate the effect of 3-month treatment with simvastatin on serum levels of Insulin-Like Growth Factor-1 (IGF-1) in patients with diagnosed hypercholesterolemia. Simvastatin 78-89 insulin like growth factor 1 Homo sapiens 109-137 19815947-2 2009 The aim of this study was to investigate the effect of 3-month treatment with simvastatin on serum levels of Insulin-Like Growth Factor-1 (IGF-1) in patients with diagnosed hypercholesterolemia. Simvastatin 78-89 insulin like growth factor 1 Homo sapiens 139-144 19815947-10 2009 Additional three-month treatment with simvastatin decreased the serum concentration of IGF-1. Simvastatin 38-49 insulin like growth factor 1 Homo sapiens 87-92 19659652-5 2009 In addition, simvastatin downregulated transforming growth factor-beta1 and connective tissue growth factor protein and gene expression in the lungs. Simvastatin 13-24 myotrophin Rattus norvegicus 94-107 19659652-7 2009 Simultaneously, the expression of RhoA and the phosphorylation of Smad2 and Smad3 in lungs exposed to cigarette smoke were inhibited during simvastatin administration. Simvastatin 140-151 ras homolog family member A Rattus norvegicus 34-38 19659652-7 2009 Simultaneously, the expression of RhoA and the phosphorylation of Smad2 and Smad3 in lungs exposed to cigarette smoke were inhibited during simvastatin administration. Simvastatin 140-151 SMAD family member 2 Rattus norvegicus 66-71 19659652-7 2009 Simultaneously, the expression of RhoA and the phosphorylation of Smad2 and Smad3 in lungs exposed to cigarette smoke were inhibited during simvastatin administration. Simvastatin 140-151 SMAD family member 3 Rattus norvegicus 76-81 19659652-10 2009 Simvastatin may inhibit cigarette smoke-induced small airway remodelling by reducing growth factor expression and inflammation. Simvastatin 0-11 myotrophin Rattus norvegicus 85-98 19659652-11 2009 The mechanism of action of simvastatin on small airway remodelling involved RhoA and the Smad signalling pathway. Simvastatin 27-38 ras homolog family member A Rattus norvegicus 76-80 19659652-11 2009 The mechanism of action of simvastatin on small airway remodelling involved RhoA and the Smad signalling pathway. Simvastatin 27-38 SMAD family member 7 Rattus norvegicus 89-93 19539078-6 2009 Significantly greater improvements in the levels of LDL cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios resulted with ezetimibe/simvastatin compared with atorvastatin at all specified dose comparisons (p <0.001). Simvastatin 182-193 apolipoprotein B Homo sapiens 111-127 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 myeloperoxidase Homo sapiens 100-115 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 tumor necrosis factor Homo sapiens 117-144 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 189-207 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 209-212 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 232-235 20005478-3 2009 Using a panel of immortalized lymphocyte cell lines incubated with simvastatin, we recently found that the magnitude of expression of an alternatively spliced HMGCR transcript lacking exon 13 was inversely correlated with in vivo reductions of total cholesterol, low-density lipoprotein cholesterol, apoB, and triglycerides after statin treatment of the individuals from whom the cells were derived. Simvastatin 67-78 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 159-164 18977478-7 2009 Simvastatin therapy significantly increased insulin levels (mean % changes; 127%, P=0.014) and decreased plasma adiponectin levels (10%, P=0.012) and insulin sensitivity as assessed by QUICKI (6%, P=0.007) when compared with baseline. Simvastatin 0-11 insulin Homo sapiens 44-51 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 CD34 molecule Rattus norvegicus 77-81 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 124-158 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 160-164 18563306-4 2009 Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 170-173 18563306-5 2009 In cultured EPC, simvastatin increased the concentrations of VEGF, AKT and eNOS. Simvastatin 17-28 vascular endothelial growth factor A Rattus norvegicus 61-65 18563306-5 2009 In cultured EPC, simvastatin increased the concentrations of VEGF, AKT and eNOS. Simvastatin 17-28 AKT serine/threonine kinase 1 Rattus norvegicus 67-70 18563306-6 2009 Western blots analysis showed that simvastatin increased the phosphorylation of eNOS and FKHRL1, which can be blocked by the PI3K/AKT pathway blocker LY294002 . Simvastatin 35-46 forkhead box O3 Rattus norvegicus 89-95 18563306-6 2009 Western blots analysis showed that simvastatin increased the phosphorylation of eNOS and FKHRL1, which can be blocked by the PI3K/AKT pathway blocker LY294002 . Simvastatin 35-46 AKT serine/threonine kinase 1 Rattus norvegicus 130-133 18563306-8 2009 In in vitro study, simvastatin increases the phosphorylation of eNOS and of FKHRL1 through the PI3K/AKT signaling pathway. Simvastatin 19-30 forkhead box O3 Rattus norvegicus 76-82 18563306-8 2009 In in vitro study, simvastatin increases the phosphorylation of eNOS and of FKHRL1 through the PI3K/AKT signaling pathway. Simvastatin 19-30 AKT serine/threonine kinase 1 Rattus norvegicus 100-103 19027114-0 2009 Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. Simvastatin 128-139 coagulation factor III, tissue factor Homo sapiens 0-13 19027114-0 2009 Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease. Simvastatin 128-139 coagulation factor II, thrombin Homo sapiens 99-107 19027114-1 2009 OBJECTIVE: We examined the hypothesis that the +5466A>G variant (rs3917643) of the tissue factor (TF) gene is associated with thrombin formation following simvastatin in patients with ischemic heart disease (IHD). Simvastatin 158-169 coagulation factor III, tissue factor Homo sapiens 86-99 19027114-1 2009 OBJECTIVE: We examined the hypothesis that the +5466A>G variant (rs3917643) of the tissue factor (TF) gene is associated with thrombin formation following simvastatin in patients with ischemic heart disease (IHD). Simvastatin 158-169 coagulation factor III, tissue factor Homo sapiens 101-103 18977478-7 2009 Simvastatin therapy significantly increased insulin levels (mean % changes; 127%, P=0.014) and decreased plasma adiponectin levels (10%, P=0.012) and insulin sensitivity as assessed by QUICKI (6%, P=0.007) when compared with baseline. Simvastatin 0-11 adiponectin, C1Q and collagen domain containing Homo sapiens 112-123 19027114-5 2009 The magnitude of reduction in maximum rates of F1.2 and TAT formation following simvastatin was larger (P<0.001) in +5466G allele carriers than in +5466AA subjects. Simvastatin 80-91 coagulation factor XII Homo sapiens 47-51 19027114-6 2009 The degree of decrease in maximum local levels of F1.2 and TAT after simvastatin was similar in both genotype groups. Simvastatin 69-80 coagulation factor XII Homo sapiens 50-54 18977478-7 2009 Simvastatin therapy significantly increased insulin levels (mean % changes; 127%, P=0.014) and decreased plasma adiponectin levels (10%, P=0.012) and insulin sensitivity as assessed by QUICKI (6%, P=0.007) when compared with baseline. Simvastatin 0-11 insulin Homo sapiens 150-157 18977478-9 2009 In addition, these effects of simvastatin were significant when compared with pravastatin (P<0.001 for insulin levels by ANOVA on Ranks, P<0.001 for adiponectin and P=0.001 for QUICKI by ANOVA). Simvastatin 30-41 adiponectin, C1Q and collagen domain containing Homo sapiens 155-166 19842842-0 2009 Simvastatin restores down-regulated GATA-6 expression in pulmonary hypertensive rats. Simvastatin 0-11 GATA binding protein 6 Rattus norvegicus 36-42 19125317-7 2009 After simvastatin treatment, CD11b expression decreased to 116.9 +/- 12.5 (P < 0.03) and CD14 expression to 107.5 +/- 6.2 (P < 0.04). Simvastatin 6-17 integrin subunit alpha M Homo sapiens 29-34 19125317-7 2009 After simvastatin treatment, CD11b expression decreased to 116.9 +/- 12.5 (P < 0.03) and CD14 expression to 107.5 +/- 6.2 (P < 0.04). Simvastatin 6-17 CD14 molecule Homo sapiens 92-96 19842842-3 2009 The aim of present study was to investigate the expression of GATA-6 gene in experimental pulmonary hypertensive rats and explore the effect of regulation of GATA-6 expression by simvastatin on pulmonary vascular remodeling. Simvastatin 179-190 GATA binding protein 6 Rattus norvegicus 158-164 19842842-8 2009 The level of GATA-6 mRNA and protein were markedly decreased in these pneumonectomy and MCT-treated rats, and they were significantly up-regulated in these rats after receiving simvastatin. Simvastatin 177-188 GATA binding protein 6 Rattus norvegicus 13-19 19842842-9 2009 These results indicate that the development and progression of pulmonary hypertension is prevented by simvastatin by up-regulating GATA-6 expression in the lung tissue. Simvastatin 102-113 GATA binding protein 6 Rattus norvegicus 131-137 19289970-12 2009 Co-administration of mevalonate abolished protective effects of simvastatin on endotoxin-provoked increases in ALT, AST, and hepatocellular apoptosis as well as leukocyte recruitment. Simvastatin 64-75 glutamic pyruvic transaminase, soluble Mus musculus 111-114 20687301-0 2009 The effect of simvastatin on mRNA expression of transforming growth factor-beta1, bone morphogenetic protein-2 and vascular endothelial growth factor in tooth extraction socket. Simvastatin 14-25 transforming growth factor, beta 1 Rattus norvegicus 48-80 20687301-0 2009 The effect of simvastatin on mRNA expression of transforming growth factor-beta1, bone morphogenetic protein-2 and vascular endothelial growth factor in tooth extraction socket. Simvastatin 14-25 bone morphogenetic protein 2 Rattus norvegicus 82-110 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 94-126 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 128-137 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 bone morphogenetic protein 2 Rattus norvegicus 140-168 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 bone morphogenetic protein 2 Rattus norvegicus 170-175 20687301-1 2009 AIM: To determine the effect of local simvastatin application on the mRNA expression level of transforming growth factor-beta1 (TGF-beta1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in the tooth sockets of rat. Simvastatin 38-49 vascular endothelial growth factor A Rattus norvegicus 181-215 19254925-0 2009 Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. Simvastatin 0-11 leptin Mus musculus 23-29 19254925-2 2009 We demonstrated that simvastatin at 1 microM markedly inhibited adipocyte differentiation measured by Oil Red O staining in preadipocyte cells (3T3-L1), while expression of leptin, a marker of adipocyte differentiation, was suppressed by 1 muM simvastatin for up to 12 days of culture. Simvastatin 21-32 leptin Mus musculus 173-179 19254925-3 2009 Next, to elucidate mechanisms underlying the reduction of leptin expression induced by simvastatin, differentiated 3T3-L1 adipocytes were treated with various inhibitors with mevalonate or its metabolite in the presence or absence of simvastatin. Simvastatin 87-98 leptin Mus musculus 58-64 19254925-4 2009 Simvastatin time- and dose-dependently suppressed leptin mRNA expression. Simvastatin 0-11 leptin Mus musculus 50-56 19254925-5 2009 Heterogeneous nuclear RNA related to leptin mRNA was inhibited by 10 muM simvastatin, while stability of the mRNA was not changed by treatment with simvastatin in transcription-arrested 3T3-L1 cells. Simvastatin 73-84 leptin Mus musculus 37-43 19254925-6 2009 Simvastatin inhibition of leptin gene transcription was not abrogated by pre-treatment with cycloheximide, an inhibitor of protein synthesis. Simvastatin 0-11 leptin Mus musculus 26-32 19254925-7 2009 Addition of mevalonate or geranylgeranyl pyrophosphate (GGPP), a mevalonate metabolite, abolished simvastatin-induced inhibition of leptin expression in 3T3-L1 cells. Simvastatin 98-109 leptin Mus musculus 132-138 19254925-13 2009 H89, an inhibitor of PKA, completely abolished simvastatin-induced suppression of leptin expression. Simvastatin 47-58 leptin Mus musculus 82-88 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 123-127 19380384-3 2009 To address these issues, we examined the effect of simvastatin and inhibitors for protein farnesylation and geranylgeranylation on the differentiation of IL-17-producing T cells (T(h)17 cells) and Foxp3(+) CD4(+) T cells. Simvastatin 51-62 interleukin 17A Homo sapiens 154-159 19380384-4 2009 Simvastatin inhibited the differentiation of T(h)17 cells through the inhibition of HMG-CoA reductase activity but enhanced the differentiation of Foxp3(+) CD4(+) T cells. Simvastatin 0-11 forkhead box P3 Homo sapiens 147-152 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 123-127 19289970-12 2009 Co-administration of mevalonate abolished protective effects of simvastatin on endotoxin-provoked increases in ALT, AST, and hepatocellular apoptosis as well as leukocyte recruitment. Simvastatin 64-75 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 116-119 19513607-4 2009 The results showed that incubation of 293-eNOS cells with simvastatin (10 microm/L) for 2 h significantly increased in the activity of eNOS as shown by the conversion of L-arginine to L-citrulline (2889.70+/-201.51 versus 5630.18+/-218.75 pmol/min . Simvastatin 58-69 nitric oxide synthase 3 Homo sapiens 42-46 19513607-4 2009 The results showed that incubation of 293-eNOS cells with simvastatin (10 microm/L) for 2 h significantly increased in the activity of eNOS as shown by the conversion of L-arginine to L-citrulline (2889.70+/-201.51 versus 5630.18+/-218.75 pmol/min . Simvastatin 58-69 nitric oxide synthase 3 Homo sapiens 135-139 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 108-126 19513607-6 2009 Western blotting revealed that simvastatin increased phosphorylation of eNOS at 1177 (ser) and also 495 (thr) but did not affect the overall expression of eNOS or inducible NOS. Simvastatin 31-42 nitric oxide synthase 3 Homo sapiens 72-76 19513607-7 2009 Further study found that simvastatin raised phosphorylation levels of Akt and AMPK, and such effect could be antagonized by Akt inhibitor or AMPK inhibitor. Simvastatin 25-36 AKT serine/threonine kinase 1 Homo sapiens 70-73 19513607-7 2009 Further study found that simvastatin raised phosphorylation levels of Akt and AMPK, and such effect could be antagonized by Akt inhibitor or AMPK inhibitor. Simvastatin 25-36 AKT serine/threonine kinase 1 Homo sapiens 124-127 19513607-8 2009 These results suggest that simvastatin could stimulate the activity of eNOS via its phosphorylation by Akt and AMPK, which provides a new mechanism, other than lipid-lowering effect, for the cardiovascular protection of statins. Simvastatin 27-38 nitric oxide synthase 3 Homo sapiens 71-75 19513607-8 2009 These results suggest that simvastatin could stimulate the activity of eNOS via its phosphorylation by Akt and AMPK, which provides a new mechanism, other than lipid-lowering effect, for the cardiovascular protection of statins. Simvastatin 27-38 AKT serine/threonine kinase 1 Homo sapiens 103-106 19513607-0 2009 Simvastatin increases the activity of endothelial nitric oxide synthase via enhancing phosphorylation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 38-71 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 63-67 19505368-0 2009 Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. Simvastatin 174-185 matrix metallopeptidase 9 Rattus norvegicus 83-88 19505368-0 2009 Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. Simvastatin 174-185 nitric oxide synthase 2 Rattus norvegicus 93-97 19505368-0 2009 Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. Simvastatin 174-185 endothelin receptor type A Rattus norvegicus 102-108 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 128-131 19694216-10 2009 These changes were correlated with reduction in CRP following simvastatin. Simvastatin 62-73 C-reactive protein Homo sapiens 48-51 19777851-5 2009 All groups were administered for 10 days with stomach tube, and then the quantity of liver microsome protein, the activity of CYP3A were determined by spectrophotograph simvastatin was incubated with the liver microsome, and the effect of gingko extract on its metabolism was estimated by measuring the amount of simvastatin by HPLC. Simvastatin 169-180 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 126-131 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 95-98 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 257-260 19429419-4 2009 Simvastatin lactone, but not the acid form, exhibited a strong inductive effect on the mRNA expression of MDR1 and CYP3A in a dose-dependent manner. Simvastatin 0-19 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 19332549-0 2009 Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta. Simvastatin 22-33 Rac family small GTPase 1 Mus musculus 14-18 19332549-5 2009 Simvastatin treatment of mice led to a significant increase in AMPK and LKB1 phosphorylation and to a decrease in protein kinase A activity relative to control animals, associated with a marked increase in Rac1 activation. Simvastatin 0-11 serine/threonine kinase 11 Mus musculus 72-76 19332549-5 2009 Simvastatin treatment of mice led to a significant increase in AMPK and LKB1 phosphorylation and to a decrease in protein kinase A activity relative to control animals, associated with a marked increase in Rac1 activation. Simvastatin 0-11 Rac family small GTPase 1 Mus musculus 206-210 19332549-6 2009 Exposure of bovine aortic endothelial cells to simvastatin for 24 h strikingly increased GTP-bound Rac1 and led to increased phosphorylation of AMPK as well as the AMPK kinase LKB1. Simvastatin 47-58 Rac family small GTPase 1 Bos taurus 99-103 19332549-6 2009 Exposure of bovine aortic endothelial cells to simvastatin for 24 h strikingly increased GTP-bound Rac1 and led to increased phosphorylation of AMPK as well as the AMPK kinase LKB1. Simvastatin 47-58 serine/threonine kinase 11 Mus musculus 176-180 19332549-8 2009 Small interfering RNA (siRNA)-mediated knockdown of AMPK abrogated simvastatin-induced Rac1 activation and LKB1 phosphorylation. Simvastatin 67-78 Rac family small GTPase 1 Mus musculus 87-91 19332549-8 2009 Small interfering RNA (siRNA)-mediated knockdown of AMPK abrogated simvastatin-induced Rac1 activation and LKB1 phosphorylation. Simvastatin 67-78 serine/threonine kinase 11 Mus musculus 107-111 19332549-9 2009 Importantly, siRNA-mediated knockdown of the key AMPK kinase, calcium/calmodulin-dependent protein kinase kinase beta, completely blocked simvastatin-induced endothelial cell migration and also abrogated statin-promoted phosphorylation of AMPK and LKB1, as did pharmacological inhibition with the specific calcium/calmodulin-dependent protein kinase beta inhibitor STO-609. Simvastatin 138-149 calcium/calmodulin-dependent protein kinase kinase 2, beta Mus musculus 62-117 19332549-9 2009 Importantly, siRNA-mediated knockdown of the key AMPK kinase, calcium/calmodulin-dependent protein kinase kinase beta, completely blocked simvastatin-induced endothelial cell migration and also abrogated statin-promoted phosphorylation of AMPK and LKB1, as did pharmacological inhibition with the specific calcium/calmodulin-dependent protein kinase beta inhibitor STO-609. Simvastatin 138-149 serine/threonine kinase 11 Mus musculus 248-252 19332549-10 2009 Moreover, siRNA-mediated knockdown of Rac1 completely blocked simvastatin-induced LKB1 phosphorylation, but without affecting simvastatin-induced AMPK phosphorylation. Simvastatin 62-73 Rac family small GTPase 1 Mus musculus 38-42 19332549-10 2009 Moreover, siRNA-mediated knockdown of Rac1 completely blocked simvastatin-induced LKB1 phosphorylation, but without affecting simvastatin-induced AMPK phosphorylation. Simvastatin 62-73 serine/threonine kinase 11 Mus musculus 82-86 19332549-11 2009 These findings establish a key role for simvastatin in activation of a novel Rac1-dependent signaling pathway in the vascular wall. Simvastatin 40-51 Rac family small GTPase 1 Mus musculus 77-81 19429419-4 2009 Simvastatin lactone, but not the acid form, exhibited a strong inductive effect on the mRNA expression of MDR1 and CYP3A in a dose-dependent manner. Simvastatin 0-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 115-120 19429419-5 2009 Sulforaphane significantly suppressed the expression of MDR1 and CYP3A mRNAs induced by atorvastatin lactone, lovastatin acid, and lovastatin lactone, comparable to the control level, and moderately inhibited that by cerivastatin acid, fluvastatin acid and simvastatin lactone. Simvastatin 257-276 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 19409105-0 2009 Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 69-85 19409105-2 2009 In this study, we hypothesized that the major benefits of simvastatin in pulmonary hypertension occur via the heme oxygenase-1 pathway. Simvastatin 58-69 heme oxygenase 1 Rattus norvegicus 110-126 19409105-9 2009 Simvastatin significantly increased HO-1 protein expression and HO activity in the lungs of rats with PH; however co-administration of SnPP reduced HO-1 activity only. Simvastatin 0-11 heme oxygenase 1 Rattus norvegicus 36-40 19409105-10 2009 These observations indicate that the simvastatin-induced amelioration of pulmonary hypertension was directly related to the activity of HO-1, rather than its expression. Simvastatin 37-48 heme oxygenase 1 Rattus norvegicus 136-140 19409105-11 2009 CONCLUSION: This study demonstrated that simvastatin treatment ameliorates established pulmonary hypertension primarily through an HO-1-dependent pathway. Simvastatin 41-52 heme oxygenase 1 Rattus norvegicus 131-135 19150877-4 2009 The effects of simvastatin were prevented by the PPARgamma antagonist GW9662 or the PPARalpha antagonist GW6471. Simvastatin 15-26 peroxisome proliferator activated receptor gamma Homo sapiens 49-58 19252096-8 2009 The release of MCP-1 by late EPCs was markedly reduced by simvastatin treatment of the cells. Simvastatin 58-69 C-C motif chemokine ligand 2 Homo sapiens 15-20 19150877-4 2009 The effects of simvastatin were prevented by the PPARgamma antagonist GW9662 or the PPARalpha antagonist GW6471. Simvastatin 15-26 peroxisome proliferator activated receptor alpha Homo sapiens 84-93 19358180-0 2009 Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Simvastatin 0-11 SMAD family member 3 Homo sapiens 20-26 19358180-0 2009 Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Simvastatin 0-11 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 84-89 19358180-3 2009 This study assessed the effects of simvastatin on TGF-beta1-mediated intestinal fibroblast activation. Simvastatin 35-46 transforming growth factor beta 1 Homo sapiens 50-59 19552746-0 2009 Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Simvastatin 72-83 cholesteryl ester transfer protein Homo sapiens 110-144 19358180-9 2009 Pretreatment with simvastatin inhibited the induction of CTGF and collagen-Ialpha2, PAI-1 activation, F-actin bundling and FPCL contraction. Simvastatin 18-29 cellular communication network factor 2 Homo sapiens 57-61 19552746-0 2009 Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Simvastatin 72-83 cholesteryl ester transfer protein Homo sapiens 146-150 19358180-9 2009 Pretreatment with simvastatin inhibited the induction of CTGF and collagen-Ialpha2, PAI-1 activation, F-actin bundling and FPCL contraction. Simvastatin 18-29 serpin family E member 1 Homo sapiens 84-89 19358180-10 2009 The inhibitory effect of simvastatin on PAI-1 activation was reversed by GGPP and FPP. Simvastatin 25-36 serpin family E member 1 Homo sapiens 40-45 19358180-11 2009 Simvastatin pretreatment inhibited TGF-beta1-mediated phosphorylation of smad-3. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 35-44 19358180-11 2009 Simvastatin pretreatment inhibited TGF-beta1-mediated phosphorylation of smad-3. Simvastatin 0-11 SMAD family member 3 Homo sapiens 73-79 19358180-12 2009 CONCLUSION: Simvastatin abrogates TGF-beta1-mediated intestinal fibroblast activation by inhibition of smad-3 phosphorylation. Simvastatin 12-23 transforming growth factor beta 1 Homo sapiens 34-43 19358180-12 2009 CONCLUSION: Simvastatin abrogates TGF-beta1-mediated intestinal fibroblast activation by inhibition of smad-3 phosphorylation. Simvastatin 12-23 SMAD family member 3 Homo sapiens 103-109 19383813-0 2009 Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Simvastatin 10-21 CD34 molecule Homo sapiens 135-139 19383813-1 2009 PURPOSE: To show whether the inhibitory effects of the cholesterol synthesis inhibitor simvastatin on human CD34(+) acute myeloid leukemia (AML) cells can be further promoted by combining it with the farnesyltransferase inhibitor tipifarnib. Simvastatin 87-98 CD34 molecule Homo sapiens 108-112 19383813-4 2009 In primary sorted CD34(+) AML cells, a heterogeneous response pattern was observed upon treatment with simvastatin when analyzing cell survival. Simvastatin 103-114 CD34 molecule Homo sapiens 18-22 19383813-7 2009 When the CD34(+) AML cells were exposed to simvastatin and tipifarnib, a significant enhanced inhibitory effect was shown exclusively in the normal AML responder group, whereas the AML CD34(-) cell fractions all showed an enhanced inhibitory effect. Simvastatin 43-54 CD34 molecule Homo sapiens 9-13 19383813-7 2009 When the CD34(+) AML cells were exposed to simvastatin and tipifarnib, a significant enhanced inhibitory effect was shown exclusively in the normal AML responder group, whereas the AML CD34(-) cell fractions all showed an enhanced inhibitory effect. Simvastatin 43-54 CD34 molecule Homo sapiens 185-189 18413153-0 2009 The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats. Simvastatin 14-25 intercellular adhesion molecule 1 Rattus norvegicus 78-111 19343037-0 2009 Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Simvastatin 0-11 caspase 3 Homo sapiens 85-94 19343037-0 2009 Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Simvastatin 0-11 baculoviral IAP repeat containing 2 Homo sapiens 96-102 19343037-0 2009 Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Simvastatin 0-11 baculoviral IAP repeat containing 3 Homo sapiens 107-113 19343037-4 2009 Conversely, simvastatin upregulated c-IAP1 and c-IAP2 expression, while attenuating Hcy-induced apoptosis and caspase-3 activation. Simvastatin 12-23 baculoviral IAP repeat containing 2 Homo sapiens 36-42 19343037-4 2009 Conversely, simvastatin upregulated c-IAP1 and c-IAP2 expression, while attenuating Hcy-induced apoptosis and caspase-3 activation. Simvastatin 12-23 baculoviral IAP repeat containing 3 Homo sapiens 47-53 19343037-4 2009 Conversely, simvastatin upregulated c-IAP1 and c-IAP2 expression, while attenuating Hcy-induced apoptosis and caspase-3 activation. Simvastatin 12-23 caspase 3 Homo sapiens 110-119 19343037-6 2009 This induction can be partially antagonized by simvastatin, possibly through upregulation of cIAP-1 and cIAP-2. Simvastatin 47-58 baculoviral IAP repeat containing 2 Homo sapiens 93-99 19343037-6 2009 This induction can be partially antagonized by simvastatin, possibly through upregulation of cIAP-1 and cIAP-2. Simvastatin 47-58 baculoviral IAP repeat containing 3 Homo sapiens 104-110 19410078-3 2009 The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. Simvastatin 33-44 tumor necrosis factor Homo sapiens 48-75 19410078-3 2009 The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. Simvastatin 33-44 tumor necrosis factor Homo sapiens 77-87 18413153-0 2009 The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats. Simvastatin 14-25 C-C motif chemokine ligand 2 Rattus norvegicus 39-73 18413153-1 2009 OBJECTIVE: This study aimed to observe the effect of simvastatin on the serum monocyte chemoattractant protein-1 (MCP-1) and intracellular adhesion molecule-1 (ICAM-1) levels and to probe its protective mechanisms on macroangiopathy in diabetic rats. Simvastatin 53-64 C-C motif chemokine ligand 2 Rattus norvegicus 78-112 19410078-12 2009 Simvastatin suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions. Simvastatin 0-11 cellular communication network factor 1 Rattus norvegicus 88-93 19410078-3 2009 The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. Simvastatin 33-44 cellular communication network factor 1 Homo sapiens 110-115 19410078-9 2009 Simvastatin also reduced the levels of TNF-alpha-induced CCL2, and exogenous Cyr61 restored the inhibitory effects. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 39-48 18413153-1 2009 OBJECTIVE: This study aimed to observe the effect of simvastatin on the serum monocyte chemoattractant protein-1 (MCP-1) and intracellular adhesion molecule-1 (ICAM-1) levels and to probe its protective mechanisms on macroangiopathy in diabetic rats. Simvastatin 53-64 C-C motif chemokine ligand 2 Rattus norvegicus 114-119 19410078-9 2009 Simvastatin also reduced the levels of TNF-alpha-induced CCL2, and exogenous Cyr61 restored the inhibitory effects. Simvastatin 0-11 C-C motif chemokine ligand 2 Rattus norvegicus 57-61 18413153-1 2009 OBJECTIVE: This study aimed to observe the effect of simvastatin on the serum monocyte chemoattractant protein-1 (MCP-1) and intracellular adhesion molecule-1 (ICAM-1) levels and to probe its protective mechanisms on macroangiopathy in diabetic rats. Simvastatin 53-64 intercellular adhesion molecule 1 Rattus norvegicus 125-158 19555809-9 2009 In addition, we found simvastatin-induced increases in aspartate transaminase and fibrinogen to be attenuated by L-arginine as compared to placebo. Simvastatin 22-33 fibrinogen beta chain Homo sapiens 82-92 19589242-1 2009 This study investigated the effect of simvastatin on the expression of OX40 and OX40 ligand (OX40L) in vitro and in vivo. Simvastatin 38-49 TNF superfamily member 4 Homo sapiens 80-91 19589242-1 2009 This study investigated the effect of simvastatin on the expression of OX40 and OX40 ligand (OX40L) in vitro and in vivo. Simvastatin 38-49 TNF superfamily member 4 Homo sapiens 93-98 19589242-2 2009 OX40 and OX40L mRNA and protein levels were measured in human peripheral blood mononuclear cells, using reverse transcription-polymerase chain reaction and Western blot, respectively, in response to simvastatin alone or given in combination with interferon-gamma, mevalonate or GW9662, a peroxisome proliferators-activated receptor-gamma (PPAR-gamma) antagonist. Simvastatin 199-210 TNF receptor superfamily member 4 Homo sapiens 0-4 19589242-3 2009 Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the interferon-gamma-induced increase in OX40 and OX40L mRNA and protein levels. Simvastatin 0-11 TNF receptor superfamily member 4 Homo sapiens 39-43 19589242-3 2009 Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the interferon-gamma-induced increase in OX40 and OX40L mRNA and protein levels. Simvastatin 0-11 TNF superfamily member 4 Homo sapiens 48-53 19589242-3 2009 Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the interferon-gamma-induced increase in OX40 and OX40L mRNA and protein levels. Simvastatin 0-11 interferon gamma Homo sapiens 128-144 19589242-3 2009 Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the interferon-gamma-induced increase in OX40 and OX40L mRNA and protein levels. Simvastatin 0-11 TNF receptor superfamily member 4 Homo sapiens 48-52 19589242-3 2009 Simvastatin induced down-regulation of OX40 and OX40L mRNA and protein in a concentration-dependent manner, and antagonized the interferon-gamma-induced increase in OX40 and OX40L mRNA and protein levels. Simvastatin 0-11 TNF superfamily member 4 Homo sapiens 174-179 19589242-4 2009 Mevalonate, but not GW9662, reversed the simvastatin-induced down-regulation of OX40 and OX40L expression, indicating that these effects were mediated through the mevalonate pathway. Simvastatin 41-52 TNF receptor superfamily member 4 Homo sapiens 80-84 19589242-4 2009 Mevalonate, but not GW9662, reversed the simvastatin-induced down-regulation of OX40 and OX40L expression, indicating that these effects were mediated through the mevalonate pathway. Simvastatin 41-52 TNF superfamily member 4 Homo sapiens 89-94 19589242-5 2009 Serum levels of soluble OX40L and matrix metalloproteinase 9 levels were significantly reduced in patients with atherosclerotic cerebral infarction who were treated for 6 months with routine therapy plus simvastatin (n = 46) compared with patients receiving routine therapy alone (n = 30). Simvastatin 204-215 TNF superfamily member 4 Homo sapiens 24-29 19589242-5 2009 Serum levels of soluble OX40L and matrix metalloproteinase 9 levels were significantly reduced in patients with atherosclerotic cerebral infarction who were treated for 6 months with routine therapy plus simvastatin (n = 46) compared with patients receiving routine therapy alone (n = 30). Simvastatin 204-215 matrix metallopeptidase 9 Homo sapiens 34-60 19589242-0 2009 Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. Simvastatin 0-11 TNF receptor superfamily member 4 Homo sapiens 20-24 19589242-0 2009 Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. Simvastatin 0-11 TNF superfamily member 4 Homo sapiens 29-40 19589242-1 2009 This study investigated the effect of simvastatin on the expression of OX40 and OX40 ligand (OX40L) in vitro and in vivo. Simvastatin 38-49 TNF receptor superfamily member 4 Homo sapiens 71-75 19299917-0 2009 Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 34-60 19299917-2 2009 We previously reported that simvastatin, an inhibitor of HMG-CoA reductase, attenuates emphysematous change and MMP-9 induction in the lungs of rats exposed to cigarette smoke. Simvastatin 28-39 matrix metallopeptidase 9 Rattus norvegicus 112-117 19360310-0 2009 Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Simvastatin 0-11 HRas proto-oncogene, GTPase Homo sapiens 67-72 19360310-5 2009 Treatment of H-Ras MCF10A cells with simvastatin and lovastatin markedly decreased isoprenylated H-Ras in membrane fraction while the unprenylated H-Ras was increased in cytosol fraction, demonstrating that these statins inhibited membrane anchoring of H-Ras in MCF10A cells. Simvastatin 37-48 HRas proto-oncogene, GTPase Homo sapiens 13-18 19360310-5 2009 Treatment of H-Ras MCF10A cells with simvastatin and lovastatin markedly decreased isoprenylated H-Ras in membrane fraction while the unprenylated H-Ras was increased in cytosol fraction, demonstrating that these statins inhibited membrane anchoring of H-Ras in MCF10A cells. Simvastatin 37-48 HRas proto-oncogene, GTPase Homo sapiens 97-102 19360310-5 2009 Treatment of H-Ras MCF10A cells with simvastatin and lovastatin markedly decreased isoprenylated H-Ras in membrane fraction while the unprenylated H-Ras was increased in cytosol fraction, demonstrating that these statins inhibited membrane anchoring of H-Ras in MCF10A cells. Simvastatin 37-48 HRas proto-oncogene, GTPase Homo sapiens 97-102 19360310-5 2009 Treatment of H-Ras MCF10A cells with simvastatin and lovastatin markedly decreased isoprenylated H-Ras in membrane fraction while the unprenylated H-Ras was increased in cytosol fraction, demonstrating that these statins inhibited membrane anchoring of H-Ras in MCF10A cells. Simvastatin 37-48 HRas proto-oncogene, GTPase Homo sapiens 97-102 19360310-6 2009 Simvastatin and lovastatin significantly inhibited H-Ras-induced invasion which was reversed by farnesyl pyrophosphate (FPP), indicating that the inhibitory effect was related to inhibition of the biosynthesis of prenylated derivatives. Simvastatin 0-11 HRas proto-oncogene, GTPase Homo sapiens 51-56 19360310-8 2009 Simvastatin and lovastatin inactivated H-Ras downstream signaling molecules, possibly by inhibiting H-Ras membrane localization and thus its function in MCF10A cells. Simvastatin 0-11 HRas proto-oncogene, GTPase Homo sapiens 39-44 19360310-8 2009 Simvastatin and lovastatin inactivated H-Ras downstream signaling molecules, possibly by inhibiting H-Ras membrane localization and thus its function in MCF10A cells. Simvastatin 0-11 HRas proto-oncogene, GTPase Homo sapiens 100-105 19360310-9 2009 Taken together, this study clearly demonstrated the inhibitory effect of simvastatin and lovastatin on H-Ras-induced invasion, MMP expression and signal transduction in MCF10A breast epithelial cells, providing supporting rationale for future statin trials as a therapeutic intervention to regulate breast cancer metastasis. Simvastatin 73-84 HRas proto-oncogene, GTPase Homo sapiens 103-108 19360310-9 2009 Taken together, this study clearly demonstrated the inhibitory effect of simvastatin and lovastatin on H-Ras-induced invasion, MMP expression and signal transduction in MCF10A breast epithelial cells, providing supporting rationale for future statin trials as a therapeutic intervention to regulate breast cancer metastasis. Simvastatin 73-84 matrix metallopeptidase 2 Homo sapiens 127-130 19299917-3 2009 However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Simvastatin 73-84 matrix metallopeptidase 9 Homo sapiens 119-124 19299917-3 2009 However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Simvastatin 73-84 matrix metallopeptidase 9 Homo sapiens 119-124 19299917-4 2009 Presently, we examined the related signaling for MMP-9 induction and the inhibitory mechanism of simvastatin on MMP-9 induction in AMs exposed to cigarette smoke extract (CSE). Simvastatin 97-108 matrix metallopeptidase 9 Rattus norvegicus 112-117 19299917-7 2009 Simvastatin reduced CSE-mediated MMP-9 induction, and simvastatin-mediated inhibition was reversed by farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP). Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 33-38 19299917-9 2009 Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Simvastatin 0-11 Eph receptor B1 Rattus norvegicus 77-80 19299917-9 2009 Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 82-85 19299917-9 2009 Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Simvastatin 0-11 synaptotagmin 1 Rattus norvegicus 87-90 19299917-9 2009 Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 113-117 19299917-10 2009 Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved. Simvastatin 43-54 matrix metallopeptidase 9 Rattus norvegicus 80-85 19299917-10 2009 Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved. Simvastatin 43-54 Eph receptor B1 Rattus norvegicus 182-185 19299917-10 2009 Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved. Simvastatin 43-54 AKT serine/threonine kinase 1 Rattus norvegicus 192-195 19299917-10 2009 Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved. Simvastatin 43-54 Jun proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 197-201 19292885-8 2009 Furthermore, the osteoblastic cells with immuno-stained BMP2, collagen type I and osteocalcin in vertebral bones were significantly increased by simvastatin treatment (20 mg kg(-1) day(-1)) in OVX rats. Simvastatin 145-156 bone morphogenetic protein 2 Rattus norvegicus 56-60 19332196-8 2009 CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Simvastatin 64-75 apolipoprotein B Homo sapiens 126-130 19298698-0 2009 Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro. Simvastatin 13-24 angiotensinogen Rattus norvegicus 48-62 19166837-0 2009 Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. Simvastatin 0-11 toll-like receptor 4 Rattus norvegicus 105-109 19166837-2 2009 This study was undertaken to evaluate the effect of simvastatin on the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kappaB) related signaling pathway and secondary brain injury in rats after traumatic brain injury (TBI). Simvastatin 52-63 toll-like receptor 4 Rattus norvegicus 71-91 19166837-2 2009 This study was undertaken to evaluate the effect of simvastatin on the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kappaB) related signaling pathway and secondary brain injury in rats after traumatic brain injury (TBI). Simvastatin 52-63 toll-like receptor 4 Rattus norvegicus 93-97 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 toll-like receptor 4 Rattus norvegicus 109-113 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 interleukin 1 beta Rattus norvegicus 173-190 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 interleukin 1 beta Rattus norvegicus 192-200 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 tumor necrosis factor Rattus norvegicus 203-230 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 tumor necrosis factor Rattus norvegicus 232-241 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 interleukin 6 Rattus norvegicus 244-257 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 interleukin 6 Rattus norvegicus 259-263 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 intercellular adhesion molecule 1 Rattus norvegicus 270-303 19166837-7 2009 As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappaB and the downstream inflammatory agents, such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1). Simvastatin 42-53 intercellular adhesion molecule 1 Rattus norvegicus 305-311 19166837-9 2009 In conclusion, post-TBI simvastatin administration may attenuate TLR4/NF-kappaB-mediated inflammatory response in the injured rat brain, and this may be one mechanism by which simvastatin improves outcome following TBI. Simvastatin 24-35 toll-like receptor 4 Rattus norvegicus 65-69 19166837-9 2009 In conclusion, post-TBI simvastatin administration may attenuate TLR4/NF-kappaB-mediated inflammatory response in the injured rat brain, and this may be one mechanism by which simvastatin improves outcome following TBI. Simvastatin 176-187 toll-like receptor 4 Rattus norvegicus 65-69 19298698-10 2009 Losartan (10(-5) M) and simvastatin (10(-5) M), either alone or in combination, significantly decreased Ang II-induced cardiomyocyte apoptosis and increased cell viability. Simvastatin 24-35 angiotensinogen Rattus norvegicus 104-110 19298698-13 2009 Losartan alone or in combination with simvastatin blocked the increased Bax expression and increased Bcl-2 expression. Simvastatin 38-49 BCL2 associated X, apoptosis regulator Rattus norvegicus 72-75 19298698-13 2009 Losartan alone or in combination with simvastatin blocked the increased Bax expression and increased Bcl-2 expression. Simvastatin 38-49 BCL2, apoptosis regulator Rattus norvegicus 101-106 19298698-15 2009 CONCLUSIONS: Our data provide the first evidence that synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro. Simvastatin 67-78 angiotensinogen Rattus norvegicus 102-116 19298698-4 2009 Here, we demonstrate that Ang II-induced apoptosis is prevented by losartan and simvastatin in neonatal cardiomyocytes. Simvastatin 80-91 angiotensinogen Rattus norvegicus 26-32 19206087-0 2009 Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Simvastatin 48-59 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 64-70 19206087-1 2009 PURPOSE: To assess spontaneous reports of rhabdomyolysis associated with simvastatin (SV) and pravastatin (PV) for evidence of CYP3A4 interaction. Simvastatin 73-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 127-133 19595129-8 2009 RESULTS: The mPAP of the simvastatin intervention group was (23 +/- 7) mm Hg, significantly lower than that of the PH group [(34 +/- 9) mm Hg, P < 0.05], but not significantly different from that of the normal control group [(20 +/- 4) mm Hg, P > 0.05]. Simvastatin 25-36 phospholipid phosphatase 1 Mus musculus 13-17 19595129-10 2009 The perivascular inflammation score of the simvastatin intervention group was (2.19 +/- 0.81), significantly lower than that of the PH group (3.40 +/- 0.65, P < 0.05), and the IL-6, TNF-alpha, and MCP-1 levels of the simvastatin intervention group [(264 +/- 127), (179 +/- 91), and (697 +/- 211) pg/ml respectively] were all significantly lower than those of the PH group [(765 +/- 179), (447 +/- 86), (4428 +/- 757) pg/ml respectively, all P < 0.01]. Simvastatin 43-54 interleukin 6 Rattus norvegicus 179-183 19595129-10 2009 The perivascular inflammation score of the simvastatin intervention group was (2.19 +/- 0.81), significantly lower than that of the PH group (3.40 +/- 0.65, P < 0.05), and the IL-6, TNF-alpha, and MCP-1 levels of the simvastatin intervention group [(264 +/- 127), (179 +/- 91), and (697 +/- 211) pg/ml respectively] were all significantly lower than those of the PH group [(765 +/- 179), (447 +/- 86), (4428 +/- 757) pg/ml respectively, all P < 0.01]. Simvastatin 43-54 tumor necrosis factor Rattus norvegicus 185-194 19595129-10 2009 The perivascular inflammation score of the simvastatin intervention group was (2.19 +/- 0.81), significantly lower than that of the PH group (3.40 +/- 0.65, P < 0.05), and the IL-6, TNF-alpha, and MCP-1 levels of the simvastatin intervention group [(264 +/- 127), (179 +/- 91), and (697 +/- 211) pg/ml respectively] were all significantly lower than those of the PH group [(765 +/- 179), (447 +/- 86), (4428 +/- 757) pg/ml respectively, all P < 0.01]. Simvastatin 43-54 C-C motif chemokine ligand 2 Rattus norvegicus 200-205 19595129-11 2009 CONCLUSION: The protective effects of simvastatin against MCT-induced PH may be associated with the inhibition of the perivascular inflammation and lung IL-6, TNF-alpha, and MCP-1 levels. Simvastatin 38-49 interleukin 6 Rattus norvegicus 153-157 19595129-11 2009 CONCLUSION: The protective effects of simvastatin against MCT-induced PH may be associated with the inhibition of the perivascular inflammation and lung IL-6, TNF-alpha, and MCP-1 levels. Simvastatin 38-49 tumor necrosis factor Rattus norvegicus 159-168 19595129-11 2009 CONCLUSION: The protective effects of simvastatin against MCT-induced PH may be associated with the inhibition of the perivascular inflammation and lung IL-6, TNF-alpha, and MCP-1 levels. Simvastatin 38-49 C-C motif chemokine ligand 2 Rattus norvegicus 174-179 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 Fms related receptor tyrosine kinase 1 Rattus norvegicus 319-326 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 Fms related receptor tyrosine kinase 1 Rattus norvegicus 328-333 19109527-0 2009 Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway. Simvastatin 0-11 notch receptor 1 Rattus norvegicus 89-94 19109527-7 2009 In addition, the intracellular cleavage of Notch (NICD) was markedly enhanced by simvastatin in BMSCs. Simvastatin 81-92 notch receptor 1 Rattus norvegicus 43-48 19109527-3 2009 The Notch signaling pathway, which plays a key role in multiple cell functions such as differentiation, proliferation, and apoptosis, can be regulated by simvastatin. Simvastatin 154-165 notch receptor 1 Rattus norvegicus 4-9 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 von Willebrand factor Rattus norvegicus 155-176 19109527-9 2009 These data suggest that simvastatin induces rat BMSCs differentiation into endothelial cells via a Notch signaling pathway. Simvastatin 24-35 notch receptor 1 Rattus norvegicus 99-104 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 von Willebrand factor Rattus norvegicus 178-181 19301201-7 2009 Simvastatin significantly reduced CRP by 26%, whereas IL-6 remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 34-37 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 platelet and endothelial cell adhesion molecule 1 Rattus norvegicus 184-188 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 cadherin 5 Rattus norvegicus 190-219 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 cadherin 5 Rattus norvegicus 221-232 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 kinase insert domain receptor Rattus norvegicus 235-280 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 kinase insert domain receptor Rattus norvegicus 282-288 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 kinase insert domain receptor Rattus norvegicus 290-295 19109527-5 2009 We observed that simvastatin stimulation of rat BMSCs resulted in significantly increased expression of endothelial-specific genes and proteins, including von Willebrand factor (vWF), CD31, vascular endothelial-cadherin (VE-cadherin), vascular endothelial growth factor receptor-2 (VEGFR2, Flk-1), and VEGF receptor 1 (VEGFR-1, Flt-1). Simvastatin 17-28 Fms related receptor tyrosine kinase 1 Rattus norvegicus 302-317 19301201-10 2009 The P-240 IgG levels after 6 weeks simvastatin therapy was strongly correlated to the relative increase in CD57+CD28 - CD8+T cells (p = 0.003). Simvastatin 35-46 beta-1,3-glucuronyltransferase 1 Homo sapiens 107-111 19301201-10 2009 The P-240 IgG levels after 6 weeks simvastatin therapy was strongly correlated to the relative increase in CD57+CD28 - CD8+T cells (p = 0.003). Simvastatin 35-46 CD28 molecule Homo sapiens 112-116 19224430-2 2009 With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. Simvastatin 79-90 insulin Homo sapiens 102-109 19224430-2 2009 With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. Simvastatin 79-90 retinol binding protein 4 Homo sapiens 125-129 19224430-2 2009 With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. Simvastatin 92-97 insulin Homo sapiens 102-109 19150339-1 2009 Besides a cholesterol-lowering effect, simvastatin possesses anti-inflammatory properties attributed to inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and/or direct binding to, and inhibition of, the integrin lymphocyte function associated antigen-1 (LFA-1). Simvastatin 39-50 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 118-175 19249597-5 2009 Quantitative RT-PCR revealed both osteocalcin and dentin sialophosphoprotein to be significantly up-regulated when DPSCs were cultured with simvastatin in comparison to bone morphogenetic protein-2 treatment. Simvastatin 140-151 bone gamma-carboxyglutamate protein Homo sapiens 34-45 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-reactive protein Homo sapiens 62-65 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-C motif chemokine ligand 2 Homo sapiens 85-89 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-C motif chemokine ligand 3 Homo sapiens 91-95 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-C motif chemokine ligand 4 Homo sapiens 100-104 19151033-9 2009 Treatments with 1 microM simvastatin or atorvastatin significantly inhibited monocyte migration in response to CRP. Simvastatin 25-36 C-reactive protein Homo sapiens 111-114 19150339-7 2009 This implies that inhibition of LFA-1 activation is important for the protective effect exerted by simvastatin. Simvastatin 99-110 integrin beta 2 Mus musculus 32-37 19150339-1 2009 Besides a cholesterol-lowering effect, simvastatin possesses anti-inflammatory properties attributed to inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and/or direct binding to, and inhibition of, the integrin lymphocyte function associated antigen-1 (LFA-1). Simvastatin 39-50 integrin beta 2 Mus musculus 234-274 19150339-1 2009 Besides a cholesterol-lowering effect, simvastatin possesses anti-inflammatory properties attributed to inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and/or direct binding to, and inhibition of, the integrin lymphocyte function associated antigen-1 (LFA-1). Simvastatin 39-50 integrin beta 2 Mus musculus 276-281 18607908-9 2009 We also found that simvastatin-induced VOT-33 apoptosis, as indicated by accumulation of the sub G0/G1 fraction, DNA-ladder formation, and caspase-3 activation. Simvastatin 19-30 caspase 3 Mus musculus 139-148 19195502-0 2009 Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Simvastatin 65-76 C-reactive protein Homo sapiens 89-107 19220274-3 2009 Simvastatin exhibits particularly high interaction potential due to substantial metabolism via cytochrome P450 3A4 (CYP3A4). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 95-114 19023089-4 2009 Transforming growth factor (TGF)-beta1 was also applied as a disease stimulus to VICs on 2-D surfaces or encapsulated in 3-D collagen gels and combined with different temporal applications of simvastatin. Simvastatin 192-203 transforming growth factor beta 1 Homo sapiens 0-38 19023089-7 2009 These effects were mimicked in 3-D cultures, wherein simvastatin reversed TGF-beta1-induced contraction. Simvastatin 53-64 transforming growth factor beta 1 Homo sapiens 74-83 19154429-7 2009 KEY RESULTS: Administration of 0.2 mg.kg(-1) simvastatin decreased ALT and AST by 87% and 83%, respectively, in BDL mice. Simvastatin 45-56 glutamic pyruvic transaminase, soluble Mus musculus 67-70 19154429-7 2009 KEY RESULTS: Administration of 0.2 mg.kg(-1) simvastatin decreased ALT and AST by 87% and 83%, respectively, in BDL mice. Simvastatin 45-56 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 75-78 19154429-9 2009 Moreover, BDL-induced leukocyte adhesion in sinusoids and postsinusoidal venules, as well as MPO levels in the liver, was significantly reduced by simvastatin. Simvastatin 147-158 myeloperoxidase Mus musculus 93-96 19220274-3 2009 Simvastatin exhibits particularly high interaction potential due to substantial metabolism via cytochrome P450 3A4 (CYP3A4). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-122 19220274-15 2009 Considering the pronounced interaction potential of simvastatin with CYP3A4 inhibitors, a negative influence of the new policy on overall statin safety seems likely. Simvastatin 52-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 18221806-0 2009 Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Simvastatin 25-36 nitric oxide synthase 3 Homo sapiens 147-180 18854995-0 2009 The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease. Simvastatin 86-97 leptin receptor Homo sapiens 34-49 19151728-6 2009 On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. Simvastatin 188-199 cerebral cavernous malformation 2 Mus musculus 64-68 18854995-6 2009 CONCLUSIONS: The 223A>G polymorphism of LEPR significantly modulates the HDL-C response to simvastatin in Chinese patients with CHD. Simvastatin 94-105 leptin receptor Homo sapiens 43-47 19014947-8 2009 BBR reduced TF mRNA degradation rates, prolonging its half-life from 1.1 to 4.3 h. The HMG-CoA reductase inhibitor simvastatin impaired thrombin induced TF expression, and BBR blunted this inhibition. Simvastatin 115-126 coagulation factor II, thrombin Homo sapiens 136-144 19014947-8 2009 BBR reduced TF mRNA degradation rates, prolonging its half-life from 1.1 to 4.3 h. The HMG-CoA reductase inhibitor simvastatin impaired thrombin induced TF expression, and BBR blunted this inhibition. Simvastatin 115-126 coagulation factor III, tissue factor Homo sapiens 12-14 19001041-7 2009 RhoA activity decreased after 4 days simvastatin (P < 0.05); however, activity was no different from Control after 12 days. Simvastatin 37-48 ras homolog family member A Homo sapiens 0-4 18992741-6 2009 Simvastatin inhibited geranylgeranylation of small GTPases Rab5B and Rac1 in ATL cells, and a geranylgeranyl transferase inhibitor GGTI-298 reduced ATL cell viability more efficiently than a farnesyl transferase inhibitor FTI-277. Simvastatin 0-11 RAB5B, member RAS oncogene family Homo sapiens 59-64 18992741-6 2009 Simvastatin inhibited geranylgeranylation of small GTPases Rab5B and Rac1 in ATL cells, and a geranylgeranyl transferase inhibitor GGTI-298 reduced ATL cell viability more efficiently than a farnesyl transferase inhibitor FTI-277. Simvastatin 0-11 Rac family small GTPase 1 Homo sapiens 69-73 19001041-8 2009 Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 32-35 19001041-8 2009 Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. Simvastatin 0-11 ras homolog family member A Homo sapiens 65-69 19893089-12 2009 Simvastatin pretreatment given orally produced acute anti-inflammatory effects by inhibiting TNF-alpha and IL-1beta, but no IL-6 production. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 93-102 19912653-9 2009 RESULTS: A single dose of simvastatin loaded in thermo-sensitive PEG-PLGA-PEG gel injected into the NP had the trend to increase aggrecan expression and sGAG content, and significantly increased mRNA levels of BMP-2, collagen type II, and the differentiation index (the ratio of collagen type II to collagen type I). Simvastatin 26-37 bone morphogenetic protein 2 Rattus norvegicus 210-215 19893089-10 2009 The peak levels of TNF-alpha and IL-1beta were significantly suppressed by simvastatin, compared to control rats only treated with dimethylsulfoxide before LPS. Simvastatin 75-86 tumor necrosis factor Rattus norvegicus 19-28 19225232-7 2009 AIM: The aim of this project was to (i) identify a repertoire of proinflammatory mesangial cell AII-inducible mRNAs; (ii) determine if the AII-induced proinflammatory mRNA responses depend on ambient glucose, and (iii) test the anti-inflammatory effectiveness of an ARB, valsartan, either alone or in combination with a statin, simvastatin. Simvastatin 328-339 angiotensinogen Homo sapiens 96-99 19225232-7 2009 AIM: The aim of this project was to (i) identify a repertoire of proinflammatory mesangial cell AII-inducible mRNAs; (ii) determine if the AII-induced proinflammatory mRNA responses depend on ambient glucose, and (iii) test the anti-inflammatory effectiveness of an ARB, valsartan, either alone or in combination with a statin, simvastatin. Simvastatin 328-339 angiotensinogen Homo sapiens 139-142 19225232-11 2009 While simvastatin inhibited expression of some mRNAs encoding chemokines/cytokines, it enhanced expression of mRNA encoding COX-2, a key mediator of inflammation. Simvastatin 6-17 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 18929563-8 2009 The toxic effect of simvastatin could be rescued by the product of HMG-CoA reductase mevalonate but not low-density lipoprotein (LDL). Simvastatin 20-31 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 67-84 19893089-10 2009 The peak levels of TNF-alpha and IL-1beta were significantly suppressed by simvastatin, compared to control rats only treated with dimethylsulfoxide before LPS. Simvastatin 75-86 interleukin 1 beta Rattus norvegicus 33-41 19893089-12 2009 Simvastatin pretreatment given orally produced acute anti-inflammatory effects by inhibiting TNF-alpha and IL-1beta, but no IL-6 production. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 107-115 19494532-14 2009 A subset of patients who received simvastatin showed a modest decrease in PAI-1 level and could contribute to beneficial vasculoprotective effect of the drug in type 2 diabetics. Simvastatin 34-45 serpin family E member 1 Homo sapiens 74-79 18840670-8 2009 We demonstrate here that pravastatin, simvastatin, and atorvastatin significantly reduce neutrophil transendothelial migration toward the chemoattractant fMLP. Simvastatin 38-49 formyl peptide receptor 1 Homo sapiens 154-158 19129682-4 2009 L6 fibroblasts were differentiated and then treated with pravastatin, simvastatin, or fluvastatin for 72 h. Hydrophobic simvastatin and fluvastatin decreased cell viability in a dose-dependent manner via apoptosis characterized by typical nuclear fragmentation and condensation and caspase-3 activation. Simvastatin 120-131 caspase 3 Rattus norvegicus 282-291 19494532-11 2009 In simvastatin-treated subjects (n = 9) significant reductions of PAI-1 were achieved (p = 0.028), while sCD40L and TAFI-Ag did not differ from baseline values. Simvastatin 3-14 serpin family E member 1 Homo sapiens 66-71 19216230-1 2009 Simvastatin is a pro-drug of the potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 40-87 19738398-7 2009 Compared to ApoE-KO mice fed only the atherosclerotic diet, ApoE-KO mice treated with simvastatin had no significant hearing loss and less severe atherosclerosis and hair cell damage in the inner ear. Simvastatin 86-97 apolipoprotein E Mus musculus 60-64 19729986-4 2009 Furthermore, nitric oxide (NO) content and inducible NO synthase (iNOS) mRNA expression were significantly higher in the simvastatin-treated group than in the corresponding control group. Simvastatin 121-132 nitric oxide synthase 2 Homo sapiens 43-64 19216230-6 2009 Simvastatin, added into culture medium with a low dose of dexamethasone, enhanced alkaline phosphatase (ALP) activity and staining, increased the gene expression of ALP and osteocalcin (OC), and promoted mineralization in a dose-dependent fashion. Simvastatin 0-11 bone gamma-carboxyglutamate protein Rattus norvegicus 173-184 19729986-4 2009 Furthermore, nitric oxide (NO) content and inducible NO synthase (iNOS) mRNA expression were significantly higher in the simvastatin-treated group than in the corresponding control group. Simvastatin 121-132 nitric oxide synthase 2 Homo sapiens 66-70 19729986-5 2009 The elevated ROS level and intracellular calcium concentration, enhanced mRNA expression of iNOS and total NO content might be responsible for the apoptotic and anti-proliferative effects of simvastatin in K562 cells. Simvastatin 191-202 nitric oxide synthase 2 Homo sapiens 92-96 19216230-6 2009 Simvastatin, added into culture medium with a low dose of dexamethasone, enhanced alkaline phosphatase (ALP) activity and staining, increased the gene expression of ALP and osteocalcin (OC), and promoted mineralization in a dose-dependent fashion. Simvastatin 0-11 bone gamma-carboxyglutamate protein Rattus norvegicus 186-188 19216230-7 2009 Simultaneously, simvastatin also decreased Oil Red O staining and inhibited the gene expression of lipoprotein lipase (LPL) and peroxisome proliferator activated receptor (PPAR gamma 2) in a dose-dependent fashion. Simvastatin 16-27 lipoprotein lipase Rattus norvegicus 99-117 19216230-7 2009 Simultaneously, simvastatin also decreased Oil Red O staining and inhibited the gene expression of lipoprotein lipase (LPL) and peroxisome proliferator activated receptor (PPAR gamma 2) in a dose-dependent fashion. Simvastatin 16-27 lipoprotein lipase Rattus norvegicus 119-122 18927449-6 2009 RESULTS: Simvastatin significantly increased arterial diameter, density, and vascular smooth muscle cell proliferation, and upregulated PS1, Notch1, and NICD expression in the ischemic border tissue and in the cerebral arteries compared with MCAo control rats, respectively. Simvastatin 9-20 presenilin 1 Rattus norvegicus 136-139 18830905-7 2009 Anti-CD3-stimulated IL-10 and tumour necrosis factor (TNF)alpha production by PBMCs was upregulated after simvastatin therapy. Simvastatin 106-117 interleukin 10 Homo sapiens 20-25 18830905-7 2009 Anti-CD3-stimulated IL-10 and tumour necrosis factor (TNF)alpha production by PBMCs was upregulated after simvastatin therapy. Simvastatin 106-117 tumor necrosis factor Homo sapiens 54-63 18927449-6 2009 RESULTS: Simvastatin significantly increased arterial diameter, density, and vascular smooth muscle cell proliferation, and upregulated PS1, Notch1, and NICD expression in the ischemic border tissue and in the cerebral arteries compared with MCAo control rats, respectively. Simvastatin 9-20 notch receptor 1 Rattus norvegicus 141-147 18927449-12 2009 simvastatin treatment significantly increased arterial cell migration compared to control MCAo artery, whereas inhibition of Notch signaling activity by the gamma40-secretase inhibitor II significantly attenuated simvastatin-induced arterial cell migration. Simvastatin 213-224 notch receptor 1 Rattus norvegicus 125-130 18927449-13 2009 CONCLUSIONS: These data indicate that simvastatin increases arteriogenesis after stroke, and that simvastatin upregulation of PS1 expression and Notch signaling activity may facilitate an increase in arteriogenesis. Simvastatin 98-109 presenilin 1 Rattus norvegicus 126-129 18927449-0 2009 Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke. Simvastatin 0-11 notch receptor 1 Rattus norvegicus 22-27 19997842-4 2009 RESULTS: During the follow-up period of 4-12 weeks, LDL-C levels were reduced by a median of 27-31% of baseline values (mean 153.1 +/- 33.5 mg/dl) mainly regardless of previous statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin) and dosing (pooled median values). Simvastatin 221-232 component of oligomeric golgi complex 2 Homo sapiens 52-57 18927449-3 2009 We tested the hypothesis that simvastatin enhances arteriogenesis after stroke by increasing PS1 activation of the Notch signaling pathway. Simvastatin 30-41 presenilin 1 Rattus norvegicus 93-96 18927449-3 2009 We tested the hypothesis that simvastatin enhances arteriogenesis after stroke by increasing PS1 activation of the Notch signaling pathway. Simvastatin 30-41 notch receptor 1 Rattus norvegicus 115-120 19997842-5 2009 LDL-C reduction correlated proportional with baseline LDL-C values and increased with increasing simvastatin dosage. Simvastatin 97-108 component of oligomeric golgi complex 2 Homo sapiens 0-5 19997842-7 2009 CONCLUSIONS: The fixed combination therapy with ezetimibe/simvastatin showed a clinically significant additional lipid-lowering potential as compared with established statin monotherapies and enabled more patients at cardiovascular risk to reach the LDL-C target level of <100 mg/dl. Simvastatin 58-69 component of oligomeric golgi complex 2 Homo sapiens 250-255 18938217-0 2008 Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington"s disease. Simvastatin 11-22 BCL2, apoptosis regulator Rattus norvegicus 60-65 18938217-10 2008 Bcl-2/Bax modulation can account, at least partly, for the beneficial effect of simvastatin in our rodent model of striatal degeneration. Simvastatin 80-91 BCL2, apoptosis regulator Rattus norvegicus 0-5 18938217-0 2008 Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington"s disease. Simvastatin 11-22 BCL2 associated X, apoptosis regulator Rattus norvegicus 70-73 18938217-10 2008 Bcl-2/Bax modulation can account, at least partly, for the beneficial effect of simvastatin in our rodent model of striatal degeneration. Simvastatin 80-91 BCL2 associated X, apoptosis regulator Rattus norvegicus 6-9 18938217-9 2008 Simvastatin also induced immunoreactivity for Bcl-2, an anti-apoptotic factor, on one hand, and down-regulated immunoreactivity for Bax, a proapoptotic factor. Simvastatin 0-11 BCL2, apoptosis regulator Rattus norvegicus 46-51 18938217-9 2008 Simvastatin also induced immunoreactivity for Bcl-2, an anti-apoptotic factor, on one hand, and down-regulated immunoreactivity for Bax, a proapoptotic factor. Simvastatin 0-11 BCL2 associated X, apoptosis regulator Rattus norvegicus 132-135 18976673-8 2008 However, simvastatin inhibited this promotion (2.5+/-0.3 mm, p<0.001 vs. TNF-alpha alone) by decreasing oxidative stress, VEGF, Akt, and eNOS. Simvastatin 9-20 tumor necrosis factor Homo sapiens 76-85 18976673-8 2008 However, simvastatin inhibited this promotion (2.5+/-0.3 mm, p<0.001 vs. TNF-alpha alone) by decreasing oxidative stress, VEGF, Akt, and eNOS. Simvastatin 9-20 vascular endothelial growth factor A Homo sapiens 125-129 18976673-8 2008 However, simvastatin inhibited this promotion (2.5+/-0.3 mm, p<0.001 vs. TNF-alpha alone) by decreasing oxidative stress, VEGF, Akt, and eNOS. Simvastatin 9-20 AKT serine/threonine kinase 1 Homo sapiens 131-134 18686224-9 2008 However, simvastatin and atorvastatin could significantly inhibit the "aberrant" HLA-DR expression on HT thyrocytes and decrease IFN-gamma- induced HLA-DR expression in both HT and normal thyroid cells (p<0.01). Simvastatin 9-20 interferon gamma Homo sapiens 129-138 18840621-4 2008 Simvastatin, aspirin, metoprolol, and isosorbide mononitrate significantly decreased plasma total adenosine activity (by 50%, 34%, 29%, and 19%, respectively; P < .05 to P < .001) mainly by decreasing the activity of ADA(2). Simvastatin 0-11 transcriptional adaptor 2A Homo sapiens 223-229 18683242-0 2008 Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 117-120 18669979-5 2008 Whereas fenofibrate reduced cholesterol mass within VLDL and IDL, and shifted cholesterol from dense LDL subfractions into the more buoyant subfractions and HDL, ezetimibe/simvastatin reduced cholesterol mass within all apolipoprotein B-containing particles without significantly shifting the LDL particle distribution profile. Simvastatin 172-183 apolipoprotein B Homo sapiens 220-236 18683242-0 2008 Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 125-158 18683242-7 2008 High-dosage simvastatin increased pAkt and peNOS (phosphorylated forms) levels without increasing Akt and eNOS expression compared with the SAH group and also improved neurological deficits at 24 and 72 hr. Simvastatin 12-23 AKT serine/threonine kinase 1 Rattus norvegicus 35-38 18683242-7 2008 High-dosage simvastatin increased pAkt and peNOS (phosphorylated forms) levels without increasing Akt and eNOS expression compared with the SAH group and also improved neurological deficits at 24 and 72 hr. Simvastatin 12-23 nitric oxide synthase 3 Rattus norvegicus 44-48 18683242-9 2008 The present study elucidates the critical role of the PI3K activation leading to phosphorylation of Akt and eNOS in simvastatin-mediated attenuation of cerebral vasospasm after SAH. Simvastatin 116-127 AKT serine/threonine kinase 1 Rattus norvegicus 100-103 18683242-9 2008 The present study elucidates the critical role of the PI3K activation leading to phosphorylation of Akt and eNOS in simvastatin-mediated attenuation of cerebral vasospasm after SAH. Simvastatin 116-127 nitric oxide synthase 3 Rattus norvegicus 108-112 18791746-1 2008 The aim of this study was to investigate the effects of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, on inflammation and glomerulosclerosis in Adriamycin (ADR)-induced nephropathy. Simvastatin 56-67 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 96-153 18760364-9 2008 A prophylactic treatment with simvastatin or hypoxic preconditioning also increased beclin 1 expression. Simvastatin 30-41 beclin 1 Homo sapiens 84-92 18791746-4 2008 Anti-inflammatory effects of simvastatin were studied by evaluating the expression of the inflammatory mediators interleukin-1 beta (IL-1beta), transforming growth factor-beta1 (TGF-beta1), and transcription factor nuclear factor kappa B (NF-kappaB). Simvastatin 29-40 interleukin 1 beta Rattus norvegicus 113-131 18791746-4 2008 Anti-inflammatory effects of simvastatin were studied by evaluating the expression of the inflammatory mediators interleukin-1 beta (IL-1beta), transforming growth factor-beta1 (TGF-beta1), and transcription factor nuclear factor kappa B (NF-kappaB). Simvastatin 29-40 interleukin 1 beta Rattus norvegicus 133-141 18791746-4 2008 Anti-inflammatory effects of simvastatin were studied by evaluating the expression of the inflammatory mediators interleukin-1 beta (IL-1beta), transforming growth factor-beta1 (TGF-beta1), and transcription factor nuclear factor kappa B (NF-kappaB). Simvastatin 29-40 transforming growth factor, beta 1 Rattus norvegicus 178-187 18791746-6 2008 Simvastatin significantly decreases IL-1beta and TGF-beta1 expression and NF-kappaB activation, accompanied by significant attenuation of glomerulosclerosis and renal function at 12 weeks after ADR injection, and these changes occurred in the absence of lowering of serum lipids. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 36-44 18791746-6 2008 Simvastatin significantly decreases IL-1beta and TGF-beta1 expression and NF-kappaB activation, accompanied by significant attenuation of glomerulosclerosis and renal function at 12 weeks after ADR injection, and these changes occurred in the absence of lowering of serum lipids. Simvastatin 0-11 transforming growth factor, beta 1 Rattus norvegicus 49-58 18791746-8 2008 The beneficial effect of simvastatin might be mediated by the effect of anti-inflammatory action through a reduction of NF-kappaB activation, and IL-1beta and TGF-beta expression. Simvastatin 25-36 interleukin 1 beta Rattus norvegicus 146-154 18791746-8 2008 The beneficial effect of simvastatin might be mediated by the effect of anti-inflammatory action through a reduction of NF-kappaB activation, and IL-1beta and TGF-beta expression. Simvastatin 25-36 transforming growth factor, beta 1 Rattus norvegicus 159-167 18981156-0 2008 Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. Simvastatin 63-74 scavenger receptor class B member 1 Homo sapiens 13-46 18981156-5 2008 Simvastatin stimulated the expression of scavenger receptor class B type I (SR-BI) and endothelial NOS. Simvastatin 0-11 scavenger receptor class B member 1 Homo sapiens 41-74 18981156-5 2008 Simvastatin stimulated the expression of scavenger receptor class B type I (SR-BI) and endothelial NOS. Simvastatin 0-11 scavenger receptor class B member 1 Homo sapiens 76-81 18981156-7 2008 The reconstituted HDL, a stimulator of SR-BI, mimicked HDL actions in a simvastatin-sensitive manner. Simvastatin 72-83 scavenger receptor class B member 1 Homo sapiens 39-44 18981156-10 2008 Administration of simvastatin in vivo stimulated endothelial SR-BI expression, which was accompanied by the inhibition of the ex vivo monocyte adhesion in aortas from TNF alpha-injected mice. Simvastatin 18-29 scavenger receptor class B, member 1 Mus musculus 61-66 18981156-10 2008 Administration of simvastatin in vivo stimulated endothelial SR-BI expression, which was accompanied by the inhibition of the ex vivo monocyte adhesion in aortas from TNF alpha-injected mice. Simvastatin 18-29 tumor necrosis factor Mus musculus 167-176 18981156-11 2008 In conclusion, simvastatin induces endothelial SR-BI expression through a RhoA- and peroxisome proliferator-activated receptor-alpha-dependent mechanism, thereby enhancing the HDL-induced activation of NOS and the inhibition of adhesion molecule expression. Simvastatin 15-26 scavenger receptor class B member 1 Homo sapiens 47-52 18981156-11 2008 In conclusion, simvastatin induces endothelial SR-BI expression through a RhoA- and peroxisome proliferator-activated receptor-alpha-dependent mechanism, thereby enhancing the HDL-induced activation of NOS and the inhibition of adhesion molecule expression. Simvastatin 15-26 ras homolog family member A Homo sapiens 74-78 18981156-11 2008 In conclusion, simvastatin induces endothelial SR-BI expression through a RhoA- and peroxisome proliferator-activated receptor-alpha-dependent mechanism, thereby enhancing the HDL-induced activation of NOS and the inhibition of adhesion molecule expression. Simvastatin 15-26 peroxisome proliferator activated receptor alpha Homo sapiens 84-132 18622892-6 2008 Statins (pitavastatin, mevastatin, and simvastatin) as well as alendronate increased the levels of Smad3 in MC3T3-E1 cells. Simvastatin 39-50 SMAD family member 3 Mus musculus 99-104 19085860-8 2008 Serum aminotransferase activity and LDH and TNFalpha levels were increased markedly by hepatic I/R, and these were suppressed significantly by simvastatin. Simvastatin 143-154 tumor necrosis factor Rattus norvegicus 44-52 18684863-3 2008 Here we show that inhibition of HMG-CoA reductase by simvastatin treatment, mimicking MKD, results in increased IL-1beta secretion in a Rac1/PI3K-dependent manner. Simvastatin 53-64 interleukin 1 beta Homo sapiens 112-120 18684863-3 2008 Here we show that inhibition of HMG-CoA reductase by simvastatin treatment, mimicking MKD, results in increased IL-1beta secretion in a Rac1/PI3K-dependent manner. Simvastatin 53-64 Rac family small GTPase 1 Homo sapiens 136-140 18684863-4 2008 Simvastatin treatment was found to activate protein kinase B (PKB)/c-akt, a primary effector of PI3K, and ectopic expression of constitutively active PKB was sufficient to induce IL-1beta release. Simvastatin 0-11 protein tyrosine kinase 2 beta Homo sapiens 44-60 18684863-4 2008 Simvastatin treatment was found to activate protein kinase B (PKB)/c-akt, a primary effector of PI3K, and ectopic expression of constitutively active PKB was sufficient to induce IL-1beta release. Simvastatin 0-11 protein tyrosine kinase 2 beta Homo sapiens 62-65 18684863-4 2008 Simvastatin treatment was found to activate protein kinase B (PKB)/c-akt, a primary effector of PI3K, and ectopic expression of constitutively active PKB was sufficient to induce IL-1beta release. Simvastatin 0-11 protein tyrosine kinase 2 beta Homo sapiens 150-153 18684863-4 2008 Simvastatin treatment was found to activate protein kinase B (PKB)/c-akt, a primary effector of PI3K, and ectopic expression of constitutively active PKB was sufficient to induce IL-1beta release. Simvastatin 0-11 interleukin 1 beta Homo sapiens 179-187 18684863-5 2008 The small GTPase Rac1 was activated by simvastatin, and this was required for both PKB activation and IL-1beta secretion. Simvastatin 39-50 Rac family small GTPase 1 Homo sapiens 17-21 18684863-5 2008 The small GTPase Rac1 was activated by simvastatin, and this was required for both PKB activation and IL-1beta secretion. Simvastatin 39-50 protein tyrosine kinase 2 beta Homo sapiens 83-86 18684863-5 2008 The small GTPase Rac1 was activated by simvastatin, and this was required for both PKB activation and IL-1beta secretion. Simvastatin 39-50 interleukin 1 beta Homo sapiens 102-110 18684863-6 2008 IL-1beta release is mediated by caspase-1, and simvastatin treatment resulted in increased caspase-1 activity in a Rac1/PI3K-dependent manner. Simvastatin 47-58 caspase 1 Homo sapiens 91-100 18684863-6 2008 IL-1beta release is mediated by caspase-1, and simvastatin treatment resulted in increased caspase-1 activity in a Rac1/PI3K-dependent manner. Simvastatin 47-58 Rac family small GTPase 1 Homo sapiens 115-119 18671946-4 2008 Stimulating proliferative VSMCs with Sm or At induced the expression of SM-alpha-actin and SM-MHC, highly specific markers of differentiated phenotype. Simvastatin 37-39 survival of motor neuron 1, telomeric Homo sapiens 72-80 18787804-0 2008 Simvastatin activates Keap1/Nrf2 signaling in rat liver. Simvastatin 0-11 Kelch-like ECH-associated protein 1 Rattus norvegicus 22-27 18787804-0 2008 Simvastatin activates Keap1/Nrf2 signaling in rat liver. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Rattus norvegicus 28-32 18787804-4 2008 Simvastatin triggered nuclear translocation of Nrf2 in rat liver and in primary rat hepatocytes in a mevalonate-dependent and cholesterol-independent way. Simvastatin 0-11 NFE2 like bZIP transcription factor 2 Rattus norvegicus 47-51 18787804-5 2008 In liver, nuclear extracts from simvastatin-treated rats, the DNA-binding activity of Nrf2, was significantly increased and the mRNA of two known targets of Nrf2 (HO-1 and GPX2) was induced. Simvastatin 32-43 NFE2 like bZIP transcription factor 2 Rattus norvegicus 86-90 18787804-5 2008 In liver, nuclear extracts from simvastatin-treated rats, the DNA-binding activity of Nrf2, was significantly increased and the mRNA of two known targets of Nrf2 (HO-1 and GPX2) was induced. Simvastatin 32-43 NFE2 like bZIP transcription factor 2 Rattus norvegicus 157-161 18787804-5 2008 In liver, nuclear extracts from simvastatin-treated rats, the DNA-binding activity of Nrf2, was significantly increased and the mRNA of two known targets of Nrf2 (HO-1 and GPX2) was induced. Simvastatin 32-43 heme oxygenase 1 Rattus norvegicus 163-167 18787804-5 2008 In liver, nuclear extracts from simvastatin-treated rats, the DNA-binding activity of Nrf2, was significantly increased and the mRNA of two known targets of Nrf2 (HO-1 and GPX2) was induced. Simvastatin 32-43 glutathione peroxidase 2 Rattus norvegicus 172-176 18787804-6 2008 In ST2 cells stably transfected with constructs bearing Nrf2-binding site (antioxidant responsive element), simvastatin enhanced Nrf2-mediated transcriptional activity in a mevalonate-dependent and cholesterol-independent fashion. Simvastatin 108-119 NFE2 like bZIP transcription factor 2 Rattus norvegicus 56-60 18787804-6 2008 In ST2 cells stably transfected with constructs bearing Nrf2-binding site (antioxidant responsive element), simvastatin enhanced Nrf2-mediated transcriptional activity in a mevalonate-dependent and cholesterol-independent fashion. Simvastatin 108-119 NFE2 like bZIP transcription factor 2 Rattus norvegicus 129-133 18787804-7 2008 In conclusion, activation of Keap1/Nrf2 signaling pathway by simvastatin might provide effective protection of the cell from the deleterious effects of oxidative stress. Simvastatin 61-72 Kelch-like ECH-associated protein 1 Rattus norvegicus 29-34 18787804-7 2008 In conclusion, activation of Keap1/Nrf2 signaling pathway by simvastatin might provide effective protection of the cell from the deleterious effects of oxidative stress. Simvastatin 61-72 NFE2 like bZIP transcription factor 2 Rattus norvegicus 35-39 19253821-5 2008 The fluorescent intensities were 43 +/- 2.9, 54 +/- 2.7 and 64 +/- 2.6, respectively in K562 cells treated with 10, 20, 30 micromol/L simvastatin, which represented the increase of [ca2+]i The expression levels of GRP78 and Calpain gene mRNA were up-regulated. Simvastatin 134-145 heat shock protein family A (Hsp70) member 5 Homo sapiens 214-219 18957124-10 2008 Decreases in total cholesterol, LDL and apoB were greater with simvastatin. Simvastatin 63-74 apolipoprotein B Homo sapiens 40-44 19211998-1 2008 Our goal was to analyze the effects of treatment with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (simvastatin, 40 mg/day) on serum S100BB and tau protein levels during the acute ischemic stroke (IS). Simvastatin 125-136 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-113 18688862-5 2008 The effect of simvastatin on RANKL signaling and consequent osteoclastogenesis was investigated. Simvastatin 14-25 TNF superfamily member 11 Homo sapiens 29-34 18688862-6 2008 RANKL induced NF-kappaB activation, whereas pretreatment with simvastatin completely suppressed such activation and correlated with suppression of RANKL-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation and IkappaBalpha degradation. Simvastatin 62-73 TNF superfamily member 11 Homo sapiens 147-152 18688862-10 2008 Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss. Simvastatin 36-47 TNF superfamily member 11 Homo sapiens 61-66 18688862-10 2008 Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss. Simvastatin 36-47 TNF superfamily member 11 Homo sapiens 163-168 18671946-4 2008 Stimulating proliferative VSMCs with Sm or At induced the expression of SM-alpha-actin and SM-MHC, highly specific markers of differentiated phenotype. Simvastatin 37-39 myosin heavy chain 11 Homo sapiens 91-97 18658277-5 2008 Confluent EC treated with simvastatin demonstrated significantly decreased thrombin-induced FITC-dextran permeability, a reflection of vascular integrity, which was linked temporally to simvastatin-mediated actin cytoskeletal rearrangement. Simvastatin 26-37 coagulation factor II, thrombin Homo sapiens 75-83 18658277-5 2008 Confluent EC treated with simvastatin demonstrated significantly decreased thrombin-induced FITC-dextran permeability, a reflection of vascular integrity, which was linked temporally to simvastatin-mediated actin cytoskeletal rearrangement. Simvastatin 186-197 coagulation factor II, thrombin Homo sapiens 75-83 18658277-6 2008 Compared with Rho inhibition alone (Y-27632), simvastatin afforded additional protection against thrombin-mediated barrier dysfunction and attenuated LPS-induced EC permeability and superoxide generation. Simvastatin 46-57 coagulation factor II, thrombin Homo sapiens 97-105 18658277-8 2008 Finally, thrombin-induced EC permeability was modestly attenuated by reduced Rac1 expression (small interfering RNA), whereas these effects were made more pronounced by simvastatin pretreatment. Simvastatin 169-180 coagulation factor II, thrombin Homo sapiens 9-17 18658277-9 2008 Together, these data suggest EC barrier protection by simvastatin is due to dual inhibitory effects on RhoA and Rac1 as well as the attenuation of superoxide generation by EC NADPH oxidase and contribute to the molecular mechanistic understanding of the modulation of EC barrier properties by simvastatin. Simvastatin 54-65 ras homolog family member A Homo sapiens 103-107 18658277-9 2008 Together, these data suggest EC barrier protection by simvastatin is due to dual inhibitory effects on RhoA and Rac1 as well as the attenuation of superoxide generation by EC NADPH oxidase and contribute to the molecular mechanistic understanding of the modulation of EC barrier properties by simvastatin. Simvastatin 54-65 Rac family small GTPase 1 Homo sapiens 112-116 18599521-9 2008 Simvastatin inhibited TGF-beta2-dependent MLC phosphorylation and gel contraction in a dose- and time-dependent manner and was capable of inhibiting translocation of Rho protein to the plasma membrane in the presence of TGF-beta2. Simvastatin 0-11 transforming growth factor beta 2 Homo sapiens 22-31 18540024-0 2008 Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Simvastatin 37-48 apolipoprotein A-I Mus musculus 66-72 18540024-0 2008 Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Simvastatin 37-48 nitric oxide synthase 2, inducible Mus musculus 87-91 18540024-3 2008 Our goal in this study was to determine whether Hcy could interfere with the ability of simvastatin to increase ApoA-I synthesis or to modify statin-dependent regulation of inflammatory factors. Simvastatin 88-99 apolipoprotein A-I Mus musculus 112-118 18540024-8 2008 Hcy increased mRNA levels of iNOS in the macrophage line; the combination of Hcy and simvastatin resulted in a trend towards greater induction. Simvastatin 85-96 nitric oxide synthase 2, inducible Mus musculus 29-33 18540024-10 2008 Simvastatin injection increased iNOS protein and mRNA levels in peripheral blood of hyperhomocysteinemic Mthfr-deficient mice, but not in Mthfr(+/+) mice. Simvastatin 0-11 nitric oxide synthase 2, inducible Mus musculus 32-36 18540024-10 2008 Simvastatin injection increased iNOS protein and mRNA levels in peripheral blood of hyperhomocysteinemic Mthfr-deficient mice, but not in Mthfr(+/+) mice. Simvastatin 0-11 methylenetetrahydrofolate reductase Mus musculus 105-110 19014834-13 2008 CONCLUSIONS: In these patients with hypertension and hypercholesterolemia, coadministration of valsartan and simvastatin was well tolerated and was associated with significant reductions from baseline in BP and LDL-C. Simvastatin 109-120 component of oligomeric golgi complex 2 Homo sapiens 211-216 19014834-14 2008 Coadministered with valsartan 160/320 mg in the evening, simvastatin 40 mg had superior LDL-C-lowering efficacy to simvastatin 20 mg. Simvastatin 57-68 component of oligomeric golgi complex 2 Homo sapiens 88-93 19238649-0 2008 ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Simvastatin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 19238649-1 2008 ABCB1 haplotypes were determined in 534 healthy Finnish volunteers, of whom 24 participated in a pharmacokinetic study on simvastatin and atorvastatin. Simvastatin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 18855257-8 2008 Hydrophilic pravastatin increased the serum adiponectin level and decreased the CRP after switching from lipophilic simvastatin in the absence of any difference in the low-density lipoprotein cholesterol level and blood pressure. Simvastatin 116-127 C-reactive protein Homo sapiens 80-83 18599521-9 2008 Simvastatin inhibited TGF-beta2-dependent MLC phosphorylation and gel contraction in a dose- and time-dependent manner and was capable of inhibiting translocation of Rho protein to the plasma membrane in the presence of TGF-beta2. Simvastatin 0-11 modulator of VRAC current 1 Homo sapiens 42-45 18599521-9 2008 Simvastatin inhibited TGF-beta2-dependent MLC phosphorylation and gel contraction in a dose- and time-dependent manner and was capable of inhibiting translocation of Rho protein to the plasma membrane in the presence of TGF-beta2. Simvastatin 0-11 transforming growth factor beta 2 Homo sapiens 220-229 18593956-1 2008 Simvastatin, an inhibitor of HMG-CoA reductase, is a potent inhibitor of cholesterol biosynthesis and has beneficial effects in the primary and secondary prevention of cardiovascular diseases. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA synthase 2 Bos taurus 29-36 18625914-0 2008 Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. Simvastatin 0-11 matrix metallopeptidase 1 Homo sapiens 35-40 18625914-0 2008 Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 124-127 18625914-2 2008 In this study, we reported that simvastatin, a 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitor, effectively inhibited LPS-stimulated MMP-1 as well as MMP-8 and MMP-9 expression by U937 mononuclear cells. Simvastatin 32-43 matrix metallopeptidase 1 Homo sapiens 137-142 18625914-2 2008 In this study, we reported that simvastatin, a 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitor, effectively inhibited LPS-stimulated MMP-1 as well as MMP-8 and MMP-9 expression by U937 mononuclear cells. Simvastatin 32-43 matrix metallopeptidase 8 Homo sapiens 154-159 18625914-2 2008 In this study, we reported that simvastatin, a 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitor, effectively inhibited LPS-stimulated MMP-1 as well as MMP-8 and MMP-9 expression by U937 mononuclear cells. Simvastatin 32-43 matrix metallopeptidase 9 Homo sapiens 164-169 18625914-3 2008 Our studies showed that the geranylgeranyl transferase inhibitor inhibited LPS-stimulated MMP-1 expression, and addition of isoprenoid intermediate geranylgeranyl pyrophosphate (GGPP) reduced the inhibitory effect of simvastatin on LPS-stimulated MMP-1 expression. Simvastatin 217-228 matrix metallopeptidase 1 Homo sapiens 247-252 18625914-5 2008 The above results indicate that protein isoprenylation is involved in the regulation of MMP-1 expression by LPS and simvastatin. Simvastatin 116-127 matrix metallopeptidase 1 Homo sapiens 88-93 18625914-7 2008 Simvastatin also inhibited LPS-stimulated ERK but not p38 MAPK and JNK. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 42-45 18625914-8 2008 Finally, we showed that the inhibition of LPS-stimulated ERK activation by simvastatin was reversed by GGPP. Simvastatin 75-86 mitogen-activated protein kinase 1 Homo sapiens 57-60 18625914-9 2008 Taken together, this study showed that simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by targeting protein isoprenylation-mediated ERK activation. Simvastatin 39-50 matrix metallopeptidase 1 Homo sapiens 74-79 18625914-9 2008 Taken together, this study showed that simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by targeting protein isoprenylation-mediated ERK activation. Simvastatin 39-50 mitogen-activated protein kinase 1 Homo sapiens 162-165 18958884-6 2008 In addition, simvastatin was found to strongly inhibit T-cell responses to the MHCI restricted hen ovalbumin peptide antigen SIINFEKL and to impair ovalbumin uptake and cross-presentation by MHCI. Simvastatin 13-24 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 99-108 18958884-6 2008 In addition, simvastatin was found to strongly inhibit T-cell responses to the MHCI restricted hen ovalbumin peptide antigen SIINFEKL and to impair ovalbumin uptake and cross-presentation by MHCI. Simvastatin 13-24 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 148-157 18958884-7 2008 Simvastatin also suppressed antibody responses to immunization with ovalbumin and delayed-type hypersensitivity to allergens. Simvastatin 0-11 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 68-77 18802482-8 2008 We also demonstrated that simvastatin and pravastatin decreased TF and PAR2 expression on neutrophils and prevented pregnancy loss. Simvastatin 26-37 coagulation factor III Mus musculus 64-66 18802482-8 2008 We also demonstrated that simvastatin and pravastatin decreased TF and PAR2 expression on neutrophils and prevented pregnancy loss. Simvastatin 26-37 coagulation factor II (thrombin) receptor-like 1 Mus musculus 71-75 18826357-0 2008 Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. Simvastatin 104-115 AKT serine/threonine kinase 1 Rattus norvegicus 31-34 18826357-6 2008 RESULTS: Simvastatin significantly decreased the modified Neurological Severity Scores from Days 7 to 35 after TBI, significantly reduced the number of TUNEL-positive cells at Day 3, suppressed the caspase-3 activity at Days 1 and 3 after TBI, and increased phosphorylation of Akt as well as Forkhead transcription factor 1, inhibitory-kappaB, and endothelial nitric oxide synthase, which are the downstream targets of the prosurvival Akt signaling protein. Simvastatin 9-20 caspase 3 Rattus norvegicus 198-207 18826357-6 2008 RESULTS: Simvastatin significantly decreased the modified Neurological Severity Scores from Days 7 to 35 after TBI, significantly reduced the number of TUNEL-positive cells at Day 3, suppressed the caspase-3 activity at Days 1 and 3 after TBI, and increased phosphorylation of Akt as well as Forkhead transcription factor 1, inhibitory-kappaB, and endothelial nitric oxide synthase, which are the downstream targets of the prosurvival Akt signaling protein. Simvastatin 9-20 AKT serine/threonine kinase 1 Rattus norvegicus 277-280 18826357-6 2008 RESULTS: Simvastatin significantly decreased the modified Neurological Severity Scores from Days 7 to 35 after TBI, significantly reduced the number of TUNEL-positive cells at Day 3, suppressed the caspase-3 activity at Days 1 and 3 after TBI, and increased phosphorylation of Akt as well as Forkhead transcription factor 1, inhibitory-kappaB, and endothelial nitric oxide synthase, which are the downstream targets of the prosurvival Akt signaling protein. Simvastatin 9-20 AKT serine/threonine kinase 1 Rattus norvegicus 435-438 18826357-8 2008 These beneficial effects of simvastatin may be mediated through activation of Akt, Forkhead transcription factor 1 and nuclear factor-kappaB signaling pathways, which suppress the activation of caspase-3 and apoptotic cell death, and thereby, lead to neuronal function recovery after TBI. Simvastatin 28-39 AKT serine/threonine kinase 1 Rattus norvegicus 78-81 18826357-8 2008 These beneficial effects of simvastatin may be mediated through activation of Akt, Forkhead transcription factor 1 and nuclear factor-kappaB signaling pathways, which suppress the activation of caspase-3 and apoptotic cell death, and thereby, lead to neuronal function recovery after TBI. Simvastatin 28-39 caspase 3 Rattus norvegicus 194-203 18581203-7 2008 Simvastatin inhibited the effects of AVP on DNA synthesis, ERK1/2, and PKC activation in a dose-dependent manner. Simvastatin 0-11 arginine vasopressin Rattus norvegicus 37-40 18581203-7 2008 Simvastatin inhibited the effects of AVP on DNA synthesis, ERK1/2, and PKC activation in a dose-dependent manner. Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 59-65 18581203-8 2008 Phosphatidylinositol-3-kinase (PI3K)-dependent AKT activation induced by AVP was also inhibited by simvastatin. Simvastatin 99-110 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma Rattus norvegicus 0-29 18581203-8 2008 Phosphatidylinositol-3-kinase (PI3K)-dependent AKT activation induced by AVP was also inhibited by simvastatin. Simvastatin 99-110 AKT serine/threonine kinase 1 Rattus norvegicus 47-50 18581203-8 2008 Phosphatidylinositol-3-kinase (PI3K)-dependent AKT activation induced by AVP was also inhibited by simvastatin. Simvastatin 99-110 arginine vasopressin Rattus norvegicus 73-76 18581203-9 2008 The effects of simvastatin on ERK1/2, PKC, and AKT activation and DNA synthesis could be reversed by mevalonate. Simvastatin 15-26 mitogen activated protein kinase 3 Rattus norvegicus 30-36 18581203-9 2008 The effects of simvastatin on ERK1/2, PKC, and AKT activation and DNA synthesis could be reversed by mevalonate. Simvastatin 15-26 AKT serine/threonine kinase 1 Rattus norvegicus 47-50 18581203-10 2008 These results support a growth-inducing effect of AVP on adult rat CFs through ERK and AKT signalings and the growth effect could be attenuated by simvastatin via inhibiting these two pathways. Simvastatin 147-158 arginine vasopressin Rattus norvegicus 50-53 19080365-9 2008 Furthermore, the inactivation of p38, RhoA and Smad2/3 signaling pathways was observed during simvastatin administration. Simvastatin 94-105 mitogen-activated protein kinase 14 Mus musculus 33-36 18625202-0 2008 HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 18625202-1 2008 Simvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway required for the biosynthesis of cholesterol and higher isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-59 18625202-4 2008 In these cells, simvastatin does not inhibit proteasome activity, but induces apoptosis, G2/M cell cycle arrest and accumulation of p21(Waf1/Cip1), and effectively inhibits hyperproliferation. Simvastatin 16-27 cyclin dependent kinase inhibitor 1A Homo sapiens 132-135 18625202-4 2008 In these cells, simvastatin does not inhibit proteasome activity, but induces apoptosis, G2/M cell cycle arrest and accumulation of p21(Waf1/Cip1), and effectively inhibits hyperproliferation. Simvastatin 16-27 cyclin dependent kinase inhibitor 1A Homo sapiens 136-140 18625202-4 2008 In these cells, simvastatin does not inhibit proteasome activity, but induces apoptosis, G2/M cell cycle arrest and accumulation of p21(Waf1/Cip1), and effectively inhibits hyperproliferation. Simvastatin 16-27 cyclin dependent kinase inhibitor 1A Homo sapiens 141-145 18841289-3 2008 We investigated the effect of cholesterol depletion on the production of prostasomes and on the TF activity in the conditioned medium of simvastatin-treated PC3 cells. Simvastatin 137-148 coagulation factor III, tissue factor Homo sapiens 96-98 18841289-3 2008 We investigated the effect of cholesterol depletion on the production of prostasomes and on the TF activity in the conditioned medium of simvastatin-treated PC3 cells. Simvastatin 137-148 chromobox 8 Homo sapiens 157-160 18841289-4 2008 Human PC3 prostate cancer cells were treated with high and low concentrations of simvastatin for different time periods. Simvastatin 81-92 chromobox 8 Homo sapiens 6-9 18841289-8 2008 A micromolar dose of simvastatin caused reduction of TF expression and induction of apoptosis in the PC3 cells. Simvastatin 21-32 coagulation factor III, tissue factor Homo sapiens 53-55 18841289-8 2008 A micromolar dose of simvastatin caused reduction of TF expression and induction of apoptosis in the PC3 cells. Simvastatin 21-32 chromobox 8 Homo sapiens 101-104 18841289-9 2008 The levels of TF on the prostasomes were also decreased but the TF activity in the conditioned medium of the simvastatin-treated PC3 cells was increased due to apoptosis-dependent release of prostasomes. Simvastatin 109-120 coagulation factor III, tissue factor Homo sapiens 64-66 18841289-9 2008 The levels of TF on the prostasomes were also decreased but the TF activity in the conditioned medium of the simvastatin-treated PC3 cells was increased due to apoptosis-dependent release of prostasomes. Simvastatin 109-120 chromobox 8 Homo sapiens 129-132 18841289-10 2008 Treatment with a nanomolar dose of simvastatin did not induce apoptosis or alter the expression of TF but instead decreased the production and release of the prostasomes. Simvastatin 35-46 coagulation factor III, tissue factor Homo sapiens 99-101 18841289-12 2008 In conclusion, in prostate cancer, a nanomolar dose of simvastatin may have an anti-thrombotic effect due to decreased levels of circulating TF-bearing prostasomes. Simvastatin 55-66 coagulation factor III, tissue factor Homo sapiens 141-143 19080365-6 2008 Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels. Simvastatin 10-21 transforming growth factor, beta 1 Mus musculus 65-97 19080365-6 2008 Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels. Simvastatin 10-21 transforming growth factor, beta 1 Mus musculus 99-108 19080365-6 2008 Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels. Simvastatin 10-21 cellular communication network factor 2 Mus musculus 114-145 19080365-6 2008 Moreover, simvastatin down-regulated the increased expression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) induced by bleomycin at both gene and protein levels. Simvastatin 10-21 cellular communication network factor 2 Mus musculus 147-151 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Simvastatin 189-200 tumor necrosis factor Mus musculus 96-123 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Simvastatin 189-200 tumor necrosis factor Mus musculus 125-134 18625202-6 2008 GGPP-dependent plasma membrane localization of the small GTPase RhoA that is required for RhoA-mediated oncogenic signaling is completely inhibited by simvastatin. Simvastatin 151-162 ras homolog family member A Homo sapiens 64-68 18625202-6 2008 GGPP-dependent plasma membrane localization of the small GTPase RhoA that is required for RhoA-mediated oncogenic signaling is completely inhibited by simvastatin. Simvastatin 151-162 ras homolog family member A Homo sapiens 90-94 19080365-9 2008 Furthermore, the inactivation of p38, RhoA and Smad2/3 signaling pathways was observed during simvastatin administration. Simvastatin 94-105 ras homolog family member A Mus musculus 38-42 19080365-9 2008 Furthermore, the inactivation of p38, RhoA and Smad2/3 signaling pathways was observed during simvastatin administration. Simvastatin 94-105 SMAD family member 2 Mus musculus 47-54 19080365-11 2008 The inhibitory effect of simvastatin on the progression of pulmonary fibrosis may be demonstrated by reducing inflammatory response and production of TGF-beta1 and CTGF. Simvastatin 25-36 transforming growth factor, beta 1 Mus musculus 150-159 19080365-11 2008 The inhibitory effect of simvastatin on the progression of pulmonary fibrosis may be demonstrated by reducing inflammatory response and production of TGF-beta1 and CTGF. Simvastatin 25-36 cellular communication network factor 2 Mus musculus 164-168 18486135-0 2008 Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Simvastatin 0-11 endothelial cell adhesion molecule Homo sapiens 25-59 18619957-7 2008 Pre-exposure of cells to simvastatin concentration-dependently blocked angiotensin II-stimulated MMP2 release. Simvastatin 25-36 angiotensinogen Homo sapiens 71-85 18619957-7 2008 Pre-exposure of cells to simvastatin concentration-dependently blocked angiotensin II-stimulated MMP2 release. Simvastatin 25-36 matrix metallopeptidase 2 Homo sapiens 97-101 18619957-8 2008 MMP2 release was reduced to1.34 fold increase in the presence of 10 microM simvastatin (P<0.01 versus angiotensin II-stimulated cells). Simvastatin 75-86 matrix metallopeptidase 2 Homo sapiens 0-4 18619957-8 2008 MMP2 release was reduced to1.34 fold increase in the presence of 10 microM simvastatin (P<0.01 versus angiotensin II-stimulated cells). Simvastatin 75-86 angiotensinogen Homo sapiens 105-119 18619957-9 2008 We further revealed that simvastatin suppression of RhoA activation mediated its inhibitory effect on angiotensin II-triggered MMP2 release. Simvastatin 25-36 ras homolog family member A Homo sapiens 52-56 18619957-9 2008 We further revealed that simvastatin suppression of RhoA activation mediated its inhibitory effect on angiotensin II-triggered MMP2 release. Simvastatin 25-36 angiotensinogen Homo sapiens 102-116 18619957-9 2008 We further revealed that simvastatin suppression of RhoA activation mediated its inhibitory effect on angiotensin II-triggered MMP2 release. Simvastatin 25-36 matrix metallopeptidase 2 Homo sapiens 127-131 18619957-10 2008 Similarly, simvastatin suppressed endothelin-1-induced MMP2 release through RhoA/ROCK pathway. Simvastatin 11-22 endothelin 1 Homo sapiens 34-46 18619957-10 2008 Similarly, simvastatin suppressed endothelin-1-induced MMP2 release through RhoA/ROCK pathway. Simvastatin 11-22 matrix metallopeptidase 2 Homo sapiens 55-59 18619957-10 2008 Similarly, simvastatin suppressed endothelin-1-induced MMP2 release through RhoA/ROCK pathway. Simvastatin 11-22 ras homolog family member A Homo sapiens 76-80 18791454-0 2008 Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells. Simvastatin 67-78 interferon gamma Homo sapiens 108-124 19024099-8 2008 Moreover, simvastatin inhibited neutrophil accumulation and the increased concentration of TNF-alpha and IL-8 in BALF follows LPS stimulation (P < 0.05). Simvastatin 10-21 tumor necrosis factor Rattus norvegicus 91-100 19024099-9 2008 The higher dose of simvastatin was associated with a more significant reduction in Muc5ac mRNA expression, neutrophil accumulation and inflammatory cytokine release. Simvastatin 19-30 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 83-89 19024099-11 2008 Simvastatin inhibited the expression of RhoA and p38 phosphorylation in lung following LPS stimulation (P < 0.05). Simvastatin 0-11 ras homolog family member A Rattus norvegicus 40-44 19024099-11 2008 Simvastatin inhibited the expression of RhoA and p38 phosphorylation in lung following LPS stimulation (P < 0.05). Simvastatin 0-11 mitogen activated protein kinase 14 Rattus norvegicus 49-52 19024099-14 2008 The inhibitory effect of simvastatin on airway mucus hypersecretion may be through, at least in part, the suppression of neutrophil accumulation and inflammatory cytokine release via inactivation of RhoA and p38 signaling pathway. Simvastatin 25-36 ras homolog family member A Rattus norvegicus 199-203 19024099-14 2008 The inhibitory effect of simvastatin on airway mucus hypersecretion may be through, at least in part, the suppression of neutrophil accumulation and inflammatory cytokine release via inactivation of RhoA and p38 signaling pathway. Simvastatin 25-36 mitogen activated protein kinase 14 Rattus norvegicus 208-211 18804536-0 2008 Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Simvastatin 0-11 tumor protein p53 Homo sapiens 175-178 18635600-7 2008 TNF-alpha/LPS and H2O2 further enhanced MSH2 expression in both control and CD cells, which were decreased by simvastatin. Simvastatin 110-121 tumor necrosis factor Homo sapiens 0-9 18635600-7 2008 TNF-alpha/LPS and H2O2 further enhanced MSH2 expression in both control and CD cells, which were decreased by simvastatin. Simvastatin 110-121 interferon regulatory factor 6 Homo sapiens 10-13 18635600-7 2008 TNF-alpha/LPS and H2O2 further enhanced MSH2 expression in both control and CD cells, which were decreased by simvastatin. Simvastatin 110-121 mutS homolog 2 Homo sapiens 40-44 18804536-1 2008 Simvastatin was reported to attenuate platelet-derived growth factor (PDGF)-induced vascular smooth muscle proliferation by up-regulation of cyclin dependent kinase (CDK) inhibitor p27, but had no effect on p16, p21, p53 expression. Simvastatin 0-11 interferon alpha inducible protein 27 Homo sapiens 181-184 18698233-5 2008 METHODS AND RESULTS: In cells expressing the 299D-399T TLR4, LPS activated the transcription factor NFkappaB and increased the expression of interleukin-6 and tumor necrosis factor-alpha, and these effects were reduced by pretreatment of the cells with pravastatin or simvastatin. Simvastatin 268-279 toll like receptor 4 Homo sapiens 55-59 18698233-5 2008 METHODS AND RESULTS: In cells expressing the 299D-399T TLR4, LPS activated the transcription factor NFkappaB and increased the expression of interleukin-6 and tumor necrosis factor-alpha, and these effects were reduced by pretreatment of the cells with pravastatin or simvastatin. Simvastatin 268-279 nuclear factor kappa B subunit 1 Homo sapiens 100-108 18698233-5 2008 METHODS AND RESULTS: In cells expressing the 299D-399T TLR4, LPS activated the transcription factor NFkappaB and increased the expression of interleukin-6 and tumor necrosis factor-alpha, and these effects were reduced by pretreatment of the cells with pravastatin or simvastatin. Simvastatin 268-279 interleukin 6 Homo sapiens 141-186 18804536-8 2008 We also found that simvastatin inhibited phosphorylation of Rb, promoted expression of p53, p16, p21, p27 and decreased CDK2/4 activity. Simvastatin 19-30 tumor protein p53 Homo sapiens 87-90 18804536-8 2008 We also found that simvastatin inhibited phosphorylation of Rb, promoted expression of p53, p16, p21, p27 and decreased CDK2/4 activity. Simvastatin 19-30 cyclin dependent kinase inhibitor 2A Homo sapiens 92-95 18804536-8 2008 We also found that simvastatin inhibited phosphorylation of Rb, promoted expression of p53, p16, p21, p27 and decreased CDK2/4 activity. Simvastatin 19-30 cyclin dependent kinase inhibitor 1A Homo sapiens 97-100 18804536-8 2008 We also found that simvastatin inhibited phosphorylation of Rb, promoted expression of p53, p16, p21, p27 and decreased CDK2/4 activity. Simvastatin 19-30 interferon alpha inducible protein 27 Homo sapiens 102-105 18804536-8 2008 We also found that simvastatin inhibited phosphorylation of Rb, promoted expression of p53, p16, p21, p27 and decreased CDK2/4 activity. Simvastatin 19-30 cyclin dependent kinase 2 Homo sapiens 120-124 18752389-10 2008 Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity. Simvastatin 173-184 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 95-98 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 RB transcriptional corepressor 1 Homo sapiens 187-190 18752389-12 2008 We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes. Simvastatin 39-50 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 148-151 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 cyclin dependent kinase 2 Homo sapiens 216-220 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 tumor protein p53 Homo sapiens 255-258 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 cyclin dependent kinase inhibitor 1A Homo sapiens 260-263 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 cyclin dependent kinase inhibitor 2A Homo sapiens 265-268 18804536-9 2008 In conclusion, simvastatin inhibits VSMC proliferation in high glucose status, mimicking diabetes, inducing a G0/G1 phase cell cycle growth arrest by acting on multiple steps upstream of pRb, including inhibition of CDK2/4 expression and up-regulation of p53, p21, p16, and p27. Simvastatin 15-26 interferon alpha inducible protein 27 Homo sapiens 274-277 18521906-9 2008 Annexin V staining significantly increased after simvastatin treatment. Simvastatin 49-60 annexin A5 Mus musculus 0-9 18766267-10 2008 Simvastatin promotes detachment and EMP release by inhibiting prenylation, presumably via a caspase 8-dependent mechanism. Simvastatin 0-11 caspase 8 Homo sapiens 92-101 18521906-12 2008 In the xenograft model, tumors from animals treated with simvastatin had smaller volumes, larger necrotic areas, lower expression of VEGF and higher apoptotic scores. Simvastatin 57-68 vascular endothelial growth factor A Mus musculus 133-137 18430057-10 2008 We conclude that the Q192R polymorphism of PON1 significantly modulates the HDL-C response to simvastatin in Chinese patients with CHD. Simvastatin 94-105 paraoxonase 1 Homo sapiens 43-47 18607173-11 2008 Simvastatin (10 micromol/l), known to translocate membrane-bound sterol regulatory element-binding protein to nuclei, attenuated PAI-1 mRNA expression induced by insulin. Simvastatin 0-11 serpin family E member 1 Homo sapiens 129-134 18607173-11 2008 Simvastatin (10 micromol/l), known to translocate membrane-bound sterol regulatory element-binding protein to nuclei, attenuated PAI-1 mRNA expression induced by insulin. Simvastatin 0-11 insulin Homo sapiens 162-169 18578957-6 2008 Average LDL-C reductions were 48%, 42%, 39%, and 32% at mean doses of 11 mg rosuvastatin, 17 mg atorvastatin, 22 mg simvastatin and 35 mg pravastatin, respectively. Simvastatin 116-127 component of oligomeric golgi complex 2 Homo sapiens 8-13 18622245-8 2008 Simvastatin did not affect smad 2/3 expression but upregulated expression of hepatocyte growth factor, bone morphogenetic factor-7, and smad 7 and prevented most of these renal structural and functional alterations. Simvastatin 0-11 hepatocyte growth factor Sus scrofa 77-101 18679777-1 2008 In the present study we analyzed the mechanisms of simvastatin toxicity for the PC3 human prostate cancer cell line. Simvastatin 51-62 chromobox 8 Homo sapiens 80-83 18679777-3 2008 At 60 microM, simvastatin induced the necrosis of PC3 cells insensitive to mevalonic acid. Simvastatin 14-25 chromobox 8 Homo sapiens 50-53 18679777-6 2008 We have concluded that simvastatin-induced PC3 cells apoptosis is dependent on 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibition and independent of MPT, whereas necrosis is dependent on mitochondrial dysfunction caused, at least in part, by calcineurin. Simvastatin 23-34 chromobox 8 Homo sapiens 43-46 18679777-6 2008 We have concluded that simvastatin-induced PC3 cells apoptosis is dependent on 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibition and independent of MPT, whereas necrosis is dependent on mitochondrial dysfunction caused, at least in part, by calcineurin. Simvastatin 23-34 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-126 18443364-0 2008 Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction. Simvastatin 74-85 apolipoprotein E Mus musculus 53-57 18443364-6 2008 Western blotting of aortae showed reduced expression of connexin37 (Cx37) and Cx40 in the diabetic mice, which were further decreased in the simvastatin-treated diabetic mice. Simvastatin 141-152 gap junction protein, alpha 4 Mus musculus 56-66 18443364-6 2008 Western blotting of aortae showed reduced expression of connexin37 (Cx37) and Cx40 in the diabetic mice, which were further decreased in the simvastatin-treated diabetic mice. Simvastatin 141-152 gap junction protein, alpha 4 Mus musculus 68-72 18443364-6 2008 Western blotting of aortae showed reduced expression of connexin37 (Cx37) and Cx40 in the diabetic mice, which were further decreased in the simvastatin-treated diabetic mice. Simvastatin 141-152 gap junction protein, alpha 5 Mus musculus 78-82 18443364-8 2008 The reduction was greater in the simvastatin-treated mice (decrease in treated diabetic vs non-diabetic: Cx37, 61%; Cx40, 79%; both p<0.01; decrease in treated diabetic vs untreated diabetic: Cx37, 34%; Cx40, 63%; both p<0.01). Simvastatin 33-44 gap junction protein, alpha 4 Mus musculus 105-109 18443364-8 2008 The reduction was greater in the simvastatin-treated mice (decrease in treated diabetic vs non-diabetic: Cx37, 61%; Cx40, 79%; both p<0.01; decrease in treated diabetic vs untreated diabetic: Cx37, 34%; Cx40, 63%; both p<0.01). Simvastatin 33-44 gap junction protein, alpha 5 Mus musculus 116-120 18443364-8 2008 The reduction was greater in the simvastatin-treated mice (decrease in treated diabetic vs non-diabetic: Cx37, 61%; Cx40, 79%; both p<0.01; decrease in treated diabetic vs untreated diabetic: Cx37, 34%; Cx40, 63%; both p<0.01). Simvastatin 33-44 gap junction protein, alpha 4 Mus musculus 195-199 18772509-7 2008 The levels of ET-1, ET-1/NO, TG, TC, and LDL-C were significantly decreased in the simvastatin group as compared with the control group after the treatment. Simvastatin 83-94 endothelin 1 Homo sapiens 14-18 18443364-8 2008 The reduction was greater in the simvastatin-treated mice (decrease in treated diabetic vs non-diabetic: Cx37, 61%; Cx40, 79%; both p<0.01; decrease in treated diabetic vs untreated diabetic: Cx37, 34%; Cx40, 63%; both p<0.01). Simvastatin 33-44 gap junction protein, alpha 5 Mus musculus 206-210 18640378-3 2008 Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies. Simvastatin 48-59 low density lipoprotein receptor Homo sapiens 82-86 18640378-3 2008 Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies. Simvastatin 61-66 low density lipoprotein receptor Homo sapiens 82-86 18463201-3 2008 To induce NF-kappaB, we took into account the effect of doxorubicin itself and of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin; as NF-kappaB inhibitors, we chose the sesquiterpene lactones parthenolide and artemisinin. Simvastatin 144-155 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-133 18463201-5 2008 Simvastatin potentiated the effect of doxorubicin on the NF-kappaB pathway and the inducible NO synthase expression. Simvastatin 0-11 nitric oxide synthase 2 Homo sapiens 83-104 18463201-6 2008 The effects of simvastatin were due to the inhibition of the small G-protein RhoA and of its effector Rho kinase. Simvastatin 15-26 ras homolog family member A Homo sapiens 77-81 18772509-7 2008 The levels of ET-1, ET-1/NO, TG, TC, and LDL-C were significantly decreased in the simvastatin group as compared with the control group after the treatment. Simvastatin 83-94 endothelin 1 Homo sapiens 20-27 18489904-0 2008 Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Simvastatin 0-11 proprotein convertase subtilisin/kexin type 1 Homo sapiens 64-68 19100117-7 2008 The myocardial activities of iNOS and MPO, the contents of NO and MDA were significantly lower while eNOS activity was significantly higher in I/R plus sim group than those in I/R group (5.02 +/- 1.64 vs. 9.19 +/- 2.89, 586.21 +/- 126.97 vs. 744.49 +/- 137.53, 257.72 +/- 93.43 vs. 384.10 +/- 40.68, 72.10 +/- 18.56 vs. 111.84 +/- 38.58, 7.08 +/- 1.74 vs. 3.72 +/- 0.98, all P < 0.05). Simvastatin 152-155 nitric oxide synthase 2 Rattus norvegicus 29-33 19100117-7 2008 The myocardial activities of iNOS and MPO, the contents of NO and MDA were significantly lower while eNOS activity was significantly higher in I/R plus sim group than those in I/R group (5.02 +/- 1.64 vs. 9.19 +/- 2.89, 586.21 +/- 126.97 vs. 744.49 +/- 137.53, 257.72 +/- 93.43 vs. 384.10 +/- 40.68, 72.10 +/- 18.56 vs. 111.84 +/- 38.58, 7.08 +/- 1.74 vs. 3.72 +/- 0.98, all P < 0.05). Simvastatin 152-155 myeloperoxidase Rattus norvegicus 38-41 18489904-6 2008 Simvastatin suppressed proliferation and induced apoptosis of PC-3, and the expression of IGF-1R was suppressed by simvastatin. Simvastatin 115-126 insulin like growth factor 1 receptor Homo sapiens 90-96 18489904-8 2008 Simvastatin also inhibited IGF-1-induced activation of both ERK and Akt signaling and IGF-1-induced PC-3 cell proliferation. Simvastatin 0-11 insulin like growth factor 1 Homo sapiens 27-32 18489904-0 2008 Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Simvastatin 0-11 insulin like growth factor 1 receptor Homo sapiens 102-139 18489904-8 2008 Simvastatin also inhibited IGF-1-induced activation of both ERK and Akt signaling and IGF-1-induced PC-3 cell proliferation. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 60-63 18489904-5 2008 In this study, the effects of simvastatin on IGF-1R signaling in prostate cancer PC-3 cells were examined. Simvastatin 30-41 insulin like growth factor 1 receptor Homo sapiens 45-51 18489904-8 2008 Simvastatin also inhibited IGF-1-induced activation of both ERK and Akt signaling and IGF-1-induced PC-3 cell proliferation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 68-71 18489904-8 2008 Simvastatin also inhibited IGF-1-induced activation of both ERK and Akt signaling and IGF-1-induced PC-3 cell proliferation. Simvastatin 0-11 insulin like growth factor 1 Homo sapiens 86-91 18489904-6 2008 Simvastatin suppressed proliferation and induced apoptosis of PC-3, and the expression of IGF-1R was suppressed by simvastatin. Simvastatin 0-11 proprotein convertase subtilisin/kexin type 1 Homo sapiens 62-66 18489904-8 2008 Simvastatin also inhibited IGF-1-induced activation of both ERK and Akt signaling and IGF-1-induced PC-3 cell proliferation. Simvastatin 0-11 proprotein convertase subtilisin/kexin type 1 Homo sapiens 100-104 18632543-0 2008 Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. Simvastatin 10-21 neurofibromin 1 Homo sapiens 64-88 18474592-3 2008 Exposure of confluent bovine aortic endothelial cells to simvastatin (statin) dose-dependently increased phosphorylation of AMPK at Thr(172) and activities of AMPK, which was in parallel with increased detection of both LKB1 phosphorylation at Ser(428) and LKB1 nuclear export. Simvastatin 57-68 serine/threonine kinase 11 Mus musculus 220-224 18474592-3 2008 Exposure of confluent bovine aortic endothelial cells to simvastatin (statin) dose-dependently increased phosphorylation of AMPK at Thr(172) and activities of AMPK, which was in parallel with increased detection of both LKB1 phosphorylation at Ser(428) and LKB1 nuclear export. Simvastatin 57-68 serine/threonine kinase 11 Mus musculus 257-261 18474592-3 2008 Exposure of confluent bovine aortic endothelial cells to simvastatin (statin) dose-dependently increased phosphorylation of AMPK at Thr(172) and activities of AMPK, which was in parallel with increased detection of both LKB1 phosphorylation at Ser(428) and LKB1 nuclear export. Simvastatin 62-68 serine/threonine kinase 11 Mus musculus 220-224 18474592-3 2008 Exposure of confluent bovine aortic endothelial cells to simvastatin (statin) dose-dependently increased phosphorylation of AMPK at Thr(172) and activities of AMPK, which was in parallel with increased detection of both LKB1 phosphorylation at Ser(428) and LKB1 nuclear export. Simvastatin 62-68 serine/threonine kinase 11 Mus musculus 257-261 18474592-6 2008 Similarly, in vivo transfection of PKC-zeta-specific small interfering RNA in C57BL/6J mice significantly attenuated statin-enhanced phosphorylation of AMPK-Thr(172), acetyl-CoA carboxylase (ACC)-Ser(79), and LKB1-Ser(428). Simvastatin 117-123 serine/threonine kinase 11 Mus musculus 209-213 18559695-3 2008 METHODS AND RESULTS: We measured mRNA expression of both the full-length and the alternatively spliced HMGCR transcript lacking exon 13 (HMGCRv_1) in 170 simvastatin-incubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. Simvastatin 154-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-108 18632543-3 2008 OBJECTIVE: To determine the effect of simvastatin on neuropsychological, neurophysiological, and neuroradiological outcome measures in children with NF1. Simvastatin 38-49 neurofibromin 1 Homo sapiens 149-152 18612412-11 2008 We also demonstrated that the pro-vascular repair mechanism of simvastatin involves VEGF stimulation, Akt phosphorylation, and nitric oxide production; and the anti-vascular repair mechanism is driven by marked intracellular cholesterol depletion and related disorganisation of key intracellular structures. Simvastatin 63-74 vascular endothelial growth factor A Homo sapiens 84-88 18628692-0 2008 Simvastatin stimulates chondrogenic phenotype of intervertebral disc cells partially through BMP-2 pathway. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 93-98 18628692-2 2008 OBJECTIVE: To evaluate the time-course effect of simvastatin on the gene expression of bone morphogenetic protein-2 (BMP-2), aggrecan, and collagen type II in rat IVD cells cultured in alginate bead. Simvastatin 49-60 bone morphogenetic protein 2 Rattus norvegicus 87-115 18628692-2 2008 OBJECTIVE: To evaluate the time-course effect of simvastatin on the gene expression of bone morphogenetic protein-2 (BMP-2), aggrecan, and collagen type II in rat IVD cells cultured in alginate bead. Simvastatin 49-60 bone morphogenetic protein 2 Rattus norvegicus 117-122 18628692-3 2008 Role of BMP-2 on the simvastatin-induced chondrogenesis of IVD cells was also investigated. Simvastatin 21-32 bone morphogenetic protein 2 Rattus norvegicus 8-13 18628692-10 2008 RESULTS: Simvastatin significantly upregulated BMP-2 mRNA expression, followed by aggrecan and type II collagen gene expression and proteoglycan content in rat IVD cells. Simvastatin 9-20 bone morphogenetic protein 2 Rattus norvegicus 47-52 18628692-11 2008 Moderate dose (500 ng/mL) of noggin completely hindered the expression of aggrecan and collagen type II induced by simvastatin on day 7, but not on day 14. Simvastatin 115-126 noggin Rattus norvegicus 29-35 18628692-13 2008 Lastly, simvastatin appeared to facilitate BMP-2, aggrecan, and type II collagen gene expression by inhibiting the production of mevalonate as evidenced that the anabolic effect was completely reversed with the addition of mevalonate. Simvastatin 8-19 bone morphogenetic protein 2 Rattus norvegicus 43-48 18628692-14 2008 CONCLUSION: Simvastatin drives a mechanism for promoting chondrogenesis of IVD cells partially mediated by upregulated BMP-2 through the inhibition of mevalonate pathway. Simvastatin 12-23 bone morphogenetic protein 2 Rattus norvegicus 119-124 18648134-9 2008 RESULTS: Serum levels of IL-10 were significantly lower in the simvastatin-treated group as well as the myeloperoxidase activity. Simvastatin 63-74 interleukin 10 Rattus norvegicus 25-30 18612412-11 2008 We also demonstrated that the pro-vascular repair mechanism of simvastatin involves VEGF stimulation, Akt phosphorylation, and nitric oxide production; and the anti-vascular repair mechanism is driven by marked intracellular cholesterol depletion and related disorganisation of key intracellular structures. Simvastatin 63-74 AKT serine/threonine kinase 1 Homo sapiens 102-105 18049901-4 2008 IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. Simvastatin 89-100 interferon gamma Mus musculus 0-9 18485137-1 2008 Simvastatin is an agent of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor group of drugs. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-78 18383345-4 2008 To assess the functional importance of the sterol synthesis pathway to adult human glial progenitors, we used simvastatin or pravastatin to inhibit HMG-CoA reductase, and then assessed the phenotypic differentiation of the progenitors, as well as the molecular concomitants thereof. Simvastatin 110-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-165 18049901-7 2008 In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Simvastatin 25-36 negative elongation factor complex member C/D, Th1l Mus musculus 52-55 18378243-0 2008 LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin. Simvastatin 106-117 parathyroid hormone-related protein Oryctolagus cuniculus 12-47 18378570-9 2008 RESULTS: These studies showed that simvastatin blocks diabetes or high-glucose-induced increases in VEGF and ICAM-1 and preserves the BRB by a process involving blockade of diabetes/high-glucose-induced activation of STAT3 and NADPH oxidase. Simvastatin 35-46 vascular endothelial growth factor A Homo sapiens 100-104 18378570-9 2008 RESULTS: These studies showed that simvastatin blocks diabetes or high-glucose-induced increases in VEGF and ICAM-1 and preserves the BRB by a process involving blockade of diabetes/high-glucose-induced activation of STAT3 and NADPH oxidase. Simvastatin 35-46 intercellular adhesion molecule 1 Homo sapiens 109-115 18378570-9 2008 RESULTS: These studies showed that simvastatin blocks diabetes or high-glucose-induced increases in VEGF and ICAM-1 and preserves the BRB by a process involving blockade of diabetes/high-glucose-induced activation of STAT3 and NADPH oxidase. Simvastatin 35-46 signal transducer and activator of transcription 3 Homo sapiens 217-222 18378570-11 2008 CONCLUSIONS: These results suggest that simvastatin protects against the early signs of diabetic retinopathy by preventing NADPH oxidase-mediated activation of STAT3. Simvastatin 40-51 signal transducer and activator of transcription 3 Homo sapiens 160-165 18441251-5 2008 We found that 1) in CHF rabbits, intracerebroventricular infusion of SIM significantly suppressed basal RSNA (1st day 69.5 +/- 8.9% maximum; 7th day 26.0 +/- 6.0% maximum; P < 0.05, n = 7) and enhanced arterial baroreflex function starting from the 2nd day and lasting through the following 5 days; 2) statin treatment significantly up-regulated neuronal nitric-oxide synthase (nNOS) protein expression in the rostral ventrolateral medulla (RVLM) (control, n = 6, 0.12 +/- 0.04; SIM-treated, n = 7, 0.31 +/- 0.05. Simvastatin 69-72 nitric oxide synthase, brain Oryctolagus cuniculus 349-379 18441251-5 2008 We found that 1) in CHF rabbits, intracerebroventricular infusion of SIM significantly suppressed basal RSNA (1st day 69.5 +/- 8.9% maximum; 7th day 26.0 +/- 6.0% maximum; P < 0.05, n = 7) and enhanced arterial baroreflex function starting from the 2nd day and lasting through the following 5 days; 2) statin treatment significantly up-regulated neuronal nitric-oxide synthase (nNOS) protein expression in the rostral ventrolateral medulla (RVLM) (control, n = 6, 0.12 +/- 0.04; SIM-treated, n = 7, 0.31 +/- 0.05. Simvastatin 69-72 nitric oxide synthase, brain Oryctolagus cuniculus 381-385 18441251-7 2008 These results suggest that central treatment with SIM decreased sympathetic outflow in CHF rabbits via up-regulation of nNOS expression in RVLM, which may be due to the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase and a decrease in Rho kinase by SIM. Simvastatin 50-53 nitric oxide synthase, brain Oryctolagus cuniculus 120-124 18213452-0 2008 Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Simvastatin 41-52 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 24-30 18213452-2 2008 MATERIALS AND METHODS: To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine, delayed release film coated tableted oral dosage forms were developed. Simvastatin 121-132 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-110 17573832-8 2008 Among the TAA-treated subgroups, rats with simvastatin treatment exerted higher motor activity counts and survival rate (P = 0.043), and a trend of lower ALT, AST, bilirubin and ammonia levels than those receiving saline. Simvastatin 43-54 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 159-162 18612546-9 2008 Simvastatin induced over-expression of S1P3 and potentiated the induction of Cox-2 expression produced by HDL (or S1P). Simvastatin 0-11 sphingosine-1-phosphate receptor 3 Homo sapiens 39-43 18612546-9 2008 Simvastatin induced over-expression of S1P3 and potentiated the induction of Cox-2 expression produced by HDL (or S1P). Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Homo sapiens 77-82 18547436-9 2008 Immunoblot analyses of endogenous PCSK9 and LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more upregulated than PCSK9 by simvastatin (2.6x vs 1.5x, respectively at 10 muM), while fenofibrate did not induce changes in either. Simvastatin 162-173 low density lipoprotein receptor Homo sapiens 123-127 18547436-9 2008 Immunoblot analyses of endogenous PCSK9 and LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more upregulated than PCSK9 by simvastatin (2.6x vs 1.5x, respectively at 10 muM), while fenofibrate did not induce changes in either. Simvastatin 162-173 proprotein convertase subtilisin/kexin type 9 Homo sapiens 153-158 18378243-5 2008 An increase in PTHrP immunostaining was observed in atherosclerotic lesions of hyperlipidemic rabbits, which was significantly reduced by simvastatin. Simvastatin 138-149 parathyroid hormone-related protein Oryctolagus cuniculus 15-20 18484901-0 2008 Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Simvastatin 0-11 serpin family E member 1 Homo sapiens 32-65 18541796-12 2008 Interestingly, simvastatin treatment induced PrP(Sc) accumulation in parallel with an induced neuroprotective effect. Simvastatin 15-26 prion protein Mus musculus 45-48 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 Cd28 molecule Rattus norvegicus 109-113 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 Cd4 molecule Rattus norvegicus 128-131 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 Cd80 molecule Rattus norvegicus 170-174 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 tumor necrosis factor-like Rattus norvegicus 242-263 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 tumor necrosis factor-like Rattus norvegicus 265-268 18471827-6 2008 During co-culture of the myocarditic splenocytes and the APCs, simvastatin not only decreased percentages of CD28 expression in CD4-positive myocarditic splenocytes, and CD80 and CD86 expressions in APCs, but also inhibited the production of tumor necrosis factor (TNF)-partial differential in the CD4-positive myocarditic splenocytes and the APCs. Simvastatin 63-74 Cd4 molecule Rattus norvegicus 298-301 18475152-0 2008 Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. Simvastatin 0-11 angiotensin II receptor type 1 Homo sapiens 72-76 18475152-4 2008 In-vitro experiments were also performed to assess the ability of simvastatin to interfere with angiotensin II signalling. Simvastatin 66-77 angiotensinogen Homo sapiens 96-110 18475152-8 2008 One-month treatment of high-risk subjects with simvastatin resulted in a reduction of angiotensin II type 1 receptor mRNA without affecting angiotensin II type 2 receptor whereas angiotensinogen mRNA expression was reduced at least in monocytes. Simvastatin 47-58 angiotensin II receptor type 1 Homo sapiens 86-116 18475152-8 2008 One-month treatment of high-risk subjects with simvastatin resulted in a reduction of angiotensin II type 1 receptor mRNA without affecting angiotensin II type 2 receptor whereas angiotensinogen mRNA expression was reduced at least in monocytes. Simvastatin 47-58 angiotensin II receptor type 2 Homo sapiens 140-170 18475152-8 2008 One-month treatment of high-risk subjects with simvastatin resulted in a reduction of angiotensin II type 1 receptor mRNA without affecting angiotensin II type 2 receptor whereas angiotensinogen mRNA expression was reduced at least in monocytes. Simvastatin 47-58 angiotensinogen Homo sapiens 179-194 18475152-9 2008 Incubation in vitro with simvastatin reduces the expression of angiotensin II type 1 receptor mRNA levels on monocytes from untreated subjects. Simvastatin 25-36 angiotensin II receptor type 1 Homo sapiens 63-93 18475152-10 2008 CONCLUSION: Simvastatin induces down-regulation of the angiotensin II type 1 receptor, interferes with angiotensin II activity in immune cells and contributes to the anti-inflammatory profile of statins that can explain the therapeutic effects of these drugs. Simvastatin 12-23 angiotensin II receptor type 1 Homo sapiens 55-85 18475152-10 2008 CONCLUSION: Simvastatin induces down-regulation of the angiotensin II type 1 receptor, interferes with angiotensin II activity in immune cells and contributes to the anti-inflammatory profile of statins that can explain the therapeutic effects of these drugs. Simvastatin 12-23 angiotensinogen Homo sapiens 55-69 18484901-5 2008 The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Simvastatin 52-63 serpin family E member 1 Homo sapiens 67-72 18484901-10 2008 Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 +/- 5.2 IU/mL at baseline vs. 21.4 +/- 3.9 IU/mL after 8 weeks of treatment). Simvastatin 22-33 serpin family E member 1 Homo sapiens 86-91 18484901-12 2008 CONCLUSION: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity. Simvastatin 35-46 serpin family E member 1 Homo sapiens 152-157 18390541-5 2008 Insulin-, but not EGF-mediated VEGF protein expression was functionally connected to co-induced HMGR activity, as simvastatin restrictively interfered only with insulin-induced translation of VEGF mRNA by inhibition of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation. Simvastatin 114-125 vascular endothelial growth factor A Mus musculus 192-196 19040069-1 2008 OBJECTIVE: To evaluate the effects of four agents including cyclophosphamide, thalidomide, total glucosides of peony (TGP) and simvastatin on cell-proliferation and endothelin-1 secretion of human endothelial cells (ECs). Simvastatin 127-138 endothelin 1 Homo sapiens 165-177 19040069-7 2008 (2) Cyclophosphamide (50-2000 micromol/L) and simvastatin (5-10 micromol/L) decreased endothelin-1 secretion but not in dose dependent manner. Simvastatin 46-57 endothelin 1 Homo sapiens 86-98 19040069-9 2008 Cyclophosphamide and simvastatin can decrease endothelin-1 secretion of human ECs. Simvastatin 21-32 endothelin 1 Homo sapiens 46-58 18390541-8 2008 The observed inhibitory effects of simvastatin on keratinocyte VEGF expression and proliferation could be reversed by mevalonate, the product of HMGR enzymatic activity. Simvastatin 35-46 vascular endothelial growth factor A Mus musculus 63-67 18390541-9 2008 In accordance, simvastatin-mediated inhibition of HMGR activity in acutely regenerating tissue of wounded mice was paralleled by a marked loss of VEGF protein expression and disturbances of normal proliferation processes in wound margin keratinocytes during skin repair. Simvastatin 15-26 vascular endothelial growth factor A Mus musculus 146-150 18453621-0 2008 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Simvastatin 0-11 interleukin 17A Homo sapiens 21-26 18453621-0 2008 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Simvastatin 0-11 interleukin 17A Homo sapiens 59-64 18453621-0 2008 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Simvastatin 0-11 interleukin 17A Homo sapiens 59-64 18453621-0 2008 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Simvastatin 0-11 CD4 molecule Homo sapiens 157-160 18453621-4 2008 Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells. Simvastatin 0-11 interferon gamma Homo sapiens 25-34 18453621-4 2008 Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells. Simvastatin 0-11 interleukin 4 Homo sapiens 36-40 18453621-4 2008 Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells. Simvastatin 0-11 interleukin 27 Homo sapiens 46-51 18453621-4 2008 Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells. Simvastatin 0-11 interleukin 17A Homo sapiens 102-107 18453621-4 2008 Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells. Simvastatin 0-11 CD4 molecule Homo sapiens 139-142 18453621-6 2008 Furthermore, simvastatin directly inhibited the expression of retinoic acid-related orphan nuclear hormone receptor C, a transcription factor that controls IL-17 production in CD4(+) T cells. Simvastatin 13-24 interleukin 17A Homo sapiens 156-161 18453621-6 2008 Furthermore, simvastatin directly inhibited the expression of retinoic acid-related orphan nuclear hormone receptor C, a transcription factor that controls IL-17 production in CD4(+) T cells. Simvastatin 13-24 CD4 molecule Homo sapiens 176-179 18453621-7 2008 This effect was reversed by mevalonic acid, a downstream metabolite of 3-hydroxy-3-methylglutaryl CoA reductase, confirming that simvastatin"s specific effect is through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase. Simvastatin 129-140 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-111 18310229-8 2008 After SS treatment, Lm decreased by 52% and PCNA-positive alveolar epithelial cells increased compared with the SS- group. Simvastatin 6-8 proliferating cell nuclear antigen Mus musculus 44-48 19099753-0 2008 [Expression of connective tissue growth factor and its down-regulation by simvastatin administration in pulmonary hypertensive rats]. Simvastatin 74-85 cellular communication network factor 2 Rattus norvegicus 15-46 18390537-5 2008 At baseline, AT1-R mRNA expression was also higher in dyslipidaemic subjects than in healthy controls and it was reduced after clinical treatment with simvastatin. Simvastatin 151-162 angiotensin II receptor type 1 Homo sapiens 13-18 18390537-6 2008 In a subgroup of patients, a reduced angiotensin II-induced ROS generation was also observed upon clinical simvastatin treatment. Simvastatin 107-118 angiotensinogen Homo sapiens 37-51 18276775-7 2008 Simvastatin, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, effectively blocked proinflammatory reactions induced by Abeta in cocultures with SVGA-Tat cells or with HIV-1-infected Jurkat cells. Simvastatin 0-11 amyloid beta precursor protein Homo sapiens 133-138 17980884-1 2008 OBJECTIVE: The combination of simvastatin, an HMG-CoA reductase inhibitor, and ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesterol synthesis and absorption and reduces circulating LDL-cholesterol concentrations. Simvastatin 30-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-63 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-92 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 97-101 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 49-60 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-92 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 49-60 low density lipoprotein receptor Homo sapiens 97-101 17980884-10 2008 The combination of ezetimibe and simvastatin increased the expression of the serine protease proprotein convertase subtilisin/kexin 9 (PCSK9), an enzyme shown to down-regulate LDLR protein levels. Simvastatin 33-44 proprotein convertase subtilisin/kexin type 9 Homo sapiens 135-140 17980884-10 2008 The combination of ezetimibe and simvastatin increased the expression of the serine protease proprotein convertase subtilisin/kexin 9 (PCSK9), an enzyme shown to down-regulate LDLR protein levels. Simvastatin 33-44 low density lipoprotein receptor Homo sapiens 176-180 17980884-11 2008 CONCLUSIONS: The co-administration of ezetimibe and simvastatin abrogates the ezetimibe-induced increase in cholesterol synthesis and up-regulates the LDLR gene but not protein expression, an effect possibly mediated through a parallel upregulation of PCSK9 expression. Simvastatin 52-63 low density lipoprotein receptor Homo sapiens 151-155 17980884-11 2008 CONCLUSIONS: The co-administration of ezetimibe and simvastatin abrogates the ezetimibe-induced increase in cholesterol synthesis and up-regulates the LDLR gene but not protein expression, an effect possibly mediated through a parallel upregulation of PCSK9 expression. Simvastatin 52-63 proprotein convertase subtilisin/kexin type 9 Homo sapiens 252-257 18569431-8 2008 Simvastatin also inhibited the IRI-induced activation of MMP-9 in the lungs. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 57-62 19099753-1 2008 OBJECTIVE: To explore the role of expression of connective tissue growth factor (CTGF) in pulmonary vascular remodeling of pulmonary hypertensive rats, and investigate the regulation of CTGF expression by simvastatin in this animal model. Simvastatin 205-216 cellular communication network factor 2 Rattus norvegicus 186-190 19099753-10 2008 The up-regulation of ET-1 and CTGF gene expression, and elevated synthesis of hydroxyproline were reversed in rats intervened with simvastatin. Simvastatin 131-142 endothelin 1 Rattus norvegicus 21-25 19099753-10 2008 The up-regulation of ET-1 and CTGF gene expression, and elevated synthesis of hydroxyproline were reversed in rats intervened with simvastatin. Simvastatin 131-142 cellular communication network factor 2 Rattus norvegicus 30-34 19099753-13 2008 Simvastatin can prevent and, to some extent, reverse the vascular remodeling via down-regulation of CTGF gene expression. Simvastatin 0-11 cellular communication network factor 2 Rattus norvegicus 100-104 18413554-9 2008 Blood pressure reductions ranged from 2.4 to 2.8 mm Hg for both SBP and DBP with both simvastatin and pravastatin, in those subjects with full follow-up, and without potential for influence by BP medications (ie, neither receiving nor meriting BP medications). Simvastatin 86-97 D-box binding PAR bZIP transcription factor Homo sapiens 72-75 18375239-5 2008 Simvastatin is representative of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) class of lipid-altering drugs, which are the most effective agents for lowering LDL cholesterol levels and also have modest benefits in raising HDL cholesterol and lowering TG levels. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-84 17904146-9 2008 Addition of simvastatin significantly reduced CD40 expression as well as platelet adhesion to fibrillating atria; its efficacy was not reversed by the addition of mevalonic acid. Simvastatin 12-23 CD40 molecule Homo sapiens 46-50 18371146-13 2008 Simvastatin inhibited activation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) but not c-Jun NH(2)-terminal kinase or p38 mitogen-activated protein (MAP) kinase. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 36-73 18371146-13 2008 Simvastatin inhibited activation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) but not c-Jun NH(2)-terminal kinase or p38 mitogen-activated protein (MAP) kinase. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 75-78 18371146-13 2008 Simvastatin inhibited activation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) but not c-Jun NH(2)-terminal kinase or p38 mitogen-activated protein (MAP) kinase. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 102-105 18192240-0 2008 Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 121-142 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 111-141 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 143-148 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 interleukin 2 receptor subunit beta Homo sapiens 201-229 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 lymphotoxin beta Homo sapiens 282-298 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 301-334 18192240-5 2008 Simvastatin treatment lead to downregulation of many pro-inflammatory genes including several chemokines [e.g. monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins-1alpha and beta, interleukin-2 receptor-beta], members of the tumour necrosis factor family (e.g. lymphotoxin beta), vascular cell adhesion molecule-1, and tissue factor (TF). Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 340-353 18192240-6 2008 Simvastatin also modulated the expression of several transcription factors essential for inflammation: NF-kappaB relA/p65 subunit and ets-1 were downregulated, and an atheroprotective transcription factor KLF-2 was upregulated. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 205-210 18192240-7 2008 The effects of simvastatin on MCP-1 and TF could be mimicked by KLF-2 overexpression using lentiviral gene transfer. Simvastatin 15-26 C-C motif chemokine ligand 2 Homo sapiens 30-35 18192240-7 2008 The effects of simvastatin on MCP-1 and TF could be mimicked by KLF-2 overexpression using lentiviral gene transfer. Simvastatin 15-26 coagulation factor III, tissue factor Homo sapiens 40-42 18192240-7 2008 The effects of simvastatin on MCP-1 and TF could be mimicked by KLF-2 overexpression using lentiviral gene transfer. Simvastatin 15-26 Kruppel like factor 2 Homo sapiens 64-69 18192240-8 2008 CONCLUSION: Simvastatin has a strong anti-inflammatory effect on HPBM cells including upregulation of the atheroprotective factor KLF-2. Simvastatin 12-23 Kruppel like factor 2 Homo sapiens 130-135 18065496-4 2008 In our current study, we show that simvastatin, pravastatin and fluvastatin can induce PTEN expression in a dose-dependent manner. Simvastatin 35-46 phosphatase and tensin homolog Homo sapiens 87-91 18184901-0 2008 Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Simvastatin 0-11 adiponectin, C1Q and collagen domain containing Homo sapiens 56-67 18184901-0 2008 Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Simvastatin 0-11 insulin Homo sapiens 79-86 18184901-1 2008 OBJECTIVE: We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Simvastatin 32-43 adiponectin, C1Q and collagen domain containing Homo sapiens 55-66 18184901-1 2008 OBJECTIVE: We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Simvastatin 32-43 insulin Homo sapiens 78-85 18184901-6 2008 Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). Simvastatin 0-11 adiponectin, C1Q and collagen domain containing Homo sapiens 74-85 18184901-6 2008 Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). Simvastatin 0-11 insulin Homo sapiens 117-124 18184901-6 2008 Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). Simvastatin 0-11 insulin Homo sapiens 169-176 18184901-6 2008 Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). Simvastatin 0-11 adiponectin, C1Q and collagen domain containing Homo sapiens 323-334 18184901-8 2008 CONCLUSIONS: Simvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction. Simvastatin 13-24 adiponectin, C1Q and collagen domain containing Homo sapiens 92-103 18184901-8 2008 CONCLUSIONS: Simvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction. Simvastatin 13-24 insulin Homo sapiens 115-122 18068200-9 2008 Caspase-3/7 activation was inhibited partially by low density lipoprotein (LDL), high density lipoprotein (HDL), z-VAD-fmk (pan-caspase inhibitor), and low doses (0.01 and 0.001 microM) of the cholesterol lowering drug, simvastatin. Simvastatin 220-231 caspase 3 Homo sapiens 0-9 18047562-4 2008 We evaluated TH positive neurons, astroglial, and microglial populations and found that simvastatin prevented the inflammatory processes, as the induction of interleukin-1beta, tumor necrosis factor-alpha, and iNOS and the consequent dopaminergic degeneration induced by LPS. Simvastatin 88-99 interleukin 1 beta Rattus norvegicus 158-204 18047562-4 2008 We evaluated TH positive neurons, astroglial, and microglial populations and found that simvastatin prevented the inflammatory processes, as the induction of interleukin-1beta, tumor necrosis factor-alpha, and iNOS and the consequent dopaminergic degeneration induced by LPS. Simvastatin 88-99 nitric oxide synthase 2 Rattus norvegicus 210-214 18047562-5 2008 Moreover, simvastatin produced the activation of the neurotrophic factor BDNF, along with the prevention of the oxidative damage to proteins. Simvastatin 10-21 brain-derived neurotrophic factor Rattus norvegicus 73-77 18391484-7 2008 The expression levels of both total Akt protein and clonidine-induced Ser-473-phosphorylated Akt were significantly decreased in diabetic aortas, while chronic simvastatin administration improved these decreased levels. Simvastatin 160-171 thymoma viral proto-oncogene 1 Mus musculus 36-39 18391484-9 2008 These results strongly suggest that simvastatin improves the endothelial dysfunction seen in type 2 diabetic mice via increases in Akt and Akt phosphorylation. Simvastatin 36-47 thymoma viral proto-oncogene 1 Mus musculus 131-134 18391484-9 2008 These results strongly suggest that simvastatin improves the endothelial dysfunction seen in type 2 diabetic mice via increases in Akt and Akt phosphorylation. Simvastatin 36-47 thymoma viral proto-oncogene 1 Mus musculus 139-142 18295249-9 2008 The beneficial effect of simvastatin on uremia enhanced vascular calcification in apoE(-/-) mice with chronic kidney disease was observed despite the absence of changes in uremia accelerated atherosclerosis progression, serum total cholesterol levels or osteopontin and alkaline phosphatase expression. Simvastatin 25-36 apolipoprotein E Mus musculus 82-86 18295249-9 2008 The beneficial effect of simvastatin on uremia enhanced vascular calcification in apoE(-/-) mice with chronic kidney disease was observed despite the absence of changes in uremia accelerated atherosclerosis progression, serum total cholesterol levels or osteopontin and alkaline phosphatase expression. Simvastatin 25-36 secreted phosphoprotein 1 Mus musculus 254-265 18309148-8 2008 Treatment with simvastatin resulted in reduced expression of macrophage chemoattractant protein-1 and vascular cell adhesion molecule-1, increased expression of endothelial nitric oxide synthase, and reduced the number of macrophage infiltration. Simvastatin 15-26 vascular cell adhesion molecule 1 Rattus norvegicus 102-135 18337644-4 2008 We treated human melanoma cell lines, A375M, G361, C8161, GAK, and MMAc with simvastatin in various concentrations for 1 to 3 days. Simvastatin 77-88 cyclin G associated kinase Homo sapiens 58-61 18337644-11 2008 Consistent with the cell cycle arrest, simvastatin caused an increase in the mRNA levels of p21 and p27 on G361 and MMAc cells. Simvastatin 39-50 H3 histone pseudogene 16 Homo sapiens 92-95 18337644-11 2008 Consistent with the cell cycle arrest, simvastatin caused an increase in the mRNA levels of p21 and p27 on G361 and MMAc cells. Simvastatin 39-50 interferon alpha inducible protein 27 Homo sapiens 100-103 18242710-4 2008 To investigate this we made use of a model in which monocytic cells (THP-1) were treated with simvastatin. Simvastatin 94-105 GLI family zinc finger 2 Homo sapiens 69-74 18242710-6 2008 Our study revealed that LPS-stimulated THP-1 cells treated with simvastatin had an increased caspase-1 mediated processing of proIL-1beta. Simvastatin 64-75 GLI family zinc finger 2 Homo sapiens 39-44 18242710-6 2008 Our study revealed that LPS-stimulated THP-1 cells treated with simvastatin had an increased caspase-1 mediated processing of proIL-1beta. Simvastatin 64-75 caspase 1 Homo sapiens 93-102 18242710-6 2008 Our study revealed that LPS-stimulated THP-1 cells treated with simvastatin had an increased caspase-1 mediated processing of proIL-1beta. Simvastatin 64-75 interleukin 1 beta Homo sapiens 126-137 18242710-8 2008 Simvastatin-induced activation of caspase-1 was caused by an impairment of non-sterol isoprenoid biosynthesis, as the isoprenyl intermediate GGPP could block activation of caspase-1 and mIL-1beta release. Simvastatin 0-11 caspase 1 Homo sapiens 34-43 18242710-8 2008 Simvastatin-induced activation of caspase-1 was caused by an impairment of non-sterol isoprenoid biosynthesis, as the isoprenyl intermediate GGPP could block activation of caspase-1 and mIL-1beta release. Simvastatin 0-11 caspase 1 Homo sapiens 172-181 18242710-10 2008 Taken together, these results demonstrate that simvastatin augments LPS-induced IL-1beta release post-translationally, by inducing caspase-1 activity. Simvastatin 47-58 interleukin 1 beta Homo sapiens 80-88 18242710-10 2008 Taken together, these results demonstrate that simvastatin augments LPS-induced IL-1beta release post-translationally, by inducing caspase-1 activity. Simvastatin 47-58 caspase 1 Homo sapiens 131-140 18598004-11 2008 Pretreatment with simvastatin protected against alpha-toxin-induced sepsis associated with reduced p53, TNF-alpha, apoptosis, and necrosis. Simvastatin 18-29 tumor necrosis factor Rattus norvegicus 104-113 18598004-11 2008 Pretreatment with simvastatin protected against alpha-toxin-induced sepsis associated with reduced p53, TNF-alpha, apoptosis, and necrosis. Simvastatin 18-29 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 99-102 18309148-9 2008 In quantitative polymerase chain reaction and immunohistochemistry, simvastatin significantly inhibited upregulated expression of interleukin-1beta, inducible nitric oxide synthase, matrix metalloproteinase-2, and matrix metalloproteinase-9 associated with CA progression. Simvastatin 68-79 interleukin 1 beta Rattus norvegicus 130-147 18309148-9 2008 In quantitative polymerase chain reaction and immunohistochemistry, simvastatin significantly inhibited upregulated expression of interleukin-1beta, inducible nitric oxide synthase, matrix metalloproteinase-2, and matrix metalloproteinase-9 associated with CA progression. Simvastatin 68-79 matrix metallopeptidase 2 Rattus norvegicus 182-208 18309148-9 2008 In quantitative polymerase chain reaction and immunohistochemistry, simvastatin significantly inhibited upregulated expression of interleukin-1beta, inducible nitric oxide synthase, matrix metalloproteinase-2, and matrix metalloproteinase-9 associated with CA progression. Simvastatin 68-79 matrix metallopeptidase 9 Rattus norvegicus 214-240 18309148-10 2008 Gelatin zymography revealed decreased activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in aneurysmal walls by simvastatin treatment. Simvastatin 131-142 matrix metallopeptidase 2 Rattus norvegicus 50-107 18323503-8 2008 Simvastatin and AY9944 reduced the association of the subunit 1 of NMDA receptors (NMDAR1) to lipid rafts by 42% and 21%, respectively, and did not change total expression of NMDAR1. Simvastatin 0-11 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 83-89 18323503-9 2008 Addition of cholesterol reduced neuroprotection by statins and AY9944, and partially reverted the effect of simvastatin on the association of NMDAR1 to lipid rafts. Simvastatin 108-119 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 142-148 18332269-6 2008 These single nucleotide polymorphisms and the common haplotypes inferred from them were tested for association with plasma LDL-C and LDL-C response to simvastatin treatment (40 mg/d for 6 weeks) in 326 blacks and 596 whites. Simvastatin 151-162 component of oligomeric golgi complex 2 Homo sapiens 133-138 18332269-10 2008 CONCLUSIONS: HMGCR gene polymorphisms are associated with reduced plasma LDL-C and LDL-C response to simvastatin, and these effects are most evident in blacks. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 13-18 18332269-10 2008 CONCLUSIONS: HMGCR gene polymorphisms are associated with reduced plasma LDL-C and LDL-C response to simvastatin, and these effects are most evident in blacks. Simvastatin 101-112 component of oligomeric golgi complex 2 Homo sapiens 83-88 18203812-8 2008 Simvastatin attenuated effects of both IL-17 and TGF-beta. Simvastatin 0-11 interleukin 17A Homo sapiens 39-44 18337668-0 2008 Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Simvastatin 37-48 heme oxygenase 1 Rattus norvegicus 100-116 18337668-3 2008 The aim was to study the role of HO-1 in pharmacological preconditioning by simvastatin in a rat model. Simvastatin 76-87 heme oxygenase 1 Rattus norvegicus 33-37 18337668-6 2008 RESULTS: HO-1 was induced and persistently overexpressed in the hepatocytes 24 hr after simvastatin treatment. Simvastatin 88-99 heme oxygenase 1 Rattus norvegicus 9-13 18337668-11 2008 CONCLUSIONS: The induction of HO-1 by simvastatin preconditioning played a protective role against hepatic I/R injury. Simvastatin 38-49 heme oxygenase 1 Rattus norvegicus 30-34 18619353-7 2008 RESULT: Data of the study demonstrated that compared with model group, the activity of NOS and the gene expression of eNOS were increased remarkably, and however the gene expression of iNOS was reduced markedly in simvastatin group and TSG 60, 120 mg x kg(-1) x d(-1) group. Simvastatin 214-225 nitric oxide synthase 3 Rattus norvegicus 118-122 18619353-7 2008 RESULT: Data of the study demonstrated that compared with model group, the activity of NOS and the gene expression of eNOS were increased remarkably, and however the gene expression of iNOS was reduced markedly in simvastatin group and TSG 60, 120 mg x kg(-1) x d(-1) group. Simvastatin 214-225 nitric oxide synthase 2 Rattus norvegicus 185-189 19578502-4 2008 RESULTS: ApoE-/- mice were treated with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin. Simvastatin 98-109 apolipoprotein E Mus musculus 9-13 19578502-4 2008 RESULTS: ApoE-/- mice were treated with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin. Simvastatin 98-109 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 70-87 18203812-8 2008 Simvastatin attenuated effects of both IL-17 and TGF-beta. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 49-57 18203812-9 2008 We have demonstrated the ability of simvastatin to attenuate release of airway neutrophilic and remodeling mediators and to inhibit their upregulation by TGF-beta and IL-17. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 154-162 18203812-9 2008 We have demonstrated the ability of simvastatin to attenuate release of airway neutrophilic and remodeling mediators and to inhibit their upregulation by TGF-beta and IL-17. Simvastatin 36-47 interleukin 17A Homo sapiens 167-172 18567413-0 2008 Diabetes mellitus downregulates expression of connexin43 in rat aortic medial smooth muscle cells and can be reversed by simvastatin and losartan therapy. Simvastatin 121-132 gap junction protein, alpha 1 Rattus norvegicus 46-56 18567413-14 2008 Both simvastatin and losartan treatment significantly reversed the effects of DM on integrity of Cx43 expression. Simvastatin 5-16 gap junction protein, alpha 1 Rattus norvegicus 97-101 18226326-8 2008 CONCLUSIONS: In CHD/DM2 patients treated with simvastatin or atorvastatin with LDL-C persistently > or = 2.5 mmol/L, switching to the EZE/SIMVA was more effective in attaining the LDL-C target of < 2.5 mmol/L than doubling the statin dose. Simvastatin 46-57 component of oligomeric golgi complex 2 Homo sapiens 79-84 18083785-4 2008 In the current study, we hypothesized that pharmacological blockade of the RhoA/ROCK pathway with either fasudil or simvastatin would ameliorate progression of diabetic nephropathy. Simvastatin 116-127 ras homolog family member A Mus musculus 75-79 18083785-12 2008 Treatment with simvastatin significantly attenuated RhoA activation in the kidney cortices of db/db mice and resulted in a significant reduction of albuminuria and mesangial matrix expansion. Simvastatin 15-26 ras homolog family member A Mus musculus 52-56 18376061-4 2008 RESULTS: Compared to placebo, individuals randomized to simvastatin for 4 months had similar changes in CSF Abeta42 (p=0.344) and total tau levels (p=0.226), yet greater improvements in some measures of verbal fluency (p=0.024) and working memory (p=0.015). Simvastatin 56-67 microtubule associated protein tau Homo sapiens 136-139 18356691-0 2008 Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 23-57 18356691-0 2008 Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 72-103 18356691-3 2008 This study examined whether simvastatin stimulates VEGF expression in endothelial cells as well as the nature of its underlying mechanism. Simvastatin 28-39 vascular endothelial growth factor A Homo sapiens 51-55 18356691-4 2008 METHODS AND RESULTS: Simvastatin induced mRNA expression and protein secretion of VEGF in endothelial cells that were reversed by pretreatment with mevalonate and geranylgeranylpyrophosphate but not by farnesylpyrophosphate. Simvastatin 21-32 vascular endothelial growth factor A Homo sapiens 82-86 18356691-6 2008 Simvastatin increased hypoxia-inducible factor-1alpha (HIF-1alpha) protein level without changing its mRNA expression. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 22-53 18356691-6 2008 Simvastatin increased hypoxia-inducible factor-1alpha (HIF-1alpha) protein level without changing its mRNA expression. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 55-65 18356691-7 2008 Inhibition of RhoA had similar effects to simvastatin on VEGF expression. Simvastatin 42-53 vascular endothelial growth factor A Homo sapiens 57-61 18356691-9 2008 Depletion of HIF-1alpha by RNA interference blocked simvastatin-induced VEGF mRNA expression. Simvastatin 52-63 hypoxia inducible factor 1 subunit alpha Homo sapiens 13-23 18310456-7 2008 In addition, cDNA array analysis revealed that simvastatin increased expression levels of Smads in C2C12 cells exposed to TNF-alpha that also activated mitogen-activated protein kinase (MAPK) signaling pathways, including extracellular signal-regulated kinase 1/2 (ERK1/2), P38, and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK). Simvastatin 47-58 mitogen-activated protein kinase 3 Mus musculus 265-271 18356691-9 2008 Depletion of HIF-1alpha by RNA interference blocked simvastatin-induced VEGF mRNA expression. Simvastatin 52-63 vascular endothelial growth factor A Homo sapiens 72-76 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 tumor necrosis factor Mus musculus 32-41 18356691-10 2008 CONCLUSIONS: Simvastatin stimulates VEGF expression by RhoA downregulation and HIF-1alpha upregulation in endothelial cells. Simvastatin 13-24 vascular endothelial growth factor A Homo sapiens 36-40 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 mitogen-activated protein kinase 3 Mus musculus 69-75 18310456-0 2008 Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. Simvastatin 0-11 tumor necrosis factor Mus musculus 24-51 18356691-10 2008 CONCLUSIONS: Simvastatin stimulates VEGF expression by RhoA downregulation and HIF-1alpha upregulation in endothelial cells. Simvastatin 13-24 ras homolog family member A Homo sapiens 55-59 18310456-0 2008 Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. Simvastatin 0-11 SMAD family member 1 Mus musculus 145-149 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 tumor necrosis factor Mus musculus 103-112 18310456-8 2008 Simvastatin potently suppressed TNF-alpha-induced phosphorylation of ERK1/2 and SAPK/JNK by inhibiting TNF-alpha-induced membrane localization of Ras and RhoA. Simvastatin 0-11 ras homolog family member A Mus musculus 154-158 18356691-10 2008 CONCLUSIONS: Simvastatin stimulates VEGF expression by RhoA downregulation and HIF-1alpha upregulation in endothelial cells. Simvastatin 13-24 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-89 18310456-9 2008 Farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) reversed the simvastatin effects on TNF-alpha-induced activation of Ras/Rho/MAPK pathways. Simvastatin 82-93 tumor necrosis factor Mus musculus 105-114 18310456-5 2008 Simvastatin had no independent effects on Runx2 and alkaline phosphatase activity; however, it reversed the suppressive effects of TNF-alpha. Simvastatin 0-11 tumor necrosis factor Mus musculus 131-140 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 15-26 tumor necrosis factor Mus musculus 38-47 18310456-10 2008 FPP and GGPP also restored the simvastatin effects on TNF-alpha-induced suppression of Runx2 and ALP activity. Simvastatin 31-42 tumor necrosis factor Mus musculus 54-63 18224302-0 2008 Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I. Simvastatin 0-11 cystathionine beta-synthase Mus musculus 67-94 18310456-10 2008 FPP and GGPP also restored the simvastatin effects on TNF-alpha-induced suppression of Runx2 and ALP activity. Simvastatin 31-42 runt related transcription factor 2 Mus musculus 87-92 18310456-12 2008 Collectively, simvastatin supports BMP-induced osteoblast differentiation through antagonizing TNF-alpha-to-Ras/Rho/MAPK pathway and augmenting BMP-Smad signaling, suggesting a potential usage of statins to ameliorate inflammatory bone damage. Simvastatin 14-25 tumor necrosis factor Mus musculus 95-104 18310456-12 2008 Collectively, simvastatin supports BMP-induced osteoblast differentiation through antagonizing TNF-alpha-to-Ras/Rho/MAPK pathway and augmenting BMP-Smad signaling, suggesting a potential usage of statins to ameliorate inflammatory bone damage. Simvastatin 14-25 SMAD family member 1 Mus musculus 148-152 18359719-0 2008 [Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]. Simvastatin 11-22 C-X3-C motif chemokine receptor 1 Homo sapiens 35-41 18359719-1 2008 OBJECTIVE: To observe the effect of simvastatin on expression of CX3CR1 in the monocytes in patients with acute coronary syndrome and investigate the non-lipid mechanisms of statins against atherosclerosis. Simvastatin 36-47 C-X3-C motif chemokine receptor 1 Homo sapiens 65-71 18359719-2 2008 METHODS: The expression of CX3CR1 in the monocytes was measured by quantitative real-time RT-PCR in 63 patients with acute coronary syndrome confirmed by coronary arteriography after treatment with simvastatin at 10(-7) approximately 10(-5) mol/L for 4, 8 and 12 h, respectively. Simvastatin 198-209 C-X3-C motif chemokine receptor 1 Homo sapiens 27-33 18359719-3 2008 RESULTS: CX3CR1 expression in the monocytes treated with different concentrations of simvastatin was significantly lower than that in the control cells (P<0.05), and the expression in the cells treated with the agent for different time lengths was also significantly lower than that in the control cells (P<0.01). Simvastatin 85-96 C-X3-C motif chemokine receptor 1 Homo sapiens 9-15 18359719-4 2008 CONCLUSION: Simvastatin can reduce CX3CR1 expression in the monocytes of the patients with acute coronary syndrome in a concentration- and time-dependent manner, so as to reduce the inflammation and stabilize the vascular plaques. Simvastatin 12-23 C-X3-C motif chemokine receptor 1 Homo sapiens 35-41 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 15-26 SMAD family member 1 Mus musculus 74-81 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 15-26 SMAD family member 1 Mus musculus 74-78 18310456-6 2008 The ability of simvastatin to reverse TNF-alpha inhibition of BMP-induced Smad1,5,8 phosphorylation and Id-1 promoter activity suggests the involvement of Smad signaling pathway in simvastatin action. Simvastatin 181-192 tumor necrosis factor Mus musculus 38-47 18310456-7 2008 In addition, cDNA array analysis revealed that simvastatin increased expression levels of Smads in C2C12 cells exposed to TNF-alpha that also activated mitogen-activated protein kinase (MAPK) signaling pathways, including extracellular signal-regulated kinase 1/2 (ERK1/2), P38, and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK). Simvastatin 47-58 tumor necrosis factor Mus musculus 122-131 18310456-7 2008 In addition, cDNA array analysis revealed that simvastatin increased expression levels of Smads in C2C12 cells exposed to TNF-alpha that also activated mitogen-activated protein kinase (MAPK) signaling pathways, including extracellular signal-regulated kinase 1/2 (ERK1/2), P38, and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK). Simvastatin 47-58 mitogen-activated protein kinase 3 Mus musculus 222-263 18224302-6 2008 Concomitant with this effect, an increase in nitric oxide levels was observed in these double heterozygous mice receiving simvastatin treatment probably mediated in part by a decrease in caveolin-1 levels. Simvastatin 122-133 caveolin 1, caveolae protein Mus musculus 187-197 18224302-8 2008 Another remarkable result was the significant increase in apoA-IV content in animals receiving simvastatin, an effect considered to be protective for the endothelium. Simvastatin 95-106 apolipoprotein A-IV Mus musculus 58-65 18224302-9 2008 In conclusion, the results of this study demonstrate that the use of simvastatin can improve blood pressure control in mice with elevated homocysteinemia and low levels of apoA-I, and this effect is mediated by mechanisms independent of plasma lipids and related to nitric oxide levels. Simvastatin 69-80 apolipoprotein A-I Mus musculus 172-178 18224302-0 2008 Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I. Simvastatin 0-11 apolipoprotein A-I Mus musculus 99-117 18036510-1 2008 We recently found that simvastatin can modulate the nuclear factor-kappaB (NF-kappaB) activation pathway, but whether other statins have similar effects to those of simvastatin is unknown. Simvastatin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 52-73 18073186-3 2008 This study was designed to explore the effect of simvastatin-induced HO-1 on cultured Neuro 2A and C6 cells exposed to lipopolysaccharide (LPS). Simvastatin 49-60 heme oxygenase 1 Mus musculus 69-73 18073186-10 2008 This study revealed that simvastatin-induced HO-1 led to increased NF-kappaB activation and superoxides production in the neuronal cells when exposed to LPS, and iron production may play a role in such a response. Simvastatin 25-36 heme oxygenase 1 Mus musculus 45-49 18073186-10 2008 This study revealed that simvastatin-induced HO-1 led to increased NF-kappaB activation and superoxides production in the neuronal cells when exposed to LPS, and iron production may play a role in such a response. Simvastatin 25-36 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 67-76 18073186-2 2008 However, we had demonstrated that simvastatin-induced HO-1 increased apoptosis of Neuro 2A cells in glucose deprivation, and iron production from HO-1 activity may be responsible for the toxicity. Simvastatin 34-45 heme oxygenase 1 Mus musculus 54-58 18073186-2 2008 However, we had demonstrated that simvastatin-induced HO-1 increased apoptosis of Neuro 2A cells in glucose deprivation, and iron production from HO-1 activity may be responsible for the toxicity. Simvastatin 34-45 heme oxygenase 1 Mus musculus 146-150 17399814-0 2008 Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 116-150 17399814-4 2008 RESULTS: From the inflammatory markers only MCP-1 was decreased significantly (217.4+/-48 versus 177+/-75 pg/ml, p<0.001) after treatment with simvastatin and this reduction was independent of lipid changes. Simvastatin 146-157 C-C motif chemokine ligand 2 Homo sapiens 44-49 17399814-5 2008 CONCLUSION: Simvastatin significantly decreases only MCP-1 levels in hypercholesterolaemic patients suggesting that this molecule is probably a sensitive marker to detect the anti-inflammatory effect of simvastatin in blood. Simvastatin 12-23 C-C motif chemokine ligand 2 Homo sapiens 53-58 17399814-5 2008 CONCLUSION: Simvastatin significantly decreases only MCP-1 levels in hypercholesterolaemic patients suggesting that this molecule is probably a sensitive marker to detect the anti-inflammatory effect of simvastatin in blood. Simvastatin 203-214 C-C motif chemokine ligand 2 Homo sapiens 53-58 18036510-1 2008 We recently found that simvastatin can modulate the nuclear factor-kappaB (NF-kappaB) activation pathway, but whether other statins have similar effects to those of simvastatin is unknown. Simvastatin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 75-84 18036510-5 2008 Simvastatin suppressed the NF-kappaB activation and potentiated the apoptosis induced by doxorubicin, paclitaxel, and 5-fluorouracil. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 27-36 18365690-0 2008 Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Simvastatin 21-32 tumor necrosis factor Homo sapiens 40-49 17350631-4 2008 We also investigated the effect of simvastatin treatment on Lp-PLA(2) and lyso-PC content in 26 hypercholesterolemic patients with type 2 diabetes mellitus. Simvastatin 35-46 phospholipase A2 group VII Homo sapiens 60-69 18365690-0 2008 Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Simvastatin 21-32 angiotensinogen Homo sapiens 55-69 17350631-8 2008 Simvastatin treatment reduced serum Lp-PLA(2) and lyso-PC content in LDL. Simvastatin 0-11 phospholipase A2 group VII Homo sapiens 36-45 18365690-4 2008 Furthermore, exogenously applied mevalonate or geranylgeranylpyrophosphate in combination with simvastatin completely prevented the inhibitory effects of simvastatin on ROS generation and monocyte-endothelial cell adhesion by TNFalpha and Ang II. Simvastatin 95-106 tumor necrosis factor Homo sapiens 226-234 18365690-2 2008 Simvastatin, a HMG-CoA reductase inhibitor, suppressed both tumor necrosis factor (TNF)-alpha- and angiotensin (Ang) II-induced monocyte adhesion to endothelial cells (an initial step in vascular inflammation) and reactive oxygen species (ROS) production. Simvastatin 0-11 tumor necrosis factor Homo sapiens 60-93 18365690-4 2008 Furthermore, exogenously applied mevalonate or geranylgeranylpyrophosphate in combination with simvastatin completely prevented the inhibitory effects of simvastatin on ROS generation and monocyte-endothelial cell adhesion by TNFalpha and Ang II. Simvastatin 154-165 tumor necrosis factor Homo sapiens 226-234 18365690-5 2008 These results suggest that monocyte adhesion to endothelial cells induced by TNF-alpha or Ang II is mediated via the geranylgeranyl isoprenoid-dependent generation of ROS, and that this is inhibited by simvastatin. Simvastatin 202-213 tumor necrosis factor Homo sapiens 77-86 18037374-0 2008 Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 156-160 18226044-13 2008 Simvastatin or pravastatin significantly reduced HCY-induced VCAM-1 expression and endothelial adhesiveness to MNCs from CAD patients. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 61-67 18037374-7 2008 By FACS analysis of freshly isolated PBMNCs, KDR (+) cells increased after simvastatin treatment while there were no differences in CD34, AC133, and VE-cadherin. Simvastatin 75-86 kinase insert domain receptor Homo sapiens 45-48 18037374-10 2008 Simvastatin-co-cultured PBMNCs showed significantly increased KDR (+) cells, in contrast to CD34, CD31, and VE-Cadherin (+) cells. Simvastatin 0-11 kinase insert domain receptor Homo sapiens 62-65 18037374-11 2008 In response to simvastatin, IL-8 was mainly increased in monocyte culture supernatants while VEGF increased in smooth muscle cell culture supernatants. Simvastatin 15-26 C-X-C motif chemokine ligand 8 Homo sapiens 28-32 18037374-11 2008 In response to simvastatin, IL-8 was mainly increased in monocyte culture supernatants while VEGF increased in smooth muscle cell culture supernatants. Simvastatin 15-26 vascular endothelial growth factor A Homo sapiens 93-97 18037374-14 2008 CONCLUSION: Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in patients with hypercholesterolemia and increases pro-angiogenic cytokine IL-8 secretion from monocytes. Simvastatin 12-23 C-X-C motif chemokine ligand 8 Homo sapiens 175-179 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 interleukin 6 Homo sapiens 133-146 18270459-0 2008 HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 18270459-7 2008 RESULTS: Simvastatin treatment significantly increased plasma levels of ApoA-I compared to the other three groups. Simvastatin 9-20 apolipoprotein A1 Homo sapiens 72-78 18270459-8 2008 Simvastatin treatment improved the expression of mRNA for LXRalpha, ABCA1, and ApoA-I compared with DMHL or control groups. Simvastatin 0-11 nuclear receptor subfamily 1 group H member 3 Homo sapiens 58-66 18270459-8 2008 Simvastatin treatment improved the expression of mRNA for LXRalpha, ABCA1, and ApoA-I compared with DMHL or control groups. Simvastatin 0-11 ATP binding cassette subfamily A member 1 Homo sapiens 68-73 18270459-8 2008 Simvastatin treatment improved the expression of mRNA for LXRalpha, ABCA1, and ApoA-I compared with DMHL or control groups. Simvastatin 0-11 apolipoprotein A1 Homo sapiens 79-85 18248300-5 2008 Combination treatment with myriocin and IFN or myriocin and simvastatin attenuated HCV RNA replication synergistically in Huh7/Rep-Feo cells. Simvastatin 60-71 MIR7-3 host gene Homo sapiens 122-126 21291710-0 2008 Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. Simvastatin 12-23 component of oligomeric golgi complex 2 Homo sapiens 49-54 21291710-2 2008 OBJECTIVE: To evaluate the efficacy of simvastatin (S) in achieving LDL-C levels <70 mg/dL in patients with type 2 diabetes mellitus (DM). Simvastatin 39-50 component of oligomeric golgi complex 2 Homo sapiens 68-73 21291712-0 2008 Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. Simvastatin 20-31 component of oligomeric golgi complex 2 Homo sapiens 70-75 18260796-0 2008 Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 37-41 18260796-0 2008 Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Simvastatin 0-11 brain-derived neurotrophic factor Rattus norvegicus 46-50 18260796-0 2008 Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 75-78 18260796-1 2008 This study was undertaken to evaluate the effect of simvastatin, a cholesterol-lowering agent, on the Akt-mediated signaling pathway and neurogenesis in the dentate gyrus (DG) of the hippocampus in rats after traumatic brain injury (TBI). Simvastatin 52-63 AKT serine/threonine kinase 1 Rattus norvegicus 102-105 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 AKT serine/threonine kinase 1 Rattus norvegicus 72-75 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 thymoma viral proto-oncogene 1 Mus musculus 115-118 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 glycogen synthase kinase 3 beta Mus musculus 121-151 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 glycogen synthase kinase 3 beta Mus musculus 153-162 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 interleukin 6 Homo sapiens 148-152 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 brain derived neurotrophic factor Mus musculus 243-247 18260796-11 2008 Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3beta (GSK-3beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. Simvastatin 19-30 vascular endothelial growth factor A Mus musculus 252-256 18260796-12 2008 These data suggest that the neurorestorative effect of simvastatin may be mediated through activation of the Akt-mediated signaling pathway, subsequently upregulating expression of growth factors and inducing neurogenesis in the DG of the hippocampus, thereby leading to restoration of cognitive function after TBI in rats. Simvastatin 55-66 AKT serine/threonine kinase 1 Rattus norvegicus 109-112 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 C-X-C motif chemokine ligand 8 Homo sapiens 158-162 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 tumor necrosis factor Homo sapiens 201-228 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 tumor necrosis factor Homo sapiens 230-239 18203325-8 2008 The apoptosis induced by simvastatin was caspase-3- and caspase-9-dependent. Simvastatin 25-36 caspase 3 Homo sapiens 41-65 18203325-11 2008 CONCLUSION: These data, together with our previous report, suggest that low (pharmacological range) and high concentrations of simvastatin affect FLS differently: (1) at a low concentration, it inhibits IL-6 and IL-8 production and the cell proliferation of FLS induced by TNF-alpha (2) at high concentrations, it induces apoptosis in FLS. Simvastatin 127-138 interleukin 6 Homo sapiens 203-207 18203325-11 2008 CONCLUSION: These data, together with our previous report, suggest that low (pharmacological range) and high concentrations of simvastatin affect FLS differently: (1) at a low concentration, it inhibits IL-6 and IL-8 production and the cell proliferation of FLS induced by TNF-alpha (2) at high concentrations, it induces apoptosis in FLS. Simvastatin 127-138 C-X-C motif chemokine ligand 8 Homo sapiens 212-216 18203325-11 2008 CONCLUSION: These data, together with our previous report, suggest that low (pharmacological range) and high concentrations of simvastatin affect FLS differently: (1) at a low concentration, it inhibits IL-6 and IL-8 production and the cell proliferation of FLS induced by TNF-alpha (2) at high concentrations, it induces apoptosis in FLS. Simvastatin 127-138 tumor necrosis factor Homo sapiens 273-282 18326912-6 2008 The IMT and MMP-9 in the simvastatin treatment group and the control group were significantly higher than those in the normal control group (all P<0.05). Simvastatin 25-36 matrix metallopeptidase 9 Homo sapiens 12-17 18316203-0 2008 Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 21-25 18316203-7 2008 Simvastatin administration in diabetic mice increased VEGF mRNA (simvastatin=4.8+/-0.6n-fold/beta-actin; vehicle=2.3+/-0.4n-fold/beta-actin) and protein expression (simvastatin=5+/-0.7 integrated intensity; vehicle=2.2+/-0.3 integrated intensity) and enhanced nitric oxide wound content at day 6. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 54-58 18316203-7 2008 Simvastatin administration in diabetic mice increased VEGF mRNA (simvastatin=4.8+/-0.6n-fold/beta-actin; vehicle=2.3+/-0.4n-fold/beta-actin) and protein expression (simvastatin=5+/-0.7 integrated intensity; vehicle=2.2+/-0.3 integrated intensity) and enhanced nitric oxide wound content at day 6. Simvastatin 0-11 actin, beta Mus musculus 93-103 18316203-7 2008 Simvastatin administration in diabetic mice increased VEGF mRNA (simvastatin=4.8+/-0.6n-fold/beta-actin; vehicle=2.3+/-0.4n-fold/beta-actin) and protein expression (simvastatin=5+/-0.7 integrated intensity; vehicle=2.2+/-0.3 integrated intensity) and enhanced nitric oxide wound content at day 6. Simvastatin 0-11 actin, beta Mus musculus 129-139 18316203-7 2008 Simvastatin administration in diabetic mice increased VEGF mRNA (simvastatin=4.8+/-0.6n-fold/beta-actin; vehicle=2.3+/-0.4n-fold/beta-actin) and protein expression (simvastatin=5+/-0.7 integrated intensity; vehicle=2.2+/-0.3 integrated intensity) and enhanced nitric oxide wound content at day 6. Simvastatin 65-76 vascular endothelial growth factor A Mus musculus 54-58 18316203-11 2008 Passive immunization with anti-VEGF antibody (10 microg/mouse) completely abrogated the beneficial effects of simvastatin on healing in diabetic mice. Simvastatin 110-121 vascular endothelial growth factor A Mus musculus 31-35 18326912-8 2008 Eight weeks after the simvastatin treatment, the serum MMP-9 levels decreased significantly(P<0.05). Simvastatin 22-33 matrix metallopeptidase 9 Homo sapiens 55-60 18326912-10 2008 The anti-atherosclerosis effect of simvastatin may partly attribute to its ability to lower the serum MMP-9. Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 102-107 18260005-4 2008 We investigated the effects of catalase treatment on the endothelium-dependent dilation of these vessels to simvastatin and acetylcholine (ACh). Simvastatin 108-119 catalase Rattus norvegicus 31-39 18260005-6 2008 RESULTS: Responses to simvastatin and ACh were attenuated by catalase in juvenile, but not weanling, arterioles. Simvastatin 22-33 catalase Rattus norvegicus 61-69 19388353-0 2008 Simvastatin attenuates cerebral vasospasm and improves outcomes by upregulation of PI3K/Akt pathway in a rat model of subarachnoid hemorrhage. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 88-91 18683797-6 2008 RESULTS: Simvastatin treatment for 4 weeks significantly improved FMD and reduced low density LDL-C and total TC levels. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 94-99 18172037-3 2008 METHODS AND RESULTS: In cultured atrial myocytes and fibroblasts, Ang II induced tyrosine phosphorylation of STAT3 through a Rac1-dependent mechanism, which was inhibited by dominant-negative Rac1, losartan, and simvastatin. Simvastatin 212-223 angiotensinogen Homo sapiens 66-72 18172037-3 2008 METHODS AND RESULTS: In cultured atrial myocytes and fibroblasts, Ang II induced tyrosine phosphorylation of STAT3 through a Rac1-dependent mechanism, which was inhibited by dominant-negative Rac1, losartan, and simvastatin. Simvastatin 212-223 signal transducer and activator of transcription 3 Homo sapiens 109-114 18172037-3 2008 METHODS AND RESULTS: In cultured atrial myocytes and fibroblasts, Ang II induced tyrosine phosphorylation of STAT3 through a Rac1-dependent mechanism, which was inhibited by dominant-negative Rac1, losartan, and simvastatin. Simvastatin 212-223 Rac family small GTPase 1 Homo sapiens 125-129 18172037-3 2008 METHODS AND RESULTS: In cultured atrial myocytes and fibroblasts, Ang II induced tyrosine phosphorylation of STAT3 through a Rac1-dependent mechanism, which was inhibited by dominant-negative Rac1, losartan, and simvastatin. Simvastatin 212-223 Rac family small GTPase 1 Homo sapiens 192-196 18172037-6 2008 Rats infused long term with Ang II exhibited higher levels of activated Rac1, phospho-STAT3, collagen synthesis, and atrial fibrosis in the atria, all of which were attenuated by oral losartan and simvastatin. Simvastatin 197-208 angiotensinogen Rattus norvegicus 28-34 18036617-9 2008 Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion. Simvastatin 0-11 interleukin 6 Mus musculus 61-74 18036617-9 2008 Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion. Simvastatin 0-11 interleukin 6 Mus musculus 76-80 19388353-3 2008 The present study investigates whether simvastatin attenuates cerebral vasospasm after subarachnoid hemorrhage (SAH) via upregulation of the PI3K/Akt pathway. Simvastatin 39-50 AKT serine/threonine kinase 1 Rattus norvegicus 146-149 19388353-12 2008 CONCLUSIONS: The beneficial effects of high dose simvastatin in ameliorating cerebral vasospasm are likely mediated by upregulation of the PI3K/Akt pathway. Simvastatin 49-60 AKT serine/threonine kinase 1 Rattus norvegicus 144-147 18004065-0 2008 Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Simvastatin 0-11 Wnt family member 4 Rattus norvegicus 89-92 18004065-2 2008 We examined the role of simvastatin (SIM) in modulation of Wnt/beta-catenin signaling in the apoptosis of high glucose (HG)-stressed mesangial cells in vitro and in vivo. Simvastatin 24-35 Wnt family member 4 Rattus norvegicus 59-62 18004065-2 2008 We examined the role of simvastatin (SIM) in modulation of Wnt/beta-catenin signaling in the apoptosis of high glucose (HG)-stressed mesangial cells in vitro and in vivo. Simvastatin 24-35 catenin beta 1 Rattus norvegicus 63-75 17452038-8 2008 CTGF upregulation by non-uniform shear stress was RhoA-dependent, because it was almost completely inhibited in cells transfected with dominant negative RhoA-N19, and when cells were treated with 1 micromol/L simvastatin during flow. Simvastatin 209-220 cellular communication network factor 2 Homo sapiens 0-4 17452038-8 2008 CTGF upregulation by non-uniform shear stress was RhoA-dependent, because it was almost completely inhibited in cells transfected with dominant negative RhoA-N19, and when cells were treated with 1 micromol/L simvastatin during flow. Simvastatin 209-220 ras homolog family member A Homo sapiens 50-54 18057884-2 2008 We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 30-41 C-reactive protein Homo sapiens 52-55 18057884-0 2008 Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 0-11 C-reactive protein Homo sapiens 21-39 18199714-6 2008 Both lovastatin and simvastatin induced activation of caspase-8, caspase-3, and, to a lesser extent, caspase-9. Simvastatin 20-31 caspase 8 Homo sapiens 54-63 18199714-6 2008 Both lovastatin and simvastatin induced activation of caspase-8, caspase-3, and, to a lesser extent, caspase-9. Simvastatin 20-31 caspase 3 Homo sapiens 65-74 18199714-6 2008 Both lovastatin and simvastatin induced activation of caspase-8, caspase-3, and, to a lesser extent, caspase-9. Simvastatin 20-31 caspase 9 Homo sapiens 101-110 18057884-5 2008 RESULTS: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-kappaB activation in human umbilical vein endothelial cells. Simvastatin 28-39 C-reactive protein Homo sapiens 69-72 18199714-8 2008 Furthermore, lovastatin and simvastatin suppressed RhoA activation and c-JUN expression, but not cyclooxygenase-2 expression. Simvastatin 28-39 ras homolog family member A Homo sapiens 51-55 18199714-8 2008 Furthermore, lovastatin and simvastatin suppressed RhoA activation and c-JUN expression, but not cyclooxygenase-2 expression. Simvastatin 28-39 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 71-76 18057884-5 2008 RESULTS: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-kappaB activation in human umbilical vein endothelial cells. Simvastatin 28-39 Fc gamma receptor IIa Homo sapiens 81-85 18057884-6 2008 Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. Simvastatin 0-11 C-reactive protein Homo sapiens 27-30 18057884-6 2008 Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. Simvastatin 0-11 vascular cell adhesion molecule 1 Homo sapiens 39-72 18057884-10 2008 CONCLUSIONS: CRP-induced CD32 expression and NF-kappaB activation were attenuated by simvastatin. Simvastatin 85-96 C-reactive protein Homo sapiens 13-16 18057884-10 2008 CONCLUSIONS: CRP-induced CD32 expression and NF-kappaB activation were attenuated by simvastatin. Simvastatin 85-96 Fc gamma receptor IIa Homo sapiens 25-29 18824851-7 2008 Fifteen downregulated, 9 upregulated cell cycle-related genes and decreased PCNA protein were observed in the presence of simvastatin. Simvastatin 122-133 proliferating cell nuclear antigen Homo sapiens 76-80 18783297-9 2008 Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies. Simvastatin 284-295 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 18558792-0 2008 Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Simvastatin 19-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 18302447-4 2008 OBJECTIVE: To evaluate the incidence and clinical consequences of the use of lovastatin or simvastatin with concomitant CYP3A4 inhibitors and inducers, and with fibrates. Simvastatin 91-102 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 18302447-14 2008 CONCLUSION: Although the pharmacokinetic interactions between lovastatin or simvastatin and CYP3A4 inhibitors and inducers are substantial, their clinical relevance seems to be limited, at least with lower statin doses. Simvastatin 76-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 18558792-2 2008 OBJECTIVE: To detect co-prescriptions of CYP3A4 inhibitors with simvastatin or atorvastatin in community pharmacies and assess the risk-preventive actions taken by the prescribing physicians who were alerted about the co-prescription by the pharmacist. Simvastatin 64-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-47 18558792-7 2008 RESULTS: In total, 245 co-prescriptions of CYP3A4 inhibitors with simvastatin (134 events) or atorvastatin (111) were detected. Simvastatin 66-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-49 18558792-14 2008 CONCLUSION: Nine out of ten physicians changed prescriptions or monitored potential adverse effects when informed by community pharmacists about the risk associated with co-prescription of CYP3A4 inhibitors with simvastatin or atorvastatin. Simvastatin 212-223 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 189-195 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 13-24 tumor necrosis factor Mus musculus 52-61 18484192-2 2008 Our recent study demonstrated that simvastatin exerts an independent immunomodulatory effect on the human monocytes and CD4+ cells. Simvastatin 35-46 CD4 molecule Homo sapiens 120-123 18484192-3 2008 In addition to the statin-mediated effect on the monocyte cytokine production, which regulates Th17 cell differentiation, simvastatin directly inhibits IL-17 production in CD4+ cells, which may collectively inhibit the autoimmune response in multiple sclerosis (MS), a central nervous system (CNS) inflammatory demyelinating disease. Simvastatin 122-133 interleukin 17A Homo sapiens 152-157 18484192-3 2008 In addition to the statin-mediated effect on the monocyte cytokine production, which regulates Th17 cell differentiation, simvastatin directly inhibits IL-17 production in CD4+ cells, which may collectively inhibit the autoimmune response in multiple sclerosis (MS), a central nervous system (CNS) inflammatory demyelinating disease. Simvastatin 122-133 CD4 molecule Homo sapiens 172-175 18504409-0 2008 HMG-CoA reductase inhibitor simvastatin inhibits proinflammatory cytokine production from murine mast cells. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 0-17 18504409-6 2008 The effect of simvastatin on the expression of tristetraprolin, an RNA-binding protein that promotes decay of TNF-alpha mRNA, was evaluated. Simvastatin 14-25 zinc finger protein 36 Mus musculus 47-62 18504409-7 2008 RESULTS: Incubation of BMMCs with simvastatin resulted in the inhibition of LPS-induced TNF-alpha production at both mRNA and protein levels. Simvastatin 34-45 tumor necrosis factor Mus musculus 88-97 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 13-24 interleukin 6 Mus musculus 66-70 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 225-236 tumor necrosis factor Mus musculus 52-61 18504409-10 2008 CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin. Simvastatin 225-236 interleukin 6 Mus musculus 66-70 19125197-8 2008 (4) Simvastatin, pravastatin, and cerivastatin markedly enhanced transcriptional activity in 293T cells cotransfected with acyl-coenzyme A oxidase promoter and PPARalpha/RXRalpha expression vectors. Simvastatin 4-15 peroxisome proliferator activated receptor alpha Homo sapiens 160-169 18504409-8 2008 Simvastatin also inhibited IL-6 production from LPS-stimulated BMMCs. Simvastatin 0-11 interleukin 6 Mus musculus 27-31 18792797-0 2008 Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 73-76 18792797-5 2008 These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the simvastatin-mediated blockage of myotube formation. Simvastatin 180-191 thymoma viral proto-oncogene 1 Mus musculus 61-64 18792797-5 2008 These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the simvastatin-mediated blockage of myotube formation. Simvastatin 180-191 cell division cycle 42 Mus musculus 69-74 18792797-7 2008 Taken together, we conclude that the differentiation of C2C12 cells into myotubes was blocked by simvastatin through the pathway mediated by Rac, not by Rho. Simvastatin 97-108 thymoma viral proto-oncogene 1 Mus musculus 141-144 20016721-10 2008 In present study, simvastatin, a HMG CoA reductase inhibitor at dose of 2mg/kg BW/day rather increased plasma total cholesterol in rats, inferring that the action mechanism of simvastatin on cholesterol metabolism differ between rat and human. Simvastatin 18-29 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 33-50 20016721-10 2008 In present study, simvastatin, a HMG CoA reductase inhibitor at dose of 2mg/kg BW/day rather increased plasma total cholesterol in rats, inferring that the action mechanism of simvastatin on cholesterol metabolism differ between rat and human. Simvastatin 176-187 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 33-50 18320471-15 2008 Furthermore, Fasudil, a Rho-Kinase inhibitor, and Simvastatin, a HMG-CoA reductase inhibitor, led to a significant reduction in mechanical stretch-induced IL-18 expression. Simvastatin 50-61 interleukin 18 Rattus norvegicus 155-160 18470660-0 2008 Simvastatin induces estrogen receptor-alpha (ER-alpha) in murine bone marrow stromal cells. Simvastatin 0-11 estrogen receptor 1 (alpha) Mus musculus 20-43 18470660-0 2008 Simvastatin induces estrogen receptor-alpha (ER-alpha) in murine bone marrow stromal cells. Simvastatin 0-11 estrogen receptor 1 (alpha) Mus musculus 45-53 18470660-3 2008 We previously reported that simvastatin promotes bone morphogenetic protein 2 (BMP-2) expression, induces osteoblastic differentiation, and inhibits adipocytic differentiation in mouse bone marrow stromal cells (BMSCs), and that this occurs, at least in part, via a BMP-2-dependent pathway. Simvastatin 28-39 bone morphogenetic protein 2 Mus musculus 49-77 18470660-3 2008 We previously reported that simvastatin promotes bone morphogenetic protein 2 (BMP-2) expression, induces osteoblastic differentiation, and inhibits adipocytic differentiation in mouse bone marrow stromal cells (BMSCs), and that this occurs, at least in part, via a BMP-2-dependent pathway. Simvastatin 28-39 bone morphogenetic protein 2 Mus musculus 79-84 18470660-3 2008 We previously reported that simvastatin promotes bone morphogenetic protein 2 (BMP-2) expression, induces osteoblastic differentiation, and inhibits adipocytic differentiation in mouse bone marrow stromal cells (BMSCs), and that this occurs, at least in part, via a BMP-2-dependent pathway. Simvastatin 28-39 bone morphogenetic protein 2 Mus musculus 266-271 18470660-7 2008 Interestingly, we found that estrogen receptor-alpha (ER-alpha) protein levels increased after mouse BMSCs were treated with simvastatin for 72 h in a concentration-dependent manner. Simvastatin 125-136 estrogen receptor 1 (alpha) Mus musculus 29-52 18470660-7 2008 Interestingly, we found that estrogen receptor-alpha (ER-alpha) protein levels increased after mouse BMSCs were treated with simvastatin for 72 h in a concentration-dependent manner. Simvastatin 125-136 estrogen receptor 1 (alpha) Mus musculus 54-62 18470660-9 2008 These results suggest that simvastatin-induced in vitro osteogenesis in mouse BMSCs is mediated, at least in part, by induction of ER-alpha and not by BMP-2 alone. Simvastatin 27-38 estrogen receptor 1 (alpha) Mus musculus 131-139 18470660-9 2008 These results suggest that simvastatin-induced in vitro osteogenesis in mouse BMSCs is mediated, at least in part, by induction of ER-alpha and not by BMP-2 alone. Simvastatin 27-38 bone morphogenetic protein 2 Mus musculus 151-156 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 126-144 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 146-149 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 interleukin 6 Homo sapiens 170-174 17928568-0 2008 HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer"s disease patients independently of cholesterol-lowering effects. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 17928568-8 2008 SIM induces a partial blockade of retinoblastoma protein phosphorylation and inhibition of cyclin E/cyclin-dependent kinase (CDK)2 activity associated with increased levels of the CDK inhibitors p21(Cip1) and p27(kip1). Simvastatin 0-3 cyclin dependent kinase 2 Homo sapiens 100-130 17928568-8 2008 SIM induces a partial blockade of retinoblastoma protein phosphorylation and inhibition of cyclin E/cyclin-dependent kinase (CDK)2 activity associated with increased levels of the CDK inhibitors p21(Cip1) and p27(kip1). Simvastatin 0-3 cyclin dependent kinase 2 Homo sapiens 125-128 17928568-8 2008 SIM induces a partial blockade of retinoblastoma protein phosphorylation and inhibition of cyclin E/cyclin-dependent kinase (CDK)2 activity associated with increased levels of the CDK inhibitors p21(Cip1) and p27(kip1). Simvastatin 0-3 cyclin dependent kinase inhibitor 1A Homo sapiens 195-198 17928568-8 2008 SIM induces a partial blockade of retinoblastoma protein phosphorylation and inhibition of cyclin E/cyclin-dependent kinase (CDK)2 activity associated with increased levels of the CDK inhibitors p21(Cip1) and p27(kip1). Simvastatin 0-3 cyclin dependent kinase inhibitor 1A Homo sapiens 199-203 17928568-8 2008 SIM induces a partial blockade of retinoblastoma protein phosphorylation and inhibition of cyclin E/cyclin-dependent kinase (CDK)2 activity associated with increased levels of the CDK inhibitors p21(Cip1) and p27(kip1). Simvastatin 0-3 cyclin dependent kinase inhibitor 1B Homo sapiens 209-217 17928568-9 2008 These effects of SIM on AD lymphoblasts are dependent on inhibition of the proteasome-mediated degradation of p21 and p27 proteins. Simvastatin 17-20 cyclin dependent kinase inhibitor 1A Homo sapiens 110-113 17928568-9 2008 These effects of SIM on AD lymphoblasts are dependent on inhibition of the proteasome-mediated degradation of p21 and p27 proteins. Simvastatin 17-20 dynactin subunit 6 Homo sapiens 118-121 19125197-8 2008 (4) Simvastatin, pravastatin, and cerivastatin markedly enhanced transcriptional activity in 293T cells cotransfected with acyl-coenzyme A oxidase promoter and PPARalpha/RXRalpha expression vectors. Simvastatin 4-15 retinoid X receptor alpha Homo sapiens 170-178 18569938-0 2008 Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 40-44 18569938-2 2008 We examined the role of simvastatin in modulating Ras signaling and the expression of VEGF in mesangial cells stressed with high doses of glucose in vitro and in vivo. Simvastatin 24-35 vascular endothelial growth factor A Rattus norvegicus 86-90 18569938-10 2008 Exogenous simvastatin and manumycin A treatment alleviated urinary albumin secretion and attenuated Ras activation and VEGF protein expression in the kidneys of diabetic rats. Simvastatin 10-21 vascular endothelial growth factor A Rattus norvegicus 119-123 18569938-6 2008 The pretreatment with 10 microM simvastatin and inhibition of Ras activity by manumycin A significantly reversed high glucose promotion of VEGF mRNA expression. Simvastatin 32-43 vascular endothelial growth factor A Rattus norvegicus 139-143 18569938-12 2008 By inhibiting Ras activation, simvastatin modulates the high glucose-induced VEGF-mediated signaling pathway in vitro and in vivo. Simvastatin 30-41 vascular endothelial growth factor A Rattus norvegicus 77-81 18390205-0 2008 [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Simvastatin 11-22 endothelin 1 Homo sapiens 26-38 18390205-6 2008 The decreases of ET-1 mRNA and ET-1 expression became more obvious when expression were interfered by 5 micromol/Land 10 micromol/L simvastatin (P < 0.01). Simvastatin 132-143 endothelin 1 Homo sapiens 17-21 18390205-6 2008 The decreases of ET-1 mRNA and ET-1 expression became more obvious when expression were interfered by 5 micromol/Land 10 micromol/L simvastatin (P < 0.01). Simvastatin 132-143 endothelin 1 Homo sapiens 31-35 18390205-7 2008 (2) ET-1 mRNA and ET-1 expression decreased at 12 h after the endothelial cells were incubated with 10 micromol/L simvastatin, which became more fewer at 24 h and reached the minimum expression at 48 h (P < 0.01). Simvastatin 114-125 endothelin 1 Homo sapiens 4-8 18390205-7 2008 (2) ET-1 mRNA and ET-1 expression decreased at 12 h after the endothelial cells were incubated with 10 micromol/L simvastatin, which became more fewer at 24 h and reached the minimum expression at 48 h (P < 0.01). Simvastatin 114-125 endothelin 1 Homo sapiens 18-22 18390205-8 2008 (3) The inhibition effect of simvastatin on ET-1 mRNA and ET-1 expression of endothelial cells could be prevented by mevalonate with concentration of 100 micromol/L. Simvastatin 29-40 endothelin 1 Homo sapiens 44-48 18390205-8 2008 (3) The inhibition effect of simvastatin on ET-1 mRNA and ET-1 expression of endothelial cells could be prevented by mevalonate with concentration of 100 micromol/L. Simvastatin 29-40 endothelin 1 Homo sapiens 58-62 18390205-9 2008 CONCLUSION: Simvastatin can inhibit ET-1 expression in endothelial cell cultured hypoxically. Simvastatin 12-23 endothelin 1 Homo sapiens 36-40 17928392-0 2008 Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation. Simvastatin 0-11 heme oxygenase 1 Mus musculus 20-36 18031796-0 2008 Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Simvastatin 0-11 coagulation factor X Homo sapiens 158-161 17928392-3 2008 This study was designed to investigate the effect of simvastatin-induced HO-1 on Neuro 2A cells in response to glucose deprivation. Simvastatin 53-64 heme oxygenase 1 Mus musculus 73-77 17928392-4 2008 We demonstrated that simvastatin induced a dose- and time-dependent upregulation of HO-1 protein expression in Neuro 2A cells. Simvastatin 21-32 heme oxygenase 1 Mus musculus 84-88 17928392-5 2008 The induction of HO-1 after simvastatin treatment was mediated by nuclear factor erythroid 2-related factor 2 (Nrf2), which was expressed by Western blots of nuclear fractions and retarded complex formation in the electrophoretic mobility shift assay reaction. Simvastatin 28-39 heme oxygenase 1 Mus musculus 17-21 17928392-5 2008 The induction of HO-1 after simvastatin treatment was mediated by nuclear factor erythroid 2-related factor 2 (Nrf2), which was expressed by Western blots of nuclear fractions and retarded complex formation in the electrophoretic mobility shift assay reaction. Simvastatin 28-39 nuclear factor, erythroid derived 2, like 2 Mus musculus 66-109 17928392-5 2008 The induction of HO-1 after simvastatin treatment was mediated by nuclear factor erythroid 2-related factor 2 (Nrf2), which was expressed by Western blots of nuclear fractions and retarded complex formation in the electrophoretic mobility shift assay reaction. Simvastatin 28-39 nuclear factor, erythroid derived 2, like 2 Mus musculus 111-115 17928392-6 2008 In addition, simvastatin activated the extracellular signal-regulated kinase and p38, but not the phosphorylation of c-Jun N-terminal kinase and Akt. Simvastatin 13-24 mitogen-activated protein kinase 14 Mus musculus 81-84 17928392-7 2008 Glucose deprivation in the cells pretreated with simvastatin induced more HO-1 expression, and the transcript could be decreased by small interfering RNA for Nrf2. Simvastatin 49-60 heme oxygenase 1 Mus musculus 74-78 17928392-7 2008 Glucose deprivation in the cells pretreated with simvastatin induced more HO-1 expression, and the transcript could be decreased by small interfering RNA for Nrf2. Simvastatin 49-60 nuclear factor, erythroid derived 2, like 2 Mus musculus 158-162 17928392-10 2008 Addition of the iron chelator desferrioxamine also resulted in blockade of the aggravated apoptosis, which implies that iron production from HO-1 activity may play an important role in the increased apoptosis in response to glucose deprivation in neuronal cells pretreated with simvastatin. Simvastatin 278-289 heme oxygenase 1 Mus musculus 141-145 18380969-1 2008 OBJECTIVE: To investigate the effect of systematic administration of simvastatin on the bone morphogenetic protein-2 (BMP-2) expression in the periodontal tissue after rat tooth movement and on the relapse of tooth movement. Simvastatin 69-80 bone morphogenetic protein 2 Rattus norvegicus 88-116 18380969-0 2008 [Effect of simvastatin on bone morphogenetic protein-2 expression in the periodontal tissue after rat tooth movement]. Simvastatin 11-22 bone morphogenetic protein 2 Rattus norvegicus 26-54 18380969-1 2008 OBJECTIVE: To investigate the effect of systematic administration of simvastatin on the bone morphogenetic protein-2 (BMP-2) expression in the periodontal tissue after rat tooth movement and on the relapse of tooth movement. Simvastatin 69-80 bone morphogenetic protein 2 Rattus norvegicus 118-123 18380969-13 2008 The possible mechanism for this may be that simvastatin functions by increasing the expression of BMP-2 in the periodontal tissue, accelerating the osteoblast activity and promoting bone formation. Simvastatin 44-55 bone morphogenetic protein 2 Rattus norvegicus 98-103 18036927-8 2007 The levels of interleukin-6, tumor necrosis factor-alpha, and monocyte chemotactic protein-1 in serum, bronchoalveolar lavage fluid, and lung tissues increased in CPB groups, whereas pretreatment with simvastatins reduced these inflammatory marks in a dose-dependent manner (p < 0.01, versus control group). Simvastatin 201-213 interleukin 6 Rattus norvegicus 14-56 18036927-8 2007 The levels of interleukin-6, tumor necrosis factor-alpha, and monocyte chemotactic protein-1 in serum, bronchoalveolar lavage fluid, and lung tissues increased in CPB groups, whereas pretreatment with simvastatins reduced these inflammatory marks in a dose-dependent manner (p < 0.01, versus control group). Simvastatin 201-213 C-C motif chemokine ligand 2 Rattus norvegicus 62-92 17804683-0 2007 Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Simvastatin 0-11 TNF receptor superfamily member 11b Homo sapiens 27-42 17109866-3 2007 Simvastatin effectively lowered plasma LDL-C and apoB levels, but did not change plasma HDL levels and HDL-related biomarkers, except for a small, significant increase in the capacity of plasma to promote SR-BI mediated cholesterol efflux. Simvastatin 0-11 apolipoprotein B Homo sapiens 49-53 18023360-0 2007 Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Simvastatin 79-90 C-reactive protein Homo sapiens 10-28 18023360-5 2007 PURPOSE: The aim of the present study, therefore, was to assess the effects of both CRP on resistin expression and simvastatin on CRP-induced of resistin expression in cultured human PBMC. Simvastatin 115-126 C-reactive protein Homo sapiens 130-133 18023360-12 2007 Co-incubation with simvastatin significantly inhibited CRP-induced up-regulation of mRNA and protein expression of resistin. Simvastatin 19-30 C-reactive protein Homo sapiens 55-58 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 56-59 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 18091590-5 2007 In rat aortic vascular smooth muscle cells (VSMC), simvastatin (0.3 to 3 microM for 24 hours) resulted in concentration-dependent inhibition of AngII-stimulated phosphorylation of extracellular-signal regulated kinase 1/2 ERK1/2 (-67 +/- 5% with 3 microM; P < 0.001) and decreased AT1-R mRNA (-34 +/- 8% with 3 microM; P < 0.01) and AT1-R protein (-32 +/- 6% with 3 microM; P < 0.01). Simvastatin 51-62 angiotensinogen Rattus norvegicus 144-149 18091590-6 2007 Removal of simvastatin led to a rebound increase in mRNA-AT1-R (+39 +/- 2%, P < 0.01), AT1-R protein (+46 +/- 2%; P < 0.01), and AngII-mediated phosphorylation of ERK1/2 (+36 +/- 3%; P < 0.01). Simvastatin 11-22 angiotensinogen Rattus norvegicus 135-140 18220561-3 2007 Linear relationships were found between midazolam and four CYP3A substrates: simvastatin, buspirone, triazolam and eplerenone. Simvastatin 77-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-64 18091590-6 2007 Removal of simvastatin led to a rebound increase in mRNA-AT1-R (+39 +/- 2%, P < 0.01), AT1-R protein (+46 +/- 2%; P < 0.01), and AngII-mediated phosphorylation of ERK1/2 (+36 +/- 3%; P < 0.01). Simvastatin 11-22 mitogen activated protein kinase 3 Rattus norvegicus 169-175 18091590-5 2007 In rat aortic vascular smooth muscle cells (VSMC), simvastatin (0.3 to 3 microM for 24 hours) resulted in concentration-dependent inhibition of AngII-stimulated phosphorylation of extracellular-signal regulated kinase 1/2 ERK1/2 (-67 +/- 5% with 3 microM; P < 0.001) and decreased AT1-R mRNA (-34 +/- 8% with 3 microM; P < 0.01) and AT1-R protein (-32 +/- 6% with 3 microM; P < 0.01). Simvastatin 51-62 mitogen activated protein kinase 3 Rattus norvegicus 222-228 18091590-5 2007 In rat aortic vascular smooth muscle cells (VSMC), simvastatin (0.3 to 3 microM for 24 hours) resulted in concentration-dependent inhibition of AngII-stimulated phosphorylation of extracellular-signal regulated kinase 1/2 ERK1/2 (-67 +/- 5% with 3 microM; P < 0.001) and decreased AT1-R mRNA (-34 +/- 8% with 3 microM; P < 0.01) and AT1-R protein (-32 +/- 6% with 3 microM; P < 0.01). Simvastatin 51-62 angiotensin II receptor, type 1a Rattus norvegicus 284-289 18091590-5 2007 In rat aortic vascular smooth muscle cells (VSMC), simvastatin (0.3 to 3 microM for 24 hours) resulted in concentration-dependent inhibition of AngII-stimulated phosphorylation of extracellular-signal regulated kinase 1/2 ERK1/2 (-67 +/- 5% with 3 microM; P < 0.001) and decreased AT1-R mRNA (-34 +/- 8% with 3 microM; P < 0.01) and AT1-R protein (-32 +/- 6% with 3 microM; P < 0.01). Simvastatin 51-62 angiotensin II receptor, type 1a Rattus norvegicus 339-344 18091590-6 2007 Removal of simvastatin led to a rebound increase in mRNA-AT1-R (+39 +/- 2%, P < 0.01), AT1-R protein (+46 +/- 2%; P < 0.01), and AngII-mediated phosphorylation of ERK1/2 (+36 +/- 3%; P < 0.01). Simvastatin 11-22 angiotensin II receptor, type 1a Rattus norvegicus 57-62 18091590-6 2007 Removal of simvastatin led to a rebound increase in mRNA-AT1-R (+39 +/- 2%, P < 0.01), AT1-R protein (+46 +/- 2%; P < 0.01), and AngII-mediated phosphorylation of ERK1/2 (+36 +/- 3%; P < 0.01). Simvastatin 11-22 angiotensin II receptor, type 1a Rattus norvegicus 90-95 17196684-1 2007 BACKGROUND: We hypothesize that high-sensitivity C-reactive protein (hs-CRP) levels and cell adhesion molecules (CAMs) significantly reflect serial changes in patients with atherosclerotic-risk factors undergoing simvastatin therapy. Simvastatin 213-224 C-reactive protein Homo sapiens 72-75 17870053-0 2007 Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients. Simvastatin 96-107 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-60 18028750-8 2007 In addition, following simvastatin treatment, some of the apoptotic and stemness-related genes showed differential expression for the BG01V, NTERA-2, TOV-112D and HT-29 cells in comparison to HES3. Simvastatin 23-34 hes family bHLH transcription factor 3 Homo sapiens 192-196 18036447-3 2007 METHODS: Monocyte chemoattractant protein-1 was measured at baseline (n = 4,244), 4 months (n = 3,603), and 12 months (n = 2,950), and correlated with clinical events in the Z phase of the A to Z (Aggrastat to Zocor) trial, which compared early intensive versus delayed and less intensive statin therapy after ACS. Simvastatin 210-215 C-C motif chemokine ligand 2 Homo sapiens 9-43 17982704-5 2007 All statins tested (RSV, pravastatin [PRA], cerivastatin [CER], and simvastatin [SIM]) caused accumulation of unprenylated Rap-1A in rabbit osteoclast-like cells and J774 macrophages in vitro and inhibited osteoclast-mediated resorption. Simvastatin 68-79 ras-related protein Rap-1A Oryctolagus cuniculus 123-129 18045152-7 2007 Simvastatin groups showed significantly smaller amount of lipid deposition and LOX-1 and MCP-1 expression, independent of serum lipid levels. Simvastatin 0-11 oxidized low density lipoprotein receptor 1 Rattus norvegicus 79-84 18045152-7 2007 Simvastatin groups showed significantly smaller amount of lipid deposition and LOX-1 and MCP-1 expression, independent of serum lipid levels. Simvastatin 0-11 C-C motif chemokine ligand 2 Rattus norvegicus 89-94 17868177-4 2007 In this study, we show how sub 2 microm porous particle LC has been coupled to hybrid quadrupole orthogonal TOF mass spectrometer to profile and identify the impurities of the common cholesterol lowering drug simvastatin. Simvastatin 209-220 FEZ family zinc finger 2 Homo sapiens 108-111 18269829-0 2007 [Simvastatin downregulates CD40L induced vascular cell adhesion molecule-1 expression and adhesive function in human umbilical vein endothelial cells]. Simvastatin 1-12 CD40 ligand Homo sapiens 27-32 18269829-0 2007 [Simvastatin downregulates CD40L induced vascular cell adhesion molecule-1 expression and adhesive function in human umbilical vein endothelial cells]. Simvastatin 1-12 vascular cell adhesion molecule 1 Homo sapiens 41-74 18269829-1 2007 OBJECTIVE: To investigate the effects of simvastatin on vascular cell adhesion molecule-1 (VCAM-1) expression and adhesive function in ECV-304 cells treated with CD40L. Simvastatin 41-52 vascular cell adhesion molecule 1 Homo sapiens 56-89 18269829-1 2007 OBJECTIVE: To investigate the effects of simvastatin on vascular cell adhesion molecule-1 (VCAM-1) expression and adhesive function in ECV-304 cells treated with CD40L. Simvastatin 41-52 vascular cell adhesion molecule 1 Homo sapiens 91-97 18269829-1 2007 OBJECTIVE: To investigate the effects of simvastatin on vascular cell adhesion molecule-1 (VCAM-1) expression and adhesive function in ECV-304 cells treated with CD40L. Simvastatin 41-52 CD40 ligand Homo sapiens 162-167 18269829-4 2007 RESULTS: Simvastatin (0 - 10 micromol/L) decreased in a concentration-dependent manner the expression of VCAM-1 induced by CD40L and this effect could be blocked by cotreatment with mevalonic acid. Simvastatin 9-20 vascular cell adhesion molecule 1 Homo sapiens 105-111 18269829-4 2007 RESULTS: Simvastatin (0 - 10 micromol/L) decreased in a concentration-dependent manner the expression of VCAM-1 induced by CD40L and this effect could be blocked by cotreatment with mevalonic acid. Simvastatin 9-20 CD40 ligand Homo sapiens 123-128 18269829-5 2007 Moreover, Simvastatin also significantly decreased adhesion capacity of lymphocytes to endothelial cells induced by CD40L. Simvastatin 10-21 CD40 ligand Homo sapiens 116-121 18269829-6 2007 CONCLUSION: Simvastatin downregulates VCAM-1 expression and adhesive capacity of lymphocytes to endothelial cells induced by CD40L. Simvastatin 12-23 vascular cell adhesion molecule 1 Homo sapiens 38-44 18269829-6 2007 CONCLUSION: Simvastatin downregulates VCAM-1 expression and adhesive capacity of lymphocytes to endothelial cells induced by CD40L. Simvastatin 12-23 CD40 ligand Homo sapiens 125-130 17196684-2 2007 We further hypothesize that the site specificity of CRP on the expression of CAMs, which can be inhibited by simvastatin, is in the cytoplasm of endothelial cells (EC). Simvastatin 109-120 C-reactive protein Homo sapiens 52-55 17196684-9 2007 After simvastatin therapy was withdrawn, the hs-CRP level was once again significantly higher on day 270 than on day 180 (p<0.05), but VCAM-1 did not differ between day 180 and day 270. Simvastatin 6-17 C-reactive protein Homo sapiens 48-51 17196684-10 2007 25 micromol/L simvastatin markedly suppressed the CRP effect on VCAM-1 and intercellular CAM-1 expressions of EC. Simvastatin 14-25 C-reactive protein Homo sapiens 50-53 17196684-10 2007 25 micromol/L simvastatin markedly suppressed the CRP effect on VCAM-1 and intercellular CAM-1 expressions of EC. Simvastatin 14-25 vascular cell adhesion molecule 1 Homo sapiens 64-70 17196684-12 2007 However, pretreatment with simvastatin reduced the intensity of CRP in cytoplasm. Simvastatin 27-38 C-reactive protein Homo sapiens 64-67 17196684-13 2007 CONCLUSIONS: CRP-mediated inflammation is inhibited by simvastatin. Simvastatin 55-66 C-reactive protein Homo sapiens 13-16 17644777-3 2007 In the present study, atorvastatin and simvastatin dose-dependently decreased LPL and EL expression as well as Rho, liver X receptor alpha (LXRalpha), and nuclear factor kappaB (NF-kappaB) activation in THP-1 macrophages. Simvastatin 39-50 lipoprotein lipase Homo sapiens 78-81 17655842-0 2007 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Simvastatin 47-58 fatty acid desaturase 1 Homo sapiens 0-17 17655842-0 2007 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Simvastatin 47-58 sterol regulatory element binding transcription factor 1 Homo sapiens 63-70 17655842-4 2007 The activity of the enzyme, evaluated as product/precursor ratio in the metabolic pathway (starting from [1-(14)C] linoleic acid), increased in treated cells with respect to controls after 24 h, whereas, mRNA levels of the delta5 desaturase increased after 12 h of incubation with simvastatin. Simvastatin 281-292 fatty acid desaturase 1 Homo sapiens 223-240 17931083-1 2007 OBJECTIVE: To examine the effect of the I405V and TaqIB polymorphisms of cholesteryl ester transfer protein (CETP) on the lipid response after simvastatin treatment in 180 hypercholesterolaemic patients. Simvastatin 143-154 cholesteryl ester transfer protein Homo sapiens 73-107 17931083-1 2007 OBJECTIVE: To examine the effect of the I405V and TaqIB polymorphisms of cholesteryl ester transfer protein (CETP) on the lipid response after simvastatin treatment in 180 hypercholesterolaemic patients. Simvastatin 143-154 cholesteryl ester transfer protein Homo sapiens 109-113 17931083-5 2007 CONCLUSIONS: The authors" findings suggest that CETP I405V polymorphism modifies the effect of simvastatin on TG reduction and HDL-C elevation; the carriers of the I allele responded better to treatment. Simvastatin 95-106 cholesteryl ester transfer protein Homo sapiens 48-52 17655842-7 2007 Simvastatin alone increased SREBP-1 levels with respect to controls, starting from 8 h of incubation, whereas PPARalpha and linoleic acid beta-oxidation (a PPARalpha mediated process) were not affected after 48 h of incubation. Simvastatin 0-11 sterol regulatory element binding transcription factor 1 Homo sapiens 28-35 17655842-8 2007 These results taken together suggest that SREBP-1 is involved in the early regulation of delta5 desaturase gene by simvastatin, in THP-1 cells. Simvastatin 115-126 sterol regulatory element binding transcription factor 1 Homo sapiens 42-49 17655842-8 2007 These results taken together suggest that SREBP-1 is involved in the early regulation of delta5 desaturase gene by simvastatin, in THP-1 cells. Simvastatin 115-126 fatty acid desaturase 1 Homo sapiens 89-106 17907956-7 2007 This is indicated by a reported ability of micromolar concentrations of lovastatin and simvastatin to strongly stimulate brain vascular endothelial cells to make this Abeta ejector. Simvastatin 87-98 amyloid beta precursor protein Homo sapiens 167-172 17952841-1 2007 OBJECTIVE: The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial. Simvastatin 84-95 adiponectin, C1Q and collagen domain containing Homo sapiens 107-118 17952841-1 2007 OBJECTIVE: The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial. Simvastatin 84-95 nicotinamide phosphoribosyltransferase Homo sapiens 123-131 17952841-1 2007 OBJECTIVE: The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial. Simvastatin 97-102 adiponectin, C1Q and collagen domain containing Homo sapiens 107-118 17952841-1 2007 OBJECTIVE: The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial. Simvastatin 97-102 nicotinamide phosphoribosyltransferase Homo sapiens 123-131 17644777-3 2007 In the present study, atorvastatin and simvastatin dose-dependently decreased LPL and EL expression as well as Rho, liver X receptor alpha (LXRalpha), and nuclear factor kappaB (NF-kappaB) activation in THP-1 macrophages. Simvastatin 39-50 lipase G, endothelial type Homo sapiens 86-88 17644777-3 2007 In the present study, atorvastatin and simvastatin dose-dependently decreased LPL and EL expression as well as Rho, liver X receptor alpha (LXRalpha), and nuclear factor kappaB (NF-kappaB) activation in THP-1 macrophages. Simvastatin 39-50 nuclear receptor subfamily 1 group H member 3 Homo sapiens 140-148 17644777-3 2007 In the present study, atorvastatin and simvastatin dose-dependently decreased LPL and EL expression as well as Rho, liver X receptor alpha (LXRalpha), and nuclear factor kappaB (NF-kappaB) activation in THP-1 macrophages. Simvastatin 39-50 nuclear factor kappa B subunit 1 Homo sapiens 178-187 17644777-3 2007 In the present study, atorvastatin and simvastatin dose-dependently decreased LPL and EL expression as well as Rho, liver X receptor alpha (LXRalpha), and nuclear factor kappaB (NF-kappaB) activation in THP-1 macrophages. Simvastatin 39-50 GLI family zinc finger 2 Homo sapiens 203-208 17342739-11 2007 In addition, and in contrast to Org 31,710, simvastatin caused a decrease in isoprenylation of a selected isoprenylation marker protein, the Ras-related protein RAB11. Simvastatin 44-55 RAB11a, member RAS oncogene family Rattus norvegicus 161-166 17655704-5 2007 Intrapatient (cycles I/II vs. III/IV) and interpatient comparison (vs. ten patients without simvastatin) showed reduction of drug resistance by inhibition of HMG-CoA-reductase. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 158-175 17938806-7 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, efficiently enhanced the mesothelial fibrinolytic capacity under these inflammatory conditions, but did not protect HMCs against S. aureus-induced cell death. Simvastatin 0-11 molybdenum cofactor sulfurase Homo sapiens 200-204 18078616-0 2007 Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Simvastatin 0-11 interleukin 1 beta Homo sapiens 77-94 18078616-1 2007 OBJECTIVES: Recent studies demonstrated in vivo the effectiveness of statins in reducing the inflammatory response in rheumatic diseases, and still more recently, simvastatin has been reported to inhibit in vitro IL-6 and IL-8 production by unstimulated fibroblast-like-synoviocytes (FLS) from rheumatoid arthritis (RA) patients. Simvastatin 163-174 interleukin 6 Homo sapiens 213-217 18078616-1 2007 OBJECTIVES: Recent studies demonstrated in vivo the effectiveness of statins in reducing the inflammatory response in rheumatic diseases, and still more recently, simvastatin has been reported to inhibit in vitro IL-6 and IL-8 production by unstimulated fibroblast-like-synoviocytes (FLS) from rheumatoid arthritis (RA) patients. Simvastatin 163-174 C-X-C motif chemokine ligand 8 Homo sapiens 222-226 18078616-7 2007 Simvastatin significantly inhibited (about 20%) IL-6 and IL-8 production from IL-1-stimulated FLS. Simvastatin 0-11 interleukin 6 Homo sapiens 48-52 18078616-7 2007 Simvastatin significantly inhibited (about 20%) IL-6 and IL-8 production from IL-1-stimulated FLS. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 57-61 18078616-7 2007 Simvastatin significantly inhibited (about 20%) IL-6 and IL-8 production from IL-1-stimulated FLS. Simvastatin 0-11 interleukin 1 beta Homo sapiens 78-82 18078616-9 2007 Moreover, simvastatin produced a clear-cut inhibition of IL-1-induced NF-kB activation. Simvastatin 10-21 interleukin 1 beta Homo sapiens 57-61 18078616-10 2007 CONCLUSION: Simvastatin significantly inhibits the production of IL-6 and IL-8 also in IL-1-stimulated FLS, even though to a lesser extent than in unstimulated cells, via a HMG-CoA-reductase block with an interference in prenylation process and NF-kB activation. Simvastatin 12-23 interleukin 6 Homo sapiens 65-69 18078616-10 2007 CONCLUSION: Simvastatin significantly inhibits the production of IL-6 and IL-8 also in IL-1-stimulated FLS, even though to a lesser extent than in unstimulated cells, via a HMG-CoA-reductase block with an interference in prenylation process and NF-kB activation. Simvastatin 12-23 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 18078616-10 2007 CONCLUSION: Simvastatin significantly inhibits the production of IL-6 and IL-8 also in IL-1-stimulated FLS, even though to a lesser extent than in unstimulated cells, via a HMG-CoA-reductase block with an interference in prenylation process and NF-kB activation. Simvastatin 12-23 interleukin 1 beta Homo sapiens 87-91 17723833-12 2007 CONCLUSIONS: Perioperative treatment of simvastatin could suppress the isograft ischemia-reperfusion injury through retarding intragraft monocyte chemoattractant protein-1 accumulation and CC chemokine receptor-2 expression. Simvastatin 40-51 C-C motif chemokine ligand 2 Rattus norvegicus 137-171 17574455-3 2007 Although recruitment closed early because of increasing statin use among eligible patients, with only 21 patients we demonstrated a 40% reduction in MMP-9 levels in the AAA wall in patients randomised to simvastatin. Simvastatin 204-215 matrix metallopeptidase 9 Homo sapiens 149-154 17729120-6 2007 The NF-kappaB was activated by the LT-treatment and was further enhanced by simvastatin, pravastatin or Y27632 addition. Simvastatin 76-87 nuclear factor kappa B subunit 1 Homo sapiens 4-13 17878758-0 2007 Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. Simvastatin 0-11 angiotensinogen Rattus norvegicus 65-79 17878758-1 2007 The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension. Simvastatin 70-81 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 19-59 17878758-1 2007 The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension. Simvastatin 70-81 angiotensinogen Rattus norvegicus 179-193 17878758-1 2007 The ability of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor simvastatin to reverse established cardiovascular and renal alterations and oxidative stress was assessed in angiotensin II (AngII) hypertension. Simvastatin 70-81 angiotensinogen Rattus norvegicus 195-200 17878758-9 2007 Our results indicate that simvastatin reverse established cardiac and renal alterations in AngII hypertension independently of arterial pressure. Simvastatin 26-37 angiotensinogen Rattus norvegicus 91-96 17585018-6 2007 Furthermore, hOAT3-mediated estrone-3-sulfate uptake could be inhibited, with a rank order of potency, by atorvastatin, rosuvastatin, simvastatin, and pravastatin, whereas hOAT1-mediated PAH uptake was only significantly inhibited by simvastatin. Simvastatin 134-145 solute carrier family 22 member 8 Homo sapiens 13-18 17585018-6 2007 Furthermore, hOAT3-mediated estrone-3-sulfate uptake could be inhibited, with a rank order of potency, by atorvastatin, rosuvastatin, simvastatin, and pravastatin, whereas hOAT1-mediated PAH uptake was only significantly inhibited by simvastatin. Simvastatin 234-245 solute carrier family 22 member 8 Homo sapiens 13-18 17716606-0 2007 High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. Simvastatin 15-26 tumor necrosis factor Homo sapiens 35-44 17716606-10 2007 A preconditioning with simvastatin [25 microM] resulted in significant inhibition of the TNF-alpha-induced apoptosis, whereas the IL-1beta-mediated apoptosis was only slightly reduced. Simvastatin 23-34 tumor necrosis factor Homo sapiens 89-98 17252541-6 2007 A significant increase in COL1A1, osteocalcin, and BMP2 gene expression was detected when hOB cultures were treated with simvastatin or atorvastatin at different concentrations. Simvastatin 121-132 collagen type I alpha 1 chain Homo sapiens 26-32 17716606-11 2007 In conclusion, this study shows clearly that TNF-alpha and IL-1beta are harmful to early EPC and that the HMG-CoA reductase inhibitor simvastatin protects EPC from TNF-alpha- and eventually from IL-1beta-mediated apoptosis. Simvastatin 134-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-123 17716606-11 2007 In conclusion, this study shows clearly that TNF-alpha and IL-1beta are harmful to early EPC and that the HMG-CoA reductase inhibitor simvastatin protects EPC from TNF-alpha- and eventually from IL-1beta-mediated apoptosis. Simvastatin 134-145 tumor necrosis factor Homo sapiens 164-173 17716606-11 2007 In conclusion, this study shows clearly that TNF-alpha and IL-1beta are harmful to early EPC and that the HMG-CoA reductase inhibitor simvastatin protects EPC from TNF-alpha- and eventually from IL-1beta-mediated apoptosis. Simvastatin 134-145 interleukin 1 beta Homo sapiens 195-203 17719471-6 2007 RESULTS: Both ezetimibe and simvastatin significantly reduced total cholesterol (-0.62 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (-0.55 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l; p < 0.0001), and C-reactive protein (-5.35 +/- 9.25 mg/l and -5.05 +/- 6.30 mg/l; p < 0.001). Simvastatin 28-39 C-reactive protein Homo sapiens 265-283 17761367-4 2007 A double-blind, crossover design comparing the effect of simvastatin (80 mg) and atorvastatin (80 mg) on serum lipid and glycosylphosphatidylinositol-specific phospholipase D levels was conducted in 13 patients with low high-density lipoproteins. Simvastatin 57-68 glycosylphosphatidylinositol specific phospholipase D1 Homo sapiens 121-174 17252541-6 2007 A significant increase in COL1A1, osteocalcin, and BMP2 gene expression was detected when hOB cultures were treated with simvastatin or atorvastatin at different concentrations. Simvastatin 121-132 bone gamma-carboxyglutamate protein Homo sapiens 34-45 17252541-6 2007 A significant increase in COL1A1, osteocalcin, and BMP2 gene expression was detected when hOB cultures were treated with simvastatin or atorvastatin at different concentrations. Simvastatin 121-132 bone morphogenetic protein 2 Homo sapiens 51-55 17558433-12 2007 simvastatin (10 microM ) caused a rottlerin (1 microM)-sensitive (cycloheximide (10 microM)-insensitive) increase of PKC-delta protein expression. Simvastatin 0-11 protein kinase C delta Homo sapiens 117-126 17671209-10 2007 Both fluvastatin and simvastatin increased iNOS mRNA and protein expression. Simvastatin 21-32 nitric oxide synthase 2 Homo sapiens 43-47 17470528-5 2007 For OATP1B1 the inhibition by gemfibrozil was substrate-dependent as the transport of fluvastatin (IC(50) of 63 microM), pravastatin, simvastatin, and taurocholate was inhibited by gemfibrozil, whereas the transport of estrone-3-sulfate and troglitazone sulfate (both used at 3 microM) was not affected. Simvastatin 134-145 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 17721043-1 2007 Simvastatin, a cholesterol synthesis inhibitor, enhances BMP2 expression in osteoblasts. Simvastatin 0-11 bone morphogenetic protein 2 Rattus norvegicus 57-61 17674978-9 2007 Surprisingly, simvastatin reduced intestinal radiation injury in TM mutant mice, indicating that the enteroprotective effect of simvastatin after localized irradiation is unrelated to protein C activation. Simvastatin 14-25 thrombomodulin Mus musculus 65-67 17519305-12 2007 Simvastatin therapy significantly inhibited lipopolysaccharide-activated monocyte release of O(2)(-) (P < 0.0005), IL-8 (P < 0.03), and TNF (P < 0.02). Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 118-122 17519305-12 2007 Simvastatin therapy significantly inhibited lipopolysaccharide-activated monocyte release of O(2)(-) (P < 0.0005), IL-8 (P < 0.03), and TNF (P < 0.02). Simvastatin 0-11 tumor necrosis factor Homo sapiens 142-145 17519305-14 2007 Simvastatin therapy also significantly reduced monocytic nuclear factor-kappaB p65 activity, compared with placebo (P < 0.01). Simvastatin 0-11 RELA proto-oncogene, NF-kB subunit Homo sapiens 79-82 17592071-4 2007 In cultured vascular smooth muscle cells (VSMCs) atorvastatin and simvastatin inhibited Ang II-induced CTGF production. Simvastatin 66-77 angiotensinogen Rattus norvegicus 88-94 17592071-4 2007 In cultured vascular smooth muscle cells (VSMCs) atorvastatin and simvastatin inhibited Ang II-induced CTGF production. Simvastatin 66-77 cellular communication network factor 2 Rattus norvegicus 103-107 17726294-10 2007 Simvastatin suppressed the LPS-induced upregulation of EL expression and uptake of nLDL. Simvastatin 0-11 lipase, endothelial Mus musculus 55-57 17560598-0 2007 Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Simvastatin 0-11 tumor necrosis factor Homo sapiens 21-29 17560598-0 2007 Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 88-93 17560598-2 2007 We have previously reported that simvastatin inhibits tumor necrosis factor-alpha (TNFalpha)-induced cardiac myofibroblast invasion and MMP-9 secretion, key events in this remodeling process. Simvastatin 33-44 tumor necrosis factor Homo sapiens 83-91 17560598-2 2007 We have previously reported that simvastatin inhibits tumor necrosis factor-alpha (TNFalpha)-induced cardiac myofibroblast invasion and MMP-9 secretion, key events in this remodeling process. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 136-141 17560598-12 2007 In summary, simvastatin reduces TNFalpha-induced invasion of human cardiac myofibroblasts through two distinct mechanisms: (i) by attenuating cell migration via Rho-kinase inhibition and subsequent cytoskeletal disruption, and (ii) by decreasing MMP-9 secretion via a post-transcriptional mechanism. Simvastatin 12-23 tumor necrosis factor Homo sapiens 32-40 17560598-12 2007 In summary, simvastatin reduces TNFalpha-induced invasion of human cardiac myofibroblasts through two distinct mechanisms: (i) by attenuating cell migration via Rho-kinase inhibition and subsequent cytoskeletal disruption, and (ii) by decreasing MMP-9 secretion via a post-transcriptional mechanism. Simvastatin 12-23 matrix metallopeptidase 9 Homo sapiens 246-251 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 82-93 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-70 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 136-147 BCL2 associated X, apoptosis regulator Homo sapiens 178-181 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 136-147 BCL2 apoptosis regulator Homo sapiens 182-187 17901590-8 2007 MTT assay demonstrated a significant dose-dependent inhibition of OE-19 cell growth by simvastatin, which also caused a significant reduction in Bcl-2 expression and an increase in Bax expression. Simvastatin 87-98 BCL2 apoptosis regulator Homo sapiens 145-150 17901590-8 2007 MTT assay demonstrated a significant dose-dependent inhibition of OE-19 cell growth by simvastatin, which also caused a significant reduction in Bcl-2 expression and an increase in Bax expression. Simvastatin 87-98 BCL2 associated X, apoptosis regulator Homo sapiens 181-184 17901590-9 2007 In OE-19 cells, the COX-2 expression was detected and significantly increased by the addition of TNFalpha into the medium, however, this effect was significantly attenuated by simvastatin. Simvastatin 176-187 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 17901590-9 2007 In OE-19 cells, the COX-2 expression was detected and significantly increased by the addition of TNFalpha into the medium, however, this effect was significantly attenuated by simvastatin. Simvastatin 176-187 tumor necrosis factor Homo sapiens 97-105 17559881-8 2007 RESULTS: Simvastatin significantly inhibited IRI-induced MPO activity but not collagen degradation in postischemic skeletal muscle. Simvastatin 9-20 myeloperoxidase Rattus norvegicus 57-60 17901590-4 2007 The aim of the present study was to analyze: 1) the impact of HMG-CoAR inhibitor, simvastatin, on human BA cell growth and 2) effect of simvastatin on apoptosis related proteins Bax/Bcl-2 and cyclooxygenase-2. Simvastatin 136-147 prostaglandin-endoperoxide synthase 2 Homo sapiens 192-208 17559881-10 2007 When both simvastatin and L-NIO were administered before IRI, the IRI-induced elevation in MPO activity was completely inhibited. Simvastatin 10-21 myeloperoxidase Rattus norvegicus 91-94 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 20-38 17583757-4 2007 The neuroprotective effects of simvastatin were shared by squalestatin, a squalene synthase inhibitor that reduces neuronal cholesterol production and crucially, does not affect isoprenoid formation. Simvastatin 31-42 farnesyl-diphosphate farnesyltransferase 1 Homo sapiens 74-91 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 40-43 16860807-7 2007 However, simvastatin tended to increase the density of HLA-DR and L-selectin per CD8+ T cell. Simvastatin 9-20 selectin L Homo sapiens 66-76 16860808-9 2007 In conclusion, simvastatin and pravastatin produced distinct effects on gamma-T metabolism, presumably as a result of different statin-CYP interactions. Simvastatin 15-26 peptidylprolyl isomerase G Homo sapiens 135-138 17466485-0 2007 Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Simvastatin 0-11 interleukin 6 Homo sapiens 35-48 17466485-0 2007 Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 53-66 17466485-2 2007 AIM: To evaluate the in vitro effect of simvastatin (S) or fluvastatin (F) on the lipopolysaccharide (LPS) stimulated secretion of IL-6 and IL-8 from monocytes of chronic kidney disease patients (CKD) in K-DOQI stages 3-5. Simvastatin 40-51 interleukin 6 Homo sapiens 131-135 17888208-2 2007 In this study we evaluate whether simvastatin could influence the production of pro-inflammatory cytokines (interleukin (IL)-6 and IL-8) and nitric oxide (NO) by activated human chondrocytes. Simvastatin 34-45 interleukin 6 Homo sapiens 108-126 17888208-2 2007 In this study we evaluate whether simvastatin could influence the production of pro-inflammatory cytokines (interleukin (IL)-6 and IL-8) and nitric oxide (NO) by activated human chondrocytes. Simvastatin 34-45 C-X-C motif chemokine ligand 8 Homo sapiens 131-135 17888208-5 2007 RESULTS: Simvastatin demonstrated significant dose-dependent inhibition of IL-6 and IL-8 production of isolated chondrocytes and cartilage explants up to 99% for IL-6 and up to 88% for IL-8 (p < 0.01). Simvastatin 9-20 interleukin 6 Homo sapiens 75-79 17888208-5 2007 RESULTS: Simvastatin demonstrated significant dose-dependent inhibition of IL-6 and IL-8 production of isolated chondrocytes and cartilage explants up to 99% for IL-6 and up to 88% for IL-8 (p < 0.01). Simvastatin 9-20 C-X-C motif chemokine ligand 8 Homo sapiens 84-88 17888208-5 2007 RESULTS: Simvastatin demonstrated significant dose-dependent inhibition of IL-6 and IL-8 production of isolated chondrocytes and cartilage explants up to 99% for IL-6 and up to 88% for IL-8 (p < 0.01). Simvastatin 9-20 interleukin 6 Homo sapiens 162-166 17888208-5 2007 RESULTS: Simvastatin demonstrated significant dose-dependent inhibition of IL-6 and IL-8 production of isolated chondrocytes and cartilage explants up to 99% for IL-6 and up to 88% for IL-8 (p < 0.01). Simvastatin 9-20 C-X-C motif chemokine ligand 8 Homo sapiens 185-189 17464088-0 2007 Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Simvastatin 0-11 ras homolog family member A Mus musculus 80-84 17615423-9 2007 Simvastatin is metabolized by CYP3A4. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 17615423-12 2007 In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors. Simvastatin 206-217 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 17697530-5 2007 Lung tissue myeloperoxidase, malondialdehyde, neutrophil count and lung injury scores in both simvastatin groups were significantly lower than in the I/R group; 10 mg/kg per day simvastatin significantly reduced lung water content although 5 mg/kg per day did not. Simvastatin 178-189 myeloperoxidase Rattus norvegicus 12-27 17697530-6 2007 Expression of haem oxygenase-1 (HO-1) protein in lung tissue was significantly greater in the simvastatin groups than in the I/R group. Simvastatin 94-105 heme oxygenase 1 Rattus norvegicus 14-36 17464088-7 2007 Loss of ESC self-renewal by simvastatin was determined by marked downregulation of ESC markers alkaline phosphatase, Oct4, Nanog, Rex-1, and SSEA-1. Simvastatin 28-39 POU domain, class 5, transcription factor 1, related sequence 1 Mus musculus 117-121 17464088-7 2007 Loss of ESC self-renewal by simvastatin was determined by marked downregulation of ESC markers alkaline phosphatase, Oct4, Nanog, Rex-1, and SSEA-1. Simvastatin 28-39 Nanog homeobox Mus musculus 123-128 17464088-7 2007 Loss of ESC self-renewal by simvastatin was determined by marked downregulation of ESC markers alkaline phosphatase, Oct4, Nanog, Rex-1, and SSEA-1. Simvastatin 28-39 REX1, RNA exonuclease 1 Mus musculus 130-135 17464088-7 2007 Loss of ESC self-renewal by simvastatin was determined by marked downregulation of ESC markers alkaline phosphatase, Oct4, Nanog, Rex-1, and SSEA-1. Simvastatin 28-39 fucosyltransferase 4 Mus musculus 141-147 17464088-11 2007 Furthermore, we identified that simvastatin selectively blocked cytosol-to-membrane translocalization of RhoA small guanosine triphosphate-binding protein, known to be the major target for geranylgeranylation, and lowered the levels of Rho-kinase (ROCK)2 protein in ESCs. Simvastatin 32-43 ras homolog family member A Mus musculus 105-109 17464088-11 2007 Furthermore, we identified that simvastatin selectively blocked cytosol-to-membrane translocalization of RhoA small guanosine triphosphate-binding protein, known to be the major target for geranylgeranylation, and lowered the levels of Rho-kinase (ROCK)2 protein in ESCs. Simvastatin 32-43 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 236-246 17464088-11 2007 Furthermore, we identified that simvastatin selectively blocked cytosol-to-membrane translocalization of RhoA small guanosine triphosphate-binding protein, known to be the major target for geranylgeranylation, and lowered the levels of Rho-kinase (ROCK)2 protein in ESCs. Simvastatin 32-43 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 248-254 17464088-12 2007 In addition, simvastatin downregulated the ROCK activity, and this effect was reversed by addition of GGPP. Simvastatin 13-24 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 43-47 17464088-13 2007 Our data suggest that simvastatin, independently of its cholesterol-lowering properties, impairs the ESC self-renewal by modulating RhoA/ROCK-dependent cell-signaling. Simvastatin 22-33 ras homolog family member A Mus musculus 132-136 17464088-13 2007 Our data suggest that simvastatin, independently of its cholesterol-lowering properties, impairs the ESC self-renewal by modulating RhoA/ROCK-dependent cell-signaling. Simvastatin 22-33 Rho-associated coiled-coil containing protein kinase 2 Mus musculus 137-141 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 35-46 C-reactive protein Homo sapiens 98-116 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 54-65 C-reactive protein Homo sapiens 98-116 17560879-3 2007 When averaged across doses, ezetimibe/simvastatin produced significantly greater reductions compared with simvastatin alone in LDL cholesterol (52.5% vs 38.0%, respectively) and CRP levels (31.0% vs 14.3%, respectively). Simvastatin 38-49 C-reactive protein Homo sapiens 178-181 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Simvastatin 68-79 C-reactive protein Homo sapiens 14-17 17125918-0 2007 Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Simvastatin 0-11 tumor protein p53 Homo sapiens 60-63 17125918-0 2007 Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Simvastatin 0-11 estrogen receptor 1 Homo sapiens 68-85 17125918-0 2007 Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Simvastatin 0-11 mitogen-activated protein kinase 8 Homo sapiens 135-138 17125918-1 2007 The effect of simvastatin, a widely used statin for the treatment of hypercholesterolemia, was investigated in the estrogen receptor (ER)-positive MCF-7, and the ER-negative MDA-MB 231 human breast cancer cell lines. Simvastatin 14-25 estrogen receptor 1 Homo sapiens 115-132 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 19-30 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 70-75 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 19-30 mitogen-activated protein kinase 8 Homo sapiens 114-139 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 19-30 mitogen-activated protein kinase 8 Homo sapiens 141-144 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 246-257 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 70-75 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 246-257 mitogen-activated protein kinase 8 Homo sapiens 114-139 17125918-6 2007 On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. Simvastatin 246-257 mitogen-activated protein kinase 8 Homo sapiens 141-144 17125918-7 2007 In conclusion, we describe here that simvastatin induces apoptosis via involvement of JNK in breast cancer cells independent of their ER or p53 expression status. Simvastatin 37-48 mitogen-activated protein kinase 8 Homo sapiens 86-89 17317725-3 2007 In the present study, we investigated the effect of simvastatin and mevastatin on COX-2 induction in human monocytic cell line U937 and analyzed the underlying mechanisms. Simvastatin 52-63 prostaglandin-endoperoxide synthase 2 Homo sapiens 82-87 17428261-0 2007 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Simvastatin 0-11 integrin subunit beta 1 Homo sapiens 24-38 17428261-6 2007 The inhibitory effect of simvastatin on cell proliferation seemed to be associated with cell cycle arrest and increased expression of p21, p27, and activated caspase-3. Simvastatin 25-36 H3 histone pseudogene 16 Homo sapiens 134-137 17428261-6 2007 The inhibitory effect of simvastatin on cell proliferation seemed to be associated with cell cycle arrest and increased expression of p21, p27, and activated caspase-3. Simvastatin 25-36 zinc ribbon domain containing 2 Homo sapiens 139-142 17428261-6 2007 The inhibitory effect of simvastatin on cell proliferation seemed to be associated with cell cycle arrest and increased expression of p21, p27, and activated caspase-3. Simvastatin 25-36 caspase 3 Homo sapiens 158-167 17428261-7 2007 The expression of beta1-integrin, a counter adhesion for the extracellular matrix, phosphorylated FAK, and phosphorylated ERK was decreased by treatment with simvastatin. Simvastatin 158-169 integrin subunit beta 1 Homo sapiens 18-32 17428261-7 2007 The expression of beta1-integrin, a counter adhesion for the extracellular matrix, phosphorylated FAK, and phosphorylated ERK was decreased by treatment with simvastatin. Simvastatin 158-169 protein tyrosine kinase 2 Homo sapiens 98-101 17428261-7 2007 The expression of beta1-integrin, a counter adhesion for the extracellular matrix, phosphorylated FAK, and phosphorylated ERK was decreased by treatment with simvastatin. Simvastatin 158-169 mitogen-activated protein kinase 1 Homo sapiens 122-125 17428261-10 2007 Of down-regulated genes induced by simvastatin treatment, a significant depletion of thymidylate synthase was confirmed using western blot analysis. Simvastatin 35-46 thymidylate synthetase Homo sapiens 85-105 17317725-4 2007 Pretreatment of U937 cells with simvastatin or mevastatin for 24 h resulted in a significant reduction in the lipopolysaccharide (LPS)-dependent induction of prostaglandin E2, thromboxane A2 synthesis, and COX-2 expression. Simvastatin 32-43 prostaglandin-endoperoxide synthase 2 Homo sapiens 206-211 17317725-10 2007 Gel retardation experiments and NFkappaB-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-kappaB complex formation. Simvastatin 84-95 nuclear factor kappa B subunit 1 Homo sapiens 32-40 17317725-10 2007 Gel retardation experiments and NFkappaB-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-kappaB complex formation. Simvastatin 84-95 RELA proto-oncogene, NF-kB subunit Homo sapiens 41-44 17641834-0 2007 Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. Simvastatin 10-21 interleukin 6 Mus musculus 25-29 17335931-0 2007 Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. Simvastatin 0-11 C-C motif chemokine ligand 4 Rattus norvegicus 75-79 17335931-10 2007 Simvastatin increased eNOS expression, Akt-dependent eNOS phosphorylation and cGMP liver content. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 22-26 17335931-10 2007 Simvastatin increased eNOS expression, Akt-dependent eNOS phosphorylation and cGMP liver content. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 39-42 17335931-10 2007 Simvastatin increased eNOS expression, Akt-dependent eNOS phosphorylation and cGMP liver content. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 53-57 17641834-0 2007 Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. Simvastatin 10-21 adiponectin, C1Q and collagen domain containing Mus musculus 34-45 17641834-1 2007 In order to investigate the effects of simvastatin on secretion and mRNA expression of interleukin-6 (IL-6) and adiponectin in 3T3-L1 adipocytes, mouse 3T3-L1 adipocytes were stimulated with lipopolysaccharide (LPS). Simvastatin 39-50 interleukin 6 Mus musculus 87-100 17641834-3 2007 The results showed that simvastatin could significantly suppress LPS-induced IL-6 production and mRNA expression in adipocytes (P<0.05), but increase the LPS-induced adiponectin secretion and mRNA expression in a dose-dependent manner (P<0.05). Simvastatin 24-35 interleukin 6 Mus musculus 77-81 17641834-3 2007 The results showed that simvastatin could significantly suppress LPS-induced IL-6 production and mRNA expression in adipocytes (P<0.05), but increase the LPS-induced adiponectin secretion and mRNA expression in a dose-dependent manner (P<0.05). Simvastatin 24-35 adiponectin, C1Q and collagen domain containing Mus musculus 169-180 17451547-0 2007 Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo. Simvastatin 35-46 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 0-16 17451547-0 2007 Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo. Simvastatin 35-46 bone morphogenetic protein 2 Rattus norvegicus 55-83 17451547-6 2007 RESULTS: Simvastatin was found to stimulate local bone morphogenetic protein-2, nitric oxide and the regional bone formation rate (p < 0.05), whereas NS-398 inhibited bone morphogenetic protein-2 and reduced the bone formation rate (p < 0.05). Simvastatin 9-20 bone morphogenetic protein 2 Rattus norvegicus 50-78 17463319-9 2007 Ang II (1 micromol/L, 2 hours) induced serine 133 phosphorylation of CREB and binding of CREB to CRE and increased LCC alpha1C subunit gene promoter activity through a protein kinase C/NADPH oxidase/reactive oxygen species pathway, which was blocked by the Ang II type 1 receptor blocker losartan and the antioxidant simvastatin. Simvastatin 317-328 angiotensinogen Rattus norvegicus 0-6 17451547-7 2007 CONCLUSION: These data suggest an association between simvastatin-induced bone morphogenetic protein-2 and bone formation in the mandibular microenvironment, and the negative effect of cyclooxygenase-2 inhibitors on bone growth. Simvastatin 54-65 bone morphogenetic protein 2 Rattus norvegicus 74-102 17502837-9 2007 Hypercholesterolemic patients homozygous for the C allele showed a significant increase in serum paraoxonase-1 activity and mass during treatment with simvastatin, whereas patients homozygous for the T allele showed no increase. Simvastatin 151-162 paraoxonase 1 Homo sapiens 97-110 17711713-10 2007 RESULTS: Simvastatin treatment reduced low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels and improved endothelial-dependent vasodilation in patients after 4 weeks. Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 76-81 17711713-12 2007 After terminating simvastatin treatment, serum NO and plasma 6-keto-PGF1(alpha) levels decreased, as well as plasma ET and serum LDL-C levels increased. Simvastatin 18-29 component of oligomeric golgi complex 2 Homo sapiens 129-134 17513194-0 2007 Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 21-34 17513194-0 2007 Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Simvastatin 0-11 serpin family E member 1 Homo sapiens 39-72 17513194-9 2007 The simvastatin treatment resulted in a significant effect in decreasing TF and PAI-1 (69.1 +/- 14.6 ng/l vs. 89.2 +/- 13.4 ng/l; 16.5 +/- 4.8 (x10(3) AU/l) vs. 23.8 +/- 3.3 (x10(3) AU/l), P<0.05) secretion in PBMCs. Simvastatin 4-15 coagulation factor III, tissue factor Homo sapiens 73-75 17513194-9 2007 The simvastatin treatment resulted in a significant effect in decreasing TF and PAI-1 (69.1 +/- 14.6 ng/l vs. 89.2 +/- 13.4 ng/l; 16.5 +/- 4.8 (x10(3) AU/l) vs. 23.8 +/- 3.3 (x10(3) AU/l), P<0.05) secretion in PBMCs. Simvastatin 4-15 serpin family E member 1 Homo sapiens 80-85 17463319-11 2007 In summary, Ang II induced LCC alpha1C subunit expression via a protein kinase C-, reactive oxygen species-, and CREB-dependent pathway and was blocked by losartan and simvastatin. Simvastatin 168-179 angiogenin Rattus norvegicus 12-15 17463319-11 2007 In summary, Ang II induced LCC alpha1C subunit expression via a protein kinase C-, reactive oxygen species-, and CREB-dependent pathway and was blocked by losartan and simvastatin. Simvastatin 168-179 cAMP responsive element binding protein 1 Rattus norvegicus 113-117 17463319-9 2007 Ang II (1 micromol/L, 2 hours) induced serine 133 phosphorylation of CREB and binding of CREB to CRE and increased LCC alpha1C subunit gene promoter activity through a protein kinase C/NADPH oxidase/reactive oxygen species pathway, which was blocked by the Ang II type 1 receptor blocker losartan and the antioxidant simvastatin. Simvastatin 317-328 cAMP responsive element binding protein 1 Rattus norvegicus 69-73 17463319-10 2007 In the rat model, Ang II infusion increased LCC alpha1C subunit expression and serine 133 phosphorylation of CREB, which were attenuated by oral losartan and simvastatin. Simvastatin 158-169 angiotensinogen Rattus norvegicus 18-24 17463319-10 2007 In the rat model, Ang II infusion increased LCC alpha1C subunit expression and serine 133 phosphorylation of CREB, which were attenuated by oral losartan and simvastatin. Simvastatin 158-169 cAMP responsive element binding protein 1 Rattus norvegicus 109-113 17277047-1 2007 The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, simvastatin, has been shown to attenuate chronic hypoxic pulmonary hypertension (CHPH). Simvastatin 66-77 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 4-54 17520029-2 2007 PRINCIPLE FINDINGS: Here we demonstrate that treatment of an enriched CD4(+) lymphocyte population with lovastatin (Lov), mevastatin (Mev) and simvastatin (activated and non-activated, Sim(A) and Sim(N), respectively) can reduce the cell surface expression of the CC-chemokine receptor CCR5 (P<0.01 for Sim(A) and Lov). Simvastatin 143-154 CD4 molecule Homo sapiens 70-73 17520029-2 2007 PRINCIPLE FINDINGS: Here we demonstrate that treatment of an enriched CD4(+) lymphocyte population with lovastatin (Lov), mevastatin (Mev) and simvastatin (activated and non-activated, Sim(A) and Sim(N), respectively) can reduce the cell surface expression of the CC-chemokine receptor CCR5 (P<0.01 for Sim(A) and Lov). Simvastatin 143-154 C-C motif chemokine receptor 5 Homo sapiens 286-290 17264303-2 2007 Exposure of U937 and U266 cells to minimally toxic concentrations of UCN-01 and various statins (eg, lovastatin, simvastatin, or fluvastatin) dramatically increased mitochondrial dysfunction, caspase activation, and apoptosis. Simvastatin 113-124 urocortin Homo sapiens 69-72 17513194-11 2007 two-week simvastatin treatment resulted in significant decrease of TF (0.535 +/- 0.028, p<0.01) and PAI-1 mRNA (0.602 +/- 0.037, p<0.01). Simvastatin 9-20 coagulation factor III, tissue factor Homo sapiens 67-69 17513194-11 2007 two-week simvastatin treatment resulted in significant decrease of TF (0.535 +/- 0.028, p<0.01) and PAI-1 mRNA (0.602 +/- 0.037, p<0.01). Simvastatin 9-20 serpin family E member 1 Homo sapiens 103-108 17513194-13 2007 Simvastatin reduced TF and PAI-1 expression and activity in PBMCs. Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 20-22 17513194-13 2007 Simvastatin reduced TF and PAI-1 expression and activity in PBMCs. Simvastatin 0-11 serpin family E member 1 Homo sapiens 27-32 17277047-7 2007 Expression of both ROCK-1 and -2 were markedly diminished in simvastatin-treated animals during normoxia and hypoxia (2- and 4-wk) exposure (P < 0.01). Simvastatin 61-72 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 19-32 17303772-9 2007 CONCLUSIONS: These results demonstrate that simvastatin, by inhibiting Rac1 activity, reduces MMP1 expression and collagen degradation in human smooth muscle cells. Simvastatin 44-55 Rac family small GTPase 1 Homo sapiens 71-75 17303772-0 2007 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Simvastatin 0-11 matrix metallopeptidase 1 Homo sapiens 20-24 17303772-9 2007 CONCLUSIONS: These results demonstrate that simvastatin, by inhibiting Rac1 activity, reduces MMP1 expression and collagen degradation in human smooth muscle cells. Simvastatin 44-55 matrix metallopeptidase 1 Homo sapiens 94-98 17303772-0 2007 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Simvastatin 0-11 Rac family small GTPase 1 Homo sapiens 112-116 17538316-2 2007 The cholesterol-lowering drug simvastatin has been shown to stimulate bone formation by increasing the gene expression of bone morphogenetic protein-2 and vascular endothelial growth factor. Simvastatin 30-41 bone morphogenetic protein 2 Rattus norvegicus 122-150 17303772-3 2007 METHODS AND RESULTS: In the present study, we show that simvastatin (3 micromol/L) reduces MMP1 expression and secretion in human smooth muscle cells cultured on polymerized type I collagen by 39.9+/-11.2% and 36.0+/-2.3%, respectively. Simvastatin 56-67 matrix metallopeptidase 1 Homo sapiens 91-95 17303772-5 2007 Mevalonate, and the isoprenoid derivative geranylgeraniol, precursors of geranylgeranylated proteins, completely prevent the inhibitory effect of simvastatin on MMP1. Simvastatin 146-157 matrix metallopeptidase 1 Homo sapiens 161-165 17303772-8 2007 Finally, simvastatin reduces GTP-bound Rac1 expression levels in smooth muscle cells cultured on polymerized collagen. Simvastatin 9-20 Rac family small GTPase 1 Homo sapiens 39-43 17650633-3 2007 Simultaneous injection of simvastatin (1 mg/kg, intragastrically) in rats with ethanol--CCl4 hepatitis decreased fatty dystrophy and produced certain anticytolytic and anticholestatic effects without potentiation of microsomal oxidation system damage by hepatotoxins. Simvastatin 26-37 C-C motif chemokine ligand 4 Rattus norvegicus 88-92 17429294-0 2007 Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease. Simvastatin 37-48 angiotensin II receptor type 1 Homo sapiens 67-97 17429294-4 2007 Simvastatin therapy reduced low-density lipoprotein-cholesterol, downregulated angiotensin II type 1 receptor, decreased 8-isoprostane, and improved flow-mediated vasodilation. Simvastatin 0-11 angiotensin II receptor type 1 Homo sapiens 79-109 17429294-6 2007 In addition, simvastatin-mediated changes in 8-isoprostane could be predicted by angiotensin II type 1 receptor downregulation, and flow-mediated vasodilation improvement by changes in 8-isoprostane. Simvastatin 13-24 angiotensin II receptor type 1 Homo sapiens 81-111 17429294-7 2007 A significant correlation existed between simvastatin-mediated changes in 8-isoprostane and angiotensin II type 1 receptor. Simvastatin 42-53 angiotensin II receptor type 1 Homo sapiens 92-122 17513949-0 2007 Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. Simvastatin 128-139 angiotensin II receptor type 1 Homo sapiens 0-30 17513949-6 2007 Treatment of high-risk subjects with simvastatin for 30 days resulted in a reduction of AT1R mRNA down to the levels of cells from healthy subjects. Simvastatin 37-48 angiotensin II receptor type 1 Homo sapiens 88-92 17513949-7 2007 In vitro, Ang II-induced activation of the guanosine triphosphate (GTP)-binding protein Rac 1 in human PMNs was inhibited by simvastatin. Simvastatin 125-136 Rac family small GTPase 1 Homo sapiens 88-93 17513949-8 2007 In conclusion, simvastatin induces downregulation of AT1R expression, interferes with Ang II activity in PMNs, and contributes to the antiinflammatory profile of statins that can explain the therapeutic effects of these drugs. Simvastatin 15-26 angiotensin II receptor type 1 Homo sapiens 53-57 17172275-10 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which is known to activate PI3K/Akt, blocks TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 99-102 17449418-0 2007 Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. Simvastatin 73-84 C-C motif chemokine receptor 2 Rattus norvegicus 33-37 17449418-0 2007 Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. Simvastatin 73-84 C-C motif chemokine receptor 5 Rattus norvegicus 42-46 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-C motif chemokine ligand 2 Rattus norvegicus 172-177 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-C motif chemokine ligand 2 Rattus norvegicus 179-213 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-C motif chemokine ligand 5 Rattus norvegicus 216-222 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-X-C motif chemokine ligand 10 Rattus norvegicus 299-304 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-X-C motif chemokine ligand 10 Rattus norvegicus 306-337 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-C motif chemokine receptor 2 Rattus norvegicus 393-397 17449418-10 2007 RESULTS: Both low and high doses of simvastatin significantly decreased the CAV score; inhibited recruitment of T lymphocytes and macrophages; reduced levels of intragraft MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T-cell expressed and secreted) protein and IP-10 (interferon-inducible protein-10); and down-regulated expression of chemokine receptors CCR2 and CCR5. Simvastatin 36-47 C-C motif chemokine receptor 5 Rattus norvegicus 402-406 17172275-10 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which is known to activate PI3K/Akt, blocks TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 111-120 17172275-10 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which is known to activate PI3K/Akt, blocks TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 0-11 insulin Homo sapiens 126-133 17172275-10 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which is known to activate PI3K/Akt, blocks TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 0-11 serpin family E member 1 Homo sapiens 142-147 17172275-11 2007 Treatment with PI3K inhibitors reversed the inhibitor effects of simvastatin on TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 65-76 tumor necrosis factor Homo sapiens 80-89 17172275-11 2007 Treatment with PI3K inhibitors reversed the inhibitor effects of simvastatin on TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 65-76 insulin Homo sapiens 95-102 17172275-11 2007 Treatment with PI3K inhibitors reversed the inhibitor effects of simvastatin on TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 65-76 serpin family E member 1 Homo sapiens 111-116 16765358-0 2007 Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Simvastatin 117-128 TNF receptor superfamily member 10c Homo sapiens 189-192 17289397-0 2007 Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Simvastatin 129-140 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 75-81 17383342-8 2007 RESULTS: Simvastatin significantly reduced the postoperative peak values of interleukin (IL)-6 and IL-8. Simvastatin 9-20 interleukin 6 Homo sapiens 76-94 17383342-8 2007 RESULTS: Simvastatin significantly reduced the postoperative peak values of interleukin (IL)-6 and IL-8. Simvastatin 9-20 C-X-C motif chemokine ligand 8 Homo sapiens 99-103 17158816-0 2007 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Simvastatin 50-61 insulin like growth factor 1 receptor Homo sapiens 100-114 17158816-0 2007 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Simvastatin 50-61 matrix metallopeptidase 2 Homo sapiens 116-120 17158816-0 2007 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Simvastatin 50-61 heat shock protein family B (small) member 1 Homo sapiens 134-139 17158816-5 2007 We hypothesized that simvastatin attenuates insuline-like growth factor-I (IGF-I) receptor expression (involved in trophoblast motility), matrix metalloproteinase (MMP) activities, and heat shock protein 27 (HSP27) levels (whose mRNA is actively transcribed during trophoblast differentiation) in trophoblast cells thus consequently effecting their migration. Simvastatin 21-32 heat shock protein family B (small) member 1 Homo sapiens 185-206 17158816-5 2007 We hypothesized that simvastatin attenuates insuline-like growth factor-I (IGF-I) receptor expression (involved in trophoblast motility), matrix metalloproteinase (MMP) activities, and heat shock protein 27 (HSP27) levels (whose mRNA is actively transcribed during trophoblast differentiation) in trophoblast cells thus consequently effecting their migration. Simvastatin 21-32 heat shock protein family B (small) member 1 Homo sapiens 208-213 17158816-11 2007 RESULTS: Simvastatin reduced IGF-I receptor membranal expression, MMP2 activity and HSP27 expression in trophoblast cells (P < 0.05). Simvastatin 9-20 insulin like growth factor 1 receptor Homo sapiens 29-43 17158816-11 2007 RESULTS: Simvastatin reduced IGF-I receptor membranal expression, MMP2 activity and HSP27 expression in trophoblast cells (P < 0.05). Simvastatin 9-20 matrix metallopeptidase 2 Homo sapiens 66-70 17158816-11 2007 RESULTS: Simvastatin reduced IGF-I receptor membranal expression, MMP2 activity and HSP27 expression in trophoblast cells (P < 0.05). Simvastatin 9-20 heat shock protein family B (small) member 1 Homo sapiens 84-89 17344424-12 2007 Furthermore, simvastatin attenuated TNF-alpha-induced angiogenesis in vitro. Simvastatin 13-24 tumor necrosis factor Sus scrofa 36-45 17241114-0 2007 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 64-69 17241114-3 2007 Recent in vivo studies from our lab reported the novel finding that simvastatin increased expression levels of a gene encoding for a major cell survival protein, bcl-2 [Johnson-Anuna et al., J. Pharmacol. Simvastatin 68-79 BCL2 apoptosis regulator Homo sapiens 162-167 17241114-6 2007 The purpose of the present experiments was to determine if simvastatin could protect neurons from excitotoxicity by altering Bcl-2 levels. Simvastatin 59-70 BCL2 apoptosis regulator Homo sapiens 125-130 17241114-8 2007 Simvastatin pre-treatment resulted in a significant reduction in cytotoxicity (lactate dehydrogenase release and caspase 3 activation) following challenge compared with unchallenged neurons. Simvastatin 0-11 caspase 3 Homo sapiens 113-122 17241114-9 2007 In addition, chronic simvastatin treatment significantly increased Bcl-2 mRNA and protein levels while challenge resulted in a significant reduction in Bcl-2 protein abundance. Simvastatin 21-32 BCL2 apoptosis regulator Homo sapiens 67-72 17241114-9 2007 In addition, chronic simvastatin treatment significantly increased Bcl-2 mRNA and protein levels while challenge resulted in a significant reduction in Bcl-2 protein abundance. Simvastatin 21-32 BCL2 apoptosis regulator Homo sapiens 152-157 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 96-107 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 123-134 BCL2 apoptosis regulator Homo sapiens 53-58 17241114-10 2007 G3139, an antisense oligonucleotide directed against Bcl-2, abolished the protective effects of simvastatin and eliminated simvastatin-induced up-regulation of Bcl-2 protein. Simvastatin 123-134 BCL2 apoptosis regulator Homo sapiens 160-165 17241114-11 2007 These findings suggest that neuroprotection by simvastatin is dependent on the drug"s previously unexplored and important effect of up-regulating Bcl-2. Simvastatin 47-58 BCL2 apoptosis regulator Homo sapiens 146-151 17381388-8 2007 The interacting mechanism likely was inhibited cytochrome P450 (CYP) 3A4 metabolism and possibly P-glycoprotein transport of simvastatin as well. Simvastatin 125-136 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-72 17381388-8 2007 The interacting mechanism likely was inhibited cytochrome P450 (CYP) 3A4 metabolism and possibly P-glycoprotein transport of simvastatin as well. Simvastatin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 17381388-9 2007 Previous reports of simvastatin-clarithromycin-related events involved additional drugs that inhibited CYP3A4 and P-glycoprotein. Simvastatin 20-31 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 17381388-9 2007 Previous reports of simvastatin-clarithromycin-related events involved additional drugs that inhibited CYP3A4 and P-glycoprotein. Simvastatin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 17577472-0 2007 A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Simvastatin 65-76 component of oligomeric golgi complex 2 Homo sapiens 99-134 17505657-5 2007 RESULTS: The expression of TNFa could be clearly demonstrated in lower degree in skin wounds treated with simvastatin (668.6 +/- 74.7 im(2)) than in saline (2120.0 +/-327.1 im(2)). Simvastatin 106-117 tumor necrosis factor Rattus norvegicus 27-31 17577472-4 2007 OBJECTIVE: This analysis compared the cost-effectiveness of atorvastatin and generic simvastatin in terms of annual drug cost per patient treated to Canadian LDL-C targets. Simvastatin 85-96 component of oligomeric golgi complex 2 Homo sapiens 158-163 17577472-7 2007 Canadian data on statin dosing were combined with efficacy data from a published meta-analysis to determine the proportion of patients who would be expected to achieve LDL-C targets after treatment with atorvastatin or generic simvastatin. Simvastatin 227-238 component of oligomeric golgi complex 2 Homo sapiens 168-173 17577472-10 2007 RESULTS: The model predicted that more patients would reach the LDL-C target with atorvastatin than with simvastatin (73% vs 57%, respectively). Simvastatin 105-116 component of oligomeric golgi complex 2 Homo sapiens 64-69 17277159-2 2007 Therefore, in this article, we investigated the effects of simvastatin on TNF-alpha-induced cell signaling. Simvastatin 59-70 tumor necrosis factor Homo sapiens 74-83 17197385-10 2007 Intriguingly, simvastatin (10 microM) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappaB in astrocytes. Simvastatin 14-25 tyrosine aminotransferase Homo sapiens 57-60 17197385-10 2007 Intriguingly, simvastatin (10 microM) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappaB in astrocytes. Simvastatin 14-25 endothelin 1 Homo sapiens 69-73 17197385-10 2007 Intriguingly, simvastatin (10 microM) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappaB in astrocytes. Simvastatin 14-25 nuclear factor kappa B subunit 1 Homo sapiens 107-116 17217948-6 2007 The effects of simvastatin or Y27632 on the type I collagen mRNA (COL1A1 and COL1A2) expression induced by TGF-beta2 were evaluated by real-time RT-PCR. Simvastatin 15-26 collagen type I alpha 1 chain Homo sapiens 66-72 17217948-6 2007 The effects of simvastatin or Y27632 on the type I collagen mRNA (COL1A1 and COL1A2) expression induced by TGF-beta2 were evaluated by real-time RT-PCR. Simvastatin 15-26 transforming growth factor beta 2 Homo sapiens 107-116 17217948-7 2007 The effects of simvastatin or Y27632 on type I collagen synthesis induced by TGF-beta2 were assessed by immunocytochemical analysis with anti-type I collagen antibody. Simvastatin 15-26 transforming growth factor beta 2 Homo sapiens 77-86 17217948-11 2007 Preincubation of ARPE-19 with simvastatin (5 microM) or Y27632 (10 microM) significantly prevented TGF-beta2-induced COL1A1 and COL1A2 gene expression. Simvastatin 30-41 transforming growth factor beta 2 Homo sapiens 99-108 17217948-11 2007 Preincubation of ARPE-19 with simvastatin (5 microM) or Y27632 (10 microM) significantly prevented TGF-beta2-induced COL1A1 and COL1A2 gene expression. Simvastatin 30-41 collagen type I alpha 1 chain Homo sapiens 117-123 17217948-11 2007 Preincubation of ARPE-19 with simvastatin (5 microM) or Y27632 (10 microM) significantly prevented TGF-beta2-induced COL1A1 and COL1A2 gene expression. Simvastatin 30-41 collagen type I alpha 2 chain Homo sapiens 128-134 17217948-15 2007 Simvastatin and Y27632 reduced active RhoA-induced COL1A2 promoter activity. Simvastatin 0-11 ras homolog family member A Homo sapiens 38-42 17217948-15 2007 Simvastatin and Y27632 reduced active RhoA-induced COL1A2 promoter activity. Simvastatin 0-11 collagen type I alpha 2 chain Homo sapiens 51-57 17217948-17 2007 In the luciferase assay using a mutation construct of the Smad binding site in COL1A2 promoter (Smad-mut/Luc), the treatment with simvastatin and Y27632 significantly reduced TGF-beta2 induction of Smad-mut/Luc promoter activity. Simvastatin 130-141 collagen type I alpha 2 chain Homo sapiens 79-85 17217948-17 2007 In the luciferase assay using a mutation construct of the Smad binding site in COL1A2 promoter (Smad-mut/Luc), the treatment with simvastatin and Y27632 significantly reduced TGF-beta2 induction of Smad-mut/Luc promoter activity. Simvastatin 130-141 transforming growth factor beta 2 Homo sapiens 175-184 17217948-18 2007 On the other hand, both simvastatin and Y27632 significantly reduced CAGA12-Luc activity induced by TGF-beta2. Simvastatin 24-35 transforming growth factor beta 2 Homo sapiens 100-109 17130282-0 2007 The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. Simvastatin 84-95 apolipoprotein B Sus scrofa 57-65 17130282-2 2007 In clinical trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does monotherapy. Simvastatin 35-46 LDL Sus scrofa 64-79 17130282-12 2007 Ezetimibe plus simvastatin decreases VLDL and LDL apoB-100 concentrations through reduced VLDL production and upregulation of LDLR-mediated LDL clearance. Simvastatin 15-26 apolipoprotein B Sus scrofa 50-58 17130282-12 2007 Ezetimibe plus simvastatin decreases VLDL and LDL apoB-100 concentrations through reduced VLDL production and upregulation of LDLR-mediated LDL clearance. Simvastatin 15-26 low density lipoprotein receptor Sus scrofa 126-130 17257798-12 2007 The protective effects of simvastatin pretreatment also correlated with a 23% improvement in tissue edema, a 75% reduction in tissue myeloperoxidase content, and a 71% increase in glutathione levels in diabetic animals (P < .01). Simvastatin 26-37 myeloperoxidase Rattus norvegicus 133-148 17277159-0 2007 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 17277159-0 2007 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Simvastatin 0-11 NFKB inhibitor alpha Homo sapiens 140-152 17277159-0 2007 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Simvastatin 0-11 mitogen-activated protein kinase kinase kinase 7 Homo sapiens 164-191 17169357-6 2007 Our data suggest that simvastatin may be used as a therapeutic agent in asthma, based on reductions of various allergic responses via regulating small G proteins/MAP kinases/NF-kappaB in mouse allergic asthma. Simvastatin 22-33 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 174-183 17277159-3 2007 We found that simvastatin potentiated the apoptosis induced by TNF-alpha as indicated by intracellular esterase activity, caspase activation, TUNEL, and annexin V staining. Simvastatin 14-25 tumor necrosis factor Homo sapiens 63-72 17277159-7 2007 Simvastatin inhibited TNF-alpha-induced IkappaBalpha kinase activation, which led to inhibition of IkappaBalpha phosphorylation and degradation, suppression of p65 phosphorylation, and translocation to the nucleus. Simvastatin 0-11 tumor necrosis factor Homo sapiens 22-31 17277159-7 2007 Simvastatin inhibited TNF-alpha-induced IkappaBalpha kinase activation, which led to inhibition of IkappaBalpha phosphorylation and degradation, suppression of p65 phosphorylation, and translocation to the nucleus. Simvastatin 0-11 NFKB inhibitor alpha Homo sapiens 40-52 17277159-7 2007 Simvastatin inhibited TNF-alpha-induced IkappaBalpha kinase activation, which led to inhibition of IkappaBalpha phosphorylation and degradation, suppression of p65 phosphorylation, and translocation to the nucleus. Simvastatin 0-11 NFKB inhibitor alpha Homo sapiens 99-111 17277159-7 2007 Simvastatin inhibited TNF-alpha-induced IkappaBalpha kinase activation, which led to inhibition of IkappaBalpha phosphorylation and degradation, suppression of p65 phosphorylation, and translocation to the nucleus. Simvastatin 0-11 RELA proto-oncogene, NF-kB subunit Homo sapiens 160-163 17277159-8 2007 NF-kappaB-dependent reporter gene expression induced by TNF-alpha, TNFR1, TNFR-associated death domain protein, TNFR-associated factor 2, TGF-beta-activated kinase 1, receptor-interacting protein, NF-kappaB-inducing kinase, and IkappaB kinase beta was abolished by simvastatin. Simvastatin 265-276 mitogen-activated protein kinase kinase kinase 7 Homo sapiens 112-195 17327694-0 2007 Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. Simvastatin 0-11 insulin-like growth factor 1 Mus musculus 20-48 17304269-8 2007 Three studies had investigated the degree to which simvastatin and atorvastatin interact with a CYP3A4 inhibitor in the same population. Simvastatin 51-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 17304269-10 2007 INTERPRETATION: Interaction studies show that atorvastatin and simvastatin display differences in interaction potential toward warfarin and drugs inhibiting CYP3A4 metabolism. Simvastatin 63-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 157-163 17464346-11 2007 Simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly inhibited the elevated concentrations of TNF-alpha and sICAM-1, the activity of NF-kappaB, and the phosphorylation of p38 MAPK and ERK(1/2) induced by ADMA. Simvastatin 0-11 tumor necrosis factor Homo sapiens 92-101 17464346-11 2007 Simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly inhibited the elevated concentrations of TNF-alpha and sICAM-1, the activity of NF-kappaB, and the phosphorylation of p38 MAPK and ERK(1/2) induced by ADMA. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 131-140 17464346-11 2007 Simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly inhibited the elevated concentrations of TNF-alpha and sICAM-1, the activity of NF-kappaB, and the phosphorylation of p38 MAPK and ERK(1/2) induced by ADMA. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 169-172 17464346-11 2007 Simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly inhibited the elevated concentrations of TNF-alpha and sICAM-1, the activity of NF-kappaB, and the phosphorylation of p38 MAPK and ERK(1/2) induced by ADMA. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 182-189 17464346-12 2007 Simvastatin inhibited ADMA-induced inflammatory reaction by p38 MAPK and ERK(1/2) pathways in cultured endothelial cells. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 60-63 17464346-12 2007 Simvastatin inhibited ADMA-induced inflammatory reaction by p38 MAPK and ERK(1/2) pathways in cultured endothelial cells. Simvastatin 0-11 mitogen-activated protein kinase 3 Homo sapiens 73-80 16999946-0 2007 Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Simvastatin 53-64 C-reactive protein Homo sapiens 13-31 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 132-135 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 219-222 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 91-94 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 122-125 16999946-6 2007 CONCLUSIONS: A single high-dose simvastatin, given in the early time on admission, is an effective therapy for controlling inflammatory response in patients with UA, and the benefit to the vascular endothelium might occur quickly by reduction of CRP concentrations in this high-risk subgroup. Simvastatin 32-43 C-reactive protein Homo sapiens 246-249 17178392-0 2007 Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Simvastatin 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 21-30 17178392-4 2007 Simvastatin (50 micro M) significantly inhibited TNF-alpha-induced IL-8 gene expression in COLO 205 cells. Simvastatin 0-11 tumor necrosis factor Mus musculus 49-58 17178392-5 2007 Simvastatin (50 micro M) blocked TNF-alpha-induced NF-kappaB transcriptional activity, IkappaB phosphorylation/degradation and DNA binding activity of NF-kappaB. Simvastatin 0-11 tumor necrosis factor Mus musculus 33-42 17178392-5 2007 Simvastatin (50 micro M) blocked TNF-alpha-induced NF-kappaB transcriptional activity, IkappaB phosphorylation/degradation and DNA binding activity of NF-kappaB. Simvastatin 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 51-60 17178392-5 2007 Simvastatin (50 micro M) blocked TNF-alpha-induced NF-kappaB transcriptional activity, IkappaB phosphorylation/degradation and DNA binding activity of NF-kappaB. Simvastatin 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 151-160 17178392-7 2007 These results suggest that simvastatin inhibits proinflammatory gene expression by blocking NF-kappaB signaling in IEC, and attenuates DSS-induced acute murine colitis. Simvastatin 27-38 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 92-101 17079794-3 2007 In these studies, we demonstrate that treatment of J774 macrophages transfected to constitutively express a human apoE3 cDNA with simvastatin, to increase LDL receptor activity, reduces the secretion of apoE. Simvastatin 130-141 apolipoprotein E Homo sapiens 114-119 17079794-3 2007 In these studies, we demonstrate that treatment of J774 macrophages transfected to constitutively express a human apoE3 cDNA with simvastatin, to increase LDL receptor activity, reduces the secretion of apoE. Simvastatin 130-141 low density lipoprotein receptor Homo sapiens 155-167 17079794-3 2007 In these studies, we demonstrate that treatment of J774 macrophages transfected to constitutively express a human apoE3 cDNA with simvastatin, to increase LDL receptor activity, reduces the secretion of apoE. Simvastatin 130-141 apolipoprotein E Homo sapiens 114-118 17161379-5 2007 Pretreatment with 1-3 microM simvastatin for 24h inhibited AII-mediated stimulation of ERK1/2 and p38 MAPK phosphorylation; without affecting the levels on non-phosphorylated MAPK. Simvastatin 29-40 angiotensinogen Rattus norvegicus 59-62 17161379-5 2007 Pretreatment with 1-3 microM simvastatin for 24h inhibited AII-mediated stimulation of ERK1/2 and p38 MAPK phosphorylation; without affecting the levels on non-phosphorylated MAPK. Simvastatin 29-40 mitogen activated protein kinase 3 Rattus norvegicus 87-93 17161379-5 2007 Pretreatment with 1-3 microM simvastatin for 24h inhibited AII-mediated stimulation of ERK1/2 and p38 MAPK phosphorylation; without affecting the levels on non-phosphorylated MAPK. Simvastatin 29-40 mitogen activated protein kinase 14 Rattus norvegicus 98-106 17161379-5 2007 Pretreatment with 1-3 microM simvastatin for 24h inhibited AII-mediated stimulation of ERK1/2 and p38 MAPK phosphorylation; without affecting the levels on non-phosphorylated MAPK. Simvastatin 29-40 mitogen activated protein kinase 3 Rattus norvegicus 102-106 17161379-6 2007 Washout of simvastatin produced a rebound increase above control levels of AII-mediated phosphorylation of ERK1/2 and p38 MAPK. Simvastatin 11-22 angiotensinogen Rattus norvegicus 75-78 17161379-6 2007 Washout of simvastatin produced a rebound increase above control levels of AII-mediated phosphorylation of ERK1/2 and p38 MAPK. Simvastatin 11-22 mitogen activated protein kinase 3 Rattus norvegicus 107-113 17161379-6 2007 Washout of simvastatin produced a rebound increase above control levels of AII-mediated phosphorylation of ERK1/2 and p38 MAPK. Simvastatin 11-22 mitogen activated protein kinase 14 Rattus norvegicus 118-126 17273659-0 2007 Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Simvastatin 45-56 insulin Homo sapiens 132-139 17273659-2 2007 The objective of the present study was to evaluate the effect of simvastatin therapy on insulin resistance and on leptin, adiponectin, and C-reactive protein (CRP) levels, as compared to metformin, in overweight pre-diabetic subjects. Simvastatin 65-76 insulin Homo sapiens 88-95 17273659-2 2007 The objective of the present study was to evaluate the effect of simvastatin therapy on insulin resistance and on leptin, adiponectin, and C-reactive protein (CRP) levels, as compared to metformin, in overweight pre-diabetic subjects. Simvastatin 65-76 adiponectin, C1Q and collagen domain containing Homo sapiens 122-133 17182966-4 2007 Two lipophilic statins (simvastatin and fluvastatin) suppressed the cytotoxic activity of fresh and IL-2-stimulated NK cells, while pravastatin, a hydrophilic statin, did not. Simvastatin 24-35 interleukin 2 Homo sapiens 100-104 17251484-1 2007 PURPOSE: Results in a prior study have demonstrated that systemic administration of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin to healthy subjects reduces intraocular pressure and increases retinal blood flow. Simvastatin 156-167 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-145 17251484-6 2007 RESULTS: Retinal arterioles dilated dose dependently to simvastatin (1 nM to 10 muM). Simvastatin 56-67 latexin Homo sapiens 80-83 17327694-2 2007 In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells. Simvastatin 46-57 insulin-like growth factor 1 Mus musculus 112-140 17327694-2 2007 In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells. Simvastatin 46-57 insulin-like growth factor 1 Mus musculus 142-147 17327694-6 2007 After induction of differentiation in the presence of 1 microM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased. Simvastatin 63-74 insulin-like growth factor 1 Mus musculus 87-92 17327694-6 2007 After induction of differentiation in the presence of 1 microM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased. Simvastatin 63-74 mitogen-activated protein kinase 3 Mus musculus 115-121 17327694-6 2007 After induction of differentiation in the presence of 1 microM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased. Simvastatin 63-74 thymoma viral proto-oncogene 1 Mus musculus 126-129 17327694-7 2007 Although mRNA expression of the IGF-1 receptor beta-chain (IGF-1R beta) did not change, protein level of the 200 kDa IGF-1Rbeta precursor was significantly increased by simvastatin in a dose-dependent manner. Simvastatin 169-180 insulin-like growth factor 1 Mus musculus 32-37 17327694-9 2007 These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rbeta in an HMG-CoA reductase inhibition-independent manner. Simvastatin 27-38 insulin-like growth factor 1 Mus musculus 49-54 16942919-0 2007 Simvastatin stimulates macrophage interleukin-1beta secretion through an isoprenylation-dependent mechanism. Simvastatin 0-11 interleukin 1 beta Homo sapiens 34-51 17157514-0 2007 Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Simvastatin 77-88 LOW QUALITY PROTEIN: apoptosis regulator Bcl-2 Cavia porcellus 0-5 17157514-1 2007 The present study determined if chronic simvastatin administration in vivo would provide neuroprotection in brain cells isolated from guinea pigs after challenge with the Bcl-2 inhibitor HA 14-1 or the NO donor sodium nitroprusside (SNP). Simvastatin 40-51 LOW QUALITY PROTEIN: apoptosis regulator Bcl-2 Cavia porcellus 171-176 17157514-2 2007 Bcl-2 levels were significantly increased in brains of simvastatin-treated guinea pigs while levels of the pro-apoptotic protein Bax were significantly reduced. Simvastatin 55-66 LOW QUALITY PROTEIN: apoptosis regulator Bcl-2 Cavia porcellus 0-5 17157514-2 2007 Bcl-2 levels were significantly increased in brains of simvastatin-treated guinea pigs while levels of the pro-apoptotic protein Bax were significantly reduced. Simvastatin 55-66 apoptosis regulator BAX Cavia porcellus 129-132 17157514-3 2007 The ratio of Bax/Bcl-2, being a critical factor of the apoptotic state of cells, was significantly reduced in simvastatin-treated animals. Simvastatin 110-121 apoptosis regulator BAX Cavia porcellus 13-16 17157514-3 2007 The ratio of Bax/Bcl-2, being a critical factor of the apoptotic state of cells, was significantly reduced in simvastatin-treated animals. Simvastatin 110-121 LOW QUALITY PROTEIN: apoptosis regulator Bcl-2 Cavia porcellus 17-22 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 interleukin 1 beta Homo sapiens 128-136 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 141-145 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 199-226 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 228-237 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 interleukin 6 Homo sapiens 275-279 16942919-5 2007 Simvastatin-stimulated IL-1beta secretion from macrophages was inhibited by isoprenoids. Simvastatin 0-11 interleukin 1 beta Homo sapiens 23-31 16942919-6 2007 We therefore hypothesized that simvastatin stimulated IL-1beta secretion by affecting isoprenylation-dependent signaling pathways. Simvastatin 31-42 interleukin 1 beta Homo sapiens 54-62 17192506-0 2007 Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. Simvastatin 57-68 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 22-28 18074758-6 2007 The objective of this study was to determine changes in PON1 activity during treatment with simvastatin (CAS 79902-63-9, Lipex) in patients with type IIa and/or IIb hyperlipoproteinemia. Simvastatin 92-103 paraoxonase 1 Homo sapiens 56-60 18074758-13 2007 The antioxidant properties of simvastatin, which play an important role in HDL protection from oxidation, could be the mechanism inducing the increase in PON1 activity. Simvastatin 30-41 paraoxonase 1 Homo sapiens 154-158 17283433-10 2007 CONCLUSION: Intraperitoneal simvastatin application decreases adhesion formation by increasing the t-PA level in abdominal surgery. Simvastatin 28-39 plasminogen activator, tissue type Rattus norvegicus 99-103 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 C-reactive protein Homo sapiens 14-17 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 vascular cell adhesion molecule 1 Homo sapiens 21-27 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 C-C motif chemokine ligand 2 Homo sapiens 75-80 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 interleukin 6 Homo sapiens 85-89 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 C-reactive protein Homo sapiens 14-17 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 vascular cell adhesion molecule 1 Homo sapiens 21-27 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 C-C motif chemokine ligand 2 Homo sapiens 75-80 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 interleukin 6 Homo sapiens 85-89 17239709-10 2007 At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). Simvastatin 30-41 C-reactive protein Homo sapiens 81-84 17610348-0 2007 Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Simvastatin 11-22 insulin Homo sapiens 57-64 17610348-2 2007 OBJECTIVE: To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers. Simvastatin 34-45 insulin Homo sapiens 63-70 16529752-4 2007 The aim of this study was the comparison of cerivastatin and simvastatin-mediated effects on inflammation-induced ICAM-1 and VCAM-1 expression in human umbilical venous endothelial cells (HUVEC). Simvastatin 61-72 intercellular adhesion molecule 1 Homo sapiens 114-120 16529752-4 2007 The aim of this study was the comparison of cerivastatin and simvastatin-mediated effects on inflammation-induced ICAM-1 and VCAM-1 expression in human umbilical venous endothelial cells (HUVEC). Simvastatin 61-72 vascular cell adhesion molecule 1 Homo sapiens 125-131 16529752-11 2007 We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion. Simvastatin 34-45 tumor necrosis factor Homo sapiens 53-62 16529752-11 2007 We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion. Simvastatin 34-45 intercellular adhesion molecule 1 Homo sapiens 88-94 16529752-11 2007 We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion. Simvastatin 34-45 vascular cell adhesion molecule 1 Homo sapiens 99-105 16829188-7 2007 Simvastatin also increased the levels of K(ATP) channel proteins (SUR2 and Kir6.2) (P<0.05), but had no effect on necrosis area. Simvastatin 0-11 potassium inwardly rectifying channel subfamily J member 11 Sus scrofa 75-81 17192506-1 2007 Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 17192506-2 2007 The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Simvastatin 106-117 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 61-67 17192506-5 2007 The mean (+/-SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 +/- 2.25 ng x h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 +/- 6.37 ng x h/mL; P = .013, Bonferroni test). Simvastatin 68-79 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 87-93 17192506-8 2007 These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition. Simvastatin 83-94 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 44-50 17192506-8 2007 These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition. Simvastatin 167-178 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 44-50 18219956-0 2007 [The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome]. Simvastatin 37-48 C-reactive protein Homo sapiens 52-70 18260853-10 2007 At the background of therapy with simvastatin we noted significant lowering of proinflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-8) in blood serum irrespective of level of low density lipoprotein cholesterol, betterment of functional state of the left ventricle, positive clinical dynamics of CHF. Simvastatin 34-45 tumor necrosis factor Homo sapiens 106-114 18260853-10 2007 At the background of therapy with simvastatin we noted significant lowering of proinflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-8) in blood serum irrespective of level of low density lipoprotein cholesterol, betterment of functional state of the left ventricle, positive clinical dynamics of CHF. Simvastatin 34-45 interleukin 1 beta Homo sapiens 116-124 18260853-10 2007 At the background of therapy with simvastatin we noted significant lowering of proinflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-8) in blood serum irrespective of level of low density lipoprotein cholesterol, betterment of functional state of the left ventricle, positive clinical dynamics of CHF. Simvastatin 34-45 interleukin 6 Homo sapiens 126-130 18260853-10 2007 At the background of therapy with simvastatin we noted significant lowering of proinflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-8) in blood serum irrespective of level of low density lipoprotein cholesterol, betterment of functional state of the left ventricle, positive clinical dynamics of CHF. Simvastatin 34-45 C-X-C motif chemokine ligand 8 Homo sapiens 132-136 18219956-6 2007 Mean CRP level decreased significantly within two weeks in the group of patients receiving simvastatin (from 14.9 +/- 9.7 to 7.6 +/- 6.0 mg/l; p = 0.02). Simvastatin 91-102 C-reactive protein Homo sapiens 5-8 17929126-10 2007 Immunological assessment in peripheral blood revealed that the Th1/Th2 and CD4/CD8 ratios were significantly reduced by simvastatin. Simvastatin 120-131 CD4 molecule Homo sapiens 75-78 17929126-0 2007 Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Simvastatin 22-33 negative elongation factor complex member C/D Homo sapiens 79-82 17929126-10 2007 Immunological assessment in peripheral blood revealed that the Th1/Th2 and CD4/CD8 ratios were significantly reduced by simvastatin. Simvastatin 120-131 CD8a molecule Homo sapiens 79-82 17929126-12 2007 Immunomodulation through the alteration of Th1/Th2 and CD4/CD8 ratios may be a pharmacological mechanism in the anti-rheumatic effect of low-dosage simvastatin. Simvastatin 148-159 negative elongation factor complex member C/D Homo sapiens 43-46 17929126-0 2007 Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Simvastatin 22-33 CD4 molecule Homo sapiens 91-94 17929126-12 2007 Immunomodulation through the alteration of Th1/Th2 and CD4/CD8 ratios may be a pharmacological mechanism in the anti-rheumatic effect of low-dosage simvastatin. Simvastatin 148-159 CD4 molecule Homo sapiens 55-58 17929126-0 2007 Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Simvastatin 22-33 CD8a molecule Homo sapiens 95-98 17929126-8 2007 Of special interest was that the median levels of erythrocytes sedimentation rate, C-reactive protein, and rheumatoid factor were significantly decreased from 54.0 mm/h to 45.5 mm/h, from 1.50 mg/dl to 0.85 mg/dl, and from 57.0 IU/ml to 28.0 IU/ml, respectively, after administration of simvastatin. Simvastatin 287-298 C-reactive protein Homo sapiens 83-124 17929126-10 2007 Immunological assessment in peripheral blood revealed that the Th1/Th2 and CD4/CD8 ratios were significantly reduced by simvastatin. Simvastatin 120-131 negative elongation factor complex member C/D Homo sapiens 63-66 17929126-12 2007 Immunomodulation through the alteration of Th1/Th2 and CD4/CD8 ratios may be a pharmacological mechanism in the anti-rheumatic effect of low-dosage simvastatin. Simvastatin 148-159 CD8a molecule Homo sapiens 59-62 17318708-9 2007 These results show that children and adolescents with hypercholesterolemia present endothelial dysfunction, and simvastatin, in addition to significantly reducing TC, LDL-C, and apo B concentrations, restores endothelial function with 1-month treatment. Simvastatin 112-123 apolipoprotein B Homo sapiens 178-183 17377212-0 2007 Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Simvastatin 0-11 tumor necrosis factor Homo sapiens 50-59 17377212-2 2007 The aim of this study was to evaluate the influence of early treatment with simvastatin, an HMG-CoA reductase inhibitor, on serum TNF-alpha level in acute ischemic stroke (AIS). Simvastatin 76-87 tumor necrosis factor Homo sapiens 130-139 17377212-5 2007 Serum TNF-alpha level was significantly elevated on day 3 after the stroke onset in comparison to day 1 only in the simvastatin-treated group (increase in median values by 16.2% [p = 0.028] and 6.1% within 3 days in Group II and I, respectively). Simvastatin 116-127 tumor necrosis factor Homo sapiens 6-15 18047388-6 2007 A modelled US analysis that also included data from IDEAL and other sources showed an ICER of $US33,400 per QALY gained, assuming the incremental difference in acquisition cost between high-dose atorvastatin and conventional-dose simvastatin was $US1.40/day (2005 value). Simvastatin 230-241 cAMP responsive element modulator Homo sapiens 86-90 17377212-6 2007 These findings indicate that simvastatin given within 24 h after the onset of stroke could prevent the increase in serum TNF-alpha level within 3 days. Simvastatin 29-40 tumor necrosis factor Homo sapiens 121-130 17477084-7 2007 RESULTS: After 2-months therapy with simvastatin in patients with hlp II it was observed significantly decrease of activity of factor X (20.94 +/- 19.04 vs. 9.44 +/- 7.31 mU/mL), thrombin generation (79.62 +/- 36.68 vs. 67.99 +/- 37.69 U/mL), clot bound thrombin (49.73 +/- 21.17 vs. 37.08 +/- 26.10 U/mL) and increase of antithrombin III activity (13.03 +/- 6.11 vs. 20.64 +/- 4.18 U/mL). Simvastatin 37-48 coagulation factor II, thrombin Homo sapiens 179-187 17087598-9 2007 Both simvastatin and alendronate significantly suppressed the activity of AChE in the frontal cortex. Simvastatin 5-16 acetylcholinesterase Rattus norvegicus 74-78 17824809-8 2007 Prominent increase in the expression of eNOS in large conduit arteries may be the pathophysiological mechanism underlying the protective effect of simvastatin in hHTG rats. Simvastatin 147-158 nitric oxide synthase 3 Rattus norvegicus 40-44 17477084-7 2007 RESULTS: After 2-months therapy with simvastatin in patients with hlp II it was observed significantly decrease of activity of factor X (20.94 +/- 19.04 vs. 9.44 +/- 7.31 mU/mL), thrombin generation (79.62 +/- 36.68 vs. 67.99 +/- 37.69 U/mL), clot bound thrombin (49.73 +/- 21.17 vs. 37.08 +/- 26.10 U/mL) and increase of antithrombin III activity (13.03 +/- 6.11 vs. 20.64 +/- 4.18 U/mL). Simvastatin 37-48 coagulation factor II, thrombin Homo sapiens 254-262 17477084-7 2007 RESULTS: After 2-months therapy with simvastatin in patients with hlp II it was observed significantly decrease of activity of factor X (20.94 +/- 19.04 vs. 9.44 +/- 7.31 mU/mL), thrombin generation (79.62 +/- 36.68 vs. 67.99 +/- 37.69 U/mL), clot bound thrombin (49.73 +/- 21.17 vs. 37.08 +/- 26.10 U/mL) and increase of antithrombin III activity (13.03 +/- 6.11 vs. 20.64 +/- 4.18 U/mL). Simvastatin 37-48 serpin family C member 1 Homo sapiens 322-338 17853009-12 2007 CONCLUSIONS: Simvastatin decreased the serum TNF-alpha level in PD patients with a non-inflammatory status. Simvastatin 13-24 tumor necrosis factor Homo sapiens 45-54 17853009-13 2007 A decrease in the TNF-alpha level could be one of the possible mechanisms of the anti-atherogeneic effect of simvastatin. Simvastatin 109-120 tumor necrosis factor Homo sapiens 18-27 16844920-0 2006 Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Simvastatin 9-20 nitric oxide synthase 3, endothelial cell Mus musculus 68-72 17214935-10 2007 CONCLUSION: WQBP and simvastatin can interfere in early atherosclerosis of ApoE-mice, attenuate and stabilize plaque in some extent. Simvastatin 21-32 apolipoprotein E Mus musculus 75-79 17145229-0 2006 Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Simvastatin 49-60 C-reactive protein Homo sapiens 15-33 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 60-78 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 80-83 17145229-7 2006 After simvastatin administration, there was a significant reduction in levels of log(hs-CRP) (p = 0.001). Simvastatin 6-17 C-reactive protein Homo sapiens 88-91 17145229-8 2006 This effect of simvastatin was seen by day 7 (p = 0.008), with maximal reduction seen at day 14 (p = 0.004; hs-CRP in original units 3.1 +/- 0.5 mg/L with simvastatin and 4.1 +/- 0.6 mg/L with placebo). Simvastatin 15-26 C-reactive protein Homo sapiens 111-114 17145229-10 2006 By day 28 with simvastatin, hs-CRP had returned to near baseline levels. Simvastatin 15-26 C-reactive protein Homo sapiens 31-34 17145229-11 2006 In conclusion, in patients with type 2 diabetes mellitus, simvastatin reduced hs-CRP within 7 days. Simvastatin 58-69 C-reactive protein Homo sapiens 81-84 17094942-0 2006 Simvastatin inhibits lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiomyocytes: The role of reactive oxygen species. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 48-75 17094942-3 2006 The present study was to investigate the effects of simvastatin on TNF-alpha expression in cardiomyocytes and the underlying molecular mechanisms. Simvastatin 52-63 tumor necrosis factor Rattus norvegicus 67-76 17094942-4 2006 In neonatal rat cardiomyocytes, RT-PCR and ELISA showed lipopolysaccharide (LPS)-induced TNF-alpha expression was attenuated by simvastatin pretreatment in a dose-dependent manner. Simvastatin 128-139 tumor necrosis factor Rattus norvegicus 89-98 17094942-9 2006 These results suggest that simvastatin attenuates LPS-induced TNF-alpha expression in cardiomyocytes via inhibition of activation of NADPH oxidase and subsequent ROS generation. Simvastatin 27-38 tumor necrosis factor Rattus norvegicus 62-71 16858009-0 2006 Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Simvastatin 89-100 ras homolog family member A Homo sapiens 8-12 16858009-7 2006 The antiproliferative effects of simvastatin were mimicked by GGTI-286, a geranylgeranyltransferase-I inhibitor, C3 exoenzyme, an inhibitor of Rho, and Y-27632, an inhibitor of Rho-kinase, a target protein of RhoA. Simvastatin 33-44 protein geranylgeranyltransferase type I subunit beta Homo sapiens 62-66 16858009-7 2006 The antiproliferative effects of simvastatin were mimicked by GGTI-286, a geranylgeranyltransferase-I inhibitor, C3 exoenzyme, an inhibitor of Rho, and Y-27632, an inhibitor of Rho-kinase, a target protein of RhoA. Simvastatin 33-44 ras homolog family member A Homo sapiens 209-213 16844920-8 2006 The protective effects of simvastatin were abrogated by delayed initiation of treatment or genetic ablation of eNOS. Simvastatin 26-37 nitric oxide synthase 3, endothelial cell Mus musculus 111-115 16844920-9 2006 In conclusion, low-dose simvastatin therapy significantly improves survival and cardiac function and reduces both cardiac hypertrophy and pulmonary edema via an eNOS-dependent mechanism in a murine model of CHF. Simvastatin 24-35 nitric oxide synthase 3, endothelial cell Mus musculus 161-165 17192930-8 2006 Simvastatin treatment was associated with increased expression levels of protein kinase B (Akt) and endothelial nitric oxide synthase in the mouse brain. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 91-94 16858009-8 2006 Western blot analysis showed that the level of membrane localization of RhoA (active Rho) was markedly increased by FBS, and that the level of active RhoA increased by FBS was reduced by simvastatin. Simvastatin 187-198 ras homolog family member A Homo sapiens 72-76 16858009-8 2006 Western blot analysis showed that the level of membrane localization of RhoA (active Rho) was markedly increased by FBS, and that the level of active RhoA increased by FBS was reduced by simvastatin. Simvastatin 187-198 ras homolog family member A Homo sapiens 150-154 16858009-9 2006 Moreover, the inhibitory effect of simvastatin on FBS-induced RhoA activation was also antagonized by geranylgeranylpyrophosphate, but not by farnesylpyrophosphate. Simvastatin 35-46 ras homolog family member A Homo sapiens 62-66 16858009-10 2006 Because these isoprenoids are required for prenylation of small G proteins RhoA and Ras, respectively, the present results demonstrate that an inhibition in airway smooth muscle cell proliferation by simvastatin is due to prevention of geranylgeranylation of RhoA, not farnesylation of Ras. Simvastatin 200-211 ras homolog family member A Homo sapiens 75-79 16858009-10 2006 Because these isoprenoids are required for prenylation of small G proteins RhoA and Ras, respectively, the present results demonstrate that an inhibition in airway smooth muscle cell proliferation by simvastatin is due to prevention of geranylgeranylation of RhoA, not farnesylation of Ras. Simvastatin 200-211 ras homolog family member A Homo sapiens 259-263 16443229-7 2006 In conclusion, high-dose simvastatin pretreatment blunted TLR4 and TLR2 expression on monocytes in a human endotoxemia model on a posttranscriptional level. Simvastatin 25-36 toll like receptor 4 Homo sapiens 58-62 16443229-7 2006 In conclusion, high-dose simvastatin pretreatment blunted TLR4 and TLR2 expression on monocytes in a human endotoxemia model on a posttranscriptional level. Simvastatin 25-36 toll like receptor 2 Homo sapiens 67-71 17038636-0 2006 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Simvastatin 34-45 long intergenic non-protein coding RNA 914 Homo sapiens 15-19 17038636-4 2006 Thus, the aim of this study was to characterize the effect of simvastatin on the expression of RAGE and RAGE-dependent plaque-destabilizing genes in human atherosclerotic plaques. Simvastatin 62-73 long intergenic non-protein coding RNA 914 Homo sapiens 95-99 17038636-4 2006 Thus, the aim of this study was to characterize the effect of simvastatin on the expression of RAGE and RAGE-dependent plaque-destabilizing genes in human atherosclerotic plaques. Simvastatin 62-73 long intergenic non-protein coding RNA 914 Homo sapiens 104-108 17038636-8 2006 Of interest, RAGE inhibition by simvastatin, observed not only in plaque sections but also in plaque-derived macrophages, was reverted by addition of AGEs in vitro. Simvastatin 32-43 long intergenic non-protein coding RNA 914 Homo sapiens 13-17 17038636-9 2006 CONCLUSIONS: This study supports the hypothesis that simvastatin inhibits plaque RAGE expression by decreasing MPO-dependent AGE generation. Simvastatin 53-64 long intergenic non-protein coding RNA 914 Homo sapiens 81-85 17038636-9 2006 CONCLUSIONS: This study supports the hypothesis that simvastatin inhibits plaque RAGE expression by decreasing MPO-dependent AGE generation. Simvastatin 53-64 myeloperoxidase Homo sapiens 111-114 17192930-8 2006 Simvastatin treatment was associated with increased expression levels of protein kinase B (Akt) and endothelial nitric oxide synthase in the mouse brain. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 100-133 17178259-4 2006 Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-86 17184493-9 2006 Macrophage inflammatory protein-1alpha protein in THP-1 monocytes was reduced from 377 to 299 and 305 pg/mL by 0.1 micro mol/L simvastatin and 0.01 micro mol/L cerivastatin, respectively. Simvastatin 127-138 C-C motif chemokine ligand 3 Homo sapiens 0-38 17184493-9 2006 Macrophage inflammatory protein-1alpha protein in THP-1 monocytes was reduced from 377 to 299 and 305 pg/mL by 0.1 micro mol/L simvastatin and 0.01 micro mol/L cerivastatin, respectively. Simvastatin 127-138 GLI family zinc finger 2 Homo sapiens 50-55 17178262-8 2006 Furthermore, estrone-3-sulfate transport into OATP2B1-overexpressing Madin-Darby canine kidney II cells was inhibited by various drugs, including atorvastatin, simvastatin, cerivastatin, glyburide (INN, glibenclamide), and gemfibrozil, with the most pronounced effect being found for atorvastatin (inhibition constant, 0.7 +/- 0.4 micromol/L). Simvastatin 160-171 solute carrier organic anion transporter family member 2B1 Homo sapiens 46-53 17178259-4 2006 Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir). Simvastatin 0-11 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 128-134 17178259-4 2006 Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 235-241 17165637-8 2006 Ezetimibe/ simvastatin, 10/20 mg/d, reduced high-sensitivity C-reactive protein and triglyceride levels significantly more than atorvastatin, 10 mg/d (P = .02), with comparable reductions at other doses. Simvastatin 11-22 C-reactive protein Homo sapiens 61-79 17082725-6 2006 In comparison with cells from controls, PMNs obtained from patients before starting simvastatin treatment showed higher resting and fMLP-stimulated IL-8 release (P = 0.007 and P = 0.002, respectively) and ROS generation (resting, P = 0.009; and fMLP-stimulated, P = 0.046), whereas migration and the chemotactic index did not significantly differ. Simvastatin 84-95 formyl peptide receptor 1 Homo sapiens 132-136 17082725-6 2006 In comparison with cells from controls, PMNs obtained from patients before starting simvastatin treatment showed higher resting and fMLP-stimulated IL-8 release (P = 0.007 and P = 0.002, respectively) and ROS generation (resting, P = 0.009; and fMLP-stimulated, P = 0.046), whereas migration and the chemotactic index did not significantly differ. Simvastatin 84-95 C-X-C motif chemokine ligand 8 Homo sapiens 148-152 17082725-6 2006 In comparison with cells from controls, PMNs obtained from patients before starting simvastatin treatment showed higher resting and fMLP-stimulated IL-8 release (P = 0.007 and P = 0.002, respectively) and ROS generation (resting, P = 0.009; and fMLP-stimulated, P = 0.046), whereas migration and the chemotactic index did not significantly differ. Simvastatin 84-95 formyl peptide receptor 1 Homo sapiens 245-249 17046792-0 2006 Simvastatin reduces CD40 expression in an experimental model of early arterialization of saphenous vein graft. Simvastatin 0-11 CD40 molecule Homo sapiens 20-24 17046792-11 2006 CONCLUSIONS: Simvastatin treatment modulates endothelial CD40-sCD40L in both venous and arterial grafts, and therefore may represent a useful tool in the pharmacological prevention of graft failure. Simvastatin 13-24 CD40 molecule Homo sapiens 57-61 17108811-10 2006 CONCLUSIONS: SLCO1B1 polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Simvastatin 82-93 solute carrier organic anion transporter family member 1B1 Homo sapiens 13-20 17108811-2 2006 This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin. Simvastatin 132-143 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-82 17108811-11 2006 Raised plasma concentrations of simvastatin acid in patients carrying the SLCO1B1 c.521C variant allele may enhance the risk of systemic adverse effects during simvastatin treatment. Simvastatin 32-43 solute carrier organic anion transporter family member 1B1 Homo sapiens 74-81 17108811-2 2006 This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin. Simvastatin 132-143 solute carrier organic anion transporter family member 1B1 Homo sapiens 97-104 17313769-20 2006 CONCLUSION: Tongxinluo and simvastatin have the same effects of stabilizing the vulnerable plaques, and the mechanism may be related with inhibition of expression of COX-2 and MMP and reduction of the apoptosis in the atherosclerotic plaque. Simvastatin 27-38 cytochrome c oxidase subunit II Oryctolagus cuniculus 166-171 17112329-8 2006 Adjusted for baseline factors, percent LDL-C reduction was significantly greater with rosuvastatin versus atorvastatin or simvastatin (37% vs 28% or 27%, respectively; P <.05). Simvastatin 122-133 component of oligomeric golgi complex 2 Homo sapiens 39-44 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 20-55 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 57-62 17084257-10 2006 Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 174-179 17084257-13 2006 The LDL-C-independent effects of simvastatin may participate in the beneficial effect. Simvastatin 33-44 component of oligomeric golgi complex 2 Homo sapiens 4-9 17112859-0 2006 Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Simvastatin 0-11 C-C motif chemokine ligand 5 Homo sapiens 46-52 16774905-0 2006 HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 16774905-0 2006 HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Simvastatin 28-39 vascular endothelial growth factor A Homo sapiens 50-54 16774905-0 2006 HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Simvastatin 28-39 ras homolog family member A Homo sapiens 124-128 16774905-8 2006 Our data also indicate that simvastatin, via mevalonate depletion, reverses VEGF-induced ECM accumulation by preventing RhoA activation. Simvastatin 28-39 vascular endothelial growth factor A Homo sapiens 76-80 16774905-8 2006 Our data also indicate that simvastatin, via mevalonate depletion, reverses VEGF-induced ECM accumulation by preventing RhoA activation. Simvastatin 28-39 ras homolog family member A Homo sapiens 120-124 16386257-6 2006 In the presence or absence of E(2) (5 nM), simvastatin treatment in the range of 0.1-5.0 microM significantly reduced macrophage MMP-9 enzymatic activity (p<0.005) in a dose-dependent manner. Simvastatin 43-54 matrix metallopeptidase 9 Homo sapiens 129-134 16386257-7 2006 In the presence or absence of E(2), simvastatin also decreased ANXII expression (p<0.05). Simvastatin 36-47 annexin A2 Homo sapiens 63-68 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 annexin A2 Homo sapiens 29-34 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 matrix metallopeptidase 9 Homo sapiens 96-101 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 annexin A2 Homo sapiens 145-150 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 matrix metallopeptidase 9 Homo sapiens 166-171 16386257-9 2006 Prevention of E(2)-mediated activation of MMP-9 by simvastatin suggests that concurrent statin use may account for early event risk of myocardial infarction seen with hormone therapy in recent clinical trials. Simvastatin 51-62 matrix metallopeptidase 9 Homo sapiens 42-47 17268124-2 2006 We postulated that peroxisome proliferator activated receptor-gamma coactivator 1alpha (PGC-alpha), a transcriptional coactivator that is the primary regulator of oxidative metabolism and mitochondrial biogenesis, and cardiac function are depressive in DM and simvastatin and losartan therapy can improve the affects of DM on mRNA expression of PGC-1alpha and cardiac function. Simvastatin 260-271 PPARG coactivator 1 alpha Rattus norvegicus 19-86 16968805-10 2006 Simvastatin therapy significantly decreased hsCRP levels in MS subjects compared with placebo (P < 0.0005) and resulted in a significant reduction in plasma and lipopolysaccharide-activated monocytic release of IL-6 and TNF (P < 0.025). Simvastatin 0-11 interleukin 6 Homo sapiens 214-226 16968805-11 2006 Simvastatin therapy significantly decreased nuclear factor-kappaB and increased Akt activity in MS subjects compared with placebo. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 80-83 17086617-0 2006 Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. Simvastatin 143-154 tumor necrosis factor Homo sapiens 0-27 17075836-0 2006 RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Simvastatin 124-135 ras homolog family member A Homo sapiens 0-4 17075836-0 2006 RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Simvastatin 124-135 tumor necrosis factor Homo sapiens 15-42 17075836-3 2006 METHODS: Rheumatoid synoviocytes obtained from patients with active rheumatoid arthritis were stimulated with TNFalpha and incubated with simvastatin (SMV) (1 muM). Simvastatin 138-149 latexin Homo sapiens 159-162 17075836-8 2006 SMV prevented the increase in NF-kappaB activation and rise in IL-1beta and IL-6 levels induced by TNFalpha, whereas mevalonate and geranylgeranyl pyrophosphate reversed the inhibitory effects of SMV on activation of NF-kappaB and RhoA. Simvastatin 0-3 interleukin 1 beta Homo sapiens 63-71 17075836-8 2006 SMV prevented the increase in NF-kappaB activation and rise in IL-1beta and IL-6 levels induced by TNFalpha, whereas mevalonate and geranylgeranyl pyrophosphate reversed the inhibitory effects of SMV on activation of NF-kappaB and RhoA. Simvastatin 0-3 interleukin 6 Homo sapiens 76-80 17075836-8 2006 SMV prevented the increase in NF-kappaB activation and rise in IL-1beta and IL-6 levels induced by TNFalpha, whereas mevalonate and geranylgeranyl pyrophosphate reversed the inhibitory effects of SMV on activation of NF-kappaB and RhoA. Simvastatin 0-3 tumor necrosis factor Homo sapiens 99-107 17075836-8 2006 SMV prevented the increase in NF-kappaB activation and rise in IL-1beta and IL-6 levels induced by TNFalpha, whereas mevalonate and geranylgeranyl pyrophosphate reversed the inhibitory effects of SMV on activation of NF-kappaB and RhoA. Simvastatin 0-3 ras homolog family member A Homo sapiens 231-235 16781696-8 2006 After simvastatin treatment, the mRNA expressions of MCP-1 and CCR2 were significantly reduced in one and a half months and decreased to the lowest levels in three months. Simvastatin 6-17 C-C motif chemokine ligand 2 Homo sapiens 53-58 16781696-8 2006 After simvastatin treatment, the mRNA expressions of MCP-1 and CCR2 were significantly reduced in one and a half months and decreased to the lowest levels in three months. Simvastatin 6-17 C-C motif chemokine receptor 2 Homo sapiens 63-67 16781696-9 2006 CONCLUSIONS: Simvastatin decreased the expressions of MCP-1 and CCR2 in post-kidney transplant patients with hyperlipidemia. Simvastatin 13-24 C-C motif chemokine ligand 2 Homo sapiens 54-59 16781696-9 2006 CONCLUSIONS: Simvastatin decreased the expressions of MCP-1 and CCR2 in post-kidney transplant patients with hyperlipidemia. Simvastatin 13-24 C-C motif chemokine receptor 2 Homo sapiens 64-68 17112859-0 2006 Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Simvastatin 0-11 C-C motif chemokine receptor 5 Homo sapiens 57-61 17112859-2 2006 In this study, the mRNA expression of RANTES and its receptor CCR5 on peripheral blood mononuclear cells were measured in renal transplant recipients with hyperlipidemia, and the effect of simvastatin treatment observed to investigate the mechanism and prevention of CAN. Simvastatin 189-200 C-C motif chemokine ligand 5 Homo sapiens 38-44 17112859-10 2006 Meanwhile, the mRNA expressions of RANTES and CCR5 were reduced significantly after 1.5 months of simvastatin treatment to a level significantly lower than that in group A after 3 months of treatment. Simvastatin 98-109 C-C motif chemokine ligand 5 Homo sapiens 35-41 17112859-10 2006 Meanwhile, the mRNA expressions of RANTES and CCR5 were reduced significantly after 1.5 months of simvastatin treatment to a level significantly lower than that in group A after 3 months of treatment. Simvastatin 98-109 C-C motif chemokine receptor 5 Homo sapiens 46-50 16698853-6 2006 In contrast, treatment of rats with established SPH with simvastatin markedly reduced mean PAP and right ventricular hypertrophy, and this reduction was associated with caspase-3 activation and pulmonary microvascular endothelial cell apoptosis. Simvastatin 57-68 caspase 3 Rattus norvegicus 169-178 16978784-0 2006 Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia. Simvastatin 22-33 interferon beta 1 Homo sapiens 37-52 16978784-0 2006 Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia. Simvastatin 22-33 C-C motif chemokine ligand 5 Homo sapiens 75-96 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 C-C motif chemokine ligand 5 Homo sapiens 66-70 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 interferon beta 1 Homo sapiens 93-101 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 interferon beta 1 Homo sapiens 114-122 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 tumor necrosis factor Homo sapiens 123-132 16978784-7 2006 In the presence of simvastatin, the IFN-beta-induced activation of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) pathway was attenuated, although this compound had little or no effect on the TNF-alpha-evoked activation of nuclear factor kappaB and c-Jun N-terminal kinase pathways. Simvastatin 19-30 interferon beta 1 Homo sapiens 36-44 16978784-7 2006 In the presence of simvastatin, the IFN-beta-induced activation of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) pathway was attenuated, although this compound had little or no effect on the TNF-alpha-evoked activation of nuclear factor kappaB and c-Jun N-terminal kinase pathways. Simvastatin 19-30 tumor necrosis factor Homo sapiens 220-229 16978784-9 2006 Taken together, these results suggest that simvastatin suppresses the IFN-beta-induced expression of CCL5 via down-regulation of Jak-STAT signaling pathway. Simvastatin 43-54 interferon beta 1 Homo sapiens 70-78 16978784-9 2006 Taken together, these results suggest that simvastatin suppresses the IFN-beta-induced expression of CCL5 via down-regulation of Jak-STAT signaling pathway. Simvastatin 43-54 C-C motif chemokine ligand 5 Homo sapiens 101-105 16973154-7 2006 Unexpectedly, simvastatin increased adhesion molecules expression VCAM-1 and ICAM-1 on cytokine-stimulated endothelial cells. Simvastatin 14-25 intercellular adhesion molecule 1 Homo sapiens 77-83 16973154-8 2006 Examination of the actin cytoskeleton on IL-1beta-activated endothelial cells showed that both 4 and 24 h of incubation with simvastatin produced a complete disappearance of F-actin, being completely restored by MVA and partially by GGPP and FPP after 24 h of coincubation. Simvastatin 125-136 interleukin 1 beta Homo sapiens 41-49 16973154-6 2006 Simvastatin also significantly reduced the adhesion of monocytes to interleukin-1beta (IL-1beta)-activated endothelium to 80% after preincubation for 24 h. This effect was completely reversed by coincubation with MVA and GGPP, and partially with FPP. Simvastatin 0-11 interleukin 1 beta Homo sapiens 68-85 16973154-6 2006 Simvastatin also significantly reduced the adhesion of monocytes to interleukin-1beta (IL-1beta)-activated endothelium to 80% after preincubation for 24 h. This effect was completely reversed by coincubation with MVA and GGPP, and partially with FPP. Simvastatin 0-11 interleukin 1 beta Homo sapiens 87-95 16973154-7 2006 Unexpectedly, simvastatin increased adhesion molecules expression VCAM-1 and ICAM-1 on cytokine-stimulated endothelial cells. Simvastatin 14-25 vascular cell adhesion molecule 1 Homo sapiens 66-72 16698853-7 2006 Simvastatin partially restored caveolin-1, caveolin-2, and phospho-caveolin expression in vessel walls. Simvastatin 0-11 caveolin 1 Rattus norvegicus 31-41 16698853-7 2006 Simvastatin partially restored caveolin-1, caveolin-2, and phospho-caveolin expression in vessel walls. Simvastatin 0-11 caveolin 2 Rattus norvegicus 43-53 16698853-8 2006 In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. Simvastatin 58-69 caspase 3 Rattus norvegicus 78-87 16698853-8 2006 In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. Simvastatin 58-69 Rac family small GTPase 1 Rattus norvegicus 103-108 16698853-8 2006 In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. Simvastatin 58-69 ras homolog family member A Rattus norvegicus 138-143 16698853-8 2006 In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. Simvastatin 58-69 AKT serine/threonine kinase 1 Rattus norvegicus 169-172 16698853-8 2006 In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. Simvastatin 58-69 Eph receptor B1 Rattus norvegicus 177-180 16920939-5 2006 Serum cholesterol levels were unaffected by simvastatin treatment, but atherosclerotic lesion area was reduced in both apoE-/- and gld.apoE-/- mice treated with simvastatin. Simvastatin 161-172 apolipoprotein E Mus musculus 119-123 16384561-10 2006 On the other hand, Lp(a) serum levels increase from baseline to 60 days in the simvastatin group alone versus a significant decrease in the combination group. Simvastatin 79-90 lipoprotein(a) Homo sapiens 19-24 16384561-11 2006 Our findings provide support for a possible role of combined treatment with l-carnitine and simvastatin in lowering Lp(a) serum levels in patients with type 2 diabetes mellitus than with simvastatin alone. Simvastatin 92-103 lipoprotein(a) Homo sapiens 116-121 16384561-11 2006 Our findings provide support for a possible role of combined treatment with l-carnitine and simvastatin in lowering Lp(a) serum levels in patients with type 2 diabetes mellitus than with simvastatin alone. Simvastatin 187-198 lipoprotein(a) Homo sapiens 116-121 16868926-6 2006 Correspondingly, specific inhibition of cholesterol synthesis in periovulatory human granulosa cells using HMG-CoA reductase inhibitors (lovastatin or simvastatin) increased apoptosis, measured as caspase-3/7 activity. Simvastatin 151-162 caspase 3 Homo sapiens 197-206 16714062-6 2006 Among the statins, simvastatin, lovastatin and atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) while fluvastatin is metabolized by CYP2C9. Simvastatin 19-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 79-98 16714062-6 2006 Among the statins, simvastatin, lovastatin and atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) while fluvastatin is metabolized by CYP2C9. Simvastatin 19-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 16740276-0 2006 Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Simvastatin 0-11 ras homolog family member A Homo sapiens 156-160 16740276-2 2006 Here we demonstrate that the HMG-CoA reductase inhibitor simvastatin potentiates TNFalpha-mediated apoptosis and TNFalpha signaling in human umbilical vein endothelial cells (HUVECs). Simvastatin 57-68 tumor necrosis factor Homo sapiens 81-89 16740276-2 2006 Here we demonstrate that the HMG-CoA reductase inhibitor simvastatin potentiates TNFalpha-mediated apoptosis and TNFalpha signaling in human umbilical vein endothelial cells (HUVECs). Simvastatin 57-68 tumor necrosis factor Homo sapiens 113-121 16740276-3 2006 While 2.5 microM simvastatin or 40 ng/ml TNFalpha alone had only a small effect on apoptosis in HUVECs, co-incubation with simvastatin and TNFalpha markedly increased apoptosis in a time- and dose-dependent manner as measured by FACS analysis of propidium iodide-stained cells. Simvastatin 17-28 tumor necrosis factor Homo sapiens 139-147 16740276-3 2006 While 2.5 microM simvastatin or 40 ng/ml TNFalpha alone had only a small effect on apoptosis in HUVECs, co-incubation with simvastatin and TNFalpha markedly increased apoptosis in a time- and dose-dependent manner as measured by FACS analysis of propidium iodide-stained cells. Simvastatin 123-134 tumor necrosis factor Homo sapiens 41-49 16740276-4 2006 Geranylgeraniol, which serves as a substrate for the geranylgeranylation of small GTP binding proteins such as RhoA, which is required for the function and membrane localization of Rho, reversed the effect of simvastatin on apoptosis. Simvastatin 209-220 ras homolog family member A Homo sapiens 111-115 16740276-5 2006 GGTI, an inhibitor of protein geranylgeranylation, mimicked the effect of simvastatin on apoptosis and interfered with the membrane localization of RhoA. Simvastatin 74-85 protein geranylgeranyltransferase type I subunit beta Homo sapiens 0-4 16740276-6 2006 Furthermore, simvastatin increased the expression of the TNFalpha type I receptor (TNFalphaRI) with a dose dependence and a dependence on geranylgeranylation similar to that demonstrated for the potentiation of TNFalpha-mediated apoptosis. Simvastatin 13-24 tumor necrosis factor Homo sapiens 57-65 16740276-6 2006 Furthermore, simvastatin increased the expression of the TNFalpha type I receptor (TNFalphaRI) with a dose dependence and a dependence on geranylgeranylation similar to that demonstrated for the potentiation of TNFalpha-mediated apoptosis. Simvastatin 13-24 tumor necrosis factor Homo sapiens 83-91 16740276-7 2006 Adenoviral expression of a dominant-negative RhoA mimicked the effect of simvastatin on the expression of TNFalphaRI, while adenoviral expression of a dominant-activating RhoA mutant reversed the effect of simvastatin on the expression of TNFalphaRI. Simvastatin 73-84 ras homolog family member A Homo sapiens 45-49 16740276-7 2006 Adenoviral expression of a dominant-negative RhoA mimicked the effect of simvastatin on the expression of TNFalphaRI, while adenoviral expression of a dominant-activating RhoA mutant reversed the effect of simvastatin on the expression of TNFalphaRI. Simvastatin 206-217 ras homolog family member A Homo sapiens 171-175 16740276-8 2006 Simvastatin also potentiated TNFalpha signaling as determined by increased TNFalpha-mediated E-selectin expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 29-37 16740276-8 2006 Simvastatin also potentiated TNFalpha signaling as determined by increased TNFalpha-mediated E-selectin expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 75-83 16740276-8 2006 Simvastatin also potentiated TNFalpha signaling as determined by increased TNFalpha-mediated E-selectin expression. Simvastatin 0-11 selectin E Homo sapiens 93-103 16375908-4 2006 We found that, in vascular endothelial cells, simvastatin increased the steady-state levels of heat shock proteins 90 and 70, and heme oxygenase-1 and caused the nuclear translocation of heat shock factor 1. Simvastatin 46-57 heme oxygenase 1 Homo sapiens 130-146 16384561-0 2006 Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Simvastatin 69-80 lipoprotein(a) Homo sapiens 93-107 17022864-6 2006 Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p < 0.001), non-high-density lipoprotein cholesterol (p < 0.001), lipid ratios (p < or = 0.003), and apolipoprotein B (p < 0.05). Simvastatin 10-21 apolipoprotein B Homo sapiens 201-217 16621408-1 2006 The aim of the present work was to establish conditions for paraoxonase 3 (PON3) activity determination in human blood serum with simvastatin (SV) as a substrate. Simvastatin 130-141 paraoxonase 3 Homo sapiens 60-73 16621408-1 2006 The aim of the present work was to establish conditions for paraoxonase 3 (PON3) activity determination in human blood serum with simvastatin (SV) as a substrate. Simvastatin 130-141 paraoxonase 3 Homo sapiens 75-79 16621408-1 2006 The aim of the present work was to establish conditions for paraoxonase 3 (PON3) activity determination in human blood serum with simvastatin (SV) as a substrate. Simvastatin 143-145 paraoxonase 3 Homo sapiens 60-73 16621408-1 2006 The aim of the present work was to establish conditions for paraoxonase 3 (PON3) activity determination in human blood serum with simvastatin (SV) as a substrate. Simvastatin 143-145 paraoxonase 3 Homo sapiens 75-79 16321392-0 2006 Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Simvastatin 0-11 C-X-C motif chemokine receptor 4 Homo sapiens 36-54 16321392-6 2006 First, we have shown by ELISA that 1 microM simvastatin significantly reduced MCP-1 in endothelial cells (ECs) and macrophages stimulated with TNF-alpha or IFN-gamma, respectively. Simvastatin 44-55 chemokine (C-C motif) ligand 2 Mus musculus 78-83 16321392-6 2006 First, we have shown by ELISA that 1 microM simvastatin significantly reduced MCP-1 in endothelial cells (ECs) and macrophages stimulated with TNF-alpha or IFN-gamma, respectively. Simvastatin 44-55 tumor necrosis factor Mus musculus 143-152 16321392-6 2006 First, we have shown by ELISA that 1 microM simvastatin significantly reduced MCP-1 in endothelial cells (ECs) and macrophages stimulated with TNF-alpha or IFN-gamma, respectively. Simvastatin 44-55 interferon gamma Mus musculus 156-165 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine ligand 2 Homo sapiens 66-71 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine ligand 3 Homo sapiens 73-83 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine ligand 4 Homo sapiens 88-97 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine receptor 1 Homo sapiens 134-138 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine receptor 2 Homo sapiens 140-144 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine receptor 4 Homo sapiens 146-150 16321392-7 2006 Messenger RNA analysis revealed that expression of the chemokines MCP-1, MIP-1alpha and MIP-1beta, as well as the chemokine receptors CCR1, CCR2, CCR4 and CCR5, was decreased by simvastatin, both in ECs and macrophages. Simvastatin 178-189 C-C motif chemokine receptor 5 Homo sapiens 155-159 16870268-3 2006 Simvastatin, the statin with the strongest antiproliferative effect, inhibited IFN-gamma-induced expression of MHC class II DR on monocytes and decreased their antigen presenting capacity. Simvastatin 0-11 interferon gamma Homo sapiens 79-88 16870268-5 2006 Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation. Simvastatin 0-11 interferon gamma Homo sapiens 22-31 16920939-5 2006 Serum cholesterol levels were unaffected by simvastatin treatment, but atherosclerotic lesion area was reduced in both apoE-/- and gld.apoE-/- mice treated with simvastatin. Simvastatin 161-172 apolipoprotein E Mus musculus 135-139 16870268-5 2006 Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation. Simvastatin 0-11 tumor necrosis factor Homo sapiens 33-42 16870268-5 2006 Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation. Simvastatin 0-11 interleukin 2 Homo sapiens 48-52 16920939-6 2006 Simvastatin also reduced the lymphadenopathy, renal disease, and proinflammatory cytokine production seen in gld.apoE-/-, but not gld, mice. Simvastatin 0-11 apolipoprotein E Mus musculus 113-117 16893434-4 2006 At 6 weeks, ezetimibe 10 mg-simvastatin 20 mg provided a mean additional LDL-C reduction of 14.6% (95% CI 10.1-19.1) compared with simvastatin monotherapy (p < 0.0001). Simvastatin 28-39 component of oligomeric golgi complex 2 Homo sapiens 73-78 16944942-8 2006 Simvastatin treatment modified the plasma expression of FGG chain isoform 1, FGB chain isoforms 1 and 2, vitamin D binding protein isoform 3, apo A-IV, and haptoglobin isoform 2. Simvastatin 0-11 fibrinogen gamma chain Homo sapiens 56-59 16944942-8 2006 Simvastatin treatment modified the plasma expression of FGG chain isoform 1, FGB chain isoforms 1 and 2, vitamin D binding protein isoform 3, apo A-IV, and haptoglobin isoform 2. Simvastatin 0-11 fibrinogen beta chain Homo sapiens 77-80 16944942-8 2006 Simvastatin treatment modified the plasma expression of FGG chain isoform 1, FGB chain isoforms 1 and 2, vitamin D binding protein isoform 3, apo A-IV, and haptoglobin isoform 2. Simvastatin 0-11 apolipoprotein A4 Homo sapiens 142-150 16971767-9 2006 Four-week simvastatin treatment resulted in significant decrease of mesangial TF and PAI-1 mRNA (p < 0.01), and also of the plasma activities of TF (p < 0.05) and PAI-1 (p < 0.01). Simvastatin 10-21 plasminogen activator inhibitor 1 Oryctolagus cuniculus 85-90 16971767-9 2006 Four-week simvastatin treatment resulted in significant decrease of mesangial TF and PAI-1 mRNA (p < 0.01), and also of the plasma activities of TF (p < 0.05) and PAI-1 (p < 0.01). Simvastatin 10-21 plasminogen activator inhibitor 1 Oryctolagus cuniculus 169-174 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Simvastatin 55-66 component of oligomeric golgi complex 2 Homo sapiens 108-113 16893434-5 2006 Moreover, a higher proportion of patients on ezetimibe/simvastatin achieved the National Standard Framework LDL-C standard (<3.0 mmol/l; 93% vs. 75%, p < 0.001) or the new Joint British Societies (JBS 2) goal of LDL-C < 2.0 mmol/l (49.3% vs. 11.1%, p < 0.001). Simvastatin 55-66 component of oligomeric golgi complex 2 Homo sapiens 218-223 16893434-6 2006 On logistic regression analysis, the odds ratio of achieving target LDL-C with ezetimibe 10 mg-simvastatin 20 mg was 5.1 (95% CI 1.8-15.0) times higher than with simvastatin monotherapy (p = 0.003). Simvastatin 95-106 component of oligomeric golgi complex 2 Homo sapiens 68-73 16893434-6 2006 On logistic regression analysis, the odds ratio of achieving target LDL-C with ezetimibe 10 mg-simvastatin 20 mg was 5.1 (95% CI 1.8-15.0) times higher than with simvastatin monotherapy (p = 0.003). Simvastatin 162-173 component of oligomeric golgi complex 2 Homo sapiens 68-73 16985065-9 2006 All three statins (lovastatin, fluvastatin, and simvastatin) inhibited cyclin E/cdk2 kinase leading to hypophosphorylation of Rb, but this inhibition was correlated with a loss of the activating phosphorylation on Thr160 of cyclin E-associated cdk2 and not dependent on the cdk inhibitors p21 and p27. Simvastatin 48-59 cyclin dependent kinase 2 Homo sapiens 80-84 16985065-9 2006 All three statins (lovastatin, fluvastatin, and simvastatin) inhibited cyclin E/cdk2 kinase leading to hypophosphorylation of Rb, but this inhibition was correlated with a loss of the activating phosphorylation on Thr160 of cyclin E-associated cdk2 and not dependent on the cdk inhibitors p21 and p27. Simvastatin 48-59 cyclin dependent kinase 2 Homo sapiens 244-248 16985065-9 2006 All three statins (lovastatin, fluvastatin, and simvastatin) inhibited cyclin E/cdk2 kinase leading to hypophosphorylation of Rb, but this inhibition was correlated with a loss of the activating phosphorylation on Thr160 of cyclin E-associated cdk2 and not dependent on the cdk inhibitors p21 and p27. Simvastatin 48-59 H3 histone pseudogene 16 Homo sapiens 289-292 16985065-9 2006 All three statins (lovastatin, fluvastatin, and simvastatin) inhibited cyclin E/cdk2 kinase leading to hypophosphorylation of Rb, but this inhibition was correlated with a loss of the activating phosphorylation on Thr160 of cyclin E-associated cdk2 and not dependent on the cdk inhibitors p21 and p27. Simvastatin 48-59 dynactin subunit 6 Homo sapiens 297-300 16825658-4 2006 Although the mechanisms involved are unclear, we previously identified activation of the small GTPase Rac and translocation of cortactin, an actin-binding protein, as key to EC barrier augmentation induced by simvastatin and sphingosine 1-phosphate and therefore examined the role of these molecules in ATP-induced EC barrier enhancement. Simvastatin 209-220 AKT serine/threonine kinase 1 Homo sapiens 102-105 16825658-4 2006 Although the mechanisms involved are unclear, we previously identified activation of the small GTPase Rac and translocation of cortactin, an actin-binding protein, as key to EC barrier augmentation induced by simvastatin and sphingosine 1-phosphate and therefore examined the role of these molecules in ATP-induced EC barrier enhancement. Simvastatin 209-220 cortactin Homo sapiens 127-136 16797728-0 2006 Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. Simvastatin 32-43 LIF interleukin 6 family cytokine Homo sapiens 47-50 16735695-3 2006 Previously, we found that pravastatin, fluvastatin, and simvastatin induced the production of IL-18 in human monocytes. Simvastatin 56-67 interleukin 18 Homo sapiens 94-99 16735695-4 2006 The addition of mevalonate abolished the IL-18 production induced by pravastatin, fluvastatin, and simvastatin, indicating that the IL-18 production might be a result of the inhibition of HMG-CoA reductase. Simvastatin 99-110 interleukin 18 Homo sapiens 41-46 16735695-4 2006 The addition of mevalonate abolished the IL-18 production induced by pravastatin, fluvastatin, and simvastatin, indicating that the IL-18 production might be a result of the inhibition of HMG-CoA reductase. Simvastatin 99-110 interleukin 18 Homo sapiens 132-137 16797728-6 2006 Furthermore, immunomodulatory agents such as leptin, IFN-beta and simvastatin were studied for their potential to alter LIF and secretion of other cytokines by T cells and monocytes of relapsing remitting MS patients and healthy controls. Simvastatin 66-77 LIF interleukin 6 family cytokine Homo sapiens 120-123 16797728-7 2006 Low doses of simvastatin, but not IFN-beta or leptin enhanced LIF secretion by CD4+ T cells of RR-MS patients. Simvastatin 13-24 LIF interleukin 6 family cytokine Homo sapiens 62-65 16729291-3 2006 RESULTS: We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [(14)C]-sucrose across human BBB-ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE-cadherin, JAM-1, zonula occluden-1, and zonula occluden-2. Simvastatin 44-55 occludin Homo sapiens 296-304 16843192-8 2006 This effect also was greatest among patients with increased baseline levels of Lp-PLA(2) greater than the median of 320.9 ng/ml (fenofibrate = -41.3%, p < 0.0001; simvastatin = -47.5%, p < 0.0001; combination = -46.8%, p < 0.0001). Simvastatin 166-177 phospholipase A2 group VII Homo sapiens 79-88 16843192-9 2006 CONCLUSIONS: Simvastatin, fenofibrate, and combination therapy each lowered hsCRP and Lp-PLA(2). Simvastatin 13-24 phospholipase A2 group VII Homo sapiens 86-95 16449352-1 2006 In the current study, we investigated the effect of simvastatin on the ability of high glucose (HG) and ANG II to activate the JAK2-STAT signaling cascade and induce glomerular mesangial cell (GMC) growth. Simvastatin 52-63 angiotensinogen Rattus norvegicus 104-110 16449352-1 2006 In the current study, we investigated the effect of simvastatin on the ability of high glucose (HG) and ANG II to activate the JAK2-STAT signaling cascade and induce glomerular mesangial cell (GMC) growth. Simvastatin 52-63 Janus kinase 2 Rattus norvegicus 127-131 16449352-2 2006 We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. Simvastatin 32-43 angiotensinogen Rattus norvegicus 76-82 16449352-2 2006 We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. Simvastatin 32-43 Janus kinase 2 Rattus norvegicus 115-119 16449352-2 2006 We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. Simvastatin 32-43 signal transducer and activator of transcription 1 Rattus norvegicus 155-160 16449352-2 2006 We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. Simvastatin 32-43 signal transducer and activator of transcription 3 Rattus norvegicus 165-170 16449352-4 2006 Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1, and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. Simvastatin 173-184 Janus kinase 2 Rattus norvegicus 94-98 16449352-4 2006 Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1, and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. Simvastatin 173-184 signal transducer and activator of transcription 1 Rattus norvegicus 100-105 16449352-4 2006 Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1, and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. Simvastatin 173-184 signal transducer and activator of transcription 3 Rattus norvegicus 111-116 16449352-5 2006 This study demonstrates that simvastatin blocks ANG II-induced activation of the JAK/STAT pathway in the diabetic environment, in vitro and in vivo, and, thereby, provides new insights into the molecular mechanisms underlying early diabetic nephropathy. Simvastatin 29-40 angiotensinogen Rattus norvegicus 48-54 16729291-3 2006 RESULTS: We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [(14)C]-sucrose across human BBB-ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE-cadherin, JAM-1, zonula occluden-1, and zonula occluden-2. Simvastatin 44-55 cadherin 5 Homo sapiens 306-317 16729291-3 2006 RESULTS: We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [(14)C]-sucrose across human BBB-ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE-cadherin, JAM-1, zonula occluden-1, and zonula occluden-2. Simvastatin 44-55 F11 receptor Homo sapiens 319-324 16729291-5 2006 We further demonstrate that lovastatin and simvastatin treatment of BBB-ECs significantly restricts the migration of clinically isolated syndrome-derived and MS-derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein-1/CCL2 and interferon-gamma-inducible protein-10/CXCL10 by BBB-ECs. Simvastatin 43-54 C-C motif chemokine ligand 2 Homo sapiens 290-320 16729291-5 2006 We further demonstrate that lovastatin and simvastatin treatment of BBB-ECs significantly restricts the migration of clinically isolated syndrome-derived and MS-derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein-1/CCL2 and interferon-gamma-inducible protein-10/CXCL10 by BBB-ECs. Simvastatin 43-54 C-C motif chemokine ligand 2 Homo sapiens 321-325 16729291-5 2006 We further demonstrate that lovastatin and simvastatin treatment of BBB-ECs significantly restricts the migration of clinically isolated syndrome-derived and MS-derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein-1/CCL2 and interferon-gamma-inducible protein-10/CXCL10 by BBB-ECs. Simvastatin 43-54 C-X-C motif chemokine ligand 10 Homo sapiens 330-367 16729291-5 2006 We further demonstrate that lovastatin and simvastatin treatment of BBB-ECs significantly restricts the migration of clinically isolated syndrome-derived and MS-derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein-1/CCL2 and interferon-gamma-inducible protein-10/CXCL10 by BBB-ECs. Simvastatin 43-54 C-X-C motif chemokine ligand 10 Homo sapiens 368-374 16741180-0 2006 Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Simvastatin 80-91 chromosome 20 open reading frame 181 Homo sapiens 13-41 16450390-2 2006 Mevastatin and simvastatin, 2 inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, potentiated the intracellular accumulation and the cytotoxicity of doxorubicin in HMM cells constitutively expressing P-glycoprotein and multidrug resistance-associated protein 3. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-100 16710349-9 2006 Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin 164-175 CD2 associated protein Homo sapiens 69-74 16710349-9 2006 Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin 164-175 actinin alpha 4 Homo sapiens 81-87 16710349-9 2006 Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin 164-175 NPHS1 adhesion molecule, nephrin Homo sapiens 89-94 16710349-9 2006 Real-time polymerase chain reaction measurement of mRNA SD proteins (CD2AP, FAT, Actn 4, NPHS1, and NPHS2) significantly increased in kidney biopsy specimens after simvastatin, but not cholestyramine treatment. Simvastatin 164-175 NPHS2 stomatin family member, podocin Homo sapiens 100-105 16799230-3 2006 Simvastatin reduced serum low-density lipoprotein cholesterol (LDL-C) by 27% in both genders, and increased serum high-density lipoprotein cholesterol (HDL-C) in men (5%) and women (4%). Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 26-61 16799230-3 2006 Simvastatin reduced serum low-density lipoprotein cholesterol (LDL-C) by 27% in both genders, and increased serum high-density lipoprotein cholesterol (HDL-C) in men (5%) and women (4%). Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 63-68 16741180-0 2006 Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Simvastatin 80-91 matrix metallopeptidase 9 Homo sapiens 50-76 16741180-6 2006 RESULTS: Simvastatin (1 to 10 micromol/L) significantly reduced tPA-induced MMP-9 in cortical astrocytes. Simvastatin 9-20 chromosome 20 open reading frame 181 Homo sapiens 64-67 16741180-6 2006 RESULTS: Simvastatin (1 to 10 micromol/L) significantly reduced tPA-induced MMP-9 in cortical astrocytes. Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 76-81 16741180-7 2006 This effect may be mediated via the Rho kinase pathway because tPA-induced activation of Rho signaling was suppressed by simvastatin, and tPA-induced MMP-9 levels were similarly reduced by the Rho kinase inhibitor Y-27632 (1 to 10 micromol/L). Simvastatin 121-132 chromosome 20 open reading frame 181 Homo sapiens 63-66 16720415-11 2006 RESULTS: We observed that simvastatin significantly reduced total plasma cholesterol, triglyceride, and apoB cholesterol compared to non-treated controls. Simvastatin 26-37 apolipoprotein B Oryctolagus cuniculus 104-108 16776827-13 2006 Furthermore, Simvastatin dose-dependently inhibited fibroblast cyclin D1 gene and protein expression, inducing G1 cell cycle arrest. Simvastatin 13-24 cyclin D1 Homo sapiens 63-72 16776827-16 2006 This potentially unravels new molecular targets for future anti-IPF strategies; accordingly, Simvastatin inhibition of Rho-mediated cyclin D1 expression in IPF fibroblasts merits further exploitation. Simvastatin 93-104 cyclin D1 Homo sapiens 132-141 16720415-0 2006 Assessing lipid lowering and plasma cholesteryl ester transfer protein activity of simvastatin following administration to rabbits fed a high fat/cholesterol diet. Simvastatin 83-94 cholesteryl ester transfer protein Oryctolagus cuniculus 36-70 16720415-1 2006 PURPOSE: The purpose of this study was to assess the lipid lowering and plasma cholesteryl ester transfer protein (CETP) activity following administration of simvastatin to rabbits fed a high fat/cholesterol diet. Simvastatin 158-169 cholesteryl ester transfer protein Oryctolagus cuniculus 79-113 16682645-0 2006 Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Simvastatin 0-11 chitinase-like 3 Mus musculus 93-96 16720415-1 2006 PURPOSE: The purpose of this study was to assess the lipid lowering and plasma cholesteryl ester transfer protein (CETP) activity following administration of simvastatin to rabbits fed a high fat/cholesterol diet. Simvastatin 158-169 cholesteryl ester transfer protein Oryctolagus cuniculus 115-119 16406704-7 2006 However, slight increase of liver weight, serum AST and ALT levels were detected in SIMVA-dosing groups. Simvastatin 84-89 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 48-51 16406704-7 2006 However, slight increase of liver weight, serum AST and ALT levels were detected in SIMVA-dosing groups. Simvastatin 84-89 glutamic pyruvic transaminase, soluble Mus musculus 56-59 16723648-0 2006 Simvastatin decreases IL-6 and IL-8 production in epithelial cells. Simvastatin 0-11 interleukin 6 Homo sapiens 22-26 16723648-0 2006 Simvastatin decreases IL-6 and IL-8 production in epithelial cells. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 31-35 16723648-3 2006 Since oral epithelial cells participate importantly in periodontal inflammation, we measured simvastatin effects on interleukin-6 and interleukin-8 production by cultured human epithelial cell line (KB cells) in response to interleukin-1alpha. Simvastatin 93-104 interleukin 6 Homo sapiens 116-129 16723648-3 2006 Since oral epithelial cells participate importantly in periodontal inflammation, we measured simvastatin effects on interleukin-6 and interleukin-8 production by cultured human epithelial cell line (KB cells) in response to interleukin-1alpha. Simvastatin 93-104 C-X-C motif chemokine ligand 8 Homo sapiens 134-147 16723648-3 2006 Since oral epithelial cells participate importantly in periodontal inflammation, we measured simvastatin effects on interleukin-6 and interleukin-8 production by cultured human epithelial cell line (KB cells) in response to interleukin-1alpha. Simvastatin 93-104 interleukin 1 alpha Homo sapiens 224-242 16723648-5 2006 Simvastatin was found to reduce NF-kappaB and AP-1 promoter activity in KB cells. Simvastatin 0-11 JunD proto-oncogene, AP-1 transcription factor subunit Homo sapiens 46-50 16723648-7 2006 Our results may indicate an anti-inflammatory effect of simvastatin on human oral epithelial cells, apparently involving Rac1 GTPase inhibition. Simvastatin 56-67 Rac family small GTPase 1 Homo sapiens 121-125 16841674-4 2006 RESULTS: GSTT can relieve the damage of CMC and attenuate the ventricular remodeling after MI; high dose of GSTT and simvastatin could decrease CMC apoptosis (P<0.05), and lower Bax protein expression (P < 0.05); and there was no significant difference among the effects in all the treated group (P> 0.05). Simvastatin 117-128 BCL2 associated X, apoptosis regulator Rattus norvegicus 181-184 16682645-5 2006 These simvastatin-conditioned DCs up-regulated GATA-3 expression and down-regulated T-bet expression in cocultured CD4+ T cells in the absence of additional simvastatin added to the coculture. Simvastatin 6-17 GATA binding protein 3 Homo sapiens 47-53 16682645-6 2006 The Th2-biased transcription factor profile induced by simvastatin-treated DCs also was accompanied by increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1 (IFN-gamma) cytokine secretion from the T cells. Simvastatin 55-66 interleukin 4 Homo sapiens 118-122 16682645-6 2006 The Th2-biased transcription factor profile induced by simvastatin-treated DCs also was accompanied by increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1 (IFN-gamma) cytokine secretion from the T cells. Simvastatin 55-66 interleukin 5 Homo sapiens 124-128 16682645-6 2006 The Th2-biased transcription factor profile induced by simvastatin-treated DCs also was accompanied by increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1 (IFN-gamma) cytokine secretion from the T cells. Simvastatin 55-66 interleukin 13 Homo sapiens 134-139 16682645-6 2006 The Th2-biased transcription factor profile induced by simvastatin-treated DCs also was accompanied by increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1 (IFN-gamma) cytokine secretion from the T cells. Simvastatin 55-66 negative elongation factor complex member C/D Homo sapiens 155-158 16682645-6 2006 The Th2-biased transcription factor profile induced by simvastatin-treated DCs also was accompanied by increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1 (IFN-gamma) cytokine secretion from the T cells. Simvastatin 55-66 interferon gamma Homo sapiens 160-169 16682645-7 2006 The Th2-promoting effect of simvastatin was found to depend on the chitinase family member Ym1, known to be a lectin. Simvastatin 28-39 chitinase-like 3 Mus musculus 91-94 16775505-10 2006 The addition of simvastatin significantly prevented thrombin-induced down-regulation of eNOS expression in a concentration-dependent manner (100 nmol/L to 10 micromol/L). Simvastatin 16-27 coagulation factor II, thrombin Homo sapiens 52-60 16682645-8 2006 Anti-Ym1 antibody abolished the Th2-promoting effect of simvastatin-treated DCs. Simvastatin 56-67 chitinase-like 3 Mus musculus 5-8 16775505-12 2006 Both simvastatin and cerivastatin-blocked thrombin-induced decrease in NOS activity. Simvastatin 5-16 coagulation factor II, thrombin Homo sapiens 42-50 16775505-14 2006 Simvastatin (10 micromol/L) and cerivastatin (10 micromol/L) significantly decreased thrombin-induced membrane translocation of Rho A. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 85-93 16775505-14 2006 Simvastatin (10 micromol/L) and cerivastatin (10 micromol/L) significantly decreased thrombin-induced membrane translocation of Rho A. Simvastatin 0-11 ras homolog family member A Homo sapiens 128-133 16621994-2 2006 We show in this study that both atorvastatin and simvastatin induced proinflammatory responses in mitogen-activated PBMCs by increasing the number of T cells secreting IFN-gamma. Simvastatin 49-60 interferon gamma Homo sapiens 168-177 16621994-9 2006 We showed that simvastatin stimulates the secretion of IL-18 and IL-1beta in monocytes. Simvastatin 15-26 interleukin 18 Homo sapiens 55-60 16621994-9 2006 We showed that simvastatin stimulates the secretion of IL-18 and IL-1beta in monocytes. Simvastatin 15-26 interleukin 1 beta Homo sapiens 65-73 16621994-10 2006 Active caspase-1, which is required for the processing and secretion of IL-18 and IL-1beta, was activated in simvastatin-treated monocytes. Simvastatin 109-120 caspase 1 Homo sapiens 7-16 16621994-10 2006 Active caspase-1, which is required for the processing and secretion of IL-18 and IL-1beta, was activated in simvastatin-treated monocytes. Simvastatin 109-120 interleukin 18 Homo sapiens 72-77 16621994-10 2006 Active caspase-1, which is required for the processing and secretion of IL-18 and IL-1beta, was activated in simvastatin-treated monocytes. Simvastatin 109-120 interleukin 1 beta Homo sapiens 82-90 16557230-8 2006 Simvastatin attenuated CLP-induced tubular damage and reversed CLP-induced reduction of intrarenal microvascular perfusion and renal tubular hypoxia at 24 h. Simvastatin also restored towards normal CLP-induced renal vascular protein leak and serum TNF-alpha. Simvastatin 0-11 tumor necrosis factor Homo sapiens 249-258 16639331-2 2006 Simvastatin, an HMG-CoA reductase inhibitor, decreases intercellular adhesion molecule-1 expression and competitively inhibits leukocyte intercellular adhesion molecule-1 binding. Simvastatin 0-11 ICAM-1 Oryctolagus cuniculus 55-88 16480888-0 2006 Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Simvastatin 78-89 nuclear factor kappa B subunit 1 Rattus norvegicus 14-19 16480888-0 2006 Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Simvastatin 78-89 mitogen activated protein kinase 3 Rattus norvegicus 24-30 16639331-2 2006 Simvastatin, an HMG-CoA reductase inhibitor, decreases intercellular adhesion molecule-1 expression and competitively inhibits leukocyte intercellular adhesion molecule-1 binding. Simvastatin 0-11 ICAM-1 Oryctolagus cuniculus 137-170 16480888-1 2006 We investigated the effects of simvastatin treatment on the expression of IL-1beta and MCP-1, the activity of NF-kB, and the signaling pathways related to NF-kB activation in a rat model of permanent middle cerebral artery occlusion (pMCAO). Simvastatin 31-42 interleukin 1 beta Rattus norvegicus 74-82 16480888-1 2006 We investigated the effects of simvastatin treatment on the expression of IL-1beta and MCP-1, the activity of NF-kB, and the signaling pathways related to NF-kB activation in a rat model of permanent middle cerebral artery occlusion (pMCAO). Simvastatin 31-42 mast cell protease 1-like 1 Rattus norvegicus 87-92 16480888-2 2006 IL-1beta and MCP-1 expression, determined using RT-PCR, was enhanced by pMCAO; this effect was inhibited by the administration of simvastatin before ischemia. Simvastatin 130-141 interleukin 1 beta Rattus norvegicus 0-8 16480888-2 2006 IL-1beta and MCP-1 expression, determined using RT-PCR, was enhanced by pMCAO; this effect was inhibited by the administration of simvastatin before ischemia. Simvastatin 130-141 mast cell protease 1-like 1 Rattus norvegicus 13-18 16628357-0 2006 [Simvastatin inhibits hypertension-induced cardiac hypertrophy in rats through activation of heme oxygenase-1/carbon monoxide pathway]. Simvastatin 1-12 heme oxygenase 1 Rattus norvegicus 93-109 16480888-3 2006 Pre-treatment with simvastatin abolished the ischemia-induced activation of NF-kB observed in vehicle-treated animals. Simvastatin 19-30 nuclear factor kappa B subunit 1 Rattus norvegicus 76-81 16480888-4 2006 The evaluation of signal transduction pathways, including extracellular signal-regulated kinase (ERK1/2), SAPK/JNK 46/54 and p38, indicated that only ERK1/2 phosphorylation was enhanced by ischemia, and this activation was prevented by simvastatin. Simvastatin 236-247 mitogen activated protein kinase 3 Rattus norvegicus 150-156 16540096-4 2006 Human adult cardiac myocytes (HACM) were treated with different statins at concentrations from 0.01 to 5 microM for up to 96 h. Whereas the lipophilic statin simvastatin at a concentration of 5 microM downregulated Mcl-1 mRNA by 49%, the hydrophilic pravastatin had no effect. Simvastatin 158-169 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 215-220 16540096-6 2006 Simvastatin but not pravastatin reduced Mcl-1 protein expression whereas Bax protein was not detectable in HACM as determined by Western blotting. Simvastatin 0-11 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 40-45 16628357-7 2006 However, compared with the model group, L-NNA-induced cardiac hypertrophy of rats was significantly relieved in simvastatin treatment groups, associated with improved left ventricular function, decreased LVMI, lower BNP levels in plasma and myocardium, lower content of myocardial hydroxyproline, and increased myocardial heme oxygenase (HO) activity. Simvastatin 112-123 natriuretic peptide B Rattus norvegicus 216-219 16628357-8 2006 In cultured rat neonatal cardiomyocytes, simvastatin (30 or 100 mumol/L) significantly increased heme oxygenase-1 (HO-1) mRNA expression, HO activity as well as the production of CO in cardiomyocytes. Simvastatin 41-52 heme oxygenase 1 Rattus norvegicus 97-113 16628357-8 2006 In cultured rat neonatal cardiomyocytes, simvastatin (30 or 100 mumol/L) significantly increased heme oxygenase-1 (HO-1) mRNA expression, HO activity as well as the production of CO in cardiomyocytes. Simvastatin 41-52 heme oxygenase 1 Rattus norvegicus 115-119 16628357-10 2006 However, cocultured with simvastatin significantly inhibited the cardiomyocyte [(3)H]leucine uptake induced by angiotensin II in a concentration-dependent manner. Simvastatin 25-36 angiotensinogen Rattus norvegicus 111-125 16537817-1 2006 OBJECTIVE: To describe the fifth reported instance, as of February 15, 2006, of a severe interaction between simvastatin and amiodarone and hypothesize inhibition of CYP3A4 as the major mechanism. Simvastatin 109-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 166-172 16581329-6 2006 In persons taking simvastatin, lovastatin, or atorvastatin, 60% of cases involved drugs known to inhibit CYP3A4 (especially erythromycin and azole antifungals), and 19% involved fibrates, principally gemfibrozil. Simvastatin 18-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 16581325-4 2006 Drug metabolism studies show simvastatin and lovastatin to be especially sensitive to the inhibiting effects of other drugs on the cytochrome P-450 3A4 (CYP3A4) isoenzyme. Simvastatin 29-40 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-151 16581325-4 2006 Drug metabolism studies show simvastatin and lovastatin to be especially sensitive to the inhibiting effects of other drugs on the cytochrome P-450 3A4 (CYP3A4) isoenzyme. Simvastatin 29-40 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 153-159 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Simvastatin 69-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 121-140 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Simvastatin 69-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 142-148 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Simvastatin 69-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 244-250 16537817-8 2006 DISCUSSION: Simvastatin is metabolized primarily by CYP3A4, and amiodarone is a recognized inhibitor of this enzyme. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 16415122-7 2006 The commonly prescribed drugs loperamide, amitriptyline, diltiazem, domperidone, lansoprazole, omeprazole, and simvastatin were identified by our in silico and in vitro screens as relatively potent inhibitors of CYP3A4 that have the potential to interact with cytotoxic agents to cause adverse effects, highlighting the likelihood of drug-drug interactions affecting chemotherapy treatment. Simvastatin 111-122 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 212-218 16005883-4 2006 Atorvastatin and simvastatin reduced plasma-oxidized LDL (-43 and -35%, respectively) in proportion to the decrease in plasma apolipoprotein B. Simvastatin 17-28 apolipoprotein B Homo sapiens 126-142 16580903-1 2006 OBJECTIVE: Our objective was to compare simvastatin with the validated probe midazolam in the assessment of cytochrome P450 (CYP) 3A activity. Simvastatin 40-51 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-132 16580903-11 2006 CONCLUSIONS: Compared with midazolam, simvastatin is a nonvalidated, suboptimal probe for studying CYP3A drug interactions because of its lack of CYP3A specificity. Simvastatin 38-49 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-104 16778328-5 2006 Interestingly, the improvement of %FMD by treatment with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (simvastatin) was greater in the group showing a decrease in FasL mRNA than in the group with no such decrease. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-106 16542205-1 2006 AIMS: To evaluate whether simvastatin influences (i) the intestinal expression of P-glycoprotein (P-gp) and MRP2, and (ii) the disposition of the beta(1)-selective blocker talinolol, a substrate of these transporter proteins. Simvastatin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 16542205-1 2006 AIMS: To evaluate whether simvastatin influences (i) the intestinal expression of P-glycoprotein (P-gp) and MRP2, and (ii) the disposition of the beta(1)-selective blocker talinolol, a substrate of these transporter proteins. Simvastatin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 16542205-1 2006 AIMS: To evaluate whether simvastatin influences (i) the intestinal expression of P-glycoprotein (P-gp) and MRP2, and (ii) the disposition of the beta(1)-selective blocker talinolol, a substrate of these transporter proteins. Simvastatin 26-37 ATP binding cassette subfamily C member 2 Homo sapiens 108-112 16085716-0 2006 Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Simvastatin 11-22 interleukin 10 Homo sapiens 70-84 16778328-5 2006 Interestingly, the improvement of %FMD by treatment with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (simvastatin) was greater in the group showing a decrease in FasL mRNA than in the group with no such decrease. Simvastatin 118-129 Fas ligand Homo sapiens 178-182 16778328-6 2006 Additionally, simvastatin suppressed the FasL mRNA expression in leukocytes and decreased plasma oxidized low-density lipoprotein (OxLDL) levels. Simvastatin 14-25 Fas ligand Homo sapiens 41-45 16623076-4 2006 The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia. Simvastatin 51-62 carboxypeptidase B2 Homo sapiens 88-92 16515553-10 2006 Simvastatin reversed the inhibition of NF-kappaB activity induced by OGD/reoxygenation or HNE. Simvastatin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 39-48 16515553-11 2006 The neuroprotection by simvastatin was significantly attenuated by various NF-kappaB inhibitors, implying that simvastatin inhibits the cytotoxicity of HNE at least in part by maintaining the activity of NF-kappaB. Simvastatin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 75-84 16515553-11 2006 The neuroprotection by simvastatin was significantly attenuated by various NF-kappaB inhibitors, implying that simvastatin inhibits the cytotoxicity of HNE at least in part by maintaining the activity of NF-kappaB. Simvastatin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 204-213 16515553-11 2006 The neuroprotection by simvastatin was significantly attenuated by various NF-kappaB inhibitors, implying that simvastatin inhibits the cytotoxicity of HNE at least in part by maintaining the activity of NF-kappaB. Simvastatin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 75-84 16515553-11 2006 The neuroprotection by simvastatin was significantly attenuated by various NF-kappaB inhibitors, implying that simvastatin inhibits the cytotoxicity of HNE at least in part by maintaining the activity of NF-kappaB. Simvastatin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 204-213 16623076-11 2006 Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Simvastatin 59-70 carboxypeptidase B2 Homo sapiens 7-11 16623076-13 2006 CONCLUSION: Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients. Simvastatin 87-98 carboxypeptidase B2 Homo sapiens 38-42 16460674-0 2006 Simvastatin causes the formation of cholesterol-rich remnants in mice lacking apoE. Simvastatin 0-11 apolipoprotein E Mus musculus 78-82 16527992-12 2006 Simvastatin (3 to 30 micromol/L) also dose-dependently inhibited LY83583-induced CyPA secretion likely via decreased isoprenylation of small GTPases. Simvastatin 0-11 peptidylprolyl isomerase A Homo sapiens 81-85 16545796-5 2006 Furthermore, both EP2300 compounds and simvastatin significantly reduced triglyceride synthesis and apoB secretion and increased LDL receptor expression and LDL uptake in HepG2 cells. Simvastatin 39-50 apolipoprotein B Homo sapiens 100-104 16545796-5 2006 Furthermore, both EP2300 compounds and simvastatin significantly reduced triglyceride synthesis and apoB secretion and increased LDL receptor expression and LDL uptake in HepG2 cells. Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 129-141 16460674-4 2006 ApoE-deficient mice fed a chow diet containing simvastatin developed, as anticipated, an enhanced increase in plasma cholesterol and a decrease in plasma triglycerides. Simvastatin 47-58 apolipoprotein E Mus musculus 0-4 16460674-8 2006 These results indicate that the enhanced hypercholesterolemia observed in apoE-deficient mice treated with simvastatin is not the result of an increased number of remnant particles in circulation but is caused by synthesis and secretion into the plasma of lipoproteins that are enriched in cholesterol and depleted of triglycerides. Simvastatin 107-118 apolipoprotein E Mus musculus 74-78 16511915-0 2006 Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Simvastatin 0-11 interleukin 6 Homo sapiens 35-48 16518530-6 2006 Simvastatin exhibited a faster statistically significant decrease over time in IL-6 and sICAM 1 levels (at 7 days, p = 0.014 and p = 0.001, respectively). Simvastatin 0-11 interleukin 6 Homo sapiens 79-83 16518530-7 2006 TNF-alpha demonstrated a faster linear trend in the simvastatin group, but the significant effect appeared late (p = 0.006). Simvastatin 52-63 tumor necrosis factor Homo sapiens 0-9 16550313-1 2006 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has long been thought to exert its benefits by reducing cholesterol synthesis, and has been shown to significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 16305803-2 2006 The aim of this study was to detect and quantify the changes of endothelial expression of VCAM-1, and ICAM-1 in the vessel wall after the short-term administration of simvastatin, atorvastatin, and micro dispersed derivatives of oxidised cellulose (MDOC) in apolipoprotein-E-deficient (apoE(-/-)) mice atherosclerotic model. Simvastatin 167-178 vascular cell adhesion molecule 1 Mus musculus 90-96 16305803-2 2006 The aim of this study was to detect and quantify the changes of endothelial expression of VCAM-1, and ICAM-1 in the vessel wall after the short-term administration of simvastatin, atorvastatin, and micro dispersed derivatives of oxidised cellulose (MDOC) in apolipoprotein-E-deficient (apoE(-/-)) mice atherosclerotic model. Simvastatin 167-178 intercellular adhesion molecule 1 Mus musculus 102-108 16439692-7 2006 Moreover, simvastatin lowers the IFN-gamma-induced expression of RFX5 and MHC II in addition to repressing collagen expression. Simvastatin 10-21 interferon gamma Homo sapiens 33-42 16439692-7 2006 Moreover, simvastatin lowers the IFN-gamma-induced expression of RFX5 and MHC II in addition to repressing collagen expression. Simvastatin 10-21 regulatory factor X5 Homo sapiens 65-69 16574035-8 2006 The LDL-C-lowering efficacy of targeting both major sources of cholesterol with ezetimibe plus simvastatin was demonstrated in several multicentre, double-blind, placebo-controlled trials in patients with hypercholesterolaemia. Simvastatin 95-106 component of oligomeric golgi complex 2 Homo sapiens 4-9 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 interleukin 6 Homo sapiens 68-81 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 interleukin 6 Homo sapiens 83-87 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 C-X-C motif chemokine ligand 8 Homo sapiens 93-97 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 tumor necrosis factor Homo sapiens 132-159 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 tumor necrosis factor Homo sapiens 161-170 16511915-6 2006 RESULTS: Real-time PCR analysis revealed that the levels of IL-6 and IL-8 mRNA expressed by FLS were reduced by simvastatin in a dose-dependent manner. Simvastatin 112-123 interleukin 6 Homo sapiens 60-64 16511915-6 2006 RESULTS: Real-time PCR analysis revealed that the levels of IL-6 and IL-8 mRNA expressed by FLS were reduced by simvastatin in a dose-dependent manner. Simvastatin 112-123 C-X-C motif chemokine ligand 8 Homo sapiens 69-73 16511915-0 2006 Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Simvastatin 0-11 interleukin 6 Homo sapiens 50-54 16511915-7 2006 Levels of IL-6 and IL-8 in FLS culture supernatants were decreased by simvastatin in a time-dependent and dose-dependent manner. Simvastatin 70-81 interleukin 6 Homo sapiens 10-14 16511915-7 2006 Levels of IL-6 and IL-8 in FLS culture supernatants were decreased by simvastatin in a time-dependent and dose-dependent manner. Simvastatin 70-81 C-X-C motif chemokine ligand 8 Homo sapiens 19-23 16511915-0 2006 Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 60-64 16511915-8 2006 MTT assay revealed that simvastatin could inhibit proliferation of FLS induced by TNF-alpha. Simvastatin 24-35 tumor necrosis factor Homo sapiens 82-91 16511915-0 2006 Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Simvastatin 0-11 tumor necrosis factor Homo sapiens 99-126 16511915-9 2006 These effects of simvastatin on IL-6 and IL-8 production and cell proliferation were reversed in the presence of mevalonic acid or geranylgeranyl-pyrophosphate, but not with farnesyl-pyrophosphate. Simvastatin 17-28 interleukin 6 Homo sapiens 32-36 16511915-9 2006 These effects of simvastatin on IL-6 and IL-8 production and cell proliferation were reversed in the presence of mevalonic acid or geranylgeranyl-pyrophosphate, but not with farnesyl-pyrophosphate. Simvastatin 17-28 C-X-C motif chemokine ligand 8 Homo sapiens 41-45 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 72-75 16511915-10 2006 CONCLUSION: Our results suggest that the beneficial effect of simvastatin in RA patients may involve inhibition of IL-6 and IL-8 production, as well as reduction of cell proliferation. Simvastatin 62-73 interleukin 6 Homo sapiens 115-119 16511915-10 2006 CONCLUSION: Our results suggest that the beneficial effect of simvastatin in RA patients may involve inhibition of IL-6 and IL-8 production, as well as reduction of cell proliferation. Simvastatin 62-73 C-X-C motif chemokine ligand 8 Homo sapiens 124-128 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 interleukin 6 Homo sapiens 154-158 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 interleukin 1 beta Homo sapiens 163-171 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 interleukin 6 Homo sapiens 293-297 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 interleukin 1 beta Homo sapiens 302-310 16206159-4 2006 It is shown that exposure of human and murine microglial cells to simvastatin reduced cell surface expression of the chemokine receptors CCR5 and CXCR3. Simvastatin 66-77 chemokine (C-C motif) receptor 5 Mus musculus 137-141 16427097-8 2006 Specifically, we demonstrate that 3 statins, simvastatin, lovastatin, and mevastatin induce dose-dependent apoptosis in the TR-PCT1 pericyte cell line, that simvastatin (empirically shown to be the most potent of the 3 statins) induces similar levels of apoptosis in freshly isolated pericytes, and that simvastatin-induced apoptosis in pericytes is cholesterol, caspase-3, and caspase-7 mediated. Simvastatin 157-168 caspase 3 Rattus norvegicus 363-372 16427097-8 2006 Specifically, we demonstrate that 3 statins, simvastatin, lovastatin, and mevastatin induce dose-dependent apoptosis in the TR-PCT1 pericyte cell line, that simvastatin (empirically shown to be the most potent of the 3 statins) induces similar levels of apoptosis in freshly isolated pericytes, and that simvastatin-induced apoptosis in pericytes is cholesterol, caspase-3, and caspase-7 mediated. Simvastatin 157-168 caspase 7 Rattus norvegicus 378-387 16955753-1 2006 Cardiovascular drugs such as lovastatin, simvastatin, amlodipine besylate, nifedipine, and hydralazine hydrochloride inhibit cholesterol esterase (CEase) in vitro. Simvastatin 41-52 carboxyl ester lipase Homo sapiens 125-145 16955753-1 2006 Cardiovascular drugs such as lovastatin, simvastatin, amlodipine besylate, nifedipine, and hydralazine hydrochloride inhibit cholesterol esterase (CEase) in vitro. Simvastatin 41-52 carboxyl ester lipase Homo sapiens 147-152 16249194-11 2006 In the in vitro studies, the average value for cell-associated IL-6 and IL-8 was higher in CKD (155+/-95 pg/ml monocytes for IL-6 and 722+/-921 pg/ml monocytes for IL-8) vs HS (137+/-87 pg/ml monocytes and 186+/-125 pg/ml monocytes) (P<0.01) and was not affected by simvastatin alone. Simvastatin 269-280 interleukin 6 Homo sapiens 63-67 16249194-11 2006 In the in vitro studies, the average value for cell-associated IL-6 and IL-8 was higher in CKD (155+/-95 pg/ml monocytes for IL-6 and 722+/-921 pg/ml monocytes for IL-8) vs HS (137+/-87 pg/ml monocytes and 186+/-125 pg/ml monocytes) (P<0.01) and was not affected by simvastatin alone. Simvastatin 269-280 C-X-C motif chemokine ligand 8 Homo sapiens 72-76 16534557-0 2006 Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Simvastatin 0-11 cardiotrophin 1 Rattus norvegicus 57-72 16534557-4 2006 The purpose of this study was to explore the effects of simvastatin on the hypertrophy of cultured rat cardiomyocytes induced by CT-1 and to investigate whether this effect was mediated via JAK-STAT signaling pathway. Simvastatin 56-67 cardiotrophin 1 Rattus norvegicus 129-133 16534557-7 2006 Simvastatin was proved, in a dose-independent manner, to decrease cardiacmyocytes size as well as protein synthesis, and inhibit ANP mRNA synthesis and JAK-STAT protein expression induced by CT-1 in cardiacmyocytes. Simvastatin 0-11 cardiotrophin 1 Rattus norvegicus 191-195 16397146-4 2006 Here we show that the peroxisome proliferator-activated receptor (PPAR) alpha mediates antiinflammatory effects of simvastatin in vivo in models of acute inflammation. Simvastatin 115-126 peroxisome proliferator activated receptor alpha Homo sapiens 22-64 16397146-4 2006 Here we show that the peroxisome proliferator-activated receptor (PPAR) alpha mediates antiinflammatory effects of simvastatin in vivo in models of acute inflammation. Simvastatin 115-126 peroxisome proliferator activated receptor alpha Homo sapiens 66-70 16397146-6 2006 Moreover, simvastatin inhibited PPARalpha phosphorylation by lipopolysaccharide-activated protein kinase C (PKC) alpha. Simvastatin 10-21 peroxisome proliferator activated receptor alpha Homo sapiens 32-41 16397146-6 2006 Moreover, simvastatin inhibited PPARalpha phosphorylation by lipopolysaccharide-activated protein kinase C (PKC) alpha. Simvastatin 10-21 protein kinase C alpha Homo sapiens 108-118 16397146-7 2006 A constitutive active form of PKCalpha inhibited nuclear factor kappaB transrepression by PPARalpha whereas simvastatin enhanced transrepression activity of wild-type PPARalpha, but not of PPARalpha mutated in its PKC phosphorylation sites. Simvastatin 108-119 peroxisome proliferator activated receptor alpha Homo sapiens 167-176 16397146-7 2006 A constitutive active form of PKCalpha inhibited nuclear factor kappaB transrepression by PPARalpha whereas simvastatin enhanced transrepression activity of wild-type PPARalpha, but not of PPARalpha mutated in its PKC phosphorylation sites. Simvastatin 108-119 peroxisome proliferator activated receptor alpha Homo sapiens 167-176 16397146-8 2006 These data indicate that the acute antiinflammatory effect of simvastatin occurs via PPARalpha by a mechanism involving inhibition of PKCalpha inactivation of PPARalpha transrepression activity. Simvastatin 62-73 peroxisome proliferator activated receptor alpha Homo sapiens 85-94 16397146-8 2006 These data indicate that the acute antiinflammatory effect of simvastatin occurs via PPARalpha by a mechanism involving inhibition of PKCalpha inactivation of PPARalpha transrepression activity. Simvastatin 62-73 protein kinase C alpha Homo sapiens 134-142 16397146-8 2006 These data indicate that the acute antiinflammatory effect of simvastatin occurs via PPARalpha by a mechanism involving inhibition of PKCalpha inactivation of PPARalpha transrepression activity. Simvastatin 62-73 peroxisome proliferator activated receptor alpha Homo sapiens 159-168 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 KIT ligand Homo sapiens 50-66 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 KIT ligand Homo sapiens 68-71 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 mitogen-activated protein kinase 1 Homo sapiens 98-135 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 mitogen-activated protein kinase 1 Homo sapiens 137-140 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 protein tyrosine kinase 2 beta Homo sapiens 143-159 16170339-5 2006 These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Simvastatin 193-204 protein tyrosine kinase 2 beta Homo sapiens 161-164 16170339-6 2006 Constitutive activation of the Erk pathway was sufficient to rescue SCLC cell from the effects of simvastatin. Simvastatin 98-109 mitogen-activated protein kinase 1 Homo sapiens 31-34 16168661-0 2006 Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Simvastatin 0-11 heat shock protein family B (small) member 1 Rattus norvegicus 21-42 16168661-0 2006 Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 58-61 16168661-4 2006 Here, we show that intravitreal injection of the 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor simvastatin induces Hsp27 expression in axotomized retinal ganglion cells (RGCs) and enhances RGC survival 7 and 14 days after optic nerve (ON) axotomy by 90% and 19%, respectively. Simvastatin 110-121 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 49-99 16168661-4 2006 Here, we show that intravitreal injection of the 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor simvastatin induces Hsp27 expression in axotomized retinal ganglion cells (RGCs) and enhances RGC survival 7 and 14 days after optic nerve (ON) axotomy by 90% and 19%, respectively. Simvastatin 110-121 heat shock protein family B (small) member 1 Rattus norvegicus 130-135 16168661-6 2006 Simvastatin increased Akt phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to central nervous system (CNS) protective effects achieved. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 22-25 16168661-6 2006 Simvastatin increased Akt phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to central nervous system (CNS) protective effects achieved. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 76-79 16206159-4 2006 It is shown that exposure of human and murine microglial cells to simvastatin reduced cell surface expression of the chemokine receptors CCR5 and CXCR3. Simvastatin 66-77 chemokine (C-X-C motif) receptor 3 Mus musculus 146-151 16214041-4 2006 In this study, we showed that lovastatin, fluvastatin, atorvastatin, simvastatin, mevastatin and pravastatin are able to upregulate the mRNA expression of HO-1 gene. Simvastatin 69-80 heme oxygenase 1 Mus musculus 155-159 16780390-7 2006 Serum levels of M-CSF were significantly decreased only in the simvastatin group (from 403 +/- 71 to 303 +/- 116 pg/mL; p = 0.009). Simvastatin 63-74 colony stimulating factor 1 Homo sapiens 16-21 16780390-9 2006 Simvastatin decreased serum M-CSF levels independently of changes in total cholesterol or low-density lipoprotein-cholesterol. Simvastatin 0-11 colony stimulating factor 1 Homo sapiens 28-33 16780390-10 2006 CONCLUSIONS: The results of this study indicate that simvastatin decreases serum levels of M-CSF while losartan increases plasma levels of TGF-beta, suggesting that the two drugs may have different anti-atherosclerotic properties. Simvastatin 53-64 colony stimulating factor 1 Homo sapiens 91-96 16297860-0 2006 Simvastatin enhances bone morphogenetic protein receptor type II expression. Simvastatin 0-11 bone morphogenetic protein receptor type 2 Homo sapiens 21-64 16297860-5 2006 Here, modulation of BMPR2 gene expression by simvastatin is characterized in human embryonic kidney (HEK) 293T, pulmonary artery smooth muscle, and lung microvascular endothelial cells (HLMVECs). Simvastatin 45-56 bone morphogenetic protein receptor type 2 Homo sapiens 20-25 16297860-6 2006 A 1.4kb BMPR2 promoter containing Egr-1 binding sites confers reporter gene activation in 293T cells which is partially inhibited by simvastatin. Simvastatin 133-144 bone morphogenetic protein receptor type 2 Homo sapiens 8-13 16297860-6 2006 A 1.4kb BMPR2 promoter containing Egr-1 binding sites confers reporter gene activation in 293T cells which is partially inhibited by simvastatin. Simvastatin 133-144 early growth response 1 Homo sapiens 34-39 16297860-7 2006 Simvastatin enhances steady-state BMPR2 mRNA and protein expression in HLMVEC, through posttranscriptional mRNA stabilization. Simvastatin 0-11 bone morphogenetic protein receptor type 2 Homo sapiens 34-39 16297860-8 2006 Simvastatin induction of BMPR2 expression may improve BMP-BMPR2 signaling thereby enhancing endothelial differentiation and function. Simvastatin 0-11 bone morphogenetic protein receptor type 2 Homo sapiens 25-30 16297860-8 2006 Simvastatin induction of BMPR2 expression may improve BMP-BMPR2 signaling thereby enhancing endothelial differentiation and function. Simvastatin 0-11 bone morphogenetic protein 1 Homo sapiens 25-28 16297860-8 2006 Simvastatin induction of BMPR2 expression may improve BMP-BMPR2 signaling thereby enhancing endothelial differentiation and function. Simvastatin 0-11 bone morphogenetic protein receptor type 2 Homo sapiens 58-63 16960448-5 2006 RESULTS: Simvastatin significantly increased CSF PLTP activity (p = 0.005). Simvastatin 9-20 phospholipid transfer protein Homo sapiens 49-53 16611111-3 2006 The assumption exists that the effect of clopidogrel in inhibiting platelet aggregation is attenuated by co-administration of lipophilic statins such as atorvastatin or simvastatin which are metabolised by the CYP3A4 system to inactive substrates. Simvastatin 169-180 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 210-216 16960448-7 2006 In the pravastatin-treated group, CSF apoE concentration decreased significantly (p = 0.026), while the simvastatin-treated group showed a tendency towards lower CSF apoE levels, with CSF apoE concentration lowered in 8 of 10 subjects. Simvastatin 104-115 apolipoprotein E Homo sapiens 166-170 16960448-7 2006 In the pravastatin-treated group, CSF apoE concentration decreased significantly (p = 0.026), while the simvastatin-treated group showed a tendency towards lower CSF apoE levels, with CSF apoE concentration lowered in 8 of 10 subjects. Simvastatin 104-115 apolipoprotein E Homo sapiens 166-170 17184595-0 2006 Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Simvastatin 0-11 TIMP metallopeptidase inhibitor 1 Homo sapiens 54-60 16944963-5 2006 Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Simvastatin 235-246 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 182-197 16944963-5 2006 Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Simvastatin 235-246 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 199-202 17184595-0 2006 Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 48-53 17184595-2 2006 The aim of our study was to analyse both serum MMP-9 and its most specific endogenous inhibitor (TIMP-1) levels in AIS and to check whether HMG-CoA reductase inhibitor (simvastatin) affects the MMP-9/TIMP-1 ratio value. Simvastatin 169-180 matrix metallopeptidase 9 Homo sapiens 194-199 17184595-2 2006 The aim of our study was to analyse both serum MMP-9 and its most specific endogenous inhibitor (TIMP-1) levels in AIS and to check whether HMG-CoA reductase inhibitor (simvastatin) affects the MMP-9/TIMP-1 ratio value. Simvastatin 169-180 TIMP metallopeptidase inhibitor 1 Homo sapiens 200-206 17184595-8 2006 These findings indicate that simvastatin given during 24 hours after the onset of stroke could have an influence on the MMP-9/TIMP-1 ratio during AIS. Simvastatin 29-40 matrix metallopeptidase 9 Homo sapiens 120-125 17184595-8 2006 These findings indicate that simvastatin given during 24 hours after the onset of stroke could have an influence on the MMP-9/TIMP-1 ratio during AIS. Simvastatin 29-40 TIMP metallopeptidase inhibitor 1 Homo sapiens 126-132 16850745-6 2006 This study demonstrated that simvastatin could decrease atherosclerosis by inhibiting the NF-kappaB-DNA binding activity and by reducing the expression of MCP-1 protein. Simvastatin 29-40 C-C motif chemokine 2 Oryctolagus cuniculus 155-160 16424782-0 2006 Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 35-69 16414398-11 2006 MMP-9 and nuclear factor-kappaB protein levels were decreased in the aortas of simvastatin-treated animals. Simvastatin 79-90 matrix metallopeptidase 9 Rattus norvegicus 0-5 16414398-15 2006 CONCLUSIONS: Simvastatin significantly suppresses experimental aneurysm expansion and reduces protein levels of MMP-9 and nuclear factor-kappaB. Simvastatin 13-24 matrix metallopeptidase 9 Rattus norvegicus 112-117 17237547-8 2006 Adenoviral expression of a DN-RhoA mutant mimicked the effect of simvastatin on tube formation and the formation of honeycombs, whereas a dominant activating mutant of RhoA reversed the effect of simvastatin on tube formation. Simvastatin 65-76 ras homolog family member A Homo sapiens 30-34 16474306-7 2006 The results of the study document positive effect of half year treatment of patients with concomitant hypertension and diabetes with simvastatin (10-20 mg/day) in combination with ACEI and verapamil on metabolism of nitric oxide and plasma content of TNF-alpha which realizes independently from degree of hypolipidemic action of simvastatin. Simvastatin 133-144 tumor necrosis factor Homo sapiens 251-260 16054375-0 2006 Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat. Simvastatin 0-11 caspase 3 Rattus norvegicus 20-29 16054375-4 2006 In simvastatin-treated ischemic animals, the expression of these proteins and caspase-3 activity were significantly lower when compared to that of ischemic animals. Simvastatin 3-14 caspase 3 Rattus norvegicus 78-87 16054375-6 2006 Poly (ADP-ribose) polymerase fragmentation, caspase-1 activation, and IL-1beta and ICAM-1 mRNA expression were increased by hypoxia-ischemia and significantly reduced in simvastatin-treated animals. Simvastatin 170-181 caspase 1 Rattus norvegicus 44-53 16054375-6 2006 Poly (ADP-ribose) polymerase fragmentation, caspase-1 activation, and IL-1beta and ICAM-1 mRNA expression were increased by hypoxia-ischemia and significantly reduced in simvastatin-treated animals. Simvastatin 170-181 interleukin 1 beta Rattus norvegicus 70-78 16054375-6 2006 Poly (ADP-ribose) polymerase fragmentation, caspase-1 activation, and IL-1beta and ICAM-1 mRNA expression were increased by hypoxia-ischemia and significantly reduced in simvastatin-treated animals. Simvastatin 170-181 intercellular adhesion molecule 1 Rattus norvegicus 83-89 16054375-7 2006 The results indicate that simvastatin-induced attenuation of hypoxia-ischemia brain injury in the newborn rat occurs through reduction of the inflammatory response, caspase-3 activation, and apoptotic cell death. Simvastatin 26-37 caspase 3 Rattus norvegicus 165-174 17237547-3 2006 Simvastatin inhibited angiogenesis in response to FGF-2 in the corneal pocket assay of the mouse and in vascular endothelial growth factor (VEGF)-stimulated angiogenesis in the chick chorioallontoic membrane. Simvastatin 0-11 fibroblast growth factor 2 Mus musculus 50-55 17237547-4 2006 Furthermore, simvastatin inhibited VEGF-stimulated tube formation by human dermal microvascular endothelial cells and the formation of honeycomb-like structures by HUVECs. Simvastatin 13-24 vascular endothelial growth factor A Homo sapiens 35-39 16858354-14 2006 CONCLUSION: Short term simvastatin use in patients with systolic heart failure due to CHD caused lowering of LDLCH and CRP however this was not associated with changes of left ventricular EF different from those in control group. Simvastatin 23-34 C-reactive protein Homo sapiens 119-122 17479860-12 2006 The activities of antioxidants enzymes (CAT, GSH-Px, SOD) significantly increased after 4 weeks therapy in patients treated with atorvastatin and simvastatin. Simvastatin 146-157 catalase Homo sapiens 40-43 17479860-12 2006 The activities of antioxidants enzymes (CAT, GSH-Px, SOD) significantly increased after 4 weeks therapy in patients treated with atorvastatin and simvastatin. Simvastatin 146-157 superoxide dismutase 1 Homo sapiens 53-56 17237547-8 2006 Adenoviral expression of a DN-RhoA mutant mimicked the effect of simvastatin on tube formation and the formation of honeycombs, whereas a dominant activating mutant of RhoA reversed the effect of simvastatin on tube formation. Simvastatin 196-207 ras homolog family member A Homo sapiens 168-172 17237547-9 2006 Finally, simvastatin interfered with the membrane localization of RhoA with a dose-dependence similar to that for the inhibition of tube formation. Simvastatin 9-20 ras homolog family member A Homo sapiens 66-70 17237547-10 2006 Simvastatin also inhibited the VEGFstimulated phosphorylation of the VEGF receptor KDR, and the tyrosine kinase FAK, which plays a role in cell migration. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 31-35 17237547-10 2006 Simvastatin also inhibited the VEGFstimulated phosphorylation of the VEGF receptor KDR, and the tyrosine kinase FAK, which plays a role in cell migration. Simvastatin 0-11 protein tyrosine kinase 2 Homo sapiens 112-115 17237547-11 2006 These data demonstrate that simvastatin interfered with angiogenesis via the inhibition of RhoA. Simvastatin 28-39 ras homolog family member A Homo sapiens 91-95 16231003-7 2005 Finally, SV did not affect the release of prostacyclin, but it inhibited the generation of thromboxane (TX) A2 from COX-2 isoform. Simvastatin 9-11 cytochrome c oxidase II, mitochondrial Rattus norvegicus 116-121 17319467-6 2006 This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C. Simvastatin 115-126 component of oligomeric golgi complex 2 Homo sapiens 140-145 16271704-7 2005 In intact rat skeletal muscle fibers from the flexor digitorum brevis muscle, the simvastatin-induced alteration of Ca2+ homeostasis is abolished when monocarboxylate transporter (MCT4) is inhibited. Simvastatin 82-93 solute carrier family 16 member 3 Rattus norvegicus 180-184 16038892-9 2005 CONCLUSION: Our study demonstrates that individual plasma HDL-cholesterol response to simvastatin is mediated, in part, by the CETP gene locus, with the B2 homozygotes having more benefit in HDL-C improvement than carriers of B1 allele. Simvastatin 86-97 cholesteryl ester transfer protein Homo sapiens 127-131 16162940-0 2005 Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. Simvastatin 25-36 apolipoprotein B Homo sapiens 58-74 16162940-3 2005 Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 51-55 16708807-1 2005 OBJECTIVE: To explore the effect of simvastatin on the cell cycle and caspase-3 expression in human omental preadipocytes. Simvastatin 36-47 caspase 3 Homo sapiens 70-79 16708807-10 2005 CONCLUSION: Simvastatin may block the cells in G0/G1 phase, and induce caspase-3 expression, which may trigger apoptosis. Simvastatin 12-23 caspase 3 Homo sapiens 71-80 16275545-7 2005 Multivariate regression analysis showed the existence of a relationship between simvastatin therapy and serum IL-6 level (r=0.83; p<0.05) in the homozygotic men. Simvastatin 80-91 interleukin 6 Homo sapiens 110-114 16280288-9 2005 Simvastatin, losartan, and the combination reduced renal Ang II, but only the combination reduced cardiac Ang II. Simvastatin 0-11 angiotensinogen Rattus norvegicus 57-63 16160062-7 2005 Remarkably, cotreatment of endothelial cells with simvastatin, a hydrophobic statin, reversed VEGF-induced GEnC hyperpermeability by preventing MLC diphosphorylation, and cytoskeletal remodeling. Simvastatin 50-61 vascular endothelial growth factor A Homo sapiens 94-98 16160062-7 2005 Remarkably, cotreatment of endothelial cells with simvastatin, a hydrophobic statin, reversed VEGF-induced GEnC hyperpermeability by preventing MLC diphosphorylation, and cytoskeletal remodeling. Simvastatin 50-61 modulator of VRAC current 1 Homo sapiens 144-147 16465063-4 2005 Both simvastatin and pravastatin strikingly suppressed MMP-9 activity in ex vivo culture of varicose veins. Simvastatin 5-16 matrix metallopeptidase 9 Homo sapiens 55-60 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 23-28 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 plasminogen activator, urokinase Homo sapiens 83-119 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 176-181 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 tumor necrosis factor Homo sapiens 202-229 15540254-9 2005 Catalase, glutathione peroxidase activities and nitric oxide levels were partially restored and accompanied by improved structure in diabetic lung by the simvastatin treatment. Simvastatin 154-165 catalase Rattus norvegicus 0-8 16321621-0 2005 The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Simvastatin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 16321621-0 2005 The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Simvastatin 104-115 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 16321621-0 2005 The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Simvastatin 104-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 50-56 16321621-1 2005 OBJECTIVE: Our objective was to investigate the interactions between common polymorphisms in ABCB1, CYP3A4, and CYP3A5 genes and the lipid-lowering efficacy and safety of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin. Simvastatin 233-244 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 16321621-1 2005 OBJECTIVE: Our objective was to investigate the interactions between common polymorphisms in ABCB1, CYP3A4, and CYP3A5 genes and the lipid-lowering efficacy and safety of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin. Simvastatin 233-244 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 112-118 16321621-1 2005 OBJECTIVE: Our objective was to investigate the interactions between common polymorphisms in ABCB1, CYP3A4, and CYP3A5 genes and the lipid-lowering efficacy and safety of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin. Simvastatin 233-244 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 175-222 16321621-15 2005 CONCLUSIONS: Our data suggest an association of ABCB1 gene polymorphisms and the efficacy and safety of simvastatin. Simvastatin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 16188573-1 2005 Simvastatin, a widely used 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, effectively reduced cardiac death and ischemic events in patients with coronary heart disease (CHD) and diabetes mellitus (DM). Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-77 16188573-7 2005 Significant reductions in F1+2 and PAI-1 levels were evident > or =6 weeks after the diabetic patients received simvastatin. Simvastatin 115-126 serpin family E member 1 Homo sapiens 35-40 16188573-9 2005 Positive correlations were found between PAI-1 versus TC, PAI-1 versus LDL-c, and FVII versus triglycerides in the plasmas of simvastatin-treated patients. Simvastatin 126-137 serpin family E member 1 Homo sapiens 41-46 16188573-9 2005 Positive correlations were found between PAI-1 versus TC, PAI-1 versus LDL-c, and FVII versus triglycerides in the plasmas of simvastatin-treated patients. Simvastatin 126-137 serpin family E member 1 Homo sapiens 58-63 16188573-10 2005 The results suggest that simvastatin reduces in vivo prothrombinase activity and PAI-1 levels in type 2 DM patients. Simvastatin 25-36 serpin family E member 1 Homo sapiens 81-86 16227255-0 2005 In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. Simvastatin 124-135 PDZ and LIM domain 7 Homo sapiens 54-58 16274305-10 2005 Simvastatin significantly upregulated procollagen, fibronectin, and matrix metalloproteinase-13 genes. Simvastatin 0-11 fibronectin 1 Rattus norvegicus 51-62 16274305-10 2005 Simvastatin significantly upregulated procollagen, fibronectin, and matrix metalloproteinase-13 genes. Simvastatin 0-11 matrix metallopeptidase 13 Rattus norvegicus 68-95 16264203-3 2005 METHODS AND RESULTS: Of the 211 consecutive patients who underwent coronary stenting after pretreatment with clopidogrel, 114 were receiving a CYP3A4-metabolized statin (59 simvastatin and 55 atorvastatin, Group 1), and 37 were receiving a non-CYP3A4-metabolized statin (30 pravastatin and 7 fluvastatin, Group 2) whereas 60 patients were not taking any statins (Control). Simvastatin 173-184 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 143-149 16265685-5 2005 RESULTS: Simvastatin treatment significantly decreased serum CRP and TNF-a [from 14 +/- 6 to 7 +/- 3 mg/l (p = 0.025) and 30 +/- 5 to 16 +/- 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. Simvastatin 9-20 C-reactive protein Homo sapiens 61-64 16265685-5 2005 RESULTS: Simvastatin treatment significantly decreased serum CRP and TNF-a [from 14 +/- 6 to 7 +/- 3 mg/l (p = 0.025) and 30 +/- 5 to 16 +/- 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. Simvastatin 9-20 tumor necrosis factor Homo sapiens 69-74 16227255-0 2005 In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. Simvastatin 124-135 galectin 9 Homo sapiens 74-84 16227255-9 2005 In subsequent experiments, NPC cells were treated with Simvastatin, a drug reported to dissociate LMP1 from membrane rafts in EBV-transformed B cells. Simvastatin 55-66 PDZ and LIM domain 7 Homo sapiens 98-102 16400401-6 2005 There is an insulin resistance state in patients with AIDS disease under treatment with HAART, who present with lipodystrophy, hypertriglyceridemia, low levels of HDL-C. Antiretroviral drugs are metabolized by CYP P450 3A4 and interactions with some statins, especially with simvastatin are expected to occur. Simvastatin 275-286 insulin Homo sapiens 12-19 16002570-6 2005 MAIN RESULTS: Simvastatin inhibited lung parenchymal destruction and development of pulmonary hypertension, and also inhibited peribronchial and perivascular infiltration of inflammatory cells and induction of matrix metalloproteinase-9 activity in lung tissue. Simvastatin 14-25 matrix metallopeptidase 9 Rattus norvegicus 210-236 16002570-7 2005 Simvastatin additionally prevented pulmonary vascular remodeling and the changes in endothelial nitric oxide synthase expression induced by smoking. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 84-117 16002570-8 2005 In human lung microvascular endothelial cells, simvastatin increased expression of endothelial nitric oxide synthase mRNA. Simvastatin 47-58 nitric oxide synthase 3 Homo sapiens 83-116 16002570-9 2005 CONCLUSIONS: Simvastatin ameliorated the structural and functional derangements of the lungs caused by cigarette smoking, partly by suppressing inflammation and matrix metalloproteinase-9 induction and preventing pulmonary vascular abnormality. Simvastatin 13-24 matrix metallopeptidase 9 Rattus norvegicus 161-187 15936011-0 2005 A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Simvastatin 23-34 calcineurin like EF-hand protein 1 Homo sapiens 85-88 15936011-1 2005 BACKGROUND: The effect of simvastatin on DNA damage in hypercholesterolemic patients was investigated, and the relationship between the C242T polymorphism of the NADPH oxidase p22phox gene and the antioxidant effects of simvastatin was examined. Simvastatin 220-231 cytochrome b-245 alpha chain Homo sapiens 176-183 16051523-1 2005 The in vitro effect of the hydrophilic statin - pravastatin - and three hydrophobic statins - atorvastatin, lovastatin and simvastatin - on the production of IL-1beta, IL-1ra, IL-2, IL-6 and IFN-gamma by human peripheral blood mononuclear cells (PBMC) and their response to mitogens was examined. Simvastatin 123-134 interleukin 1 beta Homo sapiens 158-166 16051523-1 2005 The in vitro effect of the hydrophilic statin - pravastatin - and three hydrophobic statins - atorvastatin, lovastatin and simvastatin - on the production of IL-1beta, IL-1ra, IL-2, IL-6 and IFN-gamma by human peripheral blood mononuclear cells (PBMC) and their response to mitogens was examined. Simvastatin 123-134 interleukin 1 receptor antagonist Homo sapiens 168-174 16051523-2 2005 Lovastatin and simvastatin increased the production of IL-1beta in a dose dependent manner and reduced secretion of IL-1ra at high concentration. Simvastatin 15-26 interleukin 1 beta Homo sapiens 55-63 16051523-2 2005 Lovastatin and simvastatin increased the production of IL-1beta in a dose dependent manner and reduced secretion of IL-1ra at high concentration. Simvastatin 15-26 interleukin 1 receptor antagonist Homo sapiens 116-122 15936011-8 2005 This study showed that simvastatin has a beneficial effect on the improvement of DNA damage in patients with the 242T allele of NADPH oxidase p22phox gene. Simvastatin 23-34 cytochrome b-245 alpha chain Homo sapiens 142-149 16238904-12 2005 Administration of telithromycin with drugs metabolized via CYP3A4 may result in increased exposure to the co-administered drug, as shown for simvastatin (5.3-fold) and midazolam (6-fold). Simvastatin 141-152 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 16244767-7 2005 P-sel, CD36, and LOX-1 were significantly decreased by atorvastatin and simvastatin (all p < 0.01) and related with iCit increase (r = 0.58, p < 0.001) and platelet-associated ox-LDL (r = 0.51, p < 0.01) at 9 days. Simvastatin 72-83 selectin P Homo sapiens 0-5 16320597-0 2005 [Effects of simvastatin on TGF-beta system of diabetic rat kidneys]. Simvastatin 12-23 transforming growth factor, beta 1 Rattus norvegicus 27-35 16278780-6 2005 10(-6) M mevastatin and simvastatin increased the level of OPG mRNA in mouse bone-cell cultures. Simvastatin 24-35 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 59-62 16278780-7 2005 On the other hand, 10(-6) M mevastatin and simvastatin inhibited the level of RANKL mRNA in these cultures. Simvastatin 43-54 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 78-83 16118799-5 2005 The aims of this study were to determine the effects of statins (atorvastatin and simvastatin) on microglial cells with regard to the secretion of the inflammatory cytokine interleukin-6 (IL-6) and cell viability after activation of the cells with bacterial lipopolysaccharides (LPS) or beta-amyloid1-40 (Abeta1-40) and in unstimulated cells. Simvastatin 82-93 interleukin 6 Homo sapiens 173-186 16118799-8 2005 Both atorvastatin and simvastatin reduced the basal secretion of IL-6 and the cell viability of the microglia, but only atorvastatin reduced LPS- and Abeta1-40-induced IL-6 secretion. Simvastatin 22-33 interleukin 6 Homo sapiens 65-69 16320597-5 2005 Compared with the diabetic rat group, simvastatin could markedly decrease the mRNA and protein expression of TGF-beta1 and Tbeta II R (P < 0.05). Simvastatin 38-49 transforming growth factor, beta 1 Rattus norvegicus 109-118 15936988-2 2005 Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). Simvastatin 0-11 tumor necrosis factor Homo sapiens 122-155 16020749-5 2005 Simvastatin increased ratios of stearic to palmitic, gamma-linolenic to linoleic, and arachidonic to dihomo-gamma-linolenic acid by 7.6%, 17.0%, and 10.0% (P<0.001 for all), respectively, suggesting increased fatty acid elongase and Delta6- and Delta5-desaturase enzyme activities. Simvastatin 0-11 fatty acid desaturase 2 Homo sapiens 254-265 15936988-0 2005 Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. Simvastatin 0-11 interleukin 18 Homo sapiens 20-34 15936988-2 2005 Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). Simvastatin 0-11 interferon gamma Homo sapiens 160-182 15936988-2 2005 Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). Simvastatin 0-11 integrin subunit alpha L Homo sapiens 68-73 15936988-3 2005 The IL-18 production is located upstream of the cytokine cascade activated by simvastatin. Simvastatin 78-89 interleukin 18 Homo sapiens 4-9 15936988-2 2005 Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). Simvastatin 0-11 interleukin 18 Homo sapiens 101-120 15936988-4 2005 Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes. Simvastatin 10-21 intercellular adhesion molecule 1 Homo sapiens 76-82 15936988-4 2005 Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes. Simvastatin 10-21 CD40 molecule Homo sapiens 113-117 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 interleukin 18 Homo sapiens 19-24 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 intercellular adhesion molecule 1 Homo sapiens 67-73 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 CD40 molecule Homo sapiens 78-82 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 tumor necrosis factor Homo sapiens 119-128 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 interferon gamma Homo sapiens 133-142 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 200-211 interleukin 18 Homo sapiens 19-24 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 200-211 tumor necrosis factor Homo sapiens 119-128 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 200-211 interferon gamma Homo sapiens 133-142 16051891-9 2005 Plasma von Willebrand factor and S100beta were decreased 3 to 10 days after SAH (P<0.05) in patients receiving simvastatin versus placebo. Simvastatin 114-125 S100 calcium binding protein B Homo sapiens 33-41 15914674-9 2005 Downstream of the calpain activation simvastatin led to a translocation of Bax to mitochondria in a caspase 8-independent manner. Simvastatin 37-48 BCL2 associated X, apoptosis regulator Homo sapiens 75-78 15914674-9 2005 Downstream of the calpain activation simvastatin led to a translocation of Bax to mitochondria in a caspase 8-independent manner. Simvastatin 37-48 caspase 8 Homo sapiens 100-109 15998357-3 2005 Simvastatin, lovastatin, atorvastatin and fluvastatin were the most potent inhibitors of CYP2C8 activity with K(i) (IC(50)) values of 7.1 (9.6) muM, 8.4 (15) microM, 16 (38) microM and 19 (37) microM, respectively. Simvastatin 0-11 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 89-95 16005304-0 2005 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Simvastatin 0-11 nuclear receptor subfamily 4 group A member 3 Sus scrofa 21-26 16005304-0 2005 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Simvastatin 0-11 cAMP response element binding protein Sus scrofa 82-86 16005304-6 2005 RESULTS: Simvastatin inhibited NOR-1 expression induced by LDL in VSMC and by hypercholesterolemia in the abdominal aorta of hyperlipemic pigs. Simvastatin 9-20 nuclear receptor subfamily 4 group A member 3 Sus scrofa 31-36 16005304-7 2005 The inhibition of the isoprenylation of geranylgeranylated proteins by simvastatin was key in both NOR-1 up-regulation and DNA synthesis induced by LDL. Simvastatin 71-82 nuclear receptor subfamily 4 group A member 3 Sus scrofa 99-104 16005304-8 2005 Inhibitors of RhoA (toxin B and exotoxin C3) and ROCK (Y-27632) mimicked the effect of simvastatin on NOR-1. Simvastatin 87-98 ras homolog family member A Sus scrofa 14-18 16005304-8 2005 Inhibitors of RhoA (toxin B and exotoxin C3) and ROCK (Y-27632) mimicked the effect of simvastatin on NOR-1. Simvastatin 87-98 nuclear receptor subfamily 4 group A member 3 Sus scrofa 102-107 16005304-9 2005 Similarly both simvastatin treatment and cells transfected with a RhoA dominant-negative (RhoAT19N) showed inhibition of LDL-induced NOR-1 promoter activity. Simvastatin 15-26 nuclear receptor subfamily 4 group A member 3 Sus scrofa 133-138 16005304-11 2005 Finally, simvastatin prevented LDL induction of a reporter construct containing four consensus CRE and inhibited the expression of SMemb (a marker for dedifferentiated VSMC) dependent on CREB. Simvastatin 9-20 cAMP response element binding protein Sus scrofa 187-191 16005304-12 2005 CONCLUSIONS: NOR-1 is a target for simvastatin in the vascular wall. Simvastatin 35-46 nuclear receptor subfamily 4 group A member 3 Sus scrofa 13-18 15962265-1 2005 Previously, a novel osteotropic biomaterial, OG-PLG [simvastatin grafted to poly(lactide-co-glycolide), PLG], was synthesized and shown to have degradation-controlled release kinetics. Simvastatin 53-64 plasminogen Rattus norvegicus 48-51 15981201-4 2005 Simvastatin was grafted to PLG (OG-PLG) and characterized using contact-angle measurements, attenuated total reflectance-Fourier transform infrared, and ultraviolet-visible spectroscopy to determine success of the synthesis. Simvastatin 0-11 plasminogen Homo sapiens 27-30 15981201-4 2005 Simvastatin was grafted to PLG (OG-PLG) and characterized using contact-angle measurements, attenuated total reflectance-Fourier transform infrared, and ultraviolet-visible spectroscopy to determine success of the synthesis. Simvastatin 0-11 plasminogen Homo sapiens 32-38 15981201-8 2005 The diffusion-controlled release kinetics of simvastatin from PLG + Sim seems to be more heavily affected by device morphology, whereas the degradation-controlled release kinetics seem to be less affected. Simvastatin 45-56 plasminogen Homo sapiens 62-65 16193989-0 2005 Effects of simvastatin on the expression of intercellular adhesion molecule-1 mRNA in neonatal brain with hypoxic-ischemic damage. Simvastatin 11-22 intercellular adhesion molecule 1 Rattus norvegicus 44-77 16193989-8 2005 The protective mechanisms of simvastatin and citicoline are associated with their regulative effect on ICAM-1, and simvastatin is superior to citicoline. Simvastatin 29-40 intercellular adhesion molecule 1 Rattus norvegicus 103-109 15962265-7 2005 von Kossa assay showed that simvastatin, saponified simvastatin, and OG-PLG significantly enhanced mineralization, with the effect from OG-PLG being the most significant. Simvastatin 28-39 plasminogen Rattus norvegicus 139-142 15962265-7 2005 von Kossa assay showed that simvastatin, saponified simvastatin, and OG-PLG significantly enhanced mineralization, with the effect from OG-PLG being the most significant. Simvastatin 52-63 plasminogen Rattus norvegicus 139-142 16003294-9 2005 Respiratory chain enzyme and citrate synthase activities were reduced in the patients taking simvastatin. Simvastatin 93-104 citrate synthase Homo sapiens 29-45 15855201-14 2005 Vimentin, a marker of dedifferentiation, was expressed in tubular cells of VH and decreased with SIMV treatment. Simvastatin 97-101 vimentin Rattus norvegicus 0-8 15855201-17 2005 TGF-beta1, which was highly induced in the obstructed kidneys, decreased at the post-transcriptional level with SIMV treatment (5.35+/-0.75 vs 13.10+/-2.9 OD in VH, P<0.05). Simvastatin 112-116 transforming growth factor, beta 1 Rattus norvegicus 0-9 16808312-10 2005 In conclusion, therapy with hypolipemic diet and simvastatin already after four weeks decreased plasma lipids and fibrinogen levels and improved the course of angina pectoris and exercise stress test, what suggested its effectiveness not only as the treatment improving atherosclerosis risk factors, but also with prompt and clinical important effect ameliorating the handicapped coronary reserve. Simvastatin 49-60 fibrinogen beta chain Homo sapiens 114-124 16369229-0 2005 LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. Simvastatin 42-53 component of oligomeric golgi complex 2 Homo sapiens 0-5 16369229-7 2005 The percentage reaching the optional LDL-C treatment target of < 70 mg/dL was also significantly higher with EZE/SIMVA compared with either atorvastatin or simvastatin. Simvastatin 159-170 component of oligomeric golgi complex 2 Homo sapiens 37-42 15860737-3 2005 METHODS AND RESULTS: Treatment with simvastatin, a hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor, for 24 hours attenuated the transient [Ca2+]i elevation induced by thrombin. Simvastatin 36-47 coagulation factor II, thrombin Homo sapiens 176-184 15860737-4 2005 Immunofluorescence staining revealed that simvastatin decreased the surface expression of PAR1 in a manner dependent on protein geranylgeranylation. Simvastatin 42-53 coagulation factor II thrombin receptor Homo sapiens 90-94 15860745-4 2005 METHODS AND RESULTS: Toll-like receptor (TLR) 4 expression and downstream signaling in CD14+ monocytes after incubation with simvastatin and atorvastatin were quantified via flow-cytometry, quantitative RT-PCR, kinase assay, and enzyme-linked immunosorbent assay. Simvastatin 125-136 toll like receptor 4 Homo sapiens 41-44 15860745-4 2005 METHODS AND RESULTS: Toll-like receptor (TLR) 4 expression and downstream signaling in CD14+ monocytes after incubation with simvastatin and atorvastatin were quantified via flow-cytometry, quantitative RT-PCR, kinase assay, and enzyme-linked immunosorbent assay. Simvastatin 125-136 CD14 molecule Homo sapiens 87-91 15963098-8 2005 Patients already using CYP3A4 inhibitors more frequently received fluvastatin (OR = 1.80; 95% CI 1.11, 2.94), metabolized by non-CYP3A4 pathways, and atorvastatin (OR = 1.62; 95% CI 1.06, 2.47), which is metabolized by CYP3A4, than simvastatin. Simvastatin 232-243 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 23-29 15980269-0 2005 Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 41-49 15994744-13 2005 The CRP level of the group also decreased with Simvastatin but it did not reach significance (P = 0.057). Simvastatin 47-58 C-reactive protein Homo sapiens 4-7 15802384-5 2005 Among them, HMG-CoA reductase inhibitors (cerivastatin, simvastatin, fluvastatin, and atorvastatin) enhanced the hCAR-mediated transcriptional activation of phenobarbital-responsive enhancer module reporter gene by up to 3-fold. Simvastatin 56-67 CXADR Ig-like cell adhesion molecule Homo sapiens 113-117 15802384-9 2005 Cerivastatin, simvastatin, fluvastatin, and atorvastatin induced CYP2B6 mRNA in stable hCAR-expressed FLC7 cells but not in original FLC7 cells. Simvastatin 14-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 65-71 15802384-9 2005 Cerivastatin, simvastatin, fluvastatin, and atorvastatin induced CYP2B6 mRNA in stable hCAR-expressed FLC7 cells but not in original FLC7 cells. Simvastatin 14-25 CXADR Ig-like cell adhesion molecule Homo sapiens 87-91 15931060-4 2005 DNA array and Western analysis revealed elevations in the expression of a pro-inflammatory gene family that included beta-amyloid precursor protein, cyclooxygenase-2, cytosolic phospholipase A2 and heat shock protein 70, an effect that was partially suppressed by simvastatin. Simvastatin 264-275 prostaglandin-endoperoxide synthase 2 Homo sapiens 149-165 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 42-60 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 16113803-6 2005 Simvastatin and fenofibrate significantly lowered plasma concentrations of thrombin-antithrombin complexes on days 3 and 28, but not platelet beta-thromboglobulin (betaTG) levels. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 75-83 16113803-7 2005 Soluble P-selectin was lowered only in the simvastatin group. Simvastatin 43-54 selectin P Homo sapiens 8-18 16113803-8 2005 The total amount of thrombin generated at the site of microvascular injury also declined (by about 30%) as early as after 3 days of fenofibrate or simvastatin therapy, whereas beta TG release was reduced only in the simvastatin group on days 3 and 28. Simvastatin 147-158 coagulation factor II, thrombin Homo sapiens 20-28 15843472-5 2005 Moreover, three different statins, mevastatin, pravastatin, and simvastatin, inhibited in a dose-dependent manner apoptosis and loss of nephrin induced by oxLDL by stimulating Akt activity. Simvastatin 64-75 NPHS1 adhesion molecule, nephrin Homo sapiens 136-143 15843472-5 2005 Moreover, three different statins, mevastatin, pravastatin, and simvastatin, inhibited in a dose-dependent manner apoptosis and loss of nephrin induced by oxLDL by stimulating Akt activity. Simvastatin 64-75 AKT serine/threonine kinase 1 Homo sapiens 176-179 15843472-6 2005 In addition, simvastatin significantly increased the expression of nephrin protein and mRNA by podocytes. Simvastatin 13-24 NPHS1 adhesion molecule, nephrin Homo sapiens 67-74 15970799-7 2005 RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin. Simvastatin 223-234 solute carrier organic anion transporter family member 1B1 Homo sapiens 57-64 15931060-4 2005 DNA array and Western analysis revealed elevations in the expression of a pro-inflammatory gene family that included beta-amyloid precursor protein, cyclooxygenase-2, cytosolic phospholipase A2 and heat shock protein 70, an effect that was partially suppressed by simvastatin. Simvastatin 264-275 phospholipase A2 group IVA Homo sapiens 167-193 15916736-6 2005 In simvastatin-treated isolated hearts, the levels of mRNA expression of SERCA and RyR2 were elevated compared with the control (P<0.05), while the mRNA expression of PLB did not change. Simvastatin 3-14 ryanodine receptor 2 Rattus norvegicus 83-87 15905463-5 2005 Simvastatin decreased thrombin-stimulated Weibel-Palade body exocytosis by 89%. Simvastatin 0-11 coagulation factor II Mus musculus 22-30 15905463-6 2005 Simvastatin inhibited exocytosis in part by increasing synthesis of nitric oxide (NO), which S-nitrosylated N-ethylmaleimide sensitive factor (NSF), a critical regulator of exocytosis. Simvastatin 0-11 N-ethylmaleimide sensitive fusion protein Mus musculus 108-141 15905463-6 2005 Simvastatin inhibited exocytosis in part by increasing synthesis of nitric oxide (NO), which S-nitrosylated N-ethylmaleimide sensitive factor (NSF), a critical regulator of exocytosis. Simvastatin 0-11 N-ethylmaleimide sensitive fusion protein Mus musculus 143-146 15905463-8 2005 Furthermore, simvastatin decreased endothelial exocytosis and neutrophil infiltration into ischemic-reperfused myocardium, which was mediated in part by P-selectin contained in Weibel-Palade bodies. Simvastatin 13-24 selectin, platelet Mus musculus 153-163 15916736-6 2005 In simvastatin-treated isolated hearts, the levels of mRNA expression of SERCA and RyR2 were elevated compared with the control (P<0.05), while the mRNA expression of PLB did not change. Simvastatin 3-14 phospholamban Rattus norvegicus 170-173 15916736-7 2005 After the cultured neonatal rat ventricular cardiomyocytes were incubated with 3, 10, 30, and 100 mumol/L simvastatin for 1 h, SERCA and RyR2 mRNA expressions of cardiomyocytes rose, but there was no alteration in protein expressions. Simvastatin 106-117 ryanodine receptor 2 Rattus norvegicus 137-141 15916736-8 2005 However, with the elongation of simvastatin treatment to 24 h, the protein expression of SERCA and RyR2 were also elevated. Simvastatin 32-43 ryanodine receptor 2 Rattus norvegicus 99-103 15916736-10 2005 CONCLUSION: Simvastatin improved cardiac performance accompanied by the elevation of SERCA and RyR2 gene and protein expression. Simvastatin 12-23 ryanodine receptor 2 Rattus norvegicus 95-99 15883229-9 2005 When compared with simvastatin or ramipril alone, combined therapy significantly reduced high-sensitivity C-reactive protein levels (P=0.004 by ANOVA). Simvastatin 19-30 C-reactive protein Homo sapiens 106-124 15665042-2 2005 We explored the effect of simvastatin, a 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor that mediates endothelial cell barrier protection in vitro, in a murine inflammatory model of ALI. Simvastatin 26-37 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 41-87 15665042-7 2005 LPS-mediated lung gene expression was significantly modulated by simvastatin within a number of gene ontologies (e.g., inflammation and immune response, NF-kappaB regulation) and with respect to individual genes implicated in the development or severity of ALI (e.g., IL-6, Toll-like receptor 4). Simvastatin 65-76 interleukin 6 Mus musculus 268-272 15665042-7 2005 LPS-mediated lung gene expression was significantly modulated by simvastatin within a number of gene ontologies (e.g., inflammation and immune response, NF-kappaB regulation) and with respect to individual genes implicated in the development or severity of ALI (e.g., IL-6, Toll-like receptor 4). Simvastatin 65-76 toll-like receptor 4 Mus musculus 274-294 15875154-6 2005 Simvastatin treatment decreased VLDL+LDL cholesterol, LDL cholesterol, triglycerides and apo B, CETP activity, cholesterol esterification and cholesteryl ester transfer. Simvastatin 0-11 cholesteryl ester transfer protein Homo sapiens 96-100 15953866-9 2005 Simvastatin increased the ALP activity in a dose dependent manner, and this stimulatory effect was more evident during the early period of culture. Simvastatin 0-11 alkaline phosphatase, placental Homo sapiens 26-29 15953866-12 2005 10(-6) M of simvastatin also significantly enhanced the osteocalcin mRNA expression level. Simvastatin 12-23 bone gamma-carboxyglutamate protein Homo sapiens 56-67 15728660-0 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 21-26 16045013-6 2005 TGFbeta1 decreased in the simvastatin and benazepril group compared with the benazepril group (P < 0.01). Simvastatin 26-37 transforming growth factor beta 1 Homo sapiens 0-8 15896653-8 2005 Simvastatin treatment of SLOS fibroblasts with residual DHCR7 enzymatic activity decreased 7DHC levels and increased cholesterol synthesis. Simvastatin 0-11 7-dehydrocholesterol reductase Homo sapiens 56-61 15896653-10 2005 Determination of residual enzymatic activity for specific DHCR7 mutant alleles will help in understanding the processes underlying the broad phenotypic spectrum found in this disorder and will be useful in identifying patients who may benefit from simvastatin therapy. Simvastatin 248-259 7-dehydrocholesterol reductase Homo sapiens 58-63 15817275-3 2005 In our present study, we investigated effects of simvastatin treatment on degeneration of retinal ganglion cell (RGC) bodies as well as their axons during MOG-induced optic neuritis. Simvastatin 49-60 myelin oligodendrocyte glycoprotein Rattus norvegicus 155-158 15728660-0 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Simvastatin 0-11 ras homolog family member A Homo sapiens 101-105 15728660-0 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 132-137 15728660-7 2005 Simvastatin reduced TPA- and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase (ROCK). Simvastatin 0-11 interleukin 1 alpha Homo sapiens 34-38 15728660-7 2005 Simvastatin reduced TPA- and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase (ROCK). Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 47-52 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 53-58 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 ras homolog family member A Homo sapiens 105-109 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 138-143 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 138-143 15949312-1 2005 OBJECTIVE: To investigate the effect of simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitor, on eosinophils (EOSs) apoptosis in asthma patients. Simvastatin 40-51 high mobility group AT-hook 1 Homo sapiens 97-101 15864134-2 2005 We examined endothelial nitric oxide synthase (eNOS) mRNA levels, mRNA stability and the transcriptional activities of the eNOS gene in human umbilical vein endothelial cells treated with fluvastatin and simvastatin. Simvastatin 204-215 nitric oxide synthase 3 Homo sapiens 123-127 15864134-7 2005 Simvastatin increased eNOS mRNA levels and mRNA stability, but did not affect the transcriptional activity of the eNOS gene. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 22-26 15864134-10 2005 Simvastatin increased eNOS mRNA levels only by enhancing mRNA stability. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 22-26 15821443-5 2005 Atorvastatin or simvastatin decreased NF-kappa B activation induced by oxidative stress by around 50% in both cell types and was correlated with the I kappa B-alpha levels. Simvastatin 16-27 nuclear factor kappa B subunit 1 Homo sapiens 38-48 15821443-5 2005 Atorvastatin or simvastatin decreased NF-kappa B activation induced by oxidative stress by around 50% in both cell types and was correlated with the I kappa B-alpha levels. Simvastatin 16-27 NFKB inhibitor alpha Homo sapiens 149-164 15949312-6 2005 The level of caspase-3 in EOSs was consistent with the rate of cell apoptosis [(8 +/- 3) microg/L in control, (14 +/- 4), (22 +/- 4), (24 +/- 4), (23 +/- 5) microg/L in 1, 5, 10, 20 micromol/L simvastatin, respectively; compared with control: P = 0.000 - 0.003]. Simvastatin 193-204 caspase 3 Homo sapiens 13-22 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 26-37 high mobility group AT-hook 1 Homo sapiens 73-77 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 26-37 caspase 3 Homo sapiens 385-394 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 high mobility group AT-hook 1 Homo sapiens 73-77 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 caspase 3 Homo sapiens 385-394 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 high mobility group AT-hook 1 Homo sapiens 73-77 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 caspase 3 Homo sapiens 385-394 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 high mobility group AT-hook 1 Homo sapiens 73-77 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 caspase 3 Homo sapiens 385-394 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 high mobility group AT-hook 1 Homo sapiens 73-77 15949312-7 2005 However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively. Simvastatin 115-126 caspase 3 Homo sapiens 385-394 15824212-0 2005 Simvastatin blunts endotoxin-induced tissue factor in vivo. Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 37-50 15752763-6 2005 Consequently on simvastatin application, a weak mitochondrial Ca(2+) efflux (EC(50)=7.8 microM) through permeability transient pore and Na(+)/Ca(2+) exchanger was triggered, preceding the large SR-Ca(2+) release. Simvastatin 16-27 solute carrier family 8 member A1 Homo sapiens 136-158 15824212-9 2005 In parallel, endotoxin-induced formation of F1.2 was significantly reduced by simvastatin after 4 and 8 hours. Simvastatin 78-89 coagulation factor XII Homo sapiens 44-48 15824212-11 2005 CONCLUSIONS: Simvastatin suppresses the inflammatory response to endotoxin and blunts monocyte TF expression but does not affect platelet activation. Simvastatin 13-24 coagulation factor III, tissue factor Homo sapiens 95-97 15705589-0 2005 Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 46-77 15705589-3 2005 In this study, we examined the impact of inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase with simvastatin on the expression of inducible nitric-oxide synthase (iNOS) in embryonic cardiac myoblasts stimulated with the proinflammatory cytokines, interleukin-1 or tumor necrosis factor. Simvastatin 113-124 nitric oxide synthase 2 Rattus norvegicus 146-177 15705589-3 2005 In this study, we examined the impact of inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase with simvastatin on the expression of inducible nitric-oxide synthase (iNOS) in embryonic cardiac myoblasts stimulated with the proinflammatory cytokines, interleukin-1 or tumor necrosis factor. Simvastatin 113-124 nitric oxide synthase 2 Rattus norvegicus 179-183 15705589-4 2005 Treatment with simvastatin significantly reduced the levels of iNOS mRNA and protein in cytokine-treated rat H9c2 cardiac embryonic myoblasts. Simvastatin 15-26 nitric oxide synthase 2 Rattus norvegicus 63-67 15705589-8 2005 Hence, treatment with simvastatin can attenuate iNOS expression and NO synthesis in cytokine-stimulated embryonic cardiac myoblasts. Simvastatin 22-33 nitric oxide synthase 2 Rattus norvegicus 48-52 15780535-10 2005 CONCLUSION: Both tibolone and simvastatin prevented the atherosclerosis in ovariectomized cholesterol-fed rabbits and this effect was associated with up-regulation of ERA and LDLR expression by tibolone but not by simvastatin. Simvastatin 30-41 low-density lipoprotein receptor Oryctolagus cuniculus 175-179 15677772-1 2005 Simvastatin is best known for its antilipidemic action and use in cardiovascular disease due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase, a key enzyme in the cholesterol synthesis pathway. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-170 15677772-4 2005 In this study we used human lung fibroblasts derived from healthy and IPF lungs to examine Simvastatin effects on CTGF gene and protein expression, analyzed by RT-PCR and ELISA, respectively. Simvastatin 91-102 cellular communication network factor 2 Homo sapiens 114-118 15677772-5 2005 Simvastatin significantly inhibited (P < 0.05) CTGF gene and protein expression, overriding the induction by transforming growth factor-beta1, a known potent inducer of CTGF. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 50-54 15677772-5 2005 Simvastatin significantly inhibited (P < 0.05) CTGF gene and protein expression, overriding the induction by transforming growth factor-beta1, a known potent inducer of CTGF. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 112-144 15677772-5 2005 Simvastatin significantly inhibited (P < 0.05) CTGF gene and protein expression, overriding the induction by transforming growth factor-beta1, a known potent inducer of CTGF. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 172-176 15811174-9 2005 She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. Simvastatin 25-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 15777554-1 2005 OBJECTIVE: This study assessed the effect of coadministration of ezetimibe and simvastatin on high sensitivity C-reactive protein (hs-CRP) in a large subject cohort (N=1089). Simvastatin 79-90 C-reactive protein Homo sapiens 111-129 15763545-4 2005 THP-1 cells, as in the case of LA, actively converted alpha-LNA to its products, and after simvastatin treatment, the total conversion was significantly increased (from 57.2+/-7.2 to 74.3+/-8.5%, p<0.05). Simvastatin 91-102 GLI family zinc finger 2 Homo sapiens 0-5 15763545-7 2005 In conclusion, LA, alpha-LNA and SA are differentially metabolized in THP-1 and in HepG2 cells and their increased conversion by simvastatin is lower in HepG2 than in THP-1. Simvastatin 129-140 GLI family zinc finger 2 Homo sapiens 70-75 15763545-7 2005 In conclusion, LA, alpha-LNA and SA are differentially metabolized in THP-1 and in HepG2 cells and their increased conversion by simvastatin is lower in HepG2 than in THP-1. Simvastatin 129-140 GLI family zinc finger 2 Homo sapiens 167-172 15853752-7 2005 We also found that simvastatin decreased prothrombin fragments F1+2 in plasma from type 2 diabetics, demonstrating that statins downregulate thrombin generation. Simvastatin 19-30 coagulation factor II, thrombin Homo sapiens 44-52 15776112-3 2005 Simvastatin, a cholesterol synthesis inhibitor, lowered raft cholesterol content, inhibited Akt1 serine-threonine kinase (protein kinase Balpha)/protein kinase B (Akt/PKB) pathway signaling, and induced apoptosis in caveolin- and PTEN-negative LNCaP PCa cells. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 92-96 15776112-3 2005 Simvastatin, a cholesterol synthesis inhibitor, lowered raft cholesterol content, inhibited Akt1 serine-threonine kinase (protein kinase Balpha)/protein kinase B (Akt/PKB) pathway signaling, and induced apoptosis in caveolin- and PTEN-negative LNCaP PCa cells. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 163-170 15776112-3 2005 Simvastatin, a cholesterol synthesis inhibitor, lowered raft cholesterol content, inhibited Akt1 serine-threonine kinase (protein kinase Balpha)/protein kinase B (Akt/PKB) pathway signaling, and induced apoptosis in caveolin- and PTEN-negative LNCaP PCa cells. Simvastatin 0-11 phosphatase and tensin homolog Homo sapiens 230-234 15864235-2 2005 This study tested the hypothesis that ezetimibe/simvastatin, a lipid-lowering agent that inhibits both intestinal cholesterol absorption and cholesterol synthesis, provides greater LDL-C reductions than atorvastatin across dose ranges. Simvastatin 48-59 component of oligomeric golgi complex 2 Homo sapiens 181-186 16161915-11 2005 Both simvastatin and atorvastatin markedly increased AT III (87%, 98%) in comparison to the initial values. Simvastatin 5-16 serpin family C member 1 Homo sapiens 53-59 15781755-3 2005 METHODS AND RESULTS: Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Simvastatin 121-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-154 15781755-3 2005 METHODS AND RESULTS: Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Simvastatin 121-132 C-C motif chemokine receptor 2 Homo sapiens 200-204 15781755-4 2005 Treatment of 21 normocholesterolemic men with simvastatin (20 mg/d for 2 weeks) decreased CCR2 protein and mRNA expression in circulating monocytes. Simvastatin 46-57 C-C motif chemokine receptor 2 Homo sapiens 90-94 15781755-6 2005 Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-gamma antagonist GW9662. Simvastatin 10-21 C-C motif chemokine receptor 2 Homo sapiens 30-34 15781755-6 2005 Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-gamma antagonist GW9662. Simvastatin 10-21 peroxisome proliferator activated receptor gamma Homo sapiens 91-139 15781755-7 2005 Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 79-113 15781755-7 2005 Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 115-120 15781755-7 2005 Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Simvastatin 0-11 C-C motif chemokine receptor 2 Homo sapiens 134-138 15781755-8 2005 Treatment of C57/BL6 mice with simvastatin (0.2 microg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Simvastatin 31-42 CD80 antigen Mus musculus 119-123 15781755-8 2005 Treatment of C57/BL6 mice with simvastatin (0.2 microg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Simvastatin 31-42 chemokine (C-C motif) ligand 2 Mus musculus 142-147 15781755-10 2005 CONCLUSIONS: The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis. Simvastatin 76-87 C-C motif chemokine receptor 2 Homo sapiens 31-35 15781755-10 2005 CONCLUSIONS: The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis. Simvastatin 76-87 C-C motif chemokine ligand 2 Homo sapiens 36-41 15486036-3 2005 Simvastatin has been shown to inhibit endothelin-1. Simvastatin 0-11 endothelin-1 Oryctolagus cuniculus 38-50 15486036-9 2005 The increased endothelin-1 responses can be inhibited after simvastatin administration. Simvastatin 60-71 endothelin-1 Oryctolagus cuniculus 14-26 15486036-14 2005 The results of the present study suggest that the antihypertropic and electrocardiographic effects of simvastatin at a clinical therapeutic dose are mediated through inhibition of tissue endothelin-1 expression, which is linked to mevalonate metabolism, and result in an amelioration of cardiomyocyte hypertrophy development by an atherogenic diet. Simvastatin 102-113 endothelin-1 Oryctolagus cuniculus 187-199 15777746-7 2005 Simvastatin inhibited the production of tumor necrosis factor (TNF)-alpha, nitric oxide, and superoxide in cultured rat microglia stimulated by lipopolysaccharide. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 40-73 15777746-8 2005 The results suggest that simvastatin inhibits the formation of TNF-alpha and peroxynitrite in activated microglia thereby protecting dopaminergic neurons from inflammatory damage. Simvastatin 25-36 tumor necrosis factor Mus musculus 63-72 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Simvastatin 15-26 component of oligomeric golgi complex 2 Homo sapiens 133-138 15864235-7 2005 More ezetimibe/simvastatin than atorvastatin patients with coronary heart disease (CHD) or CHD risk equivalents attained the ATP III LDL-C goal of <100 mg/dL and the optional LDL-C target of <70 mg/dL. Simvastatin 15-26 component of oligomeric golgi complex 2 Homo sapiens 178-183 15864235-11 2005 CONCLUSIONS: Ezetimibe/simvastatin was more effective than atorvastatin in lowering LDL-C at each dose comparison and provided greater increases in HDL-C at the 40- and 80-mg statin dose. Simvastatin 23-34 component of oligomeric golgi complex 2 Homo sapiens 84-89 15864235-5 2005 RESULTS: At each milligram-equivalent statin dose comparison, and averaged across doses, ezetimibe/simvastatin provided greater LDL-C reductions (47%-59%) than atorvastatin (36%-53%). Simvastatin 99-110 component of oligomeric golgi complex 2 Homo sapiens 128-133 16025229-8 2005 The same concentration of simvastatin induced apoptosis as assessed by the fluorescence-labeled annexin-V method through caspase-3 activation in monocytes. Simvastatin 26-37 Death executioner caspase related to Apopain/Yama Drosophila melanogaster 121-130 15678081-6 2005 Simvastatin (SV) induced a concentration-dependent relaxation of tonic contraction mediated by ET-1 (10 nM) (IC50 value of 1.3 microM). Simvastatin 0-11 endothelin 1 Homo sapiens 95-99 15678081-6 2005 Simvastatin (SV) induced a concentration-dependent relaxation of tonic contraction mediated by ET-1 (10 nM) (IC50 value of 1.3 microM). Simvastatin 13-15 endothelin 1 Homo sapiens 95-99 16025229-9 2005 HDL inhibited simvastatin-induced apoptosis. Simvastatin 14-25 Hdl Drosophila melanogaster 0-3 16025229-10 2005 In addition, HDL blocked simvastatin-inhibited angiogenesis in an in vitro model of EC tube formation. Simvastatin 25-36 Hdl Drosophila melanogaster 13-16 15728378-6 2005 In vitro inhibition of FOS using small interfering RNA and 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitor simvastatin (statin) affected monocyte activation and suggested an important role in pathogenesis. Simvastatin 111-122 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 23-26 15625077-8 2005 Thus, in HepG2 cells pravastatin and simvastatin pretreatment attenuated the p53 response to DNA damage induced by 5-fluorouracil and benzo(a)pyrene. Simvastatin 37-48 tumor protein p53 Homo sapiens 77-80 15639308-7 2005 Simvastatin paradoxically increased lipid and atherosclerosis in apoE-KO mice, but it decreased lipid and atherosclerosis in LDLR-KO mice, indicating that anti-atherosclerotic effect of simvastatin requires the presence of an intact apoE. Simvastatin 0-11 apolipoprotein E Mus musculus 65-69 15728378-6 2005 In vitro inhibition of FOS using small interfering RNA and 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitor simvastatin (statin) affected monocyte activation and suggested an important role in pathogenesis. Simvastatin 116-122 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 23-26 15650881-0 2005 Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Simvastatin 87-98 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-40 15679472-3 2005 Some statins (atorvastatin, lovastatin and simvastatin) also requires metabolism by the cytochrome P450 3A4 system. Simvastatin 43-54 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-107 15650881-13 2005 CYP3A4*4 was an allelic variant related to a functional decrease of CYP3A4 activity, and *4 expression seemed to increase the lipid-lowering effects of simvastatin. Simvastatin 152-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 15740995-5 2005 Serotonin transporter (SERT) activity was significantly increased following 1 month of simvastatin; the tendency to decrease the initial increase in SERT activity was evident following 2 months of therapy. Simvastatin 87-98 solute carrier family 6 member 4 Homo sapiens 0-21 15740995-5 2005 Serotonin transporter (SERT) activity was significantly increased following 1 month of simvastatin; the tendency to decrease the initial increase in SERT activity was evident following 2 months of therapy. Simvastatin 87-98 solute carrier family 6 member 4 Homo sapiens 23-27 15740995-9 2005 A significant increase in SERT activity was detected only during the first month of simvastatin therapy. Simvastatin 84-95 solute carrier family 6 member 4 Homo sapiens 26-30 15650881-13 2005 CYP3A4*4 was an allelic variant related to a functional decrease of CYP3A4 activity, and *4 expression seemed to increase the lipid-lowering effects of simvastatin. Simvastatin 152-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 15650881-10 2005 After oral intake of simvastatin 20 mg daily for 4 weeks, the change of serum lipids in CYP3A4*1/*1 and CYP3A4*1/*4 groups showed a significant difference, with a mean decrease in triglycerides and total cholesterol of 38.1 +/- 7.6% versus 25.1 +/- 8.3% (P = 0.034) and of 35.8 +/- 9.6% versus 22.0 +/-20.4% (P = 0.0015) (means +/- SD), respectively. Simvastatin 21-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 15650881-10 2005 After oral intake of simvastatin 20 mg daily for 4 weeks, the change of serum lipids in CYP3A4*1/*1 and CYP3A4*1/*4 groups showed a significant difference, with a mean decrease in triglycerides and total cholesterol of 38.1 +/- 7.6% versus 25.1 +/- 8.3% (P = 0.034) and of 35.8 +/- 9.6% versus 22.0 +/-20.4% (P = 0.0015) (means +/- SD), respectively. Simvastatin 21-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-110 15720783-4 2005 The aim of this study was to detect and quantify changes in endothelial expression of P-selectin, VCAM-1, ICAM-1 and iNOS in the vessel wall after the shortterm administration of simvastatin in a rabbit model of atherosclerosis. Simvastatin 179-190 P-selectin Oryctolagus cuniculus 86-96 15720783-4 2005 The aim of this study was to detect and quantify changes in endothelial expression of P-selectin, VCAM-1, ICAM-1 and iNOS in the vessel wall after the shortterm administration of simvastatin in a rabbit model of atherosclerosis. Simvastatin 179-190 vascular cell adhesion protein 1 Oryctolagus cuniculus 98-104 15720783-4 2005 The aim of this study was to detect and quantify changes in endothelial expression of P-selectin, VCAM-1, ICAM-1 and iNOS in the vessel wall after the shortterm administration of simvastatin in a rabbit model of atherosclerosis. Simvastatin 179-190 ICAM-1 Oryctolagus cuniculus 106-112 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 0-11 alkaline phosphatase, placental Homo sapiens 28-31 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 0-11 alkaline phosphatase, placental Homo sapiens 202-205 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 179-190 alkaline phosphatase, placental Homo sapiens 202-205 15720783-9 2005 Stereological analysis of the immunohistochemical staining revealed that administration of simvastatin (10 mg kg(-1) daily) in an atherogenic diet decreased the endothelial expression of P-selectin, ICAM-1 and iNOS in both aortic arch and carotid artery compared with the cholesterol fed-rabbits only. Simvastatin 91-102 P-selectin Oryctolagus cuniculus 187-197 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 0-11 secreted phosphoprotein 1 Homo sapiens 219-230 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 179-190 alkaline phosphatase, placental Homo sapiens 28-31 15974856-10 2005 Simvastatin also stimulated ALP activity of human PDL cells dose-dependently, and maximum effect was obtained at the concentration of 10(8) M. In time dependent analysis, 10(8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. Simvastatin 179-190 secreted phosphoprotein 1 Homo sapiens 219-230 15720783-9 2005 Stereological analysis of the immunohistochemical staining revealed that administration of simvastatin (10 mg kg(-1) daily) in an atherogenic diet decreased the endothelial expression of P-selectin, ICAM-1 and iNOS in both aortic arch and carotid artery compared with the cholesterol fed-rabbits only. Simvastatin 91-102 ICAM-1 Oryctolagus cuniculus 199-205 15720783-10 2005 We conclude that simvastatin has beneficial effects on endothelial function by decreasing expression of P-selectin, ICAM-1 and iNOS in endothelial cells in the very early stages of atherogenesis. Simvastatin 17-28 P-selectin Oryctolagus cuniculus 104-114 15720783-10 2005 We conclude that simvastatin has beneficial effects on endothelial function by decreasing expression of P-selectin, ICAM-1 and iNOS in endothelial cells in the very early stages of atherogenesis. Simvastatin 17-28 ICAM-1 Oryctolagus cuniculus 116-122 15767241-3 2005 INTERVENTION: Investigators in the STELLAR trial evaluated percentage reductions in LDL and achievement of the ATP III LDL goal for various doses of atorvastatin, pravastatin, rosuvastatin, and simvastatin. Simvastatin 194-205 developmental pluripotency associated 3 pseudogene 2 Homo sapiens 35-42 15690306-5 2005 Pitavastatin, simvastatin, and atorvastatin each significantly increased PON1 promoter activity, and the transactivation by pitavastatin was abrogated by mevalonic acid and farnesyl pyrophosphate (FPP), however, not by geranylgeranyl pyrophosphate. Simvastatin 14-25 paraoxonase 1 Homo sapiens 73-77 15768882-4 2005 RESULTS: After being fed with high fat diet for 7 weeks, the protein and mRNA expression of macrophage CD68, MMP-1 in neo-genesic intima of aorta in the model rabbits significantly increased, these changes could be significantly restored after 8 weeks treatment with WHG or simvastatin. Simvastatin 274-285 macrosialin Oryctolagus cuniculus 103-107 15768882-5 2005 At the same time, the expressions of alpha-SMA protein and C-I protein and mRNA slightly increased due to the immigration of SMC in aortic media to neo-genesic intima, these expressions could be further increased after WHG treatment but showed a reducing trend after simvastatin treatment (P < 0.05 and P < 0.01). Simvastatin 267-278 actin, aortic smooth muscle Oryctolagus cuniculus 37-46 15621996-8 2005 Suppression of AAAs in simvastatin-treated mice was associated with preservation of medial elastin and vascular smooth muscle cells, as well as a relative reduction in aortic wall expression of MMP-9 and a relative increase in expression of TIMP-1. Simvastatin 23-34 elastin Mus musculus 91-98 15678257-4 2005 The authors examined the effects of 2 statins, simvastatin (Zocor) and atorvastatin (Lipitor) on antibody titers to Hsp-60, -65, and -70 in a group of dyslipidemic patients. Simvastatin 47-58 heat shock protein family D (Hsp60) member 1 Homo sapiens 116-136 15678257-4 2005 The authors examined the effects of 2 statins, simvastatin (Zocor) and atorvastatin (Lipitor) on antibody titers to Hsp-60, -65, and -70 in a group of dyslipidemic patients. Simvastatin 60-65 heat shock protein family D (Hsp60) member 1 Homo sapiens 116-136 15621996-8 2005 Suppression of AAAs in simvastatin-treated mice was associated with preservation of medial elastin and vascular smooth muscle cells, as well as a relative reduction in aortic wall expression of MMP-9 and a relative increase in expression of TIMP-1. Simvastatin 23-34 matrix metallopeptidase 9 Mus musculus 194-199 15621996-8 2005 Suppression of AAAs in simvastatin-treated mice was associated with preservation of medial elastin and vascular smooth muscle cells, as well as a relative reduction in aortic wall expression of MMP-9 and a relative increase in expression of TIMP-1. Simvastatin 23-34 tissue inhibitor of metalloproteinase 1 Mus musculus 241-247 15585212-7 2005 In addition, simvastatin decreased CETP activity dose-dependently, although HDL-cholesterol remained unchanged. Simvastatin 13-24 cholesteryl ester transfer protein Homo sapiens 35-39 15585213-0 2005 Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Simvastatin 45-56 apolipoprotein A1 Homo sapiens 60-66 15585213-3 2005 OBJECTIVES: To compare the impact of simvastatin and atorvastatin on apoA-I kinetics in vivo. Simvastatin 37-48 apolipoprotein A1 Homo sapiens 69-75 15785028-0 2005 The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer"s disease. Simvastatin 14-25 amyloid beta precursor protein Homo sapiens 43-68 15585213-8 2005 However, compared to atorvastatin, plasma apoA-I concentrations were significantly higher after treatment with simvastatin (1.33 +/- 0.07 g/L versus 1.23 +/- 0.07 g/L, P = 0.05). Simvastatin 111-122 apolipoprotein A1 Homo sapiens 42-48 15585213-9 2005 Treatment with simvastatin also induced a significant increase in apoA-I production rate compared to atorvastatin (15.2 +/- 3.0 mg/kg/d versus 13.2 +/- 2.6 mg/kg/d, P = 0.05). Simvastatin 15-26 apolipoprotein A1 Homo sapiens 66-72 15585213-11 2005 CONCLUSIONS: These results suggest that the diverging impact of simvastatin and atorvastatin on plasma HDL-C levels in humans may be attributable, at least partly, to a greater production rate of apoA-I with simvastatin. Simvastatin 64-75 apolipoprotein A1 Homo sapiens 196-202 15585213-11 2005 CONCLUSIONS: These results suggest that the diverging impact of simvastatin and atorvastatin on plasma HDL-C levels in humans may be attributable, at least partly, to a greater production rate of apoA-I with simvastatin. Simvastatin 208-219 apolipoprotein A1 Homo sapiens 196-202 15883752-8 2005 Simvastatin markedly attenuated the production of TNF-alpha, IL-1beta, IL-6 and increased IL-10 levels in the noninfarcted and infarcted regions, reduced collagen deposition in the noninfarcted myocardium and improved left ventricular function. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 50-59 15883752-8 2005 Simvastatin markedly attenuated the production of TNF-alpha, IL-1beta, IL-6 and increased IL-10 levels in the noninfarcted and infarcted regions, reduced collagen deposition in the noninfarcted myocardium and improved left ventricular function. Simvastatin 0-11 interleukin 1 beta Rattus norvegicus 61-69 15883752-8 2005 Simvastatin markedly attenuated the production of TNF-alpha, IL-1beta, IL-6 and increased IL-10 levels in the noninfarcted and infarcted regions, reduced collagen deposition in the noninfarcted myocardium and improved left ventricular function. Simvastatin 0-11 interleukin 6 Rattus norvegicus 71-75 15960426-0 2005 Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Simvastatin 32-43 butyrylcholinesterase Homo sapiens 47-68 15960426-3 2005 The objective of this study was to determine whether the activity of BuChE changes during treatment with simvastatin (CAS 79902-63-9). Simvastatin 105-116 butyrylcholinesterase Homo sapiens 69-74 15960426-4 2005 The effects of simvastatin therapy on serum lipoproteins and plasma BuChE activity were studied in 15 patients with type IIa and 17 patients with type IIb hyperlipoproteinemia. Simvastatin 15-26 butyrylcholinesterase Homo sapiens 68-73 15960426-5 2005 Beside the expected influence on serum lipid concentration, a statistically significant decrease in BuChE activity in patients with hyperlipoproteinemia type IIa and IIb during treatment with simvastatin was not observed. Simvastatin 192-203 butyrylcholinesterase Homo sapiens 100-105 15883752-8 2005 Simvastatin markedly attenuated the production of TNF-alpha, IL-1beta, IL-6 and increased IL-10 levels in the noninfarcted and infarcted regions, reduced collagen deposition in the noninfarcted myocardium and improved left ventricular function. Simvastatin 0-11 interleukin 10 Rattus norvegicus 90-95 16327254-2 2005 HMG-CoA reductase inhibitor drugs or statins (simvastatin, atorvastatin, pravastatin) reduce the relative risk of IS by between 18 and 51% in patients with IHD, in patients with high vascular disease risk and in hypertensive patients with other RFs, acute coronary syndrome, and type 2 diabetes mellitus. Simvastatin 46-57 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 15785028-3 2005 The aim was to further investigate the effect of simvastatin treatment on cerebrospinal fluid (CSF) biomarkers of APP processing, AD biomarkers as total tau and tau phosphorylated at threonine 181, brain cholesterol metabolism as well as on cognitive decline in patients with AD. Simvastatin 49-60 microtubule associated protein tau Homo sapiens 153-156 15785028-3 2005 The aim was to further investigate the effect of simvastatin treatment on cerebrospinal fluid (CSF) biomarkers of APP processing, AD biomarkers as total tau and tau phosphorylated at threonine 181, brain cholesterol metabolism as well as on cognitive decline in patients with AD. Simvastatin 49-60 microtubule associated protein tau Homo sapiens 161-164 16113589-12 2005 mRNA renal expression for p27 and TGF-beta did not change between groups, but p21 mRNA renal expression, highly induced in this model, significantly decreased with SIMV treatment (31.6 +/- 6.6 vs. 50.2 +/- 5.8 OD, p < 0.05). Simvastatin 164-168 KRAS proto-oncogene, GTPase Rattus norvegicus 78-81 15642080-10 2005 Ezetimibe plus simvastatin 20 mg also produced significant incremental reductions in non-HDL-C (p < 0.001), very low-density lipoprotein cholesterol (p < 0.05) and apolipoprotein B (p < 0.001) relative to simvastatin 40 mg. Simvastatin 15-26 apolipoprotein B Homo sapiens 170-186 15653378-0 2005 Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. Simvastatin 0-11 tumor necrosis factor Homo sapiens 33-60 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 62-89 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 91-100 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 114-123 15653378-8 2005 At the 24(th) week after transplantation, when compared with Week 1 values, we found a significant decrease in myocardium TNF-alpha content in the simvastatin group (15.0% +/- 2.3% vs 5.8% +/- 2.4%, p = 0.02) that was not observed in the placebo group (15.0% +/- 1.5% vs 12.0% +/- 2.6%, p = not significant). Simvastatin 147-158 tumor necrosis factor Homo sapiens 122-131 15653378-9 2005 CONCLUSION: Simvastatin treatment in heart transplant recipients decreased myocardium TNF-alpha expression. Simvastatin 12-23 tumor necrosis factor Homo sapiens 86-95 16521918-11 2005 Atorva- and simvastatin also significantly decrease activity both free generated thrombin and clot bound thrombin. Simvastatin 12-23 coagulation factor II, thrombin Homo sapiens 81-89 16158080-7 2005 Our data suggest that the SCAP 2386A>G gene polymorphism was a significant predictor of TC and triglyceride responses to simvastatin treatment. Simvastatin 124-135 SREBF chaperone Homo sapiens 26-30 16158080-0 2005 Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Simvastatin 37-48 SREBF chaperone Homo sapiens 91-95 16158080-0 2005 Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Simvastatin 37-48 sterol regulatory element binding transcription factor 2 Homo sapiens 110-117 16521918-11 2005 Atorva- and simvastatin also significantly decrease activity both free generated thrombin and clot bound thrombin. Simvastatin 12-23 coagulation factor II, thrombin Homo sapiens 105-113 16185099-5 2005 In some of these trials (such as 4S [Scandinavian Simvastatin Survival Study], CARE [Cholesterol and Recurrent Events] trial, and the HPS [Heart Protection Study]), HMG-CoA reductase inhibitor treatment significantly reduced cardiovascular events in diabetic patients, whereas in other trials (ALLHAT-LLT [Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial], ASCOT [Anglo-Scandinavian Cardiac Outcomes Trial]) the reductions were not significant. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 165-182 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 66-84 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 86-89 16281491-10 2005 CONCLUSION: Use of simvastatin in ACS patients, initially normal level of LDLP cholesterol and elevated level of CRP produced a dose-dependent effect, alleviated inflammation and improved the disease course. Simvastatin 19-30 C-reactive protein Homo sapiens 113-116 15520323-8 2004 The LPS-induced increases in neutrophil oxidative burst and plasma tumor necrosis factor-alpha concentrations were mitigated by simvastatin (P<0.05 versus placebo). Simvastatin 128-139 tumor necrosis factor Homo sapiens 67-94 15769392-6 2005 These effects of simvastatin and lovastatin on eNOS mRNA expression correlated with changes in nitric oxide production. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 47-51 15569835-10 2004 These changes were significantly greater than in the group treated with simvastatin alone (P<0.001 for adiponectin, P=0.029 for QUICKI by ANOVA). Simvastatin 72-83 adiponectin, C1Q and collagen domain containing Homo sapiens 106-117 15298857-0 2004 Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Simvastatin 108-119 cellular communication network factor 2 Homo sapiens 0-31 15298857-4 2004 Simvastatin reduces basal CTGF gene and protein expression in all fibroblast lines, overriding TGF-beta induction through inhibition of the cholesterol synthesis pathway. Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 26-30 15298857-5 2004 Signaling pathways driving simvastatin"s effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Simvastatin 27-38 cellular communication network factor 2 Homo sapiens 52-56 15298857-5 2004 Signaling pathways driving simvastatin"s effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 57-65 15298857-5 2004 Signaling pathways driving simvastatin"s effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Simvastatin 27-38 cellular communication network factor 2 Homo sapiens 136-140 15298857-6 2004 Inhibition of CTGF promoter activity by simvastatin was most marked at 10 muM concentration, reducing activity by 76.2 and 51.8% over TGF-beta-stimulated cultures in IPF and normal fibroblasts, respectively. Simvastatin 40-51 cellular communication network factor 2 Homo sapiens 14-18 15298857-6 2004 Inhibition of CTGF promoter activity by simvastatin was most marked at 10 muM concentration, reducing activity by 76.2 and 51.8% over TGF-beta-stimulated cultures in IPF and normal fibroblasts, respectively. Simvastatin 40-51 transforming growth factor beta 1 Homo sapiens 134-142 15298857-8 2004 Indeed, the specific Rho inhibitor C3 exotoxin significantly (P < 0.05) suppressed TGF-beta-induced CTGF promoter activity in transfected lung fibroblasts, a finding further supported by transfection of dominant-negative and constitutively active RhoA constructs, thus demonstrating that simvastatin through a Rho signaling mechanism in lung fibroblasts can modulate CTGF expression and interaction with TGF-beta. Simvastatin 291-302 transforming growth factor beta 1 Homo sapiens 86-94 15537504-0 2004 Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Simvastatin 122-133 tumor necrosis factor Homo sapiens 0-27 15537504-0 2004 Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Simvastatin 122-133 matrix metallopeptidase 9 Homo sapiens 91-96 15537504-11 2004 Simvastatin (0.1-10 mumol/l) concentration dependently inhibited TNFalpha-induced myofibroblast proliferation, invasion and MMP-9 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 65-73 15537504-11 2004 Simvastatin (0.1-10 mumol/l) concentration dependently inhibited TNFalpha-induced myofibroblast proliferation, invasion and MMP-9 secretion. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 124-129 15537504-12 2004 CONCLUSIONS: TNFalpha, acting predominantly via the TNF-R1 receptor, increased human atrial myofibroblast proliferation, invasion and MMP-9 secretion, all of which were inhibited by simvastatin. Simvastatin 182-193 tumor necrosis factor Homo sapiens 13-21 15537504-12 2004 CONCLUSIONS: TNFalpha, acting predominantly via the TNF-R1 receptor, increased human atrial myofibroblast proliferation, invasion and MMP-9 secretion, all of which were inhibited by simvastatin. Simvastatin 182-193 matrix metallopeptidase 9 Homo sapiens 134-139 15572054-0 2004 Simvastatin enhances myocardial angiogenesis induced by vascular endothelial growth factor gene transfer. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 56-90 15572054-7 2004 Intramyocardial VEGF gene transfer increased capillary and arteriolar densities in the ApoE(-/-) mice, and simvastatin treatment further enhanced capillary density (P < 0.03) to a level similar to that of normal mice. Simvastatin 107-118 apolipoprotein E Mus musculus 87-91 15572054-8 2004 Simvastatin did not change the lipid profile but blocked p38 MAPK phosphorylation in the ApoE(-/-) myocardium. Simvastatin 0-11 mitogen-activated protein kinase 14 Mus musculus 57-65 15572054-8 2004 Simvastatin did not change the lipid profile but blocked p38 MAPK phosphorylation in the ApoE(-/-) myocardium. Simvastatin 0-11 apolipoprotein E Mus musculus 89-93 15572054-10 2004 Thus, increased myocardial angiogenesis in the ApoE(-/-) mice following transient overexpression of VEGF is further increased by additional simvastatin treatment. Simvastatin 140-151 apolipoprotein E Mus musculus 47-51 15572054-10 2004 Thus, increased myocardial angiogenesis in the ApoE(-/-) mice following transient overexpression of VEGF is further increased by additional simvastatin treatment. Simvastatin 140-151 vascular endothelial growth factor A Mus musculus 100-104 15572054-11 2004 These effects occurred concurrently with simvastatin-induced stimulation of the VEGF system, increased eNOS production and reduction in p38 MAPK phosphorylation. Simvastatin 41-52 vascular endothelial growth factor A Mus musculus 80-84 15572054-11 2004 These effects occurred concurrently with simvastatin-induced stimulation of the VEGF system, increased eNOS production and reduction in p38 MAPK phosphorylation. Simvastatin 41-52 mitogen-activated protein kinase 14 Mus musculus 136-139 15544924-3 2004 In cultured endothelial cells derived from human umbilical vein, simvastatin and lovastatin increased HO-1 mRNA levels in a concentration- and time-dependent fashion. Simvastatin 65-76 heme oxygenase 1 Homo sapiens 102-106 15531380-1 2004 Pharmacokinetic and pharmacodynamic interactions between simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and diltiazem, a calcium antagonist, were investigated in 7 male and 4 female patients with hypercholesterolemia and hypertension. Simvastatin 57-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 72-129 15531380-7 2004 These apparent pharmacokinetic interactions, namely the increase of HMG-CoA reductase inhibitor concentration by diltiazem and the decrease of diltiazem concentration by simvastatin, enhance the cholesterol-lowering effects of simvastatin during combined treatment. Simvastatin 227-238 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-85 15571475-1 2004 Simvastatin is a long-established hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, first introduced in 1988. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-87 15488325-0 2004 Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 82-87 15474503-3 2004 Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM). Simvastatin 141-152 apolipoprotein A1 Homo sapiens 20-26 15474503-3 2004 Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM). Simvastatin 141-152 apolipoprotein A1 Homo sapiens 97-103 15488325-6 2004 In immunocytochemical and immunoblotting experiments we have shown that simvastatin markedly increased the phosphorylation of ATF-2 and c-jun in the nucleus of the C6 glioma cells at early time points which was preserved even 24 h after treatment. Simvastatin 72-83 activating transcription factor 2 Homo sapiens 126-131 15488325-6 2004 In immunocytochemical and immunoblotting experiments we have shown that simvastatin markedly increased the phosphorylation of ATF-2 and c-jun in the nucleus of the C6 glioma cells at early time points which was preserved even 24 h after treatment. Simvastatin 72-83 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 136-141 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 56-67 mitogen-activated protein kinase 8 Homo sapiens 23-26 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 56-67 mitogen-activated protein kinase 8 Homo sapiens 139-142 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 56-67 activating transcription factor 2 Homo sapiens 167-172 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 56-67 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 177-182 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 213-224 mitogen-activated protein kinase 8 Homo sapiens 23-26 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 213-224 mitogen-activated protein kinase 8 Homo sapiens 139-142 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 213-224 activating transcription factor 2 Homo sapiens 167-172 15488325-8 2004 Selective inhibitor of JNK, but not p38 kinase, reduced simvastatin-induced cell death and ATF-2 and c-jun phosphorylation suggesting that JNK-dependent activation of ATF-2 and c-jun may play an important role in simvastatin-induced proliferation inhibition and apoptosis in C6 glioma cells. Simvastatin 213-224 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 177-182 15289292-4 2004 The prototypical representative of statins, simvastatin, induced consecutive activation of caspase 9 and 3 in a concentration-dependent manner. Simvastatin 44-55 caspase 9 Homo sapiens 91-106 15488877-4 2004 Simvastatin alone or combined with ramipril significantly changed lipoproteins, and improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements by 33 +/- 6% and by 50 +/- 14%, respectively (both P <0.001) and reduced plasma levels of nitrate relative to baseline measurements (P=0.413 and 0.037, respectively), the plasma MDA levels relative to baseline measurements by 8 +/- 8% and by 18 +/- 9% (P=0.039 and P <0.001, respectively) and MCP-1 relative to baseline measurements by 7 +/- 4% and by 13 +/- 3%, respectively (P=0.019 and P <0.001, respectively), and CRP from 0.22 to 0.14 mg/dl and from 0.22 to 0.15 mg/dl, respectively (P=0.124 and 0.002, respectively), and PAI-1 antigen relative to baseline measurements (P=0.690 and 0.018, respectively). Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 482-487 15488877-4 2004 Simvastatin alone or combined with ramipril significantly changed lipoproteins, and improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements by 33 +/- 6% and by 50 +/- 14%, respectively (both P <0.001) and reduced plasma levels of nitrate relative to baseline measurements (P=0.413 and 0.037, respectively), the plasma MDA levels relative to baseline measurements by 8 +/- 8% and by 18 +/- 9% (P=0.039 and P <0.001, respectively) and MCP-1 relative to baseline measurements by 7 +/- 4% and by 13 +/- 3%, respectively (P=0.019 and P <0.001, respectively), and CRP from 0.22 to 0.14 mg/dl and from 0.22 to 0.15 mg/dl, respectively (P=0.124 and 0.002, respectively), and PAI-1 antigen relative to baseline measurements (P=0.690 and 0.018, respectively). Simvastatin 0-11 serpin family E member 1 Homo sapiens 719-724 15488877-5 2004 However, simvastatin combined with ramipril changed to greater but statistically insignificant extent the percent flow-mediated dilator response to hyperemia and plasma levels of nitrate, MDA, MCP-1, and PAI-1 antigen than simvastatin alone. Simvastatin 9-20 C-C motif chemokine ligand 2 Homo sapiens 193-198 15488877-5 2004 However, simvastatin combined with ramipril changed to greater but statistically insignificant extent the percent flow-mediated dilator response to hyperemia and plasma levels of nitrate, MDA, MCP-1, and PAI-1 antigen than simvastatin alone. Simvastatin 9-20 serpin family E member 1 Homo sapiens 204-209 15289292-5 2004 The permeability transition pore inhibitor bongkrekic acid was capable of completely preventing simvastatin-induced caspase 9 and 3 activity, corroborating the mitochondrial pathway of apoptosis as the sole mechanism of statin action. Simvastatin 96-107 caspase 9 Homo sapiens 116-125 15541048-4 2004 Diabetic subjects who had been receiving simvastatin treatment had TNF-alpha mRNA production similar to that of the healthy participants. Simvastatin 41-52 tumor necrosis factor Homo sapiens 67-76 15458690-5 2004 Simvastatin and fenofibrate significantly lowered plasma levels of tumor necrosis factor alpha (TNF-alpha) by 13+/-4% and by 10+/-4%, respectively (P=0.009 and P=0.006, respectively) with a similar degree (P=0.614). Simvastatin 0-11 tumor necrosis factor Homo sapiens 67-94 15458690-5 2004 Simvastatin and fenofibrate significantly lowered plasma levels of tumor necrosis factor alpha (TNF-alpha) by 13+/-4% and by 10+/-4%, respectively (P=0.009 and P=0.006, respectively) with a similar degree (P=0.614). Simvastatin 0-11 tumor necrosis factor Homo sapiens 96-105 15458690-6 2004 Simvastatin significantly reduced plasma levels of total MMP-9 and TIMP-1 more (P=0.005 and P=0.036, respectively), compared with fenofibrate showing no reduction. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 57-62 15458690-6 2004 Simvastatin significantly reduced plasma levels of total MMP-9 and TIMP-1 more (P=0.005 and P=0.036, respectively), compared with fenofibrate showing no reduction. Simvastatin 0-11 TIMP metallopeptidase inhibitor 1 Homo sapiens 67-73 15799170-0 2004 Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. Simvastatin 142-153 interleukin 6 Homo sapiens 17-30 15799170-7 2004 After 3 weeks of treatment with simvastatin, the serum IL-6, hs-CRP, total cholesterol, and low-density lipoprotein cholesterol levels were decreased significantly in the simvastatin group (P < 0.001), but no significant changes were observed in the routine group. Simvastatin 32-43 interleukin 6 Homo sapiens 55-59 15799170-7 2004 After 3 weeks of treatment with simvastatin, the serum IL-6, hs-CRP, total cholesterol, and low-density lipoprotein cholesterol levels were decreased significantly in the simvastatin group (P < 0.001), but no significant changes were observed in the routine group. Simvastatin 171-182 interleukin 6 Homo sapiens 55-59 15662091-0 2004 Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia. Simvastatin 10-21 fibrinogen beta chain Homo sapiens 48-58 15662091-6 2004 After 4 weeks of treatment both drugs tended to increase plasma fibrinogen levels, while after 12 weeks fibrinogen level was significantly increased in the simvastatin-treated patients. Simvastatin 156-167 fibrinogen beta chain Homo sapiens 104-114 15337692-0 2004 Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 20-36 15337740-6 2004 In rat hepatocytes, simvastatin treatment induced L-FABP mRNA levels in a dose-dependent manner. Simvastatin 20-31 fatty acid binding protein 1 Rattus norvegicus 50-56 15337740-9 2004 Moreover, treatment with simvastatin and the PPARalpha agonist Wy14,649 resulted in a synergistic induction of L-FABP expression (mRNA and protein) in rat Fao hepatoma cells. Simvastatin 25-36 fatty acid binding protein 1 Rattus norvegicus 111-117 15161667-0 2004 The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 15578471-4 2004 In this study, the effects of preoperative simvastatin treatment, at doses equivalent to those used orally for cholesterol control, were studied on plasma levels of VCAM-1, ICAM-1, and ELAM-1. Simvastatin 43-54 vascular cell adhesion molecule 1 Homo sapiens 165-171 15578471-4 2004 In this study, the effects of preoperative simvastatin treatment, at doses equivalent to those used orally for cholesterol control, were studied on plasma levels of VCAM-1, ICAM-1, and ELAM-1. Simvastatin 43-54 intercellular adhesion molecule 1 Homo sapiens 173-179 15578471-4 2004 In this study, the effects of preoperative simvastatin treatment, at doses equivalent to those used orally for cholesterol control, were studied on plasma levels of VCAM-1, ICAM-1, and ELAM-1. Simvastatin 43-54 selectin E Homo sapiens 185-191 15578471-9 2004 In the late postoperative samples, the plasma levels of ICAM-1 and ELAM-1 were lower in both simvastatin-treated patients compared with the control patients. Simvastatin 93-104 intercellular adhesion molecule 1 Homo sapiens 56-62 15578471-9 2004 In the late postoperative samples, the plasma levels of ICAM-1 and ELAM-1 were lower in both simvastatin-treated patients compared with the control patients. Simvastatin 93-104 selectin E Homo sapiens 67-73 15578471-12 2004 CONCLUSIONS: Pretreatment with simvastatin significantly reduces the increase of ICAM-1 and ELAM-1 after coronary artery bypass surgery, by a mechanism that seems not related to its efficacy in lowering cholesterol levels. Simvastatin 31-42 intercellular adhesion molecule 1 Homo sapiens 81-87 15578471-12 2004 CONCLUSIONS: Pretreatment with simvastatin significantly reduces the increase of ICAM-1 and ELAM-1 after coronary artery bypass surgery, by a mechanism that seems not related to its efficacy in lowering cholesterol levels. Simvastatin 31-42 selectin E Homo sapiens 92-98 15337692-3 2004 Here, we studied whether heme oxygenase-1 (HO-1), an important cytoprotective molecule, is induced by simvastatin and the role of HO-1 in the pleiotropic effects of simvastatin. Simvastatin 102-113 heme oxygenase 1 Homo sapiens 25-41 15337692-3 2004 Here, we studied whether heme oxygenase-1 (HO-1), an important cytoprotective molecule, is induced by simvastatin and the role of HO-1 in the pleiotropic effects of simvastatin. Simvastatin 102-113 heme oxygenase 1 Homo sapiens 43-47 15337692-4 2004 METHODS AND RESULTS: Human and rat aortic smooth muscle cells treated with simvastatin showed an elevated level of HO-1 for up to 24 hours. Simvastatin 75-86 heme oxygenase 1 Rattus norvegicus 115-119 15337692-5 2004 The induction of HO-1 by simvastatin was not found in cultured endothelial cells and macrophages. Simvastatin 25-36 heme oxygenase 1 Homo sapiens 17-21 15337692-6 2004 Injecting C57BL/6J mice intraperitoneally with simvastatin increased the level of HO-1 in vascular SMCs (VSMCs) in the tunica media. Simvastatin 47-58 heme oxygenase 1 Mus musculus 82-86 15337692-7 2004 Treating VSMCs with zinc protoporphyrin, an HO-1 inhibitor, or HO-1 small interfering RNA (siRNA) blocked the antiinflammatory effect of simvastatin, including the inhibition of nuclear factor-kappaB activation and nitric oxide production. Simvastatin 137-148 heme oxygenase 1 Homo sapiens 44-48 15337692-7 2004 Treating VSMCs with zinc protoporphyrin, an HO-1 inhibitor, or HO-1 small interfering RNA (siRNA) blocked the antiinflammatory effect of simvastatin, including the inhibition of nuclear factor-kappaB activation and nitric oxide production. Simvastatin 137-148 heme oxygenase 1 Homo sapiens 63-67 15337692-8 2004 Blockade of HO-1 also abolished the simvastatin-induced p21(Waf1) and the associated antiproliferative effect. Simvastatin 36-47 heme oxygenase 1 Homo sapiens 12-16 15337692-8 2004 Blockade of HO-1 also abolished the simvastatin-induced p21(Waf1) and the associated antiproliferative effect. Simvastatin 36-47 cyclin dependent kinase inhibitor 1A Homo sapiens 56-59 15337692-8 2004 Blockade of HO-1 also abolished the simvastatin-induced p21(Waf1) and the associated antiproliferative effect. Simvastatin 36-47 cyclin dependent kinase inhibitor 1A Homo sapiens 60-64 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 22-25 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 77-80 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 167-171 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 mitogen-activated protein kinase 14 Homo sapiens 77-80 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 224-227 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 0-11 heme oxygenase 1 Homo sapiens 239-243 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 mitogen-activated protein kinase 14 Homo sapiens 22-25 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 AKT serine/threonine kinase 1 Homo sapiens 30-33 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 mitogen-activated protein kinase 14 Homo sapiens 77-80 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 85-110 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 heme oxygenase 1 Homo sapiens 167-171 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 mitogen-activated protein kinase 14 Homo sapiens 77-80 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 AKT serine/threonine kinase 1 Homo sapiens 224-227 15337692-9 2004 Simvastatin activated p38 and Akt in VSMCs, and the respective inhibitors of p38 and phosphoinositide 3-kinase (PI3K) greatly reduced the level of simvastatin-induced HO-1, which suggests the involvement of p38 and the PI3K-Akt pathway in HO-1 induction. Simvastatin 147-158 heme oxygenase 1 Homo sapiens 239-243 15337692-10 2004 CONCLUSIONS: Simvastatin activates HO-1 in VSMCs in vitro and in vivo. Simvastatin 13-24 heme oxygenase 1 Homo sapiens 35-39 15337692-11 2004 The antiinflammatory and antiproliferative effects of simvastatin occur largely through the induced HO-1. Simvastatin 54-65 heme oxygenase 1 Homo sapiens 100-104 15311154-0 2004 Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Simvastatin 56-67 CD40 ligand Homo sapiens 18-23 15311154-10 2004 Treatment with simvastatin might downregulate enhanced CD40L-CD40 interactions in CAPD patients. Simvastatin 15-26 CD40 ligand Homo sapiens 55-60 15311154-10 2004 Treatment with simvastatin might downregulate enhanced CD40L-CD40 interactions in CAPD patients. Simvastatin 15-26 CD40 molecule Homo sapiens 55-59 15339992-8 2004 EC proliferation and cell cycle progression, examined by 5,6-carboxyfluorescein diacetate succinimidyl ester staining, demonstrated that anti-HLA-induced EC proliferation was efficiently prevented by the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor simvastatin (0.1 micromol/L) through inhibition of RhoA geranylgeranylation. Simvastatin 255-266 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 204-244 15339992-8 2004 EC proliferation and cell cycle progression, examined by 5,6-carboxyfluorescein diacetate succinimidyl ester staining, demonstrated that anti-HLA-induced EC proliferation was efficiently prevented by the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor simvastatin (0.1 micromol/L) through inhibition of RhoA geranylgeranylation. Simvastatin 255-266 ras homolog family member A Homo sapiens 306-310 15339992-9 2004 Taken together, these findings support the conclusion that RhoA is a key mediator of signaling pathways that lead to cytoskeletal reorganization and EC proliferation in response to alloantibodies that bind to HLA class I and demonstrate the specific and potent inhibitory effect of simvastatin on allostimulated EC growth. Simvastatin 282-293 ras homolog family member A Homo sapiens 59-63 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Simvastatin 94-105 C-reactive protein Homo sapiens 65-68 15497697-0 2004 Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Simvastatin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 24-38 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 78-80 ATP binding cassette subfamily B member 1 Homo sapiens 24-38 15497697-1 2004 PURPOSE: In this study, P-glycoprotein (P-gp) mediated efflux of simvastatin (SV), simvastatin acid (SVA), and atorvastatin (AVA) and inhibition of P-gp by SV, SVA, and AVA were evaluated to assess the role of P-gp in drug interactions. Simvastatin 78-80 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 15475833-0 2004 Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Rattus norvegicus 115-118 15475833-7 2004 In summary, simvastatin acutely reduces the extent of myocardial necrosis in normocholesterolemic rats in an NO- dependent manner by activating the PI 3-kinase/Akt pathway. Simvastatin 12-23 AKT serine/threonine kinase 1 Rattus norvegicus 160-163 15129368-4 2004 In addition, PD098059 as well as simvastatin and the FTase inhibitor abolished alkaline phosphatase activity and/or osteocalcin mRNA induction by the IL-6/IL-6sR in these cells. Simvastatin 33-44 bone gamma-carboxyglutamate protein Homo sapiens 116-127 15262179-0 2004 Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling. Simvastatin 0-11 zinc fingers and homeoboxes 2 Homo sapiens 84-87 15262179-0 2004 Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 88-91 15262179-8 2004 Simvastatin inhibited serum-induced endothelial tube formation after 18 h. The inhibition of ERK activity suppressed serum-induced tube formation. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 93-96 15262179-12 2004 In conclusion, simvastatin-induced Ras/Raf/ERK inactivation is a potent signal in the anti-angiogenic phenotype of HCECs. Simvastatin 15-26 zinc fingers and homeoboxes 2 Homo sapiens 39-42 15262179-12 2004 In conclusion, simvastatin-induced Ras/Raf/ERK inactivation is a potent signal in the anti-angiogenic phenotype of HCECs. Simvastatin 15-26 mitogen-activated protein kinase 1 Homo sapiens 43-46 15262179-13 2004 Fpp counteracted simvastatin-induced Ras/Raf/ERK inactivation. Simvastatin 17-28 zinc fingers and homeoboxes 2 Homo sapiens 41-44 15262179-13 2004 Fpp counteracted simvastatin-induced Ras/Raf/ERK inactivation. Simvastatin 17-28 mitogen-activated protein kinase 1 Homo sapiens 45-48 15262182-5 2004 On the contrary, interference with the RhoA signaling pathway by simvastatin, an inhibitor of geranylgeranyltransferases, or the Rho-kinase inhibitor Y27632 prevented induction of CTGF. Simvastatin 65-76 cellular communication network factor 2 Homo sapiens 180-184 15262182-6 2004 Co-incubation of endothelial cells with freshly isolated human platelets significantly increased the expression of CTGF mRNA in endothelial cells, which was also sensitive to simvastatin. Simvastatin 175-186 cellular communication network factor 2 Homo sapiens 115-119 15262187-4 2004 Lymphocyte lipid raft levels, represented by Lyn and Fyn, were also reduced by simvastatin. Simvastatin 79-90 LYN proto-oncogene, Src family tyrosine kinase Homo sapiens 45-48 15129368-4 2004 In addition, PD098059 as well as simvastatin and the FTase inhibitor abolished alkaline phosphatase activity and/or osteocalcin mRNA induction by the IL-6/IL-6sR in these cells. Simvastatin 33-44 interleukin 6 Homo sapiens 150-154 15129368-4 2004 In addition, PD098059 as well as simvastatin and the FTase inhibitor abolished alkaline phosphatase activity and/or osteocalcin mRNA induction by the IL-6/IL-6sR in these cells. Simvastatin 33-44 interleukin 6 Homo sapiens 155-159 15324535-0 2004 Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Simvastatin 36-47 paraoxonase 1 Homo sapiens 79-90 15575340-7 2004 Increased malondialdehyde levels, catalase and glutathione peroxidase activities were normalised by simvastatin treatment in diabetic aorta. Simvastatin 100-111 catalase Rattus norvegicus 34-42 15324535-3 2004 The study presented here examined the effect of short-term treatment with simvastatin and atorvastatin on lipids and PON activity in patients with hyperlipoproteinaemia. Simvastatin 74-85 paraoxonase 1 Homo sapiens 117-120 15324535-10 2004 RESULTS: Simvastatin treatment significantly reduced serum cholesterol, LDL-cholesterol (LDL-C) and apolipoprotein (apo) B levels (p < 0.001). Simvastatin 9-20 component of oligomeric golgi complex 2 Homo sapiens 89-122 15300198-10 2004 Both Cav-1 and p-Cav-1 expression was significantly lower in the SMV-treated animals (P < .05) compared to mice treated with RAPA. Simvastatin 65-68 caveolin 1, caveolae protein Mus musculus 5-10 15744552-5 2004 Using whole blood flow cytometry, we evaluated the change of platelet P-selectin expression of all the patients after the 12-weeks use and the 12-weeks discontinuance of simvastatin. Simvastatin 170-181 selectin P Homo sapiens 70-80 15744552-6 2004 The platelet P-selectin expression was significant reduced after treatment of simvastatin 20 mg for 12 weeks (p < 0.001). Simvastatin 78-89 selectin P Homo sapiens 13-23 15284534-1 2004 Individuals expressing the polymorphic CYP3A5 enzyme might show a more than average efficiency in the metabolism of lovastatin, simvastatin and atorvastatin. Simvastatin 128-139 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 15284534-3 2004 Lovastatin, simvastatin and atorvastatin were significantly less effective in CYP3A5 expressors than in non-expressors. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 78-84 15184351-7 2004 In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P<0.001 and P=0.048 by ANOVA, respectively). Simvastatin 109-120 C-reactive protein Homo sapiens 183-201 15300198-10 2004 Both Cav-1 and p-Cav-1 expression was significantly lower in the SMV-treated animals (P < .05) compared to mice treated with RAPA. Simvastatin 65-68 caveolin 1, caveolae protein Mus musculus 17-22 15300198-12 2004 The increase in eNOS induced by RAPA and the inverse relationship between p-eNOS and Cav-1 protein expression observed with SMV treatment suggest different mechanisms for the regulation of aortic eNOS expression in Apo-E mice by these 2 agents. Simvastatin 124-127 caveolin 1, caveolae protein Mus musculus 85-90 15300198-12 2004 The increase in eNOS induced by RAPA and the inverse relationship between p-eNOS and Cav-1 protein expression observed with SMV treatment suggest different mechanisms for the regulation of aortic eNOS expression in Apo-E mice by these 2 agents. Simvastatin 124-127 apolipoprotein E Mus musculus 215-220 15234187-0 2004 Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 22-30 15234187-3 2004 We investigated the effect of simvastatin, an inhibitor of HMG-CoA reductase administered to reduce plasma levels of LDL-cholesterol, on the expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) by human umbilical vein endothelial cells (HUVEC) stimulated with tumor necrosis factor alpha (TNFalpha). Simvastatin 30-41 vascular cell adhesion molecule 1 Homo sapiens 155-188 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 tumor necrosis factor Homo sapiens 3-11 15234187-3 2004 We investigated the effect of simvastatin, an inhibitor of HMG-CoA reductase administered to reduce plasma levels of LDL-cholesterol, on the expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) by human umbilical vein endothelial cells (HUVEC) stimulated with tumor necrosis factor alpha (TNFalpha). Simvastatin 30-41 vascular cell adhesion molecule 1 Homo sapiens 190-196 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 vascular cell adhesion molecule 1 Homo sapiens 52-58 15234187-3 2004 We investigated the effect of simvastatin, an inhibitor of HMG-CoA reductase administered to reduce plasma levels of LDL-cholesterol, on the expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) by human umbilical vein endothelial cells (HUVEC) stimulated with tumor necrosis factor alpha (TNFalpha). Simvastatin 30-41 intercellular adhesion molecule 1 Homo sapiens 202-240 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 intercellular adhesion molecule 1 Homo sapiens 63-69 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 tumor necrosis factor Homo sapiens 93-101 15187114-6 2004 Simvastatin prevents LPS-induced c-Fos expression, thereby relieving the inhibitory effect of c-Fos on the IL-12p40 promoter. Simvastatin 0-11 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 33-38 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 185-233 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 235-244 15786696-0 2004 Simvastatin decreases concentration of interleukin-2 in hypercholesterolemic patients after treatment for 12 weeks. Simvastatin 0-11 interleukin 2 Homo sapiens 39-52 15786696-5 2004 The aim of the study was to assess the influence of simvastatin on serum levels of proinflammatory cytokines such as IL-2 and TNFalpha in hypercholesterolemic patients. Simvastatin 52-63 interleukin 2 Homo sapiens 117-121 15786696-5 2004 The aim of the study was to assess the influence of simvastatin on serum levels of proinflammatory cytokines such as IL-2 and TNFalpha in hypercholesterolemic patients. Simvastatin 52-63 tumor necrosis factor Homo sapiens 126-134 15786696-8 2004 RESULTS: There were significant reductions in IL-2 concentration after 3 months diet (p=0.0059) and significant (p=0.0003) decrease of IL-2 after 3 months of simvastatin therapy. Simvastatin 158-169 interleukin 2 Homo sapiens 135-139 15551657-9 2004 IL-6 secretion from U266 cells was abrogated on treatment with simvastatin, whereas total tyrosine phosphorylation was unaffected. Simvastatin 63-74 interleukin 6 Homo sapiens 0-4 15201699-10 2004 We also investigated the in vitro effect of simvastatin on translocation of NADPH oxidase p21 Rac2 subunit in THP-1 monocytic cell line. Simvastatin 44-55 Rac family small GTPase 2 Homo sapiens 90-98 15187114-0 2004 Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. Simvastatin 0-11 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 123-128 15187114-0 2004 Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. Simvastatin 0-11 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 133-138 15187114-3 2004 We report in this work that, unexpectedly, simvastatin enhances LPS-induced IL-12p40 production by murine macrophages, and that it does so by activating the IL-12p40 promoter. Simvastatin 43-54 interleukin 12b Mus musculus 76-84 15187114-3 2004 We report in this work that, unexpectedly, simvastatin enhances LPS-induced IL-12p40 production by murine macrophages, and that it does so by activating the IL-12p40 promoter. Simvastatin 43-54 interleukin 12b Mus musculus 157-165 15210062-5 2004 Pretreatment with simvastatin (30 or 60 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, the increased level of TNF-alpha and the decreased level of NO by LDL, but no effect on serum concentration of endogenous ADMA. Simvastatin 18-29 tumor necrosis factor Homo sapiens 134-143 15210062-7 2004 Pretreatment with simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly decreased the level of TNF-alpha and the adhesion of monocytes to endothelial cells, but did not affect the concentration of endogenous ADMA and the activity of DDAH. Simvastatin 18-29 tumor necrosis factor Homo sapiens 92-101 15210062-7 2004 Pretreatment with simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly decreased the level of TNF-alpha and the adhesion of monocytes to endothelial cells, but did not affect the concentration of endogenous ADMA and the activity of DDAH. Simvastatin 18-29 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 230-234 15210062-8 2004 CONCLUSION: Simvastatin protect the vascular endothelium against the damages induced by LDL or ox-LDL in rats or cultured ECV304 cells, and the beneficial effects of simvastatin may be related to the reduction of inflammatory cytokine TNF-alpha level. Simvastatin 12-23 tumor necrosis factor Homo sapiens 235-244 15210062-8 2004 CONCLUSION: Simvastatin protect the vascular endothelium against the damages induced by LDL or ox-LDL in rats or cultured ECV304 cells, and the beneficial effects of simvastatin may be related to the reduction of inflammatory cytokine TNF-alpha level. Simvastatin 166-177 tumor necrosis factor Homo sapiens 235-244 15194586-0 2004 Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Simvastatin 0-11 matrix metallopeptidase 3 Homo sapiens 20-25 15194586-0 2004 Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Simvastatin 0-11 interleukin 1 beta Homo sapiens 35-52 15194586-4 2004 We thus decided to investigate the effect of simvastatin on the production of MMP-3 from cultured interleukin (IL)1 stimulated human chondrocytes. Simvastatin 45-56 matrix metallopeptidase 3 Homo sapiens 78-83 15194586-8 2004 Incubation with simvastatin was associated with a dose dependent reduction in MMP-3 increase, both in the presence (-15%, -17%, and -26% with 5, 10, and 50 micromol/l, respectively) and in the absence (-32% with 50 micromol/l) of IL1beta. Simvastatin 16-27 matrix metallopeptidase 3 Homo sapiens 78-83 15194586-8 2004 Incubation with simvastatin was associated with a dose dependent reduction in MMP-3 increase, both in the presence (-15%, -17%, and -26% with 5, 10, and 50 micromol/l, respectively) and in the absence (-32% with 50 micromol/l) of IL1beta. Simvastatin 16-27 interleukin 1 beta Homo sapiens 230-237 15194586-10 2004 CONCLUSIONS: Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-73 15194586-10 2004 CONCLUSIONS: Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage. Simvastatin 32-43 matrix metallopeptidase 3 Homo sapiens 139-144 15194586-10 2004 CONCLUSIONS: Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage. Simvastatin 32-43 interleukin 1 beta Homo sapiens 243-250 15265253-4 2004 RESULTS: Both simvastatin 80 and 40 mg significantly increased total HDL-C from baseline (mean increases of 8% +/- 1 [SE] and 5% +/- 1, respectively; p < 0.001) compared with placebo, and significantly reduced plasma concentrations of LDL-C (p < 0.001), triglycerides (p < 0.001), apolipoprotein B (p < 0.001), and hs-CRP (p < or = 0.012). Simvastatin 14-25 apolipoprotein B Homo sapiens 290-306 15213258-0 2004 Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. Simvastatin 0-11 angiotensinogen Rattus norvegicus 22-36 15213258-0 2004 Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. Simvastatin 0-11 Rac family small GTPase 1 Rattus norvegicus 69-73 15213258-0 2004 Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. Simvastatin 0-11 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 99-102 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 53-64 angiotensinogen Rattus norvegicus 78-100 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 53-64 Rac family small GTPase 1 Rattus norvegicus 110-114 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 53-64 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 175-178 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 66-69 angiotensinogen Rattus norvegicus 78-100 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 66-69 Rac family small GTPase 1 Rattus norvegicus 110-114 15213258-3 2004 The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27. Simvastatin 66-69 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 175-178 15213258-5 2004 Co-treatment of cells with SMV (1 microM) inhibited Ang II-induced upregulation of p27 protein. Simvastatin 27-30 angiotensinogen Rattus norvegicus 52-58 15213258-5 2004 Co-treatment of cells with SMV (1 microM) inhibited Ang II-induced upregulation of p27 protein. Simvastatin 27-30 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 83-86 15213258-6 2004 Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inhibitory effect of SMV on p27 protein expression, suggesting that the effect of SMV is geranylgeranyl dependent. Simvastatin 113-116 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 120-123 15213258-6 2004 Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inhibitory effect of SMV on p27 protein expression, suggesting that the effect of SMV is geranylgeranyl dependent. Simvastatin 174-177 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 120-123 15213258-8 2004 It was also shown that SMV, by inhibiting Rac1 activity, reversed Ang II-induced increase in intracellular H2O2 production, Akt activation, and p27 protein expression. Simvastatin 23-26 Rac family small GTPase 1 Rattus norvegicus 42-46 15213258-8 2004 It was also shown that SMV, by inhibiting Rac1 activity, reversed Ang II-induced increase in intracellular H2O2 production, Akt activation, and p27 protein expression. Simvastatin 23-26 angiotensinogen Rattus norvegicus 66-72 15213258-8 2004 It was also shown that SMV, by inhibiting Rac1 activity, reversed Ang II-induced increase in intracellular H2O2 production, Akt activation, and p27 protein expression. Simvastatin 23-26 AKT serine/threonine kinase 1 Rattus norvegicus 124-127 15213258-8 2004 It was also shown that SMV, by inhibiting Rac1 activity, reversed Ang II-induced increase in intracellular H2O2 production, Akt activation, and p27 protein expression. Simvastatin 23-26 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 144-147 15213258-9 2004 The data presented in this study not only elucidate Ang II-mediated signaling cascade in mesangial cells but also demonstrate for the first time the modulatory effects of SMV on Ang II-induced signaling pathway at the cell cycle level. Simvastatin 171-174 angiotensinogen Rattus norvegicus 52-58 15213258-9 2004 The data presented in this study not only elucidate Ang II-mediated signaling cascade in mesangial cells but also demonstrate for the first time the modulatory effects of SMV on Ang II-induced signaling pathway at the cell cycle level. Simvastatin 171-174 angiotensinogen Rattus norvegicus 178-184 15187114-6 2004 Simvastatin prevents LPS-induced c-Fos expression, thereby relieving the inhibitory effect of c-Fos on the IL-12p40 promoter. Simvastatin 0-11 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 94-99 15187114-6 2004 Simvastatin prevents LPS-induced c-Fos expression, thereby relieving the inhibitory effect of c-Fos on the IL-12p40 promoter. Simvastatin 0-11 interleukin 12b Mus musculus 107-115 15187114-7 2004 Concomitantly, simvastatin induces the phosphorylation of c-Jun by the c-Jun N-terminal kinase, resulting in c-Jun-dependent activation of the IL-12p40 promoter. Simvastatin 15-26 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 58-63 15187114-7 2004 Concomitantly, simvastatin induces the phosphorylation of c-Jun by the c-Jun N-terminal kinase, resulting in c-Jun-dependent activation of the IL-12p40 promoter. Simvastatin 15-26 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 71-76 15187114-7 2004 Concomitantly, simvastatin induces the phosphorylation of c-Jun by the c-Jun N-terminal kinase, resulting in c-Jun-dependent activation of the IL-12p40 promoter. Simvastatin 15-26 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 71-76 15187114-7 2004 Concomitantly, simvastatin induces the phosphorylation of c-Jun by the c-Jun N-terminal kinase, resulting in c-Jun-dependent activation of the IL-12p40 promoter. Simvastatin 15-26 interleukin 12b Mus musculus 143-151 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 tumor necrosis factor Homo sapiens 105-114 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 tumor necrosis factor Homo sapiens 145-154 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 CCAAT enhancer binding protein alpha Homo sapiens 168-173 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 interleukin 12b Mus musculus 231-239 15187114-9 2004 The fact that simvastatin potently augments LPS-induced IL-12p40 and TNF-alpha production has implications for the treatment of bacterial infections in statin-treated patients. Simvastatin 14-25 interleukin 12b Mus musculus 56-64 15187114-9 2004 The fact that simvastatin potently augments LPS-induced IL-12p40 and TNF-alpha production has implications for the treatment of bacterial infections in statin-treated patients. Simvastatin 14-25 tumor necrosis factor Homo sapiens 69-78 15210533-9 2004 In contrast, simvastatin enhanced the proteolytic capacity of MMP-2 and MMP-9, with a statistically significant increase of MMP-2 activity when compared with findings in controls. Simvastatin 13-24 matrix metallopeptidase 2 Homo sapiens 62-67 15163549-5 2004 Simvastatin-induced DNA fragmentation and increased the number of cells stained with annexin V and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling, both of which were reversed by caspase inhibitors such as zDEVD-fmk, zLEHD-fmk and zIETD-fmk. Simvastatin 0-11 annexin A5 Homo sapiens 85-94 15163549-6 2004 Consistent with these data, the activities of caspase-3, caspase-9 and caspase-8 were elevated by simvastatin. Simvastatin 98-109 caspase 3 Homo sapiens 46-55 15163549-6 2004 Consistent with these data, the activities of caspase-3, caspase-9 and caspase-8 were elevated by simvastatin. Simvastatin 98-109 caspase 9 Homo sapiens 57-66 15163549-6 2004 Consistent with these data, the activities of caspase-3, caspase-9 and caspase-8 were elevated by simvastatin. Simvastatin 98-109 caspase 8 Homo sapiens 71-80 15163549-7 2004 Simvastatin reduced the protein content and mRNA expression for bcl-2 without affecting bax mRNA expression. Simvastatin 0-11 BCL2 apoptosis regulator Homo sapiens 64-69 14976045-5 2004 The effect of atorvastatin and simvastatin on huCRP expression was studied in nonatherosclerotic huCRP transgenic mice and compared with another class of hypolipidemic drugs, peroxisome proliferator-activated receptor-alpha (PPARalpha) activators, notably fenofibrate and Wy14643. Simvastatin 31-42 ISG15 ubiquitin like modifier Homo sapiens 46-51 15123521-0 2004 HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Simvastatin 28-39 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 0-17 15123521-1 2004 BACKGROUND: HMG-CoA reductase inhibitors, such as simvastatin, have been shown to exhibit pronounced immunomodulatory effects independent of lipid lowering but to date have not been used to treat severe inflammatory disease such as sepsis. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 12-29 15123521-3 2004 METHODS AND RESULTS: Mice treated with simvastatin and rendered septic by cecal ligation and perforation (CLP) show a mean survival time close to 4 times the value found in untreated mice. Simvastatin 39-50 hyaluronan and proteoglycan link protein 1 Mus musculus 106-109 15123521-7 2004 In addition, treatment with simvastatin reversed inflammatory alterations in CLP mice, namely, increased monocyte adhesion to endothelium. Simvastatin 28-39 hyaluronan and proteoglycan link protein 1 Mus musculus 77-80 15250255-1 2004 OBJECTIVE: To evaluate the effects of simvastatin combined with omega-3 fatty acids on high sensitive C-reactive protein (HsCRP), lipidemia, and fibrinolysis in coronary heart disease (CHD) and CHD risk equivalent patients with mixed dyslipidemia. Simvastatin 38-49 C-reactive protein Homo sapiens 102-120 15136060-0 2004 Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Simvastatin 0-11 prostaglandin-endoperoxide synthase 2 Homo sapiens 79-84 15136060-0 2004 Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 103-107 15149889-0 2004 Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Simvastatin 0-11 interleukin 1 beta Homo sapiens 20-37 15149889-3 2004 We studied whether individuals with essential hypertension have increased interleukin-1beta (IL-1beta) secretion in peripheral blood mononuclear cells (PBMCs) and whether treatment with simvastatin lowered IL-1beta secretion by PBMCs. Simvastatin 186-197 interleukin 1 beta Homo sapiens 206-214 15149889-9 2004 Simvastatin treatment had a significant effect of decreasing IL-1beta [668+/-98 vs. 923+/-67 pg/ml; P<0.05] secretion in PBMCs. Simvastatin 0-11 interleukin 1 beta Homo sapiens 61-69 15210533-9 2004 In contrast, simvastatin enhanced the proteolytic capacity of MMP-2 and MMP-9, with a statistically significant increase of MMP-2 activity when compared with findings in controls. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 72-77 15210533-9 2004 In contrast, simvastatin enhanced the proteolytic capacity of MMP-2 and MMP-9, with a statistically significant increase of MMP-2 activity when compared with findings in controls. Simvastatin 13-24 matrix metallopeptidase 2 Homo sapiens 124-129 15210533-11 2004 CONCLUSIONS: Interferon beta exhibits inhibitory effects at the posttranslational level of MMP activity, whereas simvastatin augments the proteolytic activity of MMP-2 and MMP-9, suggesting that statins exert anti-inflammatory and proinflammatory effects. Simvastatin 113-124 matrix metallopeptidase 2 Homo sapiens 162-167 15210533-11 2004 CONCLUSIONS: Interferon beta exhibits inhibitory effects at the posttranslational level of MMP activity, whereas simvastatin augments the proteolytic activity of MMP-2 and MMP-9, suggesting that statins exert anti-inflammatory and proinflammatory effects. Simvastatin 113-124 matrix metallopeptidase 9 Homo sapiens 172-177 15156558-4 2004 Extracellular accumulation of proteins such as VEGF, OCN, collagenase-digestive proteins, and noncollagenous proteins was increased in the cells treated with 10(-7) M simvastatin, or 10(-8) M cerivastatin. Simvastatin 167-178 vascular endothelial growth factor A Mus musculus 47-51 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 tumor necrosis factor Homo sapiens 155-188 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 intercellular adhesion molecule 1 Homo sapiens 190-228 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 intercellular adhesion molecule 1 Homo sapiens 230-236 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 tumor necrosis factor Homo sapiens 65-74 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 intercellular adhesion molecule 1 Homo sapiens 76-82 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 C-reactive protein Homo sapiens 88-91 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 bone morphogenetic protein 2 Mus musculus 63-91 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 bone morphogenetic protein 2 Mus musculus 93-98 15156558-4 2004 Extracellular accumulation of proteins such as VEGF, OCN, collagenase-digestive proteins, and noncollagenous proteins was increased in the cells treated with 10(-7) M simvastatin, or 10(-8) M cerivastatin. Simvastatin 167-178 bone gamma-carboxyglutamate protein 2 Mus musculus 53-56 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 101-135 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 137-141 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 bone gamma-carboxyglutamate protein 2 Mus musculus 206-217 15334157-11 2004 The addition of simvastatin to fenofibrate decreased TC, LDL-C and TG levels by 35.5%, 42.1% and 59.6%, respectively in comparison to before treatment volumes. Simvastatin 16-27 component of oligomeric golgi complex 2 Homo sapiens 57-62 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 bone gamma-carboxyglutamate protein 2 Mus musculus 219-222 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 matrix metallopeptidase 13 Mus musculus 311-324 15156558-3 2004 Simvastatin at 10(-7) M markedly increased mRNA expression for bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), alkaline phosphatase, type I collagen, bone sialoprotein, and osteocalcin (OCN) in nontransformed osteoblastic cells (MC3T3-E1), while suppressing gene expression for collagenase-1, and collagenase-3. Simvastatin 0-11 matrix metallopeptidase 13 Mus musculus 330-343 15334157-13 2004 The addition of fenofibrate to simvastatin decreased TC, LDL-C and TG levels by 39.3%, 48.9% and 51,6%, respectively. Simvastatin 31-42 component of oligomeric golgi complex 2 Homo sapiens 57-62 14973129-0 2004 Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone. Simvastatin 78-89 S100 calcium binding protein A6 (calcyclin) Mus musculus 0-9 15508788-3 2004 In presented work the influence of acetylsalicylic acid, metoprolol, simvastatin, isosorbide mononitrate and molsidomine on total activity of adenosine deaminase and its isoenzymes--ADA1 and ADA2 in vivo was studied. Simvastatin 69-80 adenosine deaminase Homo sapiens 142-161 14973129-1 2004 In vitro treatment with a pharmacological dose of simvastatin, a potent pro-drug of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, stimulates bone formation. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 86-133 14973129-4 2004 Calcyclin was significantly up-regulated by more than 10 times, and annexin I was also up-regulated by simvastatin. Simvastatin 103-114 annexin A1 Mus musculus 68-77 14973129-6 2004 Up-regulated calcyclin mRNA by simvastatin was validated by reverse transcription in mouse calvarial cells. Simvastatin 31-42 S100 calcium binding protein A6 (calcyclin) Mus musculus 13-22 14973129-7 2004 In confocal microscope analysis, green fluorescence protein-calcyclin fusion protein was ubiquitously observed in the of MC3T3-E1 cells transfected with green fluorescence protein-calcyclin cDNA containing plasmid and was quickly concentrated in the nucleus 20 min after simvastatin treatment. Simvastatin 271-282 S100 calcium binding protein A6 (calcyclin) Mus musculus 60-69 14973129-7 2004 In confocal microscope analysis, green fluorescence protein-calcyclin fusion protein was ubiquitously observed in the of MC3T3-E1 cells transfected with green fluorescence protein-calcyclin cDNA containing plasmid and was quickly concentrated in the nucleus 20 min after simvastatin treatment. Simvastatin 271-282 S100 calcium binding protein A6 (calcyclin) Mus musculus 180-189 14973129-10 2004 In conclusion, calcyclin is one of the candidate proteins that plays a role in osteoblastogenesis in response to simvastatin, although the precise functions of calcyclin in osteoblast remain to be verified. Simvastatin 113-124 S100 calcium binding protein A6 (calcyclin) Mus musculus 15-24 14630613-3 2004 Human pulmonary artery endothelial cells exposed to prolonged simvastatin treatment (5 microM, 16 h) demonstrated significant reductions in thrombin-induced (1 U/ml) barrier dysfunction ( approximately 70% inhibition) with accelerated barrier recovery, as measured by transendothelial resistance. Simvastatin 62-73 coagulation factor II, thrombin Homo sapiens 140-148 14630613-4 2004 Furthermore, simvastatin attenuated basal and thrombin-stimulated (1 U/ml, 5 min) myosin light chain diphosphorylation and stress fiber formation while dramatically increasing peripheral immunostaining of actin and cortactin, an actin-binding protein, in conjunction with increased Rac GTPase activity. Simvastatin 13-24 coagulation factor II, thrombin Homo sapiens 46-54 14630613-4 2004 Furthermore, simvastatin attenuated basal and thrombin-stimulated (1 U/ml, 5 min) myosin light chain diphosphorylation and stress fiber formation while dramatically increasing peripheral immunostaining of actin and cortactin, an actin-binding protein, in conjunction with increased Rac GTPase activity. Simvastatin 13-24 cortactin Homo sapiens 215-224 15023931-11 2004 Simvastatin treatment inhibited the increases in myocardial nitrotyrosine content and in p67-phox and p22-phox expression, and significantly reduced LVH. Simvastatin 0-11 methionyl aminopeptidase 2 Rattus norvegicus 89-92 15111316-10 2004 This suggests that simvastatin attenuates leukocyte-endothelial cell interactions and subsequent blood-retinal barrier breakdown via suppression of vascular endothelial growth factor-induced ICAM-1 expression in the diabetic retina. Simvastatin 19-30 intercellular adhesion molecule 1 Rattus norvegicus 191-197 24672080-3 2004 OBJECTIVE: The aim of this study was to determine whether simvastatin 20 and 40 mg/d have an effect on systolic and diastolic blood pressure (SBP and DBP, respectively) in patients with hypercholesterolemia, and, if so, whether the effect is dose dependent and/or is related to the changes in the serum lipid profile. Simvastatin 58-69 selenium binding protein 1 Homo sapiens 142-145 24672080-3 2004 OBJECTIVE: The aim of this study was to determine whether simvastatin 20 and 40 mg/d have an effect on systolic and diastolic blood pressure (SBP and DBP, respectively) in patients with hypercholesterolemia, and, if so, whether the effect is dose dependent and/or is related to the changes in the serum lipid profile. Simvastatin 58-69 D-box binding PAR bZIP transcription factor Homo sapiens 150-153 15111316-6 2004 The expression of intercellular adhesion molecule-1 (ICAM-1) and the CD18 (the common beta-chain of ICAM-1 ligands) were both suppressed with simvastatin. Simvastatin 142-153 intercellular adhesion molecule 1 Rattus norvegicus 18-51 15111316-6 2004 The expression of intercellular adhesion molecule-1 (ICAM-1) and the CD18 (the common beta-chain of ICAM-1 ligands) were both suppressed with simvastatin. Simvastatin 142-153 intercellular adhesion molecule 1 Rattus norvegicus 53-59 15111316-6 2004 The expression of intercellular adhesion molecule-1 (ICAM-1) and the CD18 (the common beta-chain of ICAM-1 ligands) were both suppressed with simvastatin. Simvastatin 142-153 integrin subunit beta 2 Rattus norvegicus 69-73 15111316-6 2004 The expression of intercellular adhesion molecule-1 (ICAM-1) and the CD18 (the common beta-chain of ICAM-1 ligands) were both suppressed with simvastatin. Simvastatin 142-153 intercellular adhesion molecule 1 Rattus norvegicus 100-106 24672080-19 2004 Also in the simvastatin group, 26 patients (22.6%) achieved their target SBP/DBP. Simvastatin 12-23 selenium binding protein 1 Homo sapiens 73-76 24672080-19 2004 Also in the simvastatin group, 26 patients (22.6%) achieved their target SBP/DBP. Simvastatin 12-23 D-box binding PAR bZIP transcription factor Homo sapiens 77-80 24672080-28 2004 CONCLUSIONS: In this group of patients with hypercholesterolemia, the starting dosage of simvastatin (20 mg/d) was associated with reductions in SBP and DBP within 3 months of treatment in patients with hypertension, and this effect was independent of the lipid-lowering properties of the drug. Simvastatin 89-100 selenium binding protein 1 Homo sapiens 145-148 24672080-28 2004 CONCLUSIONS: In this group of patients with hypercholesterolemia, the starting dosage of simvastatin (20 mg/d) was associated with reductions in SBP and DBP within 3 months of treatment in patients with hypertension, and this effect was independent of the lipid-lowering properties of the drug. Simvastatin 89-100 D-box binding PAR bZIP transcription factor Homo sapiens 153-156 15023931-11 2004 Simvastatin treatment inhibited the increases in myocardial nitrotyrosine content and in p67-phox and p22-phox expression, and significantly reduced LVH. Simvastatin 0-11 cytochrome b-245 alpha chain Rattus norvegicus 102-110 15051633-7 2004 (1) Although mRNA levels of IL-1alpha and IL-1beta were markedly reduced in PBMCs from CAD patients after 6 months of simvastatin (20 mg/d, n=15) and atorvastatin (80 mg/d, n=15) therapy, the reduction in IL-1 receptor antagonist (IL-1Ra) was more modest. Simvastatin 118-129 interleukin 1 alpha Homo sapiens 28-37 15132403-6 2004 RESULTS: Coadministration of ezetimibe/simvastatin was significantly (P<.001) more effective than simvastatin alone in reducing LDL-C levels for the pooled ezetimibe/simvastatin vs pooled simvastatin analysis and at each specific dose comparison. Simvastatin 39-50 component of oligomeric golgi complex 2 Homo sapiens 131-136 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Simvastatin 87-98 component of oligomeric golgi complex 2 Homo sapiens 16-21 15132403-7 2004 The decrease in LDL-C levels with coadministration of ezetimibe and the lowest dose of simvastatin, 10 mg, was similar to the decrease with the maximum dose of simvastatin, 80 mg. A significantly (P<.001) greater proportion of patients in the ezetimibe/simvastatin group achieved target LDL-C levels compared with those in the monotherapy group. Simvastatin 87-98 component of oligomeric golgi complex 2 Homo sapiens 290-295 15132403-8 2004 Treatment with ezetimibe/simvastatin also led to greater reductions in total cholesterol, triglyceride, non-high-density lipoprotein cholesterol, and apolipoprotein B levels compared with simvastatin alone; both treatments increased high-density lipoprotein cholesterol levels similarly. Simvastatin 25-36 apolipoprotein B Homo sapiens 150-166 15069546-1 2004 To look for new candidates for agents to use in maintenance therapy for myeloma patients, the growth inhibitory effects of a 3-hydroxy-3-mehtylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), simvastatin, was analyzed using human myeloma cell lines. Simvastatin 203-214 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 125-182 15069546-6 2004 Furthermore, myeloma cells treated with simvastatin clearly showed inactivation of various MAP-kinase pathways such as ERK1/2, MEK1/2, JNK, and p38. Simvastatin 40-51 mitogen-activated protein kinase 3 Homo sapiens 119-125 15069546-6 2004 Furthermore, myeloma cells treated with simvastatin clearly showed inactivation of various MAP-kinase pathways such as ERK1/2, MEK1/2, JNK, and p38. Simvastatin 40-51 mitogen-activated protein kinase kinase 1 Homo sapiens 127-133 15069546-6 2004 Furthermore, myeloma cells treated with simvastatin clearly showed inactivation of various MAP-kinase pathways such as ERK1/2, MEK1/2, JNK, and p38. Simvastatin 40-51 mitogen-activated protein kinase 8 Homo sapiens 135-138 15069546-6 2004 Furthermore, myeloma cells treated with simvastatin clearly showed inactivation of various MAP-kinase pathways such as ERK1/2, MEK1/2, JNK, and p38. Simvastatin 40-51 mitogen-activated protein kinase 1 Homo sapiens 144-147 15051633-7 2004 (1) Although mRNA levels of IL-1alpha and IL-1beta were markedly reduced in PBMCs from CAD patients after 6 months of simvastatin (20 mg/d, n=15) and atorvastatin (80 mg/d, n=15) therapy, the reduction in IL-1 receptor antagonist (IL-1Ra) was more modest. Simvastatin 118-129 interleukin 1 beta Homo sapiens 42-50 14985071-0 2004 Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Simvastatin 0-11 ras homolog family member A Homo sapiens 117-121 15033469-3 2004 We tested the effects of four different statins (fluvastatin, atorvastatin, simvastatin, and lovastatin) on ABCA1 expression in macrophages in vitro. Simvastatin 76-87 ATP binding cassette subfamily A member 1 Homo sapiens 108-113 15107580-0 2004 Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 71-97 15107580-3 2004 In this study, we proposed that simvastatin reduces MMP-9 expression in osteoblasts and HT1080 fibrosarcoma cell line. Simvastatin 32-43 matrix metallopeptidase 9 Homo sapiens 52-57 15107580-5 2004 The results from gelatin zymography and Western blot analysis revealed that simvastatin suppressed MMP-9 activity in these cells in concentration- and time-dependent manners. Simvastatin 76-87 matrix metallopeptidase 9 Homo sapiens 99-104 15107580-7 2004 Collectively, these results suggest that simvastatin is a potent drug for inhibition of MMP-9 expression in osteoblastic cells and HT1080 fibrosarcoma cells. Simvastatin 41-52 matrix metallopeptidase 9 Homo sapiens 88-93 15041742-2 2004 Simvastatin, but not pravastatin, binds to the inserted domain of leukocyte function antigen (LFA)-1 and inhibits the function of LFA-1, including adhesion and costimulation of lymphocytes. Simvastatin 0-11 integrin subunit alpha L Homo sapiens 66-100 15041742-2 2004 Simvastatin, but not pravastatin, binds to the inserted domain of leukocyte function antigen (LFA)-1 and inhibits the function of LFA-1, including adhesion and costimulation of lymphocytes. Simvastatin 0-11 integrin subunit alpha L Homo sapiens 130-135 15041742-5 2004 The apoptosis-inducing effect of simvastatin depends on binding to the inserted domain of LFA-1. Simvastatin 33-44 integrin subunit alpha L Homo sapiens 90-95 15041742-7 2004 Analysis of multiple EBV-positive and -negative cell lines indicated that both LFA-1 and EBV latent membrane protein 1 expression were required for simvastatin"s effects. Simvastatin 148-159 integrin subunit alpha L Homo sapiens 79-84 15050891-7 2004 Concerning cortical bone, the tibial diaphysis bending strength was increased by 8% and the periosteal bone formation rate (BFR) at the mid-diaphysis increased by twofold in the OVX + simvastatin group compared with the OVX + placebo group, in harmony with increased serum osteocalcin concentrations. Simvastatin 184-195 bone gamma-carboxyglutamate protein Rattus norvegicus 273-284 14985071-8 2004 RESULTS: Simvastatin (0.1-1.0 micromol/l) inhibited serum-induced myofibroblast proliferation in a concentration-dependent manner at a point upstream of Cyclin A expression. Simvastatin 9-20 cyclin A2 Homo sapiens 153-161 14985071-11 2004 Furthermore, we demonstrated that simvastatin inhibited RhoA function by preventing its association with the plasma membrane and hence, its interaction with downstream effectors required for cell proliferation. Simvastatin 34-45 ras homolog family member A Homo sapiens 56-60 14985071-12 2004 CONCLUSIONS: Simvastatin reduced proliferation of cultured human atrial myofibroblasts independently of cholesterol synthesis via a mechanism involving inhibition of RhoA geranylgeranylation. Simvastatin 13-24 ras homolog family member A Homo sapiens 166-170 14988255-12 2004 Long-term simvastatin treatment was accompanied by a lower increase in postprandial triglycerides, which was followed by smaller variations in ICAM-1, VCAM-1, E-selectin, and nitrotyrosine during the tests. Simvastatin 10-21 intercellular adhesion molecule 1 Homo sapiens 143-149 14988255-12 2004 Long-term simvastatin treatment was accompanied by a lower increase in postprandial triglycerides, which was followed by smaller variations in ICAM-1, VCAM-1, E-selectin, and nitrotyrosine during the tests. Simvastatin 10-21 vascular cell adhesion molecule 1 Homo sapiens 151-157 14988255-12 2004 Long-term simvastatin treatment was accompanied by a lower increase in postprandial triglycerides, which was followed by smaller variations in ICAM-1, VCAM-1, E-selectin, and nitrotyrosine during the tests. Simvastatin 10-21 selectin E Homo sapiens 159-169 14969613-0 2004 Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 25-54 14988829-2 2004 We hypothesized that simvastatin, which enhances Akt-dependent endothelial nitric oxide synthase phosphorylation, may increase hepatic nitric oxide release and decrease hepatic resistance in patients with cirrhosis and portal hypertension. Simvastatin 21-32 AKT serine/threonine kinase 1 Homo sapiens 49-52 14988829-2 2004 We hypothesized that simvastatin, which enhances Akt-dependent endothelial nitric oxide synthase phosphorylation, may increase hepatic nitric oxide release and decrease hepatic resistance in patients with cirrhosis and portal hypertension. Simvastatin 21-32 nitric oxide synthase 3 Homo sapiens 63-96 14978092-7 2004 OVA-induced IL-4, IL-5, IL-6, and IFN-gamma secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice. Simvastatin 103-114 interleukin 4 Mus musculus 12-16 14978092-7 2004 OVA-induced IL-4, IL-5, IL-6, and IFN-gamma secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice. Simvastatin 103-114 interleukin 5 Mus musculus 18-22 14978092-7 2004 OVA-induced IL-4, IL-5, IL-6, and IFN-gamma secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice. Simvastatin 103-114 interleukin 6 Mus musculus 24-28 14978092-7 2004 OVA-induced IL-4, IL-5, IL-6, and IFN-gamma secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice. Simvastatin 103-114 interferon gamma Mus musculus 34-43 15706857-5 2004 Like Simvastatin AS and PNS had the function of reducing MMP-9 and accommodating lipid metabolism. Simvastatin 5-16 matrix metallopeptidase 9 Homo sapiens 57-62 15110130-12 2004 Simvastatin produced significant reductions in concentrations of total cholesterol, triglycerides (TG), non-high-density lipoprotein cholesterol, and apolipoprotein (apo) B compared with placebo (all, P<0.001 ) and significant increases in concentrations of high-density lipoprotein cholesterol (HDL-C) ( P=0.002 ) and apo A-I ( P=0.006 ). Simvastatin 0-11 apolipoprotein B Homo sapiens 150-172 15076215-0 2004 Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 63-67 15076215-5 2004 The amount of secreted vascular endothelial cell growth factor (VEGF) by cultured vascular smooth muscle cells from hamsters treated with simvastatin was significantly increased. Simvastatin 138-149 vascular endothelial growth factor A Homo sapiens 23-62 15076215-5 2004 The amount of secreted vascular endothelial cell growth factor (VEGF) by cultured vascular smooth muscle cells from hamsters treated with simvastatin was significantly increased. Simvastatin 138-149 vascular endothelial growth factor A Homo sapiens 64-68 15076215-6 2004 Mevalonate reduced the amount of VEGF secretion by simvastatin in vitro. Simvastatin 51-62 vascular endothelial growth factor A Homo sapiens 33-37 15076215-8 2004 Simvastatin regulates endothelial regenerating by an over-release of VEGF and by this may result in prompt endothelial healing after vascular injury. Simvastatin 0-11 vascular endothelial growth factor A Homo sapiens 69-73 14969613-0 2004 Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 134-166 14969613-1 2004 The effect of simvastatin therapy on the biologic characteristics of the electronegative low-density lipoprotein (LDL) subfraction of patients with familial hypercholesterolemia (FH) was studied. Simvastatin 14-25 low density lipoprotein receptor Homo sapiens 148-177 14969613-1 2004 The effect of simvastatin therapy on the biologic characteristics of the electronegative low-density lipoprotein (LDL) subfraction of patients with familial hypercholesterolemia (FH) was studied. Simvastatin 14-25 low density lipoprotein receptor Homo sapiens 179-181 14969613-4 2004 The LDL(-) proportion was twofold higher in patients with FH than in NL subjects (17.6 +/- 1.6% vs 7.8 +/- 1.5%, respectively; p <0.05) and was progressively reduced by simvastatin therapy (15.7 +/- 1.6% at 3 months; 13.8 +/- 2.5% at 6 months; p <0.05). Simvastatin 172-183 low density lipoprotein receptor Homo sapiens 58-60 14969613-6 2004 Simvastatin progressively induced changes in lipid content of both LDL subfractions in patients with FH, and lipid composition was closer to these subfractions in NL subjects after 6 months of therapy. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 101-103 14969613-9 2004 Simvastatin-induced changes in LDL composition were accompanied by a progressive increase in affinity of LDL(+) and LDL(-) in patients with FH. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 140-142 14969613-13 2004 We conclude that simvastatin therapy was able to modify LDL subfraction composition in subjects with FH and increase their affinity to the LDL receptor. Simvastatin 17-28 low density lipoprotein receptor Homo sapiens 101-103 14969613-13 2004 We conclude that simvastatin therapy was able to modify LDL subfraction composition in subjects with FH and increase their affinity to the LDL receptor. Simvastatin 17-28 low density lipoprotein receptor Homo sapiens 139-151 15221496-8 2004 In the analysis of cytokines, while no significant change was observed in IL-6 levels, the TNF-alpha level was found to be significantly decreased after simvastatin treatment (from 77.9 +/- 31.6 pg/ml to 23.5 +/- 12.6 pg/ml [P = 0.021]). Simvastatin 153-164 tumor necrosis factor Homo sapiens 91-100 14715352-0 2004 Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. Simvastatin 10-21 C-reactive protein Homo sapiens 31-49 14729100-6 2004 Fluvastatin inhibited organic anion uptake mediated by human OAT1 in a mixture of competitive and noncompetitive manner, whereas simvastatin and fluvastatin noncompetitively inhibited the organic anion uptake mediated by human OAT3. Simvastatin 129-140 solute carrier family 22 member 8 Homo sapiens 227-231 15013132-0 2004 The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. Simvastatin 136-147 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 14-63 14603525-7 2004 This enhancement was associated to an increase of c-fos transcriptional activity, which was reversible by pretreatment with simvastatin. Simvastatin 124-135 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 50-55 15285699-8 2004 One of these enzymes, CYP2D6, plays an important role in the metabolism of simvastatin. Simvastatin 75-86 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 22-28 15285699-9 2004 It has been shown that the cholesterol-lowering effect as well as the efficacy and tolerability of simvastatin is influenced by CYP2D6 genetic polymorphism. Simvastatin 99-110 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 128-134 14675561-9 2004 Lovastatin and simvastatin significantly inhibited butyrylcholinesterase, while mevastatin, pravastatin and the "non-statins" did not. Simvastatin 15-26 butyrylcholinesterase Homo sapiens 51-72 15221496-10 2004 In conclusion; 20-mg daily simvastatin treatment for 3 months significantly increased BAP and OCL levels (markers of bone formation) in hypercholesterolemic postmenopausal subjects, without affecting bone resorption. Simvastatin 27-38 bone gamma-carboxyglutamate protein Homo sapiens 94-97 15221496-12 2004 Additionally, the presence of a negative correlation between TNF-alpha levels and the anabolic bone parameters suggests that a cytokine-lowering effect of simvastatin may also be involved in the remodeling process and could exert some additive beneficial effect on bone metabolism. Simvastatin 155-166 tumor necrosis factor Homo sapiens 61-70 14732356-0 2004 Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 35-38 14732356-0 2004 Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. Simvastatin 0-11 GLI family zinc finger 2 Homo sapiens 87-92 14732356-12 2004 Akt phosphorylation peaked after 15 min of LPS stimulation and was suppressed by pretreatment with simvastatin. Simvastatin 99-110 AKT serine/threonine kinase 1 Homo sapiens 0-3 14752252-7 2004 In apoE(-/- )mice, simvastatin caused a paradoxical increase in plasma cholesterol (1094 +/- 60.3 vs. 658 +/- 66.8 mg/dl; p < 0.001), confirmed by FPLC. Simvastatin 19-30 apolipoprotein E Mus musculus 3-7 14752252-12 2004 simvastatin treatment of apoE(-/-) mice caused paradoxical hyperlipidemia and increased intimal hyperplasia. Simvastatin 0-11 apolipoprotein E Mus musculus 25-29 14732356-13 2004 CONCLUSIONS: These data demonstrate that LPS stimulation leads to increased Akt phosphorylation, which can be suppressed with simvastatin pretreatment. Simvastatin 126-137 AKT serine/threonine kinase 1 Homo sapiens 76-79 14612892-0 2003 Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Simvastatin 73-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-107 14625131-0 2003 Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Simvastatin 116-127 leptin Homo sapiens 0-6 14527821-0 2003 Apoptosis induced by simvastatin in rat vascular smooth muscle cell through Ca2+-calpain and caspase-3 dependent pathway. Simvastatin 21-32 caspase 3 Rattus norvegicus 93-102 14527821-6 2003 Caspase-3 was also activated by simvastatin after 12 h. Verapamil and PD150606, a cell-permeable selective calpain inhibitor, significantly inhibited simvastatin-induced augmentation of calpain activity and blocked caspase-3 activation, respectively. Simvastatin 32-43 caspase 3 Rattus norvegicus 0-9 14527821-6 2003 Caspase-3 was also activated by simvastatin after 12 h. Verapamil and PD150606, a cell-permeable selective calpain inhibitor, significantly inhibited simvastatin-induced augmentation of calpain activity and blocked caspase-3 activation, respectively. Simvastatin 150-161 caspase 3 Rattus norvegicus 0-9 14527821-6 2003 Caspase-3 was also activated by simvastatin after 12 h. Verapamil and PD150606, a cell-permeable selective calpain inhibitor, significantly inhibited simvastatin-induced augmentation of calpain activity and blocked caspase-3 activation, respectively. Simvastatin 150-161 caspase 3 Rattus norvegicus 215-224 14527821-8 2003 In conclusion, we indicated that simvastatin increases cytosolic free calcium concentration mainly through calcium influx from extracellular solution and then induces apoptosis by activating caspase-3 via calcium-dependent protease calpain. Simvastatin 33-44 caspase 3 Rattus norvegicus 191-200 15050096-6 2004 In our recent study, the results demonstrate that monocytes exhibit an enhanced production of interleukin-6 (IL-6) in response to CRP, and this response is significantly inhibited by simvastatin in a dose-dependent manner. Simvastatin 183-194 interleukin 6 Homo sapiens 94-107 15050096-6 2004 In our recent study, the results demonstrate that monocytes exhibit an enhanced production of interleukin-6 (IL-6) in response to CRP, and this response is significantly inhibited by simvastatin in a dose-dependent manner. Simvastatin 183-194 interleukin 6 Homo sapiens 109-113 15050096-6 2004 In our recent study, the results demonstrate that monocytes exhibit an enhanced production of interleukin-6 (IL-6) in response to CRP, and this response is significantly inhibited by simvastatin in a dose-dependent manner. Simvastatin 183-194 C-reactive protein Homo sapiens 130-133 15050096-10 2004 Our clinical investigation suggested that treatment with a single high-dose or a short-term common dose of simvastatin could rapidly reduce CRP level. Simvastatin 107-118 C-reactive protein Homo sapiens 140-143 14616433-0 2003 Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II. Simvastatin 21-32 angiotensinogen Homo sapiens 75-89 14724693-4 2003 AIM: To examine the effects of simvastatin on IL-2 and TNFalpha levels in patients with hypercholesterolemia. Simvastatin 31-42 interleukin 2 Homo sapiens 46-50 14724693-4 2003 AIM: To examine the effects of simvastatin on IL-2 and TNFalpha levels in patients with hypercholesterolemia. Simvastatin 31-42 tumor necrosis factor Homo sapiens 55-63 14724693-9 2003 Moreover, simvastatin significantly reduced the IL-2 plasma concentration (p=0.0003). Simvastatin 10-21 interleukin 2 Homo sapiens 48-52 14724693-12 2003 Subsequent simvastatin therapy caused further decrease in the TNFalpha serum concentration but this difference did not achieve statistical significance. Simvastatin 11-22 tumor necrosis factor Homo sapiens 62-70 14724693-14 2003 The subsequent simvastatin therapy significantly reduces IL-2 but not TNFalpha when compared with the post-diet values. Simvastatin 15-26 interleukin 2 Homo sapiens 57-61 14612892-2 2003 The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a probe CYP3A4 substrate. Simvastatin 121-132 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 142-148 14500290-0 2003 Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Simvastatin 0-11 paraoxonase 1 Homo sapiens 40-44 12951326-6 2003 Interference with RhoA signaling by simvastatin, toxinB, C3 toxin, and Y27632 prevented up-regulation of CTGF. Simvastatin 36-47 ras homolog family member A Homo sapiens 18-22 12951326-6 2003 Interference with RhoA signaling by simvastatin, toxinB, C3 toxin, and Y27632 prevented up-regulation of CTGF. Simvastatin 36-47 cellular communication network factor 2 Homo sapiens 105-109 14597936-8 2003 Consecutive elevations >3x the upper limit of normal in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 [2.8%]), with most elevations observed in women taking atorvastatin (11/209 [5.3%] vs 1/199 [0.5%] for simvastatin). Simvastatin 184-195 glutamic--pyruvic transaminase Homo sapiens 59-83 14597936-8 2003 Consecutive elevations >3x the upper limit of normal in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 [2.8%]), with most elevations observed in women taking atorvastatin (11/209 [5.3%] vs 1/199 [0.5%] for simvastatin). Simvastatin 184-195 solute carrier family 17 member 5 Homo sapiens 97-123 14597936-8 2003 Consecutive elevations >3x the upper limit of normal in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 [2.8%]), with most elevations observed in women taking atorvastatin (11/209 [5.3%] vs 1/199 [0.5%] for simvastatin). Simvastatin 184-195 solute carrier family 17 member 5 Homo sapiens 125-128 14597936-8 2003 Consecutive elevations >3x the upper limit of normal in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 [2.8%]), with most elevations observed in women taking atorvastatin (11/209 [5.3%] vs 1/199 [0.5%] for simvastatin). Simvastatin 346-357 solute carrier family 17 member 5 Homo sapiens 125-128 14597936-11 2003 Significantly fewer consecutive elevations >3x the upper limit of normal in ALT and/or AST occurred in patients receiving simvastatin. Simvastatin 125-136 solute carrier family 17 member 5 Homo sapiens 90-93 14563711-3 2003 Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells. Simvastatin 64-75 heart and neural crest derivatives expressed 2 Mus musculus 116-119 14563711-3 2003 Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells. Simvastatin 64-75 negative elongation factor complex member C/D, Th1l Mus musculus 160-163 14563711-3 2003 Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells. Simvastatin 64-75 heart and neural crest derivatives expressed 2 Mus musculus 196-199 14500290-0 2003 Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Simvastatin 0-11 sterol regulatory element binding transcription factor 2 Homo sapiens 94-137 14500290-6 2003 Simvastatin increased nuclear factors, notably sterol regulatory element-binding protein-2, capable of binding to the paraoxonase promoter; this was also blocked by mevalonate. Simvastatin 0-11 sterol regulatory element binding transcription factor 2 Homo sapiens 47-90 14640465-3 2003 The results of three clinical studies are analyzed, comparing the effects of simvastatin and atorvastatin on HDL-C and apolipoprotein A-I (apo A-I) in the total cohort and in several subgroups of hypercholesterolemic patients. Simvastatin 77-88 apolipoprotein A1 Homo sapiens 119-137 14640465-3 2003 The results of three clinical studies are analyzed, comparing the effects of simvastatin and atorvastatin on HDL-C and apolipoprotein A-I (apo A-I) in the total cohort and in several subgroups of hypercholesterolemic patients. Simvastatin 77-88 apolipoprotein A1 Homo sapiens 139-146 14640465-11 2003 CONCLUSION: The data presented show that, across different hypercholesterolemic patient subgroups, simvastatin increases HDL-C and apo A-I more than atorvastatin at higher doses, with evidence of a negative dose response effect on HDL-C and apo A-I with atorvastatin, but not simvastatin. Simvastatin 99-110 apolipoprotein A1 Homo sapiens 131-138 14640465-11 2003 CONCLUSION: The data presented show that, across different hypercholesterolemic patient subgroups, simvastatin increases HDL-C and apo A-I more than atorvastatin at higher doses, with evidence of a negative dose response effect on HDL-C and apo A-I with atorvastatin, but not simvastatin. Simvastatin 99-110 apolipoprotein A1 Homo sapiens 241-248 14629460-7 2003 RESULTS: Pretreatment with simvastatin, fluvastatin or pravastatin potentiated the TNF-alpha and LPS-induced expression of E-selectin and VCAM-1, and mevalonate reversed the potentiating effect of these statins. Simvastatin 27-38 tumor necrosis factor Homo sapiens 83-92 14629460-9 2003 Furthermore, GGTI-286, but not FTI-277, mimicked the effect of simvastatin by increasing the TNF-alpha-mediated overexpression of E-selectin. Simvastatin 63-74 protein geranylgeranyltransferase type I subunit beta Homo sapiens 13-17 14602771-5 2003 Simvastatin but not bezafibrate simultaneously reduced soluble adhesin and total 8-iso-PGF(2 alpha) concentrations also. Simvastatin 0-11 placental growth factor Homo sapiens 87-90 14602771-7 2003 Changes in circulating soluble adhesion molecule levels were directly correlated with changes in total 8-iso-PGF(2 alpha) concentrations in simvastatin-treated patients also receiving vitamin E supplementation. Simvastatin 140-151 placental growth factor Homo sapiens 109-112 14629460-7 2003 RESULTS: Pretreatment with simvastatin, fluvastatin or pravastatin potentiated the TNF-alpha and LPS-induced expression of E-selectin and VCAM-1, and mevalonate reversed the potentiating effect of these statins. Simvastatin 27-38 selectin E Homo sapiens 123-133 14629460-9 2003 Furthermore, GGTI-286, but not FTI-277, mimicked the effect of simvastatin by increasing the TNF-alpha-mediated overexpression of E-selectin. Simvastatin 63-74 tumor necrosis factor Homo sapiens 93-102 14629460-7 2003 RESULTS: Pretreatment with simvastatin, fluvastatin or pravastatin potentiated the TNF-alpha and LPS-induced expression of E-selectin and VCAM-1, and mevalonate reversed the potentiating effect of these statins. Simvastatin 27-38 vascular cell adhesion molecule 1 Homo sapiens 138-144 14629460-9 2003 Furthermore, GGTI-286, but not FTI-277, mimicked the effect of simvastatin by increasing the TNF-alpha-mediated overexpression of E-selectin. Simvastatin 63-74 selectin E Homo sapiens 130-140 14504184-7 2003 Simvastatin, but not aspirin treatment, significantly lowered CRP levels (P<0.05). Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 14504184-8 2003 The change in IL-1beta levels correlated with the change in sP-selectin in patients randomized to either simvastatin (Rho, 0.42; P<0.05) or aspirin (Rho, 0.42; P<0.05). Simvastatin 105-116 interleukin 1 beta Homo sapiens 14-22 14504184-9 2003 In contrast, the simvastatin-induced change in IL-1beta did not correlate with the change in CRP levels. Simvastatin 17-28 interleukin 1 beta Homo sapiens 47-55 14612202-5 2003 Different statins (atorvastatin, simvastatin and lovastatin, 1-10 micromol/l) significantly reduced basal and cytokine-, nitric oxide- or lysophosphatidylcholine (LPC)-induced VEGF synthesis in HMEC-1 and HVSMC. Simvastatin 33-44 vascular endothelial growth factor A Homo sapiens 176-180 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Simvastatin 21-32 C-reactive protein Homo sapiens 84-87 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Simvastatin 21-32 interleukin 1 beta Homo sapiens 89-98 14612203-4 2003 Lovastatin, simvastatin, atorvastatin, fluvastatin and cerivastatin, which are hydrophobic statins, markedly reduced cell viability associated with DNA fragmentation, DNA laddering and activation of caspase-3, suggesting apoptotic cell death. Simvastatin 12-23 caspase 3 Rattus norvegicus 199-208 14601315-3 2003 RESULTS: After bone marrow stromal cells were treated with different concentration of simvastatin for 72 h, level of OCN mRNA increased, and expression of OCN and OPN also increased in a concentration-dependent manner, and cellular ALP activity significantly increased in a concentration-dependent manner. Simvastatin 86-97 bone gamma-carboxyglutamate protein 2 Mus musculus 117-120 14601315-3 2003 RESULTS: After bone marrow stromal cells were treated with different concentration of simvastatin for 72 h, level of OCN mRNA increased, and expression of OCN and OPN also increased in a concentration-dependent manner, and cellular ALP activity significantly increased in a concentration-dependent manner. Simvastatin 86-97 bone gamma-carboxyglutamate protein 2 Mus musculus 155-158 14601315-3 2003 RESULTS: After bone marrow stromal cells were treated with different concentration of simvastatin for 72 h, level of OCN mRNA increased, and expression of OCN and OPN also increased in a concentration-dependent manner, and cellular ALP activity significantly increased in a concentration-dependent manner. Simvastatin 86-97 secreted phosphoprotein 1 Mus musculus 163-166 14601315-4 2003 CONCLUSION: Simvastatin can stimulate osteoblastic differentiation, and improve cellular ALPase activity with high expression of osteocalcin and osteopontin in vitro. Simvastatin 12-23 bone gamma-carboxyglutamate protein 2 Mus musculus 129-140 14601315-4 2003 CONCLUSION: Simvastatin can stimulate osteoblastic differentiation, and improve cellular ALPase activity with high expression of osteocalcin and osteopontin in vitro. Simvastatin 12-23 secreted phosphoprotein 1 Mus musculus 145-156 14574622-14 2003 Treatment with high-dose simvastatin in normocholesterolemic Alzheimer patients for 26 weeks at early stages of the disease results in a significant decrease in Abeta-levels in cerebrospinal fluid. Simvastatin 25-36 amyloid beta precursor protein Homo sapiens 161-166 14579918-0 2003 Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Simvastatin 17-28 C-reactive protein Homo sapiens 50-68 14579918-3 2003 HYPOTHESIS: The study was undertaken to investigate whether a rapid LDL cholesterol and CRP reduction can be achieved by 2-week simvastatin therapy using a common lipid-lowering protocol in patients with hypercholesterolemia. Simvastatin 128-139 C-reactive protein Homo sapiens 88-91 14579918-10 2003 In addition, both doses of simvastatin induced significant reductions in mean CRP levels on Day 14 (22.3 and 23.1%) in a non dose-dependent manner (p < 0.001, respectively. Simvastatin 27-38 C-reactive protein Homo sapiens 78-81 14579918-11 2003 CONCLUSIONS: Our data suggest that a common daily dose of simvastatin, especially 40 mg, is an effective 2-week therapy for patients with hypercholesterolemia, and benefit to the vascular endothelium can be derived quickly by reduction of CRP levels. Simvastatin 58-69 C-reactive protein Homo sapiens 239-242 12952848-5 2003 Activation of Jurkat cells with phorbol esters and ionomycin increased FasL expression, an effect prevented by atorvastatin or simvastatin. Simvastatin 127-138 Fas ligand Homo sapiens 71-75 12962723-0 2003 Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Simvastatin 0-11 caspase 9 Homo sapiens 76-85 12777465-3 2003 Here we show that treatment of thioglycollate-elicited mouse peritoneal macrophages with various unrelated apoptotic agents, including simvastatin, camptothecin, or glucose deprivation, is associated with a specific and large increase in caveolin-1 expression. Simvastatin 135-146 caveolin 1, caveolae protein Mus musculus 238-248 14522569-4 2003 Since certain lipophilic statins (i.e. simvastatin, atorvastatin, lovastatin) are a substrate of CYP3A4, we were interested in potential drug interactions between clopidogrel and statins. Simvastatin 39-50 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 97-103 14512881-2 2003 The present study was aimed to study the changes induced on bile acid synthesis by simvastatin, a competitive inhibitor of hydroxymethyl glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol synthesis, during pharmacologic interruption of the enterohepatic circulation. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 123-169 12963647-5 2003 When rats with severe PAH received simvastatin (2 mg x kg(-1) x d(-1) by gavage) from week 11, there was 100% survival and reversal of PAH after 2 weeks (mPAP=36 mm Hg) and 6 weeks (mPAP=24 mm Hg) of therapy. Simvastatin 35-46 phospholipid phosphatase 1 Mus musculus 154-158 12963647-5 2003 When rats with severe PAH received simvastatin (2 mg x kg(-1) x d(-1) by gavage) from week 11, there was 100% survival and reversal of PAH after 2 weeks (mPAP=36 mm Hg) and 6 weeks (mPAP=24 mm Hg) of therapy. Simvastatin 35-46 phospholipid phosphatase 1 Mus musculus 182-186 12963647-7 2003 Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a. Simvastatin 53-64 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 102-105 12963647-7 2003 Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a. Simvastatin 53-64 tumor necrosis factor Rattus norvegicus 116-143 12963647-7 2003 Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a. Simvastatin 53-64 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 185-192 12963647-7 2003 Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a. Simvastatin 53-64 bone morphogenetic protein receptor type 1A Rattus norvegicus 233-276 12960612-3 2003 We show here that two different 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), atorvastatin and simvastatin, strongly increase the expression and functional activity of TM in human umbilical vein endothelial cells, human coronary artery endothelial cells, and EA.hy926 endothelial cells. Simvastatin 119-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-79 12960612-3 2003 We show here that two different 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), atorvastatin and simvastatin, strongly increase the expression and functional activity of TM in human umbilical vein endothelial cells, human coronary artery endothelial cells, and EA.hy926 endothelial cells. Simvastatin 119-130 thrombomodulin Homo sapiens 192-194 12962723-13 2003 The apoptosis induced by Sim is probably initiated by the mitochondrial caspase 9, which indirectly leads to activation of caspase 3 and 8. Simvastatin 25-28 caspase 9 Homo sapiens 72-81 12962723-13 2003 The apoptosis induced by Sim is probably initiated by the mitochondrial caspase 9, which indirectly leads to activation of caspase 3 and 8. Simvastatin 25-28 caspase 3 Homo sapiens 123-132 12958617-10 2003 Subjects treated with simvastatin after 60 days of diet showed a significant reduction of P-sel and platelet aggregation after six weeks of treatment (p < 0.01). Simvastatin 22-33 selectin P Homo sapiens 90-95 12914771-2 2003 Simvastatin treatment enhanced the expression level of mRNA for osteocalcin and protein for osteocalcin and osteopontin, and increased alkaline phosphatase activity significantly (p<0.05). Simvastatin 0-11 bone gamma-carboxyglutamate protein 2 Mus musculus 64-75 12914771-2 2003 Simvastatin treatment enhanced the expression level of mRNA for osteocalcin and protein for osteocalcin and osteopontin, and increased alkaline phosphatase activity significantly (p<0.05). Simvastatin 0-11 bone gamma-carboxyglutamate protein 2 Mus musculus 92-103 12914771-2 2003 Simvastatin treatment enhanced the expression level of mRNA for osteocalcin and protein for osteocalcin and osteopontin, and increased alkaline phosphatase activity significantly (p<0.05). Simvastatin 0-11 secreted phosphoprotein 1 Mus musculus 108-119 12914771-3 2003 After BMSCs were exposed to an adipocyte differentiation agonist, Oil Red O staining, fluorescence activated cell sorting, and decreased expression level of lipoprotein lipase mRNA showed that treatment with simvastatin significantly inhibits adipocytic differentiation compared to controls that did not receive simvastatin (p<0.05). Simvastatin 208-219 lipoprotein lipase Mus musculus 157-175 12885745-10 2003 Furthermore, plasma concentrations of tumor necrosis factor-alpha, interleukin-6, and brain natriuretic peptide were significantly lower in the simvastatin group compared with the placebo group. Simvastatin 144-155 tumor necrosis factor Homo sapiens 38-65 12885745-10 2003 Furthermore, plasma concentrations of tumor necrosis factor-alpha, interleukin-6, and brain natriuretic peptide were significantly lower in the simvastatin group compared with the placebo group. Simvastatin 144-155 interleukin 6 Homo sapiens 67-80 12829860-0 2003 Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Simvastatin 47-58 interleukin 1 beta Rattus norvegicus 181-230 12829525-0 2003 Reduced expression of endothelial connexin37 and connexin40 in hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment. Simvastatin 119-130 gap junction protein, alpha 4 Mus musculus 96-106 12829525-4 2003 After simvastatin treatment, Cx40 remained depressed, but Cx37 recovered to 94% of the level found in non-cholesterol-fed animals (P<0.01). Simvastatin 6-17 gap junction protein, alpha 5 Mus musculus 29-33 12829525-8 2003 Short-term treatment with simvastatin leads to recovery of Cx37 expression but not Cx40 expression. Simvastatin 26-37 gap junction protein, alpha 4 Mus musculus 59-63 14535628-5 2003 Therefore, we decided to investigate the effect of simvastatin on insulin sensitivity in hypercholesterolemic patients. Simvastatin 51-62 insulin Homo sapiens 66-73 12860867-10 2003 In the simvastatin arm, Lp(a) concentrations decreased to 437 mg/l after one year (p < 0.001) and to 417 mg/l after two years (p < 0.001). Simvastatin 7-18 lipoprotein(a) Homo sapiens 24-29 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Simvastatin 117-128 transforming growth factor, beta 1 Rattus norvegicus 18-28 12846751-12 2003 Overexpression of TGF beta 1 and VEGF was observed in the glomeruli of diabetic rats and was attenuated by losartan, simvastatin, or the combination of both to a similar level. Simvastatin 117-128 vascular endothelial growth factor A Rattus norvegicus 33-37 12829860-0 2003 Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Simvastatin 47-58 nitric oxide synthase 3 Rattus norvegicus 267-300 12829860-3 2003 Furthermore, we determined whether simvastatin affected endothelial nitric oxide synthase (eNOS) or inflammatory cytokines in brain tissue or cholesterol levels in serum. Simvastatin 35-46 nitric oxide synthase 3 Rattus norvegicus 91-95 12867249-2 2003 The latest landmark trial of therapy using a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is the Heart Protection Study (HPS) of simvastatin versus placebo in a cohort of patients at high risk for CAD. Simvastatin 151-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 12801507-3 2003 In this study, we investigated whether simvastatin induces heat shock protein (HSP) 27, HSP70, and HSP90 in osteoblast-like MC3T3-E1 cells. Simvastatin 39-50 heat shock protein 1 Mus musculus 59-86 12841814-1 2003 OBJECTIVE: To report a case of rhabdomyolysis after concomitant use of simvastatin, a commonly used hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and fluconazole, an azole antifungal agent. Simvastatin 71-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 100-152 12801507-3 2003 In this study, we investigated whether simvastatin induces heat shock protein (HSP) 27, HSP70, and HSP90 in osteoblast-like MC3T3-E1 cells. Simvastatin 39-50 heat shock protein 1B Mus musculus 88-93 12801507-3 2003 In this study, we investigated whether simvastatin induces heat shock protein (HSP) 27, HSP70, and HSP90 in osteoblast-like MC3T3-E1 cells. Simvastatin 39-50 heat shock protein, 3 Mus musculus 99-104 12801507-4 2003 Simvastatin increased the levels of HSP27 while having little effect on the levels of HSP70 or HSP90. Simvastatin 0-11 heat shock protein 1 Mus musculus 36-41 12801507-5 2003 The effect of simvastatin on HSP27 accumulation was dose dependent. Simvastatin 14-25 heat shock protein 1 Mus musculus 29-34 12801507-7 2003 Simvastatin induced an increase in the levels of mRNA for HSP27. Simvastatin 0-11 heat shock protein 1 Mus musculus 58-63 12801507-9 2003 Simvastatin induced the phosphorylation of p38 mitogen-activated protein (MAP) kinase among the MAP kinase superfamily. Simvastatin 0-11 mitogen-activated protein kinase 14 Mus musculus 43-46 12801507-10 2003 SB203580 and PD169316, inhibitors of p38 MAP kinase, suppressed the HSP27 accumulation by simvastatin while SB202474, a negative control of p38 MAP kinase inhibitor, had no effect. Simvastatin 90-101 mitogen-activated protein kinase 14 Mus musculus 37-40 12801507-10 2003 SB203580 and PD169316, inhibitors of p38 MAP kinase, suppressed the HSP27 accumulation by simvastatin while SB202474, a negative control of p38 MAP kinase inhibitor, had no effect. Simvastatin 90-101 heat shock protein 1 Mus musculus 68-73 12801507-11 2003 SB203580 reduced the simvastatin-increased mRNA levels for HSP27. Simvastatin 21-32 heat shock protein 1 Mus musculus 59-64 12801507-13 2003 These results strongly suggest that statins such as simvastatin do not stimulate the induction of HSP70 and HSP90, but do stimulate the induction of HSP27 in osteoblasts and that p38 MAP kinase plays a role in this induction. Simvastatin 52-63 heat shock protein 1 Mus musculus 149-154 12801507-13 2003 These results strongly suggest that statins such as simvastatin do not stimulate the induction of HSP70 and HSP90, but do stimulate the induction of HSP27 in osteoblasts and that p38 MAP kinase plays a role in this induction. Simvastatin 52-63 mitogen-activated protein kinase 14 Mus musculus 179-182 12787408-4 2003 METHODS: Apoptosis induced by simvastatin was measured in murine tubular cells with and without overexpressing Bcl-xL. Simvastatin 30-41 BCL2-like 1 Mus musculus 111-117 12860247-7 2003 Human aortic endothelial cells incubated with simvastatin exhibited up to threefold higher intracellular oxidation of DHR-123 along with a twofold increase in total e-NOS protein. Simvastatin 46-57 nitric oxide synthase 3 Homo sapiens 165-170 12860247-8 2003 The elevated e-NOS was found in the Golgi/mitochondrial fraction and not in the plasma membrane, and using immunofluorescence greater e-NOS was observed proximal to Golgi and cytoskeletal structures and away from plasma membrane in simvastatin-treated cells. Simvastatin 232-243 nitric oxide synthase 3 Rattus norvegicus 13-18 12860247-8 2003 The elevated e-NOS was found in the Golgi/mitochondrial fraction and not in the plasma membrane, and using immunofluorescence greater e-NOS was observed proximal to Golgi and cytoskeletal structures and away from plasma membrane in simvastatin-treated cells. Simvastatin 232-243 nitric oxide synthase 3 Rattus norvegicus 134-139 12848784-1 2003 AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV). Simvastatin 87-98 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 22-37 12848784-1 2003 AIMS: To identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of simvastatin hydroxy acid (SVA), the most potent metabolite of simvastatin (SV). Simvastatin 87-98 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 39-42 12756509-0 2003 Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Simvastatin 25-36 C-C motif chemokine ligand 2 Homo sapiens 65-99 12756509-2 2003 The aim of this study was to evaluate the secretion of monocyte chemoattractant protein-1 (MCP-1) by monocytes from hyperlipidemic patients treated with hypolipidemic drugs, namely fenofibrate, simvastatin, or atorvastatin to determine what role is played by these drugs in the development and stabilization of the atherosclerotic plaque. Simvastatin 194-205 C-C motif chemokine ligand 2 Homo sapiens 55-89 12756509-2 2003 The aim of this study was to evaluate the secretion of monocyte chemoattractant protein-1 (MCP-1) by monocytes from hyperlipidemic patients treated with hypolipidemic drugs, namely fenofibrate, simvastatin, or atorvastatin to determine what role is played by these drugs in the development and stabilization of the atherosclerotic plaque. Simvastatin 194-205 C-C motif chemokine ligand 2 Homo sapiens 91-96 12756509-11 2003 Fenofibrate, atorvastatin, and simvastatin significantly decreased MCP-1 levels from 15.8+/-0.47 to 8.79+/-0.89, from 16.7+/-0.23 to 7.46+/-0.73, and from 14.9+/-0.45 to 10.3+/-0.8 ng/ml, respectively. Simvastatin 31-42 C-C motif chemokine ligand 2 Homo sapiens 67-72 12787408-10 2003 We also observed the presence of active caspase 9 and 3 during apoptosis induced by simvastatin. Simvastatin 84-95 caspase 9 Mus musculus 40-55 12787408-12 2003 Simvastatin appears to alter the balance between cell-life and death-promoting genes, as reflected by the decreased Bcl-xL/Bax ratio. Simvastatin 0-11 BCL2-like 1 Mus musculus 116-122 12787408-12 2003 Simvastatin appears to alter the balance between cell-life and death-promoting genes, as reflected by the decreased Bcl-xL/Bax ratio. Simvastatin 0-11 BCL2-associated X protein Mus musculus 123-126 12787408-13 2003 Supporting this hypothesis, overexpression of Bcl-xL reduced the amount of apoptosis induced by simvastatin by 80% when compared with control vector-expressing cells. Simvastatin 96-107 BCL2-like 1 Mus musculus 46-52 12783420-1 2003 We demonstrate that the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors atorvastatin and simvastatin enhance functional outcome and induce brain plasticity when administered after stroke to rats. Simvastatin 111-122 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 24-82 12805493-9 2003 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate. Simvastatin 62-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 12805493-9 2003 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate. Simvastatin 62-73 parathyroid hormone like hormone Homo sapiens 88-93 12805493-9 2003 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate. Simvastatin 62-73 C-C motif chemokine ligand 2 Homo sapiens 141-146 12816176-0 2003 Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Simvastatin 27-38 C-C motif chemokine ligand 2 Homo sapiens 61-66 12826933-0 2003 Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Simvastatin 0-11 interleukin 6 Homo sapiens 21-34 12826933-0 2003 Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Simvastatin 0-11 C-reactive protein Homo sapiens 76-94 12826933-5 2003 Also 10-8-10-6 mol/l simvastatin was coincubated with cells in the presence of CRP and LPS. Simvastatin 21-32 C-reactive protein Homo sapiens 79-82 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 74-85 C-reactive protein Homo sapiens 13-16 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 247-258 C-reactive protein Homo sapiens 13-16 12817528-6 2003 Concomitant treatment with CYP3A4 substrates altered mean AUC0-5 h and mean Cmax for repaglinide by 1% and 17% (ethinyloestradiol/levonorgestrel), 2% and 27% (simvastatin), or 11% and 3% (nifedipine). Simvastatin 159-170 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 12753293-0 2003 Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 23-36 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 19-30 tumor necrosis factor Homo sapiens 61-70 12753293-0 2003 Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 87-114 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 19-30 plasminogen activator, tissue type Homo sapiens 151-155 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 194-205 plasminogen activator, tissue type Homo sapiens 31-35 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 194-205 tumor necrosis factor Homo sapiens 61-70 12753293-10 2003 Simvastatin dose-dependently suppressed PAI-1 production in both control and TNF-alpha-treated cells. Simvastatin 0-11 serpin family E member 1 Homo sapiens 40-45 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-116 12753293-10 2003 Simvastatin dose-dependently suppressed PAI-1 production in both control and TNF-alpha-treated cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 77-86 12753293-11 2003 At 5 micromol/L, simvastatin lowered PAI-1 synthesis 3.4-fold and 4.0-fold, respectively, thereby also completely suppressing the TNF-alpha effect itself. Simvastatin 17-28 serpin family E member 1 Homo sapiens 37-42 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 plasminogen activator, tissue type Homo sapiens 162-166 12753293-11 2003 At 5 micromol/L, simvastatin lowered PAI-1 synthesis 3.4-fold and 4.0-fold, respectively, thereby also completely suppressing the TNF-alpha effect itself. Simvastatin 17-28 tumor necrosis factor Homo sapiens 130-139 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 serpin family E member 1 Homo sapiens 168-173 12753293-12 2003 Similarly, simvastatin down-regulated the expression of tissue factor and also completely opposed the TNF-alpha-induced tissue factor expression. Simvastatin 11-22 coagulation factor III, tissue factor Homo sapiens 56-69 12753293-12 2003 Similarly, simvastatin down-regulated the expression of tissue factor and also completely opposed the TNF-alpha-induced tissue factor expression. Simvastatin 11-22 tumor necrosis factor Homo sapiens 102-111 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 coagulation factor III, tissue factor Homo sapiens 178-191 12753293-12 2003 Similarly, simvastatin down-regulated the expression of tissue factor and also completely opposed the TNF-alpha-induced tissue factor expression. Simvastatin 11-22 coagulation factor III, tissue factor Homo sapiens 120-133 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 tumor necrosis factor Homo sapiens 227-254 12753293-13 2003 The effects of simvastatin on t-PA, PAI-1 and tissue factor expression were prevented by mevalonate and geranylgeraniol (GG), suggesting the involvement of geranylgeranyl-modified intermediates in simvastatin"s mode of action. Simvastatin 15-26 plasminogen activator, tissue type Homo sapiens 30-34 12753293-13 2003 The effects of simvastatin on t-PA, PAI-1 and tissue factor expression were prevented by mevalonate and geranylgeraniol (GG), suggesting the involvement of geranylgeranyl-modified intermediates in simvastatin"s mode of action. Simvastatin 15-26 serpin family E member 1 Homo sapiens 36-41 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 tumor necrosis factor Homo sapiens 256-265 12753293-13 2003 The effects of simvastatin on t-PA, PAI-1 and tissue factor expression were prevented by mevalonate and geranylgeraniol (GG), suggesting the involvement of geranylgeranyl-modified intermediates in simvastatin"s mode of action. Simvastatin 15-26 coagulation factor III, tissue factor Homo sapiens 46-59 12753293-7 2003 Luciferase reporter gene assays and Western blot analysis in human fibrosarcoma HT1080 cells and HMC were performed to analyze the effect of simvastatin on the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1), which regulate tissue factor gene expression. Simvastatin 141-152 nuclear factor kappa B subunit 1 Homo sapiens 182-204 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 nuclear factor kappa B subunit 1 Homo sapiens 26-36 12753293-7 2003 Luciferase reporter gene assays and Western blot analysis in human fibrosarcoma HT1080 cells and HMC were performed to analyze the effect of simvastatin on the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1), which regulate tissue factor gene expression. Simvastatin 141-152 nuclear factor kappa B subunit 1 Homo sapiens 206-216 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 42-46 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 tumor necrosis factor Homo sapiens 83-92 12753293-7 2003 Luciferase reporter gene assays and Western blot analysis in human fibrosarcoma HT1080 cells and HMC were performed to analyze the effect of simvastatin on the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1), which regulate tissue factor gene expression. Simvastatin 141-152 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 222-241 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 nuclear factor kappa B subunit 1 Homo sapiens 162-165 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 19-30 plasminogen activator, tissue type Homo sapiens 31-35 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 nuclear factor kappa B subunit 1 Homo sapiens 166-176 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 nuclear factor kappa B subunit 1 Homo sapiens 166-176 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 202-206 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 218-223 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 228-233 12695460-10 2003 However, both neutrophil CD11b expression and endothelial P-selectin exocytosis were less in the simvastatin groups than in the controls. Simvastatin 97-108 integrin subunit alpha M Homo sapiens 25-30 14512087-7 2003 Both Rho inhibitor, C3 exoenzyme, and Rho kinase inhibitor, Y-27632, mimicked the inhibitory effects of simvastatin against TF and PAI-1 induced by Ang II. Simvastatin 104-115 coagulation factor III, tissue factor Rattus norvegicus 124-126 14512087-7 2003 Both Rho inhibitor, C3 exoenzyme, and Rho kinase inhibitor, Y-27632, mimicked the inhibitory effects of simvastatin against TF and PAI-1 induced by Ang II. Simvastatin 104-115 serpin family E member 1 Rattus norvegicus 131-136 14512087-7 2003 Both Rho inhibitor, C3 exoenzyme, and Rho kinase inhibitor, Y-27632, mimicked the inhibitory effects of simvastatin against TF and PAI-1 induced by Ang II. Simvastatin 104-115 angiotensinogen Rattus norvegicus 148-154 14512087-9 2003 CONCLUSION: It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. Simvastatin 34-45 coagulation factor III, tissue factor Rattus norvegicus 109-111 14512087-9 2003 CONCLUSION: It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. Simvastatin 34-45 serpin family E member 1 Rattus norvegicus 116-121 14512087-9 2003 CONCLUSION: It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. Simvastatin 34-45 angiotensinogen Rattus norvegicus 174-179 14512087-9 2003 CONCLUSION: It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. Simvastatin 34-45 coagulation factor III, tissue factor Rattus norvegicus 188-190 14512087-9 2003 CONCLUSION: It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. Simvastatin 34-45 serpin family E member 1 Rattus norvegicus 195-200 12637338-9 2003 CONCLUSIONS: Simvastatin-niacin therapy significantly increased the large apoA-I-containing alpha1 HDL particles. Simvastatin 13-24 apolipoprotein A1 Homo sapiens 74-80 12774855-12 2003 Simvastatin and pravastatin reduced the total cholesterol concentration and LDL-cholesterol in plasma, as well as the cholesterol concentration in erythrocytes membranes. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 76-91 14512087-5 2003 Pretreatment with simvastatin (0.03-3 microg/ml) significantly inhibited TF and PAI-1 induction by Ang II in a dose- and time-dependent manner. Simvastatin 18-29 coagulation factor III, tissue factor Rattus norvegicus 73-75 14512087-5 2003 Pretreatment with simvastatin (0.03-3 microg/ml) significantly inhibited TF and PAI-1 induction by Ang II in a dose- and time-dependent manner. Simvastatin 18-29 serpin family E member 1 Rattus norvegicus 80-85 14512087-5 2003 Pretreatment with simvastatin (0.03-3 microg/ml) significantly inhibited TF and PAI-1 induction by Ang II in a dose- and time-dependent manner. Simvastatin 18-29 angiotensinogen Rattus norvegicus 99-105 12695460-10 2003 However, both neutrophil CD11b expression and endothelial P-selectin exocytosis were less in the simvastatin groups than in the controls. Simvastatin 97-108 selectin P Homo sapiens 58-68 12679152-3 2003 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, simvastatin and atorvastatin (in 0.02% and 0.07% admixtures), also reduced plasma levels of non-HDL cholesterol. Simvastatin 74-85 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 4-61 12761443-11 2003 CONCLUSIONS: The result indicates that simvastatin, an inhibitor of HMG-CoA reductase and a ligand of PPAR-a and PPAR-g, reduces the tissue necrosis associated with acute myocardial infarction. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 68-85 12761443-11 2003 CONCLUSIONS: The result indicates that simvastatin, an inhibitor of HMG-CoA reductase and a ligand of PPAR-a and PPAR-g, reduces the tissue necrosis associated with acute myocardial infarction. Simvastatin 39-50 peroxisome proliferator activated receptor alpha Rattus norvegicus 102-108 12761443-11 2003 CONCLUSIONS: The result indicates that simvastatin, an inhibitor of HMG-CoA reductase and a ligand of PPAR-a and PPAR-g, reduces the tissue necrosis associated with acute myocardial infarction. Simvastatin 39-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 113-119 12706457-2 2003 The dose-response relationships for the above effects show that simvastatin, atorvastatin and fluvastatin affect linoleic acid conversion and the delta5 desaturase step more potently than the synthesis of cholesterol, simvastatin being the most effective in inhibiting sterol synthesis, whereas atorvastatin in stimulating the conversion of linoleic acid. Simvastatin 64-75 fatty acid desaturase 1 Homo sapiens 146-163 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 90-106 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 223-239 12686335-10 2003 Simvastatin therapy decreased total cholesterol by 27%, non-HDL cholesterol by 30%, total apolipoprotein B by 31%, very low-density lipoprotein (VLDL) + intermediate-density lipoprotein (IDL) cholesterol by 37%, VLDL + IDL apolipoprotein B by 14%, LDL cholesterol by 28%, and LDL apolipoprotein B by 21%. Simvastatin 0-11 apolipoprotein B Homo sapiens 223-239 12748879-7 2003 Simvastatin, atorvastatin, and fluvastatin reduced monocyte procoagulant activity in whole blood and P-selectin (P<0.01). Simvastatin 0-11 selectin P Homo sapiens 101-111 12818400-0 2003 Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Simvastatin 0-11 coagulation factor III Mus musculus 35-48 12659599-13 2003 Moreover, fibrinogen levels decreased with simvastatin and atorvastatin, but these reductions were significant only for simvastatin (p < 0.05). Simvastatin 43-54 fibrinogen beta chain Homo sapiens 10-20 12818400-0 2003 Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Simvastatin 0-11 apolipoprotein E Mus musculus 88-104 12818400-0 2003 Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Simvastatin 171-182 early growth response 1 Mus musculus 206-211 12818400-3 2003 In contrast to other experimental models and humans, simvastatin treatment increases plasma cholesterol levels in apo E-/- mice. Simvastatin 53-64 apolipoprotein E Homo sapiens 114-119 12689687-6 2003 In the simvastatin-treated group Bone-ALP showed a significant increase (P < 0.05) with respect to baseline from the sixth month, whereas serum CTx showed a weak and nonsignificant increase over the study period. Simvastatin 7-18 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 147-150 12818400-5 2003 Expression of TF was reduced to 34, 24, and 13% of control levels at 12, 18 and 24 weeks, respectively, of simvastatin administration. Simvastatin 107-118 coagulation factor III Mus musculus 14-16 12818400-6 2003 Advanced lesions in the innominate arteries of the simvastatin treated mice had reduced levels of TF, fewer macrophages and reduced expression of early growth response-1 (Egr-1). Simvastatin 51-62 coagulation factor III Mus musculus 98-100 12818400-6 2003 Advanced lesions in the innominate arteries of the simvastatin treated mice had reduced levels of TF, fewer macrophages and reduced expression of early growth response-1 (Egr-1). Simvastatin 51-62 early growth response 1 Mus musculus 146-169 12818400-6 2003 Advanced lesions in the innominate arteries of the simvastatin treated mice had reduced levels of TF, fewer macrophages and reduced expression of early growth response-1 (Egr-1). Simvastatin 51-62 early growth response 1 Mus musculus 171-176 12818400-7 2003 In vitro studies in mouse macrophages demonstrated decreased lipopolysaccharide induced binding of nuclear proteins to the Egr-1 consensus DNA sequence following pretreatment with simvastatin. Simvastatin 180-191 early growth response 1 Mus musculus 123-128 12818400-8 2003 RNA levels for MCP-1 were reduced to 30% of control values following 24 weeks of simvastatin treatment. Simvastatin 81-92 chemokine (C-C motif) ligand 2 Mus musculus 15-20 12818400-9 2003 In conclusion, these data suggest that chronic administration of simvastatin to older apo E-/- mice can inhibit the expression of pro-thrombotic/pro-inflammatory genes within established atherosclerotic lesions via mechanisms that are independent of reductions in plasma lipids. Simvastatin 65-76 apolipoprotein E Mus musculus 86-91 12544321-0 2003 Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. Simvastatin 69-80 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 20-36 12654603-0 2003 Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Simvastatin 96-107 prostaglandin-endoperoxide synthase 2 Homo sapiens 40-56 12654603-0 2003 Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Simvastatin 96-107 prostaglandin E synthase Homo sapiens 57-81 12654603-4 2003 The aim of this study was to characterize the effect of simvastatin on inflammatory infiltration and the expression of COX-2/mPGES and MMPs in human carotid plaques. Simvastatin 56-67 matrix metallopeptidase 2 Homo sapiens 135-139 12654603-8 2003 Plaques from the simvastatin group had fewer (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells; less (P<0.0001) immunoreactivity for COX-2/mPGES and MMPs; reduced (P<0.0001) gelatinolytic activity; increased (P<0.0001) collagen content; and reduced (P<0.0001) lipid and oxLDL content. Simvastatin 17-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 12654603-8 2003 Plaques from the simvastatin group had fewer (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells; less (P<0.0001) immunoreactivity for COX-2/mPGES and MMPs; reduced (P<0.0001) gelatinolytic activity; increased (P<0.0001) collagen content; and reduced (P<0.0001) lipid and oxLDL content. Simvastatin 17-28 prostaglandin E synthase Mus musculus 152-157 12654603-8 2003 Plaques from the simvastatin group had fewer (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells; less (P<0.0001) immunoreactivity for COX-2/mPGES and MMPs; reduced (P<0.0001) gelatinolytic activity; increased (P<0.0001) collagen content; and reduced (P<0.0001) lipid and oxLDL content. Simvastatin 17-28 matrix metallopeptidase 2 Homo sapiens 162-166 12654603-9 2003 Interestingly, COX-2/mPGES inhibition by simvastatin was completely reversed by mevalonate in vitro. Simvastatin 41-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 12654603-9 2003 Interestingly, COX-2/mPGES inhibition by simvastatin was completely reversed by mevalonate in vitro. Simvastatin 41-52 prostaglandin E synthase Mus musculus 21-26 12654603-10 2003 CONCLUSIONS: This study demonstrates that simvastatin decreases inflammation and inhibits COX-2/mPGES expression in plaque macrophages, and this effect in turn may contribute to plaque stabilization by inhibition of MMP-induced plaque rupture. Simvastatin 42-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 12654603-10 2003 CONCLUSIONS: This study demonstrates that simvastatin decreases inflammation and inhibits COX-2/mPGES expression in plaque macrophages, and this effect in turn may contribute to plaque stabilization by inhibition of MMP-induced plaque rupture. Simvastatin 42-53 prostaglandin E synthase Mus musculus 96-101 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 tumor necrosis factor Homo sapiens 81-114 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 intercellular adhesion molecule 1 Homo sapiens 137-141 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 lymphotoxin beta receptor Homo sapiens 146-150 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 integrin subunit alpha L Homo sapiens 151-156 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 tumor necrosis factor Homo sapiens 214-223 12671581-1 2003 INTRODUCTION: Simvastatin is a competitive inhibitor of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase which is effective in the treatment of various hyperlipidemia. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-117 12538717-5 2003 Moreover, simvastatin reduced anti-CD3/anti-CD28 proliferation and IFN-gamma release from mononuclear cells derived from peripheral blood and synovial fluid. Simvastatin 10-21 CD28 antigen Mus musculus 44-48 12538717-5 2003 Moreover, simvastatin reduced anti-CD3/anti-CD28 proliferation and IFN-gamma release from mononuclear cells derived from peripheral blood and synovial fluid. Simvastatin 10-21 interferon gamma Mus musculus 67-76 12637638-7 2003 Simvastatin-treated animals showed increased expression of endothelial nitric-oxide-synthase (eNOS), and decreased expression of the ox-LDL receptor LOX-1 in renal endothelial cells. Simvastatin 0-11 nitric oxide synthase 3 Sus scrofa 59-92 12637638-7 2003 Simvastatin-treated animals showed increased expression of endothelial nitric-oxide-synthase (eNOS), and decreased expression of the ox-LDL receptor LOX-1 in renal endothelial cells. Simvastatin 0-11 nitric oxide synthase 3 Sus scrofa 94-98 12637638-7 2003 Simvastatin-treated animals showed increased expression of endothelial nitric-oxide-synthase (eNOS), and decreased expression of the ox-LDL receptor LOX-1 in renal endothelial cells. Simvastatin 0-11 oxidized low density lipoprotein receptor 1 Sus scrofa 149-154 12615272-0 2003 Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Simvastatin 35-46 fibrinogen beta chain Homo sapiens 65-75 12901521-0 2003 The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Simvastatin 78-89 apolipoprotein B Homo sapiens 17-33 12901521-1 2003 OBJECTIVE: To investigate the effect of apolipoprotein B (apoB) and E (apoE) genetic variations on lipid profile at baseline (before treatment), and also on the subsequent response to simvastatin therapy. Simvastatin 184-195 apolipoprotein E Homo sapiens 71-75 12901521-12 2003 CONCLUSION: The relative frequency of apoB X+ allele is high in patients with hyperlipidemia, in whom the TC-lowering efficacy is decreased following treatment of simvastatin. Simvastatin 163-174 apolipoprotein B Homo sapiens 38-42 12659988-5 2003 Compared with pretreatment values, simvastatin significantly lowered plasma levels of MMP-9, TF, and PAI-1 (P=0.009, P=0.032, and P=0.007, respectively). Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 86-91 12659988-5 2003 Compared with pretreatment values, simvastatin significantly lowered plasma levels of MMP-9, TF, and PAI-1 (P=0.009, P=0.032, and P=0.007, respectively). Simvastatin 35-46 coagulation factor III, tissue factor Homo sapiens 93-95 12659988-5 2003 Compared with pretreatment values, simvastatin significantly lowered plasma levels of MMP-9, TF, and PAI-1 (P=0.009, P=0.032, and P=0.007, respectively). Simvastatin 35-46 serpin family E member 1 Homo sapiens 101-106 12659988-6 2003 There were significant inverse correlations between pretreatment MMP-9, TF activity or PAI-1 antigen and the degree of change in those levels after simvastatin (r=-0.793, P<0.001; r=-0.482, P=0.005 and r=-0.590, P<0.001, respectively). Simvastatin 148-159 matrix metallopeptidase 9 Homo sapiens 65-70 12659988-6 2003 There were significant inverse correlations between pretreatment MMP-9, TF activity or PAI-1 antigen and the degree of change in those levels after simvastatin (r=-0.793, P<0.001; r=-0.482, P=0.005 and r=-0.590, P<0.001, respectively). Simvastatin 148-159 coagulation factor III, tissue factor Homo sapiens 72-74 12659988-6 2003 There were significant inverse correlations between pretreatment MMP-9, TF activity or PAI-1 antigen and the degree of change in those levels after simvastatin (r=-0.793, P<0.001; r=-0.482, P=0.005 and r=-0.590, P<0.001, respectively). Simvastatin 148-159 serpin family E member 1 Homo sapiens 87-92 12477733-10 2003 Indeed, the isoprenylation of Ras and RhoA protein appeared normal in HIDS and MA fibroblasts under normal conditions but showed increased sensitivity toward inhibition of HMGR by simvastatin. Simvastatin 180-191 ras homolog family member A Homo sapiens 38-42 12477733-10 2003 Indeed, the isoprenylation of Ras and RhoA protein appeared normal in HIDS and MA fibroblasts under normal conditions but showed increased sensitivity toward inhibition of HMGR by simvastatin. Simvastatin 180-191 high mobility group AT-hook 1 Homo sapiens 172-176 12538631-3 2003 Hydrophobic statins including simvastatin, atorvastatin, and cerivastatin-but not a hydrophilic statin, pravastatin-markedly increased VEGF mRNA abundance in nontransformed osteoblastic cells (MC3T3-E1). Simvastatin 30-41 vascular endothelial growth factor A Mus musculus 135-139 12538631-4 2003 Simvastatin (10(-6) M) time-dependently augmented VEGF mRNA expression in MC3T3-E1 cells, mouse stromal cells (ST2), and rat osteosarcoma cells (UMR-106). Simvastatin 0-11 vascular endothelial growth factor A Mus musculus 50-54 12538631-5 2003 According to heterogeneous nuclear RNA and Northern analyses, 10(-6) M simvastatin stimulated gene expression for VEGF in MC3T3-E1 cells without altering mRNA stability. Simvastatin 71-82 vascular endothelial growth factor A Mus musculus 114-118 12538631-6 2003 Transcriptional activation of a VEGF promoter-luciferase construct (-1128 to +827), significantly increased by simvastatin administration. Simvastatin 111-122 vascular endothelial growth factor A Mus musculus 32-36 12538631-8 2003 These results indicate that the stimulation of the VEGF gene by simvastatin in MC3T3-E1 cells is transcriptional in nature. Simvastatin 64-75 vascular endothelial growth factor A Mus musculus 51-55 12538631-9 2003 VEGF secretion into medium was increased in MC3T3-E1 by 10(-6) M simvastatin. Simvastatin 65-76 vascular endothelial growth factor A Mus musculus 0-4 12538631-10 2003 Pretreating MC3T3-E1 cells with mevalonate or geranylgeranyl pyrophosphate, a mevalonate metabolite, abolished simvastatin-induced VEGF mRNA expression; manumycin A, a protein prenylation inhibitor, mimicked statin effects on VEGF expression. Simvastatin 111-122 vascular endothelial growth factor A Mus musculus 131-135 12538631-10 2003 Pretreating MC3T3-E1 cells with mevalonate or geranylgeranyl pyrophosphate, a mevalonate metabolite, abolished simvastatin-induced VEGF mRNA expression; manumycin A, a protein prenylation inhibitor, mimicked statin effects on VEGF expression. Simvastatin 111-122 vascular endothelial growth factor A Mus musculus 226-230 12535662-0 2003 Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 23-27 12535662-9 2003 These results strongly suggest that p44/p42 MAP kinase plays a role at least partly in the simvastatin-stimulated VEGF release in vascular smooth muscle cells. Simvastatin 91-102 mitogen activated protein kinase 3 Rattus norvegicus 36-39 12535662-0 2003 Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 40-43 12535662-2 2003 In the present study, we investigated the effect of simvastatin on vascular endothelial growth factor (VEGF) release, and the underlying mechanism, in a rat aortic smooth muscle cell line, A10 cells. Simvastatin 52-63 vascular endothelial growth factor A Rattus norvegicus 67-101 12535662-2 2003 In the present study, we investigated the effect of simvastatin on vascular endothelial growth factor (VEGF) release, and the underlying mechanism, in a rat aortic smooth muscle cell line, A10 cells. Simvastatin 52-63 vascular endothelial growth factor A Rattus norvegicus 103-107 12535662-3 2003 Administration of simvastatin increased the VEGF level in rat plasma in vivo. Simvastatin 18-29 vascular endothelial growth factor A Rattus norvegicus 44-48 12535662-9 2003 These results strongly suggest that p44/p42 MAP kinase plays a role at least partly in the simvastatin-stimulated VEGF release in vascular smooth muscle cells. Simvastatin 91-102 vascular endothelial growth factor A Rattus norvegicus 114-118 12535662-4 2003 In cultured cells, simvastatin significantly stimulated VEGF release in a dose-dependent manner. Simvastatin 19-30 vascular endothelial growth factor A Rattus norvegicus 56-60 12535662-5 2003 Simvastatin induced the phosphorylation of p44/p42 MAP kinase but not p38 MAP kinase or SAPK (stress-activated protein kinase)/JNK (c-Jun N-terminal kinase). Simvastatin 0-11 mitogen activated protein kinase 3 Rattus norvegicus 43-46 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. Simvastatin 115-126 mitogen activated protein kinase 3 Rattus norvegicus 69-72 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. Simvastatin 115-126 vascular endothelial growth factor A Rattus norvegicus 135-139 12535662-7 2003 The phosphorylation of p44/p42 MAP kinase induced by simvastatin was reduced by PD98059 or U-0126. Simvastatin 53-64 mitogen activated protein kinase 3 Rattus norvegicus 23-26 12535662-8 2003 Moreover, a bolus injection of PD98059 truly suppressed the simvastatin-increased VEGF level in rat plasma in vivo. Simvastatin 60-71 vascular endothelial growth factor A Rattus norvegicus 82-86 12603176-2 2003 PURPOSE: To investigate in vivo the mutual pharmacokinetic interactions between bosentan and simvastatin, a CYP3A4 substrate. Simvastatin 93-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-114 12524225-3 2003 METHODS AND RESULTS: Simvastatin, atorvastatin, and lovastatin (0.1 to 10 micro mol/L) inhibited the binding of nuclear proteins to both the nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) DNA consensus oligonucleotides in human endothelial and vascular smooth muscle cells as assessed by electrophoretic mobility shift assay (EMSA). Simvastatin 21-32 nuclear factor kappa B subunit 1 Homo sapiens 141-163 12524225-3 2003 METHODS AND RESULTS: Simvastatin, atorvastatin, and lovastatin (0.1 to 10 micro mol/L) inhibited the binding of nuclear proteins to both the nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) DNA consensus oligonucleotides in human endothelial and vascular smooth muscle cells as assessed by electrophoretic mobility shift assay (EMSA). Simvastatin 21-32 nuclear factor kappa B subunit 1 Homo sapiens 165-174 12524225-3 2003 METHODS AND RESULTS: Simvastatin, atorvastatin, and lovastatin (0.1 to 10 micro mol/L) inhibited the binding of nuclear proteins to both the nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) DNA consensus oligonucleotides in human endothelial and vascular smooth muscle cells as assessed by electrophoretic mobility shift assay (EMSA). Simvastatin 21-32 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 180-199 12524225-3 2003 METHODS AND RESULTS: Simvastatin, atorvastatin, and lovastatin (0.1 to 10 micro mol/L) inhibited the binding of nuclear proteins to both the nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) DNA consensus oligonucleotides in human endothelial and vascular smooth muscle cells as assessed by electrophoretic mobility shift assay (EMSA). Simvastatin 21-32 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 201-205 12504834-9 2003 Simvastatin markedly attenuated ox-LDL-induced MAPK activation, and concurrently reduced ACE expression (P<0.01 vs. ox-LDL alone). Simvastatin 0-11 angiotensin I converting enzyme Homo sapiens 89-92 12504834-11 2003 Simvastatin, which inhibits MAPK activation, also blocks ox-LDL-mediated upregulation of ACE. Simvastatin 0-11 angiotensin I converting enzyme Homo sapiens 89-92 12637115-15 2003 CONCLUSIONS: Atorvastatin 20 or 40 mg/d for up to 1 year of treatment was significantly more effective than simvastatin 20 or 40 mg/d in reducing LDL-C and TG levels and at achieving recommended lipid targets in this selected patient population with cardiovascular disease and dyslipidemia. Simvastatin 108-119 component of oligomeric golgi complex 2 Homo sapiens 146-151 12945719-7 2003 A significant reduction in spontaneous apoptosis of peripheral blood lymphocytes and expression of CD69 and HLA-DR was observed in SLE patients after simvastatin therapy. Simvastatin 150-161 CD69 molecule Homo sapiens 99-103 14755972-2 2003 In our study, from HMG-CoA reductase"s known inhibitors, we used simvastatin (ZOCOR), which is a semi synthetic derivative of the second generation. Simvastatin 65-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-36 14755972-2 2003 In our study, from HMG-CoA reductase"s known inhibitors, we used simvastatin (ZOCOR), which is a semi synthetic derivative of the second generation. Simvastatin 78-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-36 12472772-7 2003 Tumor necrosis factor-alpha (TNF-alpha)-primed neutrophils released 26.7 +/- 2.8 nmol O2-/0.75 x 106 PMN/45 min and 10 micromol/L simvastatin reduced this amount to 18.0 +/- 2.1 nmol. Simvastatin 130-141 tumor necrosis factor Homo sapiens 0-27 12472772-7 2003 Tumor necrosis factor-alpha (TNF-alpha)-primed neutrophils released 26.7 +/- 2.8 nmol O2-/0.75 x 106 PMN/45 min and 10 micromol/L simvastatin reduced this amount to 18.0 +/- 2.1 nmol. Simvastatin 130-141 tumor necrosis factor Homo sapiens 29-38 12472772-14 2003 By FACS, simvastatin decreased TNF-alpha-mediated ANCA antigen translocation (from 219 +/- 33 to 180 +/- 35 MFI for PR3 and 24.0 +/- 2.4 to 18.3 +/- 1.1 for MPO). Simvastatin 9-20 tumor necrosis factor Homo sapiens 31-40 12472772-14 2003 By FACS, simvastatin decreased TNF-alpha-mediated ANCA antigen translocation (from 219 +/- 33 to 180 +/- 35 MFI for PR3 and 24.0 +/- 2.4 to 18.3 +/- 1.1 for MPO). Simvastatin 9-20 proteinase 3 Homo sapiens 116-119 12472772-14 2003 By FACS, simvastatin decreased TNF-alpha-mediated ANCA antigen translocation (from 219 +/- 33 to 180 +/- 35 MFI for PR3 and 24.0 +/- 2.4 to 18.3 +/- 1.1 for MPO). Simvastatin 9-20 myeloperoxidase Homo sapiens 157-160 12856828-1 2003 Simvastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-determining enzyme for cholesterol synthesis which is used in the treatment of hypercholesterolemias, particularly in type IIa and IIb hyperlipoproteinemias, frequently in postmenopausal women. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-99 14755972-4 2003 Under treatment with simvastatin we obtained a significant decrease of total cholesterol (p < 0.0001) and an improvement of enzymatic antioxidant parameters: superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). Simvastatin 21-32 superoxide dismutase 1 Homo sapiens 161-181 14755972-4 2003 Under treatment with simvastatin we obtained a significant decrease of total cholesterol (p < 0.0001) and an improvement of enzymatic antioxidant parameters: superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). Simvastatin 21-32 superoxide dismutase 1 Homo sapiens 183-186 14755972-4 2003 Under treatment with simvastatin we obtained a significant decrease of total cholesterol (p < 0.0001) and an improvement of enzymatic antioxidant parameters: superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). Simvastatin 21-32 catalase Homo sapiens 223-231 14755972-4 2003 Under treatment with simvastatin we obtained a significant decrease of total cholesterol (p < 0.0001) and an improvement of enzymatic antioxidant parameters: superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). Simvastatin 21-32 catalase Homo sapiens 233-236 14755972-5 2003 In conclusion, simvastatin therapy determines a significant decrease in SOD, GPx, CAT, and an increase in CAT/SOD and GPx/SOD ratios. Simvastatin 15-26 superoxide dismutase 1 Homo sapiens 72-75 14755972-5 2003 In conclusion, simvastatin therapy determines a significant decrease in SOD, GPx, CAT, and an increase in CAT/SOD and GPx/SOD ratios. Simvastatin 15-26 catalase Homo sapiens 82-85 12384510-6 2002 Simvastatin increased RhoB protein levels by 8- to 10-fold. Simvastatin 0-11 ras homolog family member B Homo sapiens 22-26 14755972-5 2003 In conclusion, simvastatin therapy determines a significant decrease in SOD, GPx, CAT, and an increase in CAT/SOD and GPx/SOD ratios. Simvastatin 15-26 catalase Homo sapiens 106-109 14755972-5 2003 In conclusion, simvastatin therapy determines a significant decrease in SOD, GPx, CAT, and an increase in CAT/SOD and GPx/SOD ratios. Simvastatin 15-26 superoxide dismutase 1 Homo sapiens 110-113 14755972-5 2003 In conclusion, simvastatin therapy determines a significant decrease in SOD, GPx, CAT, and an increase in CAT/SOD and GPx/SOD ratios. Simvastatin 15-26 superoxide dismutase 1 Homo sapiens 110-113 12384510-10 2002 Simvastatin moderately augmented RhoB transcript levels, but markedly impaired the degradation of RhoB protein, which accumulated in the cytosol in its non-isoprenylated form. Simvastatin 0-11 ras homolog family member B Homo sapiens 33-37 12384510-10 2002 Simvastatin moderately augmented RhoB transcript levels, but markedly impaired the degradation of RhoB protein, which accumulated in the cytosol in its non-isoprenylated form. Simvastatin 0-11 ras homolog family member B Homo sapiens 98-102 12384510-11 2002 Inhibition of RhoB isoprenylation was apparently required for simvastatin-induced up-regulation, because levels of an isoprenylation-deficient RhoB mutant were not affected by simvastatin. Simvastatin 62-73 ras homolog family member B Homo sapiens 14-18 12384510-11 2002 Inhibition of RhoB isoprenylation was apparently required for simvastatin-induced up-regulation, because levels of an isoprenylation-deficient RhoB mutant were not affected by simvastatin. Simvastatin 62-73 ras homolog family member B Homo sapiens 143-147 12471052-8 2002 Levels of hAFP in culture medium and in serum were increased by simvastatin, a drug known to up-regulate LDLR. Simvastatin 64-75 alpha fetoprotein Homo sapiens 10-14 12505222-1 2002 OBJECTIVES: This study was designed to determine whether simvastatin improves endothelial function in children with familial hypercholesterolemia (FH). Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 116-145 12505222-1 2002 OBJECTIVES: This study was designed to determine whether simvastatin improves endothelial function in children with familial hypercholesterolemia (FH). Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 147-149 12505222-5 2002 Children with FH were randomized to receive simvastatin or placebo for 28 weeks. Simvastatin 44-55 low density lipoprotein receptor Homo sapiens 14-16 12505222-8 2002 In the simvastatin FH group, FMD improved significantly, whereas the FMD remained unaltered in the placebo FH group throughout the study period (absolute increase 3.9% +/- 4.3% vs. 1.2% +/- 3.9%, p < 0.05). Simvastatin 7-18 low density lipoprotein receptor Homo sapiens 19-21 12505222-9 2002 In the simvastatin FH group, FMD increased to a level similar to the non-FH controls (15.6% +/- 6.8% vs. 15.5% +/- 5.4%, p = 0.958). Simvastatin 7-18 low density lipoprotein receptor Homo sapiens 19-21 12505222-10 2002 Upon treatment, the simvastatin FH group showed significant absolute reductions of total cholesterol (TC) (-2.16 +/- 1.04 mmol/l, 30.1%) and low-density lipoprotein cholesterol (LDL-C) (-2.13 +/- 0.99 mmol/l, 39.8%). Simvastatin 20-31 low density lipoprotein receptor Homo sapiens 32-34 12505222-12 2002 CONCLUSIONS: Our data show significant improvement of endothelial dysfunction towards normal levels after short-term simvastatin therapy in children with FH. Simvastatin 117-128 low density lipoprotein receptor Homo sapiens 154-156 12471052-8 2002 Levels of hAFP in culture medium and in serum were increased by simvastatin, a drug known to up-regulate LDLR. Simvastatin 64-75 low density lipoprotein receptor Mus musculus 105-109 12371961-3 2002 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on the expression of t-PA and PAI-1. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-106 12433810-2 2002 Treatment of 2- to 3-day-old human hepatocyte cultures with 3 x 10(-5) M lovastatin, simvastatin, fluvastatin, or atorvastatin for 24 h increased the amounts of CYP2B6 and CYP3A mRNA by an average of 3.8- to 9.2-fold and 24- to 36-fold, respectively. Simvastatin 85-96 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 161-167 12433810-2 2002 Treatment of 2- to 3-day-old human hepatocyte cultures with 3 x 10(-5) M lovastatin, simvastatin, fluvastatin, or atorvastatin for 24 h increased the amounts of CYP2B6 and CYP3A mRNA by an average of 3.8- to 9.2-fold and 24- to 36-fold, respectively. Simvastatin 85-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 172-177 12468796-0 2002 Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 22-55 12468796-2 2002 Simvastatin increases eNOS activity. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 22-26 12468796-3 2002 We hypothesized that simvastatin would increase eNOS protein and ameliorate SAH-induced cerebral vasospasm. Simvastatin 21-32 nitric oxide synthase 3, endothelial cell Mus musculus 48-52 12468796-9 2002 Simvastatin pretreatment also increased eNOS protein. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 40-44 12427649-6 2002 8-Iso-PGF(2alpha) was significantly reduced by simvastatin, from 361+/-148 pg/mg creatinine (mean+/-SD) at baseline to 239+/-124 pg/mg creatinine after 1 month. Simvastatin 47-58 placental growth factor Homo sapiens 6-9 12398959-7 2002 Treatment with simvastatin 20, 40, and 80 mg led to significant reductions in CRP plasma levels versus placebo (p <0.05). Simvastatin 15-26 C-reactive protein Homo sapiens 78-81 12398959-10 2002 In summary, simvastatin significantly reduced CRP in patients with mixed hyperlipidemia and hypertriglyceridemia. Simvastatin 12-23 C-reactive protein Homo sapiens 46-49 12426212-0 2002 Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Simvastatin 0-11 apolipoprotein E Mus musculus 57-61 12426212-1 2002 OBJECTIVE: This study sought to determine whether simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has stabilizing effects on vulnerable atherosclerotic plaques that are independent of their lipid-lowering capabilities. Simvastatin 50-61 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 65-112 12426212-2 2002 METHODS AND RESULTS: Simvastatin (50 mg/kg per day) was administered to 30-week-old apolipoprotein E-deficient mice exhibiting advanced unstable atherosclerotic lesions within the innominate/brachiocephalic artery. Simvastatin 21-32 apolipoprotein E Mus musculus 84-100 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 149-160 serpin family E member 1 Homo sapiens 230-235 12371961-8 2002 Northern blot analysis revealed that the action of simvastatin on t-PA and PAI-1 expression in HMC can be explained by parallel changes in t-PA and PAI-1 mRNA. Simvastatin 51-62 plasminogen activator, tissue type Homo sapiens 66-70 12371961-8 2002 Northern blot analysis revealed that the action of simvastatin on t-PA and PAI-1 expression in HMC can be explained by parallel changes in t-PA and PAI-1 mRNA. Simvastatin 51-62 serpin family E member 1 Homo sapiens 75-80 12371961-8 2002 Northern blot analysis revealed that the action of simvastatin on t-PA and PAI-1 expression in HMC can be explained by parallel changes in t-PA and PAI-1 mRNA. Simvastatin 51-62 plasminogen activator, tissue type Homo sapiens 139-143 12371961-8 2002 Northern blot analysis revealed that the action of simvastatin on t-PA and PAI-1 expression in HMC can be explained by parallel changes in t-PA and PAI-1 mRNA. Simvastatin 51-62 serpin family E member 1 Homo sapiens 148-153 12371961-9 2002 The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates. Simvastatin 15-26 plasminogen activator, tissue type Homo sapiens 138-142 12371961-9 2002 The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates. Simvastatin 15-26 serpin family E member 1 Homo sapiens 147-152 12371961-9 2002 The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates. Simvastatin 123-134 plasminogen activator, tissue type Homo sapiens 138-142 12371961-9 2002 The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates. Simvastatin 123-134 serpin family E member 1 Homo sapiens 147-152 12499611-5 2002 Simvastatin reduced serum concentrations of total cholesterol (TC), low-density lipoprotein- cholesterol (LDL-C) and triglyceride (TG), by 18.4%, 26.8% and 16.1% on average, respectively, during the treatment period. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 68-104 12499611-5 2002 Simvastatin reduced serum concentrations of total cholesterol (TC), low-density lipoprotein- cholesterol (LDL-C) and triglyceride (TG), by 18.4%, 26.8% and 16.1% on average, respectively, during the treatment period. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 106-111 12417261-0 2002 Differential effect of simvastatin on activation of Rac(1) vs. activation of the heat shock protein 27-mediated pathway upon oxidative stress, in human smooth muscle cells. Simvastatin 23-34 Rac family small GTPase 1 Homo sapiens 52-58 12417261-4 2002 In these cells, simvastatin (S), an HMG-CoA reductase inhibitor, blocked, in a mevalonate-dependent way, oxidative stress-induced membrane translocation of Rac(1). Simvastatin 16-27 Rac family small GTPase 1 Homo sapiens 156-162 12398959-0 2002 Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Simvastatin 11-22 C-reactive protein Homo sapiens 26-44 12208479-10 2002 These results demonstrate that inhibition of cholesterol biosynthesis by lovastatin and simvastatin modifies the normal diurnal rhythm of cholesterol biosynthesis in female FH patients. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 173-175 12412808-3 2002 Additionally, oral simvastatin and lovastatin increased the cancellous bone volume in rats, presumably an effect of the increase of BMP-2. Simvastatin 19-30 bone morphogenetic protein 2 Rattus norvegicus 132-137 12371961-11 2002 The effects of simvastatin on t-PA and PAI-1 expression as well as on cell shape were completely mimicked by cytochalasin D, a disrupter of cellular actin filaments, but not by colchicine, a disrupter of microtubules. Simvastatin 15-26 plasminogen activator, tissue type Homo sapiens 30-34 12371961-11 2002 The effects of simvastatin on t-PA and PAI-1 expression as well as on cell shape were completely mimicked by cytochalasin D, a disrupter of cellular actin filaments, but not by colchicine, a disrupter of microtubules. Simvastatin 15-26 serpin family E member 1 Homo sapiens 39-44 12371961-3 2002 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on the expression of t-PA and PAI-1. Simvastatin 118-129 plasminogen activator, tissue type Homo sapiens 152-156 12371961-12 2002 CONCLUSIONS: In conclusion, the cholesterol-lowering drug simvastatin is an effective stimulator of local peritoneal fibrinolytic activity, as it increases t-PA and decreases PAI-1 production in mesothelial cells by a mechanism involving geranylgeranyl-modified intermediates and actin skeleton perturbation. Simvastatin 58-69 plasminogen activator, tissue type Homo sapiens 156-160 12371961-12 2002 CONCLUSIONS: In conclusion, the cholesterol-lowering drug simvastatin is an effective stimulator of local peritoneal fibrinolytic activity, as it increases t-PA and decreases PAI-1 production in mesothelial cells by a mechanism involving geranylgeranyl-modified intermediates and actin skeleton perturbation. Simvastatin 58-69 serpin family E member 1 Homo sapiens 175-180 12371961-3 2002 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on the expression of t-PA and PAI-1. Simvastatin 118-129 serpin family E member 1 Homo sapiens 161-166 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 9-20 plasminogen activator, tissue type Homo sapiens 67-71 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 9-20 serpin family E member 1 Homo sapiens 86-91 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 9-20 plasminogen activator, tissue type Homo sapiens 186-190 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 9-20 serpin family E member 1 Homo sapiens 230-235 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 149-160 plasminogen activator, tissue type Homo sapiens 67-71 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 149-160 serpin family E member 1 Homo sapiens 86-91 12371961-5 2002 RESULTS: Simvastatin time- and concentration-dependently increased t-PA and decreased PAI-1 synthesis, reaching maximal effects after 48 hours, when simvastatin (1 micromol/L) increased t-PA levels 5.1 +/- 0.1-fold and suppressed PAI-1 levels 2.6 +/- 0.2-fold. Simvastatin 149-160 plasminogen activator, tissue type Homo sapiens 186-190 12508427-1 2002 OBJECTIVE: To study the effect of simvastatin on the expression of bone morphogenetic protein-2 (BMP-2) and alkaline phosphates (ALP) activity in the primary cultured bone marrow stromal cells, and to elucidate the mechanism of the anabolic osteogenetic effect of simvastatin. Simvastatin 34-45 bone morphogenetic protein 2 Homo sapiens 97-102 12404199-9 2002 Apolipoprotein (Apo) B was decreased by simvastatin (-25%, P <.001) and by CEE (-10%, P <.05); again, simvastatin was more effective than either diet or ETP. Simvastatin 40-51 apolipoprotein B Homo sapiens 0-22 12404199-9 2002 Apolipoprotein (Apo) B was decreased by simvastatin (-25%, P <.001) and by CEE (-10%, P <.05); again, simvastatin was more effective than either diet or ETP. Simvastatin 108-119 apolipoprotein B Homo sapiens 0-22 12404199-11 2002 HDL-C and Apo A-I significantly increased in the simvastatin group (+18% and +8%, respectively), while HDL-C was unmodified by both HRT regimens and Apo A-I was reduced by ETP treatment (-17%); lipoprotein[a] (Lp[a]) was decreased by both HRTs (-38%, P <.05, and -22%, P =.07, for CEE and ETP, respectively). Simvastatin 49-60 apolipoprotein A1 Homo sapiens 10-17 12477621-0 2002 Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. Simvastatin 0-11 C-reactive protein Homo sapiens 61-79 12423572-6 2002 Simvastatin treatment upregulated eNOS expression and reduced the interaction of cytosolic protein with the 3"-untranslated region of eNOS mRNA. Simvastatin 0-11 nitric oxide synthase, endothelial Oryctolagus cuniculus 34-38 12423572-6 2002 Simvastatin treatment upregulated eNOS expression and reduced the interaction of cytosolic protein with the 3"-untranslated region of eNOS mRNA. Simvastatin 0-11 nitric oxide synthase, endothelial Oryctolagus cuniculus 134-138 12508427-0 2002 [Effect of simvastatin on bone morphogenetic protein-2 expression and alkaline phosphatase activity of bone marrow stromal cell]. Simvastatin 11-22 bone morphogenetic protein 2 Homo sapiens 26-54 12204807-9 2002 In conclusion, FH patients with the worst lipoprotein profile showed the greatest benefit from high-dose simvastatin treatment, since changes in these parameters were partly determined by baseline lipid levels. Simvastatin 105-116 low density lipoprotein receptor Homo sapiens 15-17 12508427-1 2002 OBJECTIVE: To study the effect of simvastatin on the expression of bone morphogenetic protein-2 (BMP-2) and alkaline phosphates (ALP) activity in the primary cultured bone marrow stromal cells, and to elucidate the mechanism of the anabolic osteogenetic effect of simvastatin. Simvastatin 34-45 bone morphogenetic protein 2 Homo sapiens 67-95 12508427-5 2002 RESULTS: After treated with simvastatin for 72 hours, BMP-2 expression increased, while little BMP-2 expression could be observed in the control group. Simvastatin 28-39 bone morphogenetic protein 2 Homo sapiens 54-59 12508427-5 2002 RESULTS: After treated with simvastatin for 72 hours, BMP-2 expression increased, while little BMP-2 expression could be observed in the control group. Simvastatin 28-39 bone morphogenetic protein 2 Homo sapiens 95-100 12508427-7 2002 CONCLUSION: Simvastatin lead to high expression of BMP-2 in bone marrow stromal cells, via the increased auto- or para-crine of BMP-2, and ALP activity increased. Simvastatin 12-23 bone morphogenetic protein 2 Homo sapiens 51-56 12508427-7 2002 CONCLUSION: Simvastatin lead to high expression of BMP-2 in bone marrow stromal cells, via the increased auto- or para-crine of BMP-2, and ALP activity increased. Simvastatin 12-23 bone morphogenetic protein 2 Homo sapiens 128-133 12438947-0 2002 Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 70-73 12438947-4 2002 Simvastatin activates Akt in mammalian cells; therefore, we investigated the role of simvastatin on human pancreatic islets (HPI) survival. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 22-25 12438947-11 2002 Akt activation; increase in islet viability; and decrease in Bad phosphorylation, cytochrome release, caspase-9 activation, and translocation of FKHR were observed after simvastatin treatment, effects reversed by LY294002. Simvastatin 170-181 AKT serine/threonine kinase 1 Homo sapiens 0-3 12390953-6 2002 After 48 weeks of simvastatin therapy, there were significant reductions of LDL cholesterol (-41%), total cholesterol (-31%), apolipoprotein B (-34%), VLDL cholesterol (-21%), and triglyceride (-9%) levels. Simvastatin 18-29 apolipoprotein B Homo sapiens 126-142 12390953-10 2002 CONCLUSIONS: Simvastatin significantly reduced LDL cholesterol, total cholesterol, triglyceride, VLDL cholesterol, and apolipoprotein B levels and was well tolerated in children with heFH. Simvastatin 13-24 apolipoprotein B Homo sapiens 119-135 12379583-0 2002 Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Simvastatin 53-64 HRas proto-oncogene, GTPase Rattus norvegicus 136-142 12379583-8 2002 In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1). Simvastatin 32-35 mitogen activated protein kinase 1 Rattus norvegicus 116-120 12379583-8 2002 In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1). Simvastatin 32-35 cyclin-dependent kinase 4 Rattus norvegicus 152-156 12379583-8 2002 In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1). Simvastatin 32-35 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 157-160 12379583-8 2002 In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1). Simvastatin 32-35 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 161-165 12204807-0 2002 Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. Simvastatin 65-76 low density lipoprotein receptor Homo sapiens 94-123 12438947-11 2002 Akt activation; increase in islet viability; and decrease in Bad phosphorylation, cytochrome release, caspase-9 activation, and translocation of FKHR were observed after simvastatin treatment, effects reversed by LY294002. Simvastatin 170-181 caspase 9 Homo sapiens 102-111 12375804-5 2002 At a 4-month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). Simvastatin 22-33 C-reactive protein Homo sapiens 42-45 12375804-8 2002 Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 30-33 12119202-0 2002 Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Simvastatin 30-41 apolipoprotein B Homo sapiens 45-61 12386648-1 2002 Simvastatin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a commonly used cholesterol-lowering agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-67 12352324-5 2002 In addition, simvastatin inhibited the translocation of p21 rac 2 and p67, suggesting that geranylgeranylation is required for NADPH oxidase activation. Simvastatin 13-24 Rac family small GTPase 2 Homo sapiens 56-65 12352324-5 2002 In addition, simvastatin inhibited the translocation of p21 rac 2 and p67, suggesting that geranylgeranylation is required for NADPH oxidase activation. Simvastatin 13-24 CD33 molecule Homo sapiens 70-73 12234946-0 2002 Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Simvastatin 0-11 C-reactive protein Homo sapiens 19-37 12234946-2 2002 The purpose of this study was to determine the rate at which highly sensitive C-reactive protein (hsCRP) levels change after initiation of simvastatin and whether this occurs independently of the change in LDL cholesterol. Simvastatin 139-150 C-reactive protein Homo sapiens 78-96 12119202-1 2002 Subjects with moderate combined hyperlipidemia (n=11) were assessed in an investigation of the effects of atorvastatin and simvastatin (both 40 mg per day) on apolipoprotein B (apoB) metabolism. Simvastatin 123-134 apolipoprotein B Homo sapiens 159-175 12119202-6 2002 Both drugs stimulated direct catabolism of large very low density lipoprotein (VLDL(1)) apoB (4.52+/-3.06 pools per day on atorvastatin; 5.48+/-4.76 pools per day on simvastatin versus 2.26+/-1.65 pools per day at baseline (both P<0.05)) and this was the basis of the 50% reduction in plasma VLDL(1) concentration; apoB production in this fraction was not significantly altered. Simvastatin 166-177 apolipoprotein B Homo sapiens 88-92 12119202-8 2002 IDL apoB direct catabolism rose from 0.54+/-0.30 pools per day at baseline to 1.17+/-0.87 pools per day on atorvastatin and to 0.95+/-0.43 pools per day on simvastatin (both P<0.05). Simvastatin 156-167 apolipoprotein B Homo sapiens 4-8 12119202-9 2002 Similarly the fractional transfer rate for IDL to LDL conversion was enhanced 58-84% by statin treatment (P<0.01) LDL apoB fractional catabolic rate (FCR) which was low at baseline in these subjects (0.22+/-0.04 pools per day) increased to 0.44+/-0.11 pools per day on atorvastatin and 0.38+/-0.11 pools per day on simvastatin (both P<0.01). Simvastatin 318-329 apolipoprotein B Homo sapiens 121-125 12119202-13 2002 We conclude that in patients with moderate combined hyperlipidemia who initially have a low FCR for VLDL and LDL apoB, the principal action of atorvastatin and simvastatin is to stimulate receptor-mediated catabolism across the spectrum of apoB-containing lipoproteins. Simvastatin 160-171 apolipoprotein B Homo sapiens 113-117 12119202-13 2002 We conclude that in patients with moderate combined hyperlipidemia who initially have a low FCR for VLDL and LDL apoB, the principal action of atorvastatin and simvastatin is to stimulate receptor-mediated catabolism across the spectrum of apoB-containing lipoproteins. Simvastatin 160-171 apolipoprotein B Homo sapiens 240-244 12410059-7 2002 In patients with chronic renal failure, co-administration of colchicine with simvastatin may accelerate the onset of myopathy because CYP3A4 (part of cytochrome P450) is crucial in the breakdown of both drugs. Simvastatin 77-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 134-140 12124226-5 2002 Moreover, simvastatin increased (P < 0.05) endothelial NO synthase (eNOS) protein content by >200% (82.0 +/- 14.0 vs. 21.6 +/- 7.9% II/microg). Simvastatin 10-21 nitric oxide synthase 3 Rattus norvegicus 71-75 12172079-4 2002 METHODS: The effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-dependent genes were compared with the effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-independent genes. Simvastatin 38-49 sterol regulatory element binding transcription factor 1 Homo sapiens 82-90 12172079-4 2002 METHODS: The effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-dependent genes were compared with the effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-independent genes. Simvastatin 155-166 sterol regulatory element binding transcription factor 1 Homo sapiens 199-207 12172079-6 2002 Simvastatin antagonized the indinavir-induced SREBP-1c-inhibition. Simvastatin 0-11 sterol regulatory element binding transcription factor 1 Homo sapiens 46-54 12124226-6 2002 In cultured endothelial cells, simvastatin (10 and 20 microM) increased eNOS levels by 114.7 +/- 39.9 and 212.0 +/- 75.0% II/microg protein, respectively (both P < 0.05; n = 8). Simvastatin 31-42 nitric oxide synthase 3 Rattus norvegicus 72-76 12124226-11 2002 In conclusion, chronic treatment of CHF with simvastatin restores endothelial NO-dependent dysfunction and upregulates eNOS protein content in arterial tissue. Simvastatin 45-56 nitric oxide synthase 3 Rattus norvegicus 119-123 12130721-4 2002 We examined the modulation of LOX-1 expression and its function by two different statins, simvastatin and atorvastatin, in human coronary artery endothelial cells (HCAECs). Simvastatin 90-101 oxidized low density lipoprotein receptor 1 Homo sapiens 30-35 12154104-0 2002 Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Simvastatin 0-11 angiotensinogen Rattus norvegicus 21-35 12154104-1 2002 The influence of the HMG-CoA reductase inhibitor simvastatin was assessed on the cardiovascular alterations and production of free radicals associated with chronic angiotensin II (Ang II) infusion. Simvastatin 49-60 angiotensinogen Rattus norvegicus 164-178 12154104-1 2002 The influence of the HMG-CoA reductase inhibitor simvastatin was assessed on the cardiovascular alterations and production of free radicals associated with chronic angiotensin II (Ang II) infusion. Simvastatin 49-60 angiotensinogen Rattus norvegicus 180-186 12154104-2 2002 Simvastatin (60 mg/kg per day PO) or placebo were given concomitantly for 10 days in Sprague-Dawley rats infused with Ang II (200 ng/kg per minute SC, osmotic pump). Simvastatin 0-11 angiotensinogen Rattus norvegicus 118-124 12154104-7 2002 Increases in heart weight index and carotid cross-sectional area induced by Ang II were obliterated by simvastatin (3.18+/-0.09 versus 3.46+/-0.11 mg/g body wt and 0.125+/-0.010 versus 0.177+/-0.010 mm2, respectively). Simvastatin 103-114 angiotensinogen Rattus norvegicus 76-82 12154104-8 2002 The Ang II-induced increases in leukocyte and aortic production of ROS as well as protein and lipid oxidation products were prevented by simvastatin. Simvastatin 137-148 angiotensinogen Rattus norvegicus 4-10 12154104-10 2002 These results indicate that simvastatin prevented the development of hypertension and cardiovascular hypertrophy together with inhibition of the induced angiotensin II production of ROS. Simvastatin 28-39 angiotensinogen Rattus norvegicus 153-167 12130721-7 2002 Pretreatment of HCAECs with simvastatin or atorvastatin (1 and 10 microM) reduced ox-LDL-induced expression of LOX-1 as well as adhesion molecules (all P < 0.05). Simvastatin 28-39 oxidized low density lipoprotein receptor 1 Homo sapiens 111-116 12142347-8 2002 The expression of a dominant-activating RhoA mutant reversed the effect of simvastatin on tube formation. Simvastatin 75-86 ras homolog family member A Homo sapiens 40-44 12142347-3 2002 In vivo, the HMG-CoA reductase inhibitor simvastatin dose-dependently inhibited capillary growth in both vascular endothelial growth factor-stimulated chick chorioallantoic membranes and basic fibroblast growth factor-stimulated mouse corneas. Simvastatin 41-52 vascular endothelial growth factor A Homo sapiens 105-139 12324225-3 2002 Using labelled substrates and radio HPLC separations, we observed that the potent hypocholesterolemic agent, simvastatin, activates the formation of AA from LA, mainly acting at the delta5 desaturation step, and increases also the mRNA levels, in cultured monocytic cells (THP-1). Simvastatin 109-120 GLI family zinc finger 2 Homo sapiens 273-278 12144930-4 2002 We now explored the effect of two different statins, simvastatin and atorvastatin, in the activation of the octamer transcription factor Oct-1 on the monocytic cell line THP-1. Simvastatin 53-64 POU class 2 homeobox 1 Homo sapiens 137-142 12144930-4 2002 We now explored the effect of two different statins, simvastatin and atorvastatin, in the activation of the octamer transcription factor Oct-1 on the monocytic cell line THP-1. Simvastatin 53-64 GLI family zinc finger 2 Homo sapiens 170-175 12144930-13 2002 Our results indicate that simvastatin and atorvastatin increase the activity of the transcriptional repressor Oct-1 in mononuclear cells, and could thus contribute to decrease the activation of these cells. Simvastatin 26-37 POU class 2 homeobox 1 Homo sapiens 110-115 12093764-7 2002 Simvastatin treatment was associated with reduced cellular proliferation (BrdU), leukocyte accumulation (CD45), and platelet-derived growth factor-induced phosphorylation of the survival factor Akt and increased apoptosis after injury. Simvastatin 0-11 protein tyrosine phosphatase, receptor type, C Mus musculus 105-109 12093764-0 2002 Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Simvastatin 0-11 low density lipoprotein receptor Mus musculus 45-77 12093764-7 2002 Simvastatin treatment was associated with reduced cellular proliferation (BrdU), leukocyte accumulation (CD45), and platelet-derived growth factor-induced phosphorylation of the survival factor Akt and increased apoptosis after injury. Simvastatin 0-11 thymoma viral proto-oncogene 1 Mus musculus 194-197 12048122-0 2002 Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Simvastatin 0-11 apolipoprotein A1 Homo sapiens 84-101 12048122-3 2002 Cultured cells were incubated with different doses of simvastatin (0.1-10 microM) for a period of 18 h. A dose-dependent increase in synthesis and secretion of apoAI was observed in both cell types. Simvastatin 54-65 apolipoprotein A1 Homo sapiens 160-165 12048122-8 2002 Analysis of a density fraction containing HDL particles in culture media revealed an increase in HDL-associated apoAI of 94.3+/-2.1% in HepG2 cells and 27.0+/-0.03% in hamster hepatocytes following 10 microM simvastatin-treatment. Simvastatin 208-219 apolipoprotein A1 Homo sapiens 112-117 12048122-9 2002 Comparative studies of simvastatin and lovastatin indicated a differential ability to induce apoAI synthesis and secretion, with simvastatin having a more significant effect. Simvastatin 23-34 apolipoprotein A1 Homo sapiens 93-98 12117737-0 2002 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Simvastatin 0-11 interleukin 6 Homo sapiens 44-57 12048257-8 2002 Simvastatin reversed the down-regulation of p21 protein expression and decreased CDK4 and CDK2 kinase activities. Simvastatin 0-11 KRAS proto-oncogene, GTPase Rattus norvegicus 44-47 12117737-0 2002 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Simvastatin 0-11 C-X-C motif chemokine ligand 8 Homo sapiens 59-72 12117737-0 2002 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 78-112 12117737-4 2002 METHODS AND RESULTS: In this study, we asked whether simvastatin can influence in vitro and in vivo production of the proinflammatory cytokines interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1. Simvastatin 53-64 interleukin 6 Homo sapiens 144-162 12117737-4 2002 METHODS AND RESULTS: In this study, we asked whether simvastatin can influence in vitro and in vivo production of the proinflammatory cytokines interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1. Simvastatin 53-64 C-X-C motif chemokine ligand 8 Homo sapiens 164-168 12117737-7 2002 Furthermore, simvastatin decreased the expression of IL-6, IL-8, and monocyte chemoattractant protein-1 mRNA in peripheral blood mononuclear cells. Simvastatin 13-24 interleukin 6 Homo sapiens 53-57 12117737-7 2002 Furthermore, simvastatin decreased the expression of IL-6, IL-8, and monocyte chemoattractant protein-1 mRNA in peripheral blood mononuclear cells. Simvastatin 13-24 C-X-C motif chemokine ligand 8 Homo sapiens 59-63 12117737-7 2002 Furthermore, simvastatin decreased the expression of IL-6, IL-8, and monocyte chemoattractant protein-1 mRNA in peripheral blood mononuclear cells. Simvastatin 13-24 C-C motif chemokine ligand 2 Homo sapiens 69-103 12153549-2 2002 We now investigate the effect of an HMG-CoA reductase inhibitor (simvastatin) on chylomicron remnant metabolism using the measurement of fasting apoB-48 and RLP-C in FH patients after long- and short-term simvastatin therapy and after a wash-out period. Simvastatin 65-76 apolipoprotein B Homo sapiens 145-152 12153549-7 2002 RESULTS: Both long- and short-term treatment with simvastatin were associated with decreases in the plasma concentration of apoB-48 (P < 0.05) and RLP-C (P < 0.001), but there was no significant change in the FCR of the emulsion. Simvastatin 50-61 apolipoprotein B Homo sapiens 124-131 12153549-8 2002 CONCLUSIONS: We suggest that long- and short-term treatments with simvastatin have comparable effects in decreasing the plasma concentration of triglyceride-rich remnants in heterozygous FH, as measured by fasting apoB-48 and RLP-C. Simvastatin 66-77 apolipoprotein B Homo sapiens 214-221 12353340-7 2002 RESULTS: After 8 weeks of treatment, LDL-C concentrations were reduced by 42.5% from baseline in patients receiving atorvastatin and 34.8% in those receiving simvastatin (p = 0.0006). Simvastatin 158-169 component of oligomeric golgi complex 2 Homo sapiens 37-42 12353340-11 2002 After 16 weeks of treatment, 93% of atorvastatin and 85% of simvastatin patients had achieved their National Cholesterol Education Program LDL-C goals. Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 139-144 12096273-9 2002 RESULTS: Simvastatin dose dependently reduced neointima formation (P =.004) in association with reduced MMP-9 activity (P =.03). Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 104-109 12096273-13 2002 The ancillary properties of 3-Hydroxy-3 methylglutaryl CoA reductase inhibitors typified by simvastatin may be important in this regard. Simvastatin 92-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-68 12048257-8 2002 Simvastatin reversed the down-regulation of p21 protein expression and decreased CDK4 and CDK2 kinase activities. Simvastatin 0-11 cyclin-dependent kinase 4 Rattus norvegicus 81-85 12048257-8 2002 Simvastatin reversed the down-regulation of p21 protein expression and decreased CDK4 and CDK2 kinase activities. Simvastatin 0-11 cyclin dependent kinase 2 Rattus norvegicus 90-94 12048257-12 2002 Our data suggest that simvastatin represses the HG-induced Rho GTPase/p21 signaling in glomerular MCs. Simvastatin 22-33 KRAS proto-oncogene, GTPase Rattus norvegicus 70-73 11947894-0 2002 Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Simvastatin 31-42 apolipoprotein E Mus musculus 70-86 12067916-7 2002 Thrombin-activated platelets primed neutrophils for enhanced oxygen-free radical release on triggering with formyl-Met-Leu-Phe, reduced by cerivastatin and simvastatin treatment of platelets. Simvastatin 156-167 coagulation factor II, thrombin Homo sapiens 0-8 12031956-0 2002 Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Simvastatin 39-50 diacylglycerol O-acyltransferase 1 Rattus norvegicus 108-138 11947912-6 2002 Almost the same pattern was seen within both groups although the increase in VCAM-1 was only seen in the simvastatin group (P=0.017). Simvastatin 105-116 vascular cell adhesion molecule 1 Homo sapiens 77-83 12046033-0 2002 Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Simvastatin 11-22 albumin Homo sapiens 72-79 12046033-7 2002 In the treatment group, simvastatin administration for 8 weeks significantly reduced total cholesterol levels from 232 +/- 25 to 165 +/- 39 mg/dL (P < 0.001) and hs-CRP levels from a median of 0.23 mg/dL (range, 0.05 to 1.63 mg/dL) to 0.12 mg/dL (range, <0.006 to 1.45 mg/dL; P < 0.01), whereas it increased serum albumin levels from 3.4 +/- 0.3 to 3.6 +/- 0.4 g/dL (P < 0.001). Simvastatin 24-35 C-reactive protein Homo sapiens 168-171 12046033-7 2002 In the treatment group, simvastatin administration for 8 weeks significantly reduced total cholesterol levels from 232 +/- 25 to 165 +/- 39 mg/dL (P < 0.001) and hs-CRP levels from a median of 0.23 mg/dL (range, 0.05 to 1.63 mg/dL) to 0.12 mg/dL (range, <0.006 to 1.45 mg/dL; P < 0.01), whereas it increased serum albumin levels from 3.4 +/- 0.3 to 3.6 +/- 0.4 g/dL (P < 0.001). Simvastatin 24-35 albumin Homo sapiens 323-330 12031956-9 2002 In contrast, simvastatin markedly lowered overt DGAT activity without affecting that of latent DGAT. Simvastatin 13-24 diacylglycerol O-acyltransferase 1 Rattus norvegicus 48-52 12371384-6 2002 Truncated TFPI decreased significantly as early as after 1 month and total TFPI decreased after 3 months of the therapy with simvastatin. Simvastatin 125-136 tissue factor pathway inhibitor Homo sapiens 75-79 11947894-5 2002 Simvastatin treatment also improved acetylcholine (ACh)-induced endothelium-dependent vasorelaxation in isolated aortic rings, which was associated with an increase in NOS-3 expression by approximately 88% in the aorta measured by real time polymerase chain reaction (PCR), P<0.05. Simvastatin 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 168-173 11947894-7 2002 These results suggest that the therapeutic effects of simvastatin may depend on the presence of a functional apolipoprotein E. Simvastatin 54-65 apolipoprotein E Mus musculus 109-125 11967013-17 2002 Up-regulation of monocyte chemoattractant protein-1 (MCP-1) mRNA in PHN kidneys was not affected by lisinopril, it was inhibited by 30% after simvastatin, and almost completely normalized by lisinopril plus simvastatin. Simvastatin 142-153 C-C motif chemokine ligand 2 Rattus norvegicus 17-51 11967013-17 2002 Up-regulation of monocyte chemoattractant protein-1 (MCP-1) mRNA in PHN kidneys was not affected by lisinopril, it was inhibited by 30% after simvastatin, and almost completely normalized by lisinopril plus simvastatin. Simvastatin 142-153 C-C motif chemokine ligand 2 Rattus norvegicus 53-58 11967013-17 2002 Up-regulation of monocyte chemoattractant protein-1 (MCP-1) mRNA in PHN kidneys was not affected by lisinopril, it was inhibited by 30% after simvastatin, and almost completely normalized by lisinopril plus simvastatin. Simvastatin 207-218 C-C motif chemokine ligand 2 Rattus norvegicus 17-51 11967013-17 2002 Up-regulation of monocyte chemoattractant protein-1 (MCP-1) mRNA in PHN kidneys was not affected by lisinopril, it was inhibited by 30% after simvastatin, and almost completely normalized by lisinopril plus simvastatin. Simvastatin 207-218 C-C motif chemokine ligand 2 Rattus norvegicus 53-58 12023838-6 2002 Here we report that neointima formation in organ-cultured human SV segments is inhibited by simvastatin, an effect that is associated with reduced MMP-9 activity. Simvastatin 92-103 matrix metallopeptidase 9 Homo sapiens 147-152 12056585-4 2002 Atorvastatin and simvastatin enhanced not only HMG-CoA reductase but also the expression of the SREBP-2 gene itself. Simvastatin 17-28 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 47-64 12056585-4 2002 Atorvastatin and simvastatin enhanced not only HMG-CoA reductase but also the expression of the SREBP-2 gene itself. Simvastatin 17-28 sterol regulatory element binding transcription factor 2 Rattus norvegicus 96-103 12056585-7 2002 Simvastatin raised liver cholesterol content, ACAT mRNA levels, and CTP:phosphocholine cytidylyltransferase activity, whereas it reduced liver DAG and phospholipid content. Simvastatin 0-11 phosphate cytidylyltransferase 1A, choline Rattus norvegicus 68-107 11956113-5 2002 METHODS AND RESULTS: In human aortic endothelial cells, simvastatin prevented tissue factor induction by thrombin (4 U/mL) in a concentration-dependent manner. Simvastatin 56-67 coagulation factor II, thrombin Homo sapiens 105-113 11956113-12 2002 Simvastatin prevented thrombin-induced Rho A activation but not p38 MAP kinase activation. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 22-30 11956113-12 2002 Simvastatin prevented thrombin-induced Rho A activation but not p38 MAP kinase activation. Simvastatin 0-11 ras homolog family member A Homo sapiens 39-44 11956113-13 2002 Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632. Simvastatin 54-65 AKT serine/threonine kinase 1 Homo sapiens 0-3 11956113-13 2002 Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632. Simvastatin 54-65 coagulation factor II, thrombin Homo sapiens 25-33 11956113-15 2002 Simvastatin prevents its induction through inhibition of Rho/Rho-kinase and activation of Akt. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 90-93 12029990-10 2002 Simvastatin reduced serum concentrations of TC, LDL-C and TG by 18.4, 26.8 and 16.1%, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 48-53 12269393-1 2002 An evident fatty liver, corroborated morphologically and chemically, was produced in CD-1 mice after five daily doses of simvastatin 75 mg/Kg body weight, a hypercholesterolemic diet and 20 percent ethanol in the drinking water. Simvastatin 121-132 CD1 antigen complex Mus musculus 85-89 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-5 2002 Post hoc testing showed that the 29% increase in CRP on the combination of CEEs with simvastatin was significantly less than the 70% increase in CRP on CEEs alone (P<0.05). Simvastatin 85-96 C-reactive protein Homo sapiens 49-52 11882313-0 2002 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Simvastatin 78-89 BCL2 apoptosis regulator Homo sapiens 161-166 12017409-2 2002 OBJECTIVE: The goal of this study was to develop a preliminary pharmacodynamic model for dosing of the hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors simvastatin and atorvastatin using neural network analysis. Simvastatin 167-178 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 11882313-0 2002 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Simvastatin 78-89 ras homolog family member A Homo sapiens 182-187 11882313-2 2002 In this work, we demonstrate that treatment of VSMCs with simvastatin and atorvastatin inhibited Bcl-2 expression in a time and dose-dependent manner, while Bax expression was not modified. Simvastatin 58-69 BCL2 apoptosis regulator Homo sapiens 97-102 11829698-2 2002 OBJECTIVE: To evaluate the separate and combined effects of diet and simvastatin therapy on serum levels of lipids, lipoproteins, antioxidants, and insulin. Simvastatin 69-80 insulin Homo sapiens 148-155 11854137-1 2002 Simvastatin hydroxy acid (SVA), the pharmacologically active form of simvastatin (SV), is a potent inhibitor of 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase and is formed on hydrolysis of the orally administered SV. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 112-165 11902809-0 2002 Simvastatin and lovastatin, but not pravastatin, interact with MDR1. Simvastatin 0-11 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Sus scrofa 63-67 11835933-0 2002 Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Simvastatin 11-22 C-reactive protein Homo sapiens 58-76 11902809-5 2002 In conclusion, simvastatin and lovastatin are susceptible to interaction with or via MDR1, but pravastatin is not. Simvastatin 15-26 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Sus scrofa 85-89 11829698-11 2002 CONCLUSIONS: A modified Mediterranean-type diet rich in omega-3 fatty acids efficiently potentiated the cholesterol-lowering effect of simvastatin, counteracted the fasting insulin-elevating effect of simvastatin, and, unlike simvastatin, did not decrease serum levels of beta-carotene and ubiquinol-10. Simvastatin 201-212 insulin Homo sapiens 173-180 11829698-11 2002 CONCLUSIONS: A modified Mediterranean-type diet rich in omega-3 fatty acids efficiently potentiated the cholesterol-lowering effect of simvastatin, counteracted the fasting insulin-elevating effect of simvastatin, and, unlike simvastatin, did not decrease serum levels of beta-carotene and ubiquinol-10. Simvastatin 201-212 insulin Homo sapiens 173-180 11707442-7 2002 Furthermore, the inhibition of cholesterol synthesis with simvastatin resulted in a 3-4-fold increase in both SR-BI mRNA and protein levels, whereas conversely, addition of 25-hydroxycholesterol suppressed SR-BI levels by approximately 50%. Simvastatin 58-69 scavenger receptor class B member 1 Homo sapiens 110-115 11849659-0 2002 Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Simvastatin 90-101 low density lipoprotein receptor Homo sapiens 13-25 11849659-0 2002 Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Simvastatin 90-101 apolipoprotein E Homo sapiens 44-49 11849659-5 2002 Multiple regression analyses showed that there was a significant association between the apo E polymorphism and LDL-cholesterol response to simvastatin only among heterozygotes for a receptor-negative mutation. Simvastatin 140-151 apolipoprotein E Homo sapiens 89-94 11849659-8 2002 The results of the present study have shown that the contribution of apo E polymorphism and the dosage of simvastatin to the LDL-cholesterol responsiveness is influenced by the nature of the LDL receptor gene mutation. Simvastatin 106-117 low density lipoprotein receptor Homo sapiens 191-203 11866871-0 2002 Effects of simvastatin on activities of endogenous antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy. Simvastatin 11-22 angiotensin I converting enzyme Rattus norvegicus 75-104 11866871-1 2002 AIM: To investigate effects of simvastatin (Sim) on the activities of antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy. Simvastatin 31-42 angiotensin I converting enzyme Rattus norvegicus 94-123 11866871-1 2002 AIM: To investigate effects of simvastatin (Sim) on the activities of antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy. Simvastatin 44-47 angiotensin I converting enzyme Rattus norvegicus 94-123 11866871-8 2002 Activities of catalase and glutathione peroxidase of LV tissue in LVH group were decreased by 29 % and 23 % (P < 0.01) compared with sham-operated group, and were increased by 32 % and 22 % (P < 0.01) in high dosage Sim treatment group compared with LVH group. Simvastatin 222-225 catalase Rattus norvegicus 14-22 12557325-4 2002 CONCLUSION: Simvastatin can induce apoptosis in VSMC in associated with induction of bax and activation of caspase-3. Simvastatin 12-23 BCL2 associated X, apoptosis regulator Rattus norvegicus 85-88 12557325-4 2002 CONCLUSION: Simvastatin can induce apoptosis in VSMC in associated with induction of bax and activation of caspase-3. Simvastatin 12-23 caspase 3 Rattus norvegicus 107-116 15526536-2 2002 Because VLDL synthesis is related to other hepatic protein synthesis we studied the effect of Simvastatin upon serum cholinesterase activity and factor VII activity, which are also synthetized at hepatic level. Simvastatin 94-105 butyrylcholinesterase Homo sapiens 117-131 11815421-0 2002 Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Simvastatin 0-11 DEAD-box helicase 4 Sus scrofa 60-64 11815421-8 2002 Coronary artery tissue expression of VEGF was increased in HC but not in HC+S compared with N. In parallel, immunoreactivity for HIF-1alpha, VEGF, MMP-2, and MMP-9 was accentuated in the outer media in HC but not in HC+S compared with N. CONCLUSIONS: This study demonstrates that simvastatin attenuates hypoxia in the coronary artery wall and VV neovascularization in experimental hypercholesterolemia, despite no change in plasma lipids. Simvastatin 280-291 vascular endothelial growth factor A Sus scrofa 37-41 11815421-8 2002 Coronary artery tissue expression of VEGF was increased in HC but not in HC+S compared with N. In parallel, immunoreactivity for HIF-1alpha, VEGF, MMP-2, and MMP-9 was accentuated in the outer media in HC but not in HC+S compared with N. CONCLUSIONS: This study demonstrates that simvastatin attenuates hypoxia in the coronary artery wall and VV neovascularization in experimental hypercholesterolemia, despite no change in plasma lipids. Simvastatin 280-291 hypoxia inducible factor 1 subunit alpha Sus scrofa 129-139 11786505-9 2002 Only simvastatin and lovastatin increased t-PA production in endothelial cells. Simvastatin 5-16 plasminogen activator, tissue type Homo sapiens 42-46 12429913-6 2002 Both simvastatin and lovastatin significantly augmented TRAIL-induced apoptosis in tumor cells, but not in normal keratinocytes. Simvastatin 5-16 TNF superfamily member 10 Homo sapiens 56-61 11863404-1 2002 Recent studies suggest that the HMG-CoA reductase inhibitor simvastatin--similar to vascular endothelial growth factor (VEGF)--may promote angiogenesis by activation of a protein kinase Akt-nitric oxide synthase dependent pathway in endothelial cells, an effect that may be beneficial in the treatment of ischemic heart disease. Simvastatin 60-71 AKT serine/threonine kinase 1 Homo sapiens 186-189 14727985-10 2002 Simvastatin and lovastatin are significantly metabolized by cytochrome P450 enzymes (CYP3A4) and are therefore not recommended for coadministration with protease inhibitors. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 11914545-4 2002 As shown in this study, simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the key enzyme for cholesterol biosynthesis, is able to prevent these events following the expression of the transforming Ha-ras oncogene. Simvastatin 24-35 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-110 11735122-3 2001 Pretreatment of monocytic cells (U937, THP-1, human CD14(+) monocytes) with 0.01-10 microM concentrations of atorvastatin, cerivastatin, or simvastatin significantly reduced cell adhesion to endothelium. Simvastatin 140-151 GLI family zinc finger 2 Homo sapiens 39-44 11748098-5 2001 CONCLUSIONS: Patients with elevated LDL-C, low HDL-C, and elevated triglycerides were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome, had increased risk for CHD events on placebo, and received greater benefit with simvastatin therapy. Simvastatin 279-290 component of oligomeric golgi complex 2 Homo sapiens 36-41 11735125-5 2001 Pretreatment of HCAECs with simvastatin or atorvastatin (1 and 10 microM) reduced ox-LDL-induced upregulation of LOX-1 and downregulation of eNOS (both P < 0.05). Simvastatin 28-39 oxidized low density lipoprotein receptor 1 Homo sapiens 113-118 11716837-3 2001 On the other hand, the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor simvastatin reduced both cholesterol and squalene synthesis from [14C]acetate. Simvastatin 80-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-69 11753271-1 2001 OBJECTIVE: Because clinical data about the therapeutic consequences of polymorphic oxidation of simvastatin by CYP2D6 have not been well reported, we sought to investigate the possible link between polymorphism of CYP2D6 and the efficacy and tolerability of simvastatin treatment in a group of 88 patients with hypercholesterolemia. Simvastatin 96-107 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 214-220 11753271-3 2001 RESULTS: Four of 5 patients with 2 defective CYP2D6 alleles discontinued the therapy at a low daily dose because of adverse events, with a significant mean decrease in the cholesterol levels of 0.23 mmol/L per milligram of simvastatin in the daily dose. Simvastatin 223-234 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-51 11753271-4 2001 In the group of 28 patients with 1 mutated CYP2D6 gene, 13 did not tolerate the therapy, whereas a mean decrease in the cholesterol levels of 0.20 mmol/L per milligram of simvastatin was found. Simvastatin 171-182 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 11753271-5 2001 One patient with a multiplication of the CYP2D6 gene showed a cholesterol reduction of only 0.01 mmol/L per milligram of simvastatin, at a maximal daily dose of 40 mg. Only 9 patients of the group of 54 persons who were homozygous for the wild-type allele discontinued the therapy because of intolerance. Simvastatin 121-132 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 11753271-7 2001 CONCLUSIONS: Our data provide evidence that the cholesterol-lowering effect of simvastatin is influenced by CYP2D6 polymorphism. Simvastatin 79-90 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 108-114 11902822-4 2001 DESIGN: The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. Simvastatin 89-100 proopiomelanocortin Homo sapiens 12-16 11902822-12 2001 CONCLUSIONS: In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Simvastatin 38-49 proopiomelanocortin Homo sapiens 61-65 11902822-12 2001 CONCLUSIONS: In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Simvastatin 38-49 apolipoprotein B Homo sapiens 127-143 11757504-6 2001 The protective increase in HDL2 with simvastatin plus niacin was attenuated by concurrent therapy with antioxidants. Simvastatin 37-48 junctophilin 3 Homo sapiens 27-31 11753267-2 2001 The effects of St John"s Wort on the pharmacokinetics of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors simvastatin (an inactive lactone pro-drug) and pravastatin were determined in this study. Simvastatin 116-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-104 11753267-11 2001 Because simvastatin is extensively metabolized by CYP3A4 in the intestinal wall and liver, which are induced by St John"s Wort, it is likely that this interaction is partly caused by the enhancement of the CYP3A4-mediated first-pass metabolism of simvastatin in the small intestine and liver. Simvastatin 8-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 11753267-11 2001 Because simvastatin is extensively metabolized by CYP3A4 in the intestinal wall and liver, which are induced by St John"s Wort, it is likely that this interaction is partly caused by the enhancement of the CYP3A4-mediated first-pass metabolism of simvastatin in the small intestine and liver. Simvastatin 8-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 206-212 11753267-11 2001 Because simvastatin is extensively metabolized by CYP3A4 in the intestinal wall and liver, which are induced by St John"s Wort, it is likely that this interaction is partly caused by the enhancement of the CYP3A4-mediated first-pass metabolism of simvastatin in the small intestine and liver. Simvastatin 247-258 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 11753267-11 2001 Because simvastatin is extensively metabolized by CYP3A4 in the intestinal wall and liver, which are induced by St John"s Wort, it is likely that this interaction is partly caused by the enhancement of the CYP3A4-mediated first-pass metabolism of simvastatin in the small intestine and liver. Simvastatin 247-258 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 206-212 11753271-0 2001 Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Simvastatin 90-101 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 11753271-1 2001 OBJECTIVE: Because clinical data about the therapeutic consequences of polymorphic oxidation of simvastatin by CYP2D6 have not been well reported, we sought to investigate the possible link between polymorphism of CYP2D6 and the efficacy and tolerability of simvastatin treatment in a group of 88 patients with hypercholesterolemia. Simvastatin 96-107 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 111-117 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 86-97 angiotensinogen Rattus norvegicus 133-138 11592937-3 2001 Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, increases eNOS expression in the endothelium. Simvastatin 0-11 nitric oxide synthase 3 Canis lupus familiaris 81-85 11592937-8 2001 Responses to bradykinin, ramiprilat, and amlodipine were significantly attenuated in CHF but were partially or completely restored by simvastatin. Simvastatin 134-145 kininogen 1 Canis lupus familiaris 13-23 11794990-0 2001 [Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]. Simvastatin 1-12 angiotensinogen Rattus norvegicus 79-93 11794990-7 2001 The overproduction of TBARS induced by ANG II was partially prevented by simvastatin (598 +/- 40 vs 794 +/- 79 pmol/mL). Simvastatin 73-84 angiotensinogen Rattus norvegicus 39-45 11794990-8 2001 These results indicate that simvastatin attenuates the cardiovascular effects and lipid peroxidation induced by chronic administration of angiotensin II. Simvastatin 28-39 angiotensinogen Rattus norvegicus 138-152 11711492-7 2001 Similarly, simvastatin and lovastatin (34 micromol/L) caused robust upregulation of the iNOS protein level. Simvastatin 11-22 nitric oxide synthase 2 Homo sapiens 88-92 11687759-3 2001 In men with marked hypercholesterolemia, lowering serum cholesterol by a three-month simvastatin treatment is accompanied by a reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury. Simvastatin 85-96 coagulation factor II, thrombin Homo sapiens 140-148 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 86-97 natriuretic peptide A Rattus norvegicus 189-214 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 86-97 natriuretic peptide A Rattus norvegicus 216-219 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 119-122 angiotensinogen Rattus norvegicus 46-60 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 119-122 angiotensinogen Rattus norvegicus 62-67 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 119-122 angiotensinogen Rattus norvegicus 133-138 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 119-122 natriuretic peptide A Rattus norvegicus 189-214 11714734-4 2001 We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. Simvastatin 119-122 natriuretic peptide A Rattus norvegicus 216-219 11714734-8 2001 Indeed, Sim inhibited cardiac hypertrophy and decreased myocardial Rac1 activity and O2*- production in rats treated with AngII infusion or subjected to transaortic constriction. Simvastatin 8-11 Rac family small GTPase 1 Rattus norvegicus 67-71 11714734-8 2001 Indeed, Sim inhibited cardiac hypertrophy and decreased myocardial Rac1 activity and O2*- production in rats treated with AngII infusion or subjected to transaortic constriction. Simvastatin 8-11 angiotensinogen Rattus norvegicus 122-127 11583721-10 2001 The Cmax and AUC of simvastatin were increased about eight-fold, when simvastatin was given in combination with CsA. Simvastatin 20-31 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 112-115 11583721-12 2001 Although simvastatin levels were increased with CsA, there were no abnormal changes in renal and liver functions, creatinine phosphokinase (CPK) levels or in incidence of adverse effects. Simvastatin 9-20 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 48-51 11472751-3 2001 The aim of this study was to evaluate the effect of one year of simvastatin treatment on serum levels of CRP and to assess the influence of risk factors for CVD on CRP concentrations in patients with FH. Simvastatin 64-75 C-reactive protein Homo sapiens 105-108 11557241-5 2001 In this study, we examined the modulation of LOX-1 expression and PKB activity in response to oxidized-LDL by two different statins (simvastatin and atorvastatin). Simvastatin 133-144 oxidized low density lipoprotein receptor 1 Homo sapiens 45-50 11557241-8 2001 Two different statins, simvastatin and atorvastatin (each 1 and 10 microM), upregulated the activity of PKB and decreased LOX-1 expression and [125I]-ox-LDL uptake. Simvastatin 23-34 oxidized low density lipoprotein receptor 1 Homo sapiens 122-127 11549708-0 2001 Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. Simvastatin 0-11 bone gamma-carboxyglutamate protein Homo sapiens 28-39 11549708-6 2001 Our data support that simvastatin causes a beneficial effect on bone metabolism as reflected by an increase in serum osteocalcin concentration. Simvastatin 22-33 bone gamma-carboxyglutamate protein Homo sapiens 117-128 11600564-0 2001 Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. Simvastatin 184-195 low density lipoprotein receptor Homo sapiens 105-143 11600564-1 2001 The aims of this study were to examine the presence of mutations in the low-density lipoprotein receptor gene among subjects clinically diagnosed with familial hypercholesterolemia and to analyze whether the molecular diagnosis helps to predict the response to simvastatin treatment in our familial hypercholesterolemia population. Simvastatin 261-272 low density lipoprotein receptor Homo sapiens 72-104 11780395-6 2001 PDGF-B detected by immuno-histochemistry and RT-PCR analysis showed that the release of PDGF-B was inhibited by simvastatin and gemfibrozil after de-endothelialization. Simvastatin 112-123 platelet-derived growth factor subunit B Oryctolagus cuniculus 0-6 11780395-6 2001 PDGF-B detected by immuno-histochemistry and RT-PCR analysis showed that the release of PDGF-B was inhibited by simvastatin and gemfibrozil after de-endothelialization. Simvastatin 112-123 platelet-derived growth factor subunit B Oryctolagus cuniculus 88-94 11550401-1 2001 Simvastatin, a hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, is a commonly used cholesterol lowering agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-69 11550401-4 2001 Potent inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme increase the incidence of simvastatin toxicity. Simvastatin 87-98 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-44 11550401-4 2001 Potent inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme increase the incidence of simvastatin toxicity. Simvastatin 87-98 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 46-52 11470468-1 2001 OBJECTIVE: We tested the hypothesis of beneficial effects of the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)-reductase inhibitor simvastatin in a model of ischemia-reperfusion, and investigated potential mechanisms. Simvastatin 134-145 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 65-123 11487529-3 2001 Incubation of the cells with simvastatin or lovastatin time-dependently and reversibly changed cell morphology and the actin cytoskeleton with maximal effects observed after about 18 h. Within the same time period, statins reduced the basal expression of CTGF and interfered with CTGF induction by lysophosphatidic acid (LPA) or transforming growth factor beta. Simvastatin 29-40 cellular communication network factor 2 Homo sapiens 255-259 11487529-3 2001 Incubation of the cells with simvastatin or lovastatin time-dependently and reversibly changed cell morphology and the actin cytoskeleton with maximal effects observed after about 18 h. Within the same time period, statins reduced the basal expression of CTGF and interfered with CTGF induction by lysophosphatidic acid (LPA) or transforming growth factor beta. Simvastatin 29-40 cellular communication network factor 2 Homo sapiens 280-284 11487529-7 2001 Simvastatin reduced the binding of the small GTPase RhoA to cellular membranes. Simvastatin 0-11 ras homolog family member A Homo sapiens 52-56 11470468-7 2001 Simvastatin also significantly decreased iNOS mRNA and protein, as well as nitrite production after ischemia-reperfusion. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 41-45 11489933-5 2001 The role of Akt signaling in mediating effects of statin on EPCs is suggested by the observation that simvastatin rapidly activates Akt protein kinase in EPCs, enhancing proliferative and migratory activities and cell survival. Simvastatin 102-113 thymoma viral proto-oncogene 1 Mus musculus 12-15 11489933-4 2001 Direct evidence that this increased pool of circulating EPCs originates from bone marrow and may enhance neovascularization was demonstrated in simvastatin-treated mice transplanted with bone marrow from transgenic donors expressing beta-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. Simvastatin 144-155 TEK receptor tyrosine kinase Mus musculus 313-318 11489933-5 2001 The role of Akt signaling in mediating effects of statin on EPCs is suggested by the observation that simvastatin rapidly activates Akt protein kinase in EPCs, enhancing proliferative and migratory activities and cell survival. Simvastatin 102-113 thymoma viral proto-oncogene 1 Mus musculus 132-135 11489933-3 2001 We show here, using a chemotaxis assay of bone marrow mononuclear cells in vitro and EPC culture assay of peripheral blood from simvastatin-treated animals in vivo, that the HMG-CoA reductase inhibitor, simvastatin, augments the circulating population of EPCs. Simvastatin 128-139 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 174-191 11489933-3 2001 We show here, using a chemotaxis assay of bone marrow mononuclear cells in vitro and EPC culture assay of peripheral blood from simvastatin-treated animals in vivo, that the HMG-CoA reductase inhibitor, simvastatin, augments the circulating population of EPCs. Simvastatin 203-214 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 174-191 11406471-10 2001 The aorta from simvastatin-treated group showed increase of tone-related basal NO release and eNOS mRNA and decrease of O release. Simvastatin 15-26 nitric oxide synthase, endothelial Oryctolagus cuniculus 94-98 11489933-4 2001 Direct evidence that this increased pool of circulating EPCs originates from bone marrow and may enhance neovascularization was demonstrated in simvastatin-treated mice transplanted with bone marrow from transgenic donors expressing beta-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. Simvastatin 144-155 galactosidase, beta 1 Mus musculus 233-251 11406471-11 2001 Taken together, upregulation of eNOS and decrease of O treatment were observed in vivo in the process of the sufficient stabilization of atheroma following simvastatin. Simvastatin 156-167 nitric oxide synthase, endothelial Oryctolagus cuniculus 32-36 11408375-3 2001 Using anti-P450 antisera, the main P450 isozyme responsible for the metabolism of simvastatin was identified as CYP3A in female rats and CYP2C11 in male rats. Simvastatin 82-93 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 112-117 11408375-3 2001 Using anti-P450 antisera, the main P450 isozyme responsible for the metabolism of simvastatin was identified as CYP3A in female rats and CYP2C11 in male rats. Simvastatin 82-93 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 137-144 11408375-4 2001 Therefore, the sex difference in the inhibition of simvastatin metabolism by itraconazole seems to be caused by a difference in the P450 isozymes responsible for the metabolism of simvastatin in male and female rats and the different ability of itraconazole to inhibit CYP3A and CYP2C11. Simvastatin 51-62 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 269-274 11408375-4 2001 Therefore, the sex difference in the inhibition of simvastatin metabolism by itraconazole seems to be caused by a difference in the P450 isozymes responsible for the metabolism of simvastatin in male and female rats and the different ability of itraconazole to inhibit CYP3A and CYP2C11. Simvastatin 51-62 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 279-286 11584328-7 2001 Several drugs have been shown to significantly inhibit the CYP3A4 pathway; in combination with statins such as lovastatin, simvastatin, atorvastatin, and cerivastatin, they have been shown to elevate serum concentrations of these statins, or may increase the risk of myopathy. Simvastatin 123-134 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 11452711-0 2001 The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1. Simvastatin 31-42 serpin family E member 1 Homo sapiens 62-100 11427209-9 2001 Simvastatin also induced treatment- and time-dependent reductions in apo B-100, whereas the MTP inhibitor BMS-201038 exhibited no time dependency, instead inhibiting this variable even on 1-h treatment. Simvastatin 0-11 apolipoprotein B Homo sapiens 69-78 11497338-1 2001 OBJECTIVE: The objective of our study was to evaluate in humans the drug-drug interaction occurring during the concomitant administration of cisapride and simvastatin, two well-known substrates of CYP3A4. Simvastatin 155-166 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 197-203 11440286-11 2001 Overall, 104 (78.2%) patients treated with simvastatin achieved LDL-C levels < or = 100 mg/dL at week 14, and 125 (94.0%) achieved this target at some point during the study. Simvastatin 43-54 component of oligomeric golgi complex 2 Homo sapiens 64-69 11452711-2 2001 Endothelial dysfunction and PAI-1 in patients with coronary artery disease (CAD) have been demonstrated to improve following simvastatin therapy. Simvastatin 125-136 serpin family E member 1 Homo sapiens 28-33 11452711-3 2001 The effect of converting from simvastatin to atorvastatin on PAI-1 has not been reported and may be an additional consideration when making a formulary medication switch. Simvastatin 30-41 serpin family E member 1 Homo sapiens 61-66 11428539-6 2001 Administration of simvastatin significantly lowered plasma levels of matrix metalloproteinase-9 (MMP-9) and monocyte chemoattractant protein-I [33+/-46 and 13+/-19%, respectively (P = 0.027 and 0.020, respectively)]. Simvastatin 18-29 matrix metallopeptidase 9 Homo sapiens 69-95 11428539-6 2001 Administration of simvastatin significantly lowered plasma levels of matrix metalloproteinase-9 (MMP-9) and monocyte chemoattractant protein-I [33+/-46 and 13+/-19%, respectively (P = 0.027 and 0.020, respectively)]. Simvastatin 18-29 matrix metallopeptidase 9 Homo sapiens 97-102 11428539-7 2001 Furthermore, administration of simvastatin tended to lower plasma levels of plasminogen activator inhibitor type-1 and tumor necrosis factor-alpha [by 20+/-44 and 13+/-29%, respectively (P= 0.066 and 0.110, respectively)]. Simvastatin 31-42 tumor necrosis factor Homo sapiens 76-146 11428539-8 2001 There were significant inverse correlations between pretreatment levels of MMP-9 and the degree of change in those levels after administration of simvastatin (r = -0.714, P= 0.005). Simvastatin 146-157 matrix metallopeptidase 9 Homo sapiens 75-80 11382718-7 2001 The effect of CRP on MCP-1 induction was not influenced by aspirin (at concentrations up to 1 mmol/L), but it was significantly inhibited by 5 micromol/L simvastatin. Simvastatin 154-165 C-reactive protein Homo sapiens 14-17 11404382-5 2001 Simvastatin dose dependently inhibited THP-1 cell migration mediated by monocyte chemoattractant protein 1, with a 50% inhibitory concentration of about 50 nM. Simvastatin 0-11 C-C motif chemokine ligand 2 Homo sapiens 72-106 11382718-9 2001 CONCLUSIONS: These results further strengthen the role of CRP in the pathogenesis of vascular inflammation and, likely, atherosclerosis and provide a crucial insight into a novel mechanism of action of anti-atherosclerosis drugs such as simvastatin and fenofibrate. Simvastatin 237-248 C-reactive protein Homo sapiens 58-61 11382730-0 2001 Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Simvastatin 0-11 apolipoprotein E Mus musculus 74-90 11382730-6 2001 However, the increased leukocyte rolling and adherence that occurred in cholesterol-fed apoE(-/-) mice (P<0.001 versus control diet) were significantly attenuated by simvastatin treatment (P<0.01 versus vehicle). Simvastatin 169-180 apolipoprotein E Mus musculus 88-92 11382730-8 2001 Simvastatin therapy also significantly increased vascular nitric oxide production in apoE(-/-) mice. Simvastatin 0-11 apolipoprotein E Mus musculus 85-89 11376131-10 2001 Simvastatin, an HMG CoA reductase inhibitor, inhibited ccn2 (ctgf) mRNA expression in a concentration dependent manner (IC(50): 1-2 microM). Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 55-59 11376131-10 2001 Simvastatin, an HMG CoA reductase inhibitor, inhibited ccn2 (ctgf) mRNA expression in a concentration dependent manner (IC(50): 1-2 microM). Simvastatin 0-11 cellular communication network factor 2 Homo sapiens 61-65 11382718-7 2001 The effect of CRP on MCP-1 induction was not influenced by aspirin (at concentrations up to 1 mmol/L), but it was significantly inhibited by 5 micromol/L simvastatin. Simvastatin 154-165 C-C motif chemokine ligand 2 Homo sapiens 21-26 11397960-2 2001 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, e.g., simvastatin, have been shown to reduce the incidence of graft vascular disease. Simvastatin 65-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-46 11474784-6 2001 RESULTS: Lovastatin and simvastatin are very potent and effective inhibitors of P-gp transport with IC50"s of 26 and 9 microM, respectively, for the human enzyme. Simvastatin 24-35 phosphoglycolate phosphatase Homo sapiens 80-84 11397960-4 2001 METHODS AND RESULTS: Simvastatin pretreatment inhibited MVEC HILA-DR induction by IFN-gamma, as detected by flow cytometry. Simvastatin 21-32 interferon gamma Homo sapiens 82-91 11397960-6 2001 Reverse transcription-polymerase chain reaction analysis demonstrated that induction of class II transactivator (CIITA), and consequently, HLA-DRalpha mRNA, is abrogated by simvastatin. Simvastatin 173-184 class II major histocompatibility complex transactivator Homo sapiens 88-111 11397960-6 2001 Reverse transcription-polymerase chain reaction analysis demonstrated that induction of class II transactivator (CIITA), and consequently, HLA-DRalpha mRNA, is abrogated by simvastatin. Simvastatin 173-184 class II major histocompatibility complex transactivator Homo sapiens 113-118 11397960-7 2001 Although signal transducer and activator of transcription (STAT)-1 is a critical CIITA gene transactivator, immunofluorescence studies, Western blotting, and electrophoretic mobility shift assays demonstrated that IFN-gamma-induced STAT-1 phosphorylation, nuclear translocation, and DNA binding are not affected by simvastatin. Simvastatin 315-326 signal transducer and activator of transcription 1 Homo sapiens 9-66 11397960-7 2001 Although signal transducer and activator of transcription (STAT)-1 is a critical CIITA gene transactivator, immunofluorescence studies, Western blotting, and electrophoretic mobility shift assays demonstrated that IFN-gamma-induced STAT-1 phosphorylation, nuclear translocation, and DNA binding are not affected by simvastatin. Simvastatin 315-326 interferon gamma Homo sapiens 214-223 11397960-8 2001 However, simvastatin inhibited IFN-gamma-induced transactivation of a CIITA promoter IV reporter construct, indicating the involvement of this promoter in the inhibitory effect of simvastatin. Simvastatin 9-20 interferon gamma Homo sapiens 31-40 11397960-8 2001 However, simvastatin inhibited IFN-gamma-induced transactivation of a CIITA promoter IV reporter construct, indicating the involvement of this promoter in the inhibitory effect of simvastatin. Simvastatin 9-20 class II major histocompatibility complex transactivator Homo sapiens 70-75 11397960-8 2001 However, simvastatin inhibited IFN-gamma-induced transactivation of a CIITA promoter IV reporter construct, indicating the involvement of this promoter in the inhibitory effect of simvastatin. Simvastatin 180-191 interferon gamma Homo sapiens 31-40 11397960-8 2001 However, simvastatin inhibited IFN-gamma-induced transactivation of a CIITA promoter IV reporter construct, indicating the involvement of this promoter in the inhibitory effect of simvastatin. Simvastatin 180-191 class II major histocompatibility complex transactivator Homo sapiens 70-75 11397960-9 2001 CONCLUSIONS: Simvastatin pretreatment inhibits CIITA and consequent HLA-DR induction by IFN-gamma in MVECs through interference with protein prenylation. Simvastatin 13-24 class II major histocompatibility complex transactivator Homo sapiens 47-52 11397960-9 2001 CONCLUSIONS: Simvastatin pretreatment inhibits CIITA and consequent HLA-DR induction by IFN-gamma in MVECs through interference with protein prenylation. Simvastatin 13-24 interferon gamma Homo sapiens 88-97 11465417-4 2001 RESULTS: Itraconazole competitively inhibited the metabolism of simvastatin to M-1 and M-2 with Ki values in the nM range. Simvastatin 64-75 cholinergic receptor muscarinic 1 Homo sapiens 79-82 11518463-5 2001 This possibility was investigated here by assessing the cell cycle effects of Simvastatin, a non-toxic upstream inhibitor of the mevalonate pathway, on human BC MCF-7 cells expressing either normal or enhanced levels of cyclin D1 from of a stably transfected, tet-inducible expression vector. Simvastatin 78-89 cyclin D1 Homo sapiens 220-229 11342472-0 2001 Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Simvastatin 0-11 coagulation factor II, thrombin Homo sapiens 65-76 11342472-9 2001 CONCLUSIONS: Simvastatin treatment depresses blood clotting, which leads to reduced rates of prothrombin activation, factor Va generation, fibrinogen cleavage, factor XIII activation, and an increased rate of factor Va inactivation. Simvastatin 13-24 coagulation factor II, thrombin Homo sapiens 93-104 11348878-2 2001 Here, we show that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, within the therapeutic range (0.01 to 1 micromol/L) prevented the downregulation of eNOS mRNA and protein promoted by nLDL (180 mg cholesterol/dL, 48 hours) in human umbilical vein endothelial cells. Simvastatin 19-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-81 11348878-2 2001 Here, we show that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, within the therapeutic range (0.01 to 1 micromol/L) prevented the downregulation of eNOS mRNA and protein promoted by nLDL (180 mg cholesterol/dL, 48 hours) in human umbilical vein endothelial cells. Simvastatin 19-30 nitric oxide synthase 3 Homo sapiens 177-181 11348878-4 2001 Simvastatin significantly stabilized eNOS mRNA in cells treated with nLDL during 48 hours (eNOS mRNA half-life approximately 11 hours in controls versus >24 hours in nLDL per 0.1 micromol/L simvastatin-treated cells). Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 37-41 11348878-4 2001 Simvastatin significantly stabilized eNOS mRNA in cells treated with nLDL during 48 hours (eNOS mRNA half-life approximately 11 hours in controls versus >24 hours in nLDL per 0.1 micromol/L simvastatin-treated cells). Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 91-95 11465417-9 2001 CONCLUSIONS: It was demonstrated that the competitive inhibition of CYP3A4-mediated simvastatin metabolism by itraconazole is the main cause of the drug interaction and that a Ki value corrected for drug adsorption to microsomes is the key factor in quantitatively predicting the maximum in vivo drug interactions. Simvastatin 84-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 11282095-4 2001 Serum cholestanol concentrations were decreased with the HMG-CoA reductase inhibitor simvastatin alone and greater reductions were achieved after the addition of the bile acid chenodeoxycholic acid; suggesting a synergistic effect of this combination. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-74 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Simvastatin 161-172 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Simvastatin 26-37 C-reactive protein Homo sapiens 93-96 11282093-6 2001 Simvastatin led to an increase in LpAI-HDL(3) and did not change significantly LpAI-HDL(2) particle concentration. Simvastatin 0-11 HDL3 Homo sapiens 39-45 11281303-10 2001 CONCLUSIONS: Short-term therapy with simvastatin decreases the plasma concentrations of markers of peroxidation of lipids and of stable metabolites of nitric oxide in hypercholesterolaemic patients, but leaves levels of interleukin 6 unaffected. Simvastatin 37-48 interleukin 6 Homo sapiens 220-233 11469968-9 2001 Administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (simvastatin or pravastatin, 20 mg/d) should be limited to hypercholesterolemic patients with mild chronic cholestatic liver diseases in whom HDL serum levels are below the protective range or if additional risk factors for cardiovascular diseases are present. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-75 11434192-6 2001 Treatment with simvastatin 40 and 80 mg/day, but not atorvastatin 20 and 40 mg/day, led to significant (p < 0.05) reductions in BSAP in both men (4.1-5.4% reduction) and women (4.2-7.4% reduction). Simvastatin 15-26 paired box 5 Homo sapiens 131-135 11434192-7 2001 In addition, there appeared to be a dose-dependent effect with greater reductions in BSAP seen with the 80 mg dose of simvastatin. Simvastatin 118-129 paired box 5 Homo sapiens 85-89 11434192-9 2001 CTx showed a small, but not statistically significant, decrease with simvastatin, again with an apparent dose-related trend. Simvastatin 69-80 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-3 11434192-11 2001 CONCLUSIONS: The present serum bone biomarker results show that treatment with simvastatin, but not atorvastatin, decreases BSAP and suggest that simvastatin may have a beneficial effect on bone turnover. Simvastatin 79-90 paired box 5 Homo sapiens 124-128 11394370-0 2001 The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease. Simvastatin 17-28 carboxyl ester lipase Homo sapiens 43-63 11283400-3 2001 Indeed, we have previously demonstrated that chronic simvastatin administration upregulates endothelial nitric oxide synthase (eNOS), resulting in more functional protein, augmentation of cerebral blood flow, and neuroprotection in a murine model of cerebral ischemia. Simvastatin 53-64 nitric oxide synthase 3, endothelial cell Mus musculus 92-125 11283400-3 2001 Indeed, we have previously demonstrated that chronic simvastatin administration upregulates endothelial nitric oxide synthase (eNOS), resulting in more functional protein, augmentation of cerebral blood flow, and neuroprotection in a murine model of cerebral ischemia. Simvastatin 53-64 nitric oxide synthase 3, endothelial cell Mus musculus 127-131 11318529-5 2001 Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 11165973-0 2001 Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Simvastatin 25-36 fibrinogen beta chain Homo sapiens 0-10 11275002-6 2001 All the reported effects of simvastatin were inhibited by the product of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, mevalonate (10(-3) M). Simvastatin 28-39 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 73-130 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 95-99 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 157-161 11318080-12 2001 At the end of the study, 60.8% (135/222) of patients in the simvastatin group had reached target LDL-C goals, compared with 35.1% (76/216) in the fluvastatin group (P < 0.001). Simvastatin 60-71 component of oligomeric golgi complex 2 Homo sapiens 97-102 11318080-13 2001 In the simvastatin CHD and MRF subgroups, 49% and 73%, respectively, reached the LDL-C target, compared with 19% and 50% in the corresponding fluvastatin subgroups (P < 0.001). Simvastatin 7-18 component of oligomeric golgi complex 2 Homo sapiens 81-86 11318080-16 2001 CONCLUSION: In this study, more patients with primary hypercholesterolemia and CHD or multiple risk factors for CHD reached LDL-C goals with simvastatin treatment and required less titration than those who received fluvastatin treatment. Simvastatin 141-152 component of oligomeric golgi complex 2 Homo sapiens 124-129 11165973-1 2001 The clinical and biochemical determinants of the fibrinogen response to simvastatin or atorvastatin therapy were assessed in 130 patients with severe polygenic or familial hypercholesterolemia treated in a randomized open-trial format design. Simvastatin 72-83 fibrinogen beta chain Homo sapiens 49-59 11215845-6 2001 The effects of four HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin, pravastatin) on fibrinogen have been evaluated. Simvastatin 76-87 fibrinogen beta chain Homo sapiens 105-115 11215845-9 2001 Simvastatin has been shown in multiple studies using the Clauss method to have a neutral effect on fibrinogen. Simvastatin 0-11 fibrinogen beta chain Homo sapiens 99-109 11281188-4 2001 Both troglitazone and simvastatin are metabolized by cytochrome P-450 3A4. Simvastatin 22-33 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-73 11182189-2 2001 The aim of the study was to assess the influence of simvastatin and aspirin on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in hypercholesterolemic subjects. Simvastatin 52-63 C-reactive protein Homo sapiens 95-113 11182189-7 2001 CONCLUSIONS: In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines. Simvastatin 46-57 C-reactive protein Homo sapiens 91-94 11246536-0 2001 Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Simvastatin 15-26 coagulation factor II, thrombin Homo sapiens 58-66 11383320-1 2001 BACKGROUND AND AIM: This study compares the cholesterol-lowering efficacy of atorvastatin and simvastatin in attainment of the National Cholesterol Education Program (NCEP) guidelines LDL-cholesterol (LDL-C) goal in patients with heterozygous familial hypercholesterolemia (HFH). Simvastatin 94-105 component of oligomeric golgi complex 2 Homo sapiens 184-199 11162604-1 2001 The cholesterol-lowering drug, simvastatin, is a pro-drug of a potent 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and inhibits cholesterol synthesis in humans and animals. Simvastatin 31-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 11162604-7 2001 Simvastatin (10(-7) M) slightly increased in type I collagen mRNA abundance throughout the culture period, whereas it markedly inhibited the gene expression of collagenase-1 between days 14 and 22 of culture. Simvastatin 0-11 matrix metallopeptidase 13 Mus musculus 160-173 11219190-0 2001 The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Simvastatin 32-43 interferon gamma Homo sapiens 53-62 11219190-5 2001 Using RNAse protection assay and flow cytometry, we observed that simvastatin dose-dependently reduced interferon-gamma (IFN-gamma) induced MHC class II expression (mRNA and protein). Simvastatin 66-77 interferon gamma Homo sapiens 103-130 11219190-9 2001 Interestingly, mRNA levels of CIITA were decreased after treatment with simvastatin. Simvastatin 72-83 class II major histocompatibility complex transactivator Homo sapiens 30-35 11219190-10 2001 In addition, using transient transfections of promoter-reporter constructs we observed that the activity of CIITA promoter IV was decreased by simvastatin. Simvastatin 143-154 class II major histocompatibility complex transactivator Homo sapiens 108-113 11219190-11 2001 In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Simvastatin 15-26 interferon gamma Homo sapiens 49-58 11162544-1 2001 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin is able to produce endothelium-dependent relaxation in addition to its lipid-lowering properties. Simvastatin 72-83 3-hydroxy-3-methylglutaryl-CoA reductase Bos taurus 4-61 11181283-0 2001 [Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain]. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 51-63 11181283-9 2001 The type of LDL receptor gene mutation could predict the response to simvastatin in our south European FH population. Simvastatin 69-80 low density lipoprotein receptor Homo sapiens 12-24 11219190-11 2001 In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Simvastatin 15-26 class II major histocompatibility complex transactivator Homo sapiens 149-154 11475198-4 2001 RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin. Simvastatin 133-144 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 37-40 11475198-4 2001 RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin. Simvastatin 133-144 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 86-92 11246536-3 2001 We also investigated whether in patients with borderline-high cholesterol level who have been already taking aspirin, additional treatment with simvastatin would affect thrombin generation. Simvastatin 144-155 coagulation factor II, thrombin Homo sapiens 169-177 11246536-6 2001 In these patients, already taking low-dose aspirin, additional three-month simvastatin treatment resulted in a reduction of thrombin generation. Simvastatin 75-86 coagulation factor II, thrombin Homo sapiens 124-132 11246536-7 2001 This demonstrates that low-dose aspirin depresses thrombin generation only in subjects with desirable blood cholesterol levels, while in others, with borderline-high cholesterol, thrombin formation is being reduced following the addition of simvastatin. Simvastatin 241-252 coagulation factor II, thrombin Homo sapiens 179-187 11244205-5 2001 Studies conducted on the prevention of ischemic heart disease (IHD) with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), using pravastatin and simvastatin, unequivocally show reductions in overall mortality, cardiovascular mortality, acute myocardial infarction and other coronary events. Simvastatin 165-176 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-120 12426166-1 2001 OBJECTIVE: To investigate the effects of simvastatin on the proliferation of rat cardiac fibroblasts (CFs) induced by arginine vasopressin (AVP). Simvastatin 41-52 arginine vasopressin Rattus norvegicus 127-138 14728043-6 2001 Combination therapy with colesevelam plus hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (lovastatin, simvastatin or atorvastatin) was associated with additive reductions in serum levels of LDL-cholesterol and total cholesterol, relative to either agent alone. Simvastatin 119-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-94 11197581-9 2001 DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. Simvastatin 93-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 11197581-12 2001 CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). Simvastatin 168-179 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 114-120 11336576-1 2001 Simvastatin (Zocortrade mark, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-118 11149552-9 2000 All of these drugs are cytochrome P450 3A4 and/or P-glycoprotein substrates that are known from previous pharmacokinetic studies to individually produce substantial increases in levels of simvastatin. Simvastatin 188-199 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 23-42 11868908-1 2001 Considering the therapeutic effect of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) and simvastatin in patients with coronary heart disease, our first hypothesis was that simvastatin should inhibit apoptosis (programmed cell death) in angiotensin II-treated cultured myocytes. Simvastatin 194-205 angiotensinogen Homo sapiens 258-272 11868908-3 2001 We found that simvastatin induced apoptosis in a dose-dependent manner (0.1 to 3 micromol/L), as evidenced by the appearance of increased DNA fragmentation in agarose gels and characteristic apoptotic patterns in nuclei labeled with Hoechst 33342, as well as increased activity of caspase 3. Simvastatin 14-25 caspase 3 Rattus norvegicus 281-290 11868908-6 2001 The results indicate that simvastatin-induced apoptosis in cultured heart cells is concentration-dependent and additive to the apoptotic effect of angiotensin II. Simvastatin 26-37 angiotensinogen Rattus norvegicus 147-161 11204586-7 2001 The effect of simvastatin on fibrinogen (p = 0.005) was more pronounced than the effects of atorvastatin (p = 0.48 n.s.) Simvastatin 14-25 fibrinogen beta chain Homo sapiens 29-39 11104736-5 2000 Treatment of human umbilical vein endothelial cells for 24 hours with 5 micromol/L simvastatin reduced the thrombin-induced endothelial barrier dysfunction in vitro by 55+/-3%, as assessed by the passage of peroxidase through human umbilical vein endothelial cell monolayers. Simvastatin 83-94 coagulation factor II, thrombin Homo sapiens 107-115 11104736-7 2000 This reduction in barrier dysfunction by simvastatin was both dose and time dependent and was accompanied by a reduction in the thrombin-induced formation of stress fibers and focal adhesions and membrane association of RhoA. Simvastatin 41-52 coagulation factor II, thrombin Homo sapiens 128-136 11104736-7 2000 This reduction in barrier dysfunction by simvastatin was both dose and time dependent and was accompanied by a reduction in the thrombin-induced formation of stress fibers and focal adhesions and membrane association of RhoA. Simvastatin 41-52 ras homolog family member A Homo sapiens 220-224 11074211-1 2000 The purpose of this study was to determine if long-term use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) resulted in tachyphylaxis (a decreasing response to a physiologically active agent). Simvastatin 178-189 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-110 11180018-2 2000 The cholesterol-lowering drug simvastatin has an extensive first-pass metabolism, and it is partially metabolized by CYP3A4. Simvastatin 30-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 117-123 11180018-11 2000 Because the elimination half-life of simvastatin was not affected by rifampin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction. Simvastatin 37-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 11180018-11 2000 Because the elimination half-life of simvastatin was not affected by rifampin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction. Simvastatin 137-148 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 11180018-12 2000 Concomitant use of potent inducers of CYP3A4 can lead to a considerably reduced cholesterol-lowering efficacy of simvastatin. Simvastatin 113-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 11009568-0 2000 Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Simvastatin 102-113 endothelin 1 Bos taurus 64-82 11082126-2 2000 Vascular effects of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, were studied in conductance (aorta) and resistance vessels (branch II or III of superior mesenteric artery, SMA) of the rat (12 - 14 weeks old). Simvastatin 93-104 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 24-81 11075313-1 2000 Potential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. Simvastatin 46-57 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-33 11009568-4 2000 Here, we show that the basal transcription rate of the preproendothelin-1 gene was decreased by simvastatin (10 micromol/L) in bovine aortic endothelial cells. Simvastatin 96-107 endothelin 1 Bos taurus 55-73 11009568-5 2000 Transfection studies with the preproendothelin-1 gene promoter showed that mevalonate (100 micromol/L) was able to prevent the inhibitory effect mediated by simvastatin. Simvastatin 157-168 endothelin 1 Bos taurus 30-48 11009568-7 2000 The C3 exotoxin from Clostridium botulinum that selectively inactivates Rho GTPases, the processing of which involves geranylgeranylation, reproduced the inhibitory effect of simvastatin on the expression of preproendothelin-1. Simvastatin 175-186 endothelin 1 Bos taurus 208-226 11009568-9 2000 Finally, we show that the Rho-dependent activation of the preproendothelin-1 gene transcription was inhibited by simvastatin. Simvastatin 113-124 endothelin 1 Bos taurus 58-76 11029845-8 2000 Lovastatin, simvastatin, and atorvastatin are substrates of CYP3A4, whereas fluvastatin is metabolized by CYP2C9. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 10978257-4 2000 We have undertaken a study of the effect of the lipid-lowering drug simvastatin on serum PON1 activity (in relation to paraoxon and arylesterase activity), on apoAI-containing and apolipoprotein B (apoB)-containing lipoproteins, and on lipid peroxide concentrations in 64 (39 women and 25 men) unrelated FH patients. Simvastatin 68-79 paraoxonase 1 Homo sapiens 89-93 10978257-5 2000 We have also analyzed the influence of the PON1-192 and PON1-55 genetic polymorphisms on the response of PON1 activity to simvastatin therapy. Simvastatin 122-133 paraoxonase 1 Homo sapiens 43-47 10978257-5 2000 We have also analyzed the influence of the PON1-192 and PON1-55 genetic polymorphisms on the response of PON1 activity to simvastatin therapy. Simvastatin 122-133 paraoxonase 1 Homo sapiens 56-60 10978257-5 2000 We have also analyzed the influence of the PON1-192 and PON1-55 genetic polymorphisms on the response of PON1 activity to simvastatin therapy. Simvastatin 122-133 paraoxonase 1 Homo sapiens 56-60 10978257-10 2000 Remarkably, serum PON1 activity toward paraoxon significantly increased during treatment with simvastatin (168. Simvastatin 94-105 paraoxonase 1 Homo sapiens 18-22 10978257-13 2000 Whereas PON1 activity levels were significantly lower in FH patients before simvastatin therapy compared with those of 124 normolipidemic subjects (168.7+/-100.3 versus 207.6+/-125.2 U/L, respectively; P:<0.05), this difference disappeared after simvastatin therapy. Simvastatin 76-87 paraoxonase 1 Homo sapiens 8-12 10978257-14 2000 After simvastatin therapy, a significantly negative correlation between PON1 activity and lipid peroxide concentration was observed (r=-0.35, P:=0.028). Simvastatin 6-17 paraoxonase 1 Homo sapiens 72-76 10978257-18 2000 We conclude that simvastatin may have important antioxidant properties through increasing serum PON1 activity, perhaps as a consequence of reducing oxidative stress, by a mechanism independent of apoAI-containing lipoprotein concentration and without the influence of PON1-192 and PON1-55 genetic polymorphisms. Simvastatin 17-28 paraoxonase 1 Homo sapiens 96-100 10978257-19 2000 Further studies are clearly warranted to clarify the precise mechanism by which simvastatin therapy is associated with increased PON1 activity. Simvastatin 80-91 paraoxonase 1 Homo sapiens 129-133 11005703-12 2000 Atorvastatin, cerivastatin, lovastatin and simvastatin are predominantly metabolised by the CYP3A4 isozyme. Simvastatin 43-54 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 10973320-0 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Simvastatin 32-43 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 4-21 10946302-4 2000 We studied the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, on cytokine-induced expression of CAMs in HUVEC. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 10946302-5 2000 Unexpectedly, pretreatment with simvastatin potentiated the induction of all three endothelial CAMs by IL-1 and TNF, but not LPS or PMA, as detected by flow cytometry. Simvastatin 32-43 interleukin 1 alpha Homo sapiens 103-115 10946302-6 2000 Northern blot analysis demonstrated an increase in steady state IL-1-induced E-selectin mRNA levels in cells pretreated with simvastatin. Simvastatin 125-136 selectin E Homo sapiens 77-87 11126989-3 2000 Most statins are metabolised by the CYP3A4 izoenzyme (lovastatin, simvastatin, atorvastatin, cerivastatin). Simvastatin 66-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 10880044-6 2000 Inhibition of vascular Rho guanosine-5"-triphosphate binding activity by the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin increased cerebral blood flow to ischemic regions of the brain, and mice treated with simvastatin, C3 transferase, or cytochalasin D showed smaller cerebral infarctions following MCA occlusion. Simvastatin 135-146 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 77-124 10952951-6 2000 The increase in coronary blood flow during infusion of the peak dose of substance P was blunted at baseline in both the simvastatin (42+/-50%) and placebo (55+/-71%) groups, reflecting impaired endothelium-dependent dilation of coronary microvessels. Simvastatin 120-131 tachykinin precursor 1 Homo sapiens 72-83 10933353-2 2000 BACKGROUND: Simvastatin, an inhibitor of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase, reduced cardiovascular events in patients with myocardial infarction and hypercholesterolemia. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-97 10933353-7 2000 In patients with diet plus simvastatin, significant decreases of total cholesterol (-27%, p<0.02), low density lipoprotein-cholesterol (-33%, p<0.02), and monocyte expression of TNF (-49%, p<0.02) and IL-1beta (-35%, p<0.02) were observed. Simvastatin 27-38 tumor necrosis factor Homo sapiens 184-187 10933353-7 2000 In patients with diet plus simvastatin, significant decreases of total cholesterol (-27%, p<0.02), low density lipoprotein-cholesterol (-33%, p<0.02), and monocyte expression of TNF (-49%, p<0.02) and IL-1beta (-35%, p<0.02) were observed. Simvastatin 27-38 interleukin 1 beta Homo sapiens 210-218 10933353-8 2000 At the end of treatment period, patients treated with simvastatin had lower cholesterol and monocyte TNF and IL-1beta than did patients assigned to diet alone. Simvastatin 54-65 tumor necrosis factor Homo sapiens 101-104 10933353-8 2000 At the end of treatment period, patients treated with simvastatin had lower cholesterol and monocyte TNF and IL-1beta than did patients assigned to diet alone. Simvastatin 54-65 interleukin 1 beta Homo sapiens 109-117 10933353-9 2000 CONCLUSION: This study suggests that simvastatin possesses anti-inflammatory activity via the inhibition of pro-inflammatory cytokines TNF and IL-1beta expressed by monocytes. Simvastatin 37-48 tumor necrosis factor Homo sapiens 135-138 10933353-9 2000 CONCLUSION: This study suggests that simvastatin possesses anti-inflammatory activity via the inhibition of pro-inflammatory cytokines TNF and IL-1beta expressed by monocytes. Simvastatin 37-48 interleukin 1 beta Homo sapiens 143-151 10946846-4 2000 Moreover, the mRNA levels of p22phox, a 22-kD subunit and the protein levels of p47phox, a 47-kD subunit of nicotine adenine dinucleotide phosphate (NADPH) oxidase, was decreased by treatment with either simvastatin, fluvastatin or cerivastatin, and this effect was reversed by mevalonate, geranylgeraniol, farnesol, and cholesterol. Simvastatin 204-215 cytochrome b-245 alpha chain Homo sapiens 29-36 10946846-4 2000 Moreover, the mRNA levels of p22phox, a 22-kD subunit and the protein levels of p47phox, a 47-kD subunit of nicotine adenine dinucleotide phosphate (NADPH) oxidase, was decreased by treatment with either simvastatin, fluvastatin or cerivastatin, and this effect was reversed by mevalonate, geranylgeraniol, farnesol, and cholesterol. Simvastatin 204-215 neutrophil cytosolic factor 1 Homo sapiens 80-87 10942168-10 2000 In conclusion, short-term administration of simvastatin in rats potentiates the ability of angiotensin-converting enzyme (ACE) inhibitors and amlodipine to cause NO-mediated regulation of MV(O2). Simvastatin 44-55 angiotensin I converting enzyme Rattus norvegicus 91-120 10942168-10 2000 In conclusion, short-term administration of simvastatin in rats potentiates the ability of angiotensin-converting enzyme (ACE) inhibitors and amlodipine to cause NO-mediated regulation of MV(O2). Simvastatin 44-55 angiotensin I converting enzyme Rattus norvegicus 122-125 10908155-4 2000 Lovastatin and simvastatin caused a dose-dependent inhibition of MCP-1 production in peripheral blood mononuclear cells exposed to lipopolysaccharide or inactivated Streptococcus hemoliticus and in human endothelial cells exposed to interleukin-1beta. Simvastatin 15-26 C-C motif chemokine ligand 2 Homo sapiens 65-70 10908155-4 2000 Lovastatin and simvastatin caused a dose-dependent inhibition of MCP-1 production in peripheral blood mononuclear cells exposed to lipopolysaccharide or inactivated Streptococcus hemoliticus and in human endothelial cells exposed to interleukin-1beta. Simvastatin 15-26 interleukin 1 beta Homo sapiens 233-250 10830219-3 2000 We here report that low-dose simvastatin treatment inhibits excessive expression of monocyte tissue factor (TF) and reduces the persistent hypercoagulability state seen in cardiac transplant recipients. Simvastatin 29-40 coagulation factor III, tissue factor Homo sapiens 93-106 10856525-2 2000 We found that lovastatin and simvastatin inhibited cell proliferation by provoking G0/G1 phase arrest with concomitant depression of the proliferation antigen Ki-67/MIB-1. Simvastatin 29-40 MIB E3 ubiquitin protein ligase 1 Mus musculus 165-170 10814523-6 2000 Like compactin, simvastatin also activated the BMP-2 promoter, whereas pravastatin did not. Simvastatin 16-27 bone morphogenetic protein 2 Homo sapiens 47-52 10830219-3 2000 We here report that low-dose simvastatin treatment inhibits excessive expression of monocyte tissue factor (TF) and reduces the persistent hypercoagulability state seen in cardiac transplant recipients. Simvastatin 29-40 coagulation factor III, tissue factor Homo sapiens 108-110 10830219-5 2000 Levels of TF activity in both unstimulated and lipopolysaccharide-stimulated peripheral blood mononuclear cells drawn from transplant recipients before and under simvastatin therapy were evaluated by one-stage clotting assay. Simvastatin 162-173 coagulation factor III, tissue factor Homo sapiens 10-12 10830219-9 2000 As demonstrated by reverse transcriptase-polymerase chain reaction, monocyte TF reduction by simvastatin, observed in 13 of the 15 transplant recipients investigated, could be ascribed to an inhibition of monocyte TF gene transcription. Simvastatin 93-104 coagulation factor III, tissue factor Homo sapiens 77-79 10830219-9 2000 As demonstrated by reverse transcriptase-polymerase chain reaction, monocyte TF reduction by simvastatin, observed in 13 of the 15 transplant recipients investigated, could be ascribed to an inhibition of monocyte TF gene transcription. Simvastatin 93-104 coagulation factor III, tissue factor Homo sapiens 214-216 10830219-10 2000 The reduction of monocyte TF activity during treatment with simvastatin paralleled with the normalization of elevated levels of thrombin-antithrombin complex, prothrombin fragment F1+2, and D-dimer, which are markers of thrombin and fibrin formation indicating coagulation activation after cardiac transplantation. Simvastatin 60-71 coagulation factor III, tissue factor Homo sapiens 26-28 10830219-10 2000 The reduction of monocyte TF activity during treatment with simvastatin paralleled with the normalization of elevated levels of thrombin-antithrombin complex, prothrombin fragment F1+2, and D-dimer, which are markers of thrombin and fibrin formation indicating coagulation activation after cardiac transplantation. Simvastatin 60-71 coagulation factor II, thrombin Homo sapiens 128-136 10830219-10 2000 The reduction of monocyte TF activity during treatment with simvastatin paralleled with the normalization of elevated levels of thrombin-antithrombin complex, prothrombin fragment F1+2, and D-dimer, which are markers of thrombin and fibrin formation indicating coagulation activation after cardiac transplantation. Simvastatin 60-71 coagulation factor II, thrombin Homo sapiens 141-149 10830219-11 2000 CONCLUSION: Inhibition of monocyte TF expression and attenuation of the persistent hypercoagulable state observed in cardiac transplant recipients during treatment with simvastatin may represent an important mechanism by which HMG-CoA reductase inhibitors protect against the development of transplant coronary artery disease. Simvastatin 169-180 coagulation factor III, tissue factor Homo sapiens 35-37 10779015-5 2000 After eNOS upregulation by chronic simvastatin treatment (2 mg/kg subcutaneously, daily for 14 days), L-arginine amplified and sustained the hyperemia (38%) and increased absolute brain blood flow from 86 +/- 7 to 119 +/- 10 mL/100 g per minute. Simvastatin 35-46 nitric oxide synthase 3, endothelial cell Mus musculus 6-10 10878403-1 2000 Simvastatin belongs to a class of lipid-lowering drugs which completely inhibit 3-hydroxy-3-methylglutaryl co-enzyme A (HMG CoA) reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-138 10740137-8 2000 CONCLUSIONS: The use of more potent statins such as atorvastatin and simvastatin affords greater lowering of LDL-C and triglyceride levels, allowing more patients to achieve target goals. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 109-114 10669649-16 2000 In FH-NK adults on simvastatin therapy, serum LDL cholesterol levels could be reduced even further by including a stanol ester margarine in the regimen. Simvastatin 19-30 low density lipoprotein receptor Homo sapiens 3-8 10704621-0 2000 Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Simvastatin 60-71 coagulation factor III, tissue factor Homo sapiens 14-27 10704621-0 2000 Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Simvastatin 60-71 coagulation factor II, thrombin Homo sapiens 37-45 10704621-1 2000 A previous study has shown that simvastatin reduces in vivo clotting activation and monocyte tissue factor (TF) expression. Simvastatin 32-43 coagulation factor III, tissue factor Homo sapiens 93-106 10704621-1 2000 A previous study has shown that simvastatin reduces in vivo clotting activation and monocyte tissue factor (TF) expression. Simvastatin 32-43 coagulation factor III, tissue factor Homo sapiens 108-110 10704621-7 2000 In separate experiments, we measured the expression of TF by monocytes which were incubated with simvastatin and then stimulated with LPS. Simvastatin 97-108 coagulation factor III, tissue factor Homo sapiens 55-57 10704621-9 2000 Simvastatin also inhibited dose dependently the monocyte expression of TF. Simvastatin 0-11 coagulation factor III, tissue factor Homo sapiens 71-73 10704621-10 2000 This study suggests that simvastatin inhibits the rate of thrombin generation by directly interfering with the monocyte expression of TF. Simvastatin 25-36 coagulation factor II, thrombin Homo sapiens 58-66 10704621-10 2000 This study suggests that simvastatin inhibits the rate of thrombin generation by directly interfering with the monocyte expression of TF. Simvastatin 25-36 coagulation factor III, tissue factor Homo sapiens 134-136 10741630-1 2000 BACKGROUND: Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that is used as a cholesterol-lowering agent and is metabolized by cytochrome P450 3A (CYP3A) enzymes. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-100 10741630-1 2000 BACKGROUND: Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that is used as a cholesterol-lowering agent and is metabolized by cytochrome P450 3A (CYP3A) enzymes. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 168-186 10741630-1 2000 BACKGROUND: Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that is used as a cholesterol-lowering agent and is metabolized by cytochrome P450 3A (CYP3A) enzymes. Simvastatin 12-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 188-193 10741630-2 2000 Diltiazem is a substrate and an inhibitor of CYP3A enzymes and is commonly coadministered with cholesterol-lowering agents such as simvastatin. Simvastatin 131-142 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-50 10741630-9 2000 CONCLUSION: Diltiazem coadministration resulted in a significant interaction with simvastatin, probably by inhibiting CYP3A-mediated metabolism. Simvastatin 82-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 118-123 10741630-10 2000 Concomitant use of diltiazem or other potent inhibitors of CYP3A with simvastatin should be avoided, or close clinical monitoring should be used. Simvastatin 70-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-64 10657567-9 2000 Pretreatment of SMC with simvastatin (1 microg/ml, 2 days), a hydroxymethylglutaryl Coenzyme A (HMG CoA) reductase inhibitor, synergistically enhanced SNP-induced apoptosis (% apoptosis =15. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 62-114 10720627-2 2000 Simvastatin clearly induced a transient morphological differentiation as evidenced by the occurrence of neurite outgrowth with a transient activation of the high affinity nerve growth factor receptor, Trk, but died at 36 h after its addition. Simvastatin 0-11 neurotrophic receptor tyrosine kinase 1 Rattus norvegicus 157-199 10720627-2 2000 Simvastatin clearly induced a transient morphological differentiation as evidenced by the occurrence of neurite outgrowth with a transient activation of the high affinity nerve growth factor receptor, Trk, but died at 36 h after its addition. Simvastatin 0-11 neurotrophic receptor tyrosine kinase 1 Rattus norvegicus 201-204 10720627-4 2000 During the morphological differentiation, NGF mRNA expression was upregulated transiently and returned to the basal level at 36 h after addition of simvastatin. Simvastatin 148-159 nerve growth factor Rattus norvegicus 42-45 10720627-5 2000 These results suggest that simvastatin is neurotoxic and PC12 cells elicited a protective response, involving a transient activation of a Trk-mediated intracellular signal transduction pathway by an autocrine secretion of NGF, although these responses did not persist against pro-apoptotic signals and resulted in an apoptosis of the PC12 cells. Simvastatin 27-38 neurotrophic receptor tyrosine kinase 1 Rattus norvegicus 138-141 10720627-5 2000 These results suggest that simvastatin is neurotoxic and PC12 cells elicited a protective response, involving a transient activation of a Trk-mediated intracellular signal transduction pathway by an autocrine secretion of NGF, although these responses did not persist against pro-apoptotic signals and resulted in an apoptosis of the PC12 cells. Simvastatin 27-38 nerve growth factor Rattus norvegicus 222-225 10732848-0 2000 Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Simvastatin 85-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-73 10669656-3 2000 Simvastatin reduced levels of PAI-1 antigen released from SMCs and ECs stimulated with platelet-derived growth factor or transforming growth factor-beta (IC(50) approximately 1 micromol/L). Simvastatin 0-11 serpin family E member 1 Homo sapiens 30-35 10669656-4 2000 Levels of EC-derived tPA increased 2-fold over the same concentrations of simvastatin that inhibited release of PAI-1. Simvastatin 74-85 serpin family E member 1 Homo sapiens 112-117 10669656-7 2000 By inhibiting expression of PAI-1 from SMCs and ECs while increasing expression of tPA from ECs, simvastatin may alter the local fibrinolytic balance within the vessel wall toward increased fibrinolytic capacity that, in turn, would reduce thrombotic risk after plaque rupture. Simvastatin 97-108 serpin family E member 1 Homo sapiens 28-33 10669656-7 2000 By inhibiting expression of PAI-1 from SMCs and ECs while increasing expression of tPA from ECs, simvastatin may alter the local fibrinolytic balance within the vessel wall toward increased fibrinolytic capacity that, in turn, would reduce thrombotic risk after plaque rupture. Simvastatin 97-108 plasminogen activator, tissue type Homo sapiens 83-86 10601278-7 1999 Cis-inhibition studies indicate that both OATP2 and roatp1 also transport other statins including lovastatin, simvastatin, and atorvastatin. Simvastatin 110-121 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-47 11122720-3 2000 Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis). Simvastatin 65-76 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 36-39 11480454-2 2000 Lipophilic inhibitors including mevastatin, simvastatin, atorvastatin and NK-104 were able to increase the levels of mRNAs for HMG-CoA reductase and the LDL receptor, but the hydrophilic inhibitor pravastatin was not effective in Hep G2 cells as had previously been reported. Simvastatin 44-55 low density lipoprotein receptor Homo sapiens 153-165 10617243-9 1999 RESULTS: Compared to placebo, 5 mg simvastatin/d significantly decreased total cholesterol by 20% (p < 0.01), low-density lipoprotein cholesterol (LDL cholesterol) by 29% (p < 0.01), and Apolipoprotein B (ApoB) by 26% (p < 0.01). Simvastatin 35-46 apolipoprotein B Homo sapiens 193-209 10591666-1 1999 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to lower serum cholesterol levels and normalize endothelial cell function. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 15-72 10591666-9 1999 Moreover, immunohistochemical analysis demonstrated significantly increased P-selectin expression on the mesenteric venular endothelium after superfusion with either L-NAME (P<0.01) or thrombin (P<0.01), which was significantly attenuated by simvastatin. Simvastatin 248-259 selectin P Rattus norvegicus 76-86 10617243-9 1999 RESULTS: Compared to placebo, 5 mg simvastatin/d significantly decreased total cholesterol by 20% (p < 0.01), low-density lipoprotein cholesterol (LDL cholesterol) by 29% (p < 0.01), and Apolipoprotein B (ApoB) by 26% (p < 0.01). Simvastatin 35-46 apolipoprotein B Homo sapiens 211-215 10620105-1 1999 Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is widely used to treat hyperlipidaemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-86 10665838-7 1999 Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-120 10525131-4 1999 After 10-20 months on biweekly LA combined with simvastatin 40 mg per day immediate pre-apheresis levels of TC, LDL-cholesterol, and apolipoprotein B were decreased to 5.3+/-1.3 mmol/l, 3.3+/-1.2 mmol/l, and 1.6+/-0.4 g/l, respectively, whereas apheresis induced mean acute reductions of 61, 78, and 76%, respectively. Simvastatin 48-59 apolipoprotein B Homo sapiens 133-149 10561812-0 1999 Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Simvastatin 0-11 angiotensin I converting enzyme Rattus norvegicus 45-74 10561812-2 1999 In the present study, we tested the hypothesis that long-term administration of the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may regress hypertrophy and the possible effect of simvastatin on angiotensin-converting enzyme (ACE) activity in rats with pressure-overload cardiac hypertrophy. Simvastatin 150-161 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 84-139 10561812-2 1999 In the present study, we tested the hypothesis that long-term administration of the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may regress hypertrophy and the possible effect of simvastatin on angiotensin-converting enzyme (ACE) activity in rats with pressure-overload cardiac hypertrophy. Simvastatin 150-161 angiotensin I converting enzyme Rattus norvegicus 228-257 10561812-2 1999 In the present study, we tested the hypothesis that long-term administration of the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may regress hypertrophy and the possible effect of simvastatin on angiotensin-converting enzyme (ACE) activity in rats with pressure-overload cardiac hypertrophy. Simvastatin 150-161 angiotensin I converting enzyme Rattus norvegicus 259-262 10561812-17 1999 Compared with the LVH group, in the simvastatin-treated and ACE inhibitor groups ACE activity was reduced by 36 (P < 0.05) and 48% (P < 0.01), respectively, AngII content was reduced by 11 (P < 0.05) and 43% (P < 0.01), respectively, and hydroxyproline content was reduced by 23 (P < 0.01) and 10% (P < 0.05), respectively. Simvastatin 36-47 angiotensin I converting enzyme Rattus norvegicus 81-84 10561812-17 1999 Compared with the LVH group, in the simvastatin-treated and ACE inhibitor groups ACE activity was reduced by 36 (P < 0.05) and 48% (P < 0.01), respectively, AngII content was reduced by 11 (P < 0.05) and 43% (P < 0.01), respectively, and hydroxyproline content was reduced by 23 (P < 0.01) and 10% (P < 0.05), respectively. Simvastatin 36-47 angiotensinogen Rattus norvegicus 163-168 10561812-19 1999 For the first time, the results of the present study demonstrate that simvastatin significantly reduces LVH, cardiac tissue ACE activity and improves LV performance in pressure-overloaded rats. Simvastatin 70-81 angiotensin I converting enzyme Rattus norvegicus 124-127 10561812-20 1999 Because, compared with captopril, simvastatin is more potent in its reduction of LVH and less potent in its inhibition of ACE activity, the mechanism of its antihypertrophic action, in addition to ACE inhibition, may involve inhibition of the mevalonic acid pathway, the main target of action of statins. Simvastatin 34-45 angiotensin I converting enzyme Rattus norvegicus 122-125 10561812-20 1999 Because, compared with captopril, simvastatin is more potent in its reduction of LVH and less potent in its inhibition of ACE activity, the mechanism of its antihypertrophic action, in addition to ACE inhibition, may involve inhibition of the mevalonic acid pathway, the main target of action of statins. Simvastatin 34-45 angiotensin I converting enzyme Rattus norvegicus 197-200 10583033-1 1999 AIMS: To investigate whether an interaction between diltiazem and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may enhance the cholesterol-lowering response to simvastatin in diltiazem-treated patients. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 10543307-13 1999 In summary, lovastatin and simvastatin predominantly decrease the expression of the glycoprotein thrombospondin-1, which is functionally associated with smooth muscle cell migration and proliferation. Simvastatin 27-38 thrombospondin 1 Homo sapiens 97-113 10513779-3 1999 Simvastatin is a substrate for cytochrome P450 3A4 (CYP3A4). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-50 10513779-3 1999 Simvastatin is a substrate for cytochrome P450 3A4 (CYP3A4). Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 10513779-4 1999 CYP3A4 inhibitors can elevate the plasma concentration of HMG-CoA reductase inhibitory activity derived from simvastatin. Simvastatin 109-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 10583033-1 1999 AIMS: To investigate whether an interaction between diltiazem and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may enhance the cholesterol-lowering response to simvastatin in diltiazem-treated patients. Simvastatin 199-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-127 10500210-4 1999 Inhibition of the cholesterol metabolic pathway by the hydrophobic 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase inhibitors, simvastatin and atorvastatin, reversed the effect of lipoprotein-depleted serum and up-regulated TGFbetaRII expression, whereas the hydrophilic HMGCoA reductase inhibitor, pravastatin, had no effect. Simvastatin 129-140 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 273-289 10500210-5 1999 Simvastatin stimulated the expression of TGFbetaRII, TGFbeta(1), and PAI-1 at the level of transcription. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 41-48 10500210-5 1999 Simvastatin stimulated the expression of TGFbetaRII, TGFbeta(1), and PAI-1 at the level of transcription. Simvastatin 0-11 serpin family E member 1 Homo sapiens 69-74 10500210-6 1999 Experiments using specific inhibitors of different branches of the cholesterol metabolic pathway demonstrated that simvastatin exerted its effect on TGFbeta signaling by inhibition of the geranylgeranylation pathway. Simvastatin 115-126 transforming growth factor beta 1 Homo sapiens 149-156 10500210-7 1999 C3 exotoxin, which specifically inactivates geranylgeranylated Rho GTPases, mimicked the effect of simvastatin on PAI-1 promoter activity. Simvastatin 99-110 serpin family E member 1 Homo sapiens 114-119 10575059-6 1999 Clinically important interactions with simvastatin or lovastatin and drugs that inhibit the 3A4 isoenzyme (part of the CYP450 system) may result in myopathy and rhabdomyolysis, which can be fatal. Simvastatin 39-50 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 119-125 10498134-0 1999 Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 117-146 10498134-4 1999 We evaluated the effect of 6 months of simvastatin therapy (40 mg/day) on electronegative LDL proportion and LDL susceptibility to in vitro induced oxidation in 21 patients with heterozygous familial hypercholesterolemia (FH). Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 191-220 10498134-4 1999 We evaluated the effect of 6 months of simvastatin therapy (40 mg/day) on electronegative LDL proportion and LDL susceptibility to in vitro induced oxidation in 21 patients with heterozygous familial hypercholesterolemia (FH). Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 222-224 10575059-5 1999 The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system. Simvastatin 33-44 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 113-128 10510951-1 1999 AIMS: To evaluate the effects of simvastatin on serum lipids and insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia. Simvastatin 33-44 insulin Homo sapiens 65-72 10575059-5 1999 The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system. Simvastatin 33-44 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 130-136 10519734-3 1999 Simvastatin, unlike cholestyramine, reduces hydroxymethylglutaryl coenzyme A reductase activity and may decrease a cellular pool of cholesterol, which is regulatory for CETP gene expression. Simvastatin 0-11 cholesteryl ester transfer protein Homo sapiens 169-173 10464145-10 1999 mdr2 protein levels increased in both simvastatin-fed groups. Simvastatin 38-49 ATP binding cassette subfamily B member 4 Rattus norvegicus 0-4 10464145-12 1999 mdr1b mRNA levels were moderately increased in both simvastatin-fed groups. Simvastatin 52-63 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-5 10440099-5 1999 Lipid-soluble HMG-CoA reductase inhibitors, lovastatin (10(-6) M) and simvastatin (10(-6) M) partially and significantly inhibited the angiotensin II-induced increases in these parameters, but a water-soluble HMG-CoA reductase inhibitor, pravastatin (10(-6) M) did not. Simvastatin 70-81 angiotensinogen Rattus norvegicus 135-149 10440099-6 1999 Mevalonate (10(-4) M) overcame the inhibitory effects of lovastatin and simvastatin on angiotensin II-induced increases in these parameters. Simvastatin 72-83 angiotensinogen Rattus norvegicus 87-101 10519734-10 1999 Plasma CETP level decreased by 14.8% following treatment with simvastatin (P=0.003) but did not change following cholestyramine treatment. Simvastatin 62-73 cholesteryl ester transfer protein Homo sapiens 7-11 10519734-11 1999 This study demonstrates that, compared with cholestyramine, simvastatin results in more favourable improvements in the plasma lipoprotein profile and also lowers plasma levels of CETP. Simvastatin 60-71 cholesteryl ester transfer protein Homo sapiens 179-183 10335764-0 1999 Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Simvastatin 25-36 apolipoprotein A1 Homo sapiens 98-116 10413074-6 1999 In cultured rat aortic smooth muscle cells loaded with fura-2, increases in intracellular free-Ca2+ concentration ([Ca2+]i) induced by angiotensin II were markedly inhibited in cells incubated with simvastatin and atorvastatin but not pravastatin. Simvastatin 198-209 angiotensinogen Rattus norvegicus 135-149 10412745-6 1999 The aim of the present study is to examine the effect of simvastatin, one of the HMG-CoA reductase inhibitors, on the glomerular cell proliferation and on the expression of CDK2 or p27Kip1 in mesangial cells in experimental glomerulonephritis in vivo. Simvastatin 57-68 cyclin dependent kinase 2 Rattus norvegicus 173-177 10412745-6 1999 The aim of the present study is to examine the effect of simvastatin, one of the HMG-CoA reductase inhibitors, on the glomerular cell proliferation and on the expression of CDK2 or p27Kip1 in mesangial cells in experimental glomerulonephritis in vivo. Simvastatin 57-68 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 181-188 10412745-14 1999 At day 4, alpha-smooth muscle actin expression was also decreased in simvastatin-treated GN rats. Simvastatin 69-80 actin gamma 2, smooth muscle Rattus norvegicus 10-35 10412745-20 1999 Although simvastatin suppressed mesangial cell proliferation, the increase in the number of glomerular CDK2+/OX-7+ cells was also attenuated by simvastatin treatment. Simvastatin 144-155 cyclin-dependent kinase 2 Mus musculus 103-107 10412745-23 1999 The antiproliferative effect of simvastatin in this model was also associated with the reduction of CDK2 expression in mesangial cells. Simvastatin 32-43 cyclin dependent kinase 2 Rattus norvegicus 100-104 10493153-8 1999 Simvastatin, which stimulates LDLr in man and not in rat, lowers the level of LDL in man and has no effect on the cholesterolemia of the RICO rat. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 30-34 10412775-6 1999 RESULTS: Simvastatin showed a slightly suppressive effect on mRNA expression of type IV collagen and fibronectin and a slightly up-regulative effect on that of type I collagen, whereas mRNA expression of type III collagen was markedly up-regulated. Simvastatin 9-20 fibronectin 1 Mus musculus 101-112 10412775-8 1999 Concerning matrix turnover proteins, simvastatin markedly reduced mRNA expression of plsminogen activator inhibitor-1 (PAI-1) without affecting the expression of tissue-type plasminogen activator (tPA). Simvastatin 37-48 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 85-117 10412775-8 1999 Concerning matrix turnover proteins, simvastatin markedly reduced mRNA expression of plsminogen activator inhibitor-1 (PAI-1) without affecting the expression of tissue-type plasminogen activator (tPA). Simvastatin 37-48 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 119-124 10412781-1 1999 BACKGROUND: Simvastatin, a 3-hydroxy 3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitor, is used widely for treatment of hypercholesterolemia. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-85 10563066-10 1999 Mean fasting apolipoprotein A1 and lipoprotein A1 were increased and apolipoprotein B decreased by cerivastatin and simvastatin therapy. Simvastatin 116-127 apolipoprotein A1 Homo sapiens 13-30 10563066-10 1999 Mean fasting apolipoprotein A1 and lipoprotein A1 were increased and apolipoprotein B decreased by cerivastatin and simvastatin therapy. Simvastatin 116-127 apolipoprotein B Homo sapiens 69-85 10357840-0 1999 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Simvastatin 125-136 apolipoprotein B Homo sapiens 27-43 10335764-2 1999 The 2 agents reduced low-density lipoprotein cholesterol and triglycerides to a comparable degree, but simvastatin raised high-density lipoprotein cholesterol and apolipoprotein A-I more than atorvastatin, suggesting differences in metabolic effects of the 2 agents on plasma lipids and lipoproteins. Simvastatin 103-114 apolipoprotein A1 Homo sapiens 163-181 10217372-1 1999 The aim of the present study was to search in type IIb hyperlipidemic patients for putative concomitant effects of simvastatin on the physicochemical characteristics of low density lipoproteins (LDL) and high density lipoproteins (HDL), as well as on the activities of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) that were determined in both endogenous lipoprotein-dependent and endogenous lipoprotein-independent assays. Simvastatin 115-126 cholesteryl ester transfer protein Homo sapiens 273-307 10190517-1 1999 Ten years" experience of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin in 45 hypercholesterolemic high-risk patients is reported. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-91 10190517-11 1999 HDL3 cholesterol showed a persistent elevation during simvastatin treatment. Simvastatin 54-65 HDL3 Homo sapiens 0-4 10365819-0 1999 Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. Simvastatin 10-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 25-72 10365819-0 1999 Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. Simvastatin 10-21 alpha fetoprotein Homo sapiens 87-104 10365819-2 1999 In the present study, the role of Ras signal transduction pathway in alpha-fetoprotein (AFP) gene expression was evaluated in HuH-7 human hepatoma cells using simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, which blocks Ras function through inhibition of farnesylation, and the ras(val-12) expression vector. Simvastatin 159-170 alpha fetoprotein Homo sapiens 69-86 10365819-2 1999 In the present study, the role of Ras signal transduction pathway in alpha-fetoprotein (AFP) gene expression was evaluated in HuH-7 human hepatoma cells using simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, which blocks Ras function through inhibition of farnesylation, and the ras(val-12) expression vector. Simvastatin 159-170 alpha fetoprotein Homo sapiens 88-91 10365819-2 1999 In the present study, the role of Ras signal transduction pathway in alpha-fetoprotein (AFP) gene expression was evaluated in HuH-7 human hepatoma cells using simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, which blocks Ras function through inhibition of farnesylation, and the ras(val-12) expression vector. Simvastatin 159-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 174-221 10365819-6 1999 Levels of AFP mRNA but not albumin mRNA were elevated by simvastatin in a dose-dependent manner (1-10 micromol/l). Simvastatin 57-68 alpha fetoprotein Homo sapiens 10-13 10365819-7 1999 AFP promoter and enhancer activities were stimulated by simvastatin. Simvastatin 56-67 alpha fetoprotein Homo sapiens 0-3 10217372-1 1999 The aim of the present study was to search in type IIb hyperlipidemic patients for putative concomitant effects of simvastatin on the physicochemical characteristics of low density lipoproteins (LDL) and high density lipoproteins (HDL), as well as on the activities of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) that were determined in both endogenous lipoprotein-dependent and endogenous lipoprotein-independent assays. Simvastatin 115-126 cholesteryl ester transfer protein Homo sapiens 309-313 10217372-1 1999 The aim of the present study was to search in type IIb hyperlipidemic patients for putative concomitant effects of simvastatin on the physicochemical characteristics of low density lipoproteins (LDL) and high density lipoproteins (HDL), as well as on the activities of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) that were determined in both endogenous lipoprotein-dependent and endogenous lipoprotein-independent assays. Simvastatin 115-126 phospholipid transfer protein Homo sapiens 323-352 10217372-1 1999 The aim of the present study was to search in type IIb hyperlipidemic patients for putative concomitant effects of simvastatin on the physicochemical characteristics of low density lipoproteins (LDL) and high density lipoproteins (HDL), as well as on the activities of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) that were determined in both endogenous lipoprotein-dependent and endogenous lipoprotein-independent assays. Simvastatin 115-126 phospholipid transfer protein Homo sapiens 354-358 10217372-3 1999 Simvastatin, unlike placebo, reduced the lipid and apolipoprotein B contents of the most abundant LDL-1, LDL-2, and LDL-3 subfractions without inducing significant changes in the overall size distribution of LDL and HDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 51-67 10217372-4 1999 Whereas simvastatin significantly increased PLTP activity in an endogenous lipoprotein-dependent assay (P < 0.01), no variation was observed in a lipoprotein-independent assay. Simvastatin 8-19 phospholipid transfer protein Homo sapiens 44-48 10217372-5 1999 Simvastatin significantly decreased plasma CETP activity in an endogenous lipoprotein-dependent assay (P < 0.01), and the reduction in plasma cholesteryl ester transfer rates was explained by a 16% drop in CETP mass concentration (P < 0.01). Simvastatin 0-11 cholesteryl ester transfer protein Homo sapiens 43-47 10217372-7 1999 The simvastatin-induced changes in plasma CETP mass levels correlated positively with changes in plasma CETP activity (r = 0.483, P = 0.0561), in total cholesterol levels (r = 0.769; P < 0.01), and in LDL-cholesterol levels (r = 0.736; P < 0.01). Simvastatin 4-15 cholesteryl ester transfer protein Homo sapiens 42-46 10217372-7 1999 The simvastatin-induced changes in plasma CETP mass levels correlated positively with changes in plasma CETP activity (r = 0.483, P = 0.0561), in total cholesterol levels (r = 0.769; P < 0.01), and in LDL-cholesterol levels (r = 0.736; P < 0.01). Simvastatin 4-15 cholesteryl ester transfer protein Homo sapiens 104-108 10217372-8 1999 Whereas the observations suggest that simvastatin might exert concomitant beneficial effects on plasma CETP and LDL levels, neither plasma cholesteryl ester transfer activity nor plasma phospholipid transfer activity appeared as the main determinants of the LDL and HDL distribution profiles in type IIb hyperlipidemic patients. Simvastatin 38-49 cholesteryl ester transfer protein Homo sapiens 103-107 10208479-0 1999 The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Simvastatin 146-157 low density lipoprotein receptor Homo sapiens 28-60 10090116-2 1999 METHODS: A validated model based on data from the Lipid Research Clinics cohort was used to estimate the benefits and cost-effectiveness of lipid modification with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) based on results from the Scandinavian Simvastatin Survival Study (4S), including a 35% decrease in low-density-lipoprotein (LDL)-cholesterol levels and an 8% increase in high-density-lipoprotein (HDL)-cholesterol levels. Simvastatin 272-283 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 164-211 10100621-3 1999 The present study was aimed to elucidate the molecular target(s) of these tyrosine phosphorylations induced by HCRI and demonstrated that simvastatin induces tyrosine phosphorylation of phospholipase C (PLC) gamma1. Simvastatin 138-149 phospholipase C gamma 1 Homo sapiens 186-214 10100621-5 1999 Pretreatment of the cells with herbimycin A, a specific inhibitor of protein tyrosine kinase, inhibited a simvastatin-induced increase in IP3 level in the cells as well as tyrosine phosphorylation of PLC-gamma1. Simvastatin 106-117 phospholipase C gamma 1 Homo sapiens 200-210 10100621-7 1999 Thus, these results strongly suggest that simvastatin-induced tyrosine phosphorylation of PLC-gamma1 plays, at least in part, an important role for the development of simvastatin-induced cell death. Simvastatin 42-53 phospholipase C gamma 1 Homo sapiens 90-100 10100621-7 1999 Thus, these results strongly suggest that simvastatin-induced tyrosine phosphorylation of PLC-gamma1 plays, at least in part, an important role for the development of simvastatin-induced cell death. Simvastatin 167-178 phospholipase C gamma 1 Homo sapiens 90-100 10193729-0 1999 Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. Simvastatin 37-48 coagulation factor II, thrombin Homo sapiens 14-22 10193729-10 1999 After simvastatin treatment, serum cholesterol decreased by 31% and LDL cholesterol by 42%, while thrombin generation became markedly depressed. Simvastatin 6-17 coagulation factor II, thrombin Homo sapiens 98-106 10193729-14 1999 CONCLUSIONS: In men with hypercholesterolemia, lowering serum cholesterol level by a three-month simvastatin treatment is accompanied by a marked reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury. Simvastatin 97-108 coagulation factor II, thrombin Homo sapiens 159-167 10100621-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, kills L6 myoblasts by involving Ca2+ mobilization from the Ca2+ pool in the cells but not by influx from extracellular space. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 10100621-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, kills L6 myoblasts by involving Ca2+ mobilization from the Ca2+ pool in the cells but not by influx from extracellular space. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-63 10208479-0 1999 The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Simvastatin 146-157 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 118-135 9920147-8 1999 Simvastatin treatment reduced circulating TC, LDL-C, and TG by 40%, 50%, and 33% (P<.007), respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 46-51 10070171-2 1999 Simvastatin, in micromolar concentrations, engendered cholesterol-independent inhibition of CF and PTC thymidine incorporation and cholesterol-dependent suppression of PTC apical Na+/H+ exchange (NHE) (ethylisopropylamiloride-sensitive apical 22Na+ uptake). Simvastatin 0-11 solute carrier family 9 member C1 Homo sapiens 179-194 10070171-2 1999 Simvastatin, in micromolar concentrations, engendered cholesterol-independent inhibition of CF and PTC thymidine incorporation and cholesterol-dependent suppression of PTC apical Na+/H+ exchange (NHE) (ethylisopropylamiloride-sensitive apical 22Na+ uptake). Simvastatin 0-11 solute carrier family 9 member C1 Homo sapiens 196-199 10070171-4 1999 A lower concentration (0.1 micromol/l) of simvastatin did not affect any of the above parameters under basal conditions but completely prevented CsA-stimulated CF collagen synthesis (control, 6.6 +/- 0.6; CsA, 8.3 +/- 0.6; CsA+simvastatin, 6.2 +/- 0.5%; P < 0.05) and IGF-I secretion (89.5 +/- 16.6, 204.7 +/- 57.0, and 94.6 +/- 22.3 ng. Simvastatin 42-53 insulin like growth factor 1 Homo sapiens 271-276 11563401-10 1999 Plasminogen activator inhibitor-1 levels are decreased by pravastatin, are not affected by atorvastatin, and are significantly increased by lovastatin and simvastatin. Simvastatin 155-166 serpin family E member 1 Homo sapiens 0-33 9920155-14 1999 This study suggests that a decrease in residence time by upregulation of the LDL receptor with simvastatin alters LDL composition in a way that is likely to render the particle less atherogenic. Simvastatin 95-106 low density lipoprotein receptor Homo sapiens 77-89 10215754-3 1999 RESULTS: Mibefradil inhibited, in a concentration-dependent fashion, the metabolism of the four statins (simvastatin, lovastatin, atorvastatin and cerivastatin) known to be substrates for CYP3A. Simvastatin 105-116 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 188-193 10432174-3 1999 Fasting plasma total and LDL cholesterol and apolipoprotein B (apo B) were significantly lower on simvastatin compared to placebo. Simvastatin 98-109 apolipoprotein B Homo sapiens 45-61 10037153-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, causes myopathy in rabbits and kills L6 myoblasts. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 41-58 10037153-1 1999 Our previous studies have shown that the HMG-CoA reductase (HCR) inhibitor (HCRI), simvastatin, causes myopathy in rabbits and kills L6 myoblasts. Simvastatin 83-94 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 60-63 9793596-12 1998 In comparison, currently available HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin) lower LDL-C concentrations by approximately 20-40% and TG concentrations by approximately 10-30%. Simvastatin 77-88 component of oligomeric golgi complex 2 Homo sapiens 136-141 9865510-7 1998 In the presence of simvastatin (60 microM; an inhibitor of intracellular Ca2+ release), reactivity to vasopressin was reduced substantially in female (42+/-1%) but unaltered in male aortae. Simvastatin 19-30 arginine vasopressin Rattus norvegicus 102-113 10101552-7 1998 A greater reduction of LDL-C (32%) was achieved by simvastatin monotherapy. Simvastatin 51-62 component of oligomeric golgi complex 2 Homo sapiens 23-28 9809932-10 1998 Apolipoprotein B was significantly reduced by simvastatin, alone and combined with HRT, by 39% and 35%, respectively, compared to placebo (p < 0.001). Simvastatin 46-57 apolipoprotein B Homo sapiens 0-16 9809932-11 1998 Alone and in combination with simvastatin, HRT significantly increased apolipoprotein A-I by 11% and 12%, respectively, compared to placebo (p < 0.05) and decreased lipoprotein (a) by 23% and 33%, respectively, compared to placebo (p < 0.05), whereas simvastatin had no significant effect on either of these parameters. Simvastatin 30-41 apolipoprotein A1 Homo sapiens 71-89 9726984-10 1998 Lovastatin and simvastatin, inhibitors of HMG-CoA reductase, strongly suppressed cholesterol synthesis while having no effect on autophagic activity, suggesting that AMPK inhibits autophagy independently of its effects on HMG-CoA reductase and cholesterol metabolism. Simvastatin 15-26 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 166-170 9804052-3 1998 Pharmacokinetic interaction with some of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, specifically lovastatin and simvastatin, leads to an increased incidence of muscle skeletal toxicity in transplant patients. Simvastatin 133-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 9728898-1 1998 OBJECTIVE: To study the effects of erythromycin and verapamil on the pharmacokinetics of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin 89-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 118-165 9763219-0 1998 Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4"-(6-allyl-ethyl-amino-hexyloxy)-2"-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin. Simvastatin 269-280 3-hydroxy-3-methylglutaryl-coenzyme A reductase Mesocricetus auratus 19-66 9763219-7 1998 In contrast, simvastatin, at concentrations inhibiting cholesterol synthesis by the same 50-75%, increased both HMGR mRNA levels and synthesis, as well as LDL uptake. Simvastatin 13-24 3-hydroxy-3-methylglutaryl-coenzyme A reductase Mesocricetus auratus 112-116 9763219-9 1998 Still, simvastatin markedly increased both HMGR mRNA levels and synthesis in cells incubated in the presence of LDL, leaving LDL uptake unaffected. Simvastatin 7-18 3-hydroxy-3-methylglutaryl-coenzyme A reductase Mesocricetus auratus 43-47 9701472-8 1998 The inhibitory effect of simvastatin on the generation of TRAP-positive MNCs was dose and time dependent. Simvastatin 25-36 acid phosphatase 5, tartrate resistant Mus musculus 58-62 9728898-11 1998 Concomitant administration of erythromycin, verapamil, or other potent inhibitors of CYP3A4 with simvastatin should be avoided. Simvastatin 97-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 10095800-8 1998 RESULTS: LDLc concentration significantly decreased during treatment with 80 mg atorvastatin as compared to LDLc levels on 40 mg simvastatin alone or in combination with 8-12 g colestyramin, by 24 +/- 14% (P < 0.01) and 19 +/- 22% (P < 0.01), respectively. Simvastatin 129-140 component of oligomeric golgi complex 2 Homo sapiens 108-112 9665425-5 1998 Before and after the treatment of 23 patients with simvastatin 5 mg a day for 4 weeks, plasma CETP markedly decreased in those whose pretreatment CETP was > or = 3 mg/L; no change was observed for those with lower pretreatment CETP. Simvastatin 51-62 cholesteryl ester transfer protein Homo sapiens 94-98 9695968-1 1998 SCID mice were inoculated intravenously with cells from the human HL60 myeloblastic leukaemia cell line and then treated with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, simvastatin, by subcutaneous continuous infusion. Simvastatin 199-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-187 9665425-5 1998 Before and after the treatment of 23 patients with simvastatin 5 mg a day for 4 weeks, plasma CETP markedly decreased in those whose pretreatment CETP was > or = 3 mg/L; no change was observed for those with lower pretreatment CETP. Simvastatin 51-62 cholesteryl ester transfer protein Homo sapiens 146-150 9665425-5 1998 Before and after the treatment of 23 patients with simvastatin 5 mg a day for 4 weeks, plasma CETP markedly decreased in those whose pretreatment CETP was > or = 3 mg/L; no change was observed for those with lower pretreatment CETP. Simvastatin 51-62 cholesteryl ester transfer protein Homo sapiens 146-150 9576425-4 1998 The reduction in MCEs within the simvastatin group was highly correlated with on-treatment levels and changes from baseline in total and LDL cholesterol, apolipoprotein B, and less so with HDL cholesterol, but there was no clear relationship with triglycerides. Simvastatin 33-44 apolipoprotein B Homo sapiens 154-170 9634257-0 1998 Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart Pharmacy: of benefit to whom? Simvastatin 16-27 septin 4 Homo sapiens 78-82 9637705-0 1998 Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Simvastatin 85-96 endothelin 1 Bos taurus 119-131 9637705-0 1998 Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Simvastatin 85-96 nitric oxide synthase 3 Bos taurus 136-169 9633944-0 1998 Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Simvastatin 101-112 low density lipoprotein receptor Homo sapiens 24-36 9633944-0 1998 Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Simvastatin 101-112 low density lipoprotein receptor Homo sapiens 157-186 9633944-2 1998 A randomized, double-blind, placebo-controlled clinical trial with simvastatin, an HMG-CoA reductase inhibitor, was conducted in 63 children and adolescents with heterozygous FH. Simvastatin 67-78 low density lipoprotein receptor Homo sapiens 175-177 9633944-6 1998 Multiple regression analyses suggested that 42% of the variation of the LDL cholesterol response to simvastatin can be attributed to variation in the mutant LDL receptor locus, apolipoprotein E genotype, and body mass index, while 35% of the variation in HDL cholesterol response was explained by sex and baseline HDL cholesterol. Simvastatin 100-111 low density lipoprotein receptor Homo sapiens 157-169 9633944-6 1998 Multiple regression analyses suggested that 42% of the variation of the LDL cholesterol response to simvastatin can be attributed to variation in the mutant LDL receptor locus, apolipoprotein E genotype, and body mass index, while 35% of the variation in HDL cholesterol response was explained by sex and baseline HDL cholesterol. Simvastatin 100-111 apolipoprotein E Homo sapiens 177-193 9598832-7 1998 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (5 micromol/L) reduced EC accumulation derived from agLDL uptake by 58% and 35% in platelet-derived growth factor-stimulated and unstimulated VSMCs, respectively. Simvastatin 62-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 9651568-14 1998 CONCLUSIONS: Adding acipimox to simvastatin reduced Lp(a) and substantially but not significantly lowered TG. Simvastatin 32-43 lipoprotein(a) Homo sapiens 52-57 9633944-7 1998 These results show that simvastatin was an effective and well-tolerated therapy for FH in the pediatric population for all LDL receptor gene mutations. Simvastatin 24-35 low density lipoprotein receptor Homo sapiens 84-86 9633944-7 1998 These results show that simvastatin was an effective and well-tolerated therapy for FH in the pediatric population for all LDL receptor gene mutations. Simvastatin 24-35 low density lipoprotein receptor Homo sapiens 123-135 9633944-8 1998 Moreover, the nature of LDL receptor gene mutations and other genetic and constitutional factors play a significant role in predicting the efficacy of simvastatin in the treatment of FH in children and adolescents. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 24-36 9633944-8 1998 Moreover, the nature of LDL receptor gene mutations and other genetic and constitutional factors play a significant role in predicting the efficacy of simvastatin in the treatment of FH in children and adolescents. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 183-185 9636401-0 1998 HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 9607128-9 1998 Both simvastatin and cholestyramine tended to lead to decreased cholesterol in all lipoprotein fractions and caused a significant decrease in serum CETP activity when compared with the control diet. Simvastatin 5-16 cholesteryl ester transfer protein Oryctolagus cuniculus 148-152 9537338-5 1998 Both simvastatin (1 micromol/L) and lovastatin (10 micromol/L) upregulated ecNOS expression by 3.8-fold and 3.6-fold, respectively, and completely prevented its downregulation by ox-LDL. Simvastatin 5-16 nitric oxide synthase 3 Homo sapiens 75-80 9537338-6 1998 These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 32-37 9537338-6 1998 These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 76-81 9537338-7 1998 Although L-mevalonate alone did not affect ecNOS expression, cotreatment with L-mevalonate completely reversed ecNOS upregulation by simvastatin. Simvastatin 133-144 nitric oxide synthase 3 Homo sapiens 111-116 9537338-8 1998 Actinomycin D studies revealed that simvastatin stabilized ecNOS mRNA (tau1/2, 43 versus 35 hours). Simvastatin 36-47 nitric oxide synthase 3 Homo sapiens 59-64 9607128-14 1998 The results suggest that decreasing serum CETP activity levels by treatment with simvastatin or cholestyramine may contribute to lowering of cholesterol apo B-containing lipoproteins. Simvastatin 81-92 cholesteryl ester transfer protein Oryctolagus cuniculus 42-46 18370543-8 1998 RESULTS: Ten of 15 patients on atorvastatin 10mg (66%) and four of 15 on simvastatin 10mg (27%) achieved the LDL-C <130 mg/dl goal. Simvastatin 73-84 component of oligomeric golgi complex 2 Homo sapiens 109-114 9535116-1 1998 Simvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor has been reported to inhibit cell division and induce neurite-like outgrowth in PC12 cells [Sato-Suzuki, I. and Murota, S., Neurosci. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 22-79 9535116-3 1998 In the present paper, we examined whether the induced nitric oxide (NO) in the simvastatin-treated PC12 cells is involved in the growth arrest and differentiation as reported in nerve growth factor (NGF) treated PC12 cells. Simvastatin 79-90 nerve growth factor Rattus norvegicus 178-197 9535116-3 1998 In the present paper, we examined whether the induced nitric oxide (NO) in the simvastatin-treated PC12 cells is involved in the growth arrest and differentiation as reported in nerve growth factor (NGF) treated PC12 cells. Simvastatin 79-90 nerve growth factor Rattus norvegicus 199-202 9535116-4 1998 Treatment of PC12 cells with simvastatin caused peripherin formation and enhanced NO production just like NGF-treated PC12 cells. Simvastatin 29-40 nerve growth factor Rattus norvegicus 106-109 9498648-4 1998 streptozotocin, 45 mg/kg) were fed for 4 weeks on a standard diet or on a diet supplemented with either the lipid-lowering antioxidant probucol (1% w/w in diet) or the 3-hydroxy 3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitor simvastatin (0.01% w/w in diet). Simvastatin 236-247 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 168-225 9566646-5 1998 RESULTS: As expected Simvastatin (20 mg day[-1]) reduced serum total cholesterol, triacylglycerols, apolipoproteins B and E and increased HDL-cholesterol and apolipoprotein A1. Simvastatin 21-32 apolipoprotein A1 Homo sapiens 158-175 9542477-0 1998 Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Simvastatin 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-82 18370543-9 1998 Apolipoprotein B was reduced by both drugs (-33%, p < 0.001 for atorvastatin and -18%, p < 0.05 for simvastatin), but plasma fibrinogen and triglyceride were reduced only by atorvastatin (-20%, p < 0.01; -36%, p < 0.001, respectively). Simvastatin 106-117 apolipoprotein B Homo sapiens 0-16 18370543-10 1998 During the second 16-week period seven of 11 patients receiving the simvastatin 20mg dose (64%) achieved the LDL-C <130 mg/dl goal. Simvastatin 68-79 component of oligomeric golgi complex 2 Homo sapiens 109-114 9730140-1 1998 We investigated in vitro effect of simvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the proliferation of human and bovine endothelial cells (EC) compared to that of bovine smooth muscle cells (SMC). Simvastatin 35-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-114 9509899-1 1998 The recent development of specific competitive inhibitors of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase such as lovastatin, simvastatin, pravastatin and fluvastatin has provided an important new and effective approach to the treatment of hyperlipidaemia and atherosclerosis. Simvastatin 138-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-117 9321523-13 1997 The results suggested that the in vivo inhibitory effects of SV on the metabolism of CYP3A substrates likely would be less than those of ketoconazole and itraconazole at their respective therapeutic concentrations. Simvastatin 61-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-90 9395516-5 1997 In a concentration-dependent manner, simvastatin, and to a lesser extent, lovastatin, prevented the down-regulation of ecNOS expression by hypoxia. Simvastatin 37-48 nitric oxide synthase 3 Homo sapiens 119-124 9395516-6 1997 Simvastatin-induced changes in ecNOS expression correlated with changes in endothelial NO production and were reversed by treatment with L-mevalonate. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 31-36 9395516-7 1997 Actinomycin D studies revealed that under hypoxic conditions, simvastatin increased ecNOS mRNA half-life from 13 to 38 h. Nuclear run-on studies showed that simvastatin had no effect on repression of ecNOS gene transcription by hypoxia. Simvastatin 62-73 nitric oxide synthase 3 Homo sapiens 84-89 9406661-2 1997 The main objective of the present study was to verify the speed with which two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, simvastatin and pravastatin, could revert endothelial cell dysfunction in hypercholesterolaemic rabbits. Simvastatin 139-150 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 79-126 9503394-4 1997 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, also inhibited the ACAT activity in Caco-2 cells with an IC50 value of 22.5 microM, whereas pravastatin Na, probucol and clofibrate did not affect the activity. Simvastatin 0-11 sterol O-acyltransferase 1 Homo sapiens 86-90 9520115-0 1997 Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Simvastatin 88-99 lipoprotein(a) Homo sapiens 0-5 9520115-4 1997 Numbers of deaths in the Simvastatin group differed significantly between quartiles of Lp(a) lipoprotein levels, the reduction in deaths being most pronounced in the second (next to lowest) quartile. Simvastatin 25-36 lipoprotein(a) Homo sapiens 87-92 9520115-7 1997 The findings show that Lp(a) lipoprotein predicts major coronary events as well as death in secondary prevention with Simvastatin. Simvastatin 118-129 lipoprotein(a) Homo sapiens 23-28 9350917-10 1997 Treatment of these patients with the HMG-CoA reductase inhibitors lovastatin or simvastatin (20 to 40 mg/day) for 6 weeks slightly decreased total and LDL cholesterol plasma levels and monocyte CD11b surface expression but resulted in a significant reduction of monocyte adhesion to endothelium (p < 0.01, n = 7). Simvastatin 80-91 integrin subunit alpha M Homo sapiens 194-199 9217719-0 1997 Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Simvastatin 38-49 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 64-70 9294990-12 1997 Simvastatin + ciprofibrate was more effective than pravastatin + gemfibrozil in reducing LDL, TG, and plasma fibrinogen levels. Simvastatin 0-11 fibrinogen beta chain Homo sapiens 109-119 9328167-9 1997 Simvastatin feeding produced an increased development of ER- PgR- tumours and a reduced incidence of ER+ PgR+ tumours. Simvastatin 0-11 progesterone receptor Rattus norvegicus 61-64 9328167-9 1997 Simvastatin feeding produced an increased development of ER- PgR- tumours and a reduced incidence of ER+ PgR+ tumours. Simvastatin 0-11 progesterone receptor Rattus norvegicus 105-108 9258815-1 1997 We analyzed the antiproliferative effect of simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on human glioma cell lines. Simvastatin 44-55 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 78-135 9316434-1 1997 We examined the effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the kinetics of very low-density lipoprotein apolipoprotein B-100 (VLDL apoB) in 13 normolipidemic men in a placebo-controlled crossover study. Simvastatin 26-37 apolipoprotein B Homo sapiens 152-172 9316434-4 1997 Simvastatin decreased VLDL apoB pool size by 53% and the hepatic secretion rate of VLDL apoB by 46% but did not significantly alter its fractional catabolism. Simvastatin 0-11 apolipoprotein B Homo sapiens 27-31 9377621-9 1997 Simvastatin 2.5 mg/d reduced LDL-C levels by 22.9% and total-C levels by 15.7%; simvastatin 40 mg/d reduced these levels by 40.7% and 29.7%, respectively. Simvastatin 0-11 component of oligomeric golgi complex 2 Homo sapiens 29-34 9260485-7 1997 Median Lp(a) levels tended to increase during simvastatin and to decrease during ketoconazole therapy. Simvastatin 46-57 lipoprotein(a) Homo sapiens 7-12 9254057-1 1997 In the monocytic THP-1 cells, the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin (5 microM) enhances the conversion of exogenous linoleic (18:2 n-6) and eicosapentaenoic (20:5 n-3) acids to their long-chain polyunsaturated fatty acid (LC-PUFA) derivatives, and this effect is associated with changes in the desaturation steps. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 9260485-10 1997 The increase in Lp(a) during simvastatin therapy has been reported earlier, whereas ketoconazole does not exhibit an effect on the level of Lp(a). Simvastatin 29-40 lipoprotein(a) Homo sapiens 16-21 9208356-9 1997 Results of this study confirmed that a low dose (10 mg) of simvastatin daily is a safe and effective method of reducing plasma levels of total and low-density lipoprotein cholesterol in hypercholesterolemic, hypertensive elderly patients receiving concurrent antihypertensive drug therapy, and that it has the additional potential benefit of reducing plasma levels of insulin. Simvastatin 59-70 insulin Homo sapiens 368-375 9250604-3 1997 In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis. Simvastatin 124-135 GLI family zinc finger 2 Homo sapiens 23-28 9250604-3 1997 In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis. Simvastatin 124-135 pumilio RNA binding family member 3 Homo sapiens 53-57 9250604-3 1997 In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis. Simvastatin 124-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 97-113 9220213-2 1997 The aim of this study was to investigate the safety and long-term effects on serum lipid levels of low-dose simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in Japanese patients with moderate primary hypercholesterolemia. Simvastatin 108-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-184 9077372-14 1997 CONCLUSIONS: Adding acipimox to simvastatin reduced Lp(a) and substantially but not significantly lowered TG. Simvastatin 32-43 lipoprotein(a) Homo sapiens 52-57 9160078-1 1997 Simvastatin is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase intended for use as a hypocholesterolemic agent. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-89 9150246-11 1997 Moreover, simvastatin treatment blocked the PDGF and bFGF-induced DNA synthesis in synchronized smooth muscle cells, whereas it does not affect the fetal calf serum-induced DNA synthesis in synchronized fibroblasts, suggesting that simvastatin blocks various steps of the cell cycle and that this effect depends on the cell type and the growth signalling pathway activated. Simvastatin 10-21 fibroblast growth factor 2 Homo sapiens 53-57 9070296-5 1997 Furthermore simvastatin reduced in a dose-dependent manner the expression of hsp 70 triggered by OxLDL, as detected by immunoblotting. Simvastatin 12-23 heat shock protein family A (Hsp70) member 4 Homo sapiens 77-83 9070296-9 1997 These results indicate that simvastatin increases OxLDL cytotoxicity in vitro with a concomitant decrease of hsp70 expression triggered by OxLDL and that the key step in the cholesterol synthesis responsible for these effects must be between mevalonate and squalene formation. Simvastatin 28-39 heat shock protein family A (Hsp70) member 4 Homo sapiens 109-114 9081681-2 1997 Reduction of plasma cholesterol levels by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin has been found to improve certain aspects of platelet function in vitro and in vivo, but controlled trials are largely lacking. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-93 9100218-7 1997 Addition of low dose simvastatin to soy protein induced a further decrease of serum total cholesterol, decreased VLDL and low-density lipoprotein (LDL) cholesterol, and LDL (apolipoprotein B), as well as improved VLDL-TG and HDL cholesterol levels. Simvastatin 21-32 apolipoprotein B Oryctolagus cuniculus 174-190 8994382-4 1996 Simvastatin, a potent inhibitor of the key enzyme controlling de novo cholesterol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, completely inhibited (P < 0.05) progesterone production by granulosa cells and progesterone and androstenedione production by thecal cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Bos taurus 93-150 9027779-3 1997 Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, reduces levels of these lipoproteins but the effect of treatment on cholesteryl ester transfer activity in patients on dialysis remains to be determined. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 9027779-5 1997 RESULTS: Simvastatin therapy significantly reduced serum cholesterol, LDL cholesterol, apoB concentrations, and both NCET (P = 0.001) and LCAT (P = 0.012) rates. Simvastatin 9-20 apolipoprotein B Homo sapiens 87-91 9027779-5 1997 RESULTS: Simvastatin therapy significantly reduced serum cholesterol, LDL cholesterol, apoB concentrations, and both NCET (P = 0.001) and LCAT (P = 0.012) rates. Simvastatin 9-20 lecithin-cholesterol acyltransferase Homo sapiens 138-142 9027779-7 1997 CONCLUSIONS: These data show that simvastatin therapy reduces serum NCET rates, and suggest that this may be linked to the concomitant decrease in levels of apoB-containing lipoproteins which are acceptors of transferred cholesteryl esters, and to the decrease in serum LCAT rates in patients with chronic renal failure with treatment. Simvastatin 34-45 apolipoprotein B Homo sapiens 157-161 9027779-7 1997 CONCLUSIONS: These data show that simvastatin therapy reduces serum NCET rates, and suggest that this may be linked to the concomitant decrease in levels of apoB-containing lipoproteins which are acceptors of transferred cholesteryl esters, and to the decrease in serum LCAT rates in patients with chronic renal failure with treatment. Simvastatin 34-45 lecithin-cholesterol acyltransferase Homo sapiens 270-274 8977139-1 1996 Simvastatin, a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 22-79 9086443-1 1997 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and also selectively inhibits the growth of leukaemic progenitor cells. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-88 9476046-0 1997 Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein B. Simvastatin 0-11 apolipoprotein B Homo sapiens 140-156 9241623-8 1997 Among the patients assigned simvastatin, total cholesterol was reduced by 13% (2p = 0.001), LDL cholesterol was reduced by 17% (2p = 0.003) and apolipoprotein B was reduced by 12% (2p = 0.005) compared to patients assigned placebo. Simvastatin 28-39 apolipoprotein B Homo sapiens 144-160 9125320-0 1996 Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Simvastatin 45-56 fibrinogen beta chain Homo sapiens 67-77 8880287-9 1996 The decrease in apo A-I/HDL-C ratio suggests that the increase in HDL-C after simvastatin must be regarded as an enrichment of the cholesterol core of HDL particles. Simvastatin 78-89 apolipoprotein A1 Homo sapiens 16-21 9006803-0 1996 Simvastatin increases plasma NO2- and NO3- levels in patients with hypercholesterolemia. Simvastatin 0-11 NBL1, DAN family BMP antagonist Homo sapiens 38-41 8960668-3 1996 Simvastatin strongly inhibited both erythroid and granulocyte-macrophage colony formation by total or CD34-positive bone marrow cells at the concentration of 10 microM, which is about 100-1,000 fold higher than the pharmacologically effective level. Simvastatin 0-11 CD34 molecule Homo sapiens 102-106 8993943-15 1996 CONCLUSION: Combined treatment with simvastatin and ciprofibrate effectively reduced plasma fibrinogen, triglycerides, total and LDL cholesterol and increased LDL particle size in patients with FCHL and CAD. Simvastatin 36-47 fibrinogen beta chain Homo sapiens 92-102 8937853-3 1996 Treatment of cultured hepatocytes with lovastatin, simvastatin, or fluvastatin increased CYP2B1/2, CYP3A1/2, and CYP4A mRNA and immunoreactive protein levels over the dose range (3 x 10(-6) to 3 x 10(-5) M) required to increase the amount of HMG-CoA reductase mRNA. Simvastatin 51-62 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 89-95 8937853-3 1996 Treatment of cultured hepatocytes with lovastatin, simvastatin, or fluvastatin increased CYP2B1/2, CYP3A1/2, and CYP4A mRNA and immunoreactive protein levels over the dose range (3 x 10(-6) to 3 x 10(-5) M) required to increase the amount of HMG-CoA reductase mRNA. Simvastatin 51-62 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 99-107 8937853-5 1996 In contrast, treatment of cultured hepatocytes with 3 x 10(-5) M lovastatin, simvastatin, or fluvastatin increased CYP3A1/2 and CYP4A mRNA and immunoreactive protein to lower levels than those produced by treatment with 10(-5) M dexamethasone or 10(-4) M ciprofibrate. Simvastatin 77-88 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 115-121 8958705-5 1996 While the treatment of simvastatin for one month significantly reduced serum cholesterol levels from 257 +/- 12 mg to 206 +/- 10 mg (no change in HbA1c was observed during the study), plasma tPA levels and % delta vWF (von Willebrand factor) following DDAVP infusion significantly increased from 11.4 +/- 1.2 ng/ml to 13.4 +/- 1.4 ng/ml and from 69.3 +/- 23.4% to 126.5 +/- 47.4%, respectively. Simvastatin 23-34 von Willebrand factor Homo sapiens 214-217 8958705-5 1996 While the treatment of simvastatin for one month significantly reduced serum cholesterol levels from 257 +/- 12 mg to 206 +/- 10 mg (no change in HbA1c was observed during the study), plasma tPA levels and % delta vWF (von Willebrand factor) following DDAVP infusion significantly increased from 11.4 +/- 1.2 ng/ml to 13.4 +/- 1.4 ng/ml and from 69.3 +/- 23.4% to 126.5 +/- 47.4%, respectively. Simvastatin 23-34 von Willebrand factor Homo sapiens 219-240 8904621-3 1996 It has been suggested that lipophilic HMG CoA reductase inhibitors, like lovastatin and simvastatin, may cause sleep disturbance. Simvastatin 88-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-55 8980885-7 1996 Simvastatin promotes more effective reduction in cholesterol and apoB in LDL than in VLDL, probably by increasing the hepatic LDL receptor which preferentially binds LDL. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 126-138 8831932-0 1996 Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding. Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 80-92 8831932-2 1996 If HMGCoA reductase inhibitors such as simvastatin lowered LDL mainly by up-regulating LDL-receptor mediated clearance, they should decrease the overall binding affinity of LDL from an FDB heterozygote by selectively decreasing LDL bearing normal apo B. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 3-19 8831932-2 1996 If HMGCoA reductase inhibitors such as simvastatin lowered LDL mainly by up-regulating LDL-receptor mediated clearance, they should decrease the overall binding affinity of LDL from an FDB heterozygote by selectively decreasing LDL bearing normal apo B. Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 87-99 8548414-7 1996 The levels of TC, LDL-C, apoB, and E were also lowered by simvastatin at 80 or 400 mg/d, but to a lesser extent than at 200 mg/d, while the other parameters were not influenced at these doses. Simvastatin 58-69 LDL Sus scrofa 18-23 8842455-8 1996 Statins reduced the apo B100 level secreted by the two cell types (simvastatin) or human hepatocytes (crilvastatin). Simvastatin 67-78 apolipoprotein B Homo sapiens 20-28 8824106-9 1996 Median Lp(a) levels increased after simvastatin, but were not affected by gemfibrozil. Simvastatin 36-47 lipoprotein(a) Homo sapiens 7-12 8872133-4 1996 In subjects with TC > 249 mg/dl and F1 + 2 > 1.2 nM (median value of the whole group), a cholesterol-lowering drug (simvastatin) was able to reduce F1 + 2 (p < 0.009) as well as TC and LDL-C. Simvastatin 122-133 coagulation factor XII Homo sapiens 39-45 8872133-4 1996 In subjects with TC > 249 mg/dl and F1 + 2 > 1.2 nM (median value of the whole group), a cholesterol-lowering drug (simvastatin) was able to reduce F1 + 2 (p < 0.009) as well as TC and LDL-C. Simvastatin 122-133 coagulation factor XII Homo sapiens 154-160 8682657-8 1996 Simvastatin treatment increased apo-AI mRNA nearly threefold, whereas apo-AII and apo-AIV decreased by more than 50%. Simvastatin 0-11 apolipoprotein A1 Rattus norvegicus 32-38 8769685-0 1996 Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Simvastatin 34-45 fibrinogen beta chain Homo sapiens 56-66 8611662-6 1996 Addition of 1-5 microM simvastatin resulted in a decrease of protein concentration, CK activity and percentage CK-MM, whereas 25 microM simvastatin resulted in cell death. Simvastatin 23-34 creatine kinase, M-type Rattus norvegicus 111-116 8706591-2 1996 This article discusses various aspects of cholesterol-lowering therapy using the HMG-CoA reductase inhibitor simvastatin in the light of the large Scandinavian Simvastatin Survival Study (4S). Simvastatin 109-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 81-98 8907800-1 1996 Simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity inhibits migration and proliferation of vascular smooth muscle cells (SMC). Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 34-91 8907800-1 1996 Simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity inhibits migration and proliferation of vascular smooth muscle cells (SMC). Simvastatin 13-15 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 34-91 8671811-11 1996 Simvastatin completely, and nitrosylation partially, removed the stimulatory properties of HDL. Simvastatin 0-11 HDL Sus scrofa 91-94 8620338-0 1996 Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Simvastatin 52-63 apolipoprotein B Homo sapiens 67-83 8548414-7 1996 The levels of TC, LDL-C, apoB, and E were also lowered by simvastatin at 80 or 400 mg/d, but to a lesser extent than at 200 mg/d, while the other parameters were not influenced at these doses. Simvastatin 58-69 apolipoprotein B Sus scrofa 25-29 8548414-8 1996 The simvastatin-induced decreases of LDL-C, HDL-C, and apoA-I, B, C-III, and E were significantly correlated among each other. Simvastatin 4-15 LDL Sus scrofa 37-42 8548414-8 1996 The simvastatin-induced decreases of LDL-C, HDL-C, and apoA-I, B, C-III, and E were significantly correlated among each other. Simvastatin 4-15 apolipoprotein A1 Sus scrofa 55-61 8548414-9 1996 These results show that the trend of responses in TC, LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swine is similar to that observed in humans, although the drugs is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters. Simvastatin 89-100 LDL Sus scrofa 54-59 8548414-9 1996 These results show that the trend of responses in TC, LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swine is similar to that observed in humans, although the drugs is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters. Simvastatin 89-100 apolipoprotein B Sus scrofa 61-65 8548414-9 1996 These results show that the trend of responses in TC, LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swine is similar to that observed in humans, although the drugs is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters. Simvastatin 89-100 apolipoprotein E Sus scrofa 81-85 8729584-2 1996 It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-79 8737761-1 1996 OBJECTIVE: The affinity of (+)-, (-)- and (+/-)- fluvastatin, a new synthetic HMG-CoA reductase inhibitor developed as a racemate, for specific human P450 monooxygenases in liver microsomes was compared with that of the pharmacologically active acidic forms of lovastatin, pravastatin and simvastatin. Simvastatin 289-300 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 150-154 8737761-7 1996 As already reported for lovastatin and simvastatin, in vivo drug interactions by inhibition of liver oxidation of CYP2C9 substrates (e.g. hypoglyceamic sulphonylureas and oral anticoagulants) may be expected. Simvastatin 39-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 12013483-3 1996 The tension (g) developed by angiotensin II (100 nmol/l) was measured under basal conditions and after 45 min incubation with 20 micromol/l simvastatin. Simvastatin 140-151 angiotensinogen Rattus norvegicus 29-43 12013483-6 1996 Treatment of aortic rings with simvastatin inhibited the angiotensin II-induced contraction 58 +/- 0.06%. Simvastatin 31-42 angiotensinogen Rattus norvegicus 57-71 8820110-7 1996 When incubating HepG2 cells for 16 h with the HMG-CoA reductase inhibitor simvastatin (10(-6)-10(-10) M) HMG-CoA reductase activity was increased up to 180%. Simvastatin 74-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-63 12013483-13 1996 Simvastatin, lovastatin and mevastatin significantly reduced the angiotensin II-induced calcium mobilization. Simvastatin 0-11 angiotensinogen Rattus norvegicus 65-79 8820110-7 1996 When incubating HepG2 cells for 16 h with the HMG-CoA reductase inhibitor simvastatin (10(-6)-10(-10) M) HMG-CoA reductase activity was increased up to 180%. Simvastatin 74-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-122 8546515-1 1995 A boy with a total plasma cholesterol concentration of 20.9 mmol/l which fell significantly with a low fat diet, cholestyramine and simvastatin, was shown to have two different mutations in the low density lipoprotein receptor gene, demonstrating that some patients with homozygous familial hypercholesterolaemia show a good lipid lowering response to treatment. Simvastatin 132-143 low density lipoprotein receptor Homo sapiens 194-226 8850383-0 1995 Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Simvastatin 83-94 lipoprotein(a) Homo sapiens 12-51 8850383-3 1995 Based on these considerations, we studied 15 patients affected by primary hypercholesterolemia to evaluate the effect of simvastatin in Lp(a) and apoprotein plasma levels (A1, B, C2, C3, E), in addition to the classic lipid parameters. Simvastatin 121-132 lipoprotein(a) Homo sapiens 136-141 8850383-6 1995 Simvastatin therapy further showed a significant decrease in apoC2 (p < 0.05), the apo C2/C3 ratio (p < 0.01), and apoE (p < 0.01), as well as a significant increase in Lp(a) plasma levels (p < 0.05). Simvastatin 0-11 apolipoprotein E Homo sapiens 121-125 8850383-6 1995 Simvastatin therapy further showed a significant decrease in apoC2 (p < 0.05), the apo C2/C3 ratio (p < 0.01), and apoE (p < 0.01), as well as a significant increase in Lp(a) plasma levels (p < 0.05). Simvastatin 0-11 apolipoprotein C2 Homo sapiens 61-66 8850383-6 1995 Simvastatin therapy further showed a significant decrease in apoC2 (p < 0.05), the apo C2/C3 ratio (p < 0.01), and apoE (p < 0.01), as well as a significant increase in Lp(a) plasma levels (p < 0.05). Simvastatin 0-11 lipoprotein(a) Homo sapiens 178-183 8835365-1 1995 The present study analyses the effects of simvastatin, a specific inhibitor of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA reductase) in male Syrian hamsters fed a standard diet or a diet supplemented with 0.12% cholesterol and 20% coconut oil. Simvastatin 42-53 3-hydroxy-3-methylglutaryl-coenzyme A reductase Mesocricetus auratus 122-139 8835365-7 1995 The toxicity of simvastatin could indeed result from the low basal activity of HMG-CoA reductase in hamster liver coupled with a prolonged inhibition of mevalonate synthesis. Simvastatin 16-27 3-hydroxy-3-methylglutaryl-coenzyme A reductase Mesocricetus auratus 79-96 8538379-7 1995 Cytosolic neutral cholesteryl ester hydrolase (CEH) activity was substantially elevated by simvastatin (3-fold) and by the drug combination (6-fold), whereas the effect of cholestyramine was smaller (1.5-fold). Simvastatin 91-102 epoxide hydrolase 2 Rattus norvegicus 18-45 8569435-0 1995 Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 48-89 8569435-3 1995 Moreover, both the total and dephosphorylated 3-hydroxy-3-methylglutaryl--CoA (HMG-CoA) reductase (EC 1.1.1.34) activities, particularly 1 h after treatment, were greatly reduced in liver microsomes obtained from simvastatin-treated as compared to control rats. Simvastatin 213-224 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 46-97 8538379-7 1995 Cytosolic neutral cholesteryl ester hydrolase (CEH) activity was substantially elevated by simvastatin (3-fold) and by the drug combination (6-fold), whereas the effect of cholestyramine was smaller (1.5-fold). Simvastatin 91-102 epoxide hydrolase 2 Rattus norvegicus 47-50 8538379-9 1995 Microsomal CEH activity was increased by simvastatin, alone and in combination with cholestyramine (1.4 to 1.7-fold), and was also enhanced, in the cholestyramine-treated animals, following drug withdrawal. Simvastatin 41-52 epoxide hydrolase 2 Rattus norvegicus 11-14 8538379-11 1995 The results indicate that in the rat, simvastatin and cholestyramine alter both ACAT and CEH activity, as well as inhibiting HMG-CoA reductase activity. Simvastatin 38-49 epoxide hydrolase 2 Rattus norvegicus 89-92 7670949-3 1995 Our results indicate that the HMG-CoA reductase inhibitors fluvastatin and simvastatin reduce, in a concentration-dependent manner, more than 50% of the 125I-AcLDL degradation by macrophages. Simvastatin 75-86 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 30-47 8560403-6 1995 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (20 mg/day for 2 months) significantly reduced cholesterol levels, urinary 11-dehydro-TxB2 excretion, plasma elastase and plasma F1 + 2 in 8 patients. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 7575771-1 1995 The long-term efficacy and tolerability of simvastatin, a 3-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA) reductase inhibitor, was assessed during a 24-month follow-up period in 168 elderly hypercholesterolemic patients. Simvastatin 43-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-116 7578166-7 1995 Apolipoprotein B levels were reduced by 29% at the end of 1 year with simvastatin but not with the other treatments. Simvastatin 70-81 apolipoprotein B Homo sapiens 0-16 8540887-0 1995 Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin. Simvastatin 86-97 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-73 7627709-2 1995 This study was conducted to define progression of atherosclerosis in both homozygous and heterozygous Watanabe heritable hyperlipidemic (WHHL) rabbits and to investigate the ability of the HMG CoA reductase inhibitor simvastatin to attenuate progression of the disease. Simvastatin 217-228 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 189-206 7589011-5 1995 We conclude that the hepatic secretion of VLDL apoB in FH is decreased by simvastatin, which may partly explain the fall in plasma cholesterol. Simvastatin 74-85 apolipoprotein B Homo sapiens 47-51 7559927-1 1995 It has been reported that the HMG-CoA reductase inhibitor simvastatin does not always effectively lower plasma LDL. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-47 7585842-1 1995 In this pilot study, 12 patients (6 men, 6 postmenopausal women) with hypercholesterolemia were treated with low-dose (5 mg/d) simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 4 weeks. Simvastatin 127-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 142-189 7478073-3 1995 Based on the above consideration, we studied 20 patients (7 females and 13 males), mean age 52.4 +/- 14.2 years, affected by primary hypercholesterolemia to evaluate the effect of simvastatin on Lp(a), in addition to the classic lipidic parameters. Simvastatin 180-191 lipoprotein(a) Homo sapiens 195-200 7478073-7 1995 Simvastatin therapy further determined a significant increase in Lp(a) plasma levels (43.8 +/- 25.6 vs 50.5 +/- 28.0, p < 0.02). Simvastatin 0-11 lipoprotein(a) Homo sapiens 65-70 7478073-8 1995 The our data, in agreement with those documenting the beneficial effect of Simvastatin in greatly decreasing CH and LDL-CH, but point out the need for further studies concerning the long-ter effect of simvastatin on Lp(a), in order to fully establish its role in the secondary prevention of atherosclerosis. Simvastatin 201-212 lipoprotein(a) Homo sapiens 216-221 7628131-0 1995 Effect of simvastatin on Lp(a) concentrations. Simvastatin 10-21 lipoprotein(a) Homo sapiens 25-30 7585842-3 1995 Simvastatin caused significant decreases of total cholesterol (-18.1%), LDL cholesterol (-27.6%), and apolipoprotein B (-21.8%), and significantly reduced total cholesterol, free cholesterol, cholesterol esters, phospholipids, and protein in LDL without significantly changing the component ratios and fatty acid levels of LDL. Simvastatin 0-11 apolipoprotein B Homo sapiens 102-118 7720643-3 1995 The 1 x 10(-7) M AVP-mobilized [Ca2+]i was significantly reduced in the cells pretreated with 1 x 10(-6) M simvastatin. Simvastatin 107-118 arginine vasopressin Rattus norvegicus 17-20 7720643-4 1995 AVP produced a biphasic change in cellular pH, namely, an early acidification followed by a sustained alkalinization, and the AVP-induced cellular alkalinization disappeared after exposing to simvastatin. Simvastatin 192-203 arginine vasopressin Rattus norvegicus 0-3 7720643-0 1995 Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Simvastatin 0-11 arginine vasopressin Rattus norvegicus 81-92 7720643-1 1995 The present study was undertaken to determine whether an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, simvastatin, modulates the cellular action of arginine vasopressin (AVP) in the cultured rat glomerular mesangial cells. Simvastatin 129-140 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 70-127 7720643-4 1995 AVP produced a biphasic change in cellular pH, namely, an early acidification followed by a sustained alkalinization, and the AVP-induced cellular alkalinization disappeared after exposing to simvastatin. Simvastatin 192-203 arginine vasopressin Rattus norvegicus 126-129 7720643-1 1995 The present study was undertaken to determine whether an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, simvastatin, modulates the cellular action of arginine vasopressin (AVP) in the cultured rat glomerular mesangial cells. Simvastatin 129-140 arginine vasopressin Rattus norvegicus 175-195 7720643-5 1995 1 x 10(-7) M AVP activated mitogen-activated protein (MAP) kinase from 15.5-30.4 pmol/mg protein, an effect significantly less in the presence of simvastatin. Simvastatin 146-157 arginine vasopressin Rattus norvegicus 13-16 7720643-1 1995 The present study was undertaken to determine whether an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, simvastatin, modulates the cellular action of arginine vasopressin (AVP) in the cultured rat glomerular mesangial cells. Simvastatin 129-140 arginine vasopressin Rattus norvegicus 197-200 7720643-6 1995 Also, 1 x 10(-7) M AVP significantly increased [3H]thymidine incorporation by 1.6-fold, and its incorporation was totally diminished in cells pretreated with simvastatin. Simvastatin 158-169 arginine vasopressin Rattus norvegicus 19-22 7720643-7 1995 The AVP-induced [Ca2+]i mobilization and MAP kinase activation were totally restored when cells were preexposed to a mixture of mevalonate and simvastatin. Simvastatin 143-154 arginine vasopressin Rattus norvegicus 4-7 7720643-9 1995 1 x 10(-7) AVP increased inositol trisphosphate production by 1.8-fold, which was significantly reduced by the presence of simvastatin. Simvastatin 123-134 arginine vasopressin Rattus norvegicus 11-14 7749833-6 1995 The reduction in 11-dehydro-TXB2 associated with simvastatin was correlated with the reduction in total cholesterol (r = .81, P < .0001), LDL cholesterol (r = .79, P < .0001), and apolipoprotein B (r = .76, P < .0001) levels. Simvastatin 49-60 apolipoprotein B Homo sapiens 186-202 7878672-1 1995 Pravastatin, lovastatin, and simvastatin, drugs which lower cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, have been linked to skeletal myopathies in humans and rats. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 7869918-0 1995 A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Simvastatin 52-63 insulin Homo sapiens 67-74 7869918-4 1995 Insulin sensitivity decreased by 27% and 28% during gemfibrozil and simvastatin treatment, respectively. Simvastatin 68-79 insulin Homo sapiens 0-7 7930373-1 1994 Simvastatin is an inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, the key enzyme in the synthesis of cholesterol, recently introduced in the therapy of hypercholesterolemic patients. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-89 7717016-0 1995 [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up]. Simvastatin 98-109 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-87 7717016-4 1995 In a prospective, randomized and controlled trial, we investigated the effects of monotherapy with the HMG-CoA-reductase inhibitor Simvastatin in heart transplant recipients. Simvastatin 131-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-120 7717016-15 1995 The drug induced hypercholesterolemia following HTx could be treated safely and effectively by low-dose Simvastatin. Simvastatin 104-115 Zic family member 3 Homo sapiens 48-51 7811739-4 1995 In order to show that the feedback regulation mechanism for 3-hydroxy-3-methylglutaryl-coenzyme A reductase was involved in this phenomena mRNA levels were measured in human vascular endothelial cells after incubation with the vastatins for 3.5 h and for 20 h. Indeed, lovastatin and simvastatin gave rise to higher levels of HMG-CoA reductase mRNA after 20 h than after 3.5 h of incubation. Simvastatin 284-295 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-107 19489169-2 1994 It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. Simvastatin 104-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-79 7857367-1 1994 Twelve men and thirteen women with hypercholesterolaemia participated in a 20-week controlled cross-over trial to assess the interaction between dietary fat intake, gender and an HMGCoA reductase inhibitor, simvastatin. Simvastatin 207-218 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 179-195 7857367-5 1994 Gender differences in the effect of simvastatin on HDL were confined to HDL3 cholesterol, although the drug raised HDL2 in both sexes on the low fat diet. Simvastatin 36-47 HDL3 Homo sapiens 72-76 7857367-6 1994 Simvastatin was responsible for an 11% increase in HDL3 cholesterol in men particularly when on a low fat diet but did not affect HDL3 in women. Simvastatin 0-11 HDL3 Homo sapiens 51-55 7813167-3 1994 Simvastatin therapy reduced plasma total cholesterol by 26% (p > 0.002), LDL-cholesterol by 36% (p > 0.002) and triglycerides by 28% (p > 0.05): plasma HDL-cholesterol and apo-A were raised, but not significantly. Simvastatin 0-11 lipoprotein(a) Homo sapiens 181-186 8070302-1 1994 The clinical efficacy of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMGCoA) reductase inhibitor simvastatin in the treatment of hypercholesterolaemia in non-insulin-dependent diabetes (NIDDM), was examined in a double-blind placebo-controlled study of 6 months in 70 patients with NIDDM (age 25-70 years), of whom 57 were randomised to placebo (29 patients) or simvastatin for 6 months, following a 3-month run-in on diet. Simvastatin 97-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-86 8187355-4 1994 Treatment with simvastatin in increasing doses over a period of three months (13 patients received 40 mg/day and 5 patients 20 mg/day at the end of the third month) reduced LDL-cholesterol in both groups of patients (35% and 54%) as well as apolipoprotein B (apoB) (31% and 46%) significantly, but Lp(a) levels were not influenced (57 +/- 21 vs 59 +/- 20 and 50 +/- 14 vs 53 +/- 16 mg/dl, respectively). Simvastatin 15-26 apolipoprotein B Homo sapiens 241-257 8187355-4 1994 Treatment with simvastatin in increasing doses over a period of three months (13 patients received 40 mg/day and 5 patients 20 mg/day at the end of the third month) reduced LDL-cholesterol in both groups of patients (35% and 54%) as well as apolipoprotein B (apoB) (31% and 46%) significantly, but Lp(a) levels were not influenced (57 +/- 21 vs 59 +/- 20 and 50 +/- 14 vs 53 +/- 16 mg/dl, respectively). Simvastatin 15-26 apolipoprotein B Homo sapiens 259-263 8187355-4 1994 Treatment with simvastatin in increasing doses over a period of three months (13 patients received 40 mg/day and 5 patients 20 mg/day at the end of the third month) reduced LDL-cholesterol in both groups of patients (35% and 54%) as well as apolipoprotein B (apoB) (31% and 46%) significantly, but Lp(a) levels were not influenced (57 +/- 21 vs 59 +/- 20 and 50 +/- 14 vs 53 +/- 16 mg/dl, respectively). Simvastatin 15-26 lipoprotein(a) Homo sapiens 298-303 7631993-0 1994 [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]. Simvastatin 66-77 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-53 8117177-1 1994 BACKGROUND: Few studies have been performed to compare fenofibrate, a second-generation fibrate, and simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Simvastatin 101-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-163 8293556-6 1994 Simvastatin-treated A10 cells (5 mg/L for 24 hours) showed a normal initial peak response to vasopressin, but the plateau phase of Ca2+ entry was significantly impaired. Simvastatin 0-11 arginine vasopressin Rattus norvegicus 93-104 8293556-7 1994 By use of Mn2+ quenching of intracellular fura 2 to measure divalent cation entry, the maximal rate of vasopressin-stimulated Mn2+ entry was impaired in simvastatin-treated cells by 52%. Simvastatin 153-164 arginine vasopressin Rattus norvegicus 103-114 8289597-4 1994 Plasma apo B, apo A-I, and apo A-IV concentrations were lowered by simvastatin treatment whereas plasma apo E concentration was not affected by this drug. Simvastatin 67-78 apolipoprotein A1 Rattus norvegicus 14-21 8289597-4 1994 Plasma apo B, apo A-I, and apo A-IV concentrations were lowered by simvastatin treatment whereas plasma apo E concentration was not affected by this drug. Simvastatin 67-78 apolipoprotein A4 Rattus norvegicus 27-35 8289597-5 1994 In the liver, simvastatin treatment induced a significant decrease of apo E mRNA level but had no effect on apo B, apo A-I, and apo A-IV mRNA abundances. Simvastatin 14-25 apolipoprotein E Rattus norvegicus 70-75 8243858-0 1993 Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Simvastatin 46-57 insulin Homo sapiens 19-26 7752830-8 1994 This study demonstrates that simvastatin lowers both LDL-C and apo B plasma levels together with the plasma and platelet levels of CoQ10, and that CoQ10 therapy prevents both plasma and platelet CoQ10 decrease, without affecting the cholesterol lowering effect of simvastatin. Simvastatin 29-40 component of oligomeric golgi complex 2 Homo sapiens 53-58 8292093-3 1993 In this paper we show that serum cholesterol in a homozygous FH patient with a receptor-negative LDL-receptor phenotype was reduced by 30% after treatment with simvastatin alone and by a further 11% with simvastatin in combination with probucol and nicotinic acid. Simvastatin 160-171 low density lipoprotein receptor Homo sapiens 97-109 8292093-3 1993 In this paper we show that serum cholesterol in a homozygous FH patient with a receptor-negative LDL-receptor phenotype was reduced by 30% after treatment with simvastatin alone and by a further 11% with simvastatin in combination with probucol and nicotinic acid. Simvastatin 204-215 low density lipoprotein receptor Homo sapiens 97-109 8292099-4 1993 Simvastatin increased the LDL receptor activity of cells from the PH subjects by 70% while lowering their plasma cholesterol by 26%, but reducing the fat intake from 38% to 20% of energy and cholesterol from 239 to 96 mg/day had no effect on the receptor despite a 10% reduction in plasma cholesterol. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 26-38 8292099-5 1993 Upregulation of the LDL receptor may therefore have been involved in the lowering of plasma cholesterol by simvastatin but not by the reduction in dietary fat and cholesterol. Simvastatin 107-118 low density lipoprotein receptor Homo sapiens 20-32 8200011-8 1993 Total-cholesterol, LDL-cholesterol, and triglycerides were lower in the group treated with n3-PUFA and simvastatin compared to simvastatin alone. Simvastatin 127-138 pumilio RNA binding family member 3 Homo sapiens 94-98 8264145-2 1993 We have conducted a double-blind, placebo controlled trial of the HMG CoA reductase inhibitor simvastatin in patients with the nephrotic syndrome or significant proteinuria (> 1 g/day) and hypercholesterolemia (> or = 6.5 mmol/liter). Simvastatin 94-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-83 8264145-7 1993 Apolipoprotein B100 levels fell by a mean of 31% in the simvastatin group but rose 0.3% in the placebo group (P = 0.014). Simvastatin 56-67 apolipoprotein B Homo sapiens 0-19 8243858-2 1993 In a double-blind, randomized and placebo-controlled design treatment with simvastatin (n = 8) for 36 weeks significantly reduced total cholesterol (6.7 +/- 0.3 vs 5.1 mmol.l-1 (p < 0.01)), LDL-cholesterol (4.4 +/- 0.3 vs 2.9 +/- 0.2 mmol.l-1 (p < 0.01)) and apolipoprotein B (1.05 +/- 0.04 vs 0.77 +/- 0.02 mmol.l-1 (p < 0.01)) levels as compared to placebo (n = 10). Simvastatin 75-86 apolipoprotein B Homo sapiens 265-281 8231022-6 1993 In the present study, we examined the effect of simvastatin, and HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis and PDGF B chain gene expression in human glomerular mesangial cells. Simvastatin 48-59 platelet derived growth factor subunit B Homo sapiens 127-139 8213497-5 1993 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which include lovastatin, simvastatin, and pravastatin, are the most effective of the currently available drugs and show dose-dependent effects on the concentrations of LDL cholesterol, which decrease by 20-45% in response to these drugs when used over the full dosage range. Simvastatin 99-110 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-71 8240151-0 1993 Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Simvastatin 89-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-53 8240151-1 1993 BACKGROUND: Simvastatin and pravastatin are both competitive inhibitors of the rate limiting enzyme for cholesterol biosynthesis (HMG CoA) reductase, but data from individual clinical trials suggest significant differences in potency for cholesterol reduction between the two drugs. Simvastatin 12-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 104-148 8240151-8 1993 RESULTS: Over the 18 week direct comparison of the two drugs, there was a significant difference (p < 0.001) in response between simvastatin and pravastatin for reduction in levels of total cholesterol (32% vs 21% respectively), LDL cholesterol (38% vs 27%) and apolipoprotein B levels (34% vs 23%). Simvastatin 132-143 apolipoprotein B Homo sapiens 265-281 8240151-11 1993 When pravastatin was replaced with simvastatin for the final 6 weeks of the study in the 23 patients initially randomised to pravastatin, there were further reductions (p < 0.01) in total and LDL cholesterol, and apolipoprotein B. Simvastatin 35-46 apolipoprotein B Homo sapiens 216-232 7761664-3 1993 The authors treated a group of elderly patients with Simvastatin (20 mg/day for 1 year), a HMG CoA reductase inhibitor and observed a significant reduction in total cholesterol (p < 0.001). Simvastatin 53-64 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-108 8194433-5 1993 For lowering TC, LDL-C, Apo B and elevating Apo A-I/Apo B, Simvastatin was better than gemfibrozil (P < 0.01-0.001). Simvastatin 59-70 apolipoprotein A1 Homo sapiens 44-51 8326293-13 1993 CONCLUSIONS: Simvastatin appeared to be more potent than pravastatin in lowering total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B, whereas both drugs had the same short-term safety profile. Simvastatin 13-24 apolipoprotein B Homo sapiens 140-156 8366596-6 1993 20% 3) In the attempt to increase the complete dissolution rate, bedtime administration method (one time administration instead of 3 times, every day), combination therapy of UDCA and CDCA and UDCA plus simvastatin (HMG-CoA reductase inhibitor) were tried. Simvastatin 203-214 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 216-233 8517861-3 1993 As a consequence of this inhibition, the HMG-CoA reductase mRNA levels and squalene synthase activity, both negatively-regulated by sterols, were increased equally by simvastatin and lovastatin, whereas the induction by pravastatin was much less. Simvastatin 167-178 farnesyl-diphosphate farnesyltransferase 1 Homo sapiens 75-92 8379960-6 1993 Similarly, simvastatin decreased plasma cholesterol by 74%, liver membrane cholesterol by 24% and bile cholesterol saturation by 38%, and increased liver and mononuclear cell LDL receptor activities by 80% and 62%, respectively. Simvastatin 11-22 low-density lipoprotein receptor Oryctolagus cuniculus 175-187 10146335-5 1993 In a subset of these patients who have residual LDL receptor activity, further lowering of the plasma cholesterol concentration was achieved by adding simvastatin, an hydroxy-methylglutaryl coenzyme A reductase inhibitor. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 48-60 8510521-5 1993 In eight FCH patients, treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin resulted in significantly increased mean LPL activities and plasma Lp(a) concentrations. Simvastatin 110-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-99 8510521-5 1993 In eight FCH patients, treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin resulted in significantly increased mean LPL activities and plasma Lp(a) concentrations. Simvastatin 110-121 lipoprotein lipase Homo sapiens 163-166 8510521-5 1993 In eight FCH patients, treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin resulted in significantly increased mean LPL activities and plasma Lp(a) concentrations. Simvastatin 110-121 lipoprotein(a) Homo sapiens 189-194 8471404-2 1993 It has been suggested that HMG CoA reductase inhibitors which are administered as inactive, lipophilic lactones (e.g. simvastatin) have a greater propensity to evoke nocturnal sleep disturbances than pravastatin, an inhibitor given in the active, hydrophilic, open-acid form. Simvastatin 118-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-44 8487674-3 1993 Treatment with simvastatin reduced plasma cholesterol level by 16% (mean +/- SEM, 8.1 +/- 0.8 v 6.8 +/- 0.8 mmol/L; P < .05) and plasma apolipoprotein (apo) B level by 19% (1.6 +/- 0.2 v 1.3 +/- 0.2 g/L; P < .05). Simvastatin 15-26 apolipoprotein B Homo sapiens 139-161 8461338-4 1993 While simvastatin plus cholestyramine lowered mRNAs for apo AIV, apo E and apo B by 50%, 37%, and 55%, respectively, the treatment resulted in an increase of 150% in apo AI mRNA. Simvastatin 6-17 apolipoprotein A4 Rattus norvegicus 56-63 8461338-4 1993 While simvastatin plus cholestyramine lowered mRNAs for apo AIV, apo E and apo B by 50%, 37%, and 55%, respectively, the treatment resulted in an increase of 150% in apo AI mRNA. Simvastatin 6-17 apolipoprotein E Rattus norvegicus 65-70 8343198-1 1993 Simvastatin is a methyl analogue of lovastatin and acts as an HMG-CoA reductase inhibitor effective in the treatment of hypercholesterolaemia. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-79 8343198-13 1993 Elevated HMG-CoA reductase inhibitory activity has been observed when simvastatin was administered concurrently with cyclosporin, possibly increasing the risk of myopathy and subsequent rhabdomyolysis which are associated with simvastatin use. Simvastatin 70-81 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 9-26 8343198-13 1993 Elevated HMG-CoA reductase inhibitory activity has been observed when simvastatin was administered concurrently with cyclosporin, possibly increasing the risk of myopathy and subsequent rhabdomyolysis which are associated with simvastatin use. Simvastatin 227-238 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 9-26 8482062-14 1993 Mean levels of GOT, GPT and CPK significantly increased after 6 weeks on simvastatin, but remained stable and at any rate ioitlin the normal range thereafter. Simvastatin 73-84 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 28-31 8457250-0 1993 Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Simvastatin 82-93 low density lipoprotein receptor Homo sapiens 39-51 8440592-10 1993 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in microsomal membranes from human lens cortex was inhibited by simvastatin and pravastatin to the same extent. Simvastatin 121-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 8122478-3 1993 Simvastatin was found to produce significantly greater mean percent reductions from baseline in total cholesterol (28% versus 21%), LDL cholesterol (38% versus 29%), and apolipoprotein B concentrations (25% versus 17%) than did pravastatin, and a greater percentage of patients receiving simvastatin (94% versus 80%) had at least a 20% reduction in LDL cholesterol. Simvastatin 0-11 apolipoprotein B Homo sapiens 170-186 8503950-7 1993 When HDL and VLDL/LDL of control plasma were incubated with CETP fractions of the treated subjects, a clear reduction of ECT occurred after simvastatin administration. Simvastatin 140-151 cholesteryl ester transfer protein Homo sapiens 60-64 8503950-8 1993 The decrease of plasma transfer activity was correlated to that of CETP concentration and accounted for the simvastatin-induced lowering of ECT. Simvastatin 108-119 cholesteryl ester transfer protein Homo sapiens 67-71 8503950-11 1993 In conclusion, our work shows that simvastatin administration results in a decrease of ECT and that this effect occurs through a lowering of plasma CETP activity. Simvastatin 35-46 cholesteryl ester transfer protein Homo sapiens 148-152 8427854-0 1993 Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Simvastatin 11-22 apolipoprotein B Homo sapiens 26-30 8442035-0 1993 HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Simvastatin 43-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-16 8122478-4 1993 Both simvastatin and pravastatin produced similar significant mean percent reductions from baseline in triglyceride concentrations (14% and 11%) and significant mean percent increases in the concentrations of HDL cholesterol (7% for both) and apolipoprotein A-I (4% for both). Simvastatin 5-16 apolipoprotein A1 Homo sapiens 243-261 8457250-7 1993 Female FH1 patients responded better to simvastatin treatment, however, than did males with the same gene defect. Simvastatin 40-51 filamin B Homo sapiens 7-10 8122478-5 1993 Resulting reductions in the ratios of total cholesterol: HDL cholesterol, LDL cholesterol: HDL cholesterol, and apolipoprotein B: apolipoprotein A-I were significantly greater in the simvastatin group. Simvastatin 183-194 apolipoprotein B Homo sapiens 112-128 8122478-5 1993 Resulting reductions in the ratios of total cholesterol: HDL cholesterol, LDL cholesterol: HDL cholesterol, and apolipoprotein B: apolipoprotein A-I were significantly greater in the simvastatin group. Simvastatin 183-194 apolipoprotein A1 Homo sapiens 130-148 1469449-1 1992 We induced experimental myopathy in rabbits by giving simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin 54-65 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 69-126 8446048-1 1993 The effect of simvastatin (MK-733, Banyu, Tokyo, Japan), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase on triglyceride kinetics, was studied in chronically streptozocin-diabetic rats. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 76-133 8399632-4 1993 The results, after 3, 6, 12, and 18 months of treatment, showed the following: in patients treated with CAPD and simvastatin, highly significant decreases were noted in total cholesterol (T-cho) and triglycerides (TG) (p < 0.001), and highly significant increases were noted in HDL-cholesterol (HDL-cho) (p < 0.005) and apolipoprotein-A1 (Apo-A1) (p < 0.01). Simvastatin 113-124 apolipoprotein A1 Homo sapiens 326-343 8399632-4 1993 The results, after 3, 6, 12, and 18 months of treatment, showed the following: in patients treated with CAPD and simvastatin, highly significant decreases were noted in total cholesterol (T-cho) and triglycerides (TG) (p < 0.001), and highly significant increases were noted in HDL-cholesterol (HDL-cho) (p < 0.005) and apolipoprotein-A1 (Apo-A1) (p < 0.01). Simvastatin 113-124 apolipoprotein A1 Homo sapiens 345-351 1292582-4 1992 Plasma concentrations of HDL cholesterol and of the apolipoproteins AI and AII were increased by simvastatin. Simvastatin 97-108 NLR family pyrin domain containing 3 Homo sapiens 52-78 1488408-0 1992 Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Simvastatin 175-186 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-111 1493355-4 1992 The HMG-CoA reductase inhibitors lovastatin, simvastatin and pravastatin are potent well tolerated hypolipidaemic therapies in young subjects. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 1394987-2 1992 We investigated the changes in serum TC concentrations obtained with simvastatin, an inhibitor of hydroxymethylglutaryl-CoA reductase, in 70 hypercholesterolemic subjects. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 98-133 1484945-1 1992 The effect of diet on plasma lipids and lipoproteins was examined in 19 patients with familial hypercholesterolaemia treated with the HMGCoA reductase inhibitor, simvastatin. Simvastatin 162-173 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 134-150 1433193-3 1992 Substitution of hydroxy and hydroxyalkyl functionality at C-7 of the hexahydronaphthalene nucleus of simvastatin has provided novel analogs. Simvastatin 101-112 complement C7 Rattus norvegicus 58-61 1418074-0 1992 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Simvastatin 58-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 1643632-1 1992 The effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on human glioma cell growth was investigated. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-90 1320552-7 1992 Simvastatin produced consistent reductions in total plasma cholesterol concentration (median 36.9%), plasma low-density lipoprotein-cholesterol concentration (43.6%) and apolipoprotein B pool size (29.9%). Simvastatin 0-11 apolipoprotein B Homo sapiens 170-186 1495661-4 1992 Apo-B was also significantly lower on 40 mg simvastatin (p less than 0.01). Simvastatin 44-55 apolipoprotein B Homo sapiens 0-5 1495990-8 1992 The LDL receptor stimulation caused by GH treatment was of similar magnitude as that observed upon 3 weeks of treatment with an established hypolipidemic drug (pravastatin or simvastatin). Simvastatin 175-186 low density lipoprotein receptor Rattus norvegicus 4-16 1495990-8 1992 The LDL receptor stimulation caused by GH treatment was of similar magnitude as that observed upon 3 weeks of treatment with an established hypolipidemic drug (pravastatin or simvastatin). Simvastatin 175-186 gonadotropin releasing hormone receptor Rattus norvegicus 39-41 1627634-0 1992 Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Simvastatin 112-123 low density lipoprotein receptor Homo sapiens 50-62 1627634-6 1992 Apo-B concentration in the medium of Hep G2 cells was 31% lower after 31 h incubation with simvastatin than in controls. Simvastatin 91-102 apolipoprotein B Homo sapiens 0-5 1627634-8 1992 Both LDL-receptor and its mRNA levels were raised by simvastatin at concentrations inhibiting cholesterol synthesis. Simvastatin 53-64 low density lipoprotein receptor Homo sapiens 5-17 1627634-9 1992 Our data show that, in this human hepatoma cell line, HMG-CoA reductase competitive inhibition by simvastatin triggers a coordinate regulation of the expression of genes coding for reductase and LDL receptor but not for apo-B. Simvastatin 98-109 low density lipoprotein receptor Homo sapiens 195-207 10146977-6 1992 Studies to date therefore suggest that therapy with HMG-CoA reductase inhibitors (i.e. lovastatin and simvastatin) is substantially more cost-effective than treatment with bile-acid sequestrants. Simvastatin 102-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 1572035-7 1992 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (20 mg/day for 6 months) significantly reduced cholesterol levels by 22-28% and urinary 11-dehydro-TXB2 excretion by 32-42% in 10 patients. Simvastatin 69-80 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 1587959-5 1992 Only a trend to an increase of CK mean values on combined bezafibrate-simvastatin was shown. Simvastatin 70-81 creatine kinase, M-type Homo sapiens 31-33 1588829-4 1992 Simvastatin increased Lp A-I, but did not change Lp A-II:A-I, while fenofibrate decreased Lp A-I and increased Lp A-II:A-I. Simvastatin 0-11 lipoprotein(a) Homo sapiens 22-26 1596304-1 1992 Fourteen women and five men participated in a 20-week controlled, cross-over trial of the interaction of simvastatin, an HMGCoA reductase inhibitor, with high and low fat diets. Simvastatin 105-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 121-137 1596304-7 1992 On a high fat diet, simvastatin produced almost no rise in HDL3 cholesterol whereas on a low fat diet HDL3 cholesterol was increased by 8.8% with simvastatin. Simvastatin 146-157 HDL3 Homo sapiens 102-106 10146941-3 1992 The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin is a well tolerated and highly effective antihyperlipidaemic agent. Simvastatin 72-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 1412144-1 1992 HMG-CoA reductase inhibitors: lovastatin and simvastatin]. Simvastatin 45-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 1412144-2 1992 Lovastatin and simvastatin are the first licensed compounds of a potent new class of lipid lowering drugs whose mechanism of action is to inhibit HMG-CoA reductase, a rate-limiting enzyme in the cholesterol biosynthetic pathway in the liver. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 146-163 1451715-0 1992 Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Simvastatin 87-98 lipoprotein(a) Homo sapiens 11-16 1352930-7 1992 As expected, simvastatin produced a significant reduction in serum levels of total cholesterol (33 +/- 12 and 36 +/- 12 percent, mean +/- SD, after 4 and 8 weeks respectively, p less than 0.001 vs baseline), LDL-cholesterol (36 +/- 5 and 43 +/- 6 percent respectively, p less than 0.001 vs baseline) and apolipoprotein-B (20 +/- 29 and 23 +/- 30 percent respectively, p less than 0.05 vs baseline), whereas these parameters did not change significantly in the placebo group. Simvastatin 13-24 apolipoprotein B Homo sapiens 304-320 1451715-6 1992 It appears that the effect of simvastatin on the Lp(a) level in individuals is usually insignificant, but in patients with a high Lp(a) simvastatin may further increase it. Simvastatin 30-41 lipoprotein(a) Homo sapiens 49-54 1451715-6 1992 It appears that the effect of simvastatin on the Lp(a) level in individuals is usually insignificant, but in patients with a high Lp(a) simvastatin may further increase it. Simvastatin 136-147 lipoprotein(a) Homo sapiens 130-135 1951069-1 1991 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, has been administered to approximately 2,400 patients with primary hypercholesterolemia with a mean follow-up of 1 year in controlled clinical studies and their open extensions. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 1777975-2 1991 Under simvastatin therapy the concentrations of total cholesterol, total triglyceride, very low density lipoprotein cholesterol and triglyceride, low density lipoprotein cholesterol and apolipoprotein B in serum fell significantly by 30%, 30%, 43%, 28%, 36% and 26%, respectively, and the concentration of high density lipoprotein cholesterol rose significantly by 14%. Simvastatin 6-17 apolipoprotein B Homo sapiens 186-202 1789812-8 1991 Our results suggest a conversion of HDL3 into HDL2, which could imply a beneficial effect of simvastatin upon the so-called reverse cholesterol transport, in addition to the striking reduction in atherogenic lipoproteins. Simvastatin 93-104 HDL3 Homo sapiens 36-40 1789812-8 1991 Our results suggest a conversion of HDL3 into HDL2, which could imply a beneficial effect of simvastatin upon the so-called reverse cholesterol transport, in addition to the striking reduction in atherogenic lipoproteins. Simvastatin 93-104 junctophilin 3 Homo sapiens 46-50 1789813-1 1991 The 3-years efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (S) (previously called synvinolin or MK-733) has been studied in single and combined therapy with cholestyramine (C) in 48 hypercholesterolaemic patients. Simvastatin 97-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-86 1789813-1 1991 The 3-years efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (S) (previously called synvinolin or MK-733) has been studied in single and combined therapy with cholestyramine (C) in 48 hypercholesterolaemic patients. Simvastatin 132-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-86 1789814-6 1991 Simvastatin had a more pronounced effect than fenofibrate on apolipoprotein B. Simvastatin 0-11 apolipoprotein B Homo sapiens 61-77 1436290-3 1992 Simvastatin reduced total serum cholesterol (300.0 +/- 15.5 vs. 193.0 +/- 8.0; -35%), LDL cholesterol (203.8 +/- 13.0 vs. 104.7 +/- 6.0; -48.0%) as well as apolipoprotein B (132.3 +/- 6.6 vs. 77.8 +/- 2.7 mg/dl; -40%). Simvastatin 0-11 apolipoprotein B Homo sapiens 156-172 1742319-1 1991 In primary culture of rat hepatocytes, simvastatin, a powerful HMGCoA reductase inhibitor, inhibited acetate incorporation into cellular and secreted cholesterol and cholesteryl-esters, without any significant effect on triacylglycerol synthesis and secretion. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 63-79 1742319-2 1991 When applied to the culture for 24 h at 10(-7) M, a concentration shown to inhibit cholesterol synthesis by 61%, simvastatin increased apolipoprotein BH and BL synthesis and secretion and strongly decreased apolipoprotein AI synthesis and secretion whereas apolipoprotein AIV remained unaffected. Simvastatin 113-124 apolipoprotein A1 Rattus norvegicus 207-224 1865167-1 1991 The long-term effects (66 weeks) of simvastatin (40 mg in one or two doses per day), an inhibitor of HMG CoA-reductase, were evaluated in 12 patients with familial dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Simvastatin 36-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 101-118 1800703-0 1991 Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Simvastatin 198-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-145 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 93-104 lecithin-cholesterol acyltransferase Homo sapiens 0-37 1832610-6 1991 The first includes inactive lactone prodrugs, as Lovastatin and Simvastatin, that are enzymatically hydrolyzed to the corresponding ring-opened active forms in the liver, where the HMGCoA reductase inhibitors must chiefly reduce cholesterol synthesis. Simvastatin 64-75 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 181-197 1832610-8 1991 Several clinical studies seem to demonstrate a greater cholesterol-lowering effect of the active form of Simvastatin, probably because of its more affinity for the HMGCoA reductase enzyme. Simvastatin 105-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 164-180 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 93-104 low density lipoprotein receptor Homo sapiens 50-79 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 109-120 lecithin-cholesterol acyltransferase Homo sapiens 0-37 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 109-120 low density lipoprotein receptor Homo sapiens 50-79 2047945-0 1991 A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia. Simvastatin 19-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-49 2047945-1 1991 The aim of this study was to evaluate the long-term efficacy and tolerability of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin, over a 24-week period. Simvastatin 153-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 2031860-0 1991 The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. Simvastatin 32-43 thioredoxin reductase 1 Homo sapiens 155-169 2009092-9 1991 It is considered that the mechanism of plasma TG-lowering effect of MK-733 is the removal of VLDL-TG by an increase in LPL activity in the tissues as well as a decrease in the TGSR. Simvastatin 68-74 lipoprotein lipase Rattus norvegicus 119-122 2009092-1 1991 The effect of simvastatin (MK-733), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on plasma triacylglycerol (TG) levels was studied in rats. Simvastatin 14-25 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 52-109 2009092-1 1991 The effect of simvastatin (MK-733), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on plasma triacylglycerol (TG) levels was studied in rats. Simvastatin 27-33 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 52-109 2009092-7 1991 MK-733 significantly (P less than 0.05) increased LPL activity in the post-heparin plasma by 21.5%, although it did not affect hepatic triacylglycerol lipase (H-TGL) activity. Simvastatin 0-6 lipoprotein lipase Rattus norvegicus 50-53 1903069-1 1991 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin, reduced low-density-lipoprotein (LDL) cholesterol in hypercholesterolaemic patients by 40% (P less than 0.001). Simvastatin 72-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 2051734-4 1991 Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day-1) and simvastatin (1st month 10 mg, 2nd month 20 mg and 3rd month 40 mg day-1) reduced total serum cholesterol from 280.3 +/- 9.4 to 213.0 +/- 6.7 (-24%) and 295.0 +/- 12.2 to 202.3 +/- 8.9 mg/dl (-31.4%), LDL cholesterol from 161.9 +/- 10.7 to 112.1 +/- 7.9 (-30.8%) and 181.8 +/- 14.7 to 107.4 +/- 8.1 mg/dl (-40.9%), as well as apolipoprotein B (apo B) from 116.0 +/- 6.6 to 83.3 +/- 3.7 (-28.2%) and 134.4 +/- 8.2 to 84.1 +/- 5.3 mg/dl (-37.4%), respectively. Simvastatin 65-76 apolipoprotein B Homo sapiens 390-406 2031860-2 1991 It was demonstrated that simvastatin in addition to its known inhibitory effect on HMG-CoA reductase activity, also affects the later steps of testicular steroidogenesis by selectively inhibiting the 17-ketosteroid-oxidoreductase catalyzed conversion of dehydroepiandrosterone and androstenedione to androstenediol and testosterone respectively. Simvastatin 25-36 thioredoxin reductase 1 Homo sapiens 215-229 1857842-1 1991 The effect of a 6-month treatment with simvastatin, an HMG CoA-reductase inhibitor, on serum lipoprotein pattern was investigated in patients affected by primary hypercholesterolemia. Simvastatin 39-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-72 1847705-2 1991 The present study examined whether hypolipidemic therapy with a potent HMG CoA reductase inhibitor, simvastatin, compromises the adrenal response to ACTH stimulation in adult patients with heterozygous familial hypercholesterolemia. Simvastatin 100-111 proopiomelanocortin Homo sapiens 149-153 2054273-2 1991 Total serum cholesterol, LDL-cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Simvastatin 95-106 apolipoprotein B Homo sapiens 45-57 2054273-2 1991 Total serum cholesterol, LDL-cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Simvastatin 95-106 apolipoprotein B Homo sapiens 59-63 1671145-0 1991 Poor response to simvastatin in familial defective apo-B-100. Simvastatin 17-28 apolipoprotein B Homo sapiens 51-60 2006757-4 1991 Simvastatin caused a slight decrease in factor VIIIc activity and a moderate reduction of beta-thromboglobulin. Simvastatin 0-11 pro-platelet basic protein Homo sapiens 90-110 1827401-1 1991 Cellular cholesterol homeostasis was examined in 11 hypercholesterolaemic Type 2 diabetic patients prior to and following reduction of serum cholesterol using simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase. Simvastatin 159-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 188-244 1994903-0 1991 Serum pseudocholinesterase activity in rabbits fed simvastatin. Simvastatin 51-62 cholinesterase Oryctolagus cuniculus 6-26 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 191-203 1987991-3 1991 With simvastatin treatment, the mean decreases in total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (apo B) were 39%, 46%, and 36%, respectively. Simvastatin 5-16 apolipoprotein B Homo sapiens 116-132 2044637-1 1991 Lovastatin and simvastatin are potent competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin 15-26 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 64-111 2044637-4 1991 Lovastating and simvastatin lower levels of plasma cholesterol in rats, dogs and rabbits by inhibition the endogenous cholesterol synthesis and induction of LDL receptor in the liver. Simvastatin 16-27 low-density lipoprotein receptor Oryctolagus cuniculus 157-169 1780636-1 1991 Female Sprague-Dawley rats were treated with either simvastatin (a novel competitive inhibitor of HMG CoA reductase) or phenobarbital (positive control) to ascertain the possible relationship between the effects of simvastatin on hepatic metabolism and the thyroid hypertrophy and follicular cell adenomas which it produces in this strain of rat. Simvastatin 52-63 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 98-115 2022360-0 1991 [Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits]. Simvastatin 22-33 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 62-109 2022360-1 1991 A study was made on the effect of simvastatin (the generic name of MK-733), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on coronary atherosclerosis in cholesterol-fed rabbits with focus on the serum lipids and morphology. Simvastatin 34-45 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 103-160 2022360-1 1991 A study was made on the effect of simvastatin (the generic name of MK-733), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on coronary atherosclerosis in cholesterol-fed rabbits with focus on the serum lipids and morphology. Simvastatin 67-73 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oryctolagus cuniculus 103-160 2060542-0 1991 Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Simvastatin 0-11 insulin Homo sapiens 53-60 2060542-5 1991 After simvastatin, and in the last 60 min of the glucose clamp, there was an improvement in the action of insulin as demonstrated by stronger inhibition of hepatic glucose output (2.7 vs 5.2 mumol.kg-1.min-1) and stimulation both of the glucose disappearance rate (26.3 vs 19.5 mumol.kg-1.min-1) and glucose metabolic clearance rate (4.3 vs 3.6 ml.kg-1.min-1). Simvastatin 6-17 insulin Homo sapiens 106-113 2173899-3 1990 Of the various treatments used, only simvastatin or simvastatin plus cholestyramine produced significant changes, with reductions of up to 40% and 60%, respectively, for HB1 and HB2. Simvastatin 37-48 activated leukocyte cell adhesion molecule Rattus norvegicus 178-181 2173899-3 1990 Of the various treatments used, only simvastatin or simvastatin plus cholestyramine produced significant changes, with reductions of up to 40% and 60%, respectively, for HB1 and HB2. Simvastatin 52-63 activated leukocyte cell adhesion molecule Rattus norvegicus 178-181 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 24-34 low density lipoprotein receptor Homo sapiens 191-203 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 36-42 low density lipoprotein receptor Homo sapiens 191-203 1976071-0 1990 In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Simvastatin 42-53 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-88 2206035-4 1990 These drugs, including lovastatin and simvastatin, competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of intracellular cholesterol synthesis. Simvastatin 38-49 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-120 2390138-0 1990 Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Simvastatin 51-62 apolipoprotein E Homo sapiens 13-18 2390138-0 1990 Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Simvastatin 51-62 low density lipoprotein receptor Homo sapiens 103-132 2390138-6 1990 In the combined FH patient group (males and females) a considerable interindividual variation in response to simvastatin was observed, but was not related to the apoE polymorphism. Simvastatin 109-120 low density lipoprotein receptor Homo sapiens 16-18 2390138-7 1990 However, considering males and females separately, we found that female FH patients with the apoE3E3 phenotype responded better on simvastatin treatment with respect to LDL-cholesterol than male FH patients with the apoE3E3 phenotype. Simvastatin 131-142 low density lipoprotein receptor Homo sapiens 72-74 2224187-1 1990 Simvastatin, a pro-drug lactone, forms the open carboxylic acid as a major metabolite that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin 0-11 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-163 2167097-1 1990 A new antihypercholesterolemic drug, simvastatin (MK-733), which is a prodrug of a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, inhibited cholesterol synthesis from [14C]acetate concentration dependently without inhibiting it from [3H]mevalonate in Hep G2 cells. Simvastatin 37-48 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 90-147 2167097-1 1990 A new antihypercholesterolemic drug, simvastatin (MK-733), which is a prodrug of a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, inhibited cholesterol synthesis from [14C]acetate concentration dependently without inhibiting it from [3H]mevalonate in Hep G2 cells. Simvastatin 50-56 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 90-147 2312032-3 1990 Simvastatin 40 mg decreased total serum cholesterol, LDL cholesterol and apolipoprotein B by 35%, 40% and 35%, respectively, while HDL cholesterol and apolipoprotein A-I increased by 10% (p less than 0.01) and 7% (p less than 0.05), respectively. Simvastatin 0-11 apolipoprotein B Homo sapiens 73-89 2112479-7 1990 Our results indicate that the potent hypocholesterolaemic effects of simvastatin are accompanied by increases in high-affinity LDL receptor-mediated degradation of LDL and a compensatory increase in cholesterol biosynthesis in freshly isolated mononuclear leucocytes but that rates of mevalonic acid excretion in the urine decrease. Simvastatin 69-80 low density lipoprotein receptor Homo sapiens 127-139 33034787-14 2021 Simvastatin induces skeletal muscle atrophy via increasing serum myostatin levels in mice; 2. Simvastatin 0-11 myostatin Mus musculus 65-74 2073672-11 1990 Simvastatin significantly reduces TC, LDL, and apolipoprotein (apo) B (30%, 35%, and 27%, respectively). Simvastatin 0-11 apolipoprotein B Homo sapiens 47-69 33774062-8 2021 Simvastatin treatment, in a dose-related manner, markedly improved the lung histological injury and decreased the levels of TNF-alpha, IL-1beta, and increased IL-10 in LPS induced ALI. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 124-133 33774062-8 2021 Simvastatin treatment, in a dose-related manner, markedly improved the lung histological injury and decreased the levels of TNF-alpha, IL-1beta, and increased IL-10 in LPS induced ALI. Simvastatin 0-11 interleukin 1 alpha Rattus norvegicus 135-143 33774062-8 2021 Simvastatin treatment, in a dose-related manner, markedly improved the lung histological injury and decreased the levels of TNF-alpha, IL-1beta, and increased IL-10 in LPS induced ALI. Simvastatin 0-11 interleukin 10 Rattus norvegicus 159-164 33774062-11 2021 Notably, simvastatin reduced the levels of A2BAR, CFTR, and claudin18 but upregulated claudin4 in lung tissues. Simvastatin 9-20 CF transmembrane conductance regulator Rattus norvegicus 50-54 33774062-11 2021 Notably, simvastatin reduced the levels of A2BAR, CFTR, and claudin18 but upregulated claudin4 in lung tissues. Simvastatin 9-20 claudin 18 Rattus norvegicus 60-69 33774062-11 2021 Notably, simvastatin reduced the levels of A2BAR, CFTR, and claudin18 but upregulated claudin4 in lung tissues. Simvastatin 9-20 claudin 4 Rattus norvegicus 86-94 33034787-5 2021 In this study, we uncovered that simvastatin administration increased serum myostatin levels in mice. Simvastatin 33-44 myostatin Mus musculus 76-85 33034787-6 2021 Inhibition of myostatin with follistatin, an antagonist of myostatin, improved simvastatin-induced skeletal muscle atrophy. Simvastatin 79-90 myostatin Mus musculus 14-23 33034787-6 2021 Inhibition of myostatin with follistatin, an antagonist of myostatin, improved simvastatin-induced skeletal muscle atrophy. Simvastatin 79-90 myostatin Mus musculus 59-68 33034787-7 2021 Simvastatin induced myostatin expression not only in skeletal muscle but also in brown adipose tissue (BAT). Simvastatin 0-11 myostatin Mus musculus 20-29 33034787-15 2021 Simvastatin promotes myostatin expression in both skeletal muscle and brown adipose tissue through inhibiting GGPP production; 3. Simvastatin 0-11 myostatin Mus musculus 21-30 33779364-0 2021 Surface modification of the simvastatin factor-loaded silk fibroin promotes the healing of rotator cuff injury through beta-catenin signaling. Simvastatin 28-39 catenin beta 1 Rattus norvegicus 119-131 33034787-8 2021 Mechanistically, simvastatin inhibited the phosphorylation of forkhead box protein O1 (FOXO1) in C2C12 myotubes, promoting the nuclear translocation of FOXO1 and thereby stimulating the transcription of myostatin. Simvastatin 17-28 forkhead box O1 Mus musculus 62-85 33034787-8 2021 Mechanistically, simvastatin inhibited the phosphorylation of forkhead box protein O1 (FOXO1) in C2C12 myotubes, promoting the nuclear translocation of FOXO1 and thereby stimulating the transcription of myostatin. Simvastatin 17-28 forkhead box O1 Mus musculus 87-92 33034787-8 2021 Mechanistically, simvastatin inhibited the phosphorylation of forkhead box protein O1 (FOXO1) in C2C12 myotubes, promoting the nuclear translocation of FOXO1 and thereby stimulating the transcription of myostatin. Simvastatin 17-28 forkhead box O1 Mus musculus 152-157 33034787-8 2021 Mechanistically, simvastatin inhibited the phosphorylation of forkhead box protein O1 (FOXO1) in C2C12 myotubes, promoting the nuclear translocation of FOXO1 and thereby stimulating the transcription of myostatin. Simvastatin 17-28 myostatin Mus musculus 203-212 33034787-9 2021 In differentiated brown adipocytes, simvastatin promoted myostatin expression mainly by inhibiting the expression of interferon regulatory factor 4 (IRF4). Simvastatin 36-47 myostatin Mus musculus 57-66 33034787-9 2021 In differentiated brown adipocytes, simvastatin promoted myostatin expression mainly by inhibiting the expression of interferon regulatory factor 4 (IRF4). Simvastatin 36-47 interferon regulatory factor 4 Mus musculus 117-147 33034787-9 2021 In differentiated brown adipocytes, simvastatin promoted myostatin expression mainly by inhibiting the expression of interferon regulatory factor 4 (IRF4). Simvastatin 36-47 interferon regulatory factor 4 Mus musculus 149-153 33034787-10 2021 Moreover, the stimulative effect of simvastatin on myostatin expression was blunted by geranylgeranyl diphosphate (GGPP) supplementation in both myotubes and brown adipocytes, suggesting that GGPP depletion was attributed to simvastatin-induced myostatin expression. Simvastatin 36-47 myostatin Mus musculus 51-60 33034787-10 2021 Moreover, the stimulative effect of simvastatin on myostatin expression was blunted by geranylgeranyl diphosphate (GGPP) supplementation in both myotubes and brown adipocytes, suggesting that GGPP depletion was attributed to simvastatin-induced myostatin expression. Simvastatin 36-47 myostatin Mus musculus 245-254 33034787-10 2021 Moreover, the stimulative effect of simvastatin on myostatin expression was blunted by geranylgeranyl diphosphate (GGPP) supplementation in both myotubes and brown adipocytes, suggesting that GGPP depletion was attributed to simvastatin-induced myostatin expression. Simvastatin 225-236 myostatin Mus musculus 51-60 33939900-7 2021 In the presence of simvastatin migratory abilities and vimentin expression is diminished while E-cadherin expression is increased. Simvastatin 19-30 vimentin Homo sapiens 55-63 33939900-7 2021 In the presence of simvastatin migratory abilities and vimentin expression is diminished while E-cadherin expression is increased. Simvastatin 19-30 cadherin 1 Homo sapiens 95-105 33774267-0 2021 Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and estrogen receptors" modulation. Simvastatin 0-11 NLR family, pyrin domain containing 3 Rattus norvegicus 88-93 33774267-10 2021 Furthermore, a marked elevation in hippocampal expression of ERalpha and ERbeta was noted in SIM-treated animals, without any significant effect on uterine relative weight or ERalpha expression. Simvastatin 93-96 estrogen receptor 1 Rattus norvegicus 61-68 33774267-10 2021 Furthermore, a marked elevation in hippocampal expression of ERalpha and ERbeta was noted in SIM-treated animals, without any significant effect on uterine relative weight or ERalpha expression. Simvastatin 93-96 estrogen receptor 2 Rattus norvegicus 73-79 33823318-9 2021 Mechanistically, increasing intracellular de novo cholesterol biosynthesis was the chief contributor to the malignant behaviors caused by LDLR inhibition, which could be rescued by simvastatin. Simvastatin 181-192 low density lipoprotein receptor Homo sapiens 138-142 33032653-0 2020 Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. Simvastatin 55-66 Yes1 associated transcriptional regulator Homo sapiens 141-144 33032653-11 2020 Indeed, we demonstrated, both in vitro and in vivo models, the ability of valproic acid/simvastatin combination to sensitize mCRPC cells to docetaxel and to revert docetaxel-resistance, by mevalonate pathway/YAP axis modulation. Simvastatin 88-99 yes-associated protein 1 Mus musculus 208-211 29752615-0 2018 Effects of simvastatin on the function of splenic CD4+ and CD8+ T cells in sepsis mice. Simvastatin 11-22 CD4 antigen Mus musculus 50-53 29752615-9 2018 Simvastatin-treated mice had significantly decreased the percentages of negative costimulatory receptor BTLA on CD4 T cell expression. Simvastatin 0-11 B and T lymphocyte associated Mus musculus 104-108 29752615-9 2018 Simvastatin-treated mice had significantly decreased the percentages of negative costimulatory receptor BTLA on CD4 T cell expression. Simvastatin 0-11 CD4 antigen Mus musculus 112-115 29752615-10 2018 Simvastatin markedly reduced T cell apoptosis through downregulating the Fas/FasL expression and decrease the percentage of caspase-3 activity in spleen tissue. Simvastatin 0-11 Fas ligand (TNF superfamily, member 6) Mus musculus 77-81 29752615-10 2018 Simvastatin markedly reduced T cell apoptosis through downregulating the Fas/FasL expression and decrease the percentage of caspase-3 activity in spleen tissue. Simvastatin 0-11 caspase 3 Mus musculus 124-133 29752615-11 2018 There was significantly less depletion of splenic CD4+ and CD8+ T cells in simvastatin-treated mice. Simvastatin 75-86 CD4 antigen Mus musculus 50-53 29752615-12 2018 Simvastatin reduced plasma levels of presepsin, IL-1beta, and IL-6. Simvastatin 0-11 interleukin 1 beta Mus musculus 48-56 29752615-12 2018 Simvastatin reduced plasma levels of presepsin, IL-1beta, and IL-6. Simvastatin 0-11 interleukin 6 Mus musculus 62-66 23815378-1 2013 In this study, simvastatin (SIM) drug incorporated poly(D,L-lactic-co-glycolide) (PLGA)/biphasic calcium phosphate (BCP) composite material (SPB) was coated on the BCP/ZrO2 (SPB-BCP/ZrO2) scaffold to enhance the mechanical and bioactive properties of the BCP/ZrO2 scaffold for bone engineering applications. Simvastatin 15-26 surfactant protein B Homo sapiens 141-144 25626487-10 2015 Compared to non-switchers, the adjusted least squares mean differences in the percentage change in LDL-C levels from baseline were 18.74% (p = 0.0003), 16.73% (p < 0.0001), and -0.11% (p = 0.9044) when switching from simvastatin/ezetimibe, rosuvastatin, and atorvastatin, respectively. Simvastatin 220-231 component of oligomeric golgi complex 2 Homo sapiens 99-104 25626487-11 2015 The odds of LDL-C goal attainment at follow-up among switchers from simvastatin/ezetimibe, rosuvastatin, and atorvastatin were 0.40 (95% CI: 0.23-0.70), 0.36 (95% CI: 0.26-0.51) and 1.03 (95% CI: 0.92-1.15) relative to non-switchers respectively. Simvastatin 68-79 component of oligomeric golgi complex 2 Homo sapiens 12-17 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Simvastatin 69-80 component of oligomeric golgi complex 2 Homo sapiens 169-174 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Simvastatin 119-130 component of oligomeric golgi complex 2 Homo sapiens 169-174 25626487-0 2015 Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Simvastatin 75-86 component of oligomeric golgi complex 2 Homo sapiens 90-95 25626487-2 2015 Switching from high-efficacy lipid-lowering therapies (HETs) to simvastatin might lead to sub-optimal control of LDL-C. Simvastatin 64-75 component of oligomeric golgi complex 2 Homo sapiens 113-118 25626487-3 2015 Our objective was to evaluate the impact of switching from HETs to generic simvastatin on LDL-C levels and LDL-C goal attainment among the high-risk primary and secondary prevention populations in the United Kingdom. Simvastatin 75-86 component of oligomeric golgi complex 2 Homo sapiens 90-95 23815378-1 2013 In this study, simvastatin (SIM) drug incorporated poly(D,L-lactic-co-glycolide) (PLGA)/biphasic calcium phosphate (BCP) composite material (SPB) was coated on the BCP/ZrO2 (SPB-BCP/ZrO2) scaffold to enhance the mechanical and bioactive properties of the BCP/ZrO2 scaffold for bone engineering applications. Simvastatin 15-26 surfactant protein B Homo sapiens 174-177 19722159-3 2009 This study investigated the effect of simvastatin administration in a warm intestinal I/R model on TNF-alpha, antioxidant enzymes and intestinal tissue morphology. Simvastatin 38-49 tumor necrosis factor Rattus norvegicus 99-108 19722159-9 2009 In the simvastatin treated group, intestinal tissue injury, TNF-alpha level, and tissue malondealdehyde levels were significantly lower than in the I/R group (p < 0.05). Simvastatin 7-18 tumor necrosis factor Rattus norvegicus 60-69 19722159-11 2009 Simvastatin pretreatment reduced intestinal I/R injury and was associated with down- -regulation of serum TNF-alpha and tissue malondealdehyde level, and simvastatin administration maintained cellular antioxidant enzyme contents compared to the I/R group after 3 hours reperfusion time. Simvastatin 0-11 tumor necrosis factor Rattus norvegicus 106-115 10386582-5 1999 Simvastatin administration increased the lipoprotein lipase mRNA and activity in adipose tissue and heart. Simvastatin 0-11 lipoprotein lipase Rattus norvegicus 41-59 34078115-6 2022 IL-6 inhibitors (sirukumab, tocilizumab, sarilumab) significantly enhance metabolism via CYP2C9 (s-warfarin), CYP2C19 (omeprazole), and CYP3A4 (simvastatin, midazolam) and reduce metabolism via CYP1A2 (caffeine). Simvastatin 144-155 interleukin 6 Homo sapiens 0-4 34078115-6 2022 IL-6 inhibitors (sirukumab, tocilizumab, sarilumab) significantly enhance metabolism via CYP2C9 (s-warfarin), CYP2C19 (omeprazole), and CYP3A4 (simvastatin, midazolam) and reduce metabolism via CYP1A2 (caffeine). Simvastatin 144-155 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 136-142 34843630-11 2022 In LNCaP-LA cells, the combination of darolutamide and simvastatin led to reduction in the mRNA expression of the androgen-stimulated genes, KLK2 and PSA; however, this reduction in expression did not occur in 22Rv1 cells. Simvastatin 55-66 kallikrein related peptidase 2 Homo sapiens 141-145 34403130-5 2022 We find that variants in drug transporter genes (SLCO1B1 and ABCB1) positively impacted atorvastatin and simvastatin response, whereas variants in genes of drug metabolizing enzymes (CYP3A5) decreased response. Simvastatin 105-116 solute carrier organic anion transporter family member 1B1 Homo sapiens 49-56 34403130-5 2022 We find that variants in drug transporter genes (SLCO1B1 and ABCB1) positively impacted atorvastatin and simvastatin response, whereas variants in genes of drug metabolizing enzymes (CYP3A5) decreased response. Simvastatin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 61-66 34843630-11 2022 In LNCaP-LA cells, the combination of darolutamide and simvastatin led to reduction in the mRNA expression of the androgen-stimulated genes, KLK2 and PSA; however, this reduction in expression did not occur in 22Rv1 cells. Simvastatin 55-66 kallikrein related peptidase 3 Homo sapiens 150-153 34812477-8 2022 Furthermore, simvastatin administration significantly decreased ROS production and the concentrations of TNF-alpha and IL-6, which were significantly increased in neutrophils isolated from the SP group. Simvastatin 13-24 tumor necrosis factor Homo sapiens 105-114 34896343-0 2022 Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Simvastatin 0-11 a disintegrin and metallopeptidase domain 10 Mus musculus 95-101 34896343-0 2022 Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Simvastatin 0-11 a disintegrin and metallopeptidase domain 17 Mus musculus 106-112 34896343-13 2022 SIM treatment in the presence of STZ improved biochemical and inflammatory parameters as well as it reduced the expression of CXCL16, ADAM10, ADAM17, NF-kappaBeta, T-cells migration and apoptosis in the pancreatic islets. Simvastatin 0-3 chemokine (C-X-C motif) ligand 16 Mus musculus 126-132 34896343-13 2022 SIM treatment in the presence of STZ improved biochemical and inflammatory parameters as well as it reduced the expression of CXCL16, ADAM10, ADAM17, NF-kappaBeta, T-cells migration and apoptosis in the pancreatic islets. Simvastatin 0-3 a disintegrin and metallopeptidase domain 10 Mus musculus 134-140 34896343-13 2022 SIM treatment in the presence of STZ improved biochemical and inflammatory parameters as well as it reduced the expression of CXCL16, ADAM10, ADAM17, NF-kappaBeta, T-cells migration and apoptosis in the pancreatic islets. Simvastatin 0-3 a disintegrin and metallopeptidase domain 17 Mus musculus 142-148 34896343-14 2022 SIGNIFICANCE: SIM mitigated pancreatic beta-cell death induced by STZ through down regulation of ADAM10, ADAM17and CXCL16. Simvastatin 14-17 a disintegrin and metallopeptidase domain 10 Mus musculus 97-103 34896343-14 2022 SIGNIFICANCE: SIM mitigated pancreatic beta-cell death induced by STZ through down regulation of ADAM10, ADAM17and CXCL16. Simvastatin 14-17 a disintegrin and metallopeptidase domain 17 Mus musculus 105-111 34896343-14 2022 SIGNIFICANCE: SIM mitigated pancreatic beta-cell death induced by STZ through down regulation of ADAM10, ADAM17and CXCL16. Simvastatin 14-17 chemokine (C-X-C motif) ligand 16 Mus musculus 115-121 34812477-8 2022 Furthermore, simvastatin administration significantly decreased ROS production and the concentrations of TNF-alpha and IL-6, which were significantly increased in neutrophils isolated from the SP group. Simvastatin 13-24 interleukin 6 Homo sapiens 119-123 34812477-9 2022 Simvastatin also enhanced autophagy induction, as indicated by the promotion of the conversion of LC3I to LC3II and the increased expression levels of Beclin 1 in SP neutrophils. Simvastatin 0-11 beclin 1 Homo sapiens 151-159 34710369-0 2021 Role of nitric oxide, bradykinin B2 receptor, and TRPV1 in the airway alterations caused by simvastatin in rats. Simvastatin 92-103 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 50-55 34843676-0 2021 Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 135-138 34843676-0 2021 Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Simvastatin 0-11 MYC proto-oncogene, bHLH transcription factor Homo sapiens 163-166 34843676-8 2021 Mechanistically, the cooperative interaction of simvastatin and imatinib was associated with the inactivation of the PI3K/Akt signaling pathway, which was a classical downstream pro-survival cascade of the BCR-ABL kinase. Simvastatin 48-59 AKT serine/threonine kinase 1 Homo sapiens 122-125 34710369-8 2021 ), a TRPV1 antagonist, attenuated simvastatin-induced plasma extravasation. Simvastatin 34-45 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 5-10 34710369-15 2021 These results suggest that treatment with simvastatin promotes the release of bradykinin, which, via B2 receptors, releases NO that can then activate the TRPV1 to promote plasma extravasation and bronchoconstriction. Simvastatin 42-53 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 154-159 34614511-0 2021 Simvastatin inhibits Wnt/beta-catenin pathway in uterine leiomyoma. Simvastatin 0-11 Wnt family member 4 Homo sapiens 21-24 34895042-0 2021 Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1alpha axis. Simvastatin 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 128-138 34895042-12 2021 In conclusion, simvastatin could inhibit the proliferation, migration, invasion and promote apoptosis in AML cells through miR-19a-3p/HIF-1alpha axis. Simvastatin 15-26 hypoxia inducible factor 1 subunit alpha Homo sapiens 134-144 34614511-9 2021 Simvastatin also inhibited the expression of c-Myc, a downstream target of the Wnt/beta-catenin pathway. Simvastatin 0-11 MYC proto-oncogene, bHLH transcription factor Homo sapiens 45-50 34614511-0 2021 Simvastatin inhibits Wnt/beta-catenin pathway in uterine leiomyoma. Simvastatin 0-11 catenin beta 1 Homo sapiens 25-37 34614511-9 2021 Simvastatin also inhibited the expression of c-Myc, a downstream target of the Wnt/beta-catenin pathway. Simvastatin 0-11 Wnt family member 4 Homo sapiens 79-82 34614511-9 2021 Simvastatin also inhibited the expression of c-Myc, a downstream target of the Wnt/beta-catenin pathway. Simvastatin 0-11 catenin beta 1 Homo sapiens 83-95 34614511-3 2021 The objective of this study is to examine the effects of simvastatin on the Wnt/beta-catenin signaling pathway in leiomyoma. Simvastatin 57-68 Wnt family member 4 Homo sapiens 76-79 34614511-10 2021 The effect of simvastatin on non-phosphorylated-beta-catenin, the key regulator of the Wnt/beta-catenin pathway, was recapitulated in human leiomyoma tissue. Simvastatin 14-25 catenin beta 1 Homo sapiens 48-60 34614511-3 2021 The objective of this study is to examine the effects of simvastatin on the Wnt/beta-catenin signaling pathway in leiomyoma. Simvastatin 57-68 catenin beta 1 Homo sapiens 80-92 34614511-10 2021 The effect of simvastatin on non-phosphorylated-beta-catenin, the key regulator of the Wnt/beta-catenin pathway, was recapitulated in human leiomyoma tissue. Simvastatin 14-25 Wnt family member 4 Homo sapiens 87-90 34614511-6 2021 The results of this study reveal that simvastatin significantly reduced the expression of Wnt4 and its co-receptor LRP5. Simvastatin 38-49 Wnt family member 4 Homo sapiens 90-94 34614511-10 2021 The effect of simvastatin on non-phosphorylated-beta-catenin, the key regulator of the Wnt/beta-catenin pathway, was recapitulated in human leiomyoma tissue. Simvastatin 14-25 catenin beta 1 Homo sapiens 91-103 34614511-11 2021 These results suggest that simvastatin may have a beneficial effect on uterine leiomyoma through suppressing the overactive Wnt/beta-catenin pathway. Simvastatin 27-38 Wnt family member 4 Homo sapiens 124-127 34614511-6 2021 The results of this study reveal that simvastatin significantly reduced the expression of Wnt4 and its co-receptor LRP5. Simvastatin 38-49 LDL receptor related protein 5 Homo sapiens 115-119 34614511-11 2021 These results suggest that simvastatin may have a beneficial effect on uterine leiomyoma through suppressing the overactive Wnt/beta-catenin pathway. Simvastatin 27-38 catenin beta 1 Homo sapiens 128-140 34614511-7 2021 After simvastatin treatment, levels of total beta-catenin and its active form, non-phosphorylated beta-catenin, were reduced in both cell types. Simvastatin 6-17 catenin beta 1 Homo sapiens 45-57 34614511-7 2021 After simvastatin treatment, levels of total beta-catenin and its active form, non-phosphorylated beta-catenin, were reduced in both cell types. Simvastatin 6-17 catenin beta 1 Homo sapiens 98-110 34614511-8 2021 Additionally, simvastatin reduced the expression of Wnt4 and total beta-catenin, as well as non-phosphorylated beta-catenin protein expression in response to estrogen and progesterone. Simvastatin 14-25 Wnt family member 4 Homo sapiens 52-56 34614511-8 2021 Additionally, simvastatin reduced the expression of Wnt4 and total beta-catenin, as well as non-phosphorylated beta-catenin protein expression in response to estrogen and progesterone. Simvastatin 14-25 catenin beta 1 Homo sapiens 67-79 34614511-8 2021 Additionally, simvastatin reduced the expression of Wnt4 and total beta-catenin, as well as non-phosphorylated beta-catenin protein expression in response to estrogen and progesterone. Simvastatin 14-25 catenin beta 1 Homo sapiens 111-123 34799978-0 2021 Simvastatin treatment promotes proliferation of human dental pulp stem cells via modulating PI3K/AKT/miR-9/KLF5 signalling pathway. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 97-100 34799978-0 2021 Simvastatin treatment promotes proliferation of human dental pulp stem cells via modulating PI3K/AKT/miR-9/KLF5 signalling pathway. Simvastatin 0-11 Kruppel like factor 5 Homo sapiens 107-111 34799978-2 2021 First, western-blot and real-time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR-9 and KLF5, or determine the effect of miR-9. Simvastatin 85-96 AKT serine/threonine kinase 1 Homo sapiens 137-140 34799978-2 2021 First, western-blot and real-time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR-9 and KLF5, or determine the effect of miR-9. Simvastatin 85-96 Kruppel like factor 5 Homo sapiens 152-156 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 157-160 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 117-128 Kruppel like factor 5 Homo sapiens 13-17 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 117-128 AKT serine/threonine kinase 1 Homo sapiens 22-25 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 117-128 AKT serine/threonine kinase 1 Homo sapiens 157-160 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 117-128 Kruppel like factor 5 Homo sapiens 168-172 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 194-205 Kruppel like factor 5 Homo sapiens 13-17 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. Simvastatin 194-205 AKT serine/threonine kinase 1 Homo sapiens 22-25 34799978-4 2021 Furthermore, simvastatin upregulated PI3K and p-AKT expression in a concentration-dependent manner. Simvastatin 13-24 AKT serine/threonine kinase 1 Homo sapiens 48-51 34799978-5 2021 LY294002 abrogated the upregulation of p-AKT expression levels induced by simvastatin, and LY294002 induced the miR-9 expression and simvastatin dose-dependently inhibited the expression of miR-9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose-dependently promoted the expression of KLF5. Simvastatin 74-85 AKT serine/threonine kinase 1 Homo sapiens 41-44 34799978-5 2021 LY294002 abrogated the upregulation of p-AKT expression levels induced by simvastatin, and LY294002 induced the miR-9 expression and simvastatin dose-dependently inhibited the expression of miR-9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose-dependently promoted the expression of KLF5. Simvastatin 74-85 Kruppel like factor 5 Homo sapiens 231-235 34799978-5 2021 LY294002 abrogated the upregulation of p-AKT expression levels induced by simvastatin, and LY294002 induced the miR-9 expression and simvastatin dose-dependently inhibited the expression of miR-9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose-dependently promoted the expression of KLF5. Simvastatin 74-85 Kruppel like factor 5 Homo sapiens 307-311 34799978-5 2021 LY294002 abrogated the upregulation of p-AKT expression levels induced by simvastatin, and LY294002 induced the miR-9 expression and simvastatin dose-dependently inhibited the expression of miR-9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose-dependently promoted the expression of KLF5. Simvastatin 251-262 Kruppel like factor 5 Homo sapiens 307-311 34799978-8 2021 These findings suggested simvastatin could promote the proliferation of pulp stem cells, possibly by suppressing the expression of miR-9 via activating the PI3K/AKT signalling pathway, and the downregulation of miR-9 upregulated the expression of its target gene, KLF5, which is directly responsible for the enhanced proliferation of pulp stem cells. Simvastatin 25-36 AKT serine/threonine kinase 1 Homo sapiens 161-164 34799978-8 2021 These findings suggested simvastatin could promote the proliferation of pulp stem cells, possibly by suppressing the expression of miR-9 via activating the PI3K/AKT signalling pathway, and the downregulation of miR-9 upregulated the expression of its target gene, KLF5, which is directly responsible for the enhanced proliferation of pulp stem cells. Simvastatin 25-36 Kruppel like factor 5 Homo sapiens 264-268 34829936-7 2021 Simvastatin had a significant lowering effect on both P-selectin and E-selectin. Simvastatin 0-11 selectin P Homo sapiens 54-64 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 peroxisome proliferator activated receptor gamma Mus musculus 216-264 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 peroxisome proliferator activated receptor gamma Mus musculus 266-275 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 CCAAT/enhancer binding protein (C/EBP), alpha Mus musculus 278-315 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 CCAAT/enhancer binding protein (C/EBP), alpha Mus musculus 317-327 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 sterol regulatory element binding transcription factor 1 Mus musculus 334-377 34940118-8 2021 In conclusion, the inhibitory effect of MET and SIM on adipocyte differentiation, as indicated by decreased lipid accumulation, appears to be mediated through the down-regulation of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding pro-tein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP-1C). Simvastatin 48-51 sterol regulatory element binding transcription factor 1 Mus musculus 379-387 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 tumor necrosis factor Mus musculus 272-293 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 tumor necrosis factor Mus musculus 295-298 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 interleukin 1 alpha Mus musculus 301-323 34830364-5 2021 Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6. Simvastatin 74-85 interleukin 6 Mus musculus 329-332 34829936-7 2021 Simvastatin had a significant lowering effect on both P-selectin and E-selectin. Simvastatin 0-11 selectin E Homo sapiens 69-79 34627266-6 2021 The as-obtained Fe3O4@PCBMA-SIM nanoparticles demonstrated more cytotoxicity against MDA-MB-231 than MCF-7 due to the higher expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which demonstrated that statins could effectively kill TNBC. Simvastatin 28-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-187 34549987-0 2021 Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. Simvastatin 88-99 nucleocapsid phosphoprotein Severe acute respiratory syndrome coronavirus 2 53-65 34606062-3 2021 OBJECTIVE: To identify whether variations in genes encoding cytochrome P450 (CYP) enzymes or in the SLCO1B1 gene (Solute Carrier Organic anion transporting polypeptide 1B1 gene, encoding the organic anion transporting polypeptide 1B1 (OATP1B1) drug transporter enzyme), and/or characteristics of concomitantly used drugs, predispose patients to simvastatin-associated pulmonary toxicity. Simvastatin 345-356 solute carrier organic anion transporter family member 1B1 Homo sapiens 100-107 34606062-3 2021 OBJECTIVE: To identify whether variations in genes encoding cytochrome P450 (CYP) enzymes or in the SLCO1B1 gene (Solute Carrier Organic anion transporting polypeptide 1B1 gene, encoding the organic anion transporting polypeptide 1B1 (OATP1B1) drug transporter enzyme), and/or characteristics of concomitantly used drugs, predispose patients to simvastatin-associated pulmonary toxicity. Simvastatin 345-356 solute carrier organic anion transporter family member 1B1 Homo sapiens 191-233 34606062-3 2021 OBJECTIVE: To identify whether variations in genes encoding cytochrome P450 (CYP) enzymes or in the SLCO1B1 gene (Solute Carrier Organic anion transporting polypeptide 1B1 gene, encoding the organic anion transporting polypeptide 1B1 (OATP1B1) drug transporter enzyme), and/or characteristics of concomitantly used drugs, predispose patients to simvastatin-associated pulmonary toxicity. Simvastatin 345-356 solute carrier organic anion transporter family member 1B1 Homo sapiens 235-242 34606062-6 2021 RESULTS: Multiple drug use involving either substrates and/or inhibitors of CYP3A4 and/or three or more drugs with the potential to cause acidosis explained the simvastatin-associated toxicity in 70.5% (n = 24) of cases. Simvastatin 161-172 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-82 34702519-8 2021 Computational modelling shows that Human Serum Albumin and Human alpha2-macroglobulin can be utilized to increase SIM bioavailability for cells via a molecular docking mechanism. Simvastatin 114-117 albumin Homo sapiens 41-54 34702519-8 2021 Computational modelling shows that Human Serum Albumin and Human alpha2-macroglobulin can be utilized to increase SIM bioavailability for cells via a molecular docking mechanism. Simvastatin 114-117 alpha-2-macroglobulin Homo sapiens 65-85 34762363-5 2021 Biotinylation assays showed that acute (1hr) atorvastatin, simvastatin, or fluvastatin increased AQP2 membrane accumulation in mCCDc1l cells showing that the cell line responds to acute statin treatment. Simvastatin 59-70 aquaporin 2 Mus musculus 97-101 34687147-4 2022 In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC. Simvastatin 46-57 protein tyrosine phosphatase receptor type C Homo sapiens 154-160 34687147-4 2022 In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC. Simvastatin 46-57 CD4 molecule Homo sapiens 162-165 34687147-4 2022 In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC. Simvastatin 46-57 interleukin 2 Homo sapiens 199-203 34687147-4 2022 In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC. Simvastatin 46-57 interferon gamma Homo sapiens 205-213 34687147-4 2022 In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC. Simvastatin 46-57 interleukin 6 Homo sapiens 218-222 34627266-6 2021 The as-obtained Fe3O4@PCBMA-SIM nanoparticles demonstrated more cytotoxicity against MDA-MB-231 than MCF-7 due to the higher expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), which demonstrated that statins could effectively kill TNBC. Simvastatin 28-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 189-194 34627266-7 2021 Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. Simvastatin 32-35 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-73 34627266-7 2021 Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. Simvastatin 32-35 glutathione peroxidase 4 Homo sapiens 123-147 34627266-7 2021 Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. Simvastatin 32-35 glutathione peroxidase 4 Homo sapiens 149-153 34461118-0 2021 mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - roles of Rap1 geranylgeranylation and mitochondrial dysfunction. Simvastatin 34-45 CREB regulated transcription coactivator 2 Mus musculus 0-6 34461118-0 2021 mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - roles of Rap1 geranylgeranylation and mitochondrial dysfunction. Simvastatin 34-45 RAS-related protein 1a Mus musculus 118-122 34461118-8 2021 Simvastatin impaired Rap1 geranylgeranylation and function, which was prevented by geranylgeraniol. Simvastatin 0-11 RAS-related protein 1a Mus musculus 21-25 34461118-3 2021 In C2C12 myoblasts and myotubes and mouse gastrocnemius, simvastatin was cytotoxic and inhibited S6rp and Akt Ser473 phosphorylation, indicating inhibition of mTORC1 and mTORC2, respectively. Simvastatin 57-68 thymoma viral proto-oncogene 1 Mus musculus 106-109 34461118-9 2021 In addition, simvastatin and the complex III inhibitor antimycin A caused mitochondrial superoxide accumulation and impaired the activity of mTORC2, which could partially be prevented by the antioxidant MitoTEMPO. Simvastatin 13-24 CREB regulated transcription coactivator 2 Mus musculus 141-147 34461118-10 2021 In conclusion, mTORC2 inhibition is an important mechanism of simvastatin-induced myotoxicity. Simvastatin 62-73 CREB regulated transcription coactivator 2 Mus musculus 15-21 34461118-11 2021 Simvastatin inhibits mTORC2 by impairing geranylgeranylation of Rap1 and by inducing mitochondrial dysfunction. Simvastatin 0-11 CREB regulated transcription coactivator 2 Mus musculus 21-27 34461118-11 2021 Simvastatin inhibits mTORC2 by impairing geranylgeranylation of Rap1 and by inducing mitochondrial dysfunction. Simvastatin 0-11 RAS-related protein 1a Mus musculus 64-68 34461118-3 2021 In C2C12 myoblasts and myotubes and mouse gastrocnemius, simvastatin was cytotoxic and inhibited S6rp and Akt Ser473 phosphorylation, indicating inhibition of mTORC1 and mTORC2, respectively. Simvastatin 57-68 CREB regulated transcription coactivator 1 Mus musculus 159-165 34461118-3 2021 In C2C12 myoblasts and myotubes and mouse gastrocnemius, simvastatin was cytotoxic and inhibited S6rp and Akt Ser473 phosphorylation, indicating inhibition of mTORC1 and mTORC2, respectively. Simvastatin 57-68 CREB regulated transcription coactivator 2 Mus musculus 170-176 34461118-5 2021 Like simvastatin, knock-down of Rictor, an essential component of mTORC2, impaired Akt Ser473 and S6rp phosphorylation and was cytotoxic for C2C12 myoblasts, suggesting that mTORC2 inhibition is an important myotoxic mechanism. Simvastatin 5-16 RPTOR independent companion of MTOR, complex 2 Mus musculus 32-38 34461118-5 2021 Like simvastatin, knock-down of Rictor, an essential component of mTORC2, impaired Akt Ser473 and S6rp phosphorylation and was cytotoxic for C2C12 myoblasts, suggesting that mTORC2 inhibition is an important myotoxic mechanism. Simvastatin 5-16 CREB regulated transcription coactivator 2 Mus musculus 66-72 34461118-5 2021 Like simvastatin, knock-down of Rictor, an essential component of mTORC2, impaired Akt Ser473 and S6rp phosphorylation and was cytotoxic for C2C12 myoblasts, suggesting that mTORC2 inhibition is an important myotoxic mechanism. Simvastatin 5-16 thymoma viral proto-oncogene 1 Mus musculus 83-86 34461118-5 2021 Like simvastatin, knock-down of Rictor, an essential component of mTORC2, impaired Akt Ser473 and S6rp phosphorylation and was cytotoxic for C2C12 myoblasts, suggesting that mTORC2 inhibition is an important myotoxic mechanism. Simvastatin 5-16 CREB regulated transcription coactivator 2 Mus musculus 174-180 34461118-6 2021 The investigation of the mechanism of mTORC2 inhibition showed that simvastatin impaired Ras farnesylation, which was prevented by farnesol but without restoring mTORC2 activity. Simvastatin 68-79 CREB regulated transcription coactivator 2 Mus musculus 38-44 34666502-0 2021 Ultrasound-targeted simvastatin-loaded microbubble destruction promotes OA cartilage repair by modulating the cholesterol efflux pathway mediated by PPARgamma in rabbits. Simvastatin 20-31 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 149-158 34666502-1 2021 AIMS: To evaluate the effect of ultrasound-targeted simvastatin-loaded microbubble destruction (UTMD SV ) for alleviation of the progression of osteoarthritis (OA) in rabbits through modulation of the peroxisome proliferator-activated receptor (PPARgamma). Simvastatin 52-63 peroxisome proliferator-activated receptor gamma Oryctolagus cuniculus 245-254 34586142-3 2021 Herein, simvastatin drugs used as BMP-2 stimulators are encapsulated into the layer space of LAPONITE via electrostatic interactions and ion exchange efficiently, and supramolecular hydrogels could be fabricated with a self-healing, injectable and sustained drug release nature. Simvastatin 8-19 bone morphogenetic protein 2 Homo sapiens 34-39 34428598-16 2021 Decreased levels of PAI-1 were observed in the simvastatin treated groups. Simvastatin 47-58 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 20-25 34461224-4 2021 The aim of this work is to investigate the impact of simvastatin on ER-alpha signaling in leiomyoma cells, including its expression, downstream signaling, transcriptional activity, post-translational modification, trafficking and degradation. Simvastatin 53-64 estrogen receptor 1 Homo sapiens 68-76 34461224-8 2021 Here, we found that simvastatin significantly reduced E2-induced proliferation and PCNA expression. Simvastatin 20-31 proliferating cell nuclear antigen Homo sapiens 83-87 34461224-9 2021 In addition, simvastatin reduced total ER-alpha expression in leiomyoma cells and altered its subcellular localization by inhibiting its trafficking to the plasma membrane and nucleus. Simvastatin 13-24 estrogen receptor 1 Homo sapiens 39-47 34461224-10 2021 Simvastatin also inhibited E2 downstream signaling, including ERK and AKT pathways, E2/ER transcriptional activity and E2-responsive genes. Simvastatin 0-11 mitogen-activated protein kinase 1 Homo sapiens 62-65 34461224-10 2021 Simvastatin also inhibited E2 downstream signaling, including ERK and AKT pathways, E2/ER transcriptional activity and E2-responsive genes. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 70-73 34461224-10 2021 Simvastatin also inhibited E2 downstream signaling, including ERK and AKT pathways, E2/ER transcriptional activity and E2-responsive genes. Simvastatin 0-11 cystatin 12, pseudogene Homo sapiens 84-89 34461224-11 2021 To explain simvastatin effects on ER-alpha level and trafficking, we examined its effects on ER-alpha post-translational processing. Simvastatin 11-22 estrogen receptor 1 Homo sapiens 34-42 34461224-11 2021 To explain simvastatin effects on ER-alpha level and trafficking, we examined its effects on ER-alpha post-translational processing. Simvastatin 11-22 estrogen receptor 1 Homo sapiens 93-101 34461224-12 2021 We noticed that simvastatin reduced ER-alpha palmitoylation; a required modification for its stability, trafficking to plasma membrane, and signaling. Simvastatin 16-27 estrogen receptor 1 Homo sapiens 36-44 34461224-14 2021 Importantly, we found that the effects of simvastatin on ER-alpha expression were recapitulated in the xenograft leiomyoma mouse model and human tissues. Simvastatin 42-53 estrogen receptor 1 (alpha) Mus musculus 57-65 34461224-15 2021 Thus, our data suggest that simvastatin modulates several E2/ER signaling targets with potential implications in leiomyoma therapy and beyond. Simvastatin 28-39 cystatin 12, pseudogene Homo sapiens 58-63 34586142-4 2021 Hydrogels encapsulated with 10 mug mL-1 simvastatin drug show good osteogenic differentiation in vitro. Simvastatin 40-51 L1 cell adhesion molecule Mus musculus 35-39 34680049-0 2021 HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation. Simvastatin 29-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 34680049-7 2021 As a result of EAM, there was an enhanced activation of MMP-9, which was significantly reduced in the high-dose simvastatin group compared to the low-dose group. Simvastatin 112-123 matrix metallopeptidase 9 Homo sapiens 56-61 34680049-9 2021 CONCLUSIONS: The cardioprotective effects of simvastatin in the acute phase of EAM are, at least in part, due to its ability to decrease MMP-9 activity and subsequent decline in myofilaments degradation and suppression of inflammation. Simvastatin 45-56 matrix metallopeptidase 9 Homo sapiens 137-142 34114646-1 2021 The association between the c.521T>C variant allele in SLCO1B1 (rs4149056) and simvastatin-induced myotoxicity was discovered over a decade ago; however, whether this relationship represents a class effect is still not fully known. Simvastatin 79-90 solute carrier organic anion transporter family member 1B1 Homo sapiens 55-62 34479633-7 2021 METHODS: Several methods including functional assessment of muscle function via grip strength measurement, treadmill test, and single-muscle force estimation, enzymatic assays, histological analysis of muscle damage, gene expression evaluation, and immunofluorescence staining were conducted to study simvastatin-related alterations in the mdx mouse model of DMD. Simvastatin 301-312 dystrophin, muscular dystrophy Mus musculus 359-362 34572136-4 2021 Four statins, namely simvastatin, atorvastatin, lovastatin, and fluvastatin, decreased PD-L1 expression in melanoma and lung cancer cells. Simvastatin 21-32 CD274 molecule Homo sapiens 87-92 34425670-6 2021 Moreover, HMGCR rs3846662 g.23092A>G was found to be homozygous (G/G) in the proband, probably leading to reduced response to simvastatin and pravastatin. Simvastatin 126-137 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 10-15 34674552-6 2021 Conclusion: Based on these SLCO1B1 gene variants, we confirmed that a minimum fraction of the Mexican study populations would be at risk from decreasing simvastatin transport and the development of statin-induced myopathy. Simvastatin 153-164 solute carrier organic anion transporter family member 1B1 Homo sapiens 27-34 34816650-13 2021 Conclusion: Simvastatin can reduce the degree of pulmonary fibrosis in rats through inhibiting the process of EnMT, which can enhance the expression of VE-cad and reduce the expression of VIM and alpha-SMA. Simvastatin 12-23 vimentin Rattus norvegicus 188-191 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 nitric oxide synthase 2 Rattus norvegicus 63-67 34564389-7 2021 Supra-therapeutic concentrations of simvastatin reduced glucose uptake in adipocytes and normalized fatty acid-induced insulin hypersecretion from beta-cells. Simvastatin 36-47 insulin Homo sapiens 119-126 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 matrix metallopeptidase 2 Rattus norvegicus 69-74 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 matrix metallopeptidase 9 Rattus norvegicus 76-81 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 vascular endothelial growth factor A Rattus norvegicus 86-90 34147541-9 2021 Simvastatin increased levels of circulating EPCs and decreased iNOS, MMP-2, MMP-9 and VEGF mRNA levels, while increased eNOS mRNA in aneurysmal tissue. Simvastatin 0-11 nitric oxide synthase 3 Rattus norvegicus 120-124 34439919-0 2021 Transcriptional Regulation of MECP2E1-E2 Isoforms and BDNF by Metformin and Simvastatin through Analyzing Nascent RNA Synthesis in a Human Brain Cell Line. Simvastatin 76-87 brain derived neurotrophic factor Homo sapiens 54-58 34439919-8 2021 In contrast simvastatin significantly inhibited BDNF transcription without significantly impacting MECP2E2 transcripts. Simvastatin 12-23 brain derived neurotrophic factor Homo sapiens 48-52 34439919-11 2021 Taken together, our results suggest that metformin controls MECP2E1/E2-BDNF transcriptionally and/or post-transcriptionally, and that simvastatin is a potent transcriptional inhibitor of BDNF. Simvastatin 134-145 brain derived neurotrophic factor Homo sapiens 187-191 34422919-10 2021 Concomitant treatment of cholesterol-fed ApoE-/- mice with LT, the specific synthetic Rac1 inhibitor NSC 23766 or simvastatin comparably reduced aortic Rac1 activity, NADPH oxidase activity, oxidative stress, endothelial dysfunction, atherosclerosis development, and macrophage infiltration. Simvastatin 114-125 apolipoprotein E Mus musculus 41-45 34434166-9 2021 Collectively, these findings show that exenatide was superior to simvastatin in the treatment of obesity-TECs injuries, the mechanism is partially through SIRT1 restoration, which directly reverses mitochondrial dysfunction and apoptosis. Simvastatin 65-76 sirtuin 1 Homo sapiens 155-160 34422919-10 2021 Concomitant treatment of cholesterol-fed ApoE-/- mice with LT, the specific synthetic Rac1 inhibitor NSC 23766 or simvastatin comparably reduced aortic Rac1 activity, NADPH oxidase activity, oxidative stress, endothelial dysfunction, atherosclerosis development, and macrophage infiltration. Simvastatin 114-125 Rac family small GTPase 1 Mus musculus 152-156 34349106-7 2021 Therapeutic cholesterol-lowering through simvastatin reduced systemic and neuro-inflammation, and the occurrence of memory deficits in aged ApoE-/- mice with chronic hypercholesterolemia. Simvastatin 41-52 apolipoprotein E Mus musculus 140-144 34111424-7 2021 Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate. Simvastatin 0-11 insulin receptor Homo sapiens 48-64 34111424-7 2021 Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate. Simvastatin 0-11 AKT serine/threonine kinase 1 Homo sapiens 76-79 34111424-9 2021 In addition, simvastatin impaired proliferation and fusion of myoblasts to myotubes by inhibiting the expression of the nuclear transcription factor MyoD and of the metalloprotease ADAM-12. Simvastatin 13-24 myogenic differentiation 1 Homo sapiens 149-153 34111424-7 2021 Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate. Simvastatin 0-11 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 130-134 34111424-10 2021 Decreased expression of the proliferation factor Ki-67 and of ADAM-12 were also observed in gastrocnemius of mice treated with simvastatin. Simvastatin 127-138 antigen identified by monoclonal antibody Ki 67 Mus musculus 49-54 34111424-10 2021 Decreased expression of the proliferation factor Ki-67 and of ADAM-12 were also observed in gastrocnemius of mice treated with simvastatin. Simvastatin 127-138 a disintegrin and metallopeptidase domain 12 (meltrin alpha) Mus musculus 62-69 34111424-8 2021 Simvastatin impaired oxygen consumption and increased superoxide production by myoblasts and myotubes and induced apoptosis via cytochrome c release. Simvastatin 0-11 cytochrome c, somatic Homo sapiens 128-140 34274535-4 2022 Inhibiting cholesterol synthesis in lung-colonizing breast tumor cells by the pulmonary administration of simvastatin-carrying HER3-targeting nanoparticles reduces the angiogenesis and growth of lung metastases in a syngeneic TNBC mouse model. Simvastatin 106-117 erb-b2 receptor tyrosine kinase 3 Mus musculus 127-131 34288836-2 2022 AIM: Aim of the present study is to fabricate nanofilm embedded with simvastatin loaded chitosan nanoparticles (CS-SIM-NPs) has been reported herein to explore the efficacy of SIM in diabetic wound healing. Simvastatin 69-80 citrate synthase Rattus norvegicus 112-114 34321273-12 2021 Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4+ lymphocytes, CD8+ lymphocytes, and tumor-specific CD8+ in the tumor-draining lymph nodes. Simvastatin 38-49 CD4 molecule Homo sapiens 69-72 34321273-12 2021 Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4+ lymphocytes, CD8+ lymphocytes, and tumor-specific CD8+ in the tumor-draining lymph nodes. Simvastatin 38-49 CD8a molecule Homo sapiens 87-90 34321273-9 2021 Simvastatin and atorvastatin efficiently abrogated for 8 hours the transcriptomic response to IFNalpha and enhanced the number of dendritic cells presenting an OVA-derived peptide bound to major histocompatibility complex (MHC) class I. Simvastatin 0-11 interferon alpha 1 Homo sapiens 94-102 34321273-12 2021 Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4+ lymphocytes, CD8+ lymphocytes, and tumor-specific CD8+ in the tumor-draining lymph nodes. Simvastatin 38-49 CD8a molecule Homo sapiens 124-127 34321273-14 2021 CONCLUSION: In conclusion, blockade of IFNalpha functions by simvastatin markedly enhances lymphocyte infiltration and the antitumor activity of MVA, prompting a feasible drug repurposing. Simvastatin 61-72 interferon alpha 1 Homo sapiens 39-47 34158867-6 2021 The therapeutic potential of a combinatorial miR-375-decoy/simvastatin treatment was validated by live cell imaging. Simvastatin 59-70 microRNA 375 Homo sapiens 45-52 34357979-10 2021 Furthermore, simvastatin significantly decreased numbers of duodenal CD4+IFN-gamma+, CD8+IFN-gamma+ and regulatory T cells and total duodenal activated CD4+ and CD8+ T cells in vaccinated pigs pre-challenge at PID 28. Simvastatin 13-24 CD4 molecule Sus scrofa 69-72 34357979-10 2021 Furthermore, simvastatin significantly decreased numbers of duodenal CD4+IFN-gamma+, CD8+IFN-gamma+ and regulatory T cells and total duodenal activated CD4+ and CD8+ T cells in vaccinated pigs pre-challenge at PID 28. Simvastatin 13-24 interferon gamma Sus scrofa 73-82 34357979-10 2021 Furthermore, simvastatin significantly decreased numbers of duodenal CD4+IFN-gamma+, CD8+IFN-gamma+ and regulatory T cells and total duodenal activated CD4+ and CD8+ T cells in vaccinated pigs pre-challenge at PID 28. Simvastatin 13-24 interferon gamma Sus scrofa 89-98 34357979-10 2021 Furthermore, simvastatin significantly decreased numbers of duodenal CD4+IFN-gamma+, CD8+IFN-gamma+ and regulatory T cells and total duodenal activated CD4+ and CD8+ T cells in vaccinated pigs pre-challenge at PID 28. Simvastatin 13-24 CD4 molecule Sus scrofa 152-155 34357979-11 2021 Following challenge, simvastatin prevented the IFN-gamma+ T cell response in spleen of vaccinated pigs. Simvastatin 21-32 interferon gamma Sus scrofa 47-56 34158867-11 2021 Restoring of LDHB expression potentiated inhibitory effects of simvastatin on tumor cell proliferation. Simvastatin 63-74 lactate dehydrogenase B Homo sapiens 13-17 34073952-6 2021 In this work, we investigated interactions between human adenylate kinase isoenzyme 1 (hAK1) and atorvastatin (AVS), fluvastatin (FVS), pravastatin (PVS), rosuvastatin (RVS) and simvastatin (SVS) with fluorescence spectroscopy. Simvastatin 191-194 adenylate kinase 1 Homo sapiens 57-85 34073952-9 2021 Simvastatin inhibited hAK1 with the highest yield comparable to that reported for diadenosine pentaphosphate, the only known hAK1 inhibitor. Simvastatin 0-11 adenylate kinase 1 Homo sapiens 22-26 34073952-6 2021 In this work, we investigated interactions between human adenylate kinase isoenzyme 1 (hAK1) and atorvastatin (AVS), fluvastatin (FVS), pravastatin (PVS), rosuvastatin (RVS) and simvastatin (SVS) with fluorescence spectroscopy. Simvastatin 178-189 adenylate kinase 1 Homo sapiens 57-85 34073952-6 2021 In this work, we investigated interactions between human adenylate kinase isoenzyme 1 (hAK1) and atorvastatin (AVS), fluvastatin (FVS), pravastatin (PVS), rosuvastatin (RVS) and simvastatin (SVS) with fluorescence spectroscopy. Simvastatin 178-189 adenylate kinase 1 Homo sapiens 87-91 34066911-5 2021 Simvastatin further increased the lipid droplet accumulation in PGC-1alpha OE mice and stimulated muscle glucose uptake. Simvastatin 0-11 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 64-74 34067739-2 2021 Simvastatin (SIM) was reported to promote both chondrogenic and osteogenic differentiation of ADSCs by upregulating bone morphogenetic protein-2 (BMP-2). Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 116-144 34067739-2 2021 Simvastatin (SIM) was reported to promote both chondrogenic and osteogenic differentiation of ADSCs by upregulating bone morphogenetic protein-2 (BMP-2). Simvastatin 0-11 bone morphogenetic protein 2 Homo sapiens 146-151 34067739-2 2021 Simvastatin (SIM) was reported to promote both chondrogenic and osteogenic differentiation of ADSCs by upregulating bone morphogenetic protein-2 (BMP-2). Simvastatin 13-16 bone morphogenetic protein 2 Homo sapiens 116-144 34067739-2 2021 Simvastatin (SIM) was reported to promote both chondrogenic and osteogenic differentiation of ADSCs by upregulating bone morphogenetic protein-2 (BMP-2). Simvastatin 13-16 bone morphogenetic protein 2 Homo sapiens 146-151 34067739-7 2021 In contrast, SIM-induced osteogenesis in ADSCs was reduced in SIM plus HAM, including mRNA expression of osteogenic genes, osteocalcin and alkaline phosphatase (ALP), ALP activity and mineralization. Simvastatin 13-16 bone gamma-carboxyglutamate protein Homo sapiens 123-134 34067739-7 2021 In contrast, SIM-induced osteogenesis in ADSCs was reduced in SIM plus HAM, including mRNA expression of osteogenic genes, osteocalcin and alkaline phosphatase (ALP), ALP activity and mineralization. Simvastatin 13-16 alkaline phosphatase, placental Homo sapiens 139-159 34067739-7 2021 In contrast, SIM-induced osteogenesis in ADSCs was reduced in SIM plus HAM, including mRNA expression of osteogenic genes, osteocalcin and alkaline phosphatase (ALP), ALP activity and mineralization. Simvastatin 13-16 alkaline phosphatase, placental Homo sapiens 161-164 34067739-7 2021 In contrast, SIM-induced osteogenesis in ADSCs was reduced in SIM plus HAM, including mRNA expression of osteogenic genes, osteocalcin and alkaline phosphatase (ALP), ALP activity and mineralization. Simvastatin 13-16 alkaline phosphatase, placental Homo sapiens 167-170 34067739-9 2021 HAM suppressed the levels of JNK, p-JNK, P38 and p-P38 in ADSCs, and SIM plus HAM also decreased SIM-induced phosphorylated JNK and p38 levels. Simvastatin 97-100 mitogen-activated protein kinase 8 Homo sapiens 124-127 34067739-9 2021 HAM suppressed the levels of JNK, p-JNK, P38 and p-P38 in ADSCs, and SIM plus HAM also decreased SIM-induced phosphorylated JNK and p38 levels. Simvastatin 97-100 mitogen-activated protein kinase 14 Homo sapiens 132-135 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 165-180 35599097-0 2022 Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1" (Canc. Simvastatin 16-27 transforming growth factor beta 1 Homo sapiens 136-145 35599097-0 2022 Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1" (Canc. Simvastatin 16-27 growth factor independent 1 transcriptional repressor Homo sapiens 146-151 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 182-185 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 runt related transcription factor 2 Mus musculus 213-218 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 bone gamma-carboxyglutamate protein 2 Mus musculus 223-234 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 bone gamma-carboxyglutamate protein 2 Mus musculus 236-239 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 281-331 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 333-338 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 peroxisome proliferator activated receptor gamma Mus musculus 344-392 35421557-6 2022 In details, simvastatin combined with exercise ameliorated the abnormal bone mass, microstructure and bone marrow adipocyte differentiation, significantly increased osteoprotegerin (OPG), type 1 collagen (Col-I), RUNX2 and osteocalcin (OCN) expression, decreased the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) and peroxisome proliferator-activated receptor gamma (PPARgamma). Simvastatin 12-23 peroxisome proliferator activated receptor gamma Mus musculus 394-403 35618653-0 2022 A ROS-Responsive Simvastatin Nano-Prodrug and its Fibronectin-Targeted Co-Delivery System for Atherosclerosis Treatment. Simvastatin 17-28 fibronectin 1 Mus musculus 50-61 35618653-5 2022 Moreover, by taking advantage of the self-assembly behavior of TPTS, we developed a fibronectin-targeted delivery system (TPTS/C/T) to codelivery simvastatin prodrug and ticagrelor. Simvastatin 146-157 fibronectin 1 Mus musculus 84-95 35618653-7 2022 They greatly inhibited the M1-type polarization of macrophages; reduced intracellular reactive oxygen species level and inflammatory cytokine; and TNF-alpha, MCP-1, and IL-1beta were secreted by macrophage cells, thus providing enhanced anti-inflammatory and antioxidant effects compared with free simvastatin. Simvastatin 298-309 tumor necrosis factor Mus musculus 147-156 35618653-7 2022 They greatly inhibited the M1-type polarization of macrophages; reduced intracellular reactive oxygen species level and inflammatory cytokine; and TNF-alpha, MCP-1, and IL-1beta were secreted by macrophage cells, thus providing enhanced anti-inflammatory and antioxidant effects compared with free simvastatin. Simvastatin 298-309 chemokine (C-C motif) ligand 2 Mus musculus 158-163 35618653-7 2022 They greatly inhibited the M1-type polarization of macrophages; reduced intracellular reactive oxygen species level and inflammatory cytokine; and TNF-alpha, MCP-1, and IL-1beta were secreted by macrophage cells, thus providing enhanced anti-inflammatory and antioxidant effects compared with free simvastatin. Simvastatin 298-309 interleukin 1 alpha Mus musculus 169-177 35618653-8 2022 TPTS/C/T realized targeted drug release to plaques and synergistic therapeutic effects of simvastatin and ticagrelor on atherosclerosis treatment in an ApoE-/- mouse model, resulting in excellent atherosclerosis therapeutic efficacy and a promising biosafety profile. Simvastatin 90-101 apolipoprotein E Mus musculus 152-156 35533500-3 2022 We undertook an exploratory observational study to determine the association between plasma NfL and delirium in the critically ill. METHODS: MoDUS was a randomised placebo-controlled delirium trial of simvastatin done in an UK adult general ICU. Simvastatin 201-212 neurofilament light chain Homo sapiens 92-95 35601076-0 2022 Simvastatin alleviates epithelial-mesenchymal transition and oxidative stress of high glucose-induced lens epithelial cells in vitro by inhibiting RhoA/ROCK signaling. Simvastatin 0-11 ras homolog family member A Homo sapiens 147-151 35601076-0 2022 Simvastatin alleviates epithelial-mesenchymal transition and oxidative stress of high glucose-induced lens epithelial cells in vitro by inhibiting RhoA/ROCK signaling. Simvastatin 0-11 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 152-156 35601076-7 2022 The protein expression levels of E-cadherin were increased but those of N-cadherin, Vimentin and alpha-SMA decreased after HG and simvastatin treatment, and this was reversed by U46619. Simvastatin 130-141 cadherin 1 Homo sapiens 33-43 35601076-7 2022 The protein expression levels of E-cadherin were increased but those of N-cadherin, Vimentin and alpha-SMA decreased after HG and simvastatin treatment, and this was reversed by U46619. Simvastatin 130-141 cadherin 2 Homo sapiens 72-82 35624221-8 2022 Treatment with LCL521 or simvastatin to inhibit ASAH1 or HMGCR, respectively, resulted in accumulation of ceramide at the cell surface of PGCC and prevented PGCC progeny formation. Simvastatin 25-36 N-acylsphingosine amidohydrolase 1 Homo sapiens 48-53 35601076-7 2022 The protein expression levels of E-cadherin were increased but those of N-cadherin, Vimentin and alpha-SMA decreased after HG and simvastatin treatment, and this was reversed by U46619. Simvastatin 130-141 vimentin Homo sapiens 84-92 35601076-7 2022 The protein expression levels of E-cadherin were increased but those of N-cadherin, Vimentin and alpha-SMA decreased after HG and simvastatin treatment, and this was reversed by U46619. Simvastatin 130-141 actin alpha 1, skeletal muscle Homo sapiens 97-106 35624221-8 2022 Treatment with LCL521 or simvastatin to inhibit ASAH1 or HMGCR, respectively, resulted in accumulation of ceramide at the cell surface of PGCC and prevented PGCC progeny formation. Simvastatin 25-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-62 35447349-0 2022 Anchoring beta-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells. Simvastatin 21-32 adrenocortical dysplasia Mus musculus 10-17 35543701-2 2022 Previous studies have reported an association between the p.Val174Ala missense variant in SLCO1B1 and SAMS in simvastatin-treated subjects; however, evidence for genetic predictors of SAMS in atorvastatin- or rosuvastatin-treated subjects is currently lacking. Simvastatin 110-121 solute carrier organic anion transporter family member 1B1 Homo sapiens 90-97 35619689-8 2022 Additionally, the overexpression of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the known target of statins, reversed the effects of simvastatin. Simvastatin 234-245 NLR family pyrin domain containing 3 Homo sapiens 36-101 35619689-8 2022 Additionally, the overexpression of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the known target of statins, reversed the effects of simvastatin. Simvastatin 234-245 NLR family pyrin domain containing 3 Homo sapiens 103-108 35619689-8 2022 Additionally, the overexpression of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the known target of statins, reversed the effects of simvastatin. Simvastatin 234-245 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 153-171 35619689-10 2022 Furthermore, the immunoprecipitation results confirmed the interaction between NLRP3 and HMGCR, and this interaction was inhibited by simvastatin. Simvastatin 134-145 NLR family pyrin domain containing 3 Homo sapiens 79-84 35629051-7 2022 The TLR-2 expression on granulocytes and monocytes showed higher values, whereas the TLR-4 expression was lower on lymphocytes and granulocytes in simvastatin-treated children. Simvastatin 147-158 toll like receptor 4 Homo sapiens 85-90 35619689-10 2022 Furthermore, the immunoprecipitation results confirmed the interaction between NLRP3 and HMGCR, and this interaction was inhibited by simvastatin. Simvastatin 134-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 89-94 35619689-11 2022 In conclusion, we demonstrated that topical application of simvastatin ointment might be a promising treatment for DNPX skin lesions and that this therapeutic effect may be related to pyroptosis inhibition via HMGCR inhibition in foam cells. Simvastatin 59-70 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 210-215 35447349-4 2022 Based on the superb ability of beta-cyclodextrin (beta-CD) to bind CCs and promote cholesterol efflux, simvastatin-loaded discoidal-rHDL (ST-d-rHDL) anchored with beta-CD (betaCD-ST-d-rHDL) was constructed. Simvastatin 103-114 adrenocortical dysplasia Mus musculus 50-57 35447349-4 2022 Based on the superb ability of beta-cyclodextrin (beta-CD) to bind CCs and promote cholesterol efflux, simvastatin-loaded discoidal-rHDL (ST-d-rHDL) anchored with beta-CD (betaCD-ST-d-rHDL) was constructed. Simvastatin 103-114 adrenocortical dysplasia Mus musculus 163-170 35366048-6 2022 Also, we showed that the combination therapy by Simvastatin and ATO increased cell apoptosis and inhibited cell proliferation, providing anti-proliferative and anti-angiogenic properties, possibly via downregulation of the expression of VEGF and OPN genes. Simvastatin 48-59 secreted phosphoprotein 1 Homo sapiens 246-249 35217376-3 2022 Californidine and berberine at tested doses reduced the expression of PCSK9, with an opposite behaviour to simvastatin on this target. Simvastatin 107-118 proprotein convertase subtilisin/kexin type 9 Homo sapiens 70-75 35366048-0 2022 Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. Simvastatin 31-42 vascular endothelial growth factor A Homo sapiens 120-124 35366048-0 2022 Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. Simvastatin 31-42 secreted phosphoprotein 1 Homo sapiens 129-132 35366048-6 2022 Also, we showed that the combination therapy by Simvastatin and ATO increased cell apoptosis and inhibited cell proliferation, providing anti-proliferative and anti-angiogenic properties, possibly via downregulation of the expression of VEGF and OPN genes. Simvastatin 48-59 vascular endothelial growth factor A Homo sapiens 237-241 35517821-6 2022 Using short hairpin RNA (shRNA) knockdown of caspase-3 or GSDME, and caspase-3-specific inhibitors, we provided evidence of the requirement of caspase-3/GSDME in the pyroptosis process triggered by SIM. Simvastatin 198-201 caspase 3 Mus musculus 45-54 35517821-6 2022 Using short hairpin RNA (shRNA) knockdown of caspase-3 or GSDME, and caspase-3-specific inhibitors, we provided evidence of the requirement of caspase-3/GSDME in the pyroptosis process triggered by SIM. Simvastatin 198-201 caspase 3 Mus musculus 69-78 35517821-6 2022 Using short hairpin RNA (shRNA) knockdown of caspase-3 or GSDME, and caspase-3-specific inhibitors, we provided evidence of the requirement of caspase-3/GSDME in the pyroptosis process triggered by SIM. Simvastatin 198-201 caspase 3 Mus musculus 143-152 35450036-4 2022 This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells. Simvastatin 91-102 interleukin 13 Mus musculus 119-124 35450036-4 2022 This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells. Simvastatin 91-102 interleukin 13 Mus musculus 168-173 35488520-4 2022 Simvastatin as example exhibits anti-inflammatory effects in astrocytes, which are abrogated by Nurr1 knockdown. Simvastatin 0-11 nuclear receptor subfamily 4 group A member 2 Homo sapiens 96-101 35488520-5 2022 Differential gene expression analysis in native and Nurr1-silenced cells reveals strong proinflammatory effects of Nurr1 knockdown while simvastatin treatment induces several neuroprotective mechanisms via Nurr1 involving changes in inflammatory, metabolic and cell cycle gene expression. Simvastatin 137-148 nuclear receptor subfamily 4 group A member 2 Homo sapiens 52-57 35488520-5 2022 Differential gene expression analysis in native and Nurr1-silenced cells reveals strong proinflammatory effects of Nurr1 knockdown while simvastatin treatment induces several neuroprotective mechanisms via Nurr1 involving changes in inflammatory, metabolic and cell cycle gene expression. Simvastatin 137-148 nuclear receptor subfamily 4 group A member 2 Homo sapiens 206-211 35509841-0 2022 Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism. Simvastatin 0-11 NLR family pyrin domain containing 3 Homo sapiens 21-26 35509841-0 2022 Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 135-139 35509841-8 2022 Simvastatin suppressed NLRP3 inflammasome activation and played anti-inflammatory and antioxidant roles by increasing KLF2 (Kruppel-like factor 2) expression. Simvastatin 0-11 NLR family pyrin domain containing 3 Homo sapiens 23-28 35509841-8 2022 Simvastatin suppressed NLRP3 inflammasome activation and played anti-inflammatory and antioxidant roles by increasing KLF2 (Kruppel-like factor 2) expression. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 118-122 35509841-8 2022 Simvastatin suppressed NLRP3 inflammasome activation and played anti-inflammatory and antioxidant roles by increasing KLF2 (Kruppel-like factor 2) expression. Simvastatin 0-11 Kruppel like factor 2 Homo sapiens 124-145 35509841-9 2022 In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. Simvastatin 57-68 Kruppel like factor 2 Homo sapiens 96-100 35509841-9 2022 In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. Simvastatin 57-68 Kruppel like factor 2 Homo sapiens 124-128 35509841-9 2022 In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. Simvastatin 145-156 Kruppel like factor 2 Homo sapiens 96-100 35509841-9 2022 In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. Simvastatin 145-156 Kruppel like factor 2 Homo sapiens 124-128 35509841-10 2022 In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia-induced bronchopulmonary dysplasia via KLF2-mediated mechanism. Simvastatin 39-50 NLR family pyrin domain containing 3 Homo sapiens 70-75 35509841-10 2022 In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia-induced bronchopulmonary dysplasia via KLF2-mediated mechanism. Simvastatin 39-50 Kruppel like factor 2 Homo sapiens 178-182 35397630-0 2022 Simvastatin rescues memory and granule cell maturation through the Wnt/beta-catenin signaling pathway in a mouse model of Alzheimer"s disease. Simvastatin 0-11 catenin (cadherin associated protein), beta 1 Mus musculus 71-83 35406712-11 2022 Simvastatin prevented LPS-induced fibrin deposition by preserving TM expression in sinusoidal cells and completely reverted the peripheral hypo-coagulability caused by endotoxemia. Simvastatin 0-11 thrombomodulin Rattus norvegicus 66-68 35258724-4 2022 The changes of SOD, CAT, GST, and GPx enzymatic activities, and the GSH and MDA content under SIM for 48-h exposure were also addressed. Simvastatin 94-97 glutathione S-transferase 3 Daphnia magna 25-28 35399296-6 2022 Cyclin D1 (Ccnd1), a gene both causally linked to and sufficient to infer regenerative proliferation activity, was overexpressed after exposures to carbon tetrachloride, aflatoxin B1 and thioacetamide, but not in exposures to diazepam and simvastatin. Simvastatin 239-250 cyclin D1 Rattus norvegicus 0-9 35399296-6 2022 Cyclin D1 (Ccnd1), a gene both causally linked to and sufficient to infer regenerative proliferation activity, was overexpressed after exposures to carbon tetrachloride, aflatoxin B1 and thioacetamide, but not in exposures to diazepam and simvastatin. Simvastatin 239-250 cyclin D1 Rattus norvegicus 11-16 35269994-0 2022 Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration. Simvastatin 0-11 cofilin 1 Homo sapiens 26-33 35269994-0 2022 Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration. Simvastatin 0-11 stathmin 1 Homo sapiens 38-46 35269994-8 2022 Transfection of small interfering RNAs (siRNAs) was performed to validate the role of cofilin and stathmin in the simvastatin-mediated inhibition of cell migration. Simvastatin 114-125 stathmin 1 Homo sapiens 98-106 35269994-10 2022 Simvastatin reduced the expression of cofilin and stathmin. Simvastatin 0-11 cofilin 1 Homo sapiens 38-45 35269994-10 2022 Simvastatin reduced the expression of cofilin and stathmin. Simvastatin 0-11 stathmin 1 Homo sapiens 50-58 35269994-12 2022 In conclusion, our results indicated that simvastatin inhibited skeletal muscle cell migration by reducing the expressions of cofilin and stathmin. Simvastatin 42-53 cofilin 1 Homo sapiens 126-133 35269994-12 2022 In conclusion, our results indicated that simvastatin inhibited skeletal muscle cell migration by reducing the expressions of cofilin and stathmin. Simvastatin 42-53 stathmin 1 Homo sapiens 138-146 35402395-0 2022 Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv. Simvastatin 39-50 fms related receptor tyrosine kinase 1 Homo sapiens 109-115 35402395-0 2022 Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv. Simvastatin 39-50 immunglobulin heavy chain variable region Homo sapiens 116-120 35402395-4 2022 In particular, Prodigiosin (PG) and Simvastatin (SIM) were co-loaded into the newly synthesized Ca-Gly BioMOF nanoparticles coated with maltose and functionalized with a recombinant maltose binding protein-scFv fragment of anti-VEGFR1 (Ca-Gly-Maltose-D16F7). Simvastatin 36-47 immunglobulin heavy chain variable region Homo sapiens 206-210 35402395-4 2022 In particular, Prodigiosin (PG) and Simvastatin (SIM) were co-loaded into the newly synthesized Ca-Gly BioMOF nanoparticles coated with maltose and functionalized with a recombinant maltose binding protein-scFv fragment of anti-VEGFR1 (Ca-Gly-Maltose-D16F7). Simvastatin 36-47 fms related receptor tyrosine kinase 1 Homo sapiens 228-234 35402395-4 2022 In particular, Prodigiosin (PG) and Simvastatin (SIM) were co-loaded into the newly synthesized Ca-Gly BioMOF nanoparticles coated with maltose and functionalized with a recombinant maltose binding protein-scFv fragment of anti-VEGFR1 (Ca-Gly-Maltose-D16F7). Simvastatin 49-52 immunglobulin heavy chain variable region Homo sapiens 206-210 35402395-4 2022 In particular, Prodigiosin (PG) and Simvastatin (SIM) were co-loaded into the newly synthesized Ca-Gly BioMOF nanoparticles coated with maltose and functionalized with a recombinant maltose binding protein-scFv fragment of anti-VEGFR1 (Ca-Gly-Maltose-D16F7). Simvastatin 49-52 fms related receptor tyrosine kinase 1 Homo sapiens 228-234 35342027-0 2022 Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-dependent Pyroptosis in Glioblastoma Multiforme. Simvastatin 0-11 caspase 1 Homo sapiens 61-70 35342027-9 2022 However, use of a miR-214 inhibitor reversed the simvastatin suppressive effect on GBM cells. Simvastatin 49-60 microRNA 214 Homo sapiens 18-25 35342027-10 2022 Simvastatin inhibits GBM progression by suppressing caspase-1 dependent pyroptosis, regulated by miR-214. Simvastatin 0-11 caspase 1 Homo sapiens 52-61 35342027-10 2022 Simvastatin inhibits GBM progression by suppressing caspase-1 dependent pyroptosis, regulated by miR-214. Simvastatin 0-11 microRNA 214 Homo sapiens 97-104 35356068-0 2022 Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways. Simvastatin 0-11 signal transducer and activator of transcription 3 Homo sapiens 171-221 35356068-4 2022 Objective: This study is aimed at exploring the effects and outcomes of simvastatin combined with resistance training on the mitochondrial membrane potential (MMP) of peripheral blood lymphocytes and the Janus kinase/signal transducer and activator of the transcription 3 (JAK/STAT3) signaling pathway in patients with CHF. Simvastatin 72-83 signal transducer and activator of transcription 3 Homo sapiens 277-282 34875820-9 2022 The results obtained from the in vitro cell-based studies indicated that simvastatin-loaded SFNPs embedded in the scaffold had acceptable capacity to promote the proliferation and ALP production of osteoblast cells while inducing osteogenic matrix precipitation. Simvastatin 73-84 ATHS Homo sapiens 180-183 35068607-8 2022 Binding energy values were higher for naringin (-10.75 and -9.38 kcal/mol, respectively) than simvastatin on HMGR (-9.9) and curcumin on TOPOII (-8.37). Simvastatin 94-105 high mobility group AT-hook 1 Homo sapiens 109-113 35118811-0 2022 Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-beta3 and Wnt/beta-Catenin pathways. Simvastatin 0-11 transforming growth factor beta 3 Homo sapiens 68-77 35118811-0 2022 Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-beta3 and Wnt/beta-Catenin pathways. Simvastatin 0-11 Wnt family member 4 Homo sapiens 82-85 35118811-0 2022 Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-beta3 and Wnt/beta-Catenin pathways. Simvastatin 0-11 catenin beta 1 Homo sapiens 86-98 35118811-10 2022 Simvastatin significantly decreased the production of the key ECM proteins, collagen 1 and fibronectin. Simvastatin 0-11 fibronectin 1 Homo sapiens 91-102 35251001-5 2022 We found that treatment with simvastatin significantly reduced the viral replication and lung damage in vivo, delaying SARS-CoV-2-associated physiopathology and mortality in the K18-hACE2-transgenic mice model. Simvastatin 29-40 angiotensin converting enzyme 2 Homo sapiens 182-187 35269738-0 2022 Amelioration of Endotoxin-Induced Acute Lung Injury and Alveolar Epithelial Cells Apoptosis by Simvastatin Is Associated with Up-Regulation of Survivin/NF-kB/p65 Pathway. Simvastatin 95-106 RELA proto-oncogene, NF-kB subunit Homo sapiens 158-161 35269738-7 2022 Simvastatin in a dose of 40 mg/kg showed the most significant effects in amelioration alveolar epithelial cells apoptosis, demonstrating this as a marked decrease of AI (p < 0.01 vs. LPS), cytochrome C, and cleaved caspase-3 expression. Simvastatin 0-11 cytochrome c, somatic Homo sapiens 189-201 35269738-7 2022 Simvastatin in a dose of 40 mg/kg showed the most significant effects in amelioration alveolar epithelial cells apoptosis, demonstrating this as a marked decrease of AI (p < 0.01 vs. LPS), cytochrome C, and cleaved caspase-3 expression. Simvastatin 0-11 caspase 3 Homo sapiens 215-224 35269738-8 2022 Furthermore, simvastatin significantly enhanced the expression of Bcl-xL and survivin. Simvastatin 13-24 BCL2 like 1 Homo sapiens 66-72 35269384-3 2022 Hypertension-mimicking devices and KLF2 siRNA were used to downregulate KLF2 expression, while the expression of KLF2 was upregulated by administering simvastatin. Simvastatin 151-162 Kruppel like factor 2 Homo sapiens 113-117 35269384-5 2022 Apoptosis and fibrosis rates were increased under pressure, and these phenomena were aggravated following KLF2 knockdown, but were alleviated after simvastatin treatment; additionally, these changes were observed in angiotensin II, angiotensin type-1 receptor (AT1R) mRNA, and interleukin-18 (IL-18), but not in angiotensin type-2 receptor mRNA. Simvastatin 148-159 angiotensin II receptor type 1 Homo sapiens 261-265 35269384-5 2022 Apoptosis and fibrosis rates were increased under pressure, and these phenomena were aggravated following KLF2 knockdown, but were alleviated after simvastatin treatment; additionally, these changes were observed in angiotensin II, angiotensin type-1 receptor (AT1R) mRNA, and interleukin-18 (IL-18), but not in angiotensin type-2 receptor mRNA. Simvastatin 148-159 interleukin 18 Homo sapiens 277-291 35269384-5 2022 Apoptosis and fibrosis rates were increased under pressure, and these phenomena were aggravated following KLF2 knockdown, but were alleviated after simvastatin treatment; additionally, these changes were observed in angiotensin II, angiotensin type-1 receptor (AT1R) mRNA, and interleukin-18 (IL-18), but not in angiotensin type-2 receptor mRNA. Simvastatin 148-159 interleukin 18 Homo sapiens 293-298 35250607-1 2022 We previously reported integrin beta 4 (ITGB4) is an important mediator of lung vascular protection by simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitor. Simvastatin 103-114 integrin subunit beta 4 Homo sapiens 23-38 35250607-1 2022 We previously reported integrin beta 4 (ITGB4) is an important mediator of lung vascular protection by simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitor. Simvastatin 103-114 integrin subunit beta 4 Homo sapiens 40-45 35251001-7 2022 Additionally, we also observed that simvastatin affected the course of SARS-CoV-2 infection through displacing ACE2 on cell membrane lipid rafts. Simvastatin 36-47 angiotensin converting enzyme 2 Homo sapiens 111-115 35250607-2 2022 In this study, we report increased endothelial cell (EC) expression specifically of ITGB4E, an ITGB4 mRNA splice variant, by simvastatin with effects on EC protein expression and inflammatory responses. Simvastatin 125-136 integrin subunit beta 4 Homo sapiens 95-100 35166183-6 2022 Treatment with simvastatin significantly reduced tumour volume and inhibited the Ki67 expression when compared to the control group. Simvastatin 15-26 antigen identified by monoclonal antibody Ki 67 Mus musculus 81-85 35166183-10 2022 Treatment with simvastatin significantly reduced tumour volume and inhibited the Ki67 expression when compared to the control group. Simvastatin 15-26 antigen identified by monoclonal antibody Ki 67 Mus musculus 81-85 35123844-8 2022 Phosphorylation of MAPKs and NF-kappab was evaluated by Western blot after treatment with TNF-alpha, IL-1beta, oxidized LDL, and simvastatin. Simvastatin 129-140 nuclear factor kappa B subunit 1 Homo sapiens 29-38 35277075-7 2022 SV treatment restored antioxidant enzyme activity and decreased lipid peroxidation, ALE-RAGE pathway activation, steatosis, fibrosis, and inflammatory parameters. Simvastatin 0-2 advanced glycosylation end product-specific receptor Mus musculus 88-92 35169154-7 2022 Increased risk of simvastatin-induced myopathy could be predicted in ~32% of Qataris from the diplotypes of SLCO1B1, which is higher compared to many other populations, while fewer Qataris may need tacrolimus dosage adjustments for achieving immunosuppression based on the CYP3A5 diplotypes compared to other world populations. Simvastatin 18-29 solute carrier organic anion transporter family member 1B1 Homo sapiens 108-115 35169154-7 2022 Increased risk of simvastatin-induced myopathy could be predicted in ~32% of Qataris from the diplotypes of SLCO1B1, which is higher compared to many other populations, while fewer Qataris may need tacrolimus dosage adjustments for achieving immunosuppression based on the CYP3A5 diplotypes compared to other world populations. Simvastatin 18-29 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 273-279 35123844-11 2022 Western blot analysis showed that oxidized LDL as well as TNF-alpha and IL-1beta activated the signaling of MAPKs and NF-kappab in LF cells, and that simvastatin treatment reduced the phosphorylation of all signaling. Simvastatin 150-161 tumor necrosis factor Homo sapiens 58-67 35123844-11 2022 Western blot analysis showed that oxidized LDL as well as TNF-alpha and IL-1beta activated the signaling of MAPKs and NF-kappab in LF cells, and that simvastatin treatment reduced the phosphorylation of all signaling. Simvastatin 150-161 interleukin 1 alpha Homo sapiens 72-80 35123844-11 2022 Western blot analysis showed that oxidized LDL as well as TNF-alpha and IL-1beta activated the signaling of MAPKs and NF-kappab in LF cells, and that simvastatin treatment reduced the phosphorylation of all signaling. Simvastatin 150-161 nuclear factor kappa B subunit 1 Homo sapiens 118-127 35059045-12 2022 In MIRI rats, simvastatin upregulated KLF2 and p-eNOS. Simvastatin 14-25 Kruppel-like factor 2 Rattus norvegicus 38-42 35041135-8 2022 RESULTS: We found that the severity of endotoxin-induced coagulopathy was significantly improved in simvastatin-pretreated mice, who showed attenuated depletion of coagulation factors and platelets, decreased plasminogen activator inhibitor-1 (PAI-1) expression, reduced organ fibrin deposition, and improved survival time. Simvastatin 100-111 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 209-242 35041135-8 2022 RESULTS: We found that the severity of endotoxin-induced coagulopathy was significantly improved in simvastatin-pretreated mice, who showed attenuated depletion of coagulation factors and platelets, decreased plasminogen activator inhibitor-1 (PAI-1) expression, reduced organ fibrin deposition, and improved survival time. Simvastatin 100-111 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 244-249 35146420-4 2022 This study is the first to show the molecular binding of simvastatin to catalase through molecular docking analysis. Simvastatin 57-68 catalase Homo sapiens 72-80 35146420-7 2022 The activity of catalase and superoxide dismutase (SOD) both increased significantly in oxidatively stressed HepG2 cells after the treatment with simvastatin (10 muM, 24 h). Simvastatin 146-157 catalase Homo sapiens 16-24 35146420-7 2022 The activity of catalase and superoxide dismutase (SOD) both increased significantly in oxidatively stressed HepG2 cells after the treatment with simvastatin (10 muM, 24 h). Simvastatin 146-157 superoxide dismutase 1 Homo sapiens 29-49 35146420-7 2022 The activity of catalase and superoxide dismutase (SOD) both increased significantly in oxidatively stressed HepG2 cells after the treatment with simvastatin (10 muM, 24 h). Simvastatin 146-157 superoxide dismutase 1 Homo sapiens 51-54 35146420-8 2022 In addition to this, he original cell morphology of oxidatively stressed cells was restored by simvastatin, and an increase in antioxidant enzymes, catalase (0.08 U/cells to 0.12 U/cells), and SOD (0.57 U/cells to 0.74 U/cells) was also noted in HepG2 cells. Simvastatin 95-106 superoxide dismutase 1 Homo sapiens 193-196 35146420-9 2022 Furthermore, a significant increase in the antioxidant enzymes such as Catalase, SOD, and reduced glutathione (GSH) was noted after simvastatin treatment in the HFD model. Simvastatin 132-143 catalase Homo sapiens 71-79 35146420-9 2022 Furthermore, a significant increase in the antioxidant enzymes such as Catalase, SOD, and reduced glutathione (GSH) was noted after simvastatin treatment in the HFD model. Simvastatin 132-143 superoxide dismutase 1 Homo sapiens 81-84 35308127-0 2022 Beneficial effect of simvastatin on human umbilical vein endothelial cells gap junctions induced by TNF-alpha. Simvastatin 21-32 tumor necrosis factor Homo sapiens 100-109 35308127-6 2022 In addition, simvastatin treatment significantly upregulated expression of Cx37 and Cx40 but downregulated Cx43 mRNAs and proteins. Simvastatin 13-24 gap junction protein alpha 4 Homo sapiens 75-79 35308127-6 2022 In addition, simvastatin treatment significantly upregulated expression of Cx37 and Cx40 but downregulated Cx43 mRNAs and proteins. Simvastatin 13-24 gap junction protein alpha 5 Homo sapiens 84-88 35308127-6 2022 In addition, simvastatin treatment significantly upregulated expression of Cx37 and Cx40 but downregulated Cx43 mRNAs and proteins. Simvastatin 13-24 gap junction protein alpha 1 Homo sapiens 107-111 35308127-7 2022 Taken together, these marked changes indicated that simvastatin exerts its regulatory effects on gap junction function by upregulating Cx37 and Cx40 and downregulating Cx43 expression. Simvastatin 52-63 gap junction protein alpha 4 Homo sapiens 135-139 35308127-7 2022 Taken together, these marked changes indicated that simvastatin exerts its regulatory effects on gap junction function by upregulating Cx37 and Cx40 and downregulating Cx43 expression. Simvastatin 52-63 gap junction protein alpha 5 Homo sapiens 144-148 35308127-7 2022 Taken together, these marked changes indicated that simvastatin exerts its regulatory effects on gap junction function by upregulating Cx37 and Cx40 and downregulating Cx43 expression. Simvastatin 52-63 gap junction protein alpha 1 Homo sapiens 168-172 35059045-12 2022 In MIRI rats, simvastatin upregulated KLF2 and p-eNOS. Simvastatin 14-25 nitric oxide synthase 3 Rattus norvegicus 49-53 35059045-13 2022 Conclusions: Simvastatin protects inflammatory response at post-MIRI through upregulating KLF2, thus improving cardiac function. Simvastatin 13-24 Kruppel-like factor 2 Rattus norvegicus 90-94 34983554-9 2022 We further found simvastatin restores the quiescence of activated hepatic stellate cells (aHSCs) via stimulation of KLF2-NO signaling in LSECs, and up-regulates the expression of CXCL16 in LSECs. Simvastatin 17-28 Kruppel-like factor 2 (lung) Mus musculus 116-120 35001242-12 2022 DGEA mice fed a simvastatin-containing diet demonstrated significant upregulation of procaspase-3 (p = 0.009) and cleaved caspase-3 (p = 0.034) in the distal esophagus. Simvastatin 16-27 caspase 3 Mus musculus 122-131 35012572-3 2022 This study assessed the effects of simvastatin on cytotoxicity and the release of IL-6 (Interleukin-6) production when incorporated in zinc oxide eugenol and methacrylate resin-based sealers. Simvastatin 35-46 interleukin 6 Mus musculus 88-101 34983554-9 2022 We further found simvastatin restores the quiescence of activated hepatic stellate cells (aHSCs) via stimulation of KLF2-NO signaling in LSECs, and up-regulates the expression of CXCL16 in LSECs. Simvastatin 17-28 C-X-C motif chemokine ligand 16 Homo sapiens 179-185 34983554-10 2022 In intrahepatic inoculated fibrotic HCC mouse model, LSEC-targeted nano-delivery of simvastatin not only alleviates LSEC capillarization to regress the stromal microenvironment, but also recruits natural killer T (NKT) cells through CXCL16 to suppress tumor progression. Simvastatin 84-95 chemokine (C-X-C motif) ligand 16 Mus musculus 233-239 34983554-11 2022 Together with anti-programmed death-1-ligand-1 (anti-PD-L1) antibody, targeted-delivery of simvastatin achieves an improved therapeutic effect in hemi-splenic inoculated advanced-stage HCC model. Simvastatin 91-102 CD274 antigen Mus musculus 53-58 34459464-6 2022 The clinical pharmacist found that the patient took nifedipine sustained-release tablets and simvastatin tablets simultaneously, and these medicines were all substrates of CYP3A4. Simvastatin 93-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 172-178